<SEC-DOCUMENT>0001453687-21-000069.txt : 20210513
<SEC-HEADER>0001453687-21-000069.hdr.sgml : 20210513
<ACCEPTANCE-DATETIME>20210513080337
ACCESSION NUMBER:		0001453687-21-000069
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		92
CONFORMED PERIOD OF REPORT:	20210331
FILED AS OF DATE:		20210513
DATE AS OF CHANGE:		20210513

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			SELECTA BIOSCIENCES INC
		CENTRAL INDEX KEY:			0001453687
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37798
		FILM NUMBER:		21917279

	BUSINESS ADDRESS:	
		STREET 1:		65 GROVE STREET
		CITY:			WATERTOWN
		STATE:			MA
		ZIP:			02472
		BUSINESS PHONE:		617-923-1400

	MAIL ADDRESS:	
		STREET 1:		65 GROVE STREET
		CITY:			WATERTOWN
		STATE:			MA
		ZIP:			02472
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>selb-20210331.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2021 Workiva--><!--r:f83914de-cdf0-4ece-a0a2-d7db460e8912,g:a84bda62-2062-413b-8a4e-4383ad9edaee,d:71586e7d2e304f6983634abe9e071791--><html xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:country="http://xbrl.sec.gov/country/2020-01-31" xmlns:selb="http://www.selectabio.com/20210331" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:link="http://www.xbrl.org/2003/linkbase" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>selb-20210331</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV80L2ZyYWc6NmYwMWNmODVkZTFkNGFhZDg5Y2Q2ZDZiNmMzMmFkOTAvdGFibGU6M2MyYTMxOTlhZWNjNDMwNmI3MmE0MzRlM2MzYmI2M2YvdGFibGVyYW5nZTozYzJhMzE5OWFlY2M0MzA2YjcyYTQzNGUzYzNiYjYzZl8yLTEtMS0xLTA_ced1008e-5754-4d12-9c19-a7cfabb57b47">false</ix:nonNumeric><ix:nonNumeric contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV80L2ZyYWc6NmYwMWNmODVkZTFkNGFhZDg5Y2Q2ZDZiNmMzMmFkOTAvdGFibGU6M2MyYTMxOTlhZWNjNDMwNmI3MmE0MzRlM2MzYmI2M2YvdGFibGVyYW5nZTozYzJhMzE5OWFlY2M0MzA2YjcyYTQzNGUzYzNiYjYzZl8zLTEtMS0xLTA_19589f4f-40c0-4297-9caf-4d63ea163698">2021</ix:nonNumeric><ix:nonNumeric contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV80L2ZyYWc6NmYwMWNmODVkZTFkNGFhZDg5Y2Q2ZDZiNmMzMmFkOTAvdGFibGU6M2MyYTMxOTlhZWNjNDMwNmI3MmE0MzRlM2MzYmI2M2YvdGFibGVyYW5nZTozYzJhMzE5OWFlY2M0MzA2YjcyYTQzNGUzYzNiYjYzZl80LTEtMS0xLTA_d8d5b014-960f-4465-8ba9-4d3df43a774d">Q1</ix:nonNumeric><ix:nonNumeric contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV80L2ZyYWc6NmYwMWNmODVkZTFkNGFhZDg5Y2Q2ZDZiNmMzMmFkOTAvdGFibGU6M2MyYTMxOTlhZWNjNDMwNmI3MmE0MzRlM2MzYmI2M2YvdGFibGVyYW5nZTozYzJhMzE5OWFlY2M0MzA2YjcyYTQzNGUzYzNiYjYzZl82LTEtMS0xLTA_62fc7a6f-5cb3-411f-b0f2-1fa5618adaf5">0001453687</ix:nonNumeric><ix:nonNumeric contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331" name="dei:CurrentFiscalYearEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV80L2ZyYWc6NmYwMWNmODVkZTFkNGFhZDg5Y2Q2ZDZiNmMzMmFkOTAvdGV4dHJlZ2lvbjo2ZjAxY2Y4NWRlMWQ0YWFkODljZDZkNmI2YzMyYWQ5MF80Mzk4MDQ2NTExMTgx_59340aac-e0f4-46ba-9b56-848d63e6ae86">--12-31</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="selb-20210331.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i93f17f89c13f486486776019ba38a82f_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i1872bfbdd04e4f9e825f592f3b317647_I20210507"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-05-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="ied8d945ebce54ed8a4badfed477a64e8_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib56f1adc867e406ca7face50c5da1c9c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i824a5b33f908426bad016f0eded844db_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i28d60e6e11b845dfb37da5a84a9cc1e5_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id4c7f024803c4bb7abe0167bbe5af671_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6cd8f7abd235450ab64356048dc9ec07_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie0acbe76b2ae438d975dc022af481d6c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idce850cc47714092ba1dcaa145785537_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic39deec9ab0844a9b0dab300f1a2804d_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic7469ad2eea94378b3c60b0767ec2c61_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9ba514a4defc485e94d0b416ba59c49d_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0f01a127e9094f2c9ce7fa5a13678fc4_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7a24e3ea770740729c391207bf51dce3_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i64c04c765b7b44e8b62c73e17992956e_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i697921663ff44d1ba22263ce04047fe4_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8f5d5586be294d54be1415ab00417669_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia6d22df4e633466eb268453a386261b9_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic85d5ba0da864526935be1f5158d2390_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i48c9319650af4a498d62dfe592f8cfdd_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iabdd66a36794438ab9664178bf3cf96a_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie0acb7061950472c9ffc5dee59b3f7d1_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i22171a0001464fdbaeb20c2221b2f800_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia8bafce0cbb84adc8382dec4a0321316_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie102296cb93f4d219e9e9aeb38383744_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i708ad43bbcdd433f8815781dc1dabef7_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6de5cd0af433469ea596afb9aa70a75b_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8407594575184affb099a506cf4761ad_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6914e325d1a54348910a4641d7f828c4_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iff7e2530342c41bca8c84fce55f0cc6f_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2fa0062d7932481c8274387fef46611d_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:RU</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic3c76b1f92aa42d09acee15de07994bb_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i14e2b8def247421298d392498e8d2a2c_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9c2d6525939d4e4f8c2b60bce2f66a52_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie177f33c2b9e48b2b637240e8939d8ae_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i025312c2f622403398c380c781b5be0a_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iafc609c73df642828d67d21ca85d518a_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i13a4d3bd3f0f4f058f62ef7fd2966851_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1a544c9a0a0e439c9ee87934aaffd7fe_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i65d0ac8f7c4649d2abfce4eda0ef5c55_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i73fe924a4c6b473cabf17b9976a4603b_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4f0d06e989014726b8fbec56b2c70e58_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i62606fe1b8724fb5a3af6c257e69c07f_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i34e52dcd53c6432595cfbcb02112eb8b_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id1a9f3d45e4741d9adb5d0a140f27245_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if2bb46350e76491c82ca4f7ee3718824_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i59a1a80dbf8e4190b547bba901361077_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ife613bc7097a4d25b505ac69b2a556a1_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9c477876ef1243f7b607ededf27faa28_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id5b76767b65e416baf32d9fa8ea057ac_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i78a9cb54375140a3926493d7ca71f588_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ief7e41d172914136a4d75381f191624f_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if08a10047a654aaca135de61c8732df2_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if36d86949e87479898a50e28488ef27e_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4bc11fa50e194e0fabd48feb4957cccd_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie881e34b7b6e451a8635ff1a48715e24_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3415f69e0c84403290f2c597fcafb421_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icd1ec9843c3446469cb04e17862f007e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3e2993ab72c94021ac21ee14bcd929f2_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib217ca012a534d9a9f5dedd2b37941f0_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i631a8e963f31434e8ea74e97de9ea103_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7e3199d724344066b7d92c08835c0d7b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i067beaf80d0645c0b74a43ced34f040f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibd87cf2a903e47a68471682c6f1d3125_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i09c393762b464d30a19a24b55c2f5d20_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i173ee7e9fa254b81bffe4952d975b4c0_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i519d4d01a3ff4f27a9efdf217e061704_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iba23f9d46a1d4b2f897e63f5c2c1d4bb_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i118f57dc685b47c8b1b5f190c4eed731_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icf08fe145a214d8bacaa57c857186979_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id99ce4003b574f658d3b62852041d661_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7a27424e288a444c8c666f3eeb249646_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">selb:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib5f80b2977824ab9ba0203bc6a11a58e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">selb:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia943ee9b105d42cba901af1e6a454c40_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i56d15e17ec144f96957c4fb601aba227_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iad5e74cc7867456d841ede0490c532e2_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7b0035fcfb7b4ad5a466a8875b9526aa_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i071771a6ccb1419ca97dd0dfaf4f2526_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5879070723fe4b008e2b38909e05fbe9_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibf4df6273b36402f8f2fc2b5d47437bd_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i44f41827807b4780adcd3350fc42ab49_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i62030e264c0744b68da329d325fca573_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i42237c8333f54aaa809730ac386b4ae3_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="sqft"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:context id="i8a6242358159403bbb0d1d272fafb3bc_I20190731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="selb:LeaseArrangementAxis">selb:A65GroveStreetWatertownMAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3fe0080183054a06885fd48ac35a21f1_D20190701-20190731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="selb:LeaseArrangementAxis">selb:A65GroveStreetWatertownMAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i98e030263a7d4c9fbb0733a011655549_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i012a579920bb42578031fbbc9df1dfd2_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic49c55aadcfb4e6abcca12c5093f9b95_I20200831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">selb:A2020TermLoansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idad7c718ad664d059d7a422e95802f09_I20200831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">selb:TermALoansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibf84b0dc83f74410887e49db3c27bd26_I20200831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">selb:TermBLoansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0c9896510dd84101bf9f2e4ccfe3aafb_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">selb:A2020TermLoansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idb510d90210b4690b5f24ea7b3c03117_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">selb:A2020TermLoansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i508d18807d32409296e19306139342d3_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">selb:A2020TermLoansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id40f93ddba284a1eaf4d3d96cdbe8228_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">selb:A2020TermLoansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3fe76a62c9514fceaf15e8fc84c84053_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">selb:A2020TermLoansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3303eaf5c2074c30aee9f9289696a2e5_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">selb:A2020TermLoansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2d4605e783914026a19516819dbaac3f_D20200831-20200831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">selb:A2020TermLoansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-31</xbrli:startDate><xbrli:endDate>2020-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8096110103d24ead836cc45438a9c346_I20200831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i23a2063d104e496f85ffd7168cdf9d4c_D20200831-20200831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-31</xbrli:startDate><xbrli:endDate>2020-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7dadb30c8c5644a19242b20dc3231a67_D20200831-20200831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">selb:TermBLoansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-31</xbrli:startDate><xbrli:endDate>2020-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifaf30d95979d4b7f87adf2a9bc2bf774_D20200831-20200831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">selb:A2017TermLoansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-31</xbrli:startDate><xbrli:endDate>2020-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia71eca13c1a4466f9daeb5956381a0e0_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">selb:A2017TermLoansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ied299278fc4543748c5f3ad2970fc3bb_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">selb:A2020TermLoansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie10a81ae4793423483f2db5739fafba5_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">selb:A2020TermLoansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i867f4cd50cdf4945bf8a2b4c13258dfd_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">selb:A2017TermLoansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i98fb2199c6374722852813ddab2890d7_D20200806-20200806"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">selb:August2020ShelfRegistrationStatementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-06</xbrli:startDate><xbrli:endDate>2020-08-06</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8b800c16db4f4bf39aec6ba9ec584f99_D20170801-20170831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">selb:AtTheMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-08-01</xbrli:startDate><xbrli:endDate>2017-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id4091feb67174db89de51f974b39d21c_D20170801-20170831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">selb:A2020SaleAgreementAtTheMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-08-01</xbrli:startDate><xbrli:endDate>2017-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ice2d8b62be3849c288862d2279be6e13_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">selb:AtTheMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibc930259a91a4e09996f4820308891bd_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">selb:AtTheMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i677f0fc8ad1f4d2c83a443e0a5bd7e07_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">selb:AtTheMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5a706b93dc024e0d96e8ca02c67629d7_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">selb:AtTheMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6e736a6ad22d4f7fbc1eda905bef7a23_D20200611-20200611"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">selb:SOBIPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-11</xbrli:startDate><xbrli:endDate>2020-06-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5034b14d18454b028a4c7a4a20bbac44_I20200611"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">selb:SOBIPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8d2fc88d756d4b67bf9851793506eee3_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">selb:SOBIPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0e52f92d6bcb4dd098a7fe0cf721e342_D20200728-20200728"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">selb:SOBIPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-28</xbrli:startDate><xbrli:endDate>2020-07-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iff262d3fceb04558bb91b0665eb3295e_D20191218-20191218"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">selb:DecemberTwoThousandNineteenFinancingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-18</xbrli:startDate><xbrli:endDate>2019-12-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i04e2a4ab60694adfa2dcd5d722cd132e_I20191218"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">selb:DecemberTwoThousandNineteenFinancingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i06e21592f529454490acff73efadbef0_I20191218"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">selb:DecemberTwoThousandNineteenFinancingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">selb:CommonWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifc3b4456d78b4865980e0d06be756475_D20191218-20191218"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">selb:DecemberTwoThousandNineteenFinancingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">selb:PreFundedWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-18</xbrli:startDate><xbrli:endDate>2019-12-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibb1098ccfa7945aa92c2145f660cec87_I20191218"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">selb:DecemberTwoThousandNineteenFinancingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">selb:PreFundedWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i40f7108f907b4381983c3f10bfbcbd06_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">selb:DecemberTwoThousandNineteenFinancingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3c29e75c7cde4be78a2c3d04f4678b57_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">selb:DecemberTwoThousandNineteenFinancingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2d7bd840e7b3429ba469e9ff77e35cdc_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">selb:DecemberTwoThousandNineteenFinancingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib2148f5a0b034c99a308352e1c25d052_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i23a3406d8ff1477aa084b096803061e3_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">selb:A2017PIPEMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="vote"><xbrli:measure>selb:vote</xbrli:measure></xbrli:unit><xbrli:context id="id201ea1fc8cd4bc2957bd09c9be775f9_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i766bfbe0d62646d1ae2d0abb4d722110_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic80bb38a87b34cd5bae8a1c9d61a28e8_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icaed7df33b254fc68b5b0e15b600935f_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">selb:RestrictedStockUnitsRSUsReservedForIssuanceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9ef78f70a7c34162bf4e7727fba544cc_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">selb:RestrictedStockUnitsRSUsReservedForIssuanceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8c5ceec4ab9b487193df89666ccf91d3_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">selb:RestrictedStockUnitsUnvestedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2595e8b300194cc6bb08ac9d33e9eaf8_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">selb:RestrictedStockUnitsUnvestedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idc47c16592ad4e7c88824de49ffb8420_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaa1769cc2fd04d9ab84daf10f681742a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i659c0d6b1a6b4dde9d2d66b377a3e370_I20160621"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">selb:StockIncentivePlan2016Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-06-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic5906043b3594f21b5de7208dd3fa609_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">selb:StockIncentivePlan2016Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib2627fa0b80846ab8d39c202e998d601_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">selb:StockIncentivePlan2016Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i91178c8223ca4306a02f4027a764b423_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">selb:StockIncentivePlan2016Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i897bb148c3bb4abb9ea043f39a5a1bbe_I20180925"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">selb:EmploymentInducementIncentiveAwardPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-09-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i90b02123a489453691cedc67052e854c_I20190325"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">selb:EmploymentInducementIncentiveAwardPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifb4e42c6f6c44e0f9158bb1c44089423_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">selb:EmploymentInducementIncentiveAwardPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i16033c04e5ea4cc5bbfdba5f3c1bd666_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">selb:ResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i723babe8bc8f40e0843af46b5e72961b_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">selb:ResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i448d50e1226e459ca3870f9edd8b9fef_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i45408aeb6dc44b58bc7a8d6958d23e54_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0a83cea2026d4acd853ecd648a6ff3cf_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0a02cb62522c49fd9f650c7a972a0090_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9b0d673a9945438a9e404b6c6b57eba2_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">selb:A2008Plan2016PlanAnd2018InducementIncentiveAwardPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icff59de35252465485536be51fa5f610_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">selb:A2008Plan2016PlanAnd2018InducementIncentiveAwardPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia87a6b98f0714c88b1aa992fc475f7a1_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">selb:A2008Plan2016PlanAnd2018InducementIncentiveAwardPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5a27d4e69f2d4076ab56ee85c1e0a2d3_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">selb:A2008Plan2016PlanAnd2018InducementIncentiveAwardPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i96083ba0423741b898ef5188cabae8f2_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">selb:NonEmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">selb:A2008Plan2016PlanAnd2018InducementIncentiveAwardPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7f9a0d7d151d41348d7f21ab127c2ee1_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">selb:NonEmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">selb:A2008Plan2016PlanAnd2018InducementIncentiveAwardPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1f2f087904c34f869b3d9a4b4cb9a24e_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">selb:NonEmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">selb:A2008Plan2016PlanAnd2018InducementIncentiveAwardPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1a4fb26d073f4e2aa150b70c1bdd64cd_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">selb:NonEmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">selb:A2008Plan2016PlanAnd2018InducementIncentiveAwardPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id01182d93717492b89617d993fbd0c3a_D20210101-20210131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">selb:StockIncentivePlan2016Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib1f07535b15b475490cebf99339949e2_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">selb:StockIncentivePlan2016Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i676ae38dc7694143b42a364d53aa820c_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id4c863b4912a4159803053e1c04bda2f_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">selb:EmploymentInducementIncentiveAwardPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia7f06d48c2684d27abe5106b2abf1761_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">selb:EmploymentInducementIncentiveAwardPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i23dc483d5e024cd3ab41d280f32cf960_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie9886e2c9856402e9696bea8b5c012ee_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i98884f73b2c2406a9fe17695931498a3_I20160621"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">selb:EmployeeStockPurchasePlan2016Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-06-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3a0400d76b2a4414a1b0b75fa0e22620_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">selb:EmployeeStockPurchasePlan2016Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7ecfd227500943bba7dc51fc2bd3afec_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">selb:EmployeeStockPurchasePlan2016Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib7e99ef7cdcc49a1ad08e7bc6eec6d1a_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">selb:EmployeeStockPurchasePlan2016Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i88f5a9f6a9ed48ce97bb4cbb9b6ef889_D20200611-20200611"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-11</xbrli:startDate><xbrli:endDate>2020-06-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="obligation"><xbrli:measure>selb:obligation</xbrli:measure></xbrli:unit><xbrli:context id="idfbbd3bf25a24130a9437f8a5acdb931_I20200611"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i89a2a0a3262b4bc9b05cb96efb71185e_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">selb:SOBIPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9114bf8b8ace4041b525081dc7e30132_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">selb:SOBIPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0274d7d2728b45debefc3a188dc02830_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">selb:SOBIPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieb852272fa154e92bcf4a36c0a643304_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">selb:SOBIPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i114b99e9c016452483452639f622b436_D20200613-20200613"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">selb:SareptaTherapeuticsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-13</xbrli:startDate><xbrli:endDate>2020-06-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6ede8ce092334ef1927faf29388e0af6_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">selb:SareptaTherapeuticsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7b30202348b245c093e55382ba4778e9_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">selb:SareptaTherapeuticsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie7b30c0c9db24a54aad1845efeb882c1_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">selb:SareptaTherapeuticsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i17bc05b20a3043b2acb1ee8c2e1badf9_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">selb:SareptaTherapeuticsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia04c0f8c59e54e0780747ca4c1a414d5_D20191217-20191217"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">selb:LicenseAgreementForPompeDiseaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-17</xbrli:startDate><xbrli:endDate>2019-12-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i10b61b699b8047098f9ffd1347f4a2ea_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">selb:LicenseAgreementForPompeDiseaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie2581e0def58480f85a685f932e3297b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">selb:LicenseAgreementForPompeDiseaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9d35ce32fa2b4a2b89239188060f0691_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">selb:LicenseAgreementForPompeDiseaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i52f04094420841308054f7809f206401_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">selb:LicenseAgreementForPompeDiseaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i961e2381798844178d4558010699b490_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">selb:FounderMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0f7b03d9ffec46e09e274a6faed6a815_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">selb:FounderMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2d6aabf5381c4d8eafad236940060193_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">selb:AskBioLicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i24708847c47a43ca9c76041056178569_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">selb:AskBioLicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icd96a5af167244139fa70b4e414d29c8_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">selb:ExclusivePatentLicenseAgreementWithMassachusettsInstituteOfTechnologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iec431b313cb846b2aa7358a0b7afcf53_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibb68c9bff506451eb919c2f81711b851_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">selb:LicenseAgreementWithShenyangSunshinePharmaceuticalCompanyLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i29f55711d46f4ce5a26d9adbfce75977_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">selb:LicenseAgreementWithShenyangSunshinePharmaceuticalCompanyLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i69b9f1abf0ba4aac990acd969100a523_D20210401-20210513"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">selb:A2020SaleAgreementAtTheMarketOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-05-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia74a702495ff411cac561a2aded35226_I20210513"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">selb:A2020SaleAgreementAtTheMarketOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-05-13</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iebf9f6ef11cf4e6e8cfcb2c64010f2ad_D20210413-20210413"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001453687</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">selb:SareptaTherapeuticsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-13</xbrli:startDate><xbrli:endDate>2021-04-13</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i71586e7d2e304f6983634abe9e071791_7"></div><div style="min-height:32.4pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:5pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:18.783%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.783%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.783%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.783%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.368%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:120%">&#160;&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">WASHINGTON, D.C. 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV83L2ZyYWc6MWI5OGM4ZWY5MDE1NGNhOTliMWYyMDUwMzI3ZTU1MjgvdGV4dHJlZ2lvbjoxYjk4YzhlZjkwMTU0Y2E5OWIxZjIwNTAzMjdlNTUyOF80Mzk4MDQ2NTEzNTE3_1c6b3287-8a12-4191-8a8b-f0963202d012">10-Q</ix:nonNumeric> </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:4.756%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.044%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331" format="ixt:booleantrue" name="dei:DocumentQuarterlyReport" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV83L2ZyYWc6MWI5OGM4ZWY5MDE1NGNhOTliMWYyMDUwMzI3ZTU1MjgvdGFibGU6NzVmNmY2OGQ4YjZkNDcyMzlkNWE4Y2QwZmIwNzAyZDcvdGFibGVyYW5nZTo3NWY2ZjY4ZDhiNmQ0NzIzOWQ1YThjZDBmYjA3MDJkN18wLTAtMS0xLTA_f1bf5865-347a-4aa7-bff9-d08c7632de24">&#253;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the quarterly period ended <ix:nonNumeric contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV83L2ZyYWc6MWI5OGM4ZWY5MDE1NGNhOTliMWYyMDUwMzI3ZTU1MjgvdGV4dHJlZ2lvbjoxYjk4YzhlZjkwMTU0Y2E5OWIxZjIwNTAzMjdlNTUyOF8xMjg_a42b922e-2c47-48a0-a191-9e9fa420b1ef">March 31, 2021</ix:nonNumeric></span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OR</span></div><div style="margin-bottom:11pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:4.756%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.044%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331" format="ixt:booleanfalse" name="dei:DocumentTransitionReport" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV83L2ZyYWc6MWI5OGM4ZWY5MDE1NGNhOTliMWYyMDUwMzI3ZTU1MjgvdGFibGU6OTIxZDAxOGY5MTVkNDE4OGFhZWVhM2Y3YzdkZGFjNWMvdGFibGVyYW5nZTo5MjFkMDE4ZjkxNWQ0MTg4YWFlZWEzZjdjN2RkYWM1Y18wLTAtMS0xLTA_dc623ec4-025a-440d-a972-c45f77138a8d">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:174%">For the transition period from _______ to _______</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:174%">Commission File Number: <ix:nonNumeric contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV83L2ZyYWc6MWI5OGM4ZWY5MDE1NGNhOTliMWYyMDUwMzI3ZTU1MjgvdGV4dHJlZ2lvbjoxYjk4YzhlZjkwMTU0Y2E5OWIxZjIwNTAzMjdlNTUyOF8xOTIy_effe7b8d-6762-4bcd-bc1e-c94f878b1fc2">001-37798</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:174%">   </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:24pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV83L2ZyYWc6MWI5OGM4ZWY5MDE1NGNhOTliMWYyMDUwMzI3ZTU1MjgvdGV4dHJlZ2lvbjoxYjk4YzhlZjkwMTU0Y2E5OWIxZjIwNTAzMjdlNTUyOF8xOTIz_b94ed07e-33dd-4315-b614-5a4ba40757c4">Selecta Biosciences, Inc</ix:nonNumeric>.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:89.766%"><tr><td style="width:1.0%"></td><td style="width:4.600%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.199%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.199%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.602%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:1.12pt;padding-right:1.12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV83L2ZyYWc6MWI5OGM4ZWY5MDE1NGNhOTliMWYyMDUwMzI3ZTU1MjgvdGFibGU6Y2NiZmIxYzZhNzI3NGNjOTlkYTQ4NzIyNmYwMTJkZDcvdGFibGVyYW5nZTpjY2JmYjFjNmE3Mjc0Y2M5OWRhNDg3MjI2ZjAxMmRkN18wLTEtMS0xLTMxNjI_a0cdbe2f-2440-4836-b0d6-3c855d3b260c">Delaware</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV83L2ZyYWc6MWI5OGM4ZWY5MDE1NGNhOTliMWYyMDUwMzI3ZTU1MjgvdGFibGU6Y2NiZmIxYzZhNzI3NGNjOTlkYTQ4NzIyNmYwMTJkZDcvdGFibGVyYW5nZTpjY2JmYjFjNmE3Mjc0Y2M5OWRhNDg3MjI2ZjAxMmRkN18wLTItMS0xLTMxNTU_9d400aaf-f483-4f27-a040-abfff4fc368d">26-1622110</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:1.12pt;padding-right:1.12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(State or other jurisdiction</span></div><div style="margin-bottom:1pt;padding-left:1.12pt;padding-right:1.12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">of incorporation or organization)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(I.R.S. Employer Identification No.)</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:1.12pt;padding-right:1.12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV83L2ZyYWc6MWI5OGM4ZWY5MDE1NGNhOTliMWYyMDUwMzI3ZTU1MjgvdGFibGU6Y2NiZmIxYzZhNzI3NGNjOTlkYTQ4NzIyNmYwMTJkZDcvdGFibGVyYW5nZTpjY2JmYjFjNmE3Mjc0Y2M5OWRhNDg3MjI2ZjAxMmRkN18yLTEtMS0xLTAvdGV4dHJlZ2lvbjpmMjVhNTJmMmY2YmE0MjA0YjBjMTViMWFiZTU0ZWM4MV81_dee1386c-019c-4416-87eb-bde618186441">65 Grove Street,</ix:nonNumeric> <ix:nonNumeric contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV83L2ZyYWc6MWI5OGM4ZWY5MDE1NGNhOTliMWYyMDUwMzI3ZTU1MjgvdGFibGU6Y2NiZmIxYzZhNzI3NGNjOTlkYTQ4NzIyNmYwMTJkZDcvdGFibGVyYW5nZTpjY2JmYjFjNmE3Mjc0Y2M5OWRhNDg3MjI2ZjAxMmRkN18yLTEtMS0xLTAvdGV4dHJlZ2lvbjpmMjVhNTJmMmY2YmE0MjA0YjBjMTViMWFiZTU0ZWM4MV84_0d85d18b-696d-45d6-b22d-0f461ff495ea">Watertown,</ix:nonNumeric> <ix:nonNumeric contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV83L2ZyYWc6MWI5OGM4ZWY5MDE1NGNhOTliMWYyMDUwMzI3ZTU1MjgvdGFibGU6Y2NiZmIxYzZhNzI3NGNjOTlkYTQ4NzIyNmYwMTJkZDcvdGFibGVyYW5nZTpjY2JmYjFjNmE3Mjc0Y2M5OWRhNDg3MjI2ZjAxMmRkN18yLTEtMS0xLTAvdGV4dHJlZ2lvbjpmMjVhNTJmMmY2YmE0MjA0YjBjMTViMWFiZTU0ZWM4MV8xMQ_74857121-0579-4cd3-94e1-84bf4c52f311">MA</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 2.12pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV83L2ZyYWc6MWI5OGM4ZWY5MDE1NGNhOTliMWYyMDUwMzI3ZTU1MjgvdGFibGU6Y2NiZmIxYzZhNzI3NGNjOTlkYTQ4NzIyNmYwMTJkZDcvdGFibGVyYW5nZTpjY2JmYjFjNmE3Mjc0Y2M5OWRhNDg3MjI2ZjAxMmRkN18zLTItMS0xLTMxNjU_f023f38d-6621-4f5f-a076-60ff0f32da96">02472</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:1.12pt;padding-right:1.12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Address of principal executive offices)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Zip Code)</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV83L2ZyYWc6MWI5OGM4ZWY5MDE1NGNhOTliMWYyMDUwMzI3ZTU1MjgvdGV4dHJlZ2lvbjoxYjk4YzhlZjkwMTU0Y2E5OWIxZjIwNTAzMjdlNTUyOF8xOTMw_9ce7f0d9-48e4-4561-9f9d-95f5a9651c6d">617</ix:nonNumeric>) <ix:nonNumeric contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV83L2ZyYWc6MWI5OGM4ZWY5MDE1NGNhOTliMWYyMDUwMzI3ZTU1MjgvdGV4dHJlZ2lvbjoxYjk4YzhlZjkwMTU0Y2E5OWIxZjIwNTAzMjdlNTUyOF8xOTI2_6b04bf12-2ab8-45f0-aa8a-89666241b833">923-1400</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Registrant&#8217;s telephone number,&#160;including area code)</span></div><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:39.309%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.080%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.311%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Securities registered pursuant to Section 12(b) of the Act:</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title of each class</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV83L2ZyYWc6MWI5OGM4ZWY5MDE1NGNhOTliMWYyMDUwMzI3ZTU1MjgvdGFibGU6ZWZjODQ1ZmMwNGE3NDRkNzk4OGYwNGJhZWU4ZDFlZTMvdGFibGVyYW5nZTplZmM4NDVmYzA0YTc0NGQ3OTg4ZjA0YmFlZThkMWVlM18zLTAtMS0xLTA_c4dd872a-a217-468b-a785-f37c8337f05e">Common Stock, $0.0001 par value per share</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV83L2ZyYWc6MWI5OGM4ZWY5MDE1NGNhOTliMWYyMDUwMzI3ZTU1MjgvdGFibGU6ZWZjODQ1ZmMwNGE3NDRkNzk4OGYwNGJhZWU4ZDFlZTMvdGFibGVyYW5nZTplZmM4NDVmYzA0YTc0NGQ3OTg4ZjA0YmFlZThkMWVlM18zLTEtMS0xLTA_ddd8608c-abaa-4e36-8a5d-7e0b4afe334a">SELB</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV83L2ZyYWc6MWI5OGM4ZWY5MDE1NGNhOTliMWYyMDUwMzI3ZTU1MjgvdGFibGU6ZWZjODQ1ZmMwNGE3NDRkNzk4OGYwNGJhZWU4ZDFlZTMvdGFibGVyYW5nZTplZmM4NDVmYzA0YTc0NGQ3OTg4ZjA0YmFlZThkMWVlM18zLTItMS0xLTA_ee4ade6f-5391-49de-89ac-3caf2dfde620">The Nasdaq Stock Market LLC</ix:nonNumeric></span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:2pt;margin-top:2pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d)&#160;of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90 days. <ix:nonNumeric contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV83L2ZyYWc6MWI5OGM4ZWY5MDE1NGNhOTliMWYyMDUwMzI3ZTU1MjgvdGV4dHJlZ2lvbjoxYjk4YzhlZjkwMTU0Y2E5OWIxZjIwNTAzMjdlNTUyOF8xOTI3_b6fafbd8-0ff1-4600-956e-ada9106b3f03">Yes</ix:nonNumeric> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#253;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;No&#160;&#9744;</span></div><div style="margin-bottom:2pt;margin-top:2pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). <ix:nonNumeric contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV83L2ZyYWc6MWI5OGM4ZWY5MDE1NGNhOTliMWYyMDUwMzI3ZTU1MjgvdGV4dHJlZ2lvbjoxYjk4YzhlZjkwMTU0Y2E5OWIxZjIwNTAzMjdlNTUyOF8xOTI4_66d2bc5e-d325-44c8-abb2-3ddb484e4c47">Yes</ix:nonNumeric> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#253;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;No&#160;&#9744;</span></div><div style="margin-bottom:2pt;margin-top:2pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule&#160;12b-2 of the Exchange Act.</span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.883%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.958%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.837%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.501%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Large accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accelerated filer </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV83L2ZyYWc6MWI5OGM4ZWY5MDE1NGNhOTliMWYyMDUwMzI3ZTU1MjgvdGFibGU6OGMzMDQ3MTMwZTM5NDM3YWJlZjE0N2UzYjc5MjRiMGEvdGFibGVyYW5nZTo4YzMwNDcxMzBlMzk0MzdhYmVmMTQ3ZTNiNzkyNGIwYV8xLTEtMS0xLTQ3NTE_361d1367-87ab-4742-9cbd-723825362694">Non-accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#253;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Smaller reporting company</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331" format="ixt:booleantrue" name="dei:EntitySmallBusiness" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV83L2ZyYWc6MWI5OGM4ZWY5MDE1NGNhOTliMWYyMDUwMzI3ZTU1MjgvdGFibGU6OGMzMDQ3MTMwZTM5NDM3YWJlZjE0N2UzYjc5MjRiMGEvdGFibGVyYW5nZTo4YzMwNDcxMzBlMzk0MzdhYmVmMTQ3ZTNiNzkyNGIwYV8xLTUtMS0xLTA_1d1a19ac-289b-47e1-9203-ec616aa8f2d1">&#253;</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331" format="ixt:booleantrue" name="dei:EntityEmergingGrowthCompany" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV83L2ZyYWc6MWI5OGM4ZWY5MDE1NGNhOTliMWYyMDUwMzI3ZTU1MjgvdGFibGU6OGMzMDQ3MTMwZTM5NDM3YWJlZjE0N2UzYjc5MjRiMGEvdGFibGVyYW5nZTo4YzMwNDcxMzBlMzk0MzdhYmVmMTQ3ZTNiNzkyNGIwYV8yLTUtMS0xLTA_28f96437-ac20-42b7-ae4e-a78a8d14b8e7">&#253;</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:2pt;margin-top:2pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331" format="ixt:booleantrue" name="dei:EntityExTransitionPeriod" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV83L2ZyYWc6MWI5OGM4ZWY5MDE1NGNhOTliMWYyMDUwMzI3ZTU1MjgvdGV4dHJlZ2lvbjoxYjk4YzhlZjkwMTU0Y2E5OWIxZjIwNTAzMjdlNTUyOF8xOTI0_d0942543-712f-4d6f-a804-5f9ebffe94ee">&#253;</ix:nonNumeric></span></div><div style="margin-bottom:2pt;margin-top:2pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Exchange Act). Yes&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331" format="ixt:booleanfalse" name="dei:EntityShellCompany" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV83L2ZyYWc6MWI5OGM4ZWY5MDE1NGNhOTliMWYyMDUwMzI3ZTU1MjgvdGV4dHJlZ2lvbjoxYjk4YzhlZjkwMTU0Y2E5OWIxZjIwNTAzMjdlNTUyOF8xOTI5_68077a8d-bb54-485f-99b0-a3cbbcd5f118">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;No&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#253;</span></div><div style="margin-bottom:2pt;margin-top:2pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of May&#160;7, 2021, the registrant had <ix:nonFraction unitRef="shares" contextRef="i1872bfbdd04e4f9e825f592f3b317647_I20210507" decimals="INF" format="ixt:numdotdecimal" name="dei:EntityCommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV83L2ZyYWc6MWI5OGM4ZWY5MDE1NGNhOTliMWYyMDUwMzI3ZTU1MjgvdGV4dHJlZ2lvbjoxYjk4YzhlZjkwMTU0Y2E5OWIxZjIwNTAzMjdlNTUyOF8xODU2_8366f897-e6d8-4915-924e-83633aa81d63">113,193,597</ix:nonFraction> shares of common stock, par value $0.0001 per share, outstanding.</span></div><div style="margin-bottom:5pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:18.783%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.783%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.783%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.783%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.368%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="height:32.4pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i71586e7d2e304f6983634abe9e071791_13"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:11pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.122%"><tr><td style="width:1.0%"></td><td style="width:7.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:81.053%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.045%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TABLE OF CONTENTS</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i71586e7d2e304f6983634abe9e071791_160">PART I. FINANCIAL INFORMATION</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i71586e7d2e304f6983634abe9e071791_22">Item 1.</a>&#160;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i71586e7d2e304f6983634abe9e071791_2743">Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i71586e7d2e304f6983634abe9e071791_2743">4</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i71586e7d2e304f6983634abe9e071791_175">Consolidated Balance Sheets as of March 31, 2021 (Unaudited) and December 31, 2020</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i71586e7d2e304f6983634abe9e071791_175">4</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i71586e7d2e304f6983634abe9e071791_178">Consolidated Statements of Operations and Comprehensive Loss for the Three Months ended March 31, 2021 and 2020 (Unaudited)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i71586e7d2e304f6983634abe9e071791_178">5</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i71586e7d2e304f6983634abe9e071791_181">Consolidated Statements of Changes in Stockhol</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i71586e7d2e304f6983634abe9e071791_181">ders</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i71586e7d2e304f6983634abe9e071791_181">&#8217;</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i71586e7d2e304f6983634abe9e071791_181"> (</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i71586e7d2e304f6983634abe9e071791_181">Deficit) Equity for the Three Months ended March 31, 2021 and 2020 (Unaudited)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i71586e7d2e304f6983634abe9e071791_181">6</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i71586e7d2e304f6983634abe9e071791_190">Consolidated Statements of Cash Flows for the Three Months ended March 31, 2021 and 2020 (Unaudited)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i71586e7d2e304f6983634abe9e071791_190">8</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i71586e7d2e304f6983634abe9e071791_193">Notes to Consolidated Financial Statements (Unaudited)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i71586e7d2e304f6983634abe9e071791_193">9</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 2.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i71586e7d2e304f6983634abe9e071791_97">Management's Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i71586e7d2e304f6983634abe9e071791_97">28</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 3.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i71586e7d2e304f6983634abe9e071791_124">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i71586e7d2e304f6983634abe9e071791_124">38</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 4.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i71586e7d2e304f6983634abe9e071791_136">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i71586e7d2e304f6983634abe9e071791_136">38</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i71586e7d2e304f6983634abe9e071791_19">PART II. OTHER INFORMATION</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1.&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i71586e7d2e304f6983634abe9e071791_280">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i71586e7d2e304f6983634abe9e071791_280">40</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1A.&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i71586e7d2e304f6983634abe9e071791_28">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i71586e7d2e304f6983634abe9e071791_28">40</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 2.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i71586e7d2e304f6983634abe9e071791_52">Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i71586e7d2e304f6983634abe9e071791_52">40</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 3.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i71586e7d2e304f6983634abe9e071791_55">Defaults Upon Senior Securities</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i71586e7d2e304f6983634abe9e071791_55">40</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 4.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i71586e7d2e304f6983634abe9e071791_58">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i71586e7d2e304f6983634abe9e071791_58">40</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 5.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i71586e7d2e304f6983634abe9e071791_61">Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i71586e7d2e304f6983634abe9e071791_61">40</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 6.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i71586e7d2e304f6983634abe9e071791_64">Exhibits</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i71586e7d2e304f6983634abe9e071791_64">41</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i71586e7d2e304f6983634abe9e071791_283">Signatures</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="i71586e7d2e304f6983634abe9e071791_16"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FORWARD-LOOKING STATEMENTS</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Quarterly Report on Form 10-Q, or the Quarterly Report, contains forward-looking statements. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section&#160;27A of the Securities Act of 1933, as amended, or the Securities Act, and Section&#160;21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act. All statements other than statements of historical facts contained in this Quarterly Report, including statements regarding our future results of operations and financial position, business strategy, prospective products, product approvals, research and development costs, timing and likelihood of success, the plans and objectives of management for future operations and future results of anticipated products,</span><span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the impact of the COVID-19 pandemic on our business and operations and our future financial results, and the period over which we estimate our existing cash and cash equivalents will be sufficient to fund our future operating expenses and capital expenditure requirements are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In some cases, you can identify forward-looking statements by terms such as &#8220;may,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;expect,&#8221; &#8220;plan,&#8221; &#8220;anticipate,&#8221; &#8220;could,&#8221; &#8220;intend,&#8221; &#8220;target,&#8221; &#8220;project,&#8221; &#8220;contemplate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;predict,&#8221; &#8220;potential&#8221;, or &#8220;continue&#8221; or the negative of these terms or other similar expressions. The forward-looking statements in this Quarterly Report are only predictions. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition and results of operations. These forward-looking statements speak only as of the date of this Quarterly Report and are subject to a number of important factors that could cause actual results to differ materially from those in the forward-looking statements, including the factors described under the sections in this Quarterly Report titled &#8220;Risk Factors&#8221; and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; as well as the following:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our status as a development-stage company and our expectation to incur losses in the future;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our future capital needs and our need to raise additional funds;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to build a pipeline of product candidates and develop and commercialize such pipeline;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our unproven approach to therapeutic intervention;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to enroll patients in clinical trials, timely and successfully complete those trials and receive necessary regulatory approvals;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to access manufacturing facilities and to receive or manufacture sufficient quantities of our product candidates;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to maintain our existing or future collaborations or licenses;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the continuing impact of the COVID-19 pandemic on our operations, the continuity of our business, including our preclinical studies and clinical trials, and general economic conditions;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to protect and enforce our intellectual property rights;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">federal, state, and foreign regulatory requirements, including FDA regulation of our product candidates;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to obtain and retain key executives and attract and retain qualified personnel;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">developments relating to our competitors and our industry, including the impact of government regulation; and</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to successfully manage our growth.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, we operate in an evolving environment. New risk factors and uncertainties may emerge from time to time, and it is not possible for management to predict all risk factors and uncertainties.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">You should read this Quarterly Report and the documents that we reference in this Quarterly Report completely and with the understanding that our actual future results may be materially different from what we expect. We qualify all of our forward-looking statements by these cautionary statements. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><div id="i71586e7d2e304f6983634abe9e071791_160"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i71586e7d2e304f6983634abe9e071791_13">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I.  FINANCIAL INFORMATION</span></div><div id="i71586e7d2e304f6983634abe9e071791_2743"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1. Financial Statements</span></div><div id="i71586e7d2e304f6983634abe9e071791_175"></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Selecta Biosciences, Inc. and Subsidiaries</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Consolidated Balance Sheets</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(Amounts in thousands, except share data and par value)</span></div><div style="margin-bottom:11pt;margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.976%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.498%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Unaudited)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied8d945ebce54ed8a4badfed477a64e8_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xNzUvZnJhZzphZTY3YTllM2U3MDU0YWUyYjgwMWE4OTVjNWFiMDE2MS90YWJsZTo3YjlhZGE2YTJiOWU0MmY2YTdkNTRkMDkyNmQwZGJhMC90YWJsZXJhbmdlOjdiOWFkYTZhMmI5ZTQyZjZhN2Q1NGQwOTI2ZDBkYmEwXzUtMS0xLTEtMA_8e15519f-ffbd-4c3f-89b9-a405b65d5aa6">125,407</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib56f1adc867e406ca7face50c5da1c9c_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xNzUvZnJhZzphZTY3YTllM2U3MDU0YWUyYjgwMWE4OTVjNWFiMDE2MS90YWJsZTo3YjlhZGE2YTJiOWU0MmY2YTdkNTRkMDkyNmQwZGJhMC90YWJsZXJhbmdlOjdiOWFkYTZhMmI5ZTQyZjZhN2Q1NGQwOTI2ZDBkYmEwXzUtMy0xLTEtMA_8e4b13c1-a86b-42c3-b6ae-4596edd08105">138,685</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied8d945ebce54ed8a4badfed477a64e8_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xNzUvZnJhZzphZTY3YTllM2U3MDU0YWUyYjgwMWE4OTVjNWFiMDE2MS90YWJsZTo3YjlhZGE2YTJiOWU0MmY2YTdkNTRkMDkyNmQwZGJhMC90YWJsZXJhbmdlOjdiOWFkYTZhMmI5ZTQyZjZhN2Q1NGQwOTI2ZDBkYmEwXzctMS0xLTEtMA_318d0a4f-e7fa-4b73-88c3-44dfd6dd4361">22,405</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib56f1adc867e406ca7face50c5da1c9c_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xNzUvZnJhZzphZTY3YTllM2U3MDU0YWUyYjgwMWE4OTVjNWFiMDE2MS90YWJsZTo3YjlhZGE2YTJiOWU0MmY2YTdkNTRkMDkyNmQwZGJhMC90YWJsZXJhbmdlOjdiOWFkYTZhMmI5ZTQyZjZhN2Q1NGQwOTI2ZDBkYmEwXzctMy0xLTEtMA_94f4a3d9-ad40-4cea-884a-410b29769eac">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied8d945ebce54ed8a4badfed477a64e8_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xNzUvZnJhZzphZTY3YTllM2U3MDU0YWUyYjgwMWE4OTVjNWFiMDE2MS90YWJsZTo3YjlhZGE2YTJiOWU0MmY2YTdkNTRkMDkyNmQwZGJhMC90YWJsZXJhbmdlOjdiOWFkYTZhMmI5ZTQyZjZhN2Q1NGQwOTI2ZDBkYmEwXzgtMS0xLTEtMA_7976461a-6db0-4b8c-a46e-7d96e5c75485">8,342</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib56f1adc867e406ca7face50c5da1c9c_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xNzUvZnJhZzphZTY3YTllM2U3MDU0YWUyYjgwMWE4OTVjNWFiMDE2MS90YWJsZTo3YjlhZGE2YTJiOWU0MmY2YTdkNTRkMDkyNmQwZGJhMC90YWJsZXJhbmdlOjdiOWFkYTZhMmI5ZTQyZjZhN2Q1NGQwOTI2ZDBkYmEwXzgtMy0xLTEtMA_73d57004-b9ea-4c02-a479-fd0154fdc532">7,224</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied8d945ebce54ed8a4badfed477a64e8_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xNzUvZnJhZzphZTY3YTllM2U3MDU0YWUyYjgwMWE4OTVjNWFiMDE2MS90YWJsZTo3YjlhZGE2YTJiOWU0MmY2YTdkNTRkMDkyNmQwZGJhMC90YWJsZXJhbmdlOjdiOWFkYTZhMmI5ZTQyZjZhN2Q1NGQwOTI2ZDBkYmEwXzktMS0xLTEtMA_a1c5849a-65be-4af6-84e9-df52418169a8">6,971</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib56f1adc867e406ca7face50c5da1c9c_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xNzUvZnJhZzphZTY3YTllM2U3MDU0YWUyYjgwMWE4OTVjNWFiMDE2MS90YWJsZTo3YjlhZGE2YTJiOWU0MmY2YTdkNTRkMDkyNmQwZGJhMC90YWJsZXJhbmdlOjdiOWFkYTZhMmI5ZTQyZjZhN2Q1NGQwOTI2ZDBkYmEwXzktMy0xLTEtMA_7967c533-6ba0-4263-814d-98a4c78759b0">5,434</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied8d945ebce54ed8a4badfed477a64e8_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xNzUvZnJhZzphZTY3YTllM2U3MDU0YWUyYjgwMWE4OTVjNWFiMDE2MS90YWJsZTo3YjlhZGE2YTJiOWU0MmY2YTdkNTRkMDkyNmQwZGJhMC90YWJsZXJhbmdlOjdiOWFkYTZhMmI5ZTQyZjZhN2Q1NGQwOTI2ZDBkYmEwXzEwLTEtMS0xLTA_322fa3d1-f1f9-478e-885a-50fa512760ef">163,125</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib56f1adc867e406ca7face50c5da1c9c_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xNzUvZnJhZzphZTY3YTllM2U3MDU0YWUyYjgwMWE4OTVjNWFiMDE2MS90YWJsZTo3YjlhZGE2YTJiOWU0MmY2YTdkNTRkMDkyNmQwZGJhMC90YWJsZXJhbmdlOjdiOWFkYTZhMmI5ZTQyZjZhN2Q1NGQwOTI2ZDBkYmEwXzEwLTMtMS0xLTA_846ba60a-1cd9-4e5b-b137-4991ce7fe011">151,343</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied8d945ebce54ed8a4badfed477a64e8_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xNzUvZnJhZzphZTY3YTllM2U3MDU0YWUyYjgwMWE4OTVjNWFiMDE2MS90YWJsZTo3YjlhZGE2YTJiOWU0MmY2YTdkNTRkMDkyNmQwZGJhMC90YWJsZXJhbmdlOjdiOWFkYTZhMmI5ZTQyZjZhN2Q1NGQwOTI2ZDBkYmEwXzExLTEtMS0xLTA_476e7140-f860-4b06-a0e7-d756163967c5">1,301</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib56f1adc867e406ca7face50c5da1c9c_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xNzUvZnJhZzphZTY3YTllM2U3MDU0YWUyYjgwMWE4OTVjNWFiMDE2MS90YWJsZTo3YjlhZGE2YTJiOWU0MmY2YTdkNTRkMDkyNmQwZGJhMC90YWJsZXJhbmdlOjdiOWFkYTZhMmI5ZTQyZjZhN2Q1NGQwOTI2ZDBkYmEwXzExLTMtMS0xLTA_4d89ea28-a9d4-41cf-8970-cd908fc6c4ab">1,395</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Right-of-use asset, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied8d945ebce54ed8a4badfed477a64e8_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xNzUvZnJhZzphZTY3YTllM2U3MDU0YWUyYjgwMWE4OTVjNWFiMDE2MS90YWJsZTo3YjlhZGE2YTJiOWU0MmY2YTdkNTRkMDkyNmQwZGJhMC90YWJsZXJhbmdlOjdiOWFkYTZhMmI5ZTQyZjZhN2Q1NGQwOTI2ZDBkYmEwXzEyLTEtMS0xLTA_ac32ab21-f367-4bab-9d6a-f8fd20b8d81f">10,676</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib56f1adc867e406ca7face50c5da1c9c_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xNzUvZnJhZzphZTY3YTllM2U3MDU0YWUyYjgwMWE4OTVjNWFiMDE2MS90YWJsZTo3YjlhZGE2YTJiOWU0MmY2YTdkNTRkMDkyNmQwZGJhMC90YWJsZXJhbmdlOjdiOWFkYTZhMmI5ZTQyZjZhN2Q1NGQwOTI2ZDBkYmEwXzEyLTMtMS0xLTA_327d6408-36b1-4ea6-997b-483ba61e89b1">10,948</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Long-term restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied8d945ebce54ed8a4badfed477a64e8_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xNzUvZnJhZzphZTY3YTllM2U3MDU0YWUyYjgwMWE4OTVjNWFiMDE2MS90YWJsZTo3YjlhZGE2YTJiOWU0MmY2YTdkNTRkMDkyNmQwZGJhMC90YWJsZXJhbmdlOjdiOWFkYTZhMmI5ZTQyZjZhN2Q1NGQwOTI2ZDBkYmEwXzEzLTEtMS0xLTA_7a616bf1-bda5-4d2d-ac0c-69c1c2ee2163">1,379</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib56f1adc867e406ca7face50c5da1c9c_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xNzUvZnJhZzphZTY3YTllM2U3MDU0YWUyYjgwMWE4OTVjNWFiMDE2MS90YWJsZTo3YjlhZGE2YTJiOWU0MmY2YTdkNTRkMDkyNmQwZGJhMC90YWJsZXJhbmdlOjdiOWFkYTZhMmI5ZTQyZjZhN2Q1NGQwOTI2ZDBkYmEwXzEzLTMtMS0xLTA_6280296a-9f95-48c5-ba95-784af756dbf8">1,379</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied8d945ebce54ed8a4badfed477a64e8_I20210331" decimals="-3" name="us-gaap:OtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xNzUvZnJhZzphZTY3YTllM2U3MDU0YWUyYjgwMWE4OTVjNWFiMDE2MS90YWJsZTo3YjlhZGE2YTJiOWU0MmY2YTdkNTRkMDkyNmQwZGJhMC90YWJsZXJhbmdlOjdiOWFkYTZhMmI5ZTQyZjZhN2Q1NGQwOTI2ZDBkYmEwXzE0LTEtMS0xLTA_fc598fa6-705e-4066-805e-0a8614921d4b">265</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib56f1adc867e406ca7face50c5da1c9c_I20201231" decimals="-3" name="us-gaap:OtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xNzUvZnJhZzphZTY3YTllM2U3MDU0YWUyYjgwMWE4OTVjNWFiMDE2MS90YWJsZTo3YjlhZGE2YTJiOWU0MmY2YTdkNTRkMDkyNmQwZGJhMC90YWJsZXJhbmdlOjdiOWFkYTZhMmI5ZTQyZjZhN2Q1NGQwOTI2ZDBkYmEwXzE0LTMtMS0xLTA_3b59f50e-6e31-415e-9441-ee5586a40d27">370</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied8d945ebce54ed8a4badfed477a64e8_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xNzUvZnJhZzphZTY3YTllM2U3MDU0YWUyYjgwMWE4OTVjNWFiMDE2MS90YWJsZTo3YjlhZGE2YTJiOWU0MmY2YTdkNTRkMDkyNmQwZGJhMC90YWJsZXJhbmdlOjdiOWFkYTZhMmI5ZTQyZjZhN2Q1NGQwOTI2ZDBkYmEwXzE1LTEtMS0xLTA_28c552f1-5cc3-46be-8602-294ad201b7d2">176,746</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib56f1adc867e406ca7face50c5da1c9c_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xNzUvZnJhZzphZTY3YTllM2U3MDU0YWUyYjgwMWE4OTVjNWFiMDE2MS90YWJsZTo3YjlhZGE2YTJiOWU0MmY2YTdkNTRkMDkyNmQwZGJhMC90YWJsZXJhbmdlOjdiOWFkYTZhMmI5ZTQyZjZhN2Q1NGQwOTI2ZDBkYmEwXzE1LTMtMS0xLTA_228c1ac2-1de2-4d4a-93f7-c9368780b74f">165,435</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Liabilities and stockholders&#8217; (deficit) equity </span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied8d945ebce54ed8a4badfed477a64e8_I20210331" decimals="-3" name="us-gaap:AccountsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xNzUvZnJhZzphZTY3YTllM2U3MDU0YWUyYjgwMWE4OTVjNWFiMDE2MS90YWJsZTo3YjlhZGE2YTJiOWU0MmY2YTdkNTRkMDkyNmQwZGJhMC90YWJsZXJhbmdlOjdiOWFkYTZhMmI5ZTQyZjZhN2Q1NGQwOTI2ZDBkYmEwXzE4LTEtMS0xLTA_63a1b39d-5708-4dfa-88d3-0f34136f1052">594</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib56f1adc867e406ca7face50c5da1c9c_I20201231" decimals="-3" name="us-gaap:AccountsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xNzUvZnJhZzphZTY3YTllM2U3MDU0YWUyYjgwMWE4OTVjNWFiMDE2MS90YWJsZTo3YjlhZGE2YTJiOWU0MmY2YTdkNTRkMDkyNmQwZGJhMC90YWJsZXJhbmdlOjdiOWFkYTZhMmI5ZTQyZjZhN2Q1NGQwOTI2ZDBkYmEwXzE4LTMtMS0xLTA_0bc43b87-a0e3-4f6d-bf23-897082575703">443</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied8d945ebce54ed8a4badfed477a64e8_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xNzUvZnJhZzphZTY3YTllM2U3MDU0YWUyYjgwMWE4OTVjNWFiMDE2MS90YWJsZTo3YjlhZGE2YTJiOWU0MmY2YTdkNTRkMDkyNmQwZGJhMC90YWJsZXJhbmdlOjdiOWFkYTZhMmI5ZTQyZjZhN2Q1NGQwOTI2ZDBkYmEwXzE5LTEtMS0xLTA_cf994152-b0f2-4986-af8c-90b6350a8f33">6,847</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib56f1adc867e406ca7face50c5da1c9c_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xNzUvZnJhZzphZTY3YTllM2U3MDU0YWUyYjgwMWE4OTVjNWFiMDE2MS90YWJsZTo3YjlhZGE2YTJiOWU0MmY2YTdkNTRkMDkyNmQwZGJhMC90YWJsZXJhbmdlOjdiOWFkYTZhMmI5ZTQyZjZhN2Q1NGQwOTI2ZDBkYmEwXzE5LTMtMS0xLTA_1db9b1a3-6dba-4584-99b1-346223733229">8,146</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loan payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied8d945ebce54ed8a4badfed477a64e8_I20210331" decimals="-3" name="us-gaap:LoansPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xNzUvZnJhZzphZTY3YTllM2U3MDU0YWUyYjgwMWE4OTVjNWFiMDE2MS90YWJsZTo3YjlhZGE2YTJiOWU0MmY2YTdkNTRkMDkyNmQwZGJhMC90YWJsZXJhbmdlOjdiOWFkYTZhMmI5ZTQyZjZhN2Q1NGQwOTI2ZDBkYmEwXzIwLTEtMS0xLTA_fd94f879-d5bf-4053-857c-73f747afd0cf">460</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib56f1adc867e406ca7face50c5da1c9c_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:LoansPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xNzUvZnJhZzphZTY3YTllM2U3MDU0YWUyYjgwMWE4OTVjNWFiMDE2MS90YWJsZTo3YjlhZGE2YTJiOWU0MmY2YTdkNTRkMDkyNmQwZGJhMC90YWJsZXJhbmdlOjdiOWFkYTZhMmI5ZTQyZjZhN2Q1NGQwOTI2ZDBkYmEwXzIwLTMtMS0xLTA_b6db9750-e539-4d27-a996-ca3d70885a02">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Lease liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied8d945ebce54ed8a4badfed477a64e8_I20210331" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xNzUvZnJhZzphZTY3YTllM2U3MDU0YWUyYjgwMWE4OTVjNWFiMDE2MS90YWJsZTo3YjlhZGE2YTJiOWU0MmY2YTdkNTRkMDkyNmQwZGJhMC90YWJsZXJhbmdlOjdiOWFkYTZhMmI5ZTQyZjZhN2Q1NGQwOTI2ZDBkYmEwXzIxLTEtMS0xLTA_d7356727-a0fe-42ad-a93d-c6834ecbdd8c">942</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib56f1adc867e406ca7face50c5da1c9c_I20201231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xNzUvZnJhZzphZTY3YTllM2U3MDU0YWUyYjgwMWE4OTVjNWFiMDE2MS90YWJsZTo3YjlhZGE2YTJiOWU0MmY2YTdkNTRkMDkyNmQwZGJhMC90YWJsZXJhbmdlOjdiOWFkYTZhMmI5ZTQyZjZhN2Q1NGQwOTI2ZDBkYmEwXzIxLTMtMS0xLTA_f57d6836-9cee-40cc-b33b-bf89c7d70c73">908</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied8d945ebce54ed8a4badfed477a64e8_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xNzUvZnJhZzphZTY3YTllM2U3MDU0YWUyYjgwMWE4OTVjNWFiMDE2MS90YWJsZTo3YjlhZGE2YTJiOWU0MmY2YTdkNTRkMDkyNmQwZGJhMC90YWJsZXJhbmdlOjdiOWFkYTZhMmI5ZTQyZjZhN2Q1NGQwOTI2ZDBkYmEwXzIzLTEtMS0xLTA_a3f6ab3d-db5c-4fed-8a05-9608b03d19ce">75,764</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib56f1adc867e406ca7face50c5da1c9c_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xNzUvZnJhZzphZTY3YTllM2U3MDU0YWUyYjgwMWE4OTVjNWFiMDE2MS90YWJsZTo3YjlhZGE2YTJiOWU0MmY2YTdkNTRkMDkyNmQwZGJhMC90YWJsZXJhbmdlOjdiOWFkYTZhMmI5ZTQyZjZhN2Q1NGQwOTI2ZDBkYmEwXzIzLTMtMS0xLTA_aa679167-cdef-4700-bc82-3eddd2e6b922">72,050</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied8d945ebce54ed8a4badfed477a64e8_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xNzUvZnJhZzphZTY3YTllM2U3MDU0YWUyYjgwMWE4OTVjNWFiMDE2MS90YWJsZTo3YjlhZGE2YTJiOWU0MmY2YTdkNTRkMDkyNmQwZGJhMC90YWJsZXJhbmdlOjdiOWFkYTZhMmI5ZTQyZjZhN2Q1NGQwOTI2ZDBkYmEwXzI1LTEtMS0xLTA_dfa454b9-8035-4f4e-aab1-b17e7ef26ee6">84,607</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib56f1adc867e406ca7face50c5da1c9c_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xNzUvZnJhZzphZTY3YTllM2U3MDU0YWUyYjgwMWE4OTVjNWFiMDE2MS90YWJsZTo3YjlhZGE2YTJiOWU0MmY2YTdkNTRkMDkyNmQwZGJhMC90YWJsZXJhbmdlOjdiOWFkYTZhMmI5ZTQyZjZhN2Q1NGQwOTI2ZDBkYmEwXzI1LTMtMS0xLTA_c0b2b43b-6234-4363-84a1-4111753c1bb7">81,547</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Non-current liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loan payable, net of current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied8d945ebce54ed8a4badfed477a64e8_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermLoansPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xNzUvZnJhZzphZTY3YTllM2U3MDU0YWUyYjgwMWE4OTVjNWFiMDE2MS90YWJsZTo3YjlhZGE2YTJiOWU0MmY2YTdkNTRkMDkyNmQwZGJhMC90YWJsZXJhbmdlOjdiOWFkYTZhMmI5ZTQyZjZhN2Q1NGQwOTI2ZDBkYmEwXzI4LTEtMS0xLTA_e685381e-ff32-45bb-bf86-6de8e38f659c">24,551</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib56f1adc867e406ca7face50c5da1c9c_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermLoansPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xNzUvZnJhZzphZTY3YTllM2U3MDU0YWUyYjgwMWE4OTVjNWFiMDE2MS90YWJsZTo3YjlhZGE2YTJiOWU0MmY2YTdkNTRkMDkyNmQwZGJhMC90YWJsZXJhbmdlOjdiOWFkYTZhMmI5ZTQyZjZhN2Q1NGQwOTI2ZDBkYmEwXzI4LTMtMS0xLTA_15145e40-1512-4bfe-b6dc-9ef9bb2be89e">24,793</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Lease liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied8d945ebce54ed8a4badfed477a64e8_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xNzUvZnJhZzphZTY3YTllM2U3MDU0YWUyYjgwMWE4OTVjNWFiMDE2MS90YWJsZTo3YjlhZGE2YTJiOWU0MmY2YTdkNTRkMDkyNmQwZGJhMC90YWJsZXJhbmdlOjdiOWFkYTZhMmI5ZTQyZjZhN2Q1NGQwOTI2ZDBkYmEwXzI5LTEtMS0xLTA_c0984b47-fd99-4275-ba6e-7a628eeb801c">9,403</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib56f1adc867e406ca7face50c5da1c9c_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xNzUvZnJhZzphZTY3YTllM2U3MDU0YWUyYjgwMWE4OTVjNWFiMDE2MS90YWJsZTo3YjlhZGE2YTJiOWU0MmY2YTdkNTRkMDkyNmQwZGJhMC90YWJsZXJhbmdlOjdiOWFkYTZhMmI5ZTQyZjZhN2Q1NGQwOTI2ZDBkYmEwXzI5LTMtMS0xLTA_d6296eac-5f4c-4412-b967-22c5bff29462">9,647</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied8d945ebce54ed8a4badfed477a64e8_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xNzUvZnJhZzphZTY3YTllM2U3MDU0YWUyYjgwMWE4OTVjNWFiMDE2MS90YWJsZTo3YjlhZGE2YTJiOWU0MmY2YTdkNTRkMDkyNmQwZGJhMC90YWJsZXJhbmdlOjdiOWFkYTZhMmI5ZTQyZjZhN2Q1NGQwOTI2ZDBkYmEwXzMwLTEtMS0xLTA_81f5fc9f-f9c0-4de4-a38c-f42be7c444a7">32,301</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib56f1adc867e406ca7face50c5da1c9c_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xNzUvZnJhZzphZTY3YTllM2U3MDU0YWUyYjgwMWE4OTVjNWFiMDE2MS90YWJsZTo3YjlhZGE2YTJiOWU0MmY2YTdkNTRkMDkyNmQwZGJhMC90YWJsZXJhbmdlOjdiOWFkYTZhMmI5ZTQyZjZhN2Q1NGQwOTI2ZDBkYmEwXzMwLTMtMS0xLTA_8c41c8d0-e34e-4525-8a3d-7e6102258558">38,746</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Warrant liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied8d945ebce54ed8a4badfed477a64e8_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WarrantsAndRightsOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xNzUvZnJhZzphZTY3YTllM2U3MDU0YWUyYjgwMWE4OTVjNWFiMDE2MS90YWJsZTo3YjlhZGE2YTJiOWU0MmY2YTdkNTRkMDkyNmQwZGJhMC90YWJsZXJhbmdlOjdiOWFkYTZhMmI5ZTQyZjZhN2Q1NGQwOTI2ZDBkYmEwXzMxLTEtMS0xLTA_1512a17c-d360-490f-a9c9-a25650fd9717">45,455</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib56f1adc867e406ca7face50c5da1c9c_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WarrantsAndRightsOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xNzUvZnJhZzphZTY3YTllM2U3MDU0YWUyYjgwMWE4OTVjNWFiMDE2MS90YWJsZTo3YjlhZGE2YTJiOWU0MmY2YTdkNTRkMDkyNmQwZGJhMC90YWJsZXJhbmdlOjdiOWFkYTZhMmI5ZTQyZjZhN2Q1NGQwOTI2ZDBkYmEwXzMxLTMtMS0xLTA_213a8edd-2197-4cb8-b152-b9d7ed1dbe57">28,708</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied8d945ebce54ed8a4badfed477a64e8_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xNzUvZnJhZzphZTY3YTllM2U3MDU0YWUyYjgwMWE4OTVjNWFiMDE2MS90YWJsZTo3YjlhZGE2YTJiOWU0MmY2YTdkNTRkMDkyNmQwZGJhMC90YWJsZXJhbmdlOjdiOWFkYTZhMmI5ZTQyZjZhN2Q1NGQwOTI2ZDBkYmEwXzMzLTEtMS0xLTA_830c92b0-9c56-45df-af58-9433a175a5c6">196,317</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib56f1adc867e406ca7face50c5da1c9c_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xNzUvZnJhZzphZTY3YTllM2U3MDU0YWUyYjgwMWE4OTVjNWFiMDE2MS90YWJsZTo3YjlhZGE2YTJiOWU0MmY2YTdkNTRkMDkyNmQwZGJhMC90YWJsZXJhbmdlOjdiOWFkYTZhMmI5ZTQyZjZhN2Q1NGQwOTI2ZDBkYmEwXzMzLTMtMS0xLTA_fe7d169f-3637-4184-88a9-48d039ef085e">183,441</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Commitments and contingencies (Note&#160;17)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="ied8d945ebce54ed8a4badfed477a64e8_I20210331" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xNzUvZnJhZzphZTY3YTllM2U3MDU0YWUyYjgwMWE4OTVjNWFiMDE2MS90YWJsZTo3YjlhZGE2YTJiOWU0MmY2YTdkNTRkMDkyNmQwZGJhMC90YWJsZXJhbmdlOjdiOWFkYTZhMmI5ZTQyZjZhN2Q1NGQwOTI2ZDBkYmEwXzM0LTEtMS0xLTA_a5f958eb-e682-42f6-979d-424894b29f44"></ix:nonFraction></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="ib56f1adc867e406ca7face50c5da1c9c_I20201231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xNzUvZnJhZzphZTY3YTllM2U3MDU0YWUyYjgwMWE4OTVjNWFiMDE2MS90YWJsZTo3YjlhZGE2YTJiOWU0MmY2YTdkNTRkMDkyNmQwZGJhMC90YWJsZXJhbmdlOjdiOWFkYTZhMmI5ZTQyZjZhN2Q1NGQwOTI2ZDBkYmEwXzM0LTMtMS0xLTA_6dfe56cf-de23-49f0-8b9d-b8ea63d04609"></ix:nonFraction></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Stockholders&#8217; (deficit) equity:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="ied8d945ebce54ed8a4badfed477a64e8_I20210331" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xNzUvZnJhZzphZTY3YTllM2U3MDU0YWUyYjgwMWE4OTVjNWFiMDE2MS90YWJsZTo3YjlhZGE2YTJiOWU0MmY2YTdkNTRkMDkyNmQwZGJhMC90YWJsZXJhbmdlOjdiOWFkYTZhMmI5ZTQyZjZhN2Q1NGQwOTI2ZDBkYmEwXzQ0LTAtMS0xLTAvdGV4dHJlZ2lvbjoxNWI5MDVlN2Y0MTA0NmVjYTk1MjBmZDQ2Y2NiNjc1YV8yMQ_27959425-ab91-4a64-ba5d-2c5e1723070d"><ix:nonFraction unitRef="usdPerShare" contextRef="ib56f1adc867e406ca7face50c5da1c9c_I20201231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xNzUvZnJhZzphZTY3YTllM2U3MDU0YWUyYjgwMWE4OTVjNWFiMDE2MS90YWJsZTo3YjlhZGE2YTJiOWU0MmY2YTdkNTRkMDkyNmQwZGJhMC90YWJsZXJhbmdlOjdiOWFkYTZhMmI5ZTQyZjZhN2Q1NGQwOTI2ZDBkYmEwXzQ0LTAtMS0xLTAvdGV4dHJlZ2lvbjoxNWI5MDVlN2Y0MTA0NmVjYTk1MjBmZDQ2Y2NiNjc1YV8yMQ_338ce2e8-e456-4ee9-ae04-668ba1ef9b42">0.0001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="ib56f1adc867e406ca7face50c5da1c9c_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xNzUvZnJhZzphZTY3YTllM2U3MDU0YWUyYjgwMWE4OTVjNWFiMDE2MS90YWJsZTo3YjlhZGE2YTJiOWU0MmY2YTdkNTRkMDkyNmQwZGJhMC90YWJsZXJhbmdlOjdiOWFkYTZhMmI5ZTQyZjZhN2Q1NGQwOTI2ZDBkYmEwXzQ0LTAtMS0xLTAvdGV4dHJlZ2lvbjoxNWI5MDVlN2Y0MTA0NmVjYTk1MjBmZDQ2Y2NiNjc1YV8zNQ_5f258925-e20a-4b2b-8bf1-0eb35651bd9a"><ix:nonFraction unitRef="shares" contextRef="ied8d945ebce54ed8a4badfed477a64e8_I20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xNzUvZnJhZzphZTY3YTllM2U3MDU0YWUyYjgwMWE4OTVjNWFiMDE2MS90YWJsZTo3YjlhZGE2YTJiOWU0MmY2YTdkNTRkMDkyNmQwZGJhMC90YWJsZXJhbmdlOjdiOWFkYTZhMmI5ZTQyZjZhN2Q1NGQwOTI2ZDBkYmEwXzQ0LTAtMS0xLTAvdGV4dHJlZ2lvbjoxNWI5MDVlN2Y0MTA0NmVjYTk1MjBmZDQ2Y2NiNjc1YV8zNQ_8779e9ee-d5c0-4985-88df-5e8ab8dcfee2">10,000,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="ib56f1adc867e406ca7face50c5da1c9c_I20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xNzUvZnJhZzphZTY3YTllM2U3MDU0YWUyYjgwMWE4OTVjNWFiMDE2MS90YWJsZTo3YjlhZGE2YTJiOWU0MmY2YTdkNTRkMDkyNmQwZGJhMC90YWJsZXJhbmdlOjdiOWFkYTZhMmI5ZTQyZjZhN2Q1NGQwOTI2ZDBkYmEwXzQ0LTAtMS0xLTAvdGV4dHJlZ2lvbjoxNWI5MDVlN2Y0MTA0NmVjYTk1MjBmZDQ2Y2NiNjc1YV81Nw_06711002-7177-49f9-9d23-89454ed11628"><ix:nonFraction unitRef="shares" contextRef="ied8d945ebce54ed8a4badfed477a64e8_I20210331" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xNzUvZnJhZzphZTY3YTllM2U3MDU0YWUyYjgwMWE4OTVjNWFiMDE2MS90YWJsZTo3YjlhZGE2YTJiOWU0MmY2YTdkNTRkMDkyNmQwZGJhMC90YWJsZXJhbmdlOjdiOWFkYTZhMmI5ZTQyZjZhN2Q1NGQwOTI2ZDBkYmEwXzQ0LTAtMS0xLTAvdGV4dHJlZ2lvbjoxNWI5MDVlN2Y0MTA0NmVjYTk1MjBmZDQ2Y2NiNjc1YV81Nw_533482d6-aeda-4ed3-a780-16ebc593e036"><ix:nonFraction unitRef="shares" contextRef="ib56f1adc867e406ca7face50c5da1c9c_I20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xNzUvZnJhZzphZTY3YTllM2U3MDU0YWUyYjgwMWE4OTVjNWFiMDE2MS90YWJsZTo3YjlhZGE2YTJiOWU0MmY2YTdkNTRkMDkyNmQwZGJhMC90YWJsZXJhbmdlOjdiOWFkYTZhMmI5ZTQyZjZhN2Q1NGQwOTI2ZDBkYmEwXzQ0LTAtMS0xLTAvdGV4dHJlZ2lvbjoxNWI5MDVlN2Y0MTA0NmVjYTk1MjBmZDQ2Y2NiNjc1YV81Nw_7749a829-14bc-4889-86b7-ff5f13366046"><ix:nonFraction unitRef="shares" contextRef="ied8d945ebce54ed8a4badfed477a64e8_I20210331" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xNzUvZnJhZzphZTY3YTllM2U3MDU0YWUyYjgwMWE4OTVjNWFiMDE2MS90YWJsZTo3YjlhZGE2YTJiOWU0MmY2YTdkNTRkMDkyNmQwZGJhMC90YWJsZXJhbmdlOjdiOWFkYTZhMmI5ZTQyZjZhN2Q1NGQwOTI2ZDBkYmEwXzQ0LTAtMS0xLTAvdGV4dHJlZ2lvbjoxNWI5MDVlN2Y0MTA0NmVjYTk1MjBmZDQ2Y2NiNjc1YV81Nw_a0eda247-6af2-4e5d-8217-7ff945f1dda7">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares issued and outstanding at March 31, 2021 and December 31, 2020</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied8d945ebce54ed8a4badfed477a64e8_I20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:PreferredStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xNzUvZnJhZzphZTY3YTllM2U3MDU0YWUyYjgwMWE4OTVjNWFiMDE2MS90YWJsZTo3YjlhZGE2YTJiOWU0MmY2YTdkNTRkMDkyNmQwZGJhMC90YWJsZXJhbmdlOjdiOWFkYTZhMmI5ZTQyZjZhN2Q1NGQwOTI2ZDBkYmEwXzQ0LTEtMS0xLTA_24e1ad52-11cd-4820-90ce-1d3aca45313c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib56f1adc867e406ca7face50c5da1c9c_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:PreferredStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xNzUvZnJhZzphZTY3YTllM2U3MDU0YWUyYjgwMWE4OTVjNWFiMDE2MS90YWJsZTo3YjlhZGE2YTJiOWU0MmY2YTdkNTRkMDkyNmQwZGJhMC90YWJsZXJhbmdlOjdiOWFkYTZhMmI5ZTQyZjZhN2Q1NGQwOTI2ZDBkYmEwXzQ0LTMtMS0xLTA_82d466f9-c93e-4521-82cd-4511591a04ff">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="ied8d945ebce54ed8a4badfed477a64e8_I20210331" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xNzUvZnJhZzphZTY3YTllM2U3MDU0YWUyYjgwMWE4OTVjNWFiMDE2MS90YWJsZTo3YjlhZGE2YTJiOWU0MmY2YTdkNTRkMDkyNmQwZGJhMC90YWJsZXJhbmdlOjdiOWFkYTZhMmI5ZTQyZjZhN2Q1NGQwOTI2ZDBkYmEwXzQ1LTAtMS0xLTAvdGV4dHJlZ2lvbjplMmM4NDUzZmZkNjc0OTEyODRhY2VhY2IxYTFlNzc5M18xOA_5db441d8-12bd-4126-b86f-f89f28d1a83c"><ix:nonFraction unitRef="usdPerShare" contextRef="ib56f1adc867e406ca7face50c5da1c9c_I20201231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xNzUvZnJhZzphZTY3YTllM2U3MDU0YWUyYjgwMWE4OTVjNWFiMDE2MS90YWJsZTo3YjlhZGE2YTJiOWU0MmY2YTdkNTRkMDkyNmQwZGJhMC90YWJsZXJhbmdlOjdiOWFkYTZhMmI5ZTQyZjZhN2Q1NGQwOTI2ZDBkYmEwXzQ1LTAtMS0xLTAvdGV4dHJlZ2lvbjplMmM4NDUzZmZkNjc0OTEyODRhY2VhY2IxYTFlNzc5M18xOA_6f90032c-6946-4e04-9504-961733883487">0.0001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="ied8d945ebce54ed8a4badfed477a64e8_I20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xNzUvZnJhZzphZTY3YTllM2U3MDU0YWUyYjgwMWE4OTVjNWFiMDE2MS90YWJsZTo3YjlhZGE2YTJiOWU0MmY2YTdkNTRkMDkyNmQwZGJhMC90YWJsZXJhbmdlOjdiOWFkYTZhMmI5ZTQyZjZhN2Q1NGQwOTI2ZDBkYmEwXzQ1LTAtMS0xLTAvdGV4dHJlZ2lvbjplMmM4NDUzZmZkNjc0OTEyODRhY2VhY2IxYTFlNzc5M18zMg_3896173a-2869-4fb7-bf3d-6c069b79ce68"><ix:nonFraction unitRef="shares" contextRef="ib56f1adc867e406ca7face50c5da1c9c_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xNzUvZnJhZzphZTY3YTllM2U3MDU0YWUyYjgwMWE4OTVjNWFiMDE2MS90YWJsZTo3YjlhZGE2YTJiOWU0MmY2YTdkNTRkMDkyNmQwZGJhMC90YWJsZXJhbmdlOjdiOWFkYTZhMmI5ZTQyZjZhN2Q1NGQwOTI2ZDBkYmEwXzQ1LTAtMS0xLTAvdGV4dHJlZ2lvbjplMmM4NDUzZmZkNjc0OTEyODRhY2VhY2IxYTFlNzc5M18zMg_72cc4a7a-b16d-4ba2-bf4f-c00ffcdd0d3a">200,000,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="ied8d945ebce54ed8a4badfed477a64e8_I20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xNzUvZnJhZzphZTY3YTllM2U3MDU0YWUyYjgwMWE4OTVjNWFiMDE2MS90YWJsZTo3YjlhZGE2YTJiOWU0MmY2YTdkNTRkMDkyNmQwZGJhMC90YWJsZXJhbmdlOjdiOWFkYTZhMmI5ZTQyZjZhN2Q1NGQwOTI2ZDBkYmEwXzQ1LTAtMS0xLTAvdGV4dHJlZ2lvbjplMmM4NDUzZmZkNjc0OTEyODRhY2VhY2IxYTFlNzc5M181NA_5e6b63be-c555-4ad9-bc86-b7fe92344e54"><ix:nonFraction unitRef="shares" contextRef="ied8d945ebce54ed8a4badfed477a64e8_I20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xNzUvZnJhZzphZTY3YTllM2U3MDU0YWUyYjgwMWE4OTVjNWFiMDE2MS90YWJsZTo3YjlhZGE2YTJiOWU0MmY2YTdkNTRkMDkyNmQwZGJhMC90YWJsZXJhbmdlOjdiOWFkYTZhMmI5ZTQyZjZhN2Q1NGQwOTI2ZDBkYmEwXzQ1LTAtMS0xLTAvdGV4dHJlZ2lvbjplMmM4NDUzZmZkNjc0OTEyODRhY2VhY2IxYTFlNzc5M181NA_de115b88-a39b-41d7-9371-d387957d29f6">112,977,004</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="ib56f1adc867e406ca7face50c5da1c9c_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xNzUvZnJhZzphZTY3YTllM2U3MDU0YWUyYjgwMWE4OTVjNWFiMDE2MS90YWJsZTo3YjlhZGE2YTJiOWU0MmY2YTdkNTRkMDkyNmQwZGJhMC90YWJsZXJhbmdlOjdiOWFkYTZhMmI5ZTQyZjZhN2Q1NGQwOTI2ZDBkYmEwXzQ1LTAtMS0xLTAvdGV4dHJlZ2lvbjplMmM4NDUzZmZkNjc0OTEyODRhY2VhY2IxYTFlNzc5M182MQ_4c37d477-64e4-455b-a83e-098906424296"><ix:nonFraction unitRef="shares" contextRef="ib56f1adc867e406ca7face50c5da1c9c_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xNzUvZnJhZzphZTY3YTllM2U3MDU0YWUyYjgwMWE4OTVjNWFiMDE2MS90YWJsZTo3YjlhZGE2YTJiOWU0MmY2YTdkNTRkMDkyNmQwZGJhMC90YWJsZXJhbmdlOjdiOWFkYTZhMmI5ZTQyZjZhN2Q1NGQwOTI2ZDBkYmEwXzQ1LTAtMS0xLTAvdGV4dHJlZ2lvbjplMmM4NDUzZmZkNjc0OTEyODRhY2VhY2IxYTFlNzc5M182MQ_96eb7073-a29c-403a-bbc2-5156baf71d83">108,071,249</ix:nonFraction></ix:nonFraction> shares issued and outstanding as of March 31, 2021 and December 31, 2020, respectively</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied8d945ebce54ed8a4badfed477a64e8_I20210331" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xNzUvZnJhZzphZTY3YTllM2U3MDU0YWUyYjgwMWE4OTVjNWFiMDE2MS90YWJsZTo3YjlhZGE2YTJiOWU0MmY2YTdkNTRkMDkyNmQwZGJhMC90YWJsZXJhbmdlOjdiOWFkYTZhMmI5ZTQyZjZhN2Q1NGQwOTI2ZDBkYmEwXzQ1LTEtMS0xLTA_70f7ece3-ea61-47fe-b8fa-dd7e9adf4a74">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib56f1adc867e406ca7face50c5da1c9c_I20201231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xNzUvZnJhZzphZTY3YTllM2U3MDU0YWUyYjgwMWE4OTVjNWFiMDE2MS90YWJsZTo3YjlhZGE2YTJiOWU0MmY2YTdkNTRkMDkyNmQwZGJhMC90YWJsZXJhbmdlOjdiOWFkYTZhMmI5ZTQyZjZhN2Q1NGQwOTI2ZDBkYmEwXzQ1LTMtMS0xLTA_a5645f68-6c6c-479e-9bec-be97e8695f57">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied8d945ebce54ed8a4badfed477a64e8_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xNzUvZnJhZzphZTY3YTllM2U3MDU0YWUyYjgwMWE4OTVjNWFiMDE2MS90YWJsZTo3YjlhZGE2YTJiOWU0MmY2YTdkNTRkMDkyNmQwZGJhMC90YWJsZXJhbmdlOjdiOWFkYTZhMmI5ZTQyZjZhN2Q1NGQwOTI2ZDBkYmEwXzQ2LTEtMS0xLTA_06773f84-85ce-438d-a651-bbd114bedc0f">414,214</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib56f1adc867e406ca7face50c5da1c9c_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xNzUvZnJhZzphZTY3YTllM2U3MDU0YWUyYjgwMWE4OTVjNWFiMDE2MS90YWJsZTo3YjlhZGE2YTJiOWU0MmY2YTdkNTRkMDkyNmQwZGJhMC90YWJsZXJhbmdlOjdiOWFkYTZhMmI5ZTQyZjZhN2Q1NGQwOTI2ZDBkYmEwXzQ2LTMtMS0xLTA_6a65928a-5107-4394-91b1-854891cf38be">391,175</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ied8d945ebce54ed8a4badfed477a64e8_I20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xNzUvZnJhZzphZTY3YTllM2U3MDU0YWUyYjgwMWE4OTVjNWFiMDE2MS90YWJsZTo3YjlhZGE2YTJiOWU0MmY2YTdkNTRkMDkyNmQwZGJhMC90YWJsZXJhbmdlOjdiOWFkYTZhMmI5ZTQyZjZhN2Q1NGQwOTI2ZDBkYmEwXzQ4LTEtMS0xLTA_4a0edd6d-3986-489d-81af-5203b219d683">429,226</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib56f1adc867e406ca7face50c5da1c9c_I20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xNzUvZnJhZzphZTY3YTllM2U3MDU0YWUyYjgwMWE4OTVjNWFiMDE2MS90YWJsZTo3YjlhZGE2YTJiOWU0MmY2YTdkNTRkMDkyNmQwZGJhMC90YWJsZXJhbmdlOjdiOWFkYTZhMmI5ZTQyZjZhN2Q1NGQwOTI2ZDBkYmEwXzQ4LTMtMS0xLTA_246d3f93-6a49-43e6-9673-38257c22b280">404,629</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ied8d945ebce54ed8a4badfed477a64e8_I20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xNzUvZnJhZzphZTY3YTllM2U3MDU0YWUyYjgwMWE4OTVjNWFiMDE2MS90YWJsZTo3YjlhZGE2YTJiOWU0MmY2YTdkNTRkMDkyNmQwZGJhMC90YWJsZXJhbmdlOjdiOWFkYTZhMmI5ZTQyZjZhN2Q1NGQwOTI2ZDBkYmEwXzQ5LTEtMS0xLTA_81ff1386-5a2b-475a-bb4a-1dfad81b4a8e">4,570</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib56f1adc867e406ca7face50c5da1c9c_I20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xNzUvZnJhZzphZTY3YTllM2U3MDU0YWUyYjgwMWE4OTVjNWFiMDE2MS90YWJsZTo3YjlhZGE2YTJiOWU0MmY2YTdkNTRkMDkyNmQwZGJhMC90YWJsZXJhbmdlOjdiOWFkYTZhMmI5ZTQyZjZhN2Q1NGQwOTI2ZDBkYmEwXzQ5LTMtMS0xLTA_ab503fea-0048-474c-ac45-33415ad6e8b0">4,563</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total stockholders&#8217; (deficit) equity </span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ied8d945ebce54ed8a4badfed477a64e8_I20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xNzUvZnJhZzphZTY3YTllM2U3MDU0YWUyYjgwMWE4OTVjNWFiMDE2MS90YWJsZTo3YjlhZGE2YTJiOWU0MmY2YTdkNTRkMDkyNmQwZGJhMC90YWJsZXJhbmdlOjdiOWFkYTZhMmI5ZTQyZjZhN2Q1NGQwOTI2ZDBkYmEwXzUwLTEtMS0xLTA_c2a3ed6a-8f21-4d84-b27a-6bcc8f9b1696">19,571</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib56f1adc867e406ca7face50c5da1c9c_I20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xNzUvZnJhZzphZTY3YTllM2U3MDU0YWUyYjgwMWE4OTVjNWFiMDE2MS90YWJsZTo3YjlhZGE2YTJiOWU0MmY2YTdkNTRkMDkyNmQwZGJhMC90YWJsZXJhbmdlOjdiOWFkYTZhMmI5ZTQyZjZhN2Q1NGQwOTI2ZDBkYmEwXzUwLTMtMS0xLTA_1d12a624-e1ef-44f5-aaec-b3e7e5dcaa1c">18,006</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total liabilities and stockholders&#8217; (deficit) equity </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied8d945ebce54ed8a4badfed477a64e8_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xNzUvZnJhZzphZTY3YTllM2U3MDU0YWUyYjgwMWE4OTVjNWFiMDE2MS90YWJsZTo3YjlhZGE2YTJiOWU0MmY2YTdkNTRkMDkyNmQwZGJhMC90YWJsZXJhbmdlOjdiOWFkYTZhMmI5ZTQyZjZhN2Q1NGQwOTI2ZDBkYmEwXzUxLTEtMS0xLTA_7193f4b9-d61d-4277-93b9-5aaf52e89865">176,746</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib56f1adc867e406ca7face50c5da1c9c_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xNzUvZnJhZzphZTY3YTllM2U3MDU0YWUyYjgwMWE4OTVjNWFiMDE2MS90YWJsZTo3YjlhZGE2YTJiOWU0MmY2YTdkNTRkMDkyNmQwZGJhMC90YWJsZXJhbmdlOjdiOWFkYTZhMmI5ZTQyZjZhN2Q1NGQwOTI2ZDBkYmEwXzUxLTMtMS0xLTA_080d1637-37e4-4bce-9c15-8b875fe34580">165,435</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these unaudited consolidated financial statements.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><div id="i71586e7d2e304f6983634abe9e071791_178"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i71586e7d2e304f6983634abe9e071791_13">Table of Contents</a></span></div></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Selecta Biosciences,&#160;Inc. and Subsidiaries</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Consolidated Statements of Operations and Comprehensive Loss</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(Amounts in thousands, except share and per share data)</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:11pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.976%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.498%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="9" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Unaudited)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Grant and collaboration revenue</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xNzgvZnJhZzo2YzY1MGFkMjA1Njc0OTZlYTM1YzNkY2E1MTRlMGRlNC90YWJsZTo0ZGFlNzk5OWM5MDc0ZDI2YWJhZDRhYWVmZDI4NzM0NC90YWJsZXJhbmdlOjRkYWU3OTk5YzkwNzRkMjZhYmFkNGFhZWZkMjg3MzQ0XzMtMS0xLTEtMA_021e322a-3d20-4772-8cf0-4998a03924f2">11,050</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i824a5b33f908426bad016f0eded844db_D20200101-20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xNzgvZnJhZzo2YzY1MGFkMjA1Njc0OTZlYTM1YzNkY2E1MTRlMGRlNC90YWJsZTo0ZGFlNzk5OWM5MDc0ZDI2YWJhZDRhYWVmZDI4NzM0NC90YWJsZXJhbmdlOjRkYWU3OTk5YzkwNzRkMjZhYmFkNGFhZWZkMjg3MzQ0XzMtMy0xLTEtMA_ce552572-e0a0-4dae-b70a-dac0db7c4d0c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xNzgvZnJhZzo2YzY1MGFkMjA1Njc0OTZlYTM1YzNkY2E1MTRlMGRlNC90YWJsZTo0ZGFlNzk5OWM5MDc0ZDI2YWJhZDRhYWVmZDI4NzM0NC90YWJsZXJhbmdlOjRkYWU3OTk5YzkwNzRkMjZhYmFkNGFhZWZkMjg3MzQ0XzUtMS0xLTEtMA_83a0d1f0-8464-41dc-acd0-f35f90552305">13,004</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i824a5b33f908426bad016f0eded844db_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xNzgvZnJhZzo2YzY1MGFkMjA1Njc0OTZlYTM1YzNkY2E1MTRlMGRlNC90YWJsZTo0ZGFlNzk5OWM5MDc0ZDI2YWJhZDRhYWVmZDI4NzM0NC90YWJsZXJhbmdlOjRkYWU3OTk5YzkwNzRkMjZhYmFkNGFhZWZkMjg3MzQ0XzUtMy0xLTEtMA_a0fcd936-3997-4229-9388-bf371580e1dc">14,724</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xNzgvZnJhZzo2YzY1MGFkMjA1Njc0OTZlYTM1YzNkY2E1MTRlMGRlNC90YWJsZTo0ZGFlNzk5OWM5MDc0ZDI2YWJhZDRhYWVmZDI4NzM0NC90YWJsZXJhbmdlOjRkYWU3OTk5YzkwNzRkMjZhYmFkNGFhZWZkMjg3MzQ0XzYtMS0xLTEtMA_a393499b-c7c7-40e6-975b-c02ecc1da761">5,204</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i824a5b33f908426bad016f0eded844db_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xNzgvZnJhZzo2YzY1MGFkMjA1Njc0OTZlYTM1YzNkY2E1MTRlMGRlNC90YWJsZTo0ZGFlNzk5OWM5MDc0ZDI2YWJhZDRhYWVmZDI4NzM0NC90YWJsZXJhbmdlOjRkYWU3OTk5YzkwNzRkMjZhYmFkNGFhZWZkMjg3MzQ0XzYtMy0xLTEtMA_1543e490-03d8-40bc-a25f-856145b52f01">4,098</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xNzgvZnJhZzo2YzY1MGFkMjA1Njc0OTZlYTM1YzNkY2E1MTRlMGRlNC90YWJsZTo0ZGFlNzk5OWM5MDc0ZDI2YWJhZDRhYWVmZDI4NzM0NC90YWJsZXJhbmdlOjRkYWU3OTk5YzkwNzRkMjZhYmFkNGFhZWZkMjg3MzQ0XzctMS0xLTEtMA_64909a32-66a2-4fe1-acf1-e15abef7de90">18,208</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i824a5b33f908426bad016f0eded844db_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xNzgvZnJhZzo2YzY1MGFkMjA1Njc0OTZlYTM1YzNkY2E1MTRlMGRlNC90YWJsZTo0ZGFlNzk5OWM5MDc0ZDI2YWJhZDRhYWVmZDI4NzM0NC90YWJsZXJhbmdlOjRkYWU3OTk5YzkwNzRkMjZhYmFkNGFhZWZkMjg3MzQ0XzctMy0xLTEtMA_460eb26b-44b5-490f-87da-7c28dc56f72e">18,822</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xNzgvZnJhZzo2YzY1MGFkMjA1Njc0OTZlYTM1YzNkY2E1MTRlMGRlNC90YWJsZTo0ZGFlNzk5OWM5MDc0ZDI2YWJhZDRhYWVmZDI4NzM0NC90YWJsZXJhbmdlOjRkYWU3OTk5YzkwNzRkMjZhYmFkNGFhZWZkMjg3MzQ0XzgtMS0xLTEtMA_b3d8ccb5-90b4-4af0-bc55-639048da48ba">7,158</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i824a5b33f908426bad016f0eded844db_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xNzgvZnJhZzo2YzY1MGFkMjA1Njc0OTZlYTM1YzNkY2E1MTRlMGRlNC90YWJsZTo0ZGFlNzk5OWM5MDc0ZDI2YWJhZDRhYWVmZDI4NzM0NC90YWJsZXJhbmdlOjRkYWU3OTk5YzkwNzRkMjZhYmFkNGFhZWZkMjg3MzQ0XzgtMy0xLTEtMA_00dc2b04-8ae1-4c04-aeca-b7f99f3b2e75">18,822</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Investment income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331" decimals="-3" name="us-gaap:InvestmentIncomeNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xNzgvZnJhZzo2YzY1MGFkMjA1Njc0OTZlYTM1YzNkY2E1MTRlMGRlNC90YWJsZTo0ZGFlNzk5OWM5MDc0ZDI2YWJhZDRhYWVmZDI4NzM0NC90YWJsZXJhbmdlOjRkYWU3OTk5YzkwNzRkMjZhYmFkNGFhZWZkMjg3MzQ0XzktMS0xLTEtMA_750050b1-c01d-4b0e-820a-c9c1c1fb65c7">12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i824a5b33f908426bad016f0eded844db_D20200101-20200331" decimals="-3" name="us-gaap:InvestmentIncomeNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xNzgvZnJhZzo2YzY1MGFkMjA1Njc0OTZlYTM1YzNkY2E1MTRlMGRlNC90YWJsZTo0ZGFlNzk5OWM5MDc0ZDI2YWJhZDRhYWVmZDI4NzM0NC90YWJsZXJhbmdlOjRkYWU3OTk5YzkwNzRkMjZhYmFkNGFhZWZkMjg3MzQ0XzktMy0xLTEtMA_09e622a7-fd08-4bc7-9abc-53f16878c640">240</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency transaction gain, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331" decimals="-3" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xNzgvZnJhZzo2YzY1MGFkMjA1Njc0OTZlYTM1YzNkY2E1MTRlMGRlNC90YWJsZTo0ZGFlNzk5OWM5MDc0ZDI2YWJhZDRhYWVmZDI4NzM0NC90YWJsZXJhbmdlOjRkYWU3OTk5YzkwNzRkMjZhYmFkNGFhZWZkMjg3MzQ0XzExLTEtMS0xLTA_9672513d-6c43-44e4-b354-693745be4537">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i824a5b33f908426bad016f0eded844db_D20200101-20200331" decimals="-3" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xNzgvZnJhZzo2YzY1MGFkMjA1Njc0OTZlYTM1YzNkY2E1MTRlMGRlNC90YWJsZTo0ZGFlNzk5OWM5MDc0ZDI2YWJhZDRhYWVmZDI4NzM0NC90YWJsZXJhbmdlOjRkYWU3OTk5YzkwNzRkMjZhYmFkNGFhZWZkMjg3MzQ0XzExLTMtMS0xLTA_03bf7b5c-0579-460e-87c9-1a4149f95198">82</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331" decimals="-3" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xNzgvZnJhZzo2YzY1MGFkMjA1Njc0OTZlYTM1YzNkY2E1MTRlMGRlNC90YWJsZTo0ZGFlNzk5OWM5MDc0ZDI2YWJhZDRhYWVmZDI4NzM0NC90YWJsZXJhbmdlOjRkYWU3OTk5YzkwNzRkMjZhYmFkNGFhZWZkMjg3MzQ0XzEyLTEtMS0xLTA_5554f934-930b-4317-8c2a-2e0e3c4eee15">711</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i824a5b33f908426bad016f0eded844db_D20200101-20200331" decimals="-3" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xNzgvZnJhZzo2YzY1MGFkMjA1Njc0OTZlYTM1YzNkY2E1MTRlMGRlNC90YWJsZTo0ZGFlNzk5OWM5MDc0ZDI2YWJhZDRhYWVmZDI4NzM0NC90YWJsZXJhbmdlOjRkYWU3OTk5YzkwNzRkMjZhYmFkNGFhZWZkMjg3MzQ0XzEyLTMtMS0xLTA_27805aa0-f21f-48af-8151-3593443006f7">273</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Change in fair value of warrant liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FairValueAdjustmentOfWarrants" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xNzgvZnJhZzo2YzY1MGFkMjA1Njc0OTZlYTM1YzNkY2E1MTRlMGRlNC90YWJsZTo0ZGFlNzk5OWM5MDc0ZDI2YWJhZDRhYWVmZDI4NzM0NC90YWJsZXJhbmdlOjRkYWU3OTk5YzkwNzRkMjZhYmFkNGFhZWZkMjg3MzQ0XzEzLTEtMS0xLTA_a5f25630-45dc-4bae-80b8-176590ea18ba">16,747</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i824a5b33f908426bad016f0eded844db_D20200101-20200331" decimals="-3" name="us-gaap:FairValueAdjustmentOfWarrants" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xNzgvZnJhZzo2YzY1MGFkMjA1Njc0OTZlYTM1YzNkY2E1MTRlMGRlNC90YWJsZTo0ZGFlNzk5OWM5MDc0ZDI2YWJhZDRhYWVmZDI4NzM0NC90YWJsZXJhbmdlOjRkYWU3OTk5YzkwNzRkMjZhYmFkNGFhZWZkMjg3MzQ0XzEzLTMtMS0xLTA_e72e6e28-7df5-423d-ad59-ac35c54bd1f1">846</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other income (expense), net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xNzgvZnJhZzo2YzY1MGFkMjA1Njc0OTZlYTM1YzNkY2E1MTRlMGRlNC90YWJsZTo0ZGFlNzk5OWM5MDc0ZDI2YWJhZDRhYWVmZDI4NzM0NC90YWJsZXJhbmdlOjRkYWU3OTk5YzkwNzRkMjZhYmFkNGFhZWZkMjg3MzQ0XzE0LTEtMS0xLTA_a99204bb-c6e7-4277-9dd9-340235a8cbcb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i824a5b33f908426bad016f0eded844db_D20200101-20200331" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xNzgvZnJhZzo2YzY1MGFkMjA1Njc0OTZlYTM1YzNkY2E1MTRlMGRlNC90YWJsZTo0ZGFlNzk5OWM5MDc0ZDI2YWJhZDRhYWVmZDI4NzM0NC90YWJsZXJhbmdlOjRkYWU3OTk5YzkwNzRkMjZhYmFkNGFhZWZkMjg3MzQ0XzE0LTMtMS0xLTA_401d02a0-5103-4352-bd5d-36b540b9c714">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xNzgvZnJhZzo2YzY1MGFkMjA1Njc0OTZlYTM1YzNkY2E1MTRlMGRlNC90YWJsZTo0ZGFlNzk5OWM5MDc0ZDI2YWJhZDRhYWVmZDI4NzM0NC90YWJsZXJhbmdlOjRkYWU3OTk5YzkwNzRkMjZhYmFkNGFhZWZkMjg3MzQ0XzE3LTEtMS0xLTA_0bb8308d-63b8-49da-b4b9-eb1e1c28fd69">24,597</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i824a5b33f908426bad016f0eded844db_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xNzgvZnJhZzo2YzY1MGFkMjA1Njc0OTZlYTM1YzNkY2E1MTRlMGRlNC90YWJsZTo0ZGFlNzk5OWM5MDc0ZDI2YWJhZDRhYWVmZDI4NzM0NC90YWJsZXJhbmdlOjRkYWU3OTk5YzkwNzRkMjZhYmFkNGFhZWZkMjg3MzQ0XzE3LTMtMS0xLTA_731c43ed-80ee-4870-9a73-d9de376f68d1">19,620</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive loss:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency translation adjustment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xNzgvZnJhZzo2YzY1MGFkMjA1Njc0OTZlYTM1YzNkY2E1MTRlMGRlNC90YWJsZTo0ZGFlNzk5OWM5MDc0ZDI2YWJhZDRhYWVmZDI4NzM0NC90YWJsZXJhbmdlOjRkYWU3OTk5YzkwNzRkMjZhYmFkNGFhZWZkMjg3MzQ0XzIwLTEtMS0xLTA_ffd1233b-2a09-4e82-8220-342ac76355d0">6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i824a5b33f908426bad016f0eded844db_D20200101-20200331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xNzgvZnJhZzo2YzY1MGFkMjA1Njc0OTZlYTM1YzNkY2E1MTRlMGRlNC90YWJsZTo0ZGFlNzk5OWM5MDc0ZDI2YWJhZDRhYWVmZDI4NzM0NC90YWJsZXJhbmdlOjRkYWU3OTk5YzkwNzRkMjZhYmFkNGFhZWZkMjg3MzQ0XzIwLTMtMS0xLTA_dfa2170c-13e5-4155-b1de-01ed97494089">60</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized (losses) on marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xNzgvZnJhZzo2YzY1MGFkMjA1Njc0OTZlYTM1YzNkY2E1MTRlMGRlNC90YWJsZTo0ZGFlNzk5OWM5MDc0ZDI2YWJhZDRhYWVmZDI4NzM0NC90YWJsZXJhbmdlOjRkYWU3OTk5YzkwNzRkMjZhYmFkNGFhZWZkMjg3MzQ0XzIxLTEtMS0xLTA_685d9087-59b2-4083-bc24-640e6096ded6">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i824a5b33f908426bad016f0eded844db_D20200101-20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xNzgvZnJhZzo2YzY1MGFkMjA1Njc0OTZlYTM1YzNkY2E1MTRlMGRlNC90YWJsZTo0ZGFlNzk5OWM5MDc0ZDI2YWJhZDRhYWVmZDI4NzM0NC90YWJsZXJhbmdlOjRkYWU3OTk5YzkwNzRkMjZhYmFkNGFhZWZkMjg3MzQ0XzIxLTMtMS0xLTA_ad96da1d-da59-44f9-bd64-80714d60a584">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total comprehensive loss</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xNzgvZnJhZzo2YzY1MGFkMjA1Njc0OTZlYTM1YzNkY2E1MTRlMGRlNC90YWJsZTo0ZGFlNzk5OWM5MDc0ZDI2YWJhZDRhYWVmZDI4NzM0NC90YWJsZXJhbmdlOjRkYWU3OTk5YzkwNzRkMjZhYmFkNGFhZWZkMjg3MzQ0XzIyLTEtMS0xLTA_32ce08d0-ef9c-406a-ac66-f9470645093a">24,604</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i824a5b33f908426bad016f0eded844db_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xNzgvZnJhZzo2YzY1MGFkMjA1Njc0OTZlYTM1YzNkY2E1MTRlMGRlNC90YWJsZTo0ZGFlNzk5OWM5MDc0ZDI2YWJhZDRhYWVmZDI4NzM0NC90YWJsZXJhbmdlOjRkYWU3OTk5YzkwNzRkMjZhYmFkNGFhZWZkMjg3MzQ0XzIyLTMtMS0xLTA_8cf9a41c-b4c1-41fd-9c0b-46e891fe1f6f">19,680</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss per share:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Basic and diluted</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xNzgvZnJhZzo2YzY1MGFkMjA1Njc0OTZlYTM1YzNkY2E1MTRlMGRlNC90YWJsZTo0ZGFlNzk5OWM5MDc0ZDI2YWJhZDRhYWVmZDI4NzM0NC90YWJsZXJhbmdlOjRkYWU3OTk5YzkwNzRkMjZhYmFkNGFhZWZkMjg3MzQ0XzMwLTEtMS0xLTA_132e9374-3aab-4bc4-af23-d277e923ca19">0.22</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i824a5b33f908426bad016f0eded844db_D20200101-20200331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xNzgvZnJhZzo2YzY1MGFkMjA1Njc0OTZlYTM1YzNkY2E1MTRlMGRlNC90YWJsZTo0ZGFlNzk5OWM5MDc0ZDI2YWJhZDRhYWVmZDI4NzM0NC90YWJsZXJhbmdlOjRkYWU3OTk5YzkwNzRkMjZhYmFkNGFhZWZkMjg3MzQ0XzMwLTMtMS0xLTA_3f881787-c307-418d-aa0b-dec3f374b3a3">0.21</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted average common shares outstanding:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Basic and diluted</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xNzgvZnJhZzo2YzY1MGFkMjA1Njc0OTZlYTM1YzNkY2E1MTRlMGRlNC90YWJsZTo0ZGFlNzk5OWM5MDc0ZDI2YWJhZDRhYWVmZDI4NzM0NC90YWJsZXJhbmdlOjRkYWU3OTk5YzkwNzRkMjZhYmFkNGFhZWZkMjg3MzQ0XzMyLTEtMS0xLTA_e3063f9b-8f54-46e6-8a77-2d46afb68464">110,742,150</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i824a5b33f908426bad016f0eded844db_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xNzgvZnJhZzo2YzY1MGFkMjA1Njc0OTZlYTM1YzNkY2E1MTRlMGRlNC90YWJsZTo0ZGFlNzk5OWM5MDc0ZDI2YWJhZDRhYWVmZDI4NzM0NC90YWJsZXJhbmdlOjRkYWU3OTk5YzkwNzRkMjZhYmFkNGFhZWZkMjg3MzQ0XzMyLTMtMS0xLTA_b40d2c96-67c1-4276-87b9-c19c33d96e76">94,723,513</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these unaudited consolidated financial statements.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><div id="i71586e7d2e304f6983634abe9e071791_181"></div><hr style="page-break-after:always"/><div style="min-height:28.8pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i71586e7d2e304f6983634abe9e071791_13">Table of Contents</a></span></div></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Selecta Biosciences,&#160;Inc. and Subsidiaries</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Consolidated Statements of Changes in Stockholders&#8217; (Deficit) Equity </span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(Amounts in thousands, except share data)</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">   </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.578%"><tr><td style="width:1.0%"></td><td style="width:50.277%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.209%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.209%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.329%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.361%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.329%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:7.374%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.329%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.374%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.329%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.380%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Stockholders&#8217;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common&#160;stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">paid-in</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">comprehensive</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Deficit)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">deficit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">loss</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Equity</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i28d60e6e11b845dfb37da5a84a9cc1e5_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xODEvZnJhZzpkZjY0MmVlMzkyNGY0ODhhOTY3ZTFmNTE0ZDVhMzRjZS90YWJsZTpiZmUwNWFjOTkxNjY0NTIwYjEwZGE2ZjA3YzE4ODI5NC90YWJsZXJhbmdlOmJmZTA1YWM5OTE2NjQ1MjBiMTBkYTZmMDdjMTg4Mjk0XzM2LTEtMS0xLTMxODI_3ac5911f-1f4e-4f18-a4fe-6aaff315900f">108,071,249</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28d60e6e11b845dfb37da5a84a9cc1e5_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xODEvZnJhZzpkZjY0MmVlMzkyNGY0ODhhOTY3ZTFmNTE0ZDVhMzRjZS90YWJsZTpiZmUwNWFjOTkxNjY0NTIwYjEwZGE2ZjA3YzE4ODI5NC90YWJsZXJhbmdlOmJmZTA1YWM5OTE2NjQ1MjBiMTBkYTZmMDdjMTg4Mjk0XzM2LTItMS0xLTMxODI_9510eadd-f6e6-4122-8218-7a6f88865ba1">11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id4c7f024803c4bb7abe0167bbe5af671_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xODEvZnJhZzpkZjY0MmVlMzkyNGY0ODhhOTY3ZTFmNTE0ZDVhMzRjZS90YWJsZTpiZmUwNWFjOTkxNjY0NTIwYjEwZGE2ZjA3YzE4ODI5NC90YWJsZXJhbmdlOmJmZTA1YWM5OTE2NjQ1MjBiMTBkYTZmMDdjMTg4Mjk0XzM2LTQtMS0xLTMxODI_de47d863-ae2b-45e1-b140-b4bedd77ac59">391,175</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6cd8f7abd235450ab64356048dc9ec07_I20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xODEvZnJhZzpkZjY0MmVlMzkyNGY0ODhhOTY3ZTFmNTE0ZDVhMzRjZS90YWJsZTpiZmUwNWFjOTkxNjY0NTIwYjEwZGE2ZjA3YzE4ODI5NC90YWJsZXJhbmdlOmJmZTA1YWM5OTE2NjQ1MjBiMTBkYTZmMDdjMTg4Mjk0XzM2LTgtMS0xLTMxODI_d78f1540-6815-4a06-8d34-88a442dd913d">404,629</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie0acbe76b2ae438d975dc022af481d6c_I20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xODEvZnJhZzpkZjY0MmVlMzkyNGY0ODhhOTY3ZTFmNTE0ZDVhMzRjZS90YWJsZTpiZmUwNWFjOTkxNjY0NTIwYjEwZGE2ZjA3YzE4ODI5NC90YWJsZXJhbmdlOmJmZTA1YWM5OTE2NjQ1MjBiMTBkYTZmMDdjMTg4Mjk0XzM2LTEwLTEtMS0zMTgy_950ca9ef-d679-4b96-b48b-a1456ef82f85">4,563</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib56f1adc867e406ca7face50c5da1c9c_I20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xODEvZnJhZzpkZjY0MmVlMzkyNGY0ODhhOTY3ZTFmNTE0ZDVhMzRjZS90YWJsZTpiZmUwNWFjOTkxNjY0NTIwYjEwZGE2ZjA3YzE4ODI5NC90YWJsZXJhbmdlOmJmZTA1YWM5OTE2NjQ1MjBiMTBkYTZmMDdjMTg4Mjk0XzM2LTEyLTEtMS0zMTgy_0e8e27db-ce34-47eb-976f-ee5b488efe7e">18,006</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock under Employee Stock Purchase Plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="idce850cc47714092ba1dcaa145785537_D20210101-20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xODEvZnJhZzpkZjY0MmVlMzkyNGY0ODhhOTY3ZTFmNTE0ZDVhMzRjZS90YWJsZTpiZmUwNWFjOTkxNjY0NTIwYjEwZGE2ZjA3YzE4ODI5NC90YWJsZXJhbmdlOmJmZTA1YWM5OTE2NjQ1MjBiMTBkYTZmMDdjMTg4Mjk0XzI1LTEtMS0xLTA_9d158e16-2563-4fa6-8ccc-acf413ac49db">34,696</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic39deec9ab0844a9b0dab300f1a2804d_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xODEvZnJhZzpkZjY0MmVlMzkyNGY0ODhhOTY3ZTFmNTE0ZDVhMzRjZS90YWJsZTpiZmUwNWFjOTkxNjY0NTIwYjEwZGE2ZjA3YzE4ODI5NC90YWJsZXJhbmdlOmJmZTA1YWM5OTE2NjQ1MjBiMTBkYTZmMDdjMTg4Mjk0XzI1LTQtMS0xLTA_eaa71ffc-66ae-4904-8f4d-19ca7f70eb72">72</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xODEvZnJhZzpkZjY0MmVlMzkyNGY0ODhhOTY3ZTFmNTE0ZDVhMzRjZS90YWJsZTpiZmUwNWFjOTkxNjY0NTIwYjEwZGE2ZjA3YzE4ODI5NC90YWJsZXJhbmdlOmJmZTA1YWM5OTE2NjQ1MjBiMTBkYTZmMDdjMTg4Mjk0XzI1LTEyLTEtMS0w_ee010bb7-0e5d-47fa-8134-428bcda72721">72</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock upon exercise of options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="idce850cc47714092ba1dcaa145785537_D20210101-20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xODEvZnJhZzpkZjY0MmVlMzkyNGY0ODhhOTY3ZTFmNTE0ZDVhMzRjZS90YWJsZTpiZmUwNWFjOTkxNjY0NTIwYjEwZGE2ZjA3YzE4ODI5NC90YWJsZXJhbmdlOmJmZTA1YWM5OTE2NjQ1MjBiMTBkYTZmMDdjMTg4Mjk0XzI2LTEtMS0xLTA_af5595e7-dd6c-4f47-8630-e6ba2fb8ff9c">153,278</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic39deec9ab0844a9b0dab300f1a2804d_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xODEvZnJhZzpkZjY0MmVlMzkyNGY0ODhhOTY3ZTFmNTE0ZDVhMzRjZS90YWJsZTpiZmUwNWFjOTkxNjY0NTIwYjEwZGE2ZjA3YzE4ODI5NC90YWJsZXJhbmdlOmJmZTA1YWM5OTE2NjQ1MjBiMTBkYTZmMDdjMTg4Mjk0XzI2LTQtMS0xLTA_a84b26fd-685a-4846-bd42-ebb4da7c0e9b">244</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xODEvZnJhZzpkZjY0MmVlMzkyNGY0ODhhOTY3ZTFmNTE0ZDVhMzRjZS90YWJsZTpiZmUwNWFjOTkxNjY0NTIwYjEwZGE2ZjA3YzE4ODI5NC90YWJsZXJhbmdlOmJmZTA1YWM5OTE2NjQ1MjBiMTBkYTZmMDdjMTg4Mjk0XzI2LTEyLTEtMS0w_b4584562-f045-4925-9328-62521fe90871">244</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of vested restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="idce850cc47714092ba1dcaa145785537_D20210101-20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xODEvZnJhZzpkZjY0MmVlMzkyNGY0ODhhOTY3ZTFmNTE0ZDVhMzRjZS90YWJsZTpiZmUwNWFjOTkxNjY0NTIwYjEwZGE2ZjA3YzE4ODI5NC90YWJsZXJhbmdlOmJmZTA1YWM5OTE2NjQ1MjBiMTBkYTZmMDdjMTg4Mjk0XzI3LTEtMS0xLTA_b3802b32-f002-4370-ae0f-2b940d1d7716">10,937</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xODEvZnJhZzpkZjY0MmVlMzkyNGY0ODhhOTY3ZTFmNTE0ZDVhMzRjZS90YWJsZTpiZmUwNWFjOTkxNjY0NTIwYjEwZGE2ZjA3YzE4ODI5NC90YWJsZXJhbmdlOmJmZTA1YWM5OTE2NjQ1MjBiMTBkYTZmMDdjMTg4Mjk0XzI3LTEyLTEtMS0w_24b1d781-196d-429a-9268-2618ccc9390b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock through at-the-market offering, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="idce850cc47714092ba1dcaa145785537_D20210101-20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesOther" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xODEvZnJhZzpkZjY0MmVlMzkyNGY0ODhhOTY3ZTFmNTE0ZDVhMzRjZS90YWJsZTpiZmUwNWFjOTkxNjY0NTIwYjEwZGE2ZjA3YzE4ODI5NC90YWJsZXJhbmdlOmJmZTA1YWM5OTE2NjQ1MjBiMTBkYTZmMDdjMTg4Mjk0XzI4LTEtMS0xLTA_753b71f3-c866-41be-8ae5-e3b4e4924aaa">4,706,844</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic39deec9ab0844a9b0dab300f1a2804d_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueOther" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xODEvZnJhZzpkZjY0MmVlMzkyNGY0ODhhOTY3ZTFmNTE0ZDVhMzRjZS90YWJsZTpiZmUwNWFjOTkxNjY0NTIwYjEwZGE2ZjA3YzE4ODI5NC90YWJsZXJhbmdlOmJmZTA1YWM5OTE2NjQ1MjBiMTBkYTZmMDdjMTg4Mjk0XzI4LTQtMS0xLTA_f5980420-2447-4a0f-88c2-269b3b14b510">20,943</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueOther" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xODEvZnJhZzpkZjY0MmVlMzkyNGY0ODhhOTY3ZTFmNTE0ZDVhMzRjZS90YWJsZTpiZmUwNWFjOTkxNjY0NTIwYjEwZGE2ZjA3YzE4ODI5NC90YWJsZXJhbmdlOmJmZTA1YWM5OTE2NjQ1MjBiMTBkYTZmMDdjMTg4Mjk0XzI4LTEyLTEtMS0w_29204cbc-2979-423e-bd2b-7624f5130bf3">20,943</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic39deec9ab0844a9b0dab300f1a2804d_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xODEvZnJhZzpkZjY0MmVlMzkyNGY0ODhhOTY3ZTFmNTE0ZDVhMzRjZS90YWJsZTpiZmUwNWFjOTkxNjY0NTIwYjEwZGE2ZjA3YzE4ODI5NC90YWJsZXJhbmdlOmJmZTA1YWM5OTE2NjQ1MjBiMTBkYTZmMDdjMTg4Mjk0XzM0LTQtMS0xLTA_06515a5d-c7ae-48cb-a7dc-35d874318ef8">1,780</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xODEvZnJhZzpkZjY0MmVlMzkyNGY0ODhhOTY3ZTFmNTE0ZDVhMzRjZS90YWJsZTpiZmUwNWFjOTkxNjY0NTIwYjEwZGE2ZjA3YzE4ODI5NC90YWJsZXJhbmdlOmJmZTA1YWM5OTE2NjQ1MjBiMTBkYTZmMDdjMTg4Mjk0XzM0LTEyLTEtMS0w_f1fd4bae-bd97-41ab-ad2f-802cb185da7c">1,780</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Currency translation adjustment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic7469ad2eea94378b3c60b0767ec2c61_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xODEvZnJhZzpkZjY0MmVlMzkyNGY0ODhhOTY3ZTFmNTE0ZDVhMzRjZS90YWJsZTpiZmUwNWFjOTkxNjY0NTIwYjEwZGE2ZjA3YzE4ODI5NC90YWJsZXJhbmdlOmJmZTA1YWM5OTE2NjQ1MjBiMTBkYTZmMDdjMTg4Mjk0XzM1LTEwLTEtMS0w_9834f98e-c4f8-4d0d-b45b-ff60d84a8c5f">6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xODEvZnJhZzpkZjY0MmVlMzkyNGY0ODhhOTY3ZTFmNTE0ZDVhMzRjZS90YWJsZTpiZmUwNWFjOTkxNjY0NTIwYjEwZGE2ZjA3YzE4ODI5NC90YWJsZXJhbmdlOmJmZTA1YWM5OTE2NjQ1MjBiMTBkYTZmMDdjMTg4Mjk0XzM1LTEyLTEtMS0w_70fe251e-91b8-42f3-8681-0c68f1312def">6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized (losses) on marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic7469ad2eea94378b3c60b0767ec2c61_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xODEvZnJhZzpkZjY0MmVlMzkyNGY0ODhhOTY3ZTFmNTE0ZDVhMzRjZS90YWJsZTpiZmUwNWFjOTkxNjY0NTIwYjEwZGE2ZjA3YzE4ODI5NC90YWJsZXJhbmdlOmJmZTA1YWM5OTE2NjQ1MjBiMTBkYTZmMDdjMTg4Mjk0XzQ3LTEwLTEtMS0xODc5_3627a64e-f517-4f36-be01-2c89e160625f">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xODEvZnJhZzpkZjY0MmVlMzkyNGY0ODhhOTY3ZTFmNTE0ZDVhMzRjZS90YWJsZTpiZmUwNWFjOTkxNjY0NTIwYjEwZGE2ZjA3YzE4ODI5NC90YWJsZXJhbmdlOmJmZTA1YWM5OTE2NjQ1MjBiMTBkYTZmMDdjMTg4Mjk0XzQ1LTEyLTEtMS0zMTg0_b5a418f4-4338-4be5-8d01-97de961f6d4d">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9ba514a4defc485e94d0b416ba59c49d_D20210101-20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xODEvZnJhZzpkZjY0MmVlMzkyNGY0ODhhOTY3ZTFmNTE0ZDVhMzRjZS90YWJsZTpiZmUwNWFjOTkxNjY0NTIwYjEwZGE2ZjA3YzE4ODI5NC90YWJsZXJhbmdlOmJmZTA1YWM5OTE2NjQ1MjBiMTBkYTZmMDdjMTg4Mjk0XzM3LTgtMS0xLTA_08832626-2522-4af9-846f-28a6bc937074">24,597</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xODEvZnJhZzpkZjY0MmVlMzkyNGY0ODhhOTY3ZTFmNTE0ZDVhMzRjZS90YWJsZTpiZmUwNWFjOTkxNjY0NTIwYjEwZGE2ZjA3YzE4ODI5NC90YWJsZXJhbmdlOmJmZTA1YWM5OTE2NjQ1MjBiMTBkYTZmMDdjMTg4Mjk0XzM3LTEyLTEtMS0w_2954799d-61e9-4da8-94c2-4a8bb07e1c4b">24,597</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at March 31, 2021</span></div></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0f01a127e9094f2c9ce7fa5a13678fc4_I20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xODEvZnJhZzpkZjY0MmVlMzkyNGY0ODhhOTY3ZTFmNTE0ZDVhMzRjZS90YWJsZTpiZmUwNWFjOTkxNjY0NTIwYjEwZGE2ZjA3YzE4ODI5NC90YWJsZXJhbmdlOmJmZTA1YWM5OTE2NjQ1MjBiMTBkYTZmMDdjMTg4Mjk0XzM4LTEtMS0xLTA_2eaa0c90-558f-4cd8-9445-8849eafc0da5">112,977,004</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f01a127e9094f2c9ce7fa5a13678fc4_I20210331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xODEvZnJhZzpkZjY0MmVlMzkyNGY0ODhhOTY3ZTFmNTE0ZDVhMzRjZS90YWJsZTpiZmUwNWFjOTkxNjY0NTIwYjEwZGE2ZjA3YzE4ODI5NC90YWJsZXJhbmdlOmJmZTA1YWM5OTE2NjQ1MjBiMTBkYTZmMDdjMTg4Mjk0XzM4LTItMS0xLTA_297f3a77-6172-426a-b68b-9c59a2e03090">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a24e3ea770740729c391207bf51dce3_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xODEvZnJhZzpkZjY0MmVlMzkyNGY0ODhhOTY3ZTFmNTE0ZDVhMzRjZS90YWJsZTpiZmUwNWFjOTkxNjY0NTIwYjEwZGE2ZjA3YzE4ODI5NC90YWJsZXJhbmdlOmJmZTA1YWM5OTE2NjQ1MjBiMTBkYTZmMDdjMTg4Mjk0XzM4LTQtMS0xLTA_9746126a-2e14-47d5-b2f7-931fec53f33f">414,214</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i64c04c765b7b44e8b62c73e17992956e_I20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xODEvZnJhZzpkZjY0MmVlMzkyNGY0ODhhOTY3ZTFmNTE0ZDVhMzRjZS90YWJsZTpiZmUwNWFjOTkxNjY0NTIwYjEwZGE2ZjA3YzE4ODI5NC90YWJsZXJhbmdlOmJmZTA1YWM5OTE2NjQ1MjBiMTBkYTZmMDdjMTg4Mjk0XzM4LTgtMS0xLTA_21d2c986-d2d7-4e55-92fc-be0fa86bc422">429,226</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i697921663ff44d1ba22263ce04047fe4_I20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xODEvZnJhZzpkZjY0MmVlMzkyNGY0ODhhOTY3ZTFmNTE0ZDVhMzRjZS90YWJsZTpiZmUwNWFjOTkxNjY0NTIwYjEwZGE2ZjA3YzE4ODI5NC90YWJsZXJhbmdlOmJmZTA1YWM5OTE2NjQ1MjBiMTBkYTZmMDdjMTg4Mjk0XzM4LTEwLTEtMS0w_30fd6bc9-c3fd-40f0-979c-2819d8fe365b">4,570</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ied8d945ebce54ed8a4badfed477a64e8_I20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xODEvZnJhZzpkZjY0MmVlMzkyNGY0ODhhOTY3ZTFmNTE0ZDVhMzRjZS90YWJsZTpiZmUwNWFjOTkxNjY0NTIwYjEwZGE2ZjA3YzE4ODI5NC90YWJsZXJhbmdlOmJmZTA1YWM5OTE2NjQ1MjBiMTBkYTZmMDdjMTg4Mjk0XzM4LTEyLTEtMS0w_de434fd6-b7d9-4ba5-b602-0dd81e199206">19,571</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these unaudited consolidated financial statements.</span></div><div style="height:28.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><div id="i71586e7d2e304f6983634abe9e071791_184"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i71586e7d2e304f6983634abe9e071791_13">Table of Contents</a></span></div></div><div style="margin-top:3pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Selecta Biosciences,&#160;Inc. and Subsidiaries</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Consolidated Statements of Changes in Stockholders&#8217; (Deficit) Equity </span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(Amounts in thousands, except share data)</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="margin-bottom:11pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.277%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.209%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.209%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.329%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.361%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.329%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:7.374%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.329%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.374%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.329%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.380%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Stockholders&#8217;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common&#160;stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">paid-in</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">comprehensive</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Deficit)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">deficit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">loss</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Equity</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8f5d5586be294d54be1415ab00417669_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xODQvZnJhZzoxMTE2NTQ2YjIzNDU0NmY4ODVmNmE1ODZhMGY3MDZkNS90YWJsZTo3MDQ5YTJiMmIwMjk0YTMwYjBhOGQ0MTExYzUxODAxYy90YWJsZXJhbmdlOjcwNDlhMmIyYjAyOTRhMzBiMGE4ZDQxMTFjNTE4MDFjXzUtMS0xLTEtMzE4Nw_6cd5bcd1-8200-4564-b0e8-4e5e7afde056">86,325,547</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f5d5586be294d54be1415ab00417669_I20191231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xODQvZnJhZzoxMTE2NTQ2YjIzNDU0NmY4ODVmNmE1ODZhMGY3MDZkNS90YWJsZTo3MDQ5YTJiMmIwMjk0YTMwYjBhOGQ0MTExYzUxODAxYy90YWJsZXJhbmdlOjcwNDlhMmIyYjAyOTRhMzBiMGE4ZDQxMTFjNTE4MDFjXzUtMi0xLTEtMzE4OQ_dfd20ff5-3934-476c-8bbe-27ad727bf77e">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6d22df4e633466eb268453a386261b9_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xODQvZnJhZzoxMTE2NTQ2YjIzNDU0NmY4ODVmNmE1ODZhMGY3MDZkNS90YWJsZTo3MDQ5YTJiMmIwMjk0YTMwYjBhOGQ0MTExYzUxODAxYy90YWJsZXJhbmdlOjcwNDlhMmIyYjAyOTRhMzBiMGE4ZDQxMTFjNTE4MDFjXzUtNC0xLTEtMzE5MQ_5a071dcc-4f8a-4b5e-a2c3-d5bd9b12d5d4">348,664</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic85d5ba0da864526935be1f5158d2390_I20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xODQvZnJhZzoxMTE2NTQ2YjIzNDU0NmY4ODVmNmE1ODZhMGY3MDZkNS90YWJsZTo3MDQ5YTJiMmIwMjk0YTMwYjBhOGQ0MTExYzUxODAxYy90YWJsZXJhbmdlOjcwNDlhMmIyYjAyOTRhMzBiMGE4ZDQxMTFjNTE4MDFjXzUtOC0xLTEtMzE5Nw_6d489e02-913c-4c3d-af9c-19dd0b7dbe14">335,753</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i48c9319650af4a498d62dfe592f8cfdd_I20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xODQvZnJhZzoxMTE2NTQ2YjIzNDU0NmY4ODVmNmE1ODZhMGY3MDZkNS90YWJsZTo3MDQ5YTJiMmIwMjk0YTMwYjBhOGQ0MTExYzUxODAxYy90YWJsZXJhbmdlOjcwNDlhMmIyYjAyOTRhMzBiMGE4ZDQxMTFjNTE4MDFjXzUtMTAtMS0xLTMxOTk_1b138505-a7ef-4e16-88bc-cc3a0c4ff968">4,523</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iabdd66a36794438ab9664178bf3cf96a_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xODQvZnJhZzoxMTE2NTQ2YjIzNDU0NmY4ODVmNmE1ODZhMGY3MDZkNS90YWJsZTo3MDQ5YTJiMmIwMjk0YTMwYjBhOGQ0MTExYzUxODAxYy90YWJsZXJhbmdlOjcwNDlhMmIyYjAyOTRhMzBiMGE4ZDQxMTFjNTE4MDFjXzUtMTItMS0xLTMyMDE_9908893d-7da4-4364-8388-f1b56a6c3259">8,397</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock under Employee Stock Purchase Plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie0acb7061950472c9ffc5dee59b3f7d1_D20200101-20200331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xODQvZnJhZzoxMTE2NTQ2YjIzNDU0NmY4ODVmNmE1ODZhMGY3MDZkNS90YWJsZTo3MDQ5YTJiMmIwMjk0YTMwYjBhOGQ0MTExYzUxODAxYy90YWJsZXJhbmdlOjcwNDlhMmIyYjAyOTRhMzBiMGE4ZDQxMTFjNTE4MDFjXzYtMS0xLTEtMzE4Nw_2dd612f6-38a1-414e-8f26-fd122f9454a7">78,583</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22171a0001464fdbaeb20c2221b2f800_D20200101-20200331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xODQvZnJhZzoxMTE2NTQ2YjIzNDU0NmY4ODVmNmE1ODZhMGY3MDZkNS90YWJsZTo3MDQ5YTJiMmIwMjk0YTMwYjBhOGQ0MTExYzUxODAxYy90YWJsZXJhbmdlOjcwNDlhMmIyYjAyOTRhMzBiMGE4ZDQxMTFjNTE4MDFjXzYtNC0xLTEtMzE5Mw_92fe3f2e-2abb-49b7-b04c-86b6aaf1e394">114</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i824a5b33f908426bad016f0eded844db_D20200101-20200331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xODQvZnJhZzoxMTE2NTQ2YjIzNDU0NmY4ODVmNmE1ODZhMGY3MDZkNS90YWJsZTo3MDQ5YTJiMmIwMjk0YTMwYjBhOGQ0MTExYzUxODAxYy90YWJsZXJhbmdlOjcwNDlhMmIyYjAyOTRhMzBiMGE4ZDQxMTFjNTE4MDFjXzYtMTItMS0xLTMyMDE_4619025f-6dbf-444e-8bd1-8e8898779f32">114</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock upon exercise of options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie0acb7061950472c9ffc5dee59b3f7d1_D20200101-20200331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xODQvZnJhZzoxMTE2NTQ2YjIzNDU0NmY4ODVmNmE1ODZhMGY3MDZkNS90YWJsZTo3MDQ5YTJiMmIwMjk0YTMwYjBhOGQ0MTExYzUxODAxYy90YWJsZXJhbmdlOjcwNDlhMmIyYjAyOTRhMzBiMGE4ZDQxMTFjNTE4MDFjXzctMS0xLTEtMzE4Nw_a2c089f3-5a8f-4911-9092-2c1d90107e3c">5,128</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22171a0001464fdbaeb20c2221b2f800_D20200101-20200331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xODQvZnJhZzoxMTE2NTQ2YjIzNDU0NmY4ODVmNmE1ODZhMGY3MDZkNS90YWJsZTo3MDQ5YTJiMmIwMjk0YTMwYjBhOGQ0MTExYzUxODAxYy90YWJsZXJhbmdlOjcwNDlhMmIyYjAyOTRhMzBiMGE4ZDQxMTFjNTE4MDFjXzctNC0xLTEtMzE5Mw_1b125262-7b41-41ee-b5f8-7ded1aaae327">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i824a5b33f908426bad016f0eded844db_D20200101-20200331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xODQvZnJhZzoxMTE2NTQ2YjIzNDU0NmY4ODVmNmE1ODZhMGY3MDZkNS90YWJsZTo3MDQ5YTJiMmIwMjk0YTMwYjBhOGQ0MTExYzUxODAxYy90YWJsZXJhbmdlOjcwNDlhMmIyYjAyOTRhMzBiMGE4ZDQxMTFjNTE4MDFjXzctMTItMS0xLTMyMDE_8550eaad-5b09-456f-a5a6-c03c028429da">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of vested restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie0acb7061950472c9ffc5dee59b3f7d1_D20200101-20200331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xODQvZnJhZzoxMTE2NTQ2YjIzNDU0NmY4ODVmNmE1ODZhMGY3MDZkNS90YWJsZTo3MDQ5YTJiMmIwMjk0YTMwYjBhOGQ0MTExYzUxODAxYy90YWJsZXJhbmdlOjcwNDlhMmIyYjAyOTRhMzBiMGE4ZDQxMTFjNTE4MDFjXzgtMS0xLTEtMzE4Nw_5f27e23c-f87b-4bbd-8f2f-042fe7c86c07">10,937</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i824a5b33f908426bad016f0eded844db_D20200101-20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xODQvZnJhZzoxMTE2NTQ2YjIzNDU0NmY4ODVmNmE1ODZhMGY3MDZkNS90YWJsZTo3MDQ5YTJiMmIwMjk0YTMwYjBhOGQ0MTExYzUxODAxYy90YWJsZXJhbmdlOjcwNDlhMmIyYjAyOTRhMzBiMGE4ZDQxMTFjNTE4MDFjXzgtMTItMS0xLTMyMjE_9dd5e23b-60c9-49bf-b8d2-c78f5224fd84">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock through at-the-market offering, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie0acb7061950472c9ffc5dee59b3f7d1_D20200101-20200331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesOther" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xODQvZnJhZzoxMTE2NTQ2YjIzNDU0NmY4ODVmNmE1ODZhMGY3MDZkNS90YWJsZTo3MDQ5YTJiMmIwMjk0YTMwYjBhOGQ0MTExYzUxODAxYy90YWJsZXJhbmdlOjcwNDlhMmIyYjAyOTRhMzBiMGE4ZDQxMTFjNTE4MDFjXzktMS0xLTEtMzE4Nw_684b3b54-8e98-406f-a26f-4200d4728687">598,977</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22171a0001464fdbaeb20c2221b2f800_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueOther" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xODQvZnJhZzoxMTE2NTQ2YjIzNDU0NmY4ODVmNmE1ODZhMGY3MDZkNS90YWJsZTo3MDQ5YTJiMmIwMjk0YTMwYjBhOGQ0MTExYzUxODAxYy90YWJsZXJhbmdlOjcwNDlhMmIyYjAyOTRhMzBiMGE4ZDQxMTFjNTE4MDFjXzktNC0xLTEtMzE5NQ_26ca797d-93b4-46fc-b782-c1ee9126c793">1,141</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i824a5b33f908426bad016f0eded844db_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueOther" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xODQvZnJhZzoxMTE2NTQ2YjIzNDU0NmY4ODVmNmE1ODZhMGY3MDZkNS90YWJsZTo3MDQ5YTJiMmIwMjk0YTMwYjBhOGQ0MTExYzUxODAxYy90YWJsZXJhbmdlOjcwNDlhMmIyYjAyOTRhMzBiMGE4ZDQxMTFjNTE4MDFjXzktMTItMS0xLTMyMDM_67c9ec5a-3da1-4bb8-b376-2ab93a5589bd">1,141</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other financing fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i22171a0001464fdbaeb20c2221b2f800_D20200101-20200331" decimals="-3" sign="-" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalOther" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xODQvZnJhZzoxMTE2NTQ2YjIzNDU0NmY4ODVmNmE1ODZhMGY3MDZkNS90YWJsZTo3MDQ5YTJiMmIwMjk0YTMwYjBhOGQ0MTExYzUxODAxYy90YWJsZXJhbmdlOjcwNDlhMmIyYjAyOTRhMzBiMGE4ZDQxMTFjNTE4MDFjXzEwLTQtMS0xLTMxOTU_ad9380d1-b287-4271-ba09-795c9f1efb67">147</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i824a5b33f908426bad016f0eded844db_D20200101-20200331" decimals="-3" sign="-" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalOther" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xODQvZnJhZzoxMTE2NTQ2YjIzNDU0NmY4ODVmNmE1ODZhMGY3MDZkNS90YWJsZTo3MDQ5YTJiMmIwMjk0YTMwYjBhOGQ0MTExYzUxODAxYy90YWJsZXJhbmdlOjcwNDlhMmIyYjAyOTRhMzBiMGE4ZDQxMTFjNTE4MDFjXzEwLTEyLTEtMS0zMjAz_9bf9d231-3b9e-4612-ab27-c505b01c8ab8">147</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22171a0001464fdbaeb20c2221b2f800_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xODQvZnJhZzoxMTE2NTQ2YjIzNDU0NmY4ODVmNmE1ODZhMGY3MDZkNS90YWJsZTo3MDQ5YTJiMmIwMjk0YTMwYjBhOGQ0MTExYzUxODAxYy90YWJsZXJhbmdlOjcwNDlhMmIyYjAyOTRhMzBiMGE4ZDQxMTFjNTE4MDFjXzExLTQtMS0xLTMxOTU_73e80d15-cea2-48e6-be55-18c409fe1309">1,409</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i824a5b33f908426bad016f0eded844db_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xODQvZnJhZzoxMTE2NTQ2YjIzNDU0NmY4ODVmNmE1ODZhMGY3MDZkNS90YWJsZTo3MDQ5YTJiMmIwMjk0YTMwYjBhOGQ0MTExYzUxODAxYy90YWJsZXJhbmdlOjcwNDlhMmIyYjAyOTRhMzBiMGE4ZDQxMTFjNTE4MDFjXzExLTEyLTEtMS0zMjAz_cf117ec6-e424-475e-85b3-908897a18149">1,409</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Currency translation adjustment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia8bafce0cbb84adc8382dec4a0321316_D20200101-20200331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xODQvZnJhZzoxMTE2NTQ2YjIzNDU0NmY4ODVmNmE1ODZhMGY3MDZkNS90YWJsZTo3MDQ5YTJiMmIwMjk0YTMwYjBhOGQ0MTExYzUxODAxYy90YWJsZXJhbmdlOjcwNDlhMmIyYjAyOTRhMzBiMGE4ZDQxMTFjNTE4MDFjXzEyLTEwLTEtMS0zMjA1_40b2818a-5d27-4e99-91c5-a36ee35edce5">60</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i824a5b33f908426bad016f0eded844db_D20200101-20200331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xODQvZnJhZzoxMTE2NTQ2YjIzNDU0NmY4ODVmNmE1ODZhMGY3MDZkNS90YWJsZTo3MDQ5YTJiMmIwMjk0YTMwYjBhOGQ0MTExYzUxODAxYy90YWJsZXJhbmdlOjcwNDlhMmIyYjAyOTRhMzBiMGE4ZDQxMTFjNTE4MDFjXzEyLTEyLTEtMS0zMjAz_256b62cc-beda-48b8-9577-f5edb6b63cab">60</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie102296cb93f4d219e9e9aeb38383744_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xODQvZnJhZzoxMTE2NTQ2YjIzNDU0NmY4ODVmNmE1ODZhMGY3MDZkNS90YWJsZTo3MDQ5YTJiMmIwMjk0YTMwYjBhOGQ0MTExYzUxODAxYy90YWJsZXJhbmdlOjcwNDlhMmIyYjAyOTRhMzBiMGE4ZDQxMTFjNTE4MDFjXzEzLTgtMS0xLTMyMDc_c8f3aa9d-1ca3-4c2b-9750-f64b5a7a983a">19,620</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i824a5b33f908426bad016f0eded844db_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xODQvZnJhZzoxMTE2NTQ2YjIzNDU0NmY4ODVmNmE1ODZhMGY3MDZkNS90YWJsZTo3MDQ5YTJiMmIwMjk0YTMwYjBhOGQ0MTExYzUxODAxYy90YWJsZXJhbmdlOjcwNDlhMmIyYjAyOTRhMzBiMGE4ZDQxMTFjNTE4MDFjXzEzLTEyLTEtMS0zMjAz_665f1353-8e86-4f5d-8a76-ab3f15a38acb">19,620</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at March 31, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i708ad43bbcdd433f8815781dc1dabef7_I20200331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xODQvZnJhZzoxMTE2NTQ2YjIzNDU0NmY4ODVmNmE1ODZhMGY3MDZkNS90YWJsZTo3MDQ5YTJiMmIwMjk0YTMwYjBhOGQ0MTExYzUxODAxYy90YWJsZXJhbmdlOjcwNDlhMmIyYjAyOTRhMzBiMGE4ZDQxMTFjNTE4MDFjXzE0LTEtMS0xLTMyMTc_8796ac5d-bf7d-4cdc-87db-5fa0ba81a066">87,019,172</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i708ad43bbcdd433f8815781dc1dabef7_I20200331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xODQvZnJhZzoxMTE2NTQ2YjIzNDU0NmY4ODVmNmE1ODZhMGY3MDZkNS90YWJsZTo3MDQ5YTJiMmIwMjk0YTMwYjBhOGQ0MTExYzUxODAxYy90YWJsZXJhbmdlOjcwNDlhMmIyYjAyOTRhMzBiMGE4ZDQxMTFjNTE4MDFjXzE0LTItMS0xLTMyMTU_54cc5089-613d-4b68-a503-550f5e6863b1">9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6de5cd0af433469ea596afb9aa70a75b_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xODQvZnJhZzoxMTE2NTQ2YjIzNDU0NmY4ODVmNmE1ODZhMGY3MDZkNS90YWJsZTo3MDQ5YTJiMmIwMjk0YTMwYjBhOGQ0MTExYzUxODAxYy90YWJsZXJhbmdlOjcwNDlhMmIyYjAyOTRhMzBiMGE4ZDQxMTFjNTE4MDFjXzE0LTQtMS0xLTMyMTM_78b65c62-00ac-4f58-9855-6a7ec28e3098">351,184</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8407594575184affb099a506cf4761ad_I20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xODQvZnJhZzoxMTE2NTQ2YjIzNDU0NmY4ODVmNmE1ODZhMGY3MDZkNS90YWJsZTo3MDQ5YTJiMmIwMjk0YTMwYjBhOGQ0MTExYzUxODAxYy90YWJsZXJhbmdlOjcwNDlhMmIyYjAyOTRhMzBiMGE4ZDQxMTFjNTE4MDFjXzE0LTgtMS0xLTMyMTE_33a405f4-623d-44b3-9d88-3c78624f83a5">355,373</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6914e325d1a54348910a4641d7f828c4_I20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xODQvZnJhZzoxMTE2NTQ2YjIzNDU0NmY4ODVmNmE1ODZhMGY3MDZkNS90YWJsZTo3MDQ5YTJiMmIwMjk0YTMwYjBhOGQ0MTExYzUxODAxYy90YWJsZXJhbmdlOjcwNDlhMmIyYjAyOTRhMzBiMGE4ZDQxMTFjNTE4MDFjXzE0LTEwLTEtMS0zMjA5_5f4e5ed9-f389-4ed9-9408-c0e84fdf3658">4,583</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iff7e2530342c41bca8c84fce55f0cc6f_I20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xODQvZnJhZzoxMTE2NTQ2YjIzNDU0NmY4ODVmNmE1ODZhMGY3MDZkNS90YWJsZTo3MDQ5YTJiMmIwMjk0YTMwYjBhOGQ0MTExYzUxODAxYy90YWJsZXJhbmdlOjcwNDlhMmIyYjAyOTRhMzBiMGE4ZDQxMTFjNTE4MDFjXzE0LTEyLTEtMS0zMjAz_5cac4d1f-3d88-4ed7-81bb-efe88e682db2">8,763</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span><br/></span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these unaudited consolidated financial statements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><div id="i71586e7d2e304f6983634abe9e071791_190"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i71586e7d2e304f6983634abe9e071791_13">Table of Contents</a></span></div></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Selecta Biosciences,&#160;Inc. and Subsidiaries&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Consolidated Statements of Cash Flows</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(Amounts in thousands)</span></div><div style="margin-top:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:70.935%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.516%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.517%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="9" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Unaudited)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash flows from operating activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xOTAvZnJhZzpkZWMyZWRkNjViNWU0MzNlYWY1YzJmNmZmNzFiNDNmZi90YWJsZTpiYjg2NzJmMTk1NTM0YjZkYWI3YjVlMDg2NTY0NGYyZC90YWJsZXJhbmdlOmJiODY3MmYxOTU1MzRiNmRhYjdiNWUwODY1NjQ0ZjJkXzMtMS0xLTEtMA_6dd6ca7a-3a4f-4de3-8bf7-80c6a599116f">24,597</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i824a5b33f908426bad016f0eded844db_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xOTAvZnJhZzpkZWMyZWRkNjViNWU0MzNlYWY1YzJmNmZmNzFiNDNmZi90YWJsZTpiYjg2NzJmMTk1NTM0YjZkYWI3YjVlMDg2NTY0NGYyZC90YWJsZXJhbmdlOmJiODY3MmYxOTU1MzRiNmRhYjdiNWUwODY1NjQ0ZjJkXzMtMy0xLTEtMA_7754202f-9a0d-4ebd-ab34-ffb2a2b81e9c">19,620</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash used in operating activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331" decimals="-3" name="us-gaap:OtherDepreciationAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xOTAvZnJhZzpkZWMyZWRkNjViNWU0MzNlYWY1YzJmNmZmNzFiNDNmZi90YWJsZTpiYjg2NzJmMTk1NTM0YjZkYWI3YjVlMDg2NTY0NGYyZC90YWJsZXJhbmdlOmJiODY3MmYxOTU1MzRiNmRhYjdiNWUwODY1NjQ0ZjJkXzUtMS0xLTEtMA_66a8ac28-810e-47f7-9fb5-efae43d4eee2">207</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i824a5b33f908426bad016f0eded844db_D20200101-20200331" decimals="-3" name="us-gaap:OtherDepreciationAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xOTAvZnJhZzpkZWMyZWRkNjViNWU0MzNlYWY1YzJmNmZmNzFiNDNmZi90YWJsZTpiYjg2NzJmMTk1NTM0YjZkYWI3YjVlMDg2NTY0NGYyZC90YWJsZXJhbmdlOmJiODY3MmYxOTU1MzRiNmRhYjdiNWUwODY1NjQ0ZjJkXzUtMy0xLTEtMA_08e9262f-6d0b-4a1e-8690-dec3b0474d88">231</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization of premiums and discounts on marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xOTAvZnJhZzpkZWMyZWRkNjViNWU0MzNlYWY1YzJmNmZmNzFiNDNmZi90YWJsZTpiYjg2NzJmMTk1NTM0YjZkYWI3YjVlMDg2NTY0NGYyZC90YWJsZXJhbmdlOmJiODY3MmYxOTU1MzRiNmRhYjdiNWUwODY1NjQ0ZjJkXzYtMS0xLTEtMA_b2f0435b-c863-4fe1-9d86-dffa29a0a77d">14</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i824a5b33f908426bad016f0eded844db_D20200101-20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xOTAvZnJhZzpkZWMyZWRkNjViNWU0MzNlYWY1YzJmNmZmNzFiNDNmZi90YWJsZTpiYjg2NzJmMTk1NTM0YjZkYWI3YjVlMDg2NTY0NGYyZC90YWJsZXJhbmdlOmJiODY3MmYxOTU1MzRiNmRhYjdiNWUwODY1NjQ0ZjJkXzYtMy0xLTEtMA_0cb2b913-0e84-4ae9-b0fd-d83519f33d5a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-cash lease expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331" decimals="-3" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xOTAvZnJhZzpkZWMyZWRkNjViNWU0MzNlYWY1YzJmNmZmNzFiNDNmZi90YWJsZTpiYjg2NzJmMTk1NTM0YjZkYWI3YjVlMDg2NTY0NGYyZC90YWJsZXJhbmdlOmJiODY3MmYxOTU1MzRiNmRhYjdiNWUwODY1NjQ0ZjJkXzctMS0xLTEtMA_d4d0b93b-864e-47cb-9823-480934f46a0c">272</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i824a5b33f908426bad016f0eded844db_D20200101-20200331" decimals="-3" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xOTAvZnJhZzpkZWMyZWRkNjViNWU0MzNlYWY1YzJmNmZmNzFiNDNmZi90YWJsZTpiYjg2NzJmMTk1NTM0YjZkYWI3YjVlMDg2NTY0NGYyZC90YWJsZXJhbmdlOmJiODY3MmYxOTU1MzRiNmRhYjdiNWUwODY1NjQ0ZjJkXzctMy0xLTEtMA_8247b243-d6bf-44c6-85ad-8fe3320dff3b">366</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loss on disposal of property and equipment</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xOTAvZnJhZzpkZWMyZWRkNjViNWU0MzNlYWY1YzJmNmZmNzFiNDNmZi90YWJsZTpiYjg2NzJmMTk1NTM0YjZkYWI3YjVlMDg2NTY0NGYyZC90YWJsZXJhbmdlOmJiODY3MmYxOTU1MzRiNmRhYjdiNWUwODY1NjQ0ZjJkXzgtMS0xLTEtMA_64af70e5-5ce4-4bad-b01e-3d5e60d25d21">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i824a5b33f908426bad016f0eded844db_D20200101-20200331" decimals="-3" sign="-" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xOTAvZnJhZzpkZWMyZWRkNjViNWU0MzNlYWY1YzJmNmZmNzFiNDNmZi90YWJsZTpiYjg2NzJmMTk1NTM0YjZkYWI3YjVlMDg2NTY0NGYyZC90YWJsZXJhbmdlOmJiODY3MmYxOTU1MzRiNmRhYjdiNWUwODY1NjQ0ZjJkXzgtMy0xLTEtMA_401a6e27-dd1f-4042-ba4d-ea7158182a85">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xOTAvZnJhZzpkZWMyZWRkNjViNWU0MzNlYWY1YzJmNmZmNzFiNDNmZi90YWJsZTpiYjg2NzJmMTk1NTM0YjZkYWI3YjVlMDg2NTY0NGYyZC90YWJsZXJhbmdlOmJiODY3MmYxOTU1MzRiNmRhYjdiNWUwODY1NjQ0ZjJkXzktMS0xLTEtMA_390c9267-0ed6-4271-b257-6f24fa86fe9d">1,780</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i824a5b33f908426bad016f0eded844db_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xOTAvZnJhZzpkZWMyZWRkNjViNWU0MzNlYWY1YzJmNmZmNzFiNDNmZi90YWJsZTpiYjg2NzJmMTk1NTM0YjZkYWI3YjVlMDg2NTY0NGYyZC90YWJsZXJhbmdlOmJiODY3MmYxOTU1MzRiNmRhYjdiNWUwODY1NjQ0ZjJkXzktMy0xLTEtMA_91ae9804-70fb-4238-b623-62299089c722">1,409</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-cash interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331" decimals="-3" name="us-gaap:PaidInKindInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xOTAvZnJhZzpkZWMyZWRkNjViNWU0MzNlYWY1YzJmNmZmNzFiNDNmZi90YWJsZTpiYjg2NzJmMTk1NTM0YjZkYWI3YjVlMDg2NTY0NGYyZC90YWJsZXJhbmdlOmJiODY3MmYxOTU1MzRiNmRhYjdiNWUwODY1NjQ0ZjJkXzEwLTEtMS0xLTA_af55f382-c672-4515-b953-24aa44797ab9">387</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i824a5b33f908426bad016f0eded844db_D20200101-20200331" decimals="-3" name="us-gaap:PaidInKindInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xOTAvZnJhZzpkZWMyZWRkNjViNWU0MzNlYWY1YzJmNmZmNzFiNDNmZi90YWJsZTpiYjg2NzJmMTk1NTM0YjZkYWI3YjVlMDg2NTY0NGYyZC90YWJsZXJhbmdlOmJiODY3MmYxOTU1MzRiNmRhYjdiNWUwODY1NjQ0ZjJkXzEwLTMtMS0xLTA_e1fd45ac-b314-4ec5-b236-e3588428360c">123</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Warrant liabilities revaluation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FairValueAdjustmentOfWarrants" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xOTAvZnJhZzpkZWMyZWRkNjViNWU0MzNlYWY1YzJmNmZmNzFiNDNmZi90YWJsZTpiYjg2NzJmMTk1NTM0YjZkYWI3YjVlMDg2NTY0NGYyZC90YWJsZXJhbmdlOmJiODY3MmYxOTU1MzRiNmRhYjdiNWUwODY1NjQ0ZjJkXzExLTEtMS0xLTA_2ae9ba1b-1b9e-4268-8de9-e875a5670896">16,747</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i824a5b33f908426bad016f0eded844db_D20200101-20200331" decimals="-3" name="us-gaap:FairValueAdjustmentOfWarrants" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xOTAvZnJhZzpkZWMyZWRkNjViNWU0MzNlYWY1YzJmNmZmNzFiNDNmZi90YWJsZTpiYjg2NzJmMTk1NTM0YjZkYWI3YjVlMDg2NTY0NGYyZC90YWJsZXJhbmdlOmJiODY3MmYxOTU1MzRiNmRhYjdiNWUwODY1NjQ0ZjJkXzExLTMtMS0xLTA_76c22dea-9e91-4a21-8e85-a24c246017e7">846</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xOTAvZnJhZzpkZWMyZWRkNjViNWU0MzNlYWY1YzJmNmZmNzFiNDNmZi90YWJsZTpiYjg2NzJmMTk1NTM0YjZkYWI3YjVlMDg2NTY0NGYyZC90YWJsZXJhbmdlOmJiODY3MmYxOTU1MzRiNmRhYjdiNWUwODY1NjQ0ZjJkXzE1LTEtMS0xLTA_d712aa5b-1429-4df7-ac01-ea546a559fae">1,118</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i824a5b33f908426bad016f0eded844db_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xOTAvZnJhZzpkZWMyZWRkNjViNWU0MzNlYWY1YzJmNmZmNzFiNDNmZi90YWJsZTpiYjg2NzJmMTk1NTM0YjZkYWI3YjVlMDg2NTY0NGYyZC90YWJsZXJhbmdlOmJiODY3MmYxOTU1MzRiNmRhYjdiNWUwODY1NjQ0ZjJkXzE1LTMtMS0xLTA_7a471a43-3cc1-456d-808e-0f01e04e40c4">5,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prepaid expenses, deposits and other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xOTAvZnJhZzpkZWMyZWRkNjViNWU0MzNlYWY1YzJmNmZmNzFiNDNmZi90YWJsZTpiYjg2NzJmMTk1NTM0YjZkYWI3YjVlMDg2NTY0NGYyZC90YWJsZXJhbmdlOmJiODY3MmYxOTU1MzRiNmRhYjdiNWUwODY1NjQ0ZjJkXzE2LTEtMS0xLTA_28ee2a4f-b3ec-4f5a-9331-64ddbb08a9be">1,512</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i824a5b33f908426bad016f0eded844db_D20200101-20200331" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xOTAvZnJhZzpkZWMyZWRkNjViNWU0MzNlYWY1YzJmNmZmNzFiNDNmZi90YWJsZTpiYjg2NzJmMTk1NTM0YjZkYWI3YjVlMDg2NTY0NGYyZC90YWJsZXJhbmdlOmJiODY3MmYxOTU1MzRiNmRhYjdiNWUwODY1NjQ0ZjJkXzE2LTMtMS0xLTA_5641d634-8ab7-447a-9bf1-4c51dabe9959">61</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xOTAvZnJhZzpkZWMyZWRkNjViNWU0MzNlYWY1YzJmNmZmNzFiNDNmZi90YWJsZTpiYjg2NzJmMTk1NTM0YjZkYWI3YjVlMDg2NTY0NGYyZC90YWJsZXJhbmdlOmJiODY3MmYxOTU1MzRiNmRhYjdiNWUwODY1NjQ0ZjJkXzE3LTEtMS0xLTA_c3ff11f7-54e9-4911-b21f-c452d7a5bcb6">151</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i824a5b33f908426bad016f0eded844db_D20200101-20200331" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xOTAvZnJhZzpkZWMyZWRkNjViNWU0MzNlYWY1YzJmNmZmNzFiNDNmZi90YWJsZTpiYjg2NzJmMTk1NTM0YjZkYWI3YjVlMDg2NTY0NGYyZC90YWJsZXJhbmdlOmJiODY3MmYxOTU1MzRiNmRhYjdiNWUwODY1NjQ0ZjJkXzE3LTMtMS0xLTA_8f163050-1899-4f53-9b5f-f4ae98315310">836</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xOTAvZnJhZzpkZWMyZWRkNjViNWU0MzNlYWY1YzJmNmZmNzFiNDNmZi90YWJsZTpiYjg2NzJmMTk1NTM0YjZkYWI3YjVlMDg2NTY0NGYyZC90YWJsZXJhbmdlOmJiODY3MmYxOTU1MzRiNmRhYjdiNWUwODY1NjQ0ZjJkXzE5LTEtMS0xLTA_9e2ca3bb-0982-4339-9a01-5a8fcd7eb932">2,728</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i824a5b33f908426bad016f0eded844db_D20200101-20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xOTAvZnJhZzpkZWMyZWRkNjViNWU0MzNlYWY1YzJmNmZmNzFiNDNmZi90YWJsZTpiYjg2NzJmMTk1NTM0YjZkYWI3YjVlMDg2NTY0NGYyZC90YWJsZXJhbmdlOmJiODY3MmYxOTU1MzRiNmRhYjdiNWUwODY1NjQ0ZjJkXzE5LTMtMS0xLTA_65e8fc0c-1037-4cc3-b242-cd33c0e713ce">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued expenses and other liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xOTAvZnJhZzpkZWMyZWRkNjViNWU0MzNlYWY1YzJmNmZmNzFiNDNmZi90YWJsZTpiYjg2NzJmMTk1NTM0YjZkYWI3YjVlMDg2NTY0NGYyZC90YWJsZXJhbmdlOmJiODY3MmYxOTU1MzRiNmRhYjdiNWUwODY1NjQ0ZjJkXzIxLTEtMS0xLTA_b3667325-a803-4062-a2e9-8092ed654899">1,736</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i824a5b33f908426bad016f0eded844db_D20200101-20200331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xOTAvZnJhZzpkZWMyZWRkNjViNWU0MzNlYWY1YzJmNmZmNzFiNDNmZi90YWJsZTpiYjg2NzJmMTk1NTM0YjZkYWI3YjVlMDg2NTY0NGYyZC90YWJsZXJhbmdlOmJiODY3MmYxOTU1MzRiNmRhYjdiNWUwODY1NjQ0ZjJkXzIxLTMtMS0xLTA_977fe904-3722-4775-afc3-4e0ee8dd7e4f">829</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Net cash (used in) operating activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xOTAvZnJhZzpkZWMyZWRkNjViNWU0MzNlYWY1YzJmNmZmNzFiNDNmZi90YWJsZTpiYjg2NzJmMTk1NTM0YjZkYWI3YjVlMDg2NTY0NGYyZC90YWJsZXJhbmdlOmJiODY3MmYxOTU1MzRiNmRhYjdiNWUwODY1NjQ0ZjJkXzIyLTEtMS0xLTA_cee1b110-654d-4ab1-a9b2-caf29bffe544">12,133</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i824a5b33f908426bad016f0eded844db_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xOTAvZnJhZzpkZWMyZWRkNjViNWU0MzNlYWY1YzJmNmZmNzFiNDNmZi90YWJsZTpiYjg2NzJmMTk1NTM0YjZkYWI3YjVlMDg2NTY0NGYyZC90YWJsZXJhbmdlOmJiODY3MmYxOTU1MzRiNmRhYjdiNWUwODY1NjQ0ZjJkXzIyLTMtMS0xLTA_c7084c37-3e83-44b9-9a5c-961d11243349">11,698</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash flows from investing activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchases of marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xOTAvZnJhZzpkZWMyZWRkNjViNWU0MzNlYWY1YzJmNmZmNzFiNDNmZi90YWJsZTpiYjg2NzJmMTk1NTM0YjZkYWI3YjVlMDg2NTY0NGYyZC90YWJsZXJhbmdlOmJiODY3MmYxOTU1MzRiNmRhYjdiNWUwODY1NjQ0ZjJkXzI1LTEtMS0xLTA_b4a28fd0-9738-4d1d-b3b5-94ec2f1df958">22,420</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i824a5b33f908426bad016f0eded844db_D20200101-20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xOTAvZnJhZzpkZWMyZWRkNjViNWU0MzNlYWY1YzJmNmZmNzFiNDNmZi90YWJsZTpiYjg2NzJmMTk1NTM0YjZkYWI3YjVlMDg2NTY0NGYyZC90YWJsZXJhbmdlOmJiODY3MmYxOTU1MzRiNmRhYjdiNWUwODY1NjQ0ZjJkXzI1LTMtMS0xLTA_f9c89963-d5fd-44aa-86af-c2b787c69397">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchases of property and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xOTAvZnJhZzpkZWMyZWRkNjViNWU0MzNlYWY1YzJmNmZmNzFiNDNmZi90YWJsZTpiYjg2NzJmMTk1NTM0YjZkYWI3YjVlMDg2NTY0NGYyZC90YWJsZXJhbmdlOmJiODY3MmYxOTU1MzRiNmRhYjdiNWUwODY1NjQ0ZjJkXzI3LTEtMS0xLTA_f5d24220-fc8b-4de6-b500-ea69a375bd1f">25</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i824a5b33f908426bad016f0eded844db_D20200101-20200331" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xOTAvZnJhZzpkZWMyZWRkNjViNWU0MzNlYWY1YzJmNmZmNzFiNDNmZi90YWJsZTpiYjg2NzJmMTk1NTM0YjZkYWI3YjVlMDg2NTY0NGYyZC90YWJsZXJhbmdlOmJiODY3MmYxOTU1MzRiNmRhYjdiNWUwODY1NjQ0ZjJkXzI3LTMtMS0xLTA_0e9dc9c9-143e-4db1-95ca-8d73a0d92e1c">135</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Net cash (used in) investing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xOTAvZnJhZzpkZWMyZWRkNjViNWU0MzNlYWY1YzJmNmZmNzFiNDNmZi90YWJsZTpiYjg2NzJmMTk1NTM0YjZkYWI3YjVlMDg2NTY0NGYyZC90YWJsZXJhbmdlOmJiODY3MmYxOTU1MzRiNmRhYjdiNWUwODY1NjQ0ZjJkXzMwLTEtMS0xLTA_39079ba7-180f-4098-a9e6-67a533665d69">22,445</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i824a5b33f908426bad016f0eded844db_D20200101-20200331" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xOTAvZnJhZzpkZWMyZWRkNjViNWU0MzNlYWY1YzJmNmZmNzFiNDNmZi90YWJsZTpiYjg2NzJmMTk1NTM0YjZkYWI3YjVlMDg2NTY0NGYyZC90YWJsZXJhbmdlOmJiODY3MmYxOTU1MzRiNmRhYjdiNWUwODY1NjQ0ZjJkXzMwLTMtMS0xLTA_a96d6ce1-2ac8-433a-9632-c885b9f37f99">135</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash flows from financing activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Repayments of principal on outstanding debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:RepaymentsOfLongTermDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xOTAvZnJhZzpkZWMyZWRkNjViNWU0MzNlYWY1YzJmNmZmNzFiNDNmZi90YWJsZTpiYjg2NzJmMTk1NTM0YjZkYWI3YjVlMDg2NTY0NGYyZC90YWJsZXJhbmdlOmJiODY3MmYxOTU1MzRiNmRhYjdiNWUwODY1NjQ0ZjJkXzMzLTEtMS0xLTA_92c984d7-0276-45b6-88af-e2c026e78ec1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i824a5b33f908426bad016f0eded844db_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfLongTermDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xOTAvZnJhZzpkZWMyZWRkNjViNWU0MzNlYWY1YzJmNmZmNzFiNDNmZi90YWJsZTpiYjg2NzJmMTk1NTM0YjZkYWI3YjVlMDg2NTY0NGYyZC90YWJsZXJhbmdlOmJiODY3MmYxOTU1MzRiNmRhYjdiNWUwODY1NjQ0ZjJkXzMzLTMtMS0xLTA_5511e7be-61fc-4313-aaa0-4a26b09c5250">2,100</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net proceeds from issuance of common stock- at-the-market offering</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xOTAvZnJhZzpkZWMyZWRkNjViNWU0MzNlYWY1YzJmNmZmNzFiNDNmZi90YWJsZTpiYjg2NzJmMTk1NTM0YjZkYWI3YjVlMDg2NTY0NGYyZC90YWJsZXJhbmdlOmJiODY3MmYxOTU1MzRiNmRhYjdiNWUwODY1NjQ0ZjJkXzM5LTEtMS0xLTA_2ab4172f-796d-454d-a351-00013f91b9f8">20,991</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i824a5b33f908426bad016f0eded844db_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xOTAvZnJhZzpkZWMyZWRkNjViNWU0MzNlYWY1YzJmNmZmNzFiNDNmZi90YWJsZTpiYjg2NzJmMTk1NTM0YjZkYWI3YjVlMDg2NTY0NGYyZC90YWJsZXJhbmdlOmJiODY3MmYxOTU1MzRiNmRhYjdiNWUwODY1NjQ0ZjJkXzM5LTMtMS0xLTA_7a8596db-bc8c-42c2-9984-2be0694a9c27">1,141</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance costs paid for December 2019 financing</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:PaymentsOfFinancingCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xOTAvZnJhZzpkZWMyZWRkNjViNWU0MzNlYWY1YzJmNmZmNzFiNDNmZi90YWJsZTpiYjg2NzJmMTk1NTM0YjZkYWI3YjVlMDg2NTY0NGYyZC90YWJsZXJhbmdlOmJiODY3MmYxOTU1MzRiNmRhYjdiNWUwODY1NjQ0ZjJkXzQxLTEtMS0xLTA_4e36588d-b6ed-42c3-9298-9178d1b44a84">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i824a5b33f908426bad016f0eded844db_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsOfFinancingCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xOTAvZnJhZzpkZWMyZWRkNjViNWU0MzNlYWY1YzJmNmZmNzFiNDNmZi90YWJsZTpiYjg2NzJmMTk1NTM0YjZkYWI3YjVlMDg2NTY0NGYyZC90YWJsZXJhbmdlOmJiODY3MmYxOTU1MzRiNmRhYjdiNWUwODY1NjQ0ZjJkXzQxLTMtMS0xLTA_b586c93c-508b-40c2-8c58-d5915c13bebc">4,381</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other financing fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xOTAvZnJhZzpkZWMyZWRkNjViNWU0MzNlYWY1YzJmNmZmNzFiNDNmZi90YWJsZTpiYjg2NzJmMTk1NTM0YjZkYWI3YjVlMDg2NTY0NGYyZC90YWJsZXJhbmdlOmJiODY3MmYxOTU1MzRiNmRhYjdiNWUwODY1NjQ0ZjJkXzQyLTEtMS0xLTA_c9291dcd-6e58-4f15-ba8e-70cff1c938b3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i824a5b33f908426bad016f0eded844db_D20200101-20200331" decimals="-3" sign="-" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xOTAvZnJhZzpkZWMyZWRkNjViNWU0MzNlYWY1YzJmNmZmNzFiNDNmZi90YWJsZTpiYjg2NzJmMTk1NTM0YjZkYWI3YjVlMDg2NTY0NGYyZC90YWJsZXJhbmdlOmJiODY3MmYxOTU1MzRiNmRhYjdiNWUwODY1NjQ0ZjJkXzQyLTMtMS0xLTA_f910a00a-1447-4cc7-a58a-d820869b6540">147</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from exercise of stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xOTAvZnJhZzpkZWMyZWRkNjViNWU0MzNlYWY1YzJmNmZmNzFiNDNmZi90YWJsZTpiYjg2NzJmMTk1NTM0YjZkYWI3YjVlMDg2NTY0NGYyZC90YWJsZXJhbmdlOmJiODY3MmYxOTU1MzRiNmRhYjdiNWUwODY1NjQ0ZjJkXzQ0LTEtMS0xLTA_d36580b0-c0f8-4153-837e-b4e5b1140d11">244</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i824a5b33f908426bad016f0eded844db_D20200101-20200331" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xOTAvZnJhZzpkZWMyZWRkNjViNWU0MzNlYWY1YzJmNmZmNzFiNDNmZi90YWJsZTpiYjg2NzJmMTk1NTM0YjZkYWI3YjVlMDg2NTY0NGYyZC90YWJsZXJhbmdlOmJiODY3MmYxOTU1MzRiNmRhYjdiNWUwODY1NjQ0ZjJkXzQ0LTMtMS0xLTA_9b6bd3cf-92dd-4a14-8848-79aa1f8da7d6">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from issuance of common stock under Employee Stock Purchase Plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331" decimals="-3" name="us-gaap:ProceedsFromStockPlans" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xOTAvZnJhZzpkZWMyZWRkNjViNWU0MzNlYWY1YzJmNmZmNzFiNDNmZi90YWJsZTpiYjg2NzJmMTk1NTM0YjZkYWI3YjVlMDg2NTY0NGYyZC90YWJsZXJhbmdlOmJiODY3MmYxOTU1MzRiNmRhYjdiNWUwODY1NjQ0ZjJkXzQ1LTEtMS0xLTA_c417a70e-133a-4993-94a6-9927c5481be5">72</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i824a5b33f908426bad016f0eded844db_D20200101-20200331" decimals="-3" name="us-gaap:ProceedsFromStockPlans" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xOTAvZnJhZzpkZWMyZWRkNjViNWU0MzNlYWY1YzJmNmZmNzFiNDNmZi90YWJsZTpiYjg2NzJmMTk1NTM0YjZkYWI3YjVlMDg2NTY0NGYyZC90YWJsZXJhbmdlOmJiODY3MmYxOTU1MzRiNmRhYjdiNWUwODY1NjQ0ZjJkXzQ1LTMtMS0xLTA_6f2b3d2c-5e33-4fb2-9ce7-054afc303da2">114</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Net cash provided by (used in) financing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xOTAvZnJhZzpkZWMyZWRkNjViNWU0MzNlYWY1YzJmNmZmNzFiNDNmZi90YWJsZTpiYjg2NzJmMTk1NTM0YjZkYWI3YjVlMDg2NTY0NGYyZC90YWJsZXJhbmdlOmJiODY3MmYxOTU1MzRiNmRhYjdiNWUwODY1NjQ0ZjJkXzQ2LTEtMS0xLTA_a24e7d93-cfd7-416d-815f-93a05edf160a">21,307</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i824a5b33f908426bad016f0eded844db_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xOTAvZnJhZzpkZWMyZWRkNjViNWU0MzNlYWY1YzJmNmZmNzFiNDNmZi90YWJsZTpiYjg2NzJmMTk1NTM0YjZkYWI3YjVlMDg2NTY0NGYyZC90YWJsZXJhbmdlOmJiODY3MmYxOTU1MzRiNmRhYjdiNWUwODY1NjQ0ZjJkXzQ2LTMtMS0xLTA_4ddace37-b671-43a3-9cb8-6f3a1b4d54cf">5,370</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Effect of exchange rate changes on cash</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xOTAvZnJhZzpkZWMyZWRkNjViNWU0MzNlYWY1YzJmNmZmNzFiNDNmZi90YWJsZTpiYjg2NzJmMTk1NTM0YjZkYWI3YjVlMDg2NTY0NGYyZC90YWJsZXJhbmdlOmJiODY3MmYxOTU1MzRiNmRhYjdiNWUwODY1NjQ0ZjJkXzQ3LTEtMS0xLTA_061f4216-c2fe-4333-a199-882e1abb4cf0">7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i824a5b33f908426bad016f0eded844db_D20200101-20200331" decimals="-3" sign="-" name="us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xOTAvZnJhZzpkZWMyZWRkNjViNWU0MzNlYWY1YzJmNmZmNzFiNDNmZi90YWJsZTpiYjg2NzJmMTk1NTM0YjZkYWI3YjVlMDg2NTY0NGYyZC90YWJsZXJhbmdlOmJiODY3MmYxOTU1MzRiNmRhYjdiNWUwODY1NjQ0ZjJkXzQ3LTMtMS0xLTA_30aa9f54-4753-4f2f-b677-90f069b68373">84</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net change in cash, cash equivalents, and restricted cash</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xOTAvZnJhZzpkZWMyZWRkNjViNWU0MzNlYWY1YzJmNmZmNzFiNDNmZi90YWJsZTpiYjg2NzJmMTk1NTM0YjZkYWI3YjVlMDg2NTY0NGYyZC90YWJsZXJhbmdlOmJiODY3MmYxOTU1MzRiNmRhYjdiNWUwODY1NjQ0ZjJkXzQ4LTEtMS0xLTA_c2579323-3a99-46e0-8d00-493d0c1bc91b">13,278</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i824a5b33f908426bad016f0eded844db_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xOTAvZnJhZzpkZWMyZWRkNjViNWU0MzNlYWY1YzJmNmZmNzFiNDNmZi90YWJsZTpiYjg2NzJmMTk1NTM0YjZkYWI3YjVlMDg2NTY0NGYyZC90YWJsZXJhbmdlOmJiODY3MmYxOTU1MzRiNmRhYjdiNWUwODY1NjQ0ZjJkXzQ4LTMtMS0xLTA_f2ad2805-cc03-4b3f-b307-65177ac29fdc">17,287</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash, cash equivalents, and restricted cash at beginning of period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib56f1adc867e406ca7face50c5da1c9c_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xOTAvZnJhZzpkZWMyZWRkNjViNWU0MzNlYWY1YzJmNmZmNzFiNDNmZi90YWJsZTpiYjg2NzJmMTk1NTM0YjZkYWI3YjVlMDg2NTY0NGYyZC90YWJsZXJhbmdlOmJiODY3MmYxOTU1MzRiNmRhYjdiNWUwODY1NjQ0ZjJkXzQ5LTEtMS0xLTA_ef4f931e-a518-484b-86b9-ce8207d9aa43">140,064</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iabdd66a36794438ab9664178bf3cf96a_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xOTAvZnJhZzpkZWMyZWRkNjViNWU0MzNlYWY1YzJmNmZmNzFiNDNmZi90YWJsZTpiYjg2NzJmMTk1NTM0YjZkYWI3YjVlMDg2NTY0NGYyZC90YWJsZXJhbmdlOmJiODY3MmYxOTU1MzRiNmRhYjdiNWUwODY1NjQ0ZjJkXzQ5LTMtMS0xLTA_4fbc2152-ce45-45fa-b2e6-5b295c8ae8e3">91,551</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash, cash equivalents, and restricted cash at end of period</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied8d945ebce54ed8a4badfed477a64e8_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xOTAvZnJhZzpkZWMyZWRkNjViNWU0MzNlYWY1YzJmNmZmNzFiNDNmZi90YWJsZTpiYjg2NzJmMTk1NTM0YjZkYWI3YjVlMDg2NTY0NGYyZC90YWJsZXJhbmdlOmJiODY3MmYxOTU1MzRiNmRhYjdiNWUwODY1NjQ0ZjJkXzUwLTEtMS0xLTA_35785ff5-136b-453d-9b45-8f9e9715d6bd">126,786</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff7e2530342c41bca8c84fce55f0cc6f_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xOTAvZnJhZzpkZWMyZWRkNjViNWU0MzNlYWY1YzJmNmZmNzFiNDNmZi90YWJsZTpiYjg2NzJmMTk1NTM0YjZkYWI3YjVlMDg2NTY0NGYyZC90YWJsZXJhbmdlOmJiODY3MmYxOTU1MzRiNmRhYjdiNWUwODY1NjQ0ZjJkXzUwLTMtMS0xLTA_bf150567-3b37-4595-b978-af7f39f3aba3">74,264</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Supplement cash flow information</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash paid for interest</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331" decimals="-3" name="us-gaap:InterestPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xOTAvZnJhZzpkZWMyZWRkNjViNWU0MzNlYWY1YzJmNmZmNzFiNDNmZi90YWJsZTpiYjg2NzJmMTk1NTM0YjZkYWI3YjVlMDg2NTY0NGYyZC90YWJsZXJhbmdlOmJiODY3MmYxOTU1MzRiNmRhYjdiNWUwODY1NjQ0ZjJkXzUyLTEtMS0xLTA_68701c37-1331-484a-9338-8685e0f25db2">494</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i824a5b33f908426bad016f0eded844db_D20200101-20200331" decimals="-3" name="us-gaap:InterestPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xOTAvZnJhZzpkZWMyZWRkNjViNWU0MzNlYWY1YzJmNmZmNzFiNDNmZi90YWJsZTpiYjg2NzJmMTk1NTM0YjZkYWI3YjVlMDg2NTY0NGYyZC90YWJsZXJhbmdlOmJiODY3MmYxOTU1MzRiNmRhYjdiNWUwODY1NjQ0ZjJkXzUyLTMtMS0xLTA_70f29e8d-5e2a-457b-9b70-9f490585d470">232</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Noncash investing and financing activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchase of property and equipment not yet paid</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xOTAvZnJhZzpkZWMyZWRkNjViNWU0MzNlYWY1YzJmNmZmNzFiNDNmZi90YWJsZTpiYjg2NzJmMTk1NTM0YjZkYWI3YjVlMDg2NTY0NGYyZC90YWJsZXJhbmdlOmJiODY3MmYxOTU1MzRiNmRhYjdiNWUwODY1NjQ0ZjJkXzU3LTEtMS0xLTA_4c552261-e480-4e08-94d2-87d55cc01da3">10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i824a5b33f908426bad016f0eded844db_D20200101-20200331" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xOTAvZnJhZzpkZWMyZWRkNjViNWU0MzNlYWY1YzJmNmZmNzFiNDNmZi90YWJsZTpiYjg2NzJmMTk1NTM0YjZkYWI3YjVlMDg2NTY0NGYyZC90YWJsZXJhbmdlOmJiODY3MmYxOTU1MzRiNmRhYjdiNWUwODY1NjQ0ZjJkXzU3LTMtMS0xLTA_bc1316b7-55c8-4e28-95ae-5f3e60630a76">10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Equity offering costs in accrued liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331" decimals="-3" name="selb:EquityOfferingCostsInAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xOTAvZnJhZzpkZWMyZWRkNjViNWU0MzNlYWY1YzJmNmZmNzFiNDNmZi90YWJsZTpiYjg2NzJmMTk1NTM0YjZkYWI3YjVlMDg2NTY0NGYyZC90YWJsZXJhbmdlOmJiODY3MmYxOTU1MzRiNmRhYjdiNWUwODY1NjQ0ZjJkXzU4LTEtMS0xLTA_d9a0c50f-7cc7-4271-ba97-901696e4bea8">48</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i824a5b33f908426bad016f0eded844db_D20200101-20200331" decimals="-3" name="selb:EquityOfferingCostsInAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xOTAvZnJhZzpkZWMyZWRkNjViNWU0MzNlYWY1YzJmNmZmNzFiNDNmZi90YWJsZTpiYjg2NzJmMTk1NTM0YjZkYWI3YjVlMDg2NTY0NGYyZC90YWJsZXJhbmdlOmJiODY3MmYxOTU1MzRiNmRhYjdiNWUwODY1NjQ0ZjJkXzU4LTMtMS0xLTA_752a2bbd-51dd-4bd6-b342-580a5020c220">42</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized (losses) on marketable securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:MarketableSecuritiesUnrealizedGainLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xOTAvZnJhZzpkZWMyZWRkNjViNWU0MzNlYWY1YzJmNmZmNzFiNDNmZi90YWJsZTpiYjg2NzJmMTk1NTM0YjZkYWI3YjVlMDg2NTY0NGYyZC90YWJsZXJhbmdlOmJiODY3MmYxOTU1MzRiNmRhYjdiNWUwODY1NjQ0ZjJkXzU5LTEtMS0xLTA_42497b75-5088-4b04-944f-e8a7f27c9e83">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i824a5b33f908426bad016f0eded844db_D20200101-20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:MarketableSecuritiesUnrealizedGainLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xOTAvZnJhZzpkZWMyZWRkNjViNWU0MzNlYWY1YzJmNmZmNzFiNDNmZi90YWJsZTpiYjg2NzJmMTk1NTM0YjZkYWI3YjVlMDg2NTY0NGYyZC90YWJsZXJhbmdlOmJiODY3MmYxOTU1MzRiNmRhYjdiNWUwODY1NjQ0ZjJkXzU5LTMtMS0xLTA_63f7cd7a-49d4-4f77-ba90-9e29170b1f7e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:3pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these unaudited consolidated financial statements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><div id="i71586e7d2e304f6983634abe9e071791_193"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i71586e7d2e304f6983634abe9e071791_13">Table of Contents</a></span></div></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Selecta Biosciences, Inc. and Subsidiaries</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements (Unaudited)</span></div><div id="i71586e7d2e304f6983634abe9e071791_196"></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1. <ix:nonNumeric contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xOTYvZnJhZzo5OTMzN2E4MThjODA0MzBjOWRjNDc2MjBkMmZmMDA0Yy90ZXh0cmVnaW9uOjk5MzM3YTgxOGM4MDQzMGM5ZGM0NzYyMGQyZmYwMDRjXzU2MTQ_38383a94-33b2-426b-a56d-7bb0d4074e71" continuedAt="i3a250479db194f41a6fdafc81890dcd5" escape="true">Nature of the Business and Basis of Presentation</ix:nonNumeric></span></div><ix:continuation id="i3a250479db194f41a6fdafc81890dcd5" continuedAt="i021f3de7a3ed4749a8a7a9fe7b1d0573"><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selecta Biosciences, Inc., or the Company was incorporated in Delaware on December 10, 2007, and is based in Watertown, Massachusetts. The Company is a clinical-stage biopharmaceutical company leveraging its ImmTOR&#8482; immune tolerance platform with the goals of amplifying the efficacy of biologics, including enabling the re-dosing of life-saving gene therapies, and restoring self-tolerance in autoimmune diseases. The Company&#8217;s ImmTOR platform encapsulates rapamycin, also known as sirolimus, an immunomodulator, in biodegradable nanoparticles and is designed to induce antigen-specific immune tolerance. The Company believes ImmTOR has the potential to enhance the efficacy without compromising the safety of biologic therapies, improve product candidates under development, and enable novel therapeutic modalities. Since inception, the Company has devoted its efforts principally to research and development of its technology and product candidates, recruiting management and technical staff, acquiring operating assets, and raising capital.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to risks common to companies in the biotechnology industry including, but not limited to, new technological innovations, protection of proprietary technology, dependence on key personnel, compliance with government regulations and the need to obtain additional financing. Product candidates currently under development will require significant additional research and development efforts, including extensive preclinical and clinical testing and regulatory approval, prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel infrastructure and extensive compliance-reporting capabilities.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s product candidates are in development. There can be no assurance that the Company&#8217;s research and development will be successfully completed, that adequate protection for the Company&#8217;s intellectual property will be obtained, or maintained, that any products developed will obtain necessary government regulatory approval or that any approved products will be commercially viable. Even if the Company&#8217;s product development efforts are successful, it is uncertain when, if ever, the Company will generate significant revenue from product sales. The Company operates in an environment of rapid change in technology and substantial competition from pharmaceutical and biotechnology companies. In addition, the Company is dependent upon the services of its employees and consultants.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Unaudited Interim Financial Information</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited consolidated financial statements for the three months ended March 31, 2021 and 2020 have been prepared by the Company, pursuant to the rules and regulations of the Securities and Exchange Commission, or the SEC, for interim financial statements. Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America, or U.S. GAAP, have been condensed or omitted pursuant to such rules and regulations. These consolidated financial statements should be read in conjunction with the Company&#8217;s audited consolidated financial statements and the notes thereto for the year ended December 31, 2020 included in the Company&#8217;s Annual Report on Form 10-K that was filed with the SEC on March 12, 2021. The unaudited interim financial statements have been prepared on the same basis as the audited consolidated financial statements. In the opinion of management, the accompanying unaudited interim consolidated financial statements contain all adjustments that are necessary for a fair statement of the Company&#8217;s financial position as of March 31, 2021 and consolidated results of operations and cash flows for the three months ended March 31, 2021. Such adjustments are of a normal and recurring nature. The results of operations for the three months ended March 31, 2021 are not necessarily indicative of the results of operations that may be expected for the year ending December 31, 2021.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Management&#8217;s Plan</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The future success of the Company is dependent on its ability to develop its product candidates and ultimately upon its ability to attain profitable operations. The Company is subject to a number of risks similar to other early-stage life science companies, including, but not limited to, successful development of its product candidates, raising additional capital with favorable terms, protection of proprietary technology and market acceptance of any approved future products. The successful development of product candidates requires substantial working capital which may not be available to the Company on favorable terms or at all.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, the Company has financed its operations primarily through the initial public offering of its common stock, private placements of its common stock, issuances of common and preferred stock, debt, research grants and research collaborations. The Company currently has no source of product revenue, and it does not expect to generate product revenue for the foreseeable future. To date, all of the Company&#8217;s revenue has been collaboration and grant revenue. The Company has devoted substantially all of its financial resources and efforts to developing its ImmTOR platform, identifying potential product candidates and conducting preclinical studies and its clinical trials. The Company is in the early stages of development of its product candidates, and it has not completed development of any ImmTOR-enabled therapies.</span></div></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i71586e7d2e304f6983634abe9e071791_13">Table of Contents</a></span></div></div><ix:continuation id="i021f3de7a3ed4749a8a7a9fe7b1d0573"><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2021, the Company&#8217;s cash, cash equivalents, restricted cash and marketable securities were $<ix:nonFraction unitRef="usd" contextRef="ied8d945ebce54ed8a4badfed477a64e8_I20210331" decimals="-5" format="ixt:numdotdecimal" name="selb:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndDebtSecuritiesAvailableForSale" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xOTYvZnJhZzo5OTMzN2E4MThjODA0MzBjOWRjNDc2MjBkMmZmMDA0Yy90ZXh0cmVnaW9uOjk5MzM3YTgxOGM4MDQzMGM5ZGM0NzYyMGQyZmYwMDRjXzQxMzA_f61baea5-2884-434d-b402-07406838de9c">149.2</ix:nonFraction> million, of which $<ix:nonFraction unitRef="usd" contextRef="ied8d945ebce54ed8a4badfed477a64e8_I20210331" decimals="-5" name="us-gaap:RestrictedCashAndCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xOTYvZnJhZzo5OTMzN2E4MThjODA0MzBjOWRjNDc2MjBkMmZmMDA0Yy90ZXh0cmVnaW9uOjk5MzM3YTgxOGM4MDQzMGM5ZGM0NzYyMGQyZmYwMDRjXzQxNDM_9879f30e-6773-4b7a-94d9-3a4eb1f57b96">1.4</ix:nonFraction> million was restricted cash related to lease commitments and $<ix:nonFraction unitRef="usd" contextRef="i2fa0062d7932481c8274387fef46611d_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Cash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xOTYvZnJhZzo5OTMzN2E4MThjODA0MzBjOWRjNDc2MjBkMmZmMDA0Yy90ZXh0cmVnaW9uOjk5MzM3YTgxOGM4MDQzMGM5ZGM0NzYyMGQyZmYwMDRjXzQyMDc_16bbb620-2246-47af-ac15-c655c847f408">0.3</ix:nonFraction> million was held by its Russian subsidiary designated solely for use in its operations. The Company believes the cash, cash equivalents, restricted cash and marketable securities as of March 31, 2021 will enable it to fund its operating expenses and capital expenditure requirements into the second quarter of 2023. The Company has incurred losses and negative cash flows from operating activities since inception. As of March 31, 2021, the Company had an accumulated deficit of $<ix:nonFraction unitRef="usd" contextRef="ied8d945ebce54ed8a4badfed477a64e8_I20210331" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xOTYvZnJhZzo5OTMzN2E4MThjODA0MzBjOWRjNDc2MjBkMmZmMDA0Yy90ZXh0cmVnaW9uOjk5MzM3YTgxOGM4MDQzMGM5ZGM0NzYyMGQyZmYwMDRjXzQ1Mzc_2da8002d-87c2-40e1-9e80-2bff1aa5156c">429.2</ix:nonFraction> million. The Company anticipates operating losses to continue for the foreseeable future due to, among other things, costs related to research, development of its product candidates, conducting preclinical studies and clinical trials, and its administrative organization. The Company will require substantial additional financing to fund its operations and to continue to execute its strategy, and the Company will pursue a range of options to secure additional capital.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">At this time, there is significant uncertainty relating to the trajectory of the COVID-19 pandemic and the impact of related responses. Any impact of COVID-19 on the Company&#8217;s business, revenues, results of operations and financial condition will largely depend on future developments, which are highly uncertain and cannot be predicted with confidence, such as the duration of the pandemic, travel restrictions and social distancing in the United States and other countries, business closures or business disruptions, supply chain disruptions, the ultimate impact on financial markets and the global economy, and the effectiveness of actions taken in the United States and other countries to contain and treat the disease.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Guarantees and Indemnifications</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As permitted under Delaware law, the Company indemnifies its officers, directors, consultants and employees for certain events or occurrences that happen by reason of the relationship with, or position held at, the Company. Through March 31, 2021, the Company had not experienced any losses related to these indemnification obligations, and no claims were outstanding. The Company does not expect significant claims related to these indemnification obligations and, consequently, concluded that the fair value of these obligations is negligible, and no related reserves were established.</span></div></ix:continuation><div><span><br/></span></div><div id="i71586e7d2e304f6983634abe9e071791_202"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2. <ix:nonNumeric contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMDIvZnJhZzo4M2RiZWFmN2FhNmM0YjE1OGFkZjMyNmQxM2VlNWQyMy90ZXh0cmVnaW9uOjgzZGJlYWY3YWE2YzRiMTU4YWRmMzI2ZDEzZWU1ZDIzXzMzNDQx_acafb9ae-02dd-4d85-a097-930dc002c80a" continuedAt="if47ac824499e473eb0ad6cea5507c8eb" escape="true">Summary of Significant Accounting Policies</ix:nonNumeric></span></div><ix:continuation id="if47ac824499e473eb0ad6cea5507c8eb"><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no material changes to the Company&#8217;s significant accounting policies during the three months ended March 31, 2021, as compared to the significant accounting policies disclosed in Note 2 &#8211; Summary of Significant Accounting Policies included in the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2020.</span></div><ix:nonNumeric contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMDIvZnJhZzo4M2RiZWFmN2FhNmM0YjE1OGFkZjMyNmQxM2VlNWQyMy90ZXh0cmVnaW9uOjgzZGJlYWY3YWE2YzRiMTU4YWRmMzI2ZDEzZWU1ZDIzXzMzNDU3_f0f499cb-5bc0-4e41-bfde-8f11168f9075" escape="true"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recently Adopted</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the FASB issued ASU 2019-12,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Income Taxes (Topic 740) - Simplifying the Accounting for Income Taxes.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ASU 2019-12 simplifies the accounting for income taxes by removing certain exceptions to the general principles in Topic 740. The Company adopted the new standard effective January 1, 2021, and there was no impact on its consolidated financial statements.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2020, the FASB issued ASU 2020-10, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Codification Improvements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which updates various codification topics by clarifying or improving disclosure requirements to align with the SEC&#8217;s regulations. The Company adopted the new standard effective January 1, 2021, and there was no impact on its consolidated financial statements.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Not Yet Adopted</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, the FASB issued ASU 2020-06, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt &#8211; Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging &#8211; Contracts in Entity&#8217;s Own Equity (Subtopic 815 &#8211; 40)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. ASU 2020-06 simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts on an entity&#8217;s own equity. This ASU is effective for smaller reporting companies for fiscal years beginning after December 15, 2023, with early adoption permitted no earlier than January 1, 2021. The Company is assessing the impact this standard will have on its consolidated financial statements and disclosures.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the FASB issued ASU 2016-13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments-Credit Losses (Topic 326), Measurement of Credit Losses on Financial Instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Subsequently, in November 2018, the FASB issued ASU 2018-19,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Codification Improvements to Topic 326, Financial Instruments-Credit Losses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.&#160;ASU 2016-13 requires entities to measure all expected credit losses for most financial assets held at the reporting date based on an expected loss model which includes historical experience, current conditions, and reasonable and supportable forecasts. ASU 2016-13 also requires enhanced disclosures to help financial statement users better understand significant estimates and judgments used in estimating credit losses. This ASU is effective for smaller reporting companies for fiscal years beginning after December 15, 2022, with early adoption permitted. The Company is assessing the impact this standard will have on its consolidated financial statements and disclosures.</span></div></ix:nonNumeric></ix:continuation><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><div id="i71586e7d2e304f6983634abe9e071791_205"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i71586e7d2e304f6983634abe9e071791_13">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3. <ix:nonNumeric contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331" name="us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMDUvZnJhZzo1Y2UzYTMxYjllM2Y0NGIzYTMyY2VmMTkzYjdjM2Y1MC90ZXh0cmVnaW9uOjVjZTNhMzFiOWUzZjQ0YjNhMzJjZWYxOTNiN2MzZjUwXzExMg_6e5c3b09-e9d6-405a-ab2c-f13309d7c7bb" continuedAt="ib91959062ee04147889cb0566d65bf2e" escape="true">Marketable Securities</ix:nonNumeric></span></div><ix:continuation id="ib91959062ee04147889cb0566d65bf2e"><ix:nonNumeric contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331" name="us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMDUvZnJhZzo1Y2UzYTMxYjllM2Y0NGIzYTMyY2VmMTkzYjdjM2Y1MC90ZXh0cmVnaW9uOjVjZTNhMzFiOWUzZjQ0YjNhMzJjZWYxOTNiN2MzZjUwXzQzOTgwNDY1MTI0MTE_b1b000ee-b4c5-46dc-a097-3c7638f4a64e" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the marketable securities held as of March 31, 2021 (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.923%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.602%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized gains</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized losses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3c76b1f92aa42d09acee15de07994bb_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMDUvZnJhZzo1Y2UzYTMxYjllM2Y0NGIzYTMyY2VmMTkzYjdjM2Y1MC90YWJsZTo1ZmMyNDQ4ZjZjNmM0ZjFhYTcxNzkwYTY0NWNmMGU1Ni90YWJsZXJhbmdlOjVmYzI0NDhmNmM2YzRmMWFhNzE3OTBhNjQ1Y2YwZTU2XzMtMS0xLTEtMTQ3Nw_2661b199-de05-4ecb-8b8a-136e29b9133d">2,032</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3c76b1f92aa42d09acee15de07994bb_I20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMDUvZnJhZzo1Y2UzYTMxYjllM2Y0NGIzYTMyY2VmMTkzYjdjM2Y1MC90YWJsZTo1ZmMyNDQ4ZjZjNmM0ZjFhYTcxNzkwYTY0NWNmMGU1Ni90YWJsZXJhbmdlOjVmYzI0NDhmNmM2YzRmMWFhNzE3OTBhNjQ1Y2YwZTU2XzMtMy0xLTEtMTQ3Nw_55551cd5-650f-4d52-a49b-67d8a09d0f72">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic3c76b1f92aa42d09acee15de07994bb_I20210331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMDUvZnJhZzo1Y2UzYTMxYjllM2Y0NGIzYTMyY2VmMTkzYjdjM2Y1MC90YWJsZTo1ZmMyNDQ4ZjZjNmM0ZjFhYTcxNzkwYTY0NWNmMGU1Ni90YWJsZXJhbmdlOjVmYzI0NDhmNmM2YzRmMWFhNzE3OTBhNjQ1Y2YwZTU2XzMtNS0xLTEtMTQ3Nw_53b77bdc-5c09-4fb8-9561-2f08bd553fc2">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3c76b1f92aa42d09acee15de07994bb_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMDUvZnJhZzo1Y2UzYTMxYjllM2Y0NGIzYTMyY2VmMTkzYjdjM2Y1MC90YWJsZTo1ZmMyNDQ4ZjZjNmM0ZjFhYTcxNzkwYTY0NWNmMGU1Ni90YWJsZXJhbmdlOjVmYzI0NDhmNmM2YzRmMWFhNzE3OTBhNjQ1Y2YwZTU2XzMtNy0xLTEtMzI4Mg_0bb911c9-bbb9-4a25-8200-071f190ea0cf">2,031</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14e2b8def247421298d392498e8d2a2c_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMDUvZnJhZzo1Y2UzYTMxYjllM2Y0NGIzYTMyY2VmMTkzYjdjM2Y1MC90YWJsZTo1ZmMyNDQ4ZjZjNmM0ZjFhYTcxNzkwYTY0NWNmMGU1Ni90YWJsZXJhbmdlOjVmYzI0NDhmNmM2YzRmMWFhNzE3OTBhNjQ1Y2YwZTU2XzQtMS0xLTEtMTQ3Nw_76db9aea-c1ef-408b-998f-e1c77eee8088">20,374</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14e2b8def247421298d392498e8d2a2c_I20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMDUvZnJhZzo1Y2UzYTMxYjllM2Y0NGIzYTMyY2VmMTkzYjdjM2Y1MC90YWJsZTo1ZmMyNDQ4ZjZjNmM0ZjFhYTcxNzkwYTY0NWNmMGU1Ni90YWJsZXJhbmdlOjVmYzI0NDhmNmM2YzRmMWFhNzE3OTBhNjQ1Y2YwZTU2XzQtMy0xLTEtMTQ3Nw_731a75f4-0445-4396-87d1-e94557ab2f16">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14e2b8def247421298d392498e8d2a2c_I20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMDUvZnJhZzo1Y2UzYTMxYjllM2Y0NGIzYTMyY2VmMTkzYjdjM2Y1MC90YWJsZTo1ZmMyNDQ4ZjZjNmM0ZjFhYTcxNzkwYTY0NWNmMGU1Ni90YWJsZXJhbmdlOjVmYzI0NDhmNmM2YzRmMWFhNzE3OTBhNjQ1Y2YwZTU2XzQtNS0xLTEtMTQ3Nw_dbe3c51b-72ab-4a02-9130-13142ecfb2f4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14e2b8def247421298d392498e8d2a2c_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMDUvZnJhZzo1Y2UzYTMxYjllM2Y0NGIzYTMyY2VmMTkzYjdjM2Y1MC90YWJsZTo1ZmMyNDQ4ZjZjNmM0ZjFhYTcxNzkwYTY0NWNmMGU1Ni90YWJsZXJhbmdlOjVmYzI0NDhmNmM2YzRmMWFhNzE3OTBhNjQ1Y2YwZTU2XzQtNy0xLTEtMzI4Mg_1c399d01-d711-48b2-88c5-7a5b7334ea17">20,374</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied8d945ebce54ed8a4badfed477a64e8_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMDUvZnJhZzo1Y2UzYTMxYjllM2Y0NGIzYTMyY2VmMTkzYjdjM2Y1MC90YWJsZTo1ZmMyNDQ4ZjZjNmM0ZjFhYTcxNzkwYTY0NWNmMGU1Ni90YWJsZXJhbmdlOjVmYzI0NDhmNmM2YzRmMWFhNzE3OTBhNjQ1Y2YwZTU2XzYtMS0xLTEtMzI3NQ_b3538d9c-fcc0-40fb-bf24-e872cbb62dd4">22,406</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied8d945ebce54ed8a4badfed477a64e8_I20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMDUvZnJhZzo1Y2UzYTMxYjllM2Y0NGIzYTMyY2VmMTkzYjdjM2Y1MC90YWJsZTo1ZmMyNDQ4ZjZjNmM0ZjFhYTcxNzkwYTY0NWNmMGU1Ni90YWJsZXJhbmdlOjVmYzI0NDhmNmM2YzRmMWFhNzE3OTBhNjQ1Y2YwZTU2XzYtMy0xLTEtMzI3OA_2b0b518c-aa53-4c1a-98ff-deca5f5c721a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ied8d945ebce54ed8a4badfed477a64e8_I20210331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMDUvZnJhZzo1Y2UzYTMxYjllM2Y0NGIzYTMyY2VmMTkzYjdjM2Y1MC90YWJsZTo1ZmMyNDQ4ZjZjNmM0ZjFhYTcxNzkwYTY0NWNmMGU1Ni90YWJsZXJhbmdlOjVmYzI0NDhmNmM2YzRmMWFhNzE3OTBhNjQ1Y2YwZTU2XzYtNS0xLTEtMzI4MA_f12c965a-6a0a-44c8-bb5d-a5431a3f7b1e">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied8d945ebce54ed8a4badfed477a64e8_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMDUvZnJhZzo1Y2UzYTMxYjllM2Y0NGIzYTMyY2VmMTkzYjdjM2Y1MC90YWJsZTo1ZmMyNDQ4ZjZjNmM0ZjFhYTcxNzkwYTY0NWNmMGU1Ni90YWJsZXJhbmdlOjVmYzI0NDhmNmM2YzRmMWFhNzE3OTBhNjQ1Y2YwZTU2XzYtNy0xLTEtMzI4Mg_4bab6933-e50f-4850-a988-a3978b04f40d">22,405</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All marketable securities held at March 31, 2021 had maturities of less than 12 months when purchased and are classified as short-term marketable securities on the accompanying consolidated balance sheet. During the three months ended March 31, 2021, there were <ix:nonFraction unitRef="usd" contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMDUvZnJhZzo1Y2UzYTMxYjllM2Y0NGIzYTMyY2VmMTkzYjdjM2Y1MC90ZXh0cmVnaW9uOjVjZTNhMzFiOWUzZjQ0YjNhMzJjZWYxOTNiN2MzZjUwXzIxOTkwMjMyNTczODE_77c0f5fa-9205-44d6-b0dc-4e6df8bada00">no</ix:nonFraction> marketable securities adjusted for other than temporary declines in fair value.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2020, the Company held <ix:nonFraction unitRef="usd" contextRef="ib56f1adc867e406ca7face50c5da1c9c_I20201231" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMDUvZnJhZzo1Y2UzYTMxYjllM2Y0NGIzYTMyY2VmMTkzYjdjM2Y1MC90ZXh0cmVnaW9uOjVjZTNhMzFiOWUzZjQ0YjNhMzJjZWYxOTNiN2MzZjUwXzQzOTgwNDY1MTI0MTY_a40f2c9c-bbbb-4b54-abe5-4dedd56ef179">no</ix:nonFraction> marketable securities.</span></div></ix:continuation><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div id="i71586e7d2e304f6983634abe9e071791_211"></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4. <ix:nonNumeric contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMTEvZnJhZzpkYjE5OTk1NmQ5ODU0MmNiOGM4ODJlOTFiMjk0ZjMxOS90ZXh0cmVnaW9uOmRiMTk5OTU2ZDk4NTQyY2I4Yzg4MmU5MWIyOTRmMzE5Xzk4Ng_93cbf142-7de8-4f38-93e9-5d9c7649d900" continuedAt="i12aa308d9e084dff849a23750ec35135" escape="true">Net Loss Per Share</ix:nonNumeric></span></div><ix:continuation id="i12aa308d9e084dff849a23750ec35135"><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has reported a net loss for the three months ended March 31, 2021 and 2020. For this reason basic and diluted net loss per share are the same for all periods presented. <ix:nonNumeric contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMTEvZnJhZzpkYjE5OTk1NmQ5ODU0MmNiOGM4ODJlOTFiMjk0ZjMxOS90ZXh0cmVnaW9uOmRiMTk5OTU2ZDk4NTQyY2I4Yzg4MmU5MWIyOTRmMzE5Xzk5NQ_c505c89f-5fc8-417f-96cb-30d529b0bfce" continuedAt="i619c582eaf8b4d92a113a40461c08300" escape="true">The following table sets forth the computation of basic and diluted net loss per share (in thousands, except share and per-share data):</ix:nonNumeric></span></div><div style="margin-bottom:6pt;margin-top:6pt"><ix:continuation id="i619c582eaf8b4d92a113a40461c08300"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.777%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss attributable to common stockholders</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMTEvZnJhZzpkYjE5OTk1NmQ5ODU0MmNiOGM4ODJlOTFiMjk0ZjMxOS90YWJsZTowM2VmYjk1ZTk5ZGU0NzgyYjVkYWNiMWQ0ZTE0ZTVlZC90YWJsZXJhbmdlOjAzZWZiOTVlOTlkZTQ3ODJiNWRhY2IxZDRlMTRlNWVkXzMtMS0xLTEtMA_984d3400-5719-4238-a4c2-6cbe8ac9deb6">24,597</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i824a5b33f908426bad016f0eded844db_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMTEvZnJhZzpkYjE5OTk1NmQ5ODU0MmNiOGM4ODJlOTFiMjk0ZjMxOS90YWJsZTowM2VmYjk1ZTk5ZGU0NzgyYjVkYWNiMWQ0ZTE0ZTVlZC90YWJsZXJhbmdlOjAzZWZiOTVlOTlkZTQ3ODJiNWRhY2IxZDRlMTRlNWVkXzMtMy0xLTEtMA_2b6b0e70-ffcf-4745-98ac-66ba744fb486">19,620</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-average common shares and pre-funded warrants outstanding&#8212;basic and diluted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMTEvZnJhZzpkYjE5OTk1NmQ5ODU0MmNiOGM4ODJlOTFiMjk0ZjMxOS90YWJsZTowM2VmYjk1ZTk5ZGU0NzgyYjVkYWNiMWQ0ZTE0ZTVlZC90YWJsZXJhbmdlOjAzZWZiOTVlOTlkZTQ3ODJiNWRhY2IxZDRlMTRlNWVkXzUtMS0xLTEtMA_e3063f9b-8f54-46e6-8a77-2d46afb68464">110,742,150</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i824a5b33f908426bad016f0eded844db_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMTEvZnJhZzpkYjE5OTk1NmQ5ODU0MmNiOGM4ODJlOTFiMjk0ZjMxOS90YWJsZTowM2VmYjk1ZTk5ZGU0NzgyYjVkYWNiMWQ0ZTE0ZTVlZC90YWJsZXJhbmdlOjAzZWZiOTVlOTlkZTQ3ODJiNWRhY2IxZDRlMTRlNWVkXzUtMy0xLTEtMA_b40d2c96-67c1-4276-87b9-c19c33d96e76">94,723,513</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss per share attributable to common stockholders &#8212;basic and diluted</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMTEvZnJhZzpkYjE5OTk1NmQ5ODU0MmNiOGM4ODJlOTFiMjk0ZjMxOS90YWJsZTowM2VmYjk1ZTk5ZGU0NzgyYjVkYWNiMWQ0ZTE0ZTVlZC90YWJsZXJhbmdlOjAzZWZiOTVlOTlkZTQ3ODJiNWRhY2IxZDRlMTRlNWVkXzYtMS0xLTEtMA_fb10e32b-72dd-4fef-94fd-5bd1e19c691a">0.22</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i824a5b33f908426bad016f0eded844db_D20200101-20200331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMTEvZnJhZzpkYjE5OTk1NmQ5ODU0MmNiOGM4ODJlOTFiMjk0ZjMxOS90YWJsZTowM2VmYjk1ZTk5ZGU0NzgyYjVkYWNiMWQ0ZTE0ZTVlZC90YWJsZXJhbmdlOjAzZWZiOTVlOTlkZTQ3ODJiNWRhY2IxZDRlMTRlNWVkXzYtMy0xLTEtMA_21d2164d-4289-461b-8991-6035b6189e1d">0.21</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></ix:continuation></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All potential dilutive common shares have been excluded from the computation of the diluted net loss per share for all periods presented, as the effect would have been anti-dilutive. <ix:nonNumeric contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMTEvZnJhZzpkYjE5OTk1NmQ5ODU0MmNiOGM4ODJlOTFiMjk0ZjMxOS90ZXh0cmVnaW9uOmRiMTk5OTU2ZDk4NTQyY2I4Yzg4MmU5MWIyOTRmMzE5Xzk4Mg_3bb64aeb-7ad5-458d-a2d5-eaac6385cead" continuedAt="ib6705d3c40f148ad9df0a83d6b595f53" escape="true">Potential dilutive common share equivalents consist of the following:</ix:nonNumeric></span></div><div style="margin-bottom:6pt;margin-top:6pt"><ix:continuation id="ib6705d3c40f148ad9df0a83d6b595f53"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.777%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock options to purchase common stock</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9c2d6525939d4e4f8c2b60bce2f66a52_D20210101-20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMTEvZnJhZzpkYjE5OTk1NmQ5ODU0MmNiOGM4ODJlOTFiMjk0ZjMxOS90YWJsZTo4MjliYjQ2ZTBjYjQ0OWMwYmJmZjM2NGUyYWQ1NjBjNS90YWJsZXJhbmdlOjgyOWJiNDZlMGNiNDQ5YzBiYmZmMzY0ZTJhZDU2MGM1XzItMS0xLTEtMA_5bbcad40-4925-4c9d-b845-b549b0294751">10,187,394</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie177f33c2b9e48b2b637240e8939d8ae_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMTEvZnJhZzpkYjE5OTk1NmQ5ODU0MmNiOGM4ODJlOTFiMjk0ZjMxOS90YWJsZTo4MjliYjQ2ZTBjYjQ0OWMwYmJmZjM2NGUyYWQ1NjBjNS90YWJsZXJhbmdlOjgyOWJiNDZlMGNiNDQ5YzBiYmZmMzY0ZTJhZDU2MGM1XzItMy0xLTEtMA_02524596-d8dc-4c0b-bdd6-f831125e0236">7,745,936</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unvested restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i025312c2f622403398c380c781b5be0a_D20210101-20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMTEvZnJhZzpkYjE5OTk1NmQ5ODU0MmNiOGM4ODJlOTFiMjk0ZjMxOS90YWJsZTo4MjliYjQ2ZTBjYjQ0OWMwYmJmZjM2NGUyYWQ1NjBjNS90YWJsZXJhbmdlOjgyOWJiNDZlMGNiNDQ5YzBiYmZmMzY0ZTJhZDU2MGM1XzMtMS0xLTEtMA_35aa10d6-3a15-4abd-b928-ae0283a8818f">544,313</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iafc609c73df642828d67d21ca85d518a_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMTEvZnJhZzpkYjE5OTk1NmQ5ODU0MmNiOGM4ODJlOTFiMjk0ZjMxOS90YWJsZTo4MjliYjQ2ZTBjYjQ0OWMwYmJmZjM2NGUyYWQ1NjBjNS90YWJsZXJhbmdlOjgyOWJiNDZlMGNiNDQ5YzBiYmZmMzY0ZTJhZDU2MGM1XzMtMy0xLTEtMA_828e48c3-4bbb-49fc-9cb1-c5609afbda9c">170,313</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Warrants to purchase common stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i13a4d3bd3f0f4f058f62ef7fd2966851_D20210101-20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMTEvZnJhZzpkYjE5OTk1NmQ5ODU0MmNiOGM4ODJlOTFiMjk0ZjMxOS90YWJsZTo4MjliYjQ2ZTBjYjQ0OWMwYmJmZjM2NGUyYWQ1NjBjNS90YWJsZXJhbmdlOjgyOWJiNDZlMGNiNDQ5YzBiYmZmMzY0ZTJhZDU2MGM1XzQtMS0xLTEtMA_88b9ed4f-83f8-47c8-a4c0-6fafbc44033e">12,378,016</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1a544c9a0a0e439c9ee87934aaffd7fe_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMTEvZnJhZzpkYjE5OTk1NmQ5ODU0MmNiOGM4ODJlOTFiMjk0ZjMxOS90YWJsZTo4MjliYjQ2ZTBjYjQ0OWMwYmJmZjM2NGUyYWQ1NjBjNS90YWJsZXJhbmdlOjgyOWJiNDZlMGNiNDQ5YzBiYmZmMzY0ZTJhZDU2MGM1XzQtMy0xLTEtMA_3c696a7b-15fe-49cd-8ff6-8ccab5d921d3">23,084,120</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMTEvZnJhZzpkYjE5OTk1NmQ5ODU0MmNiOGM4ODJlOTFiMjk0ZjMxOS90YWJsZTo4MjliYjQ2ZTBjYjQ0OWMwYmJmZjM2NGUyYWQ1NjBjNS90YWJsZXJhbmdlOjgyOWJiNDZlMGNiNDQ5YzBiYmZmMzY0ZTJhZDU2MGM1XzctMS0xLTEtMA_c6908419-ff9e-4fe9-84d7-c3db8ac9ec88">23,109,723</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i824a5b33f908426bad016f0eded844db_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMTEvZnJhZzpkYjE5OTk1NmQ5ODU0MmNiOGM4ODJlOTFiMjk0ZjMxOS90YWJsZTo4MjliYjQ2ZTBjYjQ0OWMwYmJmZjM2NGUyYWQ1NjBjNS90YWJsZXJhbmdlOjgyOWJiNDZlMGNiNDQ5YzBiYmZmMzY0ZTJhZDU2MGM1XzctMy0xLTEtMA_51201352-aec2-4664-b932-330c19de0407">31,000,369</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></ix:continuation></div></ix:continuation><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div id="i71586e7d2e304f6983634abe9e071791_214"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5. <ix:nonNumeric contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMTQvZnJhZzplMDZlY2YzYjhmYmQ0ZjY1YjIzZGM2NTA1MTBlZDMyMy90ZXh0cmVnaW9uOmUwNmVjZjNiOGZiZDRmNjViMjNkYzY1MDUxMGVkMzIzXzMzODE_d825d8ab-9aa1-48a5-a74b-b136e6236ee3" continuedAt="iee00fb14017a4152ae8d214fdf045e81" escape="true">Fair Value Measurements</ix:nonNumeric></span></div><ix:continuation id="iee00fb14017a4152ae8d214fdf045e81" continuedAt="ie5611756225149f988e3728cb33b1236"><ix:nonNumeric contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMTQvZnJhZzplMDZlY2YzYjhmYmQ0ZjY1YjIzZGM2NTA1MTBlZDMyMy90ZXh0cmVnaW9uOmUwNmVjZjNiOGZiZDRmNjViMjNkYzY1MDUxMGVkMzIzXzMzNzQ_b3ec7ee6-34a7-4060-8cf4-b3ece82ee8a5" continuedAt="i08c85fe55ac74235bc6cd66a0c5c743c" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present the Company&#8217;s assets and liabilities that are measured at fair value on a recurring basis as of March 31, 2021 and December 31, 2020 (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.923%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.602%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level&#160;1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level&#160;2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level&#160;3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65d0ac8f7c4649d2abfce4eda0ef5c55_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMTQvZnJhZzplMDZlY2YzYjhmYmQ0ZjY1YjIzZGM2NTA1MTBlZDMyMy90YWJsZTo2MDkzNmUzMzBkOWI0Yjc5OGY0MzkzYzY4NzM1OGIyMS90YWJsZXJhbmdlOjYwOTM2ZTMzMGQ5YjRiNzk4ZjQzOTNjNjg3MzU4YjIxXzMtMS0xLTEtMA_75fed775-5f4a-4cc2-9897-0a7e880acee5">58,158</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73fe924a4c6b473cabf17b9976a4603b_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMTQvZnJhZzplMDZlY2YzYjhmYmQ0ZjY1YjIzZGM2NTA1MTBlZDMyMy90YWJsZTo2MDkzNmUzMzBkOWI0Yjc5OGY0MzkzYzY4NzM1OGIyMS90YWJsZXJhbmdlOjYwOTM2ZTMzMGQ5YjRiNzk4ZjQzOTNjNjg3MzU4YjIxXzMtMy0xLTEtMA_62382fcb-71d7-4e20-bad0-a5aeb10f2f0e">58,158</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f0d06e989014726b8fbec56b2c70e58_I20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMTQvZnJhZzplMDZlY2YzYjhmYmQ0ZjY1YjIzZGM2NTA1MTBlZDMyMy90YWJsZTo2MDkzNmUzMzBkOWI0Yjc5OGY0MzkzYzY4NzM1OGIyMS90YWJsZXJhbmdlOjYwOTM2ZTMzMGQ5YjRiNzk4ZjQzOTNjNjg3MzU4YjIxXzMtNS0xLTEtMA_2c537341-2d35-4da6-baca-a217f36e6fe9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62606fe1b8724fb5a3af6c257e69c07f_I20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMTQvZnJhZzplMDZlY2YzYjhmYmQ0ZjY1YjIzZGM2NTA1MTBlZDMyMy90YWJsZTo2MDkzNmUzMzBkOWI0Yjc5OGY0MzkzYzY4NzM1OGIyMS90YWJsZXJhbmdlOjYwOTM2ZTMzMGQ5YjRiNzk4ZjQzOTNjNjg3MzU4YjIxXzMtNy0xLTEtMA_1b943897-d880-4bce-8d43-00ecd087483d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34e52dcd53c6432595cfbcb02112eb8b_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMTQvZnJhZzplMDZlY2YzYjhmYmQ0ZjY1YjIzZGM2NTA1MTBlZDMyMy90YWJsZTo2MDkzNmUzMzBkOWI0Yjc5OGY0MzkzYzY4NzM1OGIyMS90YWJsZXJhbmdlOjYwOTM2ZTMzMGQ5YjRiNzk4ZjQzOTNjNjg3MzU4YjIxXzUtMS0xLTEtMzMxMA_10fa9940-a050-4db9-bdf0-aa3f977eb068">2,031</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1a9f3d45e4741d9adb5d0a140f27245_I20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMTQvZnJhZzplMDZlY2YzYjhmYmQ0ZjY1YjIzZGM2NTA1MTBlZDMyMy90YWJsZTo2MDkzNmUzMzBkOWI0Yjc5OGY0MzkzYzY4NzM1OGIyMS90YWJsZXJhbmdlOjYwOTM2ZTMzMGQ5YjRiNzk4ZjQzOTNjNjg3MzU4YjIxXzUtMy0xLTEtMA_cef5674f-47ab-4acd-add9-920e2b0cb1bd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2bb46350e76491c82ca4f7ee3718824_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMTQvZnJhZzplMDZlY2YzYjhmYmQ0ZjY1YjIzZGM2NTA1MTBlZDMyMy90YWJsZTo2MDkzNmUzMzBkOWI0Yjc5OGY0MzkzYzY4NzM1OGIyMS90YWJsZXJhbmdlOjYwOTM2ZTMzMGQ5YjRiNzk4ZjQzOTNjNjg3MzU4YjIxXzUtNS0xLTEtMA_bc6f6282-5de6-4a46-b515-feaa60335172">2,031</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i59a1a80dbf8e4190b547bba901361077_I20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMTQvZnJhZzplMDZlY2YzYjhmYmQ0ZjY1YjIzZGM2NTA1MTBlZDMyMy90YWJsZTo2MDkzNmUzMzBkOWI0Yjc5OGY0MzkzYzY4NzM1OGIyMS90YWJsZXJhbmdlOjYwOTM2ZTMzMGQ5YjRiNzk4ZjQzOTNjNjg3MzU4YjIxXzUtNy0xLTEtMA_8877894f-0b3c-42a2-91f6-b5fb5dc0206a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife613bc7097a4d25b505ac69b2a556a1_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMTQvZnJhZzplMDZlY2YzYjhmYmQ0ZjY1YjIzZGM2NTA1MTBlZDMyMy90YWJsZTo2MDkzNmUzMzBkOWI0Yjc5OGY0MzkzYzY4NzM1OGIyMS90YWJsZXJhbmdlOjYwOTM2ZTMzMGQ5YjRiNzk4ZjQzOTNjNjg3MzU4YjIxXzYtMS0xLTEtMzMxMA_861164e8-a4ef-4c06-b569-d9c3da8dc812">20,374</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c477876ef1243f7b607ededf27faa28_I20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMTQvZnJhZzplMDZlY2YzYjhmYmQ0ZjY1YjIzZGM2NTA1MTBlZDMyMy90YWJsZTo2MDkzNmUzMzBkOWI0Yjc5OGY0MzkzYzY4NzM1OGIyMS90YWJsZXJhbmdlOjYwOTM2ZTMzMGQ5YjRiNzk4ZjQzOTNjNjg3MzU4YjIxXzYtMy0xLTEtMzMxMA_76d77d23-c762-498b-b658-dcb9f4d859b5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5b76767b65e416baf32d9fa8ea057ac_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMTQvZnJhZzplMDZlY2YzYjhmYmQ0ZjY1YjIzZGM2NTA1MTBlZDMyMy90YWJsZTo2MDkzNmUzMzBkOWI0Yjc5OGY0MzkzYzY4NzM1OGIyMS90YWJsZXJhbmdlOjYwOTM2ZTMzMGQ5YjRiNzk4ZjQzOTNjNjg3MzU4YjIxXzYtNS0xLTEtMjI0MA_5e09d23f-24d6-474a-a902-d07b7f5c7894">20,374</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78a9cb54375140a3926493d7ca71f588_I20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMTQvZnJhZzplMDZlY2YzYjhmYmQ0ZjY1YjIzZGM2NTA1MTBlZDMyMy90YWJsZTo2MDkzNmUzMzBkOWI0Yjc5OGY0MzkzYzY4NzM1OGIyMS90YWJsZXJhbmdlOjYwOTM2ZTMzMGQ5YjRiNzk4ZjQzOTNjNjg3MzU4YjIxXzYtNy0xLTEtMzMxMA_3019b530-b6f0-48a7-bcd6-60dd4b52807e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief7e41d172914136a4d75381f191624f_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMTQvZnJhZzplMDZlY2YzYjhmYmQ0ZjY1YjIzZGM2NTA1MTBlZDMyMy90YWJsZTo2MDkzNmUzMzBkOWI0Yjc5OGY0MzkzYzY4NzM1OGIyMS90YWJsZXJhbmdlOjYwOTM2ZTMzMGQ5YjRiNzk4ZjQzOTNjNjg3MzU4YjIxXzYtMS0xLTEtMA_b13eded4-e4d0-4740-83d0-a6b638de02e8">80,563</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if08a10047a654aaca135de61c8732df2_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMTQvZnJhZzplMDZlY2YzYjhmYmQ0ZjY1YjIzZGM2NTA1MTBlZDMyMy90YWJsZTo2MDkzNmUzMzBkOWI0Yjc5OGY0MzkzYzY4NzM1OGIyMS90YWJsZXJhbmdlOjYwOTM2ZTMzMGQ5YjRiNzk4ZjQzOTNjNjg3MzU4YjIxXzYtMy0xLTEtMA_4a23135b-c040-4cd0-b3e0-4e22888cd09a">58,158</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if36d86949e87479898a50e28488ef27e_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMTQvZnJhZzplMDZlY2YzYjhmYmQ0ZjY1YjIzZGM2NTA1MTBlZDMyMy90YWJsZTo2MDkzNmUzMzBkOWI0Yjc5OGY0MzkzYzY4NzM1OGIyMS90YWJsZXJhbmdlOjYwOTM2ZTMzMGQ5YjRiNzk4ZjQzOTNjNjg3MzU4YjIxXzYtNS0xLTEtMA_7368997b-a7ab-4fa0-a6ab-2041b16baa44">22,405</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4bc11fa50e194e0fabd48feb4957cccd_I20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMTQvZnJhZzplMDZlY2YzYjhmYmQ0ZjY1YjIzZGM2NTA1MTBlZDMyMy90YWJsZTo2MDkzNmUzMzBkOWI0Yjc5OGY0MzkzYzY4NzM1OGIyMS90YWJsZXJhbmdlOjYwOTM2ZTMzMGQ5YjRiNzk4ZjQzOTNjNjg3MzU4YjIxXzYtNy0xLTEtMA_4280fd00-0cf4-4085-8267-6ba9d12bbcf9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Warrant liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief7e41d172914136a4d75381f191624f_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WarrantsAndRightsOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMTQvZnJhZzplMDZlY2YzYjhmYmQ0ZjY1YjIzZGM2NTA1MTBlZDMyMy90YWJsZTo2MDkzNmUzMzBkOWI0Yjc5OGY0MzkzYzY4NzM1OGIyMS90YWJsZXJhbmdlOjYwOTM2ZTMzMGQ5YjRiNzk4ZjQzOTNjNjg3MzU4YjIxXzEzLTEtMS0xLTA_1c50e33e-591e-4bc3-ba48-1fc99d64f588">45,455</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if08a10047a654aaca135de61c8732df2_I20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:WarrantsAndRightsOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMTQvZnJhZzplMDZlY2YzYjhmYmQ0ZjY1YjIzZGM2NTA1MTBlZDMyMy90YWJsZTo2MDkzNmUzMzBkOWI0Yjc5OGY0MzkzYzY4NzM1OGIyMS90YWJsZXJhbmdlOjYwOTM2ZTMzMGQ5YjRiNzk4ZjQzOTNjNjg3MzU4YjIxXzEzLTMtMS0xLTA_c7e0ac1f-f496-47a0-a190-cb6cdb2ad5a8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if36d86949e87479898a50e28488ef27e_I20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:WarrantsAndRightsOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMTQvZnJhZzplMDZlY2YzYjhmYmQ0ZjY1YjIzZGM2NTA1MTBlZDMyMy90YWJsZTo2MDkzNmUzMzBkOWI0Yjc5OGY0MzkzYzY4NzM1OGIyMS90YWJsZXJhbmdlOjYwOTM2ZTMzMGQ5YjRiNzk4ZjQzOTNjNjg3MzU4YjIxXzEzLTUtMS0xLTA_79baf380-2623-4ee0-a0d9-fb6c2bd36387">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4bc11fa50e194e0fabd48feb4957cccd_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WarrantsAndRightsOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMTQvZnJhZzplMDZlY2YzYjhmYmQ0ZjY1YjIzZGM2NTA1MTBlZDMyMy90YWJsZTo2MDkzNmUzMzBkOWI0Yjc5OGY0MzkzYzY4NzM1OGIyMS90YWJsZXJhbmdlOjYwOTM2ZTMzMGQ5YjRiNzk4ZjQzOTNjNjg3MzU4YjIxXzEzLTctMS0xLTA_8f045d77-0dec-4205-ab02-d056ee9d8655">45,455</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief7e41d172914136a4d75381f191624f_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMTQvZnJhZzplMDZlY2YzYjhmYmQ0ZjY1YjIzZGM2NTA1MTBlZDMyMy90YWJsZTo2MDkzNmUzMzBkOWI0Yjc5OGY0MzkzYzY4NzM1OGIyMS90YWJsZXJhbmdlOjYwOTM2ZTMzMGQ5YjRiNzk4ZjQzOTNjNjg3MzU4YjIxXzE0LTEtMS0xLTA_6e81c94d-62c6-4221-8831-2ae91eafb219">45,455</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if08a10047a654aaca135de61c8732df2_I20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMTQvZnJhZzplMDZlY2YzYjhmYmQ0ZjY1YjIzZGM2NTA1MTBlZDMyMy90YWJsZTo2MDkzNmUzMzBkOWI0Yjc5OGY0MzkzYzY4NzM1OGIyMS90YWJsZXJhbmdlOjYwOTM2ZTMzMGQ5YjRiNzk4ZjQzOTNjNjg3MzU4YjIxXzE0LTMtMS0xLTA_638fab71-3266-406f-9258-61f2394ae2a0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if36d86949e87479898a50e28488ef27e_I20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMTQvZnJhZzplMDZlY2YzYjhmYmQ0ZjY1YjIzZGM2NTA1MTBlZDMyMy90YWJsZTo2MDkzNmUzMzBkOWI0Yjc5OGY0MzkzYzY4NzM1OGIyMS90YWJsZXJhbmdlOjYwOTM2ZTMzMGQ5YjRiNzk4ZjQzOTNjNjg3MzU4YjIxXzE0LTUtMS0xLTA_8f984131-7964-4a68-9e2e-9735f8239158">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4bc11fa50e194e0fabd48feb4957cccd_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMTQvZnJhZzplMDZlY2YzYjhmYmQ0ZjY1YjIzZGM2NTA1MTBlZDMyMy90YWJsZTo2MDkzNmUzMzBkOWI0Yjc5OGY0MzkzYzY4NzM1OGIyMS90YWJsZXJhbmdlOjYwOTM2ZTMzMGQ5YjRiNzk4ZjQzOTNjNjg3MzU4YjIxXzE0LTctMS0xLTA_ef862539-f27f-4cf8-be66-1c0ea65a7ea3">45,455</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i71586e7d2e304f6983634abe9e071791_13">Table of Contents</a></span></div></div><ix:continuation id="ie5611756225149f988e3728cb33b1236" continuedAt="ib57a58b45986458a892c52e87c6488aa"><ix:continuation id="i08c85fe55ac74235bc6cd66a0c5c743c"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.923%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.602%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level&#160;1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level&#160;2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level&#160;3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie881e34b7b6e451a8635ff1a48715e24_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMTQvZnJhZzplMDZlY2YzYjhmYmQ0ZjY1YjIzZGM2NTA1MTBlZDMyMy90YWJsZTo5ZWU4NDFhMjFhNzM0M2EzYWM2NDg5ZmZmNGZkY2I3NS90YWJsZXJhbmdlOjllZTg0MWEyMWE3MzQzYTNhYzY0ODlmZmY0ZmRjYjc1XzMtMS0xLTEtMA_4e2bf17f-b441-4749-aa99-4d03b9a96edc">80,576</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3415f69e0c84403290f2c597fcafb421_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMTQvZnJhZzplMDZlY2YzYjhmYmQ0ZjY1YjIzZGM2NTA1MTBlZDMyMy90YWJsZTo5ZWU4NDFhMjFhNzM0M2EzYWM2NDg5ZmZmNGZkY2I3NS90YWJsZXJhbmdlOjllZTg0MWEyMWE3MzQzYTNhYzY0ODlmZmY0ZmRjYjc1XzMtMy0xLTEtMA_31d34d5d-9ce7-407f-af5b-83068a9b2710">80,576</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd1ec9843c3446469cb04e17862f007e_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMTQvZnJhZzplMDZlY2YzYjhmYmQ0ZjY1YjIzZGM2NTA1MTBlZDMyMy90YWJsZTo5ZWU4NDFhMjFhNzM0M2EzYWM2NDg5ZmZmNGZkY2I3NS90YWJsZXJhbmdlOjllZTg0MWEyMWE3MzQzYTNhYzY0ODlmZmY0ZmRjYjc1XzMtNS0xLTEtMA_e441b6d8-137e-45ab-9e6d-11560c3cb546">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e2993ab72c94021ac21ee14bcd929f2_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMTQvZnJhZzplMDZlY2YzYjhmYmQ0ZjY1YjIzZGM2NTA1MTBlZDMyMy90YWJsZTo5ZWU4NDFhMjFhNzM0M2EzYWM2NDg5ZmZmNGZkY2I3NS90YWJsZXJhbmdlOjllZTg0MWEyMWE3MzQzYTNhYzY0ODlmZmY0ZmRjYjc1XzMtNy0xLTEtMA_001485f0-6030-431f-9536-d76aefd2f099">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib217ca012a534d9a9f5dedd2b37941f0_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMTQvZnJhZzplMDZlY2YzYjhmYmQ0ZjY1YjIzZGM2NTA1MTBlZDMyMy90YWJsZTo5ZWU4NDFhMjFhNzM0M2EzYWM2NDg5ZmZmNGZkY2I3NS90YWJsZXJhbmdlOjllZTg0MWEyMWE3MzQzYTNhYzY0ODlmZmY0ZmRjYjc1XzQtMS0xLTEtMA_3f8187eb-76a1-42db-91f7-9569b0438c23">80,576</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i631a8e963f31434e8ea74e97de9ea103_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMTQvZnJhZzplMDZlY2YzYjhmYmQ0ZjY1YjIzZGM2NTA1MTBlZDMyMy90YWJsZTo5ZWU4NDFhMjFhNzM0M2EzYWM2NDg5ZmZmNGZkY2I3NS90YWJsZXJhbmdlOjllZTg0MWEyMWE3MzQzYTNhYzY0ODlmZmY0ZmRjYjc1XzQtMy0xLTEtMA_10b0a5c3-8040-4e63-9b0e-2cc483255e28">80,576</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e3199d724344066b7d92c08835c0d7b_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMTQvZnJhZzplMDZlY2YzYjhmYmQ0ZjY1YjIzZGM2NTA1MTBlZDMyMy90YWJsZTo5ZWU4NDFhMjFhNzM0M2EzYWM2NDg5ZmZmNGZkY2I3NS90YWJsZXJhbmdlOjllZTg0MWEyMWE3MzQzYTNhYzY0ODlmZmY0ZmRjYjc1XzQtNS0xLTEtMA_25659ff0-f73c-4454-bead-1d701501b581">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i067beaf80d0645c0b74a43ced34f040f_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMTQvZnJhZzplMDZlY2YzYjhmYmQ0ZjY1YjIzZGM2NTA1MTBlZDMyMy90YWJsZTo5ZWU4NDFhMjFhNzM0M2EzYWM2NDg5ZmZmNGZkY2I3NS90YWJsZXJhbmdlOjllZTg0MWEyMWE3MzQzYTNhYzY0ODlmZmY0ZmRjYjc1XzQtNy0xLTEtMA_b0a22556-95c1-4904-a466-7fc49863d29f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Warrant liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib217ca012a534d9a9f5dedd2b37941f0_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WarrantsAndRightsOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMTQvZnJhZzplMDZlY2YzYjhmYmQ0ZjY1YjIzZGM2NTA1MTBlZDMyMy90YWJsZTo5ZWU4NDFhMjFhNzM0M2EzYWM2NDg5ZmZmNGZkY2I3NS90YWJsZXJhbmdlOjllZTg0MWEyMWE3MzQzYTNhYzY0ODlmZmY0ZmRjYjc1XzctMS0xLTEtMA_c0b3946a-2739-4d87-854a-081c2eda4ab7">28,708</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i631a8e963f31434e8ea74e97de9ea103_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:WarrantsAndRightsOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMTQvZnJhZzplMDZlY2YzYjhmYmQ0ZjY1YjIzZGM2NTA1MTBlZDMyMy90YWJsZTo5ZWU4NDFhMjFhNzM0M2EzYWM2NDg5ZmZmNGZkY2I3NS90YWJsZXJhbmdlOjllZTg0MWEyMWE3MzQzYTNhYzY0ODlmZmY0ZmRjYjc1XzctMy0xLTEtMA_e680eba8-cd70-40ef-89e4-fc8283b3064d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e3199d724344066b7d92c08835c0d7b_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:WarrantsAndRightsOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMTQvZnJhZzplMDZlY2YzYjhmYmQ0ZjY1YjIzZGM2NTA1MTBlZDMyMy90YWJsZTo5ZWU4NDFhMjFhNzM0M2EzYWM2NDg5ZmZmNGZkY2I3NS90YWJsZXJhbmdlOjllZTg0MWEyMWE3MzQzYTNhYzY0ODlmZmY0ZmRjYjc1XzctNS0xLTEtMA_e792f4d9-c346-44ce-a907-35ce2be1a871">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i067beaf80d0645c0b74a43ced34f040f_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WarrantsAndRightsOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMTQvZnJhZzplMDZlY2YzYjhmYmQ0ZjY1YjIzZGM2NTA1MTBlZDMyMy90YWJsZTo5ZWU4NDFhMjFhNzM0M2EzYWM2NDg5ZmZmNGZkY2I3NS90YWJsZXJhbmdlOjllZTg0MWEyMWE3MzQzYTNhYzY0ODlmZmY0ZmRjYjc1XzctNy0xLTEtMA_aa610ebc-c5fd-4ab7-8270-7484246dfccb">28,708</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib217ca012a534d9a9f5dedd2b37941f0_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMTQvZnJhZzplMDZlY2YzYjhmYmQ0ZjY1YjIzZGM2NTA1MTBlZDMyMy90YWJsZTo5ZWU4NDFhMjFhNzM0M2EzYWM2NDg5ZmZmNGZkY2I3NS90YWJsZXJhbmdlOjllZTg0MWEyMWE3MzQzYTNhYzY0ODlmZmY0ZmRjYjc1XzgtMS0xLTEtMA_3187c2a3-8486-4eee-82fd-774d583c8413">28,708</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i631a8e963f31434e8ea74e97de9ea103_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMTQvZnJhZzplMDZlY2YzYjhmYmQ0ZjY1YjIzZGM2NTA1MTBlZDMyMy90YWJsZTo5ZWU4NDFhMjFhNzM0M2EzYWM2NDg5ZmZmNGZkY2I3NS90YWJsZXJhbmdlOjllZTg0MWEyMWE3MzQzYTNhYzY0ODlmZmY0ZmRjYjc1XzgtMy0xLTEtMA_ec264ef9-41bf-4256-b85d-cd12b51ca8be">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e3199d724344066b7d92c08835c0d7b_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMTQvZnJhZzplMDZlY2YzYjhmYmQ0ZjY1YjIzZGM2NTA1MTBlZDMyMy90YWJsZTo5ZWU4NDFhMjFhNzM0M2EzYWM2NDg5ZmZmNGZkY2I3NS90YWJsZXJhbmdlOjllZTg0MWEyMWE3MzQzYTNhYzY0ODlmZmY0ZmRjYjc1XzgtNS0xLTEtMA_20985401-47e5-4b43-a5b0-342b7e034080">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i067beaf80d0645c0b74a43ced34f040f_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMTQvZnJhZzplMDZlY2YzYjhmYmQ0ZjY1YjIzZGM2NTA1MTBlZDMyMy90YWJsZTo5ZWU4NDFhMjFhNzM0M2EzYWM2NDg5ZmZmNGZkY2I3NS90YWJsZXJhbmdlOjllZTg0MWEyMWE3MzQzYTNhYzY0ODlmZmY0ZmRjYjc1XzgtNy0xLTEtMA_27cc6f70-ab57-4dc6-bcf7-69985d5e8499">28,708</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were <ix:nonFraction unitRef="usd" contextRef="ibd87cf2a903e47a68471682c6f1d3125_D20200101-20201231" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMTQvZnJhZzplMDZlY2YzYjhmYmQ0ZjY1YjIzZGM2NTA1MTBlZDMyMy90ZXh0cmVnaW9uOmUwNmVjZjNiOGZiZDRmNjViMjNkYzY1MDUxMGVkMzIzXzIxOTkwMjMyNjUyNjQ_14a18082-b7a7-425a-bcfc-148b053e69dd"><ix:nonFraction unitRef="usd" contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMTQvZnJhZzplMDZlY2YzYjhmYmQ0ZjY1YjIzZGM2NTA1MTBlZDMyMy90ZXh0cmVnaW9uOmUwNmVjZjNiOGZiZDRmNjViMjNkYzY1MDUxMGVkMzIzXzIxOTkwMjMyNjUyNjQ_5bf1d42f-1608-4657-91a7-4b28a31d15b9"><ix:nonFraction unitRef="usd" contextRef="ibd87cf2a903e47a68471682c6f1d3125_D20200101-20201231" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMTQvZnJhZzplMDZlY2YzYjhmYmQ0ZjY1YjIzZGM2NTA1MTBlZDMyMy90ZXh0cmVnaW9uOmUwNmVjZjNiOGZiZDRmNjViMjNkYzY1MDUxMGVkMzIzXzIxOTkwMjMyNjUyNjQ_68ae6f68-d2b8-441f-a326-d54127007d9b"><ix:nonFraction unitRef="usd" contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMTQvZnJhZzplMDZlY2YzYjhmYmQ0ZjY1YjIzZGM2NTA1MTBlZDMyMy90ZXh0cmVnaW9uOmUwNmVjZjNiOGZiZDRmNjViMjNkYzY1MDUxMGVkMzIzXzIxOTkwMjMyNjUyNjQ_a1d4b8de-3312-4a61-bd0b-f9e6dd919132">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> transfers within the fair value hierarchy during the three months ended March 31, 2021 or the year ended December 31, 2020.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash and Cash Equivalents</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2021 and December 31, 2020, the money market funds were classified as cash and cash equivalents on the accompanying consolidated balance sheets as they mature within 90 days from the date of purchase.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2021, the Company had restricted cash balances relating to a secured letter of credit in connection with its lease for the Company&#8217;s headquarters (see Note 8 included elsewhere in this Quarterly Report). <ix:nonNumeric contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331" name="us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMTQvZnJhZzplMDZlY2YzYjhmYmQ0ZjY1YjIzZGM2NTA1MTBlZDMyMy90ZXh0cmVnaW9uOmUwNmVjZjNiOGZiZDRmNjViMjNkYzY1MDUxMGVkMzIzXzQzOTgwNDY1MjMxMTY_3b3327de-cb58-4181-b04c-319f57a8931c" continuedAt="iab5e52f1c59946478b22f522c371d425" escape="true"><ix:nonNumeric contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331" name="us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMTQvZnJhZzplMDZlY2YzYjhmYmQ0ZjY1YjIzZGM2NTA1MTBlZDMyMy90ZXh0cmVnaW9uOmUwNmVjZjNiOGZiZDRmNjViMjNkYzY1MDUxMGVkMzIzXzQzOTgwNDY1MjMxMTY_d1832d61-078c-4909-9f28-53468aa4dad9" continuedAt="i761db5bfc2554661ba29e1a4b64f8845" escape="true">The Company&#8217;s consolidated statement of cash flows includes the following as of March 31, 2021 and 2020 (in thousands):</ix:nonNumeric></ix:nonNumeric></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><ix:continuation id="iab5e52f1c59946478b22f522c371d425"><ix:continuation id="i761db5bfc2554661ba29e1a4b64f8845"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.777%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied8d945ebce54ed8a4badfed477a64e8_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMTQvZnJhZzplMDZlY2YzYjhmYmQ0ZjY1YjIzZGM2NTA1MTBlZDMyMy90YWJsZTo1NTgwNmJlMzIyNWE0MGU2YTU2YjY2MzVlODQ4OTEzNi90YWJsZXJhbmdlOjU1ODA2YmUzMjI1YTQwZTZhNTZiNjYzNWU4NDg5MTM2XzItMS0xLTEtNjMyOA_8e15519f-ffbd-4c3f-89b9-a405b65d5aa6">125,407</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff7e2530342c41bca8c84fce55f0cc6f_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMTQvZnJhZzplMDZlY2YzYjhmYmQ0ZjY1YjIzZGM2NTA1MTBlZDMyMy90YWJsZTo1NTgwNmJlMzIyNWE0MGU2YTU2YjY2MzVlODQ4OTEzNi90YWJsZXJhbmdlOjU1ODA2YmUzMjI1YTQwZTZhNTZiNjYzNWU4NDg5MTM2XzItMy0xLTEtNjMyOA_df9307d9-eae1-4901-8304-e8e0227a1802">72,606</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Short-term restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied8d945ebce54ed8a4badfed477a64e8_I20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMTQvZnJhZzplMDZlY2YzYjhmYmQ0ZjY1YjIzZGM2NTA1MTBlZDMyMy90YWJsZTo1NTgwNmJlMzIyNWE0MGU2YTU2YjY2MzVlODQ4OTEzNi90YWJsZXJhbmdlOjU1ODA2YmUzMjI1YTQwZTZhNTZiNjYzNWU4NDg5MTM2XzMtMS0xLTEtNjMyOA_18bfff23-e3f2-483b-8a40-35702f50810c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff7e2530342c41bca8c84fce55f0cc6f_I20200331" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMTQvZnJhZzplMDZlY2YzYjhmYmQ0ZjY1YjIzZGM2NTA1MTBlZDMyMy90YWJsZTo1NTgwNmJlMzIyNWE0MGU2YTU2YjY2MzVlODQ4OTEzNi90YWJsZXJhbmdlOjU1ODA2YmUzMjI1YTQwZTZhNTZiNjYzNWU4NDg5MTM2XzMtMy0xLTEtNjMyOA_95f8878f-96a9-4edd-be4a-63f610ab6ec5">279</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Long-term restricted cash</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied8d945ebce54ed8a4badfed477a64e8_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMTQvZnJhZzplMDZlY2YzYjhmYmQ0ZjY1YjIzZGM2NTA1MTBlZDMyMy90YWJsZTo1NTgwNmJlMzIyNWE0MGU2YTU2YjY2MzVlODQ4OTEzNi90YWJsZXJhbmdlOjU1ODA2YmUzMjI1YTQwZTZhNTZiNjYzNWU4NDg5MTM2XzQtMS0xLTEtNjMyOA_f1178a41-8baf-4079-90c9-f5c4de9902a4">1,379</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff7e2530342c41bca8c84fce55f0cc6f_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMTQvZnJhZzplMDZlY2YzYjhmYmQ0ZjY1YjIzZGM2NTA1MTBlZDMyMy90YWJsZTo1NTgwNmJlMzIyNWE0MGU2YTU2YjY2MzVlODQ4OTEzNi90YWJsZXJhbmdlOjU1ODA2YmUzMjI1YTQwZTZhNTZiNjYzNWU4NDg5MTM2XzQtMy0xLTEtNjMyOA_31a5f761-9cba-4e12-8cae-7b9f5629b87d">1,379</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total cash, cash equivalents, and restricted cash shown in the consolidated statement of cash flows</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied8d945ebce54ed8a4badfed477a64e8_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMTQvZnJhZzplMDZlY2YzYjhmYmQ0ZjY1YjIzZGM2NTA1MTBlZDMyMy90YWJsZTo1NTgwNmJlMzIyNWE0MGU2YTU2YjY2MzVlODQ4OTEzNi90YWJsZXJhbmdlOjU1ODA2YmUzMjI1YTQwZTZhNTZiNjYzNWU4NDg5MTM2XzUtMS0xLTEtNjQxMQ_1a3ed0bd-6500-4ab4-b29f-791f9538c394">126,786</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff7e2530342c41bca8c84fce55f0cc6f_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMTQvZnJhZzplMDZlY2YzYjhmYmQ0ZjY1YjIzZGM2NTA1MTBlZDMyMy90YWJsZTo1NTgwNmJlMzIyNWE0MGU2YTU2YjY2MzVlODQ4OTEzNi90YWJsZXJhbmdlOjU1ODA2YmUzMjI1YTQwZTZhNTZiNjYzNWU4NDg5MTM2XzUtMy0xLTEtNjMyOA_955b8802-40cf-433b-bd84-39b0039cd66e">74,264</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></ix:continuation></ix:continuation></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Marketable Securities</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2021, marketable securities classified as Level 2 within the valuation hierarchy consist of corporate bonds and commercial paper. Marketable securities represent holdings of available-for-sale marketable debt securities in accordance with the Company&#8217;s investment policy. The Company estimates the fair values of these marketable securities by taking into consideration valuations that include market pricing based on real-time trade data for the same or similar securities, and other observable inputs. The amortized cost of available-for-sale debt securities is adjusted for amortization of premiums and accretion of discounts to the earliest call date for premiums or to maturity for discounts.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Loans Payable</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At March 31, 2021, given the recent issuance of the Term A Loan under the 2020 Term Loan, the Company believes the carrying value approximates the fair value of the loan.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Common Warrants</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the Company issued common warrants in connection with a private placement of common shares. Pursuant to the terms of the common warrants, the Company could be required to settle the common warrants in cash in the event of certain acquisitions of the Company and, as a result, the common warrants are required to be measured at fair value and reported as a liability on the balance sheet.&#160;The Company recorded the fair value of the common warrants upon issuance using the Black-Scholes valuation model and is required to revalue the common warrants at each reporting date with any changes in fair value recorded in the statement of operations. The valuation of the common warrants is considered under Level&#160;3 of the fair value hierarchy due to the need to use assumptions in the valuation that are both significant to the fair value measurement and unobservable. The significant unobservable inputs used in the fair value measurement of the warrant liabilities were the volatility rate and the estimated term of the warrants. Generally, increases (decreases) in the fair value of the underlying stock and estimated term would result in a directionally similar impact to the fair value measurement. The change in </span></div></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i71586e7d2e304f6983634abe9e071791_13">Table of Contents</a></span></div></div><ix:continuation id="ib57a58b45986458a892c52e87c6488aa"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the fair value of the&#160;Level 3 warrant liability is reflected in the statement of operations for the three months ended March 31, 2021 and 2020.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value of warrants is determined using Level 3 inputs inherent in the Black-Scholes simulation valuation.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Estimated fair value of the underlying stock</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimates the fair value of the common stock based on the closing stock price at the end of each reporting period.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk-free interest rate</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The risk-free interest rate is based on the U.S. Treasury at the valuation date commensurate with the expected remaining life assumption.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Dividend rate</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.&#160;The dividend rate is based on the historical rate, which the Company anticipates will remain at zero.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected life</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.&#160;The expected life of the warrants is assumed to be equivalent to their remaining contractual term which expires on December 23, 2024.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Volatility</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.&#160;The Company estimates stock price volatility based on the Company&#8217;s historical volatility and the historical volatility of peer companies for a period of time commensurate with the expected remaining life of the warrants.</span></div><ix:nonNumeric contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMTQvZnJhZzplMDZlY2YzYjhmYmQ0ZjY1YjIzZGM2NTA1MTBlZDMyMy90ZXh0cmVnaW9uOmUwNmVjZjNiOGZiZDRmNjViMjNkYzY1MDUxMGVkMzIzXzMzNzY_81847a8a-2a58-4100-8097-911a5589585d" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the Black-Scholes pricing model assumptions used to record the fair value of the warrant liability is as follows:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:87.204%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.596%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i09c393762b464d30a19a24b55c2f5d20_I20210331" decimals="4" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMTQvZnJhZzplMDZlY2YzYjhmYmQ0ZjY1YjIzZGM2NTA1MTBlZDMyMy90YWJsZTo2MWI0ZTJhYTZhMGE0ZGFlYjgwMDE2NWVhOGRkMTE0Yy90YWJsZXJhbmdlOjYxYjRlMmFhNmEwYTRkYWViODAwMTY1ZWE4ZGQxMTRjXzItMy0xLTEtMA_0b46ee8b-2076-447d-8aa6-66519febf8df">0.35</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i173ee7e9fa254b81bffe4952d975b4c0_I20210331" decimals="4" format="ixt:zerodash" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMTQvZnJhZzplMDZlY2YzYjhmYmQ0ZjY1YjIzZGM2NTA1MTBlZDMyMy90YWJsZTo2MWI0ZTJhYTZhMGE0ZGFlYjgwMDE2NWVhOGRkMTE0Yy90YWJsZXJhbmdlOjYxYjRlMmFhNmEwYTRkYWViODAwMTY1ZWE4ZGQxMTRjXzMtMy0xLTEtMA_4c4238f2-7e1c-481b-94c8-e1b6c113e2b8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expected life (in years)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i519d4d01a3ff4f27a9efdf217e061704_I20210331" format="ixt-sec:duryear" name="us-gaap:WarrantsAndRightsOutstandingTerm" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMTQvZnJhZzplMDZlY2YzYjhmYmQ0ZjY1YjIzZGM2NTA1MTBlZDMyMy90YWJsZTo2MWI0ZTJhYTZhMGE0ZGFlYjgwMDE2NWVhOGRkMTE0Yy90YWJsZXJhbmdlOjYxYjRlMmFhNmEwYTRkYWViODAwMTY1ZWE4ZGQxMTRjXzQtMy0xLTEtMA_29699220-663e-49d0-89c1-682329cdc926">3.73</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iba23f9d46a1d4b2f897e63f5c2c1d4bb_I20210331" decimals="4" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMTQvZnJhZzplMDZlY2YzYjhmYmQ0ZjY1YjIzZGM2NTA1MTBlZDMyMy90YWJsZTo2MWI0ZTJhYTZhMGE0ZGFlYjgwMDE2NWVhOGRkMTE0Yy90YWJsZXJhbmdlOjYxYjRlMmFhNmEwYTRkYWViODAwMTY1ZWE4ZGQxMTRjXzUtMy0xLTEtMA_6e4fffc1-5314-489c-9c2b-d51500063c7e">101.13</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Changes in Level 3 Liabilities Measured at Fair Value on a Recurring Basis</span></div><ix:nonNumeric contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMTQvZnJhZzplMDZlY2YzYjhmYmQ0ZjY1YjIzZGM2NTA1MTBlZDMyMy90ZXh0cmVnaW9uOmUwNmVjZjNiOGZiZDRmNjViMjNkYzY1MDUxMGVkMzIzXzMzNzc_df2f2b56-5228-463c-bd84-5fcf185d4404" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reflects a roll-forward of fair value for the Company&#8217;s Level 3 warrant liabilities (see Note 10), for the three months ended March 31, 2021 (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:87.204%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.596%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Warrant liabilities</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair value as of December 31, 2020</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i118f57dc685b47c8b1b5f190c4eed731_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMTQvZnJhZzplMDZlY2YzYjhmYmQ0ZjY1YjIzZGM2NTA1MTBlZDMyMy90YWJsZTo5MWEyZDlkMTU0ZTg0MDMxYjI3MDE3OTY4NmNhMzY5OC90YWJsZXJhbmdlOjkxYTJkOWQxNTRlODQwMzFiMjcwMTc5Njg2Y2EzNjk4XzEtMS0xLTEtMA_44823a44-fb59-4c29-a4f3-fe2daf207a7f">28,708</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Change in fair value</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf08fe145a214d8bacaa57c857186979_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMTQvZnJhZzplMDZlY2YzYjhmYmQ0ZjY1YjIzZGM2NTA1MTBlZDMyMy90YWJsZTo5MWEyZDlkMTU0ZTg0MDMxYjI3MDE3OTY4NmNhMzY5OC90YWJsZXJhbmdlOjkxYTJkOWQxNTRlODQwMzFiMjcwMTc5Njg2Y2EzNjk4XzMtMS0xLTEtMA_1ce910da-a948-48a9-a29d-46d8e0db68d4">16,747</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair value as of March 31, 2021</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id99ce4003b574f658d3b62852041d661_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMTQvZnJhZzplMDZlY2YzYjhmYmQ0ZjY1YjIzZGM2NTA1MTBlZDMyMy90YWJsZTo5MWEyZDlkMTU0ZTg0MDMxYjI3MDE3OTY4NmNhMzY5OC90YWJsZXJhbmdlOjkxYTJkOWQxNTRlODQwMzFiMjcwMTc5Njg2Y2EzNjk4XzQtMS0xLTEtMA_c6378e09-baaa-4b5e-a98a-bd5474e359c7">45,455</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div id="i71586e7d2e304f6983634abe9e071791_220"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6. <ix:nonNumeric contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMjAvZnJhZzpjZTg3MDdlOTAzOWE0MTg0OGE0MzkyZDBhOTgzYTBlMi90ZXh0cmVnaW9uOmNlODcwN2U5MDM5YTQxODQ4YTQzOTJkMGE5ODNhMGUyXzUyNQ_32fb5140-d4c8-464b-a7e4-680ab6ea5ee9" continuedAt="i91363c122c8643ab8fb47773caf52876" escape="true">Property and Equipment</ix:nonNumeric></span></div><ix:continuation id="i91363c122c8643ab8fb47773caf52876"><ix:nonNumeric contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMjAvZnJhZzpjZTg3MDdlOTAzOWE0MTg0OGE0MzkyZDBhOTgzYTBlMi90ZXh0cmVnaW9uOmNlODcwN2U5MDM5YTQxODQ4YTQzOTJkMGE5ODNhMGUyXzUyOQ_1cefffca-624e-4f27-8708-cea53cdc7d20" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment consists of the following (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.777%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a27424e288a444c8c666f3eeb249646_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMjAvZnJhZzpjZTg3MDdlOTAzOWE0MTg0OGE0MzkyZDBhOTgzYTBlMi90YWJsZTphODRkYWQzMTcwMTE0OWIwYTcwYWQ2ZGFhODMzYzIwMC90YWJsZXJhbmdlOmE4NGRhZDMxNzAxMTQ5YjBhNzBhZDZkYWE4MzNjMjAwXzItMS0xLTEtMA_ce64baea-8ac2-46f1-968f-cf09e6d94a5b">4,429</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5f80b2977824ab9ba0203bc6a11a58e_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMjAvZnJhZzpjZTg3MDdlOTAzOWE0MTg0OGE0MzkyZDBhOTgzYTBlMi90YWJsZTphODRkYWQzMTcwMTE0OWIwYTcwYWQ2ZGFhODMzYzIwMC90YWJsZXJhbmdlOmE4NGRhZDMxNzAxMTQ5YjBhNzBhZDZkYWE4MzNjMjAwXzItMy0xLTEtMA_8bfd167f-dff0-450c-88e9-b14135716d6d">4,427</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Computer equipment and software</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia943ee9b105d42cba901af1e6a454c40_I20210331" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMjAvZnJhZzpjZTg3MDdlOTAzOWE0MTg0OGE0MzkyZDBhOTgzYTBlMi90YWJsZTphODRkYWQzMTcwMTE0OWIwYTcwYWQ2ZGFhODMzYzIwMC90YWJsZXJhbmdlOmE4NGRhZDMxNzAxMTQ5YjBhNzBhZDZkYWE4MzNjMjAwXzMtMS0xLTEtMA_1a2b94f9-1f40-40bb-adb9-9628280f5a2e">694</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56d15e17ec144f96957c4fb601aba227_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMjAvZnJhZzpjZTg3MDdlOTAzOWE0MTg0OGE0MzkyZDBhOTgzYTBlMi90YWJsZTphODRkYWQzMTcwMTE0OWIwYTcwYWQ2ZGFhODMzYzIwMC90YWJsZXJhbmdlOmE4NGRhZDMxNzAxMTQ5YjBhNzBhZDZkYWE4MzNjMjAwXzMtMy0xLTEtMA_ec64fb99-c58d-44a3-a021-b4aa72cf68e5">532</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad5e74cc7867456d841ede0490c532e2_I20210331" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMjAvZnJhZzpjZTg3MDdlOTAzOWE0MTg0OGE0MzkyZDBhOTgzYTBlMi90YWJsZTphODRkYWQzMTcwMTE0OWIwYTcwYWQ2ZGFhODMzYzIwMC90YWJsZXJhbmdlOmE4NGRhZDMxNzAxMTQ5YjBhNzBhZDZkYWE4MzNjMjAwXzQtMS0xLTEtMA_067ce12a-d716-4be3-86ee-68b15f40ad42">38</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b0035fcfb7b4ad5a466a8875b9526aa_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMjAvZnJhZzpjZTg3MDdlOTAzOWE0MTg0OGE0MzkyZDBhOTgzYTBlMi90YWJsZTphODRkYWQzMTcwMTE0OWIwYTcwYWQ2ZGFhODMzYzIwMC90YWJsZXJhbmdlOmE4NGRhZDMxNzAxMTQ5YjBhNzBhZDZkYWE4MzNjMjAwXzQtMy0xLTEtMA_08342aa6-7503-4d12-85c4-abf7bbe53b8e">38</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i071771a6ccb1419ca97dd0dfaf4f2526_I20210331" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMjAvZnJhZzpjZTg3MDdlOTAzOWE0MTg0OGE0MzkyZDBhOTgzYTBlMi90YWJsZTphODRkYWQzMTcwMTE0OWIwYTcwYWQ2ZGFhODMzYzIwMC90YWJsZXJhbmdlOmE4NGRhZDMxNzAxMTQ5YjBhNzBhZDZkYWE4MzNjMjAwXzUtMS0xLTEtMA_74a31339-096c-4bb1-b5c5-7c99ed039da8">327</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5879070723fe4b008e2b38909e05fbe9_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMjAvZnJhZzpjZTg3MDdlOTAzOWE0MTg0OGE0MzkyZDBhOTgzYTBlMi90YWJsZTphODRkYWQzMTcwMTE0OWIwYTcwYWQ2ZGFhODMzYzIwMC90YWJsZXJhbmdlOmE4NGRhZDMxNzAxMTQ5YjBhNzBhZDZkYWE4MzNjMjAwXzUtMy0xLTEtMA_3e5cb87b-1aea-4566-b2fb-6a15ce331feb">327</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Office equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf4df6273b36402f8f2fc2b5d47437bd_I20210331" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMjAvZnJhZzpjZTg3MDdlOTAzOWE0MTg0OGE0MzkyZDBhOTgzYTBlMi90YWJsZTphODRkYWQzMTcwMTE0OWIwYTcwYWQ2ZGFhODMzYzIwMC90YWJsZXJhbmdlOmE4NGRhZDMxNzAxMTQ5YjBhNzBhZDZkYWE4MzNjMjAwXzYtMS0xLTEtMA_ebbe85a0-6404-48aa-9a47-109a69e8a6db">163</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44f41827807b4780adcd3350fc42ab49_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMjAvZnJhZzpjZTg3MDdlOTAzOWE0MTg0OGE0MzkyZDBhOTgzYTBlMi90YWJsZTphODRkYWQzMTcwMTE0OWIwYTcwYWQ2ZGFhODMzYzIwMC90YWJsZXJhbmdlOmE4NGRhZDMxNzAxMTQ5YjBhNzBhZDZkYWE4MzNjMjAwXzYtMy0xLTEtMA_996eca09-d314-44ad-8477-70653c79e43b">163</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Construction in process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62030e264c0744b68da329d325fca573_I20210331" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMjAvZnJhZzpjZTg3MDdlOTAzOWE0MTg0OGE0MzkyZDBhOTgzYTBlMi90YWJsZTphODRkYWQzMTcwMTE0OWIwYTcwYWQ2ZGFhODMzYzIwMC90YWJsZXJhbmdlOmE4NGRhZDMxNzAxMTQ5YjBhNzBhZDZkYWE4MzNjMjAwXzctMS0xLTEtMA_305ec19d-cef0-4b87-a2ce-6680fd215a69">30</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i42237c8333f54aaa809730ac386b4ae3_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMjAvZnJhZzpjZTg3MDdlOTAzOWE0MTg0OGE0MzkyZDBhOTgzYTBlMi90YWJsZTphODRkYWQzMTcwMTE0OWIwYTcwYWQ2ZGFhODMzYzIwMC90YWJsZXJhbmdlOmE4NGRhZDMxNzAxMTQ5YjBhNzBhZDZkYWE4MzNjMjAwXzctMy0xLTEtMA_a57b95a6-d908-4f11-8856-32c327e41aa0">163</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total property and equipment</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied8d945ebce54ed8a4badfed477a64e8_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMjAvZnJhZzpjZTg3MDdlOTAzOWE0MTg0OGE0MzkyZDBhOTgzYTBlMi90YWJsZTphODRkYWQzMTcwMTE0OWIwYTcwYWQ2ZGFhODMzYzIwMC90YWJsZXJhbmdlOmE4NGRhZDMxNzAxMTQ5YjBhNzBhZDZkYWE4MzNjMjAwXzgtMS0xLTEtMA_3458afe6-f3f0-4d5f-b041-6c487341a47d">5,681</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib56f1adc867e406ca7face50c5da1c9c_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMjAvZnJhZzpjZTg3MDdlOTAzOWE0MTg0OGE0MzkyZDBhOTgzYTBlMi90YWJsZTphODRkYWQzMTcwMTE0OWIwYTcwYWQ2ZGFhODMzYzIwMC90YWJsZXJhbmdlOmE4NGRhZDMxNzAxMTQ5YjBhNzBhZDZkYWE4MzNjMjAwXzgtMy0xLTEtMA_da868ab5-ff9f-4674-89c4-538e4e818ca7">5,650</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less accumulated depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ied8d945ebce54ed8a4badfed477a64e8_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMjAvZnJhZzpjZTg3MDdlOTAzOWE0MTg0OGE0MzkyZDBhOTgzYTBlMi90YWJsZTphODRkYWQzMTcwMTE0OWIwYTcwYWQ2ZGFhODMzYzIwMC90YWJsZXJhbmdlOmE4NGRhZDMxNzAxMTQ5YjBhNzBhZDZkYWE4MzNjMjAwXzktMS0xLTEtMA_058d6704-605b-461a-8769-703a68eba474">4,380</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib56f1adc867e406ca7face50c5da1c9c_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMjAvZnJhZzpjZTg3MDdlOTAzOWE0MTg0OGE0MzkyZDBhOTgzYTBlMi90YWJsZTphODRkYWQzMTcwMTE0OWIwYTcwYWQ2ZGFhODMzYzIwMC90YWJsZXJhbmdlOmE4NGRhZDMxNzAxMTQ5YjBhNzBhZDZkYWE4MzNjMjAwXzktMy0xLTEtMA_a0f7ae57-fb7e-4540-89a8-6e4fb699c6ad">4,255</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied8d945ebce54ed8a4badfed477a64e8_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMjAvZnJhZzpjZTg3MDdlOTAzOWE0MTg0OGE0MzkyZDBhOTgzYTBlMi90YWJsZTphODRkYWQzMTcwMTE0OWIwYTcwYWQ2ZGFhODMzYzIwMC90YWJsZXJhbmdlOmE4NGRhZDMxNzAxMTQ5YjBhNzBhZDZkYWE4MzNjMjAwXzEwLTEtMS0xLTA_2e6b95e4-26c2-472b-a701-5b51d693afd4">1,301</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib56f1adc867e406ca7face50c5da1c9c_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMjAvZnJhZzpjZTg3MDdlOTAzOWE0MTg0OGE0MzkyZDBhOTgzYTBlMi90YWJsZTphODRkYWQzMTcwMTE0OWIwYTcwYWQ2ZGFhODMzYzIwMC90YWJsZXJhbmdlOmE4NGRhZDMxNzAxMTQ5YjBhNzBhZDZkYWE4MzNjMjAwXzEwLTMtMS0xLTA_7cb7dd76-e6c9-4d28-87b6-22afbf8f33c8">1,395</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense was $<ix:nonFraction unitRef="usd" contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331" decimals="-5" name="us-gaap:Depreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMjAvZnJhZzpjZTg3MDdlOTAzOWE0MTg0OGE0MzkyZDBhOTgzYTBlMi90ZXh0cmVnaW9uOmNlODcwN2U5MDM5YTQxODQ4YTQzOTJkMGE5ODNhMGUyXzEyNA_d5bea276-b5fd-4e70-9c2f-efe92a43b490">0.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i824a5b33f908426bad016f0eded844db_D20200101-20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMjAvZnJhZzpjZTg3MDdlOTAzOWE0MTg0OGE0MzkyZDBhOTgzYTBlMi90ZXh0cmVnaW9uOmNlODcwN2U5MDM5YTQxODQ4YTQzOTJkMGE5ODNhMGUyXzEzNg_c3970fc7-341e-4e66-964a-6c382fcb62f7">0.2</ix:nonFraction> million for the three months ended March 31, 2021 and 2020, respectively.</span></div></ix:continuation><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><div id="i71586e7d2e304f6983634abe9e071791_223"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i71586e7d2e304f6983634abe9e071791_13">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7. <ix:nonNumeric contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331" name="us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMjMvZnJhZzowZGE3MjJkNTU3NmQ0MjA2ODgyODA3Y2NhMmJlOTUwOC90ZXh0cmVnaW9uOjBkYTcyMmQ1NTc2ZDQyMDY4ODI4MDdjY2EyYmU5NTA4Xzkw_f92835b3-ea10-4100-8927-78b2678798a4" continuedAt="i7cc013501e37404ca7bdaa70201a663d" escape="true">Accrued Expenses</ix:nonNumeric></span></div><ix:continuation id="i7cc013501e37404ca7bdaa70201a663d"><ix:nonNumeric contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMjMvZnJhZzowZGE3MjJkNTU3NmQ0MjA2ODgyODA3Y2NhMmJlOTUwOC90ZXh0cmVnaW9uOjBkYTcyMmQ1NTc2ZDQyMDY4ODI4MDdjY2EyYmU5NTA4Xzk0_2c312cba-7630-42fc-8be7-1dd7dff86c3e" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses consist of the following (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.777%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payroll and employee related expenses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied8d945ebce54ed8a4badfed477a64e8_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMjMvZnJhZzowZGE3MjJkNTU3NmQ0MjA2ODgyODA3Y2NhMmJlOTUwOC90YWJsZTplNmMxZTVmZTQzYzQ0MWY1YWJjZGU4OGJhYTFlMzBkNi90YWJsZXJhbmdlOmU2YzFlNWZlNDNjNDQxZjVhYmNkZTg4YmFhMWUzMGQ2XzItMS0xLTEtMA_1dcab7ec-7db8-47cb-9369-ae043a2f12fc">1,840</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib56f1adc867e406ca7face50c5da1c9c_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMjMvZnJhZzowZGE3MjJkNTU3NmQ0MjA2ODgyODA3Y2NhMmJlOTUwOC90YWJsZTplNmMxZTVmZTQzYzQ0MWY1YWJjZGU4OGJhYTFlMzBkNi90YWJsZXJhbmdlOmU2YzFlNWZlNDNjNDQxZjVhYmNkZTg4YmFhMWUzMGQ2XzItMy0xLTEtMA_6c80bee6-9624-4391-9506-7a01fdbd147e">3,049</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Collaboration and licensing</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied8d945ebce54ed8a4badfed477a64e8_I20210331" decimals="-3" format="ixt:numdotdecimal" name="selb:AccruedCollaborationandLicensing" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMjMvZnJhZzowZGE3MjJkNTU3NmQ0MjA2ODgyODA3Y2NhMmJlOTUwOC90YWJsZTplNmMxZTVmZTQzYzQ0MWY1YWJjZGU4OGJhYTFlMzBkNi90YWJsZXJhbmdlOmU2YzFlNWZlNDNjNDQxZjVhYmNkZTg4YmFhMWUzMGQ2XzQtMS0xLTEtMA_b399c8fc-a5dc-4cca-95b9-f15cd6b62770">1,350</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib56f1adc867e406ca7face50c5da1c9c_I20201231" decimals="-3" format="ixt:numdotdecimal" name="selb:AccruedCollaborationandLicensing" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMjMvZnJhZzowZGE3MjJkNTU3NmQ0MjA2ODgyODA3Y2NhMmJlOTUwOC90YWJsZTplNmMxZTVmZTQzYzQ0MWY1YWJjZGU4OGJhYTFlMzBkNi90YWJsZXJhbmdlOmU2YzFlNWZlNDNjNDQxZjVhYmNkZTg4YmFhMWUzMGQ2XzQtMy0xLTEtMA_dd48c3a9-b7a3-4600-813d-1ec76ad5b9a0">1,350</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued patent fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied8d945ebce54ed8a4badfed477a64e8_I20210331" decimals="-3" name="selb:AccruedPatentFeesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMjMvZnJhZzowZGE3MjJkNTU3NmQ0MjA2ODgyODA3Y2NhMmJlOTUwOC90YWJsZTplNmMxZTVmZTQzYzQ0MWY1YWJjZGU4OGJhYTFlMzBkNi90YWJsZXJhbmdlOmU2YzFlNWZlNDNjNDQxZjVhYmNkZTg4YmFhMWUzMGQ2XzUtMS0xLTEtMA_359a2c59-8a45-4b1f-970e-f5cf07a9995c">471</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib56f1adc867e406ca7face50c5da1c9c_I20201231" decimals="-3" name="selb:AccruedPatentFeesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMjMvZnJhZzowZGE3MjJkNTU3NmQ0MjA2ODgyODA3Y2NhMmJlOTUwOC90YWJsZTplNmMxZTVmZTQzYzQ0MWY1YWJjZGU4OGJhYTFlMzBkNi90YWJsZXJhbmdlOmU2YzFlNWZlNDNjNDQxZjVhYmNkZTg4YmFhMWUzMGQ2XzUtMy0xLTEtMA_de6e16f7-ac15-4d3f-b8ca-8270d28cec84">534</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued external research and development costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied8d945ebce54ed8a4badfed477a64e8_I20210331" decimals="-3" format="ixt:numdotdecimal" name="selb:AccruedResearchAndDevelopmentCostsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMjMvZnJhZzowZGE3MjJkNTU3NmQ0MjA2ODgyODA3Y2NhMmJlOTUwOC90YWJsZTplNmMxZTVmZTQzYzQ0MWY1YWJjZGU4OGJhYTFlMzBkNi90YWJsZXJhbmdlOmU2YzFlNWZlNDNjNDQxZjVhYmNkZTg4YmFhMWUzMGQ2XzYtMS0xLTEtMA_876aff8d-1560-4afc-9d4e-52bbc80b5dfc">2,010</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib56f1adc867e406ca7face50c5da1c9c_I20201231" decimals="-3" format="ixt:numdotdecimal" name="selb:AccruedResearchAndDevelopmentCostsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMjMvZnJhZzowZGE3MjJkNTU3NmQ0MjA2ODgyODA3Y2NhMmJlOTUwOC90YWJsZTplNmMxZTVmZTQzYzQ0MWY1YWJjZGU4OGJhYTFlMzBkNi90YWJsZXJhbmdlOmU2YzFlNWZlNDNjNDQxZjVhYmNkZTg4YmFhMWUzMGQ2XzYtMy0xLTEtMA_b18a82ea-fdde-4fc2-b0ed-aa48bb629ec7">2,029</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued professional and consulting services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied8d945ebce54ed8a4badfed477a64e8_I20210331" decimals="-3" name="selb:AccruedAuditFeesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMjMvZnJhZzowZGE3MjJkNTU3NmQ0MjA2ODgyODA3Y2NhMmJlOTUwOC90YWJsZTplNmMxZTVmZTQzYzQ0MWY1YWJjZGU4OGJhYTFlMzBkNi90YWJsZXJhbmdlOmU2YzFlNWZlNDNjNDQxZjVhYmNkZTg4YmFhMWUzMGQ2XzctMS0xLTEtMA_8e93f340-1a4f-4bbe-9f03-37a00ec057a7">802</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib56f1adc867e406ca7face50c5da1c9c_I20201231" decimals="-3" name="selb:AccruedAuditFeesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMjMvZnJhZzowZGE3MjJkNTU3NmQ0MjA2ODgyODA3Y2NhMmJlOTUwOC90YWJsZTplNmMxZTVmZTQzYzQ0MWY1YWJjZGU4OGJhYTFlMzBkNi90YWJsZXJhbmdlOmU2YzFlNWZlNDNjNDQxZjVhYmNkZTg4YmFhMWUzMGQ2XzctMy0xLTEtMA_400250d0-1440-443f-8f79-5442bbaa3ce4">798</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied8d945ebce54ed8a4badfed477a64e8_I20210331" decimals="-3" name="selb:AccruedInterestCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMjMvZnJhZzowZGE3MjJkNTU3NmQ0MjA2ODgyODA3Y2NhMmJlOTUwOC90YWJsZTplNmMxZTVmZTQzYzQ0MWY1YWJjZGU4OGJhYTFlMzBkNi90YWJsZXJhbmdlOmU2YzFlNWZlNDNjNDQxZjVhYmNkZTg4YmFhMWUzMGQ2XzktMS0xLTEtMA_765153f2-4637-4de5-abc0-7a09991773ec">170</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib56f1adc867e406ca7face50c5da1c9c_I20201231" decimals="-3" name="selb:AccruedInterestCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMjMvZnJhZzowZGE3MjJkNTU3NmQ0MjA2ODgyODA3Y2NhMmJlOTUwOC90YWJsZTplNmMxZTVmZTQzYzQ0MWY1YWJjZGU4OGJhYTFlMzBkNi90YWJsZXJhbmdlOmU2YzFlNWZlNDNjNDQxZjVhYmNkZTg4YmFhMWUzMGQ2XzktMy0xLTEtMA_0166f569-ccc6-4955-bc4d-6b52751bcc0b">170</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied8d945ebce54ed8a4badfed477a64e8_I20210331" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMjMvZnJhZzowZGE3MjJkNTU3NmQ0MjA2ODgyODA3Y2NhMmJlOTUwOC90YWJsZTplNmMxZTVmZTQzYzQ0MWY1YWJjZGU4OGJhYTFlMzBkNi90YWJsZXJhbmdlOmU2YzFlNWZlNDNjNDQxZjVhYmNkZTg4YmFhMWUzMGQ2XzExLTEtMS0xLTA_987f27a1-876c-4725-8f9d-d267a1937cbc">204</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib56f1adc867e406ca7face50c5da1c9c_I20201231" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMjMvZnJhZzowZGE3MjJkNTU3NmQ0MjA2ODgyODA3Y2NhMmJlOTUwOC90YWJsZTplNmMxZTVmZTQzYzQ0MWY1YWJjZGU4OGJhYTFlMzBkNi90YWJsZXJhbmdlOmU2YzFlNWZlNDNjNDQxZjVhYmNkZTg4YmFhMWUzMGQ2XzExLTMtMS0xLTA_c5486622-0b67-46b2-b2a0-d9623a43e606">216</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Accrued expenses</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied8d945ebce54ed8a4badfed477a64e8_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMjMvZnJhZzowZGE3MjJkNTU3NmQ0MjA2ODgyODA3Y2NhMmJlOTUwOC90YWJsZTplNmMxZTVmZTQzYzQ0MWY1YWJjZGU4OGJhYTFlMzBkNi90YWJsZXJhbmdlOmU2YzFlNWZlNDNjNDQxZjVhYmNkZTg4YmFhMWUzMGQ2XzEyLTEtMS0xLTA_cf994152-b0f2-4986-af8c-90b6350a8f33">6,847</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib56f1adc867e406ca7face50c5da1c9c_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMjMvZnJhZzowZGE3MjJkNTU3NmQ0MjA2ODgyODA3Y2NhMmJlOTUwOC90YWJsZTplNmMxZTVmZTQzYzQ0MWY1YWJjZGU4OGJhYTFlMzBkNi90YWJsZXJhbmdlOmU2YzFlNWZlNDNjNDQxZjVhYmNkZTg4YmFhMWUzMGQ2XzEyLTMtMS0xLTA_8974aad1-6f60-4964-b83f-4e6d901ccaab">8,146</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div id="i71586e7d2e304f6983634abe9e071791_229"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8. <ix:nonNumeric contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331" name="us-gaap:LesseeOperatingLeasesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMjkvZnJhZzo0OTNlMjJkZjg3YjE0MTcyYjQ5NWU1OTUxZWY5NWFlMS90ZXh0cmVnaW9uOjQ5M2UyMmRmODdiMTQxNzJiNDk1ZTU5NTFlZjk1YWUxXzY1NDE_ad602ce8-5c8b-438c-9886-6d6be366cbb3" continuedAt="i8e75be12d64044a79598184e55fc45a9" escape="true">Leases </ix:nonNumeric></span></div><ix:continuation id="i8e75be12d64044a79598184e55fc45a9" continuedAt="if9df6726bd3f4109b133c3aff5b92593"><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">65 Grove Street Lease</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2019, the Company entered into a lease for <ix:nonFraction unitRef="sqft" contextRef="i8a6242358159403bbb0d1d272fafb3bc_I20190731" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AreaOfRealEstateProperty" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMjkvZnJhZzo0OTNlMjJkZjg3YjE0MTcyYjQ5NWU1OTUxZWY5NWFlMS90ZXh0cmVnaW9uOjQ5M2UyMmRmODdiMTQxNzJiNDk1ZTU5NTFlZjk1YWUxXzQ0NzI_c6ed3143-5277-455c-b448-e5e8a0a7544d">25,078</ix:nonFraction> square feet of laboratory and office space located at 65 Grove Street, Watertown, Massachusetts, or the Headquarters Lease. As part of the Headquarters Lease, the Company incurred $<ix:nonFraction unitRef="usd" contextRef="i3fe0080183054a06885fd48ac35a21f1_D20190701-20190731" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LeaseCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMjkvZnJhZzo0OTNlMjJkZjg3YjE0MTcyYjQ5NWU1OTUxZWY5NWFlMS90ZXh0cmVnaW9uOjQ5M2UyMmRmODdiMTQxNzJiNDk1ZTU5NTFlZjk1YWUxXzQ2NTU_7b38a771-9705-4d46-9462-d3e5577fc082">0.8</ix:nonFraction> million in non-reimbursable construction costs. The lease began in March 2020, consistent with when the Company took control of the office space, and the lease term is <ix:nonNumeric contextRef="i8a6242358159403bbb0d1d272fafb3bc_I20190731" format="ixt-sec:duryear" name="us-gaap:LesseeOperatingLeaseTermOfContract" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMjkvZnJhZzo0OTNlMjJkZjg3YjE0MTcyYjQ5NWU1OTUxZWY5NWFlMS90ZXh0cmVnaW9uOjQ5M2UyMmRmODdiMTQxNzJiNDk1ZTU5NTFlZjk1YWUxXzQ4MTc_a177f3a1-aa67-4e0a-b43a-ba385f7f9bfa">8</ix:nonNumeric> years. The discount rate of <ix:nonFraction unitRef="number" contextRef="ied8d945ebce54ed8a4badfed477a64e8_I20210331" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMjkvZnJhZzo0OTNlMjJkZjg3YjE0MTcyYjQ5NWU1OTUxZWY5NWFlMS90ZXh0cmVnaW9uOjQ5M2UyMmRmODdiMTQxNzJiNDk1ZTU5NTFlZjk1YWUxXzQ4NDg_5cd2f345-3254-4296-9ab3-da14123109b5">8.9</ix:nonFraction>% was determined based on the Company&#8217;s incremental borrowing rate adjusted for the lease term including any reasonably certain renewal periods. In connection with the Headquarters Lease, the Company secured a letter of credit from Silicon Valley Bank, or SVB, for $<ix:nonFraction unitRef="usd" contextRef="i98e030263a7d4c9fbb0733a011655549_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMjkvZnJhZzo0OTNlMjJkZjg3YjE0MTcyYjQ5NWU1OTUxZWY5NWFlMS90ZXh0cmVnaW9uOjQ5M2UyMmRmODdiMTQxNzJiNDk1ZTU5NTFlZjk1YWUxXzUxOTI_114ea5ac-3ab1-4275-885f-30b765b493a5"><ix:nonFraction unitRef="usd" contextRef="i012a579920bb42578031fbbc9df1dfd2_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMjkvZnJhZzo0OTNlMjJkZjg3YjE0MTcyYjQ5NWU1OTUxZWY5NWFlMS90ZXh0cmVnaW9uOjQ5M2UyMmRmODdiMTQxNzJiNDk1ZTU5NTFlZjk1YWUxXzUxOTI_7f56b61a-5c03-4c88-aab9-80219734e97e">1.4</ix:nonFraction></ix:nonFraction> million, recognized as long-term restricted cash, as of March 31, 2021 and December 31, 2020, respectively, which automatically renews each year.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Moscow, Russia Lease</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has a month-to-month facility agreement for its Moscow, Russia office. Rent expense is recognized as incurred.</span></div><ix:nonNumeric contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331" name="selb:LesseeComponentsOfOperatingLeaseTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMjkvZnJhZzo0OTNlMjJkZjg3YjE0MTcyYjQ5NWU1OTUxZWY5NWFlMS90ZXh0cmVnaW9uOjQ5M2UyMmRmODdiMTQxNzJiNDk1ZTU5NTFlZjk1YWUxXzY1Mzg_05899796-ed84-4703-bf94-f35d6c544d7f" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2021 and December 31, 2020, the components of the operating leases were as follows (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.484%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, </span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Right-of-use asset, net</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied8d945ebce54ed8a4badfed477a64e8_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMjkvZnJhZzo0OTNlMjJkZjg3YjE0MTcyYjQ5NWU1OTUxZWY5NWFlMS90YWJsZToxNzE2NTY3MWY0YWU0MDk0YWRiZjE5YWZhMDExOGI0NC90YWJsZXJhbmdlOjE3MTY1NjcxZjRhZTQwOTRhZGJmMTlhZmEwMTE4YjQ0XzMtNS0xLTEtMA_ac32ab21-f367-4bab-9d6a-f8fd20b8d81f">10,676</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib56f1adc867e406ca7face50c5da1c9c_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMjkvZnJhZzo0OTNlMjJkZjg3YjE0MTcyYjQ5NWU1OTUxZWY5NWFlMS90YWJsZToxNzE2NTY3MWY0YWU0MDk0YWRiZjE5YWZhMDExOGI0NC90YWJsZXJhbmdlOjE3MTY1NjcxZjRhZTQwOTRhZGJmMTlhZmEwMTE4YjQ0XzMtNy0xLTEtMA_327d6408-36b1-4ea6-997b-483ba61e89b1">10,948</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Current operating lease liabilities</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied8d945ebce54ed8a4badfed477a64e8_I20210331" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMjkvZnJhZzo0OTNlMjJkZjg3YjE0MTcyYjQ5NWU1OTUxZWY5NWFlMS90YWJsZToxNzE2NTY3MWY0YWU0MDk0YWRiZjE5YWZhMDExOGI0NC90YWJsZXJhbmdlOjE3MTY1NjcxZjRhZTQwOTRhZGJmMTlhZmEwMTE4YjQ0XzYtNS0xLTEtMA_d7356727-a0fe-42ad-a93d-c6834ecbdd8c">942</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib56f1adc867e406ca7face50c5da1c9c_I20201231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMjkvZnJhZzo0OTNlMjJkZjg3YjE0MTcyYjQ5NWU1OTUxZWY5NWFlMS90YWJsZToxNzE2NTY3MWY0YWU0MDk0YWRiZjE5YWZhMDExOGI0NC90YWJsZXJhbmdlOjE3MTY1NjcxZjRhZTQwOTRhZGJmMTlhZmEwMTE4YjQ0XzYtNy0xLTEtMA_f57d6836-9cee-40cc-b33b-bf89c7d70c73">908</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Non-current operating lease liabilities</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied8d945ebce54ed8a4badfed477a64e8_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMjkvZnJhZzo0OTNlMjJkZjg3YjE0MTcyYjQ5NWU1OTUxZWY5NWFlMS90YWJsZToxNzE2NTY3MWY0YWU0MDk0YWRiZjE5YWZhMDExOGI0NC90YWJsZXJhbmdlOjE3MTY1NjcxZjRhZTQwOTRhZGJmMTlhZmEwMTE4YjQ0XzctNS0xLTEtMA_c0984b47-fd99-4275-ba6e-7a628eeb801c">9,403</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib56f1adc867e406ca7face50c5da1c9c_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMjkvZnJhZzo0OTNlMjJkZjg3YjE0MTcyYjQ5NWU1OTUxZWY5NWFlMS90YWJsZToxNzE2NTY3MWY0YWU0MDk0YWRiZjE5YWZhMDExOGI0NC90YWJsZXJhbmdlOjE3MTY1NjcxZjRhZTQwOTRhZGJmMTlhZmEwMTE4YjQ0XzctNy0xLTEtMA_d6296eac-5f4c-4412-b967-22c5bff29462">9,647</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total operating lease liabilities</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied8d945ebce54ed8a4badfed477a64e8_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMjkvZnJhZzo0OTNlMjJkZjg3YjE0MTcyYjQ5NWU1OTUxZWY5NWFlMS90YWJsZToxNzE2NTY3MWY0YWU0MDk0YWRiZjE5YWZhMDExOGI0NC90YWJsZXJhbmdlOjE3MTY1NjcxZjRhZTQwOTRhZGJmMTlhZmEwMTE4YjQ0XzgtNS0xLTEtMA_6caa2967-337f-4a9a-8b00-3b1b81062b86">10,345</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib56f1adc867e406ca7face50c5da1c9c_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMjkvZnJhZzo0OTNlMjJkZjg3YjE0MTcyYjQ5NWU1OTUxZWY5NWFlMS90YWJsZToxNzE2NTY3MWY0YWU0MDk0YWRiZjE5YWZhMDExOGI0NC90YWJsZXJhbmdlOjE3MTY1NjcxZjRhZTQwOTRhZGJmMTlhZmEwMTE4YjQ0XzgtNy0xLTEtMA_b82a929d-ddc0-4a5b-a862-bcc17abc8b2a">10,555</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><ix:nonNumeric contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331" name="us-gaap:LeaseCostTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMjkvZnJhZzo0OTNlMjJkZjg3YjE0MTcyYjQ5NWU1OTUxZWY5NWFlMS90ZXh0cmVnaW9uOjQ5M2UyMmRmODdiMTQxNzJiNDk1ZTU5NTFlZjk1YWUxXzY1MzQ_6620d349-2107-4d8b-aa0c-4513b14d44af" continuedAt="idb51d9a3e00d448ca465be2ea566a728" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March 31, 2021 and 2020 the components of lease costs were as follows (in thousands):  </span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.484%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331" decimals="-3" name="us-gaap:OperatingLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMjkvZnJhZzo0OTNlMjJkZjg3YjE0MTcyYjQ5NWU1OTUxZWY5NWFlMS90YWJsZTo4OTFjYzkxZTI2ZTE0ZmFiYjU5ZjA2NjFiMjQ1NTU4YS90YWJsZXJhbmdlOjg5MWNjOTFlMjZlMTRmYWJiNTlmMDY2MWIyNDU1NThhXzItNS0xLTEtMA_fc318780-f5b5-4cd3-ba56-7d564f6392a7">444</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i824a5b33f908426bad016f0eded844db_D20200101-20200331" decimals="-3" name="us-gaap:OperatingLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMjkvZnJhZzo0OTNlMjJkZjg3YjE0MTcyYjQ5NWU1OTUxZWY5NWFlMS90YWJsZTo4OTFjYzkxZTI2ZTE0ZmFiYjU5ZjA2NjFiMjQ1NTU4YS90YWJsZXJhbmdlOjg5MWNjOTFlMjZlMTRmYWJiNTlmMDY2MWIyNDU1NThhXzItNy0xLTEtMA_f84e08a0-b312-4f9b-bd82-17896f3e8144">472</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Variable lease cost</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331" decimals="-3" name="us-gaap:VariableLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMjkvZnJhZzo0OTNlMjJkZjg3YjE0MTcyYjQ5NWU1OTUxZWY5NWFlMS90YWJsZTo4OTFjYzkxZTI2ZTE0ZmFiYjU5ZjA2NjFiMjQ1NTU4YS90YWJsZXJhbmdlOjg5MWNjOTFlMjZlMTRmYWJiNTlmMDY2MWIyNDU1NThhXzMtNS0xLTEtMA_48da922a-efae-4609-85cc-20c0609fb372">288</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i824a5b33f908426bad016f0eded844db_D20200101-20200331" decimals="-3" name="us-gaap:VariableLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMjkvZnJhZzo0OTNlMjJkZjg3YjE0MTcyYjQ5NWU1OTUxZWY5NWFlMS90YWJsZTo4OTFjYzkxZTI2ZTE0ZmFiYjU5ZjA2NjFiMjQ1NTU4YS90YWJsZXJhbmdlOjg5MWNjOTFlMjZlMTRmYWJiNTlmMDY2MWIyNDU1NThhXzMtNy0xLTEtMA_79902b0a-0af8-4f7b-9007-c7ed7d77f350">199</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Short-term lease cost</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331" decimals="-3" name="us-gaap:ShortTermLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMjkvZnJhZzo0OTNlMjJkZjg3YjE0MTcyYjQ5NWU1OTUxZWY5NWFlMS90YWJsZTo4OTFjYzkxZTI2ZTE0ZmFiYjU5ZjA2NjFiMjQ1NTU4YS90YWJsZXJhbmdlOjg5MWNjOTFlMjZlMTRmYWJiNTlmMDY2MWIyNDU1NThhXzQtNS0xLTEtMA_60b37400-2cac-481c-b45d-7c68b7aa5bfd">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i824a5b33f908426bad016f0eded844db_D20200101-20200331" decimals="-3" name="us-gaap:ShortTermLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMjkvZnJhZzo0OTNlMjJkZjg3YjE0MTcyYjQ5NWU1OTUxZWY5NWFlMS90YWJsZTo4OTFjYzkxZTI2ZTE0ZmFiYjU5ZjA2NjFiMjQ1NTU4YS90YWJsZXJhbmdlOjg5MWNjOTFlMjZlMTRmYWJiNTlmMDY2MWIyNDU1NThhXzQtNy0xLTEtMA_201cb2fa-b3e5-4076-810b-ed0957fe8b02">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total lease cost</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331" decimals="-3" name="us-gaap:LeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMjkvZnJhZzo0OTNlMjJkZjg3YjE0MTcyYjQ5NWU1OTUxZWY5NWFlMS90YWJsZTo4OTFjYzkxZTI2ZTE0ZmFiYjU5ZjA2NjFiMjQ1NTU4YS90YWJsZXJhbmdlOjg5MWNjOTFlMjZlMTRmYWJiNTlmMDY2MWIyNDU1NThhXzUtNS0xLTEtMA_4d70cf5e-030b-4677-86d8-6052ced153f6">735</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i824a5b33f908426bad016f0eded844db_D20200101-20200331" decimals="-3" name="us-gaap:LeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMjkvZnJhZzo0OTNlMjJkZjg3YjE0MTcyYjQ5NWU1OTUxZWY5NWFlMS90YWJsZTo4OTFjYzkxZTI2ZTE0ZmFiYjU5ZjA2NjFiMjQ1NTU4YS90YWJsZXJhbmdlOjg5MWNjOTFlMjZlMTRmYWJiNTlmMDY2MWIyNDU1NThhXzUtNy0xLTEtMA_0d930083-b4ef-42ca-8ef1-0109f6b27836">673</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i71586e7d2e304f6983634abe9e071791_13">Table of Contents</a></span></div></div><ix:continuation id="if9df6726bd3f4109b133c3aff5b92593"><ix:nonNumeric contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMjkvZnJhZzo0OTNlMjJkZjg3YjE0MTcyYjQ5NWU1OTUxZWY5NWFlMS90ZXh0cmVnaW9uOjQ5M2UyMmRmODdiMTQxNzJiNDk1ZTU5NTFlZjk1YWUxXzY1NTA_45c54c2f-d8b5-43d5-8e25-bb9a91778cfc" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The maturity of the Company&#8217;s operating lease liabilities as of March 31, 2021 were as follows (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:87.204%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.596%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021 (remainder)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied8d945ebce54ed8a4badfed477a64e8_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMjkvZnJhZzo0OTNlMjJkZjg3YjE0MTcyYjQ5NWU1OTUxZWY5NWFlMS90YWJsZTo4NDMwYTJhZTIwOWQ0YTA4ODUzZDhlNDZlY2VjMzk0Mi90YWJsZXJhbmdlOjg0MzBhMmFlMjA5ZDRhMDg4NTNkOGU0NmVjZWMzOTQyXzItMS0xLTEtMA_93f7ce1e-219e-4f56-a959-7d77a6a9fa19">1,368</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied8d945ebce54ed8a4badfed477a64e8_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMjkvZnJhZzo0OTNlMjJkZjg3YjE0MTcyYjQ5NWU1OTUxZWY5NWFlMS90YWJsZTo4NDMwYTJhZTIwOWQ0YTA4ODUzZDhlNDZlY2VjMzk0Mi90YWJsZXJhbmdlOjg0MzBhMmFlMjA5ZDRhMDg4NTNkOGU0NmVjZWMzOTQyXzMtMS0xLTEtMA_e23e127c-cb16-460c-ad22-78874989ac6a">1,866</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied8d945ebce54ed8a4badfed477a64e8_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMjkvZnJhZzo0OTNlMjJkZjg3YjE0MTcyYjQ5NWU1OTUxZWY5NWFlMS90YWJsZTo4NDMwYTJhZTIwOWQ0YTA4ODUzZDhlNDZlY2VjMzk0Mi90YWJsZXJhbmdlOjg0MzBhMmFlMjA5ZDRhMDg4NTNkOGU0NmVjZWMzOTQyXzQtMS0xLTEtMA_92774e00-00cf-4098-b7dc-94001a341cd8">1,922</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied8d945ebce54ed8a4badfed477a64e8_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMjkvZnJhZzo0OTNlMjJkZjg3YjE0MTcyYjQ5NWU1OTUxZWY5NWFlMS90YWJsZTo4NDMwYTJhZTIwOWQ0YTA4ODUzZDhlNDZlY2VjMzk0Mi90YWJsZXJhbmdlOjg0MzBhMmFlMjA5ZDRhMDg4NTNkOGU0NmVjZWMzOTQyXzUtMS0xLTEtMA_a5b2384f-18d7-4586-acb1-79f3ad555220">1,980</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied8d945ebce54ed8a4badfed477a64e8_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMjkvZnJhZzo0OTNlMjJkZjg3YjE0MTcyYjQ5NWU1OTUxZWY5NWFlMS90YWJsZTo4NDMwYTJhZTIwOWQ0YTA4ODUzZDhlNDZlY2VjMzk0Mi90YWJsZXJhbmdlOjg0MzBhMmFlMjA5ZDRhMDg4NTNkOGU0NmVjZWMzOTQyXzYtMS0xLTEtMA_f7a620f2-0af3-4cf9-92af-08ee0f1f79a9">2,039</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied8d945ebce54ed8a4badfed477a64e8_I20210331" decimals="-3" format="ixt:numdotdecimal" name="selb:LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMjkvZnJhZzo0OTNlMjJkZjg3YjE0MTcyYjQ5NWU1OTUxZWY5NWFlMS90YWJsZTo4NDMwYTJhZTIwOWQ0YTA4ODUzZDhlNDZlY2VjMzk0Mi90YWJsZXJhbmdlOjg0MzBhMmFlMjA5ZDRhMDg4NTNkOGU0NmVjZWMzOTQyXzctMS0xLTEtMA_3895acb7-db9a-421b-b12d-d677ac4adf9f">4,945</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total future minimum lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied8d945ebce54ed8a4badfed477a64e8_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMjkvZnJhZzo0OTNlMjJkZjg3YjE0MTcyYjQ5NWU1OTUxZWY5NWFlMS90YWJsZTo4NDMwYTJhZTIwOWQ0YTA4ODUzZDhlNDZlY2VjMzk0Mi90YWJsZXJhbmdlOjg0MzBhMmFlMjA5ZDRhMDg4NTNkOGU0NmVjZWMzOTQyXzgtMS0xLTEtMA_367b906d-5c15-49da-a00f-aff34313b1cf">14,120</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied8d945ebce54ed8a4badfed477a64e8_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMjkvZnJhZzo0OTNlMjJkZjg3YjE0MTcyYjQ5NWU1OTUxZWY5NWFlMS90YWJsZTo4NDMwYTJhZTIwOWQ0YTA4ODUzZDhlNDZlY2VjMzk0Mi90YWJsZXJhbmdlOjg0MzBhMmFlMjA5ZDRhMDg4NTNkOGU0NmVjZWMzOTQyXzktMS0xLTEtMA_307ba5ae-e98c-425c-89c1-f3f12c8057ad">3,775</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total operating lease liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied8d945ebce54ed8a4badfed477a64e8_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMjkvZnJhZzo0OTNlMjJkZjg3YjE0MTcyYjQ5NWU1OTUxZWY5NWFlMS90YWJsZTo4NDMwYTJhZTIwOWQ0YTA4ODUzZDhlNDZlY2VjMzk0Mi90YWJsZXJhbmdlOjg0MzBhMmFlMjA5ZDRhMDg4NTNkOGU0NmVjZWMzOTQyXzEwLTEtMS0xLTA_7694a058-17e1-4a58-97e9-eb4ec086a98f">10,345</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><ix:nonNumeric contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331" name="us-gaap:OperatingLeaseLeaseIncomeTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMjkvZnJhZzo0OTNlMjJkZjg3YjE0MTcyYjQ5NWU1OTUxZWY5NWFlMS90ZXh0cmVnaW9uOjQ5M2UyMmRmODdiMTQxNzJiNDk1ZTU5NTFlZjk1YWUxXzY1NDM_73598da7-4c25-43a5-a88e-8ef42e090679" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The supplemental disclosure for the statement of cash flows related to operating leases were as follows (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.777%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.451%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331" decimals="-3" name="us-gaap:OperatingLeasePayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMjkvZnJhZzo0OTNlMjJkZjg3YjE0MTcyYjQ5NWU1OTUxZWY5NWFlMS90YWJsZTo4ZjM1M2E5N2JjOTU0YjE0OWM3NWI0ZDJjODYyMDIxZi90YWJsZXJhbmdlOjhmMzUzYTk3YmM5NTRiMTQ5Yzc1YjRkMmM4NjIwMjFmXzItMS0xLTEtMA_9f86ac34-4c4e-457e-aba7-1205af5b3cdf">444</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i824a5b33f908426bad016f0eded844db_D20200101-20200331" decimals="-3" name="us-gaap:OperatingLeasePayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMjkvZnJhZzo0OTNlMjJkZjg3YjE0MTcyYjQ5NWU1OTUxZWY5NWFlMS90YWJsZTo4ZjM1M2E5N2JjOTU0YjE0OWM3NWI0ZDJjODYyMDIxZi90YWJsZXJhbmdlOjhmMzUzYTk3YmM5NTRiMTQ5Yzc1YjRkMmM4NjIwMjFmXzItMy0xLTEtMA_660e8d7f-3bd9-4ae5-a381-4961917326e0">487</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other than the initial recording of the right-of-use asset and lease liability for the Headquarters Lease, which is non-cash, the changes in the Company&#8217;s right-of-use asset and lease liability for the three months ended March 31, 2021 and 2020 are reflected in the non-cash lease expense and accrued expenses and other liabilities, respectively, in the consolidated statements of cash flows.</span></div><ix:continuation id="idb51d9a3e00d448ca465be2ea566a728"><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following summarizes additional information related to operating leases:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.484%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-average remaining lease term</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ied8d945ebce54ed8a4badfed477a64e8_I20210331" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMjkvZnJhZzo0OTNlMjJkZjg3YjE0MTcyYjQ5NWU1OTUxZWY5NWFlMS90YWJsZTpiMjVmMzRhMmQxMWU0ZGY3YTdiYWI4MzcwNTE4MDllYS90YWJsZXJhbmdlOmIyNWYzNGEyZDExZTRkZjdhN2JhYjgzNzA1MTgwOWVhXzItMS0xLTEtMA_cfb126a2-de62-4bc0-ba7d-27b41aa78e57">7.1</ix:nonNumeric> years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="iff7e2530342c41bca8c84fce55f0cc6f_I20200331" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMjkvZnJhZzo0OTNlMjJkZjg3YjE0MTcyYjQ5NWU1OTUxZWY5NWFlMS90YWJsZTpiMjVmMzRhMmQxMWU0ZGY3YTdiYWI4MzcwNTE4MDllYS90YWJsZXJhbmdlOmIyNWYzNGEyZDExZTRkZjdhN2JhYjgzNzA1MTgwOWVhXzItMy0xLTEtMA_b7f6ed1b-b773-4e84-889a-ffa66cf4f8de">8.0</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-average discount rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ied8d945ebce54ed8a4badfed477a64e8_I20210331" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMjkvZnJhZzo0OTNlMjJkZjg3YjE0MTcyYjQ5NWU1OTUxZWY5NWFlMS90YWJsZTpiMjVmMzRhMmQxMWU0ZGY3YTdiYWI4MzcwNTE4MDllYS90YWJsZXJhbmdlOmIyNWYzNGEyZDExZTRkZjdhN2JhYjgzNzA1MTgwOWVhXzMtMS0xLTEtMA_5cd2f345-3254-4296-9ab3-da14123109b5">8.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iff7e2530342c41bca8c84fce55f0cc6f_I20200331" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMjkvZnJhZzo0OTNlMjJkZjg3YjE0MTcyYjQ5NWU1OTUxZWY5NWFlMS90YWJsZTpiMjVmMzRhMmQxMWU0ZGY3YTdiYWI4MzcwNTE4MDllYS90YWJsZXJhbmdlOmIyNWYzNGEyZDExZTRkZjdhN2JhYjgzNzA1MTgwOWVhXzMtMy0xLTEtMA_8eb8db4d-87cd-48a1-aa45-9d91a38f6f8d">8.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:continuation></ix:continuation><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div id="i71586e7d2e304f6983634abe9e071791_235"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9. <ix:nonNumeric contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331" name="us-gaap:DebtDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMzUvZnJhZzpmYWVkYzc2NDgyMzk0OGE4YjMwODE5MzQyYjI2YWI4Yy90ZXh0cmVnaW9uOmZhZWRjNzY0ODIzOTQ4YThiMzA4MTkzNDJiMjZhYjhjXzk5MjI_a410e0cd-59d1-4139-8ea8-3f3e1dec1486" continuedAt="i9c0c910f6a7d419aa66275fc9023ce14" escape="true">Debt</ix:nonNumeric></span></div><ix:continuation id="i9c0c910f6a7d419aa66275fc9023ce14" continuedAt="i9b2d0a007abf4964b7c66c707c83ec8b"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2020 Term Loan</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 31, 2020, the Company entered into a term loan of up to $<ix:nonFraction unitRef="usd" contextRef="ic49c55aadcfb4e6abcca12c5093f9b95_I20200831" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMzUvZnJhZzpmYWVkYzc2NDgyMzk0OGE4YjMwODE5MzQyYjI2YWI4Yy90ZXh0cmVnaW9uOmZhZWRjNzY0ODIzOTQ4YThiMzA4MTkzNDJiMjZhYjhjXzk0_d8ebc148-fa77-41d5-b4f5-fc3f950830ea">35.0</ix:nonFraction>&#160;million, or the 2020 Term Loan, consisting of term loans in an aggregate amount of $<ix:nonFraction unitRef="usd" contextRef="idad7c718ad664d059d7a422e95802f09_I20200831" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMzUvZnJhZzpmYWVkYzc2NDgyMzk0OGE4YjMwODE5MzQyYjI2YWI4Yy90ZXh0cmVnaW9uOmZhZWRjNzY0ODIzOTQ4YThiMzA4MTkzNDJiMjZhYjhjXzE3Mg_9824d892-df23-47ea-a393-ca041531cd0e">25.0</ix:nonFraction>&#160;million, or the Term A Loan, and term loans in an aggregate amount of $<ix:nonFraction unitRef="usd" contextRef="ibf84b0dc83f74410887e49db3c27bd26_I20200831" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMzUvZnJhZzpmYWVkYzc2NDgyMzk0OGE4YjMwODE5MzQyYjI2YWI4Yy90ZXh0cmVnaW9uOmZhZWRjNzY0ODIzOTQ4YThiMzA4MTkzNDJiMjZhYjhjXzIzNg_ee3bab9e-2ce5-4808-8029-793b435bb540">10.0</ix:nonFraction>&#160;million, or the Term B Loan, governed by a loan and security agreement, or the Loan Agreement, between the Company and Oxford Finance LLC, or Oxford, as Collateral Agent and a Lender, and SVB, as a Lender. The Term A Loan was funded in full on August 31, 2020, or the Funding Date.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Term B Loan will be available, subject to Collateral Agent&#8217;s discretion and customary terms and conditions, during the period commencing on the date the Company has delivered to the Collateral Agent and the Lenders evidence: (i) the Company or one of the Company&#8217;s collaboration partners has enrolled its first patient for a Phase 1 clinical trial evaluating the treatment of methylmalonic acidemia, or MMA, and (ii) the Company has enrolled the first patient in each of two Phase 3 pivotal trials evaluating SEL-212, or the Second Draw Period Milestone, and ending on the earliest of (i) the date which is 30 days following the date the Second Draw Period Milestone is achieved, (ii) September 30, 2021 (iii) and the occurrence of an event of default, other than an event of default that has been waived in writing by Collateral Agent and the Lenders in their sole discretion, with such period referred to as the Second Draw Period.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2020 Term Loan will mature on August 1, 2025. Each advance under the Term Loan accrues interest at a floating per annum rate equal to the greater of (a) <ix:nonFraction unitRef="number" contextRef="i0c9896510dd84101bf9f2e4ccfe3aafb_D20210101-20210331" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMzUvZnJhZzpmYWVkYzc2NDgyMzk0OGE4YjMwODE5MzQyYjI2YWI4Yy90ZXh0cmVnaW9uOmZhZWRjNzY0ODIzOTQ4YThiMzA4MTkzNDJiMjZhYjhjXzE2OTc_f49d2cac-5629-4bbb-a0e5-632b09dd841a">7.90</ix:nonFraction>%, and (b) the lesser of (x) the sum of (i) the prime rate reported in The Wall Street Journal on the last business day of the month that immediately precedes the month in which the interest will accrue, and (ii) <ix:nonFraction unitRef="number" contextRef="idb510d90210b4690b5f24ea7b3c03117_D20210101-20210331" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMzUvZnJhZzpmYWVkYzc2NDgyMzk0OGE4YjMwODE5MzQyYjI2YWI4Yy90ZXh0cmVnaW9uOmZhZWRjNzY0ODIzOTQ4YThiMzA4MTkzNDJiMjZhYjhjXzE5MTE_2879dc38-6dae-473b-a2a9-fc083ae990b0">4.65</ix:nonFraction>% and (y) <ix:nonFraction unitRef="number" contextRef="i508d18807d32409296e19306139342d3_D20210101-20210331" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMzUvZnJhZzpmYWVkYzc2NDgyMzk0OGE4YjMwODE5MzQyYjI2YWI4Yy90ZXh0cmVnaW9uOmZhZWRjNzY0ODIzOTQ4YThiMzA4MTkzNDJiMjZhYjhjXzE5MjI_73f09d16-b1c8-4148-a718-7f6d95ddd5f8">10.00</ix:nonFraction>%. The Term Loan provides for interest-only payments on a monthly basis until April 1, 2022; provided however, if the Company has delivered to the Collateral Agent and the Lenders prior to September 30, 2021 evidence that Borrower has achieved the Second Draw Period Milestone, the Term Loan provides for interest-only payments on a monthly basis until October 1, 2022. Thereafter, amortization payments will be payable monthly in equal installments of principal and interest to fully amortize the outstanding principal over the remaining term of the loan, subject to recalculation upon a change in the prime rate. The Company may prepay the Term Loan in full but not in part provided that the Company (i) provides ten days&#8217; prior written notice to Collateral Agent, (ii) pays on the date of such prepayment (A) all outstanding principal plus </span></div></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i71586e7d2e304f6983634abe9e071791_13">Table of Contents</a></span></div></div><ix:continuation id="i9b2d0a007abf4964b7c66c707c83ec8b" continuedAt="i5db0830666ba4c7eb0ac40b5b93ba547"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">accrued and unpaid interest, and (B) a prepayment fee of between <ix:nonFraction unitRef="number" contextRef="id40f93ddba284a1eaf4d3d96cdbe8228_D20210101-20210331" decimals="INF" name="selb:DebtInstrumentPrepaymentFeePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMzUvZnJhZzpmYWVkYzc2NDgyMzk0OGE4YjMwODE5MzQyYjI2YWI4Yy90ZXh0cmVnaW9uOmZhZWRjNzY0ODIzOTQ4YThiMzA4MTkzNDJiMjZhYjhjXzI4MzE_0c22891a-4890-4345-84da-436f8ced6d85">3.0</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i3fe76a62c9514fceaf15e8fc84c84053_D20210101-20210331" decimals="INF" name="selb:DebtInstrumentPrepaymentFeePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMzUvZnJhZzpmYWVkYzc2NDgyMzk0OGE4YjMwODE5MzQyYjI2YWI4Yy90ZXh0cmVnaW9uOmZhZWRjNzY0ODIzOTQ4YThiMzA4MTkzNDJiMjZhYjhjXzI4Mzg_8f2bfcfc-4830-4fc4-ace9-80ebfe6fccc1">1.0</ix:nonFraction>% of the aggregate original principal amount advanced by the lender depending on the timing of the prepayment. Amounts outstanding during an event of default are payable upon SVB&#8217;s demand and shall accrue interest at an additional rate of <ix:nonFraction unitRef="number" contextRef="i3303eaf5c2074c30aee9f9289696a2e5_D20210101-20210331" decimals="INF" name="selb:DebtInstrumentAdditionalAccruedInterestInTheEventOfDefault" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMzUvZnJhZzpmYWVkYzc2NDgyMzk0OGE4YjMwODE5MzQyYjI2YWI4Yy90ZXh0cmVnaW9uOmZhZWRjNzY0ODIzOTQ4YThiMzA4MTkzNDJiMjZhYjhjXzMwNzg_bf3aa208-961d-4041-916c-e0632fe985d2">5.0</ix:nonFraction>% per annum of the past due amount outstanding. At the end of the loan term (whether at maturity, by prepayment in full or otherwise), the Company shall make a final payment to the lender in the amount of <ix:nonFraction unitRef="number" contextRef="i3303eaf5c2074c30aee9f9289696a2e5_D20210101-20210331" decimals="INF" name="us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMzUvZnJhZzpmYWVkYzc2NDgyMzk0OGE4YjMwODE5MzQyYjI2YWI4Yy90ZXh0cmVnaW9uOmZhZWRjNzY0ODIzOTQ4YThiMzA4MTkzNDJiMjZhYjhjXzMyODQ_3d3ddb9f-08b5-4fa6-ab95-81a4af8a506f">9.0</ix:nonFraction>% of the aggregate original principal amount advanced by the lender. The final payment fee totaling $<ix:nonFraction unitRef="usd" contextRef="ied8d945ebce54ed8a4badfed477a64e8_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMzUvZnJhZzpmYWVkYzc2NDgyMzk0OGE4YjMwODE5MzQyYjI2YWI4Yy90ZXh0cmVnaW9uOmZhZWRjNzY0ODIzOTQ4YThiMzA4MTkzNDJiMjZhYjhjXzMzODU_be9a3e05-3963-4821-b291-56f2f6494555">2.3</ix:nonFraction>&#160;million is recorded as a loan discount.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Term Loan is secured by a lien on substantially all of the assets of the Company, other than intellectual property, provided that such lien on substantially all assets includes any rights to payments and proceeds from the sale, licensing or disposition of intellectual property. The Company has also granted the Collateral Agent a negative pledge with respect to its intellectual property.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Loan Agreement contains customary covenants and representations, including but not limited to financial reporting obligations and limitations on dividends, indebtedness, collateral, investments, distributions, transfers, mergers or acquisitions, taxes, corporate changes, deposit accounts, and subsidiaries. The Loan Agreement also contains other customary provisions, such as expense reimbursement, non-disclosure obligations as well as indemnification rights for the benefit of the Collateral Agent.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The events of default under the Loan Agreement include, but are not limited to, the Company&#8217;s failure to make any payments of principal or interest under the Loan Agreement or other transaction documents, the Company&#8217;s breach or default in the performance of any covenant under the Loan Agreement or other transaction documents, the occurrence of a material adverse change, the Company making a false or misleading representation or warranty in any material respect under the Loan Agreement, the Company&#8217;s insolvency or bankruptcy, any attachment or judgment on the Company&#8217;s assets of at least $<ix:nonFraction unitRef="usd" contextRef="i2d4605e783914026a19516819dbaac3f_D20200831-20200831" decimals="-5" format="ixt:numdotdecimal" name="selb:DebtInstrumentDefaultBankruptcyOrInsolvencyValueOfTriggeringAcceleratedRedemption" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMzUvZnJhZzpmYWVkYzc2NDgyMzk0OGE4YjMwODE5MzQyYjI2YWI4Yy90ZXh0cmVnaW9uOmZhZWRjNzY0ODIzOTQ4YThiMzA4MTkzNDJiMjZhYjhjXzQ5MTU_57aca4be-6667-4415-843f-f65722d2c01a">0.5</ix:nonFraction>&#160;million, or the occurrence of any default under any agreement or obligation of the Company involving indebtedness in excess of $<ix:nonFraction unitRef="usd" contextRef="i2d4605e783914026a19516819dbaac3f_D20200831-20200831" decimals="-5" format="ixt:numdotdecimal" name="selb:DebtInstrumentDefaultBankruptcyOrInsolvencyValueOfTriggeringAcceleratedRedemption" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMzUvZnJhZzpmYWVkYzc2NDgyMzk0OGE4YjMwODE5MzQyYjI2YWI4Yy90ZXh0cmVnaW9uOmZhZWRjNzY0ODIzOTQ4YThiMzA4MTkzNDJiMjZhYjhjXzUwMzc_57aca4be-6667-4415-843f-f65722d2c01a">0.5</ix:nonFraction>&#160;million. If an event of default occurs, the Collateral Agent is entitled to take enforcement action, including acceleration of amounts due under the Loan Agreement.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company incurred $<ix:nonFraction unitRef="usd" contextRef="ic49c55aadcfb4e6abcca12c5093f9b95_I20200831" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtIssuanceCostsLineOfCreditArrangementsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMzUvZnJhZzpmYWVkYzc2NDgyMzk0OGE4YjMwODE5MzQyYjI2YWI4Yy90ZXh0cmVnaW9uOmZhZWRjNzY0ODIzOTQ4YThiMzA4MTkzNDJiMjZhYjhjXzUyMTg_9e2b9bee-2dec-4c5d-9d6a-8db5b0a30039">0.4</ix:nonFraction>&#160;million in debt issuance costs in connection with the closing of the 2020 Term Loan. Debt issuance costs are presented in the consolidated balance sheet as a direct deduction from the associated liability and amortized to interest expense over the term of the related debt.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assessed all terms and features of the 2020 Term Loan to identify any potential embedded features that would require bifurcation. As part of this analysis, the Company assessed the economic characteristics and risks of the 2020 Term Loan, including any put, call, and contingent features. The Company determined that the interest rate collar and prepayment call option did not require bifurcation; whereas the contingent put option and default (contingent) interest rate feature met bifurcation criteria resulting in immaterial amounts.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Warrants</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 31, 2020, in connection with the 2020 Term A Loan, the Company issued warrants to the Lenders to purchase an aggregate of <ix:nonFraction unitRef="shares" contextRef="i8096110103d24ead836cc45438a9c346_I20200831" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMzUvZnJhZzpmYWVkYzc2NDgyMzk0OGE4YjMwODE5MzQyYjI2YWI4Yy90ZXh0cmVnaW9uOmZhZWRjNzY0ODIzOTQ4YThiMzA4MTkzNDJiMjZhYjhjXzYxNzc_33cbe494-46d2-45f0-99eb-e8eeca7ef30a">196,850</ix:nonFraction> shares of its common stock at an exercise price equal to $<ix:nonFraction unitRef="usdPerShare" contextRef="i8096110103d24ead836cc45438a9c346_I20200831" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMzUvZnJhZzpmYWVkYzc2NDgyMzk0OGE4YjMwODE5MzQyYjI2YWI4Yy90ZXh0cmVnaW9uOmZhZWRjNzY0ODIzOTQ4YThiMzA4MTkzNDJiMjZhYjhjXzYyMzc_cc07ebc2-ff64-4e0f-bfca-655abbe28d8b">2.54</ix:nonFraction> per share. In accordance with ASC 815-40, these warrants are classified as permanent equity in the accompanying consolidated balance sheets and will expire <ix:nonNumeric contextRef="i23a2063d104e496f85ffd7168cdf9d4c_D20200831-20200831" format="ixt-sec:durwordsen" name="selb:ClassOfWarrantOrRightExpirationPeriod" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMzUvZnJhZzpmYWVkYzc2NDgyMzk0OGE4YjMwODE5MzQyYjI2YWI4Yy90ZXh0cmVnaW9uOmZhZWRjNzY0ODIzOTQ4YThiMzA4MTkzNDJiMjZhYjhjXzYzOTY_21bc1ccc-fd7c-471e-9e3a-e882650fb1e5">ten years</ix:nonNumeric> from the date of issuance. The initial grant date fair value of the warrants was $<ix:nonFraction unitRef="usd" contextRef="i23a2063d104e496f85ffd7168cdf9d4c_D20200831-20200831" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMzUvZnJhZzpmYWVkYzc2NDgyMzk0OGE4YjMwODE5MzQyYjI2YWI4Yy90ZXh0cmVnaW9uOmZhZWRjNzY0ODIzOTQ4YThiMzA4MTkzNDJiMjZhYjhjXzY0ODA_db322d45-2aea-4056-8b0b-2a66cdc22beb">0.4</ix:nonFraction>&#160;million as determined by the Black-Scholes valuation model and recorded to shareholders' equity, with the SVB portion allocated to the reacquisition price of the 2017 Term Loan and the Oxford fair value portion as a loan discount to the Term A Loan.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, on August 31, 2020, pursuant to the terms of a Warrant Side Letter agreement among the Company and the Lenders, the Company agreed to issue to the Lenders, on the date the Company draws the Term B Loan and in accordance with each party&#8217;s respective pro rata share with respect to the Term B Loan, one or more warrants to purchase an aggregate number of shares of its common stock that is equal to $<ix:nonFraction unitRef="usd" contextRef="i7dadb30c8c5644a19242b20dc3231a67_D20200831-20200831" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMzUvZnJhZzpmYWVkYzc2NDgyMzk0OGE4YjMwODE5MzQyYjI2YWI4Yy90ZXh0cmVnaW9uOmZhZWRjNzY0ODIzOTQ4YThiMzA4MTkzNDJiMjZhYjhjXzcxMzY_d95defa6-5c03-4e26-ba3c-585ca5a54e1c">200,000</ix:nonFraction> divided by the average closing price of the Company&#8217;s common stock on The Nasdaq Stock Market LLC for the ten consecutive trading days ending the day before such issuance, rounded down to the nearest whole number of shares, and having an exercise price equal to the Term B Warrant Price.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Payoff</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On the Funding Date, the Company entered into a payoff letter with SVB, pursuant to which the Company utilized $<ix:nonFraction unitRef="usd" contextRef="ifaf30d95979d4b7f87adf2a9bc2bf774_D20200831-20200831" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfLinesOfCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMzUvZnJhZzpmYWVkYzc2NDgyMzk0OGE4YjMwODE5MzQyYjI2YWI4Yy90ZXh0cmVnaW9uOmZhZWRjNzY0ODIzOTQ4YThiMzA4MTkzNDJiMjZhYjhjXzc1NDU_a930159a-2a76-4f6d-b2b8-3723a16ca20b">13.7</ix:nonFraction>&#160;million of the 2020 Term Loan to pay off all outstanding obligations under the previous term loan, consisting of the principal payment, final prepayment and accrued interest. During the three months ended September 30, 2020, the Company recognized a loss on extinguishment of debt in the amount of $<ix:nonFraction unitRef="usd" contextRef="ia71eca13c1a4466f9daeb5956381a0e0_D20200701-20200930" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMzUvZnJhZzpmYWVkYzc2NDgyMzk0OGE4YjMwODE5MzQyYjI2YWI4Yy90ZXh0cmVnaW9uOmZhZWRjNzY0ODIzOTQ4YThiMzA4MTkzNDJiMjZhYjhjXzc4NTM_884c9aa2-023d-4920-8d07-9c3a163e5bf5">0.5</ix:nonFraction>&#160;million determined as the difference between the reacquisition price and carrying value at August 31, 2020.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2021 and December 31, 2020, the outstanding principal balance under the 2020 Term Loan was $<ix:nonFraction unitRef="usd" contextRef="ied299278fc4543748c5f3ad2970fc3bb_I20210331" decimals="-5" name="us-gaap:LineOfCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMzUvZnJhZzpmYWVkYzc2NDgyMzk0OGE4YjMwODE5MzQyYjI2YWI4Yy90ZXh0cmVnaW9uOmZhZWRjNzY0ODIzOTQ4YThiMzA4MTkzNDJiMjZhYjhjXzk1MTg_75a9e6d1-47b0-4440-b109-ff510c58ae89"><ix:nonFraction unitRef="usd" contextRef="ie10a81ae4793423483f2db5739fafba5_I20201231" decimals="-5" name="us-gaap:LineOfCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMzUvZnJhZzpmYWVkYzc2NDgyMzk0OGE4YjMwODE5MzQyYjI2YWI4Yy90ZXh0cmVnaW9uOmZhZWRjNzY0ODIzOTQ4YThiMzA4MTkzNDJiMjZhYjhjXzk1MTg_f4e91392-0cd6-46cd-b273-ebee1d742227">25.0</ix:nonFraction></ix:nonFraction> million.</span></div></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i71586e7d2e304f6983634abe9e071791_13">Table of Contents</a></span></div></div><ix:continuation id="i5db0830666ba4c7eb0ac40b5b93ba547"><ix:nonNumeric contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331" name="us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMzUvZnJhZzpmYWVkYzc2NDgyMzk0OGE4YjMwODE5MzQyYjI2YWI4Yy90ZXh0cmVnaW9uOmZhZWRjNzY0ODIzOTQ4YThiMzA4MTkzNDJiMjZhYjhjXzk5MTQ_be78a9ab-cb6f-4ef5-9210-d63072914cea" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future minimum principal and interest payments on the 2020 Term Loan as of March 31, 2021 are as follows (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:87.204%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.596%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021 (remainder)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i867f4cd50cdf4945bf8a2b4c13258dfd_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMzUvZnJhZzpmYWVkYzc2NDgyMzk0OGE4YjMwODE5MzQyYjI2YWI4Yy90YWJsZTo0ZjhlNGFhZTJkMDc0ZDgzYmI2ZGU0MDY0YTM5NmYzOS90YWJsZXJhbmdlOjRmOGU0YWFlMmQwNzRkODNiYjZkZTQwNjRhMzk2ZjM5XzAtMS0xLTEtMA_7e6d37ee-40e7-4573-b315-df38d5ed41ed">1,509</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i867f4cd50cdf4945bf8a2b4c13258dfd_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMzUvZnJhZzpmYWVkYzc2NDgyMzk0OGE4YjMwODE5MzQyYjI2YWI4Yy90YWJsZTo0ZjhlNGFhZTJkMDc0ZDgzYmI2ZGU0MDY0YTM5NmYzOS90YWJsZXJhbmdlOjRmOGU0YWFlMmQwNzRkODNiYjZkZTQwNjRhMzk2ZjM5XzEtMS0xLTEtMA_f9d94164-f33e-4717-a934-b9228448b007">7,343</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i867f4cd50cdf4945bf8a2b4c13258dfd_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMzUvZnJhZzpmYWVkYzc2NDgyMzk0OGE4YjMwODE5MzQyYjI2YWI4Yy90YWJsZTo0ZjhlNGFhZTJkMDc0ZDgzYmI2ZGU0MDY0YTM5NmYzOS90YWJsZXJhbmdlOjRmOGU0YWFlMmQwNzRkODNiYjZkZTQwNjRhMzk2ZjM5XzItMS0xLTEtMA_5fc93301-37b2-4625-bcb9-eb3ac308b258">8,611</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i867f4cd50cdf4945bf8a2b4c13258dfd_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMzUvZnJhZzpmYWVkYzc2NDgyMzk0OGE4YjMwODE5MzQyYjI2YWI4Yy90YWJsZTo0ZjhlNGFhZTJkMDc0ZDgzYmI2ZGU0MDY0YTM5NmYzOS90YWJsZXJhbmdlOjRmOGU0YWFlMmQwNzRkODNiYjZkZTQwNjRhMzk2ZjM5XzMtMS0xLTEtMA_c01bd3f0-f868-4081-a134-3e4d1cf5fd5d">8,027</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i867f4cd50cdf4945bf8a2b4c13258dfd_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMzUvZnJhZzpmYWVkYzc2NDgyMzk0OGE4YjMwODE5MzQyYjI2YWI4Yy90YWJsZTo0ZjhlNGFhZTJkMDc0ZDgzYmI2ZGU0MDY0YTM5NmYzOS90YWJsZXJhbmdlOjRmOGU0YWFlMmQwNzRkODNiYjZkZTQwNjRhMzk2ZjM5XzQtMS0xLTEtMA_310c007e-cea9-46fd-a53a-f75f56cf4f37">7,274</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total minimum debt payments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i867f4cd50cdf4945bf8a2b4c13258dfd_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMzUvZnJhZzpmYWVkYzc2NDgyMzk0OGE4YjMwODE5MzQyYjI2YWI4Yy90YWJsZTo0ZjhlNGFhZTJkMDc0ZDgzYmI2ZGU0MDY0YTM5NmYzOS90YWJsZXJhbmdlOjRmOGU0YWFlMmQwNzRkODNiYjZkZTQwNjRhMzk2ZjM5XzUtMS0xLTEtMA_78b7be1f-9738-4c7b-976e-0149c357adea">32,764</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: Amount representing interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i867f4cd50cdf4945bf8a2b4c13258dfd_I20210331" decimals="-3" format="ixt:numdotdecimal" name="selb:DebtInstrumentInterestPortion" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMzUvZnJhZzpmYWVkYzc2NDgyMzk0OGE4YjMwODE5MzQyYjI2YWI4Yy90YWJsZTo0ZjhlNGFhZTJkMDc0ZDgzYmI2ZGU0MDY0YTM5NmYzOS90YWJsZXJhbmdlOjRmOGU0YWFlMmQwNzRkODNiYjZkZTQwNjRhMzk2ZjM5XzYtMS0xLTEtMA_ef92d8c0-8c2a-4811-933e-c08c95c4d3d3">5,514</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: Debt discount and deferred charges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i867f4cd50cdf4945bf8a2b4c13258dfd_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMzUvZnJhZzpmYWVkYzc2NDgyMzk0OGE4YjMwODE5MzQyYjI2YWI4Yy90YWJsZTo0ZjhlNGFhZTJkMDc0ZDgzYmI2ZGU0MDY0YTM5NmYzOS90YWJsZXJhbmdlOjRmOGU0YWFlMmQwNzRkODNiYjZkZTQwNjRhMzk2ZjM5XzctMS0xLTEtMA_0c1de949-1a35-46e6-a784-503c141633c5">2,239</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: Current portion of loan payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i867f4cd50cdf4945bf8a2b4c13258dfd_I20210331" decimals="-3" name="us-gaap:LongTermDebtCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMzUvZnJhZzpmYWVkYzc2NDgyMzk0OGE4YjMwODE5MzQyYjI2YWI4Yy90YWJsZTo0ZjhlNGFhZTJkMDc0ZDgzYmI2ZGU0MDY0YTM5NmYzOS90YWJsZXJhbmdlOjRmOGU0YWFlMmQwNzRkODNiYjZkZTQwNjRhMzk2ZjM5XzgtMS0xLTEtMA_6c35f15e-4302-48a0-b0d4-c88fe889b70f">460</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loan payable, net of current portion</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i867f4cd50cdf4945bf8a2b4c13258dfd_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMzUvZnJhZzpmYWVkYzc2NDgyMzk0OGE4YjMwODE5MzQyYjI2YWI4Yy90YWJsZTo0ZjhlNGFhZTJkMDc0ZDgzYmI2ZGU0MDY0YTM5NmYzOS90YWJsZXJhbmdlOjRmOGU0YWFlMmQwNzRkODNiYjZkZTQwNjRhMzk2ZjM5XzktMS0xLTEtMA_a52cb948-8593-4ba8-9de3-9416bc3359dd">24,551</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span><br/></span></div><div id="i71586e7d2e304f6983634abe9e071791_241"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10. <ix:nonNumeric contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDEvZnJhZzoxMTE4YWMxYjVhM2Y0M2ViYjM4OWQ1MjQxMDE0Zjk5YS90ZXh0cmVnaW9uOjExMThhYzFiNWEzZjQzZWJiMzg5ZDUyNDEwMTRmOTlhXzExNTY2_eac3737b-e183-48b4-af17-6258874eccb2" continuedAt="i808aec94385c4bc1a58f26094b1b6500" escape="true">Equity</ix:nonNumeric></span></div><ix:continuation id="i808aec94385c4bc1a58f26094b1b6500" continuedAt="i010d27ef7f8848ea9182e5133f969b46"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Equity Financings</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">August 2020 Shelf Registration Statement</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August&#160;6, 2020, the Company filed an updated universal shelf registration statement on Form S-3 (Reg. No. 333-241692) with the SEC to sell an aggregate amount of up to $<ix:nonFraction unitRef="usd" contextRef="i98fb2199c6374722852813ddab2890d7_D20200806-20200806" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDEvZnJhZzoxMTE4YWMxYjVhM2Y0M2ViYjM4OWQ1MjQxMDE0Zjk5YS90ZXh0cmVnaW9uOjExMThhYzFiNWEzZjQzZWJiMzg5ZDUyNDEwMTRmOTlhXzIzNA_16413530-58c4-4d62-ba19-cb1f1613e0b0">200.0</ix:nonFraction> million of certain of its securities. The shelf registration statement was declared effective by the SEC on August&#160;14, 2020.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8220;At-the-Market&#8221; Offerings</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2017, the Company entered into a sales agreement, or the 2017 Sales Agreement, with Jefferies LLC, as sales agent, to sell shares of its common stock with an aggregate value of up to $<ix:nonFraction unitRef="usd" contextRef="i8b800c16db4f4bf39aec6ba9ec584f99_D20170801-20170831" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDEvZnJhZzoxMTE4YWMxYjVhM2Y0M2ViYjM4OWQ1MjQxMDE0Zjk5YS90ZXh0cmVnaW9uOjExMThhYzFiNWEzZjQzZWJiMzg5ZDUyNDEwMTRmOTlhXzQzOTgwNDY1MzM0MjY_820b532f-7ab2-4083-bd3c-3e4886027014">50.0</ix:nonFraction>&#160;million in an &#8220;at the market offering.&#8221; On August 6, 2020, concurrent with the filing of the updated shelf registration statement, the Company entered into a sales agreement, or the 2020 Sales Agreement with Jefferies LLC, as sales agent, pursuant to which the Company may, from time to time, issue and sell common stock with an aggregate value of up to $<ix:nonFraction unitRef="usd" contextRef="id4091feb67174db89de51f974b39d21c_D20170801-20170831" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDEvZnJhZzoxMTE4YWMxYjVhM2Y0M2ViYjM4OWQ1MjQxMDE0Zjk5YS90ZXh0cmVnaW9uOjExMThhYzFiNWEzZjQzZWJiMzg5ZDUyNDEwMTRmOTlhXzkxMw_95df7c0d-492a-4ef9-8101-b9589e0bbbea">50.0</ix:nonFraction>&#160;million in an &#8220;at the market offering.&#8221; The 2017 Sales Agreement terminated pursuant to its terms in August 2020.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales of common stock, if any, pursuant to the 2020 Sales Agreement, may be made in sales deemed to be an &#8220;at the market offering&#8221; as defined in Rule 415(a) of the Securities Act, including sales made directly through the Nasdaq Stock Market or on any other existing trading market for the Company&#8217;s common stock. The Company intends to use the proceeds from the offering for working capital and other general corporate purposes. The Company may suspend or terminate the 2020 Sales Agreement at any time.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2020, the Company sold <ix:nonFraction unitRef="shares" contextRef="ice2d8b62be3849c288862d2279be6e13_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDEvZnJhZzoxMTE4YWMxYjVhM2Y0M2ViYjM4OWQ1MjQxMDE0Zjk5YS90ZXh0cmVnaW9uOjExMThhYzFiNWEzZjQzZWJiMzg5ZDUyNDEwMTRmOTlhXzE1ODU_48626feb-97b5-4362-aa1f-91dea40a3922">1,069,486</ix:nonFraction> shares of its common stock pursuant to the 2020 and 2017 Sales Agreements at an average price of approximately $<ix:nonFraction unitRef="usdPerShare" contextRef="ibc930259a91a4e09996f4820308891bd_I20201231" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDEvZnJhZzoxMTE4YWMxYjVhM2Y0M2ViYjM4OWQ1MjQxMDE0Zjk5YS90ZXh0cmVnaW9uOjExMThhYzFiNWEzZjQzZWJiMzg5ZDUyNDEwMTRmOTlhXzE2OTA_b6bf0b15-b575-4aff-b58e-2e7b552ec940">2.16</ix:nonFraction> per share for aggregate net proceeds of $<ix:nonFraction unitRef="usd" contextRef="ice2d8b62be3849c288862d2279be6e13_D20200101-20201231" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDEvZnJhZzoxMTE4YWMxYjVhM2Y0M2ViYjM4OWQ1MjQxMDE0Zjk5YS90ZXh0cmVnaW9uOjExMThhYzFiNWEzZjQzZWJiMzg5ZDUyNDEwMTRmOTlhXzE3MzQ_d6b60af0-8ee1-4274-b835-1237e5c3a91d">2.1</ix:nonFraction> million, after deducting commissions and other transaction costs.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2021, the Company sold <ix:nonFraction unitRef="shares" contextRef="i677f0fc8ad1f4d2c83a443e0a5bd7e07_D20210101-20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDEvZnJhZzoxMTE4YWMxYjVhM2Y0M2ViYjM4OWQ1MjQxMDE0Zjk5YS90ZXh0cmVnaW9uOjExMThhYzFiNWEzZjQzZWJiMzg5ZDUyNDEwMTRmOTlhXzE5MTM_f67dc1d4-ad33-4b53-8b3b-e3c9178699e2">4,706,844</ix:nonFraction> shares of its common stock pursuant to the 2020 Sales Agreement at an average price of approximately $<ix:nonFraction unitRef="usdPerShare" contextRef="i5a706b93dc024e0d96e8ca02c67629d7_I20210331" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDEvZnJhZzoxMTE4YWMxYjVhM2Y0M2ViYjM4OWQ1MjQxMDE0Zjk5YS90ZXh0cmVnaW9uOjExMThhYzFiNWEzZjQzZWJiMzg5ZDUyNDEwMTRmOTlhXzIwNjM_3e37a22a-ae86-4eba-96c7-3d03c0f65724">4.59</ix:nonFraction> per share for aggregate net proceeds of $<ix:nonFraction unitRef="usd" contextRef="i677f0fc8ad1f4d2c83a443e0a5bd7e07_D20210101-20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDEvZnJhZzoxMTE4YWMxYjVhM2Y0M2ViYjM4OWQ1MjQxMDE0Zjk5YS90ZXh0cmVnaW9uOjExMThhYzFiNWEzZjQzZWJiMzg5ZDUyNDEwMTRmOTlhXzIxMDY_36e0e394-7755-4378-a69a-1af96a4a6789">20.9</ix:nonFraction> million, after deducting commissions and other transaction costs.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">June 2020 Sobi Stock Purchase</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 11, 2020, the Company entered into a stock purchase agreement with Sobi, pursuant to which the Company sold an aggregate of <ix:nonFraction unitRef="shares" contextRef="i6e736a6ad22d4f7fbc1eda905bef7a23_D20200611-20200611" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDEvZnJhZzoxMTE4YWMxYjVhM2Y0M2ViYjM4OWQ1MjQxMDE0Zjk5YS90ZXh0cmVnaW9uOjExMThhYzFiNWEzZjQzZWJiMzg5ZDUyNDEwMTRmOTlhXzIzNTk_c1a4c96a-dea1-4f2f-be69-9d27e844f929">5,416,390</ix:nonFraction> shares of its common stock at a purchase price equal to $<ix:nonFraction unitRef="usdPerShare" contextRef="i5034b14d18454b028a4c7a4a20bbac44_I20200611" decimals="4" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDEvZnJhZzoxMTE4YWMxYjVhM2Y0M2ViYjM4OWQ1MjQxMDE0Zjk5YS90ZXh0cmVnaW9uOjExMThhYzFiNWEzZjQzZWJiMzg5ZDUyNDEwMTRmOTlhXzI0MTg_cc740851-40df-4e3a-976e-6663a3ea66fe">4.6156</ix:nonFraction> per share, which represented <ix:nonFraction unitRef="number" contextRef="i6e736a6ad22d4f7fbc1eda905bef7a23_D20200611-20200611" decimals="INF" name="selb:SaleofStockPercentageOfTenDayVolumeWeightedAveragePriceOfCommonStock" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDEvZnJhZzoxMTE4YWMxYjVhM2Y0M2ViYjM4OWQ1MjQxMDE0Zjk5YS90ZXh0cmVnaW9uOjExMThhYzFiNWEzZjQzZWJiMzg5ZDUyNDEwMTRmOTlhXzI0NTA_f010be79-2da4-48de-9634-4f2af0f00940">120</ix:nonFraction>% of the 10-day volume-weighted average price of the Company&#8217;s common stock prior to signing, for aggregate gross proceeds of $<ix:nonFraction unitRef="usd" contextRef="i6e736a6ad22d4f7fbc1eda905bef7a23_D20200611-20200611" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDEvZnJhZzoxMTE4YWMxYjVhM2Y0M2ViYjM4OWQ1MjQxMDE0Zjk5YS90ZXh0cmVnaW9uOjExMThhYzFiNWEzZjQzZWJiMzg5ZDUyNDEwMTRmOTlhXzI1Nzc_d3e79301-d087-40be-9b4e-6b5c167ac6e4">25.0</ix:nonFraction>&#160;million, or the Sobi Private Placement. The closing of the Sobi Private Placement occurred on July 31, 2020. The shares of common stock acquired in the Sobi Private Placement are subject to a <ix:nonNumeric contextRef="i8d2fc88d756d4b67bf9851793506eee3_D20210101-20210331" format="ixt-sec:durwordsen" name="selb:LockUpFromClosingTerm" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDEvZnJhZzoxMTE4YWMxYjVhM2Y0M2ViYjM4OWQ1MjQxMDE0Zjk5YS90ZXh0cmVnaW9uOjExMThhYzFiNWEzZjQzZWJiMzg5ZDUyNDEwMTRmOTlhXzExNTYz_150aeadd-f3e0-4a2b-8267-7967c0ad565a">one-year</ix:nonNumeric> lock-up from closing, during which time Sobi is prohibited from selling or otherwise disposing of such shares.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with ASC 815, this forward sale treatment qualified as equity classification as the shares are not within the scope of ASC 480. The gross proceeds of $<ix:nonFraction unitRef="usd" contextRef="i6e736a6ad22d4f7fbc1eda905bef7a23_D20200611-20200611" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDEvZnJhZzoxMTE4YWMxYjVhM2Y0M2ViYjM4OWQ1MjQxMDE0Zjk5YS90ZXh0cmVnaW9uOjExMThhYzFiNWEzZjQzZWJiMzg5ZDUyNDEwMTRmOTlhXzI5Nzg_e3cefb86-1b3f-48f4-9bfa-647456e3ce0d">25.0</ix:nonFraction>&#160;million were determined to include a premium to the fair value of the Company&#8217;s shares as of July 28, 2020 of approximately $<ix:nonFraction unitRef="usd" contextRef="i0e52f92d6bcb4dd098a7fe0cf721e342_D20200728-20200728" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RedemptionPremium" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDEvZnJhZzoxMTE4YWMxYjVhM2Y0M2ViYjM4OWQ1MjQxMDE0Zjk5YS90ZXh0cmVnaW9uOjExMThhYzFiNWEzZjQzZWJiMzg5ZDUyNDEwMTRmOTlhXzMwOTc_a10c1c4e-e89d-470a-96c8-0f61fed33eb7">14.5</ix:nonFraction>&#160;million. As a result, such amount was included in the transaction price for revenue recognition of the Sobi License. See Note 12 for details.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also on June 11, 2020, the Company entered into a registration rights agreement (as amended by that certain letter agreement, dated as of November 4, 2020) with Sobi, pursuant to which the Company agreed to prepare and file a registration statement with respect to the resale of the shares of common stock acquired in the Sobi Private Placement. The Company will be required to file this resale registration statement within 30 days following receipt by the Company of a written request from </span></div></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i71586e7d2e304f6983634abe9e071791_13">Table of Contents</a></span></div></div><ix:continuation id="i010d27ef7f8848ea9182e5133f969b46" continuedAt="i293b7502b3b8415f9b69a8f921f506fc"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sobi to file such resale registration statement, and to have the registration statement declared effective within 10 business days after the SEC informs the Company that no review of such resale registration statement will be made or that the SEC has no further comments on such resale registration statement.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">December 2019 Financing</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On December 18, 2019, the Company entered into a securities purchase agreement, or the 2019 Purchase Agreement, with a group of institutional investors and certain members of the board of directors. Pursuant to the 2019 Purchase Agreement, the Company sold an aggregate of <ix:nonFraction unitRef="shares" contextRef="iff262d3fceb04558bb91b0665eb3295e_D20191218-20191218" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDEvZnJhZzoxMTE4YWMxYjVhM2Y0M2ViYjM4OWQ1MjQxMDE0Zjk5YS90ZXh0cmVnaW9uOjExMThhYzFiNWEzZjQzZWJiMzg5ZDUyNDEwMTRmOTlhXzQzODA_30a60115-9c50-44c9-9567-93f90be37938">37,634,883</ix:nonFraction> shares of its common stock at a purchase price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i04e2a4ab60694adfa2dcd5d722cd132e_I20191218" decimals="INF" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDEvZnJhZzoxMTE4YWMxYjVhM2Y0M2ViYjM4OWQ1MjQxMDE0Zjk5YS90ZXh0cmVnaW9uOjExMThhYzFiNWEzZjQzZWJiMzg5ZDUyNDEwMTRmOTlhXzQ0MzQ_3eaf3d84-43f9-4b98-9139-5b1f6082021b">1.46</ix:nonFraction> per share, warrants to purchase an aggregate of <ix:nonFraction unitRef="shares" contextRef="i04e2a4ab60694adfa2dcd5d722cd132e_I20191218" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDEvZnJhZzoxMTE4YWMxYjVhM2Y0M2ViYjM4OWQ1MjQxMDE0Zjk5YS90ZXh0cmVnaW9uOjExMThhYzFiNWEzZjQzZWJiMzg5ZDUyNDEwMTRmOTlhXzQ0ODU_f6a402e8-2873-4a12-8067-0a42c83b247d">22,988,501</ix:nonFraction> shares of common stock at a purchase price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i06e21592f529454490acff73efadbef0_I20191218" decimals="3" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDEvZnJhZzoxMTE4YWMxYjVhM2Y0M2ViYjM4OWQ1MjQxMDE0Zjk5YS90ZXh0cmVnaW9uOjExMThhYzFiNWEzZjQzZWJiMzg5ZDUyNDEwMTRmOTlhXzQ1MzU_0d29fe8b-4a0c-453b-b705-cee648346051">0.125</ix:nonFraction> per share underlying each common warrant, and pre-funded warrants to purchase an aggregate of <ix:nonFraction unitRef="shares" contextRef="ifc3b4456d78b4865980e0d06be756475_D20191218-20191218" decimals="INF" format="ixt:numdotdecimal" name="selb:ClassOfWarrantOrRightNumberOfWarrantsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDEvZnJhZzoxMTE4YWMxYjVhM2Y0M2ViYjM4OWQ1MjQxMDE0Zjk5YS90ZXh0cmVnaW9uOjExMThhYzFiNWEzZjQzZWJiMzg5ZDUyNDEwMTRmOTlhXzQ2MzI_1038372d-571e-4357-95bc-38246a23c6a5">8,342,128</ix:nonFraction> shares of common stock at a purchase price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i06e21592f529454490acff73efadbef0_I20191218" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDEvZnJhZzoxMTE4YWMxYjVhM2Y0M2ViYjM4OWQ1MjQxMDE0Zjk5YS90ZXh0cmVnaW9uOjExMThhYzFiNWEzZjQzZWJiMzg5ZDUyNDEwMTRmOTlhXzQ2ODI_5e2b437d-dbaa-4ada-b8d1-942c2be767d2">1.46</ix:nonFraction> per share, all with five year terms, or the 2019 PIPE. The closing of the 2019 PIPE occurred on December 23, 2019. The exercise price of the pre-funded warrants is $<ix:nonFraction unitRef="usdPerShare" contextRef="ibb1098ccfa7945aa92c2145f660cec87_I20191218" decimals="4" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDEvZnJhZzoxMTE4YWMxYjVhM2Y0M2ViYjM4OWQ1MjQxMDE0Zjk5YS90ZXh0cmVnaW9uOjExMThhYzFiNWEzZjQzZWJiMzg5ZDUyNDEwMTRmOTlhXzQ4NDk_6350c361-17c0-40f7-aec6-a4b80484b9df">0.0001</ix:nonFraction> per share and the exercise price for the common warrants is $<ix:nonFraction unitRef="usdPerShare" contextRef="i06e21592f529454490acff73efadbef0_I20191218" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDEvZnJhZzoxMTE4YWMxYjVhM2Y0M2ViYjM4OWQ1MjQxMDE0Zjk5YS90ZXh0cmVnaW9uOjExMThhYzFiNWEzZjQzZWJiMzg5ZDUyNDEwMTRmOTlhXzQ5MTM_5e2b437d-dbaa-4ada-b8d1-942c2be767d2">1.46</ix:nonFraction> per share. In the event of a certain sale of the Company, the terms of the common warrants require us to make a payment to such common warrant holders based on a Black-Scholes valuation (using variables as specified in the warrants). This provision does not apply to the pre-funded warrants. Therefore, the Company is required to account for the common warrants as liabilities and record them at fair value, while the pre-funded warrants met the criteria to be classified as permanent equity. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded the fair value of the common warrants of $<ix:nonFraction unitRef="usd" contextRef="iff262d3fceb04558bb91b0665eb3295e_D20191218-20191218" decimals="-5" name="selb:WarrantIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDEvZnJhZzoxMTE4YWMxYjVhM2Y0M2ViYjM4OWQ1MjQxMDE0Zjk5YS90ZXh0cmVnaW9uOjExMThhYzFiNWEzZjQzZWJiMzg5ZDUyNDEwMTRmOTlhXzU0NzM_c1b509aa-35dc-43c8-ab0b-d899c4f23e08">40.7</ix:nonFraction>&#160;million upon issuance using the Black-Scholes valuation model. Issuance costs were allocated between the equity component with an offset to additional paid-in capital and the liability component recorded as expense on a relative fair value basis. Total net proceeds from the equity offering was $<ix:nonFraction unitRef="usd" contextRef="iff262d3fceb04558bb91b0665eb3295e_D20191218-20191218" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDEvZnJhZzoxMTE4YWMxYjVhM2Y0M2ViYjM4OWQ1MjQxMDE0Zjk5YS90ZXh0cmVnaW9uOjExMThhYzFiNWEzZjQzZWJiMzg5ZDUyNDEwMTRmOTlhXzU3NzI_ba1c6582-03be-4651-a8c8-c72e78bf78be">65.6</ix:nonFraction> million, after deducting transaction costs and commissions of $<ix:nonFraction unitRef="usd" contextRef="i40f7108f907b4381983c3f10bfbcbd06_D20200101-20200331" decimals="-5" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDEvZnJhZzoxMTE4YWMxYjVhM2Y0M2ViYjM4OWQ1MjQxMDE0Zjk5YS90ZXh0cmVnaW9uOjExMThhYzFiNWEzZjQzZWJiMzg5ZDUyNDEwMTRmOTlhXzU4Mzc_c000cdd1-2b80-460f-9c47-acb8c3de7729">4.4</ix:nonFraction> million which was paid in the three months ended March 31, 2020.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The common warrants were revalued as of March 31, 2021 at $<ix:nonFraction unitRef="usd" contextRef="i3c29e75c7cde4be78a2c3d04f4678b57_I20210331" decimals="-5" name="us-gaap:WarrantsAndRightsOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDEvZnJhZzoxMTE4YWMxYjVhM2Y0M2ViYjM4OWQ1MjQxMDE0Zjk5YS90ZXh0cmVnaW9uOjExMThhYzFiNWEzZjQzZWJiMzg5ZDUyNDEwMTRmOTlhXzU5Njc_b4d1e500-8e13-43ce-bb35-6a645dea4874">45.5</ix:nonFraction> million. During the three months ended March 31, 2021 and 2020, the Company recorded losses on the increases in the fair value of the warrants of $(<ix:nonFraction unitRef="usd" contextRef="i2d7bd840e7b3429ba469e9ff77e35cdc_D20210101-20210331" decimals="-5" sign="-" name="us-gaap:WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDEvZnJhZzoxMTE4YWMxYjVhM2Y0M2ViYjM4OWQ1MjQxMDE0Zjk5YS90ZXh0cmVnaW9uOjExMThhYzFiNWEzZjQzZWJiMzg5ZDUyNDEwMTRmOTlhXzYxMTM_80ab4fc7-cbe6-4028-b00c-cfa8bbf4fbb2">16.7</ix:nonFraction>) million and $(<ix:nonFraction unitRef="usd" contextRef="i40f7108f907b4381983c3f10bfbcbd06_D20200101-20200331" decimals="-5" sign="-" name="us-gaap:WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDEvZnJhZzoxMTE4YWMxYjVhM2Y0M2ViYjM4OWQ1MjQxMDE0Zjk5YS90ZXh0cmVnaW9uOjExMThhYzFiNWEzZjQzZWJiMzg5ZDUyNDEwMTRmOTlhXzYxMjg_93ae8298-4f9e-452b-b89d-0a4b74b5901e">0.8</ix:nonFraction>) million, respectively, in the unaudited consolidated statements of operations.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Warrants</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2021 and 2020, there were no warrants issued, exercised, or canceled.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><ix:nonNumeric contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331" name="us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDEvZnJhZzoxMTE4YWMxYjVhM2Y0M2ViYjM4OWQ1MjQxMDE0Zjk5YS90ZXh0cmVnaW9uOjExMThhYzFiNWEzZjQzZWJiMzg5ZDUyNDEwMTRmOTlhXzExNTU5_7d235c3f-5857-4f73-bed5-cdb073ec9274" escape="true"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.361%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.602%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Warrants</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Equity<br/>&#160;classified</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Liability classified</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted average<br/>exercise price</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding at March 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib2148f5a0b034c99a308352e1c25d052_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDEvZnJhZzoxMTE4YWMxYjVhM2Y0M2ViYjM4OWQ1MjQxMDE0Zjk5YS90YWJsZTo5ZDg2ZjkwNDFlMmM0MWQ1YjYxNDdmNzc0MWIwYTE5Yi90YWJsZXJhbmdlOjlkODZmOTA0MWUyYzQxZDViNjE0N2Y3NzQxYjBhMTliXzctMS0xLTEtMA_e98270fb-3dd3-402d-9b04-8a60f23fdea5">292,469</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id99ce4003b574f658d3b62852041d661_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDEvZnJhZzoxMTE4YWMxYjVhM2Y0M2ViYjM4OWQ1MjQxMDE0Zjk5YS90YWJsZTo5ZDg2ZjkwNDFlMmM0MWQ1YjYxNDdmNzc0MWIwYTE5Yi90YWJsZXJhbmdlOjlkODZmOTA0MWUyYzQxZDViNjE0N2Y3NzQxYjBhMTliXzctMy0xLTEtMA_b79572b4-b849-4255-afc9-97193bec48e0">12,085,547</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ied8d945ebce54ed8a4badfed477a64e8_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDEvZnJhZzoxMTE4YWMxYjVhM2Y0M2ViYjM4OWQ1MjQxMDE0Zjk5YS90YWJsZTo5ZDg2ZjkwNDFlMmM0MWQ1YjYxNDdmNzc0MWIwYTE5Yi90YWJsZXJhbmdlOjlkODZmOTA0MWUyYzQxZDViNjE0N2Y3NzQxYjBhMTliXzctNS0xLTEtMA_bb88f0a7-9ff7-49ee-84fc-8c8129f4a17e">12,378,016</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ied8d945ebce54ed8a4badfed477a64e8_I20210331" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDEvZnJhZzoxMTE4YWMxYjVhM2Y0M2ViYjM4OWQ1MjQxMDE0Zjk5YS90YWJsZTo5ZDg2ZjkwNDFlMmM0MWQ1YjYxNDdmNzc0MWIwYTE5Yi90YWJsZXJhbmdlOjlkODZmOTA0MWUyYzQxZDViNjE0N2Y3NzQxYjBhMTliXzctNy0xLTEtMA_0cc8bd4c-e617-4d0b-ab17-542ebbf5ba37">1.60</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Common Stock</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2021, the Company had <ix:nonFraction unitRef="shares" contextRef="i23a3406d8ff1477aa084b096803061e3_I20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDEvZnJhZzoxMTE4YWMxYjVhM2Y0M2ViYjM4OWQ1MjQxMDE0Zjk5YS90ZXh0cmVnaW9uOjExMThhYzFiNWEzZjQzZWJiMzg5ZDUyNDEwMTRmOTlhXzEwNjA0_7b24854a-8893-4a18-8369-6e0ccb0faa37">200,000,000</ix:nonFraction> shares of common stock authorized for issuance, $<ix:nonFraction unitRef="usdPerShare" contextRef="i23a3406d8ff1477aa084b096803061e3_I20210331" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDEvZnJhZzoxMTE4YWMxYjVhM2Y0M2ViYjM4OWQ1MjQxMDE0Zjk5YS90ZXh0cmVnaW9uOjExMThhYzFiNWEzZjQzZWJiMzg5ZDUyNDEwMTRmOTlhXzEwNjU1_ad2f46c2-c615-4d94-afaa-6fa649a52210">0.0001</ix:nonFraction> par value per share, with <ix:nonFraction unitRef="shares" contextRef="ied8d945ebce54ed8a4badfed477a64e8_I20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDEvZnJhZzoxMTE4YWMxYjVhM2Y0M2ViYjM4OWQ1MjQxMDE0Zjk5YS90ZXh0cmVnaW9uOjExMThhYzFiNWEzZjQzZWJiMzg5ZDUyNDEwMTRmOTlhXzEwNjg0_5e6b63be-c555-4ad9-bc86-b7fe92344e54"><ix:nonFraction unitRef="shares" contextRef="ied8d945ebce54ed8a4badfed477a64e8_I20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDEvZnJhZzoxMTE4YWMxYjVhM2Y0M2ViYjM4OWQ1MjQxMDE0Zjk5YS90ZXh0cmVnaW9uOjExMThhYzFiNWEzZjQzZWJiMzg5ZDUyNDEwMTRmOTlhXzEwNjg0_de115b88-a39b-41d7-9371-d387957d29f6">112,977,004</ix:nonFraction></ix:nonFraction> shares issued and outstanding. The voting, dividend and liquidation rights of the common stockholders are subject to and qualified by the rights, powers and preferences of the preferred stock. The common stock has the following characteristics:</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Voting</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The common stockholders are entitled to <ix:nonFraction unitRef="vote" contextRef="ied8d945ebce54ed8a4badfed477a64e8_I20210331" decimals="INF" format="ixt-sec:numwordsen" name="selb:VotesPerShareofCommonStock" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDEvZnJhZzoxMTE4YWMxYjVhM2Y0M2ViYjM4OWQ1MjQxMDE0Zjk5YS90ZXh0cmVnaW9uOjExMThhYzFiNWEzZjQzZWJiMzg5ZDUyNDEwMTRmOTlhXzEwOTc5_82bae4b5-8a69-46b3-8966-467595eb26e1">one</ix:nonFraction> vote for each share of common stock held with respect to all matters voted on by the stockholders of the Company.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Dividends</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The common stockholders are entitled to receive dividends, if and when declared by the Board of Directors. Through March 31, 2021, <ix:nonFraction unitRef="usd" contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:DividendsCommonStock" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDEvZnJhZzoxMTE4YWMxYjVhM2Y0M2ViYjM4OWQ1MjQxMDE0Zjk5YS90ZXh0cmVnaW9uOjExMThhYzFiNWEzZjQzZWJiMzg5ZDUyNDEwMTRmOTlhXzExMjI2_e38cdd38-6bef-497d-9805-44be7385b69e">no</ix:nonFraction> dividends have been declared or paid on common stock.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Liquidation</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon liquidation of the Company, the common stockholders are entitled to receive all assets of the Company available for distribution to such stockholders.</span></div></ix:continuation><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i71586e7d2e304f6983634abe9e071791_13">Table of Contents</a></span></div></div><ix:continuation id="i293b7502b3b8415f9b69a8f921f506fc"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reserved Shares</span></div><ix:nonNumeric contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331" name="us-gaap:ScheduleOfStockByClassTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDEvZnJhZzoxMTE4YWMxYjVhM2Y0M2ViYjM4OWQ1MjQxMDE0Zjk5YS90ZXh0cmVnaW9uOjExMThhYzFiNWEzZjQzZWJiMzg5ZDUyNDEwMTRmOTlhXzExNTYx_e596e7c1-6a3b-44db-a628-e55502fb84b4" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has authorized shares of common stock for future issuance as follows:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.929%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.522%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Period ended</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercise of common warrants</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib2148f5a0b034c99a308352e1c25d052_I20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDEvZnJhZzoxMTE4YWMxYjVhM2Y0M2ViYjM4OWQ1MjQxMDE0Zjk5YS90YWJsZTo0MTQ1YWUzZDgxOGY0ZWZmYTM3NjZmYTdlYTU4NWQ2Ni90YWJsZXJhbmdlOjQxNDVhZTNkODE4ZjRlZmZhMzc2NmZhN2VhNTg1ZDY2XzItMS0xLTEtMA_bf8bd56b-cfb5-4bc1-84fd-c025619954dc">12,378,016</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id201ea1fc8cd4bc2957bd09c9be775f9_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDEvZnJhZzoxMTE4YWMxYjVhM2Y0M2ViYjM4OWQ1MjQxMDE0Zjk5YS90YWJsZTo0MTQ1YWUzZDgxOGY0ZWZmYTM3NjZmYTdlYTU4NWQ2Ni90YWJsZXJhbmdlOjQxNDVhZTNkODE4ZjRlZmZhMzc2NmZhN2VhNTg1ZDY2XzItMy0xLTEtMA_34ec6ed8-ecb4-4e43-827b-598c4f75a669">12,378,016</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shares available for future stock incentive awards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i766bfbe0d62646d1ae2d0abb4d722110_I20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDEvZnJhZzoxMTE4YWMxYjVhM2Y0M2ViYjM4OWQ1MjQxMDE0Zjk5YS90YWJsZTo0MTQ1YWUzZDgxOGY0ZWZmYTM3NjZmYTdlYTU4NWQ2Ni90YWJsZXJhbmdlOjQxNDVhZTNkODE4ZjRlZmZhMzc2NmZhN2VhNTg1ZDY2XzMtMS0xLTEtMA_aee106c3-8ce1-4d58-8c8c-8b1c58f277b4">7,719,817</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic80bb38a87b34cd5bae8a1c9d61a28e8_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDEvZnJhZzoxMTE4YWMxYjVhM2Y0M2ViYjM4OWQ1MjQxMDE0Zjk5YS90YWJsZTo0MTQ1YWUzZDgxOGY0ZWZmYTM3NjZmYTdlYTU4NWQ2Ni90YWJsZXJhbmdlOjQxNDVhZTNkODE4ZjRlZmZhMzc2NmZhN2VhNTg1ZDY2XzMtMy0xLTEtMA_8ae62563-68db-4a4a-9786-559d20c2d7c8">4,916,374</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">RSUs reserved for issuance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icaed7df33b254fc68b5b0e15b600935f_I20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDEvZnJhZzoxMTE4YWMxYjVhM2Y0M2ViYjM4OWQ1MjQxMDE0Zjk5YS90YWJsZTo0MTQ1YWUzZDgxOGY0ZWZmYTM3NjZmYTdlYTU4NWQ2Ni90YWJsZXJhbmdlOjQxNDVhZTNkODE4ZjRlZmZhMzc2NmZhN2VhNTg1ZDY2XzQtMS0xLTEtMA_e68526ba-b20e-40d1-8663-fd0dadbeb83b">98,750</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9ef78f70a7c34162bf4e7727fba544cc_I20201231" decimals="INF" format="ixt:zerodash" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDEvZnJhZzoxMTE4YWMxYjVhM2Y0M2ViYjM4OWQ1MjQxMDE0Zjk5YS90YWJsZTo0MTQ1YWUzZDgxOGY0ZWZmYTM3NjZmYTdlYTU4NWQ2Ni90YWJsZXJhbmdlOjQxNDVhZTNkODE4ZjRlZmZhMzc2NmZhN2VhNTg1ZDY2XzQtMy0xLTEtMA_d2f66455-f61e-44dd-bb11-29128ad851e8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unvested restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8c5ceec4ab9b487193df89666ccf91d3_I20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDEvZnJhZzoxMTE4YWMxYjVhM2Y0M2ViYjM4OWQ1MjQxMDE0Zjk5YS90YWJsZTo0MTQ1YWUzZDgxOGY0ZWZmYTM3NjZmYTdlYTU4NWQ2Ni90YWJsZXJhbmdlOjQxNDVhZTNkODE4ZjRlZmZhMzc2NmZhN2VhNTg1ZDY2XzUtMS0xLTEtMA_1fc375be-c0cf-467c-a157-5a957270b6a4">544,313</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2595e8b300194cc6bb08ac9d33e9eaf8_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDEvZnJhZzoxMTE4YWMxYjVhM2Y0M2ViYjM4OWQ1MjQxMDE0Zjk5YS90YWJsZTo0MTQ1YWUzZDgxOGY0ZWZmYTM3NjZmYTdlYTU4NWQ2Ni90YWJsZXJhbmdlOjQxNDVhZTNkODE4ZjRlZmZhMzc2NmZhN2VhNTg1ZDY2XzUtMy0xLTEtMA_b8aa61ca-4c76-49f0-ae03-d84737d68f22">87,500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding common stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="idc47c16592ad4e7c88824de49ffb8420_I20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDEvZnJhZzoxMTE4YWMxYjVhM2Y0M2ViYjM4OWQ1MjQxMDE0Zjk5YS90YWJsZTo0MTQ1YWUzZDgxOGY0ZWZmYTM3NjZmYTdlYTU4NWQ2Ni90YWJsZXJhbmdlOjQxNDVhZTNkODE4ZjRlZmZhMzc2NmZhN2VhNTg1ZDY2XzYtMS0xLTEtMA_ca597574-2d82-4725-9881-046ea30aedc4">10,187,394</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iaa1769cc2fd04d9ab84daf10f681742a_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDEvZnJhZzoxMTE4YWMxYjVhM2Y0M2ViYjM4OWQ1MjQxMDE0Zjk5YS90YWJsZTo0MTQ1YWUzZDgxOGY0ZWZmYTM3NjZmYTdlYTU4NWQ2Ni90YWJsZXJhbmdlOjQxNDVhZTNkODE4ZjRlZmZhMzc2NmZhN2VhNTg1ZDY2XzYtMy0xLTEtMA_b1b8f43d-a3d6-4494-8de5-555576a35c5d">7,775,249</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ied8d945ebce54ed8a4badfed477a64e8_I20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDEvZnJhZzoxMTE4YWMxYjVhM2Y0M2ViYjM4OWQ1MjQxMDE0Zjk5YS90YWJsZTo0MTQ1YWUzZDgxOGY0ZWZmYTM3NjZmYTdlYTU4NWQ2Ni90YWJsZXJhbmdlOjQxNDVhZTNkODE4ZjRlZmZhMzc2NmZhN2VhNTg1ZDY2XzctMS0xLTEtMA_645c945d-7f1d-4812-9a42-99b7e0ddef08">30,928,290</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib56f1adc867e406ca7face50c5da1c9c_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDEvZnJhZzoxMTE4YWMxYjVhM2Y0M2ViYjM4OWQ1MjQxMDE0Zjk5YS90YWJsZTo0MTQ1YWUzZDgxOGY0ZWZmYTM3NjZmYTdlYTU4NWQ2Ni90YWJsZXJhbmdlOjQxNDVhZTNkODE4ZjRlZmZhMzc2NmZhN2VhNTg1ZDY2XzctMy0xLTEtMA_0bbf6528-07f9-4252-baf5-0bec77138c21">25,157,139</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div id="i71586e7d2e304f6983634abe9e071791_244"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">11. <ix:nonNumeric contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDQvZnJhZzo0MjVlMGY1ZWY3ZmI0MDgxOGVlMDFlNTc4Y2VhMWNjYy90ZXh0cmVnaW9uOjQyNWUwZjVlZjdmYjQwODE4ZWUwMWU1NzhjZWExY2NjXzEwOTI1_142c91c9-7818-474c-bc1b-e96702ddb76a" continuedAt="ie43740efd13d4f4abfed0c7337483820" escape="true">Stock Incentive Plans</ix:nonNumeric></span></div><ix:continuation id="ie43740efd13d4f4abfed0c7337483820" continuedAt="i1984ab126f9745f9834d4b6b63ab8f65"><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains the 2008 Stock Incentive Plan, or the 2008 Plan, for employees, consultants, advisors, and directors. The 2008 Plan provided for the granting of incentive and non-qualified stock option and restricted stock awards as determined by the Board. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the Company&#8217;s stockholders approved the 2016 Incentive Award Plan, or the 2016 Plan, which authorized <ix:nonFraction unitRef="shares" contextRef="i659c0d6b1a6b4dde9d2d66b377a3e370_I20160621" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDQvZnJhZzo0MjVlMGY1ZWY3ZmI0MDgxOGVlMDFlNTc4Y2VhMWNjYy90ZXh0cmVnaW9uOjQyNWUwZjVlZjdmYjQwODE4ZWUwMWU1NzhjZWExY2NjXzIxOTkwMjMyNzkzOTI_2ad174f4-f1cc-486b-a560-2589b4f81023">1,210,256</ix:nonFraction> shares of common stock for future issuance under the 2016 Plan and ceased granting awards under the 2008 Plan. Upon the effective date of the 2016 Plan, awards issued under the 2008 Plan remain subject to the terms of the 2008 Plan. Awards granted under the 2008 Plan that expire, lapse or terminate become available under the 2016 Plan as shares available for future grants.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, pursuant to the terms of the 2016 Plan, the Board is authorized to grant awards with respect to common stock, and may delegate to a committee of one or more members of the Board or executive officers of the Company the authority to grant options and restricted stock units. On December 9, 2020, the Board established a Stock Option Committee authorized to grant awards to certain employees and consultants subject to conditions and limitations within the 2016 Plan. In January 2021 and 2020, the number of shares of common stock that may be issued under the 2016 Plan was increased by <ix:nonFraction unitRef="shares" contextRef="ic5906043b3594f21b5de7208dd3fa609_D20210101-20210331" decimals="INF" format="ixt:numdotdecimal" name="selb:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantIncreaseDecrease" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDQvZnJhZzo0MjVlMGY1ZWY3ZmI0MDgxOGVlMDFlNTc4Y2VhMWNjYy90ZXh0cmVnaW9uOjQyNWUwZjVlZjdmYjQwODE4ZWUwMWU1NzhjZWExY2NjXzI0NzQ_d764ffec-257a-4e5e-b47a-04b82ff5225c">4,322,850</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="ib2627fa0b80846ab8d39c202e998d601_D20200101-20200331" decimals="INF" format="ixt:numdotdecimal" name="selb:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantIncreaseDecrease" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDQvZnJhZzo0MjVlMGY1ZWY3ZmI0MDgxOGVlMDFlNTc4Y2VhMWNjYy90ZXh0cmVnaW9uOjQyNWUwZjVlZjdmYjQwODE4ZWUwMWU1NzhjZWExY2NjXzI0ODg_c205e766-d214-4715-b8ce-10f80395c709">3,453,022</ix:nonFraction> shares, respectively. As of March 31, 2021, <ix:nonFraction unitRef="shares" contextRef="i91178c8223ca4306a02f4027a764b423_I20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDQvZnJhZzo0MjVlMGY1ZWY3ZmI0MDgxOGVlMDFlNTc4Y2VhMWNjYy90ZXh0cmVnaW9uOjQyNWUwZjVlZjdmYjQwODE4ZWUwMWU1NzhjZWExY2NjXzI1MjM_99fe061b-c116-437c-85c4-9483a12abbe9">3,248,520</ix:nonFraction> shares remain available for future issuance under the 2016 Plan.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2018, the Company&#8217;s 2018 Employment Inducement Incentive Award Plan, or the 2018 Inducement Incentive Award Plan was adopted by the Board without stockholder approval pursuant to Rule 5635(c)(4) of the Nasdaq Stock Market LLC listing rules, which authorized <ix:nonFraction unitRef="shares" contextRef="i897bb148c3bb4abb9ea043f39a5a1bbe_I20180925" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDQvZnJhZzo0MjVlMGY1ZWY3ZmI0MDgxOGVlMDFlNTc4Y2VhMWNjYy90ZXh0cmVnaW9uOjQyNWUwZjVlZjdmYjQwODE4ZWUwMWU1NzhjZWExY2NjXzIxOTkwMjMyODA3NjU_100f674f-a215-43ef-8ed5-7e41941cab64">1,175,000</ix:nonFraction> shares of its common stock for issuance. In March 2019, the Board approved the amendment and restatement of the 2018 Inducement Incentive Award Plan to reserve an additional <ix:nonFraction unitRef="shares" contextRef="i90b02123a489453691cedc67052e854c_I20190325" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDQvZnJhZzo0MjVlMGY1ZWY3ZmI0MDgxOGVlMDFlNTc4Y2VhMWNjYy90ZXh0cmVnaW9uOjQyNWUwZjVlZjdmYjQwODE4ZWUwMWU1NzhjZWExY2NjXzIxOTkwMjMyODExMzQ_99c1dfcd-01b2-44bb-993d-0f3f5bdd6b75">2,000,000</ix:nonFraction> shares of the Company&#8217;s common stock for issuance thereunder. As of March 31, 2021, there are <ix:nonFraction unitRef="shares" contextRef="ifb4e42c6f6c44e0f9158bb1c44089423_I20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDQvZnJhZzo0MjVlMGY1ZWY3ZmI0MDgxOGVlMDFlNTc4Y2VhMWNjYy90ZXh0cmVnaW9uOjQyNWUwZjVlZjdmYjQwODE4ZWUwMWU1NzhjZWExY2NjXzQzNjk_e3a3017d-e3e9-468a-bb00-3e14233cb4b9">1,358,333</ix:nonFraction> shares available for future grant under the 2018 Inducement Incentive Award Plan.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock-based Compensation Expense</span></div><ix:nonNumeric contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331" name="us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDQvZnJhZzo0MjVlMGY1ZWY3ZmI0MDgxOGVlMDFlNTc4Y2VhMWNjYy90ZXh0cmVnaW9uOjQyNWUwZjVlZjdmYjQwODE4ZWUwMWU1NzhjZWExY2NjXzQzOTgwNDY1NDM3MTQ_01b2bc1c-50c6-4187-bea2-125541ca1ee0" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense by classification included within the condensed consolidated statements of operations and comprehensive loss was as follows (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.777%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16033c04e5ea4cc5bbfdba5f3c1bd666_D20210101-20210331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDQvZnJhZzo0MjVlMGY1ZWY3ZmI0MDgxOGVlMDFlNTc4Y2VhMWNjYy90YWJsZTowMjRhMTIxMDlhNjQ0NzdiYmNiMDM4OTI3ZGRjYzUyNi90YWJsZXJhbmdlOjAyNGExMjEwOWE2NDQ3N2JiY2IwMzg5MjdkZGNjNTI2XzItMS0xLTEtNTkxMw_0219efe6-209d-4dea-92e1-1491113063d8">754</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i723babe8bc8f40e0843af46b5e72961b_D20200101-20200331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDQvZnJhZzo0MjVlMGY1ZWY3ZmI0MDgxOGVlMDFlNTc4Y2VhMWNjYy90YWJsZTowMjRhMTIxMDlhNjQ0NzdiYmNiMDM4OTI3ZGRjYzUyNi90YWJsZXJhbmdlOjAyNGExMjEwOWE2NDQ3N2JiY2IwMzg5MjdkZGNjNTI2XzItMy0xLTEtNTkxMw_24d887a6-7e3a-4403-a378-8ffccb145654">623</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i448d50e1226e459ca3870f9edd8b9fef_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDQvZnJhZzo0MjVlMGY1ZWY3ZmI0MDgxOGVlMDFlNTc4Y2VhMWNjYy90YWJsZTowMjRhMTIxMDlhNjQ0NzdiYmNiMDM4OTI3ZGRjYzUyNi90YWJsZXJhbmdlOjAyNGExMjEwOWE2NDQ3N2JiY2IwMzg5MjdkZGNjNTI2XzMtMS0xLTEtNTkxMw_711564fc-7c9c-4bfa-a855-847dd19cb17d">1,026</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45408aeb6dc44b58bc7a8d6958d23e54_D20200101-20200331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDQvZnJhZzo0MjVlMGY1ZWY3ZmI0MDgxOGVlMDFlNTc4Y2VhMWNjYy90YWJsZTowMjRhMTIxMDlhNjQ0NzdiYmNiMDM4OTI3ZGRjYzUyNi90YWJsZXJhbmdlOjAyNGExMjEwOWE2NDQ3N2JiY2IwMzg5MjdkZGNjNTI2XzMtMy0xLTEtNTkxMw_e979bb2a-e2d3-4f83-853a-1a5e308a621f">786</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total stock-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDQvZnJhZzo0MjVlMGY1ZWY3ZmI0MDgxOGVlMDFlNTc4Y2VhMWNjYy90YWJsZTowMjRhMTIxMDlhNjQ0NzdiYmNiMDM4OTI3ZGRjYzUyNi90YWJsZXJhbmdlOjAyNGExMjEwOWE2NDQ3N2JiY2IwMzg5MjdkZGNjNTI2XzQtMS0xLTEtNjYyMA_4ac763dd-cbed-47fb-ba13-6c6668cc142c">1,780</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i824a5b33f908426bad016f0eded844db_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDQvZnJhZzo0MjVlMGY1ZWY3ZmI0MDgxOGVlMDFlNTc4Y2VhMWNjYy90YWJsZTowMjRhMTIxMDlhNjQ0NzdiYmNiMDM4OTI3ZGRjYzUyNi90YWJsZXJhbmdlOjAyNGExMjEwOWE2NDQ3N2JiY2IwMzg5MjdkZGNjNTI2XzQtMy0xLTEtNjYyMA_d23a6314-8df5-4930-8b17-14cb925d93b3">1,409</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock Options</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Employees</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDQvZnJhZzo0MjVlMGY1ZWY3ZmI0MDgxOGVlMDFlNTc4Y2VhMWNjYy90ZXh0cmVnaW9uOjQyNWUwZjVlZjdmYjQwODE4ZWUwMWU1NzhjZWExY2NjXzEwOTQy_2117de08-8723-434c-a2b5-4647071f007f" continuedAt="i70410ade08db457686669952b3c41d4a" escape="true">The estimated grant date fair values of employee stock option awards granted under the 2016 Plan and the 2018 Inducement Incentive Award Plan were calculated using the Black-Scholes option pricing model, based on the following weighted-average assumptions:</ix:nonNumeric></span></div></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i71586e7d2e304f6983634abe9e071791_13">Table of Contents</a></span></div></div><ix:continuation id="i1984ab126f9745f9834d4b6b63ab8f65" continuedAt="idc2d0a7b71ea4c74b164295404f364a1"><div style="margin-bottom:6pt;margin-top:6pt"><ix:continuation id="i70410ade08db457686669952b3c41d4a"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.777%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0a83cea2026d4acd853ecd648a6ff3cf_D20210101-20210331" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDQvZnJhZzo0MjVlMGY1ZWY3ZmI0MDgxOGVlMDFlNTc4Y2VhMWNjYy90YWJsZTo1MWE4MGFhZTY1YTc0N2YxYjRjYTg3OThiMjIyYWNmMy90YWJsZXJhbmdlOjUxYTgwYWFlNjVhNzQ3ZjFiNGNhODc5OGIyMjJhY2YzXzItMS0xLTEtMA_6cc444a4-5923-4b58-aee4-642ab2ea4605">0.44</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0a02cb62522c49fd9f650c7a972a0090_D20200101-20200331" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDQvZnJhZzo0MjVlMGY1ZWY3ZmI0MDgxOGVlMDFlNTc4Y2VhMWNjYy90YWJsZTo1MWE4MGFhZTY1YTc0N2YxYjRjYTg3OThiMjIyYWNmMy90YWJsZXJhbmdlOjUxYTgwYWFlNjVhNzQ3ZjFiNGNhODc5OGIyMjJhY2YzXzItMy0xLTEtMA_a50a6fc5-76c0-4f69-b149-7b2c1df7c52d">1.73</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0a83cea2026d4acd853ecd648a6ff3cf_D20210101-20210331" decimals="INF" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDQvZnJhZzo0MjVlMGY1ZWY3ZmI0MDgxOGVlMDFlNTc4Y2VhMWNjYy90YWJsZTo1MWE4MGFhZTY1YTc0N2YxYjRjYTg3OThiMjIyYWNmMy90YWJsZXJhbmdlOjUxYTgwYWFlNjVhNzQ3ZjFiNGNhODc5OGIyMjJhY2YzXzMtMS0xLTEtMA_b53eba09-6b3c-4a5e-ad7c-6184da476375">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0a02cb62522c49fd9f650c7a972a0090_D20200101-20200331" decimals="INF" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDQvZnJhZzo0MjVlMGY1ZWY3ZmI0MDgxOGVlMDFlNTc4Y2VhMWNjYy90YWJsZTo1MWE4MGFhZTY1YTc0N2YxYjRjYTg3OThiMjIyYWNmMy90YWJsZXJhbmdlOjUxYTgwYWFlNjVhNzQ3ZjFiNGNhODc5OGIyMjJhY2YzXzMtMy0xLTEtMA_d7fe0df5-906a-4b20-8fce-b6c1043b659a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expected term</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i0a83cea2026d4acd853ecd648a6ff3cf_D20210101-20210331" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDQvZnJhZzo0MjVlMGY1ZWY3ZmI0MDgxOGVlMDFlNTc4Y2VhMWNjYy90YWJsZTo1MWE4MGFhZTY1YTc0N2YxYjRjYTg3OThiMjIyYWNmMy90YWJsZXJhbmdlOjUxYTgwYWFlNjVhNzQ3ZjFiNGNhODc5OGIyMjJhY2YzXzQtMS0xLTEtMA_298b99df-fdcd-4254-8a06-31bd8708996c">5.28</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i0a02cb62522c49fd9f650c7a972a0090_D20200101-20200331" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDQvZnJhZzo0MjVlMGY1ZWY3ZmI0MDgxOGVlMDFlNTc4Y2VhMWNjYy90YWJsZTo1MWE4MGFhZTY1YTc0N2YxYjRjYTg3OThiMjIyYWNmMy90YWJsZXJhbmdlOjUxYTgwYWFlNjVhNzQ3ZjFiNGNhODc5OGIyMjJhY2YzXzQtMy0xLTEtMA_75b48c03-46c3-4e02-924c-f5fc350b4e9d">6.08</ix:nonNumeric></span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0a83cea2026d4acd853ecd648a6ff3cf_D20210101-20210331" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDQvZnJhZzo0MjVlMGY1ZWY3ZmI0MDgxOGVlMDFlNTc4Y2VhMWNjYy90YWJsZTo1MWE4MGFhZTY1YTc0N2YxYjRjYTg3OThiMjIyYWNmMy90YWJsZXJhbmdlOjUxYTgwYWFlNjVhNzQ3ZjFiNGNhODc5OGIyMjJhY2YzXzUtMS0xLTEtMA_d46f822a-db5b-44fe-b455-95089ee6e683">83.26</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0a02cb62522c49fd9f650c7a972a0090_D20200101-20200331" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDQvZnJhZzo0MjVlMGY1ZWY3ZmI0MDgxOGVlMDFlNTc4Y2VhMWNjYy90YWJsZTo1MWE4MGFhZTY1YTc0N2YxYjRjYTg3OThiMjIyYWNmMy90YWJsZXJhbmdlOjUxYTgwYWFlNjVhNzQ3ZjFiNGNhODc5OGIyMjJhY2YzXzUtMy0xLTEtMA_b9ced0da-3ca4-4785-8e3a-9505a98a4d7b">87.96</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-average fair value of common stock</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i0a83cea2026d4acd853ecd648a6ff3cf_D20210101-20210331" decimals="2" name="selb:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDQvZnJhZzo0MjVlMGY1ZWY3ZmI0MDgxOGVlMDFlNTc4Y2VhMWNjYy90YWJsZTo1MWE4MGFhZTY1YTc0N2YxYjRjYTg3OThiMjIyYWNmMy90YWJsZXJhbmdlOjUxYTgwYWFlNjVhNzQ3ZjFiNGNhODc5OGIyMjJhY2YzXzYtMS0xLTEtMA_94bef706-e969-4d94-85b2-bc3898a7fb43">3.13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i0a02cb62522c49fd9f650c7a972a0090_D20200101-20200331" decimals="2" name="selb:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDQvZnJhZzo0MjVlMGY1ZWY3ZmI0MDgxOGVlMDFlNTc4Y2VhMWNjYy90YWJsZTo1MWE4MGFhZTY1YTc0N2YxYjRjYTg3OThiMjIyYWNmMy90YWJsZXJhbmdlOjUxYTgwYWFlNjVhNzQ3ZjFiNGNhODc5OGIyMjJhY2YzXzYtMy0xLTEtMA_39fd7a9d-abaa-48cb-b6fa-71fd30eb86d3">2.30</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></ix:continuation></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average grant date fair value of stock options granted to employees during the three months ended March 31, 2021 and 2020 was $<ix:nonFraction unitRef="usdPerShare" contextRef="i0a83cea2026d4acd853ecd648a6ff3cf_D20210101-20210331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDQvZnJhZzo0MjVlMGY1ZWY3ZmI0MDgxOGVlMDFlNTc4Y2VhMWNjYy90ZXh0cmVnaW9uOjQyNWUwZjVlZjdmYjQwODE4ZWUwMWU1NzhjZWExY2NjXzYzMTc_96c73f13-1dcb-4f9e-bcf8-6aa1a1138081">1.99</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="i0a02cb62522c49fd9f650c7a972a0090_D20200101-20200331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDQvZnJhZzo0MjVlMGY1ZWY3ZmI0MDgxOGVlMDFlNTc4Y2VhMWNjYy90ZXh0cmVnaW9uOjQyNWUwZjVlZjdmYjQwODE4ZWUwMWU1NzhjZWExY2NjXzYzMjE_bde8e11d-d763-4056-836e-f89cfe00dc00">1.69</ix:nonFraction>, respectively. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2021 total unrecognized compensation expense related to unvested employee stock options was $<ix:nonFraction unitRef="usd" contextRef="i766bfbe0d62646d1ae2d0abb4d722110_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDQvZnJhZzo0MjVlMGY1ZWY3ZmI0MDgxOGVlMDFlNTc4Y2VhMWNjYy90ZXh0cmVnaW9uOjQyNWUwZjVlZjdmYjQwODE4ZWUwMWU1NzhjZWExY2NjXzY0NjY_5be765a0-700e-4f50-b234-8c2083428b93">11.8</ix:nonFraction> million, which is expected to be recognized over a weighted average period of <ix:nonNumeric contextRef="i0a83cea2026d4acd853ecd648a6ff3cf_D20210101-20210331" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDQvZnJhZzo0MjVlMGY1ZWY3ZmI0MDgxOGVlMDFlNTc4Y2VhMWNjYy90ZXh0cmVnaW9uOjQyNWUwZjVlZjdmYjQwODE4ZWUwMWU1NzhjZWExY2NjXzY1Njg_1fa312c5-68c3-49c4-bce6-e117d89cb394">2.7</ix:nonNumeric> years.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Non-employee consultants</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2021, there was <ix:nonFraction unitRef="usd" contextRef="ied8d945ebce54ed8a4badfed477a64e8_I20210331" decimals="INF" format="ixt-sec:numwordsen" name="selb:ShareBasedGoodsAndNonEmployeeServicesTransactionCompensationNotYetRecognizedStockOptions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDQvZnJhZzo0MjVlMGY1ZWY3ZmI0MDgxOGVlMDFlNTc4Y2VhMWNjYy90ZXh0cmVnaW9uOjQyNWUwZjVlZjdmYjQwODE4ZWUwMWU1NzhjZWExY2NjXzcxMzQ_286aeb9b-ce18-4267-9895-f9a4edc6de79">no</ix:nonFraction> unrecognized compensation expense related to non-employee consultants stock options.</span></div><ix:nonNumeric contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDQvZnJhZzo0MjVlMGY1ZWY3ZmI0MDgxOGVlMDFlNTc4Y2VhMWNjYy90ZXh0cmVnaW9uOjQyNWUwZjVlZjdmYjQwODE4ZWUwMWU1NzhjZWExY2NjXzEwOTQ4_5c680128-3c8e-4aae-9275-b7830a8ddcc5" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the stock option activity under the 2008 Plan, 2016 Plan, and 2018 Inducement Incentive Award Plan:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.321%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.501%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-average</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">remaining</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number&#160;of</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-average</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">contractual&#160;term</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">intrinsic&#160;value</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">exercise price ($)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in&#160;years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in&#160;thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Employees</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding at December 31, 2020</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9b0d673a9945438a9e404b6c6b57eba2_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDQvZnJhZzo0MjVlMGY1ZWY3ZmI0MDgxOGVlMDFlNTc4Y2VhMWNjYy90YWJsZTo1YmZiYjI5MjUwNTM0MGI4YmNkYmVmZGJmOTFjZDQ1ZC90YWJsZXJhbmdlOjViZmJiMjkyNTA1MzQwYjhiY2RiZWZkYmY5MWNkNDVkXzEzLTEtMS0xLTA_2bc25719-4063-46d9-a47c-e2f876b8a950">7,302,176</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i9b0d673a9945438a9e404b6c6b57eba2_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDQvZnJhZzo0MjVlMGY1ZWY3ZmI0MDgxOGVlMDFlNTc4Y2VhMWNjYy90YWJsZTo1YmZiYjI5MjUwNTM0MGI4YmNkYmVmZGJmOTFjZDQ1ZC90YWJsZXJhbmdlOjViZmJiMjkyNTA1MzQwYjhiY2RiZWZkYmY5MWNkNDVkXzEzLTMtMS0xLTA_5293d971-ddd3-4a22-b045-02f928861ece">3.98</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="icff59de35252465485536be51fa5f610_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDQvZnJhZzo0MjVlMGY1ZWY3ZmI0MDgxOGVlMDFlNTc4Y2VhMWNjYy90YWJsZTo1YmZiYjI5MjUwNTM0MGI4YmNkYmVmZGJmOTFjZDQ1ZC90YWJsZXJhbmdlOjViZmJiMjkyNTA1MzQwYjhiY2RiZWZkYmY5MWNkNDVkXzEzLTUtMS0xLTA_63a60246-1522-4762-9ea4-f8fda931cf5c">8.43</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b0d673a9945438a9e404b6c6b57eba2_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDQvZnJhZzo0MjVlMGY1ZWY3ZmI0MDgxOGVlMDFlNTc4Y2VhMWNjYy90YWJsZTo1YmZiYjI5MjUwNTM0MGI4YmNkYmVmZGJmOTFjZDQ1ZC90YWJsZXJhbmdlOjViZmJiMjkyNTA1MzQwYjhiY2RiZWZkYmY5MWNkNDVkXzEzLTctMS0xLTA_f6a7437f-71da-461c-aef3-70cc7919c0a6">4,456</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia87a6b98f0714c88b1aa992fc475f7a1_D20210101-20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDQvZnJhZzo0MjVlMGY1ZWY3ZmI0MDgxOGVlMDFlNTc4Y2VhMWNjYy90YWJsZTo1YmZiYjI5MjUwNTM0MGI4YmNkYmVmZGJmOTFjZDQ1ZC90YWJsZXJhbmdlOjViZmJiMjkyNTA1MzQwYjhiY2RiZWZkYmY5MWNkNDVkXzE0LTEtMS0xLTA_81225d78-cc12-4613-a7f5-12b8aeeb57e1">2,628,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ia87a6b98f0714c88b1aa992fc475f7a1_D20210101-20210331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDQvZnJhZzo0MjVlMGY1ZWY3ZmI0MDgxOGVlMDFlNTc4Y2VhMWNjYy90YWJsZTo1YmZiYjI5MjUwNTM0MGI4YmNkYmVmZGJmOTFjZDQ1ZC90YWJsZXJhbmdlOjViZmJiMjkyNTA1MzQwYjhiY2RiZWZkYmY5MWNkNDVkXzE0LTMtMS0xLTA_a7cb8f53-74bc-441a-8248-e1c17d03b472">3.13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ia87a6b98f0714c88b1aa992fc475f7a1_D20210101-20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDQvZnJhZzo0MjVlMGY1ZWY3ZmI0MDgxOGVlMDFlNTc4Y2VhMWNjYy90YWJsZTo1YmZiYjI5MjUwNTM0MGI4YmNkYmVmZGJmOTFjZDQ1ZC90YWJsZXJhbmdlOjViZmJiMjkyNTA1MzQwYjhiY2RiZWZkYmY5MWNkNDVkXzE1LTEtMS0xLTA_cfafece3-6d30-4863-ae5d-4d0aa2557102">153,278</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ia87a6b98f0714c88b1aa992fc475f7a1_D20210101-20210331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDQvZnJhZzo0MjVlMGY1ZWY3ZmI0MDgxOGVlMDFlNTc4Y2VhMWNjYy90YWJsZTo1YmZiYjI5MjUwNTM0MGI4YmNkYmVmZGJmOTFjZDQ1ZC90YWJsZXJhbmdlOjViZmJiMjkyNTA1MzQwYjhiY2RiZWZkYmY5MWNkNDVkXzE1LTMtMS0xLTA_ddefc01a-7454-4357-b68b-6672fcf55507">1.47</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ia87a6b98f0714c88b1aa992fc475f7a1_D20210101-20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDQvZnJhZzo0MjVlMGY1ZWY3ZmI0MDgxOGVlMDFlNTc4Y2VhMWNjYy90YWJsZTo1YmZiYjI5MjUwNTM0MGI4YmNkYmVmZGJmOTFjZDQ1ZC90YWJsZXJhbmdlOjViZmJiMjkyNTA1MzQwYjhiY2RiZWZkYmY5MWNkNDVkXzE2LTEtMS0xLTA_fed62ec7-a332-4c18-a54b-d10a81b9e79e">62,577</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ia87a6b98f0714c88b1aa992fc475f7a1_D20210101-20210331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDQvZnJhZzo0MjVlMGY1ZWY3ZmI0MDgxOGVlMDFlNTc4Y2VhMWNjYy90YWJsZTo1YmZiYjI5MjUwNTM0MGI4YmNkYmVmZGJmOTFjZDQ1ZC90YWJsZXJhbmdlOjViZmJiMjkyNTA1MzQwYjhiY2RiZWZkYmY5MWNkNDVkXzE2LTMtMS0xLTA_dde9a69f-0e0a-470f-a100-73fba8f43e4f">5.19</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding at March 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5a27d4e69f2d4076ab56ee85c1e0a2d3_I20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDQvZnJhZzo0MjVlMGY1ZWY3ZmI0MDgxOGVlMDFlNTc4Y2VhMWNjYy90YWJsZTo1YmZiYjI5MjUwNTM0MGI4YmNkYmVmZGJmOTFjZDQ1ZC90YWJsZXJhbmdlOjViZmJiMjkyNTA1MzQwYjhiY2RiZWZkYmY5MWNkNDVkXzE3LTEtMS0xLTA_9edc1f8e-9dc6-4481-ac1a-500c29ef519d">9,714,321</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i5a27d4e69f2d4076ab56ee85c1e0a2d3_I20210331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDQvZnJhZzo0MjVlMGY1ZWY3ZmI0MDgxOGVlMDFlNTc4Y2VhMWNjYy90YWJsZTo1YmZiYjI5MjUwNTM0MGI4YmNkYmVmZGJmOTFjZDQ1ZC90YWJsZXJhbmdlOjViZmJiMjkyNTA1MzQwYjhiY2RiZWZkYmY5MWNkNDVkXzE3LTMtMS0xLTA_8e6d8224-e3ff-4364-b453-624ad9d20555">3.78</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia87a6b98f0714c88b1aa992fc475f7a1_D20210101-20210331" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDQvZnJhZzo0MjVlMGY1ZWY3ZmI0MDgxOGVlMDFlNTc4Y2VhMWNjYy90YWJsZTo1YmZiYjI5MjUwNTM0MGI4YmNkYmVmZGJmOTFjZDQ1ZC90YWJsZXJhbmdlOjViZmJiMjkyNTA1MzQwYjhiY2RiZWZkYmY5MWNkNDVkXzE3LTUtMS0xLTA_aeec47c7-c37d-4383-8dd3-9c65ced5940d">8.65</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a27d4e69f2d4076ab56ee85c1e0a2d3_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDQvZnJhZzo0MjVlMGY1ZWY3ZmI0MDgxOGVlMDFlNTc4Y2VhMWNjYy90YWJsZTo1YmZiYjI5MjUwNTM0MGI4YmNkYmVmZGJmOTFjZDQ1ZC90YWJsZXJhbmdlOjViZmJiMjkyNTA1MzQwYjhiY2RiZWZkYmY5MWNkNDVkXzE3LTctMS0xLTA_356602b0-6015-4586-88a5-15dfd0436000">15,665</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested at March 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia87a6b98f0714c88b1aa992fc475f7a1_D20210101-20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDQvZnJhZzo0MjVlMGY1ZWY3ZmI0MDgxOGVlMDFlNTc4Y2VhMWNjYy90YWJsZTo1YmZiYjI5MjUwNTM0MGI4YmNkYmVmZGJmOTFjZDQ1ZC90YWJsZXJhbmdlOjViZmJiMjkyNTA1MzQwYjhiY2RiZWZkYmY5MWNkNDVkXzE5LTEtMS0xLTA_3119991b-3ed9-4049-aae2-f7922a127037">3,064,130</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ia87a6b98f0714c88b1aa992fc475f7a1_D20210101-20210331" decimals="2" name="selb:SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsVestedWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDQvZnJhZzo0MjVlMGY1ZWY3ZmI0MDgxOGVlMDFlNTc4Y2VhMWNjYy90YWJsZTo1YmZiYjI5MjUwNTM0MGI4YmNkYmVmZGJmOTFjZDQ1ZC90YWJsZXJhbmdlOjViZmJiMjkyNTA1MzQwYjhiY2RiZWZkYmY5MWNkNDVkXzE5LTMtMS0xLTA_3816bdc6-6883-437f-95f4-ab00e0861e14">5.46</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia87a6b98f0714c88b1aa992fc475f7a1_D20210101-20210331" format="ixt-sec:duryear" name="selb:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedOutstandingWeightedAverageRemainingContractualTerm" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDQvZnJhZzo0MjVlMGY1ZWY3ZmI0MDgxOGVlMDFlNTc4Y2VhMWNjYy90YWJsZTo1YmZiYjI5MjUwNTM0MGI4YmNkYmVmZGJmOTFjZDQ1ZC90YWJsZXJhbmdlOjViZmJiMjkyNTA1MzQwYjhiY2RiZWZkYmY5MWNkNDVkXzE5LTUtMS0xLTA_42c3dd3d-536b-49b5-a363-13085d158c9b">7.63</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a27d4e69f2d4076ab56ee85c1e0a2d3_I20210331" decimals="-3" format="ixt:numdotdecimal" name="selb:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedOutstandingIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDQvZnJhZzo0MjVlMGY1ZWY3ZmI0MDgxOGVlMDFlNTc4Y2VhMWNjYy90YWJsZTo1YmZiYjI5MjUwNTM0MGI4YmNkYmVmZGJmOTFjZDQ1ZC90YWJsZXJhbmdlOjViZmJiMjkyNTA1MzQwYjhiY2RiZWZkYmY5MWNkNDVkXzE5LTctMS0xLTA_7aca4143-293a-41a1-8291-a2d64f17fca2">4,313</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested and expected to vest at March 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5a27d4e69f2d4076ab56ee85c1e0a2d3_I20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDQvZnJhZzo0MjVlMGY1ZWY3ZmI0MDgxOGVlMDFlNTc4Y2VhMWNjYy90YWJsZTo1YmZiYjI5MjUwNTM0MGI4YmNkYmVmZGJmOTFjZDQ1ZC90YWJsZXJhbmdlOjViZmJiMjkyNTA1MzQwYjhiY2RiZWZkYmY5MWNkNDVkXzIwLTEtMS0xLTA_c8b88524-3c0a-4362-9192-84c10ec08fc2">8,920,548</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i5a27d4e69f2d4076ab56ee85c1e0a2d3_I20210331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDQvZnJhZzo0MjVlMGY1ZWY3ZmI0MDgxOGVlMDFlNTc4Y2VhMWNjYy90YWJsZTo1YmZiYjI5MjUwNTM0MGI4YmNkYmVmZGJmOTFjZDQ1ZC90YWJsZXJhbmdlOjViZmJiMjkyNTA1MzQwYjhiY2RiZWZkYmY5MWNkNDVkXzIwLTMtMS0xLTA_5bf6a3d1-da85-467f-9c52-23f102efd916">3.88</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia87a6b98f0714c88b1aa992fc475f7a1_D20210101-20210331" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDQvZnJhZzo0MjVlMGY1ZWY3ZmI0MDgxOGVlMDFlNTc4Y2VhMWNjYy90YWJsZTo1YmZiYjI5MjUwNTM0MGI4YmNkYmVmZGJmOTFjZDQ1ZC90YWJsZXJhbmdlOjViZmJiMjkyNTA1MzQwYjhiY2RiZWZkYmY5MWNkNDVkXzIwLTUtMS0xLTA_55522ac3-2f9b-4417-93a0-631719dbd287">8.59</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a27d4e69f2d4076ab56ee85c1e0a2d3_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDQvZnJhZzo0MjVlMGY1ZWY3ZmI0MDgxOGVlMDFlNTc4Y2VhMWNjYy90YWJsZTo1YmZiYjI5MjUwNTM0MGI4YmNkYmVmZGJmOTFjZDQ1ZC90YWJsZXJhbmdlOjViZmJiMjkyNTA1MzQwYjhiY2RiZWZkYmY5MWNkNDVkXzIwLTctMS0xLTA_d43e02ed-3c9f-483a-a3cd-bdce85b854b1">14,231</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Non-employee consultants</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding at December 31, 2020</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i96083ba0423741b898ef5188cabae8f2_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDQvZnJhZzo0MjVlMGY1ZWY3ZmI0MDgxOGVlMDFlNTc4Y2VhMWNjYy90YWJsZTo1YmZiYjI5MjUwNTM0MGI4YmNkYmVmZGJmOTFjZDQ1ZC90YWJsZXJhbmdlOjViZmJiMjkyNTA1MzQwYjhiY2RiZWZkYmY5MWNkNDVkXzMxLTEtMS0xLTA_1e3a064b-f0d9-4788-bfd1-79ac1c04103e">473,073</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i96083ba0423741b898ef5188cabae8f2_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDQvZnJhZzo0MjVlMGY1ZWY3ZmI0MDgxOGVlMDFlNTc4Y2VhMWNjYy90YWJsZTo1YmZiYjI5MjUwNTM0MGI4YmNkYmVmZGJmOTFjZDQ1ZC90YWJsZXJhbmdlOjViZmJiMjkyNTA1MzQwYjhiY2RiZWZkYmY5MWNkNDVkXzMxLTMtMS0xLTA_453a4fc1-2efc-4898-b1c9-b010f577bdba">5.89</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i7f9a0d7d151d41348d7f21ab127c2ee1_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDQvZnJhZzo0MjVlMGY1ZWY3ZmI0MDgxOGVlMDFlNTc4Y2VhMWNjYy90YWJsZTo1YmZiYjI5MjUwNTM0MGI4YmNkYmVmZGJmOTFjZDQ1ZC90YWJsZXJhbmdlOjViZmJiMjkyNTA1MzQwYjhiY2RiZWZkYmY5MWNkNDVkXzMxLTUtMS0xLTA_cac82b31-2cf5-4ffb-8af7-7e359530170e">5.23</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96083ba0423741b898ef5188cabae8f2_I20201231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDQvZnJhZzo0MjVlMGY1ZWY3ZmI0MDgxOGVlMDFlNTc4Y2VhMWNjYy90YWJsZTo1YmZiYjI5MjUwNTM0MGI4YmNkYmVmZGJmOTFjZDQ1ZC90YWJsZXJhbmdlOjViZmJiMjkyNTA1MzQwYjhiY2RiZWZkYmY5MWNkNDVkXzMxLTctMS0xLTA_d46e0a27-99ea-4496-8566-029bf056f4e8">86</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1f2f087904c34f869b3d9a4b4cb9a24e_D20210101-20210331" decimals="INF" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDQvZnJhZzo0MjVlMGY1ZWY3ZmI0MDgxOGVlMDFlNTc4Y2VhMWNjYy90YWJsZTo1YmZiYjI5MjUwNTM0MGI4YmNkYmVmZGJmOTFjZDQ1ZC90YWJsZXJhbmdlOjViZmJiMjkyNTA1MzQwYjhiY2RiZWZkYmY5MWNkNDVkXzMyLTEtMS0xLTA_ff0db3c8-0b89-4f0e-8207-90fb702893a8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i1f2f087904c34f869b3d9a4b4cb9a24e_D20210101-20210331" decimals="2" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDQvZnJhZzo0MjVlMGY1ZWY3ZmI0MDgxOGVlMDFlNTc4Y2VhMWNjYy90YWJsZTo1YmZiYjI5MjUwNTM0MGI4YmNkYmVmZGJmOTFjZDQ1ZC90YWJsZXJhbmdlOjViZmJiMjkyNTA1MzQwYjhiY2RiZWZkYmY5MWNkNDVkXzMyLTMtMS0xLTA_eec5d8e5-73da-4a3f-8a12-2b1cf165fe3a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1f2f087904c34f869b3d9a4b4cb9a24e_D20210101-20210331" decimals="INF" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDQvZnJhZzo0MjVlMGY1ZWY3ZmI0MDgxOGVlMDFlNTc4Y2VhMWNjYy90YWJsZTo1YmZiYjI5MjUwNTM0MGI4YmNkYmVmZGJmOTFjZDQ1ZC90YWJsZXJhbmdlOjViZmJiMjkyNTA1MzQwYjhiY2RiZWZkYmY5MWNkNDVkXzMzLTEtMS0xLTA_70ee0a0c-09ec-4822-a6f1-22ae26390c40">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i1f2f087904c34f869b3d9a4b4cb9a24e_D20210101-20210331" decimals="2" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDQvZnJhZzo0MjVlMGY1ZWY3ZmI0MDgxOGVlMDFlNTc4Y2VhMWNjYy90YWJsZTo1YmZiYjI5MjUwNTM0MGI4YmNkYmVmZGJmOTFjZDQ1ZC90YWJsZXJhbmdlOjViZmJiMjkyNTA1MzQwYjhiY2RiZWZkYmY5MWNkNDVkXzMzLTMtMS0xLTA_737b0b2f-529f-4c8b-a0a1-fa803f6074fb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1f2f087904c34f869b3d9a4b4cb9a24e_D20210101-20210331" decimals="INF" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDQvZnJhZzo0MjVlMGY1ZWY3ZmI0MDgxOGVlMDFlNTc4Y2VhMWNjYy90YWJsZTo1YmZiYjI5MjUwNTM0MGI4YmNkYmVmZGJmOTFjZDQ1ZC90YWJsZXJhbmdlOjViZmJiMjkyNTA1MzQwYjhiY2RiZWZkYmY5MWNkNDVkXzM0LTEtMS0xLTA_4c26e91d-a727-4785-b9e0-a6583c225f05">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i1f2f087904c34f869b3d9a4b4cb9a24e_D20210101-20210331" decimals="2" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDQvZnJhZzo0MjVlMGY1ZWY3ZmI0MDgxOGVlMDFlNTc4Y2VhMWNjYy90YWJsZTo1YmZiYjI5MjUwNTM0MGI4YmNkYmVmZGJmOTFjZDQ1ZC90YWJsZXJhbmdlOjViZmJiMjkyNTA1MzQwYjhiY2RiZWZkYmY5MWNkNDVkXzM0LTMtMS0xLTA_d1b7dfe5-8d6e-45ef-a607-39cbb005eae1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding at March 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1a4fb26d073f4e2aa150b70c1bdd64cd_I20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDQvZnJhZzo0MjVlMGY1ZWY3ZmI0MDgxOGVlMDFlNTc4Y2VhMWNjYy90YWJsZTo1YmZiYjI5MjUwNTM0MGI4YmNkYmVmZGJmOTFjZDQ1ZC90YWJsZXJhbmdlOjViZmJiMjkyNTA1MzQwYjhiY2RiZWZkYmY5MWNkNDVkXzM1LTEtMS0xLTA_49ae8e76-2909-4d4c-8a17-2a702d330c47">473,073</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i1a4fb26d073f4e2aa150b70c1bdd64cd_I20210331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDQvZnJhZzo0MjVlMGY1ZWY3ZmI0MDgxOGVlMDFlNTc4Y2VhMWNjYy90YWJsZTo1YmZiYjI5MjUwNTM0MGI4YmNkYmVmZGJmOTFjZDQ1ZC90YWJsZXJhbmdlOjViZmJiMjkyNTA1MzQwYjhiY2RiZWZkYmY5MWNkNDVkXzM1LTMtMS0xLTA_e107934c-101e-4d05-850f-c6a24de15857">5.89</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i1f2f087904c34f869b3d9a4b4cb9a24e_D20210101-20210331" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDQvZnJhZzo0MjVlMGY1ZWY3ZmI0MDgxOGVlMDFlNTc4Y2VhMWNjYy90YWJsZTo1YmZiYjI5MjUwNTM0MGI4YmNkYmVmZGJmOTFjZDQ1ZC90YWJsZXJhbmdlOjViZmJiMjkyNTA1MzQwYjhiY2RiZWZkYmY5MWNkNDVkXzM1LTUtMS0xLTA_e1f3fc8d-68d2-4e73-b91d-80491885b643">4.98</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a4fb26d073f4e2aa150b70c1bdd64cd_I20210331" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDQvZnJhZzo0MjVlMGY1ZWY3ZmI0MDgxOGVlMDFlNTc4Y2VhMWNjYy90YWJsZTo1YmZiYjI5MjUwNTM0MGI4YmNkYmVmZGJmOTFjZDQ1ZC90YWJsZXJhbmdlOjViZmJiMjkyNTA1MzQwYjhiY2RiZWZkYmY5MWNkNDVkXzM1LTctMS0xLTA_b871ee73-d144-40a4-b098-964f7bf549bd">366</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested at March 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1f2f087904c34f869b3d9a4b4cb9a24e_D20210101-20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDQvZnJhZzo0MjVlMGY1ZWY3ZmI0MDgxOGVlMDFlNTc4Y2VhMWNjYy90YWJsZTo1YmZiYjI5MjUwNTM0MGI4YmNkYmVmZGJmOTFjZDQ1ZC90YWJsZXJhbmdlOjViZmJiMjkyNTA1MzQwYjhiY2RiZWZkYmY5MWNkNDVkXzM3LTEtMS0xLTA_5077da78-90b0-4c68-8816-a3b149bb6e6d">462,186</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i1f2f087904c34f869b3d9a4b4cb9a24e_D20210101-20210331" decimals="2" name="selb:SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsVestedWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDQvZnJhZzo0MjVlMGY1ZWY3ZmI0MDgxOGVlMDFlNTc4Y2VhMWNjYy90YWJsZTo1YmZiYjI5MjUwNTM0MGI4YmNkYmVmZGJmOTFjZDQ1ZC90YWJsZXJhbmdlOjViZmJiMjkyNTA1MzQwYjhiY2RiZWZkYmY5MWNkNDVkXzM3LTMtMS0xLTA_02dc9f6f-159f-4c3c-9293-0b64a372cf5c">5.82</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i1f2f087904c34f869b3d9a4b4cb9a24e_D20210101-20210331" format="ixt-sec:duryear" name="selb:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedOutstandingWeightedAverageRemainingContractualTerm" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDQvZnJhZzo0MjVlMGY1ZWY3ZmI0MDgxOGVlMDFlNTc4Y2VhMWNjYy90YWJsZTo1YmZiYjI5MjUwNTM0MGI4YmNkYmVmZGJmOTFjZDQ1ZC90YWJsZXJhbmdlOjViZmJiMjkyNTA1MzQwYjhiY2RiZWZkYmY5MWNkNDVkXzM3LTUtMS0xLTA_4c89a4d0-489a-4469-8335-7c2d82259f3e">4.92</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a4fb26d073f4e2aa150b70c1bdd64cd_I20210331" decimals="-3" name="selb:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedOutstandingIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDQvZnJhZzo0MjVlMGY1ZWY3ZmI0MDgxOGVlMDFlNTc4Y2VhMWNjYy90YWJsZTo1YmZiYjI5MjUwNTM0MGI4YmNkYmVmZGJmOTFjZDQ1ZC90YWJsZXJhbmdlOjViZmJiMjkyNTA1MzQwYjhiY2RiZWZkYmY5MWNkNDVkXzM3LTctMS0xLTA_2631daa2-6b2f-4a2a-a959-5d0098b0a99f">366</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested and expected to vest at March 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1a4fb26d073f4e2aa150b70c1bdd64cd_I20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDQvZnJhZzo0MjVlMGY1ZWY3ZmI0MDgxOGVlMDFlNTc4Y2VhMWNjYy90YWJsZTo1YmZiYjI5MjUwNTM0MGI4YmNkYmVmZGJmOTFjZDQ1ZC90YWJsZXJhbmdlOjViZmJiMjkyNTA1MzQwYjhiY2RiZWZkYmY5MWNkNDVkXzM4LTEtMS0xLTA_da77e70a-b378-488a-a0d2-bab91fbc609c">473,073</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i1a4fb26d073f4e2aa150b70c1bdd64cd_I20210331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDQvZnJhZzo0MjVlMGY1ZWY3ZmI0MDgxOGVlMDFlNTc4Y2VhMWNjYy90YWJsZTo1YmZiYjI5MjUwNTM0MGI4YmNkYmVmZGJmOTFjZDQ1ZC90YWJsZXJhbmdlOjViZmJiMjkyNTA1MzQwYjhiY2RiZWZkYmY5MWNkNDVkXzM4LTMtMS0xLTA_7776d476-4348-4aa2-93ab-fd1a40fabe97">5.89</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i1f2f087904c34f869b3d9a4b4cb9a24e_D20210101-20210331" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDQvZnJhZzo0MjVlMGY1ZWY3ZmI0MDgxOGVlMDFlNTc4Y2VhMWNjYy90YWJsZTo1YmZiYjI5MjUwNTM0MGI4YmNkYmVmZGJmOTFjZDQ1ZC90YWJsZXJhbmdlOjViZmJiMjkyNTA1MzQwYjhiY2RiZWZkYmY5MWNkNDVkXzM4LTUtMS0xLTA_6c2dbd6c-b337-4156-ba31-91e86f26f34b">4.98</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a4fb26d073f4e2aa150b70c1bdd64cd_I20210331" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDQvZnJhZzo0MjVlMGY1ZWY3ZmI0MDgxOGVlMDFlNTc4Y2VhMWNjYy90YWJsZTo1YmZiYjI5MjUwNTM0MGI4YmNkYmVmZGJmOTFjZDQ1ZC90YWJsZXJhbmdlOjViZmJiMjkyNTA1MzQwYjhiY2RiZWZkYmY5MWNkNDVkXzM4LTctMS0xLTA_a937268f-8790-42b6-914c-96fed7f7182a">366</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Restricted Stock Units</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, the Company granted <ix:nonFraction unitRef="shares" contextRef="id01182d93717492b89617d993fbd0c3a_D20210101-20210131" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDQvZnJhZzo0MjVlMGY1ZWY3ZmI0MDgxOGVlMDFlNTc4Y2VhMWNjYy90ZXh0cmVnaW9uOjQyNWUwZjVlZjdmYjQwODE4ZWUwMWU1NzhjZWExY2NjXzI3NDg3NzkwODQ0ODg_d0facb35-2ee6-4298-8512-bfd08dc80862">369,800</ix:nonFraction> restricted stock awards to employees under the 2016 Plan which will vest over a <ix:nonNumeric contextRef="ib1f07535b15b475490cebf99339949e2_D20210101-20210331" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDQvZnJhZzo0MjVlMGY1ZWY3ZmI0MDgxOGVlMDFlNTc4Y2VhMWNjYy90ZXh0cmVnaW9uOjQyNWUwZjVlZjdmYjQwODE4ZWUwMWU1NzhjZWExY2NjXzQzOTgwNDY1NDM3MzQ_d384e646-d809-4f5e-b380-29cc908c57dc">four year</ix:nonNumeric> term.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, during the first quarter of 2021, the Company awarded <ix:nonFraction unitRef="shares" contextRef="ib1f07535b15b475490cebf99339949e2_D20210101-20210331" decimals="INF" format="ixt:numdotdecimal" name="selb:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAwardedInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDQvZnJhZzo0MjVlMGY1ZWY3ZmI0MDgxOGVlMDFlNTc4Y2VhMWNjYy90ZXh0cmVnaW9uOjQyNWUwZjVlZjdmYjQwODE4ZWUwMWU1NzhjZWExY2NjXzE2NDkyNjc0NTU3OTM_da109494-917c-42af-aead-e00543533028">197,500</ix:nonFraction> restricted stock units to executives under the 2016 Plan, of which <ix:nonFraction unitRef="shares" contextRef="ib1f07535b15b475490cebf99339949e2_D20210101-20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDQvZnJhZzo0MjVlMGY1ZWY3ZmI0MDgxOGVlMDFlNTc4Y2VhMWNjYy90ZXh0cmVnaW9uOjQyNWUwZjVlZjdmYjQwODE4ZWUwMWU1NzhjZWExY2NjXzE2NDkyNjc0NTU4MDk_ee88f426-2eec-44ae-a8dc-501254e45627">98,750</ix:nonFraction> were determined to be granted as of the award date consistent with ASC 718. The remaining <ix:nonFraction unitRef="shares" contextRef="ib1f07535b15b475490cebf99339949e2_D20210101-20210331" decimals="INF" format="ixt:numdotdecimal" name="selb:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReservedForIssuance" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDQvZnJhZzo0MjVlMGY1ZWY3ZmI0MDgxOGVlMDFlNTc4Y2VhMWNjYy90ZXh0cmVnaW9uOjQyNWUwZjVlZjdmYjQwODE4ZWUwMWU1NzhjZWExY2NjXzE2NDkyNjc0NTU4MTg_aa927e27-757f-4c8b-8611-4e56ba3db490">98,750</ix:nonFraction> restricted stock units do not have a defined performance metric as of the award date, resulting in the restricted stock units being reserved for future issuance as of March 31, 2021. These restricted stock units will vest in two equal installments on the dates </span></div></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i71586e7d2e304f6983634abe9e071791_13">Table of Contents</a></span></div></div><ix:continuation id="idc2d0a7b71ea4c74b164295404f364a1"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">an applicable performance condition is achieved, on or prior to December 31, 2021. If the performance conditions are not satisfied on or prior to December 31, 2021, the restricted stock units will be forfeited for no consideration.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The restricted stock units granted had a weighted average fair value of $<ix:nonFraction unitRef="usdPerShare" contextRef="i676ae38dc7694143b42a364d53aa820c_D20210101-20210331" decimals="2" name="selb:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReservedForIssuanceWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDQvZnJhZzo0MjVlMGY1ZWY3ZmI0MDgxOGVlMDFlNTc4Y2VhMWNjYy90ZXh0cmVnaW9uOjQyNWUwZjVlZjdmYjQwODE4ZWUwMWU1NzhjZWExY2NjXzQzOTgwNDY1MjU5MDY_b15174d4-a0f4-4bbf-8e05-8573f41b1c9d">2.99</ix:nonFraction> per share based on the closing price of the Company&#8217;s common stock on the date of grant. The restricted stock units were valued at approximately $<ix:nonFraction unitRef="usd" contextRef="ib1f07535b15b475490cebf99339949e2_D20210101-20210331" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDQvZnJhZzo0MjVlMGY1ZWY3ZmI0MDgxOGVlMDFlNTc4Y2VhMWNjYy90ZXh0cmVnaW9uOjQyNWUwZjVlZjdmYjQwODE4ZWUwMWU1NzhjZWExY2NjXzE2NDkyNjc0NTU4MjU_7b2edf84-40b9-4ddb-a2dc-4f84eeedb9dd">1.4</ix:nonFraction> million on their grant date. Forfeitures are estimated at the time of grant and are adjusted, if necessary, in subsequent periods if actual forfeitures differ from those estimates. The Company has estimated a forfeiture rate of <ix:nonFraction unitRef="number" contextRef="i0a83cea2026d4acd853ecd648a6ff3cf_D20210101-20210331" decimals="2" name="selb:ShareBasedCompensationArrangementByShareBasedPaymentAwardForfeituresRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDQvZnJhZzo0MjVlMGY1ZWY3ZmI0MDgxOGVlMDFlNTc4Y2VhMWNjYy90ZXh0cmVnaW9uOjQyNWUwZjVlZjdmYjQwODE4ZWUwMWU1NzhjZWExY2NjXzI3NDg3NzkwODQ5NTM_6b754ab2-cd6c-4b4a-88d7-9273ccea354f">10</ix:nonFraction>% for restricted stock awards to employees based on historical attrition trends.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unrecognized compensation expense for all restricted stock units was $<ix:nonFraction unitRef="usd" contextRef="id4c863b4912a4159803053e1c04bda2f_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDQvZnJhZzo0MjVlMGY1ZWY3ZmI0MDgxOGVlMDFlNTc4Y2VhMWNjYy90ZXh0cmVnaW9uOjQyNWUwZjVlZjdmYjQwODE4ZWUwMWU1NzhjZWExY2NjXzgzOTU_bcb9232d-dcff-4447-ae40-b64055d41793">1.5</ix:nonFraction> million as of March 31, 2021, which is expected to be recognized over a weighted average period of <ix:nonNumeric contextRef="ia7f06d48c2684d27abe5106b2abf1761_D20210101-20210331" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDQvZnJhZzo0MjVlMGY1ZWY3ZmI0MDgxOGVlMDFlNTc4Y2VhMWNjYy90ZXh0cmVnaW9uOjQyNWUwZjVlZjdmYjQwODE4ZWUwMWU1NzhjZWExY2NjXzg0Nzc_e2a3f770-3d5b-4c22-b0cf-743de4a2de09">3.1</ix:nonNumeric> years.</span></div><ix:nonNumeric contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331" name="us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDQvZnJhZzo0MjVlMGY1ZWY3ZmI0MDgxOGVlMDFlNTc4Y2VhMWNjYy90ZXh0cmVnaW9uOjQyNWUwZjVlZjdmYjQwODE4ZWUwMWU1NzhjZWExY2NjXzEwOTMy_1b26d848-2c60-47ae-ba68-c2bfa874c29c" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s restricted stock units under the 2016 Plan and 2018 Inducement Incentive Award Plan:</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:69.721%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.122%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.124%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted average<br/>grant date<br/>fair value ($)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unvested at December 31, 2020</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i23dc483d5e024cd3ab41d280f32cf960_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDQvZnJhZzo0MjVlMGY1ZWY3ZmI0MDgxOGVlMDFlNTc4Y2VhMWNjYy90YWJsZTowYzM5MTY0ZWEyMDA0ZTY0YjgzOGYzMzc1MDNhZTM3Zi90YWJsZXJhbmdlOjBjMzkxNjRlYTIwMDRlNjRiODM4ZjMzNzUwM2FlMzdmXzEtMS0xLTEtMA_dc4567d1-4040-4791-8b51-e8cde2f160ba">87,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i23dc483d5e024cd3ab41d280f32cf960_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDQvZnJhZzo0MjVlMGY1ZWY3ZmI0MDgxOGVlMDFlNTc4Y2VhMWNjYy90YWJsZTowYzM5MTY0ZWEyMDA0ZTY0YjgzOGYzMzc1MDNhZTM3Zi90YWJsZXJhbmdlOjBjMzkxNjRlYTIwMDRlNjRiODM4ZjMzNzUwM2FlMzdmXzEtMy0xLTEtMA_47be93ba-0c6a-4530-a0db-a188e419cfb6">6.03</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i676ae38dc7694143b42a364d53aa820c_D20210101-20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDQvZnJhZzo0MjVlMGY1ZWY3ZmI0MDgxOGVlMDFlNTc4Y2VhMWNjYy90YWJsZTowYzM5MTY0ZWEyMDA0ZTY0YjgzOGYzMzc1MDNhZTM3Zi90YWJsZXJhbmdlOjBjMzkxNjRlYTIwMDRlNjRiODM4ZjMzNzUwM2FlMzdmXzItMS0xLTEtMA_6e2de4bd-b07d-47bb-996b-3ec67ed98a0e">468,550</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i676ae38dc7694143b42a364d53aa820c_D20210101-20210331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDQvZnJhZzo0MjVlMGY1ZWY3ZmI0MDgxOGVlMDFlNTc4Y2VhMWNjYy90YWJsZTowYzM5MTY0ZWEyMDA0ZTY0YjgzOGYzMzc1MDNhZTM3Zi90YWJsZXJhbmdlOjBjMzkxNjRlYTIwMDRlNjRiODM4ZjMzNzUwM2FlMzdmXzItMy0xLTEtMA_1226477b-51da-4055-8792-2e02d6c6c1f1">2.99</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i676ae38dc7694143b42a364d53aa820c_D20210101-20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDQvZnJhZzo0MjVlMGY1ZWY3ZmI0MDgxOGVlMDFlNTc4Y2VhMWNjYy90YWJsZTowYzM5MTY0ZWEyMDA0ZTY0YjgzOGYzMzc1MDNhZTM3Zi90YWJsZXJhbmdlOjBjMzkxNjRlYTIwMDRlNjRiODM4ZjMzNzUwM2FlMzdmXzMtMS0xLTEtMA_08f62a80-ea6e-4db4-b973-2d202b4bd270">10,937</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i676ae38dc7694143b42a364d53aa820c_D20210101-20210331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDQvZnJhZzo0MjVlMGY1ZWY3ZmI0MDgxOGVlMDFlNTc4Y2VhMWNjYy90YWJsZTowYzM5MTY0ZWEyMDA0ZTY0YjgzOGYzMzc1MDNhZTM3Zi90YWJsZXJhbmdlOjBjMzkxNjRlYTIwMDRlNjRiODM4ZjMzNzUwM2FlMzdmXzMtMy0xLTEtMA_f6986af7-7bc9-477f-9799-be1dbe591816">6.03</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Reserved for issuance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i676ae38dc7694143b42a364d53aa820c_D20210101-20210331" decimals="INF" format="ixt:numdotdecimal" name="selb:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReservedForIssuance" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDQvZnJhZzo0MjVlMGY1ZWY3ZmI0MDgxOGVlMDFlNTc4Y2VhMWNjYy90YWJsZTowYzM5MTY0ZWEyMDA0ZTY0YjgzOGYzMzc1MDNhZTM3Zi90YWJsZXJhbmdlOjBjMzkxNjRlYTIwMDRlNjRiODM4ZjMzNzUwM2FlMzdmXzQtMS0xLTEtMA_f81f8b1a-55ed-4546-add2-2b415324f3de">98,750</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i676ae38dc7694143b42a364d53aa820c_D20210101-20210331" decimals="2" name="selb:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReservedForIssuanceWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDQvZnJhZzo0MjVlMGY1ZWY3ZmI0MDgxOGVlMDFlNTc4Y2VhMWNjYy90YWJsZTowYzM5MTY0ZWEyMDA0ZTY0YjgzOGYzMzc1MDNhZTM3Zi90YWJsZXJhbmdlOjBjMzkxNjRlYTIwMDRlNjRiODM4ZjMzNzUwM2FlMzdmXzQtMy0xLTEtMA_1ab6a45c-a732-427d-92c0-deaf149f569f">2.99</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i676ae38dc7694143b42a364d53aa820c_D20210101-20210331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDQvZnJhZzo0MjVlMGY1ZWY3ZmI0MDgxOGVlMDFlNTc4Y2VhMWNjYy90YWJsZTowYzM5MTY0ZWEyMDA0ZTY0YjgzOGYzMzc1MDNhZTM3Zi90YWJsZXJhbmdlOjBjMzkxNjRlYTIwMDRlNjRiODM4ZjMzNzUwM2FlMzdmXzUtMS0xLTEtMA_cae48096-a1e5-4401-8b19-cf8f803a3bb0">800</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i676ae38dc7694143b42a364d53aa820c_D20210101-20210331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDQvZnJhZzo0MjVlMGY1ZWY3ZmI0MDgxOGVlMDFlNTc4Y2VhMWNjYy90YWJsZTowYzM5MTY0ZWEyMDA0ZTY0YjgzOGYzMzc1MDNhZTM3Zi90YWJsZXJhbmdlOjBjMzkxNjRlYTIwMDRlNjRiODM4ZjMzNzUwM2FlMzdmXzUtMy0xLTEtMA_1ae484f6-23ab-4c4b-a74a-0efd5944f9c3">2.99</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unvested at March 31, 2021</span></div></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie9886e2c9856402e9696bea8b5c012ee_I20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDQvZnJhZzo0MjVlMGY1ZWY3ZmI0MDgxOGVlMDFlNTc4Y2VhMWNjYy90YWJsZTowYzM5MTY0ZWEyMDA0ZTY0YjgzOGYzMzc1MDNhZTM3Zi90YWJsZXJhbmdlOjBjMzkxNjRlYTIwMDRlNjRiODM4ZjMzNzUwM2FlMzdmXzYtMS0xLTEtMA_86f4b481-3d58-498b-a8de-52f81d5834de">643,063</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie9886e2c9856402e9696bea8b5c012ee_I20210331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDQvZnJhZzo0MjVlMGY1ZWY3ZmI0MDgxOGVlMDFlNTc4Y2VhMWNjYy90YWJsZTowYzM5MTY0ZWEyMDA0ZTY0YjgzOGYzMzc1MDNhZTM3Zi90YWJsZXJhbmdlOjBjMzkxNjRlYTIwMDRlNjRiODM4ZjMzNzUwM2FlMzdmXzYtMy0xLTEtMA_79ffdb37-f531-4e46-80c8-7625d86b3ee9">3.35</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Employee Stock Purchase Plan</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the Company approved the 2016 Employee Stock Purchase Plan, or the ESPP, which authorized <ix:nonFraction unitRef="shares" contextRef="i98884f73b2c2406a9fe17695931498a3_I20160621" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDQvZnJhZzo0MjVlMGY1ZWY3ZmI0MDgxOGVlMDFlNTc4Y2VhMWNjYy90ZXh0cmVnaW9uOjQyNWUwZjVlZjdmYjQwODE4ZWUwMWU1NzhjZWExY2NjXzk2OTk_c7804aa3-09b9-471f-b3ba-cd2a5ad8876b">173,076</ix:nonFraction> shares of common stock for future issuance under the ESPP to participating employees. In January 2021 and 2020, the number of shares of common stock authorized for issuance under the ESPP was increased by <ix:nonFraction unitRef="shares" contextRef="i3a0400d76b2a4414a1b0b75fa0e22620_D20210101-20210331" decimals="INF" format="ixt:numdotdecimal" name="selb:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantIncreaseDecrease" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDQvZnJhZzo0MjVlMGY1ZWY3ZmI0MDgxOGVlMDFlNTc4Y2VhMWNjYy90ZXh0cmVnaW9uOjQyNWUwZjVlZjdmYjQwODE4ZWUwMWU1NzhjZWExY2NjXzEwMzYx_b2ea2c77-0ef2-4e61-931e-0a12a9e4598e">1,080,711</ix:nonFraction> shares and <ix:nonFraction unitRef="shares" contextRef="i7ecfd227500943bba7dc51fc2bd3afec_D20200101-20200331" decimals="INF" format="ixt:numdotdecimal" name="selb:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantIncreaseDecrease" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDQvZnJhZzo0MjVlMGY1ZWY3ZmI0MDgxOGVlMDFlNTc4Y2VhMWNjYy90ZXh0cmVnaW9uOjQyNWUwZjVlZjdmYjQwODE4ZWUwMWU1NzhjZWExY2NjXzEwMzc1_9f1ce8e2-70d0-4f9f-a899-6f674cb3df9b">863,254</ix:nonFraction> shares, respectively. During the three months ended March 31, 2021, the Company issued <ix:nonFraction unitRef="shares" contextRef="i3a0400d76b2a4414a1b0b75fa0e22620_D20210101-20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDQvZnJhZzo0MjVlMGY1ZWY3ZmI0MDgxOGVlMDFlNTc4Y2VhMWNjYy90ZXh0cmVnaW9uOjQyNWUwZjVlZjdmYjQwODE4ZWUwMWU1NzhjZWExY2NjXzEwNDQz_1c80c6d2-40a7-4d66-af30-1d2f44e55f4e">34,696</ix:nonFraction> shares of common stock under the ESPP. As of March 31, 2021, <ix:nonFraction unitRef="shares" contextRef="ib7e99ef7cdcc49a1ad08e7bc6eec6d1a_I20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDQvZnJhZzo0MjVlMGY1ZWY3ZmI0MDgxOGVlMDFlNTc4Y2VhMWNjYy90ZXh0cmVnaW9uOjQyNWUwZjVlZjdmYjQwODE4ZWUwMWU1NzhjZWExY2NjXzEwNDk1_fdc01aa1-9a25-4d6f-86e1-21497ec7ff43">2,546,464</ix:nonFraction> shares remain available for future issuance under the ESPP.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For each of the three months ended March 31, 2021 and 2020, the Company recognized less than $<ix:nonFraction unitRef="usd" contextRef="i7ecfd227500943bba7dc51fc2bd3afec_D20200101-20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDQvZnJhZzo0MjVlMGY1ZWY3ZmI0MDgxOGVlMDFlNTc4Y2VhMWNjYy90ZXh0cmVnaW9uOjQyNWUwZjVlZjdmYjQwODE4ZWUwMWU1NzhjZWExY2NjXzEwNjE3_15cbda1d-5119-44d0-9663-53aa17d0b7d0"><ix:nonFraction unitRef="usd" contextRef="i3a0400d76b2a4414a1b0b75fa0e22620_D20210101-20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDQvZnJhZzo0MjVlMGY1ZWY3ZmI0MDgxOGVlMDFlNTc4Y2VhMWNjYy90ZXh0cmVnaW9uOjQyNWUwZjVlZjdmYjQwODE4ZWUwMWU1NzhjZWExY2NjXzEwNjE3_3a868f34-b093-4e6e-b1e0-ec717e9a76af">0.1</ix:nonFraction></ix:nonFraction> million of stock-based compensation expense under the ESPP.</span></div></ix:continuation><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span><br/></span></div><div id="i71586e7d2e304f6983634abe9e071791_247"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">12. <ix:nonNumeric contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331" name="us-gaap:RevenueFromContractWithCustomerTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDcvZnJhZzo5YjFkNTkxZmQzMWQ0NDQ4OTczNDg0ZDFiMDliZGFlNC90ZXh0cmVnaW9uOjliMWQ1OTFmZDMxZDQ0NDg5NzM0ODRkMWIwOWJkYWU0XzM1NTYz_8e0d106c-4de3-47d6-8aa2-0c498bd531dc" continuedAt="i3a67050bc39c4def86f68d48443e04c0" escape="true">Revenue Arrangements</ix:nonNumeric></span></div><ix:continuation id="i3a67050bc39c4def86f68d48443e04c0" continuedAt="i0bd1bd9302394549b4ab585af71c3a93"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Swedish Orphan Biovitrum</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">License and Development Agreement</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 11, 2020, the Company and Sobi entered into the Sobi License. Pursuant to the Sobi License, the Company has agreed to grant Sobi an exclusive, worldwide (except as to Greater China) license to develop, manufacture and commercialize the Company&#8217;s SEL-212 drug candidate, which is currently in development for the treatment of chronic refractory gout. The SEL-212 drug candidate is a pharmaceutical composition containing a combination of SEL-037, or the Compound, and ImmTOR. Pursuant to the Sobi License, in consideration of the license, Sobi agreed to pay the Company a one-time, up-front payment of $<ix:nonFraction unitRef="usd" contextRef="i88f5a9f6a9ed48ce97bb4cbb9b6ef889_D20200611-20200611" decimals="INF" format="ixt:numdotdecimal" name="selb:LicenseAndOptionAgreementUpfrontCashPayment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDcvZnJhZzo5YjFkNTkxZmQzMWQ0NDQ4OTczNDg0ZDFiMDliZGFlNC90ZXh0cmVnaW9uOjliMWQ1OTFmZDMxZDQ0NDg5NzM0ODRkMWIwOWJkYWU0XzY5OA_646179ee-d250-49f3-b10c-0e5f36937f9f">75.0</ix:nonFraction>&#160;million. Sobi has also agreed to make milestone payments totaling up to $<ix:nonFraction unitRef="usd" contextRef="i88f5a9f6a9ed48ce97bb4cbb9b6ef889_D20200611-20200611" decimals="-6" format="ixt:numdotdecimal" name="selb:LicenseAndOptionAgreementSalesMilestonePaymentsThatMayBeReceived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDcvZnJhZzo5YjFkNTkxZmQzMWQ0NDQ4OTczNDg0ZDFiMDliZGFlNC90ZXh0cmVnaW9uOjliMWQ1OTFmZDMxZDQ0NDg5NzM0ODRkMWIwOWJkYWU0Xzc2NQ_8ece6da4-6138-4047-b762-d173ea8279c0">630.0</ix:nonFraction>&#160;million to the Company upon the achievement of various development and regulatory milestones and, if commercialized, sales thresholds for annual net sales of SEL-212, and tiered royalty payments ranging from the low double digits on the lowest sales tier to the high teens on the highest sales tier.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Sobi License, the Company has agreed to supply (at cost) quantities of the Compound and ImmTOR as necessary for completion of the two Phase 3 clinical trials of SEL-212 (DISSOLVE I and DISSOLVE II) and a 6-month placebo extension. The Company is required to supply quantities of the Compound until all rights to the Compound and any materials needed to manufacture the Compound are transferred to Sobi. Sobi has agreed to reimburse the Company for all budgeted costs incurred to complete development of SEL-212, including but not limited to costs incurred while conducting and completing the Phase 3 DISSOLVE trials, except for any costs of additional development activities required that are related to ImmTOR and that are unrelated to SEL-212. Sobi will have control and responsibility over all regulatory filings, including any investigational drug applications (IND), biologics license applications (BLA), and marketing authorization applications (MAA) relating to the licensed product.</span></div></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i71586e7d2e304f6983634abe9e071791_13">Table of Contents</a></span></div></div><ix:continuation id="i0bd1bd9302394549b4ab585af71c3a93" continuedAt="i366c4f44da4447bbba8293112a1c70ab"><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The transactions contemplated by the Sobi License were consummated on July 28, 2020 following the expiration or termination of the required waiting periods under the Hart-Scott-Rodino Antitrust Improvements Act of 1976. Sobi may terminate the Sobi License for any reason upon <ix:nonNumeric contextRef="i88f5a9f6a9ed48ce97bb4cbb9b6ef889_D20200611-20200611" format="ixt-sec:durday" name="selb:LicenseAndOptionAgreementWrittenDayNoticePeriodBeforeCancellation" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDcvZnJhZzo5YjFkNTkxZmQzMWQ0NDQ4OTczNDg0ZDFiMDliZGFlNC90ZXh0cmVnaW9uOjliMWQ1OTFmZDMxZDQ0NDg5NzM0ODRkMWIwOWJkYWU0XzQzOTgwNDY1NTQ3ODg_5af03c49-9286-4c50-abb6-20b0e1b9dc8b">180</ix:nonNumeric> days&#8217; written notice to the Company, whereby all rights granted under the Sobi License would revert back to the Company. In addition, if Sobi were to terminate the Sobi License, the Company has the option to obtain a license to all patents and know-how necessary to exploit SEL-212 in existence as of the termination date from Sobi in return for making an equitable royalty payment to Sobi.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, on June 11, 2020, the Company entered into the Sobi Purchase Agreement in connection with the Sobi License. The closing of the Sobi Private Placement occurred on July 31, 2020, following the closing of the transactions contemplated under the Sobi License. See Note 10 for details.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined that the Sobi License represents a service arrangement under the scope of ASC 606. In addition, given the Sobi License and Sobi Purchase Agreement were executed contemporaneously and negotiated as a package with a single commercial objective, the Company will account for the two agreements as a single contract. The term of the Sobi License commenced upon the effective date of July 28, 2020 and will continue on a product-by-product basis until the royalty terms for each country have expired. The royalty term for a given product begins upon the first commercial sale of the product in a country and ends at the later of <ix:nonNumeric contextRef="i88f5a9f6a9ed48ce97bb4cbb9b6ef889_D20200611-20200611" format="ixt-sec:durwordsen" name="selb:EligiblePeriodToReceiveRoyalties" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDcvZnJhZzo5YjFkNTkxZmQzMWQ0NDQ4OTczNDg0ZDFiMDliZGFlNC90ZXh0cmVnaW9uOjliMWQ1OTFmZDMxZDQ0NDg5NzM0ODRkMWIwOWJkYWU0XzM2ODA_dda94778-3b95-4368-80ea-d5c7ac380024">ten years</ix:nonNumeric> from the first commercial sale, expiration of the last valid patent claim covering the product and expiration of all regulatory exclusivity periods for the product in a country. Given the reversion of the rights under the Sobi License represents a penalty in substance for a termination by Sobi, the contract term would remain the stated term of the Sobi License.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined that the Sobi License contains <ix:nonFraction unitRef="obligation" contextRef="idfbbd3bf25a24130a9437f8a5acdb931_I20200611" decimals="INF" format="ixt-sec:numwordsen" name="selb:RevenueNumberOfPerformanceObligations" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDcvZnJhZzo5YjFkNTkxZmQzMWQ0NDQ4OTczNDg0ZDFiMDliZGFlNC90ZXh0cmVnaW9uOjliMWQ1OTFmZDMxZDQ0NDg5NzM0ODRkMWIwOWJkYWU0XzQxMDE_144a11a5-0c0c-4ace-8194-5e2462f9b98a">three</ix:nonFraction> distinct performance obligations due to the nature of the promises in the contract, which includes conducting the Phase 3 DISSOLVE trials, Sobi&#8217;s option to set-up a second source supplier, and a combined obligation comprised of the delivery of the license to SEL-212, transfer of the know-how and the manufacturing and delivery of SEL-212 supply for development, or the Combined License Obligation. As the set-up of a second source supplier is optional for Sobi and the Company will be reimbursed at cost for its efforts in the subsequent set-up and technology transfer, the option for this future service was determined to be at a significant and incremental discount to its standalone selling price and treated as a material right in the arrangement, namely a distinct performance obligation.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In determining the transaction price, the Company concluded the upfront payment of $<ix:nonFraction unitRef="usd" contextRef="i88f5a9f6a9ed48ce97bb4cbb9b6ef889_D20200611-20200611" decimals="INF" format="ixt:numdotdecimal" name="selb:LicenseAndOptionAgreementUpfrontCashPayment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDcvZnJhZzo5YjFkNTkxZmQzMWQ0NDQ4OTczNDg0ZDFiMDliZGFlNC90ZXh0cmVnaW9uOjliMWQ1OTFmZDMxZDQ0NDg5NzM0ODRkMWIwOWJkYWU0XzQ5ODI_e8668e98-1994-41c3-aafb-ae27ee5ef3b2">75.0</ix:nonFraction>&#160;million and the $<ix:nonFraction unitRef="usd" contextRef="i88f5a9f6a9ed48ce97bb4cbb9b6ef889_D20200611-20200611" decimals="-6" format="ixt:numdotdecimal" name="selb:LicenseAndOptionAgreementDevelopmentMilestone" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDcvZnJhZzo5YjFkNTkxZmQzMWQ0NDQ4OTczNDg0ZDFiMDliZGFlNC90ZXh0cmVnaW9uOjliMWQ1OTFmZDMxZDQ0NDg5NzM0ODRkMWIwOWJkYWU0XzQ5OTM_51202c95-6039-42fc-9b65-790f30c46ac4">5.0</ix:nonFraction>&#160;million development milestone associated with the dosing of the first patient in the Phase 3 DISSOLVE trials will be included in the transaction price. All other development milestones will be fully constrained and only be included in the transaction price when the respective milestone is deemed probable of achievement. Each of these variable consideration items was evaluated under the most likely amount method to determine whether such amounts were probable of occurrence, or whether such amounts should be constrained until they become probable. As part of the evaluation of the constraint, the Company considered numerous factors, including that receipt of such milestones is outside the control of the Company and probability of success criteria is estimated. The Company will re-evaluate the transaction price in each reporting period, as uncertain events are resolved. In accordance with ASC 606, the Company will only recognize revenue associated with sales-based milestones and royalties when the subsequent sales thresholds are reached and underlying sales occur, respectively. In connection with the Sobi Purchase Agreement, the Company determined that the gross proceeds of $<ix:nonFraction unitRef="usd" contextRef="i6e736a6ad22d4f7fbc1eda905bef7a23_D20200611-20200611" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDcvZnJhZzo5YjFkNTkxZmQzMWQ0NDQ4OTczNDg0ZDFiMDliZGFlNC90ZXh0cmVnaW9uOjliMWQ1OTFmZDMxZDQ0NDg5NzM0ODRkMWIwOWJkYWU0XzYxNzc_e3cefb86-1b3f-48f4-9bfa-647456e3ce0d">25.0</ix:nonFraction>&#160;million from the Sobi Private Placement included a premium to the fair value of the Company&#8217;s shares as of July 28, 2020 equal to approximately $<ix:nonFraction unitRef="usd" contextRef="i0e52f92d6bcb4dd098a7fe0cf721e342_D20200728-20200728" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RedemptionPremium" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDcvZnJhZzo5YjFkNTkxZmQzMWQ0NDQ4OTczNDg0ZDFiMDliZGFlNC90ZXh0cmVnaW9uOjliMWQ1OTFmZDMxZDQ0NDg5NzM0ODRkMWIwOWJkYWU0XzYzMTY_a10c1c4e-e89d-470a-96c8-0f61fed33eb7">14.5</ix:nonFraction>&#160;million. The premium amount will be included in the transaction price for revenue recognition. The Company will estimate and include in the transaction price the total reimbursements to be received from Sobi for both the manufacturing and delivery of the Compound and ImmTOR as well as conducting the Phase 3 DISSOLVE trials. The Company determined that a significant financing component does not exist in its arrangement with Sobi.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company allocated the transaction price based on the relative standalone selling prices of the <ix:nonFraction unitRef="obligation" contextRef="idfbbd3bf25a24130a9437f8a5acdb931_I20200611" decimals="INF" format="ixt-sec:numwordsen" name="selb:RevenueNumberOfPerformanceObligations" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDcvZnJhZzo5YjFkNTkxZmQzMWQ0NDQ4OTczNDg0ZDFiMDliZGFlNC90ZXh0cmVnaW9uOjliMWQ1OTFmZDMxZDQ0NDg5NzM0ODRkMWIwOWJkYWU0XzY4NDM_f4561a59-512b-48f7-8a82-5820250728f3">three</ix:nonFraction> distinct performance obligations. The Company estimated the standalone selling price of conducting the Phase 3 DISSOLVE trials by forecasting its anticipated costs and applying a margin reflective of the industry. The Company must determine the standalone selling price of the second source supplier option by determining the discount given to Sobi multiplied by the likelihood that Sobi will exercise the option in the future. Similar to the Phase 3 program estimate, the Company estimated the discount of the option by forecasting the set-up costs and applying a margin that is reflective of the industry. As the Company will be providing the set-up and technology transfer services and the future supply at cost, the discount of the option is equal to the margin amount. The Company considered discussions with Sobi as well as probability of regulatory success of SEL-212 in determining the likelihood of exercise. The Company estimated the standalone selling price of the Combined License Obligation by utilizing a discounted cash flow model.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined that the delivery of the supply to Sobi best represents the pattern of delivery of the Combined License Obligation as the supply is essential to the utility of the license and know-how. The Company will recognize the revenue allocated to the Combined License Obligation by utilizing the output method. The Company estimated the total supply of the Compound and ImmTOR to be required during the clinical trial period and will recognize revenue as this supply is shipped for use in the clinical trials. The Company will recognize the revenue allocated to the conducting of the Phase 3 DISSOLVE trials obligation by utilizing the input method. The Company estimated the total budgeted costs to be incurred over </span></div></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i71586e7d2e304f6983634abe9e071791_13">Table of Contents</a></span></div></div><ix:continuation id="i366c4f44da4447bbba8293112a1c70ab" continuedAt="iaaac17fadc1946298ee8da41e4c72103"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the Phase 3 DISSOLVE trials and will recognize revenue as these costs are incurred. The Company&#8217;s costs best represent the pattern of transfer as these will capture all performance of the trials completed to date and can be readily measured. The Company will recognize the revenue allocated to the second source supplier option when the future services and goods are transferred.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2021 and December 31, 2020, the Company recorded $<ix:nonFraction unitRef="usd" contextRef="i89a2a0a3262b4bc9b05cb96efb71185e_I20210331" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDcvZnJhZzo5YjFkNTkxZmQzMWQ0NDQ4OTczNDg0ZDFiMDliZGFlNC90ZXh0cmVnaW9uOjliMWQ1OTFmZDMxZDQ0NDg5NzM0ODRkMWIwOWJkYWU0XzkwMzY_71b143e9-4fa2-43ba-8e01-ee931f9f09fb">72.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i9114bf8b8ace4041b525081dc7e30132_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDcvZnJhZzo5YjFkNTkxZmQzMWQ0NDQ4OTczNDg0ZDFiMDliZGFlNC90ZXh0cmVnaW9uOjliMWQ1OTFmZDMxZDQ0NDg5NzM0ODRkMWIwOWJkYWU0XzQzOTgwNDY1NTE0OTk_2c762d6d-fe83-4f1f-87e0-da51e5a05baf">68.3</ix:nonFraction>&#160;million, respectively, as a short-term contract liability and $<ix:nonFraction unitRef="usd" contextRef="i89a2a0a3262b4bc9b05cb96efb71185e_I20210331" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDcvZnJhZzo5YjFkNTkxZmQzMWQ0NDQ4OTczNDg0ZDFiMDliZGFlNC90ZXh0cmVnaW9uOjliMWQ1OTFmZDMxZDQ0NDg5NzM0ODRkMWIwOWJkYWU0XzkwODc_682a359e-a2f5-4c8e-a1c6-c9527d21a540">17.8</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i9114bf8b8ace4041b525081dc7e30132_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDcvZnJhZzo5YjFkNTkxZmQzMWQ0NDQ4OTczNDg0ZDFiMDliZGFlNC90ZXh0cmVnaW9uOjliMWQ1OTFmZDMxZDQ0NDg5NzM0ODRkMWIwOWJkYWU0XzQzOTgwNDY1NTE1MTQ_95b648c1-0c77-4e4a-a6f7-a6cde64c6dcd">24.2</ix:nonFraction>&#160;million, respectively, as a long-term contract liability, representing deferred revenue associated with this agreement.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, as of March 31, 2021 the Company has recorded $<ix:nonFraction unitRef="usd" contextRef="i89a2a0a3262b4bc9b05cb96efb71185e_I20210331" decimals="-5" name="us-gaap:ContractWithCustomerAssetNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDcvZnJhZzo5YjFkNTkxZmQzMWQ0NDQ4OTczNDg0ZDFiMDliZGFlNC90ZXh0cmVnaW9uOjliMWQ1OTFmZDMxZDQ0NDg5NzM0ODRkMWIwOWJkYWU0XzkyMzM_582e4132-68b1-4aac-92cc-b65b7bf9c96f">1.3</ix:nonFraction> million of contract assets related to incremental costs that would not have been incurred if the Sobi License had not been obtained, of which $<ix:nonFraction unitRef="usd" contextRef="i0274d7d2728b45debefc3a188dc02830_I20210331" decimals="-5" name="us-gaap:ContractWithCustomerAssetNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDcvZnJhZzo5YjFkNTkxZmQzMWQ0NDQ4OTczNDg0ZDFiMDliZGFlNC90ZXh0cmVnaW9uOjliMWQ1OTFmZDMxZDQ0NDg5NzM0ODRkMWIwOWJkYWU0XzkzNzk_85709cba-b190-4e73-b5d4-f45f24539d20">1.0</ix:nonFraction> million is presented in prepaid expenses and other current assets and $<ix:nonFraction unitRef="usd" contextRef="ieb852272fa154e92bcf4a36c0a643304_I20210331" decimals="-5" name="us-gaap:ContractWithCustomerAssetNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDcvZnJhZzo5YjFkNTkxZmQzMWQ0NDQ4OTczNDg0ZDFiMDliZGFlNC90ZXh0cmVnaW9uOjliMWQ1OTFmZDMxZDQ0NDg5NzM0ODRkMWIwOWJkYWU0Xzk0NTM_e0f2cfef-26f1-46a5-b0be-87090a560cb4">0.3</ix:nonFraction> million is presented in other assets in the accompanying unaudited consolidated balance sheets. Amortization of contract assets was less than $<ix:nonFraction unitRef="usd" contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331" decimals="-5" name="us-gaap:CapitalizedContractCostAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDcvZnJhZzo5YjFkNTkxZmQzMWQ0NDQ4OTczNDg0ZDFiMDliZGFlNC90ZXh0cmVnaW9uOjliMWQ1OTFmZDMxZDQ0NDg5NzM0ODRkMWIwOWJkYWU0Xzk1Njk_401cf24c-2b7c-44c8-9ad5-55517f7c2bf7">0.1</ix:nonFraction> million for the three months ended March 31, 2021.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2021 and December 31, 2020, the Company recorded a total outstanding receivable of $<ix:nonFraction unitRef="usd" contextRef="i89a2a0a3262b4bc9b05cb96efb71185e_I20210331" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDcvZnJhZzo5YjFkNTkxZmQzMWQ0NDQ4OTczNDg0ZDFiMDliZGFlNC90ZXh0cmVnaW9uOjliMWQ1OTFmZDMxZDQ0NDg5NzM0ODRkMWIwOWJkYWU0Xzk2Njk_129eb07d-5957-4b28-a98b-26815f51eebb">8.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i9114bf8b8ace4041b525081dc7e30132_I20201231" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDcvZnJhZzo5YjFkNTkxZmQzMWQ0NDQ4OTczNDg0ZDFiMDliZGFlNC90ZXh0cmVnaW9uOjliMWQ1OTFmZDMxZDQ0NDg5NzM0ODRkMWIwOWJkYWU0XzIxOTkwMjMyOTMyNjk_bcac0351-b105-435f-a63d-73cb62381d94">6.9</ix:nonFraction> million, respectively, representing billings for the Phase 3 DISSOLVE program that are subject to reimbursement by Sobi. Revenue of $<ix:nonFraction unitRef="usd" contextRef="i8d2fc88d756d4b67bf9851793506eee3_D20210101-20210331" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDcvZnJhZzo5YjFkNTkxZmQzMWQ0NDQ4OTczNDg0ZDFiMDliZGFlNC90ZXh0cmVnaW9uOjliMWQ1OTFmZDMxZDQ0NDg5NzM0ODRkMWIwOWJkYWU0Xzk3OTE_18780938-3229-4e7e-82b7-ffb8e9433df6">11.1</ix:nonFraction> million related to the Sobi License was recognized during the three months ended March 31, 2021.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Sarepta Therapeutics, Inc.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research License and Option Agreement</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 13, 2020, the Company and Sarepta entered into a Research License and Option Agreement, or the Sarepta Agreement. Pursuant to the Sarepta Agreement, the Company agreed to grant Sarepta a license under the Company&#8217;s intellectual property rights covering the Company&#8217;s antigen-specific biodegradable nanoparticle encapsulating ImmTOR to research and evaluate ImmTOR in combination with Sarepta&#8217;s adeno-associated virus gene therapy technology, or gene editing technology, using viral or non-viral delivery, to treat Duchenne Muscular Dystrophy and certain Limb-Girdle Muscular Dystrophy subtypes, or the Indications. Sarepta will have an option term of <ix:nonNumeric contextRef="i114b99e9c016452483452639f622b436_D20200613-20200613" format="ixt-sec:durmonth" name="selb:LicenseAndOptionAgreementOptionTerm" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDcvZnJhZzo5YjFkNTkxZmQzMWQ0NDQ4OTczNDg0ZDFiMDliZGFlNC90ZXh0cmVnaW9uOjliMWQ1OTFmZDMxZDQ0NDg5NzM0ODRkMWIwOWJkYWU0XzEwNTk1_9bd9352a-07b8-4a21-8cf9-61a77d090a11">24</ix:nonNumeric> months during which it can opt-in to obtain an exclusive license to further develop and commercialize the Product to treat at least one Indication, with a potential to extend the option term for an additional fee. The Company will supply ImmTOR to Sarepta for clinical supply on a cost-plus basis.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sarepta paid a $<ix:nonFraction unitRef="usd" contextRef="i114b99e9c016452483452639f622b436_D20200613-20200613" decimals="INF" format="ixt:numdotdecimal" name="selb:LicenseAndOptionAgreementUpfrontCashPayment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDcvZnJhZzo5YjFkNTkxZmQzMWQ0NDQ4OTczNDg0ZDFiMDliZGFlNC90ZXh0cmVnaW9uOjliMWQ1OTFmZDMxZDQ0NDg5NzM0ODRkMWIwOWJkYWU0XzEwOTA0_a4f47a9d-e388-4c2b-84ba-6c4148d1cfea">2.0</ix:nonFraction> million up-front payment to the Company upon signing of the Sarepta Agreement, and the Company is eligible to receive additional preclinical payments during the option term. If Sarepta opts-in to an exclusive license agreement, the Company could receive&#160;option exercise payments per Indication upon execution of the exclusive license, and the Company would be entitled to significant development and commercial milestone payments and tiered royalties ranging from the mid-to-high single digits based on net sales.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Sarepta Agreement, the Company determined the Sarepta Agreement represents a service arrangement under the scope of ASC 606, with a <ix:nonNumeric contextRef="i114b99e9c016452483452639f622b436_D20200613-20200613" format="ixt-sec:durmonth" name="selb:LicenseAndOptionAgreementOptionTerm" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDcvZnJhZzo5YjFkNTkxZmQzMWQ0NDQ4OTczNDg0ZDFiMDliZGFlNC90ZXh0cmVnaW9uOjliMWQ1OTFmZDMxZDQ0NDg5NzM0ODRkMWIwOWJkYWU0XzExNTYx_9bd9352a-07b8-4a21-8cf9-61a77d090a11">24</ix:nonNumeric> month contract duration. Given the reversion of the rights under the Sarepta Agreement represents a penalty in substance for a termination by Sarepta, the contract term would remain the stated term of the Sarepta Agreement.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined that the Sarepta Agreement and supply obligation including the delivery of the research license, the licensed know-how, the manufactured supply and delivery of materials represent a single promise and performance obligation to be transferred to Sarepta over time due to the nature of the promises in the contract. The delivery of the manufactured supply is the predominant promise within the arrangement, as it is essential to the utility of the licensed intellectual property. As such, consideration in the initial transaction price will be allocated to the single performance obligation based on the contractual price.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In determining the transaction price, the Company concluded the payment associated with all the performance milestones will be fully constrained and only be included in the transaction price when the respective milestone is deemed probable of achievement. Each of these variable consideration items was evaluated under the most likely amount method to determine whether such amounts were probable of occurrence, or whether such amounts should be constrained until they become probable. As part of its evaluation of the constraint, the Company considered numerous factors, including that receipt of such study milestones is outside the control of the Company and probability of success criteria is estimated. As of March 31, 2021 and December 31, 2020, all milestones were constrained. The Company will re-evaluate the transaction price in each reporting period, as uncertain events are resolved. The Company will recognize the revenue associated with the upfront payment and combined single performance obligation utilizing the output method, over the <ix:nonNumeric contextRef="i114b99e9c016452483452639f622b436_D20200613-20200613" format="ixt-sec:durmonth" name="selb:LicenseAndOptionAgreementOptionTerm" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDcvZnJhZzo5YjFkNTkxZmQzMWQ0NDQ4OTczNDg0ZDFiMDliZGFlNC90ZXh0cmVnaW9uOjliMWQ1OTFmZDMxZDQ0NDg5NzM0ODRkMWIwOWJkYWU0XzEzNDUw_9bd9352a-07b8-4a21-8cf9-61a77d090a11">24</ix:nonNumeric> month term as the manufactured supply is delivered to Sarepta.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also determined the option to enter into a future commercial license agreement and extend the term of the option does not represent a material right since it was not priced at an incremental discount. Sarepta may terminate the Sarepta Agreement for any reason upon <ix:nonNumeric contextRef="i114b99e9c016452483452639f622b436_D20200613-20200613" format="ixt-sec:durday" name="selb:LicenseAndOptionAgreementWrittenDayNoticePeriodBeforeCancellation" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDcvZnJhZzo5YjFkNTkxZmQzMWQ0NDQ4OTczNDg0ZDFiMDliZGFlNC90ZXh0cmVnaW9uOjliMWQ1OTFmZDMxZDQ0NDg5NzM0ODRkMWIwOWJkYWU0XzQzOTgwNDY1NTQ4MDM_67a3eadb-66ac-4175-be66-8c0627024c94">30</ix:nonNumeric> days&#8217; written notice to the Company. The Sarepta Agreement contains other customary terms and conditions, including representations and warranties, covenants, termination, and indemnification obligations in favor of each party. During the year ended December 31, 2020, the Company and Sarepta entered into two amendments relating to an </span></div></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i71586e7d2e304f6983634abe9e071791_13">Table of Contents</a></span></div></div><ix:continuation id="iaaac17fadc1946298ee8da41e4c72103" continuedAt="i98bddab8c57743329fe41b073df47146"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">additional feasibility study. During the three months ended March 31, 2021, the Company and Sarepta entered into a third amendment relating to feasibility study research plan. None of the amendments executed through March 31, 2021 had a material impact on deferred revenue or revenue recognition.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At each of March 31, 2021 and December 31, 2020, the Company recorded $<ix:nonFraction unitRef="usd" contextRef="i6ede8ce092334ef1927faf29388e0af6_I20201231" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDcvZnJhZzo5YjFkNTkxZmQzMWQ0NDQ4OTczNDg0ZDFiMDliZGFlNC90ZXh0cmVnaW9uOjliMWQ1OTFmZDMxZDQ0NDg5NzM0ODRkMWIwOWJkYWU0XzE0Mjcx_424823cf-8fe6-47ac-9d0b-6138ac6c2901"><ix:nonFraction unitRef="usd" contextRef="i7b30202348b245c093e55382ba4778e9_I20210331" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDcvZnJhZzo5YjFkNTkxZmQzMWQ0NDQ4OTczNDg0ZDFiMDliZGFlNC90ZXh0cmVnaW9uOjliMWQ1OTFmZDMxZDQ0NDg5NzM0ODRkMWIwOWJkYWU0XzE0Mjcx_da9b672d-66f3-4621-8b58-ccf966484fcc">2.0</ix:nonFraction></ix:nonFraction> million as a short-term contract liability representing deferred revenue associated with this agreement. <ix:nonFraction unitRef="usd" contextRef="ie7b30c0c9db24a54aad1845efeb882c1_D20210101-20210331" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDcvZnJhZzo5YjFkNTkxZmQzMWQ0NDQ4OTczNDg0ZDFiMDliZGFlNC90ZXh0cmVnaW9uOjliMWQ1OTFmZDMxZDQ0NDg5NzM0ODRkMWIwOWJkYWU0XzE0Mzkx_3bb1086c-6e7e-4b7c-b86b-289b6d672c4a"><ix:nonFraction unitRef="usd" contextRef="i17bc05b20a3043b2acb1ee8c2e1badf9_D20200101-20200331" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDcvZnJhZzo5YjFkNTkxZmQzMWQ0NDQ4OTczNDg0ZDFiMDliZGFlNC90ZXh0cmVnaW9uOjliMWQ1OTFmZDMxZDQ0NDg5NzM0ODRkMWIwOWJkYWU0XzE0Mzkx_832ac221-fe46-419d-ab15-81f02f77bc4d">No</ix:nonFraction></ix:nonFraction> revenue related to the Sarepta Agreement was recognized during the three months ended March 31, 2021 and 2020.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Asklepios Biopharmaceutical, Inc.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">License Agreement for Pompe Disease</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 17, 2019, the Company and AskBio entered into a license agreement, or the AskBio License Agreement. Pursuant to the AskBio License Agreement, AskBio has exercised its option to exclusively license the Company&#8217;s intellectual property rights covering the Company&#8217;s ImmTOR platform to research, develop, and commercialize certain AAV gene therapy products utilizing ImmTOR, and targeting the GAA gene, or derivatives thereof, to treat Pompe Disease.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the AskBio License Agreement and ancillary documents, AskBio agreed to pay to the Company upfront fees of an aggregate of $<ix:nonFraction unitRef="usd" contextRef="ia04c0f8c59e54e0780747ca4c1a414d5_D20191217-20191217" decimals="INF" format="ixt:numdotdecimal" name="selb:LicenseAndOptionAgreementUpfrontCashPayment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDcvZnJhZzo5YjFkNTkxZmQzMWQ0NDQ4OTczNDg0ZDFiMDliZGFlNC90ZXh0cmVnaW9uOjliMWQ1OTFmZDMxZDQ0NDg5NzM0ODRkMWIwOWJkYWU0XzE1MzAw_7a999d5d-05ce-42d3-8edd-b4769ae48333">7.0</ix:nonFraction> million. Assuming successful development and commercialization, the Company could receive up to an additional $<ix:nonFraction unitRef="usd" contextRef="ia04c0f8c59e54e0780747ca4c1a414d5_D20191217-20191217" decimals="-5" format="ixt:numdotdecimal" name="selb:LicenseAndOptionAgreementSalesMilestonePaymentsThatMayBeReceived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDcvZnJhZzo5YjFkNTkxZmQzMWQ0NDQ4OTczNDg0ZDFiMDliZGFlNC90ZXh0cmVnaW9uOjliMWQ1OTFmZDMxZDQ0NDg5NzM0ODRkMWIwOWJkYWU0XzE1NDA1_a1f105ae-938c-4c75-b856-46f6c7d09224">237.0</ix:nonFraction> million in development, regulatory, and sales milestone payments. If commercialized, the Company would be eligible to receive tiered royalties on global net sales at percentages ranging from mid-to-high single digits. Under the terms of the agreement, the Company will be eligible to receive these royalties commencing on the first commercial sale of the licensed product until the expiration of the later of (i) <ix:nonNumeric contextRef="ia04c0f8c59e54e0780747ca4c1a414d5_D20191217-20191217" format="ixt-sec:durwordsen" name="selb:EligiblePeriodToReceiveRoyalties" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDcvZnJhZzo5YjFkNTkxZmQzMWQ0NDQ4OTczNDg0ZDFiMDliZGFlNC90ZXh0cmVnaW9uOjliMWQ1OTFmZDMxZDQ0NDg5NzM0ODRkMWIwOWJkYWU0XzE1ODEz_dbad6229-7ba7-4380-bf8c-bbaacc2783be">ten years</ix:nonNumeric> after the first commercial sale and (ii) expiration of the last to expire valid claim on patents covering the licensed product.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the AskBio License Agreement, the Company will supply AskBio with its ImmTOR platform, or the Supply Obligation, and AskBio will be responsible for all preclinical, clinical and commercial manufacture and supply of licensed products (other than ImmTOR) and carry out all other activities related to the research, development, and commercialization of licensed products at its sole expense, including all regulatory activities related thereto.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined that the AskBio License Agreement and Supply Obligation represent a single promise and performance obligation. This is because AskBio cannot derive benefit from the license without the simultaneous transfer of the patent protected ImmTOR supply. Therefore, the License Obligation and Supply Obligation represent the only promise in the arrangement and are combined as a single performance obligation.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In determining the transaction price, the Company concluded that the future development milestones, regulatory milestones, sales milestones, and sales royalties all represent variable consideration. Each of these variable consideration items was evaluated under the most likely amount method to determine whether such amounts were probable of occurrence, or whether such amounts should be constrained until they become probable. As part of its evaluation of the constraint, the Company considered numerous factors, including that receipt of such milestones is outside the control of the Company. Consideration related to sales-based milestones as well as royalties on net sales upon commercialization by AskBio, will be recognized when the related sales occur, as they were determined to relate predominantly to the intellectual property granted to AskBio and, therefore, have also been excluded from the transaction price in accordance with the royalty recognition constraint. As of March 31, 2021 and December&#160;31, 2020, all milestones were constrained. The Company will re-evaluate the transaction price in each reporting period, as uncertain events are resolved, or as other changes in circumstances occur.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total initial transaction price of the contract on the effective date was $<ix:nonFraction unitRef="usd" contextRef="ia04c0f8c59e54e0780747ca4c1a414d5_D20191217-20191217" decimals="INF" format="ixt:numdotdecimal" name="selb:LicenseAndOptionAgreementUpfrontCashPayment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDcvZnJhZzo5YjFkNTkxZmQzMWQ0NDQ4OTczNDg0ZDFiMDliZGFlNC90ZXh0cmVnaW9uOjliMWQ1OTFmZDMxZDQ0NDg5NzM0ODRkMWIwOWJkYWU0XzE4MTM5_109f446f-f82f-4485-ac26-d4177015495d">7.0</ix:nonFraction> million, comprised of a $<ix:nonFraction unitRef="usd" contextRef="ia04c0f8c59e54e0780747ca4c1a414d5_D20191217-20191217" decimals="-5" format="ixt:numdotdecimal" name="selb:LicenseAndOptionAgreementInitialUpFrontCashPayment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDcvZnJhZzo5YjFkNTkxZmQzMWQ0NDQ4OTczNDg0ZDFiMDliZGFlNC90ZXh0cmVnaW9uOjliMWQ1OTFmZDMxZDQ0NDg5NzM0ODRkMWIwOWJkYWU0XzE4MTU4_eabb0863-a8fa-46e3-93a8-1f1c1afd198f">2.0</ix:nonFraction> million initial up-front payment upon agreement of terms, and a $<ix:nonFraction unitRef="usd" contextRef="ia04c0f8c59e54e0780747ca4c1a414d5_D20191217-20191217" decimals="-5" format="ixt:numdotdecimal" name="selb:LicenseAndOptionAgreementExecutionFeePayment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDcvZnJhZzo5YjFkNTkxZmQzMWQ0NDQ4OTczNDg0ZDFiMDliZGFlNC90ZXh0cmVnaW9uOjliMWQ1OTFmZDMxZDQ0NDg5NzM0ODRkMWIwOWJkYWU0XzE4MjE3_33faaa30-22a0-4935-a606-1e7c29fc3234">5.0</ix:nonFraction> million initial up-front execution fee.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At each of March 31, 2021 and December 31, 2020, the Company recorded $<ix:nonFraction unitRef="usd" contextRef="i10b61b699b8047098f9ffd1347f4a2ea_I20210331" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDcvZnJhZzo5YjFkNTkxZmQzMWQ0NDQ4OTczNDg0ZDFiMDliZGFlNC90ZXh0cmVnaW9uOjliMWQ1OTFmZDMxZDQ0NDg5NzM0ODRkMWIwOWJkYWU0XzE4MzA1_6f6fbb2c-0b9c-4ea2-87da-9f88282ad699"><ix:nonFraction unitRef="usd" contextRef="ie2581e0def58480f85a685f932e3297b_I20201231" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDcvZnJhZzo5YjFkNTkxZmQzMWQ0NDQ4OTczNDg0ZDFiMDliZGFlNC90ZXh0cmVnaW9uOjliMWQ1OTFmZDMxZDQ0NDg5NzM0ODRkMWIwOWJkYWU0XzE4MzA1_d297e8f8-f436-4051-9db6-a34fb37c6a7e">1.7</ix:nonFraction></ix:nonFraction> million as short-term and $<ix:nonFraction unitRef="usd" contextRef="ie2581e0def58480f85a685f932e3297b_I20201231" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDcvZnJhZzo5YjFkNTkxZmQzMWQ0NDQ4OTczNDg0ZDFiMDliZGFlNC90ZXh0cmVnaW9uOjliMWQ1OTFmZDMxZDQ0NDg5NzM0ODRkMWIwOWJkYWU0XzE4MzU1_55d528c6-5134-424e-94ad-bd7bd9d35d92"><ix:nonFraction unitRef="usd" contextRef="i10b61b699b8047098f9ffd1347f4a2ea_I20210331" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDcvZnJhZzo5YjFkNTkxZmQzMWQ0NDQ4OTczNDg0ZDFiMDliZGFlNC90ZXh0cmVnaW9uOjliMWQ1OTFmZDMxZDQ0NDg5NzM0ODRkMWIwOWJkYWU0XzE4MzU1_d7c956bf-7400-4945-a8f1-78fe0f2b9b36">5.3</ix:nonFraction></ix:nonFraction> million as a long-term, representing deferred revenue associated with this agreement. Revenue will be recognized over the period in which the particles are delivered. <ix:nonFraction unitRef="usd" contextRef="i9d35ce32fa2b4a2b89239188060f0691_D20210101-20210331" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDcvZnJhZzo5YjFkNTkxZmQzMWQ0NDQ4OTczNDg0ZDFiMDliZGFlNC90ZXh0cmVnaW9uOjliMWQ1OTFmZDMxZDQ0NDg5NzM0ODRkMWIwOWJkYWU0XzE4NTQz_abd2019a-8a5e-4eb1-8ec5-1412bbf7bf47"><ix:nonFraction unitRef="usd" contextRef="i52f04094420841308054f7809f206401_D20200101-20200331" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDcvZnJhZzo5YjFkNTkxZmQzMWQ0NDQ4OTczNDg0ZDFiMDliZGFlNC90ZXh0cmVnaW9uOjliMWQ1OTFmZDMxZDQ0NDg5NzM0ODRkMWIwOWJkYWU0XzE4NTQz_ec063c73-7693-46ed-b861-3ad4a9875375">No</ix:nonFraction></ix:nonFraction> revenue related to the AskBio License Agreement was recognized during the three months ended March 31, 2021 and 2020 as no deliveries were made during the periods.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Spark Therapeutics, Inc.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Spark License Agreement</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The disclosures relating to the Company&#8217;s license and option agreement, or the Spark License Agreement, with Spark pursuant to which the Company and Spark agreed to collaborate on the development of gene therapies for certain targets utilizing the ImmTOR platform reported in the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2020 which was filed with the SEC on March 12, 2021 have not materially changed since the Company filed such report.</span></div></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i71586e7d2e304f6983634abe9e071791_13">Table of Contents</a></span></div></div><ix:continuation id="i98bddab8c57743329fe41b073df47146"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Transaction Price Allocated to Future Performance Obligations</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Remaining performance obligations represent the transaction price of contracts for which work has not been performed (or has been partially performed). As of March 31, 2021, the aggregate amount of the transaction price allocated to remaining performance obligations was $<ix:nonFraction unitRef="usd" contextRef="ied8d945ebce54ed8a4badfed477a64e8_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueRemainingPerformanceObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDcvZnJhZzo5YjFkNTkxZmQzMWQ0NDQ4OTczNDg0ZDFiMDliZGFlNC90ZXh0cmVnaW9uOjliMWQ1OTFmZDMxZDQ0NDg5NzM0ODRkMWIwOWJkYWU0XzM1MzM4_8d51d88c-693d-4dc2-9281-91a5f90c3a37">108.1</ix:nonFraction> million.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contract Balances from Contracts with Customers (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sobi, Sarepta, AskBio, and Spark</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">)</span></div><ix:nonNumeric contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331" name="us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDcvZnJhZzo5YjFkNTkxZmQzMWQ0NDQ4OTczNDg0ZDFiMDliZGFlNC90ZXh0cmVnaW9uOjliMWQ1OTFmZDMxZDQ0NDg5NzM0ODRkMWIwOWJkYWU0XzM1NTYx_564e78a9-0092-4479-893d-320eb1968a75" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents changes in the Company&#8217;s contract liabilities during the three months ended March 31, 2021 (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:29.488%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.517%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.517%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.517%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.521%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">beginning of period</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Deductions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">end of period</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contract liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Deferred revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib56f1adc867e406ca7face50c5da1c9c_I20201231" decimals="-3" format="ixt:numdotdecimal" name="selb:ContractwithCustomerLiabilityDeferredRevenue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDcvZnJhZzo5YjFkNTkxZmQzMWQ0NDQ4OTczNDg0ZDFiMDliZGFlNC90YWJsZTozOTE1Y2FkNzFkYjY0YmNmYTM2YjFlYTAyYWZmZWRkMi90YWJsZXJhbmdlOjM5MTVjYWQ3MWRiNjRiY2ZhMzZiMWVhMDJhZmZlZGQyXzYtMi0xLTEtMA_ef0b918f-a582-4e39-a830-89f85674f06d">110,796</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331" decimals="-3" format="ixt:zerodash" name="selb:ContractwithCustomerLiabilityDeferredRevenueIncreaseFromCashReceipts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDcvZnJhZzo5YjFkNTkxZmQzMWQ0NDQ4OTczNDg0ZDFiMDliZGFlNC90YWJsZTozOTE1Y2FkNzFkYjY0YmNmYTM2YjFlYTAyYWZmZWRkMi90YWJsZXJhbmdlOjM5MTVjYWQ3MWRiNjRiY2ZhMzZiMWVhMDJhZmZlZGQyXzYtNC0xLTEtMA_22062556-b97f-4790-87d4-91cfdf125002">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="selb:ContractwithCustomerLiabilityDeferredRevenueRevenueRecognized" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDcvZnJhZzo5YjFkNTkxZmQzMWQ0NDQ4OTczNDg0ZDFiMDliZGFlNC90YWJsZTozOTE1Y2FkNzFkYjY0YmNmYTM2YjFlYTAyYWZmZWRkMi90YWJsZXJhbmdlOjM5MTVjYWQ3MWRiNjRiY2ZhMzZiMWVhMDJhZmZlZGQyXzYtNi0xLTEtMA_bc4c33c2-471f-4b38-b2ee-105fe31fe03d">2,730</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied8d945ebce54ed8a4badfed477a64e8_I20210331" decimals="-3" format="ixt:numdotdecimal" name="selb:ContractwithCustomerLiabilityDeferredRevenue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDcvZnJhZzo5YjFkNTkxZmQzMWQ0NDQ4OTczNDg0ZDFiMDliZGFlNC90YWJsZTozOTE1Y2FkNzFkYjY0YmNmYTM2YjFlYTAyYWZmZWRkMi90YWJsZXJhbmdlOjM5MTVjYWQ3MWRiNjRiY2ZhMzZiMWVhMDJhZmZlZGQyXzYtOC0xLTEtMA_c1b8ec4e-c9ba-4f1b-bc48-08b2222d7f3d">108,066</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total contract liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib56f1adc867e406ca7face50c5da1c9c_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDcvZnJhZzo5YjFkNTkxZmQzMWQ0NDQ4OTczNDg0ZDFiMDliZGFlNC90YWJsZTozOTE1Y2FkNzFkYjY0YmNmYTM2YjFlYTAyYWZmZWRkMi90YWJsZXJhbmdlOjM5MTVjYWQ3MWRiNjRiY2ZhMzZiMWVhMDJhZmZlZGQyXzctMi0xLTEtMA_57557105-fcb3-4b32-a29e-482ec9e68276">110,796</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331" decimals="-3" format="ixt:zerodash" name="selb:ContractwithCustomerLiabilityIncreaseFromCashReceipts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDcvZnJhZzo5YjFkNTkxZmQzMWQ0NDQ4OTczNDg0ZDFiMDliZGFlNC90YWJsZTozOTE1Y2FkNzFkYjY0YmNmYTM2YjFlYTAyYWZmZWRkMi90YWJsZXJhbmdlOjM5MTVjYWQ3MWRiNjRiY2ZhMzZiMWVhMDJhZmZlZGQyXzctNC0xLTEtMA_80cdb8fe-e46d-46cd-b038-67c0f2b0ade1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDcvZnJhZzo5YjFkNTkxZmQzMWQ0NDQ4OTczNDg0ZDFiMDliZGFlNC90YWJsZTozOTE1Y2FkNzFkYjY0YmNmYTM2YjFlYTAyYWZmZWRkMi90YWJsZXJhbmdlOjM5MTVjYWQ3MWRiNjRiY2ZhMzZiMWVhMDJhZmZlZGQyXzctNi0xLTEtMA_94df0c65-cd96-44dd-bec4-a51c5f4f12a5">2,730</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied8d945ebce54ed8a4badfed477a64e8_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDcvZnJhZzo5YjFkNTkxZmQzMWQ0NDQ4OTczNDg0ZDFiMDliZGFlNC90YWJsZTozOTE1Y2FkNzFkYjY0YmNmYTM2YjFlYTAyYWZmZWRkMi90YWJsZXJhbmdlOjM5MTVjYWQ3MWRiNjRiY2ZhMzZiMWVhMDJhZmZlZGQyXzctOC0xLTEtMA_6904f24d-61c9-4960-9e07-425dcc1bb293">108,066</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div id="i71586e7d2e304f6983634abe9e071791_250"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">13. <ix:nonNumeric contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNTAvZnJhZzo1MDhiODBhMWE0OWY0MDhmOGEzN2ExNTg5YmViZjBkZi90ZXh0cmVnaW9uOjUwOGI4MGExYTQ5ZjQwOGY4YTM3YTE1ODliZWJmMGRmXzQzMg_f9b375c5-00d4-4da0-bc89-bc40273faa46" continuedAt="ibbcedf66b9f540089a954a6a0ad1ca08" escape="true">Related-Party Transactions</ix:nonNumeric></span></div><ix:continuation id="ibbcedf66b9f540089a954a6a0ad1ca08"><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Consulting Services</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company incurred expenses for consulting services provided by its founders totaling less than $<ix:nonFraction unitRef="usd" contextRef="i961e2381798844178d4558010699b490_D20210101-20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNTAvZnJhZzo1MDhiODBhMWE0OWY0MDhmOGEzN2ExNTg5YmViZjBkZi90ZXh0cmVnaW9uOjUwOGI4MGExYTQ5ZjQwOGY4YTM3YTE1ODliZWJmMGRmXzE0NA_3158dd89-c7db-49e9-a83c-3537a5399aec"><ix:nonFraction unitRef="usd" contextRef="i0f7b03d9ffec46e09e274a6faed6a815_D20200101-20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNTAvZnJhZzo1MDhiODBhMWE0OWY0MDhmOGEzN2ExNTg5YmViZjBkZi90ZXh0cmVnaW9uOjUwOGI4MGExYTQ5ZjQwOGY4YTM3YTE1ODliZWJmMGRmXzE0NA_936038d0-a54b-4aaa-b78d-306830405902">0.1</ix:nonFraction></ix:nonFraction>&#160;million during each of the three months ended March 31, 2021 and 2020. The Company entered into consulting agreements with its founders to serve on its Scientific Advisory Board, effective January 1, 2020 to December 31, 2021, under which they will be paid quarterly for their services.</span></div></ix:continuation><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div id="i71586e7d2e304f6983634abe9e071791_253"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">14. <ix:nonNumeric contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331" name="selb:CollaborationAndLicenseAgreementsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNTMvZnJhZzpjODk0YzJjNWNiYjM0NzFkODBjMTE5MTMyNjZmNzdiMC90ZXh0cmVnaW9uOmM4OTRjMmM1Y2JiMzQ3MWQ4MGMxMTkxMzI2NmY3N2IwXzc5Njk_04993236-dbc0-4a1e-8366-80d67b32a4cd" continuedAt="id0e6078aa53f47b381f1c9135e16406d" escape="true">Collaboration Agreements</ix:nonNumeric></span></div><ix:continuation id="id0e6078aa53f47b381f1c9135e16406d" continuedAt="i4a28a59c15524069b84c9537254efab8"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Asklepios Biopharmaceutical, Inc.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Feasibility Study and License Agreement</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2019, the Company entered into a feasibility study and license agreement with AskBio, or the AskBio Collaboration Agreement. Pursuant to the AskBio Collaboration Agreement, the Company and AskBio agreed to license intellectual property rights to each other as part of a collaboration to research, develop, and commercialize certain AAV gene therapy products utilizing the Company&#8217;s ImmTOR platform to enable re-dosing of such AAV gene therapy products to treat serious rare and orphan genetic diseases for which there is a significant unmet medical need.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the AskBio Collaboration Agreement, the Company and AskBio agreed to conduct proof of concept studies to potentially validate the use of ImmTOR in conjunction with AskBio&#8217;s AAV gene therapy, or MMA-101, for the treatment of MMA, to mitigate the formation of neutralizing anti-AAV capsid antibodies, or the POC Studies. If the POC Studies are successful, or the parties otherwise elect to do so, the parties will proceed with a collaboration to pursue the development and commercialization of AAV gene therapy product candidates utilizing ImmTOR for the treatment of certain agreed serious rare and orphan genetic diseases. If the POC Studies fail to demonstrate a proof-of-concept, and the parties do not mutually agree in writing to proceed with the collaboration, the AskBio Collaboration Agreement will expire.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The SEL-399 program combines an empty AAV capsid (EMC-101), which is an AAV capsid containing no transgene, with ImmTOR and is being conducted in partnership with AskBio. Building on the preclinical data the Company has generated showing ImmTOR&#8217;s effect on mitigating or reducing the formation of neutralizing antibodies to AAV gene therapies, the Company has commenced a clinical trial of SEL-399 in healthy adult volunteers in Belgium. The goal of the SEL-399 clinical trial is to demonstrate the appropriate dose of ImmTOR in humans to mitigate the formation of antibodies to AAV capsids used in gene therapies.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company and AskBio will share responsibility for the research, development and commercialization of products developed under this collaboration. The parties will also share research, development, and commercialization costs equally for all collaboration products, but with a right of either party to opt out of certain products, and thereby no longer be required to share costs for such products. Each party will receive a percentage of net profits for each product sold under the collaboration equal to the percentage of shared costs borne by such party in the development of such product. Pursuant to the AskBio Collaboration Agreement, AskBio is responsible for manufacturing the AAV capsids and AAV vectors and the Company is responsible for manufacturing ImmTOR.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The AskBio Collaboration Agreement is considered to be within the scope of ASC 808, as both parties are active participants and exposed to the risks and rewards of the collaborative activity. The Company evaluated the terms of the AskBio </span></div></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i71586e7d2e304f6983634abe9e071791_13">Table of Contents</a></span></div></div><ix:continuation id="i4a28a59c15524069b84c9537254efab8"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Collaboration Agreement and have identified the following promises in the arrangement (1) conducting research and development activities to develop and commercialize products under the collaboration, or the R&amp;D Services, (2) granting a non-exclusive, non-transferable, royalty-free, fully paid up, worldwide license to certain intellectual property of the Company, or the IP Rights, for the purpose of performing the POC Studies, or the Research License, (3) granting an exclusive, nontransferable, worldwide license to the IP Rights for use in certain indications, or the Collaboration License, (4) providing manufactured supply of preclinical and clinical ImmTOR, or the Manufactured Supply, (5) participation on identified steering committees responsible for the oversight of the collaboration, or the JSC Participation, and (6) granting an exclusive option to obtain a license under the IP Rights to research, develop and commercialize Licensed Products. The Company determined that the R&amp;D Services, Research License, Collaboration License, Manufactured Supply, and JSC Participation were not capable of being distinct, and therefore must be combined into a single performance obligation. Therefore, promises (1) through (5) identified above were combined into a single performance obligation. Furthermore, the Company evaluated the Option Agreement and determined that it does not provide AskBio with a material right under ASC 606 as the option was not priced at a discount (see discussion of the option exercise in Note 12). The Company noted that AskBio did not meet the definition of a customer within the scope of ASC 606 for any distinct performance obligations as the Company concluded that such items were not an output of the Company&#8217;s ordinary activities. As such, the Company determined that the entire arrangement would be accounted for within the scope of ASC 808.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with ASC 808, collaboration expenses are recognized within R&amp;D expense and selling, general and administrative expense on the Company&#8217;s condensed consolidated statements of operations. For each of the three months ended March 31, 2021 and 2020, the Company recognized $<ix:nonFraction unitRef="usd" contextRef="i2d6aabf5381c4d8eafad236940060193_D20200101-20200331" decimals="-5" name="us-gaap:OperatingExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNTMvZnJhZzpjODk0YzJjNWNiYjM0NzFkODBjMTE5MTMyNjZmNzdiMC90ZXh0cmVnaW9uOmM4OTRjMmM1Y2JiMzQ3MWQ4MGMxMTkxMzI2NmY3N2IwXzIxOTkwMjMyNjQzNTc_e99b589a-e03f-4d34-9acd-f939dc3263e7">1.2</ix:nonFraction> million of collaboration expense under the AskBio Collaboration Agreement in which actual costs incurred by both parties approximate a <ix:nonFraction unitRef="number" contextRef="i24708847c47a43ca9c76041056178569_D20210101-20210331" decimals="2" name="selb:CollaborativeArrangementCostSharePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNTMvZnJhZzpjODk0YzJjNWNiYjM0NzFkODBjMTE5MTMyNjZmNzdiMC90ZXh0cmVnaW9uOmM4OTRjMmM1Y2JiMzQ3MWQ4MGMxMTkxMzI2NmY3N2IwXzUzODE_f73ffcff-3cda-4a55-a5ad-2a03e9ed0a1f">50</ix:nonFraction>% cost share.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under certain collaborative arrangements, the Company is entitled to reimbursement of certain R&amp;D expense. Activities under collaborative arrangements for which the Company is entitled to reimbursement are considered to be collaborative activities under the scope of ASC 808. For these units of account, the Company does not analogize to ASC 606 or recognize revenue. Rather, the Company analogizes to the guidance in ASC 730, which requires that reimbursements from counterparties be recognized as an offset to the related costs. In accordance with ASC 730, the Company records reimbursement payments received from collaborators as reductions to R&amp;D expense.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Massachusetts Institute of Technology</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2008, the Company entered into an exclusive patent license agreement, or the MIT License, with the Massachusetts Institute of Technology, or MIT, under which the Company received an exclusive royalty-bearing license to utilize patents held by MIT in exchange for upfront consideration and annual license maintenance fees. Such fees are expensed as incurred and have not been material to any period presented.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2020, the Company entered into a Fifth Amendment, or the MIT Amendment, to the MIT License, which is effective as of May 15, 2020. Pursuant to the MIT Amendment, certain of the Company&#8217;s diligence obligations were extended, including a diligence obligation to commence a Phase 3 trial for a licensed product by a specific date in the second quarter of 2021. Additionally, certain of the Company&#8217;s development and regulatory milestones and payments upon achievement of such milestones were adjusted.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2021, and in connection with the execution of the Spark License Agreement, the Company has made contractual payments pursuant to the MIT License totaling $<ix:nonFraction unitRef="usd" contextRef="icd96a5af167244139fa70b4e414d29c8_D20210101-20210331" decimals="INF" format="ixt:numdotdecimal" name="selb:LicenseAndOptionAgreementContractualPaymentsMade" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNTMvZnJhZzpjODk0YzJjNWNiYjM0NzFkODBjMTE5MTMyNjZmNzdiMC90ZXh0cmVnaW9uOmM4OTRjMmM1Y2JiMzQ3MWQ4MGMxMTkxMzI2NmY3N2IwXzcxNzQ_ee32fdd2-fc65-44c2-944e-a5446f5382bc">2.2</ix:nonFraction> million for the sublicense granted to Spark, and $<ix:nonFraction unitRef="usd" contextRef="icd96a5af167244139fa70b4e414d29c8_D20210101-20210331" decimals="-5" format="ixt:numdotdecimal" name="selb:LicenseAndOptionAgreementCalculatedPremiumPaidForEquityInvestmentUnderPurchaseAgreement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNTMvZnJhZzpjODk0YzJjNWNiYjM0NzFkODBjMTE5MTMyNjZmNzdiMC90ZXh0cmVnaW9uOmM4OTRjMmM1Y2JiMzQ3MWQ4MGMxMTkxMzI2NmY3N2IwXzcyMTg_f99f46b8-562a-4617-bd2e-534f240380c1">0.4</ix:nonFraction> million relative to the calculated premium paid by Spark for the equity investments made under the Spark Purchase Agreement. The Company made <ix:nonFraction unitRef="usd" contextRef="iec431b313cb846b2aa7358a0b7afcf53_D20210101-20210331" decimals="INF" format="ixt-sec:numwordsen" name="selb:LicenseAndOptionAgreementContractualPaymentsMade" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNTMvZnJhZzpjODk0YzJjNWNiYjM0NzFkODBjMTE5MTMyNjZmNzdiMC90ZXh0cmVnaW9uOmM4OTRjMmM1Y2JiMzQ3MWQ4MGMxMTkxMzI2NmY3N2IwXzczNTU_509a937e-f58f-4ea8-a710-dde5d6e383f1">no</ix:nonFraction> additional payments during the three months ended March 31, 2021.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Shenyang Sunshine Pharmaceutical Co., Ltd</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2014, the Company entered into a license agreement, or the 3SBio License, with Shenyang Sunshine Pharmaceutical Co., Ltd., or 3SBio. The Company has paid to 3SBio an aggregate of $<ix:nonFraction unitRef="usd" contextRef="ibb68c9bff506451eb919c2f81711b851_I20210331" decimals="-5" format="ixt:numdotdecimal" name="selb:AggregateAmountOfUpfrontAndMilestoneBasedPaymentsPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNTMvZnJhZzpjODk0YzJjNWNiYjM0NzFkODBjMTE5MTMyNjZmNzdiMC90ZXh0cmVnaW9uOmM4OTRjMmM1Y2JiMzQ3MWQ4MGMxMTkxMzI2NmY3N2IwXzc2MzA_b0aea141-edb5-4f3b-a13f-1d6ffbc0cf7b">7.0</ix:nonFraction> million in upfront and milestone-based payments under the 3SBio License as of March 31, 2021. The Company is required to make future payments to 3SBio contingent upon the occurrence of events related to the achievement of clinical and regulatory approval milestones of up to an aggregate of $<ix:nonFraction unitRef="usd" contextRef="i29f55711d46f4ce5a26d9adbfce75977_D20210101-20210331" decimals="-5" name="selb:AggregateAmountForFuturePaymentsUponAchievementOfClinicalAndRegulatoryApprovalMilestonesForProductsContainingImmTORPlatform" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNTMvZnJhZzpjODk0YzJjNWNiYjM0NzFkODBjMTE5MTMyNjZmNzdiMC90ZXh0cmVnaW9uOmM4OTRjMmM1Y2JiMzQ3MWQ4MGMxMTkxMzI2NmY3N2IwXzc5MDQ_4899e2f9-655b-4ed4-9243-9000a3839de5">15.0</ix:nonFraction> million for products containing the Company&#8217;s ImmTOR platform.</span></div></ix:continuation><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div id="i71586e7d2e304f6983634abe9e071791_259"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">15. <ix:nonNumeric contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNTkvZnJhZzpjNWYwMDdlNjRiOTk0YjM5YWNmZTExNjlmMDU3ZTI2ZC90ZXh0cmVnaW9uOmM1ZjAwN2U2NGI5OTRiMzlhY2ZlMTE2OWYwNTdlMjZkXzMxNjg_752b3429-8466-46ee-84f9-d68f80f97ede" continuedAt="i7ff3e82788204ab18e02118b39c8827e" escape="true">Income Taxes</ix:nonNumeric></span></div><ix:continuation id="i7ff3e82788204ab18e02118b39c8827e" continuedAt="i8f30200905b041a3834b517077b1d6e7"><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company provides for income taxes under ASC 740. Under ASC 740, the Company provides deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the Company&#8217;s financial statement carrying amounts and the tax bases of assets and liabilities using enacted tax rates expected to be in effect in the years in which the differences are expected to reverse.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March 31, 2021 and 2020, the Company did not record a current or deferred income tax expense or benefit.</span></div></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i71586e7d2e304f6983634abe9e071791_13">Table of Contents</a></span></div></div><ix:continuation id="i8f30200905b041a3834b517077b1d6e7"><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has provided a full valuation allowance against its net deferred tax assets, as the Company believes that it is more likely than not that the deferred tax assets will not be realized.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Utilization of the net operating loss and research and development credit carryforwards may be subject to a substantial annual limitation under Section 382 and 383 of the Internal Revenue Code due to ownership change limitations that have occurred previously, or that could occur in the future. These ownership changes may limit the amount of net operating loss and research and development credit carryforwards that can be utilized annually to offset future taxable income and tax, respectively. As of December 31, 2020, the Company completed a Section 382 study. The Company has determined that all of the $<ix:nonFraction unitRef="usd" contextRef="ied8d945ebce54ed8a4badfed477a64e8_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNTkvZnJhZzpjNWYwMDdlNjRiOTk0YjM5YWNmZTExNjlmMDU3ZTI2ZC90ZXh0cmVnaW9uOmM1ZjAwN2U2NGI5OTRiMzlhY2ZlMTE2OWYwNTdlMjZkXzQzOTgwNDY1MTkwNTY_d3bf0e90-21df-47f0-ac47-4e1f1d2d6c33">234.5</ix:nonFraction>&#160;million of net operating losses are available in the future, with approximately $<ix:nonFraction unitRef="usd" contextRef="ied8d945ebce54ed8a4badfed477a64e8_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNTkvZnJhZzpjNWYwMDdlNjRiOTk0YjM5YWNmZTExNjlmMDU3ZTI2ZC90ZXh0cmVnaW9uOmM1ZjAwN2U2NGI5OTRiMzlhY2ZlMTE2OWYwNTdlMjZkXzQzOTgwNDY1MTkwNzI_51b10208-9fec-4c5e-a24b-35cbe0bc195f">36.5</ix:nonFraction>&#160;million of that total limited under Section 382 and therefore available for future use through 2028.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company applies ASC 740,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Income Taxes </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to uncertain tax positions. As of March 31, 2021 and December 31, 2020, the Company had <ix:nonFraction unitRef="usd" contextRef="ib56f1adc867e406ca7face50c5da1c9c_I20201231" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:UnrecognizedTaxBenefits" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNTkvZnJhZzpjNWYwMDdlNjRiOTk0YjM5YWNmZTExNjlmMDU3ZTI2ZC90ZXh0cmVnaW9uOmM1ZjAwN2U2NGI5OTRiMzlhY2ZlMTE2OWYwNTdlMjZkXzQzOTgwNDY1MTkwOTA_4ef5b1c5-6588-4e84-89a8-9c504050cc00"><ix:nonFraction unitRef="usd" contextRef="ied8d945ebce54ed8a4badfed477a64e8_I20210331" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:UnrecognizedTaxBenefits" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNTkvZnJhZzpjNWYwMDdlNjRiOTk0YjM5YWNmZTExNjlmMDU3ZTI2ZC90ZXh0cmVnaW9uOmM1ZjAwN2U2NGI5OTRiMzlhY2ZlMTE2OWYwNTdlMjZkXzQzOTgwNDY1MTkwOTA_b2849216-1381-41c6-a736-d904160f5588">no</ix:nonFraction></ix:nonFraction> unrecognized tax benefits or related interest and penalties accrued.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has not, as of yet, conducted a study of its research and development credit carryforwards. This study may result in an adjustment to the Company&#8217;s research and development credit carryforwards; however, until a study is completed, and any adjustment is known, no amounts are being presented as an uncertain tax position.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The statute of limitations for assessment by the United States Internal Revenue Service and Massachusetts tax authorities is open for tax years since inception. The Company files income tax returns in the United States and Massachusetts. There are currently no federal, state or foreign audits in progress.</span></div></ix:continuation><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div id="i71586e7d2e304f6983634abe9e071791_262"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">16. <ix:nonNumeric contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331" name="us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNjIvZnJhZzoxNTkyYmZiZjk1NmI0NTIwOTg4ZDBiYTE4MGYwOGJjYi90ZXh0cmVnaW9uOjE1OTJiZmJmOTU2YjQ1MjA5ODhkMGJhMTgwZjA4YmNiXzY5Mg_0a86f290-43cf-4bbc-9dce-6c39af88bf8c" continuedAt="ic48145714cbf4962a300c75d47793774" escape="true">Defined Contribution Plan</ix:nonNumeric></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ic48145714cbf4962a300c75d47793774">The Company maintains a defined contribution plan, or the 401(k) Plan, under Section&#160;401(k) of the Internal Revenue Code. The 401(k) Plan covers all employees who meet defined minimum age and service requirements and allows participants to defer a portion of their annual compensation on a pretax basis. The 401(k) Plan provides for matching contributions on a portion of participant contributions pursuant to the 401(k) Plan&#8217;s matching formula. All matching contributions vest ratably over <ix:nonNumeric contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331" format="ixt-sec:duryear" name="selb:DefinedContributionPlanEmployersMatchingContributionVestingPeriod" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNjIvZnJhZzoxNTkyYmZiZjk1NmI0NTIwOTg4ZDBiYTE4MGYwOGJjYi90ZXh0cmVnaW9uOjE1OTJiZmJmOTU2YjQ1MjA5ODhkMGJhMTgwZjA4YmNiXzUyNg_4fea169f-f499-4ce8-9f30-1d891f68bd17">4</ix:nonNumeric> years and participant contributions vest immediately. Contributions by the Company totaled less than $<ix:nonFraction unitRef="usd" contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DefinedContributionPlanCostRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNjIvZnJhZzoxNTkyYmZiZjk1NmI0NTIwOTg4ZDBiYTE4MGYwOGJjYi90ZXh0cmVnaW9uOjE1OTJiZmJmOTU2YjQ1MjA5ODhkMGJhMTgwZjA4YmNiXzYxNA_a87c5c22-e7cc-4cc2-a873-e6e439815ec0"><ix:nonFraction unitRef="usd" contextRef="i824a5b33f908426bad016f0eded844db_D20200101-20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DefinedContributionPlanCostRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNjIvZnJhZzoxNTkyYmZiZjk1NmI0NTIwOTg4ZDBiYTE4MGYwOGJjYi90ZXh0cmVnaW9uOjE1OTJiZmJmOTU2YjQ1MjA5ODhkMGJhMTgwZjA4YmNiXzYxNA_e49ac9b9-5fca-4bbc-af50-3d0e8ed33273">0.1</ix:nonFraction></ix:nonFraction> million during each of the three months ended March 31, 2021 and 2020.</ix:continuation></span></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div id="i71586e7d2e304f6983634abe9e071791_265"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">17. <ix:nonNumeric contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNjUvZnJhZzozZGI2NzE2YmVhY2Q0NzMzYWVjNGEwYzRmMTcxN2MxZC90ZXh0cmVnaW9uOjNkYjY3MTZiZWFjZDQ3MzNhZWM0YTBjNGYxNzE3YzFkXzMyMDY_4af10e86-33ba-4741-a349-e9618ae44dd5" continuedAt="i71ca961454674ab8b5a6324693310c1c" escape="true">Commitments and Contingencies</ix:nonNumeric></span></div><ix:continuation id="i71ca961454674ab8b5a6324693310c1c" continuedAt="ic0a90e5a26fd42d3abb1081db84389b6"><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2021, the Company was not a party to any litigation that could have a material adverse effect on the Company&#8217;s business, financial position, results of operations or cash flows.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 4, 2020, a putative stockholder of Selecta filed a stockholder derivative action, purportedly on behalf of Selecta and against certain current and former members of the Company&#8217;s Board of Directors, as well as one affiliated company owned by a current board member, in the Court of Chancery of the State of Delaware, namely Franchi v. Barabe, et al. The complaint alleges that the individual defendants breached their fiduciary duties and committed corporate waste when they authorized a private placement transaction, announced on December 19, 2019, at a price allegedly below fair value. The complaint further alleges that the four defendant directors who participated in the private placement were unjustly enriched in connection with the transaction. On September 25, 2020, the defendants filed a motion to dismiss the lawsuit. On November 6, 2020, the plaintiff filed an amended complaint, and the defendants filed a second motion to dismiss on January 8, 2021. On December 31, 2020, the Company received a litigation demand letter from two other putative stockholders relating to the same private placement transaction. On April 12, 2021, the Court of Chancery in the State of Delaware granted a motion to stay the litigation pending a review by a Special Committee appointed by the Company&#8217;s Board of Directors. At this time, the Company has not accrued a liability for this matter, as any liability has been determined to be either not estimable or not probable.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As permitted under Delaware law, the Company indemnifies its directors for certain events or occurrences while the director is, or was, serving at the Company&#8217;s request in such capacity. The term of the indemnification is for the director&#8217;s lifetime. The maximum potential amount of future payments the Company could be required to make is unlimited; however, the Company has directors&#8217; insurance coverage that limits its exposure and enables it to recover a portion of any future amounts paid. The Company also has indemnification arrangements under certain of its facility leases that require it to indemnify the landlord against certain costs, expenses, fines, suits, claims, demands, liabilities, and actions directly resulting from certain breaches, violations, or non-performance of any covenant or condition of the Company&#8217;s lease. The term of the indemnification is for the term of the related lease agreement. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is unlimited. To date, the Company had not experienced any material losses related to any of its indemnification obligations, and no material claims with respect thereto were outstanding.</span></div></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i71586e7d2e304f6983634abe9e071791_13">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ic0a90e5a26fd42d3abb1081db84389b6">The Company is a party in various other contractual disputes and potential claims arising in the ordinary course of business. The Company does not believe that the resolution of these matters will have a material adverse effect the Company&#8217;s business, financial position, results of operations or cash flows.</ix:continuation></span></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div id="i71586e7d2e304f6983634abe9e071791_271"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18. <ix:nonNumeric contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331" name="us-gaap:SubsequentEventsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNzEvZnJhZzo2OWNhODJhNWMxMzI0MzU4ODdiZDQwOTMxNGQ1MjE3Zi90ZXh0cmVnaW9uOjY5Y2E4MmE1YzEzMjQzNTg4N2JkNDA5MzE0ZDUyMTdmXzQxNg_39d58b4b-2632-4331-8daf-675e8dd76fd7" continuedAt="i0bcc6607ca9f467d90f84aeed7f94acf" escape="true">Subsequent Events</ix:nonNumeric></span></div><ix:continuation id="i0bcc6607ca9f467d90f84aeed7f94acf"><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8220;At-the-Market&#8221; Offerings</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subsequent to March 31, 2021 through May 13, 2021, the Company sold <ix:nonFraction unitRef="shares" contextRef="i69b9f1abf0ba4aac990acd969100a523_D20210401-20210513" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNzEvZnJhZzo2OWNhODJhNWMxMzI0MzU4ODdiZDQwOTMxNGQ1MjE3Zi90ZXh0cmVnaW9uOjY5Y2E4MmE1YzEzMjQzNTg4N2JkNDA5MzE0ZDUyMTdmXzEyNQ_5333cdb4-aa44-4622-9cb3-40010ec98532">206,593</ix:nonFraction> shares of its common stock pursuant to the 2020 Sales Agreement, at an average price of approximately $<ix:nonFraction unitRef="usdPerShare" contextRef="ia74a702495ff411cac561a2aded35226_I20210513" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNzEvZnJhZzo2OWNhODJhNWMxMzI0MzU4ODdiZDQwOTMxNGQ1MjE3Zi90ZXh0cmVnaW9uOjY5Y2E4MmE1YzEzMjQzNTg4N2JkNDA5MzE0ZDUyMTdmXzIzMQ_2546910d-f1e2-479c-907a-1b7de71caa3e">4.51</ix:nonFraction> per share for aggregate net proceeds of $<ix:nonFraction unitRef="usd" contextRef="i69b9f1abf0ba4aac990acd969100a523_D20210401-20210513" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNzEvZnJhZzo2OWNhODJhNWMxMzI0MzU4ODdiZDQwOTMxNGQ1MjE3Zi90ZXh0cmVnaW9uOjY5Y2E4MmE1YzEzMjQzNTg4N2JkNDA5MzE0ZDUyMTdmXzI3NQ_ee8114ca-a940-4db2-9cdf-98a7ef9239b4">0.9</ix:nonFraction> million, after deducting commissions and other transaction costs.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Milestone Event</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 13, 2021, the Company was notified by Sarepta of the achievement of the milestone event related to the completion of a non-clinical study for Duchenne muscular dystrophy and certain limb-girdle muscular dystrophies under the Company&#8217;s Research License and Option Agreement. Under the terms of the Agreement, Sarepta is obligated to pay a non-refundable, non-creditable milestone payment of $<ix:nonFraction unitRef="usd" contextRef="iebf9f6ef11cf4e6e8cfcb2c64010f2ad_D20210413-20210413" decimals="-5" format="ixt:numdotdecimal" name="selb:LicenseAndOptionAgreementMilestonePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNzEvZnJhZzo2OWNhODJhNWMxMzI0MzU4ODdiZDQwOTMxNGQ1MjE3Zi90ZXh0cmVnaW9uOjY5Y2E4MmE1YzEzMjQzNTg4N2JkNDA5MzE0ZDUyMTdmXzQzOTgwNDY1MTM2MDc_d7c403b2-a28a-4c41-afe3-348d0e11a583">3.0</ix:nonFraction>&#160;million to the Company within 60 days of Sarepta&#8217;s receipt of the related invoice from the Company.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The AskBio Collaboration Agreement</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 29, 2021, the Company was notified by AskBio that it intended to opt-out of development of the MMA indication. Consequently, the Company will assume all rights to the MMA program and intends to continue to progress the MMA-101 and ImmTOR combination through clinical development.</span></div></ix:continuation><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span><br/></span></div><div id="i71586e7d2e304f6983634abe9e071791_97"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;2.  Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our unaudited consolidated financial statements and related notes appearing elsewhere in this Quarterly Report and with our audited financial statements and the notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2020, which we filed with the SEC on March 12, 2021. In addition, you should read the &#8220;Risk Factors&#8221; and &#8220;Information Regarding Forward-Looking Statements&#8221; sections of this Quarterly Report and our Annual Report on Form 10-K for the year ended December 31, 2020 for a discussion of important factors that could cause actual results to differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span><br/></span></div><div id="i71586e7d2e304f6983634abe9e071791_100"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a clinical-stage biopharmaceutical company leveraging our ImmTOR</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8482;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> immune tolerance platform with the goals of amplifying the efficacy of biologics, including enabling the re-dosing of life-saving gene therapies, and restoring self-tolerance in autoimmune diseases. Our ImmTOR platform encapsulates rapamycin, also known as sirolimus, an immunomodulator, in biodegradable nanoparticles and is designed to induce antigen-specific immune tolerance.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe ImmTOR has the potential to enhance the efficacy without compromising the safety of biologic therapies, improve product candidates under development, and enable novel therapeutic modalities. We have developed a portfolio of proprietary and collaboration-driven applications of ImmTOR, and we plan to continue to develop proprietary compounds and pursue collaboration-driven development in certain disease areas, which could include strategic collaborations, out-licensing, and in-licensing transactions.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe our ImmTOR platform has a broad range of potential applications.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Enzyme therapies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Enzyme therapies are a class of biologic drugs frequently used to treat rare diseases. Through our analysis of biologic drugs, including in our preclinical studies, we have observed that enzymes are especially prone to causing undesired immune responses. Our product candidate, SEL-212, which is currently in Phase 3 clinical development, includes pegadricase, a pegylated uricase enzyme, which is an example of an immunogenic enzyme for which we are applying ImmTOR with the intention of improving the enzyme&#8217;s efficacy and safety. We are also combining ImmTOR with an immunoglobulin A, or IgA, protease for the treatment of IgA nephropathy. We intend to seek, if appropriate, licenses to other enzymes that we would evaluate in combination with ImmTOR.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Gene therapies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We believe gene therapies have the potential to address key unmet medical needs for many rare genetic diseases, but undesired immune responses to the viral vectors used for gene replacement, augmentation and editing may be restricting their broader use. Through our analysis of genetic diseases, we have identified applications and patient segments that we believe would benefit from our ImmTOR platform. We intend to develop ImmTOR-</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i71586e7d2e304f6983634abe9e071791_13">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">enabled non-immunogenic gene therapy candidates which are designed to be utilized with adeno-associated virus, or AAV, vectors. We believe our product candidates have the potential to increase transgene expression and to prevent undesired immune responses to the vector and transgene product that can occur with the first dose of gene therapy by using our ImmTOR platform. Our initial area of focus is on genetic metabolic diseases but may also include lysosomal storage diseases and genetic muscular diseases. We believe we are the first company to systematically pursue the development of AAV gene therapy product candidates with the goal of enabling repeat administration. We have engaged third parties with experience in gene therapy and rare diseases to support the development of our products. We also have licensed our ImmTOR platform to AskBio, Sarepta, and Spark for certain pre-specified targets.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restoring self-tolerance to auto-antigens. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that ImmTOR has the potential to restore self-tolerance in autoimmune diseases. Our first program in autoimmune diseases is in primary biliary cholangitis, or PBC. PBC has a significant unmet medical need and a well-defined target antigen, known as PDC-E2.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other products and product candidates affected by undesired immune responses. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have generated preclinical data which we believe suggests a broad potential benefit of ImmTOR for immune tolerance. For many biologic drugs, undesired immune responses limit efficacy and cause safety concerns. We intend to strategically out-license ImmTOR for use with other products that are outside our focus to larger biopharmaceutical companies. We believe our ImmTOR platform may also be of interest to biopharmaceutical companies with novel biologic development concepts or product candidates in clinical development that have demonstrated initial efficacy but are experiencing issues with safety or sustained efficacy due to inhibitory ADAs.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our Current Programs</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Amplifying the Efficacy of Biologics: Enzyme therapy &#8211; Chronic Refractory Gout</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SEL-212 is designed to be a monthly treatment for chronic refractory gout, a debilitating rare disease with an unmet medical need. SEL-212 consists of a combination of our ImmTOR platform co-administered with pegadricase. Pegadricase is an investigational recombinant pegylated uricase (urate oxidase), an enzyme not naturally found in humans, and is therefore highly immunogenic. This enzyme is designed to treat patients with symptomatic gout, refractory to standard uric acid lowering treatment, by breaking down the excess uric acid to the more soluble allantoin. In preclinical studies, we observed that ImmTOR, when co-administered with pegadricase, induced antigen-specific immune tolerance to pegadricase and substantially reduced the formation of associated ADAs. Based on our clinical data, we believe that SEL-212 has the potential to control serum uric acid, or SUA levels and mitigate the formation of ADAs in response to the therapeutic enzyme. Additionally, we believe that SEL-212 serves as proof of concept for the ImmTOR platform in ameliorating the unwanted immune response to an immunogenic biologic. SEL-212 has been licensed (except as to Greater China) to Sobi, pursuant to our license and development agreement dated June 11, 2020 with Sobi, or the Sobi License.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and Sobi commenced the Phase 3 DISSOLVE clinical program of SEL-212 in September 2020. The Phase 3 clinical program consists of two double blinded, placebo-controlled trials of SEL-212, DISSOLVE I and DISSOLVE II. Each trial is expected to enroll 105 patients, with 35 patients receiving 0.1 mg/kg of ImmTOR and 0.2 mg/kg of pegadricase, 35 patients receiving 0.15 mg/kg of ImmTOR and 0.2 mg/kg of pegadricase, and 35 patients receiving placebo. DISSOLVE I and DISSOLVE II both have a six-month primary endpoint with a six-month safety extension for DISSOLVE I. The primary endpoint of the DISSOLVE program is the maintenance of SUA levels below 6 mg/dL at six months. Secondary endpoints include tender and swollen joint counts, tophus burden, patient reported outcomes of activity limitation and quality of life and gout flare incidence. Topline data from the Phase 3 DISSOLVE clinical program is expected in the second half of 2022. The Phase 3 DISSOLVE clinical program is being conducted by Selecta and funded by Sobi.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Amplifying the Efficacy of Biologics: Enzyme therapy &#8211; IgA Nephropathy</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The second indication in our enzyme therapy program is IgA nephropathy, an autoimmune kidney disease that occurs when immune complexes of a subclass of antibodies called immunoglobulin A1 (IgA1) accumulates in the kidneys.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2020, we entered into an Option and License Agreement, or the IGAN Agreement, with IGAN Biosciences, Inc., or IGAN. Pursuant to the IGAN Agreement, IGAN has granted us an exclusive license to research, evaluate, and conduct pre-clinical development activities on IGAN&#8217;s proprietary IgA proteases. Previous studies in animal models conducted at independent laboratories demonstrated that IgA protease removed injurious IgA immune complexes from kidneys and reduced inflammation, fibrosis, and hematuria. These results suggest that it is an excellent candidate to potentially decrease the rate of disease progression and possibly even reverse the disease. The barrier to IgA protease commercialization is the bacterial origin of the protease, which makes it immunogenic. Our ImmTOR platform has shown in clinical studies the ability to mitigate the formation of ADAs to immunogenic enzymes, which has been observed with SEL-212. We intend to combine IgA protease with our ImmTOR platform to develop a novel combination product candidate for the treatment of IgA nephropathy and IgA-mediated diseases. We will have an option term of 24 months, during which we can elect to obtain an exclusive license to further develop and commercialize the product candidate to treat all IgA-mediated diseases, including IgA nephropathy, Linear IgA bullous dermatitis, IgA pemphigus, and Henoch-Schonlein purpura (also known as IgA vasculitis).</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i71586e7d2e304f6983634abe9e071791_13">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We plan to file an Investigational New Drug, or IND, application, for this program by the end of 2021.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Amplifying the Efficacy of Biologics: Gene Therapies</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When used in combination with AAV gene therapy vectors, ImmTOR has been observed to inhibit the immune response to the vector and enable successful redosing in mice and non-human primates, or NHPs. Currently, the ability to re-administer systemic AAV gene therapy is limited by the development of neutralizing antibodies. The ability to safely re-dose AAV may help achieve therapeutic benefit in patients who are under-dosed; it may also help restore transgene expression in patients, particularly pediatric patients, who may lose gene expression over time as they grow. In addition, a study conducted in NHPs showed that co-administration of AAV vector and ImmTOR in NHPs enabled higher and more durable transgene expression after the first dose of gene therapy as well as robust inhibition of anti-AAV8 immunoglobulin G, or IgG, and neutralizing antibodies. The observation that co-administration of AAV vector and ImmTOR leads to higher transgene expression demonstrates the potential for dosing lower levels of AAV gene therapies when combined with ImmTOR. Thus, integrating ImmTOR into a gene therapy protocol has the potential to provide a first dose benefit by enhancing liver-directed transgene expression and durability, as well as the potential for enabling re-dosing.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our lead therapeutic gene therapy program is in methylmalonic acidemia, or MMA, an inherited disorder in which the body is unable to process certain proteins and fats (lipids) properly. This program was previously being conducted under our collaboration with AskBio. In April 2021, we were notified by AskBio that it intended to opt-out of development of the MMA indication. The feasibility study and license agreement with AskBio, or AskBio Collaboration Agreement, otherwise remains in effect. Due to a manufacturing issue with the AAV vector we believe is related to a component sourced from a third party, our plans to file an IND for this product candidate, MMA-101, have been delayed to the end of 2021. ImmTOR manufacturing, controlled by us, continues to proceed in accordance with our expectations, and we have not observed any impact to any of our ImmTOR programs. In October and November 2020, we and AskBio received rare pediatric disease designation and orphan drug designation, respectively, from the FDA for MMA-101, for the treatment of MMA due to methylmalonyl-CoA mutase, or MMUT gene mutations.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our proprietary gene therapy product candidate, SEL-313, is being developed to treat ornithine transcarbamylase, or OTC deficiency, and is currently in preclinical development. OTC deficiency is a rare genetic disorder that causes ammonia to accumulate in the blood due to mutations in the OTC gene, which is critical for proper function of the urea cycle. The most severe form of the disorder presents within the first few days of life. Severe symptoms include inability to control body temperature and breathing rate, seizures, coma, developmental delays and intellectual disability. Less severe forms of the disorder are characterized by delirium, erratic behavior, aversion to high protein foods, vomiting and seizures. We expect to file an IND and/or Clinical Trial Application for SEL-313 in 2022.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SEL-399 combines an empty AAV capsid (EMC-101), which is an AAV capsid containing no transgene, with ImmTOR and is being conducted in partnership with AskBio. Building on the preclinical data we have generated showing ImmTOR&#8217;s effect on mitigating or reducing the formation of neutralizing antibodies to AAV gene therapies, we have commenced a clinical trial of SEL-399 in healthy adult volunteers in Belgium. The goal of the SEL-399 clinical trial is to demonstrate the appropriate dose of ImmTOR in humans to mitigate the formation of antibodies to AAV capsids used in gene therapies. An initial control cohort of healthy volunteers received a single dose of EMC-101 in December 2020 and dose escalating cohorts of EMC-101 plus ImmTOR were initiated in February 2021. Topline results are expected in the fourth quarter of 2021.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restoring Self-tolerance in</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Autoimmune Diseases</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our lead autoimmune diseases indication is PBC, a T-cell driven autoimmune disease that causes progressive destruction of the bile ducts. Patients with PBC are in need of a highly targeted, liver-directed approach to treating the root cause of the disorder. We believe PBC has a well-defined target antigen, significant unmet medical need, and is well suited to the application of our ImmTOR immune tolerance platform, as preclinical data suggest that ImmTOR has the potential to enhance the tolerogenic environment in the liver and provide a hepatoprotective benefit. We expect to file an IND for our PBC program in the second half of 2022.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Licenses and Collaborations</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Swedish Orphan Biovitrum</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2020, we announced that we had entered into the Sobi License, pursuant to which we agreed to grant Sobi an exclusive, worldwide (except as to Greater China) license to develop, manufacture and commercialize SEL-212, which is currently in development for the treatment of chronic refractory gout. In September 2020, pursuant to the Sobi License, Sobi paid us a one-time, up-front payment of $75 million. Sobi has also agreed to make milestone payments totaling up to $630 million to us upon the achievement of various development and regulatory milestones and sales thresholds for annual net sales of SEL-212, and tiered royalty payments ranging from the low double digits on the lowest sales tier to the high teens on the highest sales tier.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i71586e7d2e304f6983634abe9e071791_13">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, Sobi purchased an aggregate of 5,416,390 shares of our common stock at $4.6156 for aggregate gross proceeds of $25 million, which we refer to as the Sobi Private Placement. The closing of the Sobi Private Placement occurred on July 31, 2020.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Sobi License, we will have operational oversight of the Phase 3 DISSOLVE clinical program of SEL-212 (DISSOLVE I and DISSOLVE II) that commenced in September 2020, at Sobi&#8217;s expense.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">IGAN Biosciences</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2020, we entered into the IGAN Agreement. Pursuant to the IGAN Agreement, IGAN granted us an exclusive license to research, evaluate, and conduct pre-clinical development activities on IGAN&#8217;s proprietary IgA proteases. We have an option term of 24 months, during which we can elect to obtain an exclusive license to further develop and commercialize the product to treat all IgA-mediated diseases, including IgA nephropathy, Linear IgA bullous dermatitis, IgA pemphigus, and Henoch-Schonlein purpura (also known as IgA vasculitis).</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sarepta Therapeutics</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2020, we entered into a research license and option agreement with Sarepta, or the Sarepta Agreement. Pursuant to the agreement, we granted Sarepta a license to research and evaluate ImmTOR in combination with Sarepta&#8217;s AAV gene therapy or gene editing technology, using viral or non-viral delivery, or the Sarepta Product, to treat Duchenne Muscular Dystrophy and certain Limb-Girdle Muscular Dystrophy subtypes, or the Sarepta Indications. Sarepta will have an option term of 24 months during which it can opt-in to obtain an exclusive license to further develop and commercialize the Sarepta Product to treat at least one Sarepta Indication, with a potential to extend the option term if Sarepta pays an additional fee to us. Sarepta made an up-front payment to us upon signing of the agreement, and we are eligible to receive additional payments under the option term. If Sarepta opts-in to an exclusive license agreement, we could receive option exercise payments per indication, we would be entitled to significant development and commercial milestone payments and tiered royalties ranging from the mid-to-high single digits based on net sales.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">AskBio</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2019, we entered into the AskBio Collaboration Agreement. The initial proof-of-concept study being conducted under this collaboration is in SEL-399, which combines an empty AAV capsid (EMC-101), an AAV capsid containing no transgene, with ImmTOR, and is being conducted in partnership with AskBio. Building on the preclinical data we have generated showing ImmTOR&#8217;s effect on mitigating or reducing the formation of neutralizing antibodies to AAV gene therapies, we have commenced a clinical trial of SEL-399 in healthy adult volunteers in Belgium. The goal of the SEL-399 clinical trial is to demonstrate the appropriate dose of ImmTOR in humans to mitigate the formation of antibodies to AAV capsids used in gene therapies, which currently precludes re-dosing. An initial control cohort of healthy volunteers received a single dose of EMC-101 in December 2020 and dose escalating cohorts of EMC-101 plus ImmTOR were initiated in February 2021. Topline results are expected in the fourth quarter of 2021.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Previously, we and AskBio were developing a gene therapy for MMA, which can cause severe developmental defects and premature death as a result of an accumulation of toxic metabolites. We conducted preclinical studies for this product candidate and will leverage that work within the collaboration. In April 2021, we were notified by AskBio that it intended to opt-out of development of the MMA indication. The AskBio Collaboration Agreement otherwise remains in effect and we intend to continue to develop MMA-101 combined with ImmTOR through clinical development.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, in December 2019, we entered into a License Agreement with AskBio, or the AskBio License Agreement, which provides AskBio with exclusive worldwide rights to our ImmTOR platform to research, develop and commercialize certain AAV-gene therapy products targeting the GAA gene, or derivatives thereof, to treat Pompe Disease.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Spark Therapeutics</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2016, we entered into a license and option agreement with Spark Therapeutics, or the Spark License Agreement, which provides Spark with exclusive worldwide rights to our ImmTOR platform to research, develop and commercialize gene therapies for Factor VIII, an essential blood clotting protein relevant to the treatment of hemophilia A.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impact of COVID-19</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are closely monitoring how COVID-19 is affecting our employees, business, preclinical studies and clinical trials. In response to the spread of COVID-19, we have continued to have our administrative employees work outside of our offices and limited the number of staff in any given research and development laboratory. Disruptions caused by the COVID-19 pandemic may result in difficulties or delays in initiating, enrolling, conducting or completing our planned and ongoing clinical trials, and the incurrence of unforeseen costs as a result of preclinical study or clinical trial delays.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While the COVID-19 pandemic has not had a material impact on our clinical programs as of the date of this Quarterly Report, it could have an impact on our ability to complete the Phase 3 DISSOLVE clinical program of SEL-212, our ability to commence preclinical and clinical studies of our IgA nephropathy, gene therapy, and autoimmune disease programs, and our </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i71586e7d2e304f6983634abe9e071791_13">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ability to obtain supply of both active drug substances and finished drug product as well as efficient execution of the overall supply chain for SEL-212 and our other programs. We have been proactively working with our CRO, clinical sites, and principal investigators to provide patients with more convenient locations to have their SUA measured for the primary endpoint of the study, such as at local laboratories or their homes, as well as alternative sites to receive infusions of study drug. We are also working with our primary and back-up suppliers for SEL-037 (pegadricase) and SEL-110 (ImmTOR) to ensure that we have adequate supply of our materials for both our clinical and preclinical programs. We believe we will have adequate supply of all material necessary to conduct our Phase 3 DISSOLVE clinical program of SEL-212 in chronic refractory gout and to complete our clinical trial for SEL-399 in gene therapy under our collaboration with AskBio.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">At this time, there is significant uncertainty relating to the trajectory of the COVID-19 pandemic and the impact of related responses. Any impact of COVID-19 on the Company&#8217;s business, revenues, results of operations and financial condition will largely depend on future developments, which are highly uncertain and cannot be predicted with confidence, such as the duration of the pandemic, travel restrictions and social distancing in the United States and other countries, business closures or business disruptions, supply chain disruptions, the ultimate impact on financial markets and the global economy, and the effectiveness of actions taken in the United States and other countries to contain and treat the disease.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span><br/></span></div><div id="i71586e7d2e304f6983634abe9e071791_106"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Operations</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, we have financed our operations primarily through public offerings and private placements of our securities, funding received from research grants and collaboration arrangements and our credit facility. We do not have any products approved for sale and have not generated any product sales. All of our revenue to date has been collaboration and grant revenue.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since inception, we have incurred significant operating losses. We incurred net losses of $24.6 million and $19.6 million for the three months ended March 31, 2021 and 2020, respectively. As of March 31, 2021, we had an accumulated deficit of $429.2 million. We expect to continue to incur significant expenses and operating losses for at least the next several years as we:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">continue the research and development of our other product candidates as well as product candidates that we may be developing jointly with collaboration partners;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">seek to enhance our ImmTOR platform and discover and develop additional product candidates;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">seek to enter into collaboration, licensing and other agreements, including, but not limited to research and development, and/or commercialization agreements;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">seek regulatory approvals for any product candidates that successfully complete clinical trials;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">potentially establish a sales, marketing and distribution infrastructure and scales-up external manufacturing capabilities to commercialize any products for which we may obtain regulatory approval;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">maintain, expand and protect our intellectual property portfolio, including through licensing arrangements; and</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">add clinical, scientific, operational, financial and management information systems and personnel, including personnel to support our product development and potential future commercialization efforts and to support our operations as a public company.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Until such time, if ever, as we can generate substantial product revenues, we expect to finance our cash needs through a combination of equity offerings, debt financings, license and collaboration agreements, and research grants. We may be unable to raise capital when needed or on reasonable terms, if at all, which would force us to delay, limit, reduce or terminate our product development or future commercialization efforts. We will need to generate significant revenues to achieve profitability, and we may never do so.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that our existing cash, cash equivalents, marketable securities, and restricted cash as of March 31, 2021 will enable us to fund our operating expenses and capital expenditure requirements into the second quarter of 2023. We have based this estimate on assumptions that may prove to be wrong, and we could use our capital resources sooner than we currently expect.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial information presented below includes the accounts of Selecta Biosciences,&#160;Inc. and our wholly owned subsidiaries, Selecta (RUS) LLC, a Russian limited liability company, or Selecta (RUS), and Selecta Biosciences Security Corporation, a Massachusetts securities corporation. All intercompany accounts and transactions have been eliminated.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Collaboration and grant revenue</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, we have not generated any product sales. Our revenue consists of collaboration and grant revenue, which includes amounts recognized related to upfront and milestone payments for research and development funding under collaboration and license agreements. In addition, we earn revenue under the terms of government contracts or grants, which require the </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i71586e7d2e304f6983634abe9e071791_13">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">performance of certain research and development activities. We expect that any revenue we generate will fluctuate from quarter to quarter because of the timing and amount of fees, research and development reimbursements and other payments from collaborators. We do not expect to generate revenue from product sales for at least the next several years. If we or our collaborators fail to complete the development of our product candidates in a timely manner or fail to obtain regulatory approval as needed, our ability to generate future revenue will be harmed, and will affect the results of our operations and financial position. For a further description of the agreements underlying our collaboration and grant-based revenue, see Notes 2 and 12 to our unaudited consolidated financial statements included elsewhere in this Quarterly Report.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research and development</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our research and development expenses consist of external research and development costs, which we track on a program-by-program basis and primarily include CMO-related costs, fees paid to CROs and internal research and development costs, which are primarily compensation expenses for our research and development employees, lab supplies, analytical testing, allocated overhead costs and other related expenses. Our internal research and development costs are often devoted to expanding our programs and are not necessarily allocable to a specific target.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have incurred a total of $308.3 million in research and development expenses from inception through March 31, 2021, with a majority of the expenses being spent on the development of SEL-212 and a prior nicotine vaccine candidate, and the remainder being spent on our various discovery and preclinical stage product candidate programs and the general expansion of our technology.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expense research and development costs as incurred. Conducting a significant amount of research and development is central to our business model. Product candidates in clinical development generally have higher development costs than those in earlier stages of development, primarily due to the size, duration and cost of clinical trials. The successful development of our clinical and preclinical product candidates is highly uncertain. Clinical development timelines, the probability of success and development costs can differ materially from our expectations. For example, if the FDA or another regulatory authority were to require us to conduct clinical trials beyond those which we currently expect will be required for the completion of clinical development of a product candidate, or if we experience significant delays in enrollment in any of our clinical trials, we could be required to expend significant additional financial resources and time to complete any clinical development.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the components of our research and development expenses during the periods indicated (in thousands):</span></div><div style="margin-bottom:11pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.730%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development expenses (key projects and initiatives):</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">SEL-212</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,724&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,648&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">AskBio collaboration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">813&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">976&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Discovery and preclinical stage product candidate programs, collectively</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">571&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">166&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other internal research and development expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,896&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,934&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total research and development expenses</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13,004&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,724&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 11, 2020, we and Sobi entered into the Sobi License. Pursuant to the Sobi License, clinical trial costs incurred to complete development of SEL-212, including but not limited to costs incurred while conducting and completing the Phase 3 DISSOLVE trials, will be reimbursed by Sobi. These costs, when reimbursed, will be recognized as revenue consistent with the revenue recognition methodology disclosed in Note 12 to our unaudited consolidated financial statements included elsewhere in this Quarterly Report. The reimbursable costs exclude any costs of additional development activities required that are related to ImmTOR and that are unrelated to SEL-212.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">General and administrative</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses consist primarily of salaries and related benefits, including stock-based compensation, related to our executive, finance, business development and support functions. Other general and administrative expenses include facility-related costs not otherwise allocated to research and development expenses, travel expenses for our general and administrative personnel and professional fees for auditing, tax and corporate legal services, including intellectual property-related legal services.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Investment income </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investment income consists primarily of interest income earned on our cash, cash equivalents and marketable securities.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Interest expense</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense consists of interest expense on amounts borrowed under our credit facilities.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i71586e7d2e304f6983634abe9e071791_13">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other income (expense)</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income (expense) was de minimis during the three months ended March 31, 2021 and 2020.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Change in fair value of warrant liabilities</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Common warrants classified as liabilities are remeasured at fair value, utilizing a Black-Scholes valuation methodology, quarterly with the change in fair value recognized as a component of earnings.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Foreign currency transaction gain (loss)</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The functional currency of our Russian subsidiary is the Russian ruble. In addition to holding cash denominated in Russian rubles, our Russian bank accounts also hold cash balances denominated in U.S. dollars to facilitate payments to be settled in U.S. dollars or other currencies. As of March 31, 2021 and December 31, 2020, we maintained cash of $0.3 million in Russian banks, all of which was denominated in U.S. dollars. The amounts denominated in U.S. dollars and used in transacting the day-to-day operations of our Russian subsidiary are subject to transaction gains and losses, which are reported as incurred.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span><br/></span></div><div id="i71586e7d2e304f6983634abe9e071791_109"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Comparison of the Three Months Ended March 31, 2021 and 2020</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a comparison of revenue for the three months ended March 31, 2021 and 2020 (in thousands, except percentages):</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:47.433%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.216%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.216%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.216%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.220%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Increase</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(decrease)</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Collaboration revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,050&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,050&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2021, collaboration revenue was $11.1 million, compared to no revenue recognition in 2020. During the three months ended March 31, 2021 we recognized $11.1 million under the license agreement with Sobi which began in July 2020 resulting from the shipment of clinical supply and the reimbursement of costs incurred for the Phase 3 DISSOLVE clinical program.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research and development</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a comparison of research and development expenses for the three months ended March 31, 2021 and 2020 (in thousands, except percentages):</span></div><div style="margin-bottom:11pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:47.140%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.216%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.826%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.216%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.216%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.220%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Increase</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(decrease)</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13,004&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,724&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,720)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2021</span><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, our research and development expenses decreased by $1.7 million, or 12%, as com</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">pared to 2020. The decrease in cost was primarily the result of less expense incurred for the SEL-212 clinical programs and for the AskBio Collaboration, offset by an increase of expense for discovery and preclinical programs.</span></div><div><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">General and administrative</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a comparison of general and administrative expenses for the three months ended March 31, 2021 and 2020 (in thousands, except percentages):</span></div><div style="margin-bottom:11pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:47.433%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.216%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.216%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.216%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.220%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Increase</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(decrease)</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">General and administrative</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,204&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,098&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,106&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2021, our general and administrative expenses increased by $1.1 million, or 27%, as compared to 2020. The increase in costs was the result of expenses for consulting and professional fees and salaries offset by reduced travel expenses.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i71586e7d2e304f6983634abe9e071791_13">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Investment income</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investment income was less than $0.1 million and $0.2 million for the three months ended March 31, 2021 and 2020, respectively. The decrease reflects reduced interest rates.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Foreign currency transaction gain (loss)</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognized minimal foreign currency gains of less than $0.1 million for each of the three months ended March 31, 2021 and 2020, respectively.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Interest expense</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense was $0.7 million and $0.3 million for the three ended March 31, 2021 and 2020, respectively, representing interest expense and amortization of the carrying costs of our credit facilities.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Change in fair value of warrant liabilities</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March 31, 2021, we recognized a $16.7 million charge for the increase in the fair value of warrant liabilities utilizing the Black-Scholes valuation methodology. The increase in value was primarily driven by an increase in the Company&#8217;s share price (see Note 5). For the three months ended March 31, 2020, we recognized $0.8 million as a change in the fair value of warrant liabilities primarily driven by an increase in the Company&#8217;s share price and volatility, offset by a decreased discount rate this quarter.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other income (expense)</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income (expense) was de minimis for each of the three months ended March 31, 2021 and 2020.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net Loss</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss for the three months ended March 31, 2021 was $24.6 million compared to $19.6 million for the three months ended March&#160;31, 2020.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span><br/></span></div><div id="i71586e7d2e304f6983634abe9e071791_115"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since our inception, we have incurred recurring net losses. We expect that we will continue to incur losses and that such losses will increase for the foreseeable future. We expect that our research and development and general and administrative expenses will continue to increase and, as a result, we will need additional capital to fund our operations, which we may raise through a combination of equity offerings, debt financings, third-party funding and other collaborations and strategic alliances.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">From our inception through March 31, 2021, we have raised an aggregate of $576.9 million to fund our operations, which includes $118.5 million from the sale of preferred stock, $11.1 million in government grant funding, $36.7 million from borrowings under our credit facility, $172.8 million from our collaborations and license agreements, $64.5 million in combined net proceeds from our initial public offering, $149.3 million in combined net proceeds from private placements and follow-on offerings of our common stock, and $24.0 million in aggregate net proceeds from &#8220;at-the-market&#8221; offerings of our common stock.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2021, our cash, cash equivalents, restricted cash, and marketable securities were $149.2 million, of which $1.4 million was restricted cash related to lease commitments and $0.3 million was held by our Russian subsidiary designated solely for use in its operations. Our Russian subsidiary cash is consolidated for financial reporting purposes. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to our existing cash equivalents, we receive research and development funding pursuant to our collaboration agreements. Currently, funding from payments under our collaboration agreements represent our only source of committed external funds.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Indebtedness</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 31, 2020, we entered into a term loan of up to $35.0 million, consisting of term loans in an aggregate amount of $25.0 million, or the Term A Loan, and term loans in an aggregate amount of $10.0 million, or the Term B Loan, governed by a loan and security agreement among us and Oxford Finance LLC, or Oxford, as collateral agent and a lender, and Silicon Valley Bank, or SVB, as a lender. The Term A Loan was funded in full on August 31, 2020, the proceeds of which were used to repay our previously existing 2017 Term Loan and for general corporate and working capital purposes. The Term B Loan will be available, subject to the collateral agent&#8217;s discretion and customary terms and conditions, during the period commencing on the date we have delivered to Oxford and SVB evidence: (i) we or one of the our collaboration partners has enrolled its first patient for a Phase 1 clinical trial evaluating the treatment of MMA, and (ii) we have enrolled the first patient in each of two Phase 3 pivotal trials evaluating SEL-212, or the Second Draw Period Milestone, and ending on the earliest of (i) the date which is 30 days following the date the Second Draw Period Milestone is achieved, (ii) September 30, 2021 (iii) and the occurrence of an event of default, other than an event of default that has been waived in writing by Oxford and SVB in their sole discretion.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i71586e7d2e304f6983634abe9e071791_13">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2020 Term Loan is secured by a lien on substantially all of our assets, other than intellectual property, provided that such lien on substantially all assets includes any rights to payments and proceeds from the sale, licensing or disposition of intellectual property. We also granted Oxford a negative pledge with respect to our intellectual property.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2020 Term Loan contains customary covenants and representations, including but not limited to financial reporting obligations and limitations on dividends, indebtedness, collateral, investments, distributions, transfers, mergers or acquisitions, taxes, corporate changes, deposit accounts, and subsidiaries. The 2020 Term Loan also contains other customary provisions, such as expense reimbursement, non-disclosure obligations as well as indemnification rights.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The events of default under the 2020 Term Loan include, but are not limited to, our failure to make any payments of principal or interest under the 2020 Term Loan or other transaction documents, our breach or default in the performance of any covenant under the 2020 Term Loan or other transaction documents, the occurrence of a material adverse event, making a false or misleading representation or warranty in any material respect under the 2020 Term Loan, our insolvency or bankruptcy, any attachment or judgment on our assets of at least approximately $0.5 million, or the occurrence of any default under any of our agreements or obligations involving indebtedness in excess of approximately $0.5 million. If an event of default occurs, Oxford and SVB are entitled to take enforcement action, including acceleration of amounts due under the 2020 Term Loan. If we raise any additional debt financing, the terms of such additional debt could further restrict our operating and financial flexibility.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a further description of the 2020 Term Loan, see Note 9 to our unaudited consolidated financial statements included elsewhere in this Quarterly Report.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Plan of operations and future funding requirements</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of the date of this Quarterly Report, we have not generated any product sales. We do not know when, or if, we will generate revenue from product sales. We will not generate significant revenue from product sales unless and until we obtain regulatory approval and commercialize one of our current or future product candidates. Our primary uses of capital are, and we expect will continue to be, compensation and related expenses, third-party clinical research and development services, laboratory and related supplies, clinical costs, legal and other regulatory expenses, and general overhead costs. We expect that we will continue to generate losses for the foreseeable future, and we expect the losses to increase as we continue the development of, and seek regulatory approvals for, our product candidates, and begin to commercialize any approved products. We are subject to risks in the development of our products, and we may encounter unforeseen expenses, difficulties, complications, delays and other unknown factors that may adversely affect our business. We expect that we will need substantial additional funding to support our continuing operations.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2021, we had an accumulated deficit of $429.2 million. We anticipate operating losses to continue for the foreseeable future due to, among other things, costs related to research, development of our product candidates, conducting preclinical studies and clinical trials, and our administrative organization. We will require substantial additional financing to fund our operations and to continue to execute our strategy, and we will pursue a range of options to secure additional capital.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exploring various sources of funding such as strategic collaborations and the issuance of equity to fund our operations. If we raise additional funds through strategic collaborations and alliances, which may include existing collaboration partners, we may have to relinquish valuable rights to our technologies or product candidates, or grant licenses on terms that are not favorable to us. To the extent that we raise additional capital through the sale of equity, the ownership interest of our existing shareholders will be diluted and other preferences may be necessary that adversely affect the rights of existing shareholders.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that our existing cash, cash equivalents, marketable securities and restricted cash as of March 31, 2021 will enable us to fund our operating expenses and capital expenditure requirements into the second quarter of 2023. Additionally, while the potential economic impact brought by and the duration of the COVID-19 pandemic may be difficult to assess or predict, the widespread pandemic has resulted in, and may continue to result in, significant disruption of global financial markets, reducing our ability to access capital as and when needed. We have based this estimate on assumptions that may prove to be wrong, and we could use our capital resources sooner than we currently expect.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our future capital requirements will depend on many factors, including:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the number of product candidates that we pursue;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our collaboration agreements remaining in effect, our entering into additional collaboration agreements and our ability to achieve milestones under these agreements;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost of manufacturing clinical supplies of our product candidates;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our headcount growth and associated costs;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the scope, progress, results and costs of preclinical development, laboratory testing and clinical trials for our other product candidates;</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i71586e7d2e304f6983634abe9e071791_13">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs, timing and outcome of regulatory review of our product candidates;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs and timing of future commercialization activities, including manufacturing, marketing, sales and distribution, for any of our product candidates for which we receive marketing approval;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the revenue, if any, received from commercial sales of our product candidates for which we receive marketing approval;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs and timing of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending any intellectual property-related claims;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the effect of competing technological and market developments; and</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the extent to which we acquire or invest in businesses, products and technologies, including entering into licensing or collaboration arrangements for product candidates.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As noted above, the magnitude and duration of the COVID-19 pandemic and its impact on our liquidity future funding requirements is uncertain as of the filing date of this Quarterly Report as this continues to evolve globally.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Summary of Cash Flows</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.052%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:13.958%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.960%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash (used in) and provided by:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating activities</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(12,133)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(11,698)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Investing activities</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(22,445)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(135)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Financing activities</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21,307&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5,370)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Effect of exchange rate changes on cash</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(84)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net change in cash, cash equivalents, and restricted cash</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(13,278)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(17,287)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Operating activities</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash used in operations of $12.1 million for the three months ended March 31, 2021 included approximately $5.2 million of net losses, adjusted for non-cash items, and uses of cash of approximately $6.9 million for changes in operating assets and liabilities.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash used in operations of $11.7 million for the three months ended March 31, 2020 included $16.6 million of net losses, adjusted for non-cash items, partially offset by cash generated from changes in operating assets and liabilities of $5.0 million, principally related to changes in accounts receivable.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investing activities</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in investing activities for the three months ended March 31, 2021 was $22.4 million compared to net cash used in investing activities of $0.1 million in the same period in 2020. The net cash used in investing activities in 2021 was to purchase marketable securities. The net cash used in investing activities in 2020 was to purchase property and equipment.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financing activities</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by financing activities for the three months ended March 31, 2021 was $21.3 million compared to net cash used in financing activities of $5.4 million in the same period in 2020. The net cash provided by financing activities in 2021 was primarily the result of net proceeds from </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">at-the-market</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8221; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">offerings.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net cash used in financing activities in 2020 was the result of $4.4 million of issuance costs paid for December 2019 financing, $2.1 million principal payment on outstanding debt, offset by $1.1 million net proceeds from </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">at-the-market</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8221; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">offerings.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a discussion of recently adopted or issued accounting pronouncements please see Note 2 to our unaudited consolidated financial statements included elsewhere in this Quarterly Report.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Off-Balance Sheet Arrangements</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2021, we did not have any off-balance sheet arrangements as defined in the rules and regulations of the</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities and Exchange Commission.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><div id="i71586e7d2e304f6983634abe9e071791_121"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i71586e7d2e304f6983634abe9e071791_13">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Policies and Use of Estimates</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management&#8217;s discussion and analysis of our financial condition and results of operations is based on our consolidated financial statements, which have been prepared in accordance with U.S. GAAP. The preparation of these consolidated financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements, as well as the reported revenues and expenses incurred during the reporting periods. Our estimates are based on our historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. During the three months ended March 31, 2021, there were no material changes to our critical accounting policies from those described in our Annual Report on Form 10-K for the year ended December 31, 2020.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Emerging Growth Company Status</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Jumpstart Our Business Startups Act of 2012, or the JOBS Act, permits an &#8216;&#8216;emerging growth company&#8217;&#8217; such as us to take advantage of an extended transition period to comply with new or revised accounting standards applicable to public companies until those standards would otherwise apply to private companies. We have irrevocably elected not to avail ourselves of this exemption and, therefore, we will be subject to the same new or revised accounting standards as other public companies that are not emerging growth companies. We will remain an emerging growth company until December 31, 2021, the last day of the fiscal year following the fifth anniversary of the closing of the initial public offering of our common stock. However, if certain events occur prior to December 31, 2021, including if we become a &#8220;large accelerated filer,&#8221; our annual gross revenues exceed $1.07 billion or we issue more than $1.07 billion of non-convertible debt in any three-year period, we will cease to be an emerging growth company prior to December 31, 2021.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Smaller Reporting Company</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We qualify as a &#8220;smaller reporting company&#8221; under the rules of the Securities Act and the Exchange Act. As a result, in addition to the exemptions available to us as an &#8220;emerging growth company,&#8221; we may choose to take advantage of certain scaled disclosure requirements available specifically to smaller reporting companies. Additionally, even if we cease to be an emerging growth company as noted above, as long as we continue to be a smaller reporting company, we may continue to rely on the reduced executive compensation disclosure obligations available to emerging growth companies. We will remain a smaller reporting company until the last day of the fiscal year in which the aggregate market value of our common stock held by non-affiliated persons and entities, or our public float, was less than $250 million as of the last business day of our most recently completed second fiscal quarter, or the last day of the fiscal year in which we have at least $100 million in revenue and at least $700 million in public float as of the last business day of our most recently completed second fiscal quarter.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span><br/></span></div><div id="i71586e7d2e304f6983634abe9e071791_124"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3.  Quantitative and Qualitative Disclosures About Market Risk</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The market risk inherent in our financial instruments and in our financial position represents the potential loss arising from adverse changes in interest rates. As of March 31, 2021 and December 31, 2020, we had cash, cash equivalents, restricted cash and marketable securities of $149.2 million and $140.1 million, respectively, consisting of non-interest and interest-bearing money market accounts. Our primary exposure to market risk is interest rate sensitivity, which is affected by changes in the general level of U.S. interest rates. Due to the short-term and the low risk profile of our money market accounts and marketable securities, and our current plan to hold marketable securities to maturity, an immediate 100 basis point change in interest rates would not have a material effect on the fair market value of our cash equivalents or short-term marketable securities.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we are subject to currency risk for balances held in Russian rubles in our foreign subsidiary. We hold portions of our funds in both U.S. dollars and Russian rubles. The exchange rate between the U.S. dollar and Russian ruble changes from period to period. As of March 31, 2021, we held cash and cash equivalents totaling $0.3 million in Russian banks to support our Russian subsidiary, all of which were denominated in U.S. dollars. We do not hedge against foreign currency risks. We do not believe that inflation and changing prices had a significant impact on our results of operations for any periods presented herein.</span></div><div><span><br/></span></div><div id="i71586e7d2e304f6983634abe9e071791_136"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 4.  Controls and Procedures</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Limitations on effectiveness of controls and procedures</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In designing and evaluating our disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. In addition, the design of disclosure controls and procedures must reflect the fact that there are resource constraints and that management is required to apply judgment in evaluating the benefits of possible controls and procedures relative to their costs.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i71586e7d2e304f6983634abe9e071791_13">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evaluation of disclosure controls and procedures</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated, as of the end of the period covered by this Quarterly Report, the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act). Based on that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective at the reasonable assurance level as of March 31, 2021.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Changes in internal control over financial reporting</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) during the three months ended March 31, 2021 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><div id="i71586e7d2e304f6983634abe9e071791_19"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i71586e7d2e304f6983634abe9e071791_13">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i71586e7d2e304f6983634abe9e071791_13">Contents</a></span></div></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II. OTHER INFORMATION</span></div><div id="i71586e7d2e304f6983634abe9e071791_280"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;1.  Legal Proceedings</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 4, 2020, a putative stockholder of Selecta filed a stockholder derivative action, purportedly on behalf of Selecta and against certain current and former members of the Company&#8217;s Board of Directors, as well as one affiliated company owned by a current board member, in the Court of Chancery of the State of Delaware, namely Franchi v. Barabe, et al. The complaint alleges that the individual defendants breached their fiduciary duties and committed corporate waste when they authorized a private placement transaction, announced on December 19, 2019, at a price allegedly below fair value. The complaint further alleges that the four defendant directors who participated in the private placement were unjustly enriched in connection with the transaction. On September 25, 2020, the defendants filed a motion to dismiss the lawsuit. On November 6, 2020, the plaintiff filed an amended complaint, and the defendants filed a second motion to dismiss on January 8, 2021. On December 31, 2020, we received a litigation demand letter from two other putative stockholders relating to the same private placement transaction. On April 12, 2021, the Court of Chancery in the State of Delaware granted a motion to stay the litigation pending a review by a Special Committee appointed by the Company&#8217;s Board of Directors.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span><br/></span></div><div id="i71586e7d2e304f6983634abe9e071791_28"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1A.  Risk Factors </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our risk factors are disclosed in Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2020. There have been no material changes from the risk factors previously disclosed in such filing.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span><br/></span></div><div id="i71586e7d2e304f6983634abe9e071791_52"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;2.  Unregistered Sales of Equity Securities and Use of Proceeds</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div id="i71586e7d2e304f6983634abe9e071791_55"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;3.  Defaults Upon Senior Securities</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span><br/></span></div><div id="i71586e7d2e304f6983634abe9e071791_58"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;4.  Mine Safety Disclosures</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span><br/></span></div><div id="i71586e7d2e304f6983634abe9e071791_61"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;5.  Other Information</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i71586e7d2e304f6983634abe9e071791_13">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i71586e7d2e304f6983634abe9e071791_13">Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div id="i71586e7d2e304f6983634abe9e071791_64"></div><div style="-sec-extract:summary;margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 6.&#160;&#160;Exhibits</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">    </span></div><div id="i71586e7d2e304f6983634abe9e071791_67"></div><div style="-sec-extract:summary;margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT INDEX</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:12.282%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.105%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.782%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.664%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.135%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.047%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.875%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Incorporated by Reference</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit<br/>Number</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit Description</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Form</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">File No.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Filing<br/>Date</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Filed<br/>Herewith</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1453687/000110465916129891/a16-14002_1ex3d1.htm">3.1</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1453687/000110465916129891/a16-14002_1ex3d1.htm">Restated Certificate of Incorporation of Selecta Biosciences, Inc.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-37798</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6/29/2016</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1453687/000110465916129891/a16-14002_1ex3d2.htm">3.2</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1453687/000110465916129891/a16-14002_1ex3d2.htm">Amended and Restated By-laws of Selecta Biosciences, Inc.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-37798</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6/29/2016</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit101_dircompprogram.htm">10.1</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit101_dircompprogram.htm">Non-Employee Director Compensation</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit101_dircompprogram.htm"> </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit101_dircompprogram.htm">Program</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit311_03312021.htm">31.1</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit311_03312021.htm">Rule 13a-14(a) / 15d-14(a) Certification of Chief Executive Officer</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">* </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit312_03312021.htm">31.2</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit312_03312021.htm">Rule 13a-14(a) / 15d-14(a) Certification of Chief Financial Officer</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">* </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit321_03312021.htm">32.1</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit321_03312021.htm">Section 1350 Certification of Chief Executive Officer</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit322_03312021.htm">32.2</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit322_03312021.htm">Section 1350 Certification of Chief Financial Officer</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.INS</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Instance Document - the Instance Document does not appear in the interactive data file because its XBRL tags are embedded within the Inline XBRL document.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">***</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.SCH</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Schema Document</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">***</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.CAL</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Calculation Linkbase Document</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">***</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.DEF</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Definition Linkbase Document</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">***</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.LAB</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Label Linkbase Document</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">***</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.PRE</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Presentation Linkbase Document</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">***</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">***</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:94.152%"><tr><td style="width:1.0%"></td><td style="width:3.247%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.247%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.206%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Filed herewith.</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furnished herewith.</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">***</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Submitted electronically herewith.</span></td></tr></table></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><div id="i71586e7d2e304f6983634abe9e071791_283"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i71586e7d2e304f6983634abe9e071791_13">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i71586e7d2e304f6983634abe9e071791_13">Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed by the following persons on behalf of the registrant in the capacities and on the dates indicated.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:27.785%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.920%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.152%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:42.743%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">SELECTA BIOSCIENCES, INC.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date: May 13, 2021</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Carsten Brunn, Ph.D.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carsten Brunn, Ph.D.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">President and Chief Executive Officer, and Director</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Principal Executive Officer)</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date: May 13, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Bradford D. Dahms</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bradford D. Dahms</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Chief Financial Officer</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Principal Financial Officer)</span></td></tr></table></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>exhibit101_dircompprogram.htm
<DESCRIPTION>EX-10.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="ic254a7324ae54bdd8e59e21647fc1fe8_1"></div><div style="min-height:54pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:right;text-indent:63pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Exhibit 10.1</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SELECTA BIOSCIENCES, INC.</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NON-EMPLOYEE DIRECTOR COMPENSATION PROGRAM</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Non-employee members of the board of directors (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Board</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) of Selecta Biosciences, Inc. (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) shall receive cash and equity compensation as set forth in this Non-Employee Director Compensation Program (this &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Program</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), as amended by the Board effective March 30, 2021 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;). The cash and equity compensation described in this Program shall be paid or be made, as applicable, automatically and without further action of the Board, to each member of the Board who is not an employee of the Company or any parent or subsidiary of the Company (each, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Non-Employee Director</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) who is entitled to receive such cash or equity compensation, unless such Non-Employee Director declines the receipt of such cash or equity compensation by written notice to the Company. This Program shall remain in effect until it is revised or rescinded by further action of the Board. This Program may be amended, modified or terminated by the Board at any time in its sole discretion. The terms and conditions of this Program shall supersede any prior cash and&#47;or equity compensation arrangements for service as a member of the Board between the Company and any of its Non-Employee Directors. No Non-Employee Director shall have any rights hereunder, except with respect to stock options granted pursuant to the Program. This Program shall become effective on the Effective Date.</font></div><div style="margin-bottom:12pt;padding-left:18pt;padding-right:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">I.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:10.34pt">CASH COMPENSATION</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">A.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:6.34pt;text-decoration:underline">Annual Retainers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Each Non-Employee Director shall receive an annual retainer of $40,000 for service on the Board.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">B.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:7pt;text-decoration:underline">Additional Annual Retainers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. In addition, each Non-Employee Director shall receive the following annual retainers&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;padding-left:9pt">Chairperson of the Board or Lead Independent Director</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. A Non-Employee Director serving as Chairperson of the Board shall receive an additional annual retainer of $30,000 for such service, and a Non-Employee Director serving as Lead Independent Director shall receive an additional annual retainer of $20,000 for such service.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;padding-left:9pt">Audit Committee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. A Non-Employee Director serving as Chairperson of the Audit Committee shall receive an additional annual retainer of $15,000 for such service. A Non-Employee Director serving as a member other than the Chairperson of the Audit Committee shall receive an additional annual retainer of $7,500 for such service.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;padding-left:9pt">Compensation Committee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. A Non-Employee Director serving as Chairperson of the Compensation Committee shall receive an additional annual retainer of $12,000 for such service. A Non-Employee Director serving as a member other than the Chairperson of the Compensation Committee shall receive an additional annual retainer of $6,000 for such service.</font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;padding-left:9pt">Nominating and Corporate Governance Committee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. A Non-Employee Director serving as Chairperson of the Nominating and Corporate Governance Committee shall receive an additional annual retainer of $8,000 for such service. A Non-Employee Director serving as a member other than the Chairperson of the Nominating and Corporate Governance Committee shall receive an additional annual retainer of $4,000 for such service. </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;padding-left:9pt">Science Committee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. A Non-Employee Director serving as Chairperson of the Science Committee shall receive an additional annual retainer of $8,000 for such service. A Non-Employee Director serving as a member other than the Chairperson of the Science Committee shall receive an additional annual retainer of $4,000 for such service.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">C.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:7pt;text-decoration:underline">Payment of Retainers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The annual retainers described in Sections I(A) and I(B) shall be earned on a quarterly basis based on a calendar quarter and shall be paid in cash by the Company in arrears not later than the fifteenth day following the end of each calendar quarter. In the event a Non-Employee Director does not serve as a Non-Employee Director, or in the applicable positions described in Section I(B), for an entire calendar quarter, the retainer paid to such Non-Employee Director shall be prorated for the portion of such calendar quarter actually served as a Non-Employee Director, or in such position, as applicable.</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;padding-left:18pt;padding-right:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">II.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:5.68pt">EQUITY COMPENSATION </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Non-Employee Directors shall be granted the equity awards described below. The awards described below shall be granted under and shall be subject to the terms and provisions of the Company&#8217;s 2016 Incentive Award Plan or any other applicable Company equity incentive plan then-maintained by the Company (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Equity Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) and shall be granted subject to award agreements, including attached exhibits, in substantially the form previously approved by the Board. All applicable terms of the Equity Plan apply to this Program as if fully set forth herein, and all grants of stock options hereby are subject in all respects to the terms of the Equity Plan and the applicable award agreement. For the avoidance of doubt, the share numbers in Sections II(A) and II(B) shall be subject to adjustment as provided in the Equity Plan, including without limitation with respect to any stock dividend, stock split, reverse stock split or other similar event affecting the Company&#8217;s common stock that is effected prior to the Effective Date.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">A.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:6.34pt;text-decoration:underline">Initial Awards</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Each Non-Employee Director who is initially elected or appointed to the Board after the Effective Date shall receive an option to purchase 80,000 shares of the Company&#8217;s common stock on the date of such initial election or appointment. The awards described in this Section II(A) shall be referred to as &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Initial Awards</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.&#8221; No Non-Employee Director shall be granted more than one Initial Award.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">B.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:7pt;text-decoration:underline">Subsequent Awards</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. A Non-Employee Director who (i) has been serving as a Non-Employee Director on the Board for at least six months as of the first business day of any calendar year after the Effective Date (each, a &#8220;Subsequent Award Grant Date&#8221;) and (ii) will continue to serve as a Non-Employee Director immediately following such Subsequent Award Grant Date, shall be automatically granted an option to purchase 40,000 shares of the Company&#8217;s common stock on such Subsequent Award Grant Date, </font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">provided, however that if such Non-Employee Director will serve as Chairperson of the Board as of immediately following such Subsequent Award Grant Date, such Non-Employee Director shall receive an option to purchase 60,000 shares of the Company&#8217;s common stock on such the Subsequent Award Grant Date. The awards described in this Section II(B) shall be referred to as &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Subsequent Awards</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.&#8221; Notwithstanding anything to the contrary in this paragraph, for the calendar year 2021, each Non-Employee Director, including the Chairperson of the Board, as of the Effective Date shall receive a Subsequent Award grant on the Effective Date.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">C.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:7pt;text-decoration:underline">Termination of Employment of Employee Directors</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Members of the Board who are employees of the Company or any parent or subsidiary of the Company who subsequently terminate their employment with the Company and any parent or subsidiary of the Company and remain on the Board will not receive an Initial Award pursuant to Section II(A) above, but to the extent that they are otherwise entitled, will receive, after termination from employment with the Company and any parent or subsidiary of the Company, Subsequent Awards as described in Section II(B) above.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">D.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:6.34pt;text-decoration:underline">Terms of Awards Granted to Non-Employee Directors</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;padding-left:9pt">Exercise Price</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The per share exercise price of each option granted to a Non-Employee Director shall equal the Fair Market Value (as defined in the Equity Plan) of a share of common stock on the date the option is granted. </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;padding-left:9pt">Vesting</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Each Initial Award shall vest and become exercisable in thirty-six (36) substantially equal monthly installments following the date of grant, such that the Initial Award shall be fully vested on the third anniversary of the date of grant, subject to the Non-Employee Director continuing in service as a Non-Employee Director through each such vesting date. Each Subsequent Award shall vest and become exercisable on the first anniversary of the date of grant, subject to the Non-Employee Director continuing in service on the Board as a Non-Employee Director through each such vesting date. Unless the Board otherwise determines, any portion of an Initial Award or Subsequent Award which is unvested or unexercisable at the time of a Non-Employee Director&#8217;s termination of service on the Board as a Non-Employee Director shall be immediately forfeited upon such termination of service and shall not thereafter become vested and exercisable. All of a Non-Employee Director&#8217;s Initial Awards and Subsequent Awards shall vest in full immediately prior to the occurrence of a Change in Control (as defined in the Equity Plan), to the extent outstanding at such time.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;padding-left:9pt">Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The maximum term of each stock option granted to a Non-Employee Director hereunder shall be ten (10) years from the date the option is granted. </font></div><div style="margin-bottom:12pt;padding-left:18pt;padding-right:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">III.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:1.02pt"> COMPENSATION LIMITS</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Notwithstanding anything to the contrary in this Program, all compensation payable under this Program will be subject to any limits on the maximum amount of Non-Employee Director compensation set forth in the Equity Plan, as in effect from time to time.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">* * * * *</font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>3
<FILENAME>exhibit311_03312021.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i6445804d457f44efadb52ac82483101b_1"></div><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:right;text-indent:63pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Exhibit 31.1</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">CERTIFICATIONS</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">I, Carsten Brunn, Ph.D. certify that&#58;</font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.&#160;&#160;&#160;&#160;I have reviewed this Quarterly Report on Form 10-Q of Selecta Biosciences, Inc.&#59;</font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2.&#160;&#160;&#160;&#160;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3.&#160;&#160;&#160;&#160;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4.&#160;&#160;&#160;&#160;The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:10pt;padding-left:72pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:10pt;padding-left:72pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:10pt;padding-left:72pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:10pt;padding-left:72pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and </font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">5.&#160;&#160;&#160;&#160;The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:10pt;padding-left:72pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:10pt;padding-left:72pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:47.948%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.074%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:42.678%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">May 13, 2021</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#47;s&#47; Carsten Brunn, Ph.D.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Carsten Brunn, Ph.D.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">President and Chief Executive Officer, and Director</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">(Principal Executive Officer)</font></td></tr></table></div><div style="height:18pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>4
<FILENAME>exhibit312_03312021.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i328bbb9994db4669abee858d6f483136_1"></div><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:right;text-indent:63pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Exhibit 31.2</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">CERTIFICATIONS</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">I, Bradford D. Dahms, certify that&#58;</font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.&#160;&#160;&#160;&#160;I have reviewed this Quarterly Report on Form 10-Q of Selecta Biosciences, Inc.&#59;</font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2.&#160;&#160;&#160;&#160;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3.&#160;&#160;&#160;&#160;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4.&#160;&#160;&#160;&#160;The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:10pt;padding-left:72pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:10pt;padding-left:72pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:10pt;padding-left:72pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:10pt;padding-left:72pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and </font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">5.&#160;&#160;&#160;&#160;The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:10pt;padding-left:72pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:10pt;padding-left:72pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:44.794%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.084%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.822%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">May 13, 2021</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#47;s&#47; Bradford D. Dahms</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Bradford D. Dahms</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">Chief Financial Officer</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">(Principal Financial and Accounting Officer)</font></td></tr></table></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>5
<FILENAME>exhibit321_03312021.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i4c9d90ca709e4b12b6189d2ea5958e0e_1"></div><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:right;text-indent:63pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Exhibit 32.1</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">18 U.S.C. SECTION 1350,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="text-align:center;text-indent:63pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">I, Carsten Brunn, Ph.D., President and Chief Executive Officer of Selecta Biosciences, Inc. (the &#8220;Company&#8221;), hereby certify, pursuant to 18 U.S.C. &#167;1350, as adopted pursuant to &#167;906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge&#58;</font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.&#160;&#160;&#160;&#160;The Quarterly Report on Form 10-Q of the Company for the period ended March 31, 2021 (the &#8220;Report&#8221;) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended&#59; and</font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2.&#160;&#160;&#160;&#160;The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:47.948%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.074%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:42.678%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">May 13, 2021</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#47;s&#47; Carsten Brunn, Ph.D.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Carsten Brunn, Ph.D.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">President and Chief Executive Officer, and Director</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">(Principal Executive Officer)</font></td></tr></table></div><div><font><br></font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>6
<FILENAME>exhibit322_03312021.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i98808f1c20294926b419e052d1e21e8e_1"></div><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:right;text-indent:63pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Exhibit 32.2</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">18 U.S.C. SECTION 1350,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">I, Bradford D. Dahms, Chief Financial Officer of Selecta Biosciences, Inc. (the &#8220;Company&#8221;), hereby certify, pursuant to 18 U.S.C. &#167;1350, as adopted pursuant to &#167;906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge&#58;</font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.&#160;&#160;&#160;&#160;The Quarterly Report on Form 10-Q of the Company for the period ended March 31, 2021 (the &#8220;Report&#8221;) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended&#59; and</font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2.&#160;&#160;&#160;&#160;The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:50.659%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.738%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:42.303%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">May 13, 2021</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#47;s&#47; Bradford D. Dahms</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Bradford D. Dahms</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">Chief Financial Officer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">(Principal Financial and Accounting Officer)</font></td></tr></table></div><div><font><br></font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>selb-20210331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:f83914de-cdf0-4ece-a0a2-d7db460e8912,g:a84bda62-2062-413b-8a4e-4383ad9edaee-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:selb="http://www.selectabio.com/20210331" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.selectabio.com/20210331">
  <xs:import namespace="http://fasb.org/srt/2020-01-31" schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/country/2020-01-31" schemaLocation="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2020-01-31" schemaLocation="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="selb-20210331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="selb-20210331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="selb-20210331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="selb-20210331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Coverpage" roleURI="http://www.selectabio.com/role/Coverpage">
        <link:definition>0001001 - Document - Cover page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheets" roleURI="http://www.selectabio.com/role/ConsolidatedBalanceSheets">
        <link:definition>1001002 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheetsParenthetical" roleURI="http://www.selectabio.com/role/ConsolidatedBalanceSheetsParenthetical">
        <link:definition>1002003 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofOperationsandComprehensiveLoss" roleURI="http://www.selectabio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss">
        <link:definition>1003004 - Statement - Consolidated Statements of Operations and Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofChangesinStockholdersDeficitEquity" roleURI="http://www.selectabio.com/role/ConsolidatedStatementsofChangesinStockholdersDeficitEquity">
        <link:definition>1004005 - Statement - Consolidated Statements of Changes in Stockholders&#8217; (Deficit) Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofCashFlows" roleURI="http://www.selectabio.com/role/ConsolidatedStatementsofCashFlows">
        <link:definition>1005006 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NatureoftheBusinessandBasisofPresentation" roleURI="http://www.selectabio.com/role/NatureoftheBusinessandBasisofPresentation">
        <link:definition>2101101 - Disclosure - Nature of the Business and Basis of Presentation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NatureoftheBusinessandBasisofPresentationLiquidityDetails" roleURI="http://www.selectabio.com/role/NatureoftheBusinessandBasisofPresentationLiquidityDetails">
        <link:definition>2402401 - Disclosure - Nature of the Business and Basis of Presentation - Liquidity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPolicies" roleURI="http://www.selectabio.com/role/SummaryofSignificantAccountingPolicies">
        <link:definition>2103102 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesPolicies" roleURI="http://www.selectabio.com/role/SummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>2204201 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MarketableSecurities" roleURI="http://www.selectabio.com/role/MarketableSecurities">
        <link:definition>2105103 - Disclosure - Marketable Securities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MarketableSecuritiesTables" roleURI="http://www.selectabio.com/role/MarketableSecuritiesTables">
        <link:definition>2306301 - Disclosure - Marketable Securities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MarketableSecuritiesSummaryofAvailableforSaleMarketableSecuritiesDetails" roleURI="http://www.selectabio.com/role/MarketableSecuritiesSummaryofAvailableforSaleMarketableSecuritiesDetails">
        <link:definition>2407402 - Disclosure - Marketable Securities - Summary of Available-for-Sale Marketable Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MarketableSecuritiesNarrativeDetails" roleURI="http://www.selectabio.com/role/MarketableSecuritiesNarrativeDetails">
        <link:definition>2408403 - Disclosure - Marketable Securities - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShare" roleURI="http://www.selectabio.com/role/NetLossPerShare">
        <link:definition>2109104 - Disclosure - Net Loss Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareTables" roleURI="http://www.selectabio.com/role/NetLossPerShareTables">
        <link:definition>2310302 - Disclosure - Net Loss Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareComputationofBasicandDilutedNetLossPerShareDetails" roleURI="http://www.selectabio.com/role/NetLossPerShareComputationofBasicandDilutedNetLossPerShareDetails">
        <link:definition>2411404 - Disclosure - Net Loss Per Share - Computation of Basic and Diluted Net Loss Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareScheduleofPotentialCommonSharesIssuableUponConversionofWarrantsDetails" roleURI="http://www.selectabio.com/role/NetLossPerShareScheduleofPotentialCommonSharesIssuableUponConversionofWarrantsDetails">
        <link:definition>2412405 - Disclosure - Net Loss Per Share - Schedule of Potential Common Shares Issuable Upon Conversion of Warrants (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurements" roleURI="http://www.selectabio.com/role/FairValueMeasurements">
        <link:definition>2113105 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsTables" roleURI="http://www.selectabio.com/role/FairValueMeasurementsTables">
        <link:definition>2314303 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsSummaryofAssetsMeasuredatFairValueonaRecurringBasisDetails" roleURI="http://www.selectabio.com/role/FairValueMeasurementsSummaryofAssetsMeasuredatFairValueonaRecurringBasisDetails">
        <link:definition>2415406 - Disclosure - Fair Value Measurements - Summary of Assets Measured at Fair Value on a Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsAssumptionsusedtorecordthefairvalueofthewarrantsDetails" roleURI="http://www.selectabio.com/role/FairValueMeasurementsAssumptionsusedtorecordthefairvalueofthewarrantsDetails">
        <link:definition>2416407 - Disclosure - Fair Value Measurements - Assumptions used to record the fair value of the warrants (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsChangeinthewarrantliabilitiesDetails" roleURI="http://www.selectabio.com/role/FairValueMeasurementsChangeinthewarrantliabilitiesDetails">
        <link:definition>2417408 - Disclosure - Fair Value Measurements - Change in the warrant liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsNarrativeDetails" roleURI="http://www.selectabio.com/role/FairValueMeasurementsNarrativeDetails">
        <link:definition>2418409 - Disclosure - Fair Value Measurements - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsScheduleofCashandCashEquivalentsDetails" roleURI="http://www.selectabio.com/role/FairValueMeasurementsScheduleofCashandCashEquivalentsDetails">
        <link:definition>2419410 - Disclosure - Fair Value Measurements - Schedule of Cash and Cash Equivalents (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipment" roleURI="http://www.selectabio.com/role/PropertyandEquipment">
        <link:definition>2120106 - Disclosure - Property and Equipment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentTables" roleURI="http://www.selectabio.com/role/PropertyandEquipmentTables">
        <link:definition>2321304 - Disclosure - Property and Equipment (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentScheduleofPropertyandEquipmentDetails" roleURI="http://www.selectabio.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails">
        <link:definition>2422411 - Disclosure - Property and Equipment - Schedule of Property and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentNarrativeDetails" roleURI="http://www.selectabio.com/role/PropertyandEquipmentNarrativeDetails">
        <link:definition>2423412 - Disclosure - Property and Equipment - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedExpenses" roleURI="http://www.selectabio.com/role/AccruedExpenses">
        <link:definition>2124107 - Disclosure - Accrued Expenses</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedExpensesTables" roleURI="http://www.selectabio.com/role/AccruedExpensesTables">
        <link:definition>2325305 - Disclosure - Accrued Expenses (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedExpensesDetails" roleURI="http://www.selectabio.com/role/AccruedExpensesDetails">
        <link:definition>2426413 - Disclosure - Accrued Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Leases" roleURI="http://www.selectabio.com/role/Leases">
        <link:definition>2127108 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesTables" roleURI="http://www.selectabio.com/role/LeasesTables">
        <link:definition>2328306 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesNarrativeDetails" roleURI="http://www.selectabio.com/role/LeasesNarrativeDetails">
        <link:definition>2429414 - Disclosure - Leases - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesComponentsofOperatingLeasesDetails" roleURI="http://www.selectabio.com/role/LeasesComponentsofOperatingLeasesDetails">
        <link:definition>2430415 - Disclosure - Leases - Components of Operating Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesComponentsofleasecostsDetails" roleURI="http://www.selectabio.com/role/LeasesComponentsofleasecostsDetails">
        <link:definition>2431416 - Disclosure - Leases - Components of lease costs (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesOperatingLeaseLiabilityMaturityDetails" roleURI="http://www.selectabio.com/role/LeasesOperatingLeaseLiabilityMaturityDetails">
        <link:definition>2432417 - Disclosure - Leases - Operating Lease, Liability, Maturity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesOperatingLeaseLiabilityMaturityDetails_1" roleURI="http://www.selectabio.com/role/LeasesOperatingLeaseLiabilityMaturityDetails_1">
        <link:definition>2432417 - Disclosure - Leases - Operating Lease, Liability, Maturity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesOtherInformationDetails" roleURI="http://www.selectabio.com/role/LeasesOtherInformationDetails">
        <link:definition>2433418 - Disclosure - Leases - Other Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesLeaseTermandDiscountRateDetails" roleURI="http://www.selectabio.com/role/LeasesLeaseTermandDiscountRateDetails">
        <link:definition>2434419 - Disclosure - Leases - Lease Term and Discount Rate (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Debt" roleURI="http://www.selectabio.com/role/Debt">
        <link:definition>2135109 - Disclosure - Debt</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtTables" roleURI="http://www.selectabio.com/role/DebtTables">
        <link:definition>2336307 - Disclosure - Debt (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtTermLoansNarrativeDetails" roleURI="http://www.selectabio.com/role/DebtTermLoansNarrativeDetails">
        <link:definition>2437420 - Disclosure - Debt - Term Loans (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtScheduleofFutureMinimumPaymentsontheTermLoansDetails" roleURI="http://www.selectabio.com/role/DebtScheduleofFutureMinimumPaymentsontheTermLoansDetails">
        <link:definition>2438421 - Disclosure - Debt - Schedule of Future Minimum Payments on the Term Loans (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Equity" roleURI="http://www.selectabio.com/role/Equity">
        <link:definition>2139110 - Disclosure - Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityTables" roleURI="http://www.selectabio.com/role/EquityTables">
        <link:definition>2340308 - Disclosure - Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityNarrativeDetails" roleURI="http://www.selectabio.com/role/EquityNarrativeDetails">
        <link:definition>2441422 - Disclosure - Equity - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityWarrantyActivityDetails" roleURI="http://www.selectabio.com/role/EquityWarrantyActivityDetails">
        <link:definition>2442423 - Disclosure - Equity - Warranty Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityScheduleofAuthorizedSharesofCommonStockforFutureIssuanceDetails" roleURI="http://www.selectabio.com/role/EquityScheduleofAuthorizedSharesofCommonStockforFutureIssuanceDetails">
        <link:definition>2443424 - Disclosure - Equity - Schedule of Authorized Shares of Common Stock for Future Issuance (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockIncentivePlans" roleURI="http://www.selectabio.com/role/StockIncentivePlans">
        <link:definition>2144111 - Disclosure - Stock Incentive Plans</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockIncentivePlansTables" roleURI="http://www.selectabio.com/role/StockIncentivePlansTables">
        <link:definition>2345309 - Disclosure - Stock Incentive Plans (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockIncentivePlansNarrativeDetails" roleURI="http://www.selectabio.com/role/StockIncentivePlansNarrativeDetails">
        <link:definition>2446425 - Disclosure - Stock Incentive Plans - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockIncentivePlansScheduleofStockBasedCompensationExpenseRelatedtoStockOptionsandRestrictedCommonStockDetails" roleURI="http://www.selectabio.com/role/StockIncentivePlansScheduleofStockBasedCompensationExpenseRelatedtoStockOptionsandRestrictedCommonStockDetails">
        <link:definition>2447426 - Disclosure - Stock Incentive Plans - Schedule of Stock-Based Compensation Expense Related to Stock Options and Restricted Common Stock (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockIncentivePlansScheduleofAssumptionsDetails" roleURI="http://www.selectabio.com/role/StockIncentivePlansScheduleofAssumptionsDetails">
        <link:definition>2448427 - Disclosure - Stock Incentive Plans - Schedule of Assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockIncentivePlansSummaryofOptionsActivityDetails" roleURI="http://www.selectabio.com/role/StockIncentivePlansSummaryofOptionsActivityDetails">
        <link:definition>2449428 - Disclosure - Stock Incentive Plans - Summary of Options Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockIncentivePlansRestrictedStockUnitsDetails" roleURI="http://www.selectabio.com/role/StockIncentivePlansRestrictedStockUnitsDetails">
        <link:definition>2450429 - Disclosure - Stock Incentive Plans - Restricted Stock Units (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockIncentivePlansEmployeeStockPurchasePlanNarrativeDetails" roleURI="http://www.selectabio.com/role/StockIncentivePlansEmployeeStockPurchasePlanNarrativeDetails">
        <link:definition>2451430 - Disclosure - Stock Incentive Plans - Employee Stock Purchase Plan (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueArrangements" roleURI="http://www.selectabio.com/role/RevenueArrangements">
        <link:definition>2152112 - Disclosure - Revenue Arrangements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueArrangementsTables" roleURI="http://www.selectabio.com/role/RevenueArrangementsTables">
        <link:definition>2353310 - Disclosure - Revenue Arrangements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueArrangementsNarrativeDetails" roleURI="http://www.selectabio.com/role/RevenueArrangementsNarrativeDetails">
        <link:definition>2454431 - Disclosure - Revenue Arrangements - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueArrangementsScheduleofChangesinContractLiabilitiesDetails" roleURI="http://www.selectabio.com/role/RevenueArrangementsScheduleofChangesinContractLiabilitiesDetails">
        <link:definition>2455432 - Disclosure - Revenue Arrangements - Schedule of Changes in Contract Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactions" roleURI="http://www.selectabio.com/role/RelatedPartyTransactions">
        <link:definition>2156113 - Disclosure - Related-Party Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactionsNarrativeDetails" roleURI="http://www.selectabio.com/role/RelatedPartyTransactionsNarrativeDetails">
        <link:definition>2457433 - Disclosure - Related-Party Transactions - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreements" roleURI="http://www.selectabio.com/role/CollaborationAgreements">
        <link:definition>2158114 - Disclosure - Collaboration Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreementsAskBioNarrativeDetails" roleURI="http://www.selectabio.com/role/CollaborationAgreementsAskBioNarrativeDetails">
        <link:definition>2459434 - Disclosure - Collaboration Agreements - AskBio (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreementsMITNarrativeDetails" roleURI="http://www.selectabio.com/role/CollaborationAgreementsMITNarrativeDetails">
        <link:definition>2460435 - Disclosure - Collaboration Agreements - MIT (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreementsShenyangSunshinePharmaceuticalCoLtdNarrativeDetails" roleURI="http://www.selectabio.com/role/CollaborationAgreementsShenyangSunshinePharmaceuticalCoLtdNarrativeDetails">
        <link:definition>2461436 - Disclosure - Collaboration Agreements - Shenyang Sunshine Pharmaceutical Co., Ltd (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.selectabio.com/role/IncomeTaxes">
        <link:definition>2162115 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesNarrativeDetails" roleURI="http://www.selectabio.com/role/IncomeTaxesNarrativeDetails">
        <link:definition>2463437 - Disclosure - Income Taxes - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DefinedContributionPlan" roleURI="http://www.selectabio.com/role/DefinedContributionPlan">
        <link:definition>2164116 - Disclosure - Defined Contribution Plan</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DefinedContributionPlanNarrativeDetails" roleURI="http://www.selectabio.com/role/DefinedContributionPlanNarrativeDetails">
        <link:definition>2465438 - Disclosure - Defined Contribution Plan - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://www.selectabio.com/role/CommitmentsandContingencies">
        <link:definition>2166117 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEvents" roleURI="http://www.selectabio.com/role/SubsequentEvents">
        <link:definition>2167118 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEventsDetails" roleURI="http://www.selectabio.com/role/SubsequentEventsDetails">
        <link:definition>2468439 - Disclosure - Subsequent Events (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="selb_SareptaTherapeuticsInc.Member" abstract="true" name="SareptaTherapeuticsInc.Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="selb_LesseeComponentsOfOperatingLeaseTableTextBlock" abstract="false" name="LesseeComponentsOfOperatingLeaseTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="selb_ClassOfWarrantOrRightExpirationPeriod" abstract="false" name="ClassOfWarrantOrRightExpirationPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="selb_EmployeeStockPurchasePlan2016Member" abstract="false" name="EmployeeStockPurchasePlan2016Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="selb_RevenueNumberOfPerformanceObligations" abstract="false" name="RevenueNumberOfPerformanceObligations" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="selb_VotesPerShareofCommonStock" abstract="false" name="VotesPerShareofCommonStock" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="selb_LicenseAndOptionAgreementWrittenDayNoticePeriodBeforeCancellation" abstract="false" name="LicenseAndOptionAgreementWrittenDayNoticePeriodBeforeCancellation" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="selb_August2020ShelfRegistrationStatementMember" abstract="true" name="August2020ShelfRegistrationStatementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="selb_LicenseAgreementForPompeDiseaseMember" abstract="true" name="LicenseAgreementForPompeDiseaseMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="selb_A2017PIPEMember" abstract="true" name="A2017PIPEMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="selb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValueAbstract" abstract="true" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValueAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="selb_AccruedAuditFeesCurrent" abstract="false" name="AccruedAuditFeesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="selb_CommonWarrantMember" abstract="true" name="CommonWarrantMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="selb_ChangeInContractWithCustomerLiabilityRollForward" abstract="true" name="ChangeInContractWithCustomerLiabilityRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="selb_AccruedCollaborationandLicensing" abstract="false" name="AccruedCollaborationandLicensing" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="selb_TermALoansMember" abstract="true" name="TermALoansMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="selb_EmploymentInducementIncentiveAwardPlanMember" abstract="true" name="EmploymentInducementIncentiveAwardPlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="selb_A2008Plan2016PlanAnd2018InducementIncentiveAwardPlanMember" abstract="true" name="A2008Plan2016PlanAnd2018InducementIncentiveAwardPlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="selb_LicenseAndOptionAgreementExecutionFeePayment" abstract="false" name="LicenseAndOptionAgreementExecutionFeePayment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="selb_ResearchAndDevelopmentMember" abstract="true" name="ResearchAndDevelopmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="selb_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedOutstandingWeightedAverageRemainingContractualTerm" abstract="false" name="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedOutstandingWeightedAverageRemainingContractualTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="selb_LicenseAndOptionAgreementUpfrontCashPayment" abstract="false" name="LicenseAndOptionAgreementUpfrontCashPayment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="selb_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReservedForIssuanceWeightedAverageGrantDateFairValue" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReservedForIssuanceWeightedAverageGrantDateFairValue" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:perShareItemType"/>
  <xs:element id="selb_EquityOfferingCostsInAccruedLiabilities" abstract="false" name="EquityOfferingCostsInAccruedLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="selb_RestrictedStockUnitsUnvestedMember" abstract="true" name="RestrictedStockUnitsUnvestedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="selb_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedOutstandingIntrinsicValue" abstract="false" name="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedOutstandingIntrinsicValue" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="selb_LicenseAndOptionAgreementMilestonePayments" abstract="false" name="LicenseAndOptionAgreementMilestonePayments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="selb_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReservedForIssuance" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReservedForIssuance" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="selb_LicenseAndOptionAgreementContractualPaymentsMade" abstract="false" name="LicenseAndOptionAgreementContractualPaymentsMade" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="selb_DebtInstrumentAdditionalAccruedInterestInTheEventOfDefault" abstract="false" name="DebtInstrumentAdditionalAccruedInterestInTheEventOfDefault" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="selb_LicenseAndOptionAgreementSalesMilestonePaymentsThatMayBeReceived" abstract="false" name="LicenseAndOptionAgreementSalesMilestonePaymentsThatMayBeReceived" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="selb_RestrictedStockUnitsRSUsReservedForIssuanceMember" abstract="true" name="RestrictedStockUnitsRSUsReservedForIssuanceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="selb_ClassOfWarrantOrRightNumberOfWarrantsExercised" abstract="false" name="ClassOfWarrantOrRightNumberOfWarrantsExercised" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="selb_AccruedInterestCurrent" abstract="false" name="AccruedInterestCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="selb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract" abstract="true" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="selb_DebtInstrumentInterestPortion" abstract="false" name="DebtInstrumentInterestPortion" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="selb_ContractwithCustomerLiabilityIncreaseFromCashReceipts" abstract="false" name="ContractwithCustomerLiabilityIncreaseFromCashReceipts" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="selb_AskBioLicenseMember" abstract="true" name="AskBioLicenseMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="selb_LockUpFromClosingTerm" abstract="false" name="LockUpFromClosingTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="selb_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" abstract="false" name="LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="selb_CollaborativeArrangementCostSharePercentage" abstract="false" name="CollaborativeArrangementCostSharePercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="selb_ExclusivePatentLicenseAgreementWithMassachusettsInstituteOfTechnologyMember" abstract="false" name="ExclusivePatentLicenseAgreementWithMassachusettsInstituteOfTechnologyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="selb_LicenseAndOptionAgreementDevelopmentMilestone" abstract="false" name="LicenseAndOptionAgreementDevelopmentMilestone" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="selb_WarrantIssued" abstract="false" name="WarrantIssued" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="selb_StockIncentivePlan2016Member" abstract="false" name="StockIncentivePlan2016Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="selb_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageFairValue" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageFairValue" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:perShareItemType"/>
  <xs:element id="selb_A2017TermLoansMember" abstract="true" name="A2017TermLoansMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="selb_FounderMember" abstract="false" name="FounderMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="selb_LicenseAndOptionAgreementCalculatedPremiumPaidForEquityInvestmentUnderPurchaseAgreement" abstract="false" name="LicenseAndOptionAgreementCalculatedPremiumPaidForEquityInvestmentUnderPurchaseAgreement" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="selb_ShareBasedGoodsAndNonEmployeeServicesTransactionCompensationNotYetRecognizedStockOptions" abstract="false" name="ShareBasedGoodsAndNonEmployeeServicesTransactionCompensationNotYetRecognizedStockOptions" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="selb_DefinedContributionPlanEmployersMatchingContributionVestingPeriod" abstract="false" name="DefinedContributionPlanEmployersMatchingContributionVestingPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="selb_NonEmployeeStockOptionMember" abstract="true" name="NonEmployeeStockOptionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="selb_AtTheMarketOfferingMember" abstract="true" name="AtTheMarketOfferingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="selb_DecemberTwoThousandNineteenFinancingMember" abstract="true" name="DecemberTwoThousandNineteenFinancingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="selb_LaboratoryEquipmentMember" abstract="false" name="LaboratoryEquipmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="selb_AggregateAmountForFuturePaymentsUponAchievementOfClinicalAndRegulatoryApprovalMilestonesForProductsContainingImmTORPlatform" abstract="false" name="AggregateAmountForFuturePaymentsUponAchievementOfClinicalAndRegulatoryApprovalMilestonesForProductsContainingImmTORPlatform" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="selb_LeaseArrangementAxis" abstract="true" name="LeaseArrangementAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="selb_DebtInstrumentPrepaymentFeePercentage" abstract="false" name="DebtInstrumentPrepaymentFeePercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="selb_LicenseAgreementWithShenyangSunshinePharmaceuticalCompanyLimitedMember" abstract="false" name="LicenseAgreementWithShenyangSunshinePharmaceuticalCompanyLimitedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="selb_ContractwithCustomerLiabilityDeferredRevenue" abstract="false" name="ContractwithCustomerLiabilityDeferredRevenue" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="selb_LicenseAndOptionAgreementInitialUpFrontCashPayment" abstract="false" name="LicenseAndOptionAgreementInitialUpFrontCashPayment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="selb_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndDebtSecuritiesAvailableForSale" abstract="false" name="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndDebtSecuritiesAvailableForSale" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="selb_AggregateAmountOfUpfrontAndMilestoneBasedPaymentsPaid" abstract="false" name="AggregateAmountOfUpfrontAndMilestoneBasedPaymentsPaid" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="selb_ContractwithCustomerLiabilityDeferredRevenueRevenueRecognized" abstract="false" name="ContractwithCustomerLiabilityDeferredRevenueRevenueRecognized" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="selb_CollaborationAndLicenseAgreementsTextBlock" abstract="false" name="CollaborationAndLicenseAgreementsTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="selb_AccruedResearchAndDevelopmentCostsCurrent" abstract="false" name="AccruedResearchAndDevelopmentCostsCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="selb_ContractwithCustomerLiabilityDeferredRevenueIncreaseFromCashReceipts" abstract="false" name="ContractwithCustomerLiabilityDeferredRevenueIncreaseFromCashReceipts" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="selb_LeaseArrangementDomain" abstract="true" name="LeaseArrangementDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="selb_AccruedPatentFeesCurrent" abstract="false" name="AccruedPatentFeesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="selb_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAwardedInPeriod" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAwardedInPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="selb_TermBLoansMember" abstract="true" name="TermBLoansMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="selb_PreFundedWarrantMember" abstract="true" name="PreFundedWarrantMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="selb_EligiblePeriodToReceiveRoyalties" abstract="false" name="EligiblePeriodToReceiveRoyalties" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="selb_LicenseAndOptionAgreementOptionTerm" abstract="false" name="LicenseAndOptionAgreementOptionTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="selb_A2020SaleAgreementAtTheMarketOfferingMember" abstract="true" name="A2020SaleAgreementAtTheMarketOfferingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="selb_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantIncreaseDecrease" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantIncreaseDecrease" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="selb_ShareBasedCompensationArrangementByShareBasedPaymentAwardForfeituresRate" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardForfeituresRate" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="selb_SOBIPurchaseAgreementMember" abstract="true" name="SOBIPurchaseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="selb_DebtInstrumentDefaultBankruptcyOrInsolvencyValueOfTriggeringAcceleratedRedemption" abstract="false" name="DebtInstrumentDefaultBankruptcyOrInsolvencyValueOfTriggeringAcceleratedRedemption" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="selb_A2020TermLoansMember" abstract="true" name="A2020TermLoansMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="selb_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsVestedWeightedAverageExercisePrice" abstract="false" name="SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsVestedWeightedAverageExercisePrice" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:perShareItemType"/>
  <xs:element id="selb_A65GroveStreetWatertownMAMember" abstract="true" name="A65GroveStreetWatertownMAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="selb_SaleofStockPercentageOfTenDayVolumeWeightedAveragePriceOfCommonStock" abstract="false" name="SaleofStockPercentageOfTenDayVolumeWeightedAveragePriceOfCommonStock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>8
<FILENAME>selb-20210331_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:f83914de-cdf0-4ece-a0a2-d7db460e8912,g:a84bda62-2062-413b-8a4e-4383ad9edaee-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.selectabio.com/role/Coverpage" xlink:type="simple" xlink:href="selb-20210331.xsd#Coverpage"/>
  <link:calculationLink xlink:role="http://www.selectabio.com/role/Coverpage" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.selectabio.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="selb-20210331.xsd#ConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://www.selectabio.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_44d97aa5-cee7-48aa-80da-b9565a494c66" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_2a72b9dc-194b-49a3-96f2-16d8fa7128cf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_44d97aa5-cee7-48aa-80da-b9565a494c66" xlink:to="loc_us-gaap_LiabilitiesCurrent_2a72b9dc-194b-49a3-96f2-16d8fa7128cf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermLoansPayable_b50db973-e007-4d42-aef1-8bb1977c2fc0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermLoansPayable"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_44d97aa5-cee7-48aa-80da-b9565a494c66" xlink:to="loc_us-gaap_LongTermLoansPayable_b50db973-e007-4d42-aef1-8bb1977c2fc0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_5d7096f8-0960-4d93-b43f-bc823eaa7622" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_44d97aa5-cee7-48aa-80da-b9565a494c66" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_5d7096f8-0960-4d93-b43f-bc823eaa7622" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_46f2b0fe-71b0-4f09-bf3a-c6e1ba7b699c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_44d97aa5-cee7-48aa-80da-b9565a494c66" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_46f2b0fe-71b0-4f09-bf3a-c6e1ba7b699c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding_20e6e11d-ce7f-478e-b498-1bb1c4fc777a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_44d97aa5-cee7-48aa-80da-b9565a494c66" xlink:to="loc_us-gaap_WarrantsAndRightsOutstanding_20e6e11d-ce7f-478e-b498-1bb1c4fc777a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_dde10c28-4bdc-4758-be9a-072e99e50e53" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_152e8274-93e6-4f7e-9ca3-edbf014fadcb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_dde10c28-4bdc-4758-be9a-072e99e50e53" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_152e8274-93e6-4f7e-9ca3-edbf014fadcb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_6f9ae1ed-70be-4543-a98d-0471eac4b0c6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_dde10c28-4bdc-4758-be9a-072e99e50e53" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_6f9ae1ed-70be-4543-a98d-0471eac4b0c6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_54190fb6-89c8-4297-b798-e44bd30cf632" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_dde10c28-4bdc-4758-be9a-072e99e50e53" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_54190fb6-89c8-4297-b798-e44bd30cf632" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_01caf4ec-1f48-42bf-99b6-41850780dfdf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_dde10c28-4bdc-4758-be9a-072e99e50e53" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_01caf4ec-1f48-42bf-99b6-41850780dfdf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_ebf2e5d7-6685-4c93-8b83-3fecb054ae53" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_19e325d9-8203-46fa-ba90-3399b5fdf19e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_ebf2e5d7-6685-4c93-8b83-3fecb054ae53" xlink:to="loc_us-gaap_AccountsPayableCurrent_19e325d9-8203-46fa-ba90-3399b5fdf19e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_8372df18-e670-4cf2-b2e5-9d34c8225124" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_ebf2e5d7-6685-4c93-8b83-3fecb054ae53" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_8372df18-e670-4cf2-b2e5-9d34c8225124" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansPayableCurrent_28d75468-fd1c-4e74-abfb-f2fb49b9236f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LoansPayableCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_ebf2e5d7-6685-4c93-8b83-3fecb054ae53" xlink:to="loc_us-gaap_LoansPayableCurrent_28d75468-fd1c-4e74-abfb-f2fb49b9236f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_65f5f303-132c-40b3-a4cb-c12399bbcd4f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_ebf2e5d7-6685-4c93-8b83-3fecb054ae53" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_65f5f303-132c-40b3-a4cb-c12399bbcd4f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_0c3b6264-de42-4c21-aae7-e9bf880fa8fd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_ebf2e5d7-6685-4c93-8b83-3fecb054ae53" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_0c3b6264-de42-4c21-aae7-e9bf880fa8fd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_a99bda0e-f342-42bb-b977-7ce9a7f922fc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_38f833c2-0461-42bd-8ff4-ef35c57cd17a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_a99bda0e-f342-42bb-b977-7ce9a7f922fc" xlink:to="loc_us-gaap_PreferredStockValue_38f833c2-0461-42bd-8ff4-ef35c57cd17a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_b8acd2c1-f78e-4c1b-b63e-48f4f8c2ec0e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_a99bda0e-f342-42bb-b977-7ce9a7f922fc" xlink:to="loc_us-gaap_CommonStockValue_b8acd2c1-f78e-4c1b-b63e-48f4f8c2ec0e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_662e2cfb-18de-414a-82fd-87505dc3c9f2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_a99bda0e-f342-42bb-b977-7ce9a7f922fc" xlink:to="loc_us-gaap_AdditionalPaidInCapital_662e2cfb-18de-414a-82fd-87505dc3c9f2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_e2d7cc5f-d056-42fd-849c-fddbaa2c0f43" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_a99bda0e-f342-42bb-b977-7ce9a7f922fc" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_e2d7cc5f-d056-42fd-849c-fddbaa2c0f43" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_89caf945-b8e6-41ae-bbc8-0e1f272e833b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_a99bda0e-f342-42bb-b977-7ce9a7f922fc" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_89caf945-b8e6-41ae-bbc8-0e1f272e833b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_84b3d47b-a657-4f6b-9748-bc779fec4fb3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_f399afd8-4012-466e-854b-41aac086c032" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_84b3d47b-a657-4f6b-9748-bc779fec4fb3" xlink:to="loc_us-gaap_Liabilities_f399afd8-4012-466e-854b-41aac086c032" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_186b29b4-8731-4100-bd70-c01e714782b5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_84b3d47b-a657-4f6b-9748-bc779fec4fb3" xlink:to="loc_us-gaap_StockholdersEquity_186b29b4-8731-4100-bd70-c01e714782b5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_479b86bd-f1a4-4203-9520-c93e39d29e40" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_84b3d47b-a657-4f6b-9748-bc779fec4fb3" xlink:to="loc_us-gaap_CommitmentsAndContingencies_479b86bd-f1a4-4203-9520-c93e39d29e40" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_ea427681-a56a-445a-b6b1-ae6c632bfe19" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_44d5fe49-8e9b-4c28-b8d1-c10aad0ff184" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_ea427681-a56a-445a-b6b1-ae6c632bfe19" xlink:to="loc_us-gaap_AssetsCurrent_44d5fe49-8e9b-4c28-b8d1-c10aad0ff184" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_aa4bcbd6-0f81-40ec-b14e-57edf9075b8b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_ea427681-a56a-445a-b6b1-ae6c632bfe19" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_aa4bcbd6-0f81-40ec-b14e-57edf9075b8b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_931e51e0-c537-4ece-8725-848aa806072b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_ea427681-a56a-445a-b6b1-ae6c632bfe19" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_931e51e0-c537-4ece-8725-848aa806072b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_ed3df720-22b3-4e6e-877d-7a3200ecd688" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_ea427681-a56a-445a-b6b1-ae6c632bfe19" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_ed3df720-22b3-4e6e-877d-7a3200ecd688" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssets_72280a6d-c672-4466-af2b-574fb75ca408" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssets"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_ea427681-a56a-445a-b6b1-ae6c632bfe19" xlink:to="loc_us-gaap_OtherAssets_72280a6d-c672-4466-af2b-574fb75ca408" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.selectabio.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="selb-20210331.xsd#ConsolidatedBalanceSheetsParenthetical"/>
  <link:calculationLink xlink:role="http://www.selectabio.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.selectabio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="simple" xlink:href="selb-20210331.xsd#ConsolidatedStatementsofOperationsandComprehensiveLoss"/>
  <link:calculationLink xlink:role="http://www.selectabio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_440c3a5d-9b35-473a-9f84-69be6ecf82da" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_92883a08-2b0b-46cc-be8e-93dfb2219680" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_440c3a5d-9b35-473a-9f84-69be6ecf82da" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_92883a08-2b0b-46cc-be8e-93dfb2219680" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_0311434a-cf78-41d5-9315-14c60f116a0c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_440c3a5d-9b35-473a-9f84-69be6ecf82da" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_0311434a-cf78-41d5-9315-14c60f116a0c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_91205bbe-6bfe-4354-be21-c01e81d0bd3e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_fb958c4b-d30d-4a09-9757-41c3ce07eaf6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_91205bbe-6bfe-4354-be21-c01e81d0bd3e" xlink:to="loc_us-gaap_OperatingIncomeLoss_fb958c4b-d30d-4a09-9757-41c3ce07eaf6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNet_5c8f67f9-9313-4488-96c0-d85a247aad43" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_91205bbe-6bfe-4354-be21-c01e81d0bd3e" xlink:to="loc_us-gaap_InvestmentIncomeNet_5c8f67f9-9313-4488-96c0-d85a247aad43" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_683fc880-dc7b-47ce-80ab-9abae651463b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_91205bbe-6bfe-4354-be21-c01e81d0bd3e" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_683fc880-dc7b-47ce-80ab-9abae651463b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_a59587e1-a5fd-47c3-a522-34edecf1d966" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_91205bbe-6bfe-4354-be21-c01e81d0bd3e" xlink:to="loc_us-gaap_InterestExpense_a59587e1-a5fd-47c3-a522-34edecf1d966" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_a53f02ac-4075-4312-821e-3fc9bb564289" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_91205bbe-6bfe-4354-be21-c01e81d0bd3e" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_a53f02ac-4075-4312-821e-3fc9bb564289" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_2264b092-b93f-4bef-bd71-be01988ea3b6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_91205bbe-6bfe-4354-be21-c01e81d0bd3e" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_2264b092-b93f-4bef-bd71-be01988ea3b6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_c3a4a00f-2d88-4952-853a-9e5405a4c7d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_4c876a1b-512a-4599-8f6c-f1302e9cfb3d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_c3a4a00f-2d88-4952-853a-9e5405a4c7d5" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_4c876a1b-512a-4599-8f6c-f1302e9cfb3d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_d4083d58-a0c7-4801-8dd1-3f3269d0ce7d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_c3a4a00f-2d88-4952-853a-9e5405a4c7d5" xlink:to="loc_us-gaap_OperatingExpenses_d4083d58-a0c7-4801-8dd1-3f3269d0ce7d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_571f50aa-a298-4780-b3f0-957f0d9e9424" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_b88059f8-7e93-414c-bad4-022e48e7b4ce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_571f50aa-a298-4780-b3f0-957f0d9e9424" xlink:to="loc_us-gaap_NetIncomeLoss_b88059f8-7e93-414c-bad4-022e48e7b4ce" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_6d987ccc-c3c2-43c2-b33d-9c7f89c7c7cc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_571f50aa-a298-4780-b3f0-957f0d9e9424" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_6d987ccc-c3c2-43c2-b33d-9c7f89c7c7cc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_c3ca82a9-e1a1-4904-b0d1-5e4566db1773" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_571f50aa-a298-4780-b3f0-957f0d9e9424" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_c3ca82a9-e1a1-4904-b0d1-5e4566db1773" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.selectabio.com/role/ConsolidatedStatementsofChangesinStockholdersDeficitEquity" xlink:type="simple" xlink:href="selb-20210331.xsd#ConsolidatedStatementsofChangesinStockholdersDeficitEquity"/>
  <link:calculationLink xlink:role="http://www.selectabio.com/role/ConsolidatedStatementsofChangesinStockholdersDeficitEquity" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.selectabio.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="selb-20210331.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://www.selectabio.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_41f4407b-cccb-4b2d-88fc-8fc3ba34e645" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_987923bf-05fd-4ae7-8cd3-7cc6333201c9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_41f4407b-cccb-4b2d-88fc-8fc3ba34e645" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_987923bf-05fd-4ae7-8cd3-7cc6333201c9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_d343dc7f-b98c-46ab-a5a8-fe5f75eee3ae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_41f4407b-cccb-4b2d-88fc-8fc3ba34e645" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_d343dc7f-b98c-46ab-a5a8-fe5f75eee3ae" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfFinancingCosts_ce860e9a-97fc-487e-8823-4480868cae10" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfFinancingCosts"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_41f4407b-cccb-4b2d-88fc-8fc3ba34e645" xlink:to="loc_us-gaap_PaymentsOfFinancingCosts_ce860e9a-97fc-487e-8823-4480868cae10" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_e910a57e-80bc-4c55-a749-9305acf74161" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_41f4407b-cccb-4b2d-88fc-8fc3ba34e645" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_e910a57e-80bc-4c55-a749-9305acf74161" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_d9ee09f7-1782-491f-b018-a177eccdc480" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_41f4407b-cccb-4b2d-88fc-8fc3ba34e645" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_d9ee09f7-1782-491f-b018-a177eccdc480" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockPlans_c59f88b0-cf82-478d-a641-ce6fc9c5094a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockPlans"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_41f4407b-cccb-4b2d-88fc-8fc3ba34e645" xlink:to="loc_us-gaap_ProceedsFromStockPlans_c59f88b0-cf82-478d-a641-ce6fc9c5094a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_6d54b048-7169-452d-921f-5a00b1fe8b01" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_7d62bce0-b93a-46fd-8fd8-b25f92bf9a6b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_6d54b048-7169-452d-921f-5a00b1fe8b01" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_7d62bce0-b93a-46fd-8fd8-b25f92bf9a6b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_8a6c521e-7d38-49ae-8ba0-e6a22a201325" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_6d54b048-7169-452d-921f-5a00b1fe8b01" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_8a6c521e-7d38-49ae-8ba0-e6a22a201325" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3b4bc326-8568-49d0-82fb-5b2f32082865" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_dd8f6eec-a9a2-471e-aad2-2c5e366c493d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3b4bc326-8568-49d0-82fb-5b2f32082865" xlink:to="loc_us-gaap_NetIncomeLoss_dd8f6eec-a9a2-471e-aad2-2c5e366c493d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherDepreciationAndAmortization_50f0aaf8-be67-4cac-9974-c546c6c70055" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherDepreciationAndAmortization"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3b4bc326-8568-49d0-82fb-5b2f32082865" xlink:to="loc_us-gaap_OtherDepreciationAndAmortization_50f0aaf8-be67-4cac-9974-c546c6c70055" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_f148952f-1de6-4648-8a1e-3755b6c9903c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3b4bc326-8568-49d0-82fb-5b2f32082865" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_f148952f-1de6-4648-8a1e-3755b6c9903c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_ac41016b-1da0-45ca-a2fa-c28978430ad4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3b4bc326-8568-49d0-82fb-5b2f32082865" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_ac41016b-1da0-45ca-a2fa-c28978430ad4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_4fd014c7-bd8e-40a1-b613-ffca91eb555b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3b4bc326-8568-49d0-82fb-5b2f32082865" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_4fd014c7-bd8e-40a1-b613-ffca91eb555b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_ba843dd2-dbc2-4cf4-a1c6-2cfb8c0ae105" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3b4bc326-8568-49d0-82fb-5b2f32082865" xlink:to="loc_us-gaap_ShareBasedCompensation_ba843dd2-dbc2-4cf4-a1c6-2cfb8c0ae105" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaidInKindInterest_e36ae194-4f77-4459-af09-f6035052eb44" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaidInKindInterest"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3b4bc326-8568-49d0-82fb-5b2f32082865" xlink:to="loc_us-gaap_PaidInKindInterest_e36ae194-4f77-4459-af09-f6035052eb44" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_2a9d9a9e-5d27-443b-9458-aac2db300902" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3b4bc326-8568-49d0-82fb-5b2f32082865" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_2a9d9a9e-5d27-443b-9458-aac2db300902" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_88ced7be-f315-42a6-962e-bc2333cd4725" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3b4bc326-8568-49d0-82fb-5b2f32082865" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_88ced7be-f315-42a6-962e-bc2333cd4725" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_074936a2-33d0-4b74-bdeb-33d4f8a3b8ce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3b4bc326-8568-49d0-82fb-5b2f32082865" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_074936a2-33d0-4b74-bdeb-33d4f8a3b8ce" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_fb48ee96-b1db-49c6-94a5-1b180204d1ef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3b4bc326-8568-49d0-82fb-5b2f32082865" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_fb48ee96-b1db-49c6-94a5-1b180204d1ef" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_455a530a-a77a-4d99-b80e-c07e30edcc16" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3b4bc326-8568-49d0-82fb-5b2f32082865" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_455a530a-a77a-4d99-b80e-c07e30edcc16" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_6783aba4-b4d9-4d6a-9292-35eb69857859" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <link:calculationArc order="13" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3b4bc326-8568-49d0-82fb-5b2f32082865" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_6783aba4-b4d9-4d6a-9292-35eb69857859" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0ab8736b-2f79-43e6-a35c-395c105c99dc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_bd0d9c80-6e86-4e7b-b2d5-b92d686b0344" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0ab8736b-2f79-43e6-a35c-395c105c99dc" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_bd0d9c80-6e86-4e7b-b2d5-b92d686b0344" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_d095fe88-80c7-46f8-9cde-5cfb3e50d439" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0ab8736b-2f79-43e6-a35c-395c105c99dc" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_d095fe88-80c7-46f8-9cde-5cfb3e50d439" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_98985183-1d7e-4c3b-b5e7-a9a91201196c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0ab8736b-2f79-43e6-a35c-395c105c99dc" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_98985183-1d7e-4c3b-b5e7-a9a91201196c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_b219ed04-0bf0-4c6e-a4db-0d9c7c441c98" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0ab8736b-2f79-43e6-a35c-395c105c99dc" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_b219ed04-0bf0-4c6e-a4db-0d9c7c441c98" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.selectabio.com/role/NatureoftheBusinessandBasisofPresentation" xlink:type="simple" xlink:href="selb-20210331.xsd#NatureoftheBusinessandBasisofPresentation"/>
  <link:calculationLink xlink:role="http://www.selectabio.com/role/NatureoftheBusinessandBasisofPresentation" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.selectabio.com/role/NatureoftheBusinessandBasisofPresentationLiquidityDetails" xlink:type="simple" xlink:href="selb-20210331.xsd#NatureoftheBusinessandBasisofPresentationLiquidityDetails"/>
  <link:calculationLink xlink:role="http://www.selectabio.com/role/NatureoftheBusinessandBasisofPresentationLiquidityDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.selectabio.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="selb-20210331.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:calculationLink xlink:role="http://www.selectabio.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.selectabio.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="selb-20210331.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:calculationLink xlink:role="http://www.selectabio.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.selectabio.com/role/MarketableSecurities" xlink:type="simple" xlink:href="selb-20210331.xsd#MarketableSecurities"/>
  <link:calculationLink xlink:role="http://www.selectabio.com/role/MarketableSecurities" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.selectabio.com/role/MarketableSecuritiesTables" xlink:type="simple" xlink:href="selb-20210331.xsd#MarketableSecuritiesTables"/>
  <link:calculationLink xlink:role="http://www.selectabio.com/role/MarketableSecuritiesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.selectabio.com/role/MarketableSecuritiesSummaryofAvailableforSaleMarketableSecuritiesDetails" xlink:type="simple" xlink:href="selb-20210331.xsd#MarketableSecuritiesSummaryofAvailableforSaleMarketableSecuritiesDetails"/>
  <link:calculationLink xlink:role="http://www.selectabio.com/role/MarketableSecuritiesSummaryofAvailableforSaleMarketableSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_15d86758-a723-491c-931e-450884f69ff9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_135f3696-7208-4b28-a147-7c78882704d3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_15d86758-a723-491c-931e-450884f69ff9" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_135f3696-7208-4b28-a147-7c78882704d3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_5d2190e6-b0e4-44d9-af68-e87479542740" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_15d86758-a723-491c-931e-450884f69ff9" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_5d2190e6-b0e4-44d9-af68-e87479542740" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_f11ce0a0-72c9-45d6-a986-7963b59a8efa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_15d86758-a723-491c-931e-450884f69ff9" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_f11ce0a0-72c9-45d6-a986-7963b59a8efa" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.selectabio.com/role/MarketableSecuritiesNarrativeDetails" xlink:type="simple" xlink:href="selb-20210331.xsd#MarketableSecuritiesNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.selectabio.com/role/MarketableSecuritiesNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.selectabio.com/role/NetLossPerShare" xlink:type="simple" xlink:href="selb-20210331.xsd#NetLossPerShare"/>
  <link:calculationLink xlink:role="http://www.selectabio.com/role/NetLossPerShare" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.selectabio.com/role/NetLossPerShareTables" xlink:type="simple" xlink:href="selb-20210331.xsd#NetLossPerShareTables"/>
  <link:calculationLink xlink:role="http://www.selectabio.com/role/NetLossPerShareTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.selectabio.com/role/NetLossPerShareComputationofBasicandDilutedNetLossPerShareDetails" xlink:type="simple" xlink:href="selb-20210331.xsd#NetLossPerShareComputationofBasicandDilutedNetLossPerShareDetails"/>
  <link:calculationLink xlink:role="http://www.selectabio.com/role/NetLossPerShareComputationofBasicandDilutedNetLossPerShareDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.selectabio.com/role/NetLossPerShareScheduleofPotentialCommonSharesIssuableUponConversionofWarrantsDetails" xlink:type="simple" xlink:href="selb-20210331.xsd#NetLossPerShareScheduleofPotentialCommonSharesIssuableUponConversionofWarrantsDetails"/>
  <link:calculationLink xlink:role="http://www.selectabio.com/role/NetLossPerShareScheduleofPotentialCommonSharesIssuableUponConversionofWarrantsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.selectabio.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="selb-20210331.xsd#FairValueMeasurements"/>
  <link:calculationLink xlink:role="http://www.selectabio.com/role/FairValueMeasurements" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.selectabio.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="selb-20210331.xsd#FairValueMeasurementsTables"/>
  <link:calculationLink xlink:role="http://www.selectabio.com/role/FairValueMeasurementsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.selectabio.com/role/FairValueMeasurementsSummaryofAssetsMeasuredatFairValueonaRecurringBasisDetails" xlink:type="simple" xlink:href="selb-20210331.xsd#FairValueMeasurementsSummaryofAssetsMeasuredatFairValueonaRecurringBasisDetails"/>
  <link:calculationLink xlink:role="http://www.selectabio.com/role/FairValueMeasurementsSummaryofAssetsMeasuredatFairValueonaRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_348aca75-4e0c-4f57-b6f4-8ba9be7c5b51" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_b90516e7-d650-4520-b0dd-beca14a9ad50" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_348aca75-4e0c-4f57-b6f4-8ba9be7c5b51" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_b90516e7-d650-4520-b0dd-beca14a9ad50" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_fb36a6d0-2952-4932-bfe0-8d76dc7ac177" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_348aca75-4e0c-4f57-b6f4-8ba9be7c5b51" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_fb36a6d0-2952-4932-bfe0-8d76dc7ac177" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_c6c437e7-1e5d-404d-bc2a-822738dadd5f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding_a6414591-29db-4b77-8ddf-19fd49fd6567" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure_c6c437e7-1e5d-404d-bc2a-822738dadd5f" xlink:to="loc_us-gaap_WarrantsAndRightsOutstanding_a6414591-29db-4b77-8ddf-19fd49fd6567" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.selectabio.com/role/FairValueMeasurementsAssumptionsusedtorecordthefairvalueofthewarrantsDetails" xlink:type="simple" xlink:href="selb-20210331.xsd#FairValueMeasurementsAssumptionsusedtorecordthefairvalueofthewarrantsDetails"/>
  <link:calculationLink xlink:role="http://www.selectabio.com/role/FairValueMeasurementsAssumptionsusedtorecordthefairvalueofthewarrantsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.selectabio.com/role/FairValueMeasurementsChangeinthewarrantliabilitiesDetails" xlink:type="simple" xlink:href="selb-20210331.xsd#FairValueMeasurementsChangeinthewarrantliabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.selectabio.com/role/FairValueMeasurementsChangeinthewarrantliabilitiesDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.selectabio.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="simple" xlink:href="selb-20210331.xsd#FairValueMeasurementsNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.selectabio.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.selectabio.com/role/FairValueMeasurementsScheduleofCashandCashEquivalentsDetails" xlink:type="simple" xlink:href="selb-20210331.xsd#FairValueMeasurementsScheduleofCashandCashEquivalentsDetails"/>
  <link:calculationLink xlink:role="http://www.selectabio.com/role/FairValueMeasurementsScheduleofCashandCashEquivalentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_bb8b4bab-7baa-46df-bda3-20779b06112b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_11d29595-6c7e-4909-a912-5e6e7c8149fb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_bb8b4bab-7baa-46df-bda3-20779b06112b" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_11d29595-6c7e-4909-a912-5e6e7c8149fb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_b6adb644-e214-4807-98e7-77af14c237c1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_bb8b4bab-7baa-46df-bda3-20779b06112b" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_b6adb644-e214-4807-98e7-77af14c237c1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_7895f55e-c478-4fbf-86d5-365f9203a1de" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_bb8b4bab-7baa-46df-bda3-20779b06112b" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_7895f55e-c478-4fbf-86d5-365f9203a1de" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.selectabio.com/role/PropertyandEquipment" xlink:type="simple" xlink:href="selb-20210331.xsd#PropertyandEquipment"/>
  <link:calculationLink xlink:role="http://www.selectabio.com/role/PropertyandEquipment" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.selectabio.com/role/PropertyandEquipmentTables" xlink:type="simple" xlink:href="selb-20210331.xsd#PropertyandEquipmentTables"/>
  <link:calculationLink xlink:role="http://www.selectabio.com/role/PropertyandEquipmentTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.selectabio.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails" xlink:type="simple" xlink:href="selb-20210331.xsd#PropertyandEquipmentScheduleofPropertyandEquipmentDetails"/>
  <link:calculationLink xlink:role="http://www.selectabio.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_eb3f22db-e84d-47ce-a438-c57b5a4d274e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_1b968528-e281-4a22-855c-f54c62b9046a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_eb3f22db-e84d-47ce-a438-c57b5a4d274e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_1b968528-e281-4a22-855c-f54c62b9046a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_a6832767-8316-42c8-b5b1-fd6eabd34be8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_eb3f22db-e84d-47ce-a438-c57b5a4d274e" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_a6832767-8316-42c8-b5b1-fd6eabd34be8" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.selectabio.com/role/PropertyandEquipmentNarrativeDetails" xlink:type="simple" xlink:href="selb-20210331.xsd#PropertyandEquipmentNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.selectabio.com/role/PropertyandEquipmentNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.selectabio.com/role/AccruedExpenses" xlink:type="simple" xlink:href="selb-20210331.xsd#AccruedExpenses"/>
  <link:calculationLink xlink:role="http://www.selectabio.com/role/AccruedExpenses" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.selectabio.com/role/AccruedExpensesTables" xlink:type="simple" xlink:href="selb-20210331.xsd#AccruedExpensesTables"/>
  <link:calculationLink xlink:role="http://www.selectabio.com/role/AccruedExpensesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.selectabio.com/role/AccruedExpensesDetails" xlink:type="simple" xlink:href="selb-20210331.xsd#AccruedExpensesDetails"/>
  <link:calculationLink xlink:role="http://www.selectabio.com/role/AccruedExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_f0dde97c-265c-4754-b586-414b403a1e8b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_65d72854-26b2-452d-b18a-df6be2de153c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_f0dde97c-265c-4754-b586-414b403a1e8b" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_65d72854-26b2-452d-b18a-df6be2de153c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_selb_AccruedCollaborationandLicensing_80eb6ec2-f048-4898-8982-91a2915cb81c" xlink:href="selb-20210331.xsd#selb_AccruedCollaborationandLicensing"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_f0dde97c-265c-4754-b586-414b403a1e8b" xlink:to="loc_selb_AccruedCollaborationandLicensing_80eb6ec2-f048-4898-8982-91a2915cb81c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_selb_AccruedPatentFeesCurrent_e808f88e-4cec-4694-bb6f-792562b59347" xlink:href="selb-20210331.xsd#selb_AccruedPatentFeesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_f0dde97c-265c-4754-b586-414b403a1e8b" xlink:to="loc_selb_AccruedPatentFeesCurrent_e808f88e-4cec-4694-bb6f-792562b59347" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_selb_AccruedResearchAndDevelopmentCostsCurrent_c6bec52e-84c2-4c1e-aa54-555e73442a21" xlink:href="selb-20210331.xsd#selb_AccruedResearchAndDevelopmentCostsCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_f0dde97c-265c-4754-b586-414b403a1e8b" xlink:to="loc_selb_AccruedResearchAndDevelopmentCostsCurrent_c6bec52e-84c2-4c1e-aa54-555e73442a21" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_selb_AccruedAuditFeesCurrent_52909cec-e1c3-481c-a0e9-72a1a07dba42" xlink:href="selb-20210331.xsd#selb_AccruedAuditFeesCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_f0dde97c-265c-4754-b586-414b403a1e8b" xlink:to="loc_selb_AccruedAuditFeesCurrent_52909cec-e1c3-481c-a0e9-72a1a07dba42" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_selb_AccruedInterestCurrent_79bb1368-e9be-45b2-bbb2-44acc78bd28c" xlink:href="selb-20210331.xsd#selb_AccruedInterestCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_f0dde97c-265c-4754-b586-414b403a1e8b" xlink:to="loc_selb_AccruedInterestCurrent_79bb1368-e9be-45b2-bbb2-44acc78bd28c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_582244af-2497-4e62-93b0-5101ac2a0c09" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_f0dde97c-265c-4754-b586-414b403a1e8b" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_582244af-2497-4e62-93b0-5101ac2a0c09" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.selectabio.com/role/Leases" xlink:type="simple" xlink:href="selb-20210331.xsd#Leases"/>
  <link:calculationLink xlink:role="http://www.selectabio.com/role/Leases" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.selectabio.com/role/LeasesTables" xlink:type="simple" xlink:href="selb-20210331.xsd#LeasesTables"/>
  <link:calculationLink xlink:role="http://www.selectabio.com/role/LeasesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.selectabio.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="selb-20210331.xsd#LeasesNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.selectabio.com/role/LeasesNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.selectabio.com/role/LeasesComponentsofOperatingLeasesDetails" xlink:type="simple" xlink:href="selb-20210331.xsd#LeasesComponentsofOperatingLeasesDetails"/>
  <link:calculationLink xlink:role="http://www.selectabio.com/role/LeasesComponentsofOperatingLeasesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_552ea137-8f3b-4b6e-850e-2fcf0b5b5a9c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_f1419615-d5e4-4154-9ca2-fe31e279628b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_552ea137-8f3b-4b6e-850e-2fcf0b5b5a9c" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_f1419615-d5e4-4154-9ca2-fe31e279628b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_7f0f02ec-1324-4664-94bb-2f8e9ed98176" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_552ea137-8f3b-4b6e-850e-2fcf0b5b5a9c" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_7f0f02ec-1324-4664-94bb-2f8e9ed98176" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.selectabio.com/role/LeasesComponentsofleasecostsDetails" xlink:type="simple" xlink:href="selb-20210331.xsd#LeasesComponentsofleasecostsDetails"/>
  <link:calculationLink xlink:role="http://www.selectabio.com/role/LeasesComponentsofleasecostsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_0adf9737-58b3-4102-99c3-c4b46b77c28a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_0864355f-f39e-4a33-8c3a-dccdb7cb1b15" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_0adf9737-58b3-4102-99c3-c4b46b77c28a" xlink:to="loc_us-gaap_OperatingLeaseCost_0864355f-f39e-4a33-8c3a-dccdb7cb1b15" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost_359b9d30-6b93-466f-bd28-b329b92d5237" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableLeaseCost"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_0adf9737-58b3-4102-99c3-c4b46b77c28a" xlink:to="loc_us-gaap_VariableLeaseCost_359b9d30-6b93-466f-bd28-b329b92d5237" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermLeaseCost_66030c14-1fb0-4014-8291-ec74b0dc3bec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermLeaseCost"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_0adf9737-58b3-4102-99c3-c4b46b77c28a" xlink:to="loc_us-gaap_ShortTermLeaseCost_66030c14-1fb0-4014-8291-ec74b0dc3bec" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.selectabio.com/role/LeasesOperatingLeaseLiabilityMaturityDetails" xlink:type="simple" xlink:href="selb-20210331.xsd#LeasesOperatingLeaseLiabilityMaturityDetails"/>
  <link:calculationLink xlink:role="http://www.selectabio.com/role/LeasesOperatingLeaseLiabilityMaturityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_01654f54-8854-4b85-a47c-617875182cd0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_a689a702-2bbe-44fd-9a6c-9087bb1bafd7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_01654f54-8854-4b85-a47c-617875182cd0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_a689a702-2bbe-44fd-9a6c-9087bb1bafd7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_e0b9e55b-8d27-42f9-97c7-06e6e4f6197f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_01654f54-8854-4b85-a47c-617875182cd0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_e0b9e55b-8d27-42f9-97c7-06e6e4f6197f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_fc65edf8-c082-4d2d-b6de-ea924e171c0d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_01654f54-8854-4b85-a47c-617875182cd0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_fc65edf8-c082-4d2d-b6de-ea924e171c0d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_eb441152-1b8f-49e1-85b4-31c41b645139" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_01654f54-8854-4b85-a47c-617875182cd0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_eb441152-1b8f-49e1-85b4-31c41b645139" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_5ba96175-aac0-4a8d-8422-b419d7dfdb20" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_01654f54-8854-4b85-a47c-617875182cd0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_5ba96175-aac0-4a8d-8422-b419d7dfdb20" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_selb_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_c5d4adc0-bf0d-4452-96b2-0303c927af01" xlink:href="selb-20210331.xsd#selb_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_01654f54-8854-4b85-a47c-617875182cd0" xlink:to="loc_selb_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_c5d4adc0-bf0d-4452-96b2-0303c927af01" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.selectabio.com/role/LeasesOperatingLeaseLiabilityMaturityDetails_1" xlink:type="simple" xlink:href="selb-20210331.xsd#LeasesOperatingLeaseLiabilityMaturityDetails_1"/>
  <link:calculationLink xlink:role="http://www.selectabio.com/role/LeasesOperatingLeaseLiabilityMaturityDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_c73d7825-2e24-44c5-b4bf-bf6419b491ac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_2490628f-5327-46ec-a4b2-815edf1a3fb2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_c73d7825-2e24-44c5-b4bf-bf6419b491ac" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_2490628f-5327-46ec-a4b2-815edf1a3fb2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_77ccf36f-eba4-4088-a2c8-8b8e4ed33322" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_c73d7825-2e24-44c5-b4bf-bf6419b491ac" xlink:to="loc_us-gaap_OperatingLeaseLiability_77ccf36f-eba4-4088-a2c8-8b8e4ed33322" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.selectabio.com/role/LeasesOtherInformationDetails" xlink:type="simple" xlink:href="selb-20210331.xsd#LeasesOtherInformationDetails"/>
  <link:calculationLink xlink:role="http://www.selectabio.com/role/LeasesOtherInformationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.selectabio.com/role/LeasesLeaseTermandDiscountRateDetails" xlink:type="simple" xlink:href="selb-20210331.xsd#LeasesLeaseTermandDiscountRateDetails"/>
  <link:calculationLink xlink:role="http://www.selectabio.com/role/LeasesLeaseTermandDiscountRateDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.selectabio.com/role/Debt" xlink:type="simple" xlink:href="selb-20210331.xsd#Debt"/>
  <link:calculationLink xlink:role="http://www.selectabio.com/role/Debt" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.selectabio.com/role/DebtTables" xlink:type="simple" xlink:href="selb-20210331.xsd#DebtTables"/>
  <link:calculationLink xlink:role="http://www.selectabio.com/role/DebtTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.selectabio.com/role/DebtTermLoansNarrativeDetails" xlink:type="simple" xlink:href="selb-20210331.xsd#DebtTermLoansNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.selectabio.com/role/DebtTermLoansNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.selectabio.com/role/DebtScheduleofFutureMinimumPaymentsontheTermLoansDetails" xlink:type="simple" xlink:href="selb-20210331.xsd#DebtScheduleofFutureMinimumPaymentsontheTermLoansDetails"/>
  <link:calculationLink xlink:role="http://www.selectabio.com/role/DebtScheduleofFutureMinimumPaymentsontheTermLoansDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_48f1fe99-e18b-476d-85e2-bc95c5358855" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_7925a4c6-dd40-4f0a-9d64-b3efa6268710" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_48f1fe99-e18b-476d-85e2-bc95c5358855" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_7925a4c6-dd40-4f0a-9d64-b3efa6268710" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_d536a301-4ede-4597-b27e-0f2fd6c56b4c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_48f1fe99-e18b-476d-85e2-bc95c5358855" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_d536a301-4ede-4597-b27e-0f2fd6c56b4c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_0a4f95a2-f100-4998-b370-b5c1e79bf305" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_48f1fe99-e18b-476d-85e2-bc95c5358855" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_0a4f95a2-f100-4998-b370-b5c1e79bf305" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_60c8d1af-c370-48d4-ba40-26773bcab633" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_48f1fe99-e18b-476d-85e2-bc95c5358855" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_60c8d1af-c370-48d4-ba40-26773bcab633" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_ed491133-191e-45dc-9515-3c652b816758" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_48f1fe99-e18b-476d-85e2-bc95c5358855" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_ed491133-191e-45dc-9515-3c652b816758" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.selectabio.com/role/Equity" xlink:type="simple" xlink:href="selb-20210331.xsd#Equity"/>
  <link:calculationLink xlink:role="http://www.selectabio.com/role/Equity" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.selectabio.com/role/EquityTables" xlink:type="simple" xlink:href="selb-20210331.xsd#EquityTables"/>
  <link:calculationLink xlink:role="http://www.selectabio.com/role/EquityTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.selectabio.com/role/EquityNarrativeDetails" xlink:type="simple" xlink:href="selb-20210331.xsd#EquityNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.selectabio.com/role/EquityNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.selectabio.com/role/EquityWarrantyActivityDetails" xlink:type="simple" xlink:href="selb-20210331.xsd#EquityWarrantyActivityDetails"/>
  <link:calculationLink xlink:role="http://www.selectabio.com/role/EquityWarrantyActivityDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.selectabio.com/role/EquityScheduleofAuthorizedSharesofCommonStockforFutureIssuanceDetails" xlink:type="simple" xlink:href="selb-20210331.xsd#EquityScheduleofAuthorizedSharesofCommonStockforFutureIssuanceDetails"/>
  <link:calculationLink xlink:role="http://www.selectabio.com/role/EquityScheduleofAuthorizedSharesofCommonStockforFutureIssuanceDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.selectabio.com/role/StockIncentivePlans" xlink:type="simple" xlink:href="selb-20210331.xsd#StockIncentivePlans"/>
  <link:calculationLink xlink:role="http://www.selectabio.com/role/StockIncentivePlans" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.selectabio.com/role/StockIncentivePlansTables" xlink:type="simple" xlink:href="selb-20210331.xsd#StockIncentivePlansTables"/>
  <link:calculationLink xlink:role="http://www.selectabio.com/role/StockIncentivePlansTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.selectabio.com/role/StockIncentivePlansNarrativeDetails" xlink:type="simple" xlink:href="selb-20210331.xsd#StockIncentivePlansNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.selectabio.com/role/StockIncentivePlansNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.selectabio.com/role/StockIncentivePlansScheduleofStockBasedCompensationExpenseRelatedtoStockOptionsandRestrictedCommonStockDetails" xlink:type="simple" xlink:href="selb-20210331.xsd#StockIncentivePlansScheduleofStockBasedCompensationExpenseRelatedtoStockOptionsandRestrictedCommonStockDetails"/>
  <link:calculationLink xlink:role="http://www.selectabio.com/role/StockIncentivePlansScheduleofStockBasedCompensationExpenseRelatedtoStockOptionsandRestrictedCommonStockDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.selectabio.com/role/StockIncentivePlansScheduleofAssumptionsDetails" xlink:type="simple" xlink:href="selb-20210331.xsd#StockIncentivePlansScheduleofAssumptionsDetails"/>
  <link:calculationLink xlink:role="http://www.selectabio.com/role/StockIncentivePlansScheduleofAssumptionsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.selectabio.com/role/StockIncentivePlansSummaryofOptionsActivityDetails" xlink:type="simple" xlink:href="selb-20210331.xsd#StockIncentivePlansSummaryofOptionsActivityDetails"/>
  <link:calculationLink xlink:role="http://www.selectabio.com/role/StockIncentivePlansSummaryofOptionsActivityDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.selectabio.com/role/StockIncentivePlansRestrictedStockUnitsDetails" xlink:type="simple" xlink:href="selb-20210331.xsd#StockIncentivePlansRestrictedStockUnitsDetails"/>
  <link:calculationLink xlink:role="http://www.selectabio.com/role/StockIncentivePlansRestrictedStockUnitsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.selectabio.com/role/StockIncentivePlansEmployeeStockPurchasePlanNarrativeDetails" xlink:type="simple" xlink:href="selb-20210331.xsd#StockIncentivePlansEmployeeStockPurchasePlanNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.selectabio.com/role/StockIncentivePlansEmployeeStockPurchasePlanNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.selectabio.com/role/RevenueArrangements" xlink:type="simple" xlink:href="selb-20210331.xsd#RevenueArrangements"/>
  <link:calculationLink xlink:role="http://www.selectabio.com/role/RevenueArrangements" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.selectabio.com/role/RevenueArrangementsTables" xlink:type="simple" xlink:href="selb-20210331.xsd#RevenueArrangementsTables"/>
  <link:calculationLink xlink:role="http://www.selectabio.com/role/RevenueArrangementsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.selectabio.com/role/RevenueArrangementsNarrativeDetails" xlink:type="simple" xlink:href="selb-20210331.xsd#RevenueArrangementsNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.selectabio.com/role/RevenueArrangementsNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.selectabio.com/role/RevenueArrangementsScheduleofChangesinContractLiabilitiesDetails" xlink:type="simple" xlink:href="selb-20210331.xsd#RevenueArrangementsScheduleofChangesinContractLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.selectabio.com/role/RevenueArrangementsScheduleofChangesinContractLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_e5182daa-1edf-4c99-b4b6-21cf47d3a705" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:loc xlink:type="locator" xlink:label="loc_selb_ContractwithCustomerLiabilityDeferredRevenueRevenueRecognized_ffdde47d-0027-427d-914d-605c6d6260d1" xlink:href="selb-20210331.xsd#selb_ContractwithCustomerLiabilityDeferredRevenueRevenueRecognized"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_e5182daa-1edf-4c99-b4b6-21cf47d3a705" xlink:to="loc_selb_ContractwithCustomerLiabilityDeferredRevenueRevenueRecognized_ffdde47d-0027-427d-914d-605c6d6260d1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_aa54a419-0ae5-479b-aef7-5eeb09dd5e99" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_selb_ContractwithCustomerLiabilityDeferredRevenue_b6d687bc-6d1f-4945-a5f6-6e9f961a07ce" xlink:href="selb-20210331.xsd#selb_ContractwithCustomerLiabilityDeferredRevenue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ContractWithCustomerLiability_aa54a419-0ae5-479b-aef7-5eeb09dd5e99" xlink:to="loc_selb_ContractwithCustomerLiabilityDeferredRevenue_b6d687bc-6d1f-4945-a5f6-6e9f961a07ce" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_selb_ContractwithCustomerLiabilityIncreaseFromCashReceipts_65fd5db1-3e70-412c-8f11-b2f77fcdd6f5" xlink:href="selb-20210331.xsd#selb_ContractwithCustomerLiabilityIncreaseFromCashReceipts"/>
    <link:loc xlink:type="locator" xlink:label="loc_selb_ContractwithCustomerLiabilityDeferredRevenueIncreaseFromCashReceipts_db84fe4d-d6b1-47a8-b01d-533f71989089" xlink:href="selb-20210331.xsd#selb_ContractwithCustomerLiabilityDeferredRevenueIncreaseFromCashReceipts"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_selb_ContractwithCustomerLiabilityIncreaseFromCashReceipts_65fd5db1-3e70-412c-8f11-b2f77fcdd6f5" xlink:to="loc_selb_ContractwithCustomerLiabilityDeferredRevenueIncreaseFromCashReceipts_db84fe4d-d6b1-47a8-b01d-533f71989089" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.selectabio.com/role/RelatedPartyTransactions" xlink:type="simple" xlink:href="selb-20210331.xsd#RelatedPartyTransactions"/>
  <link:calculationLink xlink:role="http://www.selectabio.com/role/RelatedPartyTransactions" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.selectabio.com/role/RelatedPartyTransactionsNarrativeDetails" xlink:type="simple" xlink:href="selb-20210331.xsd#RelatedPartyTransactionsNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.selectabio.com/role/RelatedPartyTransactionsNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.selectabio.com/role/CollaborationAgreements" xlink:type="simple" xlink:href="selb-20210331.xsd#CollaborationAgreements"/>
  <link:calculationLink xlink:role="http://www.selectabio.com/role/CollaborationAgreements" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.selectabio.com/role/CollaborationAgreementsAskBioNarrativeDetails" xlink:type="simple" xlink:href="selb-20210331.xsd#CollaborationAgreementsAskBioNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.selectabio.com/role/CollaborationAgreementsAskBioNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.selectabio.com/role/CollaborationAgreementsMITNarrativeDetails" xlink:type="simple" xlink:href="selb-20210331.xsd#CollaborationAgreementsMITNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.selectabio.com/role/CollaborationAgreementsMITNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.selectabio.com/role/CollaborationAgreementsShenyangSunshinePharmaceuticalCoLtdNarrativeDetails" xlink:type="simple" xlink:href="selb-20210331.xsd#CollaborationAgreementsShenyangSunshinePharmaceuticalCoLtdNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.selectabio.com/role/CollaborationAgreementsShenyangSunshinePharmaceuticalCoLtdNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.selectabio.com/role/IncomeTaxes" xlink:type="simple" xlink:href="selb-20210331.xsd#IncomeTaxes"/>
  <link:calculationLink xlink:role="http://www.selectabio.com/role/IncomeTaxes" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.selectabio.com/role/IncomeTaxesNarrativeDetails" xlink:type="simple" xlink:href="selb-20210331.xsd#IncomeTaxesNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.selectabio.com/role/IncomeTaxesNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.selectabio.com/role/DefinedContributionPlan" xlink:type="simple" xlink:href="selb-20210331.xsd#DefinedContributionPlan"/>
  <link:calculationLink xlink:role="http://www.selectabio.com/role/DefinedContributionPlan" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.selectabio.com/role/DefinedContributionPlanNarrativeDetails" xlink:type="simple" xlink:href="selb-20210331.xsd#DefinedContributionPlanNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.selectabio.com/role/DefinedContributionPlanNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.selectabio.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="selb-20210331.xsd#CommitmentsandContingencies"/>
  <link:calculationLink xlink:role="http://www.selectabio.com/role/CommitmentsandContingencies" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.selectabio.com/role/SubsequentEvents" xlink:type="simple" xlink:href="selb-20210331.xsd#SubsequentEvents"/>
  <link:calculationLink xlink:role="http://www.selectabio.com/role/SubsequentEvents" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.selectabio.com/role/SubsequentEventsDetails" xlink:type="simple" xlink:href="selb-20210331.xsd#SubsequentEventsDetails"/>
  <link:calculationLink xlink:role="http://www.selectabio.com/role/SubsequentEventsDetails" xlink:type="extended"/>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>9
<FILENAME>selb-20210331_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:f83914de-cdf0-4ece-a0a2-d7db460e8912,g:a84bda62-2062-413b-8a4e-4383ad9edaee-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.selectabio.com/role/Coverpage" xlink:type="simple" xlink:href="selb-20210331.xsd#Coverpage"/>
  <link:definitionLink xlink:role="http://www.selectabio.com/role/Coverpage" xlink:type="extended" id="id41e3587a90c48d38184aabff8c6d43a_Coverpage"/>
  <link:roleRef roleURI="http://www.selectabio.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="selb-20210331.xsd#ConsolidatedBalanceSheets"/>
  <link:definitionLink xlink:role="http://www.selectabio.com/role/ConsolidatedBalanceSheets" xlink:type="extended" id="if3ac717a11dd49b5be49e84368ef3d74_ConsolidatedBalanceSheets"/>
  <link:roleRef roleURI="http://www.selectabio.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="selb-20210331.xsd#ConsolidatedBalanceSheetsParenthetical"/>
  <link:definitionLink xlink:role="http://www.selectabio.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended" id="ie05633f5e95e401786083a4ca972befe_ConsolidatedBalanceSheetsParenthetical"/>
  <link:roleRef roleURI="http://www.selectabio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="simple" xlink:href="selb-20210331.xsd#ConsolidatedStatementsofOperationsandComprehensiveLoss"/>
  <link:definitionLink xlink:role="http://www.selectabio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="extended" id="if6ade4c4eb704185ab1a3857f2a7829f_ConsolidatedStatementsofOperationsandComprehensiveLoss"/>
  <link:roleRef roleURI="http://www.selectabio.com/role/ConsolidatedStatementsofChangesinStockholdersDeficitEquity" xlink:type="simple" xlink:href="selb-20210331.xsd#ConsolidatedStatementsofChangesinStockholdersDeficitEquity"/>
  <link:definitionLink xlink:role="http://www.selectabio.com/role/ConsolidatedStatementsofChangesinStockholdersDeficitEquity" xlink:type="extended" id="i8360a2c7bcf740b7a7485bc1ea825f68_ConsolidatedStatementsofChangesinStockholdersDeficitEquity">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_f82ef73f-0f16-4223-aec3-965dda949dd7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_bb3d8b41-09e7-46ec-8dae-73bf9836b413" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_f82ef73f-0f16-4223-aec3-965dda949dd7" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_bb3d8b41-09e7-46ec-8dae-73bf9836b413" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_269464c8-f13d-4302-bff9-d248387bc025" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_bb3d8b41-09e7-46ec-8dae-73bf9836b413" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_269464c8-f13d-4302-bff9-d248387bc025" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_a8d78df5-e73f-4819-9412-b859fd0c73d2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_bb3d8b41-09e7-46ec-8dae-73bf9836b413" xlink:to="loc_us-gaap_StockholdersEquity_a8d78df5-e73f-4819-9412-b859fd0c73d2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_ffa6c7c2-bc14-4371-809b-7a97c259971e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_bb3d8b41-09e7-46ec-8dae-73bf9836b413" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_ffa6c7c2-bc14-4371-809b-7a97c259971e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_8b1c5c41-d38b-43db-8fdc-1e5d3df8ec44" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_bb3d8b41-09e7-46ec-8dae-73bf9836b413" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_8b1c5c41-d38b-43db-8fdc-1e5d3df8ec44" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_7922f3f7-0d17-4178-a7b9-029957a0214f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_bb3d8b41-09e7-46ec-8dae-73bf9836b413" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_7922f3f7-0d17-4178-a7b9-029957a0214f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_354cbf92-44de-456e-87eb-d68859a89b23" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_bb3d8b41-09e7-46ec-8dae-73bf9836b413" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_354cbf92-44de-456e-87eb-d68859a89b23" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_10b6500d-1610-41ee-a8ae-7d2b0addb885" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_bb3d8b41-09e7-46ec-8dae-73bf9836b413" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_10b6500d-1610-41ee-a8ae-7d2b0addb885" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_41ec4803-5dc4-4c92-b6f2-761dad0e650b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_bb3d8b41-09e7-46ec-8dae-73bf9836b413" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_41ec4803-5dc4-4c92-b6f2-761dad0e650b" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesOther_d86d7fff-3603-458c-abb7-01225584c0dc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_bb3d8b41-09e7-46ec-8dae-73bf9836b413" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesOther_d86d7fff-3603-458c-abb7-01225584c0dc" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueOther_ce4b02da-0303-4668-a48b-fe60e7cb8bbb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_bb3d8b41-09e7-46ec-8dae-73bf9836b413" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueOther_ce4b02da-0303-4668-a48b-fe60e7cb8bbb" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther_46876cb8-42a9-4bd4-b11c-4ceff4c162a6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_bb3d8b41-09e7-46ec-8dae-73bf9836b413" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther_46876cb8-42a9-4bd4-b11c-4ceff4c162a6" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_91769971-1721-4031-8cc7-16f11f415fc2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_bb3d8b41-09e7-46ec-8dae-73bf9836b413" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_91769971-1721-4031-8cc7-16f11f415fc2" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_880341d0-7f7f-4c06-99e2-91d21c148c8a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_bb3d8b41-09e7-46ec-8dae-73bf9836b413" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_880341d0-7f7f-4c06-99e2-91d21c148c8a" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_1d665192-a41c-4b90-9d98-629baafe57b7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_bb3d8b41-09e7-46ec-8dae-73bf9836b413" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_1d665192-a41c-4b90-9d98-629baafe57b7" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_ea40cfc5-e1ff-402a-b328-9a3e21e088f2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_bb3d8b41-09e7-46ec-8dae-73bf9836b413" xlink:to="loc_us-gaap_NetIncomeLoss_ea40cfc5-e1ff-402a-b328-9a3e21e088f2" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_db00d320-6bfb-4dfe-98b1-16842642e50a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_ee7ae659-5b71-4c85-a9dd-076a9c45e947" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_b4ebbb6f-709c-4b94-bf4f-a0be181242ec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_f82ef73f-0f16-4223-aec3-965dda949dd7" xlink:to="loc_us-gaap_StatementTable_b4ebbb6f-709c-4b94-bf4f-a0be181242ec" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_fefcf08d-a36c-4e72-9ca1-63c8718fadd0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_b4ebbb6f-709c-4b94-bf4f-a0be181242ec" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_fefcf08d-a36c-4e72-9ca1-63c8718fadd0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_fefcf08d-a36c-4e72-9ca1-63c8718fadd0_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_fefcf08d-a36c-4e72-9ca1-63c8718fadd0" xlink:to="loc_us-gaap_EquityComponentDomain_fefcf08d-a36c-4e72-9ca1-63c8718fadd0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_9900b41a-c6be-4368-8580-17df6d0eb6d1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_fefcf08d-a36c-4e72-9ca1-63c8718fadd0" xlink:to="loc_us-gaap_EquityComponentDomain_9900b41a-c6be-4368-8580-17df6d0eb6d1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_4434955a-5981-4259-ba3c-14be04277afd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_9900b41a-c6be-4368-8580-17df6d0eb6d1" xlink:to="loc_us-gaap_CommonStockMember_4434955a-5981-4259-ba3c-14be04277afd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_d1da648b-0bc6-47ee-94ab-e27c92406363" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_9900b41a-c6be-4368-8580-17df6d0eb6d1" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_d1da648b-0bc6-47ee-94ab-e27c92406363" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_a0448fec-8628-4f6b-b7df-a3ff61ad5312" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_9900b41a-c6be-4368-8580-17df6d0eb6d1" xlink:to="loc_us-gaap_RetainedEarningsMember_a0448fec-8628-4f6b-b7df-a3ff61ad5312" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_e42f00f1-555d-476c-b49a-d98166d70361" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_9900b41a-c6be-4368-8580-17df6d0eb6d1" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_e42f00f1-555d-476c-b49a-d98166d70361" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.selectabio.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="selb-20210331.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:definitionLink xlink:role="http://www.selectabio.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended" id="i69fdec9f9d1846f8a853cb98ed39084f_ConsolidatedStatementsofCashFlows"/>
  <link:roleRef roleURI="http://www.selectabio.com/role/NatureoftheBusinessandBasisofPresentation" xlink:type="simple" xlink:href="selb-20210331.xsd#NatureoftheBusinessandBasisofPresentation"/>
  <link:definitionLink xlink:role="http://www.selectabio.com/role/NatureoftheBusinessandBasisofPresentation" xlink:type="extended" id="i0553f10bca1045f5acd9e0f9deda0e23_NatureoftheBusinessandBasisofPresentation"/>
  <link:roleRef roleURI="http://www.selectabio.com/role/NatureoftheBusinessandBasisofPresentationLiquidityDetails" xlink:type="simple" xlink:href="selb-20210331.xsd#NatureoftheBusinessandBasisofPresentationLiquidityDetails"/>
  <link:definitionLink xlink:role="http://www.selectabio.com/role/NatureoftheBusinessandBasisofPresentationLiquidityDetails" xlink:type="extended" id="id62b072f2524468cbe1126186b81708e_NatureoftheBusinessandBasisofPresentationLiquidityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsLineItems_1571deab-e6fb-436a-b363-e37a8af287fa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_selb_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndDebtSecuritiesAvailableForSale_1ad4cf08-51ce-4984-9009-9c993900392f" xlink:href="selb-20210331.xsd#selb_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndDebtSecuritiesAvailableForSale"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_1571deab-e6fb-436a-b363-e37a8af287fa" xlink:to="loc_selb_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndDebtSecuritiesAvailableForSale_1ad4cf08-51ce-4984-9009-9c993900392f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents_9f2b3e19-d0f5-48bc-8056-3c13e602c074" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_1571deab-e6fb-436a-b363-e37a8af287fa" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalents_9f2b3e19-d0f5-48bc-8056-3c13e602c074" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Cash_98d00d61-5f41-45e2-a7a5-ce631fc31970" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Cash"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_1571deab-e6fb-436a-b363-e37a8af287fa" xlink:to="loc_us-gaap_Cash_98d00d61-5f41-45e2-a7a5-ce631fc31970" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_a1b59a83-faa7-41b6-9bc7-94b5598e7305" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_1571deab-e6fb-436a-b363-e37a8af287fa" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_a1b59a83-faa7-41b6-9bc7-94b5598e7305" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_cd863fbb-104e-4e0f-a32b-11be5d8f8bf7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_1571deab-e6fb-436a-b363-e37a8af287fa" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_cd863fbb-104e-4e0f-a32b-11be5d8f8bf7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_d5cb2903-3891-44e2-9386-47ef21fbb23f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_cd863fbb-104e-4e0f-a32b-11be5d8f8bf7" xlink:to="loc_srt_StatementGeographicalAxis_d5cb2903-3891-44e2-9386-47ef21fbb23f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_d5cb2903-3891-44e2-9386-47ef21fbb23f_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_d5cb2903-3891-44e2-9386-47ef21fbb23f" xlink:to="loc_srt_SegmentGeographicalDomain_d5cb2903-3891-44e2-9386-47ef21fbb23f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_b1bc2940-ecab-4b6a-abc1-e06049d24766" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_d5cb2903-3891-44e2-9386-47ef21fbb23f" xlink:to="loc_srt_SegmentGeographicalDomain_b1bc2940-ecab-4b6a-abc1-e06049d24766" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_RU_1b965f15-a3d1-4008-964a-063919596549" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_RU"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_b1bc2940-ecab-4b6a-abc1-e06049d24766" xlink:to="loc_country_RU_1b965f15-a3d1-4008-964a-063919596549" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.selectabio.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="selb-20210331.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:definitionLink xlink:role="http://www.selectabio.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended" id="i6327a45502774672a6a6040ff9d49f01_SummaryofSignificantAccountingPolicies"/>
  <link:roleRef roleURI="http://www.selectabio.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="selb-20210331.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:definitionLink xlink:role="http://www.selectabio.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended" id="i0a1ed4000aee43aead28b66fbe8bccc7_SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:roleRef roleURI="http://www.selectabio.com/role/MarketableSecurities" xlink:type="simple" xlink:href="selb-20210331.xsd#MarketableSecurities"/>
  <link:definitionLink xlink:role="http://www.selectabio.com/role/MarketableSecurities" xlink:type="extended" id="i83a69dcc1fd34817830d4c3e794b6b5b_MarketableSecurities"/>
  <link:roleRef roleURI="http://www.selectabio.com/role/MarketableSecuritiesTables" xlink:type="simple" xlink:href="selb-20210331.xsd#MarketableSecuritiesTables"/>
  <link:definitionLink xlink:role="http://www.selectabio.com/role/MarketableSecuritiesTables" xlink:type="extended" id="i8658594bb39a49219cfeb74d35ed9a11_MarketableSecuritiesTables"/>
  <link:roleRef roleURI="http://www.selectabio.com/role/MarketableSecuritiesSummaryofAvailableforSaleMarketableSecuritiesDetails" xlink:type="simple" xlink:href="selb-20210331.xsd#MarketableSecuritiesSummaryofAvailableforSaleMarketableSecuritiesDetails"/>
  <link:definitionLink xlink:role="http://www.selectabio.com/role/MarketableSecuritiesSummaryofAvailableforSaleMarketableSecuritiesDetails" xlink:type="extended" id="i028d5951fe2744388049188f63a01578_MarketableSecuritiesSummaryofAvailableforSaleMarketableSecuritiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_14346cec-de4e-46f7-ad9f-635797513179" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_adadead4-48d3-4f36-b773-da321acdc185" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_14346cec-de4e-46f7-ad9f-635797513179" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_adadead4-48d3-4f36-b773-da321acdc185" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_70090f8b-48c8-4136-88b1-8839e6f81fdd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_14346cec-de4e-46f7-ad9f-635797513179" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_70090f8b-48c8-4136-88b1-8839e6f81fdd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_6a1ef6f5-613f-4fab-a50b-ba7761ab2415" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_14346cec-de4e-46f7-ad9f-635797513179" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_6a1ef6f5-613f-4fab-a50b-ba7761ab2415" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_379a2806-7b08-4f10-a163-6370f6126066" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_14346cec-de4e-46f7-ad9f-635797513179" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_379a2806-7b08-4f10-a163-6370f6126066" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_72c5d985-8f56-4cfb-9f3b-b6fd219ad5cd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_14346cec-de4e-46f7-ad9f-635797513179" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_72c5d985-8f56-4cfb-9f3b-b6fd219ad5cd" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_4399014d-bed1-4638-8388-d4f717e1062b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_72c5d985-8f56-4cfb-9f3b-b6fd219ad5cd" xlink:to="loc_us-gaap_FinancialInstrumentAxis_4399014d-bed1-4638-8388-d4f717e1062b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4399014d-bed1-4638-8388-d4f717e1062b_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_4399014d-bed1-4638-8388-d4f717e1062b" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4399014d-bed1-4638-8388-d4f717e1062b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1a86347f-0806-4e57-8fe4-b1fee7cbf134" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_4399014d-bed1-4638-8388-d4f717e1062b" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1a86347f-0806-4e57-8fe4-b1fee7cbf134" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_2bcaef29-4492-4d9e-85fd-a8e7ba30b6ef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1a86347f-0806-4e57-8fe4-b1fee7cbf134" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_2bcaef29-4492-4d9e-85fd-a8e7ba30b6ef" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_41f34846-15c7-4c25-9b9c-bacea9a63aa0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1a86347f-0806-4e57-8fe4-b1fee7cbf134" xlink:to="loc_us-gaap_CommercialPaperMember_41f34846-15c7-4c25-9b9c-bacea9a63aa0" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.selectabio.com/role/MarketableSecuritiesNarrativeDetails" xlink:type="simple" xlink:href="selb-20210331.xsd#MarketableSecuritiesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.selectabio.com/role/MarketableSecuritiesNarrativeDetails" xlink:type="extended" id="id6cdbff1bc0a4171b36703b81f9c8428_MarketableSecuritiesNarrativeDetails"/>
  <link:roleRef roleURI="http://www.selectabio.com/role/NetLossPerShare" xlink:type="simple" xlink:href="selb-20210331.xsd#NetLossPerShare"/>
  <link:definitionLink xlink:role="http://www.selectabio.com/role/NetLossPerShare" xlink:type="extended" id="i981b708c8a724caa8ebdd6286f9dee8a_NetLossPerShare"/>
  <link:roleRef roleURI="http://www.selectabio.com/role/NetLossPerShareTables" xlink:type="simple" xlink:href="selb-20210331.xsd#NetLossPerShareTables"/>
  <link:definitionLink xlink:role="http://www.selectabio.com/role/NetLossPerShareTables" xlink:type="extended" id="i0e30ea50171046c9857573d67820fb7a_NetLossPerShareTables"/>
  <link:roleRef roleURI="http://www.selectabio.com/role/NetLossPerShareComputationofBasicandDilutedNetLossPerShareDetails" xlink:type="simple" xlink:href="selb-20210331.xsd#NetLossPerShareComputationofBasicandDilutedNetLossPerShareDetails"/>
  <link:definitionLink xlink:role="http://www.selectabio.com/role/NetLossPerShareComputationofBasicandDilutedNetLossPerShareDetails" xlink:type="extended" id="i24f9d1999b79475c84ae6afa222bdf1c_NetLossPerShareComputationofBasicandDilutedNetLossPerShareDetails"/>
  <link:roleRef roleURI="http://www.selectabio.com/role/NetLossPerShareScheduleofPotentialCommonSharesIssuableUponConversionofWarrantsDetails" xlink:type="simple" xlink:href="selb-20210331.xsd#NetLossPerShareScheduleofPotentialCommonSharesIssuableUponConversionofWarrantsDetails"/>
  <link:definitionLink xlink:role="http://www.selectabio.com/role/NetLossPerShareScheduleofPotentialCommonSharesIssuableUponConversionofWarrantsDetails" xlink:type="extended" id="i99b940e4e7384ab2b59b701ae73959e2_NetLossPerShareScheduleofPotentialCommonSharesIssuableUponConversionofWarrantsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_34bdb1cf-c2d2-4f76-a461-997a210bbce0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_9e6e36b1-b397-4ae3-83e3-445dafbcd23a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_34bdb1cf-c2d2-4f76-a461-997a210bbce0" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_9e6e36b1-b397-4ae3-83e3-445dafbcd23a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_63d90327-a88c-404b-b980-7c1fc20372da" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_34bdb1cf-c2d2-4f76-a461-997a210bbce0" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_63d90327-a88c-404b-b980-7c1fc20372da" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_6063b21f-41b1-43e2-9366-7a6369dcc7ac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_63d90327-a88c-404b-b980-7c1fc20372da" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_6063b21f-41b1-43e2-9366-7a6369dcc7ac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_6063b21f-41b1-43e2-9366-7a6369dcc7ac_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_6063b21f-41b1-43e2-9366-7a6369dcc7ac" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_6063b21f-41b1-43e2-9366-7a6369dcc7ac_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_96240149-0e43-4111-9117-307ac8806952" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_6063b21f-41b1-43e2-9366-7a6369dcc7ac" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_96240149-0e43-4111-9117-307ac8806952" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_1246e80f-7391-4ea2-8b9b-93b9a12da5c0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_96240149-0e43-4111-9117-307ac8806952" xlink:to="loc_us-gaap_EmployeeStockOptionMember_1246e80f-7391-4ea2-8b9b-93b9a12da5c0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_9b7cd0c4-e3ca-427a-b38d-87f1ef1993e4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_96240149-0e43-4111-9117-307ac8806952" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_9b7cd0c4-e3ca-427a-b38d-87f1ef1993e4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_8cd56922-e183-4469-a4f5-7403a2348546" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_96240149-0e43-4111-9117-307ac8806952" xlink:to="loc_us-gaap_WarrantMember_8cd56922-e183-4469-a4f5-7403a2348546" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.selectabio.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="selb-20210331.xsd#FairValueMeasurements"/>
  <link:definitionLink xlink:role="http://www.selectabio.com/role/FairValueMeasurements" xlink:type="extended" id="id2c08288fa5c4674803c4e0e44c309db_FairValueMeasurements"/>
  <link:roleRef roleURI="http://www.selectabio.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="selb-20210331.xsd#FairValueMeasurementsTables"/>
  <link:definitionLink xlink:role="http://www.selectabio.com/role/FairValueMeasurementsTables" xlink:type="extended" id="i930fd97e2aa14543830d787a06835f2b_FairValueMeasurementsTables"/>
  <link:roleRef roleURI="http://www.selectabio.com/role/FairValueMeasurementsSummaryofAssetsMeasuredatFairValueonaRecurringBasisDetails" xlink:type="simple" xlink:href="selb-20210331.xsd#FairValueMeasurementsSummaryofAssetsMeasuredatFairValueonaRecurringBasisDetails"/>
  <link:definitionLink xlink:role="http://www.selectabio.com/role/FairValueMeasurementsSummaryofAssetsMeasuredatFairValueonaRecurringBasisDetails" xlink:type="extended" id="ie0b7d7c957374526b7757eaca37a662f_FairValueMeasurementsSummaryofAssetsMeasuredatFairValueonaRecurringBasisDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ac9f7582-0608-45d2-b082-8c8e3a972e82" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_516adaa8-7178-4aa0-bd72-91e659924c1d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ac9f7582-0608-45d2-b082-8c8e3a972e82" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_516adaa8-7178-4aa0-bd72-91e659924c1d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_3c2e2dd4-7d0d-4e09-98e7-a8d229806964" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_516adaa8-7178-4aa0-bd72-91e659924c1d" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_3c2e2dd4-7d0d-4e09-98e7-a8d229806964" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_87200f70-a1da-4f5b-b1d4-7143984f3a7c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_516adaa8-7178-4aa0-bd72-91e659924c1d" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_87200f70-a1da-4f5b-b1d4-7143984f3a7c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_6cdb19e9-ac97-4e39-ac49-4902bdd81c0e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_516adaa8-7178-4aa0-bd72-91e659924c1d" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_6cdb19e9-ac97-4e39-ac49-4902bdd81c0e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_299747e8-55ed-4b15-ae8e-fc02dcbdae2a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ac9f7582-0608-45d2-b082-8c8e3a972e82" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_299747e8-55ed-4b15-ae8e-fc02dcbdae2a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding_748ebc70-0dcf-4d99-8a40-4a886cefe404" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_299747e8-55ed-4b15-ae8e-fc02dcbdae2a" xlink:to="loc_us-gaap_WarrantsAndRightsOutstanding_748ebc70-0dcf-4d99-8a40-4a886cefe404" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_14f5a9c2-ce81-4f97-96e2-4a8d76c0b2bb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_299747e8-55ed-4b15-ae8e-fc02dcbdae2a" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_14f5a9c2-ce81-4f97-96e2-4a8d76c0b2bb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_f70eeb76-d52a-458b-be12-fcd8e08881c4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ac9f7582-0608-45d2-b082-8c8e3a972e82" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_f70eeb76-d52a-458b-be12-fcd8e08881c4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_791438af-b3a8-4c67-82b7-3e61c0489def" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_f70eeb76-d52a-458b-be12-fcd8e08881c4" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_791438af-b3a8-4c67-82b7-3e61c0489def" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_791438af-b3a8-4c67-82b7-3e61c0489def_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_791438af-b3a8-4c67-82b7-3e61c0489def" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_791438af-b3a8-4c67-82b7-3e61c0489def_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_c78c5c98-ed53-40cc-a757-81586b0aa026" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_791438af-b3a8-4c67-82b7-3e61c0489def" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_c78c5c98-ed53-40cc-a757-81586b0aa026" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_18ed0a52-e7b1-4564-93ab-d54fec180778" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_c78c5c98-ed53-40cc-a757-81586b0aa026" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_18ed0a52-e7b1-4564-93ab-d54fec180778" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_bac8332b-005c-419e-8790-617d8ead6fd8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_f70eeb76-d52a-458b-be12-fcd8e08881c4" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_bac8332b-005c-419e-8790-617d8ead6fd8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_bac8332b-005c-419e-8790-617d8ead6fd8_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_bac8332b-005c-419e-8790-617d8ead6fd8" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_bac8332b-005c-419e-8790-617d8ead6fd8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_3454f081-34f1-4fd1-9580-d5ce3963dad5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_bac8332b-005c-419e-8790-617d8ead6fd8" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_3454f081-34f1-4fd1-9580-d5ce3963dad5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_1975beb7-fccc-4cb7-bf8e-beb1bc32f57f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_3454f081-34f1-4fd1-9580-d5ce3963dad5" xlink:to="loc_us-gaap_MoneyMarketFundsMember_1975beb7-fccc-4cb7-bf8e-beb1bc32f57f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_85721bf2-e669-4bde-9b65-b55649ddd4cf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_f70eeb76-d52a-458b-be12-fcd8e08881c4" xlink:to="loc_us-gaap_FinancialInstrumentAxis_85721bf2-e669-4bde-9b65-b55649ddd4cf" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_85721bf2-e669-4bde-9b65-b55649ddd4cf_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_85721bf2-e669-4bde-9b65-b55649ddd4cf" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_85721bf2-e669-4bde-9b65-b55649ddd4cf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_70074204-f460-49e6-abfa-742b5a57d936" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_85721bf2-e669-4bde-9b65-b55649ddd4cf" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_70074204-f460-49e6-abfa-742b5a57d936" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_59c7c1a6-b13e-4322-89aa-5885c935ea2c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_70074204-f460-49e6-abfa-742b5a57d936" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_59c7c1a6-b13e-4322-89aa-5885c935ea2c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_386a6824-605c-446d-8b99-9aaaffaa034d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_70074204-f460-49e6-abfa-742b5a57d936" xlink:to="loc_us-gaap_CommercialPaperMember_386a6824-605c-446d-8b99-9aaaffaa034d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_c04f31c7-6918-4e9b-9a5c-12851f91eebf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_f70eeb76-d52a-458b-be12-fcd8e08881c4" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_c04f31c7-6918-4e9b-9a5c-12851f91eebf" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c04f31c7-6918-4e9b-9a5c-12851f91eebf_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_c04f31c7-6918-4e9b-9a5c-12851f91eebf" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c04f31c7-6918-4e9b-9a5c-12851f91eebf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_336c5ef5-14ba-4e35-bfd2-0cce50b3a0fb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_c04f31c7-6918-4e9b-9a5c-12851f91eebf" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_336c5ef5-14ba-4e35-bfd2-0cce50b3a0fb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_9ecd8777-1dc9-4c69-92b7-61119747f039" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_336c5ef5-14ba-4e35-bfd2-0cce50b3a0fb" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_9ecd8777-1dc9-4c69-92b7-61119747f039" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_760a8784-0ba7-4b74-bb71-06c119befde1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_336c5ef5-14ba-4e35-bfd2-0cce50b3a0fb" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_760a8784-0ba7-4b74-bb71-06c119befde1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_c2a6f17e-bc6c-406f-ae55-8e4d1e39e45c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_336c5ef5-14ba-4e35-bfd2-0cce50b3a0fb" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_c2a6f17e-bc6c-406f-ae55-8e4d1e39e45c" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.selectabio.com/role/FairValueMeasurementsAssumptionsusedtorecordthefairvalueofthewarrantsDetails" xlink:type="simple" xlink:href="selb-20210331.xsd#FairValueMeasurementsAssumptionsusedtorecordthefairvalueofthewarrantsDetails"/>
  <link:definitionLink xlink:role="http://www.selectabio.com/role/FairValueMeasurementsAssumptionsusedtorecordthefairvalueofthewarrantsDetails" xlink:type="extended" id="i35a34ba441ed4a18bb33f6e6a7e0b80d_FairValueMeasurementsAssumptionsusedtorecordthefairvalueofthewarrantsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_2773881a-5add-4d5a-9ec3-049962812cb6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_4ef27be2-8b02-4176-ba0d-a82f1d9b9c28" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_2773881a-5add-4d5a-9ec3-049962812cb6" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_4ef27be2-8b02-4176-ba0d-a82f1d9b9c28" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_72343faf-8a29-465f-984c-7a247f45fa63" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_2773881a-5add-4d5a-9ec3-049962812cb6" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_72343faf-8a29-465f-984c-7a247f45fa63" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_ff779963-a589-40eb-97e1-6d09ed8d67c7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_2773881a-5add-4d5a-9ec3-049962812cb6" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_ff779963-a589-40eb-97e1-6d09ed8d67c7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueAxis_b4e273f9-09dd-48f5-ae61-040f3b090cba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationTechniqueAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_ff779963-a589-40eb-97e1-6d09ed8d67c7" xlink:to="loc_us-gaap_ValuationTechniqueAxis_b4e273f9-09dd-48f5-ae61-040f3b090cba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDomain_b4e273f9-09dd-48f5-ae61-040f3b090cba_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationTechniqueDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ValuationTechniqueAxis_b4e273f9-09dd-48f5-ae61-040f3b090cba" xlink:to="loc_us-gaap_ValuationTechniqueDomain_b4e273f9-09dd-48f5-ae61-040f3b090cba_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDomain_8a13c155-a859-49e8-bb08-625b1e64bf19" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationTechniqueDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ValuationTechniqueAxis_b4e273f9-09dd-48f5-ae61-040f3b090cba" xlink:to="loc_us-gaap_ValuationTechniqueDomain_8a13c155-a859-49e8-bb08-625b1e64bf19" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueOptionPricingModelMember_a99a9054-de85-4844-98fc-8a215190ba1e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationTechniqueOptionPricingModelMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationTechniqueDomain_8a13c155-a859-49e8-bb08-625b1e64bf19" xlink:to="loc_us-gaap_ValuationTechniqueOptionPricingModelMember_a99a9054-de85-4844-98fc-8a215190ba1e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_ee75bec8-62b8-4f19-9704-943e826dfceb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_ff779963-a589-40eb-97e1-6d09ed8d67c7" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_ee75bec8-62b8-4f19-9704-943e826dfceb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_ee75bec8-62b8-4f19-9704-943e826dfceb_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_ee75bec8-62b8-4f19-9704-943e826dfceb" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_ee75bec8-62b8-4f19-9704-943e826dfceb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_024fed55-7fd5-4011-acaa-b6011c7f70bc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_ee75bec8-62b8-4f19-9704-943e826dfceb" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_024fed55-7fd5-4011-acaa-b6011c7f70bc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_f38f996c-c9fc-4125-b373-0cc72aacfc10" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_024fed55-7fd5-4011-acaa-b6011c7f70bc" xlink:to="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_f38f996c-c9fc-4125-b373-0cc72aacfc10" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedDividendRateMember_9b6b5556-fc9c-44c3-96bd-21b76ca98701" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputExpectedDividendRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_024fed55-7fd5-4011-acaa-b6011c7f70bc" xlink:to="loc_us-gaap_MeasurementInputExpectedDividendRateMember_9b6b5556-fc9c-44c3-96bd-21b76ca98701" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember_bfde7949-15d4-4dc5-94ee-8d4160efa1f2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_024fed55-7fd5-4011-acaa-b6011c7f70bc" xlink:to="loc_us-gaap_MeasurementInputExpectedTermMember_bfde7949-15d4-4dc5-94ee-8d4160efa1f2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember_8f8ef657-a9a1-4fd0-b764-9b6dabf3294a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_024fed55-7fd5-4011-acaa-b6011c7f70bc" xlink:to="loc_us-gaap_MeasurementInputPriceVolatilityMember_8f8ef657-a9a1-4fd0-b764-9b6dabf3294a" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.selectabio.com/role/FairValueMeasurementsChangeinthewarrantliabilitiesDetails" xlink:type="simple" xlink:href="selb-20210331.xsd#FairValueMeasurementsChangeinthewarrantliabilitiesDetails"/>
  <link:definitionLink xlink:role="http://www.selectabio.com/role/FairValueMeasurementsChangeinthewarrantliabilitiesDetails" xlink:type="extended" id="i9e5f473d31634508a371da32fa220d58_FairValueMeasurementsChangeinthewarrantliabilitiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_4411b1e4-478b-4529-a1f5-a99ca1103221" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_54ff0a13-f6a7-4455-bf29-0ef7637aca67" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_4411b1e4-478b-4529-a1f5-a99ca1103221" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_54ff0a13-f6a7-4455-bf29-0ef7637aca67" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_de5fe2d4-1cd3-4b11-ad50-342abc52bcfb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_54ff0a13-f6a7-4455-bf29-0ef7637aca67" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_de5fe2d4-1cd3-4b11-ad50-342abc52bcfb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_7e231ed4-c28b-4f2a-a95a-77216bb50f9d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_54ff0a13-f6a7-4455-bf29-0ef7637aca67" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_7e231ed4-c28b-4f2a-a95a-77216bb50f9d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_2046d10b-ac8c-4692-9ebd-bc47bf16a94e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_98fa0066-3936-4bf7-b317-277133387bfe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_4411b1e4-478b-4529-a1f5-a99ca1103221" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_98fa0066-3936-4bf7-b317-277133387bfe" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_6cf207b8-1d1a-4fa6-8d11-27badf19b3e9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_98fa0066-3936-4bf7-b317-277133387bfe" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_6cf207b8-1d1a-4fa6-8d11-27badf19b3e9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_6cf207b8-1d1a-4fa6-8d11-27badf19b3e9_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_6cf207b8-1d1a-4fa6-8d11-27badf19b3e9" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_6cf207b8-1d1a-4fa6-8d11-27badf19b3e9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_5e8bda08-e18f-425d-a199-38b80a6fcab3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_6cf207b8-1d1a-4fa6-8d11-27badf19b3e9" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_5e8bda08-e18f-425d-a199-38b80a6fcab3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_fff9a5ae-9455-460a-8d40-ef09b900cf94" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_5e8bda08-e18f-425d-a199-38b80a6fcab3" xlink:to="loc_us-gaap_WarrantMember_fff9a5ae-9455-460a-8d40-ef09b900cf94" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.selectabio.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="simple" xlink:href="selb-20210331.xsd#FairValueMeasurementsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.selectabio.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="extended" id="icc4780c261fb4a4a89878a6528b18c18_FairValueMeasurementsNarrativeDetails"/>
  <link:roleRef roleURI="http://www.selectabio.com/role/FairValueMeasurementsScheduleofCashandCashEquivalentsDetails" xlink:type="simple" xlink:href="selb-20210331.xsd#FairValueMeasurementsScheduleofCashandCashEquivalentsDetails"/>
  <link:definitionLink xlink:role="http://www.selectabio.com/role/FairValueMeasurementsScheduleofCashandCashEquivalentsDetails" xlink:type="extended" id="ib22ea9f18faa4708b1624ef377a50f57_FairValueMeasurementsScheduleofCashandCashEquivalentsDetails"/>
  <link:roleRef roleURI="http://www.selectabio.com/role/PropertyandEquipment" xlink:type="simple" xlink:href="selb-20210331.xsd#PropertyandEquipment"/>
  <link:definitionLink xlink:role="http://www.selectabio.com/role/PropertyandEquipment" xlink:type="extended" id="i61e14c152a5040389b0e54b46dc751d6_PropertyandEquipment"/>
  <link:roleRef roleURI="http://www.selectabio.com/role/PropertyandEquipmentTables" xlink:type="simple" xlink:href="selb-20210331.xsd#PropertyandEquipmentTables"/>
  <link:definitionLink xlink:role="http://www.selectabio.com/role/PropertyandEquipmentTables" xlink:type="extended" id="ic54fdac49add4ae8aed9958f2936bd3b_PropertyandEquipmentTables"/>
  <link:roleRef roleURI="http://www.selectabio.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails" xlink:type="simple" xlink:href="selb-20210331.xsd#PropertyandEquipmentScheduleofPropertyandEquipmentDetails"/>
  <link:definitionLink xlink:role="http://www.selectabio.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails" xlink:type="extended" id="i8729b138fc2d4c86993bdc956c720246_PropertyandEquipmentScheduleofPropertyandEquipmentDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_6d806911-f045-4851-9ee1-9037c3e58407" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_9f3f7895-fa30-4674-a72c-e81f17df7ca4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_6d806911-f045-4851-9ee1-9037c3e58407" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_9f3f7895-fa30-4674-a72c-e81f17df7ca4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_3356190e-98a0-482f-9c18-ed236fd81b90" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_6d806911-f045-4851-9ee1-9037c3e58407" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_3356190e-98a0-482f-9c18-ed236fd81b90" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_63cb6299-c5da-4396-b2c8-c98e6583ad36" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_6d806911-f045-4851-9ee1-9037c3e58407" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_63cb6299-c5da-4396-b2c8-c98e6583ad36" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_ec9de67d-b44f-4c14-be2e-88a6c81f2664" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_6d806911-f045-4851-9ee1-9037c3e58407" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_ec9de67d-b44f-4c14-be2e-88a6c81f2664" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_e36c7654-2f69-4863-9657-42a2ab4df5e9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_ec9de67d-b44f-4c14-be2e-88a6c81f2664" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_e36c7654-2f69-4863-9657-42a2ab4df5e9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_e36c7654-2f69-4863-9657-42a2ab4df5e9_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_e36c7654-2f69-4863-9657-42a2ab4df5e9" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_e36c7654-2f69-4863-9657-42a2ab4df5e9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a605bf16-4ccf-40ee-92d2-0af02a1bb1a0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_e36c7654-2f69-4863-9657-42a2ab4df5e9" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a605bf16-4ccf-40ee-92d2-0af02a1bb1a0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_selb_LaboratoryEquipmentMember_0aa54772-6836-489a-af31-2351add1e314" xlink:href="selb-20210331.xsd#selb_LaboratoryEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a605bf16-4ccf-40ee-92d2-0af02a1bb1a0" xlink:to="loc_selb_LaboratoryEquipmentMember_0aa54772-6836-489a-af31-2351add1e314" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_bf5cc10b-801f-4e78-98e8-61dc25bb3724" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a605bf16-4ccf-40ee-92d2-0af02a1bb1a0" xlink:to="loc_us-gaap_ComputerEquipmentMember_bf5cc10b-801f-4e78-98e8-61dc25bb3724" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_d2cb69b3-460d-4112-ad52-1f10d222d536" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a605bf16-4ccf-40ee-92d2-0af02a1bb1a0" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_d2cb69b3-460d-4112-ad52-1f10d222d536" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_a179350c-a481-4743-a3eb-3e5116882456" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a605bf16-4ccf-40ee-92d2-0af02a1bb1a0" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_a179350c-a481-4743-a3eb-3e5116882456" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OfficeEquipmentMember_4025cb7f-5a45-4fdd-917a-eebf8ee83f2b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OfficeEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a605bf16-4ccf-40ee-92d2-0af02a1bb1a0" xlink:to="loc_us-gaap_OfficeEquipmentMember_4025cb7f-5a45-4fdd-917a-eebf8ee83f2b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_d98174f6-38d5-45c3-afae-21a60f57c386" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a605bf16-4ccf-40ee-92d2-0af02a1bb1a0" xlink:to="loc_us-gaap_ConstructionInProgressMember_d98174f6-38d5-45c3-afae-21a60f57c386" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.selectabio.com/role/PropertyandEquipmentNarrativeDetails" xlink:type="simple" xlink:href="selb-20210331.xsd#PropertyandEquipmentNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.selectabio.com/role/PropertyandEquipmentNarrativeDetails" xlink:type="extended" id="i9b4b07092ccd4a858b817dd21c85ac48_PropertyandEquipmentNarrativeDetails"/>
  <link:roleRef roleURI="http://www.selectabio.com/role/AccruedExpenses" xlink:type="simple" xlink:href="selb-20210331.xsd#AccruedExpenses"/>
  <link:definitionLink xlink:role="http://www.selectabio.com/role/AccruedExpenses" xlink:type="extended" id="i0610b87e9f524886a487db1455fbd0bb_AccruedExpenses"/>
  <link:roleRef roleURI="http://www.selectabio.com/role/AccruedExpensesTables" xlink:type="simple" xlink:href="selb-20210331.xsd#AccruedExpensesTables"/>
  <link:definitionLink xlink:role="http://www.selectabio.com/role/AccruedExpensesTables" xlink:type="extended" id="i43b8597cff474cc591ae9bc6eb376bf5_AccruedExpensesTables"/>
  <link:roleRef roleURI="http://www.selectabio.com/role/AccruedExpensesDetails" xlink:type="simple" xlink:href="selb-20210331.xsd#AccruedExpensesDetails"/>
  <link:definitionLink xlink:role="http://www.selectabio.com/role/AccruedExpensesDetails" xlink:type="extended" id="ibbde29826a724eb99034e6974cdbdc30_AccruedExpensesDetails"/>
  <link:roleRef roleURI="http://www.selectabio.com/role/Leases" xlink:type="simple" xlink:href="selb-20210331.xsd#Leases"/>
  <link:definitionLink xlink:role="http://www.selectabio.com/role/Leases" xlink:type="extended" id="i8f308a22dc314a2dade9992045fe51d0_Leases"/>
  <link:roleRef roleURI="http://www.selectabio.com/role/LeasesTables" xlink:type="simple" xlink:href="selb-20210331.xsd#LeasesTables"/>
  <link:definitionLink xlink:role="http://www.selectabio.com/role/LeasesTables" xlink:type="extended" id="i36b26e0e678b4aaa885f882411f38588_LeasesTables"/>
  <link:roleRef roleURI="http://www.selectabio.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="selb-20210331.xsd#LeasesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.selectabio.com/role/LeasesNarrativeDetails" xlink:type="extended" id="i8bcddcaa738b489587a310035b7fecbc_LeasesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasedAssetsLineItems_52f80fe4-902f-43c2-86e5-2f795bdca869" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasedAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AreaOfRealEstateProperty_9ac915d2-9194-4582-a6c8-ff69ae53fa56" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AreaOfRealEstateProperty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_52f80fe4-902f-43c2-86e5-2f795bdca869" xlink:to="loc_us-gaap_AreaOfRealEstateProperty_9ac915d2-9194-4582-a6c8-ff69ae53fa56" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_444ac8c5-8e04-4fd3-bd63-d85496e9bcf5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_52f80fe4-902f-43c2-86e5-2f795bdca869" xlink:to="loc_us-gaap_LeaseCost_444ac8c5-8e04-4fd3-bd63-d85496e9bcf5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_909dd12d-a6c0-4727-96f3-81986df4b609" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_52f80fe4-902f-43c2-86e5-2f795bdca869" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_909dd12d-a6c0-4727-96f3-81986df4b609" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_287eb75a-6ce3-4aba-9a3c-1775cb5d47c7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_52f80fe4-902f-43c2-86e5-2f795bdca869" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_287eb75a-6ce3-4aba-9a3c-1775cb5d47c7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_ba3dbb86-fb82-45ae-9335-b109174818d2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_52f80fe4-902f-43c2-86e5-2f795bdca869" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_ba3dbb86-fb82-45ae-9335-b109174818d2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_38b038f6-faca-4928-8ff2-002ffba718d8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_52f80fe4-902f-43c2-86e5-2f795bdca869" xlink:to="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_38b038f6-faca-4928-8ff2-002ffba718d8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_962026ae-a0d7-4f5e-8c12-fbed6b01369d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_38b038f6-faca-4928-8ff2-002ffba718d8" xlink:to="loc_us-gaap_CreditFacilityAxis_962026ae-a0d7-4f5e-8c12-fbed6b01369d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_962026ae-a0d7-4f5e-8c12-fbed6b01369d_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_962026ae-a0d7-4f5e-8c12-fbed6b01369d" xlink:to="loc_us-gaap_CreditFacilityDomain_962026ae-a0d7-4f5e-8c12-fbed6b01369d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_79b0bff6-8467-4812-9395-e417cf5e2e74" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_962026ae-a0d7-4f5e-8c12-fbed6b01369d" xlink:to="loc_us-gaap_CreditFacilityDomain_79b0bff6-8467-4812-9395-e417cf5e2e74" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LetterOfCreditMember_8a7e49df-0581-4487-8b29-7c9578e3f7c7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LetterOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_79b0bff6-8467-4812-9395-e417cf5e2e74" xlink:to="loc_us-gaap_LetterOfCreditMember_8a7e49df-0581-4487-8b29-7c9578e3f7c7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_selb_LeaseArrangementAxis_ac228599-a427-46d9-a3d6-154af4581178" xlink:href="selb-20210331.xsd#selb_LeaseArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_38b038f6-faca-4928-8ff2-002ffba718d8" xlink:to="loc_selb_LeaseArrangementAxis_ac228599-a427-46d9-a3d6-154af4581178" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_selb_LeaseArrangementDomain_ac228599-a427-46d9-a3d6-154af4581178_default" xlink:href="selb-20210331.xsd#selb_LeaseArrangementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_selb_LeaseArrangementAxis_ac228599-a427-46d9-a3d6-154af4581178" xlink:to="loc_selb_LeaseArrangementDomain_ac228599-a427-46d9-a3d6-154af4581178_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_selb_LeaseArrangementDomain_e95e1981-3e3a-49b2-903f-a348040ae7a1" xlink:href="selb-20210331.xsd#selb_LeaseArrangementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_selb_LeaseArrangementAxis_ac228599-a427-46d9-a3d6-154af4581178" xlink:to="loc_selb_LeaseArrangementDomain_e95e1981-3e3a-49b2-903f-a348040ae7a1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_selb_A65GroveStreetWatertownMAMember_83247cf2-9b91-4bee-a546-300ffa41908a" xlink:href="selb-20210331.xsd#selb_A65GroveStreetWatertownMAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_selb_LeaseArrangementDomain_e95e1981-3e3a-49b2-903f-a348040ae7a1" xlink:to="loc_selb_A65GroveStreetWatertownMAMember_83247cf2-9b91-4bee-a546-300ffa41908a" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.selectabio.com/role/LeasesComponentsofOperatingLeasesDetails" xlink:type="simple" xlink:href="selb-20210331.xsd#LeasesComponentsofOperatingLeasesDetails"/>
  <link:definitionLink xlink:role="http://www.selectabio.com/role/LeasesComponentsofOperatingLeasesDetails" xlink:type="extended" id="i07e9466de2cc4c4d95eea032c6ecf910_LeasesComponentsofOperatingLeasesDetails"/>
  <link:roleRef roleURI="http://www.selectabio.com/role/LeasesComponentsofleasecostsDetails" xlink:type="simple" xlink:href="selb-20210331.xsd#LeasesComponentsofleasecostsDetails"/>
  <link:definitionLink xlink:role="http://www.selectabio.com/role/LeasesComponentsofleasecostsDetails" xlink:type="extended" id="i16ffe06f92b34efd91a988b835e1b9f9_LeasesComponentsofleasecostsDetails"/>
  <link:roleRef roleURI="http://www.selectabio.com/role/LeasesOperatingLeaseLiabilityMaturityDetails" xlink:type="simple" xlink:href="selb-20210331.xsd#LeasesOperatingLeaseLiabilityMaturityDetails"/>
  <link:definitionLink xlink:role="http://www.selectabio.com/role/LeasesOperatingLeaseLiabilityMaturityDetails" xlink:type="extended" id="i83fc0e24508f4d20a77e747583584c98_LeasesOperatingLeaseLiabilityMaturityDetails"/>
  <link:roleRef roleURI="http://www.selectabio.com/role/LeasesOtherInformationDetails" xlink:type="simple" xlink:href="selb-20210331.xsd#LeasesOtherInformationDetails"/>
  <link:definitionLink xlink:role="http://www.selectabio.com/role/LeasesOtherInformationDetails" xlink:type="extended" id="ife173334717446e1b6eb16f5ed951fc5_LeasesOtherInformationDetails"/>
  <link:roleRef roleURI="http://www.selectabio.com/role/LeasesLeaseTermandDiscountRateDetails" xlink:type="simple" xlink:href="selb-20210331.xsd#LeasesLeaseTermandDiscountRateDetails"/>
  <link:definitionLink xlink:role="http://www.selectabio.com/role/LeasesLeaseTermandDiscountRateDetails" xlink:type="extended" id="i41bd9e914abe4772b45ccb24f0efa9d9_LeasesLeaseTermandDiscountRateDetails"/>
  <link:roleRef roleURI="http://www.selectabio.com/role/Debt" xlink:type="simple" xlink:href="selb-20210331.xsd#Debt"/>
  <link:definitionLink xlink:role="http://www.selectabio.com/role/Debt" xlink:type="extended" id="i51664383e442429ba741394c1ffa407b_Debt"/>
  <link:roleRef roleURI="http://www.selectabio.com/role/DebtTables" xlink:type="simple" xlink:href="selb-20210331.xsd#DebtTables"/>
  <link:definitionLink xlink:role="http://www.selectabio.com/role/DebtTables" xlink:type="extended" id="i517af596fde74c21bc4db70d31179bdc_DebtTables"/>
  <link:roleRef roleURI="http://www.selectabio.com/role/DebtTermLoansNarrativeDetails" xlink:type="simple" xlink:href="selb-20210331.xsd#DebtTermLoansNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.selectabio.com/role/DebtTermLoansNarrativeDetails" xlink:type="extended" id="ia9f57045acb04f3aaeec84a5cb3f5df9_DebtTermLoansNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLineItems_e934e44e-3033-4259-a907-ae59676a994b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_38b5c08f-dd31-4045-a89a-3772e3810821" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_e934e44e-3033-4259-a907-ae59676a994b" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_38b5c08f-dd31-4045-a89a-3772e3810821" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_c8be113f-f637-4adb-a270-40be276e0b30" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_e934e44e-3033-4259-a907-ae59676a994b" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_c8be113f-f637-4adb-a270-40be276e0b30" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_selb_DebtInstrumentPrepaymentFeePercentage_5a493648-1e90-464b-8992-f45cacdec48b" xlink:href="selb-20210331.xsd#selb_DebtInstrumentPrepaymentFeePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_e934e44e-3033-4259-a907-ae59676a994b" xlink:to="loc_selb_DebtInstrumentPrepaymentFeePercentage_5a493648-1e90-464b-8992-f45cacdec48b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_selb_DebtInstrumentAdditionalAccruedInterestInTheEventOfDefault_d9a37a99-7d6a-4c31-ac19-496f8995715a" xlink:href="selb-20210331.xsd#selb_DebtInstrumentAdditionalAccruedInterestInTheEventOfDefault"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_e934e44e-3033-4259-a907-ae59676a994b" xlink:to="loc_selb_DebtInstrumentAdditionalAccruedInterestInTheEventOfDefault_d9a37a99-7d6a-4c31-ac19-496f8995715a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed_2fbd25c2-331d-4679-92a2-6e9947f8130c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_e934e44e-3033-4259-a907-ae59676a994b" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed_2fbd25c2-331d-4679-92a2-6e9947f8130c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid_96a23626-5f7a-459f-91ab-3a53456ffdef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_e934e44e-3033-4259-a907-ae59676a994b" xlink:to="loc_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid_96a23626-5f7a-459f-91ab-3a53456ffdef" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_selb_DebtInstrumentDefaultBankruptcyOrInsolvencyValueOfTriggeringAcceleratedRedemption_e0716f04-334a-49d9-a073-d760b3ae8eb1" xlink:href="selb-20210331.xsd#selb_DebtInstrumentDefaultBankruptcyOrInsolvencyValueOfTriggeringAcceleratedRedemption"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_e934e44e-3033-4259-a907-ae59676a994b" xlink:to="loc_selb_DebtInstrumentDefaultBankruptcyOrInsolvencyValueOfTriggeringAcceleratedRedemption_e0716f04-334a-49d9-a073-d760b3ae8eb1" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet_f6c7d998-f290-45fa-93ae-dee80acafb21" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_e934e44e-3033-4259-a907-ae59676a994b" xlink:to="loc_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet_f6c7d998-f290-45fa-93ae-dee80acafb21" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_3a9755dc-6942-496e-b51d-c60e8d8d8dd4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_e934e44e-3033-4259-a907-ae59676a994b" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_3a9755dc-6942-496e-b51d-c60e8d8d8dd4" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_8efdd457-7e3e-4287-80b0-3c51f9c63237" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_e934e44e-3033-4259-a907-ae59676a994b" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_8efdd457-7e3e-4287-80b0-3c51f9c63237" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_selb_ClassOfWarrantOrRightExpirationPeriod_7babf404-5c5c-43e6-8780-13c60f593196" xlink:href="selb-20210331.xsd#selb_ClassOfWarrantOrRightExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_e934e44e-3033-4259-a907-ae59676a994b" xlink:to="loc_selb_ClassOfWarrantOrRightExpirationPeriod_7babf404-5c5c-43e6-8780-13c60f593196" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_1c38720b-558d-4a31-874d-fd572452dcef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_e934e44e-3033-4259-a907-ae59676a994b" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_1c38720b-558d-4a31-874d-fd572452dcef" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_48976f70-e7e7-45d8-935b-df47555f4a40" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_e934e44e-3033-4259-a907-ae59676a994b" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_48976f70-e7e7-45d8-935b-df47555f4a40" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLinesOfCredit_c34537a5-82a2-4282-b738-fd4bf3d1d709" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfLinesOfCredit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_e934e44e-3033-4259-a907-ae59676a994b" xlink:to="loc_us-gaap_RepaymentsOfLinesOfCredit_c34537a5-82a2-4282-b738-fd4bf3d1d709" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_2c6e3cef-d21c-42c9-80d6-58454df44939" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_e934e44e-3033-4259-a907-ae59676a994b" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_2c6e3cef-d21c-42c9-80d6-58454df44939" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCredit_71961dff-996d-4506-bdd9-131e9fdde71f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCredit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_e934e44e-3033-4259-a907-ae59676a994b" xlink:to="loc_us-gaap_LineOfCredit_71961dff-996d-4506-bdd9-131e9fdde71f" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityTable_9e24c1a2-4036-47c0-bef4-a6468fd0e8a0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_e934e44e-3033-4259-a907-ae59676a994b" xlink:to="loc_us-gaap_LineOfCreditFacilityTable_9e24c1a2-4036-47c0-bef4-a6468fd0e8a0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_474f757b-3f78-418f-804f-9fc9f92751f9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_9e24c1a2-4036-47c0-bef4-a6468fd0e8a0" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_474f757b-3f78-418f-804f-9fc9f92751f9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_474f757b-3f78-418f-804f-9fc9f92751f9_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_474f757b-3f78-418f-804f-9fc9f92751f9" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_474f757b-3f78-418f-804f-9fc9f92751f9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_c32fcd1b-cee7-4406-b35f-4cb1f262b2d1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_474f757b-3f78-418f-804f-9fc9f92751f9" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_c32fcd1b-cee7-4406-b35f-4cb1f262b2d1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember_e2e50c22-d9c9-4210-aaf9-f40865963b6c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_c32fcd1b-cee7-4406-b35f-4cb1f262b2d1" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember_e2e50c22-d9c9-4210-aaf9-f40865963b6c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_e0502ac7-c5ec-4de1-8ad9-fb100e7abfe0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_c32fcd1b-cee7-4406-b35f-4cb1f262b2d1" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_e0502ac7-c5ec-4de1-8ad9-fb100e7abfe0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodThreeMember_f7a27130-e975-44de-8e17-3b07db5d5fca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_c32fcd1b-cee7-4406-b35f-4cb1f262b2d1" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodThreeMember_f7a27130-e975-44de-8e17-3b07db5d5fca" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_97f3ffff-6190-4e60-b8f5-1fa9a86c94d8" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_9e24c1a2-4036-47c0-bef4-a6468fd0e8a0" xlink:to="loc_srt_RangeAxis_97f3ffff-6190-4e60-b8f5-1fa9a86c94d8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_97f3ffff-6190-4e60-b8f5-1fa9a86c94d8_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_97f3ffff-6190-4e60-b8f5-1fa9a86c94d8" xlink:to="loc_srt_RangeMember_97f3ffff-6190-4e60-b8f5-1fa9a86c94d8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_216ba1eb-081f-4966-befe-05d40283d9ce" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_97f3ffff-6190-4e60-b8f5-1fa9a86c94d8" xlink:to="loc_srt_RangeMember_216ba1eb-081f-4966-befe-05d40283d9ce" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_dae8c7d7-8880-4931-9ce0-1a52402bb9a9" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_216ba1eb-081f-4966-befe-05d40283d9ce" xlink:to="loc_srt_MaximumMember_dae8c7d7-8880-4931-9ce0-1a52402bb9a9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_916cac58-6d92-4959-a41d-ce9b96efeea3" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_216ba1eb-081f-4966-befe-05d40283d9ce" xlink:to="loc_srt_MinimumMember_916cac58-6d92-4959-a41d-ce9b96efeea3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_4ac1dd98-03ed-425d-900e-1aac2cb01b71" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_9e24c1a2-4036-47c0-bef4-a6468fd0e8a0" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_4ac1dd98-03ed-425d-900e-1aac2cb01b71" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_4ac1dd98-03ed-425d-900e-1aac2cb01b71_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_4ac1dd98-03ed-425d-900e-1aac2cb01b71" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_4ac1dd98-03ed-425d-900e-1aac2cb01b71_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_144c3662-d39c-4ca4-aa4f-89de274459c5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_4ac1dd98-03ed-425d-900e-1aac2cb01b71" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_144c3662-d39c-4ca4-aa4f-89de274459c5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_5b766e30-290b-4b80-bc00-be6e12071945" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_144c3662-d39c-4ca4-aa4f-89de274459c5" xlink:to="loc_us-gaap_WarrantMember_5b766e30-290b-4b80-bc00-be6e12071945" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_3bf4dc3c-3a86-433a-8723-ec29a7ff6141" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_9e24c1a2-4036-47c0-bef4-a6468fd0e8a0" xlink:to="loc_us-gaap_VariableRateAxis_3bf4dc3c-3a86-433a-8723-ec29a7ff6141" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_3bf4dc3c-3a86-433a-8723-ec29a7ff6141_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableRateAxis_3bf4dc3c-3a86-433a-8723-ec29a7ff6141" xlink:to="loc_us-gaap_VariableRateDomain_3bf4dc3c-3a86-433a-8723-ec29a7ff6141_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_383e409d-12f9-45e8-9bde-be29b4603680" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableRateAxis_3bf4dc3c-3a86-433a-8723-ec29a7ff6141" xlink:to="loc_us-gaap_VariableRateDomain_383e409d-12f9-45e8-9bde-be29b4603680" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_fe41fcf9-2a1c-4022-ac55-8110ee8b0146" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_9e24c1a2-4036-47c0-bef4-a6468fd0e8a0" xlink:to="loc_us-gaap_CreditFacilityAxis_fe41fcf9-2a1c-4022-ac55-8110ee8b0146" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_fe41fcf9-2a1c-4022-ac55-8110ee8b0146_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_fe41fcf9-2a1c-4022-ac55-8110ee8b0146" xlink:to="loc_us-gaap_CreditFacilityDomain_fe41fcf9-2a1c-4022-ac55-8110ee8b0146_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_716cb8ab-85a5-4b55-9638-0f03ceef01e1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_fe41fcf9-2a1c-4022-ac55-8110ee8b0146" xlink:to="loc_us-gaap_CreditFacilityDomain_716cb8ab-85a5-4b55-9638-0f03ceef01e1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_selb_A2020TermLoansMember_442e45e3-7d08-44a3-869b-0955d831d913" xlink:href="selb-20210331.xsd#selb_A2020TermLoansMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_716cb8ab-85a5-4b55-9638-0f03ceef01e1" xlink:to="loc_selb_A2020TermLoansMember_442e45e3-7d08-44a3-869b-0955d831d913" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_selb_TermALoansMember_b50822df-c5de-4729-b30e-4136be8edd22" xlink:href="selb-20210331.xsd#selb_TermALoansMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_716cb8ab-85a5-4b55-9638-0f03ceef01e1" xlink:to="loc_selb_TermALoansMember_b50822df-c5de-4729-b30e-4136be8edd22" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_selb_TermBLoansMember_1c44e817-31a6-4089-abba-ac0de9036a90" xlink:href="selb-20210331.xsd#selb_TermBLoansMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_716cb8ab-85a5-4b55-9638-0f03ceef01e1" xlink:to="loc_selb_TermBLoansMember_1c44e817-31a6-4089-abba-ac0de9036a90" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_selb_A2017TermLoansMember_dfb62734-cc9b-4dc2-9430-30094c86e2b6" xlink:href="selb-20210331.xsd#selb_A2017TermLoansMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_716cb8ab-85a5-4b55-9638-0f03ceef01e1" xlink:to="loc_selb_A2017TermLoansMember_dfb62734-cc9b-4dc2-9430-30094c86e2b6" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.selectabio.com/role/DebtScheduleofFutureMinimumPaymentsontheTermLoansDetails" xlink:type="simple" xlink:href="selb-20210331.xsd#DebtScheduleofFutureMinimumPaymentsontheTermLoansDetails"/>
  <link:definitionLink xlink:role="http://www.selectabio.com/role/DebtScheduleofFutureMinimumPaymentsontheTermLoansDetails" xlink:type="extended" id="ic155aaea01fb4d678bf1b9a8a450096a_DebtScheduleofFutureMinimumPaymentsontheTermLoansDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLineItems_fcc9f68c-1a1c-406b-bcfd-51aec978637a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtByMaturityAbstract_fd452715-04ee-4e0e-ba81-6545eeb2f2ea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtByMaturityAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_fcc9f68c-1a1c-406b-bcfd-51aec978637a" xlink:to="loc_us-gaap_LongTermDebtByMaturityAbstract_fd452715-04ee-4e0e-ba81-6545eeb2f2ea" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_b480454d-6ad1-4242-8fed-ff2065b92f3f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_fd452715-04ee-4e0e-ba81-6545eeb2f2ea" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_b480454d-6ad1-4242-8fed-ff2065b92f3f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_09951dc6-d2d5-4b33-8de5-e6fb371dfd87" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_fd452715-04ee-4e0e-ba81-6545eeb2f2ea" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_09951dc6-d2d5-4b33-8de5-e6fb371dfd87" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_747893e9-91c6-4fc3-8704-71b5ea8a3b64" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_fd452715-04ee-4e0e-ba81-6545eeb2f2ea" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_747893e9-91c6-4fc3-8704-71b5ea8a3b64" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_28b40852-3dae-43e8-a60c-aa9a3052cb17" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_fd452715-04ee-4e0e-ba81-6545eeb2f2ea" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_28b40852-3dae-43e8-a60c-aa9a3052cb17" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_134b245a-9c36-49ec-8113-da22e55c3a35" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_fd452715-04ee-4e0e-ba81-6545eeb2f2ea" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_134b245a-9c36-49ec-8113-da22e55c3a35" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_b2c0416e-220e-4f97-a712-b75b68f35b5e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_fd452715-04ee-4e0e-ba81-6545eeb2f2ea" xlink:to="loc_us-gaap_LongTermDebt_b2c0416e-220e-4f97-a712-b75b68f35b5e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_selb_DebtInstrumentInterestPortion_dc9b8837-6345-41ae-aa82-bed0c0065d80" xlink:href="selb-20210331.xsd#selb_DebtInstrumentInterestPortion"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_fd452715-04ee-4e0e-ba81-6545eeb2f2ea" xlink:to="loc_selb_DebtInstrumentInterestPortion_dc9b8837-6345-41ae-aa82-bed0c0065d80" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_391213fa-d883-4327-b572-cd7c570b5c39" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_fd452715-04ee-4e0e-ba81-6545eeb2f2ea" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_391213fa-d883-4327-b572-cd7c570b5c39" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_0dc31e56-bf5f-4ffa-8b8b-4117422d8cb2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_fd452715-04ee-4e0e-ba81-6545eeb2f2ea" xlink:to="loc_us-gaap_LongTermDebtCurrent_0dc31e56-bf5f-4ffa-8b8b-4117422d8cb2" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_51052656-8442-4f47-b759-91d7b1c47bfe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_fd452715-04ee-4e0e-ba81-6545eeb2f2ea" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_51052656-8442-4f47-b759-91d7b1c47bfe" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityTable_7f55734b-673e-4953-a265-813e3aaa3326" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_fcc9f68c-1a1c-406b-bcfd-51aec978637a" xlink:to="loc_us-gaap_LineOfCreditFacilityTable_7f55734b-673e-4953-a265-813e3aaa3326" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_94dec011-5bac-4e09-9a8f-d2347c570444" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_7f55734b-673e-4953-a265-813e3aaa3326" xlink:to="loc_us-gaap_CreditFacilityAxis_94dec011-5bac-4e09-9a8f-d2347c570444" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_94dec011-5bac-4e09-9a8f-d2347c570444_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_94dec011-5bac-4e09-9a8f-d2347c570444" xlink:to="loc_us-gaap_CreditFacilityDomain_94dec011-5bac-4e09-9a8f-d2347c570444_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_c0e14bd6-0168-4490-9f5b-40bff1278aeb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_94dec011-5bac-4e09-9a8f-d2347c570444" xlink:to="loc_us-gaap_CreditFacilityDomain_c0e14bd6-0168-4490-9f5b-40bff1278aeb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_selb_A2017TermLoansMember_b3d5a0d5-e0b3-4718-815c-4852e4ec7cef" xlink:href="selb-20210331.xsd#selb_A2017TermLoansMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_c0e14bd6-0168-4490-9f5b-40bff1278aeb" xlink:to="loc_selb_A2017TermLoansMember_b3d5a0d5-e0b3-4718-815c-4852e4ec7cef" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.selectabio.com/role/Equity" xlink:type="simple" xlink:href="selb-20210331.xsd#Equity"/>
  <link:definitionLink xlink:role="http://www.selectabio.com/role/Equity" xlink:type="extended" id="i8860036a026043768eeb8996d1e47afd_Equity"/>
  <link:roleRef roleURI="http://www.selectabio.com/role/EquityTables" xlink:type="simple" xlink:href="selb-20210331.xsd#EquityTables"/>
  <link:definitionLink xlink:role="http://www.selectabio.com/role/EquityTables" xlink:type="extended" id="i4e1a2e7e3f8d428fb2486a9de07a5cd2_EquityTables"/>
  <link:roleRef roleURI="http://www.selectabio.com/role/EquityNarrativeDetails" xlink:type="simple" xlink:href="selb-20210331.xsd#EquityNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.selectabio.com/role/EquityNarrativeDetails" xlink:type="extended" id="i6e033c8493ea4e268f88f1604d735ac1_EquityNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems_aa482f4f-3611-424c-8240-d9ae53baf02b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_5082405d-aa1d-4a21-8d75-edc002b32bd5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_aa482f4f-3611-424c-8240-d9ae53baf02b" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_5082405d-aa1d-4a21-8d75-edc002b32bd5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_88395ce7-5e7c-4888-8c96-3190919191de" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_aa482f4f-3611-424c-8240-d9ae53baf02b" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_88395ce7-5e7c-4888-8c96-3190919191de" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_4f9d7b44-85da-48e1-9257-d3f0e6b5624d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_aa482f4f-3611-424c-8240-d9ae53baf02b" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_4f9d7b44-85da-48e1-9257-d3f0e6b5624d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_5f7904d3-bca8-4d9d-9392-8abe74bbec3b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_aa482f4f-3611-424c-8240-d9ae53baf02b" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_5f7904d3-bca8-4d9d-9392-8abe74bbec3b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_selb_SaleofStockPercentageOfTenDayVolumeWeightedAveragePriceOfCommonStock_97f0b142-9c75-4f53-ba56-0fdda1c06c7d" xlink:href="selb-20210331.xsd#selb_SaleofStockPercentageOfTenDayVolumeWeightedAveragePriceOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_aa482f4f-3611-424c-8240-d9ae53baf02b" xlink:to="loc_selb_SaleofStockPercentageOfTenDayVolumeWeightedAveragePriceOfCommonStock_97f0b142-9c75-4f53-ba56-0fdda1c06c7d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_selb_LockUpFromClosingTerm_caad046d-44b4-4d3d-9210-b4f5f648576c" xlink:href="selb-20210331.xsd#selb_LockUpFromClosingTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_aa482f4f-3611-424c-8240-d9ae53baf02b" xlink:to="loc_selb_LockUpFromClosingTerm_caad046d-44b4-4d3d-9210-b4f5f648576c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedemptionPremium_70e1f82b-cf0a-4bc8-85e6-503871e1b9c1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RedemptionPremium"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_aa482f4f-3611-424c-8240-d9ae53baf02b" xlink:to="loc_us-gaap_RedemptionPremium_70e1f82b-cf0a-4bc8-85e6-503871e1b9c1" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_888e25e7-7503-42e3-9b2c-00621a6e6a5f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_aa482f4f-3611-424c-8240-d9ae53baf02b" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_888e25e7-7503-42e3-9b2c-00621a6e6a5f" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_selb_ClassOfWarrantOrRightNumberOfWarrantsExercised_66d69ea5-05ac-4558-b772-9224c3c6eaec" xlink:href="selb-20210331.xsd#selb_ClassOfWarrantOrRightNumberOfWarrantsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_aa482f4f-3611-424c-8240-d9ae53baf02b" xlink:to="loc_selb_ClassOfWarrantOrRightNumberOfWarrantsExercised_66d69ea5-05ac-4558-b772-9224c3c6eaec" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_5f24b15c-ca85-4028-afaa-c819e825bf21" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_aa482f4f-3611-424c-8240-d9ae53baf02b" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_5f24b15c-ca85-4028-afaa-c819e825bf21" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_selb_WarrantIssued_595568e6-8828-4528-af54-0feb80c4ad9b" xlink:href="selb-20210331.xsd#selb_WarrantIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_aa482f4f-3611-424c-8240-d9ae53baf02b" xlink:to="loc_selb_WarrantIssued_595568e6-8828-4528-af54-0feb80c4ad9b" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_c55a249b-c351-4db7-a2d0-c7ff98472cd8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_aa482f4f-3611-424c-8240-d9ae53baf02b" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_c55a249b-c351-4db7-a2d0-c7ff98472cd8" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding_80ea1cac-495e-45a9-a9f8-d1bf2528a14d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_aa482f4f-3611-424c-8240-d9ae53baf02b" xlink:to="loc_us-gaap_WarrantsAndRightsOutstanding_80ea1cac-495e-45a9-a9f8-d1bf2528a14d" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount_9b3a68f5-236b-4006-82a0-7253ec83c3c1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_aa482f4f-3611-424c-8240-d9ae53baf02b" xlink:to="loc_us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount_9b3a68f5-236b-4006-82a0-7253ec83c3c1" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_fa29c6bf-f44b-4ff2-8f0a-47406db07bbf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_aa482f4f-3611-424c-8240-d9ae53baf02b" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_fa29c6bf-f44b-4ff2-8f0a-47406db07bbf" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_a9a8e1a0-30ac-4c0e-93ed-79b3ed8d1cf2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_aa482f4f-3611-424c-8240-d9ae53baf02b" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_a9a8e1a0-30ac-4c0e-93ed-79b3ed8d1cf2" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_07c53eff-b180-442c-806f-00b5aef20e9a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_aa482f4f-3611-424c-8240-d9ae53baf02b" xlink:to="loc_us-gaap_CommonStockSharesIssued_07c53eff-b180-442c-806f-00b5aef20e9a" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_d195629b-79ba-40e1-a483-1e93ecae4659" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_aa482f4f-3611-424c-8240-d9ae53baf02b" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_d195629b-79ba-40e1-a483-1e93ecae4659" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_selb_VotesPerShareofCommonStock_ce8609b5-08ac-4a2b-8c92-6bfc2e55e30d" xlink:href="selb-20210331.xsd#selb_VotesPerShareofCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_aa482f4f-3611-424c-8240-d9ae53baf02b" xlink:to="loc_selb_VotesPerShareofCommonStock_ce8609b5-08ac-4a2b-8c92-6bfc2e55e30d" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsCommonStock_ddd59658-c7c5-4cd2-948a-c632b429bebc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DividendsCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_aa482f4f-3611-424c-8240-d9ae53baf02b" xlink:to="loc_us-gaap_DividendsCommonStock_ddd59658-c7c5-4cd2-948a-c632b429bebc" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_6bece56e-5316-4336-828b-294cf13e3e77" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_aa482f4f-3611-424c-8240-d9ae53baf02b" xlink:to="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_6bece56e-5316-4336-828b-294cf13e3e77" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_8e484a92-8a86-4878-867e-62a00ecf19b9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_6bece56e-5316-4336-828b-294cf13e3e77" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_8e484a92-8a86-4878-867e-62a00ecf19b9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_8e484a92-8a86-4878-867e-62a00ecf19b9_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_8e484a92-8a86-4878-867e-62a00ecf19b9" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_8e484a92-8a86-4878-867e-62a00ecf19b9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_d079f237-3b78-42a5-8436-7fa944d2ccdd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_8e484a92-8a86-4878-867e-62a00ecf19b9" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_d079f237-3b78-42a5-8436-7fa944d2ccdd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_selb_August2020ShelfRegistrationStatementMember_039f208c-0641-4fcc-a3e6-8654d94431a2" xlink:href="selb-20210331.xsd#selb_August2020ShelfRegistrationStatementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_d079f237-3b78-42a5-8436-7fa944d2ccdd" xlink:to="loc_selb_August2020ShelfRegistrationStatementMember_039f208c-0641-4fcc-a3e6-8654d94431a2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_selb_AtTheMarketOfferingMember_f5b342c8-7abd-4600-b17b-e2a81d13d40e" xlink:href="selb-20210331.xsd#selb_AtTheMarketOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_d079f237-3b78-42a5-8436-7fa944d2ccdd" xlink:to="loc_selb_AtTheMarketOfferingMember_f5b342c8-7abd-4600-b17b-e2a81d13d40e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_selb_A2020SaleAgreementAtTheMarketOfferingMember_800e1f55-0c2f-4059-9eb8-e7a777d8d552" xlink:href="selb-20210331.xsd#selb_A2020SaleAgreementAtTheMarketOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_d079f237-3b78-42a5-8436-7fa944d2ccdd" xlink:to="loc_selb_A2020SaleAgreementAtTheMarketOfferingMember_800e1f55-0c2f-4059-9eb8-e7a777d8d552" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_selb_SOBIPurchaseAgreementMember_289d4773-8736-437b-8f80-69d789baf75d" xlink:href="selb-20210331.xsd#selb_SOBIPurchaseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_d079f237-3b78-42a5-8436-7fa944d2ccdd" xlink:to="loc_selb_SOBIPurchaseAgreementMember_289d4773-8736-437b-8f80-69d789baf75d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_selb_DecemberTwoThousandNineteenFinancingMember_a7eafa58-822f-4644-83a3-95e2f51b06f0" xlink:href="selb-20210331.xsd#selb_DecemberTwoThousandNineteenFinancingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_d079f237-3b78-42a5-8436-7fa944d2ccdd" xlink:to="loc_selb_DecemberTwoThousandNineteenFinancingMember_a7eafa58-822f-4644-83a3-95e2f51b06f0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_selb_A2017PIPEMember_b42d1e80-b5ae-4677-9bf4-718fdcc0d49e" xlink:href="selb-20210331.xsd#selb_A2017PIPEMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_d079f237-3b78-42a5-8436-7fa944d2ccdd" xlink:to="loc_selb_A2017PIPEMember_b42d1e80-b5ae-4677-9bf4-718fdcc0d49e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_36ac1437-b253-4b46-a3d5-fb2be2dbfa38" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_d079f237-3b78-42a5-8436-7fa944d2ccdd" xlink:to="loc_us-gaap_WarrantMember_36ac1437-b253-4b46-a3d5-fb2be2dbfa38" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_316215db-57b2-451f-a981-db0601570fb5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_6bece56e-5316-4336-828b-294cf13e3e77" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_316215db-57b2-451f-a981-db0601570fb5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_316215db-57b2-451f-a981-db0601570fb5_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_316215db-57b2-451f-a981-db0601570fb5" xlink:to="loc_us-gaap_EquityComponentDomain_316215db-57b2-451f-a981-db0601570fb5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_fa311819-cc24-4e54-ad75-d5a534cfd3cb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_316215db-57b2-451f-a981-db0601570fb5" xlink:to="loc_us-gaap_EquityComponentDomain_fa311819-cc24-4e54-ad75-d5a534cfd3cb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_selb_PreFundedWarrantMember_c4cd46ff-8d2f-444b-8c5a-a87ccfea04c4" xlink:href="selb-20210331.xsd#selb_PreFundedWarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_fa311819-cc24-4e54-ad75-d5a534cfd3cb" xlink:to="loc_selb_PreFundedWarrantMember_c4cd46ff-8d2f-444b-8c5a-a87ccfea04c4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_b829a7c5-eaec-449b-84a0-8cd9d95413ea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_fa311819-cc24-4e54-ad75-d5a534cfd3cb" xlink:to="loc_us-gaap_WarrantMember_b829a7c5-eaec-449b-84a0-8cd9d95413ea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_selb_CommonWarrantMember_a934c4f4-4517-4dca-9f4e-c54e7214249c" xlink:href="selb-20210331.xsd#selb_CommonWarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_fa311819-cc24-4e54-ad75-d5a534cfd3cb" xlink:to="loc_selb_CommonWarrantMember_a934c4f4-4517-4dca-9f4e-c54e7214249c" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.selectabio.com/role/EquityWarrantyActivityDetails" xlink:type="simple" xlink:href="selb-20210331.xsd#EquityWarrantyActivityDetails"/>
  <link:definitionLink xlink:role="http://www.selectabio.com/role/EquityWarrantyActivityDetails" xlink:type="extended" id="i6e64ce3a470240fcb7ac75464c20320c_EquityWarrantyActivityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_7a032f83-90ec-4461-94e6-d6df26c85f07" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_461e1561-180b-46db-b633-bd0437a6b513" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_7a032f83-90ec-4461-94e6-d6df26c85f07" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_461e1561-180b-46db-b633-bd0437a6b513" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_22b5f4ea-4b02-4e1a-b5bc-04f5ceccec8a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_7a032f83-90ec-4461-94e6-d6df26c85f07" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_22b5f4ea-4b02-4e1a-b5bc-04f5ceccec8a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_977bb935-3b7b-4813-8da4-06064b432669" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_7a032f83-90ec-4461-94e6-d6df26c85f07" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_977bb935-3b7b-4813-8da4-06064b432669" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_dfad5fde-126a-499a-98e7-ca86f825806c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_977bb935-3b7b-4813-8da4-06064b432669" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_dfad5fde-126a-499a-98e7-ca86f825806c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_dfad5fde-126a-499a-98e7-ca86f825806c_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_dfad5fde-126a-499a-98e7-ca86f825806c" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_dfad5fde-126a-499a-98e7-ca86f825806c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_3a6ebd36-fed0-4aa8-9b52-df59b946aa22" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_dfad5fde-126a-499a-98e7-ca86f825806c" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_3a6ebd36-fed0-4aa8-9b52-df59b946aa22" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_659e267b-8e86-421f-a982-d1e047cd3dcb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_3a6ebd36-fed0-4aa8-9b52-df59b946aa22" xlink:to="loc_us-gaap_WarrantMember_659e267b-8e86-421f-a982-d1e047cd3dcb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_8703b193-9e47-4166-b3de-87af0fdc317d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_977bb935-3b7b-4813-8da4-06064b432669" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_8703b193-9e47-4166-b3de-87af0fdc317d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_8703b193-9e47-4166-b3de-87af0fdc317d_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_8703b193-9e47-4166-b3de-87af0fdc317d" xlink:to="loc_us-gaap_EquityComponentDomain_8703b193-9e47-4166-b3de-87af0fdc317d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_e5ef7355-b111-436b-a44f-f6e71f35ea54" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_8703b193-9e47-4166-b3de-87af0fdc317d" xlink:to="loc_us-gaap_EquityComponentDomain_e5ef7355-b111-436b-a44f-f6e71f35ea54" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_e61c78ce-2bcc-4cb4-b39b-641339228898" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_e5ef7355-b111-436b-a44f-f6e71f35ea54" xlink:to="loc_us-gaap_WarrantMember_e61c78ce-2bcc-4cb4-b39b-641339228898" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.selectabio.com/role/EquityScheduleofAuthorizedSharesofCommonStockforFutureIssuanceDetails" xlink:type="simple" xlink:href="selb-20210331.xsd#EquityScheduleofAuthorizedSharesofCommonStockforFutureIssuanceDetails"/>
  <link:definitionLink xlink:role="http://www.selectabio.com/role/EquityScheduleofAuthorizedSharesofCommonStockforFutureIssuanceDetails" xlink:type="extended" id="iaf5130df342f47f6a066352b0df58d4a_EquityScheduleofAuthorizedSharesofCommonStockforFutureIssuanceDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_30de8484-3c1f-40f9-9969-d4fd3d050d0c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_2f49dd97-b033-41ec-af1e-2b63c61508a1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_30de8484-3c1f-40f9-9969-d4fd3d050d0c" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_2f49dd97-b033-41ec-af1e-2b63c61508a1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_0a9cb031-ca18-4c60-a527-889a16e43e7b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_30de8484-3c1f-40f9-9969-d4fd3d050d0c" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_0a9cb031-ca18-4c60-a527-889a16e43e7b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_edcc6853-b672-4d4f-8caf-430ed1817432" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_0a9cb031-ca18-4c60-a527-889a16e43e7b" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_edcc6853-b672-4d4f-8caf-430ed1817432" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_edcc6853-b672-4d4f-8caf-430ed1817432_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_edcc6853-b672-4d4f-8caf-430ed1817432" xlink:to="loc_us-gaap_EquityComponentDomain_edcc6853-b672-4d4f-8caf-430ed1817432_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_2f1fe0ba-6649-4776-9d80-640aa68e489a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_edcc6853-b672-4d4f-8caf-430ed1817432" xlink:to="loc_us-gaap_EquityComponentDomain_2f1fe0ba-6649-4776-9d80-640aa68e489a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_4515ed5a-aaee-4165-a161-7d9a1c0f11c1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_2f1fe0ba-6649-4776-9d80-640aa68e489a" xlink:to="loc_us-gaap_WarrantMember_4515ed5a-aaee-4165-a161-7d9a1c0f11c1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_d8dbbdcd-7a88-4d24-8e32-8c20c4046837" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_0a9cb031-ca18-4c60-a527-889a16e43e7b" xlink:to="loc_us-gaap_AwardTypeAxis_d8dbbdcd-7a88-4d24-8e32-8c20c4046837" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d8dbbdcd-7a88-4d24-8e32-8c20c4046837_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_d8dbbdcd-7a88-4d24-8e32-8c20c4046837" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d8dbbdcd-7a88-4d24-8e32-8c20c4046837_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7ae5de26-2403-484a-8637-d974ad3c2b43" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_d8dbbdcd-7a88-4d24-8e32-8c20c4046837" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7ae5de26-2403-484a-8637-d974ad3c2b43" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockCompensationPlanMember_9e32c594-c81c-4ace-9bef-88e3cef68723" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockCompensationPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7ae5de26-2403-484a-8637-d974ad3c2b43" xlink:to="loc_us-gaap_StockCompensationPlanMember_9e32c594-c81c-4ace-9bef-88e3cef68723" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_selb_RestrictedStockUnitsRSUsReservedForIssuanceMember_a78e0fd5-19de-4f04-9369-50b33161d573" xlink:href="selb-20210331.xsd#selb_RestrictedStockUnitsRSUsReservedForIssuanceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7ae5de26-2403-484a-8637-d974ad3c2b43" xlink:to="loc_selb_RestrictedStockUnitsRSUsReservedForIssuanceMember_a78e0fd5-19de-4f04-9369-50b33161d573" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_selb_RestrictedStockUnitsUnvestedMember_c182fdea-ee93-4169-95c3-066a6ca1b9c6" xlink:href="selb-20210331.xsd#selb_RestrictedStockUnitsUnvestedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7ae5de26-2403-484a-8637-d974ad3c2b43" xlink:to="loc_selb_RestrictedStockUnitsUnvestedMember_c182fdea-ee93-4169-95c3-066a6ca1b9c6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_abc5bfcc-67ac-4be7-9930-4317d4a29fc7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7ae5de26-2403-484a-8637-d974ad3c2b43" xlink:to="loc_us-gaap_EmployeeStockOptionMember_abc5bfcc-67ac-4be7-9930-4317d4a29fc7" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.selectabio.com/role/StockIncentivePlans" xlink:type="simple" xlink:href="selb-20210331.xsd#StockIncentivePlans"/>
  <link:definitionLink xlink:role="http://www.selectabio.com/role/StockIncentivePlans" xlink:type="extended" id="i5f56015dacc6410fb352159ec387137c_StockIncentivePlans"/>
  <link:roleRef roleURI="http://www.selectabio.com/role/StockIncentivePlansTables" xlink:type="simple" xlink:href="selb-20210331.xsd#StockIncentivePlansTables"/>
  <link:definitionLink xlink:role="http://www.selectabio.com/role/StockIncentivePlansTables" xlink:type="extended" id="i7a837534ea904e44b2012cc7b2c81b14_StockIncentivePlansTables"/>
  <link:roleRef roleURI="http://www.selectabio.com/role/StockIncentivePlansNarrativeDetails" xlink:type="simple" xlink:href="selb-20210331.xsd#StockIncentivePlansNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.selectabio.com/role/StockIncentivePlansNarrativeDetails" xlink:type="extended" id="i77becf42f8fe48e0a7fa583f183673eb_StockIncentivePlansNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_29640d9b-a88b-4bcb-b81f-184fde557609" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_c4e4802a-a26e-4981-86c5-5274e651a76b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_29640d9b-a88b-4bcb-b81f-184fde557609" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_c4e4802a-a26e-4981-86c5-5274e651a76b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_selb_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantIncreaseDecrease_cd4963fa-4de8-423f-9a05-2819d355fbb5" xlink:href="selb-20210331.xsd#selb_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantIncreaseDecrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_29640d9b-a88b-4bcb-b81f-184fde557609" xlink:to="loc_selb_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantIncreaseDecrease_cd4963fa-4de8-423f-9a05-2819d355fbb5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_9f0b49e7-d414-4d2e-a498-8412f028d67c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_29640d9b-a88b-4bcb-b81f-184fde557609" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_9f0b49e7-d414-4d2e-a498-8412f028d67c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_selb_ShareBasedCompensationArrangementByShareBasedPaymentAwardForfeituresRate_571fb793-1678-4b17-ade8-b12b1fd17ad0" xlink:href="selb-20210331.xsd#selb_ShareBasedCompensationArrangementByShareBasedPaymentAwardForfeituresRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_29640d9b-a88b-4bcb-b81f-184fde557609" xlink:to="loc_selb_ShareBasedCompensationArrangementByShareBasedPaymentAwardForfeituresRate_571fb793-1678-4b17-ade8-b12b1fd17ad0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_3290e5b9-5e36-48db-a30a-a3a6a46a2493" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_29640d9b-a88b-4bcb-b81f-184fde557609" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_3290e5b9-5e36-48db-a30a-a3a6a46a2493" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_30091456-83ad-49b9-bcf4-9b6e8ad47d4a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_29640d9b-a88b-4bcb-b81f-184fde557609" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_30091456-83ad-49b9-bcf4-9b6e8ad47d4a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_6b131200-01ca-4490-9d00-e85e723fb9f0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_29640d9b-a88b-4bcb-b81f-184fde557609" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_6b131200-01ca-4490-9d00-e85e723fb9f0" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_cee02d7a-036e-40a5-9daf-d72ee31d0720" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_29640d9b-a88b-4bcb-b81f-184fde557609" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_cee02d7a-036e-40a5-9daf-d72ee31d0720" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_183c6afd-be15-4d8f-b487-b752f4406d68" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_29640d9b-a88b-4bcb-b81f-184fde557609" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_183c6afd-be15-4d8f-b487-b752f4406d68" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_selb_ShareBasedGoodsAndNonEmployeeServicesTransactionCompensationNotYetRecognizedStockOptions_39a65a78-13eb-4e29-b7c2-f7af3fe9001d" xlink:href="selb-20210331.xsd#selb_ShareBasedGoodsAndNonEmployeeServicesTransactionCompensationNotYetRecognizedStockOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_29640d9b-a88b-4bcb-b81f-184fde557609" xlink:to="loc_selb_ShareBasedGoodsAndNonEmployeeServicesTransactionCompensationNotYetRecognizedStockOptions_39a65a78-13eb-4e29-b7c2-f7af3fe9001d" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1a250282-ba2a-4678-a8c2-1832b399acd2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_29640d9b-a88b-4bcb-b81f-184fde557609" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1a250282-ba2a-4678-a8c2-1832b399acd2" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_c81e6f5f-856a-4b62-b924-27651b36e4a0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_29640d9b-a88b-4bcb-b81f-184fde557609" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_c81e6f5f-856a-4b62-b924-27651b36e4a0" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_501a263f-9bcc-490f-9c3f-5394aa105804" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_29640d9b-a88b-4bcb-b81f-184fde557609" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_501a263f-9bcc-490f-9c3f-5394aa105804" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_selb_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAwardedInPeriod_f70c5eaf-33c6-4bfb-8d92-54b0e974e3b3" xlink:href="selb-20210331.xsd#selb_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAwardedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_29640d9b-a88b-4bcb-b81f-184fde557609" xlink:to="loc_selb_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAwardedInPeriod_f70c5eaf-33c6-4bfb-8d92-54b0e974e3b3" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_selb_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReservedForIssuance_d89fb7f8-a593-47d6-9182-03fa06245c58" xlink:href="selb-20210331.xsd#selb_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReservedForIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_29640d9b-a88b-4bcb-b81f-184fde557609" xlink:to="loc_selb_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReservedForIssuance_d89fb7f8-a593-47d6-9182-03fa06245c58" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_selb_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReservedForIssuanceWeightedAverageGrantDateFairValue_474b9e2f-5c5b-4dcc-99a7-44162a828343" xlink:href="selb-20210331.xsd#selb_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReservedForIssuanceWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_29640d9b-a88b-4bcb-b81f-184fde557609" xlink:to="loc_selb_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReservedForIssuanceWeightedAverageGrantDateFairValue_474b9e2f-5c5b-4dcc-99a7-44162a828343" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_75fbeb74-f6bc-49c8-89b3-f3fda8121a32" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_29640d9b-a88b-4bcb-b81f-184fde557609" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_75fbeb74-f6bc-49c8-89b3-f3fda8121a32" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_73aba6c6-3555-42bd-833d-c8511f9cbc02" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_29640d9b-a88b-4bcb-b81f-184fde557609" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_73aba6c6-3555-42bd-833d-c8511f9cbc02" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_be2c420e-211c-45d2-8ca8-d66ed9ae7b54" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_29640d9b-a88b-4bcb-b81f-184fde557609" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_be2c420e-211c-45d2-8ca8-d66ed9ae7b54" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_cd371380-b0d7-4ee3-9531-40ebf08894b4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_be2c420e-211c-45d2-8ca8-d66ed9ae7b54" xlink:to="loc_us-gaap_PlanNameAxis_cd371380-b0d7-4ee3-9531-40ebf08894b4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_cd371380-b0d7-4ee3-9531-40ebf08894b4_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_cd371380-b0d7-4ee3-9531-40ebf08894b4" xlink:to="loc_us-gaap_PlanNameDomain_cd371380-b0d7-4ee3-9531-40ebf08894b4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_1caa5049-639b-4aeb-94a9-045774a3e00c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_cd371380-b0d7-4ee3-9531-40ebf08894b4" xlink:to="loc_us-gaap_PlanNameDomain_1caa5049-639b-4aeb-94a9-045774a3e00c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_selb_StockIncentivePlan2016Member_c4e073d4-ba31-4156-91f9-82ea057d8922" xlink:href="selb-20210331.xsd#selb_StockIncentivePlan2016Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_1caa5049-639b-4aeb-94a9-045774a3e00c" xlink:to="loc_selb_StockIncentivePlan2016Member_c4e073d4-ba31-4156-91f9-82ea057d8922" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_selb_EmploymentInducementIncentiveAwardPlanMember_bc7b5f16-c0d8-4066-be20-2d513bfce213" xlink:href="selb-20210331.xsd#selb_EmploymentInducementIncentiveAwardPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_1caa5049-639b-4aeb-94a9-045774a3e00c" xlink:to="loc_selb_EmploymentInducementIncentiveAwardPlanMember_bc7b5f16-c0d8-4066-be20-2d513bfce213" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_selb_EmployeeStockPurchasePlan2016Member_1c0b670b-62a1-44e5-9a35-93f68e128d88" xlink:href="selb-20210331.xsd#selb_EmployeeStockPurchasePlan2016Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_1caa5049-639b-4aeb-94a9-045774a3e00c" xlink:to="loc_selb_EmployeeStockPurchasePlan2016Member_1c0b670b-62a1-44e5-9a35-93f68e128d88" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_73baa7ec-0b94-4543-a201-ed8b3ffc2da5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_be2c420e-211c-45d2-8ca8-d66ed9ae7b54" xlink:to="loc_us-gaap_AwardTypeAxis_73baa7ec-0b94-4543-a201-ed8b3ffc2da5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_73baa7ec-0b94-4543-a201-ed8b3ffc2da5_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_73baa7ec-0b94-4543-a201-ed8b3ffc2da5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_73baa7ec-0b94-4543-a201-ed8b3ffc2da5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ccf4d568-bf76-45ec-a758-1560c22c3cf7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_73baa7ec-0b94-4543-a201-ed8b3ffc2da5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ccf4d568-bf76-45ec-a758-1560c22c3cf7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockCompensationPlanMember_c121d939-16af-466b-8096-69f695392998" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockCompensationPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ccf4d568-bf76-45ec-a758-1560c22c3cf7" xlink:to="loc_us-gaap_StockCompensationPlanMember_c121d939-16af-466b-8096-69f695392998" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_selb_NonEmployeeStockOptionMember_7fac081e-81df-4e48-b7e5-b4c283cd10eb" xlink:href="selb-20210331.xsd#selb_NonEmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ccf4d568-bf76-45ec-a758-1560c22c3cf7" xlink:to="loc_selb_NonEmployeeStockOptionMember_7fac081e-81df-4e48-b7e5-b4c283cd10eb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_5e5b22cd-b8e1-467d-8e25-e318a339d5f7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ccf4d568-bf76-45ec-a758-1560c22c3cf7" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_5e5b22cd-b8e1-467d-8e25-e318a339d5f7" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.selectabio.com/role/StockIncentivePlansScheduleofStockBasedCompensationExpenseRelatedtoStockOptionsandRestrictedCommonStockDetails" xlink:type="simple" xlink:href="selb-20210331.xsd#StockIncentivePlansScheduleofStockBasedCompensationExpenseRelatedtoStockOptionsandRestrictedCommonStockDetails"/>
  <link:definitionLink xlink:role="http://www.selectabio.com/role/StockIncentivePlansScheduleofStockBasedCompensationExpenseRelatedtoStockOptionsandRestrictedCommonStockDetails" xlink:type="extended" id="i9499a8d711fd4ee3a07a391e7d5ea044_StockIncentivePlansScheduleofStockBasedCompensationExpenseRelatedtoStockOptionsandRestrictedCommonStockDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_1098ced6-bc1e-4fbf-920a-ebf70c6308a4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_0ea4f00c-39ae-4965-811f-8068bd78f9e7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_1098ced6-bc1e-4fbf-920a-ebf70c6308a4" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_0ea4f00c-39ae-4965-811f-8068bd78f9e7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_f52bbd9c-538b-43f8-ac6d-bf18f048cc67" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_1098ced6-bc1e-4fbf-920a-ebf70c6308a4" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_f52bbd9c-538b-43f8-ac6d-bf18f048cc67" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_87296f66-d4f4-4f29-9bf9-83159cc463e7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_f52bbd9c-538b-43f8-ac6d-bf18f048cc67" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_87296f66-d4f4-4f29-9bf9-83159cc463e7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_87296f66-d4f4-4f29-9bf9-83159cc463e7_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_87296f66-d4f4-4f29-9bf9-83159cc463e7" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_87296f66-d4f4-4f29-9bf9-83159cc463e7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_f2a133de-009c-4129-b4b7-c311b0993509" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_87296f66-d4f4-4f29-9bf9-83159cc463e7" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_f2a133de-009c-4129-b4b7-c311b0993509" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_selb_ResearchAndDevelopmentMember_335ad9ba-8f6e-483e-8dea-7e725ff852e3" xlink:href="selb-20210331.xsd#selb_ResearchAndDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_f2a133de-009c-4129-b4b7-c311b0993509" xlink:to="loc_selb_ResearchAndDevelopmentMember_335ad9ba-8f6e-483e-8dea-7e725ff852e3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_a99c98e6-6565-40a3-944c-e9e906064462" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_f2a133de-009c-4129-b4b7-c311b0993509" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_a99c98e6-6565-40a3-944c-e9e906064462" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.selectabio.com/role/StockIncentivePlansScheduleofAssumptionsDetails" xlink:type="simple" xlink:href="selb-20210331.xsd#StockIncentivePlansScheduleofAssumptionsDetails"/>
  <link:definitionLink xlink:role="http://www.selectabio.com/role/StockIncentivePlansScheduleofAssumptionsDetails" xlink:type="extended" id="i6d4eaa66f2a0444e98982aedb79b3c1a_StockIncentivePlansScheduleofAssumptionsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ca170ae5-0251-4b59-a5b2-d86004a9e12e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_ac357d1e-b654-4d52-8a2f-258262a851f6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ca170ae5-0251-4b59-a5b2-d86004a9e12e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_ac357d1e-b654-4d52-8a2f-258262a851f6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_cba24e61-6c61-4cc3-b4e7-42370672e807" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ca170ae5-0251-4b59-a5b2-d86004a9e12e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_cba24e61-6c61-4cc3-b4e7-42370672e807" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_7fe935d4-44a0-4f9d-a04e-a91d32fd6027" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ca170ae5-0251-4b59-a5b2-d86004a9e12e" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_7fe935d4-44a0-4f9d-a04e-a91d32fd6027" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_b2273536-5ec7-4e83-8deb-b16c7295dd1c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ca170ae5-0251-4b59-a5b2-d86004a9e12e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_b2273536-5ec7-4e83-8deb-b16c7295dd1c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_selb_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageFairValue_55c9da70-b6a4-42e1-9386-c33f4ef1653b" xlink:href="selb-20210331.xsd#selb_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ca170ae5-0251-4b59-a5b2-d86004a9e12e" xlink:to="loc_selb_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageFairValue_55c9da70-b6a4-42e1-9386-c33f4ef1653b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f1761cbd-9355-4807-8509-962aeb490b9c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ca170ae5-0251-4b59-a5b2-d86004a9e12e" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f1761cbd-9355-4807-8509-962aeb490b9c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_522c96f8-5a50-47dc-90b0-651900482c4b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f1761cbd-9355-4807-8509-962aeb490b9c" xlink:to="loc_us-gaap_AwardTypeAxis_522c96f8-5a50-47dc-90b0-651900482c4b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_522c96f8-5a50-47dc-90b0-651900482c4b_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_522c96f8-5a50-47dc-90b0-651900482c4b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_522c96f8-5a50-47dc-90b0-651900482c4b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_eccb2b74-2938-4b50-a36b-3963bd8af73b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_522c96f8-5a50-47dc-90b0-651900482c4b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_eccb2b74-2938-4b50-a36b-3963bd8af73b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockCompensationPlanMember_6529259f-fbb2-4c3a-a1bb-ce4c4d638e50" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockCompensationPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_eccb2b74-2938-4b50-a36b-3963bd8af73b" xlink:to="loc_us-gaap_StockCompensationPlanMember_6529259f-fbb2-4c3a-a1bb-ce4c4d638e50" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_selb_NonEmployeeStockOptionMember_fc9fc080-fccb-4bc2-9e49-287148fd2a07" xlink:href="selb-20210331.xsd#selb_NonEmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_eccb2b74-2938-4b50-a36b-3963bd8af73b" xlink:to="loc_selb_NonEmployeeStockOptionMember_fc9fc080-fccb-4bc2-9e49-287148fd2a07" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.selectabio.com/role/StockIncentivePlansSummaryofOptionsActivityDetails" xlink:type="simple" xlink:href="selb-20210331.xsd#StockIncentivePlansSummaryofOptionsActivityDetails"/>
  <link:definitionLink xlink:role="http://www.selectabio.com/role/StockIncentivePlansSummaryofOptionsActivityDetails" xlink:type="extended" id="ibfaaf5b510b6415eb2dd8d10faef3c88_StockIncentivePlansSummaryofOptionsActivityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e73a4456-f723-4b59-876c-612d642b98ac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_d1e9188a-68f4-4696-9c21-8841f97976a0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e73a4456-f723-4b59-876c-612d642b98ac" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_d1e9188a-68f4-4696-9c21-8841f97976a0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_e1dc1c5a-f684-4bee-8ba1-a8ab94f39afb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_d1e9188a-68f4-4696-9c21-8841f97976a0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_e1dc1c5a-f684-4bee-8ba1-a8ab94f39afb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_10914892-882c-43bf-94cd-c60d322fad44" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_d1e9188a-68f4-4696-9c21-8841f97976a0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_10914892-882c-43bf-94cd-c60d322fad44" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_5c7e9956-6261-40b8-89f3-4745399bcf7a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_d1e9188a-68f4-4696-9c21-8841f97976a0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_5c7e9956-6261-40b8-89f3-4745399bcf7a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_5d47428e-4880-4eba-9beb-5fe6101e2316" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_d1e9188a-68f4-4696-9c21-8841f97976a0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_5d47428e-4880-4eba-9beb-5fe6101e2316" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_ec9ed5cd-6df4-480b-a194-acbd94b93781" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_55c0fdb3-0698-4bc2-8786-a485e43e1ef3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e73a4456-f723-4b59-876c-612d642b98ac" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_55c0fdb3-0698-4bc2-8786-a485e43e1ef3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_7df7b1e3-9733-4d08-ab95-b1eff7cb1501" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e73a4456-f723-4b59-876c-612d642b98ac" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_7df7b1e3-9733-4d08-ab95-b1eff7cb1501" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_5a1c562c-cca1-49c2-8592-d388fc787772" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e73a4456-f723-4b59-876c-612d642b98ac" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_5a1c562c-cca1-49c2-8592-d388fc787772" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_eca87103-db83-4b62-a931-5a7d131963a1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_5a1c562c-cca1-49c2-8592-d388fc787772" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_eca87103-db83-4b62-a931-5a7d131963a1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_523f2a17-d89a-4b20-819c-0f1dd538b1c6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_5a1c562c-cca1-49c2-8592-d388fc787772" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_523f2a17-d89a-4b20-819c-0f1dd538b1c6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_68069811-9e35-4c7b-8a5c-49f148625da7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_5a1c562c-cca1-49c2-8592-d388fc787772" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_68069811-9e35-4c7b-8a5c-49f148625da7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_f47c2453-285c-4d57-a3de-5b2c988e2946" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_5a1c562c-cca1-49c2-8592-d388fc787772" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_f47c2453-285c-4d57-a3de-5b2c988e2946" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_14901801-5707-455a-8631-be3fe0474770" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:label="loc_selb_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsVestedWeightedAverageExercisePrice_4919ff68-0e74-49f3-848f-60f296504511" xlink:href="selb-20210331.xsd#selb_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsVestedWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e73a4456-f723-4b59-876c-612d642b98ac" xlink:to="loc_selb_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsVestedWeightedAverageExercisePrice_4919ff68-0e74-49f3-848f-60f296504511" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_44611b08-b91c-47ed-bac1-2ffb86dce961" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e73a4456-f723-4b59-876c-612d642b98ac" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_44611b08-b91c-47ed-bac1-2ffb86dce961" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_selb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract_dbc892de-025a-4033-bc8c-fdf89a8f4678" xlink:href="selb-20210331.xsd#selb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e73a4456-f723-4b59-876c-612d642b98ac" xlink:to="loc_selb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract_dbc892de-025a-4033-bc8c-fdf89a8f4678" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_bcda163c-97d0-438d-8491-9710c797b5ae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_selb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract_dbc892de-025a-4033-bc8c-fdf89a8f4678" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_bcda163c-97d0-438d-8491-9710c797b5ae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_selb_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedOutstandingWeightedAverageRemainingContractualTerm_49f350a8-e87f-43dd-97c1-e12a043148a5" xlink:href="selb-20210331.xsd#selb_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedOutstandingWeightedAverageRemainingContractualTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_selb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract_dbc892de-025a-4033-bc8c-fdf89a8f4678" xlink:to="loc_selb_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedOutstandingWeightedAverageRemainingContractualTerm_49f350a8-e87f-43dd-97c1-e12a043148a5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_64ea40ac-d847-49a8-b015-9b3844fc5a9d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_selb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract_dbc892de-025a-4033-bc8c-fdf89a8f4678" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_64ea40ac-d847-49a8-b015-9b3844fc5a9d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_selb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValueAbstract_a8ff3607-0a06-496c-8d7b-14f7e5880e61" xlink:href="selb-20210331.xsd#selb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValueAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e73a4456-f723-4b59-876c-612d642b98ac" xlink:to="loc_selb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValueAbstract_a8ff3607-0a06-496c-8d7b-14f7e5880e61" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_c3e65f75-15a9-49b3-acb7-d58515b801f2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_selb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValueAbstract_a8ff3607-0a06-496c-8d7b-14f7e5880e61" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_c3e65f75-15a9-49b3-acb7-d58515b801f2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_selb_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedOutstandingIntrinsicValue_435f1712-e103-42c5-9f4d-5b2e98a86e84" xlink:href="selb-20210331.xsd#selb_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedOutstandingIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_selb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValueAbstract_a8ff3607-0a06-496c-8d7b-14f7e5880e61" xlink:to="loc_selb_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedOutstandingIntrinsicValue_435f1712-e103-42c5-9f4d-5b2e98a86e84" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_22187ec5-0ef9-463d-9341-7b207fc2a928" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_selb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValueAbstract_a8ff3607-0a06-496c-8d7b-14f7e5880e61" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_22187ec5-0ef9-463d-9341-7b207fc2a928" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_550e272f-d7b4-45e3-8e8e-e241995e84a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e73a4456-f723-4b59-876c-612d642b98ac" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_550e272f-d7b4-45e3-8e8e-e241995e84a2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_10c0c086-2be3-4588-9180-6bd4da25d30b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_550e272f-d7b4-45e3-8e8e-e241995e84a2" xlink:to="loc_us-gaap_PlanNameAxis_10c0c086-2be3-4588-9180-6bd4da25d30b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_10c0c086-2be3-4588-9180-6bd4da25d30b_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_10c0c086-2be3-4588-9180-6bd4da25d30b" xlink:to="loc_us-gaap_PlanNameDomain_10c0c086-2be3-4588-9180-6bd4da25d30b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_6d0e2889-f3e6-420b-a813-64e3d53d71e9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_10c0c086-2be3-4588-9180-6bd4da25d30b" xlink:to="loc_us-gaap_PlanNameDomain_6d0e2889-f3e6-420b-a813-64e3d53d71e9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_selb_A2008Plan2016PlanAnd2018InducementIncentiveAwardPlanMember_0263b88e-ed55-4553-8b4d-158cbfd769f5" xlink:href="selb-20210331.xsd#selb_A2008Plan2016PlanAnd2018InducementIncentiveAwardPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_6d0e2889-f3e6-420b-a813-64e3d53d71e9" xlink:to="loc_selb_A2008Plan2016PlanAnd2018InducementIncentiveAwardPlanMember_0263b88e-ed55-4553-8b4d-158cbfd769f5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_1321660f-d158-49f3-9fe4-1079b463456a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_550e272f-d7b4-45e3-8e8e-e241995e84a2" xlink:to="loc_us-gaap_AwardTypeAxis_1321660f-d158-49f3-9fe4-1079b463456a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1321660f-d158-49f3-9fe4-1079b463456a_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_1321660f-d158-49f3-9fe4-1079b463456a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1321660f-d158-49f3-9fe4-1079b463456a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ab5a8627-4b07-4f5b-9bdf-a8021c5d7879" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_1321660f-d158-49f3-9fe4-1079b463456a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ab5a8627-4b07-4f5b-9bdf-a8021c5d7879" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockCompensationPlanMember_d314e058-8d3b-4f42-8dbb-4bf5ef4adb51" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockCompensationPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ab5a8627-4b07-4f5b-9bdf-a8021c5d7879" xlink:to="loc_us-gaap_StockCompensationPlanMember_d314e058-8d3b-4f42-8dbb-4bf5ef4adb51" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_selb_NonEmployeeStockOptionMember_38e8e796-fd0f-4d99-86fd-609621562886" xlink:href="selb-20210331.xsd#selb_NonEmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ab5a8627-4b07-4f5b-9bdf-a8021c5d7879" xlink:to="loc_selb_NonEmployeeStockOptionMember_38e8e796-fd0f-4d99-86fd-609621562886" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.selectabio.com/role/StockIncentivePlansRestrictedStockUnitsDetails" xlink:type="simple" xlink:href="selb-20210331.xsd#StockIncentivePlansRestrictedStockUnitsDetails"/>
  <link:definitionLink xlink:role="http://www.selectabio.com/role/StockIncentivePlansRestrictedStockUnitsDetails" xlink:type="extended" id="ie664cf28a05441ee9b76e17c949720d6_StockIncentivePlansRestrictedStockUnitsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_099a507a-ee4d-4e8b-b720-098e25b9860f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_1e2ff3a1-3eab-47b6-b05f-55fbdb954879" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_099a507a-ee4d-4e8b-b720-098e25b9860f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_1e2ff3a1-3eab-47b6-b05f-55fbdb954879" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_69524a0c-23a9-44e0-a686-c7c797ced2d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_1e2ff3a1-3eab-47b6-b05f-55fbdb954879" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_69524a0c-23a9-44e0-a686-c7c797ced2d5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_e0428556-bae1-45fb-bdc5-0af169032a4e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_1e2ff3a1-3eab-47b6-b05f-55fbdb954879" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_e0428556-bae1-45fb-bdc5-0af169032a4e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_b47362a7-35ff-4f70-97e0-2b51a77d679a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_1e2ff3a1-3eab-47b6-b05f-55fbdb954879" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_b47362a7-35ff-4f70-97e0-2b51a77d679a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_selb_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReservedForIssuance_bcd307c5-4a3d-44b4-bc79-4b1510603a60" xlink:href="selb-20210331.xsd#selb_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReservedForIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_1e2ff3a1-3eab-47b6-b05f-55fbdb954879" xlink:to="loc_selb_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReservedForIssuance_bcd307c5-4a3d-44b4-bc79-4b1510603a60" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_7e1c5082-3b3c-46f2-b3e0-7e28a3d8252e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_1e2ff3a1-3eab-47b6-b05f-55fbdb954879" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_7e1c5082-3b3c-46f2-b3e0-7e28a3d8252e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_578cf4d4-67f4-44c3-9762-b9d970935e8c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_4710bea7-92e5-4b47-ba1d-9d3c1084abbe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_099a507a-ee4d-4e8b-b720-098e25b9860f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_4710bea7-92e5-4b47-ba1d-9d3c1084abbe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_79e8215f-8bfb-48e5-8e0c-acde020b58c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_4710bea7-92e5-4b47-ba1d-9d3c1084abbe" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_79e8215f-8bfb-48e5-8e0c-acde020b58c8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_fc51a89a-dd43-47c4-8f36-94be25981faf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_4710bea7-92e5-4b47-ba1d-9d3c1084abbe" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_fc51a89a-dd43-47c4-8f36-94be25981faf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_9a1ed873-efbc-471b-adfa-2b2014b2e85f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_4710bea7-92e5-4b47-ba1d-9d3c1084abbe" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_9a1ed873-efbc-471b-adfa-2b2014b2e85f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_selb_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReservedForIssuanceWeightedAverageGrantDateFairValue_1fd12752-5397-490e-aa72-290044442b95" xlink:href="selb-20210331.xsd#selb_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReservedForIssuanceWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_4710bea7-92e5-4b47-ba1d-9d3c1084abbe" xlink:to="loc_selb_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReservedForIssuanceWeightedAverageGrantDateFairValue_1fd12752-5397-490e-aa72-290044442b95" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_a3023512-9a4a-4f88-b6dc-e40aa8b14851" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_4710bea7-92e5-4b47-ba1d-9d3c1084abbe" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_a3023512-9a4a-4f88-b6dc-e40aa8b14851" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_f329bead-b2c6-4949-bc2b-96462f067dc1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3318965d-da32-468a-9a6e-c001bf97d383" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_099a507a-ee4d-4e8b-b720-098e25b9860f" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3318965d-da32-468a-9a6e-c001bf97d383" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_a1238598-f868-437e-b184-b512f8e986fc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3318965d-da32-468a-9a6e-c001bf97d383" xlink:to="loc_us-gaap_AwardTypeAxis_a1238598-f868-437e-b184-b512f8e986fc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a1238598-f868-437e-b184-b512f8e986fc_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_a1238598-f868-437e-b184-b512f8e986fc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a1238598-f868-437e-b184-b512f8e986fc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_16057cad-2e1a-4983-badd-8c4fcb749b88" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_a1238598-f868-437e-b184-b512f8e986fc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_16057cad-2e1a-4983-badd-8c4fcb749b88" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_f620f5ba-9d59-4179-a0de-d3d6342f481e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_16057cad-2e1a-4983-badd-8c4fcb749b88" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_f620f5ba-9d59-4179-a0de-d3d6342f481e" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.selectabio.com/role/StockIncentivePlansEmployeeStockPurchasePlanNarrativeDetails" xlink:type="simple" xlink:href="selb-20210331.xsd#StockIncentivePlansEmployeeStockPurchasePlanNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.selectabio.com/role/StockIncentivePlansEmployeeStockPurchasePlanNarrativeDetails" xlink:type="extended" id="i6e7370703a2d4ddd86e9c9638f5e1cc3_StockIncentivePlansEmployeeStockPurchasePlanNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_635a0fa7-0d69-4cee-87b4-a22ea1d27882" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_368cb339-3c00-4cf1-b8f8-aeabf3c20f6f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_635a0fa7-0d69-4cee-87b4-a22ea1d27882" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_368cb339-3c00-4cf1-b8f8-aeabf3c20f6f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_selb_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantIncreaseDecrease_a2af102c-37a2-4208-ba74-52ecf220957b" xlink:href="selb-20210331.xsd#selb_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantIncreaseDecrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_635a0fa7-0d69-4cee-87b4-a22ea1d27882" xlink:to="loc_selb_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantIncreaseDecrease_a2af102c-37a2-4208-ba74-52ecf220957b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_c7911938-6927-4cdb-beee-b230c74bc5e1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_635a0fa7-0d69-4cee-87b4-a22ea1d27882" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_c7911938-6927-4cdb-beee-b230c74bc5e1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_281462f5-baec-47d1-a5fa-ff6865b7a801" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_635a0fa7-0d69-4cee-87b4-a22ea1d27882" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_281462f5-baec-47d1-a5fa-ff6865b7a801" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b38f6609-4fcd-46b2-a07f-cd850f0b2d0f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_635a0fa7-0d69-4cee-87b4-a22ea1d27882" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b38f6609-4fcd-46b2-a07f-cd850f0b2d0f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_d411a122-71d1-4b7d-85ac-af096b8e96ef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b38f6609-4fcd-46b2-a07f-cd850f0b2d0f" xlink:to="loc_us-gaap_PlanNameAxis_d411a122-71d1-4b7d-85ac-af096b8e96ef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_d411a122-71d1-4b7d-85ac-af096b8e96ef_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_d411a122-71d1-4b7d-85ac-af096b8e96ef" xlink:to="loc_us-gaap_PlanNameDomain_d411a122-71d1-4b7d-85ac-af096b8e96ef_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_275289a1-e4c5-414a-835a-74c00d3f769d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_d411a122-71d1-4b7d-85ac-af096b8e96ef" xlink:to="loc_us-gaap_PlanNameDomain_275289a1-e4c5-414a-835a-74c00d3f769d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_selb_EmployeeStockPurchasePlan2016Member_f46af2ce-144e-45c3-b61e-40b4acf0669f" xlink:href="selb-20210331.xsd#selb_EmployeeStockPurchasePlan2016Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_275289a1-e4c5-414a-835a-74c00d3f769d" xlink:to="loc_selb_EmployeeStockPurchasePlan2016Member_f46af2ce-144e-45c3-b61e-40b4acf0669f" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.selectabio.com/role/RevenueArrangements" xlink:type="simple" xlink:href="selb-20210331.xsd#RevenueArrangements"/>
  <link:definitionLink xlink:role="http://www.selectabio.com/role/RevenueArrangements" xlink:type="extended" id="i67efa56b47bf47e094b114469a5c49fc_RevenueArrangements"/>
  <link:roleRef roleURI="http://www.selectabio.com/role/RevenueArrangementsTables" xlink:type="simple" xlink:href="selb-20210331.xsd#RevenueArrangementsTables"/>
  <link:definitionLink xlink:role="http://www.selectabio.com/role/RevenueArrangementsTables" xlink:type="extended" id="iabbb838af41d4de3929a2895fff51d21_RevenueArrangementsTables"/>
  <link:roleRef roleURI="http://www.selectabio.com/role/RevenueArrangementsNarrativeDetails" xlink:type="simple" xlink:href="selb-20210331.xsd#RevenueArrangementsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.selectabio.com/role/RevenueArrangementsNarrativeDetails" xlink:type="extended" id="if2158308d11c4cd9a36a67a355a7f627_RevenueArrangementsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_79659bac-2442-488a-a7ad-4a70e9a916b3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_selb_LicenseAndOptionAgreementUpfrontCashPayment_13ab6ae6-ac11-4f50-ba15-3ef56d01f61b" xlink:href="selb-20210331.xsd#selb_LicenseAndOptionAgreementUpfrontCashPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_79659bac-2442-488a-a7ad-4a70e9a916b3" xlink:to="loc_selb_LicenseAndOptionAgreementUpfrontCashPayment_13ab6ae6-ac11-4f50-ba15-3ef56d01f61b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_selb_LicenseAndOptionAgreementSalesMilestonePaymentsThatMayBeReceived_76133636-e706-4a43-80b1-b965c3e6c677" xlink:href="selb-20210331.xsd#selb_LicenseAndOptionAgreementSalesMilestonePaymentsThatMayBeReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_79659bac-2442-488a-a7ad-4a70e9a916b3" xlink:to="loc_selb_LicenseAndOptionAgreementSalesMilestonePaymentsThatMayBeReceived_76133636-e706-4a43-80b1-b965c3e6c677" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_selb_LicenseAndOptionAgreementWrittenDayNoticePeriodBeforeCancellation_7c3958d3-4c79-4e27-b2e3-93efe75c2101" xlink:href="selb-20210331.xsd#selb_LicenseAndOptionAgreementWrittenDayNoticePeriodBeforeCancellation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_79659bac-2442-488a-a7ad-4a70e9a916b3" xlink:to="loc_selb_LicenseAndOptionAgreementWrittenDayNoticePeriodBeforeCancellation_7c3958d3-4c79-4e27-b2e3-93efe75c2101" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_selb_EligiblePeriodToReceiveRoyalties_455870a5-3b40-44a0-8513-0222f345e32a" xlink:href="selb-20210331.xsd#selb_EligiblePeriodToReceiveRoyalties"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_79659bac-2442-488a-a7ad-4a70e9a916b3" xlink:to="loc_selb_EligiblePeriodToReceiveRoyalties_455870a5-3b40-44a0-8513-0222f345e32a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_selb_RevenueNumberOfPerformanceObligations_00cd293e-5c90-4c75-a531-1e49ddd5bcbd" xlink:href="selb-20210331.xsd#selb_RevenueNumberOfPerformanceObligations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_79659bac-2442-488a-a7ad-4a70e9a916b3" xlink:to="loc_selb_RevenueNumberOfPerformanceObligations_00cd293e-5c90-4c75-a531-1e49ddd5bcbd" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_selb_LicenseAndOptionAgreementDevelopmentMilestone_2e7c47e9-dcbe-4d70-af42-b5c50f78c4b9" xlink:href="selb-20210331.xsd#selb_LicenseAndOptionAgreementDevelopmentMilestone"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_79659bac-2442-488a-a7ad-4a70e9a916b3" xlink:to="loc_selb_LicenseAndOptionAgreementDevelopmentMilestone_2e7c47e9-dcbe-4d70-af42-b5c50f78c4b9" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_1dfcf109-50b8-493c-bbf5-1cf56765c7df" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_79659bac-2442-488a-a7ad-4a70e9a916b3" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_1dfcf109-50b8-493c-bbf5-1cf56765c7df" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedemptionPremium_5851f9e1-b351-415f-959c-4baede187ed6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RedemptionPremium"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_79659bac-2442-488a-a7ad-4a70e9a916b3" xlink:to="loc_us-gaap_RedemptionPremium_5851f9e1-b351-415f-959c-4baede187ed6" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_21c8c43b-946e-4834-83bd-b16c1a9a2206" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_79659bac-2442-488a-a7ad-4a70e9a916b3" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_21c8c43b-946e-4834-83bd-b16c1a9a2206" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_2b1d0633-9405-45be-a46a-c64ac3e6aeba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_79659bac-2442-488a-a7ad-4a70e9a916b3" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_2b1d0633-9405-45be-a46a-c64ac3e6aeba" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetCurrent_3a24f5b6-ef0e-428a-970e-2f180fc14959" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerAssetNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_79659bac-2442-488a-a7ad-4a70e9a916b3" xlink:to="loc_us-gaap_ContractWithCustomerAssetNetCurrent_3a24f5b6-ef0e-428a-970e-2f180fc14959" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostAmortization_fcc64c1e-1e6f-4f4e-a1c2-bc786a3191cb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalizedContractCostAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_79659bac-2442-488a-a7ad-4a70e9a916b3" xlink:to="loc_us-gaap_CapitalizedContractCostAmortization_fcc64c1e-1e6f-4f4e-a1c2-bc786a3191cb" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_29e43f70-826e-41aa-8d63-47912570f7ba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_79659bac-2442-488a-a7ad-4a70e9a916b3" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_29e43f70-826e-41aa-8d63-47912570f7ba" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_e8f22053-84fb-416d-b6a2-b295ada430c3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_79659bac-2442-488a-a7ad-4a70e9a916b3" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_e8f22053-84fb-416d-b6a2-b295ada430c3" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_selb_LicenseAndOptionAgreementOptionTerm_f8233786-a695-4353-a1a3-dfbf97cd40bd" xlink:href="selb-20210331.xsd#selb_LicenseAndOptionAgreementOptionTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_79659bac-2442-488a-a7ad-4a70e9a916b3" xlink:to="loc_selb_LicenseAndOptionAgreementOptionTerm_f8233786-a695-4353-a1a3-dfbf97cd40bd" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_selb_LicenseAndOptionAgreementInitialUpFrontCashPayment_3c6fa286-bea2-4c27-a44c-1fc72a9e5110" xlink:href="selb-20210331.xsd#selb_LicenseAndOptionAgreementInitialUpFrontCashPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_79659bac-2442-488a-a7ad-4a70e9a916b3" xlink:to="loc_selb_LicenseAndOptionAgreementInitialUpFrontCashPayment_3c6fa286-bea2-4c27-a44c-1fc72a9e5110" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_selb_LicenseAndOptionAgreementExecutionFeePayment_da776e2e-0c8a-4c3f-a7d3-06a7d40271e5" xlink:href="selb-20210331.xsd#selb_LicenseAndOptionAgreementExecutionFeePayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_79659bac-2442-488a-a7ad-4a70e9a916b3" xlink:to="loc_selb_LicenseAndOptionAgreementExecutionFeePayment_da776e2e-0c8a-4c3f-a7d3-06a7d40271e5" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_85d62f48-acc5-4be8-9a8e-e761b7ce3c61" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_79659bac-2442-488a-a7ad-4a70e9a916b3" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_85d62f48-acc5-4be8-9a8e-e761b7ce3c61" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_36cd28f0-943a-4acf-b538-99fbd375a10e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_79659bac-2442-488a-a7ad-4a70e9a916b3" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_36cd28f0-943a-4acf-b538-99fbd375a10e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_28242ece-1ebb-4d98-976d-5f6974e084b9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_36cd28f0-943a-4acf-b538-99fbd375a10e" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_28242ece-1ebb-4d98-976d-5f6974e084b9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_28242ece-1ebb-4d98-976d-5f6974e084b9_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_28242ece-1ebb-4d98-976d-5f6974e084b9" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_28242ece-1ebb-4d98-976d-5f6974e084b9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_34ebf0c7-2f20-46bd-91ff-e7a8bdd60bcf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_28242ece-1ebb-4d98-976d-5f6974e084b9" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_34ebf0c7-2f20-46bd-91ff-e7a8bdd60bcf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_selb_SareptaTherapeuticsInc.Member_476968bf-8b0f-4806-b5fb-bbb5bd98f387" xlink:href="selb-20210331.xsd#selb_SareptaTherapeuticsInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_34ebf0c7-2f20-46bd-91ff-e7a8bdd60bcf" xlink:to="loc_selb_SareptaTherapeuticsInc.Member_476968bf-8b0f-4806-b5fb-bbb5bd98f387" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_selb_LicenseAgreementForPompeDiseaseMember_15884ba2-dbe0-4a1e-8611-931f5085e075" xlink:href="selb-20210331.xsd#selb_LicenseAgreementForPompeDiseaseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_34ebf0c7-2f20-46bd-91ff-e7a8bdd60bcf" xlink:to="loc_selb_LicenseAgreementForPompeDiseaseMember_15884ba2-dbe0-4a1e-8611-931f5085e075" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_849b4f1b-4df5-49dc-b1a7-d642a6afe5a7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_36cd28f0-943a-4acf-b538-99fbd375a10e" xlink:to="loc_us-gaap_TypeOfArrangementAxis_849b4f1b-4df5-49dc-b1a7-d642a6afe5a7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_849b4f1b-4df5-49dc-b1a7-d642a6afe5a7_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_849b4f1b-4df5-49dc-b1a7-d642a6afe5a7" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_849b4f1b-4df5-49dc-b1a7-d642a6afe5a7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5176bad4-235f-49ac-b37d-9453b7535dba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_849b4f1b-4df5-49dc-b1a7-d642a6afe5a7" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5176bad4-235f-49ac-b37d-9453b7535dba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember_3d4d282d-dec1-40af-82f0-3b765ffa92b8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5176bad4-235f-49ac-b37d-9453b7535dba" xlink:to="loc_us-gaap_CollaborativeArrangementMember_3d4d282d-dec1-40af-82f0-3b765ffa92b8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_680fea75-69d5-4e96-b9e9-2c94cd0b1427" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_36cd28f0-943a-4acf-b538-99fbd375a10e" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_680fea75-69d5-4e96-b9e9-2c94cd0b1427" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_680fea75-69d5-4e96-b9e9-2c94cd0b1427_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_680fea75-69d5-4e96-b9e9-2c94cd0b1427" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_680fea75-69d5-4e96-b9e9-2c94cd0b1427_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_5405eff6-60f9-4458-9e14-1d6df56739db" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_680fea75-69d5-4e96-b9e9-2c94cd0b1427" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_5405eff6-60f9-4458-9e14-1d6df56739db" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_selb_SOBIPurchaseAgreementMember_f50afca1-4fa6-416a-9ad8-ee81ddc8542e" xlink:href="selb-20210331.xsd#selb_SOBIPurchaseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_5405eff6-60f9-4458-9e14-1d6df56739db" xlink:to="loc_selb_SOBIPurchaseAgreementMember_f50afca1-4fa6-416a-9ad8-ee81ddc8542e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_90caa9dc-74d5-46dc-b2ac-e4eff4529f4f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_36cd28f0-943a-4acf-b538-99fbd375a10e" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_90caa9dc-74d5-46dc-b2ac-e4eff4529f4f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_90caa9dc-74d5-46dc-b2ac-e4eff4529f4f_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_90caa9dc-74d5-46dc-b2ac-e4eff4529f4f" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_90caa9dc-74d5-46dc-b2ac-e4eff4529f4f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_30d106c1-85e3-4bed-a462-a4649e801c04" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_90caa9dc-74d5-46dc-b2ac-e4eff4529f4f" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_30d106c1-85e3-4bed-a462-a4649e801c04" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_0bcb2086-97f9-481d-bd99-7d1979eb07d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_30d106c1-85e3-4bed-a462-a4649e801c04" xlink:to="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_0bcb2086-97f9-481d-bd99-7d1979eb07d9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentAssetsMember_210225a9-d151-4749-9c55-d7b286a445c2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCurrentAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_30d106c1-85e3-4bed-a462-a4649e801c04" xlink:to="loc_us-gaap_OtherCurrentAssetsMember_210225a9-d151-4749-9c55-d7b286a445c2" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.selectabio.com/role/RevenueArrangementsScheduleofChangesinContractLiabilitiesDetails" xlink:type="simple" xlink:href="selb-20210331.xsd#RevenueArrangementsScheduleofChangesinContractLiabilitiesDetails"/>
  <link:definitionLink xlink:role="http://www.selectabio.com/role/RevenueArrangementsScheduleofChangesinContractLiabilitiesDetails" xlink:type="extended" id="iee3f652fc43b498a81e9bd3a6b68b2f3_RevenueArrangementsScheduleofChangesinContractLiabilitiesDetails"/>
  <link:roleRef roleURI="http://www.selectabio.com/role/RelatedPartyTransactions" xlink:type="simple" xlink:href="selb-20210331.xsd#RelatedPartyTransactions"/>
  <link:definitionLink xlink:role="http://www.selectabio.com/role/RelatedPartyTransactions" xlink:type="extended" id="ibe52780a02fe45f5b49f9955caa5b3e8_RelatedPartyTransactions"/>
  <link:roleRef roleURI="http://www.selectabio.com/role/RelatedPartyTransactionsNarrativeDetails" xlink:type="simple" xlink:href="selb-20210331.xsd#RelatedPartyTransactionsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.selectabio.com/role/RelatedPartyTransactionsNarrativeDetails" xlink:type="extended" id="i8d0a469bd792434f99348f37dec4332b_RelatedPartyTransactionsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_8ca4f902-8cfb-4c6d-9de2-758a5c8e37e8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_c6c66516-5cf8-448b-8eb9-3253ab7a688e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_8ca4f902-8cfb-4c6d-9de2-758a5c8e37e8" xlink:to="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_c6c66516-5cf8-448b-8eb9-3253ab7a688e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_5d917cdc-fa04-4087-a362-bd8165d84e60" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_8ca4f902-8cfb-4c6d-9de2-758a5c8e37e8" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_5d917cdc-fa04-4087-a362-bd8165d84e60" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2d138ded-a741-4012-bb60-22715dcec991" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_5d917cdc-fa04-4087-a362-bd8165d84e60" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2d138ded-a741-4012-bb60-22715dcec991" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_2d138ded-a741-4012-bb60-22715dcec991_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2d138ded-a741-4012-bb60-22715dcec991" xlink:to="loc_us-gaap_RelatedPartyDomain_2d138ded-a741-4012-bb60-22715dcec991_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_0678c36d-60c7-4f98-89f7-5a6cc966425b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2d138ded-a741-4012-bb60-22715dcec991" xlink:to="loc_us-gaap_RelatedPartyDomain_0678c36d-60c7-4f98-89f7-5a6cc966425b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_selb_FounderMember_b4a86499-4872-4907-bba9-1d0384918e95" xlink:href="selb-20210331.xsd#selb_FounderMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_0678c36d-60c7-4f98-89f7-5a6cc966425b" xlink:to="loc_selb_FounderMember_b4a86499-4872-4907-bba9-1d0384918e95" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.selectabio.com/role/CollaborationAgreements" xlink:type="simple" xlink:href="selb-20210331.xsd#CollaborationAgreements"/>
  <link:definitionLink xlink:role="http://www.selectabio.com/role/CollaborationAgreements" xlink:type="extended" id="i25bc781aa6404c809a8ca0a9984bf53f_CollaborationAgreements"/>
  <link:roleRef roleURI="http://www.selectabio.com/role/CollaborationAgreementsAskBioNarrativeDetails" xlink:type="simple" xlink:href="selb-20210331.xsd#CollaborationAgreementsAskBioNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.selectabio.com/role/CollaborationAgreementsAskBioNarrativeDetails" xlink:type="extended" id="i7a1eefc1589f41e1a16eecd04d3068a7_CollaborationAgreementsAskBioNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b8e2fba1-011a-4f19-81ad-5dd7530ed3e7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_9325cce4-7b32-477e-a11d-9647699feb39" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b8e2fba1-011a-4f19-81ad-5dd7530ed3e7" xlink:to="loc_us-gaap_OperatingExpenses_9325cce4-7b32-477e-a11d-9647699feb39" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_selb_CollaborativeArrangementCostSharePercentage_db79dab8-075f-4d85-9661-af9d196fab97" xlink:href="selb-20210331.xsd#selb_CollaborativeArrangementCostSharePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b8e2fba1-011a-4f19-81ad-5dd7530ed3e7" xlink:to="loc_selb_CollaborativeArrangementCostSharePercentage_db79dab8-075f-4d85-9661-af9d196fab97" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_53c396ca-09ab-4321-9be1-d06f40dca429" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b8e2fba1-011a-4f19-81ad-5dd7530ed3e7" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_53c396ca-09ab-4321-9be1-d06f40dca429" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_3b234fea-c637-4a24-b92a-5b94a232a5fc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_53c396ca-09ab-4321-9be1-d06f40dca429" xlink:to="loc_us-gaap_TypeOfArrangementAxis_3b234fea-c637-4a24-b92a-5b94a232a5fc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3b234fea-c637-4a24-b92a-5b94a232a5fc_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_3b234fea-c637-4a24-b92a-5b94a232a5fc" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3b234fea-c637-4a24-b92a-5b94a232a5fc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5140dfd0-f508-4f5e-aa71-8b4f26520215" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_3b234fea-c637-4a24-b92a-5b94a232a5fc" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5140dfd0-f508-4f5e-aa71-8b4f26520215" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_selb_AskBioLicenseMember_18df95e5-08c6-4707-9805-b6c1de812347" xlink:href="selb-20210331.xsd#selb_AskBioLicenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5140dfd0-f508-4f5e-aa71-8b4f26520215" xlink:to="loc_selb_AskBioLicenseMember_18df95e5-08c6-4707-9805-b6c1de812347" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.selectabio.com/role/CollaborationAgreementsMITNarrativeDetails" xlink:type="simple" xlink:href="selb-20210331.xsd#CollaborationAgreementsMITNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.selectabio.com/role/CollaborationAgreementsMITNarrativeDetails" xlink:type="extended" id="if54670f7eb00424a9243494bd45a2e41_CollaborationAgreementsMITNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a3c0929a-eb69-4d06-bb05-75f6ac1d9194" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_selb_LicenseAndOptionAgreementContractualPaymentsMade_01f20812-6fa2-4d8a-a053-2f2b130f5382" xlink:href="selb-20210331.xsd#selb_LicenseAndOptionAgreementContractualPaymentsMade"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a3c0929a-eb69-4d06-bb05-75f6ac1d9194" xlink:to="loc_selb_LicenseAndOptionAgreementContractualPaymentsMade_01f20812-6fa2-4d8a-a053-2f2b130f5382" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_selb_LicenseAndOptionAgreementCalculatedPremiumPaidForEquityInvestmentUnderPurchaseAgreement_64315d89-5d15-4545-a20e-294221be6b25" xlink:href="selb-20210331.xsd#selb_LicenseAndOptionAgreementCalculatedPremiumPaidForEquityInvestmentUnderPurchaseAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a3c0929a-eb69-4d06-bb05-75f6ac1d9194" xlink:to="loc_selb_LicenseAndOptionAgreementCalculatedPremiumPaidForEquityInvestmentUnderPurchaseAgreement_64315d89-5d15-4545-a20e-294221be6b25" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_2e359854-5903-4add-9237-81b891e77e7c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a3c0929a-eb69-4d06-bb05-75f6ac1d9194" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_2e359854-5903-4add-9237-81b891e77e7c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_21b45901-4be0-4195-af68-4a41936b3882" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_2e359854-5903-4add-9237-81b891e77e7c" xlink:to="loc_us-gaap_TypeOfArrangementAxis_21b45901-4be0-4195-af68-4a41936b3882" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_21b45901-4be0-4195-af68-4a41936b3882_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_21b45901-4be0-4195-af68-4a41936b3882" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_21b45901-4be0-4195-af68-4a41936b3882_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2f9e6c7f-b61e-4e3f-ae77-5a1da1d792b2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_21b45901-4be0-4195-af68-4a41936b3882" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2f9e6c7f-b61e-4e3f-ae77-5a1da1d792b2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_selb_ExclusivePatentLicenseAgreementWithMassachusettsInstituteOfTechnologyMember_2580c581-0edd-42fb-9a21-22e0164097ee" xlink:href="selb-20210331.xsd#selb_ExclusivePatentLicenseAgreementWithMassachusettsInstituteOfTechnologyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2f9e6c7f-b61e-4e3f-ae77-5a1da1d792b2" xlink:to="loc_selb_ExclusivePatentLicenseAgreementWithMassachusettsInstituteOfTechnologyMember_2580c581-0edd-42fb-9a21-22e0164097ee" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_f195b507-8b8b-4881-a118-73f962830038" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_2e359854-5903-4add-9237-81b891e77e7c" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_f195b507-8b8b-4881-a118-73f962830038" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_f195b507-8b8b-4881-a118-73f962830038_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_f195b507-8b8b-4881-a118-73f962830038" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_f195b507-8b8b-4881-a118-73f962830038_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_b199355c-3bc8-41ff-a327-5ab9e6d9f54e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_f195b507-8b8b-4881-a118-73f962830038" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_b199355c-3bc8-41ff-a327-5ab9e6d9f54e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseAgreementTermsMember_2fc53041-f761-4ad9-9ea4-099b20f8cf97" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicenseAgreementTermsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_b199355c-3bc8-41ff-a327-5ab9e6d9f54e" xlink:to="loc_us-gaap_LicenseAgreementTermsMember_2fc53041-f761-4ad9-9ea4-099b20f8cf97" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.selectabio.com/role/CollaborationAgreementsShenyangSunshinePharmaceuticalCoLtdNarrativeDetails" xlink:type="simple" xlink:href="selb-20210331.xsd#CollaborationAgreementsShenyangSunshinePharmaceuticalCoLtdNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.selectabio.com/role/CollaborationAgreementsShenyangSunshinePharmaceuticalCoLtdNarrativeDetails" xlink:type="extended" id="i930f6ca8ea35496e94f8a23eb5489c58_CollaborationAgreementsShenyangSunshinePharmaceuticalCoLtdNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b0d57d48-781e-4636-912e-6f283dd53682" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_selb_AggregateAmountOfUpfrontAndMilestoneBasedPaymentsPaid_67ed3e6e-b5c6-4c6a-b0b3-671650486576" xlink:href="selb-20210331.xsd#selb_AggregateAmountOfUpfrontAndMilestoneBasedPaymentsPaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b0d57d48-781e-4636-912e-6f283dd53682" xlink:to="loc_selb_AggregateAmountOfUpfrontAndMilestoneBasedPaymentsPaid_67ed3e6e-b5c6-4c6a-b0b3-671650486576" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_selb_AggregateAmountForFuturePaymentsUponAchievementOfClinicalAndRegulatoryApprovalMilestonesForProductsContainingImmTORPlatform_73b2935a-ad27-4e31-b02c-cf7027652643" xlink:href="selb-20210331.xsd#selb_AggregateAmountForFuturePaymentsUponAchievementOfClinicalAndRegulatoryApprovalMilestonesForProductsContainingImmTORPlatform"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b0d57d48-781e-4636-912e-6f283dd53682" xlink:to="loc_selb_AggregateAmountForFuturePaymentsUponAchievementOfClinicalAndRegulatoryApprovalMilestonesForProductsContainingImmTORPlatform_73b2935a-ad27-4e31-b02c-cf7027652643" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_5c2d8b42-fc2f-4dfb-aa56-ee1ac850faf5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b0d57d48-781e-4636-912e-6f283dd53682" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_5c2d8b42-fc2f-4dfb-aa56-ee1ac850faf5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_f2aec8d9-d591-4c5c-bb28-79b67c352c80" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_5c2d8b42-fc2f-4dfb-aa56-ee1ac850faf5" xlink:to="loc_us-gaap_TypeOfArrangementAxis_f2aec8d9-d591-4c5c-bb28-79b67c352c80" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_f2aec8d9-d591-4c5c-bb28-79b67c352c80_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_f2aec8d9-d591-4c5c-bb28-79b67c352c80" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_f2aec8d9-d591-4c5c-bb28-79b67c352c80_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e8925e2e-6b61-430b-80c0-28e30cac631f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_f2aec8d9-d591-4c5c-bb28-79b67c352c80" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e8925e2e-6b61-430b-80c0-28e30cac631f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_selb_LicenseAgreementWithShenyangSunshinePharmaceuticalCompanyLimitedMember_17f4f333-5a51-40a7-a0c6-0ba99ff7bb38" xlink:href="selb-20210331.xsd#selb_LicenseAgreementWithShenyangSunshinePharmaceuticalCompanyLimitedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e8925e2e-6b61-430b-80c0-28e30cac631f" xlink:to="loc_selb_LicenseAgreementWithShenyangSunshinePharmaceuticalCompanyLimitedMember_17f4f333-5a51-40a7-a0c6-0ba99ff7bb38" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.selectabio.com/role/IncomeTaxes" xlink:type="simple" xlink:href="selb-20210331.xsd#IncomeTaxes"/>
  <link:definitionLink xlink:role="http://www.selectabio.com/role/IncomeTaxes" xlink:type="extended" id="id6bb6bef6cc549b6a26473d94c18ebbd_IncomeTaxes"/>
  <link:roleRef roleURI="http://www.selectabio.com/role/IncomeTaxesNarrativeDetails" xlink:type="simple" xlink:href="selb-20210331.xsd#IncomeTaxesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.selectabio.com/role/IncomeTaxesNarrativeDetails" xlink:type="extended" id="i693c8c56a5cf4688adf8baf4d2b74a2b_IncomeTaxesNarrativeDetails"/>
  <link:roleRef roleURI="http://www.selectabio.com/role/DefinedContributionPlan" xlink:type="simple" xlink:href="selb-20210331.xsd#DefinedContributionPlan"/>
  <link:definitionLink xlink:role="http://www.selectabio.com/role/DefinedContributionPlan" xlink:type="extended" id="ia079866fd40e4474a994ff4858e8aaff_DefinedContributionPlan"/>
  <link:roleRef roleURI="http://www.selectabio.com/role/DefinedContributionPlanNarrativeDetails" xlink:type="simple" xlink:href="selb-20210331.xsd#DefinedContributionPlanNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.selectabio.com/role/DefinedContributionPlanNarrativeDetails" xlink:type="extended" id="i2334d09b2c5840769d4bc91f24e970ee_DefinedContributionPlanNarrativeDetails"/>
  <link:roleRef roleURI="http://www.selectabio.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="selb-20210331.xsd#CommitmentsandContingencies"/>
  <link:definitionLink xlink:role="http://www.selectabio.com/role/CommitmentsandContingencies" xlink:type="extended" id="i6e8cbd60bd344479b069167e71949e36_CommitmentsandContingencies"/>
  <link:roleRef roleURI="http://www.selectabio.com/role/SubsequentEvents" xlink:type="simple" xlink:href="selb-20210331.xsd#SubsequentEvents"/>
  <link:definitionLink xlink:role="http://www.selectabio.com/role/SubsequentEvents" xlink:type="extended" id="i9fef28e7f9014cf0b230f9bd80aeb165_SubsequentEvents"/>
  <link:roleRef roleURI="http://www.selectabio.com/role/SubsequentEventsDetails" xlink:type="simple" xlink:href="selb-20210331.xsd#SubsequentEventsDetails"/>
  <link:definitionLink xlink:role="http://www.selectabio.com/role/SubsequentEventsDetails" xlink:type="extended" id="i5c2a4f5dbcbf473baaf2c69297e30cb2_SubsequentEventsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_5de94e0e-9d2a-488d-932d-089d1ac3df0f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_f608f10e-4033-4073-8c62-116aba259d1f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_5de94e0e-9d2a-488d-932d-089d1ac3df0f" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_f608f10e-4033-4073-8c62-116aba259d1f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_bb7827db-4c84-45aa-a522-4a36a2550e91" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_5de94e0e-9d2a-488d-932d-089d1ac3df0f" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_bb7827db-4c84-45aa-a522-4a36a2550e91" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_6e3f263a-0704-4c3b-9833-f885b4a846ed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_5de94e0e-9d2a-488d-932d-089d1ac3df0f" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_6e3f263a-0704-4c3b-9833-f885b4a846ed" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_selb_LicenseAndOptionAgreementMilestonePayments_96913c60-7736-4d18-8937-37724a2ea949" xlink:href="selb-20210331.xsd#selb_LicenseAndOptionAgreementMilestonePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_5de94e0e-9d2a-488d-932d-089d1ac3df0f" xlink:to="loc_selb_LicenseAndOptionAgreementMilestonePayments_96913c60-7736-4d18-8937-37724a2ea949" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_e87f466d-dd02-4fe0-869d-76b369a7656b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_5de94e0e-9d2a-488d-932d-089d1ac3df0f" xlink:to="loc_us-gaap_SubsequentEventTable_e87f466d-dd02-4fe0-869d-76b369a7656b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_19a65b54-8294-4e0e-8db8-8e6b35673ed0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_e87f466d-dd02-4fe0-869d-76b369a7656b" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_19a65b54-8294-4e0e-8db8-8e6b35673ed0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_19a65b54-8294-4e0e-8db8-8e6b35673ed0_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_19a65b54-8294-4e0e-8db8-8e6b35673ed0" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_19a65b54-8294-4e0e-8db8-8e6b35673ed0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_77917451-e28f-456c-aa19-5a603d90fdf4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_19a65b54-8294-4e0e-8db8-8e6b35673ed0" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_77917451-e28f-456c-aa19-5a603d90fdf4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_0f58e5d1-7f1d-467a-9abf-ee18036cbe70" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_77917451-e28f-456c-aa19-5a603d90fdf4" xlink:to="loc_us-gaap_SubsequentEventMember_0f58e5d1-7f1d-467a-9abf-ee18036cbe70" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_4fc40fbf-6c4d-48e8-b4a6-512f1df78abc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_e87f466d-dd02-4fe0-869d-76b369a7656b" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_4fc40fbf-6c4d-48e8-b4a6-512f1df78abc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_4fc40fbf-6c4d-48e8-b4a6-512f1df78abc_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_4fc40fbf-6c4d-48e8-b4a6-512f1df78abc" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_4fc40fbf-6c4d-48e8-b4a6-512f1df78abc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2f5d8d02-9ba1-4f1a-8eaf-4b11b4d0f48a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_4fc40fbf-6c4d-48e8-b4a6-512f1df78abc" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2f5d8d02-9ba1-4f1a-8eaf-4b11b4d0f48a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_selb_A2020SaleAgreementAtTheMarketOfferingMember_17d6d09b-27fc-4dda-959e-03ec1fa77ec5" xlink:href="selb-20210331.xsd#selb_A2020SaleAgreementAtTheMarketOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2f5d8d02-9ba1-4f1a-8eaf-4b11b4d0f48a" xlink:to="loc_selb_A2020SaleAgreementAtTheMarketOfferingMember_17d6d09b-27fc-4dda-959e-03ec1fa77ec5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_b6782ae1-36a9-49e5-baa8-aa73f9aea180" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_e87f466d-dd02-4fe0-869d-76b369a7656b" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_b6782ae1-36a9-49e5-baa8-aa73f9aea180" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_b6782ae1-36a9-49e5-baa8-aa73f9aea180_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_b6782ae1-36a9-49e5-baa8-aa73f9aea180" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_b6782ae1-36a9-49e5-baa8-aa73f9aea180_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_88956298-0bfa-4416-b129-7e5d06d0e443" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_b6782ae1-36a9-49e5-baa8-aa73f9aea180" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_88956298-0bfa-4416-b129-7e5d06d0e443" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_selb_SareptaTherapeuticsInc.Member_aa9952cf-1e20-41b4-96c9-c7d4de4609c4" xlink:href="selb-20210331.xsd#selb_SareptaTherapeuticsInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_88956298-0bfa-4416-b129-7e5d06d0e443" xlink:to="loc_selb_SareptaTherapeuticsInc.Member_aa9952cf-1e20-41b4-96c9-c7d4de4609c4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_ab767959-8821-4bc5-bedb-e8d071e49092" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_e87f466d-dd02-4fe0-869d-76b369a7656b" xlink:to="loc_srt_StatementScenarioAxis_ab767959-8821-4bc5-bedb-e8d071e49092" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_ab767959-8821-4bc5-bedb-e8d071e49092_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_ab767959-8821-4bc5-bedb-e8d071e49092" xlink:to="loc_srt_ScenarioUnspecifiedDomain_ab767959-8821-4bc5-bedb-e8d071e49092_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_42723d6d-e277-4009-87b0-61a32819b5fb" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_ab767959-8821-4bc5-bedb-e8d071e49092" xlink:to="loc_srt_ScenarioUnspecifiedDomain_42723d6d-e277-4009-87b0-61a32819b5fb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_23050e80-08cb-4920-9785-c7cff4f8488d" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_42723d6d-e277-4009-87b0-61a32819b5fb" xlink:to="loc_srt_ScenarioForecastMember_23050e80-08cb-4920-9785-c7cff4f8488d" xlink:type="arc" order="0"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>10
<FILENAME>selb-20210331_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:f83914de-cdf0-4ece-a0a2-d7db460e8912,g:a84bda62-2062-413b-8a4e-4383ad9edaee-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_AreaOfRealEstateProperty_a48972a1-14a4-40c7-a220-2001e0ab26de_terseLabel_en-US" xlink:label="lab_us-gaap_AreaOfRealEstateProperty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Area of additional office space leased</link:label>
    <link:label id="lab_us-gaap_AreaOfRealEstateProperty_label_en-US" xlink:label="lab_us-gaap_AreaOfRealEstateProperty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Area of Real Estate Property</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AreaOfRealEstateProperty" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AreaOfRealEstateProperty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AreaOfRealEstateProperty" xlink:to="lab_us-gaap_AreaOfRealEstateProperty" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_70ebd5ae-f852-4dc1-9e08-3ef94a6d17ac_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grants in period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_afcfefec-ecae-4a98-b061-b93a02903736_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_3f83a26d-f864-4207-83d0-3505ae662197_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_49a0a4ce-2e28-41d2-8bf6-9e7653ba23bd_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income (expense), net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_6598269a-74ca-48aa-87f7-a55e53fde2b7_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_5c58897f-4bb9-4daa-a1b8-a58e2aca3041_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_188e266e-d709-4f10-b7a1-0731112ed6e0_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_7a7f825d-4637-4b93-be8d-2d561c0fa21b_terseLabel_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_label_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:to="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_selb_ClassOfWarrantOrRightNumberOfWarrantsExercised_1700e57b-1464-4567-82a1-50b58804dfc1_terseLabel_en-US" xlink:label="lab_selb_ClassOfWarrantOrRightNumberOfWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of warrant or right, number of warrants exercised (in shares)</link:label>
    <link:label id="lab_selb_ClassOfWarrantOrRightNumberOfWarrantsExercised_label_en-US" xlink:label="lab_selb_ClassOfWarrantOrRightNumberOfWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right, Number Of Warrants Exercised</link:label>
    <link:label id="lab_selb_ClassOfWarrantOrRightNumberOfWarrantsExercised_documentation_en-US" xlink:label="lab_selb_ClassOfWarrantOrRightNumberOfWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Number Of Warrants Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_selb_ClassOfWarrantOrRightNumberOfWarrantsExercised" xlink:href="selb-20210331.xsd#selb_ClassOfWarrantOrRightNumberOfWarrantsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_selb_ClassOfWarrantOrRightNumberOfWarrantsExercised" xlink:to="lab_selb_ClassOfWarrantOrRightNumberOfWarrantsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_e568f0b0-addc-4380-bfc7-7427c25ee6aa_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities</link:label>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_selb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract_02f25eba-21bc-4450-8b41-bcad85b756ba_terseLabel_en-US" xlink:label="lab_selb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average remaining contractual term</link:label>
    <link:label id="lab_selb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract_label_en-US" xlink:label="lab_selb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term [Abstract]</link:label>
    <link:label id="lab_selb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract_documentation_en-US" xlink:label="lab_selb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">n/a</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_selb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract" xlink:href="selb-20210331.xsd#selb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_selb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract" xlink:to="lab_selb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_e817dcac-278c-44be-af37-a6d74bfab40c_terseLabel_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan</link:label>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:to="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_fca699f6-25c8-4eb6-80bf-257d3bd62b7d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested in period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_selb_ContractwithCustomerLiabilityIncreaseFromCashReceipts_42b21481-c1ad-4df9-9c47-d0a94db5fe1d_totalLabel_en-US" xlink:label="lab_selb_ContractwithCustomerLiabilityIncreaseFromCashReceipts" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract liabilities, additions</link:label>
    <link:label id="lab_selb_ContractwithCustomerLiabilityIncreaseFromCashReceipts_label_en-US" xlink:label="lab_selb_ContractwithCustomerLiabilityIncreaseFromCashReceipts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Increase From Cash Receipts</link:label>
    <link:label id="lab_selb_ContractwithCustomerLiabilityIncreaseFromCashReceipts_documentation_en-US" xlink:label="lab_selb_ContractwithCustomerLiabilityIncreaseFromCashReceipts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Increase From Cash Receipts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_selb_ContractwithCustomerLiabilityIncreaseFromCashReceipts" xlink:href="selb-20210331.xsd#selb_ContractwithCustomerLiabilityIncreaseFromCashReceipts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_selb_ContractwithCustomerLiabilityIncreaseFromCashReceipts" xlink:to="lab_selb_ContractwithCustomerLiabilityIncreaseFromCashReceipts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_251d251a-40bd-400a-82ff-a3795bba3331_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Level&#160;3)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_c7530214-3158-4c64-b8fc-a8c147da6ed8_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consulting services expenses (less than)</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction, Expenses from Transactions with Related Party</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:to="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCurrentAssetsMember_b291ab34-76d3-4408-9891-358cab730f43_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Current Assets</link:label>
    <link:label id="lab_us-gaap_OtherCurrentAssetsMember_label_en-US" xlink:label="lab_us-gaap_OtherCurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Current Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentAssetsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCurrentAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCurrentAssetsMember" xlink:to="lab_us-gaap_OtherCurrentAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_b27fac63-4bf6-4177-9f76-7706b8f3b147_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stockholders' Equity Note, Warrants or Rights</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_416eeeb8-98df-4207-8602-681cfe228935_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f8a2d62e-7ee8-413f-bfbc-a70fc2869386_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and stockholders&#8217; (deficit) equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_39e47cf8-6204-42e6-b6dd-5d4756d8049f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization_73543965-e4dd-4ccc-bd92-6bb7488e1aeb_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash lease expense</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Right-of-Use Asset, Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:to="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_924e9037-f863-4d60-a195-9755081f02c7_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_5de761ff-aadf-40dc-83a0-47aa5a32b2c2_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_b27422ac-ffde-4289-9ccc-07a94b035f2b_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_selb_AccruedResearchAndDevelopmentCostsCurrent_8d8b9778-960a-458f-ac86-a6df1d46133c_terseLabel_en-US" xlink:label="lab_selb_AccruedResearchAndDevelopmentCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued external research and development costs</link:label>
    <link:label id="lab_selb_AccruedResearchAndDevelopmentCostsCurrent_label_en-US" xlink:label="lab_selb_AccruedResearchAndDevelopmentCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Research And Development Costs Current</link:label>
    <link:label id="lab_selb_AccruedResearchAndDevelopmentCostsCurrent_documentation_en-US" xlink:label="lab_selb_AccruedResearchAndDevelopmentCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying value as of the balance sheet date of research and development costs.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_selb_AccruedResearchAndDevelopmentCostsCurrent" xlink:href="selb-20210331.xsd#selb_AccruedResearchAndDevelopmentCostsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_selb_AccruedResearchAndDevelopmentCostsCurrent" xlink:to="lab_selb_AccruedResearchAndDevelopmentCostsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_d1c72eaf-6a7b-40f5-9071-e379a0940f85_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Changes in Contract Liabilities</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:to="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_ee9db5a7-a4bf-4a7b-b1b9-547b1bb6ed75_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_c841a03d-d951-4bcd-9045-b3a0284939cb_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested at beginning of period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_0cf1a60e-bc57-4d3f-aa71-650b19f44873_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested at end of period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_selb_VotesPerShareofCommonStock_c67f1fb4-8ff8-43fa-b804-1836c5005c0b_terseLabel_en-US" xlink:label="lab_selb_VotesPerShareofCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of votes per share that common stockholders are entitled to</link:label>
    <link:label id="lab_selb_VotesPerShareofCommonStock_label_en-US" xlink:label="lab_selb_VotesPerShareofCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Votes Per Share of Common Stock</link:label>
    <link:label id="lab_selb_VotesPerShareofCommonStock_documentation_en-US" xlink:label="lab_selb_VotesPerShareofCommonStock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Votes Per Share of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_selb_VotesPerShareofCommonStock" xlink:href="selb-20210331.xsd#selb_VotesPerShareofCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_selb_VotesPerShareofCommonStock" xlink:to="lab_selb_VotesPerShareofCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_selb_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAwardedInPeriod_ea988630-7cd3-4f1c-bfa4-3b1498a10109_terseLabel_en-US" xlink:label="lab_selb_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAwardedInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awarded in period (in shares)</link:label>
    <link:label id="lab_selb_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAwardedInPeriod_label_en-US" xlink:label="lab_selb_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAwardedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Awarded in Period</link:label>
    <link:label id="lab_selb_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAwardedInPeriod_documentation_en-US" xlink:label="lab_selb_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAwardedInPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Awarded in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_selb_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAwardedInPeriod" xlink:href="selb-20210331.xsd#selb_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAwardedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_selb_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAwardedInPeriod" xlink:to="lab_selb_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAwardedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateDomain_d81c08e5-8636-4c41-a9d5-ba863bb8ba30_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:label id="lab_us-gaap_VariableRateDomain_label_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateDomain" xlink:to="lab_us-gaap_VariableRateDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateAxis_05899344-e22a-4e2d-934e-11f05f8c6e11_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:label id="lab_us-gaap_VariableRateAxis_label_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateAxis" xlink:to="lab_us-gaap_VariableRateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_2200cc6e-e717-411d-946b-c09ebbbbc19b_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies (Note&#160;17)</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_c5d863fd-c511-4394-a92d-1e75ca9f5b27_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_2914ef54-21c5-441c-8f68-40a4054c7350_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets:</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_13ff6d7c-bcdc-4b6b-806c-9f10739ef279_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_71ac8eaa-b837-4939-8f62-f0ea74f970af_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award vesting term</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_990d970d-afca-4283-a068-23c811d7c3ef_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_0c6e0bd9-6e0a-49b9-ba76-635f7ecf4eca_terseLabel_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and fixtures</link:label>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_label_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember" xlink:to="lab_us-gaap_FurnitureAndFixturesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_41077b2a-2889-4b8e-803d-9f72d8fc7d77_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_cd469946-3b2e-43f2-9cb4-9a4e983fc136_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested in period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockPlans_b163a5c4-c2d9-466c-a776-fd764e412c84_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockPlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of common stock under Employee Stock Purchase Plan</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockPlans_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockPlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockPlans" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockPlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockPlans" xlink:to="lab_us-gaap_ProceedsFromStockPlans" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasePayments_cf4091c1-8a81-4bf1-9966-b96d78014f7c_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for amounts included in the measurement of lease liabilities:</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_1cbd82c2-a301-4d9b-8005-aa35277fcea6_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_selb_August2020ShelfRegistrationStatementMember_b90839d3-7b46-483c-a7df-b42bf8ec538c_terseLabel_en-US" xlink:label="lab_selb_August2020ShelfRegistrationStatementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">August 2020 Shelf Registration Statement</link:label>
    <link:label id="lab_selb_August2020ShelfRegistrationStatementMember_label_en-US" xlink:label="lab_selb_August2020ShelfRegistrationStatementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">August 2020 Shelf Registration Statement [Member]</link:label>
    <link:label id="lab_selb_August2020ShelfRegistrationStatementMember_documentation_en-US" xlink:label="lab_selb_August2020ShelfRegistrationStatementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">August 2020 Shelf Registration Statement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_selb_August2020ShelfRegistrationStatementMember" xlink:href="selb-20210331.xsd#selb_August2020ShelfRegistrationStatementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_selb_August2020ShelfRegistrationStatementMember" xlink:to="lab_selb_August2020ShelfRegistrationStatementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_9b8dbc26-5e7c-4aa6-9e54-4caeb518a003_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable_5496b6f0-02c7-47fb-b8a7-a974e5f6c306_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:to="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_17165814-4c87-4348-9e35-935def447dc2_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_e7971862-712c-410f-9350-3e41361b30f3_negatedLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfLinesOfCredit_f004cc12-1475-4532-9ebe-9ae1ead01910_terseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of lines of credit</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLinesOfCredit_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Lines of Credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLinesOfCredit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfLinesOfCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLinesOfCredit" xlink:to="lab_us-gaap_RepaymentsOfLinesOfCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_75afbb77-e7b7-439b-99aa-28bac09ed8f7_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use asset, net</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_3512a3d7-363e-4e0a-bd53-5e1c27d0893a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on extinguishment of debt</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_label_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Extinguishment of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_086bfcb4-57fd-474c-bab6-841acaeaf863_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_f2bd635d-0d46-44d8-8179-831e0340e46e_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_5b415214-6fb5-408a-aeb1-2c1941c88575_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_0c8b2d7e-56f0-4818-bfa3-2f4e08c5e1c6_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_82152081-34a6-47be-a7ac-a20872ff5470_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Assets Measured at Fair Value on a Recurring Basis</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_selb_EmploymentInducementIncentiveAwardPlanMember_7aba7c2c-3ad9-4acf-85f2-c14a80fce2db_terseLabel_en-US" xlink:label="lab_selb_EmploymentInducementIncentiveAwardPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employment Inducement Incentive Award Plan</link:label>
    <link:label id="lab_selb_EmploymentInducementIncentiveAwardPlanMember_label_en-US" xlink:label="lab_selb_EmploymentInducementIncentiveAwardPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employment Inducement Incentive Award Plan [Member]</link:label>
    <link:label id="lab_selb_EmploymentInducementIncentiveAwardPlanMember_documentation_en-US" xlink:label="lab_selb_EmploymentInducementIncentiveAwardPlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employment Inducement Incentive Award Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_selb_EmploymentInducementIncentiveAwardPlanMember" xlink:href="selb-20210331.xsd#selb_EmploymentInducementIncentiveAwardPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_selb_EmploymentInducementIncentiveAwardPlanMember" xlink:to="lab_selb_EmploymentInducementIncentiveAwardPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_8ea637da-ffe2-4803-af1c-02e97cb925dc_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value by Liability Class [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value by Liability Class [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_df846fda-977a-4217-b335-de51d96fd5a5_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, $0.0001 par value; 10,000,000 shares authorized; no shares issued and outstanding at March 31, 2021 and December 31, 2020</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCost_be3d7e61-cd42-4656-9fbb-e9148259adcf_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee-paid construction costs</link:label>
    <link:label id="lab_us-gaap_LeaseCost_2c8d5e10-ace1-4826-9835-285d1a9a473d_totalLabel_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease cost</link:label>
    <link:label id="lab_us-gaap_LeaseCost_label_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCost" xlink:to="lab_us-gaap_LeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_selb_DefinedContributionPlanEmployersMatchingContributionVestingPeriod_f37327fc-3f82-4aea-93f2-cb3df6bdb946_terseLabel_en-US" xlink:label="lab_selb_DefinedContributionPlanEmployersMatchingContributionVestingPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting period</link:label>
    <link:label id="lab_selb_DefinedContributionPlanEmployersMatchingContributionVestingPeriod_label_en-US" xlink:label="lab_selb_DefinedContributionPlanEmployersMatchingContributionVestingPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan Employers Matching Contribution Vesting Period</link:label>
    <link:label id="lab_selb_DefinedContributionPlanEmployersMatchingContributionVestingPeriod_documentation_en-US" xlink:label="lab_selb_DefinedContributionPlanEmployersMatchingContributionVestingPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period which an employee's right to exercise a plan is no longer contingent on satisfaction of either a service condition, market condition or a performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_selb_DefinedContributionPlanEmployersMatchingContributionVestingPeriod" xlink:href="selb-20210331.xsd#selb_DefinedContributionPlanEmployersMatchingContributionVestingPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_selb_DefinedContributionPlanEmployersMatchingContributionVestingPeriod" xlink:to="lab_selb_DefinedContributionPlanEmployersMatchingContributionVestingPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_13a0b1a0-5549-4d1e-9abe-e24cf30e70c3_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_02b3c08c-9d0d-4dc8-bf14-59952f6515dd_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_1f1d88e9-5d44-43f8-a509-a0c61765cd96_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationTechniqueDomain_976e6911-d7e8-4036-a2be-e2c0b9e083a5_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationTechniqueDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Approach and Technique [Domain]</link:label>
    <link:label id="lab_us-gaap_ValuationTechniqueDomain_label_en-US" xlink:label="lab_us-gaap_ValuationTechniqueDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Approach and Technique [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationTechniqueDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationTechniqueDomain" xlink:to="lab_us-gaap_ValuationTechniqueDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfFinancingCosts_ae2afa9c-0dc7-4608-950a-aba5f29d11d6_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfFinancingCosts" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance costs paid for December 2019 financing</link:label>
    <link:label id="lab_us-gaap_PaymentsOfFinancingCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Financing Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfFinancingCosts" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfFinancingCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfFinancingCosts" xlink:to="lab_us-gaap_PaymentsOfFinancingCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfRevenueAbstract_7ce755a0-a201-45a4-a163-94403b06076a_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfRevenueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_CostOfRevenueAbstract_label_en-US" xlink:label="lab_us-gaap_CostOfRevenueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Revenue [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfRevenueAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfRevenueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfRevenueAbstract" xlink:to="lab_us-gaap_CostOfRevenueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByLiabilityClassAxis_59d6722b-84b8-46b5-8f1a-0d17481bf7e2_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByLiabilityClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByLiabilityClassAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByLiabilityClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis" xlink:to="lab_us-gaap_FairValueByLiabilityClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_selb_LeaseArrangementAxis_ffcaabca-abc3-4375-b994-9eea57813c41_terseLabel_en-US" xlink:label="lab_selb_LeaseArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Arrangement [Axis]</link:label>
    <link:label id="lab_selb_LeaseArrangementAxis_label_en-US" xlink:label="lab_selb_LeaseArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Arrangement [Axis]</link:label>
    <link:label id="lab_selb_LeaseArrangementAxis_documentation_en-US" xlink:label="lab_selb_LeaseArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Arrangement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_selb_LeaseArrangementAxis" xlink:href="selb-20210331.xsd#selb_LeaseArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_selb_LeaseArrangementAxis" xlink:to="lab_selb_LeaseArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_4ed54dc6-690f-499b-ae7e-a58401f36b4b_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_93f2c3a1-e467-4e0e-9576-f95c47da1243_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant and collaboration revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_37840877-fc71-4321-b921-a166273ec7b3_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_selb_AccruedInterestCurrent_f0b7a377-9c80-494d-9dd4-d6708ff7b34d_terseLabel_en-US" xlink:label="lab_selb_AccruedInterestCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued interest</link:label>
    <link:label id="lab_selb_AccruedInterestCurrent_label_en-US" xlink:label="lab_selb_AccruedInterestCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Interest, Current</link:label>
    <link:label id="lab_selb_AccruedInterestCurrent_documentation_en-US" xlink:label="lab_selb_AccruedInterestCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Interest, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_selb_AccruedInterestCurrent" xlink:href="selb-20210331.xsd#selb_AccruedInterestCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_selb_AccruedInterestCurrent" xlink:to="lab_selb_AccruedInterestCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_selb_A65GroveStreetWatertownMAMember_68491093-b487-43b0-b425-dfa0855f2055_terseLabel_en-US" xlink:label="lab_selb_A65GroveStreetWatertownMAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">65 Grove Street, Watertown,MA</link:label>
    <link:label id="lab_selb_A65GroveStreetWatertownMAMember_label_en-US" xlink:label="lab_selb_A65GroveStreetWatertownMAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">65 Grove Street, Watertown,MA [Member]</link:label>
    <link:label id="lab_selb_A65GroveStreetWatertownMAMember_documentation_en-US" xlink:label="lab_selb_A65GroveStreetWatertownMAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">65 Grove Street, Watertown,MA [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_selb_A65GroveStreetWatertownMAMember" xlink:href="selb-20210331.xsd#selb_A65GroveStreetWatertownMAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_selb_A65GroveStreetWatertownMAMember" xlink:to="lab_selb_A65GroveStreetWatertownMAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalizedContractCostAmortization_3ed83ef3-9700-4746-ae49-d88d35b5ab51_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalizedContractCostAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract assets amortization (less than)</link:label>
    <link:label id="lab_us-gaap_CapitalizedContractCostAmortization_label_en-US" xlink:label="lab_us-gaap_CapitalizedContractCostAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized Contract Cost, Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalizedContractCostAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalizedContractCostAmortization" xlink:to="lab_us-gaap_CapitalizedContractCostAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_3b3efdc2-801b-4ff4-9568-e9f333591854_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationTechniqueOptionPricingModelMember_584538b9-ac33-4802-9586-c917b3dd7563_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationTechniqueOptionPricingModelMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Technique, Option Pricing Model</link:label>
    <link:label id="lab_us-gaap_ValuationTechniqueOptionPricingModelMember_label_en-US" xlink:label="lab_us-gaap_ValuationTechniqueOptionPricingModelMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Technique, Option Pricing Model [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueOptionPricingModelMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationTechniqueOptionPricingModelMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationTechniqueOptionPricingModelMember" xlink:to="lab_us-gaap_ValuationTechniqueOptionPricingModelMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_21f22374-1663-4507-935f-24078d6552a2_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_149fb684-eccf-4602-b2e6-e18d7aa34f59_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Potential Common Shares Issuable Upon Conversion of Warrants</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioForecastMember_51297ceb-a846-4811-b7cd-1be2c0150dd3_terseLabel_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forecast</link:label>
    <link:label id="lab_srt_ScenarioForecastMember_label_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forecast [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioForecastMember" xlink:to="lab_srt_ScenarioForecastMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract_f963065d-4acb-408b-af43-ab3b5944fed9_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per share:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic and Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_selb_DebtInstrumentInterestPortion_c112f49e-1ff1-42ff-b0ab-a2ec12cfba51_negatedTerseLabel_en-US" xlink:label="lab_selb_DebtInstrumentInterestPortion" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Amount representing interest</link:label>
    <link:label id="lab_selb_DebtInstrumentInterestPortion_label_en-US" xlink:label="lab_selb_DebtInstrumentInterestPortion" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument Interest Portion</link:label>
    <link:label id="lab_selb_DebtInstrumentInterestPortion_documentation_en-US" xlink:label="lab_selb_DebtInstrumentInterestPortion" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The interest portion of gross outstanding debt.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_selb_DebtInstrumentInterestPortion" xlink:href="selb-20210331.xsd#selb_DebtInstrumentInterestPortion"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_selb_DebtInstrumentInterestPortion" xlink:to="lab_selb_DebtInstrumentInterestPortion" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComputerEquipmentMember_954abd32-1874-4e95-a3d1-366cb91f2e9f_terseLabel_en-US" xlink:label="lab_us-gaap_ComputerEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer equipment and software</link:label>
    <link:label id="lab_us-gaap_ComputerEquipmentMember_label_en-US" xlink:label="lab_us-gaap_ComputerEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComputerEquipmentMember" xlink:to="lab_us-gaap_ComputerEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_dec2e6e3-3976-41a0-a7cf-1922178368f0_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_efa93b2a-ee9d-4800-a7a9-fbbd081fe492_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (in shares)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_104b9af9-7521-4ca2-9db6-88bb0a2e0772_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeDomain" xlink:to="lab_us-gaap_MeasurementInputTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_selb_A2020SaleAgreementAtTheMarketOfferingMember_93d8ed33-de8d-4706-a9cf-5dccb5860591_terseLabel_en-US" xlink:label="lab_selb_A2020SaleAgreementAtTheMarketOfferingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 Sale Agreement - At-the-Market Offering</link:label>
    <link:label id="lab_selb_A2020SaleAgreementAtTheMarketOfferingMember_label_en-US" xlink:label="lab_selb_A2020SaleAgreementAtTheMarketOfferingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 Sale Agreement - At-The-Market Offering [Member]</link:label>
    <link:label id="lab_selb_A2020SaleAgreementAtTheMarketOfferingMember_documentation_en-US" xlink:label="lab_selb_A2020SaleAgreementAtTheMarketOfferingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 Sale Agreement - At-The-Market Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_selb_A2020SaleAgreementAtTheMarketOfferingMember" xlink:href="selb-20210331.xsd#selb_A2020SaleAgreementAtTheMarketOfferingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_selb_A2020SaleAgreementAtTheMarketOfferingMember" xlink:to="lab_selb_A2020SaleAgreementAtTheMarketOfferingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_dff6dcaa-a620-466d-87ce-c2ea66a56e9a_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_299e485b-8f63-4425-ab77-2474ba1070f9_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityAxis_b56a2ace-6db9-4f56-b9fe-18ca76a149e8_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityAxis_label_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityAxis" xlink:to="lab_us-gaap_CreditFacilityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_4628a578-0f0c-4427-b587-beafbc5a0f14_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_b4b37c43-fa46-4346-9e12-71fc03ddec60_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares issued</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_02023d19-802e-4338-b4fd-7c5ca6066c59_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_dbe3ed3f-493a-447c-9025-49bf89c4c19b_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_1c5bb210-9868-4e82-836a-9a60dde0fc10_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic and diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_52235e12-d8af-4e6a-9d9c-207adf4ec892_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per share attributable to common stockholders&#8212;basic and diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic and Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_68f3fbf7-563e-4476-8249-dd566a5f3005_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Smaller Reporting Company</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fb04a468-7adb-48e3-877f-95e9a92c3e09_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_selb_RestrictedStockUnitsRSUsReservedForIssuanceMember_7ed7c375-eeeb-43eb-974d-e29f465d38ca_terseLabel_en-US" xlink:label="lab_selb_RestrictedStockUnitsRSUsReservedForIssuanceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RSUs reserved for issuance</link:label>
    <link:label id="lab_selb_RestrictedStockUnitsRSUsReservedForIssuanceMember_label_en-US" xlink:label="lab_selb_RestrictedStockUnitsRSUsReservedForIssuanceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) Reserved For Issuance [Member]</link:label>
    <link:label id="lab_selb_RestrictedStockUnitsRSUsReservedForIssuanceMember_documentation_en-US" xlink:label="lab_selb_RestrictedStockUnitsRSUsReservedForIssuanceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) Reserved For Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_selb_RestrictedStockUnitsRSUsReservedForIssuanceMember" xlink:href="selb-20210331.xsd#selb_RestrictedStockUnitsRSUsReservedForIssuanceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_selb_RestrictedStockUnitsRSUsReservedForIssuanceMember" xlink:to="lab_selb_RestrictedStockUnitsRSUsReservedForIssuanceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_9f173ee9-c4bc-423f-84ec-83e99e0d8967_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of stock, number of shares issued in transaction (in shares)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_4817e749-5df5-4232-8faf-ae98332a6908_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_19cab0a9-4bb8-4874-9827-502d8a907ea3_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementMember_e726b4d8-312e-4ec6-a630-ebcfeea6e4f4_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementMember_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementMember" xlink:to="lab_us-gaap_CollaborativeArrangementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_160e42b9-5dc6-4dce-bebe-44a60f8d3343_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net proceeds from issuance of common stock</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_dbc3c4cf-6004-49fd-9ffd-930db12cac83_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued, value</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLeaseIncomeTableTextBlock_21c8a79a-e1c8-4856-a696-b76a31c384b4_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLeaseIncomeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Operating Lease, Lease Income</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLeaseIncomeTableTextBlock_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLeaseIncomeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Lease Income [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLeaseIncomeTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLeaseIncomeTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLeaseIncomeTableTextBlock" xlink:to="lab_us-gaap_OperatingLeaseLeaseIncomeTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember_45bb0b14-cd60-454b-907d-e6a9326c81e1_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period One</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_f67734d2-3a6c-4f2c-a345-3293a49c50eb_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_c6a018ae-f6f4-4a35-9fd0-b6a8ca525a09_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computation of Basic and Diluted Net Loss Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_selb_DecemberTwoThousandNineteenFinancingMember_a4b5c990-4291-4886-ad40-a909d5a8a30a_terseLabel_en-US" xlink:label="lab_selb_DecemberTwoThousandNineteenFinancingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">December 2019 Financing</link:label>
    <link:label id="lab_selb_DecemberTwoThousandNineteenFinancingMember_label_en-US" xlink:label="lab_selb_DecemberTwoThousandNineteenFinancingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">December Two Thousand Nineteen Financing [Member]</link:label>
    <link:label id="lab_selb_DecemberTwoThousandNineteenFinancingMember_documentation_en-US" xlink:label="lab_selb_DecemberTwoThousandNineteenFinancingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">December Two Thousand Nineteen Financing [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_selb_DecemberTwoThousandNineteenFinancingMember" xlink:href="selb-20210331.xsd#selb_DecemberTwoThousandNineteenFinancingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_selb_DecemberTwoThousandNineteenFinancingMember" xlink:to="lab_selb_DecemberTwoThousandNineteenFinancingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_b302a27c-dc7b-4ecd-8cdc-787aac9094ae_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of Share-based Compensation Arrangements by Share-based Payment Award</link:label>
    <link:label id="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:to="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_ddd76e00-da45-4733-bdfb-e6b59cda1fd4_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average common shares outstanding:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_7b8762c7-7a76-4668-8b28-82b53a0464e7_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Denominator:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_baa9a2dc-a6ce-4478-bfdb-096ed4d01606_periodStartLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value as of December 31, 2020</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_68814d70-c6f0-4351-8d0b-c63eacf18a49_periodEndLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value as of March 31, 2021</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:type="arc" order="1"/>
    <link:label id="lab_selb_AggregateAmountOfUpfrontAndMilestoneBasedPaymentsPaid_01adb6f7-e68c-4305-a83d-1b1c9b6b8b78_terseLabel_en-US" xlink:label="lab_selb_AggregateAmountOfUpfrontAndMilestoneBasedPaymentsPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate amount of upfront and milestone-based payments</link:label>
    <link:label id="lab_selb_AggregateAmountOfUpfrontAndMilestoneBasedPaymentsPaid_label_en-US" xlink:label="lab_selb_AggregateAmountOfUpfrontAndMilestoneBasedPaymentsPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Amount Of Upfront And Milestone Based Payments Paid</link:label>
    <link:label id="lab_selb_AggregateAmountOfUpfrontAndMilestoneBasedPaymentsPaid_documentation_en-US" xlink:label="lab_selb_AggregateAmountOfUpfrontAndMilestoneBasedPaymentsPaid" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Amount Of Upfront And Milestone Based Payments Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_selb_AggregateAmountOfUpfrontAndMilestoneBasedPaymentsPaid" xlink:href="selb-20210331.xsd#selb_AggregateAmountOfUpfrontAndMilestoneBasedPaymentsPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_selb_AggregateAmountOfUpfrontAndMilestoneBasedPaymentsPaid" xlink:to="lab_selb_AggregateAmountOfUpfrontAndMilestoneBasedPaymentsPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_selb_LaboratoryEquipmentMember_ad777426-af6a-433a-ba11-2fd748391b18_terseLabel_en-US" xlink:label="lab_selb_LaboratoryEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Laboratory equipment</link:label>
    <link:label id="lab_selb_LaboratoryEquipmentMember_label_en-US" xlink:label="lab_selb_LaboratoryEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Laboratory Equipment [Member]</link:label>
    <link:label id="lab_selb_LaboratoryEquipmentMember_documentation_en-US" xlink:label="lab_selb_LaboratoryEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents information pertaining to laboratory equipment.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_selb_LaboratoryEquipmentMember" xlink:href="selb-20210331.xsd#selb_LaboratoryEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_selb_LaboratoryEquipmentMember" xlink:to="lab_selb_LaboratoryEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_ad6334a7-b441-464f-bb5b-746677ba8a82_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares authorized for grants (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_24614dbd-2af5-4dd7-91e8-258ea85a4e3a_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCredit_27012266-8252-4998-8769-a5774ca4b88f_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCredit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term loan facility</link:label>
    <link:label id="lab_us-gaap_LineOfCredit_label_en-US" xlink:label="lab_us-gaap_LineOfCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Line of Credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCredit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCredit" xlink:to="lab_us-gaap_LineOfCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_selb_AggregateAmountForFuturePaymentsUponAchievementOfClinicalAndRegulatoryApprovalMilestonesForProductsContainingImmTORPlatform_040618f7-2b0f-454a-801c-5986ad3dc668_terseLabel_en-US" xlink:label="lab_selb_AggregateAmountForFuturePaymentsUponAchievementOfClinicalAndRegulatoryApprovalMilestonesForProductsContainingImmTORPlatform" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate amount for future payments upon achievement of clinical and regulatory approval milestones for products containing ImmTOR platform</link:label>
    <link:label id="lab_selb_AggregateAmountForFuturePaymentsUponAchievementOfClinicalAndRegulatoryApprovalMilestonesForProductsContainingImmTORPlatform_label_en-US" xlink:label="lab_selb_AggregateAmountForFuturePaymentsUponAchievementOfClinicalAndRegulatoryApprovalMilestonesForProductsContainingImmTORPlatform" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Amount For Future Payments Upon Achievement Of Clinical And Regulatory Approval Milestones For Products Containing ImmTOR Platform</link:label>
    <link:label id="lab_selb_AggregateAmountForFuturePaymentsUponAchievementOfClinicalAndRegulatoryApprovalMilestonesForProductsContainingImmTORPlatform_documentation_en-US" xlink:label="lab_selb_AggregateAmountForFuturePaymentsUponAchievementOfClinicalAndRegulatoryApprovalMilestonesForProductsContainingImmTORPlatform" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Amount For Future Payments Upon Achievement Of Clinical And Regulatory Approval Milestones For Products Containing ImmTOR Platform</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_selb_AggregateAmountForFuturePaymentsUponAchievementOfClinicalAndRegulatoryApprovalMilestonesForProductsContainingImmTORPlatform" xlink:href="selb-20210331.xsd#selb_AggregateAmountForFuturePaymentsUponAchievementOfClinicalAndRegulatoryApprovalMilestonesForProductsContainingImmTORPlatform"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_selb_AggregateAmountForFuturePaymentsUponAchievementOfClinicalAndRegulatoryApprovalMilestonesForProductsContainingImmTORPlatform" xlink:to="lab_selb_AggregateAmountForFuturePaymentsUponAchievementOfClinicalAndRegulatoryApprovalMilestonesForProductsContainingImmTORPlatform" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_9f32a576-0c23-4e90-b673-8d51dbe2f1d3_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash (used in) operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrentAbstract_83bc75a2-c5a2-4725-a98a-a19cf3c9fdd3_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current liabilities:</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrentAbstract_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrentAbstract" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_selb_PreFundedWarrantMember_07ff3d50-78f6-4eca-9fb1-a552b92ef5b6_terseLabel_en-US" xlink:label="lab_selb_PreFundedWarrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-Funded Warrant</link:label>
    <link:label id="lab_selb_PreFundedWarrantMember_label_en-US" xlink:label="lab_selb_PreFundedWarrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-Funded Warrant [Member]</link:label>
    <link:label id="lab_selb_PreFundedWarrantMember_documentation_en-US" xlink:label="lab_selb_PreFundedWarrantMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-Funded Warrant [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_selb_PreFundedWarrantMember" xlink:href="selb-20210331.xsd#selb_PreFundedWarrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_selb_PreFundedWarrantMember" xlink:to="lab_selb_PreFundedWarrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_35bd6c2f-7f1a-4870-b407-6dcfeb94ce90_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyDomain_c4bd6613-dc72-491c-898c-1f12df1c9437_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain" xlink:to="lab_us-gaap_RelatedPartyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_26f24e21-cfe8-4210-b605-4145906d162d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_9636e71f-58cd-4b85-8f85-0942e223af36_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:to="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_0fc0707a-0c1e-4cde-8b90-a797d8ecb332_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_81530ed9-0c62-485b-93ac-be8d3f21fecc_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodThreeMember_ebf42452-fa20-4b3d-ae32-83d1a1b91477_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodThreeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period Three</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodThreeMember_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period Three [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodThreeMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodThreeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodThreeMember" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodThreeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_b5ff7ddc-e85d-46fb-906d-d5687fe0b704_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of property and equipment not yet paid</link:label>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_label_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_2d8c5faa-8230-478f-b46b-01269cbb8574_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_1ac8a425-1aa6-4e3e-84ba-be81044d8c39_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_us-gaap_SubsequentEventsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_7bb6e420-e72a-4e58-b970-e44e72fe6c5c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares of common stock issued to employees under the ESPP (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAdjustmentOfWarrants_5fa4dd6e-822e-4a09-a738-6d9007b38233_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FairValueAdjustmentOfWarrants" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of warrant liabilities</link:label>
    <link:label id="lab_us-gaap_FairValueAdjustmentOfWarrants_28970ec1-b144-47a0-8b25-e5ffe81483f6_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAdjustmentOfWarrants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant liabilities revaluation</link:label>
    <link:label id="lab_us-gaap_FairValueAdjustmentOfWarrants_label_en-US" xlink:label="lab_us-gaap_FairValueAdjustmentOfWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Adjustment of Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAdjustmentOfWarrants" xlink:to="lab_us-gaap_FairValueAdjustmentOfWarrants" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_5151e5ae-307c-445d-947d-d5262f49a429_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_dee3c382-ac42-4106-82a6-1004185bcff9_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation expense related to unvested employee stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_449afe04-be0a-45a2-82d8-5bcf31f9d273_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_2d653977-cd4d-4e87-8bd8-66b05d1fbf99_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_selb_RevenueNumberOfPerformanceObligations_33bc89ac-d884-4099-a58d-efb4e69bc6e8_terseLabel_en-US" xlink:label="lab_selb_RevenueNumberOfPerformanceObligations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of obligations</link:label>
    <link:label id="lab_selb_RevenueNumberOfPerformanceObligations_label_en-US" xlink:label="lab_selb_RevenueNumberOfPerformanceObligations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Number Of Performance Obligations</link:label>
    <link:label id="lab_selb_RevenueNumberOfPerformanceObligations_documentation_en-US" xlink:label="lab_selb_RevenueNumberOfPerformanceObligations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Number Of Performance Obligations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_selb_RevenueNumberOfPerformanceObligations" xlink:href="selb-20210331.xsd#selb_RevenueNumberOfPerformanceObligations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_selb_RevenueNumberOfPerformanceObligations" xlink:to="lab_selb_RevenueNumberOfPerformanceObligations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_2ed1ba1f-ad33-4c63-b473-ee0b2752eb24_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_bc0abd5c-0134-4ad4-9cca-9d05ba1c27b7_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_36b1ba53-8f6a-43f6-a41a-309f0c3d8038_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of exchange rate changes on cash</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of Exchange Rate on Cash and Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_9522b5b2-d9da-4513-9a57-619b043cd0bc_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputExpectedDividendRateMember_fda33556-1be8-4397-a33b-481879b7b2fe_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputExpectedDividendRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividend yield</link:label>
    <link:label id="lab_us-gaap_MeasurementInputExpectedDividendRateMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputExpectedDividendRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Expected Dividend Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedDividendRateMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputExpectedDividendRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputExpectedDividendRateMember" xlink:to="lab_us-gaap_MeasurementInputExpectedDividendRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_a18c5f5a-d919-4ad6-9284-2da103c73b7f_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_7f4912b8-13ac-49f4-96d1-3112a66fedc4_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_selb_LockUpFromClosingTerm_94d70826-ff73-49b7-8fb5-3e22b76cd798_terseLabel_en-US" xlink:label="lab_selb_LockUpFromClosingTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lock-up from closing, term</link:label>
    <link:label id="lab_selb_LockUpFromClosingTerm_label_en-US" xlink:label="lab_selb_LockUpFromClosingTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lock-up From Closing, Term</link:label>
    <link:label id="lab_selb_LockUpFromClosingTerm_documentation_en-US" xlink:label="lab_selb_LockUpFromClosingTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lock-up From Closing, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_selb_LockUpFromClosingTerm" xlink:href="selb-20210331.xsd#selb_LockUpFromClosingTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_selb_LockUpFromClosingTerm" xlink:to="lab_selb_LockUpFromClosingTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_06a5e15b-9a6c-47e0-9a0d-4327b2809e6c_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_selb_ExclusivePatentLicenseAgreementWithMassachusettsInstituteOfTechnologyMember_e66c0f59-fa4b-49f9-a802-0d971b3bd42a_terseLabel_en-US" xlink:label="lab_selb_ExclusivePatentLicenseAgreementWithMassachusettsInstituteOfTechnologyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MIT</link:label>
    <link:label id="lab_selb_ExclusivePatentLicenseAgreementWithMassachusettsInstituteOfTechnologyMember_label_en-US" xlink:label="lab_selb_ExclusivePatentLicenseAgreementWithMassachusettsInstituteOfTechnologyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exclusive Patent License Agreement With Massachusetts Institute Of Technology [Member]</link:label>
    <link:label id="lab_selb_ExclusivePatentLicenseAgreementWithMassachusettsInstituteOfTechnologyMember_documentation_en-US" xlink:label="lab_selb_ExclusivePatentLicenseAgreementWithMassachusettsInstituteOfTechnologyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents information pertaining to Exclusive patent license agreement with Massachusetts Institute of Technology. "</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_selb_ExclusivePatentLicenseAgreementWithMassachusettsInstituteOfTechnologyMember" xlink:href="selb-20210331.xsd#selb_ExclusivePatentLicenseAgreementWithMassachusettsInstituteOfTechnologyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_selb_ExclusivePatentLicenseAgreementWithMassachusettsInstituteOfTechnologyMember" xlink:to="lab_selb_ExclusivePatentLicenseAgreementWithMassachusettsInstituteOfTechnologyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityTable_42617754-8f55-40f4-998c-89ad5d4777af_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility [Table]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityTable_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityTable" xlink:to="lab_us-gaap_LineOfCreditFacilityTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_02f50ed5-ec55-4e2f-a54c-eb8106e4dbc1_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Lease, Cost</link:label>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock" xlink:to="lab_us-gaap_LeaseCostTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_selb_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReservedForIssuance_37920b00-ff8a-453d-a538-39ab1922c853_terseLabel_en-US" xlink:label="lab_selb_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReservedForIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserved for issuance (in shares)</link:label>
    <link:label id="lab_selb_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReservedForIssuance_label_en-US" xlink:label="lab_selb_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReservedForIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Reserved For Issuance</link:label>
    <link:label id="lab_selb_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReservedForIssuance_documentation_en-US" xlink:label="lab_selb_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReservedForIssuance" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Reserved For Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_selb_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReservedForIssuance" xlink:href="selb-20210331.xsd#selb_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReservedForIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_selb_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReservedForIssuance" xlink:to="lab_selb_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReservedForIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_2f3c73e1-d5d8-4202-8c65-1b5480b1bbf9_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_f815c057-d481-4226-98cc-88050be603b8_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_e4206842-147b-481c-9e30-f22c8825fbda_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_34b9d1f2-fa7f-49a5-b6cc-e76c7f21a35a_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_a77ee9f7-378b-407c-8b5f-d6312e049170_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related-Party Transactions</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementScenarioAxis_5d3c6c0d-53cc-44fc-b50f-f0d9855cba14_terseLabel_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:label id="lab_srt_StatementScenarioAxis_label_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementScenarioAxis" xlink:to="lab_srt_StatementScenarioAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_selb_NonEmployeeStockOptionMember_1a4a7a60-07f0-44c8-9dee-cf264b17e551_terseLabel_en-US" xlink:label="lab_selb_NonEmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-employee stock options</link:label>
    <link:label id="lab_selb_NonEmployeeStockOptionMember_33fcf303-8311-4abc-86c7-1ce3e3bdb646_verboseLabel_en-US" xlink:label="lab_selb_NonEmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-employee consultants</link:label>
    <link:label id="lab_selb_NonEmployeeStockOptionMember_label_en-US" xlink:label="lab_selb_NonEmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non Employee Stock Option [Member]</link:label>
    <link:label id="lab_selb_NonEmployeeStockOptionMember_documentation_en-US" xlink:label="lab_selb_NonEmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">An arrangement whereby a non-employee is entitled to receive in the future, subject to vesting and other restrictions, a number of shares in the entity at a specified price, as defined in the agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_selb_NonEmployeeStockOptionMember" xlink:href="selb-20210331.xsd#selb_NonEmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_selb_NonEmployeeStockOptionMember" xlink:to="lab_selb_NonEmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_b412fde7-5577-4fd0-b4e0-57c474a6cbf3_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested at beginning of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_18ad4b31-60ac-45a0-a71b-4446da22a8ff_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested at end of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_51f9ebe5-9b99-4930-988b-ca31254fd79a_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_655fc74c-864d-4dcd-9614-45da144d0796_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Expenses</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_e74e70e1-47d3-448b-8dd3-9d55d19fd313_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average grant date fair value of stock options (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_dbb3690f-00c1-4950-b031-403889e67618_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_b1c642ad-3db0-40b2-b7c9-f34b10aaad1b_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized (losses) on marketable securities</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_2eb88214-af64-4700-8f92-db4523a3504f_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_selb_EligiblePeriodToReceiveRoyalties_78a2679c-ab9b-4192-b821-bdf94043b5b8_terseLabel_en-US" xlink:label="lab_selb_EligiblePeriodToReceiveRoyalties" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period after first commercial sale when the Company is eligible to receive royalties</link:label>
    <link:label id="lab_selb_EligiblePeriodToReceiveRoyalties_label_en-US" xlink:label="lab_selb_EligiblePeriodToReceiveRoyalties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eligible Period To Receive Royalties</link:label>
    <link:label id="lab_selb_EligiblePeriodToReceiveRoyalties_documentation_en-US" xlink:label="lab_selb_EligiblePeriodToReceiveRoyalties" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eligible Period To Receive Royalties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_selb_EligiblePeriodToReceiveRoyalties" xlink:href="selb-20210331.xsd#selb_EligiblePeriodToReceiveRoyalties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_selb_EligiblePeriodToReceiveRoyalties" xlink:to="lab_selb_EligiblePeriodToReceiveRoyalties" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_b01b0094-a1a0-45d1-9070-6a1d002ac1ae_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_selb_ShareBasedCompensationArrangementByShareBasedPaymentAwardForfeituresRate_4e537f62-6f30-4541-b4b2-f324e2f4e490_terseLabel_en-US" xlink:label="lab_selb_ShareBasedCompensationArrangementByShareBasedPaymentAwardForfeituresRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated forfeitures rate</link:label>
    <link:label id="lab_selb_ShareBasedCompensationArrangementByShareBasedPaymentAwardForfeituresRate_label_en-US" xlink:label="lab_selb_ShareBasedCompensationArrangementByShareBasedPaymentAwardForfeituresRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement By Share-based Payment Award Forfeitures Rate</link:label>
    <link:label id="lab_selb_ShareBasedCompensationArrangementByShareBasedPaymentAwardForfeituresRate_documentation_en-US" xlink:label="lab_selb_ShareBasedCompensationArrangementByShareBasedPaymentAwardForfeituresRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the percentage of forfeitures rate of the stock options based on the historical trends.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_selb_ShareBasedCompensationArrangementByShareBasedPaymentAwardForfeituresRate" xlink:href="selb-20210331.xsd#selb_ShareBasedCompensationArrangementByShareBasedPaymentAwardForfeituresRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_selb_ShareBasedCompensationArrangementByShareBasedPaymentAwardForfeituresRate" xlink:to="lab_selb_ShareBasedCompensationArrangementByShareBasedPaymentAwardForfeituresRate" xlink:type="arc" order="1"/>
    <link:label id="lab_selb_EmployeeStockPurchasePlan2016Member_fb232f66-961f-4bb5-83e0-4e06e502886d_terseLabel_en-US" xlink:label="lab_selb_EmployeeStockPurchasePlan2016Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ESPP</link:label>
    <link:label id="lab_selb_EmployeeStockPurchasePlan2016Member_label_en-US" xlink:label="lab_selb_EmployeeStockPurchasePlan2016Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Purchase Plan2016 [Member]</link:label>
    <link:label id="lab_selb_EmployeeStockPurchasePlan2016Member_documentation_en-US" xlink:label="lab_selb_EmployeeStockPurchasePlan2016Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represent information pertaining to the 2016 Employee Stock Purchase Plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_selb_EmployeeStockPurchasePlan2016Member" xlink:href="selb-20210331.xsd#selb_EmployeeStockPurchasePlan2016Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_selb_EmployeeStockPurchasePlan2016Member" xlink:to="lab_selb_EmployeeStockPurchasePlan2016Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_daddfc46-8dc4-456f-9c5e-ce8bb181cb75_negatedLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_2cb6960e-3cbc-45a6-b561-688fdf331bfc_verboseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale common stock</link:label>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_selb_DebtInstrumentPrepaymentFeePercentage_5b5005c0-b6de-49cb-a4f5-bb85d636daf8_terseLabel_en-US" xlink:label="lab_selb_DebtInstrumentPrepaymentFeePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, prepayment fee, percentage</link:label>
    <link:label id="lab_selb_DebtInstrumentPrepaymentFeePercentage_label_en-US" xlink:label="lab_selb_DebtInstrumentPrepaymentFeePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Prepayment Fee, Percentage</link:label>
    <link:label id="lab_selb_DebtInstrumentPrepaymentFeePercentage_documentation_en-US" xlink:label="lab_selb_DebtInstrumentPrepaymentFeePercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Prepayment Fee, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_selb_DebtInstrumentPrepaymentFeePercentage" xlink:href="selb-20210331.xsd#selb_DebtInstrumentPrepaymentFeePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_selb_DebtInstrumentPrepaymentFeePercentage" xlink:to="lab_selb_DebtInstrumentPrepaymentFeePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_a58d80b6-95c7-405d-b878-a1b15e98cb2b_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_selb_StockIncentivePlan2016Member_80d43bfd-7289-4113-be73-2c74801eb8e5_terseLabel_en-US" xlink:label="lab_selb_StockIncentivePlan2016Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2016 Plan</link:label>
    <link:label id="lab_selb_StockIncentivePlan2016Member_label_en-US" xlink:label="lab_selb_StockIncentivePlan2016Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Incentive Plan2016 [Member]</link:label>
    <link:label id="lab_selb_StockIncentivePlan2016Member_documentation_en-US" xlink:label="lab_selb_StockIncentivePlan2016Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the information pertaining to the 2016 stock incentive plan, which provides for the granting of stock based awards to employees, directors, and consultants under terms and provisions established by the board of directors.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_selb_StockIncentivePlan2016Member" xlink:href="selb-20210331.xsd#selb_StockIncentivePlan2016Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_selb_StockIncentivePlan2016Member" xlink:to="lab_selb_StockIncentivePlan2016Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_184adfd1-bbed-4287-b12c-4a4a081762ad_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average period for recognition</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_59611cbb-9e50-448b-8512-d8a222d19da6_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationTechniqueAxis_d33acef6-0646-49e6-abd0-6b344edc8430_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationTechniqueAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Approach and Technique [Axis]</link:label>
    <link:label id="lab_us-gaap_ValuationTechniqueAxis_label_en-US" xlink:label="lab_us-gaap_ValuationTechniqueAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Approach and Technique [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationTechniqueAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationTechniqueAxis" xlink:to="lab_us-gaap_ValuationTechniqueAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_078cc87e-8d12-4d71-8925-1c3c5debeb68_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less imputed interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_375c0d36-6211-495c-bc2d-c7eee153450d_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and expected to vest, term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_9610f930-b2c9-4a5d-ad0b-aee3284c823c_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_6d0a649b-3333-41da-b1c4-b07f6473efad_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTextBlock_05c8b5c5-f438-46d5-990e-55c0f4d19ae6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Authorized Shares of Common Stock for Future Issuance</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTextBlock" xlink:to="lab_us-gaap_ScheduleOfStockByClassTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_2a8d67c2-de61-4dc1-a47f-7412a78b541d_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue recognized</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_226f3ebc-4f94-4da3-b172-47fd4b3cc3fd_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract liabilities, deductions</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Revenue Recognized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_4ec1b08c-fd3c-4313-995c-5d193bced44f_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_5651095f-4a77-40ab-bca7-2115ba0fc425_netLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss attributable to common stockholders</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_selb_EquityOfferingCostsInAccruedLiabilities_488fc240-0faa-4fb8-abe0-f746cb7e44f5_terseLabel_en-US" xlink:label="lab_selb_EquityOfferingCostsInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity offering costs in accrued liabilities</link:label>
    <link:label id="lab_selb_EquityOfferingCostsInAccruedLiabilities_label_en-US" xlink:label="lab_selb_EquityOfferingCostsInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Offering Costs In Accrued Liabilities</link:label>
    <link:label id="lab_selb_EquityOfferingCostsInAccruedLiabilities_documentation_en-US" xlink:label="lab_selb_EquityOfferingCostsInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Offering Costs In Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_selb_EquityOfferingCostsInAccruedLiabilities" xlink:href="selb-20210331.xsd#selb_EquityOfferingCostsInAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_selb_EquityOfferingCostsInAccruedLiabilities" xlink:to="lab_selb_EquityOfferingCostsInAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_aa783903-b229-4304-92cd-57a6eaa36659_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Level&#160;1)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_selb_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedOutstandingWeightedAverageRemainingContractualTerm_b89f6488-da5e-4854-b873-16ea9ed35eed_terseLabel_en-US" xlink:label="lab_selb_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedOutstandingWeightedAverageRemainingContractualTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested, term</link:label>
    <link:label id="lab_selb_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedOutstandingWeightedAverageRemainingContractualTerm_label_en-US" xlink:label="lab_selb_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedOutstandingWeightedAverageRemainingContractualTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement By Share-based Payment Award, Options, Vested, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:label id="lab_selb_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedOutstandingWeightedAverageRemainingContractualTerm_documentation_en-US" xlink:label="lab_selb_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedOutstandingWeightedAverageRemainingContractualTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement By Share-based Payment Award, Options, Vested, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_selb_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedOutstandingWeightedAverageRemainingContractualTerm" xlink:href="selb-20210331.xsd#selb_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedOutstandingWeightedAverageRemainingContractualTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_selb_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedOutstandingWeightedAverageRemainingContractualTerm" xlink:to="lab_selb_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedOutstandingWeightedAverageRemainingContractualTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LoansPayableCurrent_411ff057-6d64-42e8-883d-3f7daa9dd946_terseLabel_en-US" xlink:label="lab_us-gaap_LoansPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loan payable</link:label>
    <link:label id="lab_us-gaap_LoansPayableCurrent_label_en-US" xlink:label="lab_us-gaap_LoansPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loans Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansPayableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LoansPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LoansPayableCurrent" xlink:to="lab_us-gaap_LoansPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_6ab63985-f1ba-4c50-bc2c-94f989cc3068_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_d39a23f1-4110-4791-a743-da18ed5e1586_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash and Cash Equivalents, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_37b179ec-dc47-46c6-81b6-b91f787820bb_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_77a523aa-b64a-4041-b626-84d6c34dc767_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_selb_ChangeInContractWithCustomerLiabilityRollForward_286ed8dd-28fc-4b83-bbc8-4a623be3e905_terseLabel_en-US" xlink:label="lab_selb_ChangeInContractWithCustomerLiabilityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract liabilities:</link:label>
    <link:label id="lab_selb_ChangeInContractWithCustomerLiabilityRollForward_label_en-US" xlink:label="lab_selb_ChangeInContractWithCustomerLiabilityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change In Contract With Customer, Liability [Roll Forward]</link:label>
    <link:label id="lab_selb_ChangeInContractWithCustomerLiabilityRollForward_documentation_en-US" xlink:label="lab_selb_ChangeInContractWithCustomerLiabilityRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change In Contract With Customer, Liability [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_selb_ChangeInContractWithCustomerLiabilityRollForward" xlink:href="selb-20210331.xsd#selb_ChangeInContractWithCustomerLiabilityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_selb_ChangeInContractWithCustomerLiabilityRollForward" xlink:to="lab_selb_ChangeInContractWithCustomerLiabilityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_2b53cf67-7612-41e3-9e1f-89f0f53ffb56_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssets_0ef0692c-2173-4638-b25e-ea084f46e878_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssets_label_en-US" xlink:label="lab_us-gaap_OtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssets" xlink:to="lab_us-gaap_OtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputExpectedTermMember_9d664420-6536-4357-85e1-52659190b2ff_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputExpectedTermMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected life (in years)</link:label>
    <link:label id="lab_us-gaap_MeasurementInputExpectedTermMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputExpectedTermMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Expected Term [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputExpectedTermMember" xlink:to="lab_us-gaap_MeasurementInputExpectedTermMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_7732e452-ea74-48d6-b3ce-fc4fed35409c_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_ff06747d-ee5a-4033-8445-6089e1aee3c9_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:to="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_cb785898-5c6a-4ebb-a191-4bd4bfbd3b1c_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_297fdf47-f9d0-4bc0-aecb-bc39368af391_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_6c49ff70-83a6-47f2-8726-5088fa5983b0_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsLineItems_6b137423-3743-4569-893f-ab41200ea261_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Line Items]</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsLineItems_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems" xlink:to="lab_us-gaap_CashAndCashEquivalentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_818ff16a-b36f-4e3c-acd2-5d9be4ba4210_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares outstanding</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_0f4d6bd2-af8f-480b-8e73-f43aef726174_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_22c34e27-e86b-4df5-9889-197436ddb04f_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_3c908559-4225-4a48-9fe9-4c7ffca4f270_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_selb_TermALoansMember_174a35d1-066f-4592-a7d1-7d607cf776ac_terseLabel_en-US" xlink:label="lab_selb_TermALoansMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term A Loans</link:label>
    <link:label id="lab_selb_TermALoansMember_label_en-US" xlink:label="lab_selb_TermALoansMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term A Loans [Member]</link:label>
    <link:label id="lab_selb_TermALoansMember_documentation_en-US" xlink:label="lab_selb_TermALoansMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term A Loans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_selb_TermALoansMember" xlink:href="selb-20210331.xsd#selb_TermALoansMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_selb_TermALoansMember" xlink:to="lab_selb_TermALoansMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableLeaseCost_f892112c-5bf9-46e3-922f-5f7b1acac11a_terseLabel_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable lease cost</link:label>
    <link:label id="lab_us-gaap_VariableLeaseCost_label_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableLeaseCost" xlink:to="lab_us-gaap_VariableLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LicenseAgreementTermsMember_700c60db-af5f-4ab2-8b2c-ea7da014b437_terseLabel_en-US" xlink:label="lab_us-gaap_LicenseAgreementTermsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Spark License Agreement</link:label>
    <link:label id="lab_us-gaap_LicenseAgreementTermsMember_label_en-US" xlink:label="lab_us-gaap_LicenseAgreementTermsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement Terms [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseAgreementTermsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicenseAgreementTermsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicenseAgreementTermsMember" xlink:to="lab_us-gaap_LicenseAgreementTermsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_8c3fcd84-c3d6-41a3-ac60-edd8e2eccf4c_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_cc10d836-af2b-4938-8913-7947ec4cbea2_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_8c0f9fa6-0b68-4b24-ad60-52caed563604_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_531f5008-1ae4-4d15-b6d3-e0129c3605b3_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_75410d13-7cbb-4429-9136-9188beda15dc_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_31008656-aeec-4b60-bca1-f7770114abad_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total property and equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_472adc7c-e069-455f-a1a1-5213c30d3dde_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from exercise of stock options</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b4a60dcd-2167-4ca7-9bc7-7df6a4749da4_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_27ffb784-6a55-4a57-af69-1da3c32634c2_verboseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount_8d7031ce-0f9f-4bb1-8adc-547980168e80_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant, increase (decrease) in equity, amount</link:label>
    <link:label id="lab_us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount_label_en-US" xlink:label="lab_us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant, Down Round Feature, (Increase) Decrease in Equity, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount" xlink:to="lab_us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_2d14998a-b23b-4f43-956c-7817272277df_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_c36c695e-0881-4c8a-a5b0-644a0747be48_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_b9b71085-9896-4817-92fc-99d89c441faf_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses, deposits and other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_c232856b-0473-4433-846b-069da24631b0_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Debt discount and deferred charges</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_bff5af7b-7958-4c45-a9c5-eee7557d42f2_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_c6352bba-b991-4bf4-b7d0-14c562c8d2f7_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_selb_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedOutstandingIntrinsicValue_5d9e044b-d7d9-47c4-850d-9e620afb947a_terseLabel_en-US" xlink:label="lab_selb_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested</link:label>
    <link:label id="lab_selb_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedOutstandingIntrinsicValue_label_en-US" xlink:label="lab_selb_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement By Share-based Payment Award, Options, Vested, Outstanding, Intrinsic Value</link:label>
    <link:label id="lab_selb_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedOutstandingIntrinsicValue_documentation_en-US" xlink:label="lab_selb_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement By Share-based Payment Award, Options, Vested, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_selb_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedOutstandingIntrinsicValue" xlink:href="selb-20210331.xsd#selb_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_selb_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedOutstandingIntrinsicValue" xlink:to="lab_selb_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_296a81af-2490-4421-ae5a-596d52a8af63_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_0806b2b3-a66a-45d9-b008-1821bca15873_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_selb_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageFairValue_2cae68ab-252f-4a12-b884-c66f6f6df2c9_terseLabel_en-US" xlink:label="lab_selb_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average fair value of common stock (in dollars per share)</link:label>
    <link:label id="lab_selb_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageFairValue_label_en-US" xlink:label="lab_selb_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Fair Value</link:label>
    <link:label id="lab_selb_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageFairValue_documentation_en-US" xlink:label="lab_selb_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighed-average fair value relating to the share-based payment award.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_selb_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageFairValue" xlink:href="selb-20210331.xsd#selb_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_selb_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageFairValue" xlink:to="lab_selb_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_9b9c653f-3d3a-413e-bc37-6c43019819b8_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_868dfd73-4b8b-4367-b11c-eb6346bb4095_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_d2e617d2-4fdf-4981-aa55-8e8b8d647d5f_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Numerator:</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_2788a039-625d-471c-ac2a-b9bfe6da364a_terseLabel_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_label_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioUnspecifiedDomain" xlink:to="lab_srt_ScenarioUnspecifiedDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_selb_ContractwithCustomerLiabilityDeferredRevenueIncreaseFromCashReceipts_5b192417-c08a-488e-9fb7-3b6664428b29_terseLabel_en-US" xlink:label="lab_selb_ContractwithCustomerLiabilityDeferredRevenueIncreaseFromCashReceipts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue, additions</link:label>
    <link:label id="lab_selb_ContractwithCustomerLiabilityDeferredRevenueIncreaseFromCashReceipts_label_en-US" xlink:label="lab_selb_ContractwithCustomerLiabilityDeferredRevenueIncreaseFromCashReceipts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Deferred Revenue, Increase From Cash Receipts</link:label>
    <link:label id="lab_selb_ContractwithCustomerLiabilityDeferredRevenueIncreaseFromCashReceipts_documentation_en-US" xlink:label="lab_selb_ContractwithCustomerLiabilityDeferredRevenueIncreaseFromCashReceipts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Deferred Revenue, Increase From Cash Receipts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_selb_ContractwithCustomerLiabilityDeferredRevenueIncreaseFromCashReceipts" xlink:href="selb-20210331.xsd#selb_ContractwithCustomerLiabilityDeferredRevenueIncreaseFromCashReceipts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_selb_ContractwithCustomerLiabilityDeferredRevenueIncreaseFromCashReceipts" xlink:to="lab_selb_ContractwithCustomerLiabilityDeferredRevenueIncreaseFromCashReceipts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2cf5b51c-bb01-4483-a7f1-adc06889b3e3_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_0eb487c3-2930-4989-b1d8-06eb6479b992_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_selb_LicenseAndOptionAgreementContractualPaymentsMade_c3fac0ba-ba8d-4e75-a056-b8531f505f4b_verboseLabel_en-US" xlink:label="lab_selb_LicenseAndOptionAgreementContractualPaymentsMade" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual payments defined in the Exclusive Patent License agreement</link:label>
    <link:label id="lab_selb_LicenseAndOptionAgreementContractualPaymentsMade_label_en-US" xlink:label="lab_selb_LicenseAndOptionAgreementContractualPaymentsMade" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License And Option Agreement, Contractual Payments Made</link:label>
    <link:label id="lab_selb_LicenseAndOptionAgreementContractualPaymentsMade_documentation_en-US" xlink:label="lab_selb_LicenseAndOptionAgreementContractualPaymentsMade" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License And Option Agreement, Contractual Payments Made</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_selb_LicenseAndOptionAgreementContractualPaymentsMade" xlink:href="selb-20210331.xsd#selb_LicenseAndOptionAgreementContractualPaymentsMade"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_selb_LicenseAndOptionAgreementContractualPaymentsMade" xlink:to="lab_selb_LicenseAndOptionAgreementContractualPaymentsMade" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_abe11257-f8fb-4dcf-9872-8995483db0d8_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_4cb73edc-8c19-4352-af5f-d57ee573e19d_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_b4e9e1a8-583d-456d-b5da-2e642795a8dd_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_0084b338-d705-406a-870a-17735784d473_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock authorized and reserved for future issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_label_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_4c2d1693-60a7-4c19-9840-632cfeeb2eef_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term of contract</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Term of Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_1516dfe7-569e-43f6-9730-ad7f6e7317f9_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable" xlink:to="lab_us-gaap_DisaggregationOfRevenueTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_2d40b2ec-e0e1-4f03-a5d2-23592550f1e6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Cost by Plan [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_80452f1c-a599-4297-9a22-92a1c0a215ff_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_bb142ad2-1403-405c-9010-98e127e64b9c_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021 (remainder)</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_865354db-cd6a-48e1-a1a9-b12ae3cc0428_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other financing fees</link:label>
    <link:label id="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from (Payments for) Other Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:to="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_ab71a257-b730-4bfd-80e2-f1a77a560356_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of vested restricted stock units (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_03fe57f1-edd3-4027-a106-7cee9f8752f2_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_99f3c1fd-eaef-4b1f-b184-a6950c415778_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeAxis" xlink:to="lab_us-gaap_MeasurementInputTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_a52e553c-0a78-465c-85f9-f7d136841f4b_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Available-for-Sale Marketable Securities</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_7d1e7ab3-638d-46c1-8e31-e529190532d8_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebt_0fa0ba5e-c547-4172-9c73-5905e01cb030_totalLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total minimum debt payments</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_label_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt" xlink:to="lab_us-gaap_LongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_b672c62e-f9bc-4ada-8d4f-5f6f715a6657_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_83f4008a-933c-4495-a709-7693105b3ed8_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_608c7b5c-c2af-4ff1-a59c-673ab75d90f2_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalents_c3eb4206-c9f7-46ec-8db5-3e51fef06931_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalents_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash and Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalents" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_4f93db15-ff05-47aa-8135-f27ceee98403_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of premiums and discounts on marketable securities</link:label>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_label_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accretion (Amortization) of Discounts and Premiums, Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:to="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_selb_SOBIPurchaseAgreementMember_9b930d48-2688-4e59-bdb7-6a1a4f9916f3_terseLabel_en-US" xlink:label="lab_selb_SOBIPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SOBI Purchase Agreement</link:label>
    <link:label id="lab_selb_SOBIPurchaseAgreementMember_label_en-US" xlink:label="lab_selb_SOBIPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SOBI Purchase Agreement [Member]</link:label>
    <link:label id="lab_selb_SOBIPurchaseAgreementMember_documentation_en-US" xlink:label="lab_selb_SOBIPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SOBI Purchase Agreement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_selb_SOBIPurchaseAgreementMember" xlink:href="selb-20210331.xsd#selb_SOBIPurchaseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_selb_SOBIPurchaseAgreementMember" xlink:to="lab_selb_SOBIPurchaseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_selb_CollaborativeArrangementCostSharePercentage_86038a00-4468-4db2-9353-1d84d3b139b4_terseLabel_en-US" xlink:label="lab_selb_CollaborativeArrangementCostSharePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost share percentage</link:label>
    <link:label id="lab_selb_CollaborativeArrangementCostSharePercentage_label_en-US" xlink:label="lab_selb_CollaborativeArrangementCostSharePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Cost Share Percentage</link:label>
    <link:label id="lab_selb_CollaborativeArrangementCostSharePercentage_documentation_en-US" xlink:label="lab_selb_CollaborativeArrangementCostSharePercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Cost Share Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_selb_CollaborativeArrangementCostSharePercentage" xlink:href="selb-20210331.xsd#selb_CollaborativeArrangementCostSharePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_selb_CollaborativeArrangementCostSharePercentage" xlink:to="lab_selb_CollaborativeArrangementCostSharePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_ce9b4b71-439f-4efe-a4be-ef21f0a8e23c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_83b511ba-6df3-4de9-9013-c125cb36bdad_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_7ed7510c-a129-4078-b9bb-d1aef00c5cd4_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable securities:</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_5d79248c-c8c0-42f3-8918-bc641507ef00_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_dfc32c2e-e212-4055-abb1-5ff9ff8c3921_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_48a9d604-eda9-4294-8980-71dadc983c59_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_selb_A2017TermLoansMember_b8d8bc9c-1dcf-4dc3-b6cd-f03b0c73491f_terseLabel_en-US" xlink:label="lab_selb_A2017TermLoansMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2017 Term Loans</link:label>
    <link:label id="lab_selb_A2017TermLoansMember_label_en-US" xlink:label="lab_selb_A2017TermLoansMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2017 Term Loans [Member]</link:label>
    <link:label id="lab_selb_A2017TermLoansMember_documentation_en-US" xlink:label="lab_selb_A2017TermLoansMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2017 Term Loans [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_selb_A2017TermLoansMember" xlink:href="selb-20210331.xsd#selb_A2017TermLoansMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_selb_A2017TermLoansMember" xlink:to="lab_selb_A2017TermLoansMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid_96fe5f77-6514-4817-b26c-17726ac6d7f2_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Final payment fee</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Periodic Payment Terms, Balloon Payment to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid" xlink:to="lab_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_8abaf8d5-12bb-474f-815f-6e6dea85b080_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_9e8bc725-b66d-4d93-b13a-dbcf459934cf_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_3521b97c-6efd-4cfa-8a8e-fd758fb787b2_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation expense</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_d665cd48-b34b-432f-993c-e0d733a913ae_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited in period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_f6710afc-266c-41b0-9401-1e0dcb8a734e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Weighted Average Assumptions Used</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_c6f7709e-d50d-49d3-9b9c-15298fde6b22_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateBondSecuritiesMember_af876aa9-32ae-46bf-bbe7-663e5ca14aff_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateBondSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate bonds</link:label>
    <link:label id="lab_us-gaap_CorporateBondSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateBondSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Bond Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateBondSecuritiesMember" xlink:to="lab_us-gaap_CorporateBondSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_f52188ad-cdf1-4713-b367-589562772c45_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_9c810834-35af-4568-b3a1-b4ca2c2ed3f9_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restricted Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restrictions on Cash and Cash Equivalents [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:to="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_77555674-f7b9-4b81-af08-14f11056241a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_d2899b54-9c21-483b-8af3-3ef681440873_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_3f5878e0-39b2-4fca-8004-9cfe05993cd6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Options Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasedAssetsLineItems_d4a6763f-2b46-4cb2-8e4d-f86ae0ed13ff_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasedAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leased Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_OperatingLeasedAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_OperatingLeasedAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leased Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasedAssetsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasedAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems" xlink:to="lab_us-gaap_OperatingLeasedAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_selb_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndDebtSecuritiesAvailableForSale_6d755f07-99d5-482b-83a3-f64aa7e067a2_terseLabel_en-US" xlink:label="lab_selb_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndDebtSecuritiesAvailableForSale" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents, restricted cash and marketable securities</link:label>
    <link:label id="lab_selb_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndDebtSecuritiesAvailableForSale_label_en-US" xlink:label="lab_selb_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndDebtSecuritiesAvailableForSale" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Debt Securities, Available-For-Sale</link:label>
    <link:label id="lab_selb_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndDebtSecuritiesAvailableForSale_documentation_en-US" xlink:label="lab_selb_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndDebtSecuritiesAvailableForSale" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Debt Securities, Available-For-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_selb_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndDebtSecuritiesAvailableForSale" xlink:href="selb-20210331.xsd#selb_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndDebtSecuritiesAvailableForSale"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_selb_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndDebtSecuritiesAvailableForSale" xlink:to="lab_selb_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndDebtSecuritiesAvailableForSale" xlink:type="arc" order="1"/>
    <link:label id="lab_selb_ShareBasedGoodsAndNonEmployeeServicesTransactionCompensationNotYetRecognizedStockOptions_44828100-3000-496e-a8f7-cc3a27153e6c_terseLabel_en-US" xlink:label="lab_selb_ShareBasedGoodsAndNonEmployeeServicesTransactionCompensationNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation expense related to unvested non-employee stock options</link:label>
    <link:label id="lab_selb_ShareBasedGoodsAndNonEmployeeServicesTransactionCompensationNotYetRecognizedStockOptions_label_en-US" xlink:label="lab_selb_ShareBasedGoodsAndNonEmployeeServicesTransactionCompensationNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Goods And Non Employee Services Transaction, Compensation Not Yet Recognized, Stock Options</link:label>
    <link:label id="lab_selb_ShareBasedGoodsAndNonEmployeeServicesTransactionCompensationNotYetRecognizedStockOptions_documentation_en-US" xlink:label="lab_selb_ShareBasedGoodsAndNonEmployeeServicesTransactionCompensationNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Goods And Non Employee Services Transaction, Compensation Not Yet Recognized, Stock Options</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_selb_ShareBasedGoodsAndNonEmployeeServicesTransactionCompensationNotYetRecognizedStockOptions" xlink:href="selb-20210331.xsd#selb_ShareBasedGoodsAndNonEmployeeServicesTransactionCompensationNotYetRecognizedStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_selb_ShareBasedGoodsAndNonEmployeeServicesTransactionCompensationNotYetRecognizedStockOptions" xlink:to="lab_selb_ShareBasedGoodsAndNonEmployeeServicesTransactionCompensationNotYetRecognizedStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_f83006a2-2947-4d19-8e8a-4d67df3241a0_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_d2f2e6cf-5e2c-4ad5-9afd-ddcd9fccc13e_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_selb_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsVestedWeightedAverageExercisePrice_0f64202a-d751-4904-8b74-6ab80384d8f7_verboseLabel_en-US" xlink:label="lab_selb_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsVestedWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (in dollars per share)</link:label>
    <link:label id="lab_selb_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsVestedWeightedAverageExercisePrice_label_en-US" xlink:label="lab_selb_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsVestedWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Exercise Price</link:label>
    <link:label id="lab_selb_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsVestedWeightedAverageExercisePrice_documentation_en-US" xlink:label="lab_selb_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsVestedWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_selb_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsVestedWeightedAverageExercisePrice" xlink:href="selb-20210331.xsd#selb_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsVestedWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_selb_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsVestedWeightedAverageExercisePrice" xlink:to="lab_selb_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsVestedWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_4a8e3df9-a226-4ef1-a0b2-59fcbd8e039a_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_f5935923-c39e-47e1-bb14-65de5ad13766_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease, weighted average discount rate, percent</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_d2f94200-caec-40d7-9f39-9cca71d01362_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets:</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet_6adeddb1-909e-411b-aa50-6124c3e1fb4a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, transfers, net</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" xlink:type="arc" order="1"/>
    <link:label id="lab_selb_AccruedAuditFeesCurrent_3c94fdbd-87fd-40bd-b265-2c0c9e820efa_terseLabel_en-US" xlink:label="lab_selb_AccruedAuditFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued professional and consulting services</link:label>
    <link:label id="lab_selb_AccruedAuditFeesCurrent_label_en-US" xlink:label="lab_selb_AccruedAuditFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Audit Fees, Current</link:label>
    <link:label id="lab_selb_AccruedAuditFeesCurrent_documentation_en-US" xlink:label="lab_selb_AccruedAuditFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Audit Fees, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_selb_AccruedAuditFeesCurrent" xlink:href="selb-20210331.xsd#selb_AccruedAuditFeesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_selb_AccruedAuditFeesCurrent" xlink:to="lab_selb_AccruedAuditFeesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_1a6fbe0d-9f77-4bc4-bfca-a24d5fddcb43_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average exercise price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightLineItems_b2cb58da-ec1d-495b-8d01-74877675019a_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="lab_us-gaap_ClassOfWarrantOrRightLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_country_RU_b1387e2d-2b74-42fc-ab55-848d2231852a_terseLabel_en-US" xlink:label="lab_country_RU" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Russian subsidiary</link:label>
    <link:label id="lab_country_RU_label_en-US" xlink:label="lab_country_RU" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RUSSIAN FEDERATION</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_RU" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_RU"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_RU" xlink:to="lab_country_RU" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaidInKindInterest_0bffe3b3-d733-4bad-af3f-0d6474e0ab16_terseLabel_en-US" xlink:label="lab_us-gaap_PaidInKindInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash interest expense</link:label>
    <link:label id="lab_us-gaap_PaidInKindInterest_label_en-US" xlink:label="lab_us-gaap_PaidInKindInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Paid-in-Kind Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaidInKindInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaidInKindInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaidInKindInterest" xlink:to="lab_us-gaap_PaidInKindInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_b5d36996-040a-4215-b83a-21918358cf06_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_4b36a554-74cd-48d4-b5cf-483d8b0e4eab_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_c00917cb-168b-4087-896e-05b2e5048203_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total future minimum lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale_29c57f22-3859-4773-bc00-f18106e027f3_terseLabel_en-US" xlink:label="lab_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable securities adjusted for other than temporary declines in fair value</link:label>
    <link:label id="lab_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale_label_en-US" xlink:label="lab_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other-than-temporary Impairment Loss, Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale" xlink:to="lab_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther_990a8b64-8015-4a58-9868-3aa2ee03e955_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other financing fees</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid in Capital, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_2298d99c-ec26-4dc4-a118-50cc1d44c0c4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain_d713c1d2-c6da-4b04-8065-f3424a8c2144_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashNoncurrent_d3545bb1-1bbd-4eb3-93f1-87ce95e44670_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashNoncurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashNoncurrent" xlink:to="lab_us-gaap_RestrictedCashNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_1687ecec-12fa-48eb-803f-69e0ce678d14_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_d720f9bd-f473-432c-b6d0-23c677e43d60_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_1d63472c-65c0-4a87-a286-ec9bd9a47d29_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_e3f33410-ca00-4d94-a42b-6cfa606dc9cd_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic and diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_f9501d0a-9cf8-4824-b1fa-1ab05aff1a21_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted&#8209;average common shares outstanding&#8212;basic and diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic and Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_f6faaa2b-48ac-46f4-99fc-0223978737c5_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period Two</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period Two [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_05e20b19-47c1-4ecb-9ce7-98678f8fa6a4_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Expenses</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:to="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_7107b202-ac95-439a-98eb-65cee3762ab4_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Cash_5ebeec86-d695-4a60-8807-82e49d0ad969_terseLabel_en-US" xlink:label="lab_us-gaap_Cash" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash maintained in Russian bank accounts</link:label>
    <link:label id="lab_us-gaap_Cash_label_en-US" xlink:label="lab_us-gaap_Cash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Cash" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Cash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Cash" xlink:to="lab_us-gaap_Cash" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_18a858ca-d68c-4ef1-a080-7e6912fac803_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_553465fb-5468-40f7-ab7c-13dab305cf6c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value Measurement Inputs and Valuation Techniques</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_selb_LicenseAndOptionAgreementWrittenDayNoticePeriodBeforeCancellation_92c10eb2-0a1e-4df0-b1fd-516d1a8b4988_terseLabel_en-US" xlink:label="lab_selb_LicenseAndOptionAgreementWrittenDayNoticePeriodBeforeCancellation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License and option agreement, written day notice period before cancellation</link:label>
    <link:label id="lab_selb_LicenseAndOptionAgreementWrittenDayNoticePeriodBeforeCancellation_label_en-US" xlink:label="lab_selb_LicenseAndOptionAgreementWrittenDayNoticePeriodBeforeCancellation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License And Option Agreement, Written Day Notice Period Before Cancellation</link:label>
    <link:label id="lab_selb_LicenseAndOptionAgreementWrittenDayNoticePeriodBeforeCancellation_documentation_en-US" xlink:label="lab_selb_LicenseAndOptionAgreementWrittenDayNoticePeriodBeforeCancellation" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License And Option Agreement, Written Day Notice Period Before Cancellation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_selb_LicenseAndOptionAgreementWrittenDayNoticePeriodBeforeCancellation" xlink:href="selb-20210331.xsd#selb_LicenseAndOptionAgreementWrittenDayNoticePeriodBeforeCancellation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_selb_LicenseAndOptionAgreementWrittenDayNoticePeriodBeforeCancellation" xlink:to="lab_selb_LicenseAndOptionAgreementWrittenDayNoticePeriodBeforeCancellation" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_5d03f17d-8cc4-4c34-a4fc-9e90dd88f229_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_selb_LicenseAndOptionAgreementDevelopmentMilestone_9e318851-2c9a-413f-b0c0-32206b22a9c5_terseLabel_en-US" xlink:label="lab_selb_LicenseAndOptionAgreementDevelopmentMilestone" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development milestone</link:label>
    <link:label id="lab_selb_LicenseAndOptionAgreementDevelopmentMilestone_label_en-US" xlink:label="lab_selb_LicenseAndOptionAgreementDevelopmentMilestone" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License And Option Agreement, Development Milestone</link:label>
    <link:label id="lab_selb_LicenseAndOptionAgreementDevelopmentMilestone_documentation_en-US" xlink:label="lab_selb_LicenseAndOptionAgreementDevelopmentMilestone" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License And Option Agreement, Development Milestone</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_selb_LicenseAndOptionAgreementDevelopmentMilestone" xlink:href="selb-20210331.xsd#selb_LicenseAndOptionAgreementDevelopmentMilestone"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_selb_LicenseAndOptionAgreementDevelopmentMilestone" xlink:to="lab_selb_LicenseAndOptionAgreementDevelopmentMilestone" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis_dc1df0d3-14ac-4780-9fc2-b939b0b38ec1_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_selb_SareptaTherapeuticsInc.Member_5f55b7b2-4ae1-4dda-956b-c86ec45fa525_terseLabel_en-US" xlink:label="lab_selb_SareptaTherapeuticsInc.Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sarepta Therapeutics, Inc.</link:label>
    <link:label id="lab_selb_SareptaTherapeuticsInc.Member_label_en-US" xlink:label="lab_selb_SareptaTherapeuticsInc.Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sarepta Therapeutics, Inc. [Member]</link:label>
    <link:label id="lab_selb_SareptaTherapeuticsInc.Member_documentation_en-US" xlink:label="lab_selb_SareptaTherapeuticsInc.Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sarepta Therapeutics, Inc. [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_selb_SareptaTherapeuticsInc.Member" xlink:href="selb-20210331.xsd#selb_SareptaTherapeuticsInc.Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_selb_SareptaTherapeuticsInc.Member" xlink:to="lab_selb_SareptaTherapeuticsInc.Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1f622d8e-8356-431c-9db1-f0e5a2e9548c_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_d88e0258-daed-46b9-9784-58e3f7cee0d5_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_c9f474aa-387b-4c00-b2cd-9df366529424_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of warrant or right, outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantMember_417973b9-f837-483b-a292-8c8bf08603c4_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants to purchase common stock</link:label>
    <link:label id="lab_us-gaap_WarrantMember_ee388d65-ad57-46dd-a2fd-ee78befbe21d_netLabel_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant liabilities</link:label>
    <link:label id="lab_us-gaap_WarrantMember_ae9c40c2-0f1d-478f-9b28-e06948459cd9_verboseLabel_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of common warrants</link:label>
    <link:label id="lab_us-gaap_WarrantMember_label_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantMember" xlink:to="lab_us-gaap_WarrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightTable_c45baee9-72fb-4c30-9139-9078f7229686_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Table]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightTable_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable" xlink:to="lab_us-gaap_ClassOfWarrantOrRightTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_5c8dd576-4735-4bda-9a3f-024de0f74083_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash and Cash Equivalents, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet_0e9a6cf1-dcae-4850-b12a-cd1c24893ded_terseLabel_en-US" xlink:label="lab_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt issuance costs, line of credit arrangements (less than)</link:label>
    <link:label id="lab_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet_label_en-US" xlink:label="lab_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Issuance Costs, Line of Credit Arrangements, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet" xlink:to="lab_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_432cf324-9dca-454d-82b7-b82f3fefe6b9_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Level&#160;2)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_a8b2b9f0-d62c-40ae-8196-d83c3e288e0e_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_selb_FounderMember_fb8a7001-86f0-40a5-9600-1f341623eb82_terseLabel_en-US" xlink:label="lab_selb_FounderMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Founders</link:label>
    <link:label id="lab_selb_FounderMember_label_en-US" xlink:label="lab_selb_FounderMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Founder [Member]</link:label>
    <link:label id="lab_selb_FounderMember_documentation_en-US" xlink:label="lab_selb_FounderMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents information pertaining to founder member.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_selb_FounderMember" xlink:href="selb-20210331.xsd#selb_FounderMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_selb_FounderMember" xlink:to="lab_selb_FounderMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_ede976dc-bf66-4586-932a-6cbf74a34d8a_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_66da3956-7602-4a52-bbcd-8c0c0d1859bb_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_selb_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantIncreaseDecrease_5a3cdb04-b012-49b2-8069-22e3b8f42166_terseLabel_en-US" xlink:label="lab_selb_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares authorized, increase (in shares)</link:label>
    <link:label id="lab_selb_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantIncreaseDecrease_label_en-US" xlink:label="lab_selb_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Number Of Shares Available For Grant, Increase (Decrease)</link:label>
    <link:label id="lab_selb_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantIncreaseDecrease_documentation_en-US" xlink:label="lab_selb_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Number Of Shares Available For Grant, Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_selb_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantIncreaseDecrease" xlink:href="selb-20210331.xsd#selb_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_selb_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantIncreaseDecrease" xlink:to="lab_selb_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_selb_ContractwithCustomerLiabilityDeferredRevenue_11e3a90c-089e-4844-bfa9-83ba44d5d3b6_periodStartLabel_en-US" xlink:label="lab_selb_ContractwithCustomerLiabilityDeferredRevenue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue, beginning of period</link:label>
    <link:label id="lab_selb_ContractwithCustomerLiabilityDeferredRevenue_e89d8b42-c8aa-4672-b1b9-f04521f95498_periodEndLabel_en-US" xlink:label="lab_selb_ContractwithCustomerLiabilityDeferredRevenue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue, end of period</link:label>
    <link:label id="lab_selb_ContractwithCustomerLiabilityDeferredRevenue_label_en-US" xlink:label="lab_selb_ContractwithCustomerLiabilityDeferredRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Deferred Revenue</link:label>
    <link:label id="lab_selb_ContractwithCustomerLiabilityDeferredRevenue_documentation_en-US" xlink:label="lab_selb_ContractwithCustomerLiabilityDeferredRevenue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Deferred Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_selb_ContractwithCustomerLiabilityDeferredRevenue" xlink:href="selb-20210331.xsd#selb_ContractwithCustomerLiabilityDeferredRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_selb_ContractwithCustomerLiabilityDeferredRevenue" xlink:to="lab_selb_ContractwithCustomerLiabilityDeferredRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_594bf0aa-2e68-464e-a982-791a57a2215b_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_bca97dc3-ad68-4ee7-9214-5820bf497993_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_4c1cee26-176a-48f6-a9c8-1750c6e3bf48_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_ae1aed90-1e69-43e3-95f0-130db0b994b2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_2d980dc3-d076-4761-a034-baed1594b2a4_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_53733138-4e06-4029-bb5c-ed0a53ff856f_verboseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term contract liability</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_2e60e6f5-a73d-42f4-bb08-db51db51a2d0_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_label_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventLineItems" xlink:to="lab_us-gaap_SubsequentEventLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_2190ae79-2a3b-4c67-921c-0f572f2c19b6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_a5dad67f-29d8-4fdd-843e-6236de74acc6_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and expected to vest (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityDomain_6fff1c86-524a-46a1-89d3-8aeb149cf464_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityDomain_label_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityDomain" xlink:to="lab_us-gaap_CreditFacilityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LetterOfCreditMember_22234050-8772-46d6-a761-5f41eee0c770_terseLabel_en-US" xlink:label="lab_us-gaap_LetterOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letter of credit</link:label>
    <link:label id="lab_us-gaap_LetterOfCreditMember_label_en-US" xlink:label="lab_us-gaap_LetterOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letter of Credit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LetterOfCreditMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LetterOfCreditMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LetterOfCreditMember" xlink:to="lab_us-gaap_LetterOfCreditMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet_1a52b1f1-79c5-4954-b795-208f4fedf855_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, transfers, net</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Transfers, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet" xlink:type="arc" order="1"/>
    <link:label id="lab_selb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValueAbstract_58b28c9e-7df8-4092-b63b-2af0afe4d5ba_terseLabel_en-US" xlink:label="lab_selb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value</link:label>
    <link:label id="lab_selb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValueAbstract_label_en-US" xlink:label="lab_selb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value [Abstract]</link:label>
    <link:label id="lab_selb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValueAbstract_documentation_en-US" xlink:label="lab_selb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValueAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">n/a</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_selb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValueAbstract" xlink:href="selb-20210331.xsd#selb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_selb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValueAbstract" xlink:to="lab_selb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_7ebb071b-eb3c-4d4f-8feb-01d2e7b558ad_verboseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_bc7849ee-de4e-4a7a-bfb3-ea96cba0dc6e_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_7aaa2c30-8177-4d5a-99d3-b9d8043b89cd_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited in period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_a3a2fd43-4ea5-4cbc-98b8-5a8854d89e71_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_bdb6fea3-7b2e-4d38-820e-752c41e0b395_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease, weighted average remaining lease term</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_077e4353-5f66-4526-a01b-25fb355c086e_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_c0084d4e-29b5-4d00-9912-bff0d5eb6184_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by (used in) financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_0c3f1440-9ef3-4819-873f-65a6400b9aec_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of principal on outstanding debt</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:to="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DividendsCommonStock_275abee3-17cf-4a21-afc0-8f5513561ed9_terseLabel_en-US" xlink:label="lab_us-gaap_DividendsCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends declared or paid on common stock</link:label>
    <link:label id="lab_us-gaap_DividendsCommonStock_label_en-US" xlink:label="lab_us-gaap_DividendsCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsCommonStock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DividendsCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DividendsCommonStock" xlink:to="lab_us-gaap_DividendsCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_da0885b5-6fd7-4890-84cb-b19d641151e6_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to additional paid in capital, warrant issued</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid in Capital, Warrant Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_30d136f6-f302-4ed9-82b3-fc254550e766_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining performance obligation</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligation" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_02bf37ee-3674-4a60-803c-e747c9cfacde_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock&#8209;based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_b534aab2-fc85-41e9-96ca-8dd72e5e5442_verboseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_a67ad4c3-053f-4264-9955-50ce25eebff2_netLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherDepreciationAndAmortization_9067e08c-76d6-46a1-a6d9-075ae5ddbf9e_terseLabel_en-US" xlink:label="lab_us-gaap_OtherDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_OtherDepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_OtherDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Depreciation and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherDepreciationAndAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherDepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherDepreciationAndAmortization" xlink:to="lab_us-gaap_OtherDepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_14d233d6-78b9-4870-a982-cffc037b84de_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax benefits</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_0d2b7fb1-1097-4159-bc77-b03daeaf7c67_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock under Employee Stock Purchase Plan</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Employee Stock Purchase Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_d09edb41-fdc2-41da-988c-c71946137340_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, $0.0001 par value; 200,000,000 shares authorized; 112,977,004 and 108,071,249 shares issued and outstanding as of March 31, 2021 and December 31, 2020, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_49326f29-e181-45e9-98c3-8d242a747a98_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_1be96e92-4748-4708-9de9-c7af0266a415_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommercialPaperMember_9e3c2da6-476a-44c3-b52f-e3ab840d1549_terseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaperMember_label_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Paper [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperMember" xlink:to="lab_us-gaap_CommercialPaperMember" xlink:type="arc" order="1"/>
    <link:label id="lab_selb_DebtInstrumentDefaultBankruptcyOrInsolvencyValueOfTriggeringAcceleratedRedemption_129a8509-9f2f-4cc4-918c-b4b365705f9a_terseLabel_en-US" xlink:label="lab_selb_DebtInstrumentDefaultBankruptcyOrInsolvencyValueOfTriggeringAcceleratedRedemption" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, default, bankruptcy, or insolvency value of triggering accelerated redemption</link:label>
    <link:label id="lab_selb_DebtInstrumentDefaultBankruptcyOrInsolvencyValueOfTriggeringAcceleratedRedemption_label_en-US" xlink:label="lab_selb_DebtInstrumentDefaultBankruptcyOrInsolvencyValueOfTriggeringAcceleratedRedemption" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Default, Bankruptcy, Or Insolvency Value Of Triggering Accelerated Redemption</link:label>
    <link:label id="lab_selb_DebtInstrumentDefaultBankruptcyOrInsolvencyValueOfTriggeringAcceleratedRedemption_documentation_en-US" xlink:label="lab_selb_DebtInstrumentDefaultBankruptcyOrInsolvencyValueOfTriggeringAcceleratedRedemption" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Default, Bankruptcy, Or Insolvency Value Of Triggering Accelerated Redemption</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_selb_DebtInstrumentDefaultBankruptcyOrInsolvencyValueOfTriggeringAcceleratedRedemption" xlink:href="selb-20210331.xsd#selb_DebtInstrumentDefaultBankruptcyOrInsolvencyValueOfTriggeringAcceleratedRedemption"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_selb_DebtInstrumentDefaultBankruptcyOrInsolvencyValueOfTriggeringAcceleratedRedemption" xlink:to="lab_selb_DebtInstrumentDefaultBankruptcyOrInsolvencyValueOfTriggeringAcceleratedRedemption" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_0e6d0b30-de64-408c-b803-43a4670c7d57_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:to="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_0b6fd2cc-222e-4cdd-b1bd-4170cce0b6d7_negatedLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Current portion of loan payable</link:label>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtCurrent" xlink:to="lab_us-gaap_LongTermDebtCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_1e924dc0-153a-4487-834f-7ac9b5aeb249_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_625a010a-f578-44ef-aa8b-1db7bf40d340_verboseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_label_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare" xlink:to="lab_us-gaap_SaleOfStockPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_091bee8c-331a-4241-babe-cb4a923c55d0_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputPriceVolatilityMember_cb74c57b-6737-4e63-9f91-8ae13f009b91_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputPriceVolatilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility</link:label>
    <link:label id="lab_us-gaap_MeasurementInputPriceVolatilityMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputPriceVolatilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Price Volatility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputPriceVolatilityMember" xlink:to="lab_us-gaap_MeasurementInputPriceVolatilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_4562c1c3-a6fc-4590-9e35-17ed3f2920b1_terseLabel_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTable_7339dbc0-24f3-4713-ae2b-f0a15113bbfb_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTable_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTable" xlink:to="lab_us-gaap_SubsequentEventTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_1c513599-1f1f-4011-951e-685427cba881_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of marketable securities</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:to="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_selb_CommonWarrantMember_b7685a05-1805-437e-ab61-b3d32cce3b00_terseLabel_en-US" xlink:label="lab_selb_CommonWarrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Warrant</link:label>
    <link:label id="lab_selb_CommonWarrantMember_label_en-US" xlink:label="lab_selb_CommonWarrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Warrant [Member]</link:label>
    <link:label id="lab_selb_CommonWarrantMember_documentation_en-US" xlink:label="lab_selb_CommonWarrantMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Warrant [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_selb_CommonWarrantMember" xlink:href="selb-20210331.xsd#selb_CommonWarrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_selb_CommonWarrantMember" xlink:to="lab_selb_CommonWarrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_df530336-7dd4-45c4-86d9-b771d016673e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grants in period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable_8e40e021-9615-4042-a9b9-6aa677abef39_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Operating Leased Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Operating Leased Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:to="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_79ec3cab-fe99-4dd6-bae8-02f2edea7abb_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_36e527e3-0fc9-4286-a9f7-99e393d569cc_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember_71919551-32aa-4e7c-8c1d-aa8d42045764_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Risk Free Interest Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:to="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_788b563d-f966-4948-8dc3-6f690a54282a_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_6adcb511-a4df-47f5-aed1-4d86b3a8785e_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_a96d6f83-9551-4a72-a4ce-8c23dd3a9728_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]</link:label>
    <link:label id="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_label_en-US" xlink:label="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:type="arc" order="1"/>
    <link:label id="lab_selb_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReservedForIssuanceWeightedAverageGrantDateFairValue_a2992d0d-3c8e-4ac8-8e5b-f4228122986f_terseLabel_en-US" xlink:label="lab_selb_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReservedForIssuanceWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserved for issuance (in dollars per share)</link:label>
    <link:label id="lab_selb_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReservedForIssuanceWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_selb_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReservedForIssuanceWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Reserved For Issuance, Weighted Average Grant Date Fair Value</link:label>
    <link:label id="lab_selb_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReservedForIssuanceWeightedAverageGrantDateFairValue_documentation_en-US" xlink:label="lab_selb_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReservedForIssuanceWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Reserved For Issuance, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_selb_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReservedForIssuanceWeightedAverageGrantDateFairValue" xlink:href="selb-20210331.xsd#selb_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReservedForIssuanceWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_selb_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReservedForIssuanceWeightedAverageGrantDateFairValue" xlink:to="lab_selb_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReservedForIssuanceWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_5663e938-60da-44c6-9795-65753e690b27_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loan payable, net of current portion</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Excluding Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent" xlink:to="lab_us-gaap_LongTermDebtNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed_5345f9f9-bfd3-4b37-ad37-db7c2147c775_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, redemption price, percentage of principal amount redeemed</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption Price, Percentage of Principal Amount Redeemed</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_4f8baab9-af5a-4ee9-b0e4-214851feb913_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_c7a25d2e-3a8d-48a7-af79-3f5a76d17fb6_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_f35c71a1-a159-4f05-8b87-ec7befbcf896_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders&#8217; (deficit) equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_c8a2aa5c-bfd8-4fc9-b182-91ad8d562d64_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_9fa4291b-6d83-4262-bd83-515a870bf839_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_f291110a-4b49-45f9-b3dc-7c3bb6531e9b_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance costs</link:label>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Stock Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_11de34b5-6ef1-4fc3-bd4a-5f6958b790ee_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders&#8217; (deficit) equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_5440ed9e-d576-4a6b-a55f-74e896d580c7_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_02214f2c-38e8-4f8e-9d4d-443e35c11b6d_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_d9aa253d-a994-48ad-a3d0-b8a4bdf9cbf8_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_8c00c0d8-f252-4b8b-93c8-11d1346bc130_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payroll and employee related expenses</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_selb_AskBioLicenseMember_620dcd7e-5803-4830-8f8e-89dbbc62320f_terseLabel_en-US" xlink:label="lab_selb_AskBioLicenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AskBio License</link:label>
    <link:label id="lab_selb_AskBioLicenseMember_label_en-US" xlink:label="lab_selb_AskBioLicenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AskBio License [Member]</link:label>
    <link:label id="lab_selb_AskBioLicenseMember_documentation_en-US" xlink:label="lab_selb_AskBioLicenseMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AskBio License [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_selb_AskBioLicenseMember" xlink:href="selb-20210331.xsd#selb_AskBioLicenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_selb_AskBioLicenseMember" xlink:to="lab_selb_AskBioLicenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_dce19bad-de75-4aee-bd98-250d1e7d0239_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_6bbbda91-9ffb-4fd2-b2a4-dce0f8039b3c_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested restricted stock units</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseCost_e27dfebb-6e3d-4126-83d7-9280ba8e2c23_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease cost</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_c55e8069-3e0b-4775-b964-51414afb0789_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_fb4fd5a7-dcdb-473c-94be-f16ab5f6a31a_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_selb_A2017PIPEMember_44754193-fb2a-4cb9-b568-a698c77d717b_terseLabel_en-US" xlink:label="lab_selb_A2017PIPEMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2017 PIPE</link:label>
    <link:label id="lab_selb_A2017PIPEMember_label_en-US" xlink:label="lab_selb_A2017PIPEMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2017 PIPE [Member]</link:label>
    <link:label id="lab_selb_A2017PIPEMember_documentation_en-US" xlink:label="lab_selb_A2017PIPEMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2017 PIPE [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_selb_A2017PIPEMember" xlink:href="selb-20210331.xsd#selb_A2017PIPEMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_selb_A2017PIPEMember" xlink:to="lab_selb_A2017PIPEMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_9348908e-056c-4208-a2bb-6fdeb8ff1b98_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityLineItems_9416ece5-dea5-4788-afc6-42e12775153a_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility [Line Items]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityLineItems_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems" xlink:to="lab_us-gaap_LineOfCreditFacilityLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityExTransitionPeriod_8a6fcd9d-2d1f-4b76-bf41-3ea911d65d53_terseLabel_en-US" xlink:label="lab_dei_EntityExTransitionPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Extended Transition Period</link:label>
    <link:label id="lab_dei_EntityExTransitionPeriod_label_en-US" xlink:label="lab_dei_EntityExTransitionPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityExTransitionPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityExTransitionPeriod" xlink:to="lab_dei_EntityExTransitionPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermLeaseCost_e6e02dc2-7b4f-4c71-a55e-eb07cc9663a7_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term lease cost</link:label>
    <link:label id="lab_us-gaap_ShortTermLeaseCost_label_en-US" xlink:label="lab_us-gaap_ShortTermLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermLeaseCost" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermLeaseCost" xlink:to="lab_us-gaap_ShortTermLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_b55b03ac-5f91-44b9-9ceb-3b6399ea8624_negatedLabel_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on disposal of property and equipment</link:label>
    <link:label id="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_label_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Disposition of Property Plant Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:to="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_23b724c8-12bf-4f6a-8641-22aa2b550d75_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermLoansPayable_f8f8916e-c23e-4e85-b55a-77ed6a7c9930_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermLoansPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loan payable, net of current portion</link:label>
    <link:label id="lab_us-gaap_LongTermLoansPayable_label_en-US" xlink:label="lab_us-gaap_LongTermLoansPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loans Payable, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermLoansPayable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermLoansPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermLoansPayable" xlink:to="lab_us-gaap_LongTermLoansPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAbstract_f87f3358-2951-48cc-a7ba-4eba3cbae972_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAbstract" xlink:to="lab_us-gaap_LiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_selb_DebtInstrumentAdditionalAccruedInterestInTheEventOfDefault_9759d0fb-028a-4cb9-a6a7-aaa9acdd3e65_terseLabel_en-US" xlink:label="lab_selb_DebtInstrumentAdditionalAccruedInterestInTheEventOfDefault" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, additional accrued interest in the event of default</link:label>
    <link:label id="lab_selb_DebtInstrumentAdditionalAccruedInterestInTheEventOfDefault_label_en-US" xlink:label="lab_selb_DebtInstrumentAdditionalAccruedInterestInTheEventOfDefault" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Additional Accrued Interest In the Event Of Default</link:label>
    <link:label id="lab_selb_DebtInstrumentAdditionalAccruedInterestInTheEventOfDefault_documentation_en-US" xlink:label="lab_selb_DebtInstrumentAdditionalAccruedInterestInTheEventOfDefault" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Additional Accrued Interest In the Event Of Default</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_selb_DebtInstrumentAdditionalAccruedInterestInTheEventOfDefault" xlink:href="selb-20210331.xsd#selb_DebtInstrumentAdditionalAccruedInterestInTheEventOfDefault"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_selb_DebtInstrumentAdditionalAccruedInterestInTheEventOfDefault" xlink:to="lab_selb_DebtInstrumentAdditionalAccruedInterestInTheEventOfDefault" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_af252bcc-181a-410b-b891-2ee962a1e830_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_18f35c61-6d67-444b-b636-9f139a4efd2e_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_f2e8b172-9445-4205-9d7c-56dc335ca255_terseLabel_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in process</link:label>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_label_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in Progress [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionInProgressMember" xlink:to="lab_us-gaap_ConstructionInProgressMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_6e96ddca-0063-4100-a8ad-839370b4a5c6_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstandingTerm_a76653ec-0e6f-436b-ba33-11f12a8ba39d_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants and rights outstanding, term</link:label>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstandingTerm_label_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants and Rights Outstanding, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="lab_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesUnrealizedGainLoss_c16b1ac2-23be-47e1-a98f-f5906e622c0a_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized (losses) on marketable securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesUnrealizedGainLoss_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Unrealized Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesUnrealizedGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:to="lab_us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_e8b39b71-dab4-42e6-9509-bcf3b942dc85_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Incentive Plans</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_3ccb7515-83e9-4821-a7bc-21cf6c50cf09_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_d5a09154-4c68-4517-9a3e-e1b6e29d045a_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_230f8ec0-68a6-4df6-842a-e2a19f95cf55_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_fd481157-70ce-47e1-b94f-fc163ada5429_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021 (remainder)</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_selb_LeaseArrangementDomain_84cdb03e-67ad-482c-81ef-68ea386cc122_terseLabel_en-US" xlink:label="lab_selb_LeaseArrangementDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Arrangement [Domain]</link:label>
    <link:label id="lab_selb_LeaseArrangementDomain_label_en-US" xlink:label="lab_selb_LeaseArrangementDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Arrangement [Domain]</link:label>
    <link:label id="lab_selb_LeaseArrangementDomain_documentation_en-US" xlink:label="lab_selb_LeaseArrangementDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Domain] for Lease Arrangement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_selb_LeaseArrangementDomain" xlink:href="selb-20210331.xsd#selb_LeaseArrangementDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_selb_LeaseArrangementDomain" xlink:to="lab_selb_LeaseArrangementDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_selb_AccruedCollaborationandLicensing_3b1f32d8-30f9-41a8-90ce-73330ceb7f86_terseLabel_en-US" xlink:label="lab_selb_AccruedCollaborationandLicensing" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration and licensing</link:label>
    <link:label id="lab_selb_AccruedCollaborationandLicensing_label_en-US" xlink:label="lab_selb_AccruedCollaborationandLicensing" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Collaboration and Licensing</link:label>
    <link:label id="lab_selb_AccruedCollaborationandLicensing_documentation_en-US" xlink:label="lab_selb_AccruedCollaborationandLicensing" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Collaboration and Licensing</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_selb_AccruedCollaborationandLicensing" xlink:href="selb-20210331.xsd#selb_AccruedCollaborationandLicensing"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_selb_AccruedCollaborationandLicensing" xlink:to="lab_selb_AccruedCollaborationandLicensing" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_505a05ab-3f9e-41dd-aa9b-1fe419213fa5_terseLabel_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_selb_AtTheMarketOfferingMember_b7f538a2-e8aa-44a5-bf93-98ce1192f579_terseLabel_en-US" xlink:label="lab_selb_AtTheMarketOfferingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">At-The-Market Offering</link:label>
    <link:label id="lab_selb_AtTheMarketOfferingMember_label_en-US" xlink:label="lab_selb_AtTheMarketOfferingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">At-The-Market Offering [Member]</link:label>
    <link:label id="lab_selb_AtTheMarketOfferingMember_documentation_en-US" xlink:label="lab_selb_AtTheMarketOfferingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">At-The-Market Offering [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_selb_AtTheMarketOfferingMember" xlink:href="selb-20210331.xsd#selb_AtTheMarketOfferingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_selb_AtTheMarketOfferingMember" xlink:to="lab_selb_AtTheMarketOfferingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_8afbffbb-a140-43da-8c17-e8778d4df91b_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_c2622e3b-09ea-477c-98b8-531e7f3d8c44_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_selb_LicenseAgreementForPompeDiseaseMember_96b1e2fc-6b67-42a1-9580-633fe7cdeae5_terseLabel_en-US" xlink:label="lab_selb_LicenseAgreementForPompeDiseaseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement For Pompe Disease</link:label>
    <link:label id="lab_selb_LicenseAgreementForPompeDiseaseMember_label_en-US" xlink:label="lab_selb_LicenseAgreementForPompeDiseaseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement For Pompe Disease [Member]</link:label>
    <link:label id="lab_selb_LicenseAgreementForPompeDiseaseMember_documentation_en-US" xlink:label="lab_selb_LicenseAgreementForPompeDiseaseMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement For Pompe Disease [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_selb_LicenseAgreementForPompeDiseaseMember" xlink:href="selb-20210331.xsd#selb_LicenseAgreementForPompeDiseaseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_selb_LicenseAgreementForPompeDiseaseMember" xlink:to="lab_selb_LicenseAgreementForPompeDiseaseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_47ec1bff-7659-4d20-ac21-a126a21ec069_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_selb_A2020TermLoansMember_825ff366-ff4b-456b-bbfc-294616c8674e_terseLabel_en-US" xlink:label="lab_selb_A2020TermLoansMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 Term Loans</link:label>
    <link:label id="lab_selb_A2020TermLoansMember_label_en-US" xlink:label="lab_selb_A2020TermLoansMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 Term Loans [Member]</link:label>
    <link:label id="lab_selb_A2020TermLoansMember_documentation_en-US" xlink:label="lab_selb_A2020TermLoansMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 Term Loans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_selb_A2020TermLoansMember" xlink:href="selb-20210331.xsd#selb_A2020TermLoansMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_selb_A2020TermLoansMember" xlink:to="lab_selb_A2020TermLoansMember" xlink:type="arc" order="1"/>
    <link:label id="lab_selb_WarrantIssued_0e828345-8111-4f6b-a0bd-d00ddc63fa80_terseLabel_en-US" xlink:label="lab_selb_WarrantIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant Issued</link:label>
    <link:label id="lab_selb_WarrantIssued_label_en-US" xlink:label="lab_selb_WarrantIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant Issued</link:label>
    <link:label id="lab_selb_WarrantIssued_documentation_en-US" xlink:label="lab_selb_WarrantIssued" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_selb_WarrantIssued" xlink:href="selb-20210331.xsd#selb_WarrantIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_selb_WarrantIssued" xlink:to="lab_selb_WarrantIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_selb_ClassOfWarrantOrRightExpirationPeriod_0d8920e4-16ad-43e8-a843-d2f6b4c98783_terseLabel_en-US" xlink:label="lab_selb_ClassOfWarrantOrRightExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of warrant or right, expiration period</link:label>
    <link:label id="lab_selb_ClassOfWarrantOrRightExpirationPeriod_label_en-US" xlink:label="lab_selb_ClassOfWarrantOrRightExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right, Expiration Period</link:label>
    <link:label id="lab_selb_ClassOfWarrantOrRightExpirationPeriod_documentation_en-US" xlink:label="lab_selb_ClassOfWarrantOrRightExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right, Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_selb_ClassOfWarrantOrRightExpirationPeriod" xlink:href="selb-20210331.xsd#selb_ClassOfWarrantOrRightExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_selb_ClassOfWarrantOrRightExpirationPeriod" xlink:to="lab_selb_ClassOfWarrantOrRightExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_6b68d0fe-0cdf-468c-ab3e-61f7faa5676f_verboseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential common shares</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_selb_LicenseAndOptionAgreementCalculatedPremiumPaidForEquityInvestmentUnderPurchaseAgreement_f723c409-5142-4635-b4f7-fda6796cc023_terseLabel_en-US" xlink:label="lab_selb_LicenseAndOptionAgreementCalculatedPremiumPaidForEquityInvestmentUnderPurchaseAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License and option agreement, payments made relative to calculated premium paid for initial equity investment made under the purchase agreement</link:label>
    <link:label id="lab_selb_LicenseAndOptionAgreementCalculatedPremiumPaidForEquityInvestmentUnderPurchaseAgreement_label_en-US" xlink:label="lab_selb_LicenseAndOptionAgreementCalculatedPremiumPaidForEquityInvestmentUnderPurchaseAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License And Option Agreement, Calculated Premium Paid For Equity Investment Under Purchase Agreement</link:label>
    <link:label id="lab_selb_LicenseAndOptionAgreementCalculatedPremiumPaidForEquityInvestmentUnderPurchaseAgreement_documentation_en-US" xlink:label="lab_selb_LicenseAndOptionAgreementCalculatedPremiumPaidForEquityInvestmentUnderPurchaseAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License And Option Agreement, Calculated Premium Paid For Equity Investment Under Purchase Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_selb_LicenseAndOptionAgreementCalculatedPremiumPaidForEquityInvestmentUnderPurchaseAgreement" xlink:href="selb-20210331.xsd#selb_LicenseAndOptionAgreementCalculatedPremiumPaidForEquityInvestmentUnderPurchaseAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_selb_LicenseAndOptionAgreementCalculatedPremiumPaidForEquityInvestmentUnderPurchaseAgreement" xlink:to="lab_selb_LicenseAndOptionAgreementCalculatedPremiumPaidForEquityInvestmentUnderPurchaseAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_ab10c2cc-5803-4b90-8f83-37263b750b7c_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders&#8217; (deficit) equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_7c901382-a868-4184-ae99-1a0ce214cafc_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of warrant or right, number of securities called by warrants or rights (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_95f392b0-692a-43f7-a5ab-2af509c3263e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Options</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_494d3c84-92a4-4a13-a46b-e33bc8e5b35c_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_dad9198f-0969-414b-8ddb-f3dfe16f01dd_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of vested restricted stock units</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Restricted Stock Award, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockLineItems_9c5a9f5c-fbc7-46f6-9457-3a45bb49df3b_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary, Sale of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary, Sale of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="lab_us-gaap_SubsidiarySaleOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RedemptionPremium_9458d0c4-ca56-4887-ac93-f5bda42e4bad_terseLabel_en-US" xlink:label="lab_us-gaap_RedemptionPremium" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redemption premium</link:label>
    <link:label id="lab_us-gaap_RedemptionPremium_label_en-US" xlink:label="lab_us-gaap_RedemptionPremium" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redemption Premium</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedemptionPremium" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RedemptionPremium"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RedemptionPremium" xlink:to="lab_us-gaap_RedemptionPremium" xlink:type="arc" order="1"/>
    <link:label id="lab_selb_LicenseAgreementWithShenyangSunshinePharmaceuticalCompanyLimitedMember_46f0bd64-fbdb-4b33-98c1-a83106700a8b_terseLabel_en-US" xlink:label="lab_selb_LicenseAgreementWithShenyangSunshinePharmaceuticalCompanyLimitedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3SBio License</link:label>
    <link:label id="lab_selb_LicenseAgreementWithShenyangSunshinePharmaceuticalCompanyLimitedMember_label_en-US" xlink:label="lab_selb_LicenseAgreementWithShenyangSunshinePharmaceuticalCompanyLimitedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement With Shenyang Sunshine Pharmaceutical Company Limited [Member]</link:label>
    <link:label id="lab_selb_LicenseAgreementWithShenyangSunshinePharmaceuticalCompanyLimitedMember_documentation_en-US" xlink:label="lab_selb_LicenseAgreementWithShenyangSunshinePharmaceuticalCompanyLimitedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents information pertaining to License agreement with Shenyang Sunshine Pharmaceutical co., ltd.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_selb_LicenseAgreementWithShenyangSunshinePharmaceuticalCompanyLimitedMember" xlink:href="selb-20210331.xsd#selb_LicenseAgreementWithShenyangSunshinePharmaceuticalCompanyLimitedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_selb_LicenseAgreementWithShenyangSunshinePharmaceuticalCompanyLimitedMember" xlink:to="lab_selb_LicenseAgreementWithShenyangSunshinePharmaceuticalCompanyLimitedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_1484fd99-4ee3-4ae6-86a2-fc4bf5bf75c3_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_66c7ea5e-7865-4225-8a83-0f1640832846_verboseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term contract liability</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_fd3c79c3-1fd2-4746-95de-3e92a7bcc1c3_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplement cash flow information</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_50da19b0-e02e-40a3-848f-f6f7cf5ac8be_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock under Employee Stock Purchase Plan (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Employee Stock Purchase Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="arc" order="1"/>
    <link:label id="lab_selb_TermBLoansMember_bc37f859-2b4c-495a-b3a0-02d31f8aab7e_terseLabel_en-US" xlink:label="lab_selb_TermBLoansMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term B Loans</link:label>
    <link:label id="lab_selb_TermBLoansMember_label_en-US" xlink:label="lab_selb_TermBLoansMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term B Loans [Member]</link:label>
    <link:label id="lab_selb_TermBLoansMember_documentation_en-US" xlink:label="lab_selb_TermBLoansMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term B Loans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_selb_TermBLoansMember" xlink:href="selb-20210331.xsd#selb_TermBLoansMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_selb_TermBLoansMember" xlink:to="lab_selb_TermBLoansMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_4df9072c-beae-4f25-91af-dcbef5c78dd9_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_ca9a8d1a-e1b2-41a1-83f2-9497ad69ba10_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common&#160;stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_e4816492-45bd-4c42-8460-8987a4527f83_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_selb_LicenseAndOptionAgreementSalesMilestonePaymentsThatMayBeReceived_f873685f-d5c2-4be9-8279-d23cb1539801_terseLabel_en-US" xlink:label="lab_selb_LicenseAndOptionAgreementSalesMilestonePaymentsThatMayBeReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales milestone payments</link:label>
    <link:label id="lab_selb_LicenseAndOptionAgreementSalesMilestonePaymentsThatMayBeReceived_label_en-US" xlink:label="lab_selb_LicenseAndOptionAgreementSalesMilestonePaymentsThatMayBeReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License And Option Agreement, Sales Milestone Payments That May Be Received</link:label>
    <link:label id="lab_selb_LicenseAndOptionAgreementSalesMilestonePaymentsThatMayBeReceived_documentation_en-US" xlink:label="lab_selb_LicenseAndOptionAgreementSalesMilestonePaymentsThatMayBeReceived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License And Option Agreement, Sales Milestone Payments That May Be Received</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_selb_LicenseAndOptionAgreementSalesMilestonePaymentsThatMayBeReceived" xlink:href="selb-20210331.xsd#selb_LicenseAndOptionAgreementSalesMilestonePaymentsThatMayBeReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_selb_LicenseAndOptionAgreementSalesMilestonePaymentsThatMayBeReceived" xlink:to="lab_selb_LicenseAndOptionAgreementSalesMilestonePaymentsThatMayBeReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_ba7e90f9-cd2c-4e88-8387-61a8dd0e61b8_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanCostRecognized_c702dbdc-1f79-4091-9906-86b133aa5f85_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employer contribution made</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanCostRecognized_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanCostRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanCostRecognized" xlink:to="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_selb_LicenseAndOptionAgreementOptionTerm_1f0d698a-9669-400f-98a7-6d9b3a1ff0a3_terseLabel_en-US" xlink:label="lab_selb_LicenseAndOptionAgreementOptionTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option term</link:label>
    <link:label id="lab_selb_LicenseAndOptionAgreementOptionTerm_label_en-US" xlink:label="lab_selb_LicenseAndOptionAgreementOptionTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License And Option Agreement, Option Term</link:label>
    <link:label id="lab_selb_LicenseAndOptionAgreementOptionTerm_documentation_en-US" xlink:label="lab_selb_LicenseAndOptionAgreementOptionTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License And Option Agreement, Option Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_selb_LicenseAndOptionAgreementOptionTerm" xlink:href="selb-20210331.xsd#selb_LicenseAndOptionAgreementOptionTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_selb_LicenseAndOptionAgreementOptionTerm" xlink:to="lab_selb_LicenseAndOptionAgreementOptionTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_7d8e3401-ba6e-4dac-8fe3-dd21ea6ae736_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_selb_SaleofStockPercentageOfTenDayVolumeWeightedAveragePriceOfCommonStock_856a880e-79d6-4419-b4ca-e1410ee5b6cd_terseLabel_en-US" xlink:label="lab_selb_SaleofStockPercentageOfTenDayVolumeWeightedAveragePriceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of stock, percentage of ten-day volume weighted average price of common stock</link:label>
    <link:label id="lab_selb_SaleofStockPercentageOfTenDayVolumeWeightedAveragePriceOfCommonStock_label_en-US" xlink:label="lab_selb_SaleofStockPercentageOfTenDayVolumeWeightedAveragePriceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Percentage Of Ten-Day Volume Weighted Average Price Of Common Stock</link:label>
    <link:label id="lab_selb_SaleofStockPercentageOfTenDayVolumeWeightedAveragePriceOfCommonStock_documentation_en-US" xlink:label="lab_selb_SaleofStockPercentageOfTenDayVolumeWeightedAveragePriceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Percentage Of Ten-Day Volume Weighted Average Price Of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_selb_SaleofStockPercentageOfTenDayVolumeWeightedAveragePriceOfCommonStock" xlink:href="selb-20210331.xsd#selb_SaleofStockPercentageOfTenDayVolumeWeightedAveragePriceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_selb_SaleofStockPercentageOfTenDayVolumeWeightedAveragePriceOfCommonStock" xlink:to="lab_selb_SaleofStockPercentageOfTenDayVolumeWeightedAveragePriceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_485165ad-f5db-43df-9e2b-e8b47c8af246_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_ff019b7e-8c5d-4b8d-8512-610737cd8595_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_01c56ca6-5e02-47b1-93e6-826d43bed77e_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockCompensationPlanMember_474d8b93-bb8f-46a1-8a48-43fcdc1d3c23_terseLabel_en-US" xlink:label="lab_us-gaap_StockCompensationPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares available for future stock incentive awards</link:label>
    <link:label id="lab_us-gaap_StockCompensationPlanMember_31fdac43-9e59-4744-9b43-b0d9ddc6e515_verboseLabel_en-US" xlink:label="lab_us-gaap_StockCompensationPlanMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee stock option grants</link:label>
    <link:label id="lab_us-gaap_StockCompensationPlanMember_dde4439f-2563-42e9-94ea-18db634b0b16_netLabel_en-US" xlink:label="lab_us-gaap_StockCompensationPlanMember" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employees</link:label>
    <link:label id="lab_us-gaap_StockCompensationPlanMember_label_en-US" xlink:label="lab_us-gaap_StockCompensationPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockCompensationPlanMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockCompensationPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockCompensationPlanMember" xlink:to="lab_us-gaap_StockCompensationPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_572e03aa-4f16-4005-9ea7-8f98a95c0c04_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less accumulated depreciation</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNetCurrent_8f7e3029-19cd-498d-8f02-54db2356edd1_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract assets</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNetCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Asset, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerAssetNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetNetCurrent" xlink:to="lab_us-gaap_ContractWithCustomerAssetNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_43fcfc55-f2bd-47e0-933c-93daa9d68504_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and expected to vest</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_532c7b37-600c-4c06-9388-0a6eac8da07a_terseLabel_en-US" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash investing and financing activities</link:label>
    <link:label id="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_label_en-US" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash Investing and Financing Items [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_70a01e7a-98e3-47c9-8df3-a0fb6ef37f6f_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock upon exercise of options (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_60576781-8c59-4200-afc1-31b444e90665_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_c411fea3-73e0-424e-bf26-c8335533799d_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:to="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_64f4c6f8-f633-4b9a-a7ab-943b1be12b50_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net change in cash, cash equivalents, and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_2091d5fb-08db-4aa9-a5aa-eb0ec6847036_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Lessee, Operating Lease, Liability, Maturity</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_90d9db65-eeaa-4ac4-bc71-f897d22292a4_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options to purchase common stock</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_995a97ee-0759-49b3-9d6d-3e6ecab8958b_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding common stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_59b73d24-3cc9-43f4-a111-7b93a333f673_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis spread on variable rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Basis Spread on Variable Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_34e04c9e-35cd-4a00-a4b5-20958686af24_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_06312e68-6d65-4550-918b-fa4026f3da7e_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_17fbeb4e-0f45-4886-aeef-2c645d87c7b1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_f44957cb-fb7b-4571-8b44-244f6eddfb71_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation adjustment</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_f507ad06-68c5-4090-8516-3f3410357f44_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Currency translation adjustment</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_1fa1ec9a-b03a-4395-91ff-86bf82044aac_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses and other liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_3895dab9-0024-4951-bd65-9bec801def4a_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_selb_A2008Plan2016PlanAnd2018InducementIncentiveAwardPlanMember_ab9960aa-7e79-42fc-9bd3-e74f52e3f228_terseLabel_en-US" xlink:label="lab_selb_A2008Plan2016PlanAnd2018InducementIncentiveAwardPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2008 Plan, 2016 Plan, and 2018 Inducement Incentive Award Plan</link:label>
    <link:label id="lab_selb_A2008Plan2016PlanAnd2018InducementIncentiveAwardPlanMember_label_en-US" xlink:label="lab_selb_A2008Plan2016PlanAnd2018InducementIncentiveAwardPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2008 Plan, 2016 Plan, and 2018 Inducement Incentive Award Plan [Member]</link:label>
    <link:label id="lab_selb_A2008Plan2016PlanAnd2018InducementIncentiveAwardPlanMember_documentation_en-US" xlink:label="lab_selb_A2008Plan2016PlanAnd2018InducementIncentiveAwardPlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2008 Plan, 2016 Plan, and 2018 Inducement Incentive Award Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_selb_A2008Plan2016PlanAnd2018InducementIncentiveAwardPlanMember" xlink:href="selb-20210331.xsd#selb_A2008Plan2016PlanAnd2018InducementIncentiveAwardPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_selb_A2008Plan2016PlanAnd2018InducementIncentiveAwardPlanMember" xlink:to="lab_selb_A2008Plan2016PlanAnd2018InducementIncentiveAwardPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_selb_ResearchAndDevelopmentMember_bf59109c-d8d0-4a47-9dbe-a59423b59835_terseLabel_en-US" xlink:label="lab_selb_ResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_selb_ResearchAndDevelopmentMember_label_en-US" xlink:label="lab_selb_ResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development [Member]</link:label>
    <link:label id="lab_selb_ResearchAndDevelopmentMember_documentation_en-US" xlink:label="lab_selb_ResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the information pertaining to research and development expenses included in the income statement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_selb_ResearchAndDevelopmentMember" xlink:href="selb-20210331.xsd#selb_ResearchAndDevelopmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_selb_ResearchAndDevelopmentMember" xlink:to="lab_selb_ResearchAndDevelopmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_350e925e-ff0a-4b08-83c0-deea208af7c9_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_b51a72cf-8f16-4a77-8f51-f15c9bbc7e46_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Arrangements</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidNet_d8575323-f747-467b-91a1-9cedb36342a2_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for interest</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_ea6de6a7-27b1-471e-8879-e365d06210e5_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating loss carryforwards, carried forward indefinitely</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards, Not Subject to Expiration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesOther_5966fccf-2f01-4039-b600-f7afcf411de4_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock through at-the-market offering, net (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesOther_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesOther" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesOther" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtByMaturityAbstract_f099afc7-55d8-4a58-9f4d-93af805eb780_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtByMaturityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Fiscal Year Maturity [Abstract]</link:label>
    <link:label id="lab_us-gaap_LongTermDebtByMaturityAbstract_label_en-US" xlink:label="lab_us-gaap_LongTermDebtByMaturityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Fiscal Year Maturity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtByMaturityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtByMaturityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract" xlink:to="lab_us-gaap_LongTermDebtByMaturityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_61760daa-4574-48fe-8378-c39b0bd1c9c3_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nature of the Business and Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_19fe3a38-a404-4f7e-a6ac-1702f3992993_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_selb_AccruedPatentFeesCurrent_9a483cee-5a3a-4247-99e6-075dc7f8c969_terseLabel_en-US" xlink:label="lab_selb_AccruedPatentFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued patent fees</link:label>
    <link:label id="lab_selb_AccruedPatentFeesCurrent_label_en-US" xlink:label="lab_selb_AccruedPatentFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Patent Fees Current</link:label>
    <link:label id="lab_selb_AccruedPatentFeesCurrent_documentation_en-US" xlink:label="lab_selb_AccruedPatentFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying value as of the balance sheet date of patent fees.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_selb_AccruedPatentFeesCurrent" xlink:href="selb-20210331.xsd#selb_AccruedPatentFeesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_selb_AccruedPatentFeesCurrent" xlink:to="lab_selb_AccruedPatentFeesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_93ff7bf1-2250-4eee-ac94-ca3ed557b67c_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency transaction gain, net</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Transaction Gain (Loss), before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:to="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_7a87d1b8-e5a3-4f67-99e8-a35bd81ce4df_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents, and restricted cash at beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0636ec0e-200f-4356-be3c-5c5fae9a15f8_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents, and restricted cash at end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_387766c2-3dae-4a6d-9f34-c20833c825a9_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cash, cash equivalents, and restricted cash shown in the consolidated statement of cash flows</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_selb_RestrictedStockUnitsUnvestedMember_20efc8c0-d82c-4271-8f4d-62171ddb74c8_terseLabel_en-US" xlink:label="lab_selb_RestrictedStockUnitsUnvestedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested restricted stock units</link:label>
    <link:label id="lab_selb_RestrictedStockUnitsUnvestedMember_label_en-US" xlink:label="lab_selb_RestrictedStockUnitsUnvestedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units, Unvested [Member]</link:label>
    <link:label id="lab_selb_RestrictedStockUnitsUnvestedMember_documentation_en-US" xlink:label="lab_selb_RestrictedStockUnitsUnvestedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units, Unvested</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_selb_RestrictedStockUnitsUnvestedMember" xlink:href="selb-20210331.xsd#selb_RestrictedStockUnitsUnvestedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_selb_RestrictedStockUnitsUnvestedMember" xlink:to="lab_selb_RestrictedStockUnitsUnvestedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_8c85d283-28f9-4d40-993b-0e4826cbc1f3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Future Minimum Payments on the Term Loans</link:label>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Maturities of Long-term Debt [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_4a84bbd8-7d3e-4abd-8bd3-acee353461ea_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Table]</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_b1912bf2-ab8a-407f-a603-7c116444a62d_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial and Nonfinancial Liabilities, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_d72e0308-4201-409e-bcba-73330a21375c_verboseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_6f54e511-ca6a-49ee-9841-a9f99f355583_totalLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_1483c217-3ca9-4ff3-947b-03735418b54b_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_afc0ef90-5f71-46ac-8ac6-3b8ccaf1a691_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net operating losses available for use through 2028</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_fdd1a262-b6b2-4c0e-b891-461628f4a9c2_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_8aaf9bed-577c-470a-99be-f819f63ae1d6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_c53abf21-b9cf-4768-aaa1-c1d81b76c03f_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants and rights outstanding, measurement input</link:label>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_label_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants and Rights Outstanding, Measurement Input</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:to="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_3514678e-7b25-45e5-bb52-61c5a0470e34_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Changes In The Warrant Liabilities</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_6b2cc5ed-daae-4a7e-8861-2adf69f430ea_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeNet_bade42d5-da8c-413e-8748-b0339ae0a6f1_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeNet_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeNet" xlink:to="lab_us-gaap_InvestmentIncomeNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_11e37765-cd45-481a-84f7-93d12922de38_verboseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation expense</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_bec194c6-ecdb-4239-a99f-1e3826a5cd43_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_selb_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_ba05ee7a-423d-4799-afe7-fcbfdfc2b5dd_terseLabel_en-US" xlink:label="lab_selb_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_selb_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_label_en-US" xlink:label="lab_selb_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, To Be Paid, After Year Four</link:label>
    <link:label id="lab_selb_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_documentation_en-US" xlink:label="lab_selb_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, To Be Paid, After Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_selb_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:href="selb-20210331.xsd#selb_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_selb_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:to="lab_selb_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_f5006e0c-d81c-4f3f-add9-79c23cd8a67d_periodStartLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract liabilities, beginning of period</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_2b187693-0a9a-4bbb-8998-a8676945f3ba_periodEndLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract liabilities, end of period</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiability" xlink:to="lab_us-gaap_ContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_eb909bd5-8a4f-47f4-a396-a2b62161eaf0_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_11190b18-d047-4a75-92ac-01f4562fedf3_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock upon exercise of options</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_f328a85e-948d-4984-8b0b-eae1ae7af470_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum borrowing capacity</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_fae40312-616b-4560-89f3-ad602a4da9f1_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_23041520-664a-4cdb-a365-0e83ad7a93e6_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_3013d90f-f65b-4d26-a9c0-df04fdc427fd_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_e805699f-5e2c-4286-bd1a-1b4b3283abfa_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expenses and Other Current Assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_label_en-US" xlink:label="lab_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expenses and Other Current Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:to="lab_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_ebc54a1b-08f6-4f43-aa0d-714e758960e8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested in period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_3c8fb844-95c4-4f7c-8c5a-be10346ffd20_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_selb_LicenseAndOptionAgreementExecutionFeePayment_57a57a17-c539-4a8a-b2bf-f68c80a78895_terseLabel_en-US" xlink:label="lab_selb_LicenseAndOptionAgreementExecutionFeePayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial upfront execution fee payment</link:label>
    <link:label id="lab_selb_LicenseAndOptionAgreementExecutionFeePayment_label_en-US" xlink:label="lab_selb_LicenseAndOptionAgreementExecutionFeePayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License And Option Agreement, Execution Fee Payment</link:label>
    <link:label id="lab_selb_LicenseAndOptionAgreementExecutionFeePayment_documentation_en-US" xlink:label="lab_selb_LicenseAndOptionAgreementExecutionFeePayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License And Option Agreement, Execution Fee Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_selb_LicenseAndOptionAgreementExecutionFeePayment" xlink:href="selb-20210331.xsd#selb_LicenseAndOptionAgreementExecutionFeePayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_selb_LicenseAndOptionAgreementExecutionFeePayment" xlink:to="lab_selb_LicenseAndOptionAgreementExecutionFeePayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_3781915b-8816-4062-a17c-ef0a030509a5_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares authorized</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_selb_LesseeComponentsOfOperatingLeaseTableTextBlock_896c75ec-5fc9-465a-abe1-1638fb535423_terseLabel_en-US" xlink:label="lab_selb_LesseeComponentsOfOperatingLeaseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Lessee, Components Of Operating Lease</link:label>
    <link:label id="lab_selb_LesseeComponentsOfOperatingLeaseTableTextBlock_label_en-US" xlink:label="lab_selb_LesseeComponentsOfOperatingLeaseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Components Of Operating Lease [Table Text Block]</link:label>
    <link:label id="lab_selb_LesseeComponentsOfOperatingLeaseTableTextBlock_documentation_en-US" xlink:label="lab_selb_LesseeComponentsOfOperatingLeaseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Components Of Operating Lease</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_selb_LesseeComponentsOfOperatingLeaseTableTextBlock" xlink:href="selb-20210331.xsd#selb_LesseeComponentsOfOperatingLeaseTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_selb_LesseeComponentsOfOperatingLeaseTableTextBlock" xlink:to="lab_selb_LesseeComponentsOfOperatingLeaseTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossTaxAbstract_36e437ef-4ffe-4548-abc4-515148a77826_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive loss:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossTaxAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Tax [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossTaxAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_666a35b2-69a2-465c-b89b-bcfe025b5552_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_937094b0-db78-40da-b345-6e43017f9b89_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares outstanding</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_241e1cac-73ad-420f-b19d-0ccb47d55b39_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_eddb9c41-603d-448c-a2dc-0a4c850d0cb1_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_e5f6f6ec-b4fe-4cde-b8bd-95b114aa6382_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash (used in) investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_b493c227-7127-493d-90d0-e05fc24f476e_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8a39caed-3b25-4f3d-b60c-80f5585b5c50_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_selb_CollaborationAndLicenseAgreementsTextBlock_b8a6551a-bee3-4d33-b372-775b1de434c3_terseLabel_en-US" xlink:label="lab_selb_CollaborationAndLicenseAgreementsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreements</link:label>
    <link:label id="lab_selb_CollaborationAndLicenseAgreementsTextBlock_label_en-US" xlink:label="lab_selb_CollaborationAndLicenseAgreementsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration And License Agreements [Text Block]</link:label>
    <link:label id="lab_selb_CollaborationAndLicenseAgreementsTextBlock_documentation_en-US" xlink:label="lab_selb_CollaborationAndLicenseAgreementsTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration And License Agreements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_selb_CollaborationAndLicenseAgreementsTextBlock" xlink:href="selb-20210331.xsd#selb_CollaborationAndLicenseAgreementsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_selb_CollaborationAndLicenseAgreementsTextBlock" xlink:to="lab_selb_CollaborationAndLicenseAgreementsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstanding_a94e3a79-06ad-4353-b00c-8826854d9aed_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant liabilities</link:label>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstanding_2559ee96-3dab-4704-a028-ec3f6d7024e8_verboseLabel_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant liabilities</link:label>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstanding_label_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants and Rights Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsAndRightsOutstanding" xlink:to="lab_us-gaap_WarrantsAndRightsOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3fd7f9b8-ee13-4465-a432-727bfca9b9ab_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_7dc99c51-5f21-42a9-9eb7-f67ee0515dd9_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_7f2f0166-80c5-4bcf-967d-d7029e6d602c_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_selb_LicenseAndOptionAgreementUpfrontCashPayment_73a2ca98-6460-4060-b3a1-bd7521a57a39_terseLabel_en-US" xlink:label="lab_selb_LicenseAndOptionAgreementUpfrontCashPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront cash payment</link:label>
    <link:label id="lab_selb_LicenseAndOptionAgreementUpfrontCashPayment_label_en-US" xlink:label="lab_selb_LicenseAndOptionAgreementUpfrontCashPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License And Option Agreement, Upfront Cash Payment</link:label>
    <link:label id="lab_selb_LicenseAndOptionAgreementUpfrontCashPayment_documentation_en-US" xlink:label="lab_selb_LicenseAndOptionAgreementUpfrontCashPayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License And Option Agreement, Upfront Cash Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_selb_LicenseAndOptionAgreementUpfrontCashPayment" xlink:href="selb-20210331.xsd#selb_LicenseAndOptionAgreementUpfrontCashPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_selb_LicenseAndOptionAgreementUpfrontCashPayment" xlink:to="lab_selb_LicenseAndOptionAgreementUpfrontCashPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_selb_LicenseAndOptionAgreementInitialUpFrontCashPayment_c6a01dd6-8764-4865-8fdd-f963407e1a5f_terseLabel_en-US" xlink:label="lab_selb_LicenseAndOptionAgreementInitialUpFrontCashPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial up-front cash payment</link:label>
    <link:label id="lab_selb_LicenseAndOptionAgreementInitialUpFrontCashPayment_label_en-US" xlink:label="lab_selb_LicenseAndOptionAgreementInitialUpFrontCashPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License And Option Agreement, Initial Up-Front Cash Payment</link:label>
    <link:label id="lab_selb_LicenseAndOptionAgreementInitialUpFrontCashPayment_documentation_en-US" xlink:label="lab_selb_LicenseAndOptionAgreementInitialUpFrontCashPayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License And Option Agreement, Initial Up-Front Cash Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_selb_LicenseAndOptionAgreementInitialUpFrontCashPayment" xlink:href="selb-20210331.xsd#selb_LicenseAndOptionAgreementInitialUpFrontCashPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_selb_LicenseAndOptionAgreementInitialUpFrontCashPayment" xlink:to="lab_selb_LicenseAndOptionAgreementInitialUpFrontCashPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OfficeEquipmentMember_6a03511a-e958-4351-b426-72a99bcba3b8_terseLabel_en-US" xlink:label="lab_us-gaap_OfficeEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office equipment</link:label>
    <link:label id="lab_us-gaap_OfficeEquipmentMember_label_en-US" xlink:label="lab_us-gaap_OfficeEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OfficeEquipmentMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OfficeEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OfficeEquipmentMember" xlink:to="lab_us-gaap_OfficeEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_6f08eaa6-375e-445d-a45d-ba507214c3df_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Loss Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8e666b85-bcab-4640-87a6-7ec087c6cf39_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_baa6a383-a0eb-4d78-80f3-92118e66a55b_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_cfcc3926-8a86-4b80-a58b-78784182e849_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_fbe3206d-ffcb-45ca-8a85-89e4bcad37d9_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_9d6ada0d-d6e4-40ae-b70f-900496257bf2_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_a5b758d6-3063-4387-928a-b739836a5a18_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_07abf904-e361-4ac9-b60d-89fe3128fbcb_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and expected to vest (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueOther_dc437876-7e7b-47b1-b08c-3100b6f78a90_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock through at-the-market offering, net</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueOther_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueOther" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueOther" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueOther" xlink:type="arc" order="1"/>
    <link:label id="lab_selb_LicenseAndOptionAgreementMilestonePayments_64fa1019-e045-4344-9d16-866f3b549652_terseLabel_en-US" xlink:label="lab_selb_LicenseAndOptionAgreementMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone payment</link:label>
    <link:label id="lab_selb_LicenseAndOptionAgreementMilestonePayments_label_en-US" xlink:label="lab_selb_LicenseAndOptionAgreementMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License And Option Agreement, Milestone Payments</link:label>
    <link:label id="lab_selb_LicenseAndOptionAgreementMilestonePayments_documentation_en-US" xlink:label="lab_selb_LicenseAndOptionAgreementMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License And Option Agreement, Milestone Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_selb_LicenseAndOptionAgreementMilestonePayments" xlink:href="selb-20210331.xsd#selb_LicenseAndOptionAgreementMilestonePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_selb_LicenseAndOptionAgreementMilestonePayments" xlink:to="lab_selb_LicenseAndOptionAgreementMilestonePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_selb_ContractwithCustomerLiabilityDeferredRevenueRevenueRecognized_9a90f695-f4c3-4fcc-841b-fd0286a03e5d_negatedLabel_en-US" xlink:label="lab_selb_ContractwithCustomerLiabilityDeferredRevenueRevenueRecognized" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue, deductions</link:label>
    <link:label id="lab_selb_ContractwithCustomerLiabilityDeferredRevenueRevenueRecognized_label_en-US" xlink:label="lab_selb_ContractwithCustomerLiabilityDeferredRevenueRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Deferred Revenue, Revenue Recognized</link:label>
    <link:label id="lab_selb_ContractwithCustomerLiabilityDeferredRevenueRevenueRecognized_documentation_en-US" xlink:label="lab_selb_ContractwithCustomerLiabilityDeferredRevenueRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Deferred Revenue, Revenue Recognized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_selb_ContractwithCustomerLiabilityDeferredRevenueRevenueRecognized" xlink:href="selb-20210331.xsd#selb_ContractwithCustomerLiabilityDeferredRevenueRevenueRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_selb_ContractwithCustomerLiabilityDeferredRevenueRevenueRecognized" xlink:to="lab_selb_ContractwithCustomerLiabilityDeferredRevenueRevenueRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_3307f768-0031-475c-ac7c-f58c2f5124ce_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recent Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_11605854-7b83-4fb9-af00-b069b91547fb_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>11
<FILENAME>selb-20210331_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:f83914de-cdf0-4ece-a0a2-d7db460e8912,g:a84bda62-2062-413b-8a4e-4383ad9edaee-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.selectabio.com/role/Coverpage" xlink:type="simple" xlink:href="selb-20210331.xsd#Coverpage"/>
  <link:presentationLink xlink:role="http://www.selectabio.com/role/Coverpage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_fb2e1b88-9003-4043-842c-dffdb655ae19" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_445b3fcd-82a6-4c91-867d-a6a7411f5661" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fb2e1b88-9003-4043-842c-dffdb655ae19" xlink:to="loc_dei_DocumentType_445b3fcd-82a6-4c91-867d-a6a7411f5661" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_cc5f8248-4707-46fa-8e8e-5964b2a486dc" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fb2e1b88-9003-4043-842c-dffdb655ae19" xlink:to="loc_dei_DocumentQuarterlyReport_cc5f8248-4707-46fa-8e8e-5964b2a486dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_ed61d65b-d07e-4cf1-a293-429c3c35d7b1" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fb2e1b88-9003-4043-842c-dffdb655ae19" xlink:to="loc_dei_DocumentPeriodEndDate_ed61d65b-d07e-4cf1-a293-429c3c35d7b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_7b5d22ca-7c87-4f6f-8e2d-30b0f98a4011" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fb2e1b88-9003-4043-842c-dffdb655ae19" xlink:to="loc_dei_DocumentTransitionReport_7b5d22ca-7c87-4f6f-8e2d-30b0f98a4011" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_2e8d6e1e-6432-4488-b2a3-72f5eb41a0ef" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fb2e1b88-9003-4043-842c-dffdb655ae19" xlink:to="loc_dei_EntityFileNumber_2e8d6e1e-6432-4488-b2a3-72f5eb41a0ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_bd574740-d203-4b98-a9db-7055cfbe4f05" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fb2e1b88-9003-4043-842c-dffdb655ae19" xlink:to="loc_dei_EntityRegistrantName_bd574740-d203-4b98-a9db-7055cfbe4f05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_12a6fe5c-9eda-4892-b4ed-4a222f8cb829" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fb2e1b88-9003-4043-842c-dffdb655ae19" xlink:to="loc_dei_EntityIncorporationStateCountryCode_12a6fe5c-9eda-4892-b4ed-4a222f8cb829" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_b00fed45-adfd-453e-92dd-bf3ae445f15a" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fb2e1b88-9003-4043-842c-dffdb655ae19" xlink:to="loc_dei_EntityTaxIdentificationNumber_b00fed45-adfd-453e-92dd-bf3ae445f15a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_2fa2c2b7-d3ae-44d3-9b6b-227b971f3f5a" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fb2e1b88-9003-4043-842c-dffdb655ae19" xlink:to="loc_dei_EntityAddressAddressLine1_2fa2c2b7-d3ae-44d3-9b6b-227b971f3f5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_4f59326b-d130-4ab0-89cd-2f266d4578ae" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fb2e1b88-9003-4043-842c-dffdb655ae19" xlink:to="loc_dei_EntityAddressCityOrTown_4f59326b-d130-4ab0-89cd-2f266d4578ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_294c596b-b0de-4e02-93e2-64e56e2d81e9" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fb2e1b88-9003-4043-842c-dffdb655ae19" xlink:to="loc_dei_EntityAddressStateOrProvince_294c596b-b0de-4e02-93e2-64e56e2d81e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_42621d30-5d8f-4de5-9218-910d7571b462" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fb2e1b88-9003-4043-842c-dffdb655ae19" xlink:to="loc_dei_EntityAddressPostalZipCode_42621d30-5d8f-4de5-9218-910d7571b462" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_d1d4ed5c-758e-4ad4-8c3b-3c8e57b9e2bc" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fb2e1b88-9003-4043-842c-dffdb655ae19" xlink:to="loc_dei_CityAreaCode_d1d4ed5c-758e-4ad4-8c3b-3c8e57b9e2bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_9effeecb-29fe-4909-bb74-d29d2dc5cd0f" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fb2e1b88-9003-4043-842c-dffdb655ae19" xlink:to="loc_dei_LocalPhoneNumber_9effeecb-29fe-4909-bb74-d29d2dc5cd0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_edfa8cdb-3831-4a24-aaf0-ae632358947f" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fb2e1b88-9003-4043-842c-dffdb655ae19" xlink:to="loc_dei_Security12bTitle_edfa8cdb-3831-4a24-aaf0-ae632358947f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_d89939ec-079d-42b1-bfd9-cffba00d32af" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fb2e1b88-9003-4043-842c-dffdb655ae19" xlink:to="loc_dei_TradingSymbol_d89939ec-079d-42b1-bfd9-cffba00d32af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_d63614a2-0ce2-41f0-811d-c701e69acf52" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fb2e1b88-9003-4043-842c-dffdb655ae19" xlink:to="loc_dei_SecurityExchangeName_d63614a2-0ce2-41f0-811d-c701e69acf52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_97eba7a6-4fd8-4fd7-ac15-5a4de9710931" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fb2e1b88-9003-4043-842c-dffdb655ae19" xlink:to="loc_dei_EntityCurrentReportingStatus_97eba7a6-4fd8-4fd7-ac15-5a4de9710931" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_92f2f094-a6b1-4be3-9ec4-7cd537e5a0c7" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fb2e1b88-9003-4043-842c-dffdb655ae19" xlink:to="loc_dei_EntityInteractiveDataCurrent_92f2f094-a6b1-4be3-9ec4-7cd537e5a0c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_ee9ca3b5-9680-4f00-881e-7b1fa8a667f6" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fb2e1b88-9003-4043-842c-dffdb655ae19" xlink:to="loc_dei_EntityFilerCategory_ee9ca3b5-9680-4f00-881e-7b1fa8a667f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_58fbd9cf-b30f-424d-8bfd-b50d1b5fcbc9" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fb2e1b88-9003-4043-842c-dffdb655ae19" xlink:to="loc_dei_EntitySmallBusiness_58fbd9cf-b30f-424d-8bfd-b50d1b5fcbc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_c52a7915-3614-4a69-b039-2a1bba33388d" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fb2e1b88-9003-4043-842c-dffdb655ae19" xlink:to="loc_dei_EntityEmergingGrowthCompany_c52a7915-3614-4a69-b039-2a1bba33388d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod_c9b9debb-b1b5-49cc-94be-6445f53a8dd3" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityExTransitionPeriod"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fb2e1b88-9003-4043-842c-dffdb655ae19" xlink:to="loc_dei_EntityExTransitionPeriod_c9b9debb-b1b5-49cc-94be-6445f53a8dd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_1e990c3d-bc13-4eaa-a36f-38d8772d1516" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fb2e1b88-9003-4043-842c-dffdb655ae19" xlink:to="loc_dei_EntityShellCompany_1e990c3d-bc13-4eaa-a36f-38d8772d1516" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_895b351c-52bb-45f1-940a-ae3efd831ccd" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fb2e1b88-9003-4043-842c-dffdb655ae19" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_895b351c-52bb-45f1-940a-ae3efd831ccd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_ce13a5ea-0b14-4a33-bb7b-ea27ed0cec19" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fb2e1b88-9003-4043-842c-dffdb655ae19" xlink:to="loc_dei_AmendmentFlag_ce13a5ea-0b14-4a33-bb7b-ea27ed0cec19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_d9a9dd0a-44d2-4f46-9ded-bf0dc0305956" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fb2e1b88-9003-4043-842c-dffdb655ae19" xlink:to="loc_dei_DocumentFiscalYearFocus_d9a9dd0a-44d2-4f46-9ded-bf0dc0305956" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_5e2f942f-5243-46c5-bf9b-c85832d69a3a" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fb2e1b88-9003-4043-842c-dffdb655ae19" xlink:to="loc_dei_DocumentFiscalPeriodFocus_5e2f942f-5243-46c5-bf9b-c85832d69a3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_669cd032-1c26-4a06-92c5-7922b6dc76ff" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fb2e1b88-9003-4043-842c-dffdb655ae19" xlink:to="loc_dei_CurrentFiscalYearEndDate_669cd032-1c26-4a06-92c5-7922b6dc76ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_532e2dff-8e5e-4e58-8895-ac1b968c073e" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fb2e1b88-9003-4043-842c-dffdb655ae19" xlink:to="loc_dei_EntityCentralIndexKey_532e2dff-8e5e-4e58-8895-ac1b968c073e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.selectabio.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="selb-20210331.xsd#ConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://www.selectabio.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_5ce9d9fa-2380-40e2-86c9-bf28c586537d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_52733ed4-4db0-4c83-8c78-8288eb5579d3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_5ce9d9fa-2380-40e2-86c9-bf28c586537d" xlink:to="loc_us-gaap_AssetsAbstract_52733ed4-4db0-4c83-8c78-8288eb5579d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_0d22d559-7c54-4a6d-a420-80cea39495df" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_52733ed4-4db0-4c83-8c78-8288eb5579d3" xlink:to="loc_us-gaap_AssetsCurrentAbstract_0d22d559-7c54-4a6d-a420-80cea39495df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_13d26e62-c669-48f3-b81d-eaced1c2fe96" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_0d22d559-7c54-4a6d-a420-80cea39495df" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_13d26e62-c669-48f3-b81d-eaced1c2fe96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_f374de7f-c284-479a-adad-bafda687821d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_0d22d559-7c54-4a6d-a420-80cea39495df" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_f374de7f-c284-479a-adad-bafda687821d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_d99afe2f-8da1-4811-9dee-4d7252832b27" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_0d22d559-7c54-4a6d-a420-80cea39495df" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_d99afe2f-8da1-4811-9dee-4d7252832b27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_4c64c9c2-b760-4e3f-82c2-7b5e5cacea9d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_0d22d559-7c54-4a6d-a420-80cea39495df" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_4c64c9c2-b760-4e3f-82c2-7b5e5cacea9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_c895fc6c-b846-4d23-a7a0-25980983255f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_0d22d559-7c54-4a6d-a420-80cea39495df" xlink:to="loc_us-gaap_AssetsCurrent_c895fc6c-b846-4d23-a7a0-25980983255f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_e184217a-7d52-4925-8e67-6a4e88681b5d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_52733ed4-4db0-4c83-8c78-8288eb5579d3" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_e184217a-7d52-4925-8e67-6a4e88681b5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_50af9784-f969-4388-9bb0-906dc4fb9775" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_52733ed4-4db0-4c83-8c78-8288eb5579d3" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_50af9784-f969-4388-9bb0-906dc4fb9775" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_75551fcd-7fe1-4a7e-9780-ab9378f7eecd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_52733ed4-4db0-4c83-8c78-8288eb5579d3" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_75551fcd-7fe1-4a7e-9780-ab9378f7eecd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssets_355fa101-e460-4649-85fb-c46bb6afe9a1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_52733ed4-4db0-4c83-8c78-8288eb5579d3" xlink:to="loc_us-gaap_OtherAssets_355fa101-e460-4649-85fb-c46bb6afe9a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_be242165-393b-4017-9295-c040afbc923e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_52733ed4-4db0-4c83-8c78-8288eb5579d3" xlink:to="loc_us-gaap_Assets_be242165-393b-4017-9295-c040afbc923e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_384d42af-f36e-4908-8185-3e23ff0c029d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_5ce9d9fa-2380-40e2-86c9-bf28c586537d" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_384d42af-f36e-4908-8185-3e23ff0c029d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_06a70788-d04f-411d-b423-718ecde56042" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_384d42af-f36e-4908-8185-3e23ff0c029d" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_06a70788-d04f-411d-b423-718ecde56042" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_1f30916d-e473-4e87-9282-30289bb35f5f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_06a70788-d04f-411d-b423-718ecde56042" xlink:to="loc_us-gaap_AccountsPayableCurrent_1f30916d-e473-4e87-9282-30289bb35f5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_7b4367d1-00c4-4413-aedb-997e5f2d7378" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_06a70788-d04f-411d-b423-718ecde56042" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_7b4367d1-00c4-4413-aedb-997e5f2d7378" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansPayableCurrent_6440d6d0-1a40-48c9-afd5-f520fa3fd242" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LoansPayableCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_06a70788-d04f-411d-b423-718ecde56042" xlink:to="loc_us-gaap_LoansPayableCurrent_6440d6d0-1a40-48c9-afd5-f520fa3fd242" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_bf757dc5-fae0-4887-a76b-4a79de2fb9ed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_06a70788-d04f-411d-b423-718ecde56042" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_bf757dc5-fae0-4887-a76b-4a79de2fb9ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_698cb8cc-dea9-4ec1-9566-589214a0dd3a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_06a70788-d04f-411d-b423-718ecde56042" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_698cb8cc-dea9-4ec1-9566-589214a0dd3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_d6d43510-6a91-40c5-9dd6-01ad27e60acc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_06a70788-d04f-411d-b423-718ecde56042" xlink:to="loc_us-gaap_LiabilitiesCurrent_d6d43510-6a91-40c5-9dd6-01ad27e60acc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrentAbstract_297c2b99-5ec1-4db2-9ffa-b92cae182563" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_384d42af-f36e-4908-8185-3e23ff0c029d" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrentAbstract_297c2b99-5ec1-4db2-9ffa-b92cae182563" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermLoansPayable_62438051-2ba5-4a65-97aa-0753d7690d22" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermLoansPayable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrentAbstract_297c2b99-5ec1-4db2-9ffa-b92cae182563" xlink:to="loc_us-gaap_LongTermLoansPayable_62438051-2ba5-4a65-97aa-0753d7690d22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_73c7c8a8-9530-4b33-9867-c2303bfa6723" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrentAbstract_297c2b99-5ec1-4db2-9ffa-b92cae182563" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_73c7c8a8-9530-4b33-9867-c2303bfa6723" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_f3031bbc-08d0-416d-b46e-acacd8f961c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrentAbstract_297c2b99-5ec1-4db2-9ffa-b92cae182563" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_f3031bbc-08d0-416d-b46e-acacd8f961c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding_dfd0ada2-8434-4868-ac45-d9e8c0b457cf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrentAbstract_297c2b99-5ec1-4db2-9ffa-b92cae182563" xlink:to="loc_us-gaap_WarrantsAndRightsOutstanding_dfd0ada2-8434-4868-ac45-d9e8c0b457cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_af5f4014-b49b-430c-949f-b6e3853297d3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_384d42af-f36e-4908-8185-3e23ff0c029d" xlink:to="loc_us-gaap_Liabilities_af5f4014-b49b-430c-949f-b6e3853297d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_31efc7dd-bb80-452c-a03f-c71638739f74" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_384d42af-f36e-4908-8185-3e23ff0c029d" xlink:to="loc_us-gaap_CommitmentsAndContingencies_31efc7dd-bb80-452c-a03f-c71638739f74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_0b4834c1-e5ea-4036-8c7a-3099461693dd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_384d42af-f36e-4908-8185-3e23ff0c029d" xlink:to="loc_us-gaap_StockholdersEquityAbstract_0b4834c1-e5ea-4036-8c7a-3099461693dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_3f6f84c2-c202-4778-8403-e130efe03d56" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_0b4834c1-e5ea-4036-8c7a-3099461693dd" xlink:to="loc_us-gaap_PreferredStockValue_3f6f84c2-c202-4778-8403-e130efe03d56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_e89c5a57-e607-45cc-97ba-5e06d6f8c494" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_0b4834c1-e5ea-4036-8c7a-3099461693dd" xlink:to="loc_us-gaap_CommonStockValue_e89c5a57-e607-45cc-97ba-5e06d6f8c494" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_1fcf1a2d-d710-4ba6-b77e-f040e2efe85b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_0b4834c1-e5ea-4036-8c7a-3099461693dd" xlink:to="loc_us-gaap_AdditionalPaidInCapital_1fcf1a2d-d710-4ba6-b77e-f040e2efe85b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_a9f5b044-53c1-477e-9f88-20fed6f931ef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_0b4834c1-e5ea-4036-8c7a-3099461693dd" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_a9f5b044-53c1-477e-9f88-20fed6f931ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_b2d56a99-6343-48e6-b096-9345ab53d82c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_0b4834c1-e5ea-4036-8c7a-3099461693dd" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_b2d56a99-6343-48e6-b096-9345ab53d82c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_24c0ada8-2084-4a56-b1bb-81776720f0b9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_0b4834c1-e5ea-4036-8c7a-3099461693dd" xlink:to="loc_us-gaap_StockholdersEquity_24c0ada8-2084-4a56-b1bb-81776720f0b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_9cbc01d4-20da-452d-a335-f7d44f35f197" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_384d42af-f36e-4908-8185-3e23ff0c029d" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_9cbc01d4-20da-452d-a335-f7d44f35f197" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.selectabio.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="selb-20210331.xsd#ConsolidatedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://www.selectabio.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_5eb049c2-e52d-4caf-9e7d-ea1c5a56d37f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_e316f7d8-fc27-48f0-b8f7-f7aac0bab15c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_5eb049c2-e52d-4caf-9e7d-ea1c5a56d37f" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_e316f7d8-fc27-48f0-b8f7-f7aac0bab15c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_50704f2b-5bb9-41c0-a917-173f84b163a5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_5eb049c2-e52d-4caf-9e7d-ea1c5a56d37f" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_50704f2b-5bb9-41c0-a917-173f84b163a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_f1e4e3a1-aa3a-4269-bd82-c5624b563fee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_5eb049c2-e52d-4caf-9e7d-ea1c5a56d37f" xlink:to="loc_us-gaap_PreferredStockSharesIssued_f1e4e3a1-aa3a-4269-bd82-c5624b563fee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_98de773b-c37e-4ce7-939c-cdada68b4d3d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_5eb049c2-e52d-4caf-9e7d-ea1c5a56d37f" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_98de773b-c37e-4ce7-939c-cdada68b4d3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_ed2b742f-e5cc-48aa-a801-3263e506ed6e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_5eb049c2-e52d-4caf-9e7d-ea1c5a56d37f" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_ed2b742f-e5cc-48aa-a801-3263e506ed6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_2f710797-7f99-47fe-86f6-ed334d662746" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_5eb049c2-e52d-4caf-9e7d-ea1c5a56d37f" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_2f710797-7f99-47fe-86f6-ed334d662746" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_beba5e71-263c-4e9c-a98b-de7be3dccd1b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_5eb049c2-e52d-4caf-9e7d-ea1c5a56d37f" xlink:to="loc_us-gaap_CommonStockSharesIssued_beba5e71-263c-4e9c-a98b-de7be3dccd1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_7f0a0b05-a943-4c7d-9ec8-25bb1aabcada" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_5eb049c2-e52d-4caf-9e7d-ea1c5a56d37f" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_7f0a0b05-a943-4c7d-9ec8-25bb1aabcada" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.selectabio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="simple" xlink:href="selb-20210331.xsd#ConsolidatedStatementsofOperationsandComprehensiveLoss"/>
  <link:presentationLink xlink:role="http://www.selectabio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_ac0d2543-c83c-4ed9-b33a-9eaf4ebdefcd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_d56888b1-81c6-4a6a-ad7d-6833a0e3358f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_ac0d2543-c83c-4ed9-b33a-9eaf4ebdefcd" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_d56888b1-81c6-4a6a-ad7d-6833a0e3358f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfRevenueAbstract_9e1c829a-8b26-43b5-a8bb-22bb7c23f105" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfRevenueAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_ac0d2543-c83c-4ed9-b33a-9eaf4ebdefcd" xlink:to="loc_us-gaap_CostOfRevenueAbstract_9e1c829a-8b26-43b5-a8bb-22bb7c23f105" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_f7b432ef-0971-432d-b651-99ae9704c0d3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostOfRevenueAbstract_9e1c829a-8b26-43b5-a8bb-22bb7c23f105" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_f7b432ef-0971-432d-b651-99ae9704c0d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_877b80a7-d0e3-46e8-aaf3-40ee6419dfec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostOfRevenueAbstract_9e1c829a-8b26-43b5-a8bb-22bb7c23f105" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_877b80a7-d0e3-46e8-aaf3-40ee6419dfec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_f5d69ae2-d707-4690-9a6f-e8b38364044b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostOfRevenueAbstract_9e1c829a-8b26-43b5-a8bb-22bb7c23f105" xlink:to="loc_us-gaap_OperatingExpenses_f5d69ae2-d707-4690-9a6f-e8b38364044b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_2a2b3874-ee4c-4aa5-adc3-7e779bee8504" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_ac0d2543-c83c-4ed9-b33a-9eaf4ebdefcd" xlink:to="loc_us-gaap_OperatingIncomeLoss_2a2b3874-ee4c-4aa5-adc3-7e779bee8504" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNet_37f8352a-c63f-4488-9b3d-a5538f10571f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_ac0d2543-c83c-4ed9-b33a-9eaf4ebdefcd" xlink:to="loc_us-gaap_InvestmentIncomeNet_37f8352a-c63f-4488-9b3d-a5538f10571f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_480b48eb-f384-4e0b-8fa4-024fd2958325" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_ac0d2543-c83c-4ed9-b33a-9eaf4ebdefcd" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_480b48eb-f384-4e0b-8fa4-024fd2958325" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_abce29fe-9283-4fe2-aa9a-b60b4dd60cee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_ac0d2543-c83c-4ed9-b33a-9eaf4ebdefcd" xlink:to="loc_us-gaap_InterestExpense_abce29fe-9283-4fe2-aa9a-b60b4dd60cee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_d6f12a3d-d18e-455a-afd6-c327bc4971fb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_ac0d2543-c83c-4ed9-b33a-9eaf4ebdefcd" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_d6f12a3d-d18e-455a-afd6-c327bc4971fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_796f3718-ec27-44f6-9b46-e2fee447e1b2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_ac0d2543-c83c-4ed9-b33a-9eaf4ebdefcd" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_796f3718-ec27-44f6-9b46-e2fee447e1b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_055779d1-0788-41fd-a56c-e6ee85542462" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_ac0d2543-c83c-4ed9-b33a-9eaf4ebdefcd" xlink:to="loc_us-gaap_NetIncomeLoss_055779d1-0788-41fd-a56c-e6ee85542462" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossTaxAbstract_33203624-6143-4100-8c5c-b3dbcf1e7997" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossTaxAbstract"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_ac0d2543-c83c-4ed9-b33a-9eaf4ebdefcd" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossTaxAbstract_33203624-6143-4100-8c5c-b3dbcf1e7997" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_cf8a7b79-8cb1-4f6e-b281-9c2f4f260f81" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossTaxAbstract_33203624-6143-4100-8c5c-b3dbcf1e7997" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_cf8a7b79-8cb1-4f6e-b281-9c2f4f260f81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_7dbecd56-fedd-4209-aab1-e92ae490c943" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossTaxAbstract_33203624-6143-4100-8c5c-b3dbcf1e7997" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_7dbecd56-fedd-4209-aab1-e92ae490c943" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_d5beb1e8-1463-4425-914d-4a6aeae62d44" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_ac0d2543-c83c-4ed9-b33a-9eaf4ebdefcd" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_d5beb1e8-1463-4425-914d-4a6aeae62d44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_5e90094d-02f3-4d68-80fa-c7ef72e20e87" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_ac0d2543-c83c-4ed9-b33a-9eaf4ebdefcd" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_5e90094d-02f3-4d68-80fa-c7ef72e20e87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_dc25e41c-7c03-483e-9eb0-87667aa1746f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_5e90094d-02f3-4d68-80fa-c7ef72e20e87" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_dc25e41c-7c03-483e-9eb0-87667aa1746f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_b3d1e578-be25-4423-8d0a-1e9737e8599d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_ac0d2543-c83c-4ed9-b33a-9eaf4ebdefcd" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_b3d1e578-be25-4423-8d0a-1e9737e8599d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_78b28499-08d0-42ca-bbf9-464e306f243c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_b3d1e578-be25-4423-8d0a-1e9737e8599d" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_78b28499-08d0-42ca-bbf9-464e306f243c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.selectabio.com/role/ConsolidatedStatementsofChangesinStockholdersDeficitEquity" xlink:type="simple" xlink:href="selb-20210331.xsd#ConsolidatedStatementsofChangesinStockholdersDeficitEquity"/>
  <link:presentationLink xlink:role="http://www.selectabio.com/role/ConsolidatedStatementsofChangesinStockholdersDeficitEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_2e35597c-abbb-4f3c-85cf-3806530b9265" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_b4ebbb6f-709c-4b94-bf4f-a0be181242ec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_2e35597c-abbb-4f3c-85cf-3806530b9265" xlink:to="loc_us-gaap_StatementTable_b4ebbb6f-709c-4b94-bf4f-a0be181242ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_fefcf08d-a36c-4e72-9ca1-63c8718fadd0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_b4ebbb6f-709c-4b94-bf4f-a0be181242ec" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_fefcf08d-a36c-4e72-9ca1-63c8718fadd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_9900b41a-c6be-4368-8580-17df6d0eb6d1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_fefcf08d-a36c-4e72-9ca1-63c8718fadd0" xlink:to="loc_us-gaap_EquityComponentDomain_9900b41a-c6be-4368-8580-17df6d0eb6d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_4434955a-5981-4259-ba3c-14be04277afd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_9900b41a-c6be-4368-8580-17df6d0eb6d1" xlink:to="loc_us-gaap_CommonStockMember_4434955a-5981-4259-ba3c-14be04277afd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_d1da648b-0bc6-47ee-94ab-e27c92406363" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_9900b41a-c6be-4368-8580-17df6d0eb6d1" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_d1da648b-0bc6-47ee-94ab-e27c92406363" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_a0448fec-8628-4f6b-b7df-a3ff61ad5312" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_9900b41a-c6be-4368-8580-17df6d0eb6d1" xlink:to="loc_us-gaap_RetainedEarningsMember_a0448fec-8628-4f6b-b7df-a3ff61ad5312" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_e42f00f1-555d-476c-b49a-d98166d70361" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_9900b41a-c6be-4368-8580-17df6d0eb6d1" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_e42f00f1-555d-476c-b49a-d98166d70361" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_f82ef73f-0f16-4223-aec3-965dda949dd7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_b4ebbb6f-709c-4b94-bf4f-a0be181242ec" xlink:to="loc_us-gaap_StatementLineItems_f82ef73f-0f16-4223-aec3-965dda949dd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_bb3d8b41-09e7-46ec-8dae-73bf9836b413" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_f82ef73f-0f16-4223-aec3-965dda949dd7" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_bb3d8b41-09e7-46ec-8dae-73bf9836b413" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_269464c8-f13d-4302-bff9-d248387bc025" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_bb3d8b41-09e7-46ec-8dae-73bf9836b413" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_269464c8-f13d-4302-bff9-d248387bc025" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_a8d78df5-e73f-4819-9412-b859fd0c73d2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_bb3d8b41-09e7-46ec-8dae-73bf9836b413" xlink:to="loc_us-gaap_StockholdersEquity_a8d78df5-e73f-4819-9412-b859fd0c73d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_ffa6c7c2-bc14-4371-809b-7a97c259971e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_bb3d8b41-09e7-46ec-8dae-73bf9836b413" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_ffa6c7c2-bc14-4371-809b-7a97c259971e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_8b1c5c41-d38b-43db-8fdc-1e5d3df8ec44" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_bb3d8b41-09e7-46ec-8dae-73bf9836b413" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_8b1c5c41-d38b-43db-8fdc-1e5d3df8ec44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_7922f3f7-0d17-4178-a7b9-029957a0214f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_bb3d8b41-09e7-46ec-8dae-73bf9836b413" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_7922f3f7-0d17-4178-a7b9-029957a0214f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_354cbf92-44de-456e-87eb-d68859a89b23" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_bb3d8b41-09e7-46ec-8dae-73bf9836b413" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_354cbf92-44de-456e-87eb-d68859a89b23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_10b6500d-1610-41ee-a8ae-7d2b0addb885" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_bb3d8b41-09e7-46ec-8dae-73bf9836b413" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_10b6500d-1610-41ee-a8ae-7d2b0addb885" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_41ec4803-5dc4-4c92-b6f2-761dad0e650b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_bb3d8b41-09e7-46ec-8dae-73bf9836b413" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_41ec4803-5dc4-4c92-b6f2-761dad0e650b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesOther_d86d7fff-3603-458c-abb7-01225584c0dc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_bb3d8b41-09e7-46ec-8dae-73bf9836b413" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesOther_d86d7fff-3603-458c-abb7-01225584c0dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueOther_ce4b02da-0303-4668-a48b-fe60e7cb8bbb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueOther"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_bb3d8b41-09e7-46ec-8dae-73bf9836b413" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueOther_ce4b02da-0303-4668-a48b-fe60e7cb8bbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther_46876cb8-42a9-4bd4-b11c-4ceff4c162a6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalOther"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_bb3d8b41-09e7-46ec-8dae-73bf9836b413" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther_46876cb8-42a9-4bd4-b11c-4ceff4c162a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_91769971-1721-4031-8cc7-16f11f415fc2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_bb3d8b41-09e7-46ec-8dae-73bf9836b413" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_91769971-1721-4031-8cc7-16f11f415fc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_880341d0-7f7f-4c06-99e2-91d21c148c8a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_bb3d8b41-09e7-46ec-8dae-73bf9836b413" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_880341d0-7f7f-4c06-99e2-91d21c148c8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_1d665192-a41c-4b90-9d98-629baafe57b7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_bb3d8b41-09e7-46ec-8dae-73bf9836b413" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_1d665192-a41c-4b90-9d98-629baafe57b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_ea40cfc5-e1ff-402a-b328-9a3e21e088f2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_bb3d8b41-09e7-46ec-8dae-73bf9836b413" xlink:to="loc_us-gaap_NetIncomeLoss_ea40cfc5-e1ff-402a-b328-9a3e21e088f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_db00d320-6bfb-4dfe-98b1-16842642e50a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_bb3d8b41-09e7-46ec-8dae-73bf9836b413" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_db00d320-6bfb-4dfe-98b1-16842642e50a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_ee7ae659-5b71-4c85-a9dd-076a9c45e947" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_bb3d8b41-09e7-46ec-8dae-73bf9836b413" xlink:to="loc_us-gaap_StockholdersEquity_ee7ae659-5b71-4c85-a9dd-076a9c45e947" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.selectabio.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="selb-20210331.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://www.selectabio.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_f9b189a6-6319-4932-822d-b437df70a84e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_55dd3b5b-85bb-4c59-b69f-449b4d9e6a0a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_f9b189a6-6319-4932-822d-b437df70a84e" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_55dd3b5b-85bb-4c59-b69f-449b4d9e6a0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_33c6cc00-83dc-4141-aa78-ada91697c655" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_55dd3b5b-85bb-4c59-b69f-449b4d9e6a0a" xlink:to="loc_us-gaap_NetIncomeLoss_33c6cc00-83dc-4141-aa78-ada91697c655" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_36a4f66c-2ed9-411b-8cc9-97cd64957705" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_55dd3b5b-85bb-4c59-b69f-449b4d9e6a0a" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_36a4f66c-2ed9-411b-8cc9-97cd64957705" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherDepreciationAndAmortization_45a50406-40a0-49a3-9229-a45c8a800fc5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherDepreciationAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_36a4f66c-2ed9-411b-8cc9-97cd64957705" xlink:to="loc_us-gaap_OtherDepreciationAndAmortization_45a50406-40a0-49a3-9229-a45c8a800fc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_994b37a2-f610-4541-9ede-3f00ae906a8e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_36a4f66c-2ed9-411b-8cc9-97cd64957705" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_994b37a2-f610-4541-9ede-3f00ae906a8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_e47ffda4-c7d7-4a27-a179-16073b204934" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_36a4f66c-2ed9-411b-8cc9-97cd64957705" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_e47ffda4-c7d7-4a27-a179-16073b204934" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_fecb1677-fc2e-405a-a600-99ace5d7978c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_36a4f66c-2ed9-411b-8cc9-97cd64957705" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_fecb1677-fc2e-405a-a600-99ace5d7978c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_0a6b16de-5726-438b-b328-c29faf4da837" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_36a4f66c-2ed9-411b-8cc9-97cd64957705" xlink:to="loc_us-gaap_ShareBasedCompensation_0a6b16de-5726-438b-b328-c29faf4da837" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaidInKindInterest_58a16a60-f5e4-4bcc-9173-2afcae1c66d8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaidInKindInterest"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_36a4f66c-2ed9-411b-8cc9-97cd64957705" xlink:to="loc_us-gaap_PaidInKindInterest_58a16a60-f5e4-4bcc-9173-2afcae1c66d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_6126330b-9580-4e8f-8a25-b121da5b757d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_36a4f66c-2ed9-411b-8cc9-97cd64957705" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_6126330b-9580-4e8f-8a25-b121da5b757d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c9b5e165-7da6-47bb-a50f-b3f324dd572f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_36a4f66c-2ed9-411b-8cc9-97cd64957705" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c9b5e165-7da6-47bb-a50f-b3f324dd572f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_c2674103-70b9-4369-b6c3-810a3274cf9c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c9b5e165-7da6-47bb-a50f-b3f324dd572f" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_c2674103-70b9-4369-b6c3-810a3274cf9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_d7c554f8-8581-4eac-a626-7c6ac8a12784" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c9b5e165-7da6-47bb-a50f-b3f324dd572f" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_d7c554f8-8581-4eac-a626-7c6ac8a12784" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_7111ac83-e35a-485f-ad7f-ac0822937bcc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c9b5e165-7da6-47bb-a50f-b3f324dd572f" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_7111ac83-e35a-485f-ad7f-ac0822937bcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_7c682744-d658-4897-abe0-588e1319994a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c9b5e165-7da6-47bb-a50f-b3f324dd572f" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_7c682744-d658-4897-abe0-588e1319994a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_0f47a243-f84e-44ac-8757-4f6d40a0afea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c9b5e165-7da6-47bb-a50f-b3f324dd572f" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_0f47a243-f84e-44ac-8757-4f6d40a0afea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_cb938082-e156-43ae-925b-a73912ac4d05" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_55dd3b5b-85bb-4c59-b69f-449b4d9e6a0a" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_cb938082-e156-43ae-925b-a73912ac4d05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_711ce538-93e0-44ac-9f6c-d3cbd28a2a11" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_f9b189a6-6319-4932-822d-b437df70a84e" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_711ce538-93e0-44ac-9f6c-d3cbd28a2a11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_0edb3207-9fdd-4f2c-8291-9fc4186514a5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_711ce538-93e0-44ac-9f6c-d3cbd28a2a11" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_0edb3207-9fdd-4f2c-8291-9fc4186514a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_a7a60370-1298-4fdb-8d37-fadc37801fb3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_711ce538-93e0-44ac-9f6c-d3cbd28a2a11" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_a7a60370-1298-4fdb-8d37-fadc37801fb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_f2ee283b-09cf-40a5-b656-c4e09f7521e5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_711ce538-93e0-44ac-9f6c-d3cbd28a2a11" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_f2ee283b-09cf-40a5-b656-c4e09f7521e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_bf5cbc24-0e35-46ae-a1af-f29566a568f3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_f9b189a6-6319-4932-822d-b437df70a84e" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_bf5cbc24-0e35-46ae-a1af-f29566a568f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_4f6fe462-ba68-4860-b724-73e4a6884de1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_bf5cbc24-0e35-46ae-a1af-f29566a568f3" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_4f6fe462-ba68-4860-b724-73e4a6884de1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_b08cbecc-da58-4c4e-aae2-9d3f79468ab2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_bf5cbc24-0e35-46ae-a1af-f29566a568f3" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_b08cbecc-da58-4c4e-aae2-9d3f79468ab2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfFinancingCosts_9329d9e2-dabc-4ffe-bbf4-23e6954aaa8c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfFinancingCosts"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_bf5cbc24-0e35-46ae-a1af-f29566a568f3" xlink:to="loc_us-gaap_PaymentsOfFinancingCosts_9329d9e2-dabc-4ffe-bbf4-23e6954aaa8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_bc018075-d5bd-4277-9039-a7535e59f95a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_bf5cbc24-0e35-46ae-a1af-f29566a568f3" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_bc018075-d5bd-4277-9039-a7535e59f95a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_437c9f98-4a42-4745-8a81-7a59c021b880" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_bf5cbc24-0e35-46ae-a1af-f29566a568f3" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_437c9f98-4a42-4745-8a81-7a59c021b880" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockPlans_ab62c141-b40f-4d48-8572-449ac9d48e4c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockPlans"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_bf5cbc24-0e35-46ae-a1af-f29566a568f3" xlink:to="loc_us-gaap_ProceedsFromStockPlans_ab62c141-b40f-4d48-8572-449ac9d48e4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_a86fefef-47bc-413d-b650-6bd750e7ec46" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_bf5cbc24-0e35-46ae-a1af-f29566a568f3" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_a86fefef-47bc-413d-b650-6bd750e7ec46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_29731bc2-4173-4f35-839a-00ceec9ff42c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_f9b189a6-6319-4932-822d-b437df70a84e" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_29731bc2-4173-4f35-839a-00ceec9ff42c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_90d248cf-d791-410a-bda5-483391ad547d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_f9b189a6-6319-4932-822d-b437df70a84e" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_90d248cf-d791-410a-bda5-483391ad547d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_514b3035-73ad-41e6-bada-903d98a818af" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_f9b189a6-6319-4932-822d-b437df70a84e" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_514b3035-73ad-41e6-bada-903d98a818af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3b720884-0df1-41de-9923-a7297317234b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_f9b189a6-6319-4932-822d-b437df70a84e" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3b720884-0df1-41de-9923-a7297317234b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_7575fc77-13e8-46ba-aa14-1bbbb934055a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_f9b189a6-6319-4932-822d-b437df70a84e" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_7575fc77-13e8-46ba-aa14-1bbbb934055a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_0602e0bd-aba9-4516-843c-097a857ff901" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_7575fc77-13e8-46ba-aa14-1bbbb934055a" xlink:to="loc_us-gaap_InterestPaidNet_0602e0bd-aba9-4516-843c-097a857ff901" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_5a5314f9-5bbb-4f4a-a6fd-59b5ac9d4d79" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_f9b189a6-6319-4932-822d-b437df70a84e" xlink:to="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_5a5314f9-5bbb-4f4a-a6fd-59b5ac9d4d79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_a84331b8-fb6e-4217-a945-9e83964e6d4f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_5a5314f9-5bbb-4f4a-a6fd-59b5ac9d4d79" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_a84331b8-fb6e-4217-a945-9e83964e6d4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_selb_EquityOfferingCostsInAccruedLiabilities_af375509-9022-456d-a4da-14c60397327f" xlink:href="selb-20210331.xsd#selb_EquityOfferingCostsInAccruedLiabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_5a5314f9-5bbb-4f4a-a6fd-59b5ac9d4d79" xlink:to="loc_selb_EquityOfferingCostsInAccruedLiabilities_af375509-9022-456d-a4da-14c60397327f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesUnrealizedGainLoss_4311e0c8-308d-401b-86f9-f2665a1b33ae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesUnrealizedGainLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_5a5314f9-5bbb-4f4a-a6fd-59b5ac9d4d79" xlink:to="loc_us-gaap_MarketableSecuritiesUnrealizedGainLoss_4311e0c8-308d-401b-86f9-f2665a1b33ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.selectabio.com/role/NatureoftheBusinessandBasisofPresentation" xlink:type="simple" xlink:href="selb-20210331.xsd#NatureoftheBusinessandBasisofPresentation"/>
  <link:presentationLink xlink:role="http://www.selectabio.com/role/NatureoftheBusinessandBasisofPresentation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_fea5a0af-f6a7-42da-8a58-5ebef6a75ba2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_dcf8f6a4-6e87-4919-886a-a5a4f598b7cd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_fea5a0af-f6a7-42da-8a58-5ebef6a75ba2" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_dcf8f6a4-6e87-4919-886a-a5a4f598b7cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.selectabio.com/role/NatureoftheBusinessandBasisofPresentationLiquidityDetails" xlink:type="simple" xlink:href="selb-20210331.xsd#NatureoftheBusinessandBasisofPresentationLiquidityDetails"/>
  <link:presentationLink xlink:role="http://www.selectabio.com/role/NatureoftheBusinessandBasisofPresentationLiquidityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_46ab9a42-6ff7-4a84-a5e6-cdfffa2687c7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_cd863fbb-104e-4e0f-a32b-11be5d8f8bf7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_46ab9a42-6ff7-4a84-a5e6-cdfffa2687c7" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_cd863fbb-104e-4e0f-a32b-11be5d8f8bf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_d5cb2903-3891-44e2-9386-47ef21fbb23f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_cd863fbb-104e-4e0f-a32b-11be5d8f8bf7" xlink:to="loc_srt_StatementGeographicalAxis_d5cb2903-3891-44e2-9386-47ef21fbb23f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_b1bc2940-ecab-4b6a-abc1-e06049d24766" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_d5cb2903-3891-44e2-9386-47ef21fbb23f" xlink:to="loc_srt_SegmentGeographicalDomain_b1bc2940-ecab-4b6a-abc1-e06049d24766" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_RU_1b965f15-a3d1-4008-964a-063919596549" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_RU"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_b1bc2940-ecab-4b6a-abc1-e06049d24766" xlink:to="loc_country_RU_1b965f15-a3d1-4008-964a-063919596549" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsLineItems_1571deab-e6fb-436a-b363-e37a8af287fa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_cd863fbb-104e-4e0f-a32b-11be5d8f8bf7" xlink:to="loc_us-gaap_CashAndCashEquivalentsLineItems_1571deab-e6fb-436a-b363-e37a8af287fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_selb_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndDebtSecuritiesAvailableForSale_1ad4cf08-51ce-4984-9009-9c993900392f" xlink:href="selb-20210331.xsd#selb_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndDebtSecuritiesAvailableForSale"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_1571deab-e6fb-436a-b363-e37a8af287fa" xlink:to="loc_selb_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndDebtSecuritiesAvailableForSale_1ad4cf08-51ce-4984-9009-9c993900392f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents_9f2b3e19-d0f5-48bc-8056-3c13e602c074" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalents"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_1571deab-e6fb-436a-b363-e37a8af287fa" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalents_9f2b3e19-d0f5-48bc-8056-3c13e602c074" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Cash_98d00d61-5f41-45e2-a7a5-ce631fc31970" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Cash"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_1571deab-e6fb-436a-b363-e37a8af287fa" xlink:to="loc_us-gaap_Cash_98d00d61-5f41-45e2-a7a5-ce631fc31970" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_a1b59a83-faa7-41b6-9bc7-94b5598e7305" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_1571deab-e6fb-436a-b363-e37a8af287fa" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_a1b59a83-faa7-41b6-9bc7-94b5598e7305" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.selectabio.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="selb-20210331.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.selectabio.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_75a91e54-509b-4995-b5f7-3fc102f4f855" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_de07efbc-f2a4-4014-a7e0-03d9128c504a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_75a91e54-509b-4995-b5f7-3fc102f4f855" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_de07efbc-f2a4-4014-a7e0-03d9128c504a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.selectabio.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="selb-20210331.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.selectabio.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_deb4c5e5-1970-4b2e-8716-e2c0d6093854" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_92fd8406-852d-47bf-9dbd-e1d5b3e25bd6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_deb4c5e5-1970-4b2e-8716-e2c0d6093854" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_92fd8406-852d-47bf-9dbd-e1d5b3e25bd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.selectabio.com/role/MarketableSecurities" xlink:type="simple" xlink:href="selb-20210331.xsd#MarketableSecurities"/>
  <link:presentationLink xlink:role="http://www.selectabio.com/role/MarketableSecurities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_17ff10a2-4064-4e80-ad8c-a1b0c0693741" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_180abce8-5cbf-493a-b927-3e3f894c3cc1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_17ff10a2-4064-4e80-ad8c-a1b0c0693741" xlink:to="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_180abce8-5cbf-493a-b927-3e3f894c3cc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.selectabio.com/role/MarketableSecuritiesTables" xlink:type="simple" xlink:href="selb-20210331.xsd#MarketableSecuritiesTables"/>
  <link:presentationLink xlink:role="http://www.selectabio.com/role/MarketableSecuritiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_65335622-0322-4155-a6b7-0591d2b87879" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_a8f4506b-a86f-4798-8e33-ec7e2fde29f0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_65335622-0322-4155-a6b7-0591d2b87879" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_a8f4506b-a86f-4798-8e33-ec7e2fde29f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.selectabio.com/role/MarketableSecuritiesSummaryofAvailableforSaleMarketableSecuritiesDetails" xlink:type="simple" xlink:href="selb-20210331.xsd#MarketableSecuritiesSummaryofAvailableforSaleMarketableSecuritiesDetails"/>
  <link:presentationLink xlink:role="http://www.selectabio.com/role/MarketableSecuritiesSummaryofAvailableforSaleMarketableSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_909d08cb-2be5-4dac-b56a-1a83e5f49164" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_72c5d985-8f56-4cfb-9f3b-b6fd219ad5cd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_909d08cb-2be5-4dac-b56a-1a83e5f49164" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_72c5d985-8f56-4cfb-9f3b-b6fd219ad5cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_4399014d-bed1-4638-8388-d4f717e1062b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_72c5d985-8f56-4cfb-9f3b-b6fd219ad5cd" xlink:to="loc_us-gaap_FinancialInstrumentAxis_4399014d-bed1-4638-8388-d4f717e1062b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1a86347f-0806-4e57-8fe4-b1fee7cbf134" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_4399014d-bed1-4638-8388-d4f717e1062b" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1a86347f-0806-4e57-8fe4-b1fee7cbf134" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_2bcaef29-4492-4d9e-85fd-a8e7ba30b6ef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1a86347f-0806-4e57-8fe4-b1fee7cbf134" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_2bcaef29-4492-4d9e-85fd-a8e7ba30b6ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_41f34846-15c7-4c25-9b9c-bacea9a63aa0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1a86347f-0806-4e57-8fe4-b1fee7cbf134" xlink:to="loc_us-gaap_CommercialPaperMember_41f34846-15c7-4c25-9b9c-bacea9a63aa0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_14346cec-de4e-46f7-ad9f-635797513179" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_72c5d985-8f56-4cfb-9f3b-b6fd219ad5cd" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_14346cec-de4e-46f7-ad9f-635797513179" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_adadead4-48d3-4f36-b773-da321acdc185" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_14346cec-de4e-46f7-ad9f-635797513179" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_adadead4-48d3-4f36-b773-da321acdc185" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_70090f8b-48c8-4136-88b1-8839e6f81fdd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_14346cec-de4e-46f7-ad9f-635797513179" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_70090f8b-48c8-4136-88b1-8839e6f81fdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_6a1ef6f5-613f-4fab-a50b-ba7761ab2415" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_14346cec-de4e-46f7-ad9f-635797513179" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_6a1ef6f5-613f-4fab-a50b-ba7761ab2415" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_379a2806-7b08-4f10-a163-6370f6126066" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_14346cec-de4e-46f7-ad9f-635797513179" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_379a2806-7b08-4f10-a163-6370f6126066" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.selectabio.com/role/MarketableSecuritiesNarrativeDetails" xlink:type="simple" xlink:href="selb-20210331.xsd#MarketableSecuritiesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.selectabio.com/role/MarketableSecuritiesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_1c4ef215-f4ac-4cbb-812e-fb39ffe3d3fd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale_18f27dea-cdf4-4c94-ac1e-168d299a9115" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_1c4ef215-f4ac-4cbb-812e-fb39ffe3d3fd" xlink:to="loc_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale_18f27dea-cdf4-4c94-ac1e-168d299a9115" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_7af7d816-a249-423d-9904-3fd5b4c5259e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_1c4ef215-f4ac-4cbb-812e-fb39ffe3d3fd" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_7af7d816-a249-423d-9904-3fd5b4c5259e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.selectabio.com/role/NetLossPerShare" xlink:type="simple" xlink:href="selb-20210331.xsd#NetLossPerShare"/>
  <link:presentationLink xlink:role="http://www.selectabio.com/role/NetLossPerShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_50d8d537-f682-4d15-94bd-c79ac6ac7475" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_d2a1c010-1c02-4f11-bc84-0e717b0f446c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_50d8d537-f682-4d15-94bd-c79ac6ac7475" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_d2a1c010-1c02-4f11-bc84-0e717b0f446c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.selectabio.com/role/NetLossPerShareTables" xlink:type="simple" xlink:href="selb-20210331.xsd#NetLossPerShareTables"/>
  <link:presentationLink xlink:role="http://www.selectabio.com/role/NetLossPerShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_3f98597b-3d78-4b50-bb6a-b68796a980f4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_d71d961a-ba0a-46ff-b294-101575e07f72" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_3f98597b-3d78-4b50-bb6a-b68796a980f4" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_d71d961a-ba0a-46ff-b294-101575e07f72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_ae641f1c-345b-4fc9-aac8-1b39ec2b3526" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_3f98597b-3d78-4b50-bb6a-b68796a980f4" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_ae641f1c-345b-4fc9-aac8-1b39ec2b3526" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.selectabio.com/role/NetLossPerShareComputationofBasicandDilutedNetLossPerShareDetails" xlink:type="simple" xlink:href="selb-20210331.xsd#NetLossPerShareComputationofBasicandDilutedNetLossPerShareDetails"/>
  <link:presentationLink xlink:role="http://www.selectabio.com/role/NetLossPerShareComputationofBasicandDilutedNetLossPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_1aaca007-1f70-468f-999e-b72df92e084b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_50a49014-9541-43f0-9fc9-72fc9005f3ad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_1aaca007-1f70-468f-999e-b72df92e084b" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_50a49014-9541-43f0-9fc9-72fc9005f3ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_65d00359-114e-477f-8eea-2fddb1d6898c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_50a49014-9541-43f0-9fc9-72fc9005f3ad" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_65d00359-114e-477f-8eea-2fddb1d6898c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_1ad78b8e-9017-4f03-aa58-a3668195a634" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_1aaca007-1f70-468f-999e-b72df92e084b" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_1ad78b8e-9017-4f03-aa58-a3668195a634" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_866908ce-d93b-4ce1-aee1-781da7934f09" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_1ad78b8e-9017-4f03-aa58-a3668195a634" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_866908ce-d93b-4ce1-aee1-781da7934f09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_ffa6607b-fcec-40a8-bfcb-9b4c8d602f94" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_1ad78b8e-9017-4f03-aa58-a3668195a634" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_ffa6607b-fcec-40a8-bfcb-9b4c8d602f94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.selectabio.com/role/NetLossPerShareScheduleofPotentialCommonSharesIssuableUponConversionofWarrantsDetails" xlink:type="simple" xlink:href="selb-20210331.xsd#NetLossPerShareScheduleofPotentialCommonSharesIssuableUponConversionofWarrantsDetails"/>
  <link:presentationLink xlink:role="http://www.selectabio.com/role/NetLossPerShareScheduleofPotentialCommonSharesIssuableUponConversionofWarrantsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_0dfff750-ba5a-43ca-a29c-935c18277b5b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_63d90327-a88c-404b-b980-7c1fc20372da" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_0dfff750-ba5a-43ca-a29c-935c18277b5b" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_63d90327-a88c-404b-b980-7c1fc20372da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_6063b21f-41b1-43e2-9366-7a6369dcc7ac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_63d90327-a88c-404b-b980-7c1fc20372da" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_6063b21f-41b1-43e2-9366-7a6369dcc7ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_96240149-0e43-4111-9117-307ac8806952" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_6063b21f-41b1-43e2-9366-7a6369dcc7ac" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_96240149-0e43-4111-9117-307ac8806952" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_1246e80f-7391-4ea2-8b9b-93b9a12da5c0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_96240149-0e43-4111-9117-307ac8806952" xlink:to="loc_us-gaap_EmployeeStockOptionMember_1246e80f-7391-4ea2-8b9b-93b9a12da5c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_9b7cd0c4-e3ca-427a-b38d-87f1ef1993e4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_96240149-0e43-4111-9117-307ac8806952" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_9b7cd0c4-e3ca-427a-b38d-87f1ef1993e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_8cd56922-e183-4469-a4f5-7403a2348546" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_96240149-0e43-4111-9117-307ac8806952" xlink:to="loc_us-gaap_WarrantMember_8cd56922-e183-4469-a4f5-7403a2348546" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_34bdb1cf-c2d2-4f76-a461-997a210bbce0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_63d90327-a88c-404b-b980-7c1fc20372da" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_34bdb1cf-c2d2-4f76-a461-997a210bbce0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_9e6e36b1-b397-4ae3-83e3-445dafbcd23a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_34bdb1cf-c2d2-4f76-a461-997a210bbce0" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_9e6e36b1-b397-4ae3-83e3-445dafbcd23a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.selectabio.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="selb-20210331.xsd#FairValueMeasurements"/>
  <link:presentationLink xlink:role="http://www.selectabio.com/role/FairValueMeasurements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_ea630653-41f9-413e-bf10-db7bf14acad3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_53944a45-ac23-4e69-834d-aa241f8570a9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_ea630653-41f9-413e-bf10-db7bf14acad3" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_53944a45-ac23-4e69-834d-aa241f8570a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.selectabio.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="selb-20210331.xsd#FairValueMeasurementsTables"/>
  <link:presentationLink xlink:role="http://www.selectabio.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_e5aa9e5b-3957-4b7f-aeab-1ed454741b9d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_f05a1baf-e7cb-4cc5-b029-6a9faddb7e89" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_e5aa9e5b-3957-4b7f-aeab-1ed454741b9d" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_f05a1baf-e7cb-4cc5-b029-6a9faddb7e89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_2e377274-8322-4d46-9f98-d34a24c00e78" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_e5aa9e5b-3957-4b7f-aeab-1ed454741b9d" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_2e377274-8322-4d46-9f98-d34a24c00e78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_980d6df6-158b-486d-992a-263e7679484b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_e5aa9e5b-3957-4b7f-aeab-1ed454741b9d" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_980d6df6-158b-486d-992a-263e7679484b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_24982e96-5b5f-4708-b8fb-4b885f9fbab6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_e5aa9e5b-3957-4b7f-aeab-1ed454741b9d" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_24982e96-5b5f-4708-b8fb-4b885f9fbab6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_4cc8877c-d66e-4b6d-ba8e-451c96ffe7d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_e5aa9e5b-3957-4b7f-aeab-1ed454741b9d" xlink:to="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_4cc8877c-d66e-4b6d-ba8e-451c96ffe7d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.selectabio.com/role/FairValueMeasurementsSummaryofAssetsMeasuredatFairValueonaRecurringBasisDetails" xlink:type="simple" xlink:href="selb-20210331.xsd#FairValueMeasurementsSummaryofAssetsMeasuredatFairValueonaRecurringBasisDetails"/>
  <link:presentationLink xlink:role="http://www.selectabio.com/role/FairValueMeasurementsSummaryofAssetsMeasuredatFairValueonaRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_943b34e6-8ec1-4c70-a847-2fbad303d574" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_f70eeb76-d52a-458b-be12-fcd8e08881c4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_943b34e6-8ec1-4c70-a847-2fbad303d574" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_f70eeb76-d52a-458b-be12-fcd8e08881c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_791438af-b3a8-4c67-82b7-3e61c0489def" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_f70eeb76-d52a-458b-be12-fcd8e08881c4" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_791438af-b3a8-4c67-82b7-3e61c0489def" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_c78c5c98-ed53-40cc-a757-81586b0aa026" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_791438af-b3a8-4c67-82b7-3e61c0489def" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_c78c5c98-ed53-40cc-a757-81586b0aa026" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_18ed0a52-e7b1-4564-93ab-d54fec180778" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_c78c5c98-ed53-40cc-a757-81586b0aa026" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_18ed0a52-e7b1-4564-93ab-d54fec180778" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_bac8332b-005c-419e-8790-617d8ead6fd8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_f70eeb76-d52a-458b-be12-fcd8e08881c4" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_bac8332b-005c-419e-8790-617d8ead6fd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_3454f081-34f1-4fd1-9580-d5ce3963dad5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_bac8332b-005c-419e-8790-617d8ead6fd8" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_3454f081-34f1-4fd1-9580-d5ce3963dad5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_1975beb7-fccc-4cb7-bf8e-beb1bc32f57f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_3454f081-34f1-4fd1-9580-d5ce3963dad5" xlink:to="loc_us-gaap_MoneyMarketFundsMember_1975beb7-fccc-4cb7-bf8e-beb1bc32f57f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_85721bf2-e669-4bde-9b65-b55649ddd4cf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_f70eeb76-d52a-458b-be12-fcd8e08881c4" xlink:to="loc_us-gaap_FinancialInstrumentAxis_85721bf2-e669-4bde-9b65-b55649ddd4cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_70074204-f460-49e6-abfa-742b5a57d936" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_85721bf2-e669-4bde-9b65-b55649ddd4cf" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_70074204-f460-49e6-abfa-742b5a57d936" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_59c7c1a6-b13e-4322-89aa-5885c935ea2c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_70074204-f460-49e6-abfa-742b5a57d936" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_59c7c1a6-b13e-4322-89aa-5885c935ea2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_386a6824-605c-446d-8b99-9aaaffaa034d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_70074204-f460-49e6-abfa-742b5a57d936" xlink:to="loc_us-gaap_CommercialPaperMember_386a6824-605c-446d-8b99-9aaaffaa034d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_c04f31c7-6918-4e9b-9a5c-12851f91eebf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_f70eeb76-d52a-458b-be12-fcd8e08881c4" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_c04f31c7-6918-4e9b-9a5c-12851f91eebf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_336c5ef5-14ba-4e35-bfd2-0cce50b3a0fb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_c04f31c7-6918-4e9b-9a5c-12851f91eebf" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_336c5ef5-14ba-4e35-bfd2-0cce50b3a0fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_9ecd8777-1dc9-4c69-92b7-61119747f039" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_336c5ef5-14ba-4e35-bfd2-0cce50b3a0fb" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_9ecd8777-1dc9-4c69-92b7-61119747f039" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_760a8784-0ba7-4b74-bb71-06c119befde1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_336c5ef5-14ba-4e35-bfd2-0cce50b3a0fb" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_760a8784-0ba7-4b74-bb71-06c119befde1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_c2a6f17e-bc6c-406f-ae55-8e4d1e39e45c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_336c5ef5-14ba-4e35-bfd2-0cce50b3a0fb" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_c2a6f17e-bc6c-406f-ae55-8e4d1e39e45c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ac9f7582-0608-45d2-b082-8c8e3a972e82" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_f70eeb76-d52a-458b-be12-fcd8e08881c4" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ac9f7582-0608-45d2-b082-8c8e3a972e82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_516adaa8-7178-4aa0-bd72-91e659924c1d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ac9f7582-0608-45d2-b082-8c8e3a972e82" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_516adaa8-7178-4aa0-bd72-91e659924c1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_3c2e2dd4-7d0d-4e09-98e7-a8d229806964" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_516adaa8-7178-4aa0-bd72-91e659924c1d" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_3c2e2dd4-7d0d-4e09-98e7-a8d229806964" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_87200f70-a1da-4f5b-b1d4-7143984f3a7c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_516adaa8-7178-4aa0-bd72-91e659924c1d" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_87200f70-a1da-4f5b-b1d4-7143984f3a7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_6cdb19e9-ac97-4e39-ac49-4902bdd81c0e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_516adaa8-7178-4aa0-bd72-91e659924c1d" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_6cdb19e9-ac97-4e39-ac49-4902bdd81c0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_299747e8-55ed-4b15-ae8e-fc02dcbdae2a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ac9f7582-0608-45d2-b082-8c8e3a972e82" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_299747e8-55ed-4b15-ae8e-fc02dcbdae2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding_748ebc70-0dcf-4d99-8a40-4a886cefe404" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_299747e8-55ed-4b15-ae8e-fc02dcbdae2a" xlink:to="loc_us-gaap_WarrantsAndRightsOutstanding_748ebc70-0dcf-4d99-8a40-4a886cefe404" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_14f5a9c2-ce81-4f97-96e2-4a8d76c0b2bb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_299747e8-55ed-4b15-ae8e-fc02dcbdae2a" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_14f5a9c2-ce81-4f97-96e2-4a8d76c0b2bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.selectabio.com/role/FairValueMeasurementsAssumptionsusedtorecordthefairvalueofthewarrantsDetails" xlink:type="simple" xlink:href="selb-20210331.xsd#FairValueMeasurementsAssumptionsusedtorecordthefairvalueofthewarrantsDetails"/>
  <link:presentationLink xlink:role="http://www.selectabio.com/role/FairValueMeasurementsAssumptionsusedtorecordthefairvalueofthewarrantsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_d4421de4-6b10-4ab1-a794-8e891449b7d4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_ff779963-a589-40eb-97e1-6d09ed8d67c7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_d4421de4-6b10-4ab1-a794-8e891449b7d4" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_ff779963-a589-40eb-97e1-6d09ed8d67c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueAxis_b4e273f9-09dd-48f5-ae61-040f3b090cba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationTechniqueAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_ff779963-a589-40eb-97e1-6d09ed8d67c7" xlink:to="loc_us-gaap_ValuationTechniqueAxis_b4e273f9-09dd-48f5-ae61-040f3b090cba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDomain_8a13c155-a859-49e8-bb08-625b1e64bf19" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationTechniqueDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationTechniqueAxis_b4e273f9-09dd-48f5-ae61-040f3b090cba" xlink:to="loc_us-gaap_ValuationTechniqueDomain_8a13c155-a859-49e8-bb08-625b1e64bf19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueOptionPricingModelMember_a99a9054-de85-4844-98fc-8a215190ba1e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationTechniqueOptionPricingModelMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationTechniqueDomain_8a13c155-a859-49e8-bb08-625b1e64bf19" xlink:to="loc_us-gaap_ValuationTechniqueOptionPricingModelMember_a99a9054-de85-4844-98fc-8a215190ba1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_ee75bec8-62b8-4f19-9704-943e826dfceb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_ff779963-a589-40eb-97e1-6d09ed8d67c7" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_ee75bec8-62b8-4f19-9704-943e826dfceb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_024fed55-7fd5-4011-acaa-b6011c7f70bc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_ee75bec8-62b8-4f19-9704-943e826dfceb" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_024fed55-7fd5-4011-acaa-b6011c7f70bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_f38f996c-c9fc-4125-b373-0cc72aacfc10" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_024fed55-7fd5-4011-acaa-b6011c7f70bc" xlink:to="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_f38f996c-c9fc-4125-b373-0cc72aacfc10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedDividendRateMember_9b6b5556-fc9c-44c3-96bd-21b76ca98701" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputExpectedDividendRateMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_024fed55-7fd5-4011-acaa-b6011c7f70bc" xlink:to="loc_us-gaap_MeasurementInputExpectedDividendRateMember_9b6b5556-fc9c-44c3-96bd-21b76ca98701" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember_bfde7949-15d4-4dc5-94ee-8d4160efa1f2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_024fed55-7fd5-4011-acaa-b6011c7f70bc" xlink:to="loc_us-gaap_MeasurementInputExpectedTermMember_bfde7949-15d4-4dc5-94ee-8d4160efa1f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember_8f8ef657-a9a1-4fd0-b764-9b6dabf3294a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_024fed55-7fd5-4011-acaa-b6011c7f70bc" xlink:to="loc_us-gaap_MeasurementInputPriceVolatilityMember_8f8ef657-a9a1-4fd0-b764-9b6dabf3294a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_2773881a-5add-4d5a-9ec3-049962812cb6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_ff779963-a589-40eb-97e1-6d09ed8d67c7" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_2773881a-5add-4d5a-9ec3-049962812cb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_4ef27be2-8b02-4176-ba0d-a82f1d9b9c28" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_2773881a-5add-4d5a-9ec3-049962812cb6" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_4ef27be2-8b02-4176-ba0d-a82f1d9b9c28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_72343faf-8a29-465f-984c-7a247f45fa63" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_2773881a-5add-4d5a-9ec3-049962812cb6" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_72343faf-8a29-465f-984c-7a247f45fa63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.selectabio.com/role/FairValueMeasurementsChangeinthewarrantliabilitiesDetails" xlink:type="simple" xlink:href="selb-20210331.xsd#FairValueMeasurementsChangeinthewarrantliabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.selectabio.com/role/FairValueMeasurementsChangeinthewarrantliabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_0db00be1-4d17-4c85-b5a2-46f8012c0504" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_98fa0066-3936-4bf7-b317-277133387bfe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_0db00be1-4d17-4c85-b5a2-46f8012c0504" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_98fa0066-3936-4bf7-b317-277133387bfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_6cf207b8-1d1a-4fa6-8d11-27badf19b3e9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_98fa0066-3936-4bf7-b317-277133387bfe" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_6cf207b8-1d1a-4fa6-8d11-27badf19b3e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_5e8bda08-e18f-425d-a199-38b80a6fcab3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_6cf207b8-1d1a-4fa6-8d11-27badf19b3e9" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_5e8bda08-e18f-425d-a199-38b80a6fcab3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_fff9a5ae-9455-460a-8d40-ef09b900cf94" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_5e8bda08-e18f-425d-a199-38b80a6fcab3" xlink:to="loc_us-gaap_WarrantMember_fff9a5ae-9455-460a-8d40-ef09b900cf94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_4411b1e4-478b-4529-a1f5-a99ca1103221" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_98fa0066-3936-4bf7-b317-277133387bfe" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_4411b1e4-478b-4529-a1f5-a99ca1103221" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_54ff0a13-f6a7-4455-bf29-0ef7637aca67" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_4411b1e4-478b-4529-a1f5-a99ca1103221" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_54ff0a13-f6a7-4455-bf29-0ef7637aca67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_de5fe2d4-1cd3-4b11-ad50-342abc52bcfb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_54ff0a13-f6a7-4455-bf29-0ef7637aca67" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_de5fe2d4-1cd3-4b11-ad50-342abc52bcfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_7e231ed4-c28b-4f2a-a95a-77216bb50f9d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_54ff0a13-f6a7-4455-bf29-0ef7637aca67" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_7e231ed4-c28b-4f2a-a95a-77216bb50f9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_2046d10b-ac8c-4692-9ebd-bc47bf16a94e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_54ff0a13-f6a7-4455-bf29-0ef7637aca67" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_2046d10b-ac8c-4692-9ebd-bc47bf16a94e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.selectabio.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="simple" xlink:href="selb-20210331.xsd#FairValueMeasurementsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.selectabio.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_40a6d0c3-3bbf-4ca0-b4d7-5597c39b8b9c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet_b248e557-fc0a-4aab-8870-224ebd96d588" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_40a6d0c3-3bbf-4ca0-b4d7-5597c39b8b9c" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet_b248e557-fc0a-4aab-8870-224ebd96d588" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet_99bc29df-6e08-4aa8-a63f-a6bfdbe65c26" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_40a6d0c3-3bbf-4ca0-b4d7-5597c39b8b9c" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet_99bc29df-6e08-4aa8-a63f-a6bfdbe65c26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.selectabio.com/role/FairValueMeasurementsScheduleofCashandCashEquivalentsDetails" xlink:type="simple" xlink:href="selb-20210331.xsd#FairValueMeasurementsScheduleofCashandCashEquivalentsDetails"/>
  <link:presentationLink xlink:role="http://www.selectabio.com/role/FairValueMeasurementsScheduleofCashandCashEquivalentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_79ca1489-ce42-4b5a-9a65-bbc4bde39391" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_908dfcc1-93b7-4d92-b554-53c6243d885c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_79ca1489-ce42-4b5a-9a65-bbc4bde39391" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_908dfcc1-93b7-4d92-b554-53c6243d885c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_078a1813-1624-41a8-bf22-f9bd7ef8fba6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_79ca1489-ce42-4b5a-9a65-bbc4bde39391" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_078a1813-1624-41a8-bf22-f9bd7ef8fba6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_aef58d46-3637-4f98-a788-dccc82aa4298" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_79ca1489-ce42-4b5a-9a65-bbc4bde39391" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_aef58d46-3637-4f98-a788-dccc82aa4298" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4bfdd6a4-fb32-431a-8398-e94ed62c68ad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_79ca1489-ce42-4b5a-9a65-bbc4bde39391" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4bfdd6a4-fb32-431a-8398-e94ed62c68ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.selectabio.com/role/PropertyandEquipment" xlink:type="simple" xlink:href="selb-20210331.xsd#PropertyandEquipment"/>
  <link:presentationLink xlink:role="http://www.selectabio.com/role/PropertyandEquipment" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_4fde7717-a9e6-474b-9891-e0440b1b2b30" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_bc95cd9e-45fb-4f93-9da6-2a147eae008e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_4fde7717-a9e6-474b-9891-e0440b1b2b30" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_bc95cd9e-45fb-4f93-9da6-2a147eae008e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.selectabio.com/role/PropertyandEquipmentTables" xlink:type="simple" xlink:href="selb-20210331.xsd#PropertyandEquipmentTables"/>
  <link:presentationLink xlink:role="http://www.selectabio.com/role/PropertyandEquipmentTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_f55a9574-1a39-47c9-8cf2-955f23b69085" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_86734c46-35dd-496e-aa3b-1cdbd72a0132" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_f55a9574-1a39-47c9-8cf2-955f23b69085" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_86734c46-35dd-496e-aa3b-1cdbd72a0132" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.selectabio.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails" xlink:type="simple" xlink:href="selb-20210331.xsd#PropertyandEquipmentScheduleofPropertyandEquipmentDetails"/>
  <link:presentationLink xlink:role="http://www.selectabio.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_10c1e35c-890b-40fb-8a8c-b08b947fe89d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_ec9de67d-b44f-4c14-be2e-88a6c81f2664" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_10c1e35c-890b-40fb-8a8c-b08b947fe89d" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_ec9de67d-b44f-4c14-be2e-88a6c81f2664" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_e36c7654-2f69-4863-9657-42a2ab4df5e9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_ec9de67d-b44f-4c14-be2e-88a6c81f2664" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_e36c7654-2f69-4863-9657-42a2ab4df5e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a605bf16-4ccf-40ee-92d2-0af02a1bb1a0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_e36c7654-2f69-4863-9657-42a2ab4df5e9" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a605bf16-4ccf-40ee-92d2-0af02a1bb1a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_selb_LaboratoryEquipmentMember_0aa54772-6836-489a-af31-2351add1e314" xlink:href="selb-20210331.xsd#selb_LaboratoryEquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a605bf16-4ccf-40ee-92d2-0af02a1bb1a0" xlink:to="loc_selb_LaboratoryEquipmentMember_0aa54772-6836-489a-af31-2351add1e314" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_bf5cc10b-801f-4e78-98e8-61dc25bb3724" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a605bf16-4ccf-40ee-92d2-0af02a1bb1a0" xlink:to="loc_us-gaap_ComputerEquipmentMember_bf5cc10b-801f-4e78-98e8-61dc25bb3724" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_d2cb69b3-460d-4112-ad52-1f10d222d536" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a605bf16-4ccf-40ee-92d2-0af02a1bb1a0" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_d2cb69b3-460d-4112-ad52-1f10d222d536" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_a179350c-a481-4743-a3eb-3e5116882456" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a605bf16-4ccf-40ee-92d2-0af02a1bb1a0" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_a179350c-a481-4743-a3eb-3e5116882456" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OfficeEquipmentMember_4025cb7f-5a45-4fdd-917a-eebf8ee83f2b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OfficeEquipmentMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a605bf16-4ccf-40ee-92d2-0af02a1bb1a0" xlink:to="loc_us-gaap_OfficeEquipmentMember_4025cb7f-5a45-4fdd-917a-eebf8ee83f2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_d98174f6-38d5-45c3-afae-21a60f57c386" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a605bf16-4ccf-40ee-92d2-0af02a1bb1a0" xlink:to="loc_us-gaap_ConstructionInProgressMember_d98174f6-38d5-45c3-afae-21a60f57c386" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_6d806911-f045-4851-9ee1-9037c3e58407" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_ec9de67d-b44f-4c14-be2e-88a6c81f2664" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_6d806911-f045-4851-9ee1-9037c3e58407" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_9f3f7895-fa30-4674-a72c-e81f17df7ca4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_6d806911-f045-4851-9ee1-9037c3e58407" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_9f3f7895-fa30-4674-a72c-e81f17df7ca4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_3356190e-98a0-482f-9c18-ed236fd81b90" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_6d806911-f045-4851-9ee1-9037c3e58407" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_3356190e-98a0-482f-9c18-ed236fd81b90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_63cb6299-c5da-4396-b2c8-c98e6583ad36" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_6d806911-f045-4851-9ee1-9037c3e58407" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_63cb6299-c5da-4396-b2c8-c98e6583ad36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.selectabio.com/role/PropertyandEquipmentNarrativeDetails" xlink:type="simple" xlink:href="selb-20210331.xsd#PropertyandEquipmentNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.selectabio.com/role/PropertyandEquipmentNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_b5859b02-b8d4-43d5-bd22-c0dd9ff6a24e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_88500733-1d65-4aac-8766-50772f9befc5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_b5859b02-b8d4-43d5-bd22-c0dd9ff6a24e" xlink:to="loc_us-gaap_Depreciation_88500733-1d65-4aac-8766-50772f9befc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.selectabio.com/role/AccruedExpenses" xlink:type="simple" xlink:href="selb-20210331.xsd#AccruedExpenses"/>
  <link:presentationLink xlink:role="http://www.selectabio.com/role/AccruedExpenses" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_4fe98e35-4544-4beb-b77c-0ec9d39b1735" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_08ad2406-6f9c-44eb-a46e-6828b4a30bb5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_4fe98e35-4544-4beb-b77c-0ec9d39b1735" xlink:to="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_08ad2406-6f9c-44eb-a46e-6828b4a30bb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.selectabio.com/role/AccruedExpensesTables" xlink:type="simple" xlink:href="selb-20210331.xsd#AccruedExpensesTables"/>
  <link:presentationLink xlink:role="http://www.selectabio.com/role/AccruedExpensesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_def6b557-bb97-4ab5-98e0-098d8055a06e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_d12bb59e-d2e2-43ea-90ef-428a72aa1674" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_def6b557-bb97-4ab5-98e0-098d8055a06e" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_d12bb59e-d2e2-43ea-90ef-428a72aa1674" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.selectabio.com/role/AccruedExpensesDetails" xlink:type="simple" xlink:href="selb-20210331.xsd#AccruedExpensesDetails"/>
  <link:presentationLink xlink:role="http://www.selectabio.com/role/AccruedExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_16da8f6a-67ae-4a69-a1d1-bb0af40567af" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_bd3b6d81-c90f-42aa-9681-fda5a633aff4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_16da8f6a-67ae-4a69-a1d1-bb0af40567af" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_bd3b6d81-c90f-42aa-9681-fda5a633aff4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_selb_AccruedCollaborationandLicensing_47cca8ab-474f-4f0d-9a9f-3cfe75d217b0" xlink:href="selb-20210331.xsd#selb_AccruedCollaborationandLicensing"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_16da8f6a-67ae-4a69-a1d1-bb0af40567af" xlink:to="loc_selb_AccruedCollaborationandLicensing_47cca8ab-474f-4f0d-9a9f-3cfe75d217b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_selb_AccruedPatentFeesCurrent_21adab07-0636-4e06-b995-363ed94b842e" xlink:href="selb-20210331.xsd#selb_AccruedPatentFeesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_16da8f6a-67ae-4a69-a1d1-bb0af40567af" xlink:to="loc_selb_AccruedPatentFeesCurrent_21adab07-0636-4e06-b995-363ed94b842e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_selb_AccruedResearchAndDevelopmentCostsCurrent_5f24cffc-fb3d-4227-8c79-21138944c7a3" xlink:href="selb-20210331.xsd#selb_AccruedResearchAndDevelopmentCostsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_16da8f6a-67ae-4a69-a1d1-bb0af40567af" xlink:to="loc_selb_AccruedResearchAndDevelopmentCostsCurrent_5f24cffc-fb3d-4227-8c79-21138944c7a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_selb_AccruedAuditFeesCurrent_4bab8736-79af-4016-878b-b460d841ff80" xlink:href="selb-20210331.xsd#selb_AccruedAuditFeesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_16da8f6a-67ae-4a69-a1d1-bb0af40567af" xlink:to="loc_selb_AccruedAuditFeesCurrent_4bab8736-79af-4016-878b-b460d841ff80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_selb_AccruedInterestCurrent_7efef7fb-4416-4136-a29c-048c14a5704b" xlink:href="selb-20210331.xsd#selb_AccruedInterestCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_16da8f6a-67ae-4a69-a1d1-bb0af40567af" xlink:to="loc_selb_AccruedInterestCurrent_7efef7fb-4416-4136-a29c-048c14a5704b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_10c53141-f72e-4619-8fc1-2844bf13cd65" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_16da8f6a-67ae-4a69-a1d1-bb0af40567af" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_10c53141-f72e-4619-8fc1-2844bf13cd65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_e3c6ef7f-52fc-4eda-9ab4-9bbb6f8e650a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_16da8f6a-67ae-4a69-a1d1-bb0af40567af" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_e3c6ef7f-52fc-4eda-9ab4-9bbb6f8e650a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.selectabio.com/role/Leases" xlink:type="simple" xlink:href="selb-20210331.xsd#Leases"/>
  <link:presentationLink xlink:role="http://www.selectabio.com/role/Leases" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_78f1ffcc-ed08-4d90-b5b8-43fcd03a4b65" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_e0a2cca0-a46f-43ef-888d-24be87a825b5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_78f1ffcc-ed08-4d90-b5b8-43fcd03a4b65" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_e0a2cca0-a46f-43ef-888d-24be87a825b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.selectabio.com/role/LeasesTables" xlink:type="simple" xlink:href="selb-20210331.xsd#LeasesTables"/>
  <link:presentationLink xlink:role="http://www.selectabio.com/role/LeasesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_22bff053-a5cf-4bb3-985c-d1313992ee3a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_selb_LesseeComponentsOfOperatingLeaseTableTextBlock_af1cd61d-4f4e-417c-b89f-cef18a0f9db5" xlink:href="selb-20210331.xsd#selb_LesseeComponentsOfOperatingLeaseTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_22bff053-a5cf-4bb3-985c-d1313992ee3a" xlink:to="loc_selb_LesseeComponentsOfOperatingLeaseTableTextBlock_af1cd61d-4f4e-417c-b89f-cef18a0f9db5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_482b0f71-bd10-4594-aff5-e1a979897e2c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_22bff053-a5cf-4bb3-985c-d1313992ee3a" xlink:to="loc_us-gaap_LeaseCostTableTextBlock_482b0f71-bd10-4594-aff5-e1a979897e2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_20e18202-06b0-4dce-8412-d7ed525a1fa2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_22bff053-a5cf-4bb3-985c-d1313992ee3a" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_20e18202-06b0-4dce-8412-d7ed525a1fa2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLeaseIncomeTableTextBlock_0c52c232-b5cc-4024-9783-cdc8994b50d1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLeaseIncomeTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_22bff053-a5cf-4bb3-985c-d1313992ee3a" xlink:to="loc_us-gaap_OperatingLeaseLeaseIncomeTableTextBlock_0c52c232-b5cc-4024-9783-cdc8994b50d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.selectabio.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="selb-20210331.xsd#LeasesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.selectabio.com/role/LeasesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_e271ffc1-1016-4cd3-ba1a-1aa1847ad534" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_38b038f6-faca-4928-8ff2-002ffba718d8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_e271ffc1-1016-4cd3-ba1a-1aa1847ad534" xlink:to="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_38b038f6-faca-4928-8ff2-002ffba718d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_962026ae-a0d7-4f5e-8c12-fbed6b01369d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_38b038f6-faca-4928-8ff2-002ffba718d8" xlink:to="loc_us-gaap_CreditFacilityAxis_962026ae-a0d7-4f5e-8c12-fbed6b01369d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_79b0bff6-8467-4812-9395-e417cf5e2e74" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_962026ae-a0d7-4f5e-8c12-fbed6b01369d" xlink:to="loc_us-gaap_CreditFacilityDomain_79b0bff6-8467-4812-9395-e417cf5e2e74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LetterOfCreditMember_8a7e49df-0581-4487-8b29-7c9578e3f7c7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LetterOfCreditMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_79b0bff6-8467-4812-9395-e417cf5e2e74" xlink:to="loc_us-gaap_LetterOfCreditMember_8a7e49df-0581-4487-8b29-7c9578e3f7c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_selb_LeaseArrangementAxis_ac228599-a427-46d9-a3d6-154af4581178" xlink:href="selb-20210331.xsd#selb_LeaseArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_38b038f6-faca-4928-8ff2-002ffba718d8" xlink:to="loc_selb_LeaseArrangementAxis_ac228599-a427-46d9-a3d6-154af4581178" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_selb_LeaseArrangementDomain_e95e1981-3e3a-49b2-903f-a348040ae7a1" xlink:href="selb-20210331.xsd#selb_LeaseArrangementDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_selb_LeaseArrangementAxis_ac228599-a427-46d9-a3d6-154af4581178" xlink:to="loc_selb_LeaseArrangementDomain_e95e1981-3e3a-49b2-903f-a348040ae7a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_selb_A65GroveStreetWatertownMAMember_83247cf2-9b91-4bee-a546-300ffa41908a" xlink:href="selb-20210331.xsd#selb_A65GroveStreetWatertownMAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_selb_LeaseArrangementDomain_e95e1981-3e3a-49b2-903f-a348040ae7a1" xlink:to="loc_selb_A65GroveStreetWatertownMAMember_83247cf2-9b91-4bee-a546-300ffa41908a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasedAssetsLineItems_52f80fe4-902f-43c2-86e5-2f795bdca869" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasedAssetsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_38b038f6-faca-4928-8ff2-002ffba718d8" xlink:to="loc_us-gaap_OperatingLeasedAssetsLineItems_52f80fe4-902f-43c2-86e5-2f795bdca869" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AreaOfRealEstateProperty_9ac915d2-9194-4582-a6c8-ff69ae53fa56" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AreaOfRealEstateProperty"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_52f80fe4-902f-43c2-86e5-2f795bdca869" xlink:to="loc_us-gaap_AreaOfRealEstateProperty_9ac915d2-9194-4582-a6c8-ff69ae53fa56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_444ac8c5-8e04-4fd3-bd63-d85496e9bcf5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_52f80fe4-902f-43c2-86e5-2f795bdca869" xlink:to="loc_us-gaap_LeaseCost_444ac8c5-8e04-4fd3-bd63-d85496e9bcf5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_909dd12d-a6c0-4727-96f3-81986df4b609" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_52f80fe4-902f-43c2-86e5-2f795bdca869" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_909dd12d-a6c0-4727-96f3-81986df4b609" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_287eb75a-6ce3-4aba-9a3c-1775cb5d47c7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_52f80fe4-902f-43c2-86e5-2f795bdca869" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_287eb75a-6ce3-4aba-9a3c-1775cb5d47c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_ba3dbb86-fb82-45ae-9335-b109174818d2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_52f80fe4-902f-43c2-86e5-2f795bdca869" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_ba3dbb86-fb82-45ae-9335-b109174818d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.selectabio.com/role/LeasesComponentsofOperatingLeasesDetails" xlink:type="simple" xlink:href="selb-20210331.xsd#LeasesComponentsofOperatingLeasesDetails"/>
  <link:presentationLink xlink:role="http://www.selectabio.com/role/LeasesComponentsofOperatingLeasesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_291c2e97-3692-4a6c-a809-5163e5370eef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_cdd21801-059f-4b4a-85bd-5cca2112cdcb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_291c2e97-3692-4a6c-a809-5163e5370eef" xlink:to="loc_us-gaap_AssetsAbstract_cdd21801-059f-4b4a-85bd-5cca2112cdcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_dde17acd-6d9b-4b3c-8787-318c37fba36f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_cdd21801-059f-4b4a-85bd-5cca2112cdcb" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_dde17acd-6d9b-4b3c-8787-318c37fba36f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAbstract_b7f606ae-8d93-4967-926b-d4f9c433381c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_291c2e97-3692-4a6c-a809-5163e5370eef" xlink:to="loc_us-gaap_LiabilitiesAbstract_b7f606ae-8d93-4967-926b-d4f9c433381c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_d30143ac-095b-49d3-bb1c-c4b494c516fc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_b7f606ae-8d93-4967-926b-d4f9c433381c" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_d30143ac-095b-49d3-bb1c-c4b494c516fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_10f98da8-ea42-4a2f-9641-6a952628e0bc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_b7f606ae-8d93-4967-926b-d4f9c433381c" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_10f98da8-ea42-4a2f-9641-6a952628e0bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_448d0efb-6a29-49b0-a057-64a67d1bc4fd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_b7f606ae-8d93-4967-926b-d4f9c433381c" xlink:to="loc_us-gaap_OperatingLeaseLiability_448d0efb-6a29-49b0-a057-64a67d1bc4fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.selectabio.com/role/LeasesComponentsofleasecostsDetails" xlink:type="simple" xlink:href="selb-20210331.xsd#LeasesComponentsofleasecostsDetails"/>
  <link:presentationLink xlink:role="http://www.selectabio.com/role/LeasesComponentsofleasecostsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_6a7195ee-187f-4700-aa6a-ac6a389bb3fa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_3bbe1783-96e7-4d2c-8387-bf51b06838dc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_6a7195ee-187f-4700-aa6a-ac6a389bb3fa" xlink:to="loc_us-gaap_OperatingLeaseCost_3bbe1783-96e7-4d2c-8387-bf51b06838dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost_bef9c6c9-b208-40a1-b591-49b085d481d6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableLeaseCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_6a7195ee-187f-4700-aa6a-ac6a389bb3fa" xlink:to="loc_us-gaap_VariableLeaseCost_bef9c6c9-b208-40a1-b591-49b085d481d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermLeaseCost_a395cda5-e5bb-42f0-82a6-5286c45c71cb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermLeaseCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_6a7195ee-187f-4700-aa6a-ac6a389bb3fa" xlink:to="loc_us-gaap_ShortTermLeaseCost_a395cda5-e5bb-42f0-82a6-5286c45c71cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_daab7dc0-4998-443d-82e2-5c8acb76ee34" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCost"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_6a7195ee-187f-4700-aa6a-ac6a389bb3fa" xlink:to="loc_us-gaap_LeaseCost_daab7dc0-4998-443d-82e2-5c8acb76ee34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.selectabio.com/role/LeasesOperatingLeaseLiabilityMaturityDetails" xlink:type="simple" xlink:href="selb-20210331.xsd#LeasesOperatingLeaseLiabilityMaturityDetails"/>
  <link:presentationLink xlink:role="http://www.selectabio.com/role/LeasesOperatingLeaseLiabilityMaturityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_c4789754-82ff-4ab6-ad4c-cbf07ef7a585" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_e4da3531-09e5-4774-be55-6af632e2addb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_c4789754-82ff-4ab6-ad4c-cbf07ef7a585" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_e4da3531-09e5-4774-be55-6af632e2addb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_081dde0c-f259-45fe-bd79-c9c7fb8154cf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_c4789754-82ff-4ab6-ad4c-cbf07ef7a585" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_081dde0c-f259-45fe-bd79-c9c7fb8154cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_09a8cbfe-3aaa-48fe-82dc-2d28feccb032" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_c4789754-82ff-4ab6-ad4c-cbf07ef7a585" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_09a8cbfe-3aaa-48fe-82dc-2d28feccb032" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_eb30ba93-9684-4a7f-9313-753540be53ae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_c4789754-82ff-4ab6-ad4c-cbf07ef7a585" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_eb30ba93-9684-4a7f-9313-753540be53ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_b413ff4e-7584-4a6c-b71e-d5908930274a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_c4789754-82ff-4ab6-ad4c-cbf07ef7a585" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_b413ff4e-7584-4a6c-b71e-d5908930274a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_selb_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_eab63357-21c9-43ce-b1aa-d721a6362af6" xlink:href="selb-20210331.xsd#selb_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_c4789754-82ff-4ab6-ad4c-cbf07ef7a585" xlink:to="loc_selb_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_eab63357-21c9-43ce-b1aa-d721a6362af6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2651dc7e-04d0-4574-bfca-7059bd615850" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_c4789754-82ff-4ab6-ad4c-cbf07ef7a585" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2651dc7e-04d0-4574-bfca-7059bd615850" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_1b24f4f6-4aed-4f4a-831a-aafb39075fe3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_c4789754-82ff-4ab6-ad4c-cbf07ef7a585" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_1b24f4f6-4aed-4f4a-831a-aafb39075fe3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_bae5c4b8-87c4-4b54-838a-f867f62079bc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_c4789754-82ff-4ab6-ad4c-cbf07ef7a585" xlink:to="loc_us-gaap_OperatingLeaseLiability_bae5c4b8-87c4-4b54-838a-f867f62079bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.selectabio.com/role/LeasesOperatingLeaseLiabilityMaturityDetails_1" xlink:type="simple" xlink:href="selb-20210331.xsd#LeasesOperatingLeaseLiabilityMaturityDetails_1"/>
  <link:presentationLink xlink:role="http://www.selectabio.com/role/LeasesOperatingLeaseLiabilityMaturityDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.selectabio.com/role/LeasesOtherInformationDetails" xlink:type="simple" xlink:href="selb-20210331.xsd#LeasesOtherInformationDetails"/>
  <link:presentationLink xlink:role="http://www.selectabio.com/role/LeasesOtherInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_63797d7f-f26e-4aa6-9e36-a69436ae0069" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_db911af1-5491-4c0b-b0fd-1b35da9efd5e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_63797d7f-f26e-4aa6-9e36-a69436ae0069" xlink:to="loc_us-gaap_OperatingLeasePayments_db911af1-5491-4c0b-b0fd-1b35da9efd5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.selectabio.com/role/LeasesLeaseTermandDiscountRateDetails" xlink:type="simple" xlink:href="selb-20210331.xsd#LeasesLeaseTermandDiscountRateDetails"/>
  <link:presentationLink xlink:role="http://www.selectabio.com/role/LeasesLeaseTermandDiscountRateDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_7c802461-d703-48d3-a2e7-c1e2cf56bc36" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_11b550c4-61fd-40ba-9276-170bc5e49a9e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_7c802461-d703-48d3-a2e7-c1e2cf56bc36" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_11b550c4-61fd-40ba-9276-170bc5e49a9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_66571aa4-50d6-4e30-97ab-ed71bf829821" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_7c802461-d703-48d3-a2e7-c1e2cf56bc36" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_66571aa4-50d6-4e30-97ab-ed71bf829821" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.selectabio.com/role/Debt" xlink:type="simple" xlink:href="selb-20210331.xsd#Debt"/>
  <link:presentationLink xlink:role="http://www.selectabio.com/role/Debt" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_ec2c2d3f-32e3-484c-8430-744f91856a21" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_2066c4f7-ac64-442e-ba2b-4d5e7fd8bad6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_ec2c2d3f-32e3-484c-8430-744f91856a21" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_2066c4f7-ac64-442e-ba2b-4d5e7fd8bad6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.selectabio.com/role/DebtTables" xlink:type="simple" xlink:href="selb-20210331.xsd#DebtTables"/>
  <link:presentationLink xlink:role="http://www.selectabio.com/role/DebtTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_a25dd4a2-f2aa-4f82-ae63-f3283909849c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_9397d5ea-d830-4952-bb99-7b635f94e156" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_a25dd4a2-f2aa-4f82-ae63-f3283909849c" xlink:to="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_9397d5ea-d830-4952-bb99-7b635f94e156" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.selectabio.com/role/DebtTermLoansNarrativeDetails" xlink:type="simple" xlink:href="selb-20210331.xsd#DebtTermLoansNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.selectabio.com/role/DebtTermLoansNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_393e25f4-c03b-4d03-8521-01fbe619716f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityTable_9e24c1a2-4036-47c0-bef4-a6468fd0e8a0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_393e25f4-c03b-4d03-8521-01fbe619716f" xlink:to="loc_us-gaap_LineOfCreditFacilityTable_9e24c1a2-4036-47c0-bef4-a6468fd0e8a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_474f757b-3f78-418f-804f-9fc9f92751f9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_9e24c1a2-4036-47c0-bef4-a6468fd0e8a0" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_474f757b-3f78-418f-804f-9fc9f92751f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_c32fcd1b-cee7-4406-b35f-4cb1f262b2d1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_474f757b-3f78-418f-804f-9fc9f92751f9" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_c32fcd1b-cee7-4406-b35f-4cb1f262b2d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember_e2e50c22-d9c9-4210-aaf9-f40865963b6c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_c32fcd1b-cee7-4406-b35f-4cb1f262b2d1" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember_e2e50c22-d9c9-4210-aaf9-f40865963b6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_e0502ac7-c5ec-4de1-8ad9-fb100e7abfe0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_c32fcd1b-cee7-4406-b35f-4cb1f262b2d1" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_e0502ac7-c5ec-4de1-8ad9-fb100e7abfe0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodThreeMember_f7a27130-e975-44de-8e17-3b07db5d5fca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodThreeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_c32fcd1b-cee7-4406-b35f-4cb1f262b2d1" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodThreeMember_f7a27130-e975-44de-8e17-3b07db5d5fca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_97f3ffff-6190-4e60-b8f5-1fa9a86c94d8" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_9e24c1a2-4036-47c0-bef4-a6468fd0e8a0" xlink:to="loc_srt_RangeAxis_97f3ffff-6190-4e60-b8f5-1fa9a86c94d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_216ba1eb-081f-4966-befe-05d40283d9ce" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_97f3ffff-6190-4e60-b8f5-1fa9a86c94d8" xlink:to="loc_srt_RangeMember_216ba1eb-081f-4966-befe-05d40283d9ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_dae8c7d7-8880-4931-9ce0-1a52402bb9a9" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_216ba1eb-081f-4966-befe-05d40283d9ce" xlink:to="loc_srt_MaximumMember_dae8c7d7-8880-4931-9ce0-1a52402bb9a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_916cac58-6d92-4959-a41d-ce9b96efeea3" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_216ba1eb-081f-4966-befe-05d40283d9ce" xlink:to="loc_srt_MinimumMember_916cac58-6d92-4959-a41d-ce9b96efeea3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_4ac1dd98-03ed-425d-900e-1aac2cb01b71" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_9e24c1a2-4036-47c0-bef4-a6468fd0e8a0" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_4ac1dd98-03ed-425d-900e-1aac2cb01b71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_144c3662-d39c-4ca4-aa4f-89de274459c5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_4ac1dd98-03ed-425d-900e-1aac2cb01b71" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_144c3662-d39c-4ca4-aa4f-89de274459c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_5b766e30-290b-4b80-bc00-be6e12071945" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_144c3662-d39c-4ca4-aa4f-89de274459c5" xlink:to="loc_us-gaap_WarrantMember_5b766e30-290b-4b80-bc00-be6e12071945" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_3bf4dc3c-3a86-433a-8723-ec29a7ff6141" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_9e24c1a2-4036-47c0-bef4-a6468fd0e8a0" xlink:to="loc_us-gaap_VariableRateAxis_3bf4dc3c-3a86-433a-8723-ec29a7ff6141" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_383e409d-12f9-45e8-9bde-be29b4603680" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateAxis_3bf4dc3c-3a86-433a-8723-ec29a7ff6141" xlink:to="loc_us-gaap_VariableRateDomain_383e409d-12f9-45e8-9bde-be29b4603680" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_fe41fcf9-2a1c-4022-ac55-8110ee8b0146" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_9e24c1a2-4036-47c0-bef4-a6468fd0e8a0" xlink:to="loc_us-gaap_CreditFacilityAxis_fe41fcf9-2a1c-4022-ac55-8110ee8b0146" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_716cb8ab-85a5-4b55-9638-0f03ceef01e1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_fe41fcf9-2a1c-4022-ac55-8110ee8b0146" xlink:to="loc_us-gaap_CreditFacilityDomain_716cb8ab-85a5-4b55-9638-0f03ceef01e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_selb_A2020TermLoansMember_442e45e3-7d08-44a3-869b-0955d831d913" xlink:href="selb-20210331.xsd#selb_A2020TermLoansMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_716cb8ab-85a5-4b55-9638-0f03ceef01e1" xlink:to="loc_selb_A2020TermLoansMember_442e45e3-7d08-44a3-869b-0955d831d913" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_selb_TermALoansMember_b50822df-c5de-4729-b30e-4136be8edd22" xlink:href="selb-20210331.xsd#selb_TermALoansMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_716cb8ab-85a5-4b55-9638-0f03ceef01e1" xlink:to="loc_selb_TermALoansMember_b50822df-c5de-4729-b30e-4136be8edd22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_selb_TermBLoansMember_1c44e817-31a6-4089-abba-ac0de9036a90" xlink:href="selb-20210331.xsd#selb_TermBLoansMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_716cb8ab-85a5-4b55-9638-0f03ceef01e1" xlink:to="loc_selb_TermBLoansMember_1c44e817-31a6-4089-abba-ac0de9036a90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_selb_A2017TermLoansMember_dfb62734-cc9b-4dc2-9430-30094c86e2b6" xlink:href="selb-20210331.xsd#selb_A2017TermLoansMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_716cb8ab-85a5-4b55-9638-0f03ceef01e1" xlink:to="loc_selb_A2017TermLoansMember_dfb62734-cc9b-4dc2-9430-30094c86e2b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLineItems_e934e44e-3033-4259-a907-ae59676a994b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_9e24c1a2-4036-47c0-bef4-a6468fd0e8a0" xlink:to="loc_us-gaap_LineOfCreditFacilityLineItems_e934e44e-3033-4259-a907-ae59676a994b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_38b5c08f-dd31-4045-a89a-3772e3810821" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_e934e44e-3033-4259-a907-ae59676a994b" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_38b5c08f-dd31-4045-a89a-3772e3810821" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_c8be113f-f637-4adb-a270-40be276e0b30" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_e934e44e-3033-4259-a907-ae59676a994b" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_c8be113f-f637-4adb-a270-40be276e0b30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_selb_DebtInstrumentPrepaymentFeePercentage_5a493648-1e90-464b-8992-f45cacdec48b" xlink:href="selb-20210331.xsd#selb_DebtInstrumentPrepaymentFeePercentage"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_e934e44e-3033-4259-a907-ae59676a994b" xlink:to="loc_selb_DebtInstrumentPrepaymentFeePercentage_5a493648-1e90-464b-8992-f45cacdec48b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_selb_DebtInstrumentAdditionalAccruedInterestInTheEventOfDefault_d9a37a99-7d6a-4c31-ac19-496f8995715a" xlink:href="selb-20210331.xsd#selb_DebtInstrumentAdditionalAccruedInterestInTheEventOfDefault"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_e934e44e-3033-4259-a907-ae59676a994b" xlink:to="loc_selb_DebtInstrumentAdditionalAccruedInterestInTheEventOfDefault_d9a37a99-7d6a-4c31-ac19-496f8995715a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed_2fbd25c2-331d-4679-92a2-6e9947f8130c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_e934e44e-3033-4259-a907-ae59676a994b" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed_2fbd25c2-331d-4679-92a2-6e9947f8130c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid_96a23626-5f7a-459f-91ab-3a53456ffdef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_e934e44e-3033-4259-a907-ae59676a994b" xlink:to="loc_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid_96a23626-5f7a-459f-91ab-3a53456ffdef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_selb_DebtInstrumentDefaultBankruptcyOrInsolvencyValueOfTriggeringAcceleratedRedemption_e0716f04-334a-49d9-a073-d760b3ae8eb1" xlink:href="selb-20210331.xsd#selb_DebtInstrumentDefaultBankruptcyOrInsolvencyValueOfTriggeringAcceleratedRedemption"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_e934e44e-3033-4259-a907-ae59676a994b" xlink:to="loc_selb_DebtInstrumentDefaultBankruptcyOrInsolvencyValueOfTriggeringAcceleratedRedemption_e0716f04-334a-49d9-a073-d760b3ae8eb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet_f6c7d998-f290-45fa-93ae-dee80acafb21" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_e934e44e-3033-4259-a907-ae59676a994b" xlink:to="loc_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet_f6c7d998-f290-45fa-93ae-dee80acafb21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_3a9755dc-6942-496e-b51d-c60e8d8d8dd4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_e934e44e-3033-4259-a907-ae59676a994b" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_3a9755dc-6942-496e-b51d-c60e8d8d8dd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_8efdd457-7e3e-4287-80b0-3c51f9c63237" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_e934e44e-3033-4259-a907-ae59676a994b" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_8efdd457-7e3e-4287-80b0-3c51f9c63237" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_selb_ClassOfWarrantOrRightExpirationPeriod_7babf404-5c5c-43e6-8780-13c60f593196" xlink:href="selb-20210331.xsd#selb_ClassOfWarrantOrRightExpirationPeriod"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_e934e44e-3033-4259-a907-ae59676a994b" xlink:to="loc_selb_ClassOfWarrantOrRightExpirationPeriod_7babf404-5c5c-43e6-8780-13c60f593196" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_1c38720b-558d-4a31-874d-fd572452dcef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_e934e44e-3033-4259-a907-ae59676a994b" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_1c38720b-558d-4a31-874d-fd572452dcef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_48976f70-e7e7-45d8-935b-df47555f4a40" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_e934e44e-3033-4259-a907-ae59676a994b" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_48976f70-e7e7-45d8-935b-df47555f4a40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLinesOfCredit_c34537a5-82a2-4282-b738-fd4bf3d1d709" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfLinesOfCredit"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_e934e44e-3033-4259-a907-ae59676a994b" xlink:to="loc_us-gaap_RepaymentsOfLinesOfCredit_c34537a5-82a2-4282-b738-fd4bf3d1d709" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_2c6e3cef-d21c-42c9-80d6-58454df44939" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_e934e44e-3033-4259-a907-ae59676a994b" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_2c6e3cef-d21c-42c9-80d6-58454df44939" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCredit_71961dff-996d-4506-bdd9-131e9fdde71f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCredit"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_e934e44e-3033-4259-a907-ae59676a994b" xlink:to="loc_us-gaap_LineOfCredit_71961dff-996d-4506-bdd9-131e9fdde71f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.selectabio.com/role/DebtScheduleofFutureMinimumPaymentsontheTermLoansDetails" xlink:type="simple" xlink:href="selb-20210331.xsd#DebtScheduleofFutureMinimumPaymentsontheTermLoansDetails"/>
  <link:presentationLink xlink:role="http://www.selectabio.com/role/DebtScheduleofFutureMinimumPaymentsontheTermLoansDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_50f203f7-1965-4143-a8eb-105824a83c23" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityTable_7f55734b-673e-4953-a265-813e3aaa3326" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_50f203f7-1965-4143-a8eb-105824a83c23" xlink:to="loc_us-gaap_LineOfCreditFacilityTable_7f55734b-673e-4953-a265-813e3aaa3326" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_94dec011-5bac-4e09-9a8f-d2347c570444" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_7f55734b-673e-4953-a265-813e3aaa3326" xlink:to="loc_us-gaap_CreditFacilityAxis_94dec011-5bac-4e09-9a8f-d2347c570444" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_c0e14bd6-0168-4490-9f5b-40bff1278aeb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_94dec011-5bac-4e09-9a8f-d2347c570444" xlink:to="loc_us-gaap_CreditFacilityDomain_c0e14bd6-0168-4490-9f5b-40bff1278aeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_selb_A2017TermLoansMember_b3d5a0d5-e0b3-4718-815c-4852e4ec7cef" xlink:href="selb-20210331.xsd#selb_A2017TermLoansMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_c0e14bd6-0168-4490-9f5b-40bff1278aeb" xlink:to="loc_selb_A2017TermLoansMember_b3d5a0d5-e0b3-4718-815c-4852e4ec7cef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLineItems_fcc9f68c-1a1c-406b-bcfd-51aec978637a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_7f55734b-673e-4953-a265-813e3aaa3326" xlink:to="loc_us-gaap_LineOfCreditFacilityLineItems_fcc9f68c-1a1c-406b-bcfd-51aec978637a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtByMaturityAbstract_fd452715-04ee-4e0e-ba81-6545eeb2f2ea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtByMaturityAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_fcc9f68c-1a1c-406b-bcfd-51aec978637a" xlink:to="loc_us-gaap_LongTermDebtByMaturityAbstract_fd452715-04ee-4e0e-ba81-6545eeb2f2ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_b480454d-6ad1-4242-8fed-ff2065b92f3f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_fd452715-04ee-4e0e-ba81-6545eeb2f2ea" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_b480454d-6ad1-4242-8fed-ff2065b92f3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_09951dc6-d2d5-4b33-8de5-e6fb371dfd87" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_fd452715-04ee-4e0e-ba81-6545eeb2f2ea" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_09951dc6-d2d5-4b33-8de5-e6fb371dfd87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_747893e9-91c6-4fc3-8704-71b5ea8a3b64" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_fd452715-04ee-4e0e-ba81-6545eeb2f2ea" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_747893e9-91c6-4fc3-8704-71b5ea8a3b64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_28b40852-3dae-43e8-a60c-aa9a3052cb17" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_fd452715-04ee-4e0e-ba81-6545eeb2f2ea" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_28b40852-3dae-43e8-a60c-aa9a3052cb17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_134b245a-9c36-49ec-8113-da22e55c3a35" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_fd452715-04ee-4e0e-ba81-6545eeb2f2ea" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_134b245a-9c36-49ec-8113-da22e55c3a35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_b2c0416e-220e-4f97-a712-b75b68f35b5e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_fd452715-04ee-4e0e-ba81-6545eeb2f2ea" xlink:to="loc_us-gaap_LongTermDebt_b2c0416e-220e-4f97-a712-b75b68f35b5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_selb_DebtInstrumentInterestPortion_dc9b8837-6345-41ae-aa82-bed0c0065d80" xlink:href="selb-20210331.xsd#selb_DebtInstrumentInterestPortion"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_fd452715-04ee-4e0e-ba81-6545eeb2f2ea" xlink:to="loc_selb_DebtInstrumentInterestPortion_dc9b8837-6345-41ae-aa82-bed0c0065d80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_391213fa-d883-4327-b572-cd7c570b5c39" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_fd452715-04ee-4e0e-ba81-6545eeb2f2ea" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_391213fa-d883-4327-b572-cd7c570b5c39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_0dc31e56-bf5f-4ffa-8b8b-4117422d8cb2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_fd452715-04ee-4e0e-ba81-6545eeb2f2ea" xlink:to="loc_us-gaap_LongTermDebtCurrent_0dc31e56-bf5f-4ffa-8b8b-4117422d8cb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_51052656-8442-4f47-b759-91d7b1c47bfe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_fd452715-04ee-4e0e-ba81-6545eeb2f2ea" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_51052656-8442-4f47-b759-91d7b1c47bfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.selectabio.com/role/Equity" xlink:type="simple" xlink:href="selb-20210331.xsd#Equity"/>
  <link:presentationLink xlink:role="http://www.selectabio.com/role/Equity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_2ab97726-7828-45ff-9407-9caad2aa5261" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_ae632589-19b2-4b18-b1a3-89ca7c040e23" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_2ab97726-7828-45ff-9407-9caad2aa5261" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_ae632589-19b2-4b18-b1a3-89ca7c040e23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.selectabio.com/role/EquityTables" xlink:type="simple" xlink:href="selb-20210331.xsd#EquityTables"/>
  <link:presentationLink xlink:role="http://www.selectabio.com/role/EquityTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_49392349-0d10-470b-a939-df194983493d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_58bfb4f9-493f-4954-8305-2f337fb507e2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_49392349-0d10-470b-a939-df194983493d" xlink:to="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_58bfb4f9-493f-4954-8305-2f337fb507e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTextBlock_e03830fd-1e08-4267-91fe-4aa181c5fcd9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_49392349-0d10-470b-a939-df194983493d" xlink:to="loc_us-gaap_ScheduleOfStockByClassTextBlock_e03830fd-1e08-4267-91fe-4aa181c5fcd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.selectabio.com/role/EquityNarrativeDetails" xlink:type="simple" xlink:href="selb-20210331.xsd#EquityNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.selectabio.com/role/EquityNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_b6401b8a-0358-4211-aa04-5631743b69e8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_6bece56e-5316-4336-828b-294cf13e3e77" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_b6401b8a-0358-4211-aa04-5631743b69e8" xlink:to="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_6bece56e-5316-4336-828b-294cf13e3e77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_8e484a92-8a86-4878-867e-62a00ecf19b9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_6bece56e-5316-4336-828b-294cf13e3e77" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_8e484a92-8a86-4878-867e-62a00ecf19b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_d079f237-3b78-42a5-8436-7fa944d2ccdd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_8e484a92-8a86-4878-867e-62a00ecf19b9" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_d079f237-3b78-42a5-8436-7fa944d2ccdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_selb_August2020ShelfRegistrationStatementMember_039f208c-0641-4fcc-a3e6-8654d94431a2" xlink:href="selb-20210331.xsd#selb_August2020ShelfRegistrationStatementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_d079f237-3b78-42a5-8436-7fa944d2ccdd" xlink:to="loc_selb_August2020ShelfRegistrationStatementMember_039f208c-0641-4fcc-a3e6-8654d94431a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_selb_AtTheMarketOfferingMember_f5b342c8-7abd-4600-b17b-e2a81d13d40e" xlink:href="selb-20210331.xsd#selb_AtTheMarketOfferingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_d079f237-3b78-42a5-8436-7fa944d2ccdd" xlink:to="loc_selb_AtTheMarketOfferingMember_f5b342c8-7abd-4600-b17b-e2a81d13d40e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_selb_A2020SaleAgreementAtTheMarketOfferingMember_800e1f55-0c2f-4059-9eb8-e7a777d8d552" xlink:href="selb-20210331.xsd#selb_A2020SaleAgreementAtTheMarketOfferingMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_d079f237-3b78-42a5-8436-7fa944d2ccdd" xlink:to="loc_selb_A2020SaleAgreementAtTheMarketOfferingMember_800e1f55-0c2f-4059-9eb8-e7a777d8d552" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_selb_SOBIPurchaseAgreementMember_289d4773-8736-437b-8f80-69d789baf75d" xlink:href="selb-20210331.xsd#selb_SOBIPurchaseAgreementMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_d079f237-3b78-42a5-8436-7fa944d2ccdd" xlink:to="loc_selb_SOBIPurchaseAgreementMember_289d4773-8736-437b-8f80-69d789baf75d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_selb_DecemberTwoThousandNineteenFinancingMember_a7eafa58-822f-4644-83a3-95e2f51b06f0" xlink:href="selb-20210331.xsd#selb_DecemberTwoThousandNineteenFinancingMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_d079f237-3b78-42a5-8436-7fa944d2ccdd" xlink:to="loc_selb_DecemberTwoThousandNineteenFinancingMember_a7eafa58-822f-4644-83a3-95e2f51b06f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_selb_A2017PIPEMember_b42d1e80-b5ae-4677-9bf4-718fdcc0d49e" xlink:href="selb-20210331.xsd#selb_A2017PIPEMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_d079f237-3b78-42a5-8436-7fa944d2ccdd" xlink:to="loc_selb_A2017PIPEMember_b42d1e80-b5ae-4677-9bf4-718fdcc0d49e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_36ac1437-b253-4b46-a3d5-fb2be2dbfa38" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_d079f237-3b78-42a5-8436-7fa944d2ccdd" xlink:to="loc_us-gaap_WarrantMember_36ac1437-b253-4b46-a3d5-fb2be2dbfa38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_316215db-57b2-451f-a981-db0601570fb5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_6bece56e-5316-4336-828b-294cf13e3e77" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_316215db-57b2-451f-a981-db0601570fb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_fa311819-cc24-4e54-ad75-d5a534cfd3cb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_316215db-57b2-451f-a981-db0601570fb5" xlink:to="loc_us-gaap_EquityComponentDomain_fa311819-cc24-4e54-ad75-d5a534cfd3cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_selb_PreFundedWarrantMember_c4cd46ff-8d2f-444b-8c5a-a87ccfea04c4" xlink:href="selb-20210331.xsd#selb_PreFundedWarrantMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_fa311819-cc24-4e54-ad75-d5a534cfd3cb" xlink:to="loc_selb_PreFundedWarrantMember_c4cd46ff-8d2f-444b-8c5a-a87ccfea04c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_b829a7c5-eaec-449b-84a0-8cd9d95413ea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_fa311819-cc24-4e54-ad75-d5a534cfd3cb" xlink:to="loc_us-gaap_WarrantMember_b829a7c5-eaec-449b-84a0-8cd9d95413ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_selb_CommonWarrantMember_a934c4f4-4517-4dca-9f4e-c54e7214249c" xlink:href="selb-20210331.xsd#selb_CommonWarrantMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_fa311819-cc24-4e54-ad75-d5a534cfd3cb" xlink:to="loc_selb_CommonWarrantMember_a934c4f4-4517-4dca-9f4e-c54e7214249c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems_aa482f4f-3611-424c-8240-d9ae53baf02b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_6bece56e-5316-4336-828b-294cf13e3e77" xlink:to="loc_us-gaap_SubsidiarySaleOfStockLineItems_aa482f4f-3611-424c-8240-d9ae53baf02b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_5082405d-aa1d-4a21-8d75-edc002b32bd5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_aa482f4f-3611-424c-8240-d9ae53baf02b" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_5082405d-aa1d-4a21-8d75-edc002b32bd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_88395ce7-5e7c-4888-8c96-3190919191de" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_aa482f4f-3611-424c-8240-d9ae53baf02b" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_88395ce7-5e7c-4888-8c96-3190919191de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_4f9d7b44-85da-48e1-9257-d3f0e6b5624d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_aa482f4f-3611-424c-8240-d9ae53baf02b" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_4f9d7b44-85da-48e1-9257-d3f0e6b5624d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_5f7904d3-bca8-4d9d-9392-8abe74bbec3b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_aa482f4f-3611-424c-8240-d9ae53baf02b" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_5f7904d3-bca8-4d9d-9392-8abe74bbec3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_selb_SaleofStockPercentageOfTenDayVolumeWeightedAveragePriceOfCommonStock_97f0b142-9c75-4f53-ba56-0fdda1c06c7d" xlink:href="selb-20210331.xsd#selb_SaleofStockPercentageOfTenDayVolumeWeightedAveragePriceOfCommonStock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_aa482f4f-3611-424c-8240-d9ae53baf02b" xlink:to="loc_selb_SaleofStockPercentageOfTenDayVolumeWeightedAveragePriceOfCommonStock_97f0b142-9c75-4f53-ba56-0fdda1c06c7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_selb_LockUpFromClosingTerm_caad046d-44b4-4d3d-9210-b4f5f648576c" xlink:href="selb-20210331.xsd#selb_LockUpFromClosingTerm"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_aa482f4f-3611-424c-8240-d9ae53baf02b" xlink:to="loc_selb_LockUpFromClosingTerm_caad046d-44b4-4d3d-9210-b4f5f648576c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedemptionPremium_70e1f82b-cf0a-4bc8-85e6-503871e1b9c1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RedemptionPremium"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_aa482f4f-3611-424c-8240-d9ae53baf02b" xlink:to="loc_us-gaap_RedemptionPremium_70e1f82b-cf0a-4bc8-85e6-503871e1b9c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_888e25e7-7503-42e3-9b2c-00621a6e6a5f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_aa482f4f-3611-424c-8240-d9ae53baf02b" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_888e25e7-7503-42e3-9b2c-00621a6e6a5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_selb_ClassOfWarrantOrRightNumberOfWarrantsExercised_66d69ea5-05ac-4558-b772-9224c3c6eaec" xlink:href="selb-20210331.xsd#selb_ClassOfWarrantOrRightNumberOfWarrantsExercised"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_aa482f4f-3611-424c-8240-d9ae53baf02b" xlink:to="loc_selb_ClassOfWarrantOrRightNumberOfWarrantsExercised_66d69ea5-05ac-4558-b772-9224c3c6eaec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_5f24b15c-ca85-4028-afaa-c819e825bf21" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_aa482f4f-3611-424c-8240-d9ae53baf02b" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_5f24b15c-ca85-4028-afaa-c819e825bf21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_selb_WarrantIssued_595568e6-8828-4528-af54-0feb80c4ad9b" xlink:href="selb-20210331.xsd#selb_WarrantIssued"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_aa482f4f-3611-424c-8240-d9ae53baf02b" xlink:to="loc_selb_WarrantIssued_595568e6-8828-4528-af54-0feb80c4ad9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_c55a249b-c351-4db7-a2d0-c7ff98472cd8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_aa482f4f-3611-424c-8240-d9ae53baf02b" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_c55a249b-c351-4db7-a2d0-c7ff98472cd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding_80ea1cac-495e-45a9-a9f8-d1bf2528a14d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_aa482f4f-3611-424c-8240-d9ae53baf02b" xlink:to="loc_us-gaap_WarrantsAndRightsOutstanding_80ea1cac-495e-45a9-a9f8-d1bf2528a14d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount_9b3a68f5-236b-4006-82a0-7253ec83c3c1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_aa482f4f-3611-424c-8240-d9ae53baf02b" xlink:to="loc_us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount_9b3a68f5-236b-4006-82a0-7253ec83c3c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_fa29c6bf-f44b-4ff2-8f0a-47406db07bbf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_aa482f4f-3611-424c-8240-d9ae53baf02b" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_fa29c6bf-f44b-4ff2-8f0a-47406db07bbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_a9a8e1a0-30ac-4c0e-93ed-79b3ed8d1cf2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_aa482f4f-3611-424c-8240-d9ae53baf02b" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_a9a8e1a0-30ac-4c0e-93ed-79b3ed8d1cf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_07c53eff-b180-442c-806f-00b5aef20e9a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_aa482f4f-3611-424c-8240-d9ae53baf02b" xlink:to="loc_us-gaap_CommonStockSharesIssued_07c53eff-b180-442c-806f-00b5aef20e9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_d195629b-79ba-40e1-a483-1e93ecae4659" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_aa482f4f-3611-424c-8240-d9ae53baf02b" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_d195629b-79ba-40e1-a483-1e93ecae4659" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_selb_VotesPerShareofCommonStock_ce8609b5-08ac-4a2b-8c92-6bfc2e55e30d" xlink:href="selb-20210331.xsd#selb_VotesPerShareofCommonStock"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_aa482f4f-3611-424c-8240-d9ae53baf02b" xlink:to="loc_selb_VotesPerShareofCommonStock_ce8609b5-08ac-4a2b-8c92-6bfc2e55e30d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsCommonStock_ddd59658-c7c5-4cd2-948a-c632b429bebc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DividendsCommonStock"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_aa482f4f-3611-424c-8240-d9ae53baf02b" xlink:to="loc_us-gaap_DividendsCommonStock_ddd59658-c7c5-4cd2-948a-c632b429bebc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.selectabio.com/role/EquityWarrantyActivityDetails" xlink:type="simple" xlink:href="selb-20210331.xsd#EquityWarrantyActivityDetails"/>
  <link:presentationLink xlink:role="http://www.selectabio.com/role/EquityWarrantyActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_97df9481-c649-45ad-8df4-861dc7ac99cf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_977bb935-3b7b-4813-8da4-06064b432669" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_97df9481-c649-45ad-8df4-861dc7ac99cf" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_977bb935-3b7b-4813-8da4-06064b432669" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_dfad5fde-126a-499a-98e7-ca86f825806c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_977bb935-3b7b-4813-8da4-06064b432669" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_dfad5fde-126a-499a-98e7-ca86f825806c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_3a6ebd36-fed0-4aa8-9b52-df59b946aa22" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_dfad5fde-126a-499a-98e7-ca86f825806c" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_3a6ebd36-fed0-4aa8-9b52-df59b946aa22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_659e267b-8e86-421f-a982-d1e047cd3dcb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_3a6ebd36-fed0-4aa8-9b52-df59b946aa22" xlink:to="loc_us-gaap_WarrantMember_659e267b-8e86-421f-a982-d1e047cd3dcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_8703b193-9e47-4166-b3de-87af0fdc317d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_977bb935-3b7b-4813-8da4-06064b432669" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_8703b193-9e47-4166-b3de-87af0fdc317d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_e5ef7355-b111-436b-a44f-f6e71f35ea54" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_8703b193-9e47-4166-b3de-87af0fdc317d" xlink:to="loc_us-gaap_EquityComponentDomain_e5ef7355-b111-436b-a44f-f6e71f35ea54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_e61c78ce-2bcc-4cb4-b39b-641339228898" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_e5ef7355-b111-436b-a44f-f6e71f35ea54" xlink:to="loc_us-gaap_WarrantMember_e61c78ce-2bcc-4cb4-b39b-641339228898" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_7a032f83-90ec-4461-94e6-d6df26c85f07" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_977bb935-3b7b-4813-8da4-06064b432669" xlink:to="loc_us-gaap_ClassOfWarrantOrRightLineItems_7a032f83-90ec-4461-94e6-d6df26c85f07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_461e1561-180b-46db-b633-bd0437a6b513" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_7a032f83-90ec-4461-94e6-d6df26c85f07" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_461e1561-180b-46db-b633-bd0437a6b513" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_22b5f4ea-4b02-4e1a-b5bc-04f5ceccec8a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_7a032f83-90ec-4461-94e6-d6df26c85f07" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_22b5f4ea-4b02-4e1a-b5bc-04f5ceccec8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.selectabio.com/role/EquityScheduleofAuthorizedSharesofCommonStockforFutureIssuanceDetails" xlink:type="simple" xlink:href="selb-20210331.xsd#EquityScheduleofAuthorizedSharesofCommonStockforFutureIssuanceDetails"/>
  <link:presentationLink xlink:role="http://www.selectabio.com/role/EquityScheduleofAuthorizedSharesofCommonStockforFutureIssuanceDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_768ed739-5021-4ab5-9906-f5f090007832" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_0a9cb031-ca18-4c60-a527-889a16e43e7b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_768ed739-5021-4ab5-9906-f5f090007832" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_0a9cb031-ca18-4c60-a527-889a16e43e7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_edcc6853-b672-4d4f-8caf-430ed1817432" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_0a9cb031-ca18-4c60-a527-889a16e43e7b" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_edcc6853-b672-4d4f-8caf-430ed1817432" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_2f1fe0ba-6649-4776-9d80-640aa68e489a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_edcc6853-b672-4d4f-8caf-430ed1817432" xlink:to="loc_us-gaap_EquityComponentDomain_2f1fe0ba-6649-4776-9d80-640aa68e489a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_4515ed5a-aaee-4165-a161-7d9a1c0f11c1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_2f1fe0ba-6649-4776-9d80-640aa68e489a" xlink:to="loc_us-gaap_WarrantMember_4515ed5a-aaee-4165-a161-7d9a1c0f11c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_d8dbbdcd-7a88-4d24-8e32-8c20c4046837" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_0a9cb031-ca18-4c60-a527-889a16e43e7b" xlink:to="loc_us-gaap_AwardTypeAxis_d8dbbdcd-7a88-4d24-8e32-8c20c4046837" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7ae5de26-2403-484a-8637-d974ad3c2b43" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_d8dbbdcd-7a88-4d24-8e32-8c20c4046837" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7ae5de26-2403-484a-8637-d974ad3c2b43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockCompensationPlanMember_9e32c594-c81c-4ace-9bef-88e3cef68723" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockCompensationPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7ae5de26-2403-484a-8637-d974ad3c2b43" xlink:to="loc_us-gaap_StockCompensationPlanMember_9e32c594-c81c-4ace-9bef-88e3cef68723" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_selb_RestrictedStockUnitsRSUsReservedForIssuanceMember_a78e0fd5-19de-4f04-9369-50b33161d573" xlink:href="selb-20210331.xsd#selb_RestrictedStockUnitsRSUsReservedForIssuanceMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7ae5de26-2403-484a-8637-d974ad3c2b43" xlink:to="loc_selb_RestrictedStockUnitsRSUsReservedForIssuanceMember_a78e0fd5-19de-4f04-9369-50b33161d573" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_selb_RestrictedStockUnitsUnvestedMember_c182fdea-ee93-4169-95c3-066a6ca1b9c6" xlink:href="selb-20210331.xsd#selb_RestrictedStockUnitsUnvestedMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7ae5de26-2403-484a-8637-d974ad3c2b43" xlink:to="loc_selb_RestrictedStockUnitsUnvestedMember_c182fdea-ee93-4169-95c3-066a6ca1b9c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_abc5bfcc-67ac-4be7-9930-4317d4a29fc7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7ae5de26-2403-484a-8637-d974ad3c2b43" xlink:to="loc_us-gaap_EmployeeStockOptionMember_abc5bfcc-67ac-4be7-9930-4317d4a29fc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_30de8484-3c1f-40f9-9969-d4fd3d050d0c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_0a9cb031-ca18-4c60-a527-889a16e43e7b" xlink:to="loc_us-gaap_ClassOfStockLineItems_30de8484-3c1f-40f9-9969-d4fd3d050d0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_2f49dd97-b033-41ec-af1e-2b63c61508a1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_30de8484-3c1f-40f9-9969-d4fd3d050d0c" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_2f49dd97-b033-41ec-af1e-2b63c61508a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.selectabio.com/role/StockIncentivePlans" xlink:type="simple" xlink:href="selb-20210331.xsd#StockIncentivePlans"/>
  <link:presentationLink xlink:role="http://www.selectabio.com/role/StockIncentivePlans" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c5ed5941-7b34-45e8-a90a-01c8d967496c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_9e70306f-3092-40b5-9535-065a05541c7e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c5ed5941-7b34-45e8-a90a-01c8d967496c" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_9e70306f-3092-40b5-9535-065a05541c7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.selectabio.com/role/StockIncentivePlansTables" xlink:type="simple" xlink:href="selb-20210331.xsd#StockIncentivePlansTables"/>
  <link:presentationLink xlink:role="http://www.selectabio.com/role/StockIncentivePlansTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ee0027b5-68af-4ed4-abfb-423b6c3a8c89" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_59f09754-68e4-4d2e-aa79-d40cc81a0fa5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ee0027b5-68af-4ed4-abfb-423b6c3a8c89" xlink:to="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_59f09754-68e4-4d2e-aa79-d40cc81a0fa5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_309c05d6-8336-4332-aa3b-e1c6901a8634" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ee0027b5-68af-4ed4-abfb-423b6c3a8c89" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_309c05d6-8336-4332-aa3b-e1c6901a8634" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_a80843a7-49e4-4e05-8aef-cd9239ad3ef7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ee0027b5-68af-4ed4-abfb-423b6c3a8c89" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_a80843a7-49e4-4e05-8aef-cd9239ad3ef7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_be5871d3-10c3-436d-9a77-39798fff409c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ee0027b5-68af-4ed4-abfb-423b6c3a8c89" xlink:to="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_be5871d3-10c3-436d-9a77-39798fff409c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.selectabio.com/role/StockIncentivePlansNarrativeDetails" xlink:type="simple" xlink:href="selb-20210331.xsd#StockIncentivePlansNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.selectabio.com/role/StockIncentivePlansNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_67b6b0d0-f6ff-41a4-be90-7e3de70392d6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_be2c420e-211c-45d2-8ca8-d66ed9ae7b54" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_67b6b0d0-f6ff-41a4-be90-7e3de70392d6" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_be2c420e-211c-45d2-8ca8-d66ed9ae7b54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_cd371380-b0d7-4ee3-9531-40ebf08894b4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_be2c420e-211c-45d2-8ca8-d66ed9ae7b54" xlink:to="loc_us-gaap_PlanNameAxis_cd371380-b0d7-4ee3-9531-40ebf08894b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_1caa5049-639b-4aeb-94a9-045774a3e00c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_cd371380-b0d7-4ee3-9531-40ebf08894b4" xlink:to="loc_us-gaap_PlanNameDomain_1caa5049-639b-4aeb-94a9-045774a3e00c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_selb_StockIncentivePlan2016Member_c4e073d4-ba31-4156-91f9-82ea057d8922" xlink:href="selb-20210331.xsd#selb_StockIncentivePlan2016Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_1caa5049-639b-4aeb-94a9-045774a3e00c" xlink:to="loc_selb_StockIncentivePlan2016Member_c4e073d4-ba31-4156-91f9-82ea057d8922" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_selb_EmploymentInducementIncentiveAwardPlanMember_bc7b5f16-c0d8-4066-be20-2d513bfce213" xlink:href="selb-20210331.xsd#selb_EmploymentInducementIncentiveAwardPlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_1caa5049-639b-4aeb-94a9-045774a3e00c" xlink:to="loc_selb_EmploymentInducementIncentiveAwardPlanMember_bc7b5f16-c0d8-4066-be20-2d513bfce213" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_selb_EmployeeStockPurchasePlan2016Member_1c0b670b-62a1-44e5-9a35-93f68e128d88" xlink:href="selb-20210331.xsd#selb_EmployeeStockPurchasePlan2016Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_1caa5049-639b-4aeb-94a9-045774a3e00c" xlink:to="loc_selb_EmployeeStockPurchasePlan2016Member_1c0b670b-62a1-44e5-9a35-93f68e128d88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_73baa7ec-0b94-4543-a201-ed8b3ffc2da5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_be2c420e-211c-45d2-8ca8-d66ed9ae7b54" xlink:to="loc_us-gaap_AwardTypeAxis_73baa7ec-0b94-4543-a201-ed8b3ffc2da5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ccf4d568-bf76-45ec-a758-1560c22c3cf7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_73baa7ec-0b94-4543-a201-ed8b3ffc2da5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ccf4d568-bf76-45ec-a758-1560c22c3cf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockCompensationPlanMember_c121d939-16af-466b-8096-69f695392998" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockCompensationPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ccf4d568-bf76-45ec-a758-1560c22c3cf7" xlink:to="loc_us-gaap_StockCompensationPlanMember_c121d939-16af-466b-8096-69f695392998" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_selb_NonEmployeeStockOptionMember_7fac081e-81df-4e48-b7e5-b4c283cd10eb" xlink:href="selb-20210331.xsd#selb_NonEmployeeStockOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ccf4d568-bf76-45ec-a758-1560c22c3cf7" xlink:to="loc_selb_NonEmployeeStockOptionMember_7fac081e-81df-4e48-b7e5-b4c283cd10eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_5e5b22cd-b8e1-467d-8e25-e318a339d5f7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ccf4d568-bf76-45ec-a758-1560c22c3cf7" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_5e5b22cd-b8e1-467d-8e25-e318a339d5f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_29640d9b-a88b-4bcb-b81f-184fde557609" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_be2c420e-211c-45d2-8ca8-d66ed9ae7b54" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_29640d9b-a88b-4bcb-b81f-184fde557609" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_c4e4802a-a26e-4981-86c5-5274e651a76b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_29640d9b-a88b-4bcb-b81f-184fde557609" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_c4e4802a-a26e-4981-86c5-5274e651a76b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_selb_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantIncreaseDecrease_cd4963fa-4de8-423f-9a05-2819d355fbb5" xlink:href="selb-20210331.xsd#selb_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantIncreaseDecrease"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_29640d9b-a88b-4bcb-b81f-184fde557609" xlink:to="loc_selb_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantIncreaseDecrease_cd4963fa-4de8-423f-9a05-2819d355fbb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_9f0b49e7-d414-4d2e-a498-8412f028d67c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_29640d9b-a88b-4bcb-b81f-184fde557609" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_9f0b49e7-d414-4d2e-a498-8412f028d67c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_selb_ShareBasedCompensationArrangementByShareBasedPaymentAwardForfeituresRate_571fb793-1678-4b17-ade8-b12b1fd17ad0" xlink:href="selb-20210331.xsd#selb_ShareBasedCompensationArrangementByShareBasedPaymentAwardForfeituresRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_29640d9b-a88b-4bcb-b81f-184fde557609" xlink:to="loc_selb_ShareBasedCompensationArrangementByShareBasedPaymentAwardForfeituresRate_571fb793-1678-4b17-ade8-b12b1fd17ad0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_3290e5b9-5e36-48db-a30a-a3a6a46a2493" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_29640d9b-a88b-4bcb-b81f-184fde557609" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_3290e5b9-5e36-48db-a30a-a3a6a46a2493" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_30091456-83ad-49b9-bcf4-9b6e8ad47d4a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_29640d9b-a88b-4bcb-b81f-184fde557609" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_30091456-83ad-49b9-bcf4-9b6e8ad47d4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_6b131200-01ca-4490-9d00-e85e723fb9f0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_29640d9b-a88b-4bcb-b81f-184fde557609" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_6b131200-01ca-4490-9d00-e85e723fb9f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_cee02d7a-036e-40a5-9daf-d72ee31d0720" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_29640d9b-a88b-4bcb-b81f-184fde557609" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_cee02d7a-036e-40a5-9daf-d72ee31d0720" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_183c6afd-be15-4d8f-b487-b752f4406d68" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_29640d9b-a88b-4bcb-b81f-184fde557609" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_183c6afd-be15-4d8f-b487-b752f4406d68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_selb_ShareBasedGoodsAndNonEmployeeServicesTransactionCompensationNotYetRecognizedStockOptions_39a65a78-13eb-4e29-b7c2-f7af3fe9001d" xlink:href="selb-20210331.xsd#selb_ShareBasedGoodsAndNonEmployeeServicesTransactionCompensationNotYetRecognizedStockOptions"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_29640d9b-a88b-4bcb-b81f-184fde557609" xlink:to="loc_selb_ShareBasedGoodsAndNonEmployeeServicesTransactionCompensationNotYetRecognizedStockOptions_39a65a78-13eb-4e29-b7c2-f7af3fe9001d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1a250282-ba2a-4678-a8c2-1832b399acd2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_29640d9b-a88b-4bcb-b81f-184fde557609" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1a250282-ba2a-4678-a8c2-1832b399acd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_c81e6f5f-856a-4b62-b924-27651b36e4a0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_29640d9b-a88b-4bcb-b81f-184fde557609" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_c81e6f5f-856a-4b62-b924-27651b36e4a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_501a263f-9bcc-490f-9c3f-5394aa105804" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_29640d9b-a88b-4bcb-b81f-184fde557609" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_501a263f-9bcc-490f-9c3f-5394aa105804" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_selb_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAwardedInPeriod_f70c5eaf-33c6-4bfb-8d92-54b0e974e3b3" xlink:href="selb-20210331.xsd#selb_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAwardedInPeriod"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_29640d9b-a88b-4bcb-b81f-184fde557609" xlink:to="loc_selb_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAwardedInPeriod_f70c5eaf-33c6-4bfb-8d92-54b0e974e3b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_selb_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReservedForIssuance_d89fb7f8-a593-47d6-9182-03fa06245c58" xlink:href="selb-20210331.xsd#selb_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReservedForIssuance"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_29640d9b-a88b-4bcb-b81f-184fde557609" xlink:to="loc_selb_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReservedForIssuance_d89fb7f8-a593-47d6-9182-03fa06245c58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_selb_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReservedForIssuanceWeightedAverageGrantDateFairValue_474b9e2f-5c5b-4dcc-99a7-44162a828343" xlink:href="selb-20210331.xsd#selb_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReservedForIssuanceWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_29640d9b-a88b-4bcb-b81f-184fde557609" xlink:to="loc_selb_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReservedForIssuanceWeightedAverageGrantDateFairValue_474b9e2f-5c5b-4dcc-99a7-44162a828343" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_75fbeb74-f6bc-49c8-89b3-f3fda8121a32" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_29640d9b-a88b-4bcb-b81f-184fde557609" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_75fbeb74-f6bc-49c8-89b3-f3fda8121a32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_73aba6c6-3555-42bd-833d-c8511f9cbc02" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_29640d9b-a88b-4bcb-b81f-184fde557609" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_73aba6c6-3555-42bd-833d-c8511f9cbc02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.selectabio.com/role/StockIncentivePlansScheduleofStockBasedCompensationExpenseRelatedtoStockOptionsandRestrictedCommonStockDetails" xlink:type="simple" xlink:href="selb-20210331.xsd#StockIncentivePlansScheduleofStockBasedCompensationExpenseRelatedtoStockOptionsandRestrictedCommonStockDetails"/>
  <link:presentationLink xlink:role="http://www.selectabio.com/role/StockIncentivePlansScheduleofStockBasedCompensationExpenseRelatedtoStockOptionsandRestrictedCommonStockDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b7e93b43-81a7-452e-a5ca-915e6e5acd97" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_f52bbd9c-538b-43f8-ac6d-bf18f048cc67" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b7e93b43-81a7-452e-a5ca-915e6e5acd97" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_f52bbd9c-538b-43f8-ac6d-bf18f048cc67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_87296f66-d4f4-4f29-9bf9-83159cc463e7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_f52bbd9c-538b-43f8-ac6d-bf18f048cc67" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_87296f66-d4f4-4f29-9bf9-83159cc463e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_f2a133de-009c-4129-b4b7-c311b0993509" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_87296f66-d4f4-4f29-9bf9-83159cc463e7" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_f2a133de-009c-4129-b4b7-c311b0993509" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_selb_ResearchAndDevelopmentMember_335ad9ba-8f6e-483e-8dea-7e725ff852e3" xlink:href="selb-20210331.xsd#selb_ResearchAndDevelopmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_f2a133de-009c-4129-b4b7-c311b0993509" xlink:to="loc_selb_ResearchAndDevelopmentMember_335ad9ba-8f6e-483e-8dea-7e725ff852e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_a99c98e6-6565-40a3-944c-e9e906064462" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_f2a133de-009c-4129-b4b7-c311b0993509" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_a99c98e6-6565-40a3-944c-e9e906064462" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_1098ced6-bc1e-4fbf-920a-ebf70c6308a4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_f52bbd9c-538b-43f8-ac6d-bf18f048cc67" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_1098ced6-bc1e-4fbf-920a-ebf70c6308a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_0ea4f00c-39ae-4965-811f-8068bd78f9e7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_1098ced6-bc1e-4fbf-920a-ebf70c6308a4" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_0ea4f00c-39ae-4965-811f-8068bd78f9e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.selectabio.com/role/StockIncentivePlansScheduleofAssumptionsDetails" xlink:type="simple" xlink:href="selb-20210331.xsd#StockIncentivePlansScheduleofAssumptionsDetails"/>
  <link:presentationLink xlink:role="http://www.selectabio.com/role/StockIncentivePlansScheduleofAssumptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_23b82c01-3267-4cab-8364-25b074fe1762" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f1761cbd-9355-4807-8509-962aeb490b9c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_23b82c01-3267-4cab-8364-25b074fe1762" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f1761cbd-9355-4807-8509-962aeb490b9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_522c96f8-5a50-47dc-90b0-651900482c4b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f1761cbd-9355-4807-8509-962aeb490b9c" xlink:to="loc_us-gaap_AwardTypeAxis_522c96f8-5a50-47dc-90b0-651900482c4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_eccb2b74-2938-4b50-a36b-3963bd8af73b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_522c96f8-5a50-47dc-90b0-651900482c4b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_eccb2b74-2938-4b50-a36b-3963bd8af73b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockCompensationPlanMember_6529259f-fbb2-4c3a-a1bb-ce4c4d638e50" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockCompensationPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_eccb2b74-2938-4b50-a36b-3963bd8af73b" xlink:to="loc_us-gaap_StockCompensationPlanMember_6529259f-fbb2-4c3a-a1bb-ce4c4d638e50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_selb_NonEmployeeStockOptionMember_fc9fc080-fccb-4bc2-9e49-287148fd2a07" xlink:href="selb-20210331.xsd#selb_NonEmployeeStockOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_eccb2b74-2938-4b50-a36b-3963bd8af73b" xlink:to="loc_selb_NonEmployeeStockOptionMember_fc9fc080-fccb-4bc2-9e49-287148fd2a07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ca170ae5-0251-4b59-a5b2-d86004a9e12e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f1761cbd-9355-4807-8509-962aeb490b9c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ca170ae5-0251-4b59-a5b2-d86004a9e12e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_ac357d1e-b654-4d52-8a2f-258262a851f6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ca170ae5-0251-4b59-a5b2-d86004a9e12e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_ac357d1e-b654-4d52-8a2f-258262a851f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_cba24e61-6c61-4cc3-b4e7-42370672e807" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ca170ae5-0251-4b59-a5b2-d86004a9e12e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_cba24e61-6c61-4cc3-b4e7-42370672e807" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_7fe935d4-44a0-4f9d-a04e-a91d32fd6027" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ca170ae5-0251-4b59-a5b2-d86004a9e12e" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_7fe935d4-44a0-4f9d-a04e-a91d32fd6027" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_b2273536-5ec7-4e83-8deb-b16c7295dd1c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ca170ae5-0251-4b59-a5b2-d86004a9e12e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_b2273536-5ec7-4e83-8deb-b16c7295dd1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_selb_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageFairValue_55c9da70-b6a4-42e1-9386-c33f4ef1653b" xlink:href="selb-20210331.xsd#selb_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ca170ae5-0251-4b59-a5b2-d86004a9e12e" xlink:to="loc_selb_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageFairValue_55c9da70-b6a4-42e1-9386-c33f4ef1653b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.selectabio.com/role/StockIncentivePlansSummaryofOptionsActivityDetails" xlink:type="simple" xlink:href="selb-20210331.xsd#StockIncentivePlansSummaryofOptionsActivityDetails"/>
  <link:presentationLink xlink:role="http://www.selectabio.com/role/StockIncentivePlansSummaryofOptionsActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_853efc62-9867-4514-8ae5-f20f4d0d8b8d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_550e272f-d7b4-45e3-8e8e-e241995e84a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_853efc62-9867-4514-8ae5-f20f4d0d8b8d" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_550e272f-d7b4-45e3-8e8e-e241995e84a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_10c0c086-2be3-4588-9180-6bd4da25d30b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_550e272f-d7b4-45e3-8e8e-e241995e84a2" xlink:to="loc_us-gaap_PlanNameAxis_10c0c086-2be3-4588-9180-6bd4da25d30b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_6d0e2889-f3e6-420b-a813-64e3d53d71e9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_10c0c086-2be3-4588-9180-6bd4da25d30b" xlink:to="loc_us-gaap_PlanNameDomain_6d0e2889-f3e6-420b-a813-64e3d53d71e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_selb_A2008Plan2016PlanAnd2018InducementIncentiveAwardPlanMember_0263b88e-ed55-4553-8b4d-158cbfd769f5" xlink:href="selb-20210331.xsd#selb_A2008Plan2016PlanAnd2018InducementIncentiveAwardPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_6d0e2889-f3e6-420b-a813-64e3d53d71e9" xlink:to="loc_selb_A2008Plan2016PlanAnd2018InducementIncentiveAwardPlanMember_0263b88e-ed55-4553-8b4d-158cbfd769f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_1321660f-d158-49f3-9fe4-1079b463456a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_550e272f-d7b4-45e3-8e8e-e241995e84a2" xlink:to="loc_us-gaap_AwardTypeAxis_1321660f-d158-49f3-9fe4-1079b463456a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ab5a8627-4b07-4f5b-9bdf-a8021c5d7879" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_1321660f-d158-49f3-9fe4-1079b463456a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ab5a8627-4b07-4f5b-9bdf-a8021c5d7879" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockCompensationPlanMember_d314e058-8d3b-4f42-8dbb-4bf5ef4adb51" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockCompensationPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ab5a8627-4b07-4f5b-9bdf-a8021c5d7879" xlink:to="loc_us-gaap_StockCompensationPlanMember_d314e058-8d3b-4f42-8dbb-4bf5ef4adb51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_selb_NonEmployeeStockOptionMember_38e8e796-fd0f-4d99-86fd-609621562886" xlink:href="selb-20210331.xsd#selb_NonEmployeeStockOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ab5a8627-4b07-4f5b-9bdf-a8021c5d7879" xlink:to="loc_selb_NonEmployeeStockOptionMember_38e8e796-fd0f-4d99-86fd-609621562886" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e73a4456-f723-4b59-876c-612d642b98ac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_550e272f-d7b4-45e3-8e8e-e241995e84a2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e73a4456-f723-4b59-876c-612d642b98ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_d1e9188a-68f4-4696-9c21-8841f97976a0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e73a4456-f723-4b59-876c-612d642b98ac" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_d1e9188a-68f4-4696-9c21-8841f97976a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_e1dc1c5a-f684-4bee-8ba1-a8ab94f39afb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_d1e9188a-68f4-4696-9c21-8841f97976a0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_e1dc1c5a-f684-4bee-8ba1-a8ab94f39afb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_10914892-882c-43bf-94cd-c60d322fad44" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_d1e9188a-68f4-4696-9c21-8841f97976a0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_10914892-882c-43bf-94cd-c60d322fad44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_5c7e9956-6261-40b8-89f3-4745399bcf7a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_d1e9188a-68f4-4696-9c21-8841f97976a0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_5c7e9956-6261-40b8-89f3-4745399bcf7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_5d47428e-4880-4eba-9beb-5fe6101e2316" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_d1e9188a-68f4-4696-9c21-8841f97976a0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_5d47428e-4880-4eba-9beb-5fe6101e2316" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_ec9ed5cd-6df4-480b-a194-acbd94b93781" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_d1e9188a-68f4-4696-9c21-8841f97976a0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_ec9ed5cd-6df4-480b-a194-acbd94b93781" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_55c0fdb3-0698-4bc2-8786-a485e43e1ef3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e73a4456-f723-4b59-876c-612d642b98ac" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_55c0fdb3-0698-4bc2-8786-a485e43e1ef3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_7df7b1e3-9733-4d08-ab95-b1eff7cb1501" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e73a4456-f723-4b59-876c-612d642b98ac" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_7df7b1e3-9733-4d08-ab95-b1eff7cb1501" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_5a1c562c-cca1-49c2-8592-d388fc787772" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e73a4456-f723-4b59-876c-612d642b98ac" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_5a1c562c-cca1-49c2-8592-d388fc787772" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_eca87103-db83-4b62-a931-5a7d131963a1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_5a1c562c-cca1-49c2-8592-d388fc787772" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_eca87103-db83-4b62-a931-5a7d131963a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_523f2a17-d89a-4b20-819c-0f1dd538b1c6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_5a1c562c-cca1-49c2-8592-d388fc787772" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_523f2a17-d89a-4b20-819c-0f1dd538b1c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_68069811-9e35-4c7b-8a5c-49f148625da7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_5a1c562c-cca1-49c2-8592-d388fc787772" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_68069811-9e35-4c7b-8a5c-49f148625da7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_f47c2453-285c-4d57-a3de-5b2c988e2946" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_5a1c562c-cca1-49c2-8592-d388fc787772" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_f47c2453-285c-4d57-a3de-5b2c988e2946" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_14901801-5707-455a-8631-be3fe0474770" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_5a1c562c-cca1-49c2-8592-d388fc787772" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_14901801-5707-455a-8631-be3fe0474770" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_selb_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsVestedWeightedAverageExercisePrice_4919ff68-0e74-49f3-848f-60f296504511" xlink:href="selb-20210331.xsd#selb_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsVestedWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e73a4456-f723-4b59-876c-612d642b98ac" xlink:to="loc_selb_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsVestedWeightedAverageExercisePrice_4919ff68-0e74-49f3-848f-60f296504511" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_44611b08-b91c-47ed-bac1-2ffb86dce961" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e73a4456-f723-4b59-876c-612d642b98ac" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_44611b08-b91c-47ed-bac1-2ffb86dce961" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_selb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract_dbc892de-025a-4033-bc8c-fdf89a8f4678" xlink:href="selb-20210331.xsd#selb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e73a4456-f723-4b59-876c-612d642b98ac" xlink:to="loc_selb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract_dbc892de-025a-4033-bc8c-fdf89a8f4678" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_bcda163c-97d0-438d-8491-9710c797b5ae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_selb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract_dbc892de-025a-4033-bc8c-fdf89a8f4678" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_bcda163c-97d0-438d-8491-9710c797b5ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_selb_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedOutstandingWeightedAverageRemainingContractualTerm_49f350a8-e87f-43dd-97c1-e12a043148a5" xlink:href="selb-20210331.xsd#selb_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedOutstandingWeightedAverageRemainingContractualTerm"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_selb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract_dbc892de-025a-4033-bc8c-fdf89a8f4678" xlink:to="loc_selb_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedOutstandingWeightedAverageRemainingContractualTerm_49f350a8-e87f-43dd-97c1-e12a043148a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_64ea40ac-d847-49a8-b015-9b3844fc5a9d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_selb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract_dbc892de-025a-4033-bc8c-fdf89a8f4678" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_64ea40ac-d847-49a8-b015-9b3844fc5a9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_selb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValueAbstract_a8ff3607-0a06-496c-8d7b-14f7e5880e61" xlink:href="selb-20210331.xsd#selb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValueAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e73a4456-f723-4b59-876c-612d642b98ac" xlink:to="loc_selb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValueAbstract_a8ff3607-0a06-496c-8d7b-14f7e5880e61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_c3e65f75-15a9-49b3-acb7-d58515b801f2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_selb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValueAbstract_a8ff3607-0a06-496c-8d7b-14f7e5880e61" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_c3e65f75-15a9-49b3-acb7-d58515b801f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_selb_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedOutstandingIntrinsicValue_435f1712-e103-42c5-9f4d-5b2e98a86e84" xlink:href="selb-20210331.xsd#selb_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedOutstandingIntrinsicValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_selb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValueAbstract_a8ff3607-0a06-496c-8d7b-14f7e5880e61" xlink:to="loc_selb_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedOutstandingIntrinsicValue_435f1712-e103-42c5-9f4d-5b2e98a86e84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_22187ec5-0ef9-463d-9341-7b207fc2a928" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_selb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValueAbstract_a8ff3607-0a06-496c-8d7b-14f7e5880e61" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_22187ec5-0ef9-463d-9341-7b207fc2a928" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.selectabio.com/role/StockIncentivePlansRestrictedStockUnitsDetails" xlink:type="simple" xlink:href="selb-20210331.xsd#StockIncentivePlansRestrictedStockUnitsDetails"/>
  <link:presentationLink xlink:role="http://www.selectabio.com/role/StockIncentivePlansRestrictedStockUnitsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_92bff1cc-67dc-4f87-a9b4-8611dda9a0de" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3318965d-da32-468a-9a6e-c001bf97d383" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_92bff1cc-67dc-4f87-a9b4-8611dda9a0de" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3318965d-da32-468a-9a6e-c001bf97d383" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_a1238598-f868-437e-b184-b512f8e986fc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3318965d-da32-468a-9a6e-c001bf97d383" xlink:to="loc_us-gaap_AwardTypeAxis_a1238598-f868-437e-b184-b512f8e986fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_16057cad-2e1a-4983-badd-8c4fcb749b88" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_a1238598-f868-437e-b184-b512f8e986fc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_16057cad-2e1a-4983-badd-8c4fcb749b88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_f620f5ba-9d59-4179-a0de-d3d6342f481e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_16057cad-2e1a-4983-badd-8c4fcb749b88" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_f620f5ba-9d59-4179-a0de-d3d6342f481e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_099a507a-ee4d-4e8b-b720-098e25b9860f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3318965d-da32-468a-9a6e-c001bf97d383" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_099a507a-ee4d-4e8b-b720-098e25b9860f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_1e2ff3a1-3eab-47b6-b05f-55fbdb954879" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_099a507a-ee4d-4e8b-b720-098e25b9860f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_1e2ff3a1-3eab-47b6-b05f-55fbdb954879" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_69524a0c-23a9-44e0-a686-c7c797ced2d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_1e2ff3a1-3eab-47b6-b05f-55fbdb954879" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_69524a0c-23a9-44e0-a686-c7c797ced2d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_e0428556-bae1-45fb-bdc5-0af169032a4e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_1e2ff3a1-3eab-47b6-b05f-55fbdb954879" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_e0428556-bae1-45fb-bdc5-0af169032a4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_b47362a7-35ff-4f70-97e0-2b51a77d679a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_1e2ff3a1-3eab-47b6-b05f-55fbdb954879" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_b47362a7-35ff-4f70-97e0-2b51a77d679a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_selb_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReservedForIssuance_bcd307c5-4a3d-44b4-bc79-4b1510603a60" xlink:href="selb-20210331.xsd#selb_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReservedForIssuance"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_1e2ff3a1-3eab-47b6-b05f-55fbdb954879" xlink:to="loc_selb_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReservedForIssuance_bcd307c5-4a3d-44b4-bc79-4b1510603a60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_7e1c5082-3b3c-46f2-b3e0-7e28a3d8252e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_1e2ff3a1-3eab-47b6-b05f-55fbdb954879" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_7e1c5082-3b3c-46f2-b3e0-7e28a3d8252e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_578cf4d4-67f4-44c3-9762-b9d970935e8c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_1e2ff3a1-3eab-47b6-b05f-55fbdb954879" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_578cf4d4-67f4-44c3-9762-b9d970935e8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_4710bea7-92e5-4b47-ba1d-9d3c1084abbe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_099a507a-ee4d-4e8b-b720-098e25b9860f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_4710bea7-92e5-4b47-ba1d-9d3c1084abbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_79e8215f-8bfb-48e5-8e0c-acde020b58c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_4710bea7-92e5-4b47-ba1d-9d3c1084abbe" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_79e8215f-8bfb-48e5-8e0c-acde020b58c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_fc51a89a-dd43-47c4-8f36-94be25981faf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_4710bea7-92e5-4b47-ba1d-9d3c1084abbe" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_fc51a89a-dd43-47c4-8f36-94be25981faf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_9a1ed873-efbc-471b-adfa-2b2014b2e85f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_4710bea7-92e5-4b47-ba1d-9d3c1084abbe" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_9a1ed873-efbc-471b-adfa-2b2014b2e85f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_selb_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReservedForIssuanceWeightedAverageGrantDateFairValue_1fd12752-5397-490e-aa72-290044442b95" xlink:href="selb-20210331.xsd#selb_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReservedForIssuanceWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_4710bea7-92e5-4b47-ba1d-9d3c1084abbe" xlink:to="loc_selb_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReservedForIssuanceWeightedAverageGrantDateFairValue_1fd12752-5397-490e-aa72-290044442b95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_a3023512-9a4a-4f88-b6dc-e40aa8b14851" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_4710bea7-92e5-4b47-ba1d-9d3c1084abbe" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_a3023512-9a4a-4f88-b6dc-e40aa8b14851" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_f329bead-b2c6-4949-bc2b-96462f067dc1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_4710bea7-92e5-4b47-ba1d-9d3c1084abbe" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_f329bead-b2c6-4949-bc2b-96462f067dc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.selectabio.com/role/StockIncentivePlansEmployeeStockPurchasePlanNarrativeDetails" xlink:type="simple" xlink:href="selb-20210331.xsd#StockIncentivePlansEmployeeStockPurchasePlanNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.selectabio.com/role/StockIncentivePlansEmployeeStockPurchasePlanNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0fbec399-f5d2-47e5-b3c8-9cd083c0b5db" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b38f6609-4fcd-46b2-a07f-cd850f0b2d0f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0fbec399-f5d2-47e5-b3c8-9cd083c0b5db" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b38f6609-4fcd-46b2-a07f-cd850f0b2d0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_d411a122-71d1-4b7d-85ac-af096b8e96ef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b38f6609-4fcd-46b2-a07f-cd850f0b2d0f" xlink:to="loc_us-gaap_PlanNameAxis_d411a122-71d1-4b7d-85ac-af096b8e96ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_275289a1-e4c5-414a-835a-74c00d3f769d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_d411a122-71d1-4b7d-85ac-af096b8e96ef" xlink:to="loc_us-gaap_PlanNameDomain_275289a1-e4c5-414a-835a-74c00d3f769d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_selb_EmployeeStockPurchasePlan2016Member_f46af2ce-144e-45c3-b61e-40b4acf0669f" xlink:href="selb-20210331.xsd#selb_EmployeeStockPurchasePlan2016Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_275289a1-e4c5-414a-835a-74c00d3f769d" xlink:to="loc_selb_EmployeeStockPurchasePlan2016Member_f46af2ce-144e-45c3-b61e-40b4acf0669f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_635a0fa7-0d69-4cee-87b4-a22ea1d27882" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b38f6609-4fcd-46b2-a07f-cd850f0b2d0f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_635a0fa7-0d69-4cee-87b4-a22ea1d27882" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_368cb339-3c00-4cf1-b8f8-aeabf3c20f6f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_635a0fa7-0d69-4cee-87b4-a22ea1d27882" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_368cb339-3c00-4cf1-b8f8-aeabf3c20f6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_selb_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantIncreaseDecrease_a2af102c-37a2-4208-ba74-52ecf220957b" xlink:href="selb-20210331.xsd#selb_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantIncreaseDecrease"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_635a0fa7-0d69-4cee-87b4-a22ea1d27882" xlink:to="loc_selb_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantIncreaseDecrease_a2af102c-37a2-4208-ba74-52ecf220957b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_c7911938-6927-4cdb-beee-b230c74bc5e1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_635a0fa7-0d69-4cee-87b4-a22ea1d27882" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_c7911938-6927-4cdb-beee-b230c74bc5e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_281462f5-baec-47d1-a5fa-ff6865b7a801" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_635a0fa7-0d69-4cee-87b4-a22ea1d27882" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_281462f5-baec-47d1-a5fa-ff6865b7a801" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.selectabio.com/role/RevenueArrangements" xlink:type="simple" xlink:href="selb-20210331.xsd#RevenueArrangements"/>
  <link:presentationLink xlink:role="http://www.selectabio.com/role/RevenueArrangements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_50b7fbec-104b-4f5e-b3a9-c114944b9c70" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_b01a150a-e990-42b8-84ef-072afd9841ec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_50b7fbec-104b-4f5e-b3a9-c114944b9c70" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_b01a150a-e990-42b8-84ef-072afd9841ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.selectabio.com/role/RevenueArrangementsTables" xlink:type="simple" xlink:href="selb-20210331.xsd#RevenueArrangementsTables"/>
  <link:presentationLink xlink:role="http://www.selectabio.com/role/RevenueArrangementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_b43b4ffa-58bf-4bd9-a872-6175e1b9ce5c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_ef84651a-fdf6-420c-bacc-1185b2313fc4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_b43b4ffa-58bf-4bd9-a872-6175e1b9ce5c" xlink:to="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_ef84651a-fdf6-420c-bacc-1185b2313fc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.selectabio.com/role/RevenueArrangementsNarrativeDetails" xlink:type="simple" xlink:href="selb-20210331.xsd#RevenueArrangementsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.selectabio.com/role/RevenueArrangementsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_823a3c6c-9d59-4d1f-9e0c-5852d1ef10a9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_36cd28f0-943a-4acf-b538-99fbd375a10e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_823a3c6c-9d59-4d1f-9e0c-5852d1ef10a9" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_36cd28f0-943a-4acf-b538-99fbd375a10e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_28242ece-1ebb-4d98-976d-5f6974e084b9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_36cd28f0-943a-4acf-b538-99fbd375a10e" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_28242ece-1ebb-4d98-976d-5f6974e084b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_34ebf0c7-2f20-46bd-91ff-e7a8bdd60bcf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_28242ece-1ebb-4d98-976d-5f6974e084b9" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_34ebf0c7-2f20-46bd-91ff-e7a8bdd60bcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_selb_SareptaTherapeuticsInc.Member_476968bf-8b0f-4806-b5fb-bbb5bd98f387" xlink:href="selb-20210331.xsd#selb_SareptaTherapeuticsInc.Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_34ebf0c7-2f20-46bd-91ff-e7a8bdd60bcf" xlink:to="loc_selb_SareptaTherapeuticsInc.Member_476968bf-8b0f-4806-b5fb-bbb5bd98f387" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_selb_LicenseAgreementForPompeDiseaseMember_15884ba2-dbe0-4a1e-8611-931f5085e075" xlink:href="selb-20210331.xsd#selb_LicenseAgreementForPompeDiseaseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_34ebf0c7-2f20-46bd-91ff-e7a8bdd60bcf" xlink:to="loc_selb_LicenseAgreementForPompeDiseaseMember_15884ba2-dbe0-4a1e-8611-931f5085e075" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_849b4f1b-4df5-49dc-b1a7-d642a6afe5a7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_36cd28f0-943a-4acf-b538-99fbd375a10e" xlink:to="loc_us-gaap_TypeOfArrangementAxis_849b4f1b-4df5-49dc-b1a7-d642a6afe5a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5176bad4-235f-49ac-b37d-9453b7535dba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_849b4f1b-4df5-49dc-b1a7-d642a6afe5a7" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5176bad4-235f-49ac-b37d-9453b7535dba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember_3d4d282d-dec1-40af-82f0-3b765ffa92b8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5176bad4-235f-49ac-b37d-9453b7535dba" xlink:to="loc_us-gaap_CollaborativeArrangementMember_3d4d282d-dec1-40af-82f0-3b765ffa92b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_680fea75-69d5-4e96-b9e9-2c94cd0b1427" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_36cd28f0-943a-4acf-b538-99fbd375a10e" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_680fea75-69d5-4e96-b9e9-2c94cd0b1427" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_5405eff6-60f9-4458-9e14-1d6df56739db" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_680fea75-69d5-4e96-b9e9-2c94cd0b1427" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_5405eff6-60f9-4458-9e14-1d6df56739db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_selb_SOBIPurchaseAgreementMember_f50afca1-4fa6-416a-9ad8-ee81ddc8542e" xlink:href="selb-20210331.xsd#selb_SOBIPurchaseAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_5405eff6-60f9-4458-9e14-1d6df56739db" xlink:to="loc_selb_SOBIPurchaseAgreementMember_f50afca1-4fa6-416a-9ad8-ee81ddc8542e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_90caa9dc-74d5-46dc-b2ac-e4eff4529f4f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_36cd28f0-943a-4acf-b538-99fbd375a10e" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_90caa9dc-74d5-46dc-b2ac-e4eff4529f4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_30d106c1-85e3-4bed-a462-a4649e801c04" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_90caa9dc-74d5-46dc-b2ac-e4eff4529f4f" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_30d106c1-85e3-4bed-a462-a4649e801c04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_0bcb2086-97f9-481d-bd99-7d1979eb07d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_30d106c1-85e3-4bed-a462-a4649e801c04" xlink:to="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_0bcb2086-97f9-481d-bd99-7d1979eb07d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentAssetsMember_210225a9-d151-4749-9c55-d7b286a445c2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCurrentAssetsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_30d106c1-85e3-4bed-a462-a4649e801c04" xlink:to="loc_us-gaap_OtherCurrentAssetsMember_210225a9-d151-4749-9c55-d7b286a445c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_79659bac-2442-488a-a7ad-4a70e9a916b3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_36cd28f0-943a-4acf-b538-99fbd375a10e" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_79659bac-2442-488a-a7ad-4a70e9a916b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_selb_LicenseAndOptionAgreementUpfrontCashPayment_13ab6ae6-ac11-4f50-ba15-3ef56d01f61b" xlink:href="selb-20210331.xsd#selb_LicenseAndOptionAgreementUpfrontCashPayment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_79659bac-2442-488a-a7ad-4a70e9a916b3" xlink:to="loc_selb_LicenseAndOptionAgreementUpfrontCashPayment_13ab6ae6-ac11-4f50-ba15-3ef56d01f61b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_selb_LicenseAndOptionAgreementSalesMilestonePaymentsThatMayBeReceived_76133636-e706-4a43-80b1-b965c3e6c677" xlink:href="selb-20210331.xsd#selb_LicenseAndOptionAgreementSalesMilestonePaymentsThatMayBeReceived"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_79659bac-2442-488a-a7ad-4a70e9a916b3" xlink:to="loc_selb_LicenseAndOptionAgreementSalesMilestonePaymentsThatMayBeReceived_76133636-e706-4a43-80b1-b965c3e6c677" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_selb_LicenseAndOptionAgreementWrittenDayNoticePeriodBeforeCancellation_7c3958d3-4c79-4e27-b2e3-93efe75c2101" xlink:href="selb-20210331.xsd#selb_LicenseAndOptionAgreementWrittenDayNoticePeriodBeforeCancellation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_79659bac-2442-488a-a7ad-4a70e9a916b3" xlink:to="loc_selb_LicenseAndOptionAgreementWrittenDayNoticePeriodBeforeCancellation_7c3958d3-4c79-4e27-b2e3-93efe75c2101" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_selb_EligiblePeriodToReceiveRoyalties_455870a5-3b40-44a0-8513-0222f345e32a" xlink:href="selb-20210331.xsd#selb_EligiblePeriodToReceiveRoyalties"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_79659bac-2442-488a-a7ad-4a70e9a916b3" xlink:to="loc_selb_EligiblePeriodToReceiveRoyalties_455870a5-3b40-44a0-8513-0222f345e32a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_selb_RevenueNumberOfPerformanceObligations_00cd293e-5c90-4c75-a531-1e49ddd5bcbd" xlink:href="selb-20210331.xsd#selb_RevenueNumberOfPerformanceObligations"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_79659bac-2442-488a-a7ad-4a70e9a916b3" xlink:to="loc_selb_RevenueNumberOfPerformanceObligations_00cd293e-5c90-4c75-a531-1e49ddd5bcbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_selb_LicenseAndOptionAgreementDevelopmentMilestone_2e7c47e9-dcbe-4d70-af42-b5c50f78c4b9" xlink:href="selb-20210331.xsd#selb_LicenseAndOptionAgreementDevelopmentMilestone"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_79659bac-2442-488a-a7ad-4a70e9a916b3" xlink:to="loc_selb_LicenseAndOptionAgreementDevelopmentMilestone_2e7c47e9-dcbe-4d70-af42-b5c50f78c4b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_1dfcf109-50b8-493c-bbf5-1cf56765c7df" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_79659bac-2442-488a-a7ad-4a70e9a916b3" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_1dfcf109-50b8-493c-bbf5-1cf56765c7df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedemptionPremium_5851f9e1-b351-415f-959c-4baede187ed6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RedemptionPremium"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_79659bac-2442-488a-a7ad-4a70e9a916b3" xlink:to="loc_us-gaap_RedemptionPremium_5851f9e1-b351-415f-959c-4baede187ed6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_21c8c43b-946e-4834-83bd-b16c1a9a2206" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_79659bac-2442-488a-a7ad-4a70e9a916b3" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_21c8c43b-946e-4834-83bd-b16c1a9a2206" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_2b1d0633-9405-45be-a46a-c64ac3e6aeba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_79659bac-2442-488a-a7ad-4a70e9a916b3" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_2b1d0633-9405-45be-a46a-c64ac3e6aeba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetCurrent_3a24f5b6-ef0e-428a-970e-2f180fc14959" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerAssetNetCurrent"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_79659bac-2442-488a-a7ad-4a70e9a916b3" xlink:to="loc_us-gaap_ContractWithCustomerAssetNetCurrent_3a24f5b6-ef0e-428a-970e-2f180fc14959" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostAmortization_fcc64c1e-1e6f-4f4e-a1c2-bc786a3191cb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalizedContractCostAmortization"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_79659bac-2442-488a-a7ad-4a70e9a916b3" xlink:to="loc_us-gaap_CapitalizedContractCostAmortization_fcc64c1e-1e6f-4f4e-a1c2-bc786a3191cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_29e43f70-826e-41aa-8d63-47912570f7ba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_79659bac-2442-488a-a7ad-4a70e9a916b3" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_29e43f70-826e-41aa-8d63-47912570f7ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_e8f22053-84fb-416d-b6a2-b295ada430c3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_79659bac-2442-488a-a7ad-4a70e9a916b3" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_e8f22053-84fb-416d-b6a2-b295ada430c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_selb_LicenseAndOptionAgreementOptionTerm_f8233786-a695-4353-a1a3-dfbf97cd40bd" xlink:href="selb-20210331.xsd#selb_LicenseAndOptionAgreementOptionTerm"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_79659bac-2442-488a-a7ad-4a70e9a916b3" xlink:to="loc_selb_LicenseAndOptionAgreementOptionTerm_f8233786-a695-4353-a1a3-dfbf97cd40bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_selb_LicenseAndOptionAgreementInitialUpFrontCashPayment_3c6fa286-bea2-4c27-a44c-1fc72a9e5110" xlink:href="selb-20210331.xsd#selb_LicenseAndOptionAgreementInitialUpFrontCashPayment"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_79659bac-2442-488a-a7ad-4a70e9a916b3" xlink:to="loc_selb_LicenseAndOptionAgreementInitialUpFrontCashPayment_3c6fa286-bea2-4c27-a44c-1fc72a9e5110" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_selb_LicenseAndOptionAgreementExecutionFeePayment_da776e2e-0c8a-4c3f-a7d3-06a7d40271e5" xlink:href="selb-20210331.xsd#selb_LicenseAndOptionAgreementExecutionFeePayment"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_79659bac-2442-488a-a7ad-4a70e9a916b3" xlink:to="loc_selb_LicenseAndOptionAgreementExecutionFeePayment_da776e2e-0c8a-4c3f-a7d3-06a7d40271e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_85d62f48-acc5-4be8-9a8e-e761b7ce3c61" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_79659bac-2442-488a-a7ad-4a70e9a916b3" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_85d62f48-acc5-4be8-9a8e-e761b7ce3c61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.selectabio.com/role/RevenueArrangementsScheduleofChangesinContractLiabilitiesDetails" xlink:type="simple" xlink:href="selb-20210331.xsd#RevenueArrangementsScheduleofChangesinContractLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.selectabio.com/role/RevenueArrangementsScheduleofChangesinContractLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_a0b8b66d-4aec-476e-97cf-0eb02682639f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_selb_ChangeInContractWithCustomerLiabilityRollForward_9679cea4-8ef7-4547-84c7-b95ee2bb40ae" xlink:href="selb-20210331.xsd#selb_ChangeInContractWithCustomerLiabilityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_a0b8b66d-4aec-476e-97cf-0eb02682639f" xlink:to="loc_selb_ChangeInContractWithCustomerLiabilityRollForward_9679cea4-8ef7-4547-84c7-b95ee2bb40ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_selb_ContractwithCustomerLiabilityDeferredRevenue_597c3b4b-775f-4a6a-9ec3-f51f3572354e" xlink:href="selb-20210331.xsd#selb_ContractwithCustomerLiabilityDeferredRevenue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_selb_ChangeInContractWithCustomerLiabilityRollForward_9679cea4-8ef7-4547-84c7-b95ee2bb40ae" xlink:to="loc_selb_ContractwithCustomerLiabilityDeferredRevenue_597c3b4b-775f-4a6a-9ec3-f51f3572354e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_1116dd94-0698-4468-b319-529d301b3502" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_selb_ChangeInContractWithCustomerLiabilityRollForward_9679cea4-8ef7-4547-84c7-b95ee2bb40ae" xlink:to="loc_us-gaap_ContractWithCustomerLiability_1116dd94-0698-4468-b319-529d301b3502" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_selb_ContractwithCustomerLiabilityDeferredRevenueIncreaseFromCashReceipts_b17d6738-86ae-4715-a498-eb9146e73d0f" xlink:href="selb-20210331.xsd#selb_ContractwithCustomerLiabilityDeferredRevenueIncreaseFromCashReceipts"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_selb_ChangeInContractWithCustomerLiabilityRollForward_9679cea4-8ef7-4547-84c7-b95ee2bb40ae" xlink:to="loc_selb_ContractwithCustomerLiabilityDeferredRevenueIncreaseFromCashReceipts_b17d6738-86ae-4715-a498-eb9146e73d0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_selb_ContractwithCustomerLiabilityIncreaseFromCashReceipts_c225a3f7-3801-4f5a-bef6-28d695531622" xlink:href="selb-20210331.xsd#selb_ContractwithCustomerLiabilityIncreaseFromCashReceipts"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_selb_ChangeInContractWithCustomerLiabilityRollForward_9679cea4-8ef7-4547-84c7-b95ee2bb40ae" xlink:to="loc_selb_ContractwithCustomerLiabilityIncreaseFromCashReceipts_c225a3f7-3801-4f5a-bef6-28d695531622" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_selb_ContractwithCustomerLiabilityDeferredRevenueRevenueRecognized_5a5e18c5-f566-4cc0-b7f9-d7de32c94cbf" xlink:href="selb-20210331.xsd#selb_ContractwithCustomerLiabilityDeferredRevenueRevenueRecognized"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_selb_ChangeInContractWithCustomerLiabilityRollForward_9679cea4-8ef7-4547-84c7-b95ee2bb40ae" xlink:to="loc_selb_ContractwithCustomerLiabilityDeferredRevenueRevenueRecognized_5a5e18c5-f566-4cc0-b7f9-d7de32c94cbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_d3dd8f39-4aa4-4a37-9138-9a8ab96052be" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_selb_ChangeInContractWithCustomerLiabilityRollForward_9679cea4-8ef7-4547-84c7-b95ee2bb40ae" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_d3dd8f39-4aa4-4a37-9138-9a8ab96052be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_selb_ContractwithCustomerLiabilityDeferredRevenue_392738da-2f3a-4be7-8c30-6d69cce5714e" xlink:href="selb-20210331.xsd#selb_ContractwithCustomerLiabilityDeferredRevenue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_selb_ChangeInContractWithCustomerLiabilityRollForward_9679cea4-8ef7-4547-84c7-b95ee2bb40ae" xlink:to="loc_selb_ContractwithCustomerLiabilityDeferredRevenue_392738da-2f3a-4be7-8c30-6d69cce5714e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_1c57b517-b1a5-4f6b-b2e0-cc836ae2008c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_selb_ChangeInContractWithCustomerLiabilityRollForward_9679cea4-8ef7-4547-84c7-b95ee2bb40ae" xlink:to="loc_us-gaap_ContractWithCustomerLiability_1c57b517-b1a5-4f6b-b2e0-cc836ae2008c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.selectabio.com/role/RelatedPartyTransactions" xlink:type="simple" xlink:href="selb-20210331.xsd#RelatedPartyTransactions"/>
  <link:presentationLink xlink:role="http://www.selectabio.com/role/RelatedPartyTransactions" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_6d420b02-d304-46bc-bced-52987c98920b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_dcfbb488-4dfe-41ca-a972-0107e358488f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_6d420b02-d304-46bc-bced-52987c98920b" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_dcfbb488-4dfe-41ca-a972-0107e358488f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.selectabio.com/role/RelatedPartyTransactionsNarrativeDetails" xlink:type="simple" xlink:href="selb-20210331.xsd#RelatedPartyTransactionsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.selectabio.com/role/RelatedPartyTransactionsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_98e97918-2826-440f-b8ff-b3f48a7d7811" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_5d917cdc-fa04-4087-a362-bd8165d84e60" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_98e97918-2826-440f-b8ff-b3f48a7d7811" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_5d917cdc-fa04-4087-a362-bd8165d84e60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2d138ded-a741-4012-bb60-22715dcec991" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_5d917cdc-fa04-4087-a362-bd8165d84e60" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2d138ded-a741-4012-bb60-22715dcec991" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_0678c36d-60c7-4f98-89f7-5a6cc966425b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2d138ded-a741-4012-bb60-22715dcec991" xlink:to="loc_us-gaap_RelatedPartyDomain_0678c36d-60c7-4f98-89f7-5a6cc966425b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_selb_FounderMember_b4a86499-4872-4907-bba9-1d0384918e95" xlink:href="selb-20210331.xsd#selb_FounderMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_0678c36d-60c7-4f98-89f7-5a6cc966425b" xlink:to="loc_selb_FounderMember_b4a86499-4872-4907-bba9-1d0384918e95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_8ca4f902-8cfb-4c6d-9de2-758a5c8e37e8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_5d917cdc-fa04-4087-a362-bd8165d84e60" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_8ca4f902-8cfb-4c6d-9de2-758a5c8e37e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_c6c66516-5cf8-448b-8eb9-3253ab7a688e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_8ca4f902-8cfb-4c6d-9de2-758a5c8e37e8" xlink:to="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_c6c66516-5cf8-448b-8eb9-3253ab7a688e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.selectabio.com/role/CollaborationAgreements" xlink:type="simple" xlink:href="selb-20210331.xsd#CollaborationAgreements"/>
  <link:presentationLink xlink:role="http://www.selectabio.com/role/CollaborationAgreements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_fdae8543-7f3e-4704-ae27-f0af25f010f2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_selb_CollaborationAndLicenseAgreementsTextBlock_7ab26e1f-f5b1-45ca-a21f-c732b5dca1c5" xlink:href="selb-20210331.xsd#selb_CollaborationAndLicenseAgreementsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_fdae8543-7f3e-4704-ae27-f0af25f010f2" xlink:to="loc_selb_CollaborationAndLicenseAgreementsTextBlock_7ab26e1f-f5b1-45ca-a21f-c732b5dca1c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.selectabio.com/role/CollaborationAgreementsAskBioNarrativeDetails" xlink:type="simple" xlink:href="selb-20210331.xsd#CollaborationAgreementsAskBioNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.selectabio.com/role/CollaborationAgreementsAskBioNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_c8951e7c-9907-49a6-88e2-33128667fcb0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_53c396ca-09ab-4321-9be1-d06f40dca429" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_c8951e7c-9907-49a6-88e2-33128667fcb0" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_53c396ca-09ab-4321-9be1-d06f40dca429" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_3b234fea-c637-4a24-b92a-5b94a232a5fc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_53c396ca-09ab-4321-9be1-d06f40dca429" xlink:to="loc_us-gaap_TypeOfArrangementAxis_3b234fea-c637-4a24-b92a-5b94a232a5fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5140dfd0-f508-4f5e-aa71-8b4f26520215" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_3b234fea-c637-4a24-b92a-5b94a232a5fc" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5140dfd0-f508-4f5e-aa71-8b4f26520215" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_selb_AskBioLicenseMember_18df95e5-08c6-4707-9805-b6c1de812347" xlink:href="selb-20210331.xsd#selb_AskBioLicenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5140dfd0-f508-4f5e-aa71-8b4f26520215" xlink:to="loc_selb_AskBioLicenseMember_18df95e5-08c6-4707-9805-b6c1de812347" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b8e2fba1-011a-4f19-81ad-5dd7530ed3e7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_53c396ca-09ab-4321-9be1-d06f40dca429" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b8e2fba1-011a-4f19-81ad-5dd7530ed3e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_9325cce4-7b32-477e-a11d-9647699feb39" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b8e2fba1-011a-4f19-81ad-5dd7530ed3e7" xlink:to="loc_us-gaap_OperatingExpenses_9325cce4-7b32-477e-a11d-9647699feb39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_selb_CollaborativeArrangementCostSharePercentage_db79dab8-075f-4d85-9661-af9d196fab97" xlink:href="selb-20210331.xsd#selb_CollaborativeArrangementCostSharePercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b8e2fba1-011a-4f19-81ad-5dd7530ed3e7" xlink:to="loc_selb_CollaborativeArrangementCostSharePercentage_db79dab8-075f-4d85-9661-af9d196fab97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.selectabio.com/role/CollaborationAgreementsMITNarrativeDetails" xlink:type="simple" xlink:href="selb-20210331.xsd#CollaborationAgreementsMITNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.selectabio.com/role/CollaborationAgreementsMITNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_f78bafeb-2a10-4cf4-89ab-a932dbb03015" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_2e359854-5903-4add-9237-81b891e77e7c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_f78bafeb-2a10-4cf4-89ab-a932dbb03015" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_2e359854-5903-4add-9237-81b891e77e7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_21b45901-4be0-4195-af68-4a41936b3882" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_2e359854-5903-4add-9237-81b891e77e7c" xlink:to="loc_us-gaap_TypeOfArrangementAxis_21b45901-4be0-4195-af68-4a41936b3882" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2f9e6c7f-b61e-4e3f-ae77-5a1da1d792b2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_21b45901-4be0-4195-af68-4a41936b3882" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2f9e6c7f-b61e-4e3f-ae77-5a1da1d792b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_selb_ExclusivePatentLicenseAgreementWithMassachusettsInstituteOfTechnologyMember_2580c581-0edd-42fb-9a21-22e0164097ee" xlink:href="selb-20210331.xsd#selb_ExclusivePatentLicenseAgreementWithMassachusettsInstituteOfTechnologyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2f9e6c7f-b61e-4e3f-ae77-5a1da1d792b2" xlink:to="loc_selb_ExclusivePatentLicenseAgreementWithMassachusettsInstituteOfTechnologyMember_2580c581-0edd-42fb-9a21-22e0164097ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_f195b507-8b8b-4881-a118-73f962830038" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_2e359854-5903-4add-9237-81b891e77e7c" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_f195b507-8b8b-4881-a118-73f962830038" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_b199355c-3bc8-41ff-a327-5ab9e6d9f54e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_f195b507-8b8b-4881-a118-73f962830038" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_b199355c-3bc8-41ff-a327-5ab9e6d9f54e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseAgreementTermsMember_2fc53041-f761-4ad9-9ea4-099b20f8cf97" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicenseAgreementTermsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_b199355c-3bc8-41ff-a327-5ab9e6d9f54e" xlink:to="loc_us-gaap_LicenseAgreementTermsMember_2fc53041-f761-4ad9-9ea4-099b20f8cf97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a3c0929a-eb69-4d06-bb05-75f6ac1d9194" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_2e359854-5903-4add-9237-81b891e77e7c" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a3c0929a-eb69-4d06-bb05-75f6ac1d9194" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_selb_LicenseAndOptionAgreementContractualPaymentsMade_01f20812-6fa2-4d8a-a053-2f2b130f5382" xlink:href="selb-20210331.xsd#selb_LicenseAndOptionAgreementContractualPaymentsMade"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a3c0929a-eb69-4d06-bb05-75f6ac1d9194" xlink:to="loc_selb_LicenseAndOptionAgreementContractualPaymentsMade_01f20812-6fa2-4d8a-a053-2f2b130f5382" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_selb_LicenseAndOptionAgreementCalculatedPremiumPaidForEquityInvestmentUnderPurchaseAgreement_64315d89-5d15-4545-a20e-294221be6b25" xlink:href="selb-20210331.xsd#selb_LicenseAndOptionAgreementCalculatedPremiumPaidForEquityInvestmentUnderPurchaseAgreement"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a3c0929a-eb69-4d06-bb05-75f6ac1d9194" xlink:to="loc_selb_LicenseAndOptionAgreementCalculatedPremiumPaidForEquityInvestmentUnderPurchaseAgreement_64315d89-5d15-4545-a20e-294221be6b25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.selectabio.com/role/CollaborationAgreementsShenyangSunshinePharmaceuticalCoLtdNarrativeDetails" xlink:type="simple" xlink:href="selb-20210331.xsd#CollaborationAgreementsShenyangSunshinePharmaceuticalCoLtdNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.selectabio.com/role/CollaborationAgreementsShenyangSunshinePharmaceuticalCoLtdNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_e5959ca3-0b03-4030-87b1-a92168004053" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_5c2d8b42-fc2f-4dfb-aa56-ee1ac850faf5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_e5959ca3-0b03-4030-87b1-a92168004053" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_5c2d8b42-fc2f-4dfb-aa56-ee1ac850faf5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_f2aec8d9-d591-4c5c-bb28-79b67c352c80" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_5c2d8b42-fc2f-4dfb-aa56-ee1ac850faf5" xlink:to="loc_us-gaap_TypeOfArrangementAxis_f2aec8d9-d591-4c5c-bb28-79b67c352c80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e8925e2e-6b61-430b-80c0-28e30cac631f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_f2aec8d9-d591-4c5c-bb28-79b67c352c80" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e8925e2e-6b61-430b-80c0-28e30cac631f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_selb_LicenseAgreementWithShenyangSunshinePharmaceuticalCompanyLimitedMember_17f4f333-5a51-40a7-a0c6-0ba99ff7bb38" xlink:href="selb-20210331.xsd#selb_LicenseAgreementWithShenyangSunshinePharmaceuticalCompanyLimitedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e8925e2e-6b61-430b-80c0-28e30cac631f" xlink:to="loc_selb_LicenseAgreementWithShenyangSunshinePharmaceuticalCompanyLimitedMember_17f4f333-5a51-40a7-a0c6-0ba99ff7bb38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b0d57d48-781e-4636-912e-6f283dd53682" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_5c2d8b42-fc2f-4dfb-aa56-ee1ac850faf5" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b0d57d48-781e-4636-912e-6f283dd53682" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_selb_AggregateAmountOfUpfrontAndMilestoneBasedPaymentsPaid_67ed3e6e-b5c6-4c6a-b0b3-671650486576" xlink:href="selb-20210331.xsd#selb_AggregateAmountOfUpfrontAndMilestoneBasedPaymentsPaid"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b0d57d48-781e-4636-912e-6f283dd53682" xlink:to="loc_selb_AggregateAmountOfUpfrontAndMilestoneBasedPaymentsPaid_67ed3e6e-b5c6-4c6a-b0b3-671650486576" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_selb_AggregateAmountForFuturePaymentsUponAchievementOfClinicalAndRegulatoryApprovalMilestonesForProductsContainingImmTORPlatform_73b2935a-ad27-4e31-b02c-cf7027652643" xlink:href="selb-20210331.xsd#selb_AggregateAmountForFuturePaymentsUponAchievementOfClinicalAndRegulatoryApprovalMilestonesForProductsContainingImmTORPlatform"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b0d57d48-781e-4636-912e-6f283dd53682" xlink:to="loc_selb_AggregateAmountForFuturePaymentsUponAchievementOfClinicalAndRegulatoryApprovalMilestonesForProductsContainingImmTORPlatform_73b2935a-ad27-4e31-b02c-cf7027652643" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.selectabio.com/role/IncomeTaxes" xlink:type="simple" xlink:href="selb-20210331.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://www.selectabio.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_b2397c80-cb0d-4845-b923-d48dbbd634f3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_99a51bba-a7d7-40e6-8979-8d819ca8fdde" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_b2397c80-cb0d-4845-b923-d48dbbd634f3" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_99a51bba-a7d7-40e6-8979-8d819ca8fdde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.selectabio.com/role/IncomeTaxesNarrativeDetails" xlink:type="simple" xlink:href="selb-20210331.xsd#IncomeTaxesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.selectabio.com/role/IncomeTaxesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_4585b044-3ec4-4c07-bd54-ee504d55730c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_eec4addb-c8c6-4669-a928-463eb8b305a9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_4585b044-3ec4-4c07-bd54-ee504d55730c" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_eec4addb-c8c6-4669-a928-463eb8b305a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_c2262d3a-4283-4ada-8f82-17d0f14ab3b2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_4585b044-3ec4-4c07-bd54-ee504d55730c" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_c2262d3a-4283-4ada-8f82-17d0f14ab3b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_b43c96a5-cca3-4188-9be5-9862d4bce3d7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_4585b044-3ec4-4c07-bd54-ee504d55730c" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_b43c96a5-cca3-4188-9be5-9862d4bce3d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.selectabio.com/role/DefinedContributionPlan" xlink:type="simple" xlink:href="selb-20210331.xsd#DefinedContributionPlan"/>
  <link:presentationLink xlink:role="http://www.selectabio.com/role/DefinedContributionPlan" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_3c0bd034-40d7-4ec6-99d5-995ee5b7c841" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_50a8890b-fc7b-4b63-aea2-e7a2784aa5aa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_3c0bd034-40d7-4ec6-99d5-995ee5b7c841" xlink:to="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_50a8890b-fc7b-4b63-aea2-e7a2784aa5aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.selectabio.com/role/DefinedContributionPlanNarrativeDetails" xlink:type="simple" xlink:href="selb-20210331.xsd#DefinedContributionPlanNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.selectabio.com/role/DefinedContributionPlanNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_90b60373-eb5c-4131-88fc-98139d530cfd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_selb_DefinedContributionPlanEmployersMatchingContributionVestingPeriod_a7423aca-10b1-4340-8154-b6eb82ee665c" xlink:href="selb-20210331.xsd#selb_DefinedContributionPlanEmployersMatchingContributionVestingPeriod"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_90b60373-eb5c-4131-88fc-98139d530cfd" xlink:to="loc_selb_DefinedContributionPlanEmployersMatchingContributionVestingPeriod_a7423aca-10b1-4340-8154-b6eb82ee665c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized_e0aa409e-8e45-4098-80eb-9c8f78e5e71f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanCostRecognized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_90b60373-eb5c-4131-88fc-98139d530cfd" xlink:to="loc_us-gaap_DefinedContributionPlanCostRecognized_e0aa409e-8e45-4098-80eb-9c8f78e5e71f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.selectabio.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="selb-20210331.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://www.selectabio.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_ba4202f8-467f-41b6-b93c-862b89505028" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_dedf9c62-a4d7-4d24-a96a-9d2344755e42" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_ba4202f8-467f-41b6-b93c-862b89505028" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_dedf9c62-a4d7-4d24-a96a-9d2344755e42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.selectabio.com/role/SubsequentEvents" xlink:type="simple" xlink:href="selb-20210331.xsd#SubsequentEvents"/>
  <link:presentationLink xlink:role="http://www.selectabio.com/role/SubsequentEvents" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_48fb3a52-3920-413c-9ffe-9cd849b57bd8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_712f7349-d632-4954-83e3-b2d0bec3b49e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_48fb3a52-3920-413c-9ffe-9cd849b57bd8" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_712f7349-d632-4954-83e3-b2d0bec3b49e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.selectabio.com/role/SubsequentEventsDetails" xlink:type="simple" xlink:href="selb-20210331.xsd#SubsequentEventsDetails"/>
  <link:presentationLink xlink:role="http://www.selectabio.com/role/SubsequentEventsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_bf2b5177-dc86-4e02-8b93-e8c2a9bf81b9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_e87f466d-dd02-4fe0-869d-76b369a7656b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_bf2b5177-dc86-4e02-8b93-e8c2a9bf81b9" xlink:to="loc_us-gaap_SubsequentEventTable_e87f466d-dd02-4fe0-869d-76b369a7656b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_19a65b54-8294-4e0e-8db8-8e6b35673ed0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_e87f466d-dd02-4fe0-869d-76b369a7656b" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_19a65b54-8294-4e0e-8db8-8e6b35673ed0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_77917451-e28f-456c-aa19-5a603d90fdf4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_19a65b54-8294-4e0e-8db8-8e6b35673ed0" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_77917451-e28f-456c-aa19-5a603d90fdf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_0f58e5d1-7f1d-467a-9abf-ee18036cbe70" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_77917451-e28f-456c-aa19-5a603d90fdf4" xlink:to="loc_us-gaap_SubsequentEventMember_0f58e5d1-7f1d-467a-9abf-ee18036cbe70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_4fc40fbf-6c4d-48e8-b4a6-512f1df78abc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_e87f466d-dd02-4fe0-869d-76b369a7656b" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_4fc40fbf-6c4d-48e8-b4a6-512f1df78abc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2f5d8d02-9ba1-4f1a-8eaf-4b11b4d0f48a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_4fc40fbf-6c4d-48e8-b4a6-512f1df78abc" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2f5d8d02-9ba1-4f1a-8eaf-4b11b4d0f48a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_selb_A2020SaleAgreementAtTheMarketOfferingMember_17d6d09b-27fc-4dda-959e-03ec1fa77ec5" xlink:href="selb-20210331.xsd#selb_A2020SaleAgreementAtTheMarketOfferingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2f5d8d02-9ba1-4f1a-8eaf-4b11b4d0f48a" xlink:to="loc_selb_A2020SaleAgreementAtTheMarketOfferingMember_17d6d09b-27fc-4dda-959e-03ec1fa77ec5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_b6782ae1-36a9-49e5-baa8-aa73f9aea180" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_e87f466d-dd02-4fe0-869d-76b369a7656b" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_b6782ae1-36a9-49e5-baa8-aa73f9aea180" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_88956298-0bfa-4416-b129-7e5d06d0e443" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_b6782ae1-36a9-49e5-baa8-aa73f9aea180" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_88956298-0bfa-4416-b129-7e5d06d0e443" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_selb_SareptaTherapeuticsInc.Member_aa9952cf-1e20-41b4-96c9-c7d4de4609c4" xlink:href="selb-20210331.xsd#selb_SareptaTherapeuticsInc.Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_88956298-0bfa-4416-b129-7e5d06d0e443" xlink:to="loc_selb_SareptaTherapeuticsInc.Member_aa9952cf-1e20-41b4-96c9-c7d4de4609c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_ab767959-8821-4bc5-bedb-e8d071e49092" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_e87f466d-dd02-4fe0-869d-76b369a7656b" xlink:to="loc_srt_StatementScenarioAxis_ab767959-8821-4bc5-bedb-e8d071e49092" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_42723d6d-e277-4009-87b0-61a32819b5fb" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_ab767959-8821-4bc5-bedb-e8d071e49092" xlink:to="loc_srt_ScenarioUnspecifiedDomain_42723d6d-e277-4009-87b0-61a32819b5fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_23050e80-08cb-4920-9785-c7cff4f8488d" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_42723d6d-e277-4009-87b0-61a32819b5fb" xlink:to="loc_srt_ScenarioForecastMember_23050e80-08cb-4920-9785-c7cff4f8488d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_5de94e0e-9d2a-488d-932d-089d1ac3df0f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_e87f466d-dd02-4fe0-869d-76b369a7656b" xlink:to="loc_us-gaap_SubsequentEventLineItems_5de94e0e-9d2a-488d-932d-089d1ac3df0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_f608f10e-4033-4073-8c62-116aba259d1f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_5de94e0e-9d2a-488d-932d-089d1ac3df0f" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_f608f10e-4033-4073-8c62-116aba259d1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_bb7827db-4c84-45aa-a522-4a36a2550e91" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_5de94e0e-9d2a-488d-932d-089d1ac3df0f" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_bb7827db-4c84-45aa-a522-4a36a2550e91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_6e3f263a-0704-4c3b-9833-f885b4a846ed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_5de94e0e-9d2a-488d-932d-089d1ac3df0f" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_6e3f263a-0704-4c3b-9833-f885b4a846ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_selb_LicenseAndOptionAgreementMilestonePayments_96913c60-7736-4d18-8937-37724a2ea949" xlink:href="selb-20210331.xsd#selb_LicenseAndOptionAgreementMilestonePayments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_5de94e0e-9d2a-488d-932d-089d1ac3df0f" xlink:to="loc_selb_LicenseAndOptionAgreementMilestonePayments_96913c60-7736-4d18-8937-37724a2ea949" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>selb-20210331_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2020-01-31"
  xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:selb="http://www.selectabio.com/20210331"
  xmlns:srt="http://fasb.org/srt/2020-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="selb-20210331.xsd" xlink:type="simple"/>
    <context id="i93f17f89c13f486486776019ba38a82f_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i1872bfbdd04e4f9e825f592f3b317647_I20210507">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
        </entity>
        <period>
            <instant>2021-05-07</instant>
        </period>
    </context>
    <context id="ied8d945ebce54ed8a4badfed477a64e8_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ib56f1adc867e406ca7face50c5da1c9c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i824a5b33f908426bad016f0eded844db_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i28d60e6e11b845dfb37da5a84a9cc1e5_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id4c7f024803c4bb7abe0167bbe5af671_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6cd8f7abd235450ab64356048dc9ec07_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie0acbe76b2ae438d975dc022af481d6c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="idce850cc47714092ba1dcaa145785537_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ic39deec9ab0844a9b0dab300f1a2804d_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ic7469ad2eea94378b3c60b0767ec2c61_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i9ba514a4defc485e94d0b416ba59c49d_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i0f01a127e9094f2c9ce7fa5a13678fc4_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i7a24e3ea770740729c391207bf51dce3_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i64c04c765b7b44e8b62c73e17992956e_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i697921663ff44d1ba22263ce04047fe4_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i8f5d5586be294d54be1415ab00417669_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ia6d22df4e633466eb268453a386261b9_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ic85d5ba0da864526935be1f5158d2390_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i48c9319650af4a498d62dfe592f8cfdd_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="iabdd66a36794438ab9664178bf3cf96a_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ie0acb7061950472c9ffc5dee59b3f7d1_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i22171a0001464fdbaeb20c2221b2f800_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ia8bafce0cbb84adc8382dec4a0321316_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ie102296cb93f4d219e9e9aeb38383744_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i708ad43bbcdd433f8815781dc1dabef7_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i6de5cd0af433469ea596afb9aa70a75b_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i8407594575184affb099a506cf4761ad_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i6914e325d1a54348910a4641d7f828c4_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="iff7e2530342c41bca8c84fce55f0cc6f_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i2fa0062d7932481c8274387fef46611d_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:RU</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ic3c76b1f92aa42d09acee15de07994bb_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i14e2b8def247421298d392498e8d2a2c_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i9c2d6525939d4e4f8c2b60bce2f66a52_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ie177f33c2b9e48b2b637240e8939d8ae_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i025312c2f622403398c380c781b5be0a_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="iafc609c73df642828d67d21ca85d518a_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i13a4d3bd3f0f4f058f62ef7fd2966851_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i1a544c9a0a0e439c9ee87934aaffd7fe_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i65d0ac8f7c4649d2abfce4eda0ef5c55_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i73fe924a4c6b473cabf17b9976a4603b_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i4f0d06e989014726b8fbec56b2c70e58_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i62606fe1b8724fb5a3af6c257e69c07f_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i34e52dcd53c6432595cfbcb02112eb8b_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="id1a9f3d45e4741d9adb5d0a140f27245_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="if2bb46350e76491c82ca4f7ee3718824_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i59a1a80dbf8e4190b547bba901361077_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ife613bc7097a4d25b505ac69b2a556a1_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i9c477876ef1243f7b607ededf27faa28_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="id5b76767b65e416baf32d9fa8ea057ac_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i78a9cb54375140a3926493d7ca71f588_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ief7e41d172914136a4d75381f191624f_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="if08a10047a654aaca135de61c8732df2_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="if36d86949e87479898a50e28488ef27e_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i4bc11fa50e194e0fabd48feb4957cccd_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ie881e34b7b6e451a8635ff1a48715e24_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3415f69e0c84403290f2c597fcafb421_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="icd1ec9843c3446469cb04e17862f007e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3e2993ab72c94021ac21ee14bcd929f2_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib217ca012a534d9a9f5dedd2b37941f0_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i631a8e963f31434e8ea74e97de9ea103_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7e3199d724344066b7d92c08835c0d7b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i067beaf80d0645c0b74a43ced34f040f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ibd87cf2a903e47a68471682c6f1d3125_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i09c393762b464d30a19a24b55c2f5d20_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i173ee7e9fa254b81bffe4952d975b4c0_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i519d4d01a3ff4f27a9efdf217e061704_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="iba23f9d46a1d4b2f897e63f5c2c1d4bb_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i118f57dc685b47c8b1b5f190c4eed731_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="icf08fe145a214d8bacaa57c857186979_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="id99ce4003b574f658d3b62852041d661_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i7a27424e288a444c8c666f3eeb249646_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">selb:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ib5f80b2977824ab9ba0203bc6a11a58e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">selb:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia943ee9b105d42cba901af1e6a454c40_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i56d15e17ec144f96957c4fb601aba227_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iad5e74cc7867456d841ede0490c532e2_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i7b0035fcfb7b4ad5a466a8875b9526aa_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i071771a6ccb1419ca97dd0dfaf4f2526_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i5879070723fe4b008e2b38909e05fbe9_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ibf4df6273b36402f8f2fc2b5d47437bd_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i44f41827807b4780adcd3350fc42ab49_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i62030e264c0744b68da329d325fca573_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i42237c8333f54aaa809730ac386b4ae3_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8a6242358159403bbb0d1d272fafb3bc_I20190731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="selb:LeaseArrangementAxis">selb:A65GroveStreetWatertownMAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-07-31</instant>
        </period>
    </context>
    <context id="i3fe0080183054a06885fd48ac35a21f1_D20190701-20190731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="selb:LeaseArrangementAxis">selb:A65GroveStreetWatertownMAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-07-31</endDate>
        </period>
    </context>
    <context id="i98e030263a7d4c9fbb0733a011655549_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i012a579920bb42578031fbbc9df1dfd2_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ic49c55aadcfb4e6abcca12c5093f9b95_I20200831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">selb:A2020TermLoansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-08-31</instant>
        </period>
    </context>
    <context id="idad7c718ad664d059d7a422e95802f09_I20200831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">selb:TermALoansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-08-31</instant>
        </period>
    </context>
    <context id="ibf84b0dc83f74410887e49db3c27bd26_I20200831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">selb:TermBLoansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-08-31</instant>
        </period>
    </context>
    <context id="i0c9896510dd84101bf9f2e4ccfe3aafb_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">selb:A2020TermLoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="idb510d90210b4690b5f24ea7b3c03117_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">selb:A2020TermLoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i508d18807d32409296e19306139342d3_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">selb:A2020TermLoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="id40f93ddba284a1eaf4d3d96cdbe8228_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">selb:A2020TermLoansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i3fe76a62c9514fceaf15e8fc84c84053_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">selb:A2020TermLoansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i3303eaf5c2074c30aee9f9289696a2e5_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">selb:A2020TermLoansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i2d4605e783914026a19516819dbaac3f_D20200831-20200831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">selb:A2020TermLoansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-31</startDate>
            <endDate>2020-08-31</endDate>
        </period>
    </context>
    <context id="i8096110103d24ead836cc45438a9c346_I20200831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
        </entity>
        <period>
            <instant>2020-08-31</instant>
        </period>
    </context>
    <context id="i23a2063d104e496f85ffd7168cdf9d4c_D20200831-20200831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
        </entity>
        <period>
            <startDate>2020-08-31</startDate>
            <endDate>2020-08-31</endDate>
        </period>
    </context>
    <context id="i7dadb30c8c5644a19242b20dc3231a67_D20200831-20200831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">selb:TermBLoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-31</startDate>
            <endDate>2020-08-31</endDate>
        </period>
    </context>
    <context id="ifaf30d95979d4b7f87adf2a9bc2bf774_D20200831-20200831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">selb:A2017TermLoansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-31</startDate>
            <endDate>2020-08-31</endDate>
        </period>
    </context>
    <context id="ia71eca13c1a4466f9daeb5956381a0e0_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">selb:A2017TermLoansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ied299278fc4543748c5f3ad2970fc3bb_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">selb:A2020TermLoansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ie10a81ae4793423483f2db5739fafba5_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">selb:A2020TermLoansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i867f4cd50cdf4945bf8a2b4c13258dfd_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">selb:A2017TermLoansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i98fb2199c6374722852813ddab2890d7_D20200806-20200806">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">selb:August2020ShelfRegistrationStatementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-06</startDate>
            <endDate>2020-08-06</endDate>
        </period>
    </context>
    <context id="i8b800c16db4f4bf39aec6ba9ec584f99_D20170801-20170831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">selb:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-08-01</startDate>
            <endDate>2017-08-31</endDate>
        </period>
    </context>
    <context id="id4091feb67174db89de51f974b39d21c_D20170801-20170831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">selb:A2020SaleAgreementAtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-08-01</startDate>
            <endDate>2017-08-31</endDate>
        </period>
    </context>
    <context id="ice2d8b62be3849c288862d2279be6e13_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">selb:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ibc930259a91a4e09996f4820308891bd_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">selb:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i677f0fc8ad1f4d2c83a443e0a5bd7e07_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">selb:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i5a706b93dc024e0d96e8ca02c67629d7_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">selb:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i6e736a6ad22d4f7fbc1eda905bef7a23_D20200611-20200611">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">selb:SOBIPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-11</startDate>
            <endDate>2020-06-11</endDate>
        </period>
    </context>
    <context id="i5034b14d18454b028a4c7a4a20bbac44_I20200611">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">selb:SOBIPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-11</instant>
        </period>
    </context>
    <context id="i8d2fc88d756d4b67bf9851793506eee3_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">selb:SOBIPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i0e52f92d6bcb4dd098a7fe0cf721e342_D20200728-20200728">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">selb:SOBIPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-28</startDate>
            <endDate>2020-07-28</endDate>
        </period>
    </context>
    <context id="iff262d3fceb04558bb91b0665eb3295e_D20191218-20191218">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">selb:DecemberTwoThousandNineteenFinancingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-18</startDate>
            <endDate>2019-12-18</endDate>
        </period>
    </context>
    <context id="i04e2a4ab60694adfa2dcd5d722cd132e_I20191218">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">selb:DecemberTwoThousandNineteenFinancingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-18</instant>
        </period>
    </context>
    <context id="i06e21592f529454490acff73efadbef0_I20191218">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">selb:CommonWarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">selb:DecemberTwoThousandNineteenFinancingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-18</instant>
        </period>
    </context>
    <context id="ifc3b4456d78b4865980e0d06be756475_D20191218-20191218">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">selb:PreFundedWarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">selb:DecemberTwoThousandNineteenFinancingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-18</startDate>
            <endDate>2019-12-18</endDate>
        </period>
    </context>
    <context id="ibb1098ccfa7945aa92c2145f660cec87_I20191218">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">selb:PreFundedWarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">selb:DecemberTwoThousandNineteenFinancingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-18</instant>
        </period>
    </context>
    <context id="i40f7108f907b4381983c3f10bfbcbd06_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">selb:DecemberTwoThousandNineteenFinancingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i3c29e75c7cde4be78a2c3d04f4678b57_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">selb:DecemberTwoThousandNineteenFinancingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i2d7bd840e7b3429ba469e9ff77e35cdc_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">selb:DecemberTwoThousandNineteenFinancingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ib2148f5a0b034c99a308352e1c25d052_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i23a3406d8ff1477aa084b096803061e3_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">selb:A2017PIPEMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="id201ea1fc8cd4bc2957bd09c9be775f9_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i766bfbe0d62646d1ae2d0abb4d722110_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ic80bb38a87b34cd5bae8a1c9d61a28e8_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="icaed7df33b254fc68b5b0e15b600935f_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">selb:RestrictedStockUnitsRSUsReservedForIssuanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i9ef78f70a7c34162bf4e7727fba544cc_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">selb:RestrictedStockUnitsRSUsReservedForIssuanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8c5ceec4ab9b487193df89666ccf91d3_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">selb:RestrictedStockUnitsUnvestedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i2595e8b300194cc6bb08ac9d33e9eaf8_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">selb:RestrictedStockUnitsUnvestedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="idc47c16592ad4e7c88824de49ffb8420_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="iaa1769cc2fd04d9ab84daf10f681742a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i659c0d6b1a6b4dde9d2d66b377a3e370_I20160621">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">selb:StockIncentivePlan2016Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-06-21</instant>
        </period>
    </context>
    <context id="ic5906043b3594f21b5de7208dd3fa609_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">selb:StockIncentivePlan2016Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ib2627fa0b80846ab8d39c202e998d601_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">selb:StockIncentivePlan2016Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i91178c8223ca4306a02f4027a764b423_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">selb:StockIncentivePlan2016Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i897bb148c3bb4abb9ea043f39a5a1bbe_I20180925">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">selb:EmploymentInducementIncentiveAwardPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-25</instant>
        </period>
    </context>
    <context id="i90b02123a489453691cedc67052e854c_I20190325">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">selb:EmploymentInducementIncentiveAwardPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-25</instant>
        </period>
    </context>
    <context id="ifb4e42c6f6c44e0f9158bb1c44089423_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">selb:EmploymentInducementIncentiveAwardPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i16033c04e5ea4cc5bbfdba5f3c1bd666_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">selb:ResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i723babe8bc8f40e0843af46b5e72961b_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">selb:ResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i448d50e1226e459ca3870f9edd8b9fef_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i45408aeb6dc44b58bc7a8d6958d23e54_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i0a83cea2026d4acd853ecd648a6ff3cf_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i0a02cb62522c49fd9f650c7a972a0090_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i9b0d673a9945438a9e404b6c6b57eba2_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">selb:A2008Plan2016PlanAnd2018InducementIncentiveAwardPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="icff59de35252465485536be51fa5f610_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">selb:A2008Plan2016PlanAnd2018InducementIncentiveAwardPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia87a6b98f0714c88b1aa992fc475f7a1_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">selb:A2008Plan2016PlanAnd2018InducementIncentiveAwardPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i5a27d4e69f2d4076ab56ee85c1e0a2d3_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">selb:A2008Plan2016PlanAnd2018InducementIncentiveAwardPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i96083ba0423741b898ef5188cabae8f2_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">selb:NonEmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">selb:A2008Plan2016PlanAnd2018InducementIncentiveAwardPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7f9a0d7d151d41348d7f21ab127c2ee1_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">selb:NonEmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">selb:A2008Plan2016PlanAnd2018InducementIncentiveAwardPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i1f2f087904c34f869b3d9a4b4cb9a24e_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">selb:NonEmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">selb:A2008Plan2016PlanAnd2018InducementIncentiveAwardPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i1a4fb26d073f4e2aa150b70c1bdd64cd_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">selb:NonEmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">selb:A2008Plan2016PlanAnd2018InducementIncentiveAwardPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="id01182d93717492b89617d993fbd0c3a_D20210101-20210131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">selb:StockIncentivePlan2016Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-01-31</endDate>
        </period>
    </context>
    <context id="ib1f07535b15b475490cebf99339949e2_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">selb:StockIncentivePlan2016Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i676ae38dc7694143b42a364d53aa820c_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="id4c863b4912a4159803053e1c04bda2f_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">selb:EmploymentInducementIncentiveAwardPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ia7f06d48c2684d27abe5106b2abf1761_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">selb:EmploymentInducementIncentiveAwardPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i23dc483d5e024cd3ab41d280f32cf960_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie9886e2c9856402e9696bea8b5c012ee_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i98884f73b2c2406a9fe17695931498a3_I20160621">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">selb:EmployeeStockPurchasePlan2016Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-06-21</instant>
        </period>
    </context>
    <context id="i3a0400d76b2a4414a1b0b75fa0e22620_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">selb:EmployeeStockPurchasePlan2016Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i7ecfd227500943bba7dc51fc2bd3afec_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">selb:EmployeeStockPurchasePlan2016Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ib7e99ef7cdcc49a1ad08e7bc6eec6d1a_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">selb:EmployeeStockPurchasePlan2016Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i88f5a9f6a9ed48ce97bb4cbb9b6ef889_D20200611-20200611">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-11</startDate>
            <endDate>2020-06-11</endDate>
        </period>
    </context>
    <context id="idfbbd3bf25a24130a9437f8a5acdb931_I20200611">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-11</instant>
        </period>
    </context>
    <context id="i89a2a0a3262b4bc9b05cb96efb71185e_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">selb:SOBIPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i9114bf8b8ace4041b525081dc7e30132_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">selb:SOBIPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0274d7d2728b45debefc3a188dc02830_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">selb:SOBIPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ieb852272fa154e92bcf4a36c0a643304_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">selb:SOBIPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i114b99e9c016452483452639f622b436_D20200613-20200613">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">selb:SareptaTherapeuticsInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-13</startDate>
            <endDate>2020-06-13</endDate>
        </period>
    </context>
    <context id="i6ede8ce092334ef1927faf29388e0af6_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">selb:SareptaTherapeuticsInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7b30202348b245c093e55382ba4778e9_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">selb:SareptaTherapeuticsInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ie7b30c0c9db24a54aad1845efeb882c1_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">selb:SareptaTherapeuticsInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i17bc05b20a3043b2acb1ee8c2e1badf9_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">selb:SareptaTherapeuticsInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ia04c0f8c59e54e0780747ca4c1a414d5_D20191217-20191217">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">selb:LicenseAgreementForPompeDiseaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-17</startDate>
            <endDate>2019-12-17</endDate>
        </period>
    </context>
    <context id="i10b61b699b8047098f9ffd1347f4a2ea_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">selb:LicenseAgreementForPompeDiseaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ie2581e0def58480f85a685f932e3297b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">selb:LicenseAgreementForPompeDiseaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9d35ce32fa2b4a2b89239188060f0691_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">selb:LicenseAgreementForPompeDiseaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i52f04094420841308054f7809f206401_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">selb:LicenseAgreementForPompeDiseaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i961e2381798844178d4558010699b490_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">selb:FounderMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i0f7b03d9ffec46e09e274a6faed6a815_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">selb:FounderMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i2d6aabf5381c4d8eafad236940060193_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">selb:AskBioLicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i24708847c47a43ca9c76041056178569_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">selb:AskBioLicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="icd96a5af167244139fa70b4e414d29c8_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">selb:ExclusivePatentLicenseAgreementWithMassachusettsInstituteOfTechnologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="iec431b313cb846b2aa7358a0b7afcf53_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ibb68c9bff506451eb919c2f81711b851_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">selb:LicenseAgreementWithShenyangSunshinePharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i29f55711d46f4ce5a26d9adbfce75977_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">selb:LicenseAgreementWithShenyangSunshinePharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i69b9f1abf0ba4aac990acd969100a523_D20210401-20210513">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">selb:A2020SaleAgreementAtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-05-13</endDate>
        </period>
    </context>
    <context id="ia74a702495ff411cac561a2aded35226_I20210513">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">selb:A2020SaleAgreementAtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-05-13</instant>
        </period>
    </context>
    <context id="iebf9f6ef11cf4e6e8cfcb2c64010f2ad_D20210413-20210413">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">selb:SareptaTherapeuticsInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-13</startDate>
            <endDate>2021-04-13</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="sqft">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="vote">
        <measure>selb:vote</measure>
    </unit>
    <unit id="obligation">
        <measure>selb:obligation</measure>
    </unit>
    <dei:AmendmentFlag
      contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV80L2ZyYWc6NmYwMWNmODVkZTFkNGFhZDg5Y2Q2ZDZiNmMzMmFkOTAvdGFibGU6M2MyYTMxOTlhZWNjNDMwNmI3MmE0MzRlM2MzYmI2M2YvdGFibGVyYW5nZTozYzJhMzE5OWFlY2M0MzA2YjcyYTQzNGUzYzNiYjYzZl8yLTEtMS0xLTA_ced1008e-5754-4d12-9c19-a7cfabb57b47">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus
      contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV80L2ZyYWc6NmYwMWNmODVkZTFkNGFhZDg5Y2Q2ZDZiNmMzMmFkOTAvdGFibGU6M2MyYTMxOTlhZWNjNDMwNmI3MmE0MzRlM2MzYmI2M2YvdGFibGVyYW5nZTozYzJhMzE5OWFlY2M0MzA2YjcyYTQzNGUzYzNiYjYzZl8zLTEtMS0xLTA_19589f4f-40c0-4297-9caf-4d63ea163698">2021</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV80L2ZyYWc6NmYwMWNmODVkZTFkNGFhZDg5Y2Q2ZDZiNmMzMmFkOTAvdGFibGU6M2MyYTMxOTlhZWNjNDMwNmI3MmE0MzRlM2MzYmI2M2YvdGFibGVyYW5nZTozYzJhMzE5OWFlY2M0MzA2YjcyYTQzNGUzYzNiYjYzZl80LTEtMS0xLTA_d8d5b014-960f-4465-8ba9-4d3df43a774d">Q1</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey
      contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV80L2ZyYWc6NmYwMWNmODVkZTFkNGFhZDg5Y2Q2ZDZiNmMzMmFkOTAvdGFibGU6M2MyYTMxOTlhZWNjNDMwNmI3MmE0MzRlM2MzYmI2M2YvdGFibGVyYW5nZTozYzJhMzE5OWFlY2M0MzA2YjcyYTQzNGUzYzNiYjYzZl82LTEtMS0xLTA_62fc7a6f-5cb3-411f-b0f2-1fa5618adaf5">0001453687</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV80L2ZyYWc6NmYwMWNmODVkZTFkNGFhZDg5Y2Q2ZDZiNmMzMmFkOTAvdGV4dHJlZ2lvbjo2ZjAxY2Y4NWRlMWQ0YWFkODljZDZkNmI2YzMyYWQ5MF80Mzk4MDQ2NTExMTgx_59340aac-e0f4-46ba-9b56-848d63e6ae86">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentType
      contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV83L2ZyYWc6MWI5OGM4ZWY5MDE1NGNhOTliMWYyMDUwMzI3ZTU1MjgvdGV4dHJlZ2lvbjoxYjk4YzhlZjkwMTU0Y2E5OWIxZjIwNTAzMjdlNTUyOF80Mzk4MDQ2NTEzNTE3_1c6b3287-8a12-4191-8a8b-f0963202d012">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV83L2ZyYWc6MWI5OGM4ZWY5MDE1NGNhOTliMWYyMDUwMzI3ZTU1MjgvdGFibGU6NzVmNmY2OGQ4YjZkNDcyMzlkNWE4Y2QwZmIwNzAyZDcvdGFibGVyYW5nZTo3NWY2ZjY4ZDhiNmQ0NzIzOWQ1YThjZDBmYjA3MDJkN18wLTAtMS0xLTA_f1bf5865-347a-4aa7-bff9-d08c7632de24">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV83L2ZyYWc6MWI5OGM4ZWY5MDE1NGNhOTliMWYyMDUwMzI3ZTU1MjgvdGV4dHJlZ2lvbjoxYjk4YzhlZjkwMTU0Y2E5OWIxZjIwNTAzMjdlNTUyOF8xMjg_a42b922e-2c47-48a0-a191-9e9fa420b1ef">2021-03-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV83L2ZyYWc6MWI5OGM4ZWY5MDE1NGNhOTliMWYyMDUwMzI3ZTU1MjgvdGFibGU6OTIxZDAxOGY5MTVkNDE4OGFhZWVhM2Y3YzdkZGFjNWMvdGFibGVyYW5nZTo5MjFkMDE4ZjkxNWQ0MTg4YWFlZWEzZjdjN2RkYWM1Y18wLTAtMS0xLTA_dc623ec4-025a-440d-a972-c45f77138a8d">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV83L2ZyYWc6MWI5OGM4ZWY5MDE1NGNhOTliMWYyMDUwMzI3ZTU1MjgvdGV4dHJlZ2lvbjoxYjk4YzhlZjkwMTU0Y2E5OWIxZjIwNTAzMjdlNTUyOF8xOTIy_effe7b8d-6762-4bcd-bc1e-c94f878b1fc2">001-37798</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV83L2ZyYWc6MWI5OGM4ZWY5MDE1NGNhOTliMWYyMDUwMzI3ZTU1MjgvdGV4dHJlZ2lvbjoxYjk4YzhlZjkwMTU0Y2E5OWIxZjIwNTAzMjdlNTUyOF8xOTIz_b94ed07e-33dd-4315-b614-5a4ba40757c4">Selecta Biosciences, Inc</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV83L2ZyYWc6MWI5OGM4ZWY5MDE1NGNhOTliMWYyMDUwMzI3ZTU1MjgvdGFibGU6Y2NiZmIxYzZhNzI3NGNjOTlkYTQ4NzIyNmYwMTJkZDcvdGFibGVyYW5nZTpjY2JmYjFjNmE3Mjc0Y2M5OWRhNDg3MjI2ZjAxMmRkN18wLTEtMS0xLTMxNjI_a0cdbe2f-2440-4836-b0d6-3c855d3b260c">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV83L2ZyYWc6MWI5OGM4ZWY5MDE1NGNhOTliMWYyMDUwMzI3ZTU1MjgvdGFibGU6Y2NiZmIxYzZhNzI3NGNjOTlkYTQ4NzIyNmYwMTJkZDcvdGFibGVyYW5nZTpjY2JmYjFjNmE3Mjc0Y2M5OWRhNDg3MjI2ZjAxMmRkN18wLTItMS0xLTMxNTU_9d400aaf-f483-4f27-a040-abfff4fc368d">26-1622110</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV83L2ZyYWc6MWI5OGM4ZWY5MDE1NGNhOTliMWYyMDUwMzI3ZTU1MjgvdGFibGU6Y2NiZmIxYzZhNzI3NGNjOTlkYTQ4NzIyNmYwMTJkZDcvdGFibGVyYW5nZTpjY2JmYjFjNmE3Mjc0Y2M5OWRhNDg3MjI2ZjAxMmRkN18yLTEtMS0xLTAvdGV4dHJlZ2lvbjpmMjVhNTJmMmY2YmE0MjA0YjBjMTViMWFiZTU0ZWM4MV81_dee1386c-019c-4416-87eb-bde618186441">65 Grove Street,</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV83L2ZyYWc6MWI5OGM4ZWY5MDE1NGNhOTliMWYyMDUwMzI3ZTU1MjgvdGFibGU6Y2NiZmIxYzZhNzI3NGNjOTlkYTQ4NzIyNmYwMTJkZDcvdGFibGVyYW5nZTpjY2JmYjFjNmE3Mjc0Y2M5OWRhNDg3MjI2ZjAxMmRkN18yLTEtMS0xLTAvdGV4dHJlZ2lvbjpmMjVhNTJmMmY2YmE0MjA0YjBjMTViMWFiZTU0ZWM4MV84_0d85d18b-696d-45d6-b22d-0f461ff495ea">Watertown,</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV83L2ZyYWc6MWI5OGM4ZWY5MDE1NGNhOTliMWYyMDUwMzI3ZTU1MjgvdGFibGU6Y2NiZmIxYzZhNzI3NGNjOTlkYTQ4NzIyNmYwMTJkZDcvdGFibGVyYW5nZTpjY2JmYjFjNmE3Mjc0Y2M5OWRhNDg3MjI2ZjAxMmRkN18yLTEtMS0xLTAvdGV4dHJlZ2lvbjpmMjVhNTJmMmY2YmE0MjA0YjBjMTViMWFiZTU0ZWM4MV8xMQ_74857121-0579-4cd3-94e1-84bf4c52f311">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV83L2ZyYWc6MWI5OGM4ZWY5MDE1NGNhOTliMWYyMDUwMzI3ZTU1MjgvdGFibGU6Y2NiZmIxYzZhNzI3NGNjOTlkYTQ4NzIyNmYwMTJkZDcvdGFibGVyYW5nZTpjY2JmYjFjNmE3Mjc0Y2M5OWRhNDg3MjI2ZjAxMmRkN18zLTItMS0xLTMxNjU_f023f38d-6621-4f5f-a076-60ff0f32da96">02472</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV83L2ZyYWc6MWI5OGM4ZWY5MDE1NGNhOTliMWYyMDUwMzI3ZTU1MjgvdGV4dHJlZ2lvbjoxYjk4YzhlZjkwMTU0Y2E5OWIxZjIwNTAzMjdlNTUyOF8xOTMw_9ce7f0d9-48e4-4561-9f9d-95f5a9651c6d">617</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV83L2ZyYWc6MWI5OGM4ZWY5MDE1NGNhOTliMWYyMDUwMzI3ZTU1MjgvdGV4dHJlZ2lvbjoxYjk4YzhlZjkwMTU0Y2E5OWIxZjIwNTAzMjdlNTUyOF8xOTI2_6b04bf12-2ab8-45f0-aa8a-89666241b833">923-1400</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV83L2ZyYWc6MWI5OGM4ZWY5MDE1NGNhOTliMWYyMDUwMzI3ZTU1MjgvdGFibGU6ZWZjODQ1ZmMwNGE3NDRkNzk4OGYwNGJhZWU4ZDFlZTMvdGFibGVyYW5nZTplZmM4NDVmYzA0YTc0NGQ3OTg4ZjA0YmFlZThkMWVlM18zLTAtMS0xLTA_c4dd872a-a217-468b-a785-f37c8337f05e">Common Stock, $0.0001 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV83L2ZyYWc6MWI5OGM4ZWY5MDE1NGNhOTliMWYyMDUwMzI3ZTU1MjgvdGFibGU6ZWZjODQ1ZmMwNGE3NDRkNzk4OGYwNGJhZWU4ZDFlZTMvdGFibGVyYW5nZTplZmM4NDVmYzA0YTc0NGQ3OTg4ZjA0YmFlZThkMWVlM18zLTEtMS0xLTA_ddd8608c-abaa-4e36-8a5d-7e0b4afe334a">SELB</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV83L2ZyYWc6MWI5OGM4ZWY5MDE1NGNhOTliMWYyMDUwMzI3ZTU1MjgvdGFibGU6ZWZjODQ1ZmMwNGE3NDRkNzk4OGYwNGJhZWU4ZDFlZTMvdGFibGVyYW5nZTplZmM4NDVmYzA0YTc0NGQ3OTg4ZjA0YmFlZThkMWVlM18zLTItMS0xLTA_ee4ade6f-5391-49de-89ac-3caf2dfde620">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV83L2ZyYWc6MWI5OGM4ZWY5MDE1NGNhOTliMWYyMDUwMzI3ZTU1MjgvdGV4dHJlZ2lvbjoxYjk4YzhlZjkwMTU0Y2E5OWIxZjIwNTAzMjdlNTUyOF8xOTI3_b6fafbd8-0ff1-4600-956e-ada9106b3f03">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV83L2ZyYWc6MWI5OGM4ZWY5MDE1NGNhOTliMWYyMDUwMzI3ZTU1MjgvdGV4dHJlZ2lvbjoxYjk4YzhlZjkwMTU0Y2E5OWIxZjIwNTAzMjdlNTUyOF8xOTI4_66d2bc5e-d325-44c8-abb2-3ddb484e4c47">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV83L2ZyYWc6MWI5OGM4ZWY5MDE1NGNhOTliMWYyMDUwMzI3ZTU1MjgvdGFibGU6OGMzMDQ3MTMwZTM5NDM3YWJlZjE0N2UzYjc5MjRiMGEvdGFibGVyYW5nZTo4YzMwNDcxMzBlMzk0MzdhYmVmMTQ3ZTNiNzkyNGIwYV8xLTEtMS0xLTQ3NTE_361d1367-87ab-4742-9cbd-723825362694">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV83L2ZyYWc6MWI5OGM4ZWY5MDE1NGNhOTliMWYyMDUwMzI3ZTU1MjgvdGFibGU6OGMzMDQ3MTMwZTM5NDM3YWJlZjE0N2UzYjc5MjRiMGEvdGFibGVyYW5nZTo4YzMwNDcxMzBlMzk0MzdhYmVmMTQ3ZTNiNzkyNGIwYV8xLTUtMS0xLTA_1d1a19ac-289b-47e1-9203-ec616aa8f2d1">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV83L2ZyYWc6MWI5OGM4ZWY5MDE1NGNhOTliMWYyMDUwMzI3ZTU1MjgvdGFibGU6OGMzMDQ3MTMwZTM5NDM3YWJlZjE0N2UzYjc5MjRiMGEvdGFibGVyYW5nZTo4YzMwNDcxMzBlMzk0MzdhYmVmMTQ3ZTNiNzkyNGIwYV8yLTUtMS0xLTA_28f96437-ac20-42b7-ae4e-a78a8d14b8e7">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod
      contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV83L2ZyYWc6MWI5OGM4ZWY5MDE1NGNhOTliMWYyMDUwMzI3ZTU1MjgvdGV4dHJlZ2lvbjoxYjk4YzhlZjkwMTU0Y2E5OWIxZjIwNTAzMjdlNTUyOF8xOTI0_d0942543-712f-4d6f-a804-5f9ebffe94ee">true</dei:EntityExTransitionPeriod>
    <dei:EntityShellCompany
      contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV83L2ZyYWc6MWI5OGM4ZWY5MDE1NGNhOTliMWYyMDUwMzI3ZTU1MjgvdGV4dHJlZ2lvbjoxYjk4YzhlZjkwMTU0Y2E5OWIxZjIwNTAzMjdlNTUyOF8xOTI5_68077a8d-bb54-485f-99b0-a3cbbcd5f118">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i1872bfbdd04e4f9e825f592f3b317647_I20210507"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV83L2ZyYWc6MWI5OGM4ZWY5MDE1NGNhOTliMWYyMDUwMzI3ZTU1MjgvdGV4dHJlZ2lvbjoxYjk4YzhlZjkwMTU0Y2E5OWIxZjIwNTAzMjdlNTUyOF8xODU2_8366f897-e6d8-4915-924e-83633aa81d63"
      unitRef="shares">113193597</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ied8d945ebce54ed8a4badfed477a64e8_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xNzUvZnJhZzphZTY3YTllM2U3MDU0YWUyYjgwMWE4OTVjNWFiMDE2MS90YWJsZTo3YjlhZGE2YTJiOWU0MmY2YTdkNTRkMDkyNmQwZGJhMC90YWJsZXJhbmdlOjdiOWFkYTZhMmI5ZTQyZjZhN2Q1NGQwOTI2ZDBkYmEwXzUtMS0xLTEtMA_8e15519f-ffbd-4c3f-89b9-a405b65d5aa6"
      unitRef="usd">125407000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ib56f1adc867e406ca7face50c5da1c9c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xNzUvZnJhZzphZTY3YTllM2U3MDU0YWUyYjgwMWE4OTVjNWFiMDE2MS90YWJsZTo3YjlhZGE2YTJiOWU0MmY2YTdkNTRkMDkyNmQwZGJhMC90YWJsZXJhbmdlOjdiOWFkYTZhMmI5ZTQyZjZhN2Q1NGQwOTI2ZDBkYmEwXzUtMy0xLTEtMA_8e4b13c1-a86b-42c3-b6ae-4596edd08105"
      unitRef="usd">138685000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="ied8d945ebce54ed8a4badfed477a64e8_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xNzUvZnJhZzphZTY3YTllM2U3MDU0YWUyYjgwMWE4OTVjNWFiMDE2MS90YWJsZTo3YjlhZGE2YTJiOWU0MmY2YTdkNTRkMDkyNmQwZGJhMC90YWJsZXJhbmdlOjdiOWFkYTZhMmI5ZTQyZjZhN2Q1NGQwOTI2ZDBkYmEwXzctMS0xLTEtMA_318d0a4f-e7fa-4b73-88c3-44dfd6dd4361"
      unitRef="usd">22405000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="ib56f1adc867e406ca7face50c5da1c9c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xNzUvZnJhZzphZTY3YTllM2U3MDU0YWUyYjgwMWE4OTVjNWFiMDE2MS90YWJsZTo3YjlhZGE2YTJiOWU0MmY2YTdkNTRkMDkyNmQwZGJhMC90YWJsZXJhbmdlOjdiOWFkYTZhMmI5ZTQyZjZhN2Q1NGQwOTI2ZDBkYmEwXzctMy0xLTEtMA_94f4a3d9-ad40-4cea-884a-410b29769eac"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="ied8d945ebce54ed8a4badfed477a64e8_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xNzUvZnJhZzphZTY3YTllM2U3MDU0YWUyYjgwMWE4OTVjNWFiMDE2MS90YWJsZTo3YjlhZGE2YTJiOWU0MmY2YTdkNTRkMDkyNmQwZGJhMC90YWJsZXJhbmdlOjdiOWFkYTZhMmI5ZTQyZjZhN2Q1NGQwOTI2ZDBkYmEwXzgtMS0xLTEtMA_7976461a-6db0-4b8c-a46e-7d96e5c75485"
      unitRef="usd">8342000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="ib56f1adc867e406ca7face50c5da1c9c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xNzUvZnJhZzphZTY3YTllM2U3MDU0YWUyYjgwMWE4OTVjNWFiMDE2MS90YWJsZTo3YjlhZGE2YTJiOWU0MmY2YTdkNTRkMDkyNmQwZGJhMC90YWJsZXJhbmdlOjdiOWFkYTZhMmI5ZTQyZjZhN2Q1NGQwOTI2ZDBkYmEwXzgtMy0xLTEtMA_73d57004-b9ea-4c02-a479-fd0154fdc532"
      unitRef="usd">7224000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="ied8d945ebce54ed8a4badfed477a64e8_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xNzUvZnJhZzphZTY3YTllM2U3MDU0YWUyYjgwMWE4OTVjNWFiMDE2MS90YWJsZTo3YjlhZGE2YTJiOWU0MmY2YTdkNTRkMDkyNmQwZGJhMC90YWJsZXJhbmdlOjdiOWFkYTZhMmI5ZTQyZjZhN2Q1NGQwOTI2ZDBkYmEwXzktMS0xLTEtMA_a1c5849a-65be-4af6-84e9-df52418169a8"
      unitRef="usd">6971000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="ib56f1adc867e406ca7face50c5da1c9c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xNzUvZnJhZzphZTY3YTllM2U3MDU0YWUyYjgwMWE4OTVjNWFiMDE2MS90YWJsZTo3YjlhZGE2YTJiOWU0MmY2YTdkNTRkMDkyNmQwZGJhMC90YWJsZXJhbmdlOjdiOWFkYTZhMmI5ZTQyZjZhN2Q1NGQwOTI2ZDBkYmEwXzktMy0xLTEtMA_7967c533-6ba0-4263-814d-98a4c78759b0"
      unitRef="usd">5434000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="ied8d945ebce54ed8a4badfed477a64e8_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xNzUvZnJhZzphZTY3YTllM2U3MDU0YWUyYjgwMWE4OTVjNWFiMDE2MS90YWJsZTo3YjlhZGE2YTJiOWU0MmY2YTdkNTRkMDkyNmQwZGJhMC90YWJsZXJhbmdlOjdiOWFkYTZhMmI5ZTQyZjZhN2Q1NGQwOTI2ZDBkYmEwXzEwLTEtMS0xLTA_322fa3d1-f1f9-478e-885a-50fa512760ef"
      unitRef="usd">163125000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="ib56f1adc867e406ca7face50c5da1c9c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xNzUvZnJhZzphZTY3YTllM2U3MDU0YWUyYjgwMWE4OTVjNWFiMDE2MS90YWJsZTo3YjlhZGE2YTJiOWU0MmY2YTdkNTRkMDkyNmQwZGJhMC90YWJsZXJhbmdlOjdiOWFkYTZhMmI5ZTQyZjZhN2Q1NGQwOTI2ZDBkYmEwXzEwLTMtMS0xLTA_846ba60a-1cd9-4e5b-b137-4991ce7fe011"
      unitRef="usd">151343000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ied8d945ebce54ed8a4badfed477a64e8_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xNzUvZnJhZzphZTY3YTllM2U3MDU0YWUyYjgwMWE4OTVjNWFiMDE2MS90YWJsZTo3YjlhZGE2YTJiOWU0MmY2YTdkNTRkMDkyNmQwZGJhMC90YWJsZXJhbmdlOjdiOWFkYTZhMmI5ZTQyZjZhN2Q1NGQwOTI2ZDBkYmEwXzExLTEtMS0xLTA_476e7140-f860-4b06-a0e7-d756163967c5"
      unitRef="usd">1301000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ib56f1adc867e406ca7face50c5da1c9c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xNzUvZnJhZzphZTY3YTllM2U3MDU0YWUyYjgwMWE4OTVjNWFiMDE2MS90YWJsZTo3YjlhZGE2YTJiOWU0MmY2YTdkNTRkMDkyNmQwZGJhMC90YWJsZXJhbmdlOjdiOWFkYTZhMmI5ZTQyZjZhN2Q1NGQwOTI2ZDBkYmEwXzExLTMtMS0xLTA_4d89ea28-a9d4-41cf-8970-cd908fc6c4ab"
      unitRef="usd">1395000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="ied8d945ebce54ed8a4badfed477a64e8_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xNzUvZnJhZzphZTY3YTllM2U3MDU0YWUyYjgwMWE4OTVjNWFiMDE2MS90YWJsZTo3YjlhZGE2YTJiOWU0MmY2YTdkNTRkMDkyNmQwZGJhMC90YWJsZXJhbmdlOjdiOWFkYTZhMmI5ZTQyZjZhN2Q1NGQwOTI2ZDBkYmEwXzEyLTEtMS0xLTA_ac32ab21-f367-4bab-9d6a-f8fd20b8d81f"
      unitRef="usd">10676000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="ib56f1adc867e406ca7face50c5da1c9c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xNzUvZnJhZzphZTY3YTllM2U3MDU0YWUyYjgwMWE4OTVjNWFiMDE2MS90YWJsZTo3YjlhZGE2YTJiOWU0MmY2YTdkNTRkMDkyNmQwZGJhMC90YWJsZXJhbmdlOjdiOWFkYTZhMmI5ZTQyZjZhN2Q1NGQwOTI2ZDBkYmEwXzEyLTMtMS0xLTA_327d6408-36b1-4ea6-997b-483ba61e89b1"
      unitRef="usd">10948000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent
      contextRef="ied8d945ebce54ed8a4badfed477a64e8_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xNzUvZnJhZzphZTY3YTllM2U3MDU0YWUyYjgwMWE4OTVjNWFiMDE2MS90YWJsZTo3YjlhZGE2YTJiOWU0MmY2YTdkNTRkMDkyNmQwZGJhMC90YWJsZXJhbmdlOjdiOWFkYTZhMmI5ZTQyZjZhN2Q1NGQwOTI2ZDBkYmEwXzEzLTEtMS0xLTA_7a616bf1-bda5-4d2d-ac0c-69c1c2ee2163"
      unitRef="usd">1379000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent
      contextRef="ib56f1adc867e406ca7face50c5da1c9c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xNzUvZnJhZzphZTY3YTllM2U3MDU0YWUyYjgwMWE4OTVjNWFiMDE2MS90YWJsZTo3YjlhZGE2YTJiOWU0MmY2YTdkNTRkMDkyNmQwZGJhMC90YWJsZXJhbmdlOjdiOWFkYTZhMmI5ZTQyZjZhN2Q1NGQwOTI2ZDBkYmEwXzEzLTMtMS0xLTA_6280296a-9f95-48c5-ba95-784af756dbf8"
      unitRef="usd">1379000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:OtherAssets
      contextRef="ied8d945ebce54ed8a4badfed477a64e8_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xNzUvZnJhZzphZTY3YTllM2U3MDU0YWUyYjgwMWE4OTVjNWFiMDE2MS90YWJsZTo3YjlhZGE2YTJiOWU0MmY2YTdkNTRkMDkyNmQwZGJhMC90YWJsZXJhbmdlOjdiOWFkYTZhMmI5ZTQyZjZhN2Q1NGQwOTI2ZDBkYmEwXzE0LTEtMS0xLTA_fc598fa6-705e-4066-805e-0a8614921d4b"
      unitRef="usd">265000</us-gaap:OtherAssets>
    <us-gaap:OtherAssets
      contextRef="ib56f1adc867e406ca7face50c5da1c9c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xNzUvZnJhZzphZTY3YTllM2U3MDU0YWUyYjgwMWE4OTVjNWFiMDE2MS90YWJsZTo3YjlhZGE2YTJiOWU0MmY2YTdkNTRkMDkyNmQwZGJhMC90YWJsZXJhbmdlOjdiOWFkYTZhMmI5ZTQyZjZhN2Q1NGQwOTI2ZDBkYmEwXzE0LTMtMS0xLTA_3b59f50e-6e31-415e-9441-ee5586a40d27"
      unitRef="usd">370000</us-gaap:OtherAssets>
    <us-gaap:Assets
      contextRef="ied8d945ebce54ed8a4badfed477a64e8_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xNzUvZnJhZzphZTY3YTllM2U3MDU0YWUyYjgwMWE4OTVjNWFiMDE2MS90YWJsZTo3YjlhZGE2YTJiOWU0MmY2YTdkNTRkMDkyNmQwZGJhMC90YWJsZXJhbmdlOjdiOWFkYTZhMmI5ZTQyZjZhN2Q1NGQwOTI2ZDBkYmEwXzE1LTEtMS0xLTA_28c552f1-5cc3-46be-8602-294ad201b7d2"
      unitRef="usd">176746000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="ib56f1adc867e406ca7face50c5da1c9c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xNzUvZnJhZzphZTY3YTllM2U3MDU0YWUyYjgwMWE4OTVjNWFiMDE2MS90YWJsZTo3YjlhZGE2YTJiOWU0MmY2YTdkNTRkMDkyNmQwZGJhMC90YWJsZXJhbmdlOjdiOWFkYTZhMmI5ZTQyZjZhN2Q1NGQwOTI2ZDBkYmEwXzE1LTMtMS0xLTA_228c1ac2-1de2-4d4a-93f7-c9368780b74f"
      unitRef="usd">165435000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="ied8d945ebce54ed8a4badfed477a64e8_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xNzUvZnJhZzphZTY3YTllM2U3MDU0YWUyYjgwMWE4OTVjNWFiMDE2MS90YWJsZTo3YjlhZGE2YTJiOWU0MmY2YTdkNTRkMDkyNmQwZGJhMC90YWJsZXJhbmdlOjdiOWFkYTZhMmI5ZTQyZjZhN2Q1NGQwOTI2ZDBkYmEwXzE4LTEtMS0xLTA_63a1b39d-5708-4dfa-88d3-0f34136f1052"
      unitRef="usd">594000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="ib56f1adc867e406ca7face50c5da1c9c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xNzUvZnJhZzphZTY3YTllM2U3MDU0YWUyYjgwMWE4OTVjNWFiMDE2MS90YWJsZTo3YjlhZGE2YTJiOWU0MmY2YTdkNTRkMDkyNmQwZGJhMC90YWJsZXJhbmdlOjdiOWFkYTZhMmI5ZTQyZjZhN2Q1NGQwOTI2ZDBkYmEwXzE4LTMtMS0xLTA_0bc43b87-a0e3-4f6d-bf23-897082575703"
      unitRef="usd">443000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="ied8d945ebce54ed8a4badfed477a64e8_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xNzUvZnJhZzphZTY3YTllM2U3MDU0YWUyYjgwMWE4OTVjNWFiMDE2MS90YWJsZTo3YjlhZGE2YTJiOWU0MmY2YTdkNTRkMDkyNmQwZGJhMC90YWJsZXJhbmdlOjdiOWFkYTZhMmI5ZTQyZjZhN2Q1NGQwOTI2ZDBkYmEwXzE5LTEtMS0xLTA_cf994152-b0f2-4986-af8c-90b6350a8f33"
      unitRef="usd">6847000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="ib56f1adc867e406ca7face50c5da1c9c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xNzUvZnJhZzphZTY3YTllM2U3MDU0YWUyYjgwMWE4OTVjNWFiMDE2MS90YWJsZTo3YjlhZGE2YTJiOWU0MmY2YTdkNTRkMDkyNmQwZGJhMC90YWJsZXJhbmdlOjdiOWFkYTZhMmI5ZTQyZjZhN2Q1NGQwOTI2ZDBkYmEwXzE5LTMtMS0xLTA_1db9b1a3-6dba-4584-99b1-346223733229"
      unitRef="usd">8146000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:LoansPayableCurrent
      contextRef="ied8d945ebce54ed8a4badfed477a64e8_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xNzUvZnJhZzphZTY3YTllM2U3MDU0YWUyYjgwMWE4OTVjNWFiMDE2MS90YWJsZTo3YjlhZGE2YTJiOWU0MmY2YTdkNTRkMDkyNmQwZGJhMC90YWJsZXJhbmdlOjdiOWFkYTZhMmI5ZTQyZjZhN2Q1NGQwOTI2ZDBkYmEwXzIwLTEtMS0xLTA_fd94f879-d5bf-4053-857c-73f747afd0cf"
      unitRef="usd">460000</us-gaap:LoansPayableCurrent>
    <us-gaap:LoansPayableCurrent
      contextRef="ib56f1adc867e406ca7face50c5da1c9c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xNzUvZnJhZzphZTY3YTllM2U3MDU0YWUyYjgwMWE4OTVjNWFiMDE2MS90YWJsZTo3YjlhZGE2YTJiOWU0MmY2YTdkNTRkMDkyNmQwZGJhMC90YWJsZXJhbmdlOjdiOWFkYTZhMmI5ZTQyZjZhN2Q1NGQwOTI2ZDBkYmEwXzIwLTMtMS0xLTA_b6db9750-e539-4d27-a996-ca3d70885a02"
      unitRef="usd">0</us-gaap:LoansPayableCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="ied8d945ebce54ed8a4badfed477a64e8_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xNzUvZnJhZzphZTY3YTllM2U3MDU0YWUyYjgwMWE4OTVjNWFiMDE2MS90YWJsZTo3YjlhZGE2YTJiOWU0MmY2YTdkNTRkMDkyNmQwZGJhMC90YWJsZXJhbmdlOjdiOWFkYTZhMmI5ZTQyZjZhN2Q1NGQwOTI2ZDBkYmEwXzIxLTEtMS0xLTA_d7356727-a0fe-42ad-a93d-c6834ecbdd8c"
      unitRef="usd">942000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="ib56f1adc867e406ca7face50c5da1c9c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xNzUvZnJhZzphZTY3YTllM2U3MDU0YWUyYjgwMWE4OTVjNWFiMDE2MS90YWJsZTo3YjlhZGE2YTJiOWU0MmY2YTdkNTRkMDkyNmQwZGJhMC90YWJsZXJhbmdlOjdiOWFkYTZhMmI5ZTQyZjZhN2Q1NGQwOTI2ZDBkYmEwXzIxLTMtMS0xLTA_f57d6836-9cee-40cc-b33b-bf89c7d70c73"
      unitRef="usd">908000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="ied8d945ebce54ed8a4badfed477a64e8_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xNzUvZnJhZzphZTY3YTllM2U3MDU0YWUyYjgwMWE4OTVjNWFiMDE2MS90YWJsZTo3YjlhZGE2YTJiOWU0MmY2YTdkNTRkMDkyNmQwZGJhMC90YWJsZXJhbmdlOjdiOWFkYTZhMmI5ZTQyZjZhN2Q1NGQwOTI2ZDBkYmEwXzIzLTEtMS0xLTA_a3f6ab3d-db5c-4fed-8a05-9608b03d19ce"
      unitRef="usd">75764000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="ib56f1adc867e406ca7face50c5da1c9c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xNzUvZnJhZzphZTY3YTllM2U3MDU0YWUyYjgwMWE4OTVjNWFiMDE2MS90YWJsZTo3YjlhZGE2YTJiOWU0MmY2YTdkNTRkMDkyNmQwZGJhMC90YWJsZXJhbmdlOjdiOWFkYTZhMmI5ZTQyZjZhN2Q1NGQwOTI2ZDBkYmEwXzIzLTMtMS0xLTA_aa679167-cdef-4700-bc82-3eddd2e6b922"
      unitRef="usd">72050000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="ied8d945ebce54ed8a4badfed477a64e8_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xNzUvZnJhZzphZTY3YTllM2U3MDU0YWUyYjgwMWE4OTVjNWFiMDE2MS90YWJsZTo3YjlhZGE2YTJiOWU0MmY2YTdkNTRkMDkyNmQwZGJhMC90YWJsZXJhbmdlOjdiOWFkYTZhMmI5ZTQyZjZhN2Q1NGQwOTI2ZDBkYmEwXzI1LTEtMS0xLTA_dfa454b9-8035-4f4e-aab1-b17e7ef26ee6"
      unitRef="usd">84607000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="ib56f1adc867e406ca7face50c5da1c9c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xNzUvZnJhZzphZTY3YTllM2U3MDU0YWUyYjgwMWE4OTVjNWFiMDE2MS90YWJsZTo3YjlhZGE2YTJiOWU0MmY2YTdkNTRkMDkyNmQwZGJhMC90YWJsZXJhbmdlOjdiOWFkYTZhMmI5ZTQyZjZhN2Q1NGQwOTI2ZDBkYmEwXzI1LTMtMS0xLTA_c0b2b43b-6234-4363-84a1-4111753c1bb7"
      unitRef="usd">81547000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermLoansPayable
      contextRef="ied8d945ebce54ed8a4badfed477a64e8_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xNzUvZnJhZzphZTY3YTllM2U3MDU0YWUyYjgwMWE4OTVjNWFiMDE2MS90YWJsZTo3YjlhZGE2YTJiOWU0MmY2YTdkNTRkMDkyNmQwZGJhMC90YWJsZXJhbmdlOjdiOWFkYTZhMmI5ZTQyZjZhN2Q1NGQwOTI2ZDBkYmEwXzI4LTEtMS0xLTA_e685381e-ff32-45bb-bf86-6de8e38f659c"
      unitRef="usd">24551000</us-gaap:LongTermLoansPayable>
    <us-gaap:LongTermLoansPayable
      contextRef="ib56f1adc867e406ca7face50c5da1c9c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xNzUvZnJhZzphZTY3YTllM2U3MDU0YWUyYjgwMWE4OTVjNWFiMDE2MS90YWJsZTo3YjlhZGE2YTJiOWU0MmY2YTdkNTRkMDkyNmQwZGJhMC90YWJsZXJhbmdlOjdiOWFkYTZhMmI5ZTQyZjZhN2Q1NGQwOTI2ZDBkYmEwXzI4LTMtMS0xLTA_15145e40-1512-4bfe-b6dc-9ef9bb2be89e"
      unitRef="usd">24793000</us-gaap:LongTermLoansPayable>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="ied8d945ebce54ed8a4badfed477a64e8_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xNzUvZnJhZzphZTY3YTllM2U3MDU0YWUyYjgwMWE4OTVjNWFiMDE2MS90YWJsZTo3YjlhZGE2YTJiOWU0MmY2YTdkNTRkMDkyNmQwZGJhMC90YWJsZXJhbmdlOjdiOWFkYTZhMmI5ZTQyZjZhN2Q1NGQwOTI2ZDBkYmEwXzI5LTEtMS0xLTA_c0984b47-fd99-4275-ba6e-7a628eeb801c"
      unitRef="usd">9403000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="ib56f1adc867e406ca7face50c5da1c9c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xNzUvZnJhZzphZTY3YTllM2U3MDU0YWUyYjgwMWE4OTVjNWFiMDE2MS90YWJsZTo3YjlhZGE2YTJiOWU0MmY2YTdkNTRkMDkyNmQwZGJhMC90YWJsZXJhbmdlOjdiOWFkYTZhMmI5ZTQyZjZhN2Q1NGQwOTI2ZDBkYmEwXzI5LTMtMS0xLTA_d6296eac-5f4c-4412-b967-22c5bff29462"
      unitRef="usd">9647000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="ied8d945ebce54ed8a4badfed477a64e8_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xNzUvZnJhZzphZTY3YTllM2U3MDU0YWUyYjgwMWE4OTVjNWFiMDE2MS90YWJsZTo3YjlhZGE2YTJiOWU0MmY2YTdkNTRkMDkyNmQwZGJhMC90YWJsZXJhbmdlOjdiOWFkYTZhMmI5ZTQyZjZhN2Q1NGQwOTI2ZDBkYmEwXzMwLTEtMS0xLTA_81f5fc9f-f9c0-4de4-a38c-f42be7c444a7"
      unitRef="usd">32301000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="ib56f1adc867e406ca7face50c5da1c9c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xNzUvZnJhZzphZTY3YTllM2U3MDU0YWUyYjgwMWE4OTVjNWFiMDE2MS90YWJsZTo3YjlhZGE2YTJiOWU0MmY2YTdkNTRkMDkyNmQwZGJhMC90YWJsZXJhbmdlOjdiOWFkYTZhMmI5ZTQyZjZhN2Q1NGQwOTI2ZDBkYmEwXzMwLTMtMS0xLTA_8c41c8d0-e34e-4525-8a3d-7e6102258558"
      unitRef="usd">38746000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="ied8d945ebce54ed8a4badfed477a64e8_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xNzUvZnJhZzphZTY3YTllM2U3MDU0YWUyYjgwMWE4OTVjNWFiMDE2MS90YWJsZTo3YjlhZGE2YTJiOWU0MmY2YTdkNTRkMDkyNmQwZGJhMC90YWJsZXJhbmdlOjdiOWFkYTZhMmI5ZTQyZjZhN2Q1NGQwOTI2ZDBkYmEwXzMxLTEtMS0xLTA_1512a17c-d360-490f-a9c9-a25650fd9717"
      unitRef="usd">45455000</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="ib56f1adc867e406ca7face50c5da1c9c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xNzUvZnJhZzphZTY3YTllM2U3MDU0YWUyYjgwMWE4OTVjNWFiMDE2MS90YWJsZTo3YjlhZGE2YTJiOWU0MmY2YTdkNTRkMDkyNmQwZGJhMC90YWJsZXJhbmdlOjdiOWFkYTZhMmI5ZTQyZjZhN2Q1NGQwOTI2ZDBkYmEwXzMxLTMtMS0xLTA_213a8edd-2197-4cb8-b152-b9d7ed1dbe57"
      unitRef="usd">28708000</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:Liabilities
      contextRef="ied8d945ebce54ed8a4badfed477a64e8_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xNzUvZnJhZzphZTY3YTllM2U3MDU0YWUyYjgwMWE4OTVjNWFiMDE2MS90YWJsZTo3YjlhZGE2YTJiOWU0MmY2YTdkNTRkMDkyNmQwZGJhMC90YWJsZXJhbmdlOjdiOWFkYTZhMmI5ZTQyZjZhN2Q1NGQwOTI2ZDBkYmEwXzMzLTEtMS0xLTA_830c92b0-9c56-45df-af58-9433a175a5c6"
      unitRef="usd">196317000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="ib56f1adc867e406ca7face50c5da1c9c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xNzUvZnJhZzphZTY3YTllM2U3MDU0YWUyYjgwMWE4OTVjNWFiMDE2MS90YWJsZTo3YjlhZGE2YTJiOWU0MmY2YTdkNTRkMDkyNmQwZGJhMC90YWJsZXJhbmdlOjdiOWFkYTZhMmI5ZTQyZjZhN2Q1NGQwOTI2ZDBkYmEwXzMzLTMtMS0xLTA_fe7d169f-3637-4184-88a9-48d039ef085e"
      unitRef="usd">183441000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="ied8d945ebce54ed8a4badfed477a64e8_I20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xNzUvZnJhZzphZTY3YTllM2U3MDU0YWUyYjgwMWE4OTVjNWFiMDE2MS90YWJsZTo3YjlhZGE2YTJiOWU0MmY2YTdkNTRkMDkyNmQwZGJhMC90YWJsZXJhbmdlOjdiOWFkYTZhMmI5ZTQyZjZhN2Q1NGQwOTI2ZDBkYmEwXzM0LTEtMS0xLTA_a5f958eb-e682-42f6-979d-424894b29f44"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="ib56f1adc867e406ca7face50c5da1c9c_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xNzUvZnJhZzphZTY3YTllM2U3MDU0YWUyYjgwMWE4OTVjNWFiMDE2MS90YWJsZTo3YjlhZGE2YTJiOWU0MmY2YTdkNTRkMDkyNmQwZGJhMC90YWJsZXJhbmdlOjdiOWFkYTZhMmI5ZTQyZjZhN2Q1NGQwOTI2ZDBkYmEwXzM0LTMtMS0xLTA_6dfe56cf-de23-49f0-8b9d-b8ea63d04609"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="ied8d945ebce54ed8a4badfed477a64e8_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xNzUvZnJhZzphZTY3YTllM2U3MDU0YWUyYjgwMWE4OTVjNWFiMDE2MS90YWJsZTo3YjlhZGE2YTJiOWU0MmY2YTdkNTRkMDkyNmQwZGJhMC90YWJsZXJhbmdlOjdiOWFkYTZhMmI5ZTQyZjZhN2Q1NGQwOTI2ZDBkYmEwXzQ0LTAtMS0xLTAvdGV4dHJlZ2lvbjoxNWI5MDVlN2Y0MTA0NmVjYTk1MjBmZDQ2Y2NiNjc1YV8yMQ_27959425-ab91-4a64-ba5d-2c5e1723070d"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="ib56f1adc867e406ca7face50c5da1c9c_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xNzUvZnJhZzphZTY3YTllM2U3MDU0YWUyYjgwMWE4OTVjNWFiMDE2MS90YWJsZTo3YjlhZGE2YTJiOWU0MmY2YTdkNTRkMDkyNmQwZGJhMC90YWJsZXJhbmdlOjdiOWFkYTZhMmI5ZTQyZjZhN2Q1NGQwOTI2ZDBkYmEwXzQ0LTAtMS0xLTAvdGV4dHJlZ2lvbjoxNWI5MDVlN2Y0MTA0NmVjYTk1MjBmZDQ2Y2NiNjc1YV8yMQ_338ce2e8-e456-4ee9-ae04-668ba1ef9b42"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="ib56f1adc867e406ca7face50c5da1c9c_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xNzUvZnJhZzphZTY3YTllM2U3MDU0YWUyYjgwMWE4OTVjNWFiMDE2MS90YWJsZTo3YjlhZGE2YTJiOWU0MmY2YTdkNTRkMDkyNmQwZGJhMC90YWJsZXJhbmdlOjdiOWFkYTZhMmI5ZTQyZjZhN2Q1NGQwOTI2ZDBkYmEwXzQ0LTAtMS0xLTAvdGV4dHJlZ2lvbjoxNWI5MDVlN2Y0MTA0NmVjYTk1MjBmZDQ2Y2NiNjc1YV8zNQ_5f258925-e20a-4b2b-8bf1-0eb35651bd9a"
      unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="ied8d945ebce54ed8a4badfed477a64e8_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xNzUvZnJhZzphZTY3YTllM2U3MDU0YWUyYjgwMWE4OTVjNWFiMDE2MS90YWJsZTo3YjlhZGE2YTJiOWU0MmY2YTdkNTRkMDkyNmQwZGJhMC90YWJsZXJhbmdlOjdiOWFkYTZhMmI5ZTQyZjZhN2Q1NGQwOTI2ZDBkYmEwXzQ0LTAtMS0xLTAvdGV4dHJlZ2lvbjoxNWI5MDVlN2Y0MTA0NmVjYTk1MjBmZDQ2Y2NiNjc1YV8zNQ_8779e9ee-d5c0-4985-88df-5e8ab8dcfee2"
      unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="ib56f1adc867e406ca7face50c5da1c9c_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xNzUvZnJhZzphZTY3YTllM2U3MDU0YWUyYjgwMWE4OTVjNWFiMDE2MS90YWJsZTo3YjlhZGE2YTJiOWU0MmY2YTdkNTRkMDkyNmQwZGJhMC90YWJsZXJhbmdlOjdiOWFkYTZhMmI5ZTQyZjZhN2Q1NGQwOTI2ZDBkYmEwXzQ0LTAtMS0xLTAvdGV4dHJlZ2lvbjoxNWI5MDVlN2Y0MTA0NmVjYTk1MjBmZDQ2Y2NiNjc1YV81Nw_06711002-7177-49f9-9d23-89454ed11628"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="ied8d945ebce54ed8a4badfed477a64e8_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xNzUvZnJhZzphZTY3YTllM2U3MDU0YWUyYjgwMWE4OTVjNWFiMDE2MS90YWJsZTo3YjlhZGE2YTJiOWU0MmY2YTdkNTRkMDkyNmQwZGJhMC90YWJsZXJhbmdlOjdiOWFkYTZhMmI5ZTQyZjZhN2Q1NGQwOTI2ZDBkYmEwXzQ0LTAtMS0xLTAvdGV4dHJlZ2lvbjoxNWI5MDVlN2Y0MTA0NmVjYTk1MjBmZDQ2Y2NiNjc1YV81Nw_533482d6-aeda-4ed3-a780-16ebc593e036"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="ib56f1adc867e406ca7face50c5da1c9c_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xNzUvZnJhZzphZTY3YTllM2U3MDU0YWUyYjgwMWE4OTVjNWFiMDE2MS90YWJsZTo3YjlhZGE2YTJiOWU0MmY2YTdkNTRkMDkyNmQwZGJhMC90YWJsZXJhbmdlOjdiOWFkYTZhMmI5ZTQyZjZhN2Q1NGQwOTI2ZDBkYmEwXzQ0LTAtMS0xLTAvdGV4dHJlZ2lvbjoxNWI5MDVlN2Y0MTA0NmVjYTk1MjBmZDQ2Y2NiNjc1YV81Nw_7749a829-14bc-4889-86b7-ff5f13366046"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="ied8d945ebce54ed8a4badfed477a64e8_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xNzUvZnJhZzphZTY3YTllM2U3MDU0YWUyYjgwMWE4OTVjNWFiMDE2MS90YWJsZTo3YjlhZGE2YTJiOWU0MmY2YTdkNTRkMDkyNmQwZGJhMC90YWJsZXJhbmdlOjdiOWFkYTZhMmI5ZTQyZjZhN2Q1NGQwOTI2ZDBkYmEwXzQ0LTAtMS0xLTAvdGV4dHJlZ2lvbjoxNWI5MDVlN2Y0MTA0NmVjYTk1MjBmZDQ2Y2NiNjc1YV81Nw_a0eda247-6af2-4e5d-8217-7ff945f1dda7"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockValue
      contextRef="ied8d945ebce54ed8a4badfed477a64e8_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xNzUvZnJhZzphZTY3YTllM2U3MDU0YWUyYjgwMWE4OTVjNWFiMDE2MS90YWJsZTo3YjlhZGE2YTJiOWU0MmY2YTdkNTRkMDkyNmQwZGJhMC90YWJsZXJhbmdlOjdiOWFkYTZhMmI5ZTQyZjZhN2Q1NGQwOTI2ZDBkYmEwXzQ0LTEtMS0xLTA_24e1ad52-11cd-4820-90ce-1d3aca45313c"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="ib56f1adc867e406ca7face50c5da1c9c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xNzUvZnJhZzphZTY3YTllM2U3MDU0YWUyYjgwMWE4OTVjNWFiMDE2MS90YWJsZTo3YjlhZGE2YTJiOWU0MmY2YTdkNTRkMDkyNmQwZGJhMC90YWJsZXJhbmdlOjdiOWFkYTZhMmI5ZTQyZjZhN2Q1NGQwOTI2ZDBkYmEwXzQ0LTMtMS0xLTA_82d466f9-c93e-4521-82cd-4511591a04ff"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="ied8d945ebce54ed8a4badfed477a64e8_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xNzUvZnJhZzphZTY3YTllM2U3MDU0YWUyYjgwMWE4OTVjNWFiMDE2MS90YWJsZTo3YjlhZGE2YTJiOWU0MmY2YTdkNTRkMDkyNmQwZGJhMC90YWJsZXJhbmdlOjdiOWFkYTZhMmI5ZTQyZjZhN2Q1NGQwOTI2ZDBkYmEwXzQ1LTAtMS0xLTAvdGV4dHJlZ2lvbjplMmM4NDUzZmZkNjc0OTEyODRhY2VhY2IxYTFlNzc5M18xOA_5db441d8-12bd-4126-b86f-f89f28d1a83c"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="ib56f1adc867e406ca7face50c5da1c9c_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xNzUvZnJhZzphZTY3YTllM2U3MDU0YWUyYjgwMWE4OTVjNWFiMDE2MS90YWJsZTo3YjlhZGE2YTJiOWU0MmY2YTdkNTRkMDkyNmQwZGJhMC90YWJsZXJhbmdlOjdiOWFkYTZhMmI5ZTQyZjZhN2Q1NGQwOTI2ZDBkYmEwXzQ1LTAtMS0xLTAvdGV4dHJlZ2lvbjplMmM4NDUzZmZkNjc0OTEyODRhY2VhY2IxYTFlNzc5M18xOA_6f90032c-6946-4e04-9504-961733883487"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="ied8d945ebce54ed8a4badfed477a64e8_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xNzUvZnJhZzphZTY3YTllM2U3MDU0YWUyYjgwMWE4OTVjNWFiMDE2MS90YWJsZTo3YjlhZGE2YTJiOWU0MmY2YTdkNTRkMDkyNmQwZGJhMC90YWJsZXJhbmdlOjdiOWFkYTZhMmI5ZTQyZjZhN2Q1NGQwOTI2ZDBkYmEwXzQ1LTAtMS0xLTAvdGV4dHJlZ2lvbjplMmM4NDUzZmZkNjc0OTEyODRhY2VhY2IxYTFlNzc5M18zMg_3896173a-2869-4fb7-bf3d-6c069b79ce68"
      unitRef="shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="ib56f1adc867e406ca7face50c5da1c9c_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xNzUvZnJhZzphZTY3YTllM2U3MDU0YWUyYjgwMWE4OTVjNWFiMDE2MS90YWJsZTo3YjlhZGE2YTJiOWU0MmY2YTdkNTRkMDkyNmQwZGJhMC90YWJsZXJhbmdlOjdiOWFkYTZhMmI5ZTQyZjZhN2Q1NGQwOTI2ZDBkYmEwXzQ1LTAtMS0xLTAvdGV4dHJlZ2lvbjplMmM4NDUzZmZkNjc0OTEyODRhY2VhY2IxYTFlNzc5M18zMg_72cc4a7a-b16d-4ba2-bf4f-c00ffcdd0d3a"
      unitRef="shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ied8d945ebce54ed8a4badfed477a64e8_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xNzUvZnJhZzphZTY3YTllM2U3MDU0YWUyYjgwMWE4OTVjNWFiMDE2MS90YWJsZTo3YjlhZGE2YTJiOWU0MmY2YTdkNTRkMDkyNmQwZGJhMC90YWJsZXJhbmdlOjdiOWFkYTZhMmI5ZTQyZjZhN2Q1NGQwOTI2ZDBkYmEwXzQ1LTAtMS0xLTAvdGV4dHJlZ2lvbjplMmM4NDUzZmZkNjc0OTEyODRhY2VhY2IxYTFlNzc5M181NA_5e6b63be-c555-4ad9-bc86-b7fe92344e54"
      unitRef="shares">112977004</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="ied8d945ebce54ed8a4badfed477a64e8_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xNzUvZnJhZzphZTY3YTllM2U3MDU0YWUyYjgwMWE4OTVjNWFiMDE2MS90YWJsZTo3YjlhZGE2YTJiOWU0MmY2YTdkNTRkMDkyNmQwZGJhMC90YWJsZXJhbmdlOjdiOWFkYTZhMmI5ZTQyZjZhN2Q1NGQwOTI2ZDBkYmEwXzQ1LTAtMS0xLTAvdGV4dHJlZ2lvbjplMmM4NDUzZmZkNjc0OTEyODRhY2VhY2IxYTFlNzc5M181NA_de115b88-a39b-41d7-9371-d387957d29f6"
      unitRef="shares">112977004</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ib56f1adc867e406ca7face50c5da1c9c_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xNzUvZnJhZzphZTY3YTllM2U3MDU0YWUyYjgwMWE4OTVjNWFiMDE2MS90YWJsZTo3YjlhZGE2YTJiOWU0MmY2YTdkNTRkMDkyNmQwZGJhMC90YWJsZXJhbmdlOjdiOWFkYTZhMmI5ZTQyZjZhN2Q1NGQwOTI2ZDBkYmEwXzQ1LTAtMS0xLTAvdGV4dHJlZ2lvbjplMmM4NDUzZmZkNjc0OTEyODRhY2VhY2IxYTFlNzc5M182MQ_4c37d477-64e4-455b-a83e-098906424296"
      unitRef="shares">108071249</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="ib56f1adc867e406ca7face50c5da1c9c_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xNzUvZnJhZzphZTY3YTllM2U3MDU0YWUyYjgwMWE4OTVjNWFiMDE2MS90YWJsZTo3YjlhZGE2YTJiOWU0MmY2YTdkNTRkMDkyNmQwZGJhMC90YWJsZXJhbmdlOjdiOWFkYTZhMmI5ZTQyZjZhN2Q1NGQwOTI2ZDBkYmEwXzQ1LTAtMS0xLTAvdGV4dHJlZ2lvbjplMmM4NDUzZmZkNjc0OTEyODRhY2VhY2IxYTFlNzc5M182MQ_96eb7073-a29c-403a-bbc2-5156baf71d83"
      unitRef="shares">108071249</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="ied8d945ebce54ed8a4badfed477a64e8_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xNzUvZnJhZzphZTY3YTllM2U3MDU0YWUyYjgwMWE4OTVjNWFiMDE2MS90YWJsZTo3YjlhZGE2YTJiOWU0MmY2YTdkNTRkMDkyNmQwZGJhMC90YWJsZXJhbmdlOjdiOWFkYTZhMmI5ZTQyZjZhN2Q1NGQwOTI2ZDBkYmEwXzQ1LTEtMS0xLTA_70f7ece3-ea61-47fe-b8fa-dd7e9adf4a74"
      unitRef="usd">11000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="ib56f1adc867e406ca7face50c5da1c9c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xNzUvZnJhZzphZTY3YTllM2U3MDU0YWUyYjgwMWE4OTVjNWFiMDE2MS90YWJsZTo3YjlhZGE2YTJiOWU0MmY2YTdkNTRkMDkyNmQwZGJhMC90YWJsZXJhbmdlOjdiOWFkYTZhMmI5ZTQyZjZhN2Q1NGQwOTI2ZDBkYmEwXzQ1LTMtMS0xLTA_a5645f68-6c6c-479e-9bec-be97e8695f57"
      unitRef="usd">11000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="ied8d945ebce54ed8a4badfed477a64e8_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xNzUvZnJhZzphZTY3YTllM2U3MDU0YWUyYjgwMWE4OTVjNWFiMDE2MS90YWJsZTo3YjlhZGE2YTJiOWU0MmY2YTdkNTRkMDkyNmQwZGJhMC90YWJsZXJhbmdlOjdiOWFkYTZhMmI5ZTQyZjZhN2Q1NGQwOTI2ZDBkYmEwXzQ2LTEtMS0xLTA_06773f84-85ce-438d-a651-bbd114bedc0f"
      unitRef="usd">414214000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="ib56f1adc867e406ca7face50c5da1c9c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xNzUvZnJhZzphZTY3YTllM2U3MDU0YWUyYjgwMWE4OTVjNWFiMDE2MS90YWJsZTo3YjlhZGE2YTJiOWU0MmY2YTdkNTRkMDkyNmQwZGJhMC90YWJsZXJhbmdlOjdiOWFkYTZhMmI5ZTQyZjZhN2Q1NGQwOTI2ZDBkYmEwXzQ2LTMtMS0xLTA_6a65928a-5107-4394-91b1-854891cf38be"
      unitRef="usd">391175000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="ied8d945ebce54ed8a4badfed477a64e8_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xNzUvZnJhZzphZTY3YTllM2U3MDU0YWUyYjgwMWE4OTVjNWFiMDE2MS90YWJsZTo3YjlhZGE2YTJiOWU0MmY2YTdkNTRkMDkyNmQwZGJhMC90YWJsZXJhbmdlOjdiOWFkYTZhMmI5ZTQyZjZhN2Q1NGQwOTI2ZDBkYmEwXzQ4LTEtMS0xLTA_4a0edd6d-3986-489d-81af-5203b219d683"
      unitRef="usd">-429226000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="ib56f1adc867e406ca7face50c5da1c9c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xNzUvZnJhZzphZTY3YTllM2U3MDU0YWUyYjgwMWE4OTVjNWFiMDE2MS90YWJsZTo3YjlhZGE2YTJiOWU0MmY2YTdkNTRkMDkyNmQwZGJhMC90YWJsZXJhbmdlOjdiOWFkYTZhMmI5ZTQyZjZhN2Q1NGQwOTI2ZDBkYmEwXzQ4LTMtMS0xLTA_246d3f93-6a49-43e6-9673-38257c22b280"
      unitRef="usd">-404629000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="ied8d945ebce54ed8a4badfed477a64e8_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xNzUvZnJhZzphZTY3YTllM2U3MDU0YWUyYjgwMWE4OTVjNWFiMDE2MS90YWJsZTo3YjlhZGE2YTJiOWU0MmY2YTdkNTRkMDkyNmQwZGJhMC90YWJsZXJhbmdlOjdiOWFkYTZhMmI5ZTQyZjZhN2Q1NGQwOTI2ZDBkYmEwXzQ5LTEtMS0xLTA_81ff1386-5a2b-475a-bb4a-1dfad81b4a8e"
      unitRef="usd">-4570000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="ib56f1adc867e406ca7face50c5da1c9c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xNzUvZnJhZzphZTY3YTllM2U3MDU0YWUyYjgwMWE4OTVjNWFiMDE2MS90YWJsZTo3YjlhZGE2YTJiOWU0MmY2YTdkNTRkMDkyNmQwZGJhMC90YWJsZXJhbmdlOjdiOWFkYTZhMmI5ZTQyZjZhN2Q1NGQwOTI2ZDBkYmEwXzQ5LTMtMS0xLTA_ab503fea-0048-474c-ac45-33415ad6e8b0"
      unitRef="usd">-4563000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquity
      contextRef="ied8d945ebce54ed8a4badfed477a64e8_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xNzUvZnJhZzphZTY3YTllM2U3MDU0YWUyYjgwMWE4OTVjNWFiMDE2MS90YWJsZTo3YjlhZGE2YTJiOWU0MmY2YTdkNTRkMDkyNmQwZGJhMC90YWJsZXJhbmdlOjdiOWFkYTZhMmI5ZTQyZjZhN2Q1NGQwOTI2ZDBkYmEwXzUwLTEtMS0xLTA_c2a3ed6a-8f21-4d84-b27a-6bcc8f9b1696"
      unitRef="usd">-19571000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ib56f1adc867e406ca7face50c5da1c9c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xNzUvZnJhZzphZTY3YTllM2U3MDU0YWUyYjgwMWE4OTVjNWFiMDE2MS90YWJsZTo3YjlhZGE2YTJiOWU0MmY2YTdkNTRkMDkyNmQwZGJhMC90YWJsZXJhbmdlOjdiOWFkYTZhMmI5ZTQyZjZhN2Q1NGQwOTI2ZDBkYmEwXzUwLTMtMS0xLTA_1d12a624-e1ef-44f5-aaec-b3e7e5dcaa1c"
      unitRef="usd">-18006000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="ied8d945ebce54ed8a4badfed477a64e8_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xNzUvZnJhZzphZTY3YTllM2U3MDU0YWUyYjgwMWE4OTVjNWFiMDE2MS90YWJsZTo3YjlhZGE2YTJiOWU0MmY2YTdkNTRkMDkyNmQwZGJhMC90YWJsZXJhbmdlOjdiOWFkYTZhMmI5ZTQyZjZhN2Q1NGQwOTI2ZDBkYmEwXzUxLTEtMS0xLTA_7193f4b9-d61d-4277-93b9-5aaf52e89865"
      unitRef="usd">176746000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="ib56f1adc867e406ca7face50c5da1c9c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xNzUvZnJhZzphZTY3YTllM2U3MDU0YWUyYjgwMWE4OTVjNWFiMDE2MS90YWJsZTo3YjlhZGE2YTJiOWU0MmY2YTdkNTRkMDkyNmQwZGJhMC90YWJsZXJhbmdlOjdiOWFkYTZhMmI5ZTQyZjZhN2Q1NGQwOTI2ZDBkYmEwXzUxLTMtMS0xLTA_080d1637-37e4-4bce-9c15-8b875fe34580"
      unitRef="usd">165435000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xNzgvZnJhZzo2YzY1MGFkMjA1Njc0OTZlYTM1YzNkY2E1MTRlMGRlNC90YWJsZTo0ZGFlNzk5OWM5MDc0ZDI2YWJhZDRhYWVmZDI4NzM0NC90YWJsZXJhbmdlOjRkYWU3OTk5YzkwNzRkMjZhYmFkNGFhZWZkMjg3MzQ0XzMtMS0xLTEtMA_021e322a-3d20-4772-8cf0-4998a03924f2"
      unitRef="usd">11050000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i824a5b33f908426bad016f0eded844db_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xNzgvZnJhZzo2YzY1MGFkMjA1Njc0OTZlYTM1YzNkY2E1MTRlMGRlNC90YWJsZTo0ZGFlNzk5OWM5MDc0ZDI2YWJhZDRhYWVmZDI4NzM0NC90YWJsZXJhbmdlOjRkYWU3OTk5YzkwNzRkMjZhYmFkNGFhZWZkMjg3MzQ0XzMtMy0xLTEtMA_ce552572-e0a0-4dae-b70a-dac0db7c4d0c"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xNzgvZnJhZzo2YzY1MGFkMjA1Njc0OTZlYTM1YzNkY2E1MTRlMGRlNC90YWJsZTo0ZGFlNzk5OWM5MDc0ZDI2YWJhZDRhYWVmZDI4NzM0NC90YWJsZXJhbmdlOjRkYWU3OTk5YzkwNzRkMjZhYmFkNGFhZWZkMjg3MzQ0XzUtMS0xLTEtMA_83a0d1f0-8464-41dc-acd0-f35f90552305"
      unitRef="usd">13004000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i824a5b33f908426bad016f0eded844db_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xNzgvZnJhZzo2YzY1MGFkMjA1Njc0OTZlYTM1YzNkY2E1MTRlMGRlNC90YWJsZTo0ZGFlNzk5OWM5MDc0ZDI2YWJhZDRhYWVmZDI4NzM0NC90YWJsZXJhbmdlOjRkYWU3OTk5YzkwNzRkMjZhYmFkNGFhZWZkMjg3MzQ0XzUtMy0xLTEtMA_a0fcd936-3997-4229-9388-bf371580e1dc"
      unitRef="usd">14724000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xNzgvZnJhZzo2YzY1MGFkMjA1Njc0OTZlYTM1YzNkY2E1MTRlMGRlNC90YWJsZTo0ZGFlNzk5OWM5MDc0ZDI2YWJhZDRhYWVmZDI4NzM0NC90YWJsZXJhbmdlOjRkYWU3OTk5YzkwNzRkMjZhYmFkNGFhZWZkMjg3MzQ0XzYtMS0xLTEtMA_a393499b-c7c7-40e6-975b-c02ecc1da761"
      unitRef="usd">5204000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i824a5b33f908426bad016f0eded844db_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xNzgvZnJhZzo2YzY1MGFkMjA1Njc0OTZlYTM1YzNkY2E1MTRlMGRlNC90YWJsZTo0ZGFlNzk5OWM5MDc0ZDI2YWJhZDRhYWVmZDI4NzM0NC90YWJsZXJhbmdlOjRkYWU3OTk5YzkwNzRkMjZhYmFkNGFhZWZkMjg3MzQ0XzYtMy0xLTEtMA_1543e490-03d8-40bc-a25f-856145b52f01"
      unitRef="usd">4098000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xNzgvZnJhZzo2YzY1MGFkMjA1Njc0OTZlYTM1YzNkY2E1MTRlMGRlNC90YWJsZTo0ZGFlNzk5OWM5MDc0ZDI2YWJhZDRhYWVmZDI4NzM0NC90YWJsZXJhbmdlOjRkYWU3OTk5YzkwNzRkMjZhYmFkNGFhZWZkMjg3MzQ0XzctMS0xLTEtMA_64909a32-66a2-4fe1-acf1-e15abef7de90"
      unitRef="usd">18208000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i824a5b33f908426bad016f0eded844db_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xNzgvZnJhZzo2YzY1MGFkMjA1Njc0OTZlYTM1YzNkY2E1MTRlMGRlNC90YWJsZTo0ZGFlNzk5OWM5MDc0ZDI2YWJhZDRhYWVmZDI4NzM0NC90YWJsZXJhbmdlOjRkYWU3OTk5YzkwNzRkMjZhYmFkNGFhZWZkMjg3MzQ0XzctMy0xLTEtMA_460eb26b-44b5-490f-87da-7c28dc56f72e"
      unitRef="usd">18822000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xNzgvZnJhZzo2YzY1MGFkMjA1Njc0OTZlYTM1YzNkY2E1MTRlMGRlNC90YWJsZTo0ZGFlNzk5OWM5MDc0ZDI2YWJhZDRhYWVmZDI4NzM0NC90YWJsZXJhbmdlOjRkYWU3OTk5YzkwNzRkMjZhYmFkNGFhZWZkMjg3MzQ0XzgtMS0xLTEtMA_b3d8ccb5-90b4-4af0-bc55-639048da48ba"
      unitRef="usd">-7158000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i824a5b33f908426bad016f0eded844db_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xNzgvZnJhZzo2YzY1MGFkMjA1Njc0OTZlYTM1YzNkY2E1MTRlMGRlNC90YWJsZTo0ZGFlNzk5OWM5MDc0ZDI2YWJhZDRhYWVmZDI4NzM0NC90YWJsZXJhbmdlOjRkYWU3OTk5YzkwNzRkMjZhYmFkNGFhZWZkMjg3MzQ0XzgtMy0xLTEtMA_00dc2b04-8ae1-4c04-aeca-b7f99f3b2e75"
      unitRef="usd">-18822000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeNet
      contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xNzgvZnJhZzo2YzY1MGFkMjA1Njc0OTZlYTM1YzNkY2E1MTRlMGRlNC90YWJsZTo0ZGFlNzk5OWM5MDc0ZDI2YWJhZDRhYWVmZDI4NzM0NC90YWJsZXJhbmdlOjRkYWU3OTk5YzkwNzRkMjZhYmFkNGFhZWZkMjg3MzQ0XzktMS0xLTEtMA_750050b1-c01d-4b0e-820a-c9c1c1fb65c7"
      unitRef="usd">12000</us-gaap:InvestmentIncomeNet>
    <us-gaap:InvestmentIncomeNet
      contextRef="i824a5b33f908426bad016f0eded844db_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xNzgvZnJhZzo2YzY1MGFkMjA1Njc0OTZlYTM1YzNkY2E1MTRlMGRlNC90YWJsZTo0ZGFlNzk5OWM5MDc0ZDI2YWJhZDRhYWVmZDI4NzM0NC90YWJsZXJhbmdlOjRkYWU3OTk5YzkwNzRkMjZhYmFkNGFhZWZkMjg3MzQ0XzktMy0xLTEtMA_09e622a7-fd08-4bc7-9abc-53f16878c640"
      unitRef="usd">240000</us-gaap:InvestmentIncomeNet>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xNzgvZnJhZzo2YzY1MGFkMjA1Njc0OTZlYTM1YzNkY2E1MTRlMGRlNC90YWJsZTo0ZGFlNzk5OWM5MDc0ZDI2YWJhZDRhYWVmZDI4NzM0NC90YWJsZXJhbmdlOjRkYWU3OTk5YzkwNzRkMjZhYmFkNGFhZWZkMjg3MzQ0XzExLTEtMS0xLTA_9672513d-6c43-44e4-b354-693745be4537"
      unitRef="usd">7000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="i824a5b33f908426bad016f0eded844db_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xNzgvZnJhZzo2YzY1MGFkMjA1Njc0OTZlYTM1YzNkY2E1MTRlMGRlNC90YWJsZTo0ZGFlNzk5OWM5MDc0ZDI2YWJhZDRhYWVmZDI4NzM0NC90YWJsZXJhbmdlOjRkYWU3OTk5YzkwNzRkMjZhYmFkNGFhZWZkMjg3MzQ0XzExLTMtMS0xLTA_03bf7b5c-0579-460e-87c9-1a4149f95198"
      unitRef="usd">82000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:InterestExpense
      contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xNzgvZnJhZzo2YzY1MGFkMjA1Njc0OTZlYTM1YzNkY2E1MTRlMGRlNC90YWJsZTo0ZGFlNzk5OWM5MDc0ZDI2YWJhZDRhYWVmZDI4NzM0NC90YWJsZXJhbmdlOjRkYWU3OTk5YzkwNzRkMjZhYmFkNGFhZWZkMjg3MzQ0XzEyLTEtMS0xLTA_5554f934-930b-4317-8c2a-2e0e3c4eee15"
      unitRef="usd">711000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i824a5b33f908426bad016f0eded844db_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xNzgvZnJhZzo2YzY1MGFkMjA1Njc0OTZlYTM1YzNkY2E1MTRlMGRlNC90YWJsZTo0ZGFlNzk5OWM5MDc0ZDI2YWJhZDRhYWVmZDI4NzM0NC90YWJsZXJhbmdlOjRkYWU3OTk5YzkwNzRkMjZhYmFkNGFhZWZkMjg3MzQ0XzEyLTMtMS0xLTA_27805aa0-f21f-48af-8151-3593443006f7"
      unitRef="usd">273000</us-gaap:InterestExpense>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xNzgvZnJhZzo2YzY1MGFkMjA1Njc0OTZlYTM1YzNkY2E1MTRlMGRlNC90YWJsZTo0ZGFlNzk5OWM5MDc0ZDI2YWJhZDRhYWVmZDI4NzM0NC90YWJsZXJhbmdlOjRkYWU3OTk5YzkwNzRkMjZhYmFkNGFhZWZkMjg3MzQ0XzEzLTEtMS0xLTA_a5f25630-45dc-4bae-80b8-176590ea18ba"
      unitRef="usd">16747000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="i824a5b33f908426bad016f0eded844db_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xNzgvZnJhZzo2YzY1MGFkMjA1Njc0OTZlYTM1YzNkY2E1MTRlMGRlNC90YWJsZTo0ZGFlNzk5OWM5MDc0ZDI2YWJhZDRhYWVmZDI4NzM0NC90YWJsZXJhbmdlOjRkYWU3OTk5YzkwNzRkMjZhYmFkNGFhZWZkMjg3MzQ0XzEzLTMtMS0xLTA_e72e6e28-7df5-423d-ad59-ac35c54bd1f1"
      unitRef="usd">846000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xNzgvZnJhZzo2YzY1MGFkMjA1Njc0OTZlYTM1YzNkY2E1MTRlMGRlNC90YWJsZTo0ZGFlNzk5OWM5MDc0ZDI2YWJhZDRhYWVmZDI4NzM0NC90YWJsZXJhbmdlOjRkYWU3OTk5YzkwNzRkMjZhYmFkNGFhZWZkMjg3MzQ0XzE0LTEtMS0xLTA_a99204bb-c6e7-4277-9dd9-340235a8cbcb"
      unitRef="usd">0</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i824a5b33f908426bad016f0eded844db_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xNzgvZnJhZzo2YzY1MGFkMjA1Njc0OTZlYTM1YzNkY2E1MTRlMGRlNC90YWJsZTo0ZGFlNzk5OWM5MDc0ZDI2YWJhZDRhYWVmZDI4NzM0NC90YWJsZXJhbmdlOjRkYWU3OTk5YzkwNzRkMjZhYmFkNGFhZWZkMjg3MzQ0XzE0LTMtMS0xLTA_401d02a0-5103-4352-bd5d-36b540b9c714"
      unitRef="usd">-1000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xNzgvZnJhZzo2YzY1MGFkMjA1Njc0OTZlYTM1YzNkY2E1MTRlMGRlNC90YWJsZTo0ZGFlNzk5OWM5MDc0ZDI2YWJhZDRhYWVmZDI4NzM0NC90YWJsZXJhbmdlOjRkYWU3OTk5YzkwNzRkMjZhYmFkNGFhZWZkMjg3MzQ0XzE3LTEtMS0xLTA_0bb8308d-63b8-49da-b4b9-eb1e1c28fd69"
      unitRef="usd">-24597000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i824a5b33f908426bad016f0eded844db_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xNzgvZnJhZzo2YzY1MGFkMjA1Njc0OTZlYTM1YzNkY2E1MTRlMGRlNC90YWJsZTo0ZGFlNzk5OWM5MDc0ZDI2YWJhZDRhYWVmZDI4NzM0NC90YWJsZXJhbmdlOjRkYWU3OTk5YzkwNzRkMjZhYmFkNGFhZWZkMjg3MzQ0XzE3LTMtMS0xLTA_731c43ed-80ee-4870-9a73-d9de376f68d1"
      unitRef="usd">-19620000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xNzgvZnJhZzo2YzY1MGFkMjA1Njc0OTZlYTM1YzNkY2E1MTRlMGRlNC90YWJsZTo0ZGFlNzk5OWM5MDc0ZDI2YWJhZDRhYWVmZDI4NzM0NC90YWJsZXJhbmdlOjRkYWU3OTk5YzkwNzRkMjZhYmFkNGFhZWZkMjg3MzQ0XzIwLTEtMS0xLTA_ffd1233b-2a09-4e82-8220-342ac76355d0"
      unitRef="usd">-6000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i824a5b33f908426bad016f0eded844db_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xNzgvZnJhZzo2YzY1MGFkMjA1Njc0OTZlYTM1YzNkY2E1MTRlMGRlNC90YWJsZTo0ZGFlNzk5OWM5MDc0ZDI2YWJhZDRhYWVmZDI4NzM0NC90YWJsZXJhbmdlOjRkYWU3OTk5YzkwNzRkMjZhYmFkNGFhZWZkMjg3MzQ0XzIwLTMtMS0xLTA_dfa2170c-13e5-4155-b1de-01ed97494089"
      unitRef="usd">-60000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xNzgvZnJhZzo2YzY1MGFkMjA1Njc0OTZlYTM1YzNkY2E1MTRlMGRlNC90YWJsZTo0ZGFlNzk5OWM5MDc0ZDI2YWJhZDRhYWVmZDI4NzM0NC90YWJsZXJhbmdlOjRkYWU3OTk5YzkwNzRkMjZhYmFkNGFhZWZkMjg3MzQ0XzIxLTEtMS0xLTA_685d9087-59b2-4083-bc24-640e6096ded6"
      unitRef="usd">-1000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i824a5b33f908426bad016f0eded844db_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xNzgvZnJhZzo2YzY1MGFkMjA1Njc0OTZlYTM1YzNkY2E1MTRlMGRlNC90YWJsZTo0ZGFlNzk5OWM5MDc0ZDI2YWJhZDRhYWVmZDI4NzM0NC90YWJsZXJhbmdlOjRkYWU3OTk5YzkwNzRkMjZhYmFkNGFhZWZkMjg3MzQ0XzIxLTMtMS0xLTA_ad96da1d-da59-44f9-bd64-80714d60a584"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xNzgvZnJhZzo2YzY1MGFkMjA1Njc0OTZlYTM1YzNkY2E1MTRlMGRlNC90YWJsZTo0ZGFlNzk5OWM5MDc0ZDI2YWJhZDRhYWVmZDI4NzM0NC90YWJsZXJhbmdlOjRkYWU3OTk5YzkwNzRkMjZhYmFkNGFhZWZkMjg3MzQ0XzIyLTEtMS0xLTA_32ce08d0-ef9c-406a-ac66-f9470645093a"
      unitRef="usd">-24604000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i824a5b33f908426bad016f0eded844db_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xNzgvZnJhZzo2YzY1MGFkMjA1Njc0OTZlYTM1YzNkY2E1MTRlMGRlNC90YWJsZTo0ZGFlNzk5OWM5MDc0ZDI2YWJhZDRhYWVmZDI4NzM0NC90YWJsZXJhbmdlOjRkYWU3OTk5YzkwNzRkMjZhYmFkNGFhZWZkMjg3MzQ0XzIyLTMtMS0xLTA_8cf9a41c-b4c1-41fd-9c0b-46e891fe1f6f"
      unitRef="usd">-19680000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xNzgvZnJhZzo2YzY1MGFkMjA1Njc0OTZlYTM1YzNkY2E1MTRlMGRlNC90YWJsZTo0ZGFlNzk5OWM5MDc0ZDI2YWJhZDRhYWVmZDI4NzM0NC90YWJsZXJhbmdlOjRkYWU3OTk5YzkwNzRkMjZhYmFkNGFhZWZkMjg3MzQ0XzMwLTEtMS0xLTA_132e9374-3aab-4bc4-af23-d277e923ca19"
      unitRef="usdPerShare">-0.22</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="i824a5b33f908426bad016f0eded844db_D20200101-20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xNzgvZnJhZzo2YzY1MGFkMjA1Njc0OTZlYTM1YzNkY2E1MTRlMGRlNC90YWJsZTo0ZGFlNzk5OWM5MDc0ZDI2YWJhZDRhYWVmZDI4NzM0NC90YWJsZXJhbmdlOjRkYWU3OTk5YzkwNzRkMjZhYmFkNGFhZWZkMjg3MzQ0XzMwLTMtMS0xLTA_3f881787-c307-418d-aa0b-dec3f374b3a3"
      unitRef="usdPerShare">-0.21</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xNzgvZnJhZzo2YzY1MGFkMjA1Njc0OTZlYTM1YzNkY2E1MTRlMGRlNC90YWJsZTo0ZGFlNzk5OWM5MDc0ZDI2YWJhZDRhYWVmZDI4NzM0NC90YWJsZXJhbmdlOjRkYWU3OTk5YzkwNzRkMjZhYmFkNGFhZWZkMjg3MzQ0XzMyLTEtMS0xLTA_e3063f9b-8f54-46e6-8a77-2d46afb68464"
      unitRef="shares">110742150</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="i824a5b33f908426bad016f0eded844db_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xNzgvZnJhZzo2YzY1MGFkMjA1Njc0OTZlYTM1YzNkY2E1MTRlMGRlNC90YWJsZTo0ZGFlNzk5OWM5MDc0ZDI2YWJhZDRhYWVmZDI4NzM0NC90YWJsZXJhbmdlOjRkYWU3OTk5YzkwNzRkMjZhYmFkNGFhZWZkMjg3MzQ0XzMyLTMtMS0xLTA_b40d2c96-67c1-4276-87b9-c19c33d96e76"
      unitRef="shares">94723513</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i28d60e6e11b845dfb37da5a84a9cc1e5_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xODEvZnJhZzpkZjY0MmVlMzkyNGY0ODhhOTY3ZTFmNTE0ZDVhMzRjZS90YWJsZTpiZmUwNWFjOTkxNjY0NTIwYjEwZGE2ZjA3YzE4ODI5NC90YWJsZXJhbmdlOmJmZTA1YWM5OTE2NjQ1MjBiMTBkYTZmMDdjMTg4Mjk0XzM2LTEtMS0xLTMxODI_3ac5911f-1f4e-4f18-a4fe-6aaff315900f"
      unitRef="shares">108071249</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i28d60e6e11b845dfb37da5a84a9cc1e5_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xODEvZnJhZzpkZjY0MmVlMzkyNGY0ODhhOTY3ZTFmNTE0ZDVhMzRjZS90YWJsZTpiZmUwNWFjOTkxNjY0NTIwYjEwZGE2ZjA3YzE4ODI5NC90YWJsZXJhbmdlOmJmZTA1YWM5OTE2NjQ1MjBiMTBkYTZmMDdjMTg4Mjk0XzM2LTItMS0xLTMxODI_9510eadd-f6e6-4122-8218-7a6f88865ba1"
      unitRef="usd">11000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="id4c7f024803c4bb7abe0167bbe5af671_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xODEvZnJhZzpkZjY0MmVlMzkyNGY0ODhhOTY3ZTFmNTE0ZDVhMzRjZS90YWJsZTpiZmUwNWFjOTkxNjY0NTIwYjEwZGE2ZjA3YzE4ODI5NC90YWJsZXJhbmdlOmJmZTA1YWM5OTE2NjQ1MjBiMTBkYTZmMDdjMTg4Mjk0XzM2LTQtMS0xLTMxODI_de47d863-ae2b-45e1-b140-b4bedd77ac59"
      unitRef="usd">391175000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i6cd8f7abd235450ab64356048dc9ec07_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xODEvZnJhZzpkZjY0MmVlMzkyNGY0ODhhOTY3ZTFmNTE0ZDVhMzRjZS90YWJsZTpiZmUwNWFjOTkxNjY0NTIwYjEwZGE2ZjA3YzE4ODI5NC90YWJsZXJhbmdlOmJmZTA1YWM5OTE2NjQ1MjBiMTBkYTZmMDdjMTg4Mjk0XzM2LTgtMS0xLTMxODI_d78f1540-6815-4a06-8d34-88a442dd913d"
      unitRef="usd">-404629000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ie0acbe76b2ae438d975dc022af481d6c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xODEvZnJhZzpkZjY0MmVlMzkyNGY0ODhhOTY3ZTFmNTE0ZDVhMzRjZS90YWJsZTpiZmUwNWFjOTkxNjY0NTIwYjEwZGE2ZjA3YzE4ODI5NC90YWJsZXJhbmdlOmJmZTA1YWM5OTE2NjQ1MjBiMTBkYTZmMDdjMTg4Mjk0XzM2LTEwLTEtMS0zMTgy_950ca9ef-d679-4b96-b48b-a1456ef82f85"
      unitRef="usd">-4563000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ib56f1adc867e406ca7face50c5da1c9c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xODEvZnJhZzpkZjY0MmVlMzkyNGY0ODhhOTY3ZTFmNTE0ZDVhMzRjZS90YWJsZTpiZmUwNWFjOTkxNjY0NTIwYjEwZGE2ZjA3YzE4ODI5NC90YWJsZXJhbmdlOmJmZTA1YWM5OTE2NjQ1MjBiMTBkYTZmMDdjMTg4Mjk0XzM2LTEyLTEtMS0zMTgy_0e8e27db-ce34-47eb-976f-ee5b488efe7e"
      unitRef="usd">-18006000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="idce850cc47714092ba1dcaa145785537_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xODEvZnJhZzpkZjY0MmVlMzkyNGY0ODhhOTY3ZTFmNTE0ZDVhMzRjZS90YWJsZTpiZmUwNWFjOTkxNjY0NTIwYjEwZGE2ZjA3YzE4ODI5NC90YWJsZXJhbmdlOmJmZTA1YWM5OTE2NjQ1MjBiMTBkYTZmMDdjMTg4Mjk0XzI1LTEtMS0xLTA_9d158e16-2563-4fa6-8ccc-acf413ac49db"
      unitRef="shares">34696</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="ic39deec9ab0844a9b0dab300f1a2804d_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xODEvZnJhZzpkZjY0MmVlMzkyNGY0ODhhOTY3ZTFmNTE0ZDVhMzRjZS90YWJsZTpiZmUwNWFjOTkxNjY0NTIwYjEwZGE2ZjA3YzE4ODI5NC90YWJsZXJhbmdlOmJmZTA1YWM5OTE2NjQ1MjBiMTBkYTZmMDdjMTg4Mjk0XzI1LTQtMS0xLTA_eaa71ffc-66ae-4904-8f4d-19ca7f70eb72"
      unitRef="usd">72000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xODEvZnJhZzpkZjY0MmVlMzkyNGY0ODhhOTY3ZTFmNTE0ZDVhMzRjZS90YWJsZTpiZmUwNWFjOTkxNjY0NTIwYjEwZGE2ZjA3YzE4ODI5NC90YWJsZXJhbmdlOmJmZTA1YWM5OTE2NjQ1MjBiMTBkYTZmMDdjMTg4Mjk0XzI1LTEyLTEtMS0w_ee010bb7-0e5d-47fa-8134-428bcda72721"
      unitRef="usd">72000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="idce850cc47714092ba1dcaa145785537_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xODEvZnJhZzpkZjY0MmVlMzkyNGY0ODhhOTY3ZTFmNTE0ZDVhMzRjZS90YWJsZTpiZmUwNWFjOTkxNjY0NTIwYjEwZGE2ZjA3YzE4ODI5NC90YWJsZXJhbmdlOmJmZTA1YWM5OTE2NjQ1MjBiMTBkYTZmMDdjMTg4Mjk0XzI2LTEtMS0xLTA_af5595e7-dd6c-4f47-8630-e6ba2fb8ff9c"
      unitRef="shares">153278</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ic39deec9ab0844a9b0dab300f1a2804d_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xODEvZnJhZzpkZjY0MmVlMzkyNGY0ODhhOTY3ZTFmNTE0ZDVhMzRjZS90YWJsZTpiZmUwNWFjOTkxNjY0NTIwYjEwZGE2ZjA3YzE4ODI5NC90YWJsZXJhbmdlOmJmZTA1YWM5OTE2NjQ1MjBiMTBkYTZmMDdjMTg4Mjk0XzI2LTQtMS0xLTA_a84b26fd-685a-4846-bd42-ebb4da7c0e9b"
      unitRef="usd">244000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xODEvZnJhZzpkZjY0MmVlMzkyNGY0ODhhOTY3ZTFmNTE0ZDVhMzRjZS90YWJsZTpiZmUwNWFjOTkxNjY0NTIwYjEwZGE2ZjA3YzE4ODI5NC90YWJsZXJhbmdlOmJmZTA1YWM5OTE2NjQ1MjBiMTBkYTZmMDdjMTg4Mjk0XzI2LTEyLTEtMS0w_b4584562-f045-4925-9328-62521fe90871"
      unitRef="usd">244000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="idce850cc47714092ba1dcaa145785537_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xODEvZnJhZzpkZjY0MmVlMzkyNGY0ODhhOTY3ZTFmNTE0ZDVhMzRjZS90YWJsZTpiZmUwNWFjOTkxNjY0NTIwYjEwZGE2ZjA3YzE4ODI5NC90YWJsZXJhbmdlOmJmZTA1YWM5OTE2NjQ1MjBiMTBkYTZmMDdjMTg4Mjk0XzI3LTEtMS0xLTA_b3802b32-f002-4370-ae0f-2b940d1d7716"
      unitRef="shares">10937</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xODEvZnJhZzpkZjY0MmVlMzkyNGY0ODhhOTY3ZTFmNTE0ZDVhMzRjZS90YWJsZTpiZmUwNWFjOTkxNjY0NTIwYjEwZGE2ZjA3YzE4ODI5NC90YWJsZXJhbmdlOmJmZTA1YWM5OTE2NjQ1MjBiMTBkYTZmMDdjMTg4Mjk0XzI3LTEyLTEtMS0w_24b1d781-196d-429a-9268-2618ccc9390b"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodSharesOther
      contextRef="idce850cc47714092ba1dcaa145785537_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xODEvZnJhZzpkZjY0MmVlMzkyNGY0ODhhOTY3ZTFmNTE0ZDVhMzRjZS90YWJsZTpiZmUwNWFjOTkxNjY0NTIwYjEwZGE2ZjA3YzE4ODI5NC90YWJsZXJhbmdlOmJmZTA1YWM5OTE2NjQ1MjBiMTBkYTZmMDdjMTg4Mjk0XzI4LTEtMS0xLTA_753b71f3-c866-41be-8ae5-e3b4e4924aaa"
      unitRef="shares">4706844</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="ic39deec9ab0844a9b0dab300f1a2804d_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xODEvZnJhZzpkZjY0MmVlMzkyNGY0ODhhOTY3ZTFmNTE0ZDVhMzRjZS90YWJsZTpiZmUwNWFjOTkxNjY0NTIwYjEwZGE2ZjA3YzE4ODI5NC90YWJsZXJhbmdlOmJmZTA1YWM5OTE2NjQ1MjBiMTBkYTZmMDdjMTg4Mjk0XzI4LTQtMS0xLTA_f5980420-2447-4a0f-88c2-269b3b14b510"
      unitRef="usd">20943000</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xODEvZnJhZzpkZjY0MmVlMzkyNGY0ODhhOTY3ZTFmNTE0ZDVhMzRjZS90YWJsZTpiZmUwNWFjOTkxNjY0NTIwYjEwZGE2ZjA3YzE4ODI5NC90YWJsZXJhbmdlOmJmZTA1YWM5OTE2NjQ1MjBiMTBkYTZmMDdjMTg4Mjk0XzI4LTEyLTEtMS0w_29204cbc-2979-423e-bd2b-7624f5130bf3"
      unitRef="usd">20943000</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ic39deec9ab0844a9b0dab300f1a2804d_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xODEvZnJhZzpkZjY0MmVlMzkyNGY0ODhhOTY3ZTFmNTE0ZDVhMzRjZS90YWJsZTpiZmUwNWFjOTkxNjY0NTIwYjEwZGE2ZjA3YzE4ODI5NC90YWJsZXJhbmdlOmJmZTA1YWM5OTE2NjQ1MjBiMTBkYTZmMDdjMTg4Mjk0XzM0LTQtMS0xLTA_06515a5d-c7ae-48cb-a7dc-35d874318ef8"
      unitRef="usd">1780000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xODEvZnJhZzpkZjY0MmVlMzkyNGY0ODhhOTY3ZTFmNTE0ZDVhMzRjZS90YWJsZTpiZmUwNWFjOTkxNjY0NTIwYjEwZGE2ZjA3YzE4ODI5NC90YWJsZXJhbmdlOmJmZTA1YWM5OTE2NjQ1MjBiMTBkYTZmMDdjMTg4Mjk0XzM0LTEyLTEtMS0w_f1fd4bae-bd97-41ab-ad2f-802cb185da7c"
      unitRef="usd">1780000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="ic7469ad2eea94378b3c60b0767ec2c61_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xODEvZnJhZzpkZjY0MmVlMzkyNGY0ODhhOTY3ZTFmNTE0ZDVhMzRjZS90YWJsZTpiZmUwNWFjOTkxNjY0NTIwYjEwZGE2ZjA3YzE4ODI5NC90YWJsZXJhbmdlOmJmZTA1YWM5OTE2NjQ1MjBiMTBkYTZmMDdjMTg4Mjk0XzM1LTEwLTEtMS0w_9834f98e-c4f8-4d0d-b45b-ff60d84a8c5f"
      unitRef="usd">-6000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xODEvZnJhZzpkZjY0MmVlMzkyNGY0ODhhOTY3ZTFmNTE0ZDVhMzRjZS90YWJsZTpiZmUwNWFjOTkxNjY0NTIwYjEwZGE2ZjA3YzE4ODI5NC90YWJsZXJhbmdlOmJmZTA1YWM5OTE2NjQ1MjBiMTBkYTZmMDdjMTg4Mjk0XzM1LTEyLTEtMS0w_70fe251e-91b8-42f3-8681-0c68f1312def"
      unitRef="usd">-6000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="ic7469ad2eea94378b3c60b0767ec2c61_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xODEvZnJhZzpkZjY0MmVlMzkyNGY0ODhhOTY3ZTFmNTE0ZDVhMzRjZS90YWJsZTpiZmUwNWFjOTkxNjY0NTIwYjEwZGE2ZjA3YzE4ODI5NC90YWJsZXJhbmdlOmJmZTA1YWM5OTE2NjQ1MjBiMTBkYTZmMDdjMTg4Mjk0XzQ3LTEwLTEtMS0xODc5_3627a64e-f517-4f36-be01-2c89e160625f"
      unitRef="usd">-1000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xODEvZnJhZzpkZjY0MmVlMzkyNGY0ODhhOTY3ZTFmNTE0ZDVhMzRjZS90YWJsZTpiZmUwNWFjOTkxNjY0NTIwYjEwZGE2ZjA3YzE4ODI5NC90YWJsZXJhbmdlOmJmZTA1YWM5OTE2NjQ1MjBiMTBkYTZmMDdjMTg4Mjk0XzQ1LTEyLTEtMS0zMTg0_b5a418f4-4338-4be5-8d01-97de961f6d4d"
      unitRef="usd">-1000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="i9ba514a4defc485e94d0b416ba59c49d_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xODEvZnJhZzpkZjY0MmVlMzkyNGY0ODhhOTY3ZTFmNTE0ZDVhMzRjZS90YWJsZTpiZmUwNWFjOTkxNjY0NTIwYjEwZGE2ZjA3YzE4ODI5NC90YWJsZXJhbmdlOmJmZTA1YWM5OTE2NjQ1MjBiMTBkYTZmMDdjMTg4Mjk0XzM3LTgtMS0xLTA_08832626-2522-4af9-846f-28a6bc937074"
      unitRef="usd">-24597000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xODEvZnJhZzpkZjY0MmVlMzkyNGY0ODhhOTY3ZTFmNTE0ZDVhMzRjZS90YWJsZTpiZmUwNWFjOTkxNjY0NTIwYjEwZGE2ZjA3YzE4ODI5NC90YWJsZXJhbmdlOmJmZTA1YWM5OTE2NjQ1MjBiMTBkYTZmMDdjMTg4Mjk0XzM3LTEyLTEtMS0w_2954799d-61e9-4da8-94c2-4a8bb07e1c4b"
      unitRef="usd">-24597000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i0f01a127e9094f2c9ce7fa5a13678fc4_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xODEvZnJhZzpkZjY0MmVlMzkyNGY0ODhhOTY3ZTFmNTE0ZDVhMzRjZS90YWJsZTpiZmUwNWFjOTkxNjY0NTIwYjEwZGE2ZjA3YzE4ODI5NC90YWJsZXJhbmdlOmJmZTA1YWM5OTE2NjQ1MjBiMTBkYTZmMDdjMTg4Mjk0XzM4LTEtMS0xLTA_2eaa0c90-558f-4cd8-9445-8849eafc0da5"
      unitRef="shares">112977004</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i0f01a127e9094f2c9ce7fa5a13678fc4_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xODEvZnJhZzpkZjY0MmVlMzkyNGY0ODhhOTY3ZTFmNTE0ZDVhMzRjZS90YWJsZTpiZmUwNWFjOTkxNjY0NTIwYjEwZGE2ZjA3YzE4ODI5NC90YWJsZXJhbmdlOmJmZTA1YWM5OTE2NjQ1MjBiMTBkYTZmMDdjMTg4Mjk0XzM4LTItMS0xLTA_297f3a77-6172-426a-b68b-9c59a2e03090"
      unitRef="usd">11000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i7a24e3ea770740729c391207bf51dce3_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xODEvZnJhZzpkZjY0MmVlMzkyNGY0ODhhOTY3ZTFmNTE0ZDVhMzRjZS90YWJsZTpiZmUwNWFjOTkxNjY0NTIwYjEwZGE2ZjA3YzE4ODI5NC90YWJsZXJhbmdlOmJmZTA1YWM5OTE2NjQ1MjBiMTBkYTZmMDdjMTg4Mjk0XzM4LTQtMS0xLTA_9746126a-2e14-47d5-b2f7-931fec53f33f"
      unitRef="usd">414214000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i64c04c765b7b44e8b62c73e17992956e_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xODEvZnJhZzpkZjY0MmVlMzkyNGY0ODhhOTY3ZTFmNTE0ZDVhMzRjZS90YWJsZTpiZmUwNWFjOTkxNjY0NTIwYjEwZGE2ZjA3YzE4ODI5NC90YWJsZXJhbmdlOmJmZTA1YWM5OTE2NjQ1MjBiMTBkYTZmMDdjMTg4Mjk0XzM4LTgtMS0xLTA_21d2c986-d2d7-4e55-92fc-be0fa86bc422"
      unitRef="usd">-429226000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i697921663ff44d1ba22263ce04047fe4_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xODEvZnJhZzpkZjY0MmVlMzkyNGY0ODhhOTY3ZTFmNTE0ZDVhMzRjZS90YWJsZTpiZmUwNWFjOTkxNjY0NTIwYjEwZGE2ZjA3YzE4ODI5NC90YWJsZXJhbmdlOmJmZTA1YWM5OTE2NjQ1MjBiMTBkYTZmMDdjMTg4Mjk0XzM4LTEwLTEtMS0w_30fd6bc9-c3fd-40f0-979c-2819d8fe365b"
      unitRef="usd">-4570000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ied8d945ebce54ed8a4badfed477a64e8_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xODEvZnJhZzpkZjY0MmVlMzkyNGY0ODhhOTY3ZTFmNTE0ZDVhMzRjZS90YWJsZTpiZmUwNWFjOTkxNjY0NTIwYjEwZGE2ZjA3YzE4ODI5NC90YWJsZXJhbmdlOmJmZTA1YWM5OTE2NjQ1MjBiMTBkYTZmMDdjMTg4Mjk0XzM4LTEyLTEtMS0w_de434fd6-b7d9-4ba5-b602-0dd81e199206"
      unitRef="usd">-19571000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i8f5d5586be294d54be1415ab00417669_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xODQvZnJhZzoxMTE2NTQ2YjIzNDU0NmY4ODVmNmE1ODZhMGY3MDZkNS90YWJsZTo3MDQ5YTJiMmIwMjk0YTMwYjBhOGQ0MTExYzUxODAxYy90YWJsZXJhbmdlOjcwNDlhMmIyYjAyOTRhMzBiMGE4ZDQxMTFjNTE4MDFjXzUtMS0xLTEtMzE4Nw_6cd5bcd1-8200-4564-b0e8-4e5e7afde056"
      unitRef="shares">86325547</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i8f5d5586be294d54be1415ab00417669_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xODQvZnJhZzoxMTE2NTQ2YjIzNDU0NmY4ODVmNmE1ODZhMGY3MDZkNS90YWJsZTo3MDQ5YTJiMmIwMjk0YTMwYjBhOGQ0MTExYzUxODAxYy90YWJsZXJhbmdlOjcwNDlhMmIyYjAyOTRhMzBiMGE4ZDQxMTFjNTE4MDFjXzUtMi0xLTEtMzE4OQ_dfd20ff5-3934-476c-8bbe-27ad727bf77e"
      unitRef="usd">9000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ia6d22df4e633466eb268453a386261b9_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xODQvZnJhZzoxMTE2NTQ2YjIzNDU0NmY4ODVmNmE1ODZhMGY3MDZkNS90YWJsZTo3MDQ5YTJiMmIwMjk0YTMwYjBhOGQ0MTExYzUxODAxYy90YWJsZXJhbmdlOjcwNDlhMmIyYjAyOTRhMzBiMGE4ZDQxMTFjNTE4MDFjXzUtNC0xLTEtMzE5MQ_5a071dcc-4f8a-4b5e-a2c3-d5bd9b12d5d4"
      unitRef="usd">348664000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ic85d5ba0da864526935be1f5158d2390_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xODQvZnJhZzoxMTE2NTQ2YjIzNDU0NmY4ODVmNmE1ODZhMGY3MDZkNS90YWJsZTo3MDQ5YTJiMmIwMjk0YTMwYjBhOGQ0MTExYzUxODAxYy90YWJsZXJhbmdlOjcwNDlhMmIyYjAyOTRhMzBiMGE4ZDQxMTFjNTE4MDFjXzUtOC0xLTEtMzE5Nw_6d489e02-913c-4c3d-af9c-19dd0b7dbe14"
      unitRef="usd">-335753000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i48c9319650af4a498d62dfe592f8cfdd_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xODQvZnJhZzoxMTE2NTQ2YjIzNDU0NmY4ODVmNmE1ODZhMGY3MDZkNS90YWJsZTo3MDQ5YTJiMmIwMjk0YTMwYjBhOGQ0MTExYzUxODAxYy90YWJsZXJhbmdlOjcwNDlhMmIyYjAyOTRhMzBiMGE4ZDQxMTFjNTE4MDFjXzUtMTAtMS0xLTMxOTk_1b138505-a7ef-4e16-88bc-cc3a0c4ff968"
      unitRef="usd">-4523000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iabdd66a36794438ab9664178bf3cf96a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xODQvZnJhZzoxMTE2NTQ2YjIzNDU0NmY4ODVmNmE1ODZhMGY3MDZkNS90YWJsZTo3MDQ5YTJiMmIwMjk0YTMwYjBhOGQ0MTExYzUxODAxYy90YWJsZXJhbmdlOjcwNDlhMmIyYjAyOTRhMzBiMGE4ZDQxMTFjNTE4MDFjXzUtMTItMS0xLTMyMDE_9908893d-7da4-4364-8388-f1b56a6c3259"
      unitRef="usd">8397000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="ie0acb7061950472c9ffc5dee59b3f7d1_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xODQvZnJhZzoxMTE2NTQ2YjIzNDU0NmY4ODVmNmE1ODZhMGY3MDZkNS90YWJsZTo3MDQ5YTJiMmIwMjk0YTMwYjBhOGQ0MTExYzUxODAxYy90YWJsZXJhbmdlOjcwNDlhMmIyYjAyOTRhMzBiMGE4ZDQxMTFjNTE4MDFjXzYtMS0xLTEtMzE4Nw_2dd612f6-38a1-414e-8f26-fd122f9454a7"
      unitRef="shares">78583</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i22171a0001464fdbaeb20c2221b2f800_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xODQvZnJhZzoxMTE2NTQ2YjIzNDU0NmY4ODVmNmE1ODZhMGY3MDZkNS90YWJsZTo3MDQ5YTJiMmIwMjk0YTMwYjBhOGQ0MTExYzUxODAxYy90YWJsZXJhbmdlOjcwNDlhMmIyYjAyOTRhMzBiMGE4ZDQxMTFjNTE4MDFjXzYtNC0xLTEtMzE5Mw_92fe3f2e-2abb-49b7-b04c-86b6aaf1e394"
      unitRef="usd">114000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i824a5b33f908426bad016f0eded844db_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xODQvZnJhZzoxMTE2NTQ2YjIzNDU0NmY4ODVmNmE1ODZhMGY3MDZkNS90YWJsZTo3MDQ5YTJiMmIwMjk0YTMwYjBhOGQ0MTExYzUxODAxYy90YWJsZXJhbmdlOjcwNDlhMmIyYjAyOTRhMzBiMGE4ZDQxMTFjNTE4MDFjXzYtMTItMS0xLTMyMDE_4619025f-6dbf-444e-8bd1-8e8898779f32"
      unitRef="usd">114000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="ie0acb7061950472c9ffc5dee59b3f7d1_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xODQvZnJhZzoxMTE2NTQ2YjIzNDU0NmY4ODVmNmE1ODZhMGY3MDZkNS90YWJsZTo3MDQ5YTJiMmIwMjk0YTMwYjBhOGQ0MTExYzUxODAxYy90YWJsZXJhbmdlOjcwNDlhMmIyYjAyOTRhMzBiMGE4ZDQxMTFjNTE4MDFjXzctMS0xLTEtMzE4Nw_a2c089f3-5a8f-4911-9092-2c1d90107e3c"
      unitRef="shares">5128</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i22171a0001464fdbaeb20c2221b2f800_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xODQvZnJhZzoxMTE2NTQ2YjIzNDU0NmY4ODVmNmE1ODZhMGY3MDZkNS90YWJsZTo3MDQ5YTJiMmIwMjk0YTMwYjBhOGQ0MTExYzUxODAxYy90YWJsZXJhbmdlOjcwNDlhMmIyYjAyOTRhMzBiMGE4ZDQxMTFjNTE4MDFjXzctNC0xLTEtMzE5Mw_1b125262-7b41-41ee-b5f8-7ded1aaae327"
      unitRef="usd">3000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i824a5b33f908426bad016f0eded844db_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xODQvZnJhZzoxMTE2NTQ2YjIzNDU0NmY4ODVmNmE1ODZhMGY3MDZkNS90YWJsZTo3MDQ5YTJiMmIwMjk0YTMwYjBhOGQ0MTExYzUxODAxYy90YWJsZXJhbmdlOjcwNDlhMmIyYjAyOTRhMzBiMGE4ZDQxMTFjNTE4MDFjXzctMTItMS0xLTMyMDE_8550eaad-5b09-456f-a5a6-c03c028429da"
      unitRef="usd">3000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="ie0acb7061950472c9ffc5dee59b3f7d1_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xODQvZnJhZzoxMTE2NTQ2YjIzNDU0NmY4ODVmNmE1ODZhMGY3MDZkNS90YWJsZTo3MDQ5YTJiMmIwMjk0YTMwYjBhOGQ0MTExYzUxODAxYy90YWJsZXJhbmdlOjcwNDlhMmIyYjAyOTRhMzBiMGE4ZDQxMTFjNTE4MDFjXzgtMS0xLTEtMzE4Nw_5f27e23c-f87b-4bbd-8f2f-042fe7c86c07"
      unitRef="shares">10937</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="i824a5b33f908426bad016f0eded844db_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xODQvZnJhZzoxMTE2NTQ2YjIzNDU0NmY4ODVmNmE1ODZhMGY3MDZkNS90YWJsZTo3MDQ5YTJiMmIwMjk0YTMwYjBhOGQ0MTExYzUxODAxYy90YWJsZXJhbmdlOjcwNDlhMmIyYjAyOTRhMzBiMGE4ZDQxMTFjNTE4MDFjXzgtMTItMS0xLTMyMjE_9dd5e23b-60c9-49bf-b8d2-c78f5224fd84"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodSharesOther
      contextRef="ie0acb7061950472c9ffc5dee59b3f7d1_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xODQvZnJhZzoxMTE2NTQ2YjIzNDU0NmY4ODVmNmE1ODZhMGY3MDZkNS90YWJsZTo3MDQ5YTJiMmIwMjk0YTMwYjBhOGQ0MTExYzUxODAxYy90YWJsZXJhbmdlOjcwNDlhMmIyYjAyOTRhMzBiMGE4ZDQxMTFjNTE4MDFjXzktMS0xLTEtMzE4Nw_684b3b54-8e98-406f-a26f-4200d4728687"
      unitRef="shares">598977</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="i22171a0001464fdbaeb20c2221b2f800_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xODQvZnJhZzoxMTE2NTQ2YjIzNDU0NmY4ODVmNmE1ODZhMGY3MDZkNS90YWJsZTo3MDQ5YTJiMmIwMjk0YTMwYjBhOGQ0MTExYzUxODAxYy90YWJsZXJhbmdlOjcwNDlhMmIyYjAyOTRhMzBiMGE4ZDQxMTFjNTE4MDFjXzktNC0xLTEtMzE5NQ_26ca797d-93b4-46fc-b782-c1ee9126c793"
      unitRef="usd">1141000</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="i824a5b33f908426bad016f0eded844db_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xODQvZnJhZzoxMTE2NTQ2YjIzNDU0NmY4ODVmNmE1ODZhMGY3MDZkNS90YWJsZTo3MDQ5YTJiMmIwMjk0YTMwYjBhOGQ0MTExYzUxODAxYy90YWJsZXJhbmdlOjcwNDlhMmIyYjAyOTRhMzBiMGE4ZDQxMTFjNTE4MDFjXzktMTItMS0xLTMyMDM_67c9ec5a-3da1-4bb8-b376-2ab93a5589bd"
      unitRef="usd">1141000</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther
      contextRef="i22171a0001464fdbaeb20c2221b2f800_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xODQvZnJhZzoxMTE2NTQ2YjIzNDU0NmY4ODVmNmE1ODZhMGY3MDZkNS90YWJsZTo3MDQ5YTJiMmIwMjk0YTMwYjBhOGQ0MTExYzUxODAxYy90YWJsZXJhbmdlOjcwNDlhMmIyYjAyOTRhMzBiMGE4ZDQxMTFjNTE4MDFjXzEwLTQtMS0xLTMxOTU_ad9380d1-b287-4271-ba09-795c9f1efb67"
      unitRef="usd">-147000</us-gaap:AdjustmentsToAdditionalPaidInCapitalOther>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther
      contextRef="i824a5b33f908426bad016f0eded844db_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xODQvZnJhZzoxMTE2NTQ2YjIzNDU0NmY4ODVmNmE1ODZhMGY3MDZkNS90YWJsZTo3MDQ5YTJiMmIwMjk0YTMwYjBhOGQ0MTExYzUxODAxYy90YWJsZXJhbmdlOjcwNDlhMmIyYjAyOTRhMzBiMGE4ZDQxMTFjNTE4MDFjXzEwLTEyLTEtMS0zMjAz_9bf9d231-3b9e-4612-ab27-c505b01c8ab8"
      unitRef="usd">-147000</us-gaap:AdjustmentsToAdditionalPaidInCapitalOther>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i22171a0001464fdbaeb20c2221b2f800_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xODQvZnJhZzoxMTE2NTQ2YjIzNDU0NmY4ODVmNmE1ODZhMGY3MDZkNS90YWJsZTo3MDQ5YTJiMmIwMjk0YTMwYjBhOGQ0MTExYzUxODAxYy90YWJsZXJhbmdlOjcwNDlhMmIyYjAyOTRhMzBiMGE4ZDQxMTFjNTE4MDFjXzExLTQtMS0xLTMxOTU_73e80d15-cea2-48e6-be55-18c409fe1309"
      unitRef="usd">1409000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i824a5b33f908426bad016f0eded844db_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xODQvZnJhZzoxMTE2NTQ2YjIzNDU0NmY4ODVmNmE1ODZhMGY3MDZkNS90YWJsZTo3MDQ5YTJiMmIwMjk0YTMwYjBhOGQ0MTExYzUxODAxYy90YWJsZXJhbmdlOjcwNDlhMmIyYjAyOTRhMzBiMGE4ZDQxMTFjNTE4MDFjXzExLTEyLTEtMS0zMjAz_cf117ec6-e424-475e-85b3-908897a18149"
      unitRef="usd">1409000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="ia8bafce0cbb84adc8382dec4a0321316_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xODQvZnJhZzoxMTE2NTQ2YjIzNDU0NmY4ODVmNmE1ODZhMGY3MDZkNS90YWJsZTo3MDQ5YTJiMmIwMjk0YTMwYjBhOGQ0MTExYzUxODAxYy90YWJsZXJhbmdlOjcwNDlhMmIyYjAyOTRhMzBiMGE4ZDQxMTFjNTE4MDFjXzEyLTEwLTEtMS0zMjA1_40b2818a-5d27-4e99-91c5-a36ee35edce5"
      unitRef="usd">-60000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i824a5b33f908426bad016f0eded844db_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xODQvZnJhZzoxMTE2NTQ2YjIzNDU0NmY4ODVmNmE1ODZhMGY3MDZkNS90YWJsZTo3MDQ5YTJiMmIwMjk0YTMwYjBhOGQ0MTExYzUxODAxYy90YWJsZXJhbmdlOjcwNDlhMmIyYjAyOTRhMzBiMGE4ZDQxMTFjNTE4MDFjXzEyLTEyLTEtMS0zMjAz_256b62cc-beda-48b8-9577-f5edb6b63cab"
      unitRef="usd">-60000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="ie102296cb93f4d219e9e9aeb38383744_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xODQvZnJhZzoxMTE2NTQ2YjIzNDU0NmY4ODVmNmE1ODZhMGY3MDZkNS90YWJsZTo3MDQ5YTJiMmIwMjk0YTMwYjBhOGQ0MTExYzUxODAxYy90YWJsZXJhbmdlOjcwNDlhMmIyYjAyOTRhMzBiMGE4ZDQxMTFjNTE4MDFjXzEzLTgtMS0xLTMyMDc_c8f3aa9d-1ca3-4c2b-9750-f64b5a7a983a"
      unitRef="usd">-19620000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i824a5b33f908426bad016f0eded844db_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xODQvZnJhZzoxMTE2NTQ2YjIzNDU0NmY4ODVmNmE1ODZhMGY3MDZkNS90YWJsZTo3MDQ5YTJiMmIwMjk0YTMwYjBhOGQ0MTExYzUxODAxYy90YWJsZXJhbmdlOjcwNDlhMmIyYjAyOTRhMzBiMGE4ZDQxMTFjNTE4MDFjXzEzLTEyLTEtMS0zMjAz_665f1353-8e86-4f5d-8a76-ab3f15a38acb"
      unitRef="usd">-19620000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i708ad43bbcdd433f8815781dc1dabef7_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xODQvZnJhZzoxMTE2NTQ2YjIzNDU0NmY4ODVmNmE1ODZhMGY3MDZkNS90YWJsZTo3MDQ5YTJiMmIwMjk0YTMwYjBhOGQ0MTExYzUxODAxYy90YWJsZXJhbmdlOjcwNDlhMmIyYjAyOTRhMzBiMGE4ZDQxMTFjNTE4MDFjXzE0LTEtMS0xLTMyMTc_8796ac5d-bf7d-4cdc-87db-5fa0ba81a066"
      unitRef="shares">87019172</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i708ad43bbcdd433f8815781dc1dabef7_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xODQvZnJhZzoxMTE2NTQ2YjIzNDU0NmY4ODVmNmE1ODZhMGY3MDZkNS90YWJsZTo3MDQ5YTJiMmIwMjk0YTMwYjBhOGQ0MTExYzUxODAxYy90YWJsZXJhbmdlOjcwNDlhMmIyYjAyOTRhMzBiMGE4ZDQxMTFjNTE4MDFjXzE0LTItMS0xLTMyMTU_54cc5089-613d-4b68-a503-550f5e6863b1"
      unitRef="usd">9000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i6de5cd0af433469ea596afb9aa70a75b_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xODQvZnJhZzoxMTE2NTQ2YjIzNDU0NmY4ODVmNmE1ODZhMGY3MDZkNS90YWJsZTo3MDQ5YTJiMmIwMjk0YTMwYjBhOGQ0MTExYzUxODAxYy90YWJsZXJhbmdlOjcwNDlhMmIyYjAyOTRhMzBiMGE4ZDQxMTFjNTE4MDFjXzE0LTQtMS0xLTMyMTM_78b65c62-00ac-4f58-9855-6a7ec28e3098"
      unitRef="usd">351184000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i8407594575184affb099a506cf4761ad_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xODQvZnJhZzoxMTE2NTQ2YjIzNDU0NmY4ODVmNmE1ODZhMGY3MDZkNS90YWJsZTo3MDQ5YTJiMmIwMjk0YTMwYjBhOGQ0MTExYzUxODAxYy90YWJsZXJhbmdlOjcwNDlhMmIyYjAyOTRhMzBiMGE4ZDQxMTFjNTE4MDFjXzE0LTgtMS0xLTMyMTE_33a405f4-623d-44b3-9d88-3c78624f83a5"
      unitRef="usd">-355373000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i6914e325d1a54348910a4641d7f828c4_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xODQvZnJhZzoxMTE2NTQ2YjIzNDU0NmY4ODVmNmE1ODZhMGY3MDZkNS90YWJsZTo3MDQ5YTJiMmIwMjk0YTMwYjBhOGQ0MTExYzUxODAxYy90YWJsZXJhbmdlOjcwNDlhMmIyYjAyOTRhMzBiMGE4ZDQxMTFjNTE4MDFjXzE0LTEwLTEtMS0zMjA5_5f4e5ed9-f389-4ed9-9408-c0e84fdf3658"
      unitRef="usd">-4583000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iff7e2530342c41bca8c84fce55f0cc6f_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xODQvZnJhZzoxMTE2NTQ2YjIzNDU0NmY4ODVmNmE1ODZhMGY3MDZkNS90YWJsZTo3MDQ5YTJiMmIwMjk0YTMwYjBhOGQ0MTExYzUxODAxYy90YWJsZXJhbmdlOjcwNDlhMmIyYjAyOTRhMzBiMGE4ZDQxMTFjNTE4MDFjXzE0LTEyLTEtMS0zMjAz_5cac4d1f-3d88-4ed7-81bb-efe88e682db2"
      unitRef="usd">-8763000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xOTAvZnJhZzpkZWMyZWRkNjViNWU0MzNlYWY1YzJmNmZmNzFiNDNmZi90YWJsZTpiYjg2NzJmMTk1NTM0YjZkYWI3YjVlMDg2NTY0NGYyZC90YWJsZXJhbmdlOmJiODY3MmYxOTU1MzRiNmRhYjdiNWUwODY1NjQ0ZjJkXzMtMS0xLTEtMA_6dd6ca7a-3a4f-4de3-8bf7-80c6a599116f"
      unitRef="usd">-24597000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i824a5b33f908426bad016f0eded844db_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xOTAvZnJhZzpkZWMyZWRkNjViNWU0MzNlYWY1YzJmNmZmNzFiNDNmZi90YWJsZTpiYjg2NzJmMTk1NTM0YjZkYWI3YjVlMDg2NTY0NGYyZC90YWJsZXJhbmdlOmJiODY3MmYxOTU1MzRiNmRhYjdiNWUwODY1NjQ0ZjJkXzMtMy0xLTEtMA_7754202f-9a0d-4ebd-ab34-ffb2a2b81e9c"
      unitRef="usd">-19620000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherDepreciationAndAmortization
      contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xOTAvZnJhZzpkZWMyZWRkNjViNWU0MzNlYWY1YzJmNmZmNzFiNDNmZi90YWJsZTpiYjg2NzJmMTk1NTM0YjZkYWI3YjVlMDg2NTY0NGYyZC90YWJsZXJhbmdlOmJiODY3MmYxOTU1MzRiNmRhYjdiNWUwODY1NjQ0ZjJkXzUtMS0xLTEtMA_66a8ac28-810e-47f7-9fb5-efae43d4eee2"
      unitRef="usd">207000</us-gaap:OtherDepreciationAndAmortization>
    <us-gaap:OtherDepreciationAndAmortization
      contextRef="i824a5b33f908426bad016f0eded844db_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xOTAvZnJhZzpkZWMyZWRkNjViNWU0MzNlYWY1YzJmNmZmNzFiNDNmZi90YWJsZTpiYjg2NzJmMTk1NTM0YjZkYWI3YjVlMDg2NTY0NGYyZC90YWJsZXJhbmdlOmJiODY3MmYxOTU1MzRiNmRhYjdiNWUwODY1NjQ0ZjJkXzUtMy0xLTEtMA_08e9262f-6d0b-4a1e-8690-dec3b0474d88"
      unitRef="usd">231000</us-gaap:OtherDepreciationAndAmortization>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xOTAvZnJhZzpkZWMyZWRkNjViNWU0MzNlYWY1YzJmNmZmNzFiNDNmZi90YWJsZTpiYjg2NzJmMTk1NTM0YjZkYWI3YjVlMDg2NTY0NGYyZC90YWJsZXJhbmdlOmJiODY3MmYxOTU1MzRiNmRhYjdiNWUwODY1NjQ0ZjJkXzYtMS0xLTEtMA_b2f0435b-c863-4fe1-9d86-dffa29a0a77d"
      unitRef="usd">-14000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="i824a5b33f908426bad016f0eded844db_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xOTAvZnJhZzpkZWMyZWRkNjViNWU0MzNlYWY1YzJmNmZmNzFiNDNmZi90YWJsZTpiYjg2NzJmMTk1NTM0YjZkYWI3YjVlMDg2NTY0NGYyZC90YWJsZXJhbmdlOmJiODY3MmYxOTU1MzRiNmRhYjdiNWUwODY1NjQ0ZjJkXzYtMy0xLTEtMA_0cb2b913-0e84-4ae9-b0fd-d83519f33d5a"
      unitRef="usd">0</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xOTAvZnJhZzpkZWMyZWRkNjViNWU0MzNlYWY1YzJmNmZmNzFiNDNmZi90YWJsZTpiYjg2NzJmMTk1NTM0YjZkYWI3YjVlMDg2NTY0NGYyZC90YWJsZXJhbmdlOmJiODY3MmYxOTU1MzRiNmRhYjdiNWUwODY1NjQ0ZjJkXzctMS0xLTEtMA_d4d0b93b-864e-47cb-9823-480934f46a0c"
      unitRef="usd">272000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="i824a5b33f908426bad016f0eded844db_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xOTAvZnJhZzpkZWMyZWRkNjViNWU0MzNlYWY1YzJmNmZmNzFiNDNmZi90YWJsZTpiYjg2NzJmMTk1NTM0YjZkYWI3YjVlMDg2NTY0NGYyZC90YWJsZXJhbmdlOmJiODY3MmYxOTU1MzRiNmRhYjdiNWUwODY1NjQ0ZjJkXzctMy0xLTEtMA_8247b243-d6bf-44c6-85ad-8fe3320dff3b"
      unitRef="usd">366000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xOTAvZnJhZzpkZWMyZWRkNjViNWU0MzNlYWY1YzJmNmZmNzFiNDNmZi90YWJsZTpiYjg2NzJmMTk1NTM0YjZkYWI3YjVlMDg2NTY0NGYyZC90YWJsZXJhbmdlOmJiODY3MmYxOTU1MzRiNmRhYjdiNWUwODY1NjQ0ZjJkXzgtMS0xLTEtMA_64af70e5-5ce4-4bad-b01e-3d5e60d25d21"
      unitRef="usd">0</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="i824a5b33f908426bad016f0eded844db_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xOTAvZnJhZzpkZWMyZWRkNjViNWU0MzNlYWY1YzJmNmZmNzFiNDNmZi90YWJsZTpiYjg2NzJmMTk1NTM0YjZkYWI3YjVlMDg2NTY0NGYyZC90YWJsZXJhbmdlOmJiODY3MmYxOTU1MzRiNmRhYjdiNWUwODY1NjQ0ZjJkXzgtMy0xLTEtMA_401a6e27-dd1f-4042-ba4d-ea7158182a85"
      unitRef="usd">-1000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:ShareBasedCompensation
      contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xOTAvZnJhZzpkZWMyZWRkNjViNWU0MzNlYWY1YzJmNmZmNzFiNDNmZi90YWJsZTpiYjg2NzJmMTk1NTM0YjZkYWI3YjVlMDg2NTY0NGYyZC90YWJsZXJhbmdlOmJiODY3MmYxOTU1MzRiNmRhYjdiNWUwODY1NjQ0ZjJkXzktMS0xLTEtMA_390c9267-0ed6-4271-b257-6f24fa86fe9d"
      unitRef="usd">1780000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i824a5b33f908426bad016f0eded844db_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xOTAvZnJhZzpkZWMyZWRkNjViNWU0MzNlYWY1YzJmNmZmNzFiNDNmZi90YWJsZTpiYjg2NzJmMTk1NTM0YjZkYWI3YjVlMDg2NTY0NGYyZC90YWJsZXJhbmdlOmJiODY3MmYxOTU1MzRiNmRhYjdiNWUwODY1NjQ0ZjJkXzktMy0xLTEtMA_91ae9804-70fb-4238-b623-62299089c722"
      unitRef="usd">1409000</us-gaap:ShareBasedCompensation>
    <us-gaap:PaidInKindInterest
      contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xOTAvZnJhZzpkZWMyZWRkNjViNWU0MzNlYWY1YzJmNmZmNzFiNDNmZi90YWJsZTpiYjg2NzJmMTk1NTM0YjZkYWI3YjVlMDg2NTY0NGYyZC90YWJsZXJhbmdlOmJiODY3MmYxOTU1MzRiNmRhYjdiNWUwODY1NjQ0ZjJkXzEwLTEtMS0xLTA_af55f382-c672-4515-b953-24aa44797ab9"
      unitRef="usd">387000</us-gaap:PaidInKindInterest>
    <us-gaap:PaidInKindInterest
      contextRef="i824a5b33f908426bad016f0eded844db_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xOTAvZnJhZzpkZWMyZWRkNjViNWU0MzNlYWY1YzJmNmZmNzFiNDNmZi90YWJsZTpiYjg2NzJmMTk1NTM0YjZkYWI3YjVlMDg2NTY0NGYyZC90YWJsZXJhbmdlOmJiODY3MmYxOTU1MzRiNmRhYjdiNWUwODY1NjQ0ZjJkXzEwLTMtMS0xLTA_e1fd45ac-b314-4ec5-b236-e3588428360c"
      unitRef="usd">123000</us-gaap:PaidInKindInterest>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xOTAvZnJhZzpkZWMyZWRkNjViNWU0MzNlYWY1YzJmNmZmNzFiNDNmZi90YWJsZTpiYjg2NzJmMTk1NTM0YjZkYWI3YjVlMDg2NTY0NGYyZC90YWJsZXJhbmdlOmJiODY3MmYxOTU1MzRiNmRhYjdiNWUwODY1NjQ0ZjJkXzExLTEtMS0xLTA_2ae9ba1b-1b9e-4268-8de9-e875a5670896"
      unitRef="usd">16747000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="i824a5b33f908426bad016f0eded844db_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xOTAvZnJhZzpkZWMyZWRkNjViNWU0MzNlYWY1YzJmNmZmNzFiNDNmZi90YWJsZTpiYjg2NzJmMTk1NTM0YjZkYWI3YjVlMDg2NTY0NGYyZC90YWJsZXJhbmdlOmJiODY3MmYxOTU1MzRiNmRhYjdiNWUwODY1NjQ0ZjJkXzExLTMtMS0xLTA_76c22dea-9e91-4a21-8e85-a24c246017e7"
      unitRef="usd">846000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xOTAvZnJhZzpkZWMyZWRkNjViNWU0MzNlYWY1YzJmNmZmNzFiNDNmZi90YWJsZTpiYjg2NzJmMTk1NTM0YjZkYWI3YjVlMDg2NTY0NGYyZC90YWJsZXJhbmdlOmJiODY3MmYxOTU1MzRiNmRhYjdiNWUwODY1NjQ0ZjJkXzE1LTEtMS0xLTA_d712aa5b-1429-4df7-ac01-ea546a559fae"
      unitRef="usd">1118000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i824a5b33f908426bad016f0eded844db_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xOTAvZnJhZzpkZWMyZWRkNjViNWU0MzNlYWY1YzJmNmZmNzFiNDNmZi90YWJsZTpiYjg2NzJmMTk1NTM0YjZkYWI3YjVlMDg2NTY0NGYyZC90YWJsZXJhbmdlOmJiODY3MmYxOTU1MzRiNmRhYjdiNWUwODY1NjQ0ZjJkXzE1LTMtMS0xLTA_7a471a43-3cc1-456d-808e-0f01e04e40c4"
      unitRef="usd">-5000000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xOTAvZnJhZzpkZWMyZWRkNjViNWU0MzNlYWY1YzJmNmZmNzFiNDNmZi90YWJsZTpiYjg2NzJmMTk1NTM0YjZkYWI3YjVlMDg2NTY0NGYyZC90YWJsZXJhbmdlOmJiODY3MmYxOTU1MzRiNmRhYjdiNWUwODY1NjQ0ZjJkXzE2LTEtMS0xLTA_28ee2a4f-b3ec-4f5a-9331-64ddbb08a9be"
      unitRef="usd">1512000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i824a5b33f908426bad016f0eded844db_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xOTAvZnJhZzpkZWMyZWRkNjViNWU0MzNlYWY1YzJmNmZmNzFiNDNmZi90YWJsZTpiYjg2NzJmMTk1NTM0YjZkYWI3YjVlMDg2NTY0NGYyZC90YWJsZXJhbmdlOmJiODY3MmYxOTU1MzRiNmRhYjdiNWUwODY1NjQ0ZjJkXzE2LTMtMS0xLTA_5641d634-8ab7-447a-9bf1-4c51dabe9959"
      unitRef="usd">61000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xOTAvZnJhZzpkZWMyZWRkNjViNWU0MzNlYWY1YzJmNmZmNzFiNDNmZi90YWJsZTpiYjg2NzJmMTk1NTM0YjZkYWI3YjVlMDg2NTY0NGYyZC90YWJsZXJhbmdlOmJiODY3MmYxOTU1MzRiNmRhYjdiNWUwODY1NjQ0ZjJkXzE3LTEtMS0xLTA_c3ff11f7-54e9-4911-b21f-c452d7a5bcb6"
      unitRef="usd">151000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i824a5b33f908426bad016f0eded844db_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xOTAvZnJhZzpkZWMyZWRkNjViNWU0MzNlYWY1YzJmNmZmNzFiNDNmZi90YWJsZTpiYjg2NzJmMTk1NTM0YjZkYWI3YjVlMDg2NTY0NGYyZC90YWJsZXJhbmdlOmJiODY3MmYxOTU1MzRiNmRhYjdiNWUwODY1NjQ0ZjJkXzE3LTMtMS0xLTA_8f163050-1899-4f53-9b5f-f4ae98315310"
      unitRef="usd">836000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xOTAvZnJhZzpkZWMyZWRkNjViNWU0MzNlYWY1YzJmNmZmNzFiNDNmZi90YWJsZTpiYjg2NzJmMTk1NTM0YjZkYWI3YjVlMDg2NTY0NGYyZC90YWJsZXJhbmdlOmJiODY3MmYxOTU1MzRiNmRhYjdiNWUwODY1NjQ0ZjJkXzE5LTEtMS0xLTA_9e2ca3bb-0982-4339-9a01-5a8fcd7eb932"
      unitRef="usd">-2728000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="i824a5b33f908426bad016f0eded844db_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xOTAvZnJhZzpkZWMyZWRkNjViNWU0MzNlYWY1YzJmNmZmNzFiNDNmZi90YWJsZTpiYjg2NzJmMTk1NTM0YjZkYWI3YjVlMDg2NTY0NGYyZC90YWJsZXJhbmdlOmJiODY3MmYxOTU1MzRiNmRhYjdiNWUwODY1NjQ0ZjJkXzE5LTMtMS0xLTA_65e8fc0c-1037-4cc3-b242-cd33c0e713ce"
      unitRef="usd">0</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xOTAvZnJhZzpkZWMyZWRkNjViNWU0MzNlYWY1YzJmNmZmNzFiNDNmZi90YWJsZTpiYjg2NzJmMTk1NTM0YjZkYWI3YjVlMDg2NTY0NGYyZC90YWJsZXJhbmdlOmJiODY3MmYxOTU1MzRiNmRhYjdiNWUwODY1NjQ0ZjJkXzIxLTEtMS0xLTA_b3667325-a803-4062-a2e9-8092ed654899"
      unitRef="usd">-1736000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="i824a5b33f908426bad016f0eded844db_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xOTAvZnJhZzpkZWMyZWRkNjViNWU0MzNlYWY1YzJmNmZmNzFiNDNmZi90YWJsZTpiYjg2NzJmMTk1NTM0YjZkYWI3YjVlMDg2NTY0NGYyZC90YWJsZXJhbmdlOmJiODY3MmYxOTU1MzRiNmRhYjdiNWUwODY1NjQ0ZjJkXzIxLTMtMS0xLTA_977fe904-3722-4775-afc3-4e0ee8dd7e4f"
      unitRef="usd">-829000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xOTAvZnJhZzpkZWMyZWRkNjViNWU0MzNlYWY1YzJmNmZmNzFiNDNmZi90YWJsZTpiYjg2NzJmMTk1NTM0YjZkYWI3YjVlMDg2NTY0NGYyZC90YWJsZXJhbmdlOmJiODY3MmYxOTU1MzRiNmRhYjdiNWUwODY1NjQ0ZjJkXzIyLTEtMS0xLTA_cee1b110-654d-4ab1-a9b2-caf29bffe544"
      unitRef="usd">-12133000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i824a5b33f908426bad016f0eded844db_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xOTAvZnJhZzpkZWMyZWRkNjViNWU0MzNlYWY1YzJmNmZmNzFiNDNmZi90YWJsZTpiYjg2NzJmMTk1NTM0YjZkYWI3YjVlMDg2NTY0NGYyZC90YWJsZXJhbmdlOmJiODY3MmYxOTU1MzRiNmRhYjdiNWUwODY1NjQ0ZjJkXzIyLTMtMS0xLTA_c7084c37-3e83-44b9-9a5c-961d11243349"
      unitRef="usd">-11698000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xOTAvZnJhZzpkZWMyZWRkNjViNWU0MzNlYWY1YzJmNmZmNzFiNDNmZi90YWJsZTpiYjg2NzJmMTk1NTM0YjZkYWI3YjVlMDg2NTY0NGYyZC90YWJsZXJhbmdlOmJiODY3MmYxOTU1MzRiNmRhYjdiNWUwODY1NjQ0ZjJkXzI1LTEtMS0xLTA_b4a28fd0-9738-4d1d-b3b5-94ec2f1df958"
      unitRef="usd">22420000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="i824a5b33f908426bad016f0eded844db_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xOTAvZnJhZzpkZWMyZWRkNjViNWU0MzNlYWY1YzJmNmZmNzFiNDNmZi90YWJsZTpiYjg2NzJmMTk1NTM0YjZkYWI3YjVlMDg2NTY0NGYyZC90YWJsZXJhbmdlOmJiODY3MmYxOTU1MzRiNmRhYjdiNWUwODY1NjQ0ZjJkXzI1LTMtMS0xLTA_f9c89963-d5fd-44aa-86af-c2b787c69397"
      unitRef="usd">0</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xOTAvZnJhZzpkZWMyZWRkNjViNWU0MzNlYWY1YzJmNmZmNzFiNDNmZi90YWJsZTpiYjg2NzJmMTk1NTM0YjZkYWI3YjVlMDg2NTY0NGYyZC90YWJsZXJhbmdlOmJiODY3MmYxOTU1MzRiNmRhYjdiNWUwODY1NjQ0ZjJkXzI3LTEtMS0xLTA_f5d24220-fc8b-4de6-b500-ea69a375bd1f"
      unitRef="usd">25000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i824a5b33f908426bad016f0eded844db_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xOTAvZnJhZzpkZWMyZWRkNjViNWU0MzNlYWY1YzJmNmZmNzFiNDNmZi90YWJsZTpiYjg2NzJmMTk1NTM0YjZkYWI3YjVlMDg2NTY0NGYyZC90YWJsZXJhbmdlOmJiODY3MmYxOTU1MzRiNmRhYjdiNWUwODY1NjQ0ZjJkXzI3LTMtMS0xLTA_0e9dc9c9-143e-4db1-95ca-8d73a0d92e1c"
      unitRef="usd">135000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xOTAvZnJhZzpkZWMyZWRkNjViNWU0MzNlYWY1YzJmNmZmNzFiNDNmZi90YWJsZTpiYjg2NzJmMTk1NTM0YjZkYWI3YjVlMDg2NTY0NGYyZC90YWJsZXJhbmdlOmJiODY3MmYxOTU1MzRiNmRhYjdiNWUwODY1NjQ0ZjJkXzMwLTEtMS0xLTA_39079ba7-180f-4098-a9e6-67a533665d69"
      unitRef="usd">-22445000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i824a5b33f908426bad016f0eded844db_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xOTAvZnJhZzpkZWMyZWRkNjViNWU0MzNlYWY1YzJmNmZmNzFiNDNmZi90YWJsZTpiYjg2NzJmMTk1NTM0YjZkYWI3YjVlMDg2NTY0NGYyZC90YWJsZXJhbmdlOmJiODY3MmYxOTU1MzRiNmRhYjdiNWUwODY1NjQ0ZjJkXzMwLTMtMS0xLTA_a96d6ce1-2ac8-433a-9632-c885b9f37f99"
      unitRef="usd">-135000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xOTAvZnJhZzpkZWMyZWRkNjViNWU0MzNlYWY1YzJmNmZmNzFiNDNmZi90YWJsZTpiYjg2NzJmMTk1NTM0YjZkYWI3YjVlMDg2NTY0NGYyZC90YWJsZXJhbmdlOmJiODY3MmYxOTU1MzRiNmRhYjdiNWUwODY1NjQ0ZjJkXzMzLTEtMS0xLTA_92c984d7-0276-45b6-88af-e2c026e78ec1"
      unitRef="usd">0</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="i824a5b33f908426bad016f0eded844db_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xOTAvZnJhZzpkZWMyZWRkNjViNWU0MzNlYWY1YzJmNmZmNzFiNDNmZi90YWJsZTpiYjg2NzJmMTk1NTM0YjZkYWI3YjVlMDg2NTY0NGYyZC90YWJsZXJhbmdlOmJiODY3MmYxOTU1MzRiNmRhYjdiNWUwODY1NjQ0ZjJkXzMzLTMtMS0xLTA_5511e7be-61fc-4313-aaa0-4a26b09c5250"
      unitRef="usd">2100000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xOTAvZnJhZzpkZWMyZWRkNjViNWU0MzNlYWY1YzJmNmZmNzFiNDNmZi90YWJsZTpiYjg2NzJmMTk1NTM0YjZkYWI3YjVlMDg2NTY0NGYyZC90YWJsZXJhbmdlOmJiODY3MmYxOTU1MzRiNmRhYjdiNWUwODY1NjQ0ZjJkXzM5LTEtMS0xLTA_2ab4172f-796d-454d-a351-00013f91b9f8"
      unitRef="usd">20991000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i824a5b33f908426bad016f0eded844db_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xOTAvZnJhZzpkZWMyZWRkNjViNWU0MzNlYWY1YzJmNmZmNzFiNDNmZi90YWJsZTpiYjg2NzJmMTk1NTM0YjZkYWI3YjVlMDg2NTY0NGYyZC90YWJsZXJhbmdlOmJiODY3MmYxOTU1MzRiNmRhYjdiNWUwODY1NjQ0ZjJkXzM5LTMtMS0xLTA_7a8596db-bc8c-42c2-9984-2be0694a9c27"
      unitRef="usd">1141000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsOfFinancingCosts
      contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xOTAvZnJhZzpkZWMyZWRkNjViNWU0MzNlYWY1YzJmNmZmNzFiNDNmZi90YWJsZTpiYjg2NzJmMTk1NTM0YjZkYWI3YjVlMDg2NTY0NGYyZC90YWJsZXJhbmdlOmJiODY3MmYxOTU1MzRiNmRhYjdiNWUwODY1NjQ0ZjJkXzQxLTEtMS0xLTA_4e36588d-b6ed-42c3-9298-9178d1b44a84"
      unitRef="usd">0</us-gaap:PaymentsOfFinancingCosts>
    <us-gaap:PaymentsOfFinancingCosts
      contextRef="i824a5b33f908426bad016f0eded844db_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xOTAvZnJhZzpkZWMyZWRkNjViNWU0MzNlYWY1YzJmNmZmNzFiNDNmZi90YWJsZTpiYjg2NzJmMTk1NTM0YjZkYWI3YjVlMDg2NTY0NGYyZC90YWJsZXJhbmdlOmJiODY3MmYxOTU1MzRiNmRhYjdiNWUwODY1NjQ0ZjJkXzQxLTMtMS0xLTA_b586c93c-508b-40c2-8c58-d5915c13bebc"
      unitRef="usd">4381000</us-gaap:PaymentsOfFinancingCosts>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xOTAvZnJhZzpkZWMyZWRkNjViNWU0MzNlYWY1YzJmNmZmNzFiNDNmZi90YWJsZTpiYjg2NzJmMTk1NTM0YjZkYWI3YjVlMDg2NTY0NGYyZC90YWJsZXJhbmdlOmJiODY3MmYxOTU1MzRiNmRhYjdiNWUwODY1NjQ0ZjJkXzQyLTEtMS0xLTA_c9291dcd-6e58-4f15-ba8e-70cff1c938b3"
      unitRef="usd">0</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="i824a5b33f908426bad016f0eded844db_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xOTAvZnJhZzpkZWMyZWRkNjViNWU0MzNlYWY1YzJmNmZmNzFiNDNmZi90YWJsZTpiYjg2NzJmMTk1NTM0YjZkYWI3YjVlMDg2NTY0NGYyZC90YWJsZXJhbmdlOmJiODY3MmYxOTU1MzRiNmRhYjdiNWUwODY1NjQ0ZjJkXzQyLTMtMS0xLTA_f910a00a-1447-4cc7-a58a-d820869b6540"
      unitRef="usd">-147000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xOTAvZnJhZzpkZWMyZWRkNjViNWU0MzNlYWY1YzJmNmZmNzFiNDNmZi90YWJsZTpiYjg2NzJmMTk1NTM0YjZkYWI3YjVlMDg2NTY0NGYyZC90YWJsZXJhbmdlOmJiODY3MmYxOTU1MzRiNmRhYjdiNWUwODY1NjQ0ZjJkXzQ0LTEtMS0xLTA_d36580b0-c0f8-4153-837e-b4e5b1140d11"
      unitRef="usd">244000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i824a5b33f908426bad016f0eded844db_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xOTAvZnJhZzpkZWMyZWRkNjViNWU0MzNlYWY1YzJmNmZmNzFiNDNmZi90YWJsZTpiYjg2NzJmMTk1NTM0YjZkYWI3YjVlMDg2NTY0NGYyZC90YWJsZXJhbmdlOmJiODY3MmYxOTU1MzRiNmRhYjdiNWUwODY1NjQ0ZjJkXzQ0LTMtMS0xLTA_9b6bd3cf-92dd-4a14-8848-79aa1f8da7d6"
      unitRef="usd">3000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockPlans
      contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xOTAvZnJhZzpkZWMyZWRkNjViNWU0MzNlYWY1YzJmNmZmNzFiNDNmZi90YWJsZTpiYjg2NzJmMTk1NTM0YjZkYWI3YjVlMDg2NTY0NGYyZC90YWJsZXJhbmdlOmJiODY3MmYxOTU1MzRiNmRhYjdiNWUwODY1NjQ0ZjJkXzQ1LTEtMS0xLTA_c417a70e-133a-4993-94a6-9927c5481be5"
      unitRef="usd">72000</us-gaap:ProceedsFromStockPlans>
    <us-gaap:ProceedsFromStockPlans
      contextRef="i824a5b33f908426bad016f0eded844db_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xOTAvZnJhZzpkZWMyZWRkNjViNWU0MzNlYWY1YzJmNmZmNzFiNDNmZi90YWJsZTpiYjg2NzJmMTk1NTM0YjZkYWI3YjVlMDg2NTY0NGYyZC90YWJsZXJhbmdlOmJiODY3MmYxOTU1MzRiNmRhYjdiNWUwODY1NjQ0ZjJkXzQ1LTMtMS0xLTA_6f2b3d2c-5e33-4fb2-9ce7-054afc303da2"
      unitRef="usd">114000</us-gaap:ProceedsFromStockPlans>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xOTAvZnJhZzpkZWMyZWRkNjViNWU0MzNlYWY1YzJmNmZmNzFiNDNmZi90YWJsZTpiYjg2NzJmMTk1NTM0YjZkYWI3YjVlMDg2NTY0NGYyZC90YWJsZXJhbmdlOmJiODY3MmYxOTU1MzRiNmRhYjdiNWUwODY1NjQ0ZjJkXzQ2LTEtMS0xLTA_a24e7d93-cfd7-416d-815f-93a05edf160a"
      unitRef="usd">21307000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i824a5b33f908426bad016f0eded844db_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xOTAvZnJhZzpkZWMyZWRkNjViNWU0MzNlYWY1YzJmNmZmNzFiNDNmZi90YWJsZTpiYjg2NzJmMTk1NTM0YjZkYWI3YjVlMDg2NTY0NGYyZC90YWJsZXJhbmdlOmJiODY3MmYxOTU1MzRiNmRhYjdiNWUwODY1NjQ0ZjJkXzQ2LTMtMS0xLTA_4ddace37-b671-43a3-9cb8-6f3a1b4d54cf"
      unitRef="usd">-5370000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents
      contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xOTAvZnJhZzpkZWMyZWRkNjViNWU0MzNlYWY1YzJmNmZmNzFiNDNmZi90YWJsZTpiYjg2NzJmMTk1NTM0YjZkYWI3YjVlMDg2NTY0NGYyZC90YWJsZXJhbmdlOmJiODY3MmYxOTU1MzRiNmRhYjdiNWUwODY1NjQ0ZjJkXzQ3LTEtMS0xLTA_061f4216-c2fe-4333-a199-882e1abb4cf0"
      unitRef="usd">-7000</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents
      contextRef="i824a5b33f908426bad016f0eded844db_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xOTAvZnJhZzpkZWMyZWRkNjViNWU0MzNlYWY1YzJmNmZmNzFiNDNmZi90YWJsZTpiYjg2NzJmMTk1NTM0YjZkYWI3YjVlMDg2NTY0NGYyZC90YWJsZXJhbmdlOmJiODY3MmYxOTU1MzRiNmRhYjdiNWUwODY1NjQ0ZjJkXzQ3LTMtMS0xLTA_30aa9f54-4753-4f2f-b677-90f069b68373"
      unitRef="usd">-84000</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xOTAvZnJhZzpkZWMyZWRkNjViNWU0MzNlYWY1YzJmNmZmNzFiNDNmZi90YWJsZTpiYjg2NzJmMTk1NTM0YjZkYWI3YjVlMDg2NTY0NGYyZC90YWJsZXJhbmdlOmJiODY3MmYxOTU1MzRiNmRhYjdiNWUwODY1NjQ0ZjJkXzQ4LTEtMS0xLTA_c2579323-3a99-46e0-8d00-493d0c1bc91b"
      unitRef="usd">-13278000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i824a5b33f908426bad016f0eded844db_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xOTAvZnJhZzpkZWMyZWRkNjViNWU0MzNlYWY1YzJmNmZmNzFiNDNmZi90YWJsZTpiYjg2NzJmMTk1NTM0YjZkYWI3YjVlMDg2NTY0NGYyZC90YWJsZXJhbmdlOmJiODY3MmYxOTU1MzRiNmRhYjdiNWUwODY1NjQ0ZjJkXzQ4LTMtMS0xLTA_f2ad2805-cc03-4b3f-b307-65177ac29fdc"
      unitRef="usd">-17287000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ib56f1adc867e406ca7face50c5da1c9c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xOTAvZnJhZzpkZWMyZWRkNjViNWU0MzNlYWY1YzJmNmZmNzFiNDNmZi90YWJsZTpiYjg2NzJmMTk1NTM0YjZkYWI3YjVlMDg2NTY0NGYyZC90YWJsZXJhbmdlOmJiODY3MmYxOTU1MzRiNmRhYjdiNWUwODY1NjQ0ZjJkXzQ5LTEtMS0xLTA_ef4f931e-a518-484b-86b9-ce8207d9aa43"
      unitRef="usd">140064000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="iabdd66a36794438ab9664178bf3cf96a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xOTAvZnJhZzpkZWMyZWRkNjViNWU0MzNlYWY1YzJmNmZmNzFiNDNmZi90YWJsZTpiYjg2NzJmMTk1NTM0YjZkYWI3YjVlMDg2NTY0NGYyZC90YWJsZXJhbmdlOmJiODY3MmYxOTU1MzRiNmRhYjdiNWUwODY1NjQ0ZjJkXzQ5LTMtMS0xLTA_4fbc2152-ce45-45fa-b2e6-5b295c8ae8e3"
      unitRef="usd">91551000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ied8d945ebce54ed8a4badfed477a64e8_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xOTAvZnJhZzpkZWMyZWRkNjViNWU0MzNlYWY1YzJmNmZmNzFiNDNmZi90YWJsZTpiYjg2NzJmMTk1NTM0YjZkYWI3YjVlMDg2NTY0NGYyZC90YWJsZXJhbmdlOmJiODY3MmYxOTU1MzRiNmRhYjdiNWUwODY1NjQ0ZjJkXzUwLTEtMS0xLTA_35785ff5-136b-453d-9b45-8f9e9715d6bd"
      unitRef="usd">126786000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="iff7e2530342c41bca8c84fce55f0cc6f_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xOTAvZnJhZzpkZWMyZWRkNjViNWU0MzNlYWY1YzJmNmZmNzFiNDNmZi90YWJsZTpiYjg2NzJmMTk1NTM0YjZkYWI3YjVlMDg2NTY0NGYyZC90YWJsZXJhbmdlOmJiODY3MmYxOTU1MzRiNmRhYjdiNWUwODY1NjQ0ZjJkXzUwLTMtMS0xLTA_bf150567-3b37-4595-b978-af7f39f3aba3"
      unitRef="usd">74264000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaidNet
      contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xOTAvZnJhZzpkZWMyZWRkNjViNWU0MzNlYWY1YzJmNmZmNzFiNDNmZi90YWJsZTpiYjg2NzJmMTk1NTM0YjZkYWI3YjVlMDg2NTY0NGYyZC90YWJsZXJhbmdlOmJiODY3MmYxOTU1MzRiNmRhYjdiNWUwODY1NjQ0ZjJkXzUyLTEtMS0xLTA_68701c37-1331-484a-9338-8685e0f25db2"
      unitRef="usd">494000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="i824a5b33f908426bad016f0eded844db_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xOTAvZnJhZzpkZWMyZWRkNjViNWU0MzNlYWY1YzJmNmZmNzFiNDNmZi90YWJsZTpiYjg2NzJmMTk1NTM0YjZkYWI3YjVlMDg2NTY0NGYyZC90YWJsZXJhbmdlOmJiODY3MmYxOTU1MzRiNmRhYjdiNWUwODY1NjQ0ZjJkXzUyLTMtMS0xLTA_70f29e8d-5e2a-457b-9b70-9f490585d470"
      unitRef="usd">232000</us-gaap:InterestPaidNet>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xOTAvZnJhZzpkZWMyZWRkNjViNWU0MzNlYWY1YzJmNmZmNzFiNDNmZi90YWJsZTpiYjg2NzJmMTk1NTM0YjZkYWI3YjVlMDg2NTY0NGYyZC90YWJsZXJhbmdlOmJiODY3MmYxOTU1MzRiNmRhYjdiNWUwODY1NjQ0ZjJkXzU3LTEtMS0xLTA_4c552261-e480-4e08-94d2-87d55cc01da3"
      unitRef="usd">10000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="i824a5b33f908426bad016f0eded844db_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xOTAvZnJhZzpkZWMyZWRkNjViNWU0MzNlYWY1YzJmNmZmNzFiNDNmZi90YWJsZTpiYjg2NzJmMTk1NTM0YjZkYWI3YjVlMDg2NTY0NGYyZC90YWJsZXJhbmdlOmJiODY3MmYxOTU1MzRiNmRhYjdiNWUwODY1NjQ0ZjJkXzU3LTMtMS0xLTA_bc1316b7-55c8-4e28-95ae-5f3e60630a76"
      unitRef="usd">10000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <selb:EquityOfferingCostsInAccruedLiabilities
      contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xOTAvZnJhZzpkZWMyZWRkNjViNWU0MzNlYWY1YzJmNmZmNzFiNDNmZi90YWJsZTpiYjg2NzJmMTk1NTM0YjZkYWI3YjVlMDg2NTY0NGYyZC90YWJsZXJhbmdlOmJiODY3MmYxOTU1MzRiNmRhYjdiNWUwODY1NjQ0ZjJkXzU4LTEtMS0xLTA_d9a0c50f-7cc7-4271-ba97-901696e4bea8"
      unitRef="usd">48000</selb:EquityOfferingCostsInAccruedLiabilities>
    <selb:EquityOfferingCostsInAccruedLiabilities
      contextRef="i824a5b33f908426bad016f0eded844db_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xOTAvZnJhZzpkZWMyZWRkNjViNWU0MzNlYWY1YzJmNmZmNzFiNDNmZi90YWJsZTpiYjg2NzJmMTk1NTM0YjZkYWI3YjVlMDg2NTY0NGYyZC90YWJsZXJhbmdlOmJiODY3MmYxOTU1MzRiNmRhYjdiNWUwODY1NjQ0ZjJkXzU4LTMtMS0xLTA_752a2bbd-51dd-4bd6-b342-580a5020c220"
      unitRef="usd">42000</selb:EquityOfferingCostsInAccruedLiabilities>
    <us-gaap:MarketableSecuritiesUnrealizedGainLoss
      contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xOTAvZnJhZzpkZWMyZWRkNjViNWU0MzNlYWY1YzJmNmZmNzFiNDNmZi90YWJsZTpiYjg2NzJmMTk1NTM0YjZkYWI3YjVlMDg2NTY0NGYyZC90YWJsZXJhbmdlOmJiODY3MmYxOTU1MzRiNmRhYjdiNWUwODY1NjQ0ZjJkXzU5LTEtMS0xLTA_42497b75-5088-4b04-944f-e8a7f27c9e83"
      unitRef="usd">-1000</us-gaap:MarketableSecuritiesUnrealizedGainLoss>
    <us-gaap:MarketableSecuritiesUnrealizedGainLoss
      contextRef="i824a5b33f908426bad016f0eded844db_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xOTAvZnJhZzpkZWMyZWRkNjViNWU0MzNlYWY1YzJmNmZmNzFiNDNmZi90YWJsZTpiYjg2NzJmMTk1NTM0YjZkYWI3YjVlMDg2NTY0NGYyZC90YWJsZXJhbmdlOmJiODY3MmYxOTU1MzRiNmRhYjdiNWUwODY1NjQ0ZjJkXzU5LTMtMS0xLTA_63f7cd7a-49d4-4f77-ba90-9e29170b1f7e"
      unitRef="usd">0</us-gaap:MarketableSecuritiesUnrealizedGainLoss>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xOTYvZnJhZzo5OTMzN2E4MThjODA0MzBjOWRjNDc2MjBkMmZmMDA0Yy90ZXh0cmVnaW9uOjk5MzM3YTgxOGM4MDQzMGM5ZGM0NzYyMGQyZmYwMDRjXzU2MTQ_38383a94-33b2-426b-a56d-7bb0d4074e71">Nature of the Business and Basis of Presentation&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Selecta Biosciences, Inc., or the Company was incorporated in Delaware on December 10, 2007, and is based in Watertown, Massachusetts. The Company is a clinical-stage biopharmaceutical company leveraging its ImmTOR&#x2122; immune tolerance platform with the goals of amplifying the efficacy of biologics, including enabling the re-dosing of life-saving gene therapies, and restoring self-tolerance in autoimmune diseases. The Company&#x2019;s ImmTOR platform encapsulates rapamycin, also known as sirolimus, an immunomodulator, in biodegradable nanoparticles and is designed to induce antigen-specific immune tolerance. The Company believes ImmTOR has the potential to enhance the efficacy without compromising the safety of biologic therapies, improve product candidates under development, and enable novel therapeutic modalities. Since inception, the Company has devoted its efforts principally to research and development of its technology and product candidates, recruiting management and technical staff, acquiring operating assets, and raising capital.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is subject to risks common to companies in the biotechnology industry including, but not limited to, new technological innovations, protection of proprietary technology, dependence on key personnel, compliance with government regulations and the need to obtain additional financing. Product candidates currently under development will require significant additional research and development efforts, including extensive preclinical and clinical testing and regulatory approval, prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel infrastructure and extensive compliance-reporting capabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s product candidates are in development. There can be no assurance that the Company&#x2019;s research and development will be successfully completed, that adequate protection for the Company&#x2019;s intellectual property will be obtained, or maintained, that any products developed will obtain necessary government regulatory approval or that any approved products will be commercially viable. Even if the Company&#x2019;s product development efforts are successful, it is uncertain when, if ever, the Company will generate significant revenue from product sales. The Company operates in an environment of rapid change in technology and substantial competition from pharmaceutical and biotechnology companies. In addition, the Company is dependent upon the services of its employees and consultants.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Unaudited Interim Financial Information&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying unaudited consolidated financial statements for the three months ended March 31, 2021 and 2020 have been prepared by the Company, pursuant to the rules and regulations of the Securities and Exchange Commission, or the SEC, for interim financial statements. Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America, or U.S. GAAP, have been condensed or omitted pursuant to such rules and regulations. These consolidated financial statements should be read in conjunction with the Company&#x2019;s audited consolidated financial statements and the notes thereto for the year ended December 31, 2020 included in the Company&#x2019;s Annual Report on Form 10-K that was filed with the SEC on March 12, 2021. The unaudited interim financial statements have been prepared on the same basis as the audited consolidated financial statements. In the opinion of management, the accompanying unaudited interim consolidated financial statements contain all adjustments that are necessary for a fair statement of the Company&#x2019;s financial position as of March 31, 2021 and consolidated results of operations and cash flows for the three months ended March 31, 2021. Such adjustments are of a normal and recurring nature. The results of operations for the three months ended March 31, 2021 are not necessarily indicative of the results of operations that may be expected for the year ending December 31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Liquidity and Management&#x2019;s Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The future success of the Company is dependent on its ability to develop its product candidates and ultimately upon its ability to attain profitable operations. The Company is subject to a number of risks similar to other early-stage life science companies, including, but not limited to, successful development of its product candidates, raising additional capital with favorable terms, protection of proprietary technology and market acceptance of any approved future products. The successful development of product candidates requires substantial working capital which may not be available to the Company on favorable terms or at all.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;To date, the Company has financed its operations primarily through the initial public offering of its common stock, private placements of its common stock, issuances of common and preferred stock, debt, research grants and research collaborations. The Company currently has no source of product revenue, and it does not expect to generate product revenue for the foreseeable future. To date, all of the Company&#x2019;s revenue has been collaboration and grant revenue. The Company has devoted substantially all of its financial resources and efforts to developing its ImmTOR platform, identifying potential product candidates and conducting preclinical studies and its clinical trials. The Company is in the early stages of development of its product candidates, and it has not completed development of any ImmTOR-enabled therapies.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March 31, 2021, the Company&#x2019;s cash, cash equivalents, restricted cash and marketable securities were $149.2 million, of which $1.4 million was restricted cash related to lease commitments and $0.3 million was held by its Russian subsidiary designated solely for use in its operations. The Company believes the cash, cash equivalents, restricted cash and marketable securities as of March 31, 2021 will enable it to fund its operating expenses and capital expenditure requirements into the second quarter of 2023. The Company has incurred losses and negative cash flows from operating activities since inception. As of March 31, 2021, the Company had an accumulated deficit of $429.2 million. The Company anticipates operating losses to continue for the foreseeable future due to, among other things, costs related to research, development of its product candidates, conducting preclinical studies and clinical trials, and its administrative organization. The Company will require substantial additional financing to fund its operations and to continue to execute its strategy, and the Company will pursue a range of options to secure additional capital.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;At this time, there is significant uncertainty relating to the trajectory of the COVID-19 pandemic and the impact of related responses. Any impact of COVID-19 on the Company&#x2019;s business, revenues, results of operations and financial condition will largely depend on future developments, which are highly uncertain and cannot be predicted with confidence, such as the duration of the pandemic, travel restrictions and social distancing in the United States and other countries, business closures or business disruptions, supply chain disruptions, the ultimate impact on financial markets and the global economy, and the effectiveness of actions taken in the United States and other countries to contain and treat the disease.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Guarantees and Indemnifications&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As permitted under Delaware law, the Company indemnifies its officers, directors, consultants and employees for certain events or occurrences that happen by reason of the relationship with, or position held at, the Company. Through March 31, 2021, the Company had not experienced any losses related to these indemnification obligations, and no claims were outstanding. The Company does not expect significant claims related to these indemnification obligations and, consequently, concluded that the fair value of these obligations is negligible, and no related reserves were established.&lt;/span&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <selb:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndDebtSecuritiesAvailableForSale
      contextRef="ied8d945ebce54ed8a4badfed477a64e8_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xOTYvZnJhZzo5OTMzN2E4MThjODA0MzBjOWRjNDc2MjBkMmZmMDA0Yy90ZXh0cmVnaW9uOjk5MzM3YTgxOGM4MDQzMGM5ZGM0NzYyMGQyZmYwMDRjXzQxMzA_f61baea5-2884-434d-b402-07406838de9c"
      unitRef="usd">149200000</selb:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndDebtSecuritiesAvailableForSale>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="ied8d945ebce54ed8a4badfed477a64e8_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xOTYvZnJhZzo5OTMzN2E4MThjODA0MzBjOWRjNDc2MjBkMmZmMDA0Yy90ZXh0cmVnaW9uOjk5MzM3YTgxOGM4MDQzMGM5ZGM0NzYyMGQyZmYwMDRjXzQxNDM_9879f30e-6773-4b7a-94d9-3a4eb1f57b96"
      unitRef="usd">1400000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:Cash
      contextRef="i2fa0062d7932481c8274387fef46611d_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xOTYvZnJhZzo5OTMzN2E4MThjODA0MzBjOWRjNDc2MjBkMmZmMDA0Yy90ZXh0cmVnaW9uOjk5MzM3YTgxOGM4MDQzMGM5ZGM0NzYyMGQyZmYwMDRjXzQyMDc_16bbb620-2246-47af-ac15-c655c847f408"
      unitRef="usd">300000</us-gaap:Cash>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="ied8d945ebce54ed8a4badfed477a64e8_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8xOTYvZnJhZzo5OTMzN2E4MThjODA0MzBjOWRjNDc2MjBkMmZmMDA0Yy90ZXh0cmVnaW9uOjk5MzM3YTgxOGM4MDQzMGM5ZGM0NzYyMGQyZmYwMDRjXzQ1Mzc_2da8002d-87c2-40e1-9e80-2bff1aa5156c"
      unitRef="usd">-429200000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMDIvZnJhZzo4M2RiZWFmN2FhNmM0YjE1OGFkZjMyNmQxM2VlNWQyMy90ZXh0cmVnaW9uOjgzZGJlYWY3YWE2YzRiMTU4YWRmMzI2ZDEzZWU1ZDIzXzMzNDQx_acafb9ae-02dd-4d85-a097-930dc002c80a">Summary of Significant Accounting Policies&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There have been no material changes to the Company&#x2019;s significant accounting policies during the three months ended March 31, 2021, as compared to the significant accounting policies disclosed in Note 2 &#x2013; Summary of Significant Accounting Policies included in the Company&#x2019;s Annual Report on Form 10-K for the year ended December 31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Recently Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2019, the FASB issued ASU 2019-12,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Income Taxes (Topic 740) - Simplifying the Accounting for Income Taxes.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; ASU 2019-12 simplifies the accounting for income taxes by removing certain exceptions to the general principles in Topic 740. The Company adopted the new standard effective January 1, 2021, and there was no impact on its consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2020, the FASB issued ASU 2020-10, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Codification Improvements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which updates various codification topics by clarifying or improving disclosure requirements to align with the SEC&#x2019;s regulations. The Company adopted the new standard effective January 1, 2021, and there was no impact on its consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Not Yet Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2020, the FASB issued ASU 2020-06, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Debt &#x2013; Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging &#x2013; Contracts in Entity&#x2019;s Own Equity (Subtopic 815 &#x2013; 40)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. ASU 2020-06 simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts on an entity&#x2019;s own equity. This ASU is effective for smaller reporting companies for fiscal years beginning after December 15, 2023, with early adoption permitted no earlier than January 1, 2021. The Company is assessing the impact this standard will have on its consolidated financial statements and disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2016, the FASB issued ASU 2016-13, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Financial Instruments-Credit Losses (Topic 326), Measurement of Credit Losses on Financial Instruments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. Subsequently, in November 2018, the FASB issued ASU 2018-19,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Codification Improvements to Topic 326, Financial Instruments-Credit Losses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&#160;ASU 2016-13 requires entities to measure all expected credit losses for most financial assets held at the reporting date based on an expected loss model which includes historical experience, current conditions, and reasonable and supportable forecasts. ASU 2016-13 also requires enhanced disclosures to help financial statement users better understand significant estimates and judgments used in estimating credit losses. This ASU is effective for smaller reporting companies for fiscal years beginning after December 15, 2022, with early adoption permitted. The Company is assessing the impact this standard will have on its consolidated financial statements and disclosures.&lt;/span&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMDIvZnJhZzo4M2RiZWFmN2FhNmM0YjE1OGFkZjMyNmQxM2VlNWQyMy90ZXh0cmVnaW9uOjgzZGJlYWY3YWE2YzRiMTU4YWRmMzI2ZDEzZWU1ZDIzXzMzNDU3_f0f499cb-5bc0-4e41-bfde-8f11168f9075">&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Recently Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2019, the FASB issued ASU 2019-12,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Income Taxes (Topic 740) - Simplifying the Accounting for Income Taxes.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; ASU 2019-12 simplifies the accounting for income taxes by removing certain exceptions to the general principles in Topic 740. The Company adopted the new standard effective January 1, 2021, and there was no impact on its consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2020, the FASB issued ASU 2020-10, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Codification Improvements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which updates various codification topics by clarifying or improving disclosure requirements to align with the SEC&#x2019;s regulations. The Company adopted the new standard effective January 1, 2021, and there was no impact on its consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Not Yet Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2020, the FASB issued ASU 2020-06, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Debt &#x2013; Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging &#x2013; Contracts in Entity&#x2019;s Own Equity (Subtopic 815 &#x2013; 40)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. ASU 2020-06 simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts on an entity&#x2019;s own equity. This ASU is effective for smaller reporting companies for fiscal years beginning after December 15, 2023, with early adoption permitted no earlier than January 1, 2021. The Company is assessing the impact this standard will have on its consolidated financial statements and disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2016, the FASB issued ASU 2016-13, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Financial Instruments-Credit Losses (Topic 326), Measurement of Credit Losses on Financial Instruments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. Subsequently, in November 2018, the FASB issued ASU 2018-19,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Codification Improvements to Topic 326, Financial Instruments-Credit Losses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&#160;ASU 2016-13 requires entities to measure all expected credit losses for most financial assets held at the reporting date based on an expected loss model which includes historical experience, current conditions, and reasonable and supportable forecasts. ASU 2016-13 also requires enhanced disclosures to help financial statement users better understand significant estimates and judgments used in estimating credit losses. This ASU is effective for smaller reporting companies for fiscal years beginning after December 15, 2022, with early adoption permitted. The Company is assessing the impact this standard will have on its consolidated financial statements and disclosures.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock
      contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMDUvZnJhZzo1Y2UzYTMxYjllM2Y0NGIzYTMyY2VmMTkzYjdjM2Y1MC90ZXh0cmVnaW9uOjVjZTNhMzFiOWUzZjQ0YjNhMzJjZWYxOTNiN2MzZjUwXzExMg_6e5c3b09-e9d6-405a-ab2c-f13309d7c7bb">Marketable Securities&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the marketable securities held as of March 31, 2021 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.923%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,032&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,031&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20,374&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20,374&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;22,406&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;22,405&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All marketable securities held at March 31, 2021 had maturities of less than 12 months when purchased and are classified as short-term marketable securities on the accompanying consolidated balance sheet. During the three months ended March 31, 2021, there were no marketable securities adjusted for other than temporary declines in fair value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December 31, 2020, the Company held no marketable securities.&lt;/span&gt;&lt;/div&gt;</us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock
      contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMDUvZnJhZzo1Y2UzYTMxYjllM2Y0NGIzYTMyY2VmMTkzYjdjM2Y1MC90ZXh0cmVnaW9uOjVjZTNhMzFiOWUzZjQ0YjNhMzJjZWYxOTNiN2MzZjUwXzQzOTgwNDY1MTI0MTE_b1b000ee-b4c5-46dc-a097-3c7638f4a64e">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the marketable securities held as of March 31, 2021 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.923%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,032&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,031&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20,374&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20,374&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;22,406&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;22,405&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ic3c76b1f92aa42d09acee15de07994bb_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMDUvZnJhZzo1Y2UzYTMxYjllM2Y0NGIzYTMyY2VmMTkzYjdjM2Y1MC90YWJsZTo1ZmMyNDQ4ZjZjNmM0ZjFhYTcxNzkwYTY0NWNmMGU1Ni90YWJsZXJhbmdlOjVmYzI0NDhmNmM2YzRmMWFhNzE3OTBhNjQ1Y2YwZTU2XzMtMS0xLTEtMTQ3Nw_2661b199-de05-4ecb-8b8a-136e29b9133d"
      unitRef="usd">2032000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ic3c76b1f92aa42d09acee15de07994bb_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMDUvZnJhZzo1Y2UzYTMxYjllM2Y0NGIzYTMyY2VmMTkzYjdjM2Y1MC90YWJsZTo1ZmMyNDQ4ZjZjNmM0ZjFhYTcxNzkwYTY0NWNmMGU1Ni90YWJsZXJhbmdlOjVmYzI0NDhmNmM2YzRmMWFhNzE3OTBhNjQ1Y2YwZTU2XzMtMy0xLTEtMTQ3Nw_55551cd5-650f-4d52-a49b-67d8a09d0f72"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ic3c76b1f92aa42d09acee15de07994bb_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMDUvZnJhZzo1Y2UzYTMxYjllM2Y0NGIzYTMyY2VmMTkzYjdjM2Y1MC90YWJsZTo1ZmMyNDQ4ZjZjNmM0ZjFhYTcxNzkwYTY0NWNmMGU1Ni90YWJsZXJhbmdlOjVmYzI0NDhmNmM2YzRmMWFhNzE3OTBhNjQ1Y2YwZTU2XzMtNS0xLTEtMTQ3Nw_53b77bdc-5c09-4fb8-9561-2f08bd553fc2"
      unitRef="usd">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ic3c76b1f92aa42d09acee15de07994bb_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMDUvZnJhZzo1Y2UzYTMxYjllM2Y0NGIzYTMyY2VmMTkzYjdjM2Y1MC90YWJsZTo1ZmMyNDQ4ZjZjNmM0ZjFhYTcxNzkwYTY0NWNmMGU1Ni90YWJsZXJhbmdlOjVmYzI0NDhmNmM2YzRmMWFhNzE3OTBhNjQ1Y2YwZTU2XzMtNy0xLTEtMzI4Mg_0bb911c9-bbb9-4a25-8200-071f190ea0cf"
      unitRef="usd">2031000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i14e2b8def247421298d392498e8d2a2c_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMDUvZnJhZzo1Y2UzYTMxYjllM2Y0NGIzYTMyY2VmMTkzYjdjM2Y1MC90YWJsZTo1ZmMyNDQ4ZjZjNmM0ZjFhYTcxNzkwYTY0NWNmMGU1Ni90YWJsZXJhbmdlOjVmYzI0NDhmNmM2YzRmMWFhNzE3OTBhNjQ1Y2YwZTU2XzQtMS0xLTEtMTQ3Nw_76db9aea-c1ef-408b-998f-e1c77eee8088"
      unitRef="usd">20374000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i14e2b8def247421298d392498e8d2a2c_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMDUvZnJhZzo1Y2UzYTMxYjllM2Y0NGIzYTMyY2VmMTkzYjdjM2Y1MC90YWJsZTo1ZmMyNDQ4ZjZjNmM0ZjFhYTcxNzkwYTY0NWNmMGU1Ni90YWJsZXJhbmdlOjVmYzI0NDhmNmM2YzRmMWFhNzE3OTBhNjQ1Y2YwZTU2XzQtMy0xLTEtMTQ3Nw_731a75f4-0445-4396-87d1-e94557ab2f16"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i14e2b8def247421298d392498e8d2a2c_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMDUvZnJhZzo1Y2UzYTMxYjllM2Y0NGIzYTMyY2VmMTkzYjdjM2Y1MC90YWJsZTo1ZmMyNDQ4ZjZjNmM0ZjFhYTcxNzkwYTY0NWNmMGU1Ni90YWJsZXJhbmdlOjVmYzI0NDhmNmM2YzRmMWFhNzE3OTBhNjQ1Y2YwZTU2XzQtNS0xLTEtMTQ3Nw_dbe3c51b-72ab-4a02-9130-13142ecfb2f4"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i14e2b8def247421298d392498e8d2a2c_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMDUvZnJhZzo1Y2UzYTMxYjllM2Y0NGIzYTMyY2VmMTkzYjdjM2Y1MC90YWJsZTo1ZmMyNDQ4ZjZjNmM0ZjFhYTcxNzkwYTY0NWNmMGU1Ni90YWJsZXJhbmdlOjVmYzI0NDhmNmM2YzRmMWFhNzE3OTBhNjQ1Y2YwZTU2XzQtNy0xLTEtMzI4Mg_1c399d01-d711-48b2-88c5-7a5b7334ea17"
      unitRef="usd">20374000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ied8d945ebce54ed8a4badfed477a64e8_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMDUvZnJhZzo1Y2UzYTMxYjllM2Y0NGIzYTMyY2VmMTkzYjdjM2Y1MC90YWJsZTo1ZmMyNDQ4ZjZjNmM0ZjFhYTcxNzkwYTY0NWNmMGU1Ni90YWJsZXJhbmdlOjVmYzI0NDhmNmM2YzRmMWFhNzE3OTBhNjQ1Y2YwZTU2XzYtMS0xLTEtMzI3NQ_b3538d9c-fcc0-40fb-bf24-e872cbb62dd4"
      unitRef="usd">22406000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ied8d945ebce54ed8a4badfed477a64e8_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMDUvZnJhZzo1Y2UzYTMxYjllM2Y0NGIzYTMyY2VmMTkzYjdjM2Y1MC90YWJsZTo1ZmMyNDQ4ZjZjNmM0ZjFhYTcxNzkwYTY0NWNmMGU1Ni90YWJsZXJhbmdlOjVmYzI0NDhmNmM2YzRmMWFhNzE3OTBhNjQ1Y2YwZTU2XzYtMy0xLTEtMzI3OA_2b0b518c-aa53-4c1a-98ff-deca5f5c721a"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ied8d945ebce54ed8a4badfed477a64e8_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMDUvZnJhZzo1Y2UzYTMxYjllM2Y0NGIzYTMyY2VmMTkzYjdjM2Y1MC90YWJsZTo1ZmMyNDQ4ZjZjNmM0ZjFhYTcxNzkwYTY0NWNmMGU1Ni90YWJsZXJhbmdlOjVmYzI0NDhmNmM2YzRmMWFhNzE3OTBhNjQ1Y2YwZTU2XzYtNS0xLTEtMzI4MA_f12c965a-6a0a-44c8-bb5d-a5431a3f7b1e"
      unitRef="usd">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ied8d945ebce54ed8a4badfed477a64e8_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMDUvZnJhZzo1Y2UzYTMxYjllM2Y0NGIzYTMyY2VmMTkzYjdjM2Y1MC90YWJsZTo1ZmMyNDQ4ZjZjNmM0ZjFhYTcxNzkwYTY0NWNmMGU1Ni90YWJsZXJhbmdlOjVmYzI0NDhmNmM2YzRmMWFhNzE3OTBhNjQ1Y2YwZTU2XzYtNy0xLTEtMzI4Mg_4bab6933-e50f-4850-a988-a3978b04f40d"
      unitRef="usd">22405000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale
      contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMDUvZnJhZzo1Y2UzYTMxYjllM2Y0NGIzYTMyY2VmMTkzYjdjM2Y1MC90ZXh0cmVnaW9uOjVjZTNhMzFiOWUzZjQ0YjNhMzJjZWYxOTNiN2MzZjUwXzIxOTkwMjMyNTczODE_77c0f5fa-9205-44d6-b0dc-4e6df8bada00"
      unitRef="usd">0</us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ib56f1adc867e406ca7face50c5da1c9c_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMDUvZnJhZzo1Y2UzYTMxYjllM2Y0NGIzYTMyY2VmMTkzYjdjM2Y1MC90ZXh0cmVnaW9uOjVjZTNhMzFiOWUzZjQ0YjNhMzJjZWYxOTNiN2MzZjUwXzQzOTgwNDY1MTI0MTY_a40f2c9c-bbbb-4b54-abe5-4dedd56ef179"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMTEvZnJhZzpkYjE5OTk1NmQ5ODU0MmNiOGM4ODJlOTFiMjk0ZjMxOS90ZXh0cmVnaW9uOmRiMTk5OTU2ZDk4NTQyY2I4Yzg4MmU5MWIyOTRmMzE5Xzk4Ng_93cbf142-7de8-4f38-93e9-5d9c7649d900">Net Loss Per Share&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has reported a net loss for the three months ended March 31, 2021 and 2020. For this reason basic and diluted net loss per share are the same for all periods presented. The following table sets forth the computation of basic and diluted net loss per share (in thousands, except share and per-share data):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.777%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net loss attributable to common stockholders&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(24,597)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(19,620)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Weighted-average common shares and pre-funded warrants outstanding&#x2014;basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;110,742,150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;94,723,513&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net loss per share attributable to common stockholders &#x2014;basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.22)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.21)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All potential dilutive common shares have been excluded from the computation of the diluted net loss per share for all periods presented, as the effect would have been anti-dilutive. Potential dilutive common share equivalents consist of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.777%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Stock options to purchase common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10,187,394&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,745,936&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Unvested restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;544,313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;170,313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Warrants to purchase common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12,378,016&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;23,084,120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;23,109,723&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;31,000,369&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMTEvZnJhZzpkYjE5OTk1NmQ5ODU0MmNiOGM4ODJlOTFiMjk0ZjMxOS90ZXh0cmVnaW9uOmRiMTk5OTU2ZDk4NTQyY2I4Yzg4MmU5MWIyOTRmMzE5Xzk5NQ_c505c89f-5fc8-417f-96cb-30d529b0bfce">The following table sets forth the computation of basic and diluted net loss per share (in thousands, except share and per-share data):&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.777%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net loss attributable to common stockholders&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(24,597)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(19,620)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Weighted-average common shares and pre-funded warrants outstanding&#x2014;basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;110,742,150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;94,723,513&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net loss per share attributable to common stockholders &#x2014;basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.22)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.21)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMTEvZnJhZzpkYjE5OTk1NmQ5ODU0MmNiOGM4ODJlOTFiMjk0ZjMxOS90YWJsZTowM2VmYjk1ZTk5ZGU0NzgyYjVkYWNiMWQ0ZTE0ZTVlZC90YWJsZXJhbmdlOjAzZWZiOTVlOTlkZTQ3ODJiNWRhY2IxZDRlMTRlNWVkXzMtMS0xLTEtMA_984d3400-5719-4238-a4c2-6cbe8ac9deb6"
      unitRef="usd">-24597000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="i824a5b33f908426bad016f0eded844db_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMTEvZnJhZzpkYjE5OTk1NmQ5ODU0MmNiOGM4ODJlOTFiMjk0ZjMxOS90YWJsZTowM2VmYjk1ZTk5ZGU0NzgyYjVkYWNiMWQ0ZTE0ZTVlZC90YWJsZXJhbmdlOjAzZWZiOTVlOTlkZTQ3ODJiNWRhY2IxZDRlMTRlNWVkXzMtMy0xLTEtMA_2b6b0e70-ffcf-4745-98ac-66ba744fb486"
      unitRef="usd">-19620000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMTEvZnJhZzpkYjE5OTk1NmQ5ODU0MmNiOGM4ODJlOTFiMjk0ZjMxOS90YWJsZTowM2VmYjk1ZTk5ZGU0NzgyYjVkYWNiMWQ0ZTE0ZTVlZC90YWJsZXJhbmdlOjAzZWZiOTVlOTlkZTQ3ODJiNWRhY2IxZDRlMTRlNWVkXzUtMS0xLTEtMA_e3063f9b-8f54-46e6-8a77-2d46afb68464"
      unitRef="shares">110742150</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="i824a5b33f908426bad016f0eded844db_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMTEvZnJhZzpkYjE5OTk1NmQ5ODU0MmNiOGM4ODJlOTFiMjk0ZjMxOS90YWJsZTowM2VmYjk1ZTk5ZGU0NzgyYjVkYWNiMWQ0ZTE0ZTVlZC90YWJsZXJhbmdlOjAzZWZiOTVlOTlkZTQ3ODJiNWRhY2IxZDRlMTRlNWVkXzUtMy0xLTEtMA_b40d2c96-67c1-4276-87b9-c19c33d96e76"
      unitRef="shares">94723513</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMTEvZnJhZzpkYjE5OTk1NmQ5ODU0MmNiOGM4ODJlOTFiMjk0ZjMxOS90YWJsZTowM2VmYjk1ZTk5ZGU0NzgyYjVkYWNiMWQ0ZTE0ZTVlZC90YWJsZXJhbmdlOjAzZWZiOTVlOTlkZTQ3ODJiNWRhY2IxZDRlMTRlNWVkXzYtMS0xLTEtMA_fb10e32b-72dd-4fef-94fd-5bd1e19c691a"
      unitRef="usdPerShare">-0.22</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="i824a5b33f908426bad016f0eded844db_D20200101-20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMTEvZnJhZzpkYjE5OTk1NmQ5ODU0MmNiOGM4ODJlOTFiMjk0ZjMxOS90YWJsZTowM2VmYjk1ZTk5ZGU0NzgyYjVkYWNiMWQ0ZTE0ZTVlZC90YWJsZXJhbmdlOjAzZWZiOTVlOTlkZTQ3ODJiNWRhY2IxZDRlMTRlNWVkXzYtMy0xLTEtMA_21d2164d-4289-461b-8991-6035b6189e1d"
      unitRef="usdPerShare">-0.21</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMTEvZnJhZzpkYjE5OTk1NmQ5ODU0MmNiOGM4ODJlOTFiMjk0ZjMxOS90ZXh0cmVnaW9uOmRiMTk5OTU2ZDk4NTQyY2I4Yzg4MmU5MWIyOTRmMzE5Xzk4Mg_3bb64aeb-7ad5-458d-a2d5-eaac6385cead">Potential dilutive common share equivalents consist of the following:&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.777%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Stock options to purchase common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10,187,394&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,745,936&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Unvested restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;544,313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;170,313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Warrants to purchase common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12,378,016&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;23,084,120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;23,109,723&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;31,000,369&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i9c2d6525939d4e4f8c2b60bce2f66a52_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMTEvZnJhZzpkYjE5OTk1NmQ5ODU0MmNiOGM4ODJlOTFiMjk0ZjMxOS90YWJsZTo4MjliYjQ2ZTBjYjQ0OWMwYmJmZjM2NGUyYWQ1NjBjNS90YWJsZXJhbmdlOjgyOWJiNDZlMGNiNDQ5YzBiYmZmMzY0ZTJhZDU2MGM1XzItMS0xLTEtMA_5bbcad40-4925-4c9d-b845-b549b0294751"
      unitRef="shares">10187394</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ie177f33c2b9e48b2b637240e8939d8ae_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMTEvZnJhZzpkYjE5OTk1NmQ5ODU0MmNiOGM4ODJlOTFiMjk0ZjMxOS90YWJsZTo4MjliYjQ2ZTBjYjQ0OWMwYmJmZjM2NGUyYWQ1NjBjNS90YWJsZXJhbmdlOjgyOWJiNDZlMGNiNDQ5YzBiYmZmMzY0ZTJhZDU2MGM1XzItMy0xLTEtMA_02524596-d8dc-4c0b-bdd6-f831125e0236"
      unitRef="shares">7745936</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i025312c2f622403398c380c781b5be0a_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMTEvZnJhZzpkYjE5OTk1NmQ5ODU0MmNiOGM4ODJlOTFiMjk0ZjMxOS90YWJsZTo4MjliYjQ2ZTBjYjQ0OWMwYmJmZjM2NGUyYWQ1NjBjNS90YWJsZXJhbmdlOjgyOWJiNDZlMGNiNDQ5YzBiYmZmMzY0ZTJhZDU2MGM1XzMtMS0xLTEtMA_35aa10d6-3a15-4abd-b928-ae0283a8818f"
      unitRef="shares">544313</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="iafc609c73df642828d67d21ca85d518a_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMTEvZnJhZzpkYjE5OTk1NmQ5ODU0MmNiOGM4ODJlOTFiMjk0ZjMxOS90YWJsZTo4MjliYjQ2ZTBjYjQ0OWMwYmJmZjM2NGUyYWQ1NjBjNS90YWJsZXJhbmdlOjgyOWJiNDZlMGNiNDQ5YzBiYmZmMzY0ZTJhZDU2MGM1XzMtMy0xLTEtMA_828e48c3-4bbb-49fc-9cb1-c5609afbda9c"
      unitRef="shares">170313</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i13a4d3bd3f0f4f058f62ef7fd2966851_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMTEvZnJhZzpkYjE5OTk1NmQ5ODU0MmNiOGM4ODJlOTFiMjk0ZjMxOS90YWJsZTo4MjliYjQ2ZTBjYjQ0OWMwYmJmZjM2NGUyYWQ1NjBjNS90YWJsZXJhbmdlOjgyOWJiNDZlMGNiNDQ5YzBiYmZmMzY0ZTJhZDU2MGM1XzQtMS0xLTEtMA_88b9ed4f-83f8-47c8-a4c0-6fafbc44033e"
      unitRef="shares">12378016</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i1a544c9a0a0e439c9ee87934aaffd7fe_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMTEvZnJhZzpkYjE5OTk1NmQ5ODU0MmNiOGM4ODJlOTFiMjk0ZjMxOS90YWJsZTo4MjliYjQ2ZTBjYjQ0OWMwYmJmZjM2NGUyYWQ1NjBjNS90YWJsZXJhbmdlOjgyOWJiNDZlMGNiNDQ5YzBiYmZmMzY0ZTJhZDU2MGM1XzQtMy0xLTEtMA_3c696a7b-15fe-49cd-8ff6-8ccab5d921d3"
      unitRef="shares">23084120</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMTEvZnJhZzpkYjE5OTk1NmQ5ODU0MmNiOGM4ODJlOTFiMjk0ZjMxOS90YWJsZTo4MjliYjQ2ZTBjYjQ0OWMwYmJmZjM2NGUyYWQ1NjBjNS90YWJsZXJhbmdlOjgyOWJiNDZlMGNiNDQ5YzBiYmZmMzY0ZTJhZDU2MGM1XzctMS0xLTEtMA_c6908419-ff9e-4fe9-84d7-c3db8ac9ec88"
      unitRef="shares">23109723</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i824a5b33f908426bad016f0eded844db_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMTEvZnJhZzpkYjE5OTk1NmQ5ODU0MmNiOGM4ODJlOTFiMjk0ZjMxOS90YWJsZTo4MjliYjQ2ZTBjYjQ0OWMwYmJmZjM2NGUyYWQ1NjBjNS90YWJsZXJhbmdlOjgyOWJiNDZlMGNiNDQ5YzBiYmZmMzY0ZTJhZDU2MGM1XzctMy0xLTEtMA_51201352-aec2-4664-b932-330c19de0407"
      unitRef="shares">31000369</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMTQvZnJhZzplMDZlY2YzYjhmYmQ0ZjY1YjIzZGM2NTA1MTBlZDMyMy90ZXh0cmVnaW9uOmUwNmVjZjNiOGZiZDRmNjViMjNkYzY1MDUxMGVkMzIzXzMzODE_d825d8ab-9aa1-48a5-a74b-b136e6236ee3">Fair Value Measurements&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables present the Company&#x2019;s assets and liabilities that are measured at fair value on a recurring basis as of March 31, 2021 and December 31, 2020 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.923%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Level&#160;1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Level&#160;2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Level&#160;3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;58,158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;58,158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Marketable securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,031&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,031&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20,374&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20,374&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;80,563&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;58,158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;22,405&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Warrant liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;45,455&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;45,455&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;45,455&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;45,455&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.923%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Level&#160;1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Level&#160;2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Level&#160;3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;80,576&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;80,576&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;80,576&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;80,576&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Warrant liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;28,708&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;28,708&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;28,708&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;28,708&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were no transfers within the fair value hierarchy during the three months ended March 31, 2021 or the year ended December 31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March 31, 2021 and December 31, 2020, the money market funds were classified as cash and cash equivalents on the accompanying consolidated balance sheets as they mature within 90 days from the date of purchase.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March 31, 2021, the Company had restricted cash balances relating to a secured letter of credit in connection with its lease for the Company&#x2019;s headquarters (see Note 8 included elsewhere in this Quarterly Report). The Company&#x2019;s consolidated statement of cash flows includes the following as of March 31, 2021 and 2020 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.777%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;125,407&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;72,606&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Short-term restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Long-term restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,379&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,379&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total cash, cash equivalents, and restricted cash shown in the consolidated statement of cash flows&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;126,786&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;74,264&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Marketable Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March 31, 2021, marketable securities classified as Level 2 within the valuation hierarchy consist of corporate bonds and commercial paper. Marketable securities represent holdings of available-for-sale marketable debt securities in accordance with the Company&#x2019;s investment policy. The Company estimates the fair values of these marketable securities by taking into consideration valuations that include market pricing based on real-time trade data for the same or similar securities, and other observable inputs. The amortized cost of available-for-sale debt securities is adjusted for amortization of premiums and accretion of discounts to the earliest call date for premiums or to maturity for discounts.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Loans Payable&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At March 31, 2021, given the recent issuance of the Term A Loan under the 2020 Term Loan, the Company believes the carrying value approximates the fair value of the loan.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Common Warrants&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2019, the Company issued common warrants in connection with a private placement of common shares. Pursuant to the terms of the common warrants, the Company could be required to settle the common warrants in cash in the event of certain acquisitions of the Company and, as a result, the common warrants are required to be measured at fair value and reported as a liability on the balance sheet.&#160;The Company recorded the fair value of the common warrants upon issuance using the Black-Scholes valuation model and is required to revalue the common warrants at each reporting date with any changes in fair value recorded in the statement of operations. The valuation of the common warrants is considered under Level&#160;3 of the fair value hierarchy due to the need to use assumptions in the valuation that are both significant to the fair value measurement and unobservable. The significant unobservable inputs used in the fair value measurement of the warrant liabilities were the volatility rate and the estimated term of the warrants. Generally, increases (decreases) in the fair value of the underlying stock and estimated term would result in a directionally similar impact to the fair value measurement. The change in &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;the fair value of the&#160;Level 3 warrant liability is reflected in the statement of operations for the three months ended March 31, 2021 and 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated fair value of warrants is determined using Level 3 inputs inherent in the Black-Scholes simulation valuation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Estimated fair value of the underlying stock&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company estimates the fair value of the common stock based on the closing stock price at the end of each reporting period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Risk-free interest rate&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The risk-free interest rate is based on the U.S. Treasury at the valuation date commensurate with the expected remaining life assumption.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Dividend rate&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&#160;The dividend rate is based on the historical rate, which the Company anticipates will remain at zero.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Expected life&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&#160;The expected life of the warrants is assumed to be equivalent to their remaining contractual term which expires on December 23, 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Volatility&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&#160;The Company estimates stock price volatility based on the Company&#x2019;s historical volatility and the historical volatility of peer companies for a period of time commensurate with the expected remaining life of the warrants.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the Black-Scholes pricing model assumptions used to record the fair value of the warrant liability is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:87.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.596%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Expected life (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.73&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;101.13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Changes in Level 3 Liabilities Measured at Fair Value on a Recurring Basis&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table reflects a roll-forward of fair value for the Company&#x2019;s Level 3 warrant liabilities (see Note 10), for the three months ended March 31, 2021 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:87.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.596%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Warrant liabilities&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fair value as of December 31, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;28,708&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Change in fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;16,747&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fair value as of March 31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;45,455&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMTQvZnJhZzplMDZlY2YzYjhmYmQ0ZjY1YjIzZGM2NTA1MTBlZDMyMy90ZXh0cmVnaW9uOmUwNmVjZjNiOGZiZDRmNjViMjNkYzY1MDUxMGVkMzIzXzMzNzQ_b3ec7ee6-34a7-4060-8cf4-b3ece82ee8a5">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables present the Company&#x2019;s assets and liabilities that are measured at fair value on a recurring basis as of March 31, 2021 and December 31, 2020 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.923%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Level&#160;1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Level&#160;2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Level&#160;3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;58,158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;58,158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Marketable securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,031&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,031&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20,374&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20,374&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;80,563&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;58,158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;22,405&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Warrant liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;45,455&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;45,455&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;45,455&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;45,455&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.923%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Level&#160;1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Level&#160;2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Level&#160;3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;80,576&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;80,576&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;80,576&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;80,576&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Warrant liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;28,708&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;28,708&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;28,708&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;28,708&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i65d0ac8f7c4649d2abfce4eda0ef5c55_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMTQvZnJhZzplMDZlY2YzYjhmYmQ0ZjY1YjIzZGM2NTA1MTBlZDMyMy90YWJsZTo2MDkzNmUzMzBkOWI0Yjc5OGY0MzkzYzY4NzM1OGIyMS90YWJsZXJhbmdlOjYwOTM2ZTMzMGQ5YjRiNzk4ZjQzOTNjNjg3MzU4YjIxXzMtMS0xLTEtMA_75fed775-5f4a-4cc2-9897-0a7e880acee5"
      unitRef="usd">58158000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i73fe924a4c6b473cabf17b9976a4603b_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMTQvZnJhZzplMDZlY2YzYjhmYmQ0ZjY1YjIzZGM2NTA1MTBlZDMyMy90YWJsZTo2MDkzNmUzMzBkOWI0Yjc5OGY0MzkzYzY4NzM1OGIyMS90YWJsZXJhbmdlOjYwOTM2ZTMzMGQ5YjRiNzk4ZjQzOTNjNjg3MzU4YjIxXzMtMy0xLTEtMA_62382fcb-71d7-4e20-bad0-a5aeb10f2f0e"
      unitRef="usd">58158000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i4f0d06e989014726b8fbec56b2c70e58_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMTQvZnJhZzplMDZlY2YzYjhmYmQ0ZjY1YjIzZGM2NTA1MTBlZDMyMy90YWJsZTo2MDkzNmUzMzBkOWI0Yjc5OGY0MzkzYzY4NzM1OGIyMS90YWJsZXJhbmdlOjYwOTM2ZTMzMGQ5YjRiNzk4ZjQzOTNjNjg3MzU4YjIxXzMtNS0xLTEtMA_2c537341-2d35-4da6-baca-a217f36e6fe9"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i62606fe1b8724fb5a3af6c257e69c07f_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMTQvZnJhZzplMDZlY2YzYjhmYmQ0ZjY1YjIzZGM2NTA1MTBlZDMyMy90YWJsZTo2MDkzNmUzMzBkOWI0Yjc5OGY0MzkzYzY4NzM1OGIyMS90YWJsZXJhbmdlOjYwOTM2ZTMzMGQ5YjRiNzk4ZjQzOTNjNjg3MzU4YjIxXzMtNy0xLTEtMA_1b943897-d880-4bce-8d43-00ecd087483d"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i34e52dcd53c6432595cfbcb02112eb8b_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMTQvZnJhZzplMDZlY2YzYjhmYmQ0ZjY1YjIzZGM2NTA1MTBlZDMyMy90YWJsZTo2MDkzNmUzMzBkOWI0Yjc5OGY0MzkzYzY4NzM1OGIyMS90YWJsZXJhbmdlOjYwOTM2ZTMzMGQ5YjRiNzk4ZjQzOTNjNjg3MzU4YjIxXzUtMS0xLTEtMzMxMA_10fa9940-a050-4db9-bdf0-aa3f977eb068"
      unitRef="usd">2031000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="id1a9f3d45e4741d9adb5d0a140f27245_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMTQvZnJhZzplMDZlY2YzYjhmYmQ0ZjY1YjIzZGM2NTA1MTBlZDMyMy90YWJsZTo2MDkzNmUzMzBkOWI0Yjc5OGY0MzkzYzY4NzM1OGIyMS90YWJsZXJhbmdlOjYwOTM2ZTMzMGQ5YjRiNzk4ZjQzOTNjNjg3MzU4YjIxXzUtMy0xLTEtMA_cef5674f-47ab-4acd-add9-920e2b0cb1bd"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="if2bb46350e76491c82ca4f7ee3718824_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMTQvZnJhZzplMDZlY2YzYjhmYmQ0ZjY1YjIzZGM2NTA1MTBlZDMyMy90YWJsZTo2MDkzNmUzMzBkOWI0Yjc5OGY0MzkzYzY4NzM1OGIyMS90YWJsZXJhbmdlOjYwOTM2ZTMzMGQ5YjRiNzk4ZjQzOTNjNjg3MzU4YjIxXzUtNS0xLTEtMA_bc6f6282-5de6-4a46-b515-feaa60335172"
      unitRef="usd">2031000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i59a1a80dbf8e4190b547bba901361077_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMTQvZnJhZzplMDZlY2YzYjhmYmQ0ZjY1YjIzZGM2NTA1MTBlZDMyMy90YWJsZTo2MDkzNmUzMzBkOWI0Yjc5OGY0MzkzYzY4NzM1OGIyMS90YWJsZXJhbmdlOjYwOTM2ZTMzMGQ5YjRiNzk4ZjQzOTNjNjg3MzU4YjIxXzUtNy0xLTEtMA_8877894f-0b3c-42a2-91f6-b5fb5dc0206a"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ife613bc7097a4d25b505ac69b2a556a1_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMTQvZnJhZzplMDZlY2YzYjhmYmQ0ZjY1YjIzZGM2NTA1MTBlZDMyMy90YWJsZTo2MDkzNmUzMzBkOWI0Yjc5OGY0MzkzYzY4NzM1OGIyMS90YWJsZXJhbmdlOjYwOTM2ZTMzMGQ5YjRiNzk4ZjQzOTNjNjg3MzU4YjIxXzYtMS0xLTEtMzMxMA_861164e8-a4ef-4c06-b569-d9c3da8dc812"
      unitRef="usd">20374000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i9c477876ef1243f7b607ededf27faa28_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMTQvZnJhZzplMDZlY2YzYjhmYmQ0ZjY1YjIzZGM2NTA1MTBlZDMyMy90YWJsZTo2MDkzNmUzMzBkOWI0Yjc5OGY0MzkzYzY4NzM1OGIyMS90YWJsZXJhbmdlOjYwOTM2ZTMzMGQ5YjRiNzk4ZjQzOTNjNjg3MzU4YjIxXzYtMy0xLTEtMzMxMA_76d77d23-c762-498b-b658-dcb9f4d859b5"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="id5b76767b65e416baf32d9fa8ea057ac_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMTQvZnJhZzplMDZlY2YzYjhmYmQ0ZjY1YjIzZGM2NTA1MTBlZDMyMy90YWJsZTo2MDkzNmUzMzBkOWI0Yjc5OGY0MzkzYzY4NzM1OGIyMS90YWJsZXJhbmdlOjYwOTM2ZTMzMGQ5YjRiNzk4ZjQzOTNjNjg3MzU4YjIxXzYtNS0xLTEtMjI0MA_5e09d23f-24d6-474a-a902-d07b7f5c7894"
      unitRef="usd">20374000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i78a9cb54375140a3926493d7ca71f588_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMTQvZnJhZzplMDZlY2YzYjhmYmQ0ZjY1YjIzZGM2NTA1MTBlZDMyMy90YWJsZTo2MDkzNmUzMzBkOWI0Yjc5OGY0MzkzYzY4NzM1OGIyMS90YWJsZXJhbmdlOjYwOTM2ZTMzMGQ5YjRiNzk4ZjQzOTNjNjg3MzU4YjIxXzYtNy0xLTEtMzMxMA_3019b530-b6f0-48a7-bcd6-60dd4b52807e"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ief7e41d172914136a4d75381f191624f_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMTQvZnJhZzplMDZlY2YzYjhmYmQ0ZjY1YjIzZGM2NTA1MTBlZDMyMy90YWJsZTo2MDkzNmUzMzBkOWI0Yjc5OGY0MzkzYzY4NzM1OGIyMS90YWJsZXJhbmdlOjYwOTM2ZTMzMGQ5YjRiNzk4ZjQzOTNjNjg3MzU4YjIxXzYtMS0xLTEtMA_b13eded4-e4d0-4740-83d0-a6b638de02e8"
      unitRef="usd">80563000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="if08a10047a654aaca135de61c8732df2_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMTQvZnJhZzplMDZlY2YzYjhmYmQ0ZjY1YjIzZGM2NTA1MTBlZDMyMy90YWJsZTo2MDkzNmUzMzBkOWI0Yjc5OGY0MzkzYzY4NzM1OGIyMS90YWJsZXJhbmdlOjYwOTM2ZTMzMGQ5YjRiNzk4ZjQzOTNjNjg3MzU4YjIxXzYtMy0xLTEtMA_4a23135b-c040-4cd0-b3e0-4e22888cd09a"
      unitRef="usd">58158000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="if36d86949e87479898a50e28488ef27e_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMTQvZnJhZzplMDZlY2YzYjhmYmQ0ZjY1YjIzZGM2NTA1MTBlZDMyMy90YWJsZTo2MDkzNmUzMzBkOWI0Yjc5OGY0MzkzYzY4NzM1OGIyMS90YWJsZXJhbmdlOjYwOTM2ZTMzMGQ5YjRiNzk4ZjQzOTNjNjg3MzU4YjIxXzYtNS0xLTEtMA_7368997b-a7ab-4fa0-a6ab-2041b16baa44"
      unitRef="usd">22405000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i4bc11fa50e194e0fabd48feb4957cccd_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMTQvZnJhZzplMDZlY2YzYjhmYmQ0ZjY1YjIzZGM2NTA1MTBlZDMyMy90YWJsZTo2MDkzNmUzMzBkOWI0Yjc5OGY0MzkzYzY4NzM1OGIyMS90YWJsZXJhbmdlOjYwOTM2ZTMzMGQ5YjRiNzk4ZjQzOTNjNjg3MzU4YjIxXzYtNy0xLTEtMA_4280fd00-0cf4-4085-8267-6ba9d12bbcf9"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="ief7e41d172914136a4d75381f191624f_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMTQvZnJhZzplMDZlY2YzYjhmYmQ0ZjY1YjIzZGM2NTA1MTBlZDMyMy90YWJsZTo2MDkzNmUzMzBkOWI0Yjc5OGY0MzkzYzY4NzM1OGIyMS90YWJsZXJhbmdlOjYwOTM2ZTMzMGQ5YjRiNzk4ZjQzOTNjNjg3MzU4YjIxXzEzLTEtMS0xLTA_1c50e33e-591e-4bc3-ba48-1fc99d64f588"
      unitRef="usd">45455000</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="if08a10047a654aaca135de61c8732df2_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMTQvZnJhZzplMDZlY2YzYjhmYmQ0ZjY1YjIzZGM2NTA1MTBlZDMyMy90YWJsZTo2MDkzNmUzMzBkOWI0Yjc5OGY0MzkzYzY4NzM1OGIyMS90YWJsZXJhbmdlOjYwOTM2ZTMzMGQ5YjRiNzk4ZjQzOTNjNjg3MzU4YjIxXzEzLTMtMS0xLTA_c7e0ac1f-f496-47a0-a190-cb6cdb2ad5a8"
      unitRef="usd">0</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="if36d86949e87479898a50e28488ef27e_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMTQvZnJhZzplMDZlY2YzYjhmYmQ0ZjY1YjIzZGM2NTA1MTBlZDMyMy90YWJsZTo2MDkzNmUzMzBkOWI0Yjc5OGY0MzkzYzY4NzM1OGIyMS90YWJsZXJhbmdlOjYwOTM2ZTMzMGQ5YjRiNzk4ZjQzOTNjNjg3MzU4YjIxXzEzLTUtMS0xLTA_79baf380-2623-4ee0-a0d9-fb6c2bd36387"
      unitRef="usd">0</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="i4bc11fa50e194e0fabd48feb4957cccd_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMTQvZnJhZzplMDZlY2YzYjhmYmQ0ZjY1YjIzZGM2NTA1MTBlZDMyMy90YWJsZTo2MDkzNmUzMzBkOWI0Yjc5OGY0MzkzYzY4NzM1OGIyMS90YWJsZXJhbmdlOjYwOTM2ZTMzMGQ5YjRiNzk4ZjQzOTNjNjg3MzU4YjIxXzEzLTctMS0xLTA_8f045d77-0dec-4205-ab02-d056ee9d8655"
      unitRef="usd">45455000</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="ief7e41d172914136a4d75381f191624f_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMTQvZnJhZzplMDZlY2YzYjhmYmQ0ZjY1YjIzZGM2NTA1MTBlZDMyMy90YWJsZTo2MDkzNmUzMzBkOWI0Yjc5OGY0MzkzYzY4NzM1OGIyMS90YWJsZXJhbmdlOjYwOTM2ZTMzMGQ5YjRiNzk4ZjQzOTNjNjg3MzU4YjIxXzE0LTEtMS0xLTA_6e81c94d-62c6-4221-8831-2ae91eafb219"
      unitRef="usd">45455000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="if08a10047a654aaca135de61c8732df2_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMTQvZnJhZzplMDZlY2YzYjhmYmQ0ZjY1YjIzZGM2NTA1MTBlZDMyMy90YWJsZTo2MDkzNmUzMzBkOWI0Yjc5OGY0MzkzYzY4NzM1OGIyMS90YWJsZXJhbmdlOjYwOTM2ZTMzMGQ5YjRiNzk4ZjQzOTNjNjg3MzU4YjIxXzE0LTMtMS0xLTA_638fab71-3266-406f-9258-61f2394ae2a0"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="if36d86949e87479898a50e28488ef27e_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMTQvZnJhZzplMDZlY2YzYjhmYmQ0ZjY1YjIzZGM2NTA1MTBlZDMyMy90YWJsZTo2MDkzNmUzMzBkOWI0Yjc5OGY0MzkzYzY4NzM1OGIyMS90YWJsZXJhbmdlOjYwOTM2ZTMzMGQ5YjRiNzk4ZjQzOTNjNjg3MzU4YjIxXzE0LTUtMS0xLTA_8f984131-7964-4a68-9e2e-9735f8239158"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i4bc11fa50e194e0fabd48feb4957cccd_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMTQvZnJhZzplMDZlY2YzYjhmYmQ0ZjY1YjIzZGM2NTA1MTBlZDMyMy90YWJsZTo2MDkzNmUzMzBkOWI0Yjc5OGY0MzkzYzY4NzM1OGIyMS90YWJsZXJhbmdlOjYwOTM2ZTMzMGQ5YjRiNzk4ZjQzOTNjNjg3MzU4YjIxXzE0LTctMS0xLTA_ef862539-f27f-4cf8-be66-1c0ea65a7ea3"
      unitRef="usd">45455000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ie881e34b7b6e451a8635ff1a48715e24_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMTQvZnJhZzplMDZlY2YzYjhmYmQ0ZjY1YjIzZGM2NTA1MTBlZDMyMy90YWJsZTo5ZWU4NDFhMjFhNzM0M2EzYWM2NDg5ZmZmNGZkY2I3NS90YWJsZXJhbmdlOjllZTg0MWEyMWE3MzQzYTNhYzY0ODlmZmY0ZmRjYjc1XzMtMS0xLTEtMA_4e2bf17f-b441-4749-aa99-4d03b9a96edc"
      unitRef="usd">80576000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i3415f69e0c84403290f2c597fcafb421_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMTQvZnJhZzplMDZlY2YzYjhmYmQ0ZjY1YjIzZGM2NTA1MTBlZDMyMy90YWJsZTo5ZWU4NDFhMjFhNzM0M2EzYWM2NDg5ZmZmNGZkY2I3NS90YWJsZXJhbmdlOjllZTg0MWEyMWE3MzQzYTNhYzY0ODlmZmY0ZmRjYjc1XzMtMy0xLTEtMA_31d34d5d-9ce7-407f-af5b-83068a9b2710"
      unitRef="usd">80576000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="icd1ec9843c3446469cb04e17862f007e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMTQvZnJhZzplMDZlY2YzYjhmYmQ0ZjY1YjIzZGM2NTA1MTBlZDMyMy90YWJsZTo5ZWU4NDFhMjFhNzM0M2EzYWM2NDg5ZmZmNGZkY2I3NS90YWJsZXJhbmdlOjllZTg0MWEyMWE3MzQzYTNhYzY0ODlmZmY0ZmRjYjc1XzMtNS0xLTEtMA_e441b6d8-137e-45ab-9e6d-11560c3cb546"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i3e2993ab72c94021ac21ee14bcd929f2_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMTQvZnJhZzplMDZlY2YzYjhmYmQ0ZjY1YjIzZGM2NTA1MTBlZDMyMy90YWJsZTo5ZWU4NDFhMjFhNzM0M2EzYWM2NDg5ZmZmNGZkY2I3NS90YWJsZXJhbmdlOjllZTg0MWEyMWE3MzQzYTNhYzY0ODlmZmY0ZmRjYjc1XzMtNy0xLTEtMA_001485f0-6030-431f-9536-d76aefd2f099"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ib217ca012a534d9a9f5dedd2b37941f0_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMTQvZnJhZzplMDZlY2YzYjhmYmQ0ZjY1YjIzZGM2NTA1MTBlZDMyMy90YWJsZTo5ZWU4NDFhMjFhNzM0M2EzYWM2NDg5ZmZmNGZkY2I3NS90YWJsZXJhbmdlOjllZTg0MWEyMWE3MzQzYTNhYzY0ODlmZmY0ZmRjYjc1XzQtMS0xLTEtMA_3f8187eb-76a1-42db-91f7-9569b0438c23"
      unitRef="usd">80576000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i631a8e963f31434e8ea74e97de9ea103_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMTQvZnJhZzplMDZlY2YzYjhmYmQ0ZjY1YjIzZGM2NTA1MTBlZDMyMy90YWJsZTo5ZWU4NDFhMjFhNzM0M2EzYWM2NDg5ZmZmNGZkY2I3NS90YWJsZXJhbmdlOjllZTg0MWEyMWE3MzQzYTNhYzY0ODlmZmY0ZmRjYjc1XzQtMy0xLTEtMA_10b0a5c3-8040-4e63-9b0e-2cc483255e28"
      unitRef="usd">80576000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i7e3199d724344066b7d92c08835c0d7b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMTQvZnJhZzplMDZlY2YzYjhmYmQ0ZjY1YjIzZGM2NTA1MTBlZDMyMy90YWJsZTo5ZWU4NDFhMjFhNzM0M2EzYWM2NDg5ZmZmNGZkY2I3NS90YWJsZXJhbmdlOjllZTg0MWEyMWE3MzQzYTNhYzY0ODlmZmY0ZmRjYjc1XzQtNS0xLTEtMA_25659ff0-f73c-4454-bead-1d701501b581"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i067beaf80d0645c0b74a43ced34f040f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMTQvZnJhZzplMDZlY2YzYjhmYmQ0ZjY1YjIzZGM2NTA1MTBlZDMyMy90YWJsZTo5ZWU4NDFhMjFhNzM0M2EzYWM2NDg5ZmZmNGZkY2I3NS90YWJsZXJhbmdlOjllZTg0MWEyMWE3MzQzYTNhYzY0ODlmZmY0ZmRjYjc1XzQtNy0xLTEtMA_b0a22556-95c1-4904-a466-7fc49863d29f"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="ib217ca012a534d9a9f5dedd2b37941f0_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMTQvZnJhZzplMDZlY2YzYjhmYmQ0ZjY1YjIzZGM2NTA1MTBlZDMyMy90YWJsZTo5ZWU4NDFhMjFhNzM0M2EzYWM2NDg5ZmZmNGZkY2I3NS90YWJsZXJhbmdlOjllZTg0MWEyMWE3MzQzYTNhYzY0ODlmZmY0ZmRjYjc1XzctMS0xLTEtMA_c0b3946a-2739-4d87-854a-081c2eda4ab7"
      unitRef="usd">28708000</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="i631a8e963f31434e8ea74e97de9ea103_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMTQvZnJhZzplMDZlY2YzYjhmYmQ0ZjY1YjIzZGM2NTA1MTBlZDMyMy90YWJsZTo5ZWU4NDFhMjFhNzM0M2EzYWM2NDg5ZmZmNGZkY2I3NS90YWJsZXJhbmdlOjllZTg0MWEyMWE3MzQzYTNhYzY0ODlmZmY0ZmRjYjc1XzctMy0xLTEtMA_e680eba8-cd70-40ef-89e4-fc8283b3064d"
      unitRef="usd">0</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="i7e3199d724344066b7d92c08835c0d7b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMTQvZnJhZzplMDZlY2YzYjhmYmQ0ZjY1YjIzZGM2NTA1MTBlZDMyMy90YWJsZTo5ZWU4NDFhMjFhNzM0M2EzYWM2NDg5ZmZmNGZkY2I3NS90YWJsZXJhbmdlOjllZTg0MWEyMWE3MzQzYTNhYzY0ODlmZmY0ZmRjYjc1XzctNS0xLTEtMA_e792f4d9-c346-44ce-a907-35ce2be1a871"
      unitRef="usd">0</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="i067beaf80d0645c0b74a43ced34f040f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMTQvZnJhZzplMDZlY2YzYjhmYmQ0ZjY1YjIzZGM2NTA1MTBlZDMyMy90YWJsZTo5ZWU4NDFhMjFhNzM0M2EzYWM2NDg5ZmZmNGZkY2I3NS90YWJsZXJhbmdlOjllZTg0MWEyMWE3MzQzYTNhYzY0ODlmZmY0ZmRjYjc1XzctNy0xLTEtMA_aa610ebc-c5fd-4ab7-8270-7484246dfccb"
      unitRef="usd">28708000</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="ib217ca012a534d9a9f5dedd2b37941f0_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMTQvZnJhZzplMDZlY2YzYjhmYmQ0ZjY1YjIzZGM2NTA1MTBlZDMyMy90YWJsZTo5ZWU4NDFhMjFhNzM0M2EzYWM2NDg5ZmZmNGZkY2I3NS90YWJsZXJhbmdlOjllZTg0MWEyMWE3MzQzYTNhYzY0ODlmZmY0ZmRjYjc1XzgtMS0xLTEtMA_3187c2a3-8486-4eee-82fd-774d583c8413"
      unitRef="usd">28708000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i631a8e963f31434e8ea74e97de9ea103_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMTQvZnJhZzplMDZlY2YzYjhmYmQ0ZjY1YjIzZGM2NTA1MTBlZDMyMy90YWJsZTo5ZWU4NDFhMjFhNzM0M2EzYWM2NDg5ZmZmNGZkY2I3NS90YWJsZXJhbmdlOjllZTg0MWEyMWE3MzQzYTNhYzY0ODlmZmY0ZmRjYjc1XzgtMy0xLTEtMA_ec264ef9-41bf-4256-b85d-cd12b51ca8be"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i7e3199d724344066b7d92c08835c0d7b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMTQvZnJhZzplMDZlY2YzYjhmYmQ0ZjY1YjIzZGM2NTA1MTBlZDMyMy90YWJsZTo5ZWU4NDFhMjFhNzM0M2EzYWM2NDg5ZmZmNGZkY2I3NS90YWJsZXJhbmdlOjllZTg0MWEyMWE3MzQzYTNhYzY0ODlmZmY0ZmRjYjc1XzgtNS0xLTEtMA_20985401-47e5-4b43-a5b0-342b7e034080"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i067beaf80d0645c0b74a43ced34f040f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMTQvZnJhZzplMDZlY2YzYjhmYmQ0ZjY1YjIzZGM2NTA1MTBlZDMyMy90YWJsZTo5ZWU4NDFhMjFhNzM0M2EzYWM2NDg5ZmZmNGZkY2I3NS90YWJsZXJhbmdlOjllZTg0MWEyMWE3MzQzYTNhYzY0ODlmZmY0ZmRjYjc1XzgtNy0xLTEtMA_27cc6f70-ab57-4dc6-bcf7-69985d5e8499"
      unitRef="usd">28708000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet
      contextRef="ibd87cf2a903e47a68471682c6f1d3125_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMTQvZnJhZzplMDZlY2YzYjhmYmQ0ZjY1YjIzZGM2NTA1MTBlZDMyMy90ZXh0cmVnaW9uOmUwNmVjZjNiOGZiZDRmNjViMjNkYzY1MDUxMGVkMzIzXzIxOTkwMjMyNjUyNjQ_14a18082-b7a7-425a-bcfc-148b053e69dd"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet
      contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMTQvZnJhZzplMDZlY2YzYjhmYmQ0ZjY1YjIzZGM2NTA1MTBlZDMyMy90ZXh0cmVnaW9uOmUwNmVjZjNiOGZiZDRmNjViMjNkYzY1MDUxMGVkMzIzXzIxOTkwMjMyNjUyNjQ_5bf1d42f-1608-4657-91a7-4b28a31d15b9"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet
      contextRef="ibd87cf2a903e47a68471682c6f1d3125_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMTQvZnJhZzplMDZlY2YzYjhmYmQ0ZjY1YjIzZGM2NTA1MTBlZDMyMy90ZXh0cmVnaW9uOmUwNmVjZjNiOGZiZDRmNjViMjNkYzY1MDUxMGVkMzIzXzIxOTkwMjMyNjUyNjQ_68ae6f68-d2b8-441f-a326-d54127007d9b"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet
      contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMTQvZnJhZzplMDZlY2YzYjhmYmQ0ZjY1YjIzZGM2NTA1MTBlZDMyMy90ZXh0cmVnaW9uOmUwNmVjZjNiOGZiZDRmNjViMjNkYzY1MDUxMGVkMzIzXzIxOTkwMjMyNjUyNjQ_a1d4b8de-3312-4a61-bd0b-f9e6dd919132"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet>
    <us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock
      contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMTQvZnJhZzplMDZlY2YzYjhmYmQ0ZjY1YjIzZGM2NTA1MTBlZDMyMy90ZXh0cmVnaW9uOmUwNmVjZjNiOGZiZDRmNjViMjNkYzY1MDUxMGVkMzIzXzQzOTgwNDY1MjMxMTY_3b3327de-cb58-4181-b04c-319f57a8931c">The Company&#x2019;s consolidated statement of cash flows includes the following as of March 31, 2021 and 2020 (in thousands):&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.777%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;125,407&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;72,606&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Short-term restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Long-term restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,379&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,379&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total cash, cash equivalents, and restricted cash shown in the consolidated statement of cash flows&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;126,786&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;74,264&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock>
    <us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock
      contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMTQvZnJhZzplMDZlY2YzYjhmYmQ0ZjY1YjIzZGM2NTA1MTBlZDMyMy90ZXh0cmVnaW9uOmUwNmVjZjNiOGZiZDRmNjViMjNkYzY1MDUxMGVkMzIzXzQzOTgwNDY1MjMxMTY_d1832d61-078c-4909-9f28-53468aa4dad9">The Company&#x2019;s consolidated statement of cash flows includes the following as of March 31, 2021 and 2020 (in thousands):&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.777%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;125,407&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;72,606&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Short-term restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Long-term restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,379&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,379&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total cash, cash equivalents, and restricted cash shown in the consolidated statement of cash flows&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;126,786&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;74,264&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ied8d945ebce54ed8a4badfed477a64e8_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMTQvZnJhZzplMDZlY2YzYjhmYmQ0ZjY1YjIzZGM2NTA1MTBlZDMyMy90YWJsZTo1NTgwNmJlMzIyNWE0MGU2YTU2YjY2MzVlODQ4OTEzNi90YWJsZXJhbmdlOjU1ODA2YmUzMjI1YTQwZTZhNTZiNjYzNWU4NDg5MTM2XzItMS0xLTEtNjMyOA_8e15519f-ffbd-4c3f-89b9-a405b65d5aa6"
      unitRef="usd">125407000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="iff7e2530342c41bca8c84fce55f0cc6f_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMTQvZnJhZzplMDZlY2YzYjhmYmQ0ZjY1YjIzZGM2NTA1MTBlZDMyMy90YWJsZTo1NTgwNmJlMzIyNWE0MGU2YTU2YjY2MzVlODQ4OTEzNi90YWJsZXJhbmdlOjU1ODA2YmUzMjI1YTQwZTZhNTZiNjYzNWU4NDg5MTM2XzItMy0xLTEtNjMyOA_df9307d9-eae1-4901-8304-e8e0227a1802"
      unitRef="usd">72606000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue
      contextRef="ied8d945ebce54ed8a4badfed477a64e8_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMTQvZnJhZzplMDZlY2YzYjhmYmQ0ZjY1YjIzZGM2NTA1MTBlZDMyMy90YWJsZTo1NTgwNmJlMzIyNWE0MGU2YTU2YjY2MzVlODQ4OTEzNi90YWJsZXJhbmdlOjU1ODA2YmUzMjI1YTQwZTZhNTZiNjYzNWU4NDg5MTM2XzMtMS0xLTEtNjMyOA_18bfff23-e3f2-483b-8a40-35702f50810c"
      unitRef="usd">0</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue
      contextRef="iff7e2530342c41bca8c84fce55f0cc6f_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMTQvZnJhZzplMDZlY2YzYjhmYmQ0ZjY1YjIzZGM2NTA1MTBlZDMyMy90YWJsZTo1NTgwNmJlMzIyNWE0MGU2YTU2YjY2MzVlODQ4OTEzNi90YWJsZXJhbmdlOjU1ODA2YmUzMjI1YTQwZTZhNTZiNjYzNWU4NDg5MTM2XzMtMy0xLTEtNjMyOA_95f8878f-96a9-4edd-be4a-63f610ab6ec5"
      unitRef="usd">279000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent
      contextRef="ied8d945ebce54ed8a4badfed477a64e8_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMTQvZnJhZzplMDZlY2YzYjhmYmQ0ZjY1YjIzZGM2NTA1MTBlZDMyMy90YWJsZTo1NTgwNmJlMzIyNWE0MGU2YTU2YjY2MzVlODQ4OTEzNi90YWJsZXJhbmdlOjU1ODA2YmUzMjI1YTQwZTZhNTZiNjYzNWU4NDg5MTM2XzQtMS0xLTEtNjMyOA_f1178a41-8baf-4079-90c9-f5c4de9902a4"
      unitRef="usd">1379000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent
      contextRef="iff7e2530342c41bca8c84fce55f0cc6f_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMTQvZnJhZzplMDZlY2YzYjhmYmQ0ZjY1YjIzZGM2NTA1MTBlZDMyMy90YWJsZTo1NTgwNmJlMzIyNWE0MGU2YTU2YjY2MzVlODQ4OTEzNi90YWJsZXJhbmdlOjU1ODA2YmUzMjI1YTQwZTZhNTZiNjYzNWU4NDg5MTM2XzQtMy0xLTEtNjMyOA_31a5f761-9cba-4e12-8cae-7b9f5629b87d"
      unitRef="usd">1379000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ied8d945ebce54ed8a4badfed477a64e8_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMTQvZnJhZzplMDZlY2YzYjhmYmQ0ZjY1YjIzZGM2NTA1MTBlZDMyMy90YWJsZTo1NTgwNmJlMzIyNWE0MGU2YTU2YjY2MzVlODQ4OTEzNi90YWJsZXJhbmdlOjU1ODA2YmUzMjI1YTQwZTZhNTZiNjYzNWU4NDg5MTM2XzUtMS0xLTEtNjQxMQ_1a3ed0bd-6500-4ab4-b29f-791f9538c394"
      unitRef="usd">126786000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="iff7e2530342c41bca8c84fce55f0cc6f_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMTQvZnJhZzplMDZlY2YzYjhmYmQ0ZjY1YjIzZGM2NTA1MTBlZDMyMy90YWJsZTo1NTgwNmJlMzIyNWE0MGU2YTU2YjY2MzVlODQ4OTEzNi90YWJsZXJhbmdlOjU1ODA2YmUzMjI1YTQwZTZhNTZiNjYzNWU4NDg5MTM2XzUtMy0xLTEtNjMyOA_955b8802-40cf-433b-bd84-39b0039cd66e"
      unitRef="usd">74264000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock
      contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMTQvZnJhZzplMDZlY2YzYjhmYmQ0ZjY1YjIzZGM2NTA1MTBlZDMyMy90ZXh0cmVnaW9uOmUwNmVjZjNiOGZiZDRmNjViMjNkYzY1MDUxMGVkMzIzXzMzNzY_81847a8a-2a58-4100-8097-911a5589585d">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the Black-Scholes pricing model assumptions used to record the fair value of the warrant liability is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:87.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.596%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Expected life (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.73&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;101.13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i09c393762b464d30a19a24b55c2f5d20_I20210331"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMTQvZnJhZzplMDZlY2YzYjhmYmQ0ZjY1YjIzZGM2NTA1MTBlZDMyMy90YWJsZTo2MWI0ZTJhYTZhMGE0ZGFlYjgwMDE2NWVhOGRkMTE0Yy90YWJsZXJhbmdlOjYxYjRlMmFhNmEwYTRkYWViODAwMTY1ZWE4ZGQxMTRjXzItMy0xLTEtMA_0b46ee8b-2076-447d-8aa6-66519febf8df"
      unitRef="number">0.0035</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i173ee7e9fa254b81bffe4952d975b4c0_I20210331"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMTQvZnJhZzplMDZlY2YzYjhmYmQ0ZjY1YjIzZGM2NTA1MTBlZDMyMy90YWJsZTo2MWI0ZTJhYTZhMGE0ZGFlYjgwMDE2NWVhOGRkMTE0Yy90YWJsZXJhbmdlOjYxYjRlMmFhNmEwYTRkYWViODAwMTY1ZWE4ZGQxMTRjXzMtMy0xLTEtMA_4c4238f2-7e1c-481b-94c8-e1b6c113e2b8"
      unitRef="number">0</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="i519d4d01a3ff4f27a9efdf217e061704_I20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMTQvZnJhZzplMDZlY2YzYjhmYmQ0ZjY1YjIzZGM2NTA1MTBlZDMyMy90YWJsZTo2MWI0ZTJhYTZhMGE0ZGFlYjgwMDE2NWVhOGRkMTE0Yy90YWJsZXJhbmdlOjYxYjRlMmFhNmEwYTRkYWViODAwMTY1ZWE4ZGQxMTRjXzQtMy0xLTEtMA_29699220-663e-49d0-89c1-682329cdc926">P3Y8M23D</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="iba23f9d46a1d4b2f897e63f5c2c1d4bb_I20210331"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMTQvZnJhZzplMDZlY2YzYjhmYmQ0ZjY1YjIzZGM2NTA1MTBlZDMyMy90YWJsZTo2MWI0ZTJhYTZhMGE0ZGFlYjgwMDE2NWVhOGRkMTE0Yy90YWJsZXJhbmdlOjYxYjRlMmFhNmEwYTRkYWViODAwMTY1ZWE4ZGQxMTRjXzUtMy0xLTEtMA_6e4fffc1-5314-489c-9c2b-d51500063c7e"
      unitRef="number">1.0113</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock
      contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMTQvZnJhZzplMDZlY2YzYjhmYmQ0ZjY1YjIzZGM2NTA1MTBlZDMyMy90ZXh0cmVnaW9uOmUwNmVjZjNiOGZiZDRmNjViMjNkYzY1MDUxMGVkMzIzXzMzNzc_df2f2b56-5228-463c-bd84-5fcf185d4404">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table reflects a roll-forward of fair value for the Company&#x2019;s Level 3 warrant liabilities (see Note 10), for the three months ended March 31, 2021 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:87.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.596%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Warrant liabilities&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fair value as of December 31, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;28,708&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Change in fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;16,747&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fair value as of March 31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;45,455&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i118f57dc685b47c8b1b5f190c4eed731_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMTQvZnJhZzplMDZlY2YzYjhmYmQ0ZjY1YjIzZGM2NTA1MTBlZDMyMy90YWJsZTo5MWEyZDlkMTU0ZTg0MDMxYjI3MDE3OTY4NmNhMzY5OC90YWJsZXJhbmdlOjkxYTJkOWQxNTRlODQwMzFiMjcwMTc5Njg2Y2EzNjk4XzEtMS0xLTEtMA_44823a44-fb59-4c29-a4f3-fe2daf207a7f"
      unitRef="usd">28708000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="icf08fe145a214d8bacaa57c857186979_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMTQvZnJhZzplMDZlY2YzYjhmYmQ0ZjY1YjIzZGM2NTA1MTBlZDMyMy90YWJsZTo5MWEyZDlkMTU0ZTg0MDMxYjI3MDE3OTY4NmNhMzY5OC90YWJsZXJhbmdlOjkxYTJkOWQxNTRlODQwMzFiMjcwMTc5Njg2Y2EzNjk4XzMtMS0xLTEtMA_1ce910da-a948-48a9-a29d-46d8e0db68d4"
      unitRef="usd">16747000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="id99ce4003b574f658d3b62852041d661_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMTQvZnJhZzplMDZlY2YzYjhmYmQ0ZjY1YjIzZGM2NTA1MTBlZDMyMy90YWJsZTo5MWEyZDlkMTU0ZTg0MDMxYjI3MDE3OTY4NmNhMzY5OC90YWJsZXJhbmdlOjkxYTJkOWQxNTRlODQwMzFiMjcwMTc5Njg2Y2EzNjk4XzQtMS0xLTEtMA_c6378e09-baaa-4b5e-a98a-bd5474e359c7"
      unitRef="usd">45455000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMjAvZnJhZzpjZTg3MDdlOTAzOWE0MTg0OGE0MzkyZDBhOTgzYTBlMi90ZXh0cmVnaW9uOmNlODcwN2U5MDM5YTQxODQ4YTQzOTJkMGE5ODNhMGUyXzUyNQ_32fb5140-d4c8-464b-a7e4-680ab6ea5ee9">Property and Equipment&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment consists of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.777%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Laboratory equipment&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,429&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,427&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Computer equipment and software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;694&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;532&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;327&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;327&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Office equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;163&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;163&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Construction in process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;163&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,681&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Less accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4,380)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4,255)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,301&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,395&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation expense was $0.1 million and $0.2 million for the three months ended March 31, 2021 and 2020, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMjAvZnJhZzpjZTg3MDdlOTAzOWE0MTg0OGE0MzkyZDBhOTgzYTBlMi90ZXh0cmVnaW9uOmNlODcwN2U5MDM5YTQxODQ4YTQzOTJkMGE5ODNhMGUyXzUyOQ_1cefffca-624e-4f27-8708-cea53cdc7d20">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment consists of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.777%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Laboratory equipment&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,429&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,427&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Computer equipment and software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;694&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;532&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;327&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;327&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Office equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;163&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;163&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Construction in process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;163&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,681&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Less accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4,380)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4,255)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,301&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,395&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i7a27424e288a444c8c666f3eeb249646_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMjAvZnJhZzpjZTg3MDdlOTAzOWE0MTg0OGE0MzkyZDBhOTgzYTBlMi90YWJsZTphODRkYWQzMTcwMTE0OWIwYTcwYWQ2ZGFhODMzYzIwMC90YWJsZXJhbmdlOmE4NGRhZDMxNzAxMTQ5YjBhNzBhZDZkYWE4MzNjMjAwXzItMS0xLTEtMA_ce64baea-8ac2-46f1-968f-cf09e6d94a5b"
      unitRef="usd">4429000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ib5f80b2977824ab9ba0203bc6a11a58e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMjAvZnJhZzpjZTg3MDdlOTAzOWE0MTg0OGE0MzkyZDBhOTgzYTBlMi90YWJsZTphODRkYWQzMTcwMTE0OWIwYTcwYWQ2ZGFhODMzYzIwMC90YWJsZXJhbmdlOmE4NGRhZDMxNzAxMTQ5YjBhNzBhZDZkYWE4MzNjMjAwXzItMy0xLTEtMA_8bfd167f-dff0-450c-88e9-b14135716d6d"
      unitRef="usd">4427000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ia943ee9b105d42cba901af1e6a454c40_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMjAvZnJhZzpjZTg3MDdlOTAzOWE0MTg0OGE0MzkyZDBhOTgzYTBlMi90YWJsZTphODRkYWQzMTcwMTE0OWIwYTcwYWQ2ZGFhODMzYzIwMC90YWJsZXJhbmdlOmE4NGRhZDMxNzAxMTQ5YjBhNzBhZDZkYWE4MzNjMjAwXzMtMS0xLTEtMA_1a2b94f9-1f40-40bb-adb9-9628280f5a2e"
      unitRef="usd">694000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i56d15e17ec144f96957c4fb601aba227_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMjAvZnJhZzpjZTg3MDdlOTAzOWE0MTg0OGE0MzkyZDBhOTgzYTBlMi90YWJsZTphODRkYWQzMTcwMTE0OWIwYTcwYWQ2ZGFhODMzYzIwMC90YWJsZXJhbmdlOmE4NGRhZDMxNzAxMTQ5YjBhNzBhZDZkYWE4MzNjMjAwXzMtMy0xLTEtMA_ec64fb99-c58d-44a3-a021-b4aa72cf68e5"
      unitRef="usd">532000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="iad5e74cc7867456d841ede0490c532e2_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMjAvZnJhZzpjZTg3MDdlOTAzOWE0MTg0OGE0MzkyZDBhOTgzYTBlMi90YWJsZTphODRkYWQzMTcwMTE0OWIwYTcwYWQ2ZGFhODMzYzIwMC90YWJsZXJhbmdlOmE4NGRhZDMxNzAxMTQ5YjBhNzBhZDZkYWE4MzNjMjAwXzQtMS0xLTEtMA_067ce12a-d716-4be3-86ee-68b15f40ad42"
      unitRef="usd">38000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i7b0035fcfb7b4ad5a466a8875b9526aa_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMjAvZnJhZzpjZTg3MDdlOTAzOWE0MTg0OGE0MzkyZDBhOTgzYTBlMi90YWJsZTphODRkYWQzMTcwMTE0OWIwYTcwYWQ2ZGFhODMzYzIwMC90YWJsZXJhbmdlOmE4NGRhZDMxNzAxMTQ5YjBhNzBhZDZkYWE4MzNjMjAwXzQtMy0xLTEtMA_08342aa6-7503-4d12-85c4-abf7bbe53b8e"
      unitRef="usd">38000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i071771a6ccb1419ca97dd0dfaf4f2526_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMjAvZnJhZzpjZTg3MDdlOTAzOWE0MTg0OGE0MzkyZDBhOTgzYTBlMi90YWJsZTphODRkYWQzMTcwMTE0OWIwYTcwYWQ2ZGFhODMzYzIwMC90YWJsZXJhbmdlOmE4NGRhZDMxNzAxMTQ5YjBhNzBhZDZkYWE4MzNjMjAwXzUtMS0xLTEtMA_74a31339-096c-4bb1-b5c5-7c99ed039da8"
      unitRef="usd">327000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i5879070723fe4b008e2b38909e05fbe9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMjAvZnJhZzpjZTg3MDdlOTAzOWE0MTg0OGE0MzkyZDBhOTgzYTBlMi90YWJsZTphODRkYWQzMTcwMTE0OWIwYTcwYWQ2ZGFhODMzYzIwMC90YWJsZXJhbmdlOmE4NGRhZDMxNzAxMTQ5YjBhNzBhZDZkYWE4MzNjMjAwXzUtMy0xLTEtMA_3e5cb87b-1aea-4566-b2fb-6a15ce331feb"
      unitRef="usd">327000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ibf4df6273b36402f8f2fc2b5d47437bd_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMjAvZnJhZzpjZTg3MDdlOTAzOWE0MTg0OGE0MzkyZDBhOTgzYTBlMi90YWJsZTphODRkYWQzMTcwMTE0OWIwYTcwYWQ2ZGFhODMzYzIwMC90YWJsZXJhbmdlOmE4NGRhZDMxNzAxMTQ5YjBhNzBhZDZkYWE4MzNjMjAwXzYtMS0xLTEtMA_ebbe85a0-6404-48aa-9a47-109a69e8a6db"
      unitRef="usd">163000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i44f41827807b4780adcd3350fc42ab49_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMjAvZnJhZzpjZTg3MDdlOTAzOWE0MTg0OGE0MzkyZDBhOTgzYTBlMi90YWJsZTphODRkYWQzMTcwMTE0OWIwYTcwYWQ2ZGFhODMzYzIwMC90YWJsZXJhbmdlOmE4NGRhZDMxNzAxMTQ5YjBhNzBhZDZkYWE4MzNjMjAwXzYtMy0xLTEtMA_996eca09-d314-44ad-8477-70653c79e43b"
      unitRef="usd">163000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i62030e264c0744b68da329d325fca573_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMjAvZnJhZzpjZTg3MDdlOTAzOWE0MTg0OGE0MzkyZDBhOTgzYTBlMi90YWJsZTphODRkYWQzMTcwMTE0OWIwYTcwYWQ2ZGFhODMzYzIwMC90YWJsZXJhbmdlOmE4NGRhZDMxNzAxMTQ5YjBhNzBhZDZkYWE4MzNjMjAwXzctMS0xLTEtMA_305ec19d-cef0-4b87-a2ce-6680fd215a69"
      unitRef="usd">30000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i42237c8333f54aaa809730ac386b4ae3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMjAvZnJhZzpjZTg3MDdlOTAzOWE0MTg0OGE0MzkyZDBhOTgzYTBlMi90YWJsZTphODRkYWQzMTcwMTE0OWIwYTcwYWQ2ZGFhODMzYzIwMC90YWJsZXJhbmdlOmE4NGRhZDMxNzAxMTQ5YjBhNzBhZDZkYWE4MzNjMjAwXzctMy0xLTEtMA_a57b95a6-d908-4f11-8856-32c327e41aa0"
      unitRef="usd">163000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ied8d945ebce54ed8a4badfed477a64e8_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMjAvZnJhZzpjZTg3MDdlOTAzOWE0MTg0OGE0MzkyZDBhOTgzYTBlMi90YWJsZTphODRkYWQzMTcwMTE0OWIwYTcwYWQ2ZGFhODMzYzIwMC90YWJsZXJhbmdlOmE4NGRhZDMxNzAxMTQ5YjBhNzBhZDZkYWE4MzNjMjAwXzgtMS0xLTEtMA_3458afe6-f3f0-4d5f-b041-6c487341a47d"
      unitRef="usd">5681000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ib56f1adc867e406ca7face50c5da1c9c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMjAvZnJhZzpjZTg3MDdlOTAzOWE0MTg0OGE0MzkyZDBhOTgzYTBlMi90YWJsZTphODRkYWQzMTcwMTE0OWIwYTcwYWQ2ZGFhODMzYzIwMC90YWJsZXJhbmdlOmE4NGRhZDMxNzAxMTQ5YjBhNzBhZDZkYWE4MzNjMjAwXzgtMy0xLTEtMA_da868ab5-ff9f-4674-89c4-538e4e818ca7"
      unitRef="usd">5650000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="ied8d945ebce54ed8a4badfed477a64e8_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMjAvZnJhZzpjZTg3MDdlOTAzOWE0MTg0OGE0MzkyZDBhOTgzYTBlMi90YWJsZTphODRkYWQzMTcwMTE0OWIwYTcwYWQ2ZGFhODMzYzIwMC90YWJsZXJhbmdlOmE4NGRhZDMxNzAxMTQ5YjBhNzBhZDZkYWE4MzNjMjAwXzktMS0xLTEtMA_058d6704-605b-461a-8769-703a68eba474"
      unitRef="usd">4380000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="ib56f1adc867e406ca7face50c5da1c9c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMjAvZnJhZzpjZTg3MDdlOTAzOWE0MTg0OGE0MzkyZDBhOTgzYTBlMi90YWJsZTphODRkYWQzMTcwMTE0OWIwYTcwYWQ2ZGFhODMzYzIwMC90YWJsZXJhbmdlOmE4NGRhZDMxNzAxMTQ5YjBhNzBhZDZkYWE4MzNjMjAwXzktMy0xLTEtMA_a0f7ae57-fb7e-4540-89a8-6e4fb699c6ad"
      unitRef="usd">4255000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ied8d945ebce54ed8a4badfed477a64e8_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMjAvZnJhZzpjZTg3MDdlOTAzOWE0MTg0OGE0MzkyZDBhOTgzYTBlMi90YWJsZTphODRkYWQzMTcwMTE0OWIwYTcwYWQ2ZGFhODMzYzIwMC90YWJsZXJhbmdlOmE4NGRhZDMxNzAxMTQ5YjBhNzBhZDZkYWE4MzNjMjAwXzEwLTEtMS0xLTA_2e6b95e4-26c2-472b-a701-5b51d693afd4"
      unitRef="usd">1301000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ib56f1adc867e406ca7face50c5da1c9c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMjAvZnJhZzpjZTg3MDdlOTAzOWE0MTg0OGE0MzkyZDBhOTgzYTBlMi90YWJsZTphODRkYWQzMTcwMTE0OWIwYTcwYWQ2ZGFhODMzYzIwMC90YWJsZXJhbmdlOmE4NGRhZDMxNzAxMTQ5YjBhNzBhZDZkYWE4MzNjMjAwXzEwLTMtMS0xLTA_7cb7dd76-e6c9-4d28-87b6-22afbf8f33c8"
      unitRef="usd">1395000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation
      contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMjAvZnJhZzpjZTg3MDdlOTAzOWE0MTg0OGE0MzkyZDBhOTgzYTBlMi90ZXh0cmVnaW9uOmNlODcwN2U5MDM5YTQxODQ4YTQzOTJkMGE5ODNhMGUyXzEyNA_d5bea276-b5fd-4e70-9c2f-efe92a43b490"
      unitRef="usd">100000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i824a5b33f908426bad016f0eded844db_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMjAvZnJhZzpjZTg3MDdlOTAzOWE0MTg0OGE0MzkyZDBhOTgzYTBlMi90ZXh0cmVnaW9uOmNlODcwN2U5MDM5YTQxODQ4YTQzOTJkMGE5ODNhMGUyXzEzNg_c3970fc7-341e-4e66-964a-6c382fcb62f7"
      unitRef="usd">200000</us-gaap:Depreciation>
    <us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock
      contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMjMvZnJhZzowZGE3MjJkNTU3NmQ0MjA2ODgyODA3Y2NhMmJlOTUwOC90ZXh0cmVnaW9uOjBkYTcyMmQ1NTc2ZDQyMDY4ODI4MDdjY2EyYmU5NTA4Xzkw_f92835b3-ea10-4100-8927-78b2678798a4">Accrued Expenses&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expenses consist of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.777%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Payroll and employee related expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,840&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,049&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Collaboration and licensing&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accrued patent fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;471&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;534&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accrued external research and development costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,010&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,029&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accrued professional and consulting services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;802&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;798&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accrued interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;204&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,847&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,146&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMjMvZnJhZzowZGE3MjJkNTU3NmQ0MjA2ODgyODA3Y2NhMmJlOTUwOC90ZXh0cmVnaW9uOjBkYTcyMmQ1NTc2ZDQyMDY4ODI4MDdjY2EyYmU5NTA4Xzk0_2c312cba-7630-42fc-8be7-1dd7dff86c3e">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expenses consist of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.777%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Payroll and employee related expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,840&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,049&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Collaboration and licensing&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accrued patent fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;471&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;534&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accrued external research and development costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,010&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,029&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accrued professional and consulting services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;802&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;798&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accrued interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;204&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,847&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,146&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="ied8d945ebce54ed8a4badfed477a64e8_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMjMvZnJhZzowZGE3MjJkNTU3NmQ0MjA2ODgyODA3Y2NhMmJlOTUwOC90YWJsZTplNmMxZTVmZTQzYzQ0MWY1YWJjZGU4OGJhYTFlMzBkNi90YWJsZXJhbmdlOmU2YzFlNWZlNDNjNDQxZjVhYmNkZTg4YmFhMWUzMGQ2XzItMS0xLTEtMA_1dcab7ec-7db8-47cb-9369-ae043a2f12fc"
      unitRef="usd">1840000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="ib56f1adc867e406ca7face50c5da1c9c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMjMvZnJhZzowZGE3MjJkNTU3NmQ0MjA2ODgyODA3Y2NhMmJlOTUwOC90YWJsZTplNmMxZTVmZTQzYzQ0MWY1YWJjZGU4OGJhYTFlMzBkNi90YWJsZXJhbmdlOmU2YzFlNWZlNDNjNDQxZjVhYmNkZTg4YmFhMWUzMGQ2XzItMy0xLTEtMA_6c80bee6-9624-4391-9506-7a01fdbd147e"
      unitRef="usd">3049000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <selb:AccruedCollaborationandLicensing
      contextRef="ied8d945ebce54ed8a4badfed477a64e8_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMjMvZnJhZzowZGE3MjJkNTU3NmQ0MjA2ODgyODA3Y2NhMmJlOTUwOC90YWJsZTplNmMxZTVmZTQzYzQ0MWY1YWJjZGU4OGJhYTFlMzBkNi90YWJsZXJhbmdlOmU2YzFlNWZlNDNjNDQxZjVhYmNkZTg4YmFhMWUzMGQ2XzQtMS0xLTEtMA_b399c8fc-a5dc-4cca-95b9-f15cd6b62770"
      unitRef="usd">1350000</selb:AccruedCollaborationandLicensing>
    <selb:AccruedCollaborationandLicensing
      contextRef="ib56f1adc867e406ca7face50c5da1c9c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMjMvZnJhZzowZGE3MjJkNTU3NmQ0MjA2ODgyODA3Y2NhMmJlOTUwOC90YWJsZTplNmMxZTVmZTQzYzQ0MWY1YWJjZGU4OGJhYTFlMzBkNi90YWJsZXJhbmdlOmU2YzFlNWZlNDNjNDQxZjVhYmNkZTg4YmFhMWUzMGQ2XzQtMy0xLTEtMA_dd48c3a9-b7a3-4600-813d-1ec76ad5b9a0"
      unitRef="usd">1350000</selb:AccruedCollaborationandLicensing>
    <selb:AccruedPatentFeesCurrent
      contextRef="ied8d945ebce54ed8a4badfed477a64e8_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMjMvZnJhZzowZGE3MjJkNTU3NmQ0MjA2ODgyODA3Y2NhMmJlOTUwOC90YWJsZTplNmMxZTVmZTQzYzQ0MWY1YWJjZGU4OGJhYTFlMzBkNi90YWJsZXJhbmdlOmU2YzFlNWZlNDNjNDQxZjVhYmNkZTg4YmFhMWUzMGQ2XzUtMS0xLTEtMA_359a2c59-8a45-4b1f-970e-f5cf07a9995c"
      unitRef="usd">471000</selb:AccruedPatentFeesCurrent>
    <selb:AccruedPatentFeesCurrent
      contextRef="ib56f1adc867e406ca7face50c5da1c9c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMjMvZnJhZzowZGE3MjJkNTU3NmQ0MjA2ODgyODA3Y2NhMmJlOTUwOC90YWJsZTplNmMxZTVmZTQzYzQ0MWY1YWJjZGU4OGJhYTFlMzBkNi90YWJsZXJhbmdlOmU2YzFlNWZlNDNjNDQxZjVhYmNkZTg4YmFhMWUzMGQ2XzUtMy0xLTEtMA_de6e16f7-ac15-4d3f-b8ca-8270d28cec84"
      unitRef="usd">534000</selb:AccruedPatentFeesCurrent>
    <selb:AccruedResearchAndDevelopmentCostsCurrent
      contextRef="ied8d945ebce54ed8a4badfed477a64e8_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMjMvZnJhZzowZGE3MjJkNTU3NmQ0MjA2ODgyODA3Y2NhMmJlOTUwOC90YWJsZTplNmMxZTVmZTQzYzQ0MWY1YWJjZGU4OGJhYTFlMzBkNi90YWJsZXJhbmdlOmU2YzFlNWZlNDNjNDQxZjVhYmNkZTg4YmFhMWUzMGQ2XzYtMS0xLTEtMA_876aff8d-1560-4afc-9d4e-52bbc80b5dfc"
      unitRef="usd">2010000</selb:AccruedResearchAndDevelopmentCostsCurrent>
    <selb:AccruedResearchAndDevelopmentCostsCurrent
      contextRef="ib56f1adc867e406ca7face50c5da1c9c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMjMvZnJhZzowZGE3MjJkNTU3NmQ0MjA2ODgyODA3Y2NhMmJlOTUwOC90YWJsZTplNmMxZTVmZTQzYzQ0MWY1YWJjZGU4OGJhYTFlMzBkNi90YWJsZXJhbmdlOmU2YzFlNWZlNDNjNDQxZjVhYmNkZTg4YmFhMWUzMGQ2XzYtMy0xLTEtMA_b18a82ea-fdde-4fc2-b0ed-aa48bb629ec7"
      unitRef="usd">2029000</selb:AccruedResearchAndDevelopmentCostsCurrent>
    <selb:AccruedAuditFeesCurrent
      contextRef="ied8d945ebce54ed8a4badfed477a64e8_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMjMvZnJhZzowZGE3MjJkNTU3NmQ0MjA2ODgyODA3Y2NhMmJlOTUwOC90YWJsZTplNmMxZTVmZTQzYzQ0MWY1YWJjZGU4OGJhYTFlMzBkNi90YWJsZXJhbmdlOmU2YzFlNWZlNDNjNDQxZjVhYmNkZTg4YmFhMWUzMGQ2XzctMS0xLTEtMA_8e93f340-1a4f-4bbe-9f03-37a00ec057a7"
      unitRef="usd">802000</selb:AccruedAuditFeesCurrent>
    <selb:AccruedAuditFeesCurrent
      contextRef="ib56f1adc867e406ca7face50c5da1c9c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMjMvZnJhZzowZGE3MjJkNTU3NmQ0MjA2ODgyODA3Y2NhMmJlOTUwOC90YWJsZTplNmMxZTVmZTQzYzQ0MWY1YWJjZGU4OGJhYTFlMzBkNi90YWJsZXJhbmdlOmU2YzFlNWZlNDNjNDQxZjVhYmNkZTg4YmFhMWUzMGQ2XzctMy0xLTEtMA_400250d0-1440-443f-8f79-5442bbaa3ce4"
      unitRef="usd">798000</selb:AccruedAuditFeesCurrent>
    <selb:AccruedInterestCurrent
      contextRef="ied8d945ebce54ed8a4badfed477a64e8_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMjMvZnJhZzowZGE3MjJkNTU3NmQ0MjA2ODgyODA3Y2NhMmJlOTUwOC90YWJsZTplNmMxZTVmZTQzYzQ0MWY1YWJjZGU4OGJhYTFlMzBkNi90YWJsZXJhbmdlOmU2YzFlNWZlNDNjNDQxZjVhYmNkZTg4YmFhMWUzMGQ2XzktMS0xLTEtMA_765153f2-4637-4de5-abc0-7a09991773ec"
      unitRef="usd">170000</selb:AccruedInterestCurrent>
    <selb:AccruedInterestCurrent
      contextRef="ib56f1adc867e406ca7face50c5da1c9c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMjMvZnJhZzowZGE3MjJkNTU3NmQ0MjA2ODgyODA3Y2NhMmJlOTUwOC90YWJsZTplNmMxZTVmZTQzYzQ0MWY1YWJjZGU4OGJhYTFlMzBkNi90YWJsZXJhbmdlOmU2YzFlNWZlNDNjNDQxZjVhYmNkZTg4YmFhMWUzMGQ2XzktMy0xLTEtMA_0166f569-ccc6-4955-bc4d-6b52751bcc0b"
      unitRef="usd">170000</selb:AccruedInterestCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="ied8d945ebce54ed8a4badfed477a64e8_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMjMvZnJhZzowZGE3MjJkNTU3NmQ0MjA2ODgyODA3Y2NhMmJlOTUwOC90YWJsZTplNmMxZTVmZTQzYzQ0MWY1YWJjZGU4OGJhYTFlMzBkNi90YWJsZXJhbmdlOmU2YzFlNWZlNDNjNDQxZjVhYmNkZTg4YmFhMWUzMGQ2XzExLTEtMS0xLTA_987f27a1-876c-4725-8f9d-d267a1937cbc"
      unitRef="usd">204000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="ib56f1adc867e406ca7face50c5da1c9c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMjMvZnJhZzowZGE3MjJkNTU3NmQ0MjA2ODgyODA3Y2NhMmJlOTUwOC90YWJsZTplNmMxZTVmZTQzYzQ0MWY1YWJjZGU4OGJhYTFlMzBkNi90YWJsZXJhbmdlOmU2YzFlNWZlNDNjNDQxZjVhYmNkZTg4YmFhMWUzMGQ2XzExLTMtMS0xLTA_c5486622-0b67-46b2-b2a0-d9623a43e606"
      unitRef="usd">216000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="ied8d945ebce54ed8a4badfed477a64e8_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMjMvZnJhZzowZGE3MjJkNTU3NmQ0MjA2ODgyODA3Y2NhMmJlOTUwOC90YWJsZTplNmMxZTVmZTQzYzQ0MWY1YWJjZGU4OGJhYTFlMzBkNi90YWJsZXJhbmdlOmU2YzFlNWZlNDNjNDQxZjVhYmNkZTg4YmFhMWUzMGQ2XzEyLTEtMS0xLTA_cf994152-b0f2-4986-af8c-90b6350a8f33"
      unitRef="usd">6847000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="ib56f1adc867e406ca7face50c5da1c9c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMjMvZnJhZzowZGE3MjJkNTU3NmQ0MjA2ODgyODA3Y2NhMmJlOTUwOC90YWJsZTplNmMxZTVmZTQzYzQ0MWY1YWJjZGU4OGJhYTFlMzBkNi90YWJsZXJhbmdlOmU2YzFlNWZlNDNjNDQxZjVhYmNkZTg4YmFhMWUzMGQ2XzEyLTMtMS0xLTA_8974aad1-6f60-4964-b83f-4e6d901ccaab"
      unitRef="usd">8146000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMjkvZnJhZzo0OTNlMjJkZjg3YjE0MTcyYjQ5NWU1OTUxZWY5NWFlMS90ZXh0cmVnaW9uOjQ5M2UyMmRmODdiMTQxNzJiNDk1ZTU5NTFlZjk1YWUxXzY1NDE_ad602ce8-5c8b-438c-9886-6d6be366cbb3">Leases &lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;65 Grove Street Lease&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 2019, the Company entered into a lease for 25,078 square feet of laboratory and office space located at 65 Grove Street, Watertown, Massachusetts, or the Headquarters Lease. As part of the Headquarters Lease, the Company incurred $0.8 million in non-reimbursable construction costs. The lease began in March 2020, consistent with when the Company took control of the office space, and the lease term is 8 years. The discount rate of 8.9% was determined based on the Company&#x2019;s incremental borrowing rate adjusted for the lease term including any reasonably certain renewal periods. In connection with the Headquarters Lease, the Company secured a letter of credit from Silicon Valley Bank, or SVB, for $1.4 million, recognized as long-term restricted cash, as of March 31, 2021 and December 31, 2020, respectively, which automatically renews each year.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Moscow, Russia Lease&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has a month-to-month facility agreement for its Moscow, Russia office. Rent expense is recognized as incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March 31, 2021 and December 31, 2020, the components of the operating leases were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.484%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Right-of-use asset, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10,676&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10,948&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Current operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;942&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;908&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Non-current operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9,403&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9,647&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10,345&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10,555&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the three months ended March 31, 2021 and 2020 the components of lease costs were as follows (in thousands):  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.484%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;444&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;472&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Variable lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Short-term lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;735&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;673&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The maturity of the Company&#x2019;s operating lease liabilities as of March 31, 2021 were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:87.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.596%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2021 (remainder)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,368&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,866&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,922&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,980&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,039&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,945&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Total future minimum lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14,120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Less imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,775&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Total operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10,345&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The supplemental disclosure for the statement of cash flows related to operating leases were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.777%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.449%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.451%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;444&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;487&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other than the initial recording of the right-of-use asset and lease liability for the Headquarters Lease, which is non-cash, the changes in the Company&#x2019;s right-of-use asset and lease liability for the three months ended March 31, 2021 and 2020 are reflected in the non-cash lease expense and accrued expenses and other liabilities, respectively, in the consolidated statements of cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following summarizes additional information related to operating leases:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.484%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Weighted-average remaining lease term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.1 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.0 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Weighted-average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:AreaOfRealEstateProperty
      contextRef="i8a6242358159403bbb0d1d272fafb3bc_I20190731"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMjkvZnJhZzo0OTNlMjJkZjg3YjE0MTcyYjQ5NWU1OTUxZWY5NWFlMS90ZXh0cmVnaW9uOjQ5M2UyMmRmODdiMTQxNzJiNDk1ZTU5NTFlZjk1YWUxXzQ0NzI_c6ed3143-5277-455c-b448-e5e8a0a7544d"
      unitRef="sqft">25078</us-gaap:AreaOfRealEstateProperty>
    <us-gaap:LeaseCost
      contextRef="i3fe0080183054a06885fd48ac35a21f1_D20190701-20190731"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMjkvZnJhZzo0OTNlMjJkZjg3YjE0MTcyYjQ5NWU1OTUxZWY5NWFlMS90ZXh0cmVnaW9uOjQ5M2UyMmRmODdiMTQxNzJiNDk1ZTU5NTFlZjk1YWUxXzQ2NTU_7b38a771-9705-4d46-9462-d3e5577fc082"
      unitRef="usd">800000</us-gaap:LeaseCost>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="i8a6242358159403bbb0d1d272fafb3bc_I20190731"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMjkvZnJhZzo0OTNlMjJkZjg3YjE0MTcyYjQ5NWU1OTUxZWY5NWFlMS90ZXh0cmVnaW9uOjQ5M2UyMmRmODdiMTQxNzJiNDk1ZTU5NTFlZjk1YWUxXzQ4MTc_a177f3a1-aa67-4e0a-b43a-ba385f7f9bfa">P8Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="ied8d945ebce54ed8a4badfed477a64e8_I20210331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMjkvZnJhZzo0OTNlMjJkZjg3YjE0MTcyYjQ5NWU1OTUxZWY5NWFlMS90ZXh0cmVnaW9uOjQ5M2UyMmRmODdiMTQxNzJiNDk1ZTU5NTFlZjk1YWUxXzQ4NDg_5cd2f345-3254-4296-9ab3-da14123109b5"
      unitRef="number">0.089</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="i98e030263a7d4c9fbb0733a011655549_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMjkvZnJhZzo0OTNlMjJkZjg3YjE0MTcyYjQ5NWU1OTUxZWY5NWFlMS90ZXh0cmVnaW9uOjQ5M2UyMmRmODdiMTQxNzJiNDk1ZTU5NTFlZjk1YWUxXzUxOTI_114ea5ac-3ab1-4275-885f-30b765b493a5"
      unitRef="usd">1400000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="i012a579920bb42578031fbbc9df1dfd2_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMjkvZnJhZzo0OTNlMjJkZjg3YjE0MTcyYjQ5NWU1OTUxZWY5NWFlMS90ZXh0cmVnaW9uOjQ5M2UyMmRmODdiMTQxNzJiNDk1ZTU5NTFlZjk1YWUxXzUxOTI_7f56b61a-5c03-4c88-aab9-80219734e97e"
      unitRef="usd">1400000</us-gaap:RestrictedCashNoncurrent>
    <selb:LesseeComponentsOfOperatingLeaseTableTextBlock
      contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMjkvZnJhZzo0OTNlMjJkZjg3YjE0MTcyYjQ5NWU1OTUxZWY5NWFlMS90ZXh0cmVnaW9uOjQ5M2UyMmRmODdiMTQxNzJiNDk1ZTU5NTFlZjk1YWUxXzY1Mzg_05899796-ed84-4703-bf94-f35d6c544d7f">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March 31, 2021 and December 31, 2020, the components of the operating leases were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.484%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Right-of-use asset, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10,676&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10,948&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Current operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;942&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;908&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Non-current operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9,403&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9,647&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10,345&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10,555&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</selb:LesseeComponentsOfOperatingLeaseTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="ied8d945ebce54ed8a4badfed477a64e8_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMjkvZnJhZzo0OTNlMjJkZjg3YjE0MTcyYjQ5NWU1OTUxZWY5NWFlMS90YWJsZToxNzE2NTY3MWY0YWU0MDk0YWRiZjE5YWZhMDExOGI0NC90YWJsZXJhbmdlOjE3MTY1NjcxZjRhZTQwOTRhZGJmMTlhZmEwMTE4YjQ0XzMtNS0xLTEtMA_ac32ab21-f367-4bab-9d6a-f8fd20b8d81f"
      unitRef="usd">10676000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="ib56f1adc867e406ca7face50c5da1c9c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMjkvZnJhZzo0OTNlMjJkZjg3YjE0MTcyYjQ5NWU1OTUxZWY5NWFlMS90YWJsZToxNzE2NTY3MWY0YWU0MDk0YWRiZjE5YWZhMDExOGI0NC90YWJsZXJhbmdlOjE3MTY1NjcxZjRhZTQwOTRhZGJmMTlhZmEwMTE4YjQ0XzMtNy0xLTEtMA_327d6408-36b1-4ea6-997b-483ba61e89b1"
      unitRef="usd">10948000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="ied8d945ebce54ed8a4badfed477a64e8_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMjkvZnJhZzo0OTNlMjJkZjg3YjE0MTcyYjQ5NWU1OTUxZWY5NWFlMS90YWJsZToxNzE2NTY3MWY0YWU0MDk0YWRiZjE5YWZhMDExOGI0NC90YWJsZXJhbmdlOjE3MTY1NjcxZjRhZTQwOTRhZGJmMTlhZmEwMTE4YjQ0XzYtNS0xLTEtMA_d7356727-a0fe-42ad-a93d-c6834ecbdd8c"
      unitRef="usd">942000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="ib56f1adc867e406ca7face50c5da1c9c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMjkvZnJhZzo0OTNlMjJkZjg3YjE0MTcyYjQ5NWU1OTUxZWY5NWFlMS90YWJsZToxNzE2NTY3MWY0YWU0MDk0YWRiZjE5YWZhMDExOGI0NC90YWJsZXJhbmdlOjE3MTY1NjcxZjRhZTQwOTRhZGJmMTlhZmEwMTE4YjQ0XzYtNy0xLTEtMA_f57d6836-9cee-40cc-b33b-bf89c7d70c73"
      unitRef="usd">908000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="ied8d945ebce54ed8a4badfed477a64e8_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMjkvZnJhZzo0OTNlMjJkZjg3YjE0MTcyYjQ5NWU1OTUxZWY5NWFlMS90YWJsZToxNzE2NTY3MWY0YWU0MDk0YWRiZjE5YWZhMDExOGI0NC90YWJsZXJhbmdlOjE3MTY1NjcxZjRhZTQwOTRhZGJmMTlhZmEwMTE4YjQ0XzctNS0xLTEtMA_c0984b47-fd99-4275-ba6e-7a628eeb801c"
      unitRef="usd">9403000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="ib56f1adc867e406ca7face50c5da1c9c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMjkvZnJhZzo0OTNlMjJkZjg3YjE0MTcyYjQ5NWU1OTUxZWY5NWFlMS90YWJsZToxNzE2NTY3MWY0YWU0MDk0YWRiZjE5YWZhMDExOGI0NC90YWJsZXJhbmdlOjE3MTY1NjcxZjRhZTQwOTRhZGJmMTlhZmEwMTE4YjQ0XzctNy0xLTEtMA_d6296eac-5f4c-4412-b967-22c5bff29462"
      unitRef="usd">9647000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiability
      contextRef="ied8d945ebce54ed8a4badfed477a64e8_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMjkvZnJhZzo0OTNlMjJkZjg3YjE0MTcyYjQ5NWU1OTUxZWY5NWFlMS90YWJsZToxNzE2NTY3MWY0YWU0MDk0YWRiZjE5YWZhMDExOGI0NC90YWJsZXJhbmdlOjE3MTY1NjcxZjRhZTQwOTRhZGJmMTlhZmEwMTE4YjQ0XzgtNS0xLTEtMA_6caa2967-337f-4a9a-8b00-3b1b81062b86"
      unitRef="usd">10345000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiability
      contextRef="ib56f1adc867e406ca7face50c5da1c9c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMjkvZnJhZzo0OTNlMjJkZjg3YjE0MTcyYjQ5NWU1OTUxZWY5NWFlMS90YWJsZToxNzE2NTY3MWY0YWU0MDk0YWRiZjE5YWZhMDExOGI0NC90YWJsZXJhbmdlOjE3MTY1NjcxZjRhZTQwOTRhZGJmMTlhZmEwMTE4YjQ0XzgtNy0xLTEtMA_b82a929d-ddc0-4a5b-a862-bcc17abc8b2a"
      unitRef="usd">10555000</us-gaap:OperatingLeaseLiability>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMjkvZnJhZzo0OTNlMjJkZjg3YjE0MTcyYjQ5NWU1OTUxZWY5NWFlMS90ZXh0cmVnaW9uOjQ5M2UyMmRmODdiMTQxNzJiNDk1ZTU5NTFlZjk1YWUxXzY1MzQ_6620d349-2107-4d8b-aa0c-4513b14d44af">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the three months ended March 31, 2021 and 2020 the components of lease costs were as follows (in thousands):  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.484%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;444&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;472&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Variable lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Short-term lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;735&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;673&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following summarizes additional information related to operating leases:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.484%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Weighted-average remaining lease term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.1 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.0 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Weighted-average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMjkvZnJhZzo0OTNlMjJkZjg3YjE0MTcyYjQ5NWU1OTUxZWY5NWFlMS90YWJsZTo4OTFjYzkxZTI2ZTE0ZmFiYjU5ZjA2NjFiMjQ1NTU4YS90YWJsZXJhbmdlOjg5MWNjOTFlMjZlMTRmYWJiNTlmMDY2MWIyNDU1NThhXzItNS0xLTEtMA_fc318780-f5b5-4cd3-ba56-7d564f6392a7"
      unitRef="usd">444000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="i824a5b33f908426bad016f0eded844db_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMjkvZnJhZzo0OTNlMjJkZjg3YjE0MTcyYjQ5NWU1OTUxZWY5NWFlMS90YWJsZTo4OTFjYzkxZTI2ZTE0ZmFiYjU5ZjA2NjFiMjQ1NTU4YS90YWJsZXJhbmdlOjg5MWNjOTFlMjZlMTRmYWJiNTlmMDY2MWIyNDU1NThhXzItNy0xLTEtMA_f84e08a0-b312-4f9b-bd82-17896f3e8144"
      unitRef="usd">472000</us-gaap:OperatingLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMjkvZnJhZzo0OTNlMjJkZjg3YjE0MTcyYjQ5NWU1OTUxZWY5NWFlMS90YWJsZTo4OTFjYzkxZTI2ZTE0ZmFiYjU5ZjA2NjFiMjQ1NTU4YS90YWJsZXJhbmdlOjg5MWNjOTFlMjZlMTRmYWJiNTlmMDY2MWIyNDU1NThhXzMtNS0xLTEtMA_48da922a-efae-4609-85cc-20c0609fb372"
      unitRef="usd">288000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="i824a5b33f908426bad016f0eded844db_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMjkvZnJhZzo0OTNlMjJkZjg3YjE0MTcyYjQ5NWU1OTUxZWY5NWFlMS90YWJsZTo4OTFjYzkxZTI2ZTE0ZmFiYjU5ZjA2NjFiMjQ1NTU4YS90YWJsZXJhbmdlOjg5MWNjOTFlMjZlMTRmYWJiNTlmMDY2MWIyNDU1NThhXzMtNy0xLTEtMA_79902b0a-0af8-4f7b-9007-c7ed7d77f350"
      unitRef="usd">199000</us-gaap:VariableLeaseCost>
    <us-gaap:ShortTermLeaseCost
      contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMjkvZnJhZzo0OTNlMjJkZjg3YjE0MTcyYjQ5NWU1OTUxZWY5NWFlMS90YWJsZTo4OTFjYzkxZTI2ZTE0ZmFiYjU5ZjA2NjFiMjQ1NTU4YS90YWJsZXJhbmdlOjg5MWNjOTFlMjZlMTRmYWJiNTlmMDY2MWIyNDU1NThhXzQtNS0xLTEtMA_60b37400-2cac-481c-b45d-7c68b7aa5bfd"
      unitRef="usd">3000</us-gaap:ShortTermLeaseCost>
    <us-gaap:ShortTermLeaseCost
      contextRef="i824a5b33f908426bad016f0eded844db_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMjkvZnJhZzo0OTNlMjJkZjg3YjE0MTcyYjQ5NWU1OTUxZWY5NWFlMS90YWJsZTo4OTFjYzkxZTI2ZTE0ZmFiYjU5ZjA2NjFiMjQ1NTU4YS90YWJsZXJhbmdlOjg5MWNjOTFlMjZlMTRmYWJiNTlmMDY2MWIyNDU1NThhXzQtNy0xLTEtMA_201cb2fa-b3e5-4076-810b-ed0957fe8b02"
      unitRef="usd">2000</us-gaap:ShortTermLeaseCost>
    <us-gaap:LeaseCost
      contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMjkvZnJhZzo0OTNlMjJkZjg3YjE0MTcyYjQ5NWU1OTUxZWY5NWFlMS90YWJsZTo4OTFjYzkxZTI2ZTE0ZmFiYjU5ZjA2NjFiMjQ1NTU4YS90YWJsZXJhbmdlOjg5MWNjOTFlMjZlMTRmYWJiNTlmMDY2MWIyNDU1NThhXzUtNS0xLTEtMA_4d70cf5e-030b-4677-86d8-6052ced153f6"
      unitRef="usd">735000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="i824a5b33f908426bad016f0eded844db_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMjkvZnJhZzo0OTNlMjJkZjg3YjE0MTcyYjQ5NWU1OTUxZWY5NWFlMS90YWJsZTo4OTFjYzkxZTI2ZTE0ZmFiYjU5ZjA2NjFiMjQ1NTU4YS90YWJsZXJhbmdlOjg5MWNjOTFlMjZlMTRmYWJiNTlmMDY2MWIyNDU1NThhXzUtNy0xLTEtMA_0d930083-b4ef-42ca-8ef1-0109f6b27836"
      unitRef="usd">673000</us-gaap:LeaseCost>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMjkvZnJhZzo0OTNlMjJkZjg3YjE0MTcyYjQ5NWU1OTUxZWY5NWFlMS90ZXh0cmVnaW9uOjQ5M2UyMmRmODdiMTQxNzJiNDk1ZTU5NTFlZjk1YWUxXzY1NTA_45c54c2f-d8b5-43d5-8e25-bb9a91778cfc">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The maturity of the Company&#x2019;s operating lease liabilities as of March 31, 2021 were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:87.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.596%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2021 (remainder)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,368&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,866&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,922&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,980&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,039&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,945&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Total future minimum lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14,120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Less imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,775&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Total operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10,345&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
      contextRef="ied8d945ebce54ed8a4badfed477a64e8_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMjkvZnJhZzo0OTNlMjJkZjg3YjE0MTcyYjQ5NWU1OTUxZWY5NWFlMS90YWJsZTo4NDMwYTJhZTIwOWQ0YTA4ODUzZDhlNDZlY2VjMzk0Mi90YWJsZXJhbmdlOjg0MzBhMmFlMjA5ZDRhMDg4NTNkOGU0NmVjZWMzOTQyXzItMS0xLTEtMA_93f7ce1e-219e-4f56-a959-7d77a6a9fa19"
      unitRef="usd">1368000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="ied8d945ebce54ed8a4badfed477a64e8_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMjkvZnJhZzo0OTNlMjJkZjg3YjE0MTcyYjQ5NWU1OTUxZWY5NWFlMS90YWJsZTo4NDMwYTJhZTIwOWQ0YTA4ODUzZDhlNDZlY2VjMzk0Mi90YWJsZXJhbmdlOjg0MzBhMmFlMjA5ZDRhMDg4NTNkOGU0NmVjZWMzOTQyXzMtMS0xLTEtMA_e23e127c-cb16-460c-ad22-78874989ac6a"
      unitRef="usd">1866000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="ied8d945ebce54ed8a4badfed477a64e8_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMjkvZnJhZzo0OTNlMjJkZjg3YjE0MTcyYjQ5NWU1OTUxZWY5NWFlMS90YWJsZTo4NDMwYTJhZTIwOWQ0YTA4ODUzZDhlNDZlY2VjMzk0Mi90YWJsZXJhbmdlOjg0MzBhMmFlMjA5ZDRhMDg4NTNkOGU0NmVjZWMzOTQyXzQtMS0xLTEtMA_92774e00-00cf-4098-b7dc-94001a341cd8"
      unitRef="usd">1922000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="ied8d945ebce54ed8a4badfed477a64e8_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMjkvZnJhZzo0OTNlMjJkZjg3YjE0MTcyYjQ5NWU1OTUxZWY5NWFlMS90YWJsZTo4NDMwYTJhZTIwOWQ0YTA4ODUzZDhlNDZlY2VjMzk0Mi90YWJsZXJhbmdlOjg0MzBhMmFlMjA5ZDRhMDg4NTNkOGU0NmVjZWMzOTQyXzUtMS0xLTEtMA_a5b2384f-18d7-4586-acb1-79f3ad555220"
      unitRef="usd">1980000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="ied8d945ebce54ed8a4badfed477a64e8_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMjkvZnJhZzo0OTNlMjJkZjg3YjE0MTcyYjQ5NWU1OTUxZWY5NWFlMS90YWJsZTo4NDMwYTJhZTIwOWQ0YTA4ODUzZDhlNDZlY2VjMzk0Mi90YWJsZXJhbmdlOjg0MzBhMmFlMjA5ZDRhMDg4NTNkOGU0NmVjZWMzOTQyXzYtMS0xLTEtMA_f7a620f2-0af3-4cf9-92af-08ee0f1f79a9"
      unitRef="usd">2039000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <selb:LesseeOperatingLeaseLiabilityToBePaidAfterYearFour
      contextRef="ied8d945ebce54ed8a4badfed477a64e8_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMjkvZnJhZzo0OTNlMjJkZjg3YjE0MTcyYjQ5NWU1OTUxZWY5NWFlMS90YWJsZTo4NDMwYTJhZTIwOWQ0YTA4ODUzZDhlNDZlY2VjMzk0Mi90YWJsZXJhbmdlOjg0MzBhMmFlMjA5ZDRhMDg4NTNkOGU0NmVjZWMzOTQyXzctMS0xLTEtMA_3895acb7-db9a-421b-b12d-d677ac4adf9f"
      unitRef="usd">4945000</selb:LesseeOperatingLeaseLiabilityToBePaidAfterYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="ied8d945ebce54ed8a4badfed477a64e8_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMjkvZnJhZzo0OTNlMjJkZjg3YjE0MTcyYjQ5NWU1OTUxZWY5NWFlMS90YWJsZTo4NDMwYTJhZTIwOWQ0YTA4ODUzZDhlNDZlY2VjMzk0Mi90YWJsZXJhbmdlOjg0MzBhMmFlMjA5ZDRhMDg4NTNkOGU0NmVjZWMzOTQyXzgtMS0xLTEtMA_367b906d-5c15-49da-a00f-aff34313b1cf"
      unitRef="usd">14120000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="ied8d945ebce54ed8a4badfed477a64e8_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMjkvZnJhZzo0OTNlMjJkZjg3YjE0MTcyYjQ5NWU1OTUxZWY5NWFlMS90YWJsZTo4NDMwYTJhZTIwOWQ0YTA4ODUzZDhlNDZlY2VjMzk0Mi90YWJsZXJhbmdlOjg0MzBhMmFlMjA5ZDRhMDg4NTNkOGU0NmVjZWMzOTQyXzktMS0xLTEtMA_307ba5ae-e98c-425c-89c1-f3f12c8057ad"
      unitRef="usd">3775000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="ied8d945ebce54ed8a4badfed477a64e8_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMjkvZnJhZzo0OTNlMjJkZjg3YjE0MTcyYjQ5NWU1OTUxZWY5NWFlMS90YWJsZTo4NDMwYTJhZTIwOWQ0YTA4ODUzZDhlNDZlY2VjMzk0Mi90YWJsZXJhbmdlOjg0MzBhMmFlMjA5ZDRhMDg4NTNkOGU0NmVjZWMzOTQyXzEwLTEtMS0xLTA_7694a058-17e1-4a58-97e9-eb4ec086a98f"
      unitRef="usd">10345000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLeaseIncomeTableTextBlock
      contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMjkvZnJhZzo0OTNlMjJkZjg3YjE0MTcyYjQ5NWU1OTUxZWY5NWFlMS90ZXh0cmVnaW9uOjQ5M2UyMmRmODdiMTQxNzJiNDk1ZTU5NTFlZjk1YWUxXzY1NDM_73598da7-4c25-43a5-a88e-8ef42e090679">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The supplemental disclosure for the statement of cash flows related to operating leases were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.777%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.449%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.451%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;444&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;487&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:OperatingLeaseLeaseIncomeTableTextBlock>
    <us-gaap:OperatingLeasePayments
      contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMjkvZnJhZzo0OTNlMjJkZjg3YjE0MTcyYjQ5NWU1OTUxZWY5NWFlMS90YWJsZTo4ZjM1M2E5N2JjOTU0YjE0OWM3NWI0ZDJjODYyMDIxZi90YWJsZXJhbmdlOjhmMzUzYTk3YmM5NTRiMTQ5Yzc1YjRkMmM4NjIwMjFmXzItMS0xLTEtMA_9f86ac34-4c4e-457e-aba7-1205af5b3cdf"
      unitRef="usd">444000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="i824a5b33f908426bad016f0eded844db_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMjkvZnJhZzo0OTNlMjJkZjg3YjE0MTcyYjQ5NWU1OTUxZWY5NWFlMS90YWJsZTo4ZjM1M2E5N2JjOTU0YjE0OWM3NWI0ZDJjODYyMDIxZi90YWJsZXJhbmdlOjhmMzUzYTk3YmM5NTRiMTQ5Yzc1YjRkMmM4NjIwMjFmXzItMy0xLTEtMA_660e8d7f-3bd9-4ae5-a381-4961917326e0"
      unitRef="usd">487000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="ied8d945ebce54ed8a4badfed477a64e8_I20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMjkvZnJhZzo0OTNlMjJkZjg3YjE0MTcyYjQ5NWU1OTUxZWY5NWFlMS90YWJsZTpiMjVmMzRhMmQxMWU0ZGY3YTdiYWI4MzcwNTE4MDllYS90YWJsZXJhbmdlOmIyNWYzNGEyZDExZTRkZjdhN2JhYjgzNzA1MTgwOWVhXzItMS0xLTEtMA_cfb126a2-de62-4bc0-ba7d-27b41aa78e57">P7Y1M6D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="iff7e2530342c41bca8c84fce55f0cc6f_I20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMjkvZnJhZzo0OTNlMjJkZjg3YjE0MTcyYjQ5NWU1OTUxZWY5NWFlMS90YWJsZTpiMjVmMzRhMmQxMWU0ZGY3YTdiYWI4MzcwNTE4MDllYS90YWJsZXJhbmdlOmIyNWYzNGEyZDExZTRkZjdhN2JhYjgzNzA1MTgwOWVhXzItMy0xLTEtMA_b7f6ed1b-b773-4e84-889a-ffa66cf4f8de">P8Y</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="ied8d945ebce54ed8a4badfed477a64e8_I20210331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMjkvZnJhZzo0OTNlMjJkZjg3YjE0MTcyYjQ5NWU1OTUxZWY5NWFlMS90YWJsZTpiMjVmMzRhMmQxMWU0ZGY3YTdiYWI4MzcwNTE4MDllYS90YWJsZXJhbmdlOmIyNWYzNGEyZDExZTRkZjdhN2JhYjgzNzA1MTgwOWVhXzMtMS0xLTEtMA_5cd2f345-3254-4296-9ab3-da14123109b5"
      unitRef="number">0.089</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="iff7e2530342c41bca8c84fce55f0cc6f_I20200331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMjkvZnJhZzo0OTNlMjJkZjg3YjE0MTcyYjQ5NWU1OTUxZWY5NWFlMS90YWJsZTpiMjVmMzRhMmQxMWU0ZGY3YTdiYWI4MzcwNTE4MDllYS90YWJsZXJhbmdlOmIyNWYzNGEyZDExZTRkZjdhN2JhYjgzNzA1MTgwOWVhXzMtMy0xLTEtMA_8eb8db4d-87cd-48a1-aa45-9d91a38f6f8d"
      unitRef="number">0.089</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMzUvZnJhZzpmYWVkYzc2NDgyMzk0OGE4YjMwODE5MzQyYjI2YWI4Yy90ZXh0cmVnaW9uOmZhZWRjNzY0ODIzOTQ4YThiMzA4MTkzNDJiMjZhYjhjXzk5MjI_a410e0cd-59d1-4139-8ea8-3f3e1dec1486">Debt&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2020 Term Loan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August 31, 2020, the Company entered into a term loan of up to $35.0&#160;million, or the 2020 Term Loan, consisting of term loans in an aggregate amount of $25.0&#160;million, or the Term A Loan, and term loans in an aggregate amount of $10.0&#160;million, or the Term B Loan, governed by a loan and security agreement, or the Loan Agreement, between the Company and Oxford Finance LLC, or Oxford, as Collateral Agent and a Lender, and SVB, as a Lender. The Term A Loan was funded in full on August 31, 2020, or the Funding Date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Term B Loan will be available, subject to Collateral Agent&#x2019;s discretion and customary terms and conditions, during the period commencing on the date the Company has delivered to the Collateral Agent and the Lenders evidence: (i) the Company or one of the Company&#x2019;s collaboration partners has enrolled its first patient for a Phase 1 clinical trial evaluating the treatment of methylmalonic acidemia, or MMA, and (ii) the Company has enrolled the first patient in each of two Phase 3 pivotal trials evaluating SEL-212, or the Second Draw Period Milestone, and ending on the earliest of (i) the date which is 30 days following the date the Second Draw Period Milestone is achieved, (ii) September 30, 2021 (iii) and the occurrence of an event of default, other than an event of default that has been waived in writing by Collateral Agent and the Lenders in their sole discretion, with such period referred to as the Second Draw Period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 2020 Term Loan will mature on August 1, 2025. Each advance under the Term Loan accrues interest at a floating per annum rate equal to the greater of (a) 7.90%, and (b) the lesser of (x) the sum of (i) the prime rate reported in The Wall Street Journal on the last business day of the month that immediately precedes the month in which the interest will accrue, and (ii) 4.65% and (y) 10.00%. The Term Loan provides for interest-only payments on a monthly basis until April 1, 2022; provided however, if the Company has delivered to the Collateral Agent and the Lenders prior to September 30, 2021 evidence that Borrower has achieved the Second Draw Period Milestone, the Term Loan provides for interest-only payments on a monthly basis until October 1, 2022. Thereafter, amortization payments will be payable monthly in equal installments of principal and interest to fully amortize the outstanding principal over the remaining term of the loan, subject to recalculation upon a change in the prime rate. The Company may prepay the Term Loan in full but not in part provided that the Company (i) provides ten days&#x2019; prior written notice to Collateral Agent, (ii) pays on the date of such prepayment (A) all outstanding principal plus &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;accrued and unpaid interest, and (B) a prepayment fee of between 3.0% and 1.0% of the aggregate original principal amount advanced by the lender depending on the timing of the prepayment. Amounts outstanding during an event of default are payable upon SVB&#x2019;s demand and shall accrue interest at an additional rate of 5.0% per annum of the past due amount outstanding. At the end of the loan term (whether at maturity, by prepayment in full or otherwise), the Company shall make a final payment to the lender in the amount of 9.0% of the aggregate original principal amount advanced by the lender. The final payment fee totaling $2.3&#160;million is recorded as a loan discount.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Term Loan is secured by a lien on substantially all of the assets of the Company, other than intellectual property, provided that such lien on substantially all assets includes any rights to payments and proceeds from the sale, licensing or disposition of intellectual property. The Company has also granted the Collateral Agent a negative pledge with respect to its intellectual property.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Loan Agreement contains customary covenants and representations, including but not limited to financial reporting obligations and limitations on dividends, indebtedness, collateral, investments, distributions, transfers, mergers or acquisitions, taxes, corporate changes, deposit accounts, and subsidiaries. The Loan Agreement also contains other customary provisions, such as expense reimbursement, non-disclosure obligations as well as indemnification rights for the benefit of the Collateral Agent.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The events of default under the Loan Agreement include, but are not limited to, the Company&#x2019;s failure to make any payments of principal or interest under the Loan Agreement or other transaction documents, the Company&#x2019;s breach or default in the performance of any covenant under the Loan Agreement or other transaction documents, the occurrence of a material adverse change, the Company making a false or misleading representation or warranty in any material respect under the Loan Agreement, the Company&#x2019;s insolvency or bankruptcy, any attachment or judgment on the Company&#x2019;s assets of at least $0.5&#160;million, or the occurrence of any default under any agreement or obligation of the Company involving indebtedness in excess of $0.5&#160;million. If an event of default occurs, the Collateral Agent is entitled to take enforcement action, including acceleration of amounts due under the Loan Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company incurred $0.4&#160;million in debt issuance costs in connection with the closing of the 2020 Term Loan. Debt issuance costs are presented in the consolidated balance sheet as a direct deduction from the associated liability and amortized to interest expense over the term of the related debt.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company assessed all terms and features of the 2020 Term Loan to identify any potential embedded features that would require bifurcation. As part of this analysis, the Company assessed the economic characteristics and risks of the 2020 Term Loan, including any put, call, and contingent features. The Company determined that the interest rate collar and prepayment call option did not require bifurcation; whereas the contingent put option and default (contingent) interest rate feature met bifurcation criteria resulting in immaterial amounts.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Warrants&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August 31, 2020, in connection with the 2020 Term A Loan, the Company issued warrants to the Lenders to purchase an aggregate of 196,850 shares of its common stock at an exercise price equal to $2.54 per share. In accordance with ASC 815-40, these warrants are classified as permanent equity in the accompanying consolidated balance sheets and will expire ten years from the date of issuance. The initial grant date fair value of the warrants was $0.4&#160;million as determined by the Black-Scholes valuation model and recorded to shareholders' equity, with the SVB portion allocated to the reacquisition price of the 2017 Term Loan and the Oxford fair value portion as a loan discount to the Term A Loan.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additionally, on August 31, 2020, pursuant to the terms of a Warrant Side Letter agreement among the Company and the Lenders, the Company agreed to issue to the Lenders, on the date the Company draws the Term B Loan and in accordance with each party&#x2019;s respective pro rata share with respect to the Term B Loan, one or more warrants to purchase an aggregate number of shares of its common stock that is equal to $200,000 divided by the average closing price of the Company&#x2019;s common stock on The Nasdaq Stock Market LLC for the ten consecutive trading days ending the day before such issuance, rounded down to the nearest whole number of shares, and having an exercise price equal to the Term B Warrant Price.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Payoff&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On the Funding Date, the Company entered into a payoff letter with SVB, pursuant to which the Company utilized $13.7&#160;million of the 2020 Term Loan to pay off all outstanding obligations under the previous term loan, consisting of the principal payment, final prepayment and accrued interest. During the three months ended September 30, 2020, the Company recognized a loss on extinguishment of debt in the amount of $0.5&#160;million determined as the difference between the reacquisition price and carrying value at August 31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March 31, 2021 and December 31, 2020, the outstanding principal balance under the 2020 Term Loan was $25.0 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Future minimum principal and interest payments on the 2020 Term Loan as of March 31, 2021 are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:87.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.596%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2021 (remainder)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,509&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,343&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,611&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,027&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total minimum debt payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;32,764&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Less: Amount representing interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5,514)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Less: Debt discount and deferred charges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2,239)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Less: Current portion of loan payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(460)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Loan payable, net of current portion&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;24,551&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="ic49c55aadcfb4e6abcca12c5093f9b95_I20200831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMzUvZnJhZzpmYWVkYzc2NDgyMzk0OGE4YjMwODE5MzQyYjI2YWI4Yy90ZXh0cmVnaW9uOmZhZWRjNzY0ODIzOTQ4YThiMzA4MTkzNDJiMjZhYjhjXzk0_d8ebc148-fa77-41d5-b4f5-fc3f950830ea"
      unitRef="usd">35000000.0</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="idad7c718ad664d059d7a422e95802f09_I20200831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMzUvZnJhZzpmYWVkYzc2NDgyMzk0OGE4YjMwODE5MzQyYjI2YWI4Yy90ZXh0cmVnaW9uOmZhZWRjNzY0ODIzOTQ4YThiMzA4MTkzNDJiMjZhYjhjXzE3Mg_9824d892-df23-47ea-a393-ca041531cd0e"
      unitRef="usd">25000000.0</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="ibf84b0dc83f74410887e49db3c27bd26_I20200831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMzUvZnJhZzpmYWVkYzc2NDgyMzk0OGE4YjMwODE5MzQyYjI2YWI4Yy90ZXh0cmVnaW9uOmZhZWRjNzY0ODIzOTQ4YThiMzA4MTkzNDJiMjZhYjhjXzIzNg_ee3bab9e-2ce5-4808-8029-793b435bb540"
      unitRef="usd">10000000.0</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i0c9896510dd84101bf9f2e4ccfe3aafb_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMzUvZnJhZzpmYWVkYzc2NDgyMzk0OGE4YjMwODE5MzQyYjI2YWI4Yy90ZXh0cmVnaW9uOmZhZWRjNzY0ODIzOTQ4YThiMzA4MTkzNDJiMjZhYjhjXzE2OTc_f49d2cac-5629-4bbb-a0e5-632b09dd841a"
      unitRef="number">0.0790</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="idb510d90210b4690b5f24ea7b3c03117_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMzUvZnJhZzpmYWVkYzc2NDgyMzk0OGE4YjMwODE5MzQyYjI2YWI4Yy90ZXh0cmVnaW9uOmZhZWRjNzY0ODIzOTQ4YThiMzA4MTkzNDJiMjZhYjhjXzE5MTE_2879dc38-6dae-473b-a2a9-fc083ae990b0"
      unitRef="number">0.0465</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i508d18807d32409296e19306139342d3_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMzUvZnJhZzpmYWVkYzc2NDgyMzk0OGE4YjMwODE5MzQyYjI2YWI4Yy90ZXh0cmVnaW9uOmZhZWRjNzY0ODIzOTQ4YThiMzA4MTkzNDJiMjZhYjhjXzE5MjI_73f09d16-b1c8-4148-a718-7f6d95ddd5f8"
      unitRef="number">0.1000</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <selb:DebtInstrumentPrepaymentFeePercentage
      contextRef="id40f93ddba284a1eaf4d3d96cdbe8228_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMzUvZnJhZzpmYWVkYzc2NDgyMzk0OGE4YjMwODE5MzQyYjI2YWI4Yy90ZXh0cmVnaW9uOmZhZWRjNzY0ODIzOTQ4YThiMzA4MTkzNDJiMjZhYjhjXzI4MzE_0c22891a-4890-4345-84da-436f8ced6d85"
      unitRef="number">0.030</selb:DebtInstrumentPrepaymentFeePercentage>
    <selb:DebtInstrumentPrepaymentFeePercentage
      contextRef="i3fe76a62c9514fceaf15e8fc84c84053_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMzUvZnJhZzpmYWVkYzc2NDgyMzk0OGE4YjMwODE5MzQyYjI2YWI4Yy90ZXh0cmVnaW9uOmZhZWRjNzY0ODIzOTQ4YThiMzA4MTkzNDJiMjZhYjhjXzI4Mzg_8f2bfcfc-4830-4fc4-ace9-80ebfe6fccc1"
      unitRef="number">0.010</selb:DebtInstrumentPrepaymentFeePercentage>
    <selb:DebtInstrumentAdditionalAccruedInterestInTheEventOfDefault
      contextRef="i3303eaf5c2074c30aee9f9289696a2e5_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMzUvZnJhZzpmYWVkYzc2NDgyMzk0OGE4YjMwODE5MzQyYjI2YWI4Yy90ZXh0cmVnaW9uOmZhZWRjNzY0ODIzOTQ4YThiMzA4MTkzNDJiMjZhYjhjXzMwNzg_bf3aa208-961d-4041-916c-e0632fe985d2"
      unitRef="number">0.050</selb:DebtInstrumentAdditionalAccruedInterestInTheEventOfDefault>
    <us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed
      contextRef="i3303eaf5c2074c30aee9f9289696a2e5_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMzUvZnJhZzpmYWVkYzc2NDgyMzk0OGE4YjMwODE5MzQyYjI2YWI4Yy90ZXh0cmVnaW9uOmZhZWRjNzY0ODIzOTQ4YThiMzA4MTkzNDJiMjZhYjhjXzMyODQ_3d3ddb9f-08b5-4fa6-ab95-81a4af8a506f"
      unitRef="number">0.090</us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed>
    <us-gaap:DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid
      contextRef="ied8d945ebce54ed8a4badfed477a64e8_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMzUvZnJhZzpmYWVkYzc2NDgyMzk0OGE4YjMwODE5MzQyYjI2YWI4Yy90ZXh0cmVnaW9uOmZhZWRjNzY0ODIzOTQ4YThiMzA4MTkzNDJiMjZhYjhjXzMzODU_be9a3e05-3963-4821-b291-56f2f6494555"
      unitRef="usd">2300000</us-gaap:DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid>
    <selb:DebtInstrumentDefaultBankruptcyOrInsolvencyValueOfTriggeringAcceleratedRedemption
      contextRef="i2d4605e783914026a19516819dbaac3f_D20200831-20200831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMzUvZnJhZzpmYWVkYzc2NDgyMzk0OGE4YjMwODE5MzQyYjI2YWI4Yy90ZXh0cmVnaW9uOmZhZWRjNzY0ODIzOTQ4YThiMzA4MTkzNDJiMjZhYjhjXzQ5MTU_57aca4be-6667-4415-843f-f65722d2c01a"
      unitRef="usd">500000</selb:DebtInstrumentDefaultBankruptcyOrInsolvencyValueOfTriggeringAcceleratedRedemption>
    <selb:DebtInstrumentDefaultBankruptcyOrInsolvencyValueOfTriggeringAcceleratedRedemption
      contextRef="i2d4605e783914026a19516819dbaac3f_D20200831-20200831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMzUvZnJhZzpmYWVkYzc2NDgyMzk0OGE4YjMwODE5MzQyYjI2YWI4Yy90ZXh0cmVnaW9uOmZhZWRjNzY0ODIzOTQ4YThiMzA4MTkzNDJiMjZhYjhjXzUwMzc_57aca4be-6667-4415-843f-f65722d2c01a"
      unitRef="usd">500000</selb:DebtInstrumentDefaultBankruptcyOrInsolvencyValueOfTriggeringAcceleratedRedemption>
    <us-gaap:DebtIssuanceCostsLineOfCreditArrangementsNet
      contextRef="ic49c55aadcfb4e6abcca12c5093f9b95_I20200831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMzUvZnJhZzpmYWVkYzc2NDgyMzk0OGE4YjMwODE5MzQyYjI2YWI4Yy90ZXh0cmVnaW9uOmZhZWRjNzY0ODIzOTQ4YThiMzA4MTkzNDJiMjZhYjhjXzUyMTg_9e2b9bee-2dec-4c5d-9d6a-8db5b0a30039"
      unitRef="usd">400000</us-gaap:DebtIssuanceCostsLineOfCreditArrangementsNet>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i8096110103d24ead836cc45438a9c346_I20200831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMzUvZnJhZzpmYWVkYzc2NDgyMzk0OGE4YjMwODE5MzQyYjI2YWI4Yy90ZXh0cmVnaW9uOmZhZWRjNzY0ODIzOTQ4YThiMzA4MTkzNDJiMjZhYjhjXzYxNzc_33cbe494-46d2-45f0-99eb-e8eeca7ef30a"
      unitRef="shares">196850</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i8096110103d24ead836cc45438a9c346_I20200831"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMzUvZnJhZzpmYWVkYzc2NDgyMzk0OGE4YjMwODE5MzQyYjI2YWI4Yy90ZXh0cmVnaW9uOmZhZWRjNzY0ODIzOTQ4YThiMzA4MTkzNDJiMjZhYjhjXzYyMzc_cc07ebc2-ff64-4e0f-bfca-655abbe28d8b"
      unitRef="usdPerShare">2.54</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <selb:ClassOfWarrantOrRightExpirationPeriod
      contextRef="i23a2063d104e496f85ffd7168cdf9d4c_D20200831-20200831"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMzUvZnJhZzpmYWVkYzc2NDgyMzk0OGE4YjMwODE5MzQyYjI2YWI4Yy90ZXh0cmVnaW9uOmZhZWRjNzY0ODIzOTQ4YThiMzA4MTkzNDJiMjZhYjhjXzYzOTY_21bc1ccc-fd7c-471e-9e3a-e882650fb1e5">P10Y</selb:ClassOfWarrantOrRightExpirationPeriod>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="i23a2063d104e496f85ffd7168cdf9d4c_D20200831-20200831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMzUvZnJhZzpmYWVkYzc2NDgyMzk0OGE4YjMwODE5MzQyYjI2YWI4Yy90ZXh0cmVnaW9uOmZhZWRjNzY0ODIzOTQ4YThiMzA4MTkzNDJiMjZhYjhjXzY0ODA_db322d45-2aea-4056-8b0b-2a66cdc22beb"
      unitRef="usd">400000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="i7dadb30c8c5644a19242b20dc3231a67_D20200831-20200831"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMzUvZnJhZzpmYWVkYzc2NDgyMzk0OGE4YjMwODE5MzQyYjI2YWI4Yy90ZXh0cmVnaW9uOmZhZWRjNzY0ODIzOTQ4YThiMzA4MTkzNDJiMjZhYjhjXzcxMzY_d95defa6-5c03-4e26-ba3c-585ca5a54e1c"
      unitRef="usd">200000000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:RepaymentsOfLinesOfCredit
      contextRef="ifaf30d95979d4b7f87adf2a9bc2bf774_D20200831-20200831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMzUvZnJhZzpmYWVkYzc2NDgyMzk0OGE4YjMwODE5MzQyYjI2YWI4Yy90ZXh0cmVnaW9uOmZhZWRjNzY0ODIzOTQ4YThiMzA4MTkzNDJiMjZhYjhjXzc1NDU_a930159a-2a76-4f6d-b2b8-3723a16ca20b"
      unitRef="usd">13700000</us-gaap:RepaymentsOfLinesOfCredit>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="ia71eca13c1a4466f9daeb5956381a0e0_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMzUvZnJhZzpmYWVkYzc2NDgyMzk0OGE4YjMwODE5MzQyYjI2YWI4Yy90ZXh0cmVnaW9uOmZhZWRjNzY0ODIzOTQ4YThiMzA4MTkzNDJiMjZhYjhjXzc4NTM_884c9aa2-023d-4920-8d07-9c3a163e5bf5"
      unitRef="usd">-500000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:LineOfCredit
      contextRef="ied299278fc4543748c5f3ad2970fc3bb_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMzUvZnJhZzpmYWVkYzc2NDgyMzk0OGE4YjMwODE5MzQyYjI2YWI4Yy90ZXh0cmVnaW9uOmZhZWRjNzY0ODIzOTQ4YThiMzA4MTkzNDJiMjZhYjhjXzk1MTg_75a9e6d1-47b0-4440-b109-ff510c58ae89"
      unitRef="usd">25000000.0</us-gaap:LineOfCredit>
    <us-gaap:LineOfCredit
      contextRef="ie10a81ae4793423483f2db5739fafba5_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMzUvZnJhZzpmYWVkYzc2NDgyMzk0OGE4YjMwODE5MzQyYjI2YWI4Yy90ZXh0cmVnaW9uOmZhZWRjNzY0ODIzOTQ4YThiMzA4MTkzNDJiMjZhYjhjXzk1MTg_f4e91392-0cd6-46cd-b273-ebee1d742227"
      unitRef="usd">25000000.0</us-gaap:LineOfCredit>
    <us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock
      contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMzUvZnJhZzpmYWVkYzc2NDgyMzk0OGE4YjMwODE5MzQyYjI2YWI4Yy90ZXh0cmVnaW9uOmZhZWRjNzY0ODIzOTQ4YThiMzA4MTkzNDJiMjZhYjhjXzk5MTQ_be78a9ab-cb6f-4ef5-9210-d63072914cea">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Future minimum principal and interest payments on the 2020 Term Loan as of March 31, 2021 are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:87.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.596%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2021 (remainder)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,509&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,343&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,611&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,027&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total minimum debt payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;32,764&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Less: Amount representing interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5,514)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Less: Debt discount and deferred charges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2,239)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Less: Current portion of loan payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(460)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Loan payable, net of current portion&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;24,551&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
      contextRef="i867f4cd50cdf4945bf8a2b4c13258dfd_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMzUvZnJhZzpmYWVkYzc2NDgyMzk0OGE4YjMwODE5MzQyYjI2YWI4Yy90YWJsZTo0ZjhlNGFhZTJkMDc0ZDgzYmI2ZGU0MDY0YTM5NmYzOS90YWJsZXJhbmdlOjRmOGU0YWFlMmQwNzRkODNiYjZkZTQwNjRhMzk2ZjM5XzAtMS0xLTEtMA_7e6d37ee-40e7-4573-b315-df38d5ed41ed"
      unitRef="usd">1509000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
      contextRef="i867f4cd50cdf4945bf8a2b4c13258dfd_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMzUvZnJhZzpmYWVkYzc2NDgyMzk0OGE4YjMwODE5MzQyYjI2YWI4Yy90YWJsZTo0ZjhlNGFhZTJkMDc0ZDgzYmI2ZGU0MDY0YTM5NmYzOS90YWJsZXJhbmdlOjRmOGU0YWFlMmQwNzRkODNiYjZkZTQwNjRhMzk2ZjM5XzEtMS0xLTEtMA_f9d94164-f33e-4717-a934-b9228448b007"
      unitRef="usd">7343000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
      contextRef="i867f4cd50cdf4945bf8a2b4c13258dfd_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMzUvZnJhZzpmYWVkYzc2NDgyMzk0OGE4YjMwODE5MzQyYjI2YWI4Yy90YWJsZTo0ZjhlNGFhZTJkMDc0ZDgzYmI2ZGU0MDY0YTM5NmYzOS90YWJsZXJhbmdlOjRmOGU0YWFlMmQwNzRkODNiYjZkZTQwNjRhMzk2ZjM5XzItMS0xLTEtMA_5fc93301-37b2-4625-bcb9-eb3ac308b258"
      unitRef="usd">8611000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
      contextRef="i867f4cd50cdf4945bf8a2b4c13258dfd_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMzUvZnJhZzpmYWVkYzc2NDgyMzk0OGE4YjMwODE5MzQyYjI2YWI4Yy90YWJsZTo0ZjhlNGFhZTJkMDc0ZDgzYmI2ZGU0MDY0YTM5NmYzOS90YWJsZXJhbmdlOjRmOGU0YWFlMmQwNzRkODNiYjZkZTQwNjRhMzk2ZjM5XzMtMS0xLTEtMA_c01bd3f0-f868-4081-a134-3e4d1cf5fd5d"
      unitRef="usd">8027000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
      contextRef="i867f4cd50cdf4945bf8a2b4c13258dfd_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMzUvZnJhZzpmYWVkYzc2NDgyMzk0OGE4YjMwODE5MzQyYjI2YWI4Yy90YWJsZTo0ZjhlNGFhZTJkMDc0ZDgzYmI2ZGU0MDY0YTM5NmYzOS90YWJsZXJhbmdlOjRmOGU0YWFlMmQwNzRkODNiYjZkZTQwNjRhMzk2ZjM5XzQtMS0xLTEtMA_310c007e-cea9-46fd-a53a-f75f56cf4f37"
      unitRef="usd">7274000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour>
    <us-gaap:LongTermDebt
      contextRef="i867f4cd50cdf4945bf8a2b4c13258dfd_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMzUvZnJhZzpmYWVkYzc2NDgyMzk0OGE4YjMwODE5MzQyYjI2YWI4Yy90YWJsZTo0ZjhlNGFhZTJkMDc0ZDgzYmI2ZGU0MDY0YTM5NmYzOS90YWJsZXJhbmdlOjRmOGU0YWFlMmQwNzRkODNiYjZkZTQwNjRhMzk2ZjM5XzUtMS0xLTEtMA_78b7be1f-9738-4c7b-976e-0149c357adea"
      unitRef="usd">32764000</us-gaap:LongTermDebt>
    <selb:DebtInstrumentInterestPortion
      contextRef="i867f4cd50cdf4945bf8a2b4c13258dfd_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMzUvZnJhZzpmYWVkYzc2NDgyMzk0OGE4YjMwODE5MzQyYjI2YWI4Yy90YWJsZTo0ZjhlNGFhZTJkMDc0ZDgzYmI2ZGU0MDY0YTM5NmYzOS90YWJsZXJhbmdlOjRmOGU0YWFlMmQwNzRkODNiYjZkZTQwNjRhMzk2ZjM5XzYtMS0xLTEtMA_ef92d8c0-8c2a-4811-933e-c08c95c4d3d3"
      unitRef="usd">5514000</selb:DebtInstrumentInterestPortion>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="i867f4cd50cdf4945bf8a2b4c13258dfd_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMzUvZnJhZzpmYWVkYzc2NDgyMzk0OGE4YjMwODE5MzQyYjI2YWI4Yy90YWJsZTo0ZjhlNGFhZTJkMDc0ZDgzYmI2ZGU0MDY0YTM5NmYzOS90YWJsZXJhbmdlOjRmOGU0YWFlMmQwNzRkODNiYjZkZTQwNjRhMzk2ZjM5XzctMS0xLTEtMA_0c1de949-1a35-46e6-a784-503c141633c5"
      unitRef="usd">2239000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:LongTermDebtCurrent
      contextRef="i867f4cd50cdf4945bf8a2b4c13258dfd_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMzUvZnJhZzpmYWVkYzc2NDgyMzk0OGE4YjMwODE5MzQyYjI2YWI4Yy90YWJsZTo0ZjhlNGFhZTJkMDc0ZDgzYmI2ZGU0MDY0YTM5NmYzOS90YWJsZXJhbmdlOjRmOGU0YWFlMmQwNzRkODNiYjZkZTQwNjRhMzk2ZjM5XzgtMS0xLTEtMA_6c35f15e-4302-48a0-b0d4-c88fe889b70f"
      unitRef="usd">460000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i867f4cd50cdf4945bf8a2b4c13258dfd_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yMzUvZnJhZzpmYWVkYzc2NDgyMzk0OGE4YjMwODE5MzQyYjI2YWI4Yy90YWJsZTo0ZjhlNGFhZTJkMDc0ZDgzYmI2ZGU0MDY0YTM5NmYzOS90YWJsZXJhbmdlOjRmOGU0YWFlMmQwNzRkODNiYjZkZTQwNjRhMzk2ZjM5XzktMS0xLTEtMA_a52cb948-8593-4ba8-9de3-9416bc3359dd"
      unitRef="usd">24551000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDEvZnJhZzoxMTE4YWMxYjVhM2Y0M2ViYjM4OWQ1MjQxMDE0Zjk5YS90ZXh0cmVnaW9uOjExMThhYzFiNWEzZjQzZWJiMzg5ZDUyNDEwMTRmOTlhXzExNTY2_eac3737b-e183-48b4-af17-6258874eccb2">Equity&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Equity Financings&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;August 2020 Shelf Registration Statement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August&#160;6, 2020, the Company filed an updated universal shelf registration statement on Form S-3 (Reg. No. 333-241692) with the SEC to sell an aggregate amount of up to $200.0 million of certain of its securities. The shelf registration statement was declared effective by the SEC on August&#160;14, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x201c;At-the-Market&#x201d; Offerings&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2017, the Company entered into a sales agreement, or the 2017 Sales Agreement, with Jefferies LLC, as sales agent, to sell shares of its common stock with an aggregate value of up to $50.0&#160;million in an &#x201c;at the market offering.&#x201d; On August 6, 2020, concurrent with the filing of the updated shelf registration statement, the Company entered into a sales agreement, or the 2020 Sales Agreement with Jefferies LLC, as sales agent, pursuant to which the Company may, from time to time, issue and sell common stock with an aggregate value of up to $50.0&#160;million in an &#x201c;at the market offering.&#x201d; The 2017 Sales Agreement terminated pursuant to its terms in August 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Sales of common stock, if any, pursuant to the 2020 Sales Agreement, may be made in sales deemed to be an &#x201c;at the market offering&#x201d; as defined in Rule 415(a) of the Securities Act, including sales made directly through the Nasdaq Stock Market or on any other existing trading market for the Company&#x2019;s common stock. The Company intends to use the proceeds from the offering for working capital and other general corporate purposes. The Company may suspend or terminate the 2020 Sales Agreement at any time.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the year ended December 31, 2020, the Company sold 1,069,486 shares of its common stock pursuant to the 2020 and 2017 Sales Agreements at an average price of approximately $2.16 per share for aggregate net proceeds of $2.1 million, after deducting commissions and other transaction costs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended March 31, 2021, the Company sold 4,706,844 shares of its common stock pursuant to the 2020 Sales Agreement at an average price of approximately $4.59 per share for aggregate net proceeds of $20.9 million, after deducting commissions and other transaction costs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;June 2020 Sobi Stock Purchase&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 11, 2020, the Company entered into a stock purchase agreement with Sobi, pursuant to which the Company sold an aggregate of 5,416,390 shares of its common stock at a purchase price equal to $4.6156 per share, which represented 120% of the 10-day volume-weighted average price of the Company&#x2019;s common stock prior to signing, for aggregate gross proceeds of $25.0&#160;million, or the Sobi Private Placement. The closing of the Sobi Private Placement occurred on July 31, 2020. The shares of common stock acquired in the Sobi Private Placement are subject to a one-year lock-up from closing, during which time Sobi is prohibited from selling or otherwise disposing of such shares.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In accordance with ASC 815, this forward sale treatment qualified as equity classification as the shares are not within the scope of ASC 480. The gross proceeds of $25.0&#160;million were determined to include a premium to the fair value of the Company&#x2019;s shares as of July 28, 2020 of approximately $14.5&#160;million. As a result, such amount was included in the transaction price for revenue recognition of the Sobi License. See Note 12 for details.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Also on June 11, 2020, the Company entered into a registration rights agreement (as amended by that certain letter agreement, dated as of November 4, 2020) with Sobi, pursuant to which the Company agreed to prepare and file a registration statement with respect to the resale of the shares of common stock acquired in the Sobi Private Placement. The Company will be required to file this resale registration statement within 30 days following receipt by the Company of a written request from &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Sobi to file such resale registration statement, and to have the registration statement declared effective within 10 business days after the SEC informs the Company that no review of such resale registration statement will be made or that the SEC has no further comments on such resale registration statement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;December 2019 Financing&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;On December 18, 2019, the Company entered into a securities purchase agreement, or the 2019 Purchase Agreement, with a group of institutional investors and certain members of the board of directors. Pursuant to the 2019 Purchase Agreement, the Company sold an aggregate of 37,634,883 shares of its common stock at a purchase price of $1.46 per share, warrants to purchase an aggregate of 22,988,501 shares of common stock at a purchase price of $0.125 per share underlying each common warrant, and pre-funded warrants to purchase an aggregate of 8,342,128 shares of common stock at a purchase price of $1.46 per share, all with five year terms, or the 2019 PIPE. The closing of the 2019 PIPE occurred on December 23, 2019. The exercise price of the pre-funded warrants is $0.0001 per share and the exercise price for the common warrants is $1.46 per share. In the event of a certain sale of the Company, the terms of the common warrants require us to make a payment to such common warrant holders based on a Black-Scholes valuation (using variables as specified in the warrants). This provision does not apply to the pre-funded warrants. Therefore, the Company is required to account for the common warrants as liabilities and record them at fair value, while the pre-funded warrants met the criteria to be classified as permanent equity. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recorded the fair value of the common warrants of $40.7&#160;million upon issuance using the Black-Scholes valuation model. Issuance costs were allocated between the equity component with an offset to additional paid-in capital and the liability component recorded as expense on a relative fair value basis. Total net proceeds from the equity offering was $65.6 million, after deducting transaction costs and commissions of $4.4 million which was paid in the three months ended March 31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The common warrants were revalued as of March 31, 2021 at $45.5 million. During the three months ended March 31, 2021 and 2020, the Company recorded losses on the increases in the fair value of the warrants of $(16.7) million and $(0.8) million, respectively, in the unaudited consolidated statements of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Warrants&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended March 31, 2021 and 2020, there were no warrants issued, exercised, or canceled.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.361%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of Warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Equity&lt;br/&gt;&#160;classified&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Liability classified&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted average&lt;br/&gt;exercise price&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Outstanding at March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;292,469&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12,085,547&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12,378,016&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Common Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March 31, 2021, the Company had 200,000,000 shares of common stock authorized for issuance, $0.0001 par value per share, with 112,977,004 shares issued and outstanding. The voting, dividend and liquidation rights of the common stockholders are subject to and qualified by the rights, powers and preferences of the preferred stock. The common stock has the following characteristics:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Voting&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The common stockholders are entitled to one vote for each share of common stock held with respect to all matters voted on by the stockholders of the Company.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Dividends&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The common stockholders are entitled to receive dividends, if and when declared by the Board of Directors. Through March 31, 2021, no dividends have been declared or paid on common stock.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Liquidation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upon liquidation of the Company, the common stockholders are entitled to receive all assets of the Company available for distribution to such stockholders.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Reserved Shares&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has authorized shares of common stock for future issuance as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.929%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.522%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Period ended&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Exercise of common warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12,378,016&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12,378,016&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Shares available for future stock incentive awards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,719,817&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,916,374&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;RSUs reserved for issuance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;98,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Unvested restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;544,313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;87,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Outstanding common stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10,187,394&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,775,249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;30,928,290&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;25,157,139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="i98fb2199c6374722852813ddab2890d7_D20200806-20200806"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDEvZnJhZzoxMTE4YWMxYjVhM2Y0M2ViYjM4OWQ1MjQxMDE0Zjk5YS90ZXh0cmVnaW9uOjExMThhYzFiNWEzZjQzZWJiMzg5ZDUyNDEwMTRmOTlhXzIzNA_16413530-58c4-4d62-ba19-cb1f1613e0b0"
      unitRef="usd">200000000.0</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="i8b800c16db4f4bf39aec6ba9ec584f99_D20170801-20170831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDEvZnJhZzoxMTE4YWMxYjVhM2Y0M2ViYjM4OWQ1MjQxMDE0Zjk5YS90ZXh0cmVnaW9uOjExMThhYzFiNWEzZjQzZWJiMzg5ZDUyNDEwMTRmOTlhXzQzOTgwNDY1MzM0MjY_820b532f-7ab2-4083-bd3c-3e4886027014"
      unitRef="usd">50000000.0</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="id4091feb67174db89de51f974b39d21c_D20170801-20170831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDEvZnJhZzoxMTE4YWMxYjVhM2Y0M2ViYjM4OWQ1MjQxMDE0Zjk5YS90ZXh0cmVnaW9uOjExMThhYzFiNWEzZjQzZWJiMzg5ZDUyNDEwMTRmOTlhXzkxMw_95df7c0d-492a-4ef9-8101-b9589e0bbbea"
      unitRef="usd">50000000.0</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="ice2d8b62be3849c288862d2279be6e13_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDEvZnJhZzoxMTE4YWMxYjVhM2Y0M2ViYjM4OWQ1MjQxMDE0Zjk5YS90ZXh0cmVnaW9uOjExMThhYzFiNWEzZjQzZWJiMzg5ZDUyNDEwMTRmOTlhXzE1ODU_48626feb-97b5-4362-aa1f-91dea40a3922"
      unitRef="shares">1069486</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="ibc930259a91a4e09996f4820308891bd_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDEvZnJhZzoxMTE4YWMxYjVhM2Y0M2ViYjM4OWQ1MjQxMDE0Zjk5YS90ZXh0cmVnaW9uOjExMThhYzFiNWEzZjQzZWJiMzg5ZDUyNDEwMTRmOTlhXzE2OTA_b6bf0b15-b575-4aff-b58e-2e7b552ec940"
      unitRef="usdPerShare">2.16</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="ice2d8b62be3849c288862d2279be6e13_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDEvZnJhZzoxMTE4YWMxYjVhM2Y0M2ViYjM4OWQ1MjQxMDE0Zjk5YS90ZXh0cmVnaW9uOjExMThhYzFiNWEzZjQzZWJiMzg5ZDUyNDEwMTRmOTlhXzE3MzQ_d6b60af0-8ee1-4274-b835-1237e5c3a91d"
      unitRef="usd">2100000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i677f0fc8ad1f4d2c83a443e0a5bd7e07_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDEvZnJhZzoxMTE4YWMxYjVhM2Y0M2ViYjM4OWQ1MjQxMDE0Zjk5YS90ZXh0cmVnaW9uOjExMThhYzFiNWEzZjQzZWJiMzg5ZDUyNDEwMTRmOTlhXzE5MTM_f67dc1d4-ad33-4b53-8b3b-e3c9178699e2"
      unitRef="shares">4706844</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="i5a706b93dc024e0d96e8ca02c67629d7_I20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDEvZnJhZzoxMTE4YWMxYjVhM2Y0M2ViYjM4OWQ1MjQxMDE0Zjk5YS90ZXh0cmVnaW9uOjExMThhYzFiNWEzZjQzZWJiMzg5ZDUyNDEwMTRmOTlhXzIwNjM_3e37a22a-ae86-4eba-96c7-3d03c0f65724"
      unitRef="usdPerShare">4.59</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i677f0fc8ad1f4d2c83a443e0a5bd7e07_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDEvZnJhZzoxMTE4YWMxYjVhM2Y0M2ViYjM4OWQ1MjQxMDE0Zjk5YS90ZXh0cmVnaW9uOjExMThhYzFiNWEzZjQzZWJiMzg5ZDUyNDEwMTRmOTlhXzIxMDY_36e0e394-7755-4378-a69a-1af96a4a6789"
      unitRef="usd">20900000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i6e736a6ad22d4f7fbc1eda905bef7a23_D20200611-20200611"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDEvZnJhZzoxMTE4YWMxYjVhM2Y0M2ViYjM4OWQ1MjQxMDE0Zjk5YS90ZXh0cmVnaW9uOjExMThhYzFiNWEzZjQzZWJiMzg5ZDUyNDEwMTRmOTlhXzIzNTk_c1a4c96a-dea1-4f2f-be69-9d27e844f929"
      unitRef="shares">5416390</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="i5034b14d18454b028a4c7a4a20bbac44_I20200611"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDEvZnJhZzoxMTE4YWMxYjVhM2Y0M2ViYjM4OWQ1MjQxMDE0Zjk5YS90ZXh0cmVnaW9uOjExMThhYzFiNWEzZjQzZWJiMzg5ZDUyNDEwMTRmOTlhXzI0MTg_cc740851-40df-4e3a-976e-6663a3ea66fe"
      unitRef="usdPerShare">4.6156</us-gaap:SaleOfStockPricePerShare>
    <selb:SaleofStockPercentageOfTenDayVolumeWeightedAveragePriceOfCommonStock
      contextRef="i6e736a6ad22d4f7fbc1eda905bef7a23_D20200611-20200611"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDEvZnJhZzoxMTE4YWMxYjVhM2Y0M2ViYjM4OWQ1MjQxMDE0Zjk5YS90ZXh0cmVnaW9uOjExMThhYzFiNWEzZjQzZWJiMzg5ZDUyNDEwMTRmOTlhXzI0NTA_f010be79-2da4-48de-9634-4f2af0f00940"
      unitRef="number">1.20</selb:SaleofStockPercentageOfTenDayVolumeWeightedAveragePriceOfCommonStock>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="i6e736a6ad22d4f7fbc1eda905bef7a23_D20200611-20200611"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDEvZnJhZzoxMTE4YWMxYjVhM2Y0M2ViYjM4OWQ1MjQxMDE0Zjk5YS90ZXh0cmVnaW9uOjExMThhYzFiNWEzZjQzZWJiMzg5ZDUyNDEwMTRmOTlhXzI1Nzc_d3e79301-d087-40be-9b4e-6b5c167ac6e4"
      unitRef="usd">25000000.0</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <selb:LockUpFromClosingTerm
      contextRef="i8d2fc88d756d4b67bf9851793506eee3_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDEvZnJhZzoxMTE4YWMxYjVhM2Y0M2ViYjM4OWQ1MjQxMDE0Zjk5YS90ZXh0cmVnaW9uOjExMThhYzFiNWEzZjQzZWJiMzg5ZDUyNDEwMTRmOTlhXzExNTYz_150aeadd-f3e0-4a2b-8267-7967c0ad565a">P1Y</selb:LockUpFromClosingTerm>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="i6e736a6ad22d4f7fbc1eda905bef7a23_D20200611-20200611"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDEvZnJhZzoxMTE4YWMxYjVhM2Y0M2ViYjM4OWQ1MjQxMDE0Zjk5YS90ZXh0cmVnaW9uOjExMThhYzFiNWEzZjQzZWJiMzg5ZDUyNDEwMTRmOTlhXzI5Nzg_e3cefb86-1b3f-48f4-9bfa-647456e3ce0d"
      unitRef="usd">25000000.0</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:RedemptionPremium
      contextRef="i0e52f92d6bcb4dd098a7fe0cf721e342_D20200728-20200728"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDEvZnJhZzoxMTE4YWMxYjVhM2Y0M2ViYjM4OWQ1MjQxMDE0Zjk5YS90ZXh0cmVnaW9uOjExMThhYzFiNWEzZjQzZWJiMzg5ZDUyNDEwMTRmOTlhXzMwOTc_a10c1c4e-e89d-470a-96c8-0f61fed33eb7"
      unitRef="usd">14500000</us-gaap:RedemptionPremium>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="iff262d3fceb04558bb91b0665eb3295e_D20191218-20191218"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDEvZnJhZzoxMTE4YWMxYjVhM2Y0M2ViYjM4OWQ1MjQxMDE0Zjk5YS90ZXh0cmVnaW9uOjExMThhYzFiNWEzZjQzZWJiMzg5ZDUyNDEwMTRmOTlhXzQzODA_30a60115-9c50-44c9-9567-93f90be37938"
      unitRef="shares">37634883</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="i04e2a4ab60694adfa2dcd5d722cd132e_I20191218"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDEvZnJhZzoxMTE4YWMxYjVhM2Y0M2ViYjM4OWQ1MjQxMDE0Zjk5YS90ZXh0cmVnaW9uOjExMThhYzFiNWEzZjQzZWJiMzg5ZDUyNDEwMTRmOTlhXzQ0MzQ_3eaf3d84-43f9-4b98-9139-5b1f6082021b"
      unitRef="usdPerShare">1.46</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i04e2a4ab60694adfa2dcd5d722cd132e_I20191218"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDEvZnJhZzoxMTE4YWMxYjVhM2Y0M2ViYjM4OWQ1MjQxMDE0Zjk5YS90ZXh0cmVnaW9uOjExMThhYzFiNWEzZjQzZWJiMzg5ZDUyNDEwMTRmOTlhXzQ0ODU_f6a402e8-2873-4a12-8067-0a42c83b247d"
      unitRef="shares">22988501</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="i06e21592f529454490acff73efadbef0_I20191218"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDEvZnJhZzoxMTE4YWMxYjVhM2Y0M2ViYjM4OWQ1MjQxMDE0Zjk5YS90ZXh0cmVnaW9uOjExMThhYzFiNWEzZjQzZWJiMzg5ZDUyNDEwMTRmOTlhXzQ1MzU_0d29fe8b-4a0c-453b-b705-cee648346051"
      unitRef="usdPerShare">0.125</us-gaap:SaleOfStockPricePerShare>
    <selb:ClassOfWarrantOrRightNumberOfWarrantsExercised
      contextRef="ifc3b4456d78b4865980e0d06be756475_D20191218-20191218"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDEvZnJhZzoxMTE4YWMxYjVhM2Y0M2ViYjM4OWQ1MjQxMDE0Zjk5YS90ZXh0cmVnaW9uOjExMThhYzFiNWEzZjQzZWJiMzg5ZDUyNDEwMTRmOTlhXzQ2MzI_1038372d-571e-4357-95bc-38246a23c6a5"
      unitRef="shares">8342128</selb:ClassOfWarrantOrRightNumberOfWarrantsExercised>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i06e21592f529454490acff73efadbef0_I20191218"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDEvZnJhZzoxMTE4YWMxYjVhM2Y0M2ViYjM4OWQ1MjQxMDE0Zjk5YS90ZXh0cmVnaW9uOjExMThhYzFiNWEzZjQzZWJiMzg5ZDUyNDEwMTRmOTlhXzQ2ODI_5e2b437d-dbaa-4ada-b8d1-942c2be767d2"
      unitRef="usdPerShare">1.46</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="ibb1098ccfa7945aa92c2145f660cec87_I20191218"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDEvZnJhZzoxMTE4YWMxYjVhM2Y0M2ViYjM4OWQ1MjQxMDE0Zjk5YS90ZXh0cmVnaW9uOjExMThhYzFiNWEzZjQzZWJiMzg5ZDUyNDEwMTRmOTlhXzQ4NDk_6350c361-17c0-40f7-aec6-a4b80484b9df"
      unitRef="usdPerShare">0.0001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i06e21592f529454490acff73efadbef0_I20191218"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDEvZnJhZzoxMTE4YWMxYjVhM2Y0M2ViYjM4OWQ1MjQxMDE0Zjk5YS90ZXh0cmVnaW9uOjExMThhYzFiNWEzZjQzZWJiMzg5ZDUyNDEwMTRmOTlhXzQ5MTM_5e2b437d-dbaa-4ada-b8d1-942c2be767d2"
      unitRef="usdPerShare">1.46</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <selb:WarrantIssued
      contextRef="iff262d3fceb04558bb91b0665eb3295e_D20191218-20191218"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDEvZnJhZzoxMTE4YWMxYjVhM2Y0M2ViYjM4OWQ1MjQxMDE0Zjk5YS90ZXh0cmVnaW9uOjExMThhYzFiNWEzZjQzZWJiMzg5ZDUyNDEwMTRmOTlhXzU0NzM_c1b509aa-35dc-43c8-ab0b-d899c4f23e08"
      unitRef="usd">40700000</selb:WarrantIssued>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="iff262d3fceb04558bb91b0665eb3295e_D20191218-20191218"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDEvZnJhZzoxMTE4YWMxYjVhM2Y0M2ViYjM4OWQ1MjQxMDE0Zjk5YS90ZXh0cmVnaW9uOjExMThhYzFiNWEzZjQzZWJiMzg5ZDUyNDEwMTRmOTlhXzU3NzI_ba1c6582-03be-4651-a8c8-c72e78bf78be"
      unitRef="usd">65600000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="i40f7108f907b4381983c3f10bfbcbd06_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDEvZnJhZzoxMTE4YWMxYjVhM2Y0M2ViYjM4OWQ1MjQxMDE0Zjk5YS90ZXh0cmVnaW9uOjExMThhYzFiNWEzZjQzZWJiMzg5ZDUyNDEwMTRmOTlhXzU4Mzc_c000cdd1-2b80-460f-9c47-acb8c3de7729"
      unitRef="usd">4400000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="i3c29e75c7cde4be78a2c3d04f4678b57_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDEvZnJhZzoxMTE4YWMxYjVhM2Y0M2ViYjM4OWQ1MjQxMDE0Zjk5YS90ZXh0cmVnaW9uOjExMThhYzFiNWEzZjQzZWJiMzg5ZDUyNDEwMTRmOTlhXzU5Njc_b4d1e500-8e13-43ce-bb35-6a645dea4874"
      unitRef="usd">45500000</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount
      contextRef="i2d7bd840e7b3429ba469e9ff77e35cdc_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDEvZnJhZzoxMTE4YWMxYjVhM2Y0M2ViYjM4OWQ1MjQxMDE0Zjk5YS90ZXh0cmVnaW9uOjExMThhYzFiNWEzZjQzZWJiMzg5ZDUyNDEwMTRmOTlhXzYxMTM_80ab4fc7-cbe6-4028-b00c-cfa8bbf4fbb2"
      unitRef="usd">-16700000</us-gaap:WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount>
    <us-gaap:WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount
      contextRef="i40f7108f907b4381983c3f10bfbcbd06_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDEvZnJhZzoxMTE4YWMxYjVhM2Y0M2ViYjM4OWQ1MjQxMDE0Zjk5YS90ZXh0cmVnaW9uOjExMThhYzFiNWEzZjQzZWJiMzg5ZDUyNDEwMTRmOTlhXzYxMjg_93ae8298-4f9e-452b-b89d-0a4b74b5901e"
      unitRef="usd">-800000</us-gaap:WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock
      contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDEvZnJhZzoxMTE4YWMxYjVhM2Y0M2ViYjM4OWQ1MjQxMDE0Zjk5YS90ZXh0cmVnaW9uOjExMThhYzFiNWEzZjQzZWJiMzg5ZDUyNDEwMTRmOTlhXzExNTU5_7d235c3f-5857-4f73-bed5-cdb073ec9274">&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.361%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of Warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Equity&lt;br/&gt;&#160;classified&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Liability classified&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted average&lt;br/&gt;exercise price&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Outstanding at March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;292,469&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12,085,547&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12,378,016&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="ib2148f5a0b034c99a308352e1c25d052_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDEvZnJhZzoxMTE4YWMxYjVhM2Y0M2ViYjM4OWQ1MjQxMDE0Zjk5YS90YWJsZTo5ZDg2ZjkwNDFlMmM0MWQ1YjYxNDdmNzc0MWIwYTE5Yi90YWJsZXJhbmdlOjlkODZmOTA0MWUyYzQxZDViNjE0N2Y3NzQxYjBhMTliXzctMS0xLTEtMA_e98270fb-3dd3-402d-9b04-8a60f23fdea5"
      unitRef="shares">292469000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="id99ce4003b574f658d3b62852041d661_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDEvZnJhZzoxMTE4YWMxYjVhM2Y0M2ViYjM4OWQ1MjQxMDE0Zjk5YS90YWJsZTo5ZDg2ZjkwNDFlMmM0MWQ1YjYxNDdmNzc0MWIwYTE5Yi90YWJsZXJhbmdlOjlkODZmOTA0MWUyYzQxZDViNjE0N2Y3NzQxYjBhMTliXzctMy0xLTEtMA_b79572b4-b849-4255-afc9-97193bec48e0"
      unitRef="shares">12085547000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="ied8d945ebce54ed8a4badfed477a64e8_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDEvZnJhZzoxMTE4YWMxYjVhM2Y0M2ViYjM4OWQ1MjQxMDE0Zjk5YS90YWJsZTo5ZDg2ZjkwNDFlMmM0MWQ1YjYxNDdmNzc0MWIwYTE5Yi90YWJsZXJhbmdlOjlkODZmOTA0MWUyYzQxZDViNjE0N2Y3NzQxYjBhMTliXzctNS0xLTEtMA_bb88f0a7-9ff7-49ee-84fc-8c8129f4a17e"
      unitRef="shares">12378016000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="ied8d945ebce54ed8a4badfed477a64e8_I20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDEvZnJhZzoxMTE4YWMxYjVhM2Y0M2ViYjM4OWQ1MjQxMDE0Zjk5YS90YWJsZTo5ZDg2ZjkwNDFlMmM0MWQ1YjYxNDdmNzc0MWIwYTE5Yi90YWJsZXJhbmdlOjlkODZmOTA0MWUyYzQxZDViNjE0N2Y3NzQxYjBhMTliXzctNy0xLTEtMA_0cc8bd4c-e617-4d0b-ab17-542ebbf5ba37"
      unitRef="usdPerShare">1.60</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i23a3406d8ff1477aa084b096803061e3_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDEvZnJhZzoxMTE4YWMxYjVhM2Y0M2ViYjM4OWQ1MjQxMDE0Zjk5YS90ZXh0cmVnaW9uOjExMThhYzFiNWEzZjQzZWJiMzg5ZDUyNDEwMTRmOTlhXzEwNjA0_7b24854a-8893-4a18-8369-6e0ccb0faa37"
      unitRef="shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i23a3406d8ff1477aa084b096803061e3_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDEvZnJhZzoxMTE4YWMxYjVhM2Y0M2ViYjM4OWQ1MjQxMDE0Zjk5YS90ZXh0cmVnaW9uOjExMThhYzFiNWEzZjQzZWJiMzg5ZDUyNDEwMTRmOTlhXzEwNjU1_ad2f46c2-c615-4d94-afaa-6fa649a52210"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ied8d945ebce54ed8a4badfed477a64e8_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDEvZnJhZzoxMTE4YWMxYjVhM2Y0M2ViYjM4OWQ1MjQxMDE0Zjk5YS90ZXh0cmVnaW9uOjExMThhYzFiNWEzZjQzZWJiMzg5ZDUyNDEwMTRmOTlhXzEwNjg0_5e6b63be-c555-4ad9-bc86-b7fe92344e54"
      unitRef="shares">112977004</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="ied8d945ebce54ed8a4badfed477a64e8_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDEvZnJhZzoxMTE4YWMxYjVhM2Y0M2ViYjM4OWQ1MjQxMDE0Zjk5YS90ZXh0cmVnaW9uOjExMThhYzFiNWEzZjQzZWJiMzg5ZDUyNDEwMTRmOTlhXzEwNjg0_de115b88-a39b-41d7-9371-d387957d29f6"
      unitRef="shares">112977004</us-gaap:CommonStockSharesIssued>
    <selb:VotesPerShareofCommonStock
      contextRef="ied8d945ebce54ed8a4badfed477a64e8_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDEvZnJhZzoxMTE4YWMxYjVhM2Y0M2ViYjM4OWQ1MjQxMDE0Zjk5YS90ZXh0cmVnaW9uOjExMThhYzFiNWEzZjQzZWJiMzg5ZDUyNDEwMTRmOTlhXzEwOTc5_82bae4b5-8a69-46b3-8966-467595eb26e1"
      unitRef="vote">1</selb:VotesPerShareofCommonStock>
    <us-gaap:DividendsCommonStock
      contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDEvZnJhZzoxMTE4YWMxYjVhM2Y0M2ViYjM4OWQ1MjQxMDE0Zjk5YS90ZXh0cmVnaW9uOjExMThhYzFiNWEzZjQzZWJiMzg5ZDUyNDEwMTRmOTlhXzExMjI2_e38cdd38-6bef-497d-9805-44be7385b69e"
      unitRef="usd">0</us-gaap:DividendsCommonStock>
    <us-gaap:ScheduleOfStockByClassTextBlock
      contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDEvZnJhZzoxMTE4YWMxYjVhM2Y0M2ViYjM4OWQ1MjQxMDE0Zjk5YS90ZXh0cmVnaW9uOjExMThhYzFiNWEzZjQzZWJiMzg5ZDUyNDEwMTRmOTlhXzExNTYx_e596e7c1-6a3b-44db-a628-e55502fb84b4">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has authorized shares of common stock for future issuance as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.929%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.522%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Period ended&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Exercise of common warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12,378,016&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12,378,016&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Shares available for future stock incentive awards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,719,817&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,916,374&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;RSUs reserved for issuance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;98,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Unvested restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;544,313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;87,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Outstanding common stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10,187,394&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,775,249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;30,928,290&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;25,157,139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfStockByClassTextBlock>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="ib2148f5a0b034c99a308352e1c25d052_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDEvZnJhZzoxMTE4YWMxYjVhM2Y0M2ViYjM4OWQ1MjQxMDE0Zjk5YS90YWJsZTo0MTQ1YWUzZDgxOGY0ZWZmYTM3NjZmYTdlYTU4NWQ2Ni90YWJsZXJhbmdlOjQxNDVhZTNkODE4ZjRlZmZhMzc2NmZhN2VhNTg1ZDY2XzItMS0xLTEtMA_bf8bd56b-cfb5-4bc1-84fd-c025619954dc"
      unitRef="shares">12378016</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="id201ea1fc8cd4bc2957bd09c9be775f9_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDEvZnJhZzoxMTE4YWMxYjVhM2Y0M2ViYjM4OWQ1MjQxMDE0Zjk5YS90YWJsZTo0MTQ1YWUzZDgxOGY0ZWZmYTM3NjZmYTdlYTU4NWQ2Ni90YWJsZXJhbmdlOjQxNDVhZTNkODE4ZjRlZmZhMzc2NmZhN2VhNTg1ZDY2XzItMy0xLTEtMA_34ec6ed8-ecb4-4e43-827b-598c4f75a669"
      unitRef="shares">12378016</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i766bfbe0d62646d1ae2d0abb4d722110_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDEvZnJhZzoxMTE4YWMxYjVhM2Y0M2ViYjM4OWQ1MjQxMDE0Zjk5YS90YWJsZTo0MTQ1YWUzZDgxOGY0ZWZmYTM3NjZmYTdlYTU4NWQ2Ni90YWJsZXJhbmdlOjQxNDVhZTNkODE4ZjRlZmZhMzc2NmZhN2VhNTg1ZDY2XzMtMS0xLTEtMA_aee106c3-8ce1-4d58-8c8c-8b1c58f277b4"
      unitRef="shares">7719817</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="ic80bb38a87b34cd5bae8a1c9d61a28e8_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDEvZnJhZzoxMTE4YWMxYjVhM2Y0M2ViYjM4OWQ1MjQxMDE0Zjk5YS90YWJsZTo0MTQ1YWUzZDgxOGY0ZWZmYTM3NjZmYTdlYTU4NWQ2Ni90YWJsZXJhbmdlOjQxNDVhZTNkODE4ZjRlZmZhMzc2NmZhN2VhNTg1ZDY2XzMtMy0xLTEtMA_8ae62563-68db-4a4a-9786-559d20c2d7c8"
      unitRef="shares">4916374</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="icaed7df33b254fc68b5b0e15b600935f_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDEvZnJhZzoxMTE4YWMxYjVhM2Y0M2ViYjM4OWQ1MjQxMDE0Zjk5YS90YWJsZTo0MTQ1YWUzZDgxOGY0ZWZmYTM3NjZmYTdlYTU4NWQ2Ni90YWJsZXJhbmdlOjQxNDVhZTNkODE4ZjRlZmZhMzc2NmZhN2VhNTg1ZDY2XzQtMS0xLTEtMA_e68526ba-b20e-40d1-8663-fd0dadbeb83b"
      unitRef="shares">98750</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i9ef78f70a7c34162bf4e7727fba544cc_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDEvZnJhZzoxMTE4YWMxYjVhM2Y0M2ViYjM4OWQ1MjQxMDE0Zjk5YS90YWJsZTo0MTQ1YWUzZDgxOGY0ZWZmYTM3NjZmYTdlYTU4NWQ2Ni90YWJsZXJhbmdlOjQxNDVhZTNkODE4ZjRlZmZhMzc2NmZhN2VhNTg1ZDY2XzQtMy0xLTEtMA_d2f66455-f61e-44dd-bb11-29128ad851e8"
      unitRef="shares">0</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i8c5ceec4ab9b487193df89666ccf91d3_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDEvZnJhZzoxMTE4YWMxYjVhM2Y0M2ViYjM4OWQ1MjQxMDE0Zjk5YS90YWJsZTo0MTQ1YWUzZDgxOGY0ZWZmYTM3NjZmYTdlYTU4NWQ2Ni90YWJsZXJhbmdlOjQxNDVhZTNkODE4ZjRlZmZhMzc2NmZhN2VhNTg1ZDY2XzUtMS0xLTEtMA_1fc375be-c0cf-467c-a157-5a957270b6a4"
      unitRef="shares">544313</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i2595e8b300194cc6bb08ac9d33e9eaf8_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDEvZnJhZzoxMTE4YWMxYjVhM2Y0M2ViYjM4OWQ1MjQxMDE0Zjk5YS90YWJsZTo0MTQ1YWUzZDgxOGY0ZWZmYTM3NjZmYTdlYTU4NWQ2Ni90YWJsZXJhbmdlOjQxNDVhZTNkODE4ZjRlZmZhMzc2NmZhN2VhNTg1ZDY2XzUtMy0xLTEtMA_b8aa61ca-4c76-49f0-ae03-d84737d68f22"
      unitRef="shares">87500</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="idc47c16592ad4e7c88824de49ffb8420_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDEvZnJhZzoxMTE4YWMxYjVhM2Y0M2ViYjM4OWQ1MjQxMDE0Zjk5YS90YWJsZTo0MTQ1YWUzZDgxOGY0ZWZmYTM3NjZmYTdlYTU4NWQ2Ni90YWJsZXJhbmdlOjQxNDVhZTNkODE4ZjRlZmZhMzc2NmZhN2VhNTg1ZDY2XzYtMS0xLTEtMA_ca597574-2d82-4725-9881-046ea30aedc4"
      unitRef="shares">10187394</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="iaa1769cc2fd04d9ab84daf10f681742a_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDEvZnJhZzoxMTE4YWMxYjVhM2Y0M2ViYjM4OWQ1MjQxMDE0Zjk5YS90YWJsZTo0MTQ1YWUzZDgxOGY0ZWZmYTM3NjZmYTdlYTU4NWQ2Ni90YWJsZXJhbmdlOjQxNDVhZTNkODE4ZjRlZmZhMzc2NmZhN2VhNTg1ZDY2XzYtMy0xLTEtMA_b1b8f43d-a3d6-4494-8de5-555576a35c5d"
      unitRef="shares">7775249</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="ied8d945ebce54ed8a4badfed477a64e8_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDEvZnJhZzoxMTE4YWMxYjVhM2Y0M2ViYjM4OWQ1MjQxMDE0Zjk5YS90YWJsZTo0MTQ1YWUzZDgxOGY0ZWZmYTM3NjZmYTdlYTU4NWQ2Ni90YWJsZXJhbmdlOjQxNDVhZTNkODE4ZjRlZmZhMzc2NmZhN2VhNTg1ZDY2XzctMS0xLTEtMA_645c945d-7f1d-4812-9a42-99b7e0ddef08"
      unitRef="shares">30928290</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="ib56f1adc867e406ca7face50c5da1c9c_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDEvZnJhZzoxMTE4YWMxYjVhM2Y0M2ViYjM4OWQ1MjQxMDE0Zjk5YS90YWJsZTo0MTQ1YWUzZDgxOGY0ZWZmYTM3NjZmYTdlYTU4NWQ2Ni90YWJsZXJhbmdlOjQxNDVhZTNkODE4ZjRlZmZhMzc2NmZhN2VhNTg1ZDY2XzctMy0xLTEtMA_0bbf6528-07f9-4252-baf5-0bec77138c21"
      unitRef="shares">25157139</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDQvZnJhZzo0MjVlMGY1ZWY3ZmI0MDgxOGVlMDFlNTc4Y2VhMWNjYy90ZXh0cmVnaW9uOjQyNWUwZjVlZjdmYjQwODE4ZWUwMWU1NzhjZWExY2NjXzEwOTI1_142c91c9-7818-474c-bc1b-e96702ddb76a">Stock Incentive Plans&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company maintains the 2008 Stock Incentive Plan, or the 2008 Plan, for employees, consultants, advisors, and directors. The 2008 Plan provided for the granting of incentive and non-qualified stock option and restricted stock awards as determined by the Board. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2016, the Company&#x2019;s stockholders approved the 2016 Incentive Award Plan, or the 2016 Plan, which authorized 1,210,256 shares of common stock for future issuance under the 2016 Plan and ceased granting awards under the 2008 Plan. Upon the effective date of the 2016 Plan, awards issued under the 2008 Plan remain subject to the terms of the 2008 Plan. Awards granted under the 2008 Plan that expire, lapse or terminate become available under the 2016 Plan as shares available for future grants.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additionally, pursuant to the terms of the 2016 Plan, the Board is authorized to grant awards with respect to common stock, and may delegate to a committee of one or more members of the Board or executive officers of the Company the authority to grant options and restricted stock units. On December 9, 2020, the Board established a Stock Option Committee authorized to grant awards to certain employees and consultants subject to conditions and limitations within the 2016 Plan. In January 2021 and 2020, the number of shares of common stock that may be issued under the 2016 Plan was increased by 4,322,850 and 3,453,022 shares, respectively. As of March 31, 2021, 3,248,520 shares remain available for future issuance under the 2016 Plan.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2018, the Company&#x2019;s 2018 Employment Inducement Incentive Award Plan, or the 2018 Inducement Incentive Award Plan was adopted by the Board without stockholder approval pursuant to Rule 5635(c)(4) of the Nasdaq Stock Market LLC listing rules, which authorized 1,175,000 shares of its common stock for issuance. In March 2019, the Board approved the amendment and restatement of the 2018 Inducement Incentive Award Plan to reserve an additional 2,000,000 shares of the Company&#x2019;s common stock for issuance thereunder. As of March 31, 2021, there are 1,358,333 shares available for future grant under the 2018 Inducement Incentive Award Plan.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Stock-based Compensation Expense&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock-based compensation expense by classification included within the condensed consolidated statements of operations and comprehensive loss was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.777%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;754&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;623&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,026&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;786&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Total stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,780&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,409&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Stock Options&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Employees&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated grant date fair values of employee stock option awards granted under the 2016 Plan and the 2018 Inducement Incentive Award Plan were calculated using the Black-Scholes option pricing model, based on the following weighted-average assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.777%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Expected term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.28&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.08&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;83.26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;87.96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Weighted-average fair value of common stock&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted average grant date fair value of stock options granted to employees during the three months ended March 31, 2021 and 2020 was $1.99 and $1.69, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March 31, 2021 total unrecognized compensation expense related to unvested employee stock options was $11.8 million, which is expected to be recognized over a weighted average period of 2.7 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Non-employee consultants&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March 31, 2021, there was no unrecognized compensation expense related to non-employee consultants stock options.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the stock option activity under the 2008 Plan, 2016 Plan, and 2018 Inducement Incentive Award Plan:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.321%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.501%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-average&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;remaining&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number&#160;of&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-average&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;contractual&#160;term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;intrinsic&#160;value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;exercise price ($)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in&#160;years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in&#160;thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Employees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,302,176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.43&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,456&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,628,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(153,278)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(62,577)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Outstanding at March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9,714,321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.65&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15,665&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Vested at March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,064,130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.63&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Vested and expected to vest at March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,920,548&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.59&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14,231&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Non-employee consultants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;473,073&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.23&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Outstanding at March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;473,073&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.98&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;366&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Vested at March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;462,186&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.92&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;366&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Vested and expected to vest at March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;473,073&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.98&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;366&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Restricted Stock Units&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2021, the Company granted 369,800 restricted stock awards to employees under the 2016 Plan which will vest over a four year term.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, during the first quarter of 2021, the Company awarded 197,500 restricted stock units to executives under the 2016 Plan, of which 98,750 were determined to be granted as of the award date consistent with ASC 718. The remaining 98,750 restricted stock units do not have a defined performance metric as of the award date, resulting in the restricted stock units being reserved for future issuance as of March 31, 2021. These restricted stock units will vest in two equal installments on the dates &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;an applicable performance condition is achieved, on or prior to December 31, 2021. If the performance conditions are not satisfied on or prior to December 31, 2021, the restricted stock units will be forfeited for no consideration.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The restricted stock units granted had a weighted average fair value of $2.99 per share based on the closing price of the Company&#x2019;s common stock on the date of grant. The restricted stock units were valued at approximately $1.4 million on their grant date. Forfeitures are estimated at the time of grant and are adjusted, if necessary, in subsequent periods if actual forfeitures differ from those estimates. The Company has estimated a forfeiture rate of 10% for restricted stock awards to employees based on historical attrition trends.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unrecognized compensation expense for all restricted stock units was $1.5 million as of March 31, 2021, which is expected to be recognized over a weighted average period of 3.1 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the Company&#x2019;s restricted stock units under the 2016 Plan and 2018 Inducement Incentive Award Plan:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:69.721%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.122%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.124%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted average&lt;br/&gt;grant date&lt;br/&gt;fair value ($)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Unvested at December 31, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;87,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.03&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;468,550&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(10,937)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.03&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Reserved for issuance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;98,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(800)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Unvested at March 31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;643,063&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Employee Stock Purchase Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2016, the Company approved the 2016 Employee Stock Purchase Plan, or the ESPP, which authorized 173,076 shares of common stock for future issuance under the ESPP to participating employees. In January 2021 and 2020, the number of shares of common stock authorized for issuance under the ESPP was increased by 1,080,711 shares and 863,254 shares, respectively. During the three months ended March 31, 2021, the Company issued 34,696 shares of common stock under the ESPP. As of March 31, 2021, 2,546,464 shares remain available for future issuance under the ESPP.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For each of the three months ended March 31, 2021 and 2020, the Company recognized less than $0.1 million of stock-based compensation expense under the ESPP.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i659c0d6b1a6b4dde9d2d66b377a3e370_I20160621"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDQvZnJhZzo0MjVlMGY1ZWY3ZmI0MDgxOGVlMDFlNTc4Y2VhMWNjYy90ZXh0cmVnaW9uOjQyNWUwZjVlZjdmYjQwODE4ZWUwMWU1NzhjZWExY2NjXzIxOTkwMjMyNzkzOTI_2ad174f4-f1cc-486b-a560-2589b4f81023"
      unitRef="shares">1210256</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <selb:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantIncreaseDecrease
      contextRef="ic5906043b3594f21b5de7208dd3fa609_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDQvZnJhZzo0MjVlMGY1ZWY3ZmI0MDgxOGVlMDFlNTc4Y2VhMWNjYy90ZXh0cmVnaW9uOjQyNWUwZjVlZjdmYjQwODE4ZWUwMWU1NzhjZWExY2NjXzI0NzQ_d764ffec-257a-4e5e-b47a-04b82ff5225c"
      unitRef="shares">4322850</selb:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantIncreaseDecrease>
    <selb:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantIncreaseDecrease
      contextRef="ib2627fa0b80846ab8d39c202e998d601_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDQvZnJhZzo0MjVlMGY1ZWY3ZmI0MDgxOGVlMDFlNTc4Y2VhMWNjYy90ZXh0cmVnaW9uOjQyNWUwZjVlZjdmYjQwODE4ZWUwMWU1NzhjZWExY2NjXzI0ODg_c205e766-d214-4715-b8ce-10f80395c709"
      unitRef="shares">3453022</selb:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantIncreaseDecrease>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i91178c8223ca4306a02f4027a764b423_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDQvZnJhZzo0MjVlMGY1ZWY3ZmI0MDgxOGVlMDFlNTc4Y2VhMWNjYy90ZXh0cmVnaW9uOjQyNWUwZjVlZjdmYjQwODE4ZWUwMWU1NzhjZWExY2NjXzI1MjM_99fe061b-c116-437c-85c4-9483a12abbe9"
      unitRef="shares">3248520</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i897bb148c3bb4abb9ea043f39a5a1bbe_I20180925"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDQvZnJhZzo0MjVlMGY1ZWY3ZmI0MDgxOGVlMDFlNTc4Y2VhMWNjYy90ZXh0cmVnaW9uOjQyNWUwZjVlZjdmYjQwODE4ZWUwMWU1NzhjZWExY2NjXzIxOTkwMjMyODA3NjU_100f674f-a215-43ef-8ed5-7e41941cab64"
      unitRef="shares">1175000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i90b02123a489453691cedc67052e854c_I20190325"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDQvZnJhZzo0MjVlMGY1ZWY3ZmI0MDgxOGVlMDFlNTc4Y2VhMWNjYy90ZXh0cmVnaW9uOjQyNWUwZjVlZjdmYjQwODE4ZWUwMWU1NzhjZWExY2NjXzIxOTkwMjMyODExMzQ_99c1dfcd-01b2-44bb-993d-0f3f5bdd6b75"
      unitRef="shares">2000000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="ifb4e42c6f6c44e0f9158bb1c44089423_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDQvZnJhZzo0MjVlMGY1ZWY3ZmI0MDgxOGVlMDFlNTc4Y2VhMWNjYy90ZXh0cmVnaW9uOjQyNWUwZjVlZjdmYjQwODE4ZWUwMWU1NzhjZWExY2NjXzQzNjk_e3a3017d-e3e9-468a-bb00-3e14233cb4b9"
      unitRef="shares">1358333</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock
      contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDQvZnJhZzo0MjVlMGY1ZWY3ZmI0MDgxOGVlMDFlNTc4Y2VhMWNjYy90ZXh0cmVnaW9uOjQyNWUwZjVlZjdmYjQwODE4ZWUwMWU1NzhjZWExY2NjXzQzOTgwNDY1NDM3MTQ_01b2bc1c-50c6-4187-bea2-125541ca1ee0">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock-based compensation expense by classification included within the condensed consolidated statements of operations and comprehensive loss was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.777%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;754&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;623&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,026&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;786&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Total stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,780&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,409&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i16033c04e5ea4cc5bbfdba5f3c1bd666_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDQvZnJhZzo0MjVlMGY1ZWY3ZmI0MDgxOGVlMDFlNTc4Y2VhMWNjYy90YWJsZTowMjRhMTIxMDlhNjQ0NzdiYmNiMDM4OTI3ZGRjYzUyNi90YWJsZXJhbmdlOjAyNGExMjEwOWE2NDQ3N2JiY2IwMzg5MjdkZGNjNTI2XzItMS0xLTEtNTkxMw_0219efe6-209d-4dea-92e1-1491113063d8"
      unitRef="usd">754000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i723babe8bc8f40e0843af46b5e72961b_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDQvZnJhZzo0MjVlMGY1ZWY3ZmI0MDgxOGVlMDFlNTc4Y2VhMWNjYy90YWJsZTowMjRhMTIxMDlhNjQ0NzdiYmNiMDM4OTI3ZGRjYzUyNi90YWJsZXJhbmdlOjAyNGExMjEwOWE2NDQ3N2JiY2IwMzg5MjdkZGNjNTI2XzItMy0xLTEtNTkxMw_24d887a6-7e3a-4403-a378-8ffccb145654"
      unitRef="usd">623000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i448d50e1226e459ca3870f9edd8b9fef_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDQvZnJhZzo0MjVlMGY1ZWY3ZmI0MDgxOGVlMDFlNTc4Y2VhMWNjYy90YWJsZTowMjRhMTIxMDlhNjQ0NzdiYmNiMDM4OTI3ZGRjYzUyNi90YWJsZXJhbmdlOjAyNGExMjEwOWE2NDQ3N2JiY2IwMzg5MjdkZGNjNTI2XzMtMS0xLTEtNTkxMw_711564fc-7c9c-4bfa-a855-847dd19cb17d"
      unitRef="usd">1026000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i45408aeb6dc44b58bc7a8d6958d23e54_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDQvZnJhZzo0MjVlMGY1ZWY3ZmI0MDgxOGVlMDFlNTc4Y2VhMWNjYy90YWJsZTowMjRhMTIxMDlhNjQ0NzdiYmNiMDM4OTI3ZGRjYzUyNi90YWJsZXJhbmdlOjAyNGExMjEwOWE2NDQ3N2JiY2IwMzg5MjdkZGNjNTI2XzMtMy0xLTEtNTkxMw_e979bb2a-e2d3-4f83-853a-1a5e308a621f"
      unitRef="usd">786000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDQvZnJhZzo0MjVlMGY1ZWY3ZmI0MDgxOGVlMDFlNTc4Y2VhMWNjYy90YWJsZTowMjRhMTIxMDlhNjQ0NzdiYmNiMDM4OTI3ZGRjYzUyNi90YWJsZXJhbmdlOjAyNGExMjEwOWE2NDQ3N2JiY2IwMzg5MjdkZGNjNTI2XzQtMS0xLTEtNjYyMA_4ac763dd-cbed-47fb-ba13-6c6668cc142c"
      unitRef="usd">1780000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i824a5b33f908426bad016f0eded844db_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDQvZnJhZzo0MjVlMGY1ZWY3ZmI0MDgxOGVlMDFlNTc4Y2VhMWNjYy90YWJsZTowMjRhMTIxMDlhNjQ0NzdiYmNiMDM4OTI3ZGRjYzUyNi90YWJsZXJhbmdlOjAyNGExMjEwOWE2NDQ3N2JiY2IwMzg5MjdkZGNjNTI2XzQtMy0xLTEtNjYyMA_d23a6314-8df5-4930-8b17-14cb925d93b3"
      unitRef="usd">1409000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDQvZnJhZzo0MjVlMGY1ZWY3ZmI0MDgxOGVlMDFlNTc4Y2VhMWNjYy90ZXh0cmVnaW9uOjQyNWUwZjVlZjdmYjQwODE4ZWUwMWU1NzhjZWExY2NjXzEwOTQy_2117de08-8723-434c-a2b5-4647071f007f">The estimated grant date fair values of employee stock option awards granted under the 2016 Plan and the 2018 Inducement Incentive Award Plan were calculated using the Black-Scholes option pricing model, based on the following weighted-average assumptions:&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.777%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Expected term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.28&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.08&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;83.26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;87.96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Weighted-average fair value of common stock&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i0a83cea2026d4acd853ecd648a6ff3cf_D20210101-20210331"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDQvZnJhZzo0MjVlMGY1ZWY3ZmI0MDgxOGVlMDFlNTc4Y2VhMWNjYy90YWJsZTo1MWE4MGFhZTY1YTc0N2YxYjRjYTg3OThiMjIyYWNmMy90YWJsZXJhbmdlOjUxYTgwYWFlNjVhNzQ3ZjFiNGNhODc5OGIyMjJhY2YzXzItMS0xLTEtMA_6cc444a4-5923-4b58-aee4-642ab2ea4605"
      unitRef="number">0.0044</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i0a02cb62522c49fd9f650c7a972a0090_D20200101-20200331"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDQvZnJhZzo0MjVlMGY1ZWY3ZmI0MDgxOGVlMDFlNTc4Y2VhMWNjYy90YWJsZTo1MWE4MGFhZTY1YTc0N2YxYjRjYTg3OThiMjIyYWNmMy90YWJsZXJhbmdlOjUxYTgwYWFlNjVhNzQ3ZjFiNGNhODc5OGIyMjJhY2YzXzItMy0xLTEtMA_a50a6fc5-76c0-4f69-b149-7b2c1df7c52d"
      unitRef="number">0.0173</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i0a83cea2026d4acd853ecd648a6ff3cf_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDQvZnJhZzo0MjVlMGY1ZWY3ZmI0MDgxOGVlMDFlNTc4Y2VhMWNjYy90YWJsZTo1MWE4MGFhZTY1YTc0N2YxYjRjYTg3OThiMjIyYWNmMy90YWJsZXJhbmdlOjUxYTgwYWFlNjVhNzQ3ZjFiNGNhODc5OGIyMjJhY2YzXzMtMS0xLTEtMA_b53eba09-6b3c-4a5e-ad7c-6184da476375"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i0a02cb62522c49fd9f650c7a972a0090_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDQvZnJhZzo0MjVlMGY1ZWY3ZmI0MDgxOGVlMDFlNTc4Y2VhMWNjYy90YWJsZTo1MWE4MGFhZTY1YTc0N2YxYjRjYTg3OThiMjIyYWNmMy90YWJsZXJhbmdlOjUxYTgwYWFlNjVhNzQ3ZjFiNGNhODc5OGIyMjJhY2YzXzMtMy0xLTEtMA_d7fe0df5-906a-4b20-8fce-b6c1043b659a"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i0a83cea2026d4acd853ecd648a6ff3cf_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDQvZnJhZzo0MjVlMGY1ZWY3ZmI0MDgxOGVlMDFlNTc4Y2VhMWNjYy90YWJsZTo1MWE4MGFhZTY1YTc0N2YxYjRjYTg3OThiMjIyYWNmMy90YWJsZXJhbmdlOjUxYTgwYWFlNjVhNzQ3ZjFiNGNhODc5OGIyMjJhY2YzXzQtMS0xLTEtMA_298b99df-fdcd-4254-8a06-31bd8708996c">P5Y3M10D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i0a02cb62522c49fd9f650c7a972a0090_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDQvZnJhZzo0MjVlMGY1ZWY3ZmI0MDgxOGVlMDFlNTc4Y2VhMWNjYy90YWJsZTo1MWE4MGFhZTY1YTc0N2YxYjRjYTg3OThiMjIyYWNmMy90YWJsZXJhbmdlOjUxYTgwYWFlNjVhNzQ3ZjFiNGNhODc5OGIyMjJhY2YzXzQtMy0xLTEtMA_75b48c03-46c3-4e02-924c-f5fc350b4e9d">P6Y29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i0a83cea2026d4acd853ecd648a6ff3cf_D20210101-20210331"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDQvZnJhZzo0MjVlMGY1ZWY3ZmI0MDgxOGVlMDFlNTc4Y2VhMWNjYy90YWJsZTo1MWE4MGFhZTY1YTc0N2YxYjRjYTg3OThiMjIyYWNmMy90YWJsZXJhbmdlOjUxYTgwYWFlNjVhNzQ3ZjFiNGNhODc5OGIyMjJhY2YzXzUtMS0xLTEtMA_d46f822a-db5b-44fe-b455-95089ee6e683"
      unitRef="number">0.8326</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i0a02cb62522c49fd9f650c7a972a0090_D20200101-20200331"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDQvZnJhZzo0MjVlMGY1ZWY3ZmI0MDgxOGVlMDFlNTc4Y2VhMWNjYy90YWJsZTo1MWE4MGFhZTY1YTc0N2YxYjRjYTg3OThiMjIyYWNmMy90YWJsZXJhbmdlOjUxYTgwYWFlNjVhNzQ3ZjFiNGNhODc5OGIyMjJhY2YzXzUtMy0xLTEtMA_b9ced0da-3ca4-4785-8e3a-9505a98a4d7b"
      unitRef="number">0.8796</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <selb:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageFairValue
      contextRef="i0a83cea2026d4acd853ecd648a6ff3cf_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDQvZnJhZzo0MjVlMGY1ZWY3ZmI0MDgxOGVlMDFlNTc4Y2VhMWNjYy90YWJsZTo1MWE4MGFhZTY1YTc0N2YxYjRjYTg3OThiMjIyYWNmMy90YWJsZXJhbmdlOjUxYTgwYWFlNjVhNzQ3ZjFiNGNhODc5OGIyMjJhY2YzXzYtMS0xLTEtMA_94bef706-e969-4d94-85b2-bc3898a7fb43"
      unitRef="usdPerShare">3.13</selb:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageFairValue>
    <selb:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageFairValue
      contextRef="i0a02cb62522c49fd9f650c7a972a0090_D20200101-20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDQvZnJhZzo0MjVlMGY1ZWY3ZmI0MDgxOGVlMDFlNTc4Y2VhMWNjYy90YWJsZTo1MWE4MGFhZTY1YTc0N2YxYjRjYTg3OThiMjIyYWNmMy90YWJsZXJhbmdlOjUxYTgwYWFlNjVhNzQ3ZjFiNGNhODc5OGIyMjJhY2YzXzYtMy0xLTEtMA_39fd7a9d-abaa-48cb-b6fa-71fd30eb86d3"
      unitRef="usdPerShare">2.30</selb:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i0a83cea2026d4acd853ecd648a6ff3cf_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDQvZnJhZzo0MjVlMGY1ZWY3ZmI0MDgxOGVlMDFlNTc4Y2VhMWNjYy90ZXh0cmVnaW9uOjQyNWUwZjVlZjdmYjQwODE4ZWUwMWU1NzhjZWExY2NjXzYzMTc_96c73f13-1dcb-4f9e-bcf8-6aa1a1138081"
      unitRef="usdPerShare">1.99</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i0a02cb62522c49fd9f650c7a972a0090_D20200101-20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDQvZnJhZzo0MjVlMGY1ZWY3ZmI0MDgxOGVlMDFlNTc4Y2VhMWNjYy90ZXh0cmVnaW9uOjQyNWUwZjVlZjdmYjQwODE4ZWUwMWU1NzhjZWExY2NjXzYzMjE_bde8e11d-d763-4056-836e-f89cfe00dc00"
      unitRef="usdPerShare">1.69</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="i766bfbe0d62646d1ae2d0abb4d722110_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDQvZnJhZzo0MjVlMGY1ZWY3ZmI0MDgxOGVlMDFlNTc4Y2VhMWNjYy90ZXh0cmVnaW9uOjQyNWUwZjVlZjdmYjQwODE4ZWUwMWU1NzhjZWExY2NjXzY0NjY_5be765a0-700e-4f50-b234-8c2083428b93"
      unitRef="usd">11800000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i0a83cea2026d4acd853ecd648a6ff3cf_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDQvZnJhZzo0MjVlMGY1ZWY3ZmI0MDgxOGVlMDFlNTc4Y2VhMWNjYy90ZXh0cmVnaW9uOjQyNWUwZjVlZjdmYjQwODE4ZWUwMWU1NzhjZWExY2NjXzY1Njg_1fa312c5-68c3-49c4-bce6-e117d89cb394">P2Y8M12D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <selb:ShareBasedGoodsAndNonEmployeeServicesTransactionCompensationNotYetRecognizedStockOptions
      contextRef="ied8d945ebce54ed8a4badfed477a64e8_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDQvZnJhZzo0MjVlMGY1ZWY3ZmI0MDgxOGVlMDFlNTc4Y2VhMWNjYy90ZXh0cmVnaW9uOjQyNWUwZjVlZjdmYjQwODE4ZWUwMWU1NzhjZWExY2NjXzcxMzQ_286aeb9b-ce18-4267-9895-f9a4edc6de79"
      unitRef="usd">0</selb:ShareBasedGoodsAndNonEmployeeServicesTransactionCompensationNotYetRecognizedStockOptions>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDQvZnJhZzo0MjVlMGY1ZWY3ZmI0MDgxOGVlMDFlNTc4Y2VhMWNjYy90ZXh0cmVnaW9uOjQyNWUwZjVlZjdmYjQwODE4ZWUwMWU1NzhjZWExY2NjXzEwOTQ4_5c680128-3c8e-4aae-9275-b7830a8ddcc5">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the stock option activity under the 2008 Plan, 2016 Plan, and 2018 Inducement Incentive Award Plan:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.321%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.501%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-average&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;remaining&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number&#160;of&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-average&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;contractual&#160;term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;intrinsic&#160;value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;exercise price ($)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in&#160;years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in&#160;thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Employees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,302,176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.43&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,456&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,628,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(153,278)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(62,577)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Outstanding at March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9,714,321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.65&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15,665&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Vested at March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,064,130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.63&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Vested and expected to vest at March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,920,548&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.59&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14,231&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Non-employee consultants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;473,073&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.23&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Outstanding at March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;473,073&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.98&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;366&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Vested at March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;462,186&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.92&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;366&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Vested and expected to vest at March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;473,073&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.98&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;366&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i9b0d673a9945438a9e404b6c6b57eba2_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDQvZnJhZzo0MjVlMGY1ZWY3ZmI0MDgxOGVlMDFlNTc4Y2VhMWNjYy90YWJsZTo1YmZiYjI5MjUwNTM0MGI4YmNkYmVmZGJmOTFjZDQ1ZC90YWJsZXJhbmdlOjViZmJiMjkyNTA1MzQwYjhiY2RiZWZkYmY5MWNkNDVkXzEzLTEtMS0xLTA_2bc25719-4063-46d9-a47c-e2f876b8a950"
      unitRef="shares">7302176</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i9b0d673a9945438a9e404b6c6b57eba2_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDQvZnJhZzo0MjVlMGY1ZWY3ZmI0MDgxOGVlMDFlNTc4Y2VhMWNjYy90YWJsZTo1YmZiYjI5MjUwNTM0MGI4YmNkYmVmZGJmOTFjZDQ1ZC90YWJsZXJhbmdlOjViZmJiMjkyNTA1MzQwYjhiY2RiZWZkYmY5MWNkNDVkXzEzLTMtMS0xLTA_5293d971-ddd3-4a22-b045-02f928861ece"
      unitRef="usdPerShare">3.98</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="icff59de35252465485536be51fa5f610_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDQvZnJhZzo0MjVlMGY1ZWY3ZmI0MDgxOGVlMDFlNTc4Y2VhMWNjYy90YWJsZTo1YmZiYjI5MjUwNTM0MGI4YmNkYmVmZGJmOTFjZDQ1ZC90YWJsZXJhbmdlOjViZmJiMjkyNTA1MzQwYjhiY2RiZWZkYmY5MWNkNDVkXzEzLTUtMS0xLTA_63a60246-1522-4762-9ea4-f8fda931cf5c">P8Y5M4D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i9b0d673a9945438a9e404b6c6b57eba2_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDQvZnJhZzo0MjVlMGY1ZWY3ZmI0MDgxOGVlMDFlNTc4Y2VhMWNjYy90YWJsZTo1YmZiYjI5MjUwNTM0MGI4YmNkYmVmZGJmOTFjZDQ1ZC90YWJsZXJhbmdlOjViZmJiMjkyNTA1MzQwYjhiY2RiZWZkYmY5MWNkNDVkXzEzLTctMS0xLTA_f6a7437f-71da-461c-aef3-70cc7919c0a6"
      unitRef="usd">4456000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="ia87a6b98f0714c88b1aa992fc475f7a1_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDQvZnJhZzo0MjVlMGY1ZWY3ZmI0MDgxOGVlMDFlNTc4Y2VhMWNjYy90YWJsZTo1YmZiYjI5MjUwNTM0MGI4YmNkYmVmZGJmOTFjZDQ1ZC90YWJsZXJhbmdlOjViZmJiMjkyNTA1MzQwYjhiY2RiZWZkYmY5MWNkNDVkXzE0LTEtMS0xLTA_81225d78-cc12-4613-a7f5-12b8aeeb57e1"
      unitRef="shares">2628000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="ia87a6b98f0714c88b1aa992fc475f7a1_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDQvZnJhZzo0MjVlMGY1ZWY3ZmI0MDgxOGVlMDFlNTc4Y2VhMWNjYy90YWJsZTo1YmZiYjI5MjUwNTM0MGI4YmNkYmVmZGJmOTFjZDQ1ZC90YWJsZXJhbmdlOjViZmJiMjkyNTA1MzQwYjhiY2RiZWZkYmY5MWNkNDVkXzE0LTMtMS0xLTA_a7cb8f53-74bc-441a-8248-e1c17d03b472"
      unitRef="usdPerShare">3.13</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="ia87a6b98f0714c88b1aa992fc475f7a1_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDQvZnJhZzo0MjVlMGY1ZWY3ZmI0MDgxOGVlMDFlNTc4Y2VhMWNjYy90YWJsZTo1YmZiYjI5MjUwNTM0MGI4YmNkYmVmZGJmOTFjZDQ1ZC90YWJsZXJhbmdlOjViZmJiMjkyNTA1MzQwYjhiY2RiZWZkYmY5MWNkNDVkXzE1LTEtMS0xLTA_cfafece3-6d30-4863-ae5d-4d0aa2557102"
      unitRef="shares">153278</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="ia87a6b98f0714c88b1aa992fc475f7a1_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDQvZnJhZzo0MjVlMGY1ZWY3ZmI0MDgxOGVlMDFlNTc4Y2VhMWNjYy90YWJsZTo1YmZiYjI5MjUwNTM0MGI4YmNkYmVmZGJmOTFjZDQ1ZC90YWJsZXJhbmdlOjViZmJiMjkyNTA1MzQwYjhiY2RiZWZkYmY5MWNkNDVkXzE1LTMtMS0xLTA_ddefc01a-7454-4357-b68b-6672fcf55507"
      unitRef="usdPerShare">1.47</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="ia87a6b98f0714c88b1aa992fc475f7a1_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDQvZnJhZzo0MjVlMGY1ZWY3ZmI0MDgxOGVlMDFlNTc4Y2VhMWNjYy90YWJsZTo1YmZiYjI5MjUwNTM0MGI4YmNkYmVmZGJmOTFjZDQ1ZC90YWJsZXJhbmdlOjViZmJiMjkyNTA1MzQwYjhiY2RiZWZkYmY5MWNkNDVkXzE2LTEtMS0xLTA_fed62ec7-a332-4c18-a54b-d10a81b9e79e"
      unitRef="shares">62577</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="ia87a6b98f0714c88b1aa992fc475f7a1_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDQvZnJhZzo0MjVlMGY1ZWY3ZmI0MDgxOGVlMDFlNTc4Y2VhMWNjYy90YWJsZTo1YmZiYjI5MjUwNTM0MGI4YmNkYmVmZGJmOTFjZDQ1ZC90YWJsZXJhbmdlOjViZmJiMjkyNTA1MzQwYjhiY2RiZWZkYmY5MWNkNDVkXzE2LTMtMS0xLTA_dde9a69f-0e0a-470f-a100-73fba8f43e4f"
      unitRef="usdPerShare">5.19</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i5a27d4e69f2d4076ab56ee85c1e0a2d3_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDQvZnJhZzo0MjVlMGY1ZWY3ZmI0MDgxOGVlMDFlNTc4Y2VhMWNjYy90YWJsZTo1YmZiYjI5MjUwNTM0MGI4YmNkYmVmZGJmOTFjZDQ1ZC90YWJsZXJhbmdlOjViZmJiMjkyNTA1MzQwYjhiY2RiZWZkYmY5MWNkNDVkXzE3LTEtMS0xLTA_9edc1f8e-9dc6-4481-ac1a-500c29ef519d"
      unitRef="shares">9714321</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i5a27d4e69f2d4076ab56ee85c1e0a2d3_I20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDQvZnJhZzo0MjVlMGY1ZWY3ZmI0MDgxOGVlMDFlNTc4Y2VhMWNjYy90YWJsZTo1YmZiYjI5MjUwNTM0MGI4YmNkYmVmZGJmOTFjZDQ1ZC90YWJsZXJhbmdlOjViZmJiMjkyNTA1MzQwYjhiY2RiZWZkYmY5MWNkNDVkXzE3LTMtMS0xLTA_8e6d8224-e3ff-4364-b453-624ad9d20555"
      unitRef="usdPerShare">3.78</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="ia87a6b98f0714c88b1aa992fc475f7a1_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDQvZnJhZzo0MjVlMGY1ZWY3ZmI0MDgxOGVlMDFlNTc4Y2VhMWNjYy90YWJsZTo1YmZiYjI5MjUwNTM0MGI4YmNkYmVmZGJmOTFjZDQ1ZC90YWJsZXJhbmdlOjViZmJiMjkyNTA1MzQwYjhiY2RiZWZkYmY5MWNkNDVkXzE3LTUtMS0xLTA_aeec47c7-c37d-4383-8dd3-9c65ced5940d">P8Y7M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i5a27d4e69f2d4076ab56ee85c1e0a2d3_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDQvZnJhZzo0MjVlMGY1ZWY3ZmI0MDgxOGVlMDFlNTc4Y2VhMWNjYy90YWJsZTo1YmZiYjI5MjUwNTM0MGI4YmNkYmVmZGJmOTFjZDQ1ZC90YWJsZXJhbmdlOjViZmJiMjkyNTA1MzQwYjhiY2RiZWZkYmY5MWNkNDVkXzE3LTctMS0xLTA_356602b0-6015-4586-88a5-15dfd0436000"
      unitRef="usd">15665000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="ia87a6b98f0714c88b1aa992fc475f7a1_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDQvZnJhZzo0MjVlMGY1ZWY3ZmI0MDgxOGVlMDFlNTc4Y2VhMWNjYy90YWJsZTo1YmZiYjI5MjUwNTM0MGI4YmNkYmVmZGJmOTFjZDQ1ZC90YWJsZXJhbmdlOjViZmJiMjkyNTA1MzQwYjhiY2RiZWZkYmY5MWNkNDVkXzE5LTEtMS0xLTA_3119991b-3ed9-4049-aae2-f7922a127037"
      unitRef="shares">3064130</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <selb:SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsVestedWeightedAverageExercisePrice
      contextRef="ia87a6b98f0714c88b1aa992fc475f7a1_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDQvZnJhZzo0MjVlMGY1ZWY3ZmI0MDgxOGVlMDFlNTc4Y2VhMWNjYy90YWJsZTo1YmZiYjI5MjUwNTM0MGI4YmNkYmVmZGJmOTFjZDQ1ZC90YWJsZXJhbmdlOjViZmJiMjkyNTA1MzQwYjhiY2RiZWZkYmY5MWNkNDVkXzE5LTMtMS0xLTA_3816bdc6-6883-437f-95f4-ab00e0861e14"
      unitRef="usdPerShare">5.46</selb:SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsVestedWeightedAverageExercisePrice>
    <selb:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedOutstandingWeightedAverageRemainingContractualTerm
      contextRef="ia87a6b98f0714c88b1aa992fc475f7a1_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDQvZnJhZzo0MjVlMGY1ZWY3ZmI0MDgxOGVlMDFlNTc4Y2VhMWNjYy90YWJsZTo1YmZiYjI5MjUwNTM0MGI4YmNkYmVmZGJmOTFjZDQ1ZC90YWJsZXJhbmdlOjViZmJiMjkyNTA1MzQwYjhiY2RiZWZkYmY5MWNkNDVkXzE5LTUtMS0xLTA_42c3dd3d-536b-49b5-a363-13085d158c9b">P7Y7M17D</selb:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedOutstandingWeightedAverageRemainingContractualTerm>
    <selb:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedOutstandingIntrinsicValue
      contextRef="i5a27d4e69f2d4076ab56ee85c1e0a2d3_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDQvZnJhZzo0MjVlMGY1ZWY3ZmI0MDgxOGVlMDFlNTc4Y2VhMWNjYy90YWJsZTo1YmZiYjI5MjUwNTM0MGI4YmNkYmVmZGJmOTFjZDQ1ZC90YWJsZXJhbmdlOjViZmJiMjkyNTA1MzQwYjhiY2RiZWZkYmY5MWNkNDVkXzE5LTctMS0xLTA_7aca4143-293a-41a1-8291-a2d64f17fca2"
      unitRef="usd">4313000</selb:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="i5a27d4e69f2d4076ab56ee85c1e0a2d3_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDQvZnJhZzo0MjVlMGY1ZWY3ZmI0MDgxOGVlMDFlNTc4Y2VhMWNjYy90YWJsZTo1YmZiYjI5MjUwNTM0MGI4YmNkYmVmZGJmOTFjZDQ1ZC90YWJsZXJhbmdlOjViZmJiMjkyNTA1MzQwYjhiY2RiZWZkYmY5MWNkNDVkXzIwLTEtMS0xLTA_c8b88524-3c0a-4362-9192-84c10ec08fc2"
      unitRef="shares">8920548</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="i5a27d4e69f2d4076ab56ee85c1e0a2d3_I20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDQvZnJhZzo0MjVlMGY1ZWY3ZmI0MDgxOGVlMDFlNTc4Y2VhMWNjYy90YWJsZTo1YmZiYjI5MjUwNTM0MGI4YmNkYmVmZGJmOTFjZDQ1ZC90YWJsZXJhbmdlOjViZmJiMjkyNTA1MzQwYjhiY2RiZWZkYmY5MWNkNDVkXzIwLTMtMS0xLTA_5bf6a3d1-da85-467f-9c52-23f102efd916"
      unitRef="usdPerShare">3.88</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="ia87a6b98f0714c88b1aa992fc475f7a1_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDQvZnJhZzo0MjVlMGY1ZWY3ZmI0MDgxOGVlMDFlNTc4Y2VhMWNjYy90YWJsZTo1YmZiYjI5MjUwNTM0MGI4YmNkYmVmZGJmOTFjZDQ1ZC90YWJsZXJhbmdlOjViZmJiMjkyNTA1MzQwYjhiY2RiZWZkYmY5MWNkNDVkXzIwLTUtMS0xLTA_55522ac3-2f9b-4417-93a0-631719dbd287">P8Y7M2D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="i5a27d4e69f2d4076ab56ee85c1e0a2d3_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDQvZnJhZzo0MjVlMGY1ZWY3ZmI0MDgxOGVlMDFlNTc4Y2VhMWNjYy90YWJsZTo1YmZiYjI5MjUwNTM0MGI4YmNkYmVmZGJmOTFjZDQ1ZC90YWJsZXJhbmdlOjViZmJiMjkyNTA1MzQwYjhiY2RiZWZkYmY5MWNkNDVkXzIwLTctMS0xLTA_d43e02ed-3c9f-483a-a3cd-bdce85b854b1"
      unitRef="usd">14231000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i96083ba0423741b898ef5188cabae8f2_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDQvZnJhZzo0MjVlMGY1ZWY3ZmI0MDgxOGVlMDFlNTc4Y2VhMWNjYy90YWJsZTo1YmZiYjI5MjUwNTM0MGI4YmNkYmVmZGJmOTFjZDQ1ZC90YWJsZXJhbmdlOjViZmJiMjkyNTA1MzQwYjhiY2RiZWZkYmY5MWNkNDVkXzMxLTEtMS0xLTA_1e3a064b-f0d9-4788-bfd1-79ac1c04103e"
      unitRef="shares">473073</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i96083ba0423741b898ef5188cabae8f2_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDQvZnJhZzo0MjVlMGY1ZWY3ZmI0MDgxOGVlMDFlNTc4Y2VhMWNjYy90YWJsZTo1YmZiYjI5MjUwNTM0MGI4YmNkYmVmZGJmOTFjZDQ1ZC90YWJsZXJhbmdlOjViZmJiMjkyNTA1MzQwYjhiY2RiZWZkYmY5MWNkNDVkXzMxLTMtMS0xLTA_453a4fc1-2efc-4898-b1c9-b010f577bdba"
      unitRef="usdPerShare">5.89</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i7f9a0d7d151d41348d7f21ab127c2ee1_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDQvZnJhZzo0MjVlMGY1ZWY3ZmI0MDgxOGVlMDFlNTc4Y2VhMWNjYy90YWJsZTo1YmZiYjI5MjUwNTM0MGI4YmNkYmVmZGJmOTFjZDQ1ZC90YWJsZXJhbmdlOjViZmJiMjkyNTA1MzQwYjhiY2RiZWZkYmY5MWNkNDVkXzMxLTUtMS0xLTA_cac82b31-2cf5-4ffb-8af7-7e359530170e">P5Y2M23D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i96083ba0423741b898ef5188cabae8f2_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDQvZnJhZzo0MjVlMGY1ZWY3ZmI0MDgxOGVlMDFlNTc4Y2VhMWNjYy90YWJsZTo1YmZiYjI5MjUwNTM0MGI4YmNkYmVmZGJmOTFjZDQ1ZC90YWJsZXJhbmdlOjViZmJiMjkyNTA1MzQwYjhiY2RiZWZkYmY5MWNkNDVkXzMxLTctMS0xLTA_d46e0a27-99ea-4496-8566-029bf056f4e8"
      unitRef="usd">86000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i1f2f087904c34f869b3d9a4b4cb9a24e_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDQvZnJhZzo0MjVlMGY1ZWY3ZmI0MDgxOGVlMDFlNTc4Y2VhMWNjYy90YWJsZTo1YmZiYjI5MjUwNTM0MGI4YmNkYmVmZGJmOTFjZDQ1ZC90YWJsZXJhbmdlOjViZmJiMjkyNTA1MzQwYjhiY2RiZWZkYmY5MWNkNDVkXzMyLTEtMS0xLTA_ff0db3c8-0b89-4f0e-8207-90fb702893a8"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i1f2f087904c34f869b3d9a4b4cb9a24e_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDQvZnJhZzo0MjVlMGY1ZWY3ZmI0MDgxOGVlMDFlNTc4Y2VhMWNjYy90YWJsZTo1YmZiYjI5MjUwNTM0MGI4YmNkYmVmZGJmOTFjZDQ1ZC90YWJsZXJhbmdlOjViZmJiMjkyNTA1MzQwYjhiY2RiZWZkYmY5MWNkNDVkXzMyLTMtMS0xLTA_eec5d8e5-73da-4a3f-8a12-2b1cf165fe3a"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i1f2f087904c34f869b3d9a4b4cb9a24e_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDQvZnJhZzo0MjVlMGY1ZWY3ZmI0MDgxOGVlMDFlNTc4Y2VhMWNjYy90YWJsZTo1YmZiYjI5MjUwNTM0MGI4YmNkYmVmZGJmOTFjZDQ1ZC90YWJsZXJhbmdlOjViZmJiMjkyNTA1MzQwYjhiY2RiZWZkYmY5MWNkNDVkXzMzLTEtMS0xLTA_70ee0a0c-09ec-4822-a6f1-22ae26390c40"
      unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="i1f2f087904c34f869b3d9a4b4cb9a24e_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDQvZnJhZzo0MjVlMGY1ZWY3ZmI0MDgxOGVlMDFlNTc4Y2VhMWNjYy90YWJsZTo1YmZiYjI5MjUwNTM0MGI4YmNkYmVmZGJmOTFjZDQ1ZC90YWJsZXJhbmdlOjViZmJiMjkyNTA1MzQwYjhiY2RiZWZkYmY5MWNkNDVkXzMzLTMtMS0xLTA_737b0b2f-529f-4c8b-a0a1-fa803f6074fb"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="i1f2f087904c34f869b3d9a4b4cb9a24e_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDQvZnJhZzo0MjVlMGY1ZWY3ZmI0MDgxOGVlMDFlNTc4Y2VhMWNjYy90YWJsZTo1YmZiYjI5MjUwNTM0MGI4YmNkYmVmZGJmOTFjZDQ1ZC90YWJsZXJhbmdlOjViZmJiMjkyNTA1MzQwYjhiY2RiZWZkYmY5MWNkNDVkXzM0LTEtMS0xLTA_4c26e91d-a727-4785-b9e0-a6583c225f05"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="i1f2f087904c34f869b3d9a4b4cb9a24e_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDQvZnJhZzo0MjVlMGY1ZWY3ZmI0MDgxOGVlMDFlNTc4Y2VhMWNjYy90YWJsZTo1YmZiYjI5MjUwNTM0MGI4YmNkYmVmZGJmOTFjZDQ1ZC90YWJsZXJhbmdlOjViZmJiMjkyNTA1MzQwYjhiY2RiZWZkYmY5MWNkNDVkXzM0LTMtMS0xLTA_d1b7dfe5-8d6e-45ef-a607-39cbb005eae1"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i1a4fb26d073f4e2aa150b70c1bdd64cd_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDQvZnJhZzo0MjVlMGY1ZWY3ZmI0MDgxOGVlMDFlNTc4Y2VhMWNjYy90YWJsZTo1YmZiYjI5MjUwNTM0MGI4YmNkYmVmZGJmOTFjZDQ1ZC90YWJsZXJhbmdlOjViZmJiMjkyNTA1MzQwYjhiY2RiZWZkYmY5MWNkNDVkXzM1LTEtMS0xLTA_49ae8e76-2909-4d4c-8a17-2a702d330c47"
      unitRef="shares">473073</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i1a4fb26d073f4e2aa150b70c1bdd64cd_I20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDQvZnJhZzo0MjVlMGY1ZWY3ZmI0MDgxOGVlMDFlNTc4Y2VhMWNjYy90YWJsZTo1YmZiYjI5MjUwNTM0MGI4YmNkYmVmZGJmOTFjZDQ1ZC90YWJsZXJhbmdlOjViZmJiMjkyNTA1MzQwYjhiY2RiZWZkYmY5MWNkNDVkXzM1LTMtMS0xLTA_e107934c-101e-4d05-850f-c6a24de15857"
      unitRef="usdPerShare">5.89</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i1f2f087904c34f869b3d9a4b4cb9a24e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDQvZnJhZzo0MjVlMGY1ZWY3ZmI0MDgxOGVlMDFlNTc4Y2VhMWNjYy90YWJsZTo1YmZiYjI5MjUwNTM0MGI4YmNkYmVmZGJmOTFjZDQ1ZC90YWJsZXJhbmdlOjViZmJiMjkyNTA1MzQwYjhiY2RiZWZkYmY5MWNkNDVkXzM1LTUtMS0xLTA_e1f3fc8d-68d2-4e73-b91d-80491885b643">P4Y11M23D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i1a4fb26d073f4e2aa150b70c1bdd64cd_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDQvZnJhZzo0MjVlMGY1ZWY3ZmI0MDgxOGVlMDFlNTc4Y2VhMWNjYy90YWJsZTo1YmZiYjI5MjUwNTM0MGI4YmNkYmVmZGJmOTFjZDQ1ZC90YWJsZXJhbmdlOjViZmJiMjkyNTA1MzQwYjhiY2RiZWZkYmY5MWNkNDVkXzM1LTctMS0xLTA_b871ee73-d144-40a4-b098-964f7bf549bd"
      unitRef="usd">366000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="i1f2f087904c34f869b3d9a4b4cb9a24e_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDQvZnJhZzo0MjVlMGY1ZWY3ZmI0MDgxOGVlMDFlNTc4Y2VhMWNjYy90YWJsZTo1YmZiYjI5MjUwNTM0MGI4YmNkYmVmZGJmOTFjZDQ1ZC90YWJsZXJhbmdlOjViZmJiMjkyNTA1MzQwYjhiY2RiZWZkYmY5MWNkNDVkXzM3LTEtMS0xLTA_5077da78-90b0-4c68-8816-a3b149bb6e6d"
      unitRef="shares">462186</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <selb:SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsVestedWeightedAverageExercisePrice
      contextRef="i1f2f087904c34f869b3d9a4b4cb9a24e_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDQvZnJhZzo0MjVlMGY1ZWY3ZmI0MDgxOGVlMDFlNTc4Y2VhMWNjYy90YWJsZTo1YmZiYjI5MjUwNTM0MGI4YmNkYmVmZGJmOTFjZDQ1ZC90YWJsZXJhbmdlOjViZmJiMjkyNTA1MzQwYjhiY2RiZWZkYmY5MWNkNDVkXzM3LTMtMS0xLTA_02dc9f6f-159f-4c3c-9293-0b64a372cf5c"
      unitRef="usdPerShare">5.82</selb:SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsVestedWeightedAverageExercisePrice>
    <selb:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedOutstandingWeightedAverageRemainingContractualTerm
      contextRef="i1f2f087904c34f869b3d9a4b4cb9a24e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDQvZnJhZzo0MjVlMGY1ZWY3ZmI0MDgxOGVlMDFlNTc4Y2VhMWNjYy90YWJsZTo1YmZiYjI5MjUwNTM0MGI4YmNkYmVmZGJmOTFjZDQ1ZC90YWJsZXJhbmdlOjViZmJiMjkyNTA1MzQwYjhiY2RiZWZkYmY5MWNkNDVkXzM3LTUtMS0xLTA_4c89a4d0-489a-4469-8335-7c2d82259f3e">P4Y11M1D</selb:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedOutstandingWeightedAverageRemainingContractualTerm>
    <selb:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedOutstandingIntrinsicValue
      contextRef="i1a4fb26d073f4e2aa150b70c1bdd64cd_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDQvZnJhZzo0MjVlMGY1ZWY3ZmI0MDgxOGVlMDFlNTc4Y2VhMWNjYy90YWJsZTo1YmZiYjI5MjUwNTM0MGI4YmNkYmVmZGJmOTFjZDQ1ZC90YWJsZXJhbmdlOjViZmJiMjkyNTA1MzQwYjhiY2RiZWZkYmY5MWNkNDVkXzM3LTctMS0xLTA_2631daa2-6b2f-4a2a-a959-5d0098b0a99f"
      unitRef="usd">366000</selb:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="i1a4fb26d073f4e2aa150b70c1bdd64cd_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDQvZnJhZzo0MjVlMGY1ZWY3ZmI0MDgxOGVlMDFlNTc4Y2VhMWNjYy90YWJsZTo1YmZiYjI5MjUwNTM0MGI4YmNkYmVmZGJmOTFjZDQ1ZC90YWJsZXJhbmdlOjViZmJiMjkyNTA1MzQwYjhiY2RiZWZkYmY5MWNkNDVkXzM4LTEtMS0xLTA_da77e70a-b378-488a-a0d2-bab91fbc609c"
      unitRef="shares">473073</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="i1a4fb26d073f4e2aa150b70c1bdd64cd_I20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDQvZnJhZzo0MjVlMGY1ZWY3ZmI0MDgxOGVlMDFlNTc4Y2VhMWNjYy90YWJsZTo1YmZiYjI5MjUwNTM0MGI4YmNkYmVmZGJmOTFjZDQ1ZC90YWJsZXJhbmdlOjViZmJiMjkyNTA1MzQwYjhiY2RiZWZkYmY5MWNkNDVkXzM4LTMtMS0xLTA_7776d476-4348-4aa2-93ab-fd1a40fabe97"
      unitRef="usdPerShare">5.89</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="i1f2f087904c34f869b3d9a4b4cb9a24e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDQvZnJhZzo0MjVlMGY1ZWY3ZmI0MDgxOGVlMDFlNTc4Y2VhMWNjYy90YWJsZTo1YmZiYjI5MjUwNTM0MGI4YmNkYmVmZGJmOTFjZDQ1ZC90YWJsZXJhbmdlOjViZmJiMjkyNTA1MzQwYjhiY2RiZWZkYmY5MWNkNDVkXzM4LTUtMS0xLTA_6c2dbd6c-b337-4156-ba31-91e86f26f34b">P4Y11M23D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="i1a4fb26d073f4e2aa150b70c1bdd64cd_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDQvZnJhZzo0MjVlMGY1ZWY3ZmI0MDgxOGVlMDFlNTc4Y2VhMWNjYy90YWJsZTo1YmZiYjI5MjUwNTM0MGI4YmNkYmVmZGJmOTFjZDQ1ZC90YWJsZXJhbmdlOjViZmJiMjkyNTA1MzQwYjhiY2RiZWZkYmY5MWNkNDVkXzM4LTctMS0xLTA_a937268f-8790-42b6-914c-96fed7f7182a"
      unitRef="usd">366000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="id01182d93717492b89617d993fbd0c3a_D20210101-20210131"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDQvZnJhZzo0MjVlMGY1ZWY3ZmI0MDgxOGVlMDFlNTc4Y2VhMWNjYy90ZXh0cmVnaW9uOjQyNWUwZjVlZjdmYjQwODE4ZWUwMWU1NzhjZWExY2NjXzI3NDg3NzkwODQ0ODg_d0facb35-2ee6-4298-8512-bfd08dc80862"
      unitRef="shares">369800</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="ib1f07535b15b475490cebf99339949e2_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDQvZnJhZzo0MjVlMGY1ZWY3ZmI0MDgxOGVlMDFlNTc4Y2VhMWNjYy90ZXh0cmVnaW9uOjQyNWUwZjVlZjdmYjQwODE4ZWUwMWU1NzhjZWExY2NjXzQzOTgwNDY1NDM3MzQ_d384e646-d809-4f5e-b380-29cc908c57dc">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <selb:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAwardedInPeriod
      contextRef="ib1f07535b15b475490cebf99339949e2_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDQvZnJhZzo0MjVlMGY1ZWY3ZmI0MDgxOGVlMDFlNTc4Y2VhMWNjYy90ZXh0cmVnaW9uOjQyNWUwZjVlZjdmYjQwODE4ZWUwMWU1NzhjZWExY2NjXzE2NDkyNjc0NTU3OTM_da109494-917c-42af-aead-e00543533028"
      unitRef="shares">197500</selb:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAwardedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="ib1f07535b15b475490cebf99339949e2_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDQvZnJhZzo0MjVlMGY1ZWY3ZmI0MDgxOGVlMDFlNTc4Y2VhMWNjYy90ZXh0cmVnaW9uOjQyNWUwZjVlZjdmYjQwODE4ZWUwMWU1NzhjZWExY2NjXzE2NDkyNjc0NTU4MDk_ee88f426-2eec-44ae-a8dc-501254e45627"
      unitRef="shares">98750</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <selb:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReservedForIssuance
      contextRef="ib1f07535b15b475490cebf99339949e2_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDQvZnJhZzo0MjVlMGY1ZWY3ZmI0MDgxOGVlMDFlNTc4Y2VhMWNjYy90ZXh0cmVnaW9uOjQyNWUwZjVlZjdmYjQwODE4ZWUwMWU1NzhjZWExY2NjXzE2NDkyNjc0NTU4MTg_aa927e27-757f-4c8b-8611-4e56ba3db490"
      unitRef="shares">98750</selb:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReservedForIssuance>
    <selb:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReservedForIssuanceWeightedAverageGrantDateFairValue
      contextRef="i676ae38dc7694143b42a364d53aa820c_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDQvZnJhZzo0MjVlMGY1ZWY3ZmI0MDgxOGVlMDFlNTc4Y2VhMWNjYy90ZXh0cmVnaW9uOjQyNWUwZjVlZjdmYjQwODE4ZWUwMWU1NzhjZWExY2NjXzQzOTgwNDY1MjU5MDY_b15174d4-a0f4-4bbf-8e05-8573f41b1c9d"
      unitRef="usdPerShare">2.99</selb:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReservedForIssuanceWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="ib1f07535b15b475490cebf99339949e2_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDQvZnJhZzo0MjVlMGY1ZWY3ZmI0MDgxOGVlMDFlNTc4Y2VhMWNjYy90ZXh0cmVnaW9uOjQyNWUwZjVlZjdmYjQwODE4ZWUwMWU1NzhjZWExY2NjXzE2NDkyNjc0NTU4MjU_7b2edf84-40b9-4ddb-a2dc-4f84eeedb9dd"
      unitRef="usd">1400000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <selb:ShareBasedCompensationArrangementByShareBasedPaymentAwardForfeituresRate
      contextRef="i0a83cea2026d4acd853ecd648a6ff3cf_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDQvZnJhZzo0MjVlMGY1ZWY3ZmI0MDgxOGVlMDFlNTc4Y2VhMWNjYy90ZXh0cmVnaW9uOjQyNWUwZjVlZjdmYjQwODE4ZWUwMWU1NzhjZWExY2NjXzI3NDg3NzkwODQ5NTM_6b754ab2-cd6c-4b4a-88d7-9273ccea354f"
      unitRef="number">0.10</selb:ShareBasedCompensationArrangementByShareBasedPaymentAwardForfeituresRate>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="id4c863b4912a4159803053e1c04bda2f_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDQvZnJhZzo0MjVlMGY1ZWY3ZmI0MDgxOGVlMDFlNTc4Y2VhMWNjYy90ZXh0cmVnaW9uOjQyNWUwZjVlZjdmYjQwODE4ZWUwMWU1NzhjZWExY2NjXzgzOTU_bcb9232d-dcff-4447-ae40-b64055d41793"
      unitRef="usd">1500000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="ia7f06d48c2684d27abe5106b2abf1761_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDQvZnJhZzo0MjVlMGY1ZWY3ZmI0MDgxOGVlMDFlNTc4Y2VhMWNjYy90ZXh0cmVnaW9uOjQyNWUwZjVlZjdmYjQwODE4ZWUwMWU1NzhjZWExY2NjXzg0Nzc_e2a3f770-3d5b-4c22-b0cf-743de4a2de09">P3Y1M6D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock
      contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDQvZnJhZzo0MjVlMGY1ZWY3ZmI0MDgxOGVlMDFlNTc4Y2VhMWNjYy90ZXh0cmVnaW9uOjQyNWUwZjVlZjdmYjQwODE4ZWUwMWU1NzhjZWExY2NjXzEwOTMy_1b26d848-2c60-47ae-ba68-c2bfa874c29c">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the Company&#x2019;s restricted stock units under the 2016 Plan and 2018 Inducement Incentive Award Plan:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:69.721%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.122%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.124%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted average&lt;br/&gt;grant date&lt;br/&gt;fair value ($)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Unvested at December 31, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;87,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.03&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;468,550&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(10,937)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.03&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Reserved for issuance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;98,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(800)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Unvested at March 31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;643,063&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i23dc483d5e024cd3ab41d280f32cf960_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDQvZnJhZzo0MjVlMGY1ZWY3ZmI0MDgxOGVlMDFlNTc4Y2VhMWNjYy90YWJsZTowYzM5MTY0ZWEyMDA0ZTY0YjgzOGYzMzc1MDNhZTM3Zi90YWJsZXJhbmdlOjBjMzkxNjRlYTIwMDRlNjRiODM4ZjMzNzUwM2FlMzdmXzEtMS0xLTEtMA_dc4567d1-4040-4791-8b51-e8cde2f160ba"
      unitRef="shares">87500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i23dc483d5e024cd3ab41d280f32cf960_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDQvZnJhZzo0MjVlMGY1ZWY3ZmI0MDgxOGVlMDFlNTc4Y2VhMWNjYy90YWJsZTowYzM5MTY0ZWEyMDA0ZTY0YjgzOGYzMzc1MDNhZTM3Zi90YWJsZXJhbmdlOjBjMzkxNjRlYTIwMDRlNjRiODM4ZjMzNzUwM2FlMzdmXzEtMy0xLTEtMA_47be93ba-0c6a-4530-a0db-a188e419cfb6"
      unitRef="usdPerShare">6.03</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i676ae38dc7694143b42a364d53aa820c_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDQvZnJhZzo0MjVlMGY1ZWY3ZmI0MDgxOGVlMDFlNTc4Y2VhMWNjYy90YWJsZTowYzM5MTY0ZWEyMDA0ZTY0YjgzOGYzMzc1MDNhZTM3Zi90YWJsZXJhbmdlOjBjMzkxNjRlYTIwMDRlNjRiODM4ZjMzNzUwM2FlMzdmXzItMS0xLTEtMA_6e2de4bd-b07d-47bb-996b-3ec67ed98a0e"
      unitRef="shares">468550</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i676ae38dc7694143b42a364d53aa820c_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDQvZnJhZzo0MjVlMGY1ZWY3ZmI0MDgxOGVlMDFlNTc4Y2VhMWNjYy90YWJsZTowYzM5MTY0ZWEyMDA0ZTY0YjgzOGYzMzc1MDNhZTM3Zi90YWJsZXJhbmdlOjBjMzkxNjRlYTIwMDRlNjRiODM4ZjMzNzUwM2FlMzdmXzItMy0xLTEtMA_1226477b-51da-4055-8792-2e02d6c6c1f1"
      unitRef="usdPerShare">2.99</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="i676ae38dc7694143b42a364d53aa820c_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDQvZnJhZzo0MjVlMGY1ZWY3ZmI0MDgxOGVlMDFlNTc4Y2VhMWNjYy90YWJsZTowYzM5MTY0ZWEyMDA0ZTY0YjgzOGYzMzc1MDNhZTM3Zi90YWJsZXJhbmdlOjBjMzkxNjRlYTIwMDRlNjRiODM4ZjMzNzUwM2FlMzdmXzMtMS0xLTEtMA_08f62a80-ea6e-4db4-b973-2d202b4bd270"
      unitRef="shares">10937</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="i676ae38dc7694143b42a364d53aa820c_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDQvZnJhZzo0MjVlMGY1ZWY3ZmI0MDgxOGVlMDFlNTc4Y2VhMWNjYy90YWJsZTowYzM5MTY0ZWEyMDA0ZTY0YjgzOGYzMzc1MDNhZTM3Zi90YWJsZXJhbmdlOjBjMzkxNjRlYTIwMDRlNjRiODM4ZjMzNzUwM2FlMzdmXzMtMy0xLTEtMA_f6986af7-7bc9-477f-9799-be1dbe591816"
      unitRef="usdPerShare">6.03</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <selb:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReservedForIssuance
      contextRef="i676ae38dc7694143b42a364d53aa820c_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDQvZnJhZzo0MjVlMGY1ZWY3ZmI0MDgxOGVlMDFlNTc4Y2VhMWNjYy90YWJsZTowYzM5MTY0ZWEyMDA0ZTY0YjgzOGYzMzc1MDNhZTM3Zi90YWJsZXJhbmdlOjBjMzkxNjRlYTIwMDRlNjRiODM4ZjMzNzUwM2FlMzdmXzQtMS0xLTEtMA_f81f8b1a-55ed-4546-add2-2b415324f3de"
      unitRef="shares">98750</selb:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReservedForIssuance>
    <selb:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReservedForIssuanceWeightedAverageGrantDateFairValue
      contextRef="i676ae38dc7694143b42a364d53aa820c_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDQvZnJhZzo0MjVlMGY1ZWY3ZmI0MDgxOGVlMDFlNTc4Y2VhMWNjYy90YWJsZTowYzM5MTY0ZWEyMDA0ZTY0YjgzOGYzMzc1MDNhZTM3Zi90YWJsZXJhbmdlOjBjMzkxNjRlYTIwMDRlNjRiODM4ZjMzNzUwM2FlMzdmXzQtMy0xLTEtMA_1ab6a45c-a732-427d-92c0-deaf149f569f"
      unitRef="usdPerShare">2.99</selb:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReservedForIssuanceWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="i676ae38dc7694143b42a364d53aa820c_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDQvZnJhZzo0MjVlMGY1ZWY3ZmI0MDgxOGVlMDFlNTc4Y2VhMWNjYy90YWJsZTowYzM5MTY0ZWEyMDA0ZTY0YjgzOGYzMzc1MDNhZTM3Zi90YWJsZXJhbmdlOjBjMzkxNjRlYTIwMDRlNjRiODM4ZjMzNzUwM2FlMzdmXzUtMS0xLTEtMA_cae48096-a1e5-4401-8b19-cf8f803a3bb0"
      unitRef="shares">800</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="i676ae38dc7694143b42a364d53aa820c_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDQvZnJhZzo0MjVlMGY1ZWY3ZmI0MDgxOGVlMDFlNTc4Y2VhMWNjYy90YWJsZTowYzM5MTY0ZWEyMDA0ZTY0YjgzOGYzMzc1MDNhZTM3Zi90YWJsZXJhbmdlOjBjMzkxNjRlYTIwMDRlNjRiODM4ZjMzNzUwM2FlMzdmXzUtMy0xLTEtMA_1ae484f6-23ab-4c4b-a74a-0efd5944f9c3"
      unitRef="usdPerShare">2.99</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="ie9886e2c9856402e9696bea8b5c012ee_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDQvZnJhZzo0MjVlMGY1ZWY3ZmI0MDgxOGVlMDFlNTc4Y2VhMWNjYy90YWJsZTowYzM5MTY0ZWEyMDA0ZTY0YjgzOGYzMzc1MDNhZTM3Zi90YWJsZXJhbmdlOjBjMzkxNjRlYTIwMDRlNjRiODM4ZjMzNzUwM2FlMzdmXzYtMS0xLTEtMA_86f4b481-3d58-498b-a8de-52f81d5834de"
      unitRef="shares">643063</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="ie9886e2c9856402e9696bea8b5c012ee_I20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDQvZnJhZzo0MjVlMGY1ZWY3ZmI0MDgxOGVlMDFlNTc4Y2VhMWNjYy90YWJsZTowYzM5MTY0ZWEyMDA0ZTY0YjgzOGYzMzc1MDNhZTM3Zi90YWJsZXJhbmdlOjBjMzkxNjRlYTIwMDRlNjRiODM4ZjMzNzUwM2FlMzdmXzYtMy0xLTEtMA_79ffdb37-f531-4e46-80c8-7625d86b3ee9"
      unitRef="usdPerShare">3.35</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i98884f73b2c2406a9fe17695931498a3_I20160621"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDQvZnJhZzo0MjVlMGY1ZWY3ZmI0MDgxOGVlMDFlNTc4Y2VhMWNjYy90ZXh0cmVnaW9uOjQyNWUwZjVlZjdmYjQwODE4ZWUwMWU1NzhjZWExY2NjXzk2OTk_c7804aa3-09b9-471f-b3ba-cd2a5ad8876b"
      unitRef="shares">173076</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <selb:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantIncreaseDecrease
      contextRef="i3a0400d76b2a4414a1b0b75fa0e22620_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDQvZnJhZzo0MjVlMGY1ZWY3ZmI0MDgxOGVlMDFlNTc4Y2VhMWNjYy90ZXh0cmVnaW9uOjQyNWUwZjVlZjdmYjQwODE4ZWUwMWU1NzhjZWExY2NjXzEwMzYx_b2ea2c77-0ef2-4e61-931e-0a12a9e4598e"
      unitRef="shares">1080711</selb:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantIncreaseDecrease>
    <selb:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantIncreaseDecrease
      contextRef="i7ecfd227500943bba7dc51fc2bd3afec_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDQvZnJhZzo0MjVlMGY1ZWY3ZmI0MDgxOGVlMDFlNTc4Y2VhMWNjYy90ZXh0cmVnaW9uOjQyNWUwZjVlZjdmYjQwODE4ZWUwMWU1NzhjZWExY2NjXzEwMzc1_9f1ce8e2-70d0-4f9f-a899-6f674cb3df9b"
      unitRef="shares">863254</selb:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantIncreaseDecrease>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="i3a0400d76b2a4414a1b0b75fa0e22620_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDQvZnJhZzo0MjVlMGY1ZWY3ZmI0MDgxOGVlMDFlNTc4Y2VhMWNjYy90ZXh0cmVnaW9uOjQyNWUwZjVlZjdmYjQwODE4ZWUwMWU1NzhjZWExY2NjXzEwNDQz_1c80c6d2-40a7-4d66-af30-1d2f44e55f4e"
      unitRef="shares">34696</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="ib7e99ef7cdcc49a1ad08e7bc6eec6d1a_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDQvZnJhZzo0MjVlMGY1ZWY3ZmI0MDgxOGVlMDFlNTc4Y2VhMWNjYy90ZXh0cmVnaW9uOjQyNWUwZjVlZjdmYjQwODE4ZWUwMWU1NzhjZWExY2NjXzEwNDk1_fdc01aa1-9a25-4d6f-86e1-21497ec7ff43"
      unitRef="shares">2546464</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i7ecfd227500943bba7dc51fc2bd3afec_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDQvZnJhZzo0MjVlMGY1ZWY3ZmI0MDgxOGVlMDFlNTc4Y2VhMWNjYy90ZXh0cmVnaW9uOjQyNWUwZjVlZjdmYjQwODE4ZWUwMWU1NzhjZWExY2NjXzEwNjE3_15cbda1d-5119-44d0-9663-53aa17d0b7d0"
      unitRef="usd">100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i3a0400d76b2a4414a1b0b75fa0e22620_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDQvZnJhZzo0MjVlMGY1ZWY3ZmI0MDgxOGVlMDFlNTc4Y2VhMWNjYy90ZXh0cmVnaW9uOjQyNWUwZjVlZjdmYjQwODE4ZWUwMWU1NzhjZWExY2NjXzEwNjE3_3a868f34-b093-4e6e-b1e0-ec717e9a76af"
      unitRef="usd">100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:RevenueFromContractWithCustomerTextBlock
      contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDcvZnJhZzo5YjFkNTkxZmQzMWQ0NDQ4OTczNDg0ZDFiMDliZGFlNC90ZXh0cmVnaW9uOjliMWQ1OTFmZDMxZDQ0NDg5NzM0ODRkMWIwOWJkYWU0XzM1NTYz_8e0d106c-4de3-47d6-8aa2-0c498bd531dc">Revenue Arrangements&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Swedish Orphan Biovitrum&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;License and Development Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 11, 2020, the Company and Sobi entered into the Sobi License. Pursuant to the Sobi License, the Company has agreed to grant Sobi an exclusive, worldwide (except as to Greater China) license to develop, manufacture and commercialize the Company&#x2019;s SEL-212 drug candidate, which is currently in development for the treatment of chronic refractory gout. The SEL-212 drug candidate is a pharmaceutical composition containing a combination of SEL-037, or the Compound, and ImmTOR. Pursuant to the Sobi License, in consideration of the license, Sobi agreed to pay the Company a one-time, up-front payment of $75.0&#160;million. Sobi has also agreed to make milestone payments totaling up to $630.0&#160;million to the Company upon the achievement of various development and regulatory milestones and, if commercialized, sales thresholds for annual net sales of SEL-212, and tiered royalty payments ranging from the low double digits on the lowest sales tier to the high teens on the highest sales tier.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pursuant to the Sobi License, the Company has agreed to supply (at cost) quantities of the Compound and ImmTOR as necessary for completion of the two Phase 3 clinical trials of SEL-212 (DISSOLVE I and DISSOLVE II) and a 6-month placebo extension. The Company is required to supply quantities of the Compound until all rights to the Compound and any materials needed to manufacture the Compound are transferred to Sobi. Sobi has agreed to reimburse the Company for all budgeted costs incurred to complete development of SEL-212, including but not limited to costs incurred while conducting and completing the Phase 3 DISSOLVE trials, except for any costs of additional development activities required that are related to ImmTOR and that are unrelated to SEL-212. Sobi will have control and responsibility over all regulatory filings, including any investigational drug applications (IND), biologics license applications (BLA), and marketing authorization applications (MAA) relating to the licensed product.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The transactions contemplated by the Sobi License were consummated on July 28, 2020 following the expiration or termination of the required waiting periods under the Hart-Scott-Rodino Antitrust Improvements Act of 1976. Sobi may terminate the Sobi License for any reason upon 180 days&#x2019; written notice to the Company, whereby all rights granted under the Sobi License would revert back to the Company. In addition, if Sobi were to terminate the Sobi License, the Company has the option to obtain a license to all patents and know-how necessary to exploit SEL-212 in existence as of the termination date from Sobi in return for making an equitable royalty payment to Sobi.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additionally, on June 11, 2020, the Company entered into the Sobi Purchase Agreement in connection with the Sobi License. The closing of the Sobi Private Placement occurred on July 31, 2020, following the closing of the transactions contemplated under the Sobi License. See Note 10 for details.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determined that the Sobi License represents a service arrangement under the scope of ASC 606. In addition, given the Sobi License and Sobi Purchase Agreement were executed contemporaneously and negotiated as a package with a single commercial objective, the Company will account for the two agreements as a single contract. The term of the Sobi License commenced upon the effective date of July 28, 2020 and will continue on a product-by-product basis until the royalty terms for each country have expired. The royalty term for a given product begins upon the first commercial sale of the product in a country and ends at the later of ten years from the first commercial sale, expiration of the last valid patent claim covering the product and expiration of all regulatory exclusivity periods for the product in a country. Given the reversion of the rights under the Sobi License represents a penalty in substance for a termination by Sobi, the contract term would remain the stated term of the Sobi License.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determined that the Sobi License contains three distinct performance obligations due to the nature of the promises in the contract, which includes conducting the Phase 3 DISSOLVE trials, Sobi&#x2019;s option to set-up a second source supplier, and a combined obligation comprised of the delivery of the license to SEL-212, transfer of the know-how and the manufacturing and delivery of SEL-212 supply for development, or the Combined License Obligation. As the set-up of a second source supplier is optional for Sobi and the Company will be reimbursed at cost for its efforts in the subsequent set-up and technology transfer, the option for this future service was determined to be at a significant and incremental discount to its standalone selling price and treated as a material right in the arrangement, namely a distinct performance obligation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In determining the transaction price, the Company concluded the upfront payment of $75.0&#160;million and the $5.0&#160;million development milestone associated with the dosing of the first patient in the Phase 3 DISSOLVE trials will be included in the transaction price. All other development milestones will be fully constrained and only be included in the transaction price when the respective milestone is deemed probable of achievement. Each of these variable consideration items was evaluated under the most likely amount method to determine whether such amounts were probable of occurrence, or whether such amounts should be constrained until they become probable. As part of the evaluation of the constraint, the Company considered numerous factors, including that receipt of such milestones is outside the control of the Company and probability of success criteria is estimated. The Company will re-evaluate the transaction price in each reporting period, as uncertain events are resolved. In accordance with ASC 606, the Company will only recognize revenue associated with sales-based milestones and royalties when the subsequent sales thresholds are reached and underlying sales occur, respectively. In connection with the Sobi Purchase Agreement, the Company determined that the gross proceeds of $25.0&#160;million from the Sobi Private Placement included a premium to the fair value of the Company&#x2019;s shares as of July 28, 2020 equal to approximately $14.5&#160;million. The premium amount will be included in the transaction price for revenue recognition. The Company will estimate and include in the transaction price the total reimbursements to be received from Sobi for both the manufacturing and delivery of the Compound and ImmTOR as well as conducting the Phase 3 DISSOLVE trials. The Company determined that a significant financing component does not exist in its arrangement with Sobi.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company allocated the transaction price based on the relative standalone selling prices of the three distinct performance obligations. The Company estimated the standalone selling price of conducting the Phase 3 DISSOLVE trials by forecasting its anticipated costs and applying a margin reflective of the industry. The Company must determine the standalone selling price of the second source supplier option by determining the discount given to Sobi multiplied by the likelihood that Sobi will exercise the option in the future. Similar to the Phase 3 program estimate, the Company estimated the discount of the option by forecasting the set-up costs and applying a margin that is reflective of the industry. As the Company will be providing the set-up and technology transfer services and the future supply at cost, the discount of the option is equal to the margin amount. The Company considered discussions with Sobi as well as probability of regulatory success of SEL-212 in determining the likelihood of exercise. The Company estimated the standalone selling price of the Combined License Obligation by utilizing a discounted cash flow model.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determined that the delivery of the supply to Sobi best represents the pattern of delivery of the Combined License Obligation as the supply is essential to the utility of the license and know-how. The Company will recognize the revenue allocated to the Combined License Obligation by utilizing the output method. The Company estimated the total supply of the Compound and ImmTOR to be required during the clinical trial period and will recognize revenue as this supply is shipped for use in the clinical trials. The Company will recognize the revenue allocated to the conducting of the Phase 3 DISSOLVE trials obligation by utilizing the input method. The Company estimated the total budgeted costs to be incurred over &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;the Phase 3 DISSOLVE trials and will recognize revenue as these costs are incurred. The Company&#x2019;s costs best represent the pattern of transfer as these will capture all performance of the trials completed to date and can be readily measured. The Company will recognize the revenue allocated to the second source supplier option when the future services and goods are transferred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March 31, 2021 and December 31, 2020, the Company recorded $72.0 million and $68.3&#160;million, respectively, as a short-term contract liability and $17.8 million and $24.2&#160;million, respectively, as a long-term contract liability, representing deferred revenue associated with this agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, as of March 31, 2021 the Company has recorded $1.3 million of contract assets related to incremental costs that would not have been incurred if the Sobi License had not been obtained, of which $1.0 million is presented in prepaid expenses and other current assets and $0.3 million is presented in other assets in the accompanying unaudited consolidated balance sheets. Amortization of contract assets was less than $0.1 million for the three months ended March 31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March 31, 2021 and December 31, 2020, the Company recorded a total outstanding receivable of $8.3 million and $6.9 million, respectively, representing billings for the Phase 3 DISSOLVE program that are subject to reimbursement by Sobi. Revenue of $11.1 million related to the Sobi License was recognized during the three months ended March 31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Sarepta Therapeutics, Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research License and Option Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 13, 2020, the Company and Sarepta entered into a Research License and Option Agreement, or the Sarepta Agreement. Pursuant to the Sarepta Agreement, the Company agreed to grant Sarepta a license under the Company&#x2019;s intellectual property rights covering the Company&#x2019;s antigen-specific biodegradable nanoparticle encapsulating ImmTOR to research and evaluate ImmTOR in combination with Sarepta&#x2019;s adeno-associated virus gene therapy technology, or gene editing technology, using viral or non-viral delivery, to treat Duchenne Muscular Dystrophy and certain Limb-Girdle Muscular Dystrophy subtypes, or the Indications. Sarepta will have an option term of 24 months during which it can opt-in to obtain an exclusive license to further develop and commercialize the Product to treat at least one Indication, with a potential to extend the option term for an additional fee. The Company will supply ImmTOR to Sarepta for clinical supply on a cost-plus basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Sarepta paid a $2.0 million up-front payment to the Company upon signing of the Sarepta Agreement, and the Company is eligible to receive additional preclinical payments during the option term. If Sarepta opts-in to an exclusive license agreement, the Company could receive&#160;option exercise payments per Indication upon execution of the exclusive license, and the Company would be entitled to significant development and commercial milestone payments and tiered royalties ranging from the mid-to-high single digits based on net sales.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pursuant to the Sarepta Agreement, the Company determined the Sarepta Agreement represents a service arrangement under the scope of ASC 606, with a 24 month contract duration. Given the reversion of the rights under the Sarepta Agreement represents a penalty in substance for a termination by Sarepta, the contract term would remain the stated term of the Sarepta Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determined that the Sarepta Agreement and supply obligation including the delivery of the research license, the licensed know-how, the manufactured supply and delivery of materials represent a single promise and performance obligation to be transferred to Sarepta over time due to the nature of the promises in the contract. The delivery of the manufactured supply is the predominant promise within the arrangement, as it is essential to the utility of the licensed intellectual property. As such, consideration in the initial transaction price will be allocated to the single performance obligation based on the contractual price.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In determining the transaction price, the Company concluded the payment associated with all the performance milestones will be fully constrained and only be included in the transaction price when the respective milestone is deemed probable of achievement. Each of these variable consideration items was evaluated under the most likely amount method to determine whether such amounts were probable of occurrence, or whether such amounts should be constrained until they become probable. As part of its evaluation of the constraint, the Company considered numerous factors, including that receipt of such study milestones is outside the control of the Company and probability of success criteria is estimated. As of March 31, 2021 and December 31, 2020, all milestones were constrained. The Company will re-evaluate the transaction price in each reporting period, as uncertain events are resolved. The Company will recognize the revenue associated with the upfront payment and combined single performance obligation utilizing the output method, over the 24 month term as the manufactured supply is delivered to Sarepta.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company also determined the option to enter into a future commercial license agreement and extend the term of the option does not represent a material right since it was not priced at an incremental discount. Sarepta may terminate the Sarepta Agreement for any reason upon 30 days&#x2019; written notice to the Company. The Sarepta Agreement contains other customary terms and conditions, including representations and warranties, covenants, termination, and indemnification obligations in favor of each party. During the year ended December 31, 2020, the Company and Sarepta entered into two amendments relating to an &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;additional feasibility study. During the three months ended March 31, 2021, the Company and Sarepta entered into a third amendment relating to feasibility study research plan. None of the amendments executed through March 31, 2021 had a material impact on deferred revenue or revenue recognition.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At each of March 31, 2021 and December 31, 2020, the Company recorded $2.0 million as a short-term contract liability representing deferred revenue associated with this agreement. No revenue related to the Sarepta Agreement was recognized during the three months ended March 31, 2021 and 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Asklepios Biopharmaceutical, Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;License Agreement for Pompe Disease&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December 17, 2019, the Company and AskBio entered into a license agreement, or the AskBio License Agreement. Pursuant to the AskBio License Agreement, AskBio has exercised its option to exclusively license the Company&#x2019;s intellectual property rights covering the Company&#x2019;s ImmTOR platform to research, develop, and commercialize certain AAV gene therapy products utilizing ImmTOR, and targeting the GAA gene, or derivatives thereof, to treat Pompe Disease.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pursuant to the AskBio License Agreement and ancillary documents, AskBio agreed to pay to the Company upfront fees of an aggregate of $7.0 million. Assuming successful development and commercialization, the Company could receive up to an additional $237.0 million in development, regulatory, and sales milestone payments. If commercialized, the Company would be eligible to receive tiered royalties on global net sales at percentages ranging from mid-to-high single digits. Under the terms of the agreement, the Company will be eligible to receive these royalties commencing on the first commercial sale of the licensed product until the expiration of the later of (i) ten years after the first commercial sale and (ii) expiration of the last to expire valid claim on patents covering the licensed product.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pursuant to the AskBio License Agreement, the Company will supply AskBio with its ImmTOR platform, or the Supply Obligation, and AskBio will be responsible for all preclinical, clinical and commercial manufacture and supply of licensed products (other than ImmTOR) and carry out all other activities related to the research, development, and commercialization of licensed products at its sole expense, including all regulatory activities related thereto.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determined that the AskBio License Agreement and Supply Obligation represent a single promise and performance obligation. This is because AskBio cannot derive benefit from the license without the simultaneous transfer of the patent protected ImmTOR supply. Therefore, the License Obligation and Supply Obligation represent the only promise in the arrangement and are combined as a single performance obligation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In determining the transaction price, the Company concluded that the future development milestones, regulatory milestones, sales milestones, and sales royalties all represent variable consideration. Each of these variable consideration items was evaluated under the most likely amount method to determine whether such amounts were probable of occurrence, or whether such amounts should be constrained until they become probable. As part of its evaluation of the constraint, the Company considered numerous factors, including that receipt of such milestones is outside the control of the Company. Consideration related to sales-based milestones as well as royalties on net sales upon commercialization by AskBio, will be recognized when the related sales occur, as they were determined to relate predominantly to the intellectual property granted to AskBio and, therefore, have also been excluded from the transaction price in accordance with the royalty recognition constraint. As of March 31, 2021 and December&#160;31, 2020, all milestones were constrained. The Company will re-evaluate the transaction price in each reporting period, as uncertain events are resolved, or as other changes in circumstances occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The total initial transaction price of the contract on the effective date was $7.0 million, comprised of a $2.0 million initial up-front payment upon agreement of terms, and a $5.0 million initial up-front execution fee.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At each of March 31, 2021 and December 31, 2020, the Company recorded $1.7 million as short-term and $5.3 million as a long-term, representing deferred revenue associated with this agreement. Revenue will be recognized over the period in which the particles are delivered. No revenue related to the AskBio License Agreement was recognized during the three months ended March 31, 2021 and 2020 as no deliveries were made during the periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Spark Therapeutics, Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Spark License Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The disclosures relating to the Company&#x2019;s license and option agreement, or the Spark License Agreement, with Spark pursuant to which the Company and Spark agreed to collaborate on the development of gene therapies for certain targets utilizing the ImmTOR platform reported in the Company&#x2019;s Annual Report on Form 10-K for the year ended December 31, 2020 which was filed with the SEC on March 12, 2021 have not materially changed since the Company filed such report.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Transaction Price Allocated to Future Performance Obligations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Remaining performance obligations represent the transaction price of contracts for which work has not been performed (or has been partially performed). As of March 31, 2021, the aggregate amount of the transaction price allocated to remaining performance obligations was $108.1 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Contract Balances from Contracts with Customers (&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Sobi, Sarepta, AskBio, and Spark&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents changes in the Company&#x2019;s contract liabilities during the three months ended March 31, 2021 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:29.488%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.517%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.517%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.517%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.521%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balance at&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balance at&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;beginning of period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Deductions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;end of period&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Contract liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;110,796&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2,730)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;108,066&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total contract liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;110,796&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2,730)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;108,066&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <selb:LicenseAndOptionAgreementUpfrontCashPayment
      contextRef="i88f5a9f6a9ed48ce97bb4cbb9b6ef889_D20200611-20200611"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDcvZnJhZzo5YjFkNTkxZmQzMWQ0NDQ4OTczNDg0ZDFiMDliZGFlNC90ZXh0cmVnaW9uOjliMWQ1OTFmZDMxZDQ0NDg5NzM0ODRkMWIwOWJkYWU0XzY5OA_646179ee-d250-49f3-b10c-0e5f36937f9f"
      unitRef="usd">75000000.0</selb:LicenseAndOptionAgreementUpfrontCashPayment>
    <selb:LicenseAndOptionAgreementSalesMilestonePaymentsThatMayBeReceived
      contextRef="i88f5a9f6a9ed48ce97bb4cbb9b6ef889_D20200611-20200611"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDcvZnJhZzo5YjFkNTkxZmQzMWQ0NDQ4OTczNDg0ZDFiMDliZGFlNC90ZXh0cmVnaW9uOjliMWQ1OTFmZDMxZDQ0NDg5NzM0ODRkMWIwOWJkYWU0Xzc2NQ_8ece6da4-6138-4047-b762-d173ea8279c0"
      unitRef="usd">630000000.0</selb:LicenseAndOptionAgreementSalesMilestonePaymentsThatMayBeReceived>
    <selb:LicenseAndOptionAgreementWrittenDayNoticePeriodBeforeCancellation
      contextRef="i88f5a9f6a9ed48ce97bb4cbb9b6ef889_D20200611-20200611"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDcvZnJhZzo5YjFkNTkxZmQzMWQ0NDQ4OTczNDg0ZDFiMDliZGFlNC90ZXh0cmVnaW9uOjliMWQ1OTFmZDMxZDQ0NDg5NzM0ODRkMWIwOWJkYWU0XzQzOTgwNDY1NTQ3ODg_5af03c49-9286-4c50-abb6-20b0e1b9dc8b">P180D</selb:LicenseAndOptionAgreementWrittenDayNoticePeriodBeforeCancellation>
    <selb:EligiblePeriodToReceiveRoyalties
      contextRef="i88f5a9f6a9ed48ce97bb4cbb9b6ef889_D20200611-20200611"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDcvZnJhZzo5YjFkNTkxZmQzMWQ0NDQ4OTczNDg0ZDFiMDliZGFlNC90ZXh0cmVnaW9uOjliMWQ1OTFmZDMxZDQ0NDg5NzM0ODRkMWIwOWJkYWU0XzM2ODA_dda94778-3b95-4368-80ea-d5c7ac380024">P10Y</selb:EligiblePeriodToReceiveRoyalties>
    <selb:RevenueNumberOfPerformanceObligations
      contextRef="idfbbd3bf25a24130a9437f8a5acdb931_I20200611"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDcvZnJhZzo5YjFkNTkxZmQzMWQ0NDQ4OTczNDg0ZDFiMDliZGFlNC90ZXh0cmVnaW9uOjliMWQ1OTFmZDMxZDQ0NDg5NzM0ODRkMWIwOWJkYWU0XzQxMDE_144a11a5-0c0c-4ace-8194-5e2462f9b98a"
      unitRef="obligation">3</selb:RevenueNumberOfPerformanceObligations>
    <selb:LicenseAndOptionAgreementUpfrontCashPayment
      contextRef="i88f5a9f6a9ed48ce97bb4cbb9b6ef889_D20200611-20200611"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDcvZnJhZzo5YjFkNTkxZmQzMWQ0NDQ4OTczNDg0ZDFiMDliZGFlNC90ZXh0cmVnaW9uOjliMWQ1OTFmZDMxZDQ0NDg5NzM0ODRkMWIwOWJkYWU0XzQ5ODI_e8668e98-1994-41c3-aafb-ae27ee5ef3b2"
      unitRef="usd">75000000.0</selb:LicenseAndOptionAgreementUpfrontCashPayment>
    <selb:LicenseAndOptionAgreementDevelopmentMilestone
      contextRef="i88f5a9f6a9ed48ce97bb4cbb9b6ef889_D20200611-20200611"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDcvZnJhZzo5YjFkNTkxZmQzMWQ0NDQ4OTczNDg0ZDFiMDliZGFlNC90ZXh0cmVnaW9uOjliMWQ1OTFmZDMxZDQ0NDg5NzM0ODRkMWIwOWJkYWU0XzQ5OTM_51202c95-6039-42fc-9b65-790f30c46ac4"
      unitRef="usd">5000000.0</selb:LicenseAndOptionAgreementDevelopmentMilestone>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="i6e736a6ad22d4f7fbc1eda905bef7a23_D20200611-20200611"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDcvZnJhZzo5YjFkNTkxZmQzMWQ0NDQ4OTczNDg0ZDFiMDliZGFlNC90ZXh0cmVnaW9uOjliMWQ1OTFmZDMxZDQ0NDg5NzM0ODRkMWIwOWJkYWU0XzYxNzc_e3cefb86-1b3f-48f4-9bfa-647456e3ce0d"
      unitRef="usd">25000000.0</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:RedemptionPremium
      contextRef="i0e52f92d6bcb4dd098a7fe0cf721e342_D20200728-20200728"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDcvZnJhZzo5YjFkNTkxZmQzMWQ0NDQ4OTczNDg0ZDFiMDliZGFlNC90ZXh0cmVnaW9uOjliMWQ1OTFmZDMxZDQ0NDg5NzM0ODRkMWIwOWJkYWU0XzYzMTY_a10c1c4e-e89d-470a-96c8-0f61fed33eb7"
      unitRef="usd">14500000</us-gaap:RedemptionPremium>
    <selb:RevenueNumberOfPerformanceObligations
      contextRef="idfbbd3bf25a24130a9437f8a5acdb931_I20200611"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDcvZnJhZzo5YjFkNTkxZmQzMWQ0NDQ4OTczNDg0ZDFiMDliZGFlNC90ZXh0cmVnaW9uOjliMWQ1OTFmZDMxZDQ0NDg5NzM0ODRkMWIwOWJkYWU0XzY4NDM_f4561a59-512b-48f7-8a82-5820250728f3"
      unitRef="obligation">3</selb:RevenueNumberOfPerformanceObligations>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i89a2a0a3262b4bc9b05cb96efb71185e_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDcvZnJhZzo5YjFkNTkxZmQzMWQ0NDQ4OTczNDg0ZDFiMDliZGFlNC90ZXh0cmVnaW9uOjliMWQ1OTFmZDMxZDQ0NDg5NzM0ODRkMWIwOWJkYWU0XzkwMzY_71b143e9-4fa2-43ba-8e01-ee931f9f09fb"
      unitRef="usd">72000000.0</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i9114bf8b8ace4041b525081dc7e30132_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDcvZnJhZzo5YjFkNTkxZmQzMWQ0NDQ4OTczNDg0ZDFiMDliZGFlNC90ZXh0cmVnaW9uOjliMWQ1OTFmZDMxZDQ0NDg5NzM0ODRkMWIwOWJkYWU0XzQzOTgwNDY1NTE0OTk_2c762d6d-fe83-4f1f-87e0-da51e5a05baf"
      unitRef="usd">68300000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="i89a2a0a3262b4bc9b05cb96efb71185e_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDcvZnJhZzo5YjFkNTkxZmQzMWQ0NDQ4OTczNDg0ZDFiMDliZGFlNC90ZXh0cmVnaW9uOjliMWQ1OTFmZDMxZDQ0NDg5NzM0ODRkMWIwOWJkYWU0XzkwODc_682a359e-a2f5-4c8e-a1c6-c9527d21a540"
      unitRef="usd">17800000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="i9114bf8b8ace4041b525081dc7e30132_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDcvZnJhZzo5YjFkNTkxZmQzMWQ0NDQ4OTczNDg0ZDFiMDliZGFlNC90ZXh0cmVnaW9uOjliMWQ1OTFmZDMxZDQ0NDg5NzM0ODRkMWIwOWJkYWU0XzQzOTgwNDY1NTE1MTQ_95b648c1-0c77-4e4a-a6f7-a6cde64c6dcd"
      unitRef="usd">24200000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerAssetNetCurrent
      contextRef="i89a2a0a3262b4bc9b05cb96efb71185e_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDcvZnJhZzo5YjFkNTkxZmQzMWQ0NDQ4OTczNDg0ZDFiMDliZGFlNC90ZXh0cmVnaW9uOjliMWQ1OTFmZDMxZDQ0NDg5NzM0ODRkMWIwOWJkYWU0XzkyMzM_582e4132-68b1-4aac-92cc-b65b7bf9c96f"
      unitRef="usd">1300000</us-gaap:ContractWithCustomerAssetNetCurrent>
    <us-gaap:ContractWithCustomerAssetNetCurrent
      contextRef="i0274d7d2728b45debefc3a188dc02830_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDcvZnJhZzo5YjFkNTkxZmQzMWQ0NDQ4OTczNDg0ZDFiMDliZGFlNC90ZXh0cmVnaW9uOjliMWQ1OTFmZDMxZDQ0NDg5NzM0ODRkMWIwOWJkYWU0XzkzNzk_85709cba-b190-4e73-b5d4-f45f24539d20"
      unitRef="usd">1000000.0</us-gaap:ContractWithCustomerAssetNetCurrent>
    <us-gaap:ContractWithCustomerAssetNetCurrent
      contextRef="ieb852272fa154e92bcf4a36c0a643304_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDcvZnJhZzo5YjFkNTkxZmQzMWQ0NDQ4OTczNDg0ZDFiMDliZGFlNC90ZXh0cmVnaW9uOjliMWQ1OTFmZDMxZDQ0NDg5NzM0ODRkMWIwOWJkYWU0Xzk0NTM_e0f2cfef-26f1-46a5-b0be-87090a560cb4"
      unitRef="usd">300000</us-gaap:ContractWithCustomerAssetNetCurrent>
    <us-gaap:CapitalizedContractCostAmortization
      contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDcvZnJhZzo5YjFkNTkxZmQzMWQ0NDQ4OTczNDg0ZDFiMDliZGFlNC90ZXh0cmVnaW9uOjliMWQ1OTFmZDMxZDQ0NDg5NzM0ODRkMWIwOWJkYWU0Xzk1Njk_401cf24c-2b7c-44c8-9ad5-55517f7c2bf7"
      unitRef="usd">100000</us-gaap:CapitalizedContractCostAmortization>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i89a2a0a3262b4bc9b05cb96efb71185e_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDcvZnJhZzo5YjFkNTkxZmQzMWQ0NDQ4OTczNDg0ZDFiMDliZGFlNC90ZXh0cmVnaW9uOjliMWQ1OTFmZDMxZDQ0NDg5NzM0ODRkMWIwOWJkYWU0Xzk2Njk_129eb07d-5957-4b28-a98b-26815f51eebb"
      unitRef="usd">8300000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i9114bf8b8ace4041b525081dc7e30132_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDcvZnJhZzo5YjFkNTkxZmQzMWQ0NDQ4OTczNDg0ZDFiMDliZGFlNC90ZXh0cmVnaW9uOjliMWQ1OTFmZDMxZDQ0NDg5NzM0ODRkMWIwOWJkYWU0XzIxOTkwMjMyOTMyNjk_bcac0351-b105-435f-a63d-73cb62381d94"
      unitRef="usd">6900000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="i8d2fc88d756d4b67bf9851793506eee3_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDcvZnJhZzo5YjFkNTkxZmQzMWQ0NDQ4OTczNDg0ZDFiMDliZGFlNC90ZXh0cmVnaW9uOjliMWQ1OTFmZDMxZDQ0NDg5NzM0ODRkMWIwOWJkYWU0Xzk3OTE_18780938-3229-4e7e-82b7-ffb8e9433df6"
      unitRef="usd">11100000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <selb:LicenseAndOptionAgreementOptionTerm
      contextRef="i114b99e9c016452483452639f622b436_D20200613-20200613"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDcvZnJhZzo5YjFkNTkxZmQzMWQ0NDQ4OTczNDg0ZDFiMDliZGFlNC90ZXh0cmVnaW9uOjliMWQ1OTFmZDMxZDQ0NDg5NzM0ODRkMWIwOWJkYWU0XzEwNTk1_9bd9352a-07b8-4a21-8cf9-61a77d090a11">P24M</selb:LicenseAndOptionAgreementOptionTerm>
    <selb:LicenseAndOptionAgreementUpfrontCashPayment
      contextRef="i114b99e9c016452483452639f622b436_D20200613-20200613"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDcvZnJhZzo5YjFkNTkxZmQzMWQ0NDQ4OTczNDg0ZDFiMDliZGFlNC90ZXh0cmVnaW9uOjliMWQ1OTFmZDMxZDQ0NDg5NzM0ODRkMWIwOWJkYWU0XzEwOTA0_a4f47a9d-e388-4c2b-84ba-6c4148d1cfea"
      unitRef="usd">2000000.0</selb:LicenseAndOptionAgreementUpfrontCashPayment>
    <selb:LicenseAndOptionAgreementOptionTerm
      contextRef="i114b99e9c016452483452639f622b436_D20200613-20200613"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDcvZnJhZzo5YjFkNTkxZmQzMWQ0NDQ4OTczNDg0ZDFiMDliZGFlNC90ZXh0cmVnaW9uOjliMWQ1OTFmZDMxZDQ0NDg5NzM0ODRkMWIwOWJkYWU0XzExNTYx_9bd9352a-07b8-4a21-8cf9-61a77d090a11">P24M</selb:LicenseAndOptionAgreementOptionTerm>
    <selb:LicenseAndOptionAgreementOptionTerm
      contextRef="i114b99e9c016452483452639f622b436_D20200613-20200613"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDcvZnJhZzo5YjFkNTkxZmQzMWQ0NDQ4OTczNDg0ZDFiMDliZGFlNC90ZXh0cmVnaW9uOjliMWQ1OTFmZDMxZDQ0NDg5NzM0ODRkMWIwOWJkYWU0XzEzNDUw_9bd9352a-07b8-4a21-8cf9-61a77d090a11">P24M</selb:LicenseAndOptionAgreementOptionTerm>
    <selb:LicenseAndOptionAgreementWrittenDayNoticePeriodBeforeCancellation
      contextRef="i114b99e9c016452483452639f622b436_D20200613-20200613"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDcvZnJhZzo5YjFkNTkxZmQzMWQ0NDQ4OTczNDg0ZDFiMDliZGFlNC90ZXh0cmVnaW9uOjliMWQ1OTFmZDMxZDQ0NDg5NzM0ODRkMWIwOWJkYWU0XzQzOTgwNDY1NTQ4MDM_67a3eadb-66ac-4175-be66-8c0627024c94">P30D</selb:LicenseAndOptionAgreementWrittenDayNoticePeriodBeforeCancellation>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i6ede8ce092334ef1927faf29388e0af6_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDcvZnJhZzo5YjFkNTkxZmQzMWQ0NDQ4OTczNDg0ZDFiMDliZGFlNC90ZXh0cmVnaW9uOjliMWQ1OTFmZDMxZDQ0NDg5NzM0ODRkMWIwOWJkYWU0XzE0Mjcx_424823cf-8fe6-47ac-9d0b-6138ac6c2901"
      unitRef="usd">2000000.0</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i7b30202348b245c093e55382ba4778e9_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDcvZnJhZzo5YjFkNTkxZmQzMWQ0NDQ4OTczNDg0ZDFiMDliZGFlNC90ZXh0cmVnaW9uOjliMWQ1OTFmZDMxZDQ0NDg5NzM0ODRkMWIwOWJkYWU0XzE0Mjcx_da9b672d-66f3-4621-8b58-ccf966484fcc"
      unitRef="usd">2000000.0</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="ie7b30c0c9db24a54aad1845efeb882c1_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDcvZnJhZzo5YjFkNTkxZmQzMWQ0NDQ4OTczNDg0ZDFiMDliZGFlNC90ZXh0cmVnaW9uOjliMWQ1OTFmZDMxZDQ0NDg5NzM0ODRkMWIwOWJkYWU0XzE0Mzkx_3bb1086c-6e7e-4b7c-b86b-289b6d672c4a"
      unitRef="usd">0</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="i17bc05b20a3043b2acb1ee8c2e1badf9_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDcvZnJhZzo5YjFkNTkxZmQzMWQ0NDQ4OTczNDg0ZDFiMDliZGFlNC90ZXh0cmVnaW9uOjliMWQ1OTFmZDMxZDQ0NDg5NzM0ODRkMWIwOWJkYWU0XzE0Mzkx_832ac221-fe46-419d-ab15-81f02f77bc4d"
      unitRef="usd">0</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <selb:LicenseAndOptionAgreementUpfrontCashPayment
      contextRef="ia04c0f8c59e54e0780747ca4c1a414d5_D20191217-20191217"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDcvZnJhZzo5YjFkNTkxZmQzMWQ0NDQ4OTczNDg0ZDFiMDliZGFlNC90ZXh0cmVnaW9uOjliMWQ1OTFmZDMxZDQ0NDg5NzM0ODRkMWIwOWJkYWU0XzE1MzAw_7a999d5d-05ce-42d3-8edd-b4769ae48333"
      unitRef="usd">7000000.0</selb:LicenseAndOptionAgreementUpfrontCashPayment>
    <selb:LicenseAndOptionAgreementSalesMilestonePaymentsThatMayBeReceived
      contextRef="ia04c0f8c59e54e0780747ca4c1a414d5_D20191217-20191217"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDcvZnJhZzo5YjFkNTkxZmQzMWQ0NDQ4OTczNDg0ZDFiMDliZGFlNC90ZXh0cmVnaW9uOjliMWQ1OTFmZDMxZDQ0NDg5NzM0ODRkMWIwOWJkYWU0XzE1NDA1_a1f105ae-938c-4c75-b856-46f6c7d09224"
      unitRef="usd">237000000.0</selb:LicenseAndOptionAgreementSalesMilestonePaymentsThatMayBeReceived>
    <selb:EligiblePeriodToReceiveRoyalties
      contextRef="ia04c0f8c59e54e0780747ca4c1a414d5_D20191217-20191217"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDcvZnJhZzo5YjFkNTkxZmQzMWQ0NDQ4OTczNDg0ZDFiMDliZGFlNC90ZXh0cmVnaW9uOjliMWQ1OTFmZDMxZDQ0NDg5NzM0ODRkMWIwOWJkYWU0XzE1ODEz_dbad6229-7ba7-4380-bf8c-bbaacc2783be">P10Y</selb:EligiblePeriodToReceiveRoyalties>
    <selb:LicenseAndOptionAgreementUpfrontCashPayment
      contextRef="ia04c0f8c59e54e0780747ca4c1a414d5_D20191217-20191217"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDcvZnJhZzo5YjFkNTkxZmQzMWQ0NDQ4OTczNDg0ZDFiMDliZGFlNC90ZXh0cmVnaW9uOjliMWQ1OTFmZDMxZDQ0NDg5NzM0ODRkMWIwOWJkYWU0XzE4MTM5_109f446f-f82f-4485-ac26-d4177015495d"
      unitRef="usd">7000000.0</selb:LicenseAndOptionAgreementUpfrontCashPayment>
    <selb:LicenseAndOptionAgreementInitialUpFrontCashPayment
      contextRef="ia04c0f8c59e54e0780747ca4c1a414d5_D20191217-20191217"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDcvZnJhZzo5YjFkNTkxZmQzMWQ0NDQ4OTczNDg0ZDFiMDliZGFlNC90ZXh0cmVnaW9uOjliMWQ1OTFmZDMxZDQ0NDg5NzM0ODRkMWIwOWJkYWU0XzE4MTU4_eabb0863-a8fa-46e3-93a8-1f1c1afd198f"
      unitRef="usd">2000000.0</selb:LicenseAndOptionAgreementInitialUpFrontCashPayment>
    <selb:LicenseAndOptionAgreementExecutionFeePayment
      contextRef="ia04c0f8c59e54e0780747ca4c1a414d5_D20191217-20191217"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDcvZnJhZzo5YjFkNTkxZmQzMWQ0NDQ4OTczNDg0ZDFiMDliZGFlNC90ZXh0cmVnaW9uOjliMWQ1OTFmZDMxZDQ0NDg5NzM0ODRkMWIwOWJkYWU0XzE4MjE3_33faaa30-22a0-4935-a606-1e7c29fc3234"
      unitRef="usd">5000000.0</selb:LicenseAndOptionAgreementExecutionFeePayment>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i10b61b699b8047098f9ffd1347f4a2ea_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDcvZnJhZzo5YjFkNTkxZmQzMWQ0NDQ4OTczNDg0ZDFiMDliZGFlNC90ZXh0cmVnaW9uOjliMWQ1OTFmZDMxZDQ0NDg5NzM0ODRkMWIwOWJkYWU0XzE4MzA1_6f6fbb2c-0b9c-4ea2-87da-9f88282ad699"
      unitRef="usd">1700000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="ie2581e0def58480f85a685f932e3297b_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDcvZnJhZzo5YjFkNTkxZmQzMWQ0NDQ4OTczNDg0ZDFiMDliZGFlNC90ZXh0cmVnaW9uOjliMWQ1OTFmZDMxZDQ0NDg5NzM0ODRkMWIwOWJkYWU0XzE4MzA1_d297e8f8-f436-4051-9db6-a34fb37c6a7e"
      unitRef="usd">1700000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="ie2581e0def58480f85a685f932e3297b_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDcvZnJhZzo5YjFkNTkxZmQzMWQ0NDQ4OTczNDg0ZDFiMDliZGFlNC90ZXh0cmVnaW9uOjliMWQ1OTFmZDMxZDQ0NDg5NzM0ODRkMWIwOWJkYWU0XzE4MzU1_55d528c6-5134-424e-94ad-bd7bd9d35d92"
      unitRef="usd">5300000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="i10b61b699b8047098f9ffd1347f4a2ea_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDcvZnJhZzo5YjFkNTkxZmQzMWQ0NDQ4OTczNDg0ZDFiMDliZGFlNC90ZXh0cmVnaW9uOjliMWQ1OTFmZDMxZDQ0NDg5NzM0ODRkMWIwOWJkYWU0XzE4MzU1_d7c956bf-7400-4945-a8f1-78fe0f2b9b36"
      unitRef="usd">5300000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="i9d35ce32fa2b4a2b89239188060f0691_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDcvZnJhZzo5YjFkNTkxZmQzMWQ0NDQ4OTczNDg0ZDFiMDliZGFlNC90ZXh0cmVnaW9uOjliMWQ1OTFmZDMxZDQ0NDg5NzM0ODRkMWIwOWJkYWU0XzE4NTQz_abd2019a-8a5e-4eb1-8ec5-1412bbf7bf47"
      unitRef="usd">0</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="i52f04094420841308054f7809f206401_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDcvZnJhZzo5YjFkNTkxZmQzMWQ0NDQ4OTczNDg0ZDFiMDliZGFlNC90ZXh0cmVnaW9uOjliMWQ1OTFmZDMxZDQ0NDg5NzM0ODRkMWIwOWJkYWU0XzE4NTQz_ec063c73-7693-46ed-b861-3ad4a9875375"
      unitRef="usd">0</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="ied8d945ebce54ed8a4badfed477a64e8_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDcvZnJhZzo5YjFkNTkxZmQzMWQ0NDQ4OTczNDg0ZDFiMDliZGFlNC90ZXh0cmVnaW9uOjliMWQ1OTFmZDMxZDQ0NDg5NzM0ODRkMWIwOWJkYWU0XzM1MzM4_8d51d88c-693d-4dc2-9281-91a5f90c3a37"
      unitRef="usd">108100000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock
      contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDcvZnJhZzo5YjFkNTkxZmQzMWQ0NDQ4OTczNDg0ZDFiMDliZGFlNC90ZXh0cmVnaW9uOjliMWQ1OTFmZDMxZDQ0NDg5NzM0ODRkMWIwOWJkYWU0XzM1NTYx_564e78a9-0092-4479-893d-320eb1968a75">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents changes in the Company&#x2019;s contract liabilities during the three months ended March 31, 2021 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:29.488%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.517%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.517%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.517%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.521%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balance at&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balance at&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;beginning of period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Deductions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;end of period&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Contract liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;110,796&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2,730)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;108,066&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total contract liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;110,796&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2,730)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;108,066&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock>
    <selb:ContractwithCustomerLiabilityDeferredRevenue
      contextRef="ib56f1adc867e406ca7face50c5da1c9c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDcvZnJhZzo5YjFkNTkxZmQzMWQ0NDQ4OTczNDg0ZDFiMDliZGFlNC90YWJsZTozOTE1Y2FkNzFkYjY0YmNmYTM2YjFlYTAyYWZmZWRkMi90YWJsZXJhbmdlOjM5MTVjYWQ3MWRiNjRiY2ZhMzZiMWVhMDJhZmZlZGQyXzYtMi0xLTEtMA_ef0b918f-a582-4e39-a830-89f85674f06d"
      unitRef="usd">110796000</selb:ContractwithCustomerLiabilityDeferredRevenue>
    <selb:ContractwithCustomerLiabilityDeferredRevenueIncreaseFromCashReceipts
      contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDcvZnJhZzo5YjFkNTkxZmQzMWQ0NDQ4OTczNDg0ZDFiMDliZGFlNC90YWJsZTozOTE1Y2FkNzFkYjY0YmNmYTM2YjFlYTAyYWZmZWRkMi90YWJsZXJhbmdlOjM5MTVjYWQ3MWRiNjRiY2ZhMzZiMWVhMDJhZmZlZGQyXzYtNC0xLTEtMA_22062556-b97f-4790-87d4-91cfdf125002"
      unitRef="usd">0</selb:ContractwithCustomerLiabilityDeferredRevenueIncreaseFromCashReceipts>
    <selb:ContractwithCustomerLiabilityDeferredRevenueRevenueRecognized
      contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDcvZnJhZzo5YjFkNTkxZmQzMWQ0NDQ4OTczNDg0ZDFiMDliZGFlNC90YWJsZTozOTE1Y2FkNzFkYjY0YmNmYTM2YjFlYTAyYWZmZWRkMi90YWJsZXJhbmdlOjM5MTVjYWQ3MWRiNjRiY2ZhMzZiMWVhMDJhZmZlZGQyXzYtNi0xLTEtMA_bc4c33c2-471f-4b38-b2ee-105fe31fe03d"
      unitRef="usd">2730000</selb:ContractwithCustomerLiabilityDeferredRevenueRevenueRecognized>
    <selb:ContractwithCustomerLiabilityDeferredRevenue
      contextRef="ied8d945ebce54ed8a4badfed477a64e8_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDcvZnJhZzo5YjFkNTkxZmQzMWQ0NDQ4OTczNDg0ZDFiMDliZGFlNC90YWJsZTozOTE1Y2FkNzFkYjY0YmNmYTM2YjFlYTAyYWZmZWRkMi90YWJsZXJhbmdlOjM5MTVjYWQ3MWRiNjRiY2ZhMzZiMWVhMDJhZmZlZGQyXzYtOC0xLTEtMA_c1b8ec4e-c9ba-4f1b-bc48-08b2222d7f3d"
      unitRef="usd">108066000</selb:ContractwithCustomerLiabilityDeferredRevenue>
    <us-gaap:ContractWithCustomerLiability
      contextRef="ib56f1adc867e406ca7face50c5da1c9c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDcvZnJhZzo5YjFkNTkxZmQzMWQ0NDQ4OTczNDg0ZDFiMDliZGFlNC90YWJsZTozOTE1Y2FkNzFkYjY0YmNmYTM2YjFlYTAyYWZmZWRkMi90YWJsZXJhbmdlOjM5MTVjYWQ3MWRiNjRiY2ZhMzZiMWVhMDJhZmZlZGQyXzctMi0xLTEtMA_57557105-fcb3-4b32-a29e-482ec9e68276"
      unitRef="usd">110796000</us-gaap:ContractWithCustomerLiability>
    <selb:ContractwithCustomerLiabilityIncreaseFromCashReceipts
      contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDcvZnJhZzo5YjFkNTkxZmQzMWQ0NDQ4OTczNDg0ZDFiMDliZGFlNC90YWJsZTozOTE1Y2FkNzFkYjY0YmNmYTM2YjFlYTAyYWZmZWRkMi90YWJsZXJhbmdlOjM5MTVjYWQ3MWRiNjRiY2ZhMzZiMWVhMDJhZmZlZGQyXzctNC0xLTEtMA_80cdb8fe-e46d-46cd-b038-67c0f2b0ade1"
      unitRef="usd">0</selb:ContractwithCustomerLiabilityIncreaseFromCashReceipts>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDcvZnJhZzo5YjFkNTkxZmQzMWQ0NDQ4OTczNDg0ZDFiMDliZGFlNC90YWJsZTozOTE1Y2FkNzFkYjY0YmNmYTM2YjFlYTAyYWZmZWRkMi90YWJsZXJhbmdlOjM5MTVjYWQ3MWRiNjRiY2ZhMzZiMWVhMDJhZmZlZGQyXzctNi0xLTEtMA_94df0c65-cd96-44dd-bec4-a51c5f4f12a5"
      unitRef="usd">2730000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiability
      contextRef="ied8d945ebce54ed8a4badfed477a64e8_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNDcvZnJhZzo5YjFkNTkxZmQzMWQ0NDQ4OTczNDg0ZDFiMDliZGFlNC90YWJsZTozOTE1Y2FkNzFkYjY0YmNmYTM2YjFlYTAyYWZmZWRkMi90YWJsZXJhbmdlOjM5MTVjYWQ3MWRiNjRiY2ZhMzZiMWVhMDJhZmZlZGQyXzctOC0xLTEtMA_6904f24d-61c9-4960-9e07-425dcc1bb293"
      unitRef="usd">108066000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock
      contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNTAvZnJhZzo1MDhiODBhMWE0OWY0MDhmOGEzN2ExNTg5YmViZjBkZi90ZXh0cmVnaW9uOjUwOGI4MGExYTQ5ZjQwOGY4YTM3YTE1ODliZWJmMGRmXzQzMg_f9b375c5-00d4-4da0-bc89-bc40273faa46">Related-Party Transactions&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Consulting Services&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company incurred expenses for consulting services provided by its founders totaling less than $0.1&#160;million during each of the three months ended March 31, 2021 and 2020. The Company entered into consulting agreements with its founders to serve on its Scientific Advisory Board, effective January 1, 2020 to December 31, 2021, under which they will be paid quarterly for their services.&lt;/span&gt;&lt;/div&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="i961e2381798844178d4558010699b490_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNTAvZnJhZzo1MDhiODBhMWE0OWY0MDhmOGEzN2ExNTg5YmViZjBkZi90ZXh0cmVnaW9uOjUwOGI4MGExYTQ5ZjQwOGY4YTM3YTE1ODliZWJmMGRmXzE0NA_3158dd89-c7db-49e9-a83c-3537a5399aec"
      unitRef="usd">100000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="i0f7b03d9ffec46e09e274a6faed6a815_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNTAvZnJhZzo1MDhiODBhMWE0OWY0MDhmOGEzN2ExNTg5YmViZjBkZi90ZXh0cmVnaW9uOjUwOGI4MGExYTQ5ZjQwOGY4YTM3YTE1ODliZWJmMGRmXzE0NA_936038d0-a54b-4aaa-b78d-306830405902"
      unitRef="usd">100000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <selb:CollaborationAndLicenseAgreementsTextBlock
      contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNTMvZnJhZzpjODk0YzJjNWNiYjM0NzFkODBjMTE5MTMyNjZmNzdiMC90ZXh0cmVnaW9uOmM4OTRjMmM1Y2JiMzQ3MWQ4MGMxMTkxMzI2NmY3N2IwXzc5Njk_04993236-dbc0-4a1e-8366-80d67b32a4cd">Collaboration Agreements&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Asklepios Biopharmaceutical, Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Feasibility Study and License Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2019, the Company entered into a feasibility study and license agreement with AskBio, or the AskBio Collaboration Agreement. Pursuant to the AskBio Collaboration Agreement, the Company and AskBio agreed to license intellectual property rights to each other as part of a collaboration to research, develop, and commercialize certain AAV gene therapy products utilizing the Company&#x2019;s ImmTOR platform to enable re-dosing of such AAV gene therapy products to treat serious rare and orphan genetic diseases for which there is a significant unmet medical need.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pursuant to the AskBio Collaboration Agreement, the Company and AskBio agreed to conduct proof of concept studies to potentially validate the use of ImmTOR in conjunction with AskBio&#x2019;s AAV gene therapy, or MMA-101, for the treatment of MMA, to mitigate the formation of neutralizing anti-AAV capsid antibodies, or the POC Studies. If the POC Studies are successful, or the parties otherwise elect to do so, the parties will proceed with a collaboration to pursue the development and commercialization of AAV gene therapy product candidates utilizing ImmTOR for the treatment of certain agreed serious rare and orphan genetic diseases. If the POC Studies fail to demonstrate a proof-of-concept, and the parties do not mutually agree in writing to proceed with the collaboration, the AskBio Collaboration Agreement will expire.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The SEL-399 program combines an empty AAV capsid (EMC-101), which is an AAV capsid containing no transgene, with ImmTOR and is being conducted in partnership with AskBio. Building on the preclinical data the Company has generated showing ImmTOR&#x2019;s effect on mitigating or reducing the formation of neutralizing antibodies to AAV gene therapies, the Company has commenced a clinical trial of SEL-399 in healthy adult volunteers in Belgium. The goal of the SEL-399 clinical trial is to demonstrate the appropriate dose of ImmTOR in humans to mitigate the formation of antibodies to AAV capsids used in gene therapies.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company and AskBio will share responsibility for the research, development and commercialization of products developed under this collaboration. The parties will also share research, development, and commercialization costs equally for all collaboration products, but with a right of either party to opt out of certain products, and thereby no longer be required to share costs for such products. Each party will receive a percentage of net profits for each product sold under the collaboration equal to the percentage of shared costs borne by such party in the development of such product. Pursuant to the AskBio Collaboration Agreement, AskBio is responsible for manufacturing the AAV capsids and AAV vectors and the Company is responsible for manufacturing ImmTOR.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The AskBio Collaboration Agreement is considered to be within the scope of ASC 808, as both parties are active participants and exposed to the risks and rewards of the collaborative activity. The Company evaluated the terms of the AskBio &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Collaboration Agreement and have identified the following promises in the arrangement (1) conducting research and development activities to develop and commercialize products under the collaboration, or the R&amp;amp;D Services, (2) granting a non-exclusive, non-transferable, royalty-free, fully paid up, worldwide license to certain intellectual property of the Company, or the IP Rights, for the purpose of performing the POC Studies, or the Research License, (3) granting an exclusive, nontransferable, worldwide license to the IP Rights for use in certain indications, or the Collaboration License, (4) providing manufactured supply of preclinical and clinical ImmTOR, or the Manufactured Supply, (5) participation on identified steering committees responsible for the oversight of the collaboration, or the JSC Participation, and (6) granting an exclusive option to obtain a license under the IP Rights to research, develop and commercialize Licensed Products. The Company determined that the R&amp;amp;D Services, Research License, Collaboration License, Manufactured Supply, and JSC Participation were not capable of being distinct, and therefore must be combined into a single performance obligation. Therefore, promises (1) through (5) identified above were combined into a single performance obligation. Furthermore, the Company evaluated the Option Agreement and determined that it does not provide AskBio with a material right under ASC 606 as the option was not priced at a discount (see discussion of the option exercise in Note 12). The Company noted that AskBio did not meet the definition of a customer within the scope of ASC 606 for any distinct performance obligations as the Company concluded that such items were not an output of the Company&#x2019;s ordinary activities. As such, the Company determined that the entire arrangement would be accounted for within the scope of ASC 808.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In accordance with ASC 808, collaboration expenses are recognized within R&amp;amp;D expense and selling, general and administrative expense on the Company&#x2019;s condensed consolidated statements of operations. For each of the three months ended March 31, 2021 and 2020, the Company recognized $1.2 million of collaboration expense under the AskBio Collaboration Agreement in which actual costs incurred by both parties approximate a 50% cost share.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under certain collaborative arrangements, the Company is entitled to reimbursement of certain R&amp;amp;D expense. Activities under collaborative arrangements for which the Company is entitled to reimbursement are considered to be collaborative activities under the scope of ASC 808. For these units of account, the Company does not analogize to ASC 606 or recognize revenue. Rather, the Company analogizes to the guidance in ASC 730, which requires that reimbursements from counterparties be recognized as an offset to the related costs. In accordance with ASC 730, the Company records reimbursement payments received from collaborators as reductions to R&amp;amp;D expense.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Massachusetts Institute of Technology&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2008, the Company entered into an exclusive patent license agreement, or the MIT License, with the Massachusetts Institute of Technology, or MIT, under which the Company received an exclusive royalty-bearing license to utilize patents held by MIT in exchange for upfront consideration and annual license maintenance fees. Such fees are expensed as incurred and have not been material to any period presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2020, the Company entered into a Fifth Amendment, or the MIT Amendment, to the MIT License, which is effective as of May 15, 2020. Pursuant to the MIT Amendment, certain of the Company&#x2019;s diligence obligations were extended, including a diligence obligation to commence a Phase 3 trial for a licensed product by a specific date in the second quarter of 2021. Additionally, certain of the Company&#x2019;s development and regulatory milestones and payments upon achievement of such milestones were adjusted.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March 31, 2021, and in connection with the execution of the Spark License Agreement, the Company has made contractual payments pursuant to the MIT License totaling $2.2 million for the sublicense granted to Spark, and $0.4 million relative to the calculated premium paid by Spark for the equity investments made under the Spark Purchase Agreement. The Company made no additional payments during the three months ended March 31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Shenyang Sunshine Pharmaceutical Co., Ltd&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2014, the Company entered into a license agreement, or the 3SBio License, with Shenyang Sunshine Pharmaceutical Co., Ltd., or 3SBio. The Company has paid to 3SBio an aggregate of $7.0 million in upfront and milestone-based payments under the 3SBio License as of March 31, 2021. The Company is required to make future payments to 3SBio contingent upon the occurrence of events related to the achievement of clinical and regulatory approval milestones of up to an aggregate of $15.0 million for products containing the Company&#x2019;s ImmTOR platform.&lt;/span&gt;&lt;/div&gt;</selb:CollaborationAndLicenseAgreementsTextBlock>
    <us-gaap:OperatingExpenses
      contextRef="i2d6aabf5381c4d8eafad236940060193_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNTMvZnJhZzpjODk0YzJjNWNiYjM0NzFkODBjMTE5MTMyNjZmNzdiMC90ZXh0cmVnaW9uOmM4OTRjMmM1Y2JiMzQ3MWQ4MGMxMTkxMzI2NmY3N2IwXzIxOTkwMjMyNjQzNTc_e99b589a-e03f-4d34-9acd-f939dc3263e7"
      unitRef="usd">1200000</us-gaap:OperatingExpenses>
    <selb:CollaborativeArrangementCostSharePercentage
      contextRef="i24708847c47a43ca9c76041056178569_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNTMvZnJhZzpjODk0YzJjNWNiYjM0NzFkODBjMTE5MTMyNjZmNzdiMC90ZXh0cmVnaW9uOmM4OTRjMmM1Y2JiMzQ3MWQ4MGMxMTkxMzI2NmY3N2IwXzUzODE_f73ffcff-3cda-4a55-a5ad-2a03e9ed0a1f"
      unitRef="number">0.50</selb:CollaborativeArrangementCostSharePercentage>
    <selb:LicenseAndOptionAgreementContractualPaymentsMade
      contextRef="icd96a5af167244139fa70b4e414d29c8_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNTMvZnJhZzpjODk0YzJjNWNiYjM0NzFkODBjMTE5MTMyNjZmNzdiMC90ZXh0cmVnaW9uOmM4OTRjMmM1Y2JiMzQ3MWQ4MGMxMTkxMzI2NmY3N2IwXzcxNzQ_ee32fdd2-fc65-44c2-944e-a5446f5382bc"
      unitRef="usd">2200000</selb:LicenseAndOptionAgreementContractualPaymentsMade>
    <selb:LicenseAndOptionAgreementCalculatedPremiumPaidForEquityInvestmentUnderPurchaseAgreement
      contextRef="icd96a5af167244139fa70b4e414d29c8_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNTMvZnJhZzpjODk0YzJjNWNiYjM0NzFkODBjMTE5MTMyNjZmNzdiMC90ZXh0cmVnaW9uOmM4OTRjMmM1Y2JiMzQ3MWQ4MGMxMTkxMzI2NmY3N2IwXzcyMTg_f99f46b8-562a-4617-bd2e-534f240380c1"
      unitRef="usd">400000</selb:LicenseAndOptionAgreementCalculatedPremiumPaidForEquityInvestmentUnderPurchaseAgreement>
    <selb:LicenseAndOptionAgreementContractualPaymentsMade
      contextRef="iec431b313cb846b2aa7358a0b7afcf53_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNTMvZnJhZzpjODk0YzJjNWNiYjM0NzFkODBjMTE5MTMyNjZmNzdiMC90ZXh0cmVnaW9uOmM4OTRjMmM1Y2JiMzQ3MWQ4MGMxMTkxMzI2NmY3N2IwXzczNTU_509a937e-f58f-4ea8-a710-dde5d6e383f1"
      unitRef="usd">0</selb:LicenseAndOptionAgreementContractualPaymentsMade>
    <selb:AggregateAmountOfUpfrontAndMilestoneBasedPaymentsPaid
      contextRef="ibb68c9bff506451eb919c2f81711b851_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNTMvZnJhZzpjODk0YzJjNWNiYjM0NzFkODBjMTE5MTMyNjZmNzdiMC90ZXh0cmVnaW9uOmM4OTRjMmM1Y2JiMzQ3MWQ4MGMxMTkxMzI2NmY3N2IwXzc2MzA_b0aea141-edb5-4f3b-a13f-1d6ffbc0cf7b"
      unitRef="usd">7000000.0</selb:AggregateAmountOfUpfrontAndMilestoneBasedPaymentsPaid>
    <selb:AggregateAmountForFuturePaymentsUponAchievementOfClinicalAndRegulatoryApprovalMilestonesForProductsContainingImmTORPlatform
      contextRef="i29f55711d46f4ce5a26d9adbfce75977_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNTMvZnJhZzpjODk0YzJjNWNiYjM0NzFkODBjMTE5MTMyNjZmNzdiMC90ZXh0cmVnaW9uOmM4OTRjMmM1Y2JiMzQ3MWQ4MGMxMTkxMzI2NmY3N2IwXzc5MDQ_4899e2f9-655b-4ed4-9243-9000a3839de5"
      unitRef="usd">15000000.0</selb:AggregateAmountForFuturePaymentsUponAchievementOfClinicalAndRegulatoryApprovalMilestonesForProductsContainingImmTORPlatform>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNTkvZnJhZzpjNWYwMDdlNjRiOTk0YjM5YWNmZTExNjlmMDU3ZTI2ZC90ZXh0cmVnaW9uOmM1ZjAwN2U2NGI5OTRiMzlhY2ZlMTE2OWYwNTdlMjZkXzMxNjg_752b3429-8466-46ee-84f9-d68f80f97ede">Income Taxes&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company provides for income taxes under ASC 740. Under ASC 740, the Company provides deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the Company&#x2019;s financial statement carrying amounts and the tax bases of assets and liabilities using enacted tax rates expected to be in effect in the years in which the differences are expected to reverse.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the three months ended March 31, 2021 and 2020, the Company did not record a current or deferred income tax expense or benefit.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has provided a full valuation allowance against its net deferred tax assets, as the Company believes that it is more likely than not that the deferred tax assets will not be realized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Utilization of the net operating loss and research and development credit carryforwards may be subject to a substantial annual limitation under Section 382 and 383 of the Internal Revenue Code due to ownership change limitations that have occurred previously, or that could occur in the future. These ownership changes may limit the amount of net operating loss and research and development credit carryforwards that can be utilized annually to offset future taxable income and tax, respectively. As of December 31, 2020, the Company completed a Section 382 study. The Company has determined that all of the $234.5&#160;million of net operating losses are available in the future, with approximately $36.5&#160;million of that total limited under Section 382 and therefore available for future use through 2028.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company applies ASC 740,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Income Taxes &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;to uncertain tax positions. As of March 31, 2021 and December 31, 2020, the Company had no unrecognized tax benefits or related interest and penalties accrued.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has not, as of yet, conducted a study of its research and development credit carryforwards. This study may result in an adjustment to the Company&#x2019;s research and development credit carryforwards; however, until a study is completed, and any adjustment is known, no amounts are being presented as an uncertain tax position.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The statute of limitations for assessment by the United States Internal Revenue Service and Massachusetts tax authorities is open for tax years since inception. The Company files income tax returns in the United States and Massachusetts. There are currently no federal, state or foreign audits in progress.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration
      contextRef="ied8d945ebce54ed8a4badfed477a64e8_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNTkvZnJhZzpjNWYwMDdlNjRiOTk0YjM5YWNmZTExNjlmMDU3ZTI2ZC90ZXh0cmVnaW9uOmM1ZjAwN2U2NGI5OTRiMzlhY2ZlMTE2OWYwNTdlMjZkXzQzOTgwNDY1MTkwNTY_d3bf0e90-21df-47f0-ac47-4e1f1d2d6c33"
      unitRef="usd">234500000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration
      contextRef="ied8d945ebce54ed8a4badfed477a64e8_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNTkvZnJhZzpjNWYwMDdlNjRiOTk0YjM5YWNmZTExNjlmMDU3ZTI2ZC90ZXh0cmVnaW9uOmM1ZjAwN2U2NGI5OTRiMzlhY2ZlMTE2OWYwNTdlMjZkXzQzOTgwNDY1MTkwNzI_51b10208-9fec-4c5e-a24b-35cbe0bc195f"
      unitRef="usd">36500000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="ib56f1adc867e406ca7face50c5da1c9c_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNTkvZnJhZzpjNWYwMDdlNjRiOTk0YjM5YWNmZTExNjlmMDU3ZTI2ZC90ZXh0cmVnaW9uOmM1ZjAwN2U2NGI5OTRiMzlhY2ZlMTE2OWYwNTdlMjZkXzQzOTgwNDY1MTkwOTA_4ef5b1c5-6588-4e84-89a8-9c504050cc00"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="ied8d945ebce54ed8a4badfed477a64e8_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNTkvZnJhZzpjNWYwMDdlNjRiOTk0YjM5YWNmZTExNjlmMDU3ZTI2ZC90ZXh0cmVnaW9uOmM1ZjAwN2U2NGI5OTRiMzlhY2ZlMTE2OWYwNTdlMjZkXzQzOTgwNDY1MTkwOTA_b2849216-1381-41c6-a736-d904160f5588"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock
      contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNjIvZnJhZzoxNTkyYmZiZjk1NmI0NTIwOTg4ZDBiYTE4MGYwOGJjYi90ZXh0cmVnaW9uOjE1OTJiZmJmOTU2YjQ1MjA5ODhkMGJhMTgwZjA4YmNiXzY5Mg_0a86f290-43cf-4bbc-9dce-6c39af88bf8c">Defined Contribution PlanThe Company maintains a defined contribution plan, or the 401(k) Plan, under Section&#160;401(k) of the Internal Revenue Code. The 401(k) Plan covers all employees who meet defined minimum age and service requirements and allows participants to defer a portion of their annual compensation on a pretax basis. The 401(k) Plan provides for matching contributions on a portion of participant contributions pursuant to the 401(k) Plan&#x2019;s matching formula. All matching contributions vest ratably over 4 years and participant contributions vest immediately. Contributions by the Company totaled less than $0.1 million during each of the three months ended March 31, 2021 and 2020.</us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>
    <selb:DefinedContributionPlanEmployersMatchingContributionVestingPeriod
      contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNjIvZnJhZzoxNTkyYmZiZjk1NmI0NTIwOTg4ZDBiYTE4MGYwOGJjYi90ZXh0cmVnaW9uOjE1OTJiZmJmOTU2YjQ1MjA5ODhkMGJhMTgwZjA4YmNiXzUyNg_4fea169f-f499-4ce8-9f30-1d891f68bd17">P4Y</selb:DefinedContributionPlanEmployersMatchingContributionVestingPeriod>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNjIvZnJhZzoxNTkyYmZiZjk1NmI0NTIwOTg4ZDBiYTE4MGYwOGJjYi90ZXh0cmVnaW9uOjE1OTJiZmJmOTU2YjQ1MjA5ODhkMGJhMTgwZjA4YmNiXzYxNA_a87c5c22-e7cc-4cc2-a873-e6e439815ec0"
      unitRef="usd">100000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="i824a5b33f908426bad016f0eded844db_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNjIvZnJhZzoxNTkyYmZiZjk1NmI0NTIwOTg4ZDBiYTE4MGYwOGJjYi90ZXh0cmVnaW9uOjE1OTJiZmJmOTU2YjQ1MjA5ODhkMGJhMTgwZjA4YmNiXzYxNA_e49ac9b9-5fca-4bbc-af50-3d0e8ed33273"
      unitRef="usd">100000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNjUvZnJhZzozZGI2NzE2YmVhY2Q0NzMzYWVjNGEwYzRmMTcxN2MxZC90ZXh0cmVnaW9uOjNkYjY3MTZiZWFjZDQ3MzNhZWM0YTBjNGYxNzE3YzFkXzMyMDY_4af10e86-33ba-4741-a349-e9618ae44dd5">Commitments and Contingencies&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March 31, 2021, the Company was not a party to any litigation that could have a material adverse effect on the Company&#x2019;s business, financial position, results of operations or cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August 4, 2020, a putative stockholder of Selecta filed a stockholder derivative action, purportedly on behalf of Selecta and against certain current and former members of the Company&#x2019;s Board of Directors, as well as one affiliated company owned by a current board member, in the Court of Chancery of the State of Delaware, namely Franchi v. Barabe, et al. The complaint alleges that the individual defendants breached their fiduciary duties and committed corporate waste when they authorized a private placement transaction, announced on December 19, 2019, at a price allegedly below fair value. The complaint further alleges that the four defendant directors who participated in the private placement were unjustly enriched in connection with the transaction. On September 25, 2020, the defendants filed a motion to dismiss the lawsuit. On November 6, 2020, the plaintiff filed an amended complaint, and the defendants filed a second motion to dismiss on January 8, 2021. On December 31, 2020, the Company received a litigation demand letter from two other putative stockholders relating to the same private placement transaction. On April 12, 2021, the Court of Chancery in the State of Delaware granted a motion to stay the litigation pending a review by a Special Committee appointed by the Company&#x2019;s Board of Directors. At this time, the Company has not accrued a liability for this matter, as any liability has been determined to be either not estimable or not probable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As permitted under Delaware law, the Company indemnifies its directors for certain events or occurrences while the director is, or was, serving at the Company&#x2019;s request in such capacity. The term of the indemnification is for the director&#x2019;s lifetime. The maximum potential amount of future payments the Company could be required to make is unlimited; however, the Company has directors&#x2019; insurance coverage that limits its exposure and enables it to recover a portion of any future amounts paid. The Company also has indemnification arrangements under certain of its facility leases that require it to indemnify the landlord against certain costs, expenses, fines, suits, claims, demands, liabilities, and actions directly resulting from certain breaches, violations, or non-performance of any covenant or condition of the Company&#x2019;s lease. The term of the indemnification is for the term of the related lease agreement. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is unlimited. To date, the Company had not experienced any material losses related to any of its indemnification obligations, and no material claims with respect thereto were outstanding.&lt;/span&gt;&lt;/div&gt;The Company is a party in various other contractual disputes and potential claims arising in the ordinary course of business. The Company does not believe that the resolution of these matters will have a material adverse effect the Company&#x2019;s business, financial position, results of operations or cash flows.</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="i93f17f89c13f486486776019ba38a82f_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNzEvZnJhZzo2OWNhODJhNWMxMzI0MzU4ODdiZDQwOTMxNGQ1MjE3Zi90ZXh0cmVnaW9uOjY5Y2E4MmE1YzEzMjQzNTg4N2JkNDA5MzE0ZDUyMTdmXzQxNg_39d58b4b-2632-4331-8daf-675e8dd76fd7">Subsequent Events&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x201c;At-the-Market&#x201d; Offerings&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Subsequent to March 31, 2021 through May 13, 2021, the Company sold 206,593 shares of its common stock pursuant to the 2020 Sales Agreement, at an average price of approximately $4.51 per share for aggregate net proceeds of $0.9 million, after deducting commissions and other transaction costs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Milestone Event&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On April 13, 2021, the Company was notified by Sarepta of the achievement of the milestone event related to the completion of a non-clinical study for Duchenne muscular dystrophy and certain limb-girdle muscular dystrophies under the Company&#x2019;s Research License and Option Agreement. Under the terms of the Agreement, Sarepta is obligated to pay a non-refundable, non-creditable milestone payment of $3.0&#160;million to the Company within 60 days of Sarepta&#x2019;s receipt of the related invoice from the Company.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;The AskBio Collaboration Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On April 29, 2021, the Company was notified by AskBio that it intended to opt-out of development of the MMA indication. Consequently, the Company will assume all rights to the MMA program and intends to continue to progress the MMA-101 and ImmTOR combination through clinical development.&lt;/span&gt;&lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i69b9f1abf0ba4aac990acd969100a523_D20210401-20210513"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNzEvZnJhZzo2OWNhODJhNWMxMzI0MzU4ODdiZDQwOTMxNGQ1MjE3Zi90ZXh0cmVnaW9uOjY5Y2E4MmE1YzEzMjQzNTg4N2JkNDA5MzE0ZDUyMTdmXzEyNQ_5333cdb4-aa44-4622-9cb3-40010ec98532"
      unitRef="shares">206593</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="ia74a702495ff411cac561a2aded35226_I20210513"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNzEvZnJhZzo2OWNhODJhNWMxMzI0MzU4ODdiZDQwOTMxNGQ1MjE3Zi90ZXh0cmVnaW9uOjY5Y2E4MmE1YzEzMjQzNTg4N2JkNDA5MzE0ZDUyMTdmXzIzMQ_2546910d-f1e2-479c-907a-1b7de71caa3e"
      unitRef="usdPerShare">4.51</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="i69b9f1abf0ba4aac990acd969100a523_D20210401-20210513"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNzEvZnJhZzo2OWNhODJhNWMxMzI0MzU4ODdiZDQwOTMxNGQ1MjE3Zi90ZXh0cmVnaW9uOjY5Y2E4MmE1YzEzMjQzNTg4N2JkNDA5MzE0ZDUyMTdmXzI3NQ_ee8114ca-a940-4db2-9cdf-98a7ef9239b4"
      unitRef="usd">900000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <selb:LicenseAndOptionAgreementMilestonePayments
      contextRef="iebf9f6ef11cf4e6e8cfcb2c64010f2ad_D20210413-20210413"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTg2ZTdkMmUzMDRmNjk4MzYzNGFiZTllMDcxNzkxL3NlYzo3MTU4NmU3ZDJlMzA0ZjY5ODM2MzRhYmU5ZTA3MTc5MV8yNzEvZnJhZzo2OWNhODJhNWMxMzI0MzU4ODdiZDQwOTMxNGQ1MjE3Zi90ZXh0cmVnaW9uOjY5Y2E4MmE1YzEzMjQzNTg4N2JkNDA5MzE0ZDUyMTdmXzQzOTgwNDY1MTM2MDc_d7c403b2-a28a-4c41-afe3-348d0e11a583"
      unitRef="usd">3000000.0</selb:LicenseAndOptionAgreementMilestonePayments>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140279312184888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover page - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>May 07, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-37798<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Selecta Biosciences, Inc<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">26-1622110<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">65 Grove Street,<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Watertown,<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02472<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">617<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">923-1400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.0001 par value per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">SELB<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Smaller Reporting Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Extended Transition Period</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">113,193,597<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001453687<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140279224565800">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 125,407<span></span>
</td>
<td class="nump">$ 138,685<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">22,405<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">8,342<span></span>
</td>
<td class="nump">7,224<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">6,971<span></span>
</td>
<td class="nump">5,434<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">163,125<span></span>
</td>
<td class="nump">151,343<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">1,301<span></span>
</td>
<td class="nump">1,395<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use asset, net</a></td>
<td class="nump">10,676<span></span>
</td>
<td class="nump">10,948<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent', window );">Long-term restricted cash</a></td>
<td class="nump">1,379<span></span>
</td>
<td class="nump">1,379<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssets', window );">Other assets</a></td>
<td class="nump">265<span></span>
</td>
<td class="nump">370<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">176,746<span></span>
</td>
<td class="nump">165,435<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">594<span></span>
</td>
<td class="nump">443<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">6,847<span></span>
</td>
<td class="nump">8,146<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LoansPayableCurrent', window );">Loan payable</a></td>
<td class="nump">460<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Lease liability</a></td>
<td class="nump">942<span></span>
</td>
<td class="nump">908<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue</a></td>
<td class="nump">75,764<span></span>
</td>
<td class="nump">72,050<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">84,607<span></span>
</td>
<td class="nump">81,547<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrentAbstract', window );"><strong>Non-current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermLoansPayable', window );">Loan payable, net of current portion</a></td>
<td class="nump">24,551<span></span>
</td>
<td class="nump">24,793<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Lease liability</a></td>
<td class="nump">9,403<span></span>
</td>
<td class="nump">9,647<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue</a></td>
<td class="nump">32,301<span></span>
</td>
<td class="nump">38,746<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrant liabilities</a></td>
<td class="nump">45,455<span></span>
</td>
<td class="nump">28,708<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">196,317<span></span>
</td>
<td class="nump">183,441<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note&#160;17)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; (deficit) equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.0001 par value; 10,000,000 shares authorized; no shares issued and outstanding at March 31, 2021 and December 31, 2020</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.0001 par value; 200,000,000 shares authorized; 112,977,004 and 108,071,249 shares issued and outstanding as of March 31, 2021 and December 31, 2020, respectively</a></td>
<td class="nump">11<span></span>
</td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">414,214<span></span>
</td>
<td class="nump">391,175<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(429,226)<span></span>
</td>
<td class="num">(404,629)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(4,570)<span></span>
</td>
<td class="num">(4,563)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; (deficit) equity</a></td>
<td class="num">(19,571)<span></span>
</td>
<td class="num">(18,006)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; (deficit) equity</a></td>
<td class="nump">$ 176,746<span></span>
</td>
<td class="nump">$ 165,435<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LoansPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of portion of long-term loans payable due within one year or the operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LoansPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermLoansPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of loans payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermLoansPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6812-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140279225011464">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">112,977,004<span></span>
</td>
<td class="nump">108,071,249<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">112,977,004<span></span>
</td>
<td class="nump">108,071,249<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140279224683464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations and Comprehensive Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Grant and collaboration revenue</a></td>
<td class="nump">$ 11,050<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfRevenueAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">13,004<span></span>
</td>
<td class="nump">14,724<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">5,204<span></span>
</td>
<td class="nump">4,098<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">18,208<span></span>
</td>
<td class="nump">18,822<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(7,158)<span></span>
</td>
<td class="num">(18,822)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeNet', window );">Investment income</a></td>
<td class="nump">12<span></span>
</td>
<td class="nump">240<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Foreign currency transaction gain, net</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">82<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(711)<span></span>
</td>
<td class="num">(273)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of warrant liabilities</a></td>
<td class="num">(16,747)<span></span>
</td>
<td class="num">(846)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income (expense), net</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(24,597)<span></span>
</td>
<td class="num">(19,620)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossTaxAbstract', window );"><strong>Other comprehensive loss:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustment</a></td>
<td class="num">(6)<span></span>
</td>
<td class="num">(60)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized (losses) on marketable securities</a></td>
<td class="num">(1)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Total comprehensive loss</a></td>
<td class="num">$ (24,604)<span></span>
</td>
<td class="num">$ (19,680)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract', window );"><strong>Net loss per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Basic and diluted (in dollars per share)</a></td>
<td class="num">$ (0.22)<span></span>
</td>
<td class="num">$ (0.21)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Weighted average common shares outstanding:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Basic and diluted (in shares)</a></td>
<td class="nump">110,742,150<span></span>
</td>
<td class="nump">94,723,513<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfRevenueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfRevenueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=109262497&amp;loc=d3e20148-110875<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109240200&amp;loc=d3e30690-110894<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 35<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121605123&amp;loc=d3e30226-110892<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=120253306&amp;loc=d3e28228-110885<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450222&amp;loc=d3e30840-110895<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accretion (amortization) of discount (premium), and investment expense, of interest income and dividend income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(a),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140279220294984">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Changes in Stockholders&#8217; (Deficit) Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common&#160;stock</div></th>
<th class="th"><div>Additional paid-in capital</div></th>
<th class="th"><div>Accumulated deficit</div></th>
<th class="th"><div>Accumulated other comprehensive loss</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">86,325,547<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2019</a></td>
<td class="nump">$ 8,397<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
<td class="nump">$ 348,664<span></span>
</td>
<td class="num">$ (335,753)<span></span>
</td>
<td class="num">$ (4,523)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock under Employee Stock Purchase Plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">78,583<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock under Employee Stock Purchase Plan</a></td>
<td class="nump">114<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">114<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon exercise of options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,128<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock upon exercise of options</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Issuance of vested restricted stock units (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,937<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Issuance of vested restricted stock units</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Issuance of common stock through at-the-market offering, net (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">598,977<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Issuance of common stock through at-the-market offering, net</a></td>
<td class="nump">1,141<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,141<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther', window );">Other financing fees</a></td>
<td class="num">(147)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(147)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">1,409<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,409<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Currency translation adjustment</a></td>
<td class="num">(60)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(60)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized (losses) on marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(19,620)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(19,620)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">87,019,172<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2020</a></td>
<td class="num">$ (8,763)<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
<td class="nump">351,184<span></span>
</td>
<td class="num">(355,373)<span></span>
</td>
<td class="num">(4,583)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2020</a></td>
<td class="nump">108,071,249<span></span>
</td>
<td class="nump">108,071,249<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2020</a></td>
<td class="num">$ (18,006)<span></span>
</td>
<td class="nump">$ 11<span></span>
</td>
<td class="nump">391,175<span></span>
</td>
<td class="num">(404,629)<span></span>
</td>
<td class="num">(4,563)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock under Employee Stock Purchase Plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,696<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock under Employee Stock Purchase Plan</a></td>
<td class="nump">72<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">72<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon exercise of options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">153,278<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock upon exercise of options</a></td>
<td class="nump">244<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">244<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Issuance of vested restricted stock units (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,937<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Issuance of vested restricted stock units</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Issuance of common stock through at-the-market offering, net (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,706,844<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Issuance of common stock through at-the-market offering, net</a></td>
<td class="nump">20,943<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,943<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">1,780<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,780<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Currency translation adjustment</a></td>
<td class="num">(6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized (losses) on marketable securities</a></td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (24,597)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(24,597)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2021</a></td>
<td class="nump">112,977,004<span></span>
</td>
<td class="nump">112,977,004<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2021</a></td>
<td class="num">$ (19,571)<span></span>
</td>
<td class="nump">$ 11<span></span>
</td>
<td class="nump">$ 414,214<span></span>
</td>
<td class="num">$ (429,226)<span></span>
</td>
<td class="num">$ (4,570)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of other increase (decrease) in additional paid in capital (APIC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326096&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate value of stock related to Restricted Stock Awards issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140279224648296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract', window );"><strong>Cash flows from operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (24,597)<span></span>
</td>
<td class="num">$ (19,620)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherDepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">207<span></span>
</td>
<td class="nump">231<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments', window );">Amortization of premiums and discounts on marketable securities</a></td>
<td class="nump">14<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization', window );">Non-cash lease expense</a></td>
<td class="nump">272<span></span>
</td>
<td class="nump">366<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Loss on disposal of property and equipment</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">1,780<span></span>
</td>
<td class="nump">1,409<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaidInKindInterest', window );">Non-cash interest expense</a></td>
<td class="nump">387<span></span>
</td>
<td class="nump">123<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Warrant liabilities revaluation</a></td>
<td class="nump">16,747<span></span>
</td>
<td class="nump">846<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="num">(1,118)<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses, deposits and other assets</a></td>
<td class="num">(1,512)<span></span>
</td>
<td class="num">(61)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">151<span></span>
</td>
<td class="nump">836<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="num">(2,728)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities', window );">Accrued expenses and other liabilities</a></td>
<td class="num">(1,736)<span></span>
</td>
<td class="num">(829)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash (used in) operating activities</a></td>
<td class="num">(12,133)<span></span>
</td>
<td class="num">(11,698)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract', window );"><strong>Cash flows from investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt', window );">Purchases of marketable securities</a></td>
<td class="num">(22,420)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(25)<span></span>
</td>
<td class="num">(135)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash (used in) investing activities</a></td>
<td class="num">(22,445)<span></span>
</td>
<td class="num">(135)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract', window );"><strong>Cash flows from financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayments of principal on outstanding debt</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(2,100)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds from issuance of common stock</a></td>
<td class="nump">20,991<span></span>
</td>
<td class="nump">1,141<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfFinancingCosts', window );">Issuance costs paid for December 2019 financing</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(4,381)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities', window );">Other financing fees</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(147)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of stock options</a></td>
<td class="nump">244<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockPlans', window );">Proceeds from issuance of common stock under Employee Stock Purchase Plan</a></td>
<td class="nump">72<span></span>
</td>
<td class="nump">114<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by (used in) financing activities</a></td>
<td class="nump">21,307<span></span>
</td>
<td class="num">(5,370)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents', window );">Effect of exchange rate changes on cash</a></td>
<td class="num">(7)<span></span>
</td>
<td class="num">(84)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net change in cash, cash equivalents, and restricted cash</a></td>
<td class="num">(13,278)<span></span>
</td>
<td class="num">(17,287)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, and restricted cash at beginning of period</a></td>
<td class="nump">140,064<span></span>
</td>
<td class="nump">91,551<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, and restricted cash at end of period</a></td>
<td class="nump">126,786<span></span>
</td>
<td class="nump">74,264<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplement cash flow information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="nump">494<span></span>
</td>
<td class="nump">232<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Noncash investing and financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Purchase of property and equipment not yet paid</a></td>
<td class="nump">10<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_selb_EquityOfferingCostsInAccruedLiabilities', window );">Equity offering costs in accrued liabilities</a></td>
<td class="nump">48<span></span>
</td>
<td class="nump">42<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesUnrealizedGainLoss', window );">Unrealized (losses) on marketable securities</a></td>
<td class="num">$ (1)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_selb_EquityOfferingCostsInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Offering Costs In Accrued Liabilities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">selb_EquityOfferingCostsInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>selb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from the effect of exchange rate changes on cash and cash equivalent balances held in foreign currencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=109262497&amp;loc=d3e20148-110875<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918638-209977<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in accrued expenses, and obligations classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in marketable security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense charged against earnings to allocate the cost of tangible and intangible assets over their remaining economic lives, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaidInKindInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interest paid other than in cash for example by issuing additional debt securities. As a noncash item, it is added to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaidInKindInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for loan and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3151-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromPaymentsForOtherFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from the stock plan during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140279312179848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of the Business and Basis of Presentation<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Nature of the Business and Basis of Presentation</a></td>
<td class="text">Nature of the Business and Basis of Presentation<div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selecta Biosciences, Inc., or the Company was incorporated in Delaware on December 10, 2007, and is based in Watertown, Massachusetts. The Company is a clinical-stage biopharmaceutical company leveraging its ImmTOR&#8482; immune tolerance platform with the goals of amplifying the efficacy of biologics, including enabling the re-dosing of life-saving gene therapies, and restoring self-tolerance in autoimmune diseases. The Company&#8217;s ImmTOR platform encapsulates rapamycin, also known as sirolimus, an immunomodulator, in biodegradable nanoparticles and is designed to induce antigen-specific immune tolerance. The Company believes ImmTOR has the potential to enhance the efficacy without compromising the safety of biologic therapies, improve product candidates under development, and enable novel therapeutic modalities. Since inception, the Company has devoted its efforts principally to research and development of its technology and product candidates, recruiting management and technical staff, acquiring operating assets, and raising capital.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to risks common to companies in the biotechnology industry including, but not limited to, new technological innovations, protection of proprietary technology, dependence on key personnel, compliance with government regulations and the need to obtain additional financing. Product candidates currently under development will require significant additional research and development efforts, including extensive preclinical and clinical testing and regulatory approval, prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel infrastructure and extensive compliance-reporting capabilities.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s product candidates are in development. There can be no assurance that the Company&#8217;s research and development will be successfully completed, that adequate protection for the Company&#8217;s intellectual property will be obtained, or maintained, that any products developed will obtain necessary government regulatory approval or that any approved products will be commercially viable. Even if the Company&#8217;s product development efforts are successful, it is uncertain when, if ever, the Company will generate significant revenue from product sales. The Company operates in an environment of rapid change in technology and substantial competition from pharmaceutical and biotechnology companies. In addition, the Company is dependent upon the services of its employees and consultants.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Unaudited Interim Financial Information</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited consolidated financial statements for the three months ended March 31, 2021 and 2020 have been prepared by the Company, pursuant to the rules and regulations of the Securities and Exchange Commission, or the SEC, for interim financial statements. Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America, or U.S. GAAP, have been condensed or omitted pursuant to such rules and regulations. These consolidated financial statements should be read in conjunction with the Company&#8217;s audited consolidated financial statements and the notes thereto for the year ended December 31, 2020 included in the Company&#8217;s Annual Report on Form 10-K that was filed with the SEC on March 12, 2021. The unaudited interim financial statements have been prepared on the same basis as the audited consolidated financial statements. In the opinion of management, the accompanying unaudited interim consolidated financial statements contain all adjustments that are necessary for a fair statement of the Company&#8217;s financial position as of March 31, 2021 and consolidated results of operations and cash flows for the three months ended March 31, 2021. Such adjustments are of a normal and recurring nature. The results of operations for the three months ended March 31, 2021 are not necessarily indicative of the results of operations that may be expected for the year ending December 31, 2021.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Management&#8217;s Plan</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The future success of the Company is dependent on its ability to develop its product candidates and ultimately upon its ability to attain profitable operations. The Company is subject to a number of risks similar to other early-stage life science companies, including, but not limited to, successful development of its product candidates, raising additional capital with favorable terms, protection of proprietary technology and market acceptance of any approved future products. The successful development of product candidates requires substantial working capital which may not be available to the Company on favorable terms or at all.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, the Company has financed its operations primarily through the initial public offering of its common stock, private placements of its common stock, issuances of common and preferred stock, debt, research grants and research collaborations. The Company currently has no source of product revenue, and it does not expect to generate product revenue for the foreseeable future. To date, all of the Company&#8217;s revenue has been collaboration and grant revenue. The Company has devoted substantially all of its financial resources and efforts to developing its ImmTOR platform, identifying potential product candidates and conducting preclinical studies and its clinical trials. The Company is in the early stages of development of its product candidates, and it has not completed development of any ImmTOR-enabled therapies.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2021, the Company&#8217;s cash, cash equivalents, restricted cash and marketable securities were $149.2 million, of which $1.4 million was restricted cash related to lease commitments and $0.3 million was held by its Russian subsidiary designated solely for use in its operations. The Company believes the cash, cash equivalents, restricted cash and marketable securities as of March 31, 2021 will enable it to fund its operating expenses and capital expenditure requirements into the second quarter of 2023. The Company has incurred losses and negative cash flows from operating activities since inception. As of March 31, 2021, the Company had an accumulated deficit of $429.2 million. The Company anticipates operating losses to continue for the foreseeable future due to, among other things, costs related to research, development of its product candidates, conducting preclinical studies and clinical trials, and its administrative organization. The Company will require substantial additional financing to fund its operations and to continue to execute its strategy, and the Company will pursue a range of options to secure additional capital.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">At this time, there is significant uncertainty relating to the trajectory of the COVID-19 pandemic and the impact of related responses. Any impact of COVID-19 on the Company&#8217;s business, revenues, results of operations and financial condition will largely depend on future developments, which are highly uncertain and cannot be predicted with confidence, such as the duration of the pandemic, travel restrictions and social distancing in the United States and other countries, business closures or business disruptions, supply chain disruptions, the ultimate impact on financial markets and the global economy, and the effectiveness of actions taken in the United States and other countries to contain and treat the disease.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Guarantees and Indemnifications</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As permitted under Delaware law, the Company indemnifies its officers, directors, consultants and employees for certain events or occurrences that happen by reason of the relationship with, or position held at, the Company. Through March 31, 2021, the Company had not experienced any losses related to these indemnification obligations, and no claims were outstanding. The Company does not expect significant claims related to these indemnification obligations and, consequently, concluded that the fair value of these obligations is negligible, and no related reserves were established.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140279218352088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text">Summary of Significant Accounting Policies<div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no material changes to the Company&#8217;s significant accounting policies during the three months ended March 31, 2021, as compared to the significant accounting policies disclosed in Note 2 &#8211; Summary of Significant Accounting Policies included in the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2020.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recently Adopted</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the FASB issued ASU 2019-12,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Income Taxes (Topic 740) - Simplifying the Accounting for Income Taxes.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ASU 2019-12 simplifies the accounting for income taxes by removing certain exceptions to the general principles in Topic 740. The Company adopted the new standard effective January 1, 2021, and there was no impact on its consolidated financial statements.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2020, the FASB issued ASU 2020-10, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Codification Improvements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which updates various codification topics by clarifying or improving disclosure requirements to align with the SEC&#8217;s regulations. The Company adopted the new standard effective January 1, 2021, and there was no impact on its consolidated financial statements.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Not Yet Adopted</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, the FASB issued ASU 2020-06, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt &#8211; Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging &#8211; Contracts in Entity&#8217;s Own Equity (Subtopic 815 &#8211; 40)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. ASU 2020-06 simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts on an entity&#8217;s own equity. This ASU is effective for smaller reporting companies for fiscal years beginning after December 15, 2023, with early adoption permitted no earlier than January 1, 2021. The Company is assessing the impact this standard will have on its consolidated financial statements and disclosures.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the FASB issued ASU 2016-13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments-Credit Losses (Topic 326), Measurement of Credit Losses on Financial Instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Subsequently, in November 2018, the FASB issued ASU 2018-19,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Codification Improvements to Topic 326, Financial Instruments-Credit Losses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.&#160;ASU 2016-13 requires entities to measure all expected credit losses for most financial assets held at the reporting date based on an expected loss model which includes historical experience, current conditions, and reasonable and supportable forecasts. ASU 2016-13 also requires enhanced disclosures to help financial statement users better understand significant estimates and judgments used in estimating credit losses. This ASU is effective for smaller reporting companies for fiscal years beginning after December 15, 2022, with early adoption permitted. The Company is assessing the impact this standard will have on its consolidated financial statements and disclosures.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140279218666760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable Securities<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock', window );">Marketable Securities</a></td>
<td class="text">Marketable Securities<div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the marketable securities held as of March 31, 2021 (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.923%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.602%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized gains</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,032&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,031&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20,374&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20,374&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22,406&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22,405&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All marketable securities held at March 31, 2021 had maturities of less than 12 months when purchased and are classified as short-term marketable securities on the accompanying consolidated balance sheet. During the three months ended March 31, 2021, there were no marketable securities adjusted for other than temporary declines in fair value.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2020, the Company held no marketable securities.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for  investments in certain debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2209399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2324412<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2176304<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140279219765800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss Per Share</a></td>
<td class="text">Net Loss Per Share<div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has reported a net loss for the three months ended March 31, 2021 and 2020. For this reason basic and diluted net loss per share are the same for all periods presented. The following table sets forth the computation of basic and diluted net loss per share (in thousands, except share and per-share data):</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.777%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss attributable to common stockholders</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(24,597)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(19,620)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-average common shares and pre-funded warrants outstanding&#8212;basic and diluted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">110,742,150&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">94,723,513&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss per share attributable to common stockholders &#8212;basic and diluted</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.22)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.21)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All potential dilutive common shares have been excluded from the computation of the diluted net loss per share for all periods presented, as the effect would have been anti-dilutive. Potential dilutive common share equivalents consist of the following:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.777%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock options to purchase common stock</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,187,394&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,745,936&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unvested restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">544,313&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">170,313&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Warrants to purchase common stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,378,016&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23,084,120&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23,109,723&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31,000,369&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140279234148232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text">Fair Value Measurements<div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present the Company&#8217;s assets and liabilities that are measured at fair value on a recurring basis as of March 31, 2021 and December 31, 2020 (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.923%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.602%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level&#160;1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level&#160;2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level&#160;3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">58,158&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">58,158&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,031&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,031&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20,374&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20,374&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">80,563&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">58,158&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22,405&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Warrant liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">45,455&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">45,455&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">45,455&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">45,455&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.923%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.602%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level&#160;1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level&#160;2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level&#160;3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">80,576&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">80,576&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">80,576&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">80,576&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Warrant liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28,708&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28,708&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28,708&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28,708&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no transfers within the fair value hierarchy during the three months ended March 31, 2021 or the year ended December 31, 2020.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash and Cash Equivalents</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2021 and December 31, 2020, the money market funds were classified as cash and cash equivalents on the accompanying consolidated balance sheets as they mature within 90 days from the date of purchase.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2021, the Company had restricted cash balances relating to a secured letter of credit in connection with its lease for the Company&#8217;s headquarters (see Note 8 included elsewhere in this Quarterly Report). The Company&#8217;s consolidated statement of cash flows includes the following as of March 31, 2021 and 2020 (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.777%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">125,407&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">72,606&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Short-term restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">279&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Long-term restricted cash</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,379&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,379&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total cash, cash equivalents, and restricted cash shown in the consolidated statement of cash flows</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">126,786&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">74,264&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Marketable Securities</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2021, marketable securities classified as Level 2 within the valuation hierarchy consist of corporate bonds and commercial paper. Marketable securities represent holdings of available-for-sale marketable debt securities in accordance with the Company&#8217;s investment policy. The Company estimates the fair values of these marketable securities by taking into consideration valuations that include market pricing based on real-time trade data for the same or similar securities, and other observable inputs. The amortized cost of available-for-sale debt securities is adjusted for amortization of premiums and accretion of discounts to the earliest call date for premiums or to maturity for discounts.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Loans Payable</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At March 31, 2021, given the recent issuance of the Term A Loan under the 2020 Term Loan, the Company believes the carrying value approximates the fair value of the loan.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Common Warrants</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the Company issued common warrants in connection with a private placement of common shares. Pursuant to the terms of the common warrants, the Company could be required to settle the common warrants in cash in the event of certain acquisitions of the Company and, as a result, the common warrants are required to be measured at fair value and reported as a liability on the balance sheet.&#160;The Company recorded the fair value of the common warrants upon issuance using the Black-Scholes valuation model and is required to revalue the common warrants at each reporting date with any changes in fair value recorded in the statement of operations. The valuation of the common warrants is considered under Level&#160;3 of the fair value hierarchy due to the need to use assumptions in the valuation that are both significant to the fair value measurement and unobservable. The significant unobservable inputs used in the fair value measurement of the warrant liabilities were the volatility rate and the estimated term of the warrants. Generally, increases (decreases) in the fair value of the underlying stock and estimated term would result in a directionally similar impact to the fair value measurement. The change in </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the fair value of the&#160;Level 3 warrant liability is reflected in the statement of operations for the three months ended March 31, 2021 and 2020.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value of warrants is determined using Level 3 inputs inherent in the Black-Scholes simulation valuation.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Estimated fair value of the underlying stock</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimates the fair value of the common stock based on the closing stock price at the end of each reporting period.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk-free interest rate</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The risk-free interest rate is based on the U.S. Treasury at the valuation date commensurate with the expected remaining life assumption.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Dividend rate</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.&#160;The dividend rate is based on the historical rate, which the Company anticipates will remain at zero.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected life</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.&#160;The expected life of the warrants is assumed to be equivalent to their remaining contractual term which expires on December 23, 2024.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Volatility</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.&#160;The Company estimates stock price volatility based on the Company&#8217;s historical volatility and the historical volatility of peer companies for a period of time commensurate with the expected remaining life of the warrants.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the Black-Scholes pricing model assumptions used to record the fair value of the warrant liability is as follows:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:87.204%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.596%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.35&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expected life (in years)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.73</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">101.13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Changes in Level 3 Liabilities Measured at Fair Value on a Recurring Basis</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reflects a roll-forward of fair value for the Company&#8217;s Level 3 warrant liabilities (see Note 10), for the three months ended March 31, 2021 (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:87.204%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.596%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Warrant liabilities</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair value as of December 31, 2020</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28,708&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Change in fair value</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16,747&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair value as of March 31, 2021</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">45,455&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140279218675512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment</a></td>
<td class="text">Property and Equipment<div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment consists of the following (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.777%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,429&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,427&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Computer equipment and software</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">694&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">532&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">327&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">327&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Office equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">163&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">163&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Construction in process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">163&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total property and equipment</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,681&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,650&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less accumulated depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4,380)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4,255)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,301&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,395&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense was $0.1 million and $0.2 million for the three months ended March 31, 2021 and 2020, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140279220398696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock', window );">Accrued Expenses</a></td>
<td class="text">Accrued Expenses<div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses consist of the following (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.777%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payroll and employee related expenses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,840&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,049&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Collaboration and licensing</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,350&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,350&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued patent fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">471&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">534&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued external research and development costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,010&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,029&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued professional and consulting services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">802&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">798&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">170&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">170&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">204&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">216&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Accrued expenses</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,847&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,146&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140279218347736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text">Leases <div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">65 Grove Street Lease</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2019, the Company entered into a lease for 25,078 square feet of laboratory and office space located at 65 Grove Street, Watertown, Massachusetts, or the Headquarters Lease. As part of the Headquarters Lease, the Company incurred $0.8 million in non-reimbursable construction costs. The lease began in March 2020, consistent with when the Company took control of the office space, and the lease term is 8 years. The discount rate of 8.9% was determined based on the Company&#8217;s incremental borrowing rate adjusted for the lease term including any reasonably certain renewal periods. In connection with the Headquarters Lease, the Company secured a letter of credit from Silicon Valley Bank, or SVB, for $1.4 million, recognized as long-term restricted cash, as of March 31, 2021 and December 31, 2020, respectively, which automatically renews each year.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Moscow, Russia Lease</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has a month-to-month facility agreement for its Moscow, Russia office. Rent expense is recognized as incurred.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2021 and December 31, 2020, the components of the operating leases were as follows (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.484%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, </span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Right-of-use asset, net</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,676&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,948&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Current operating lease liabilities</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">942&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">908&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Non-current operating lease liabilities</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,403&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,647&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total operating lease liabilities</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,345&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,555&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March 31, 2021 and 2020 the components of lease costs were as follows (in thousands):  </span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.484%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">444&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">472&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Variable lease cost</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">288&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">199&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Short-term lease cost</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total lease cost</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">735&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">673&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The maturity of the Company&#8217;s operating lease liabilities as of March 31, 2021 were as follows (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:87.204%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.596%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021 (remainder)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,368&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,866&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,922&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,980&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,039&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,945&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total future minimum lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,120&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,775&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total operating lease liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,345&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The supplemental disclosure for the statement of cash flows related to operating leases were as follows (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.777%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.451%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">444&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">487&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other than the initial recording of the right-of-use asset and lease liability for the Headquarters Lease, which is non-cash, the changes in the Company&#8217;s right-of-use asset and lease liability for the three months ended March 31, 2021 and 2020 are reflected in the non-cash lease expense and accrued expenses and other liabilities, respectively, in the consolidated statements of cash flows.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following summarizes additional information related to operating leases:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.484%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-average remaining lease term</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.1 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.0 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-average discount rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140279220548056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Debt</a></td>
<td class="text">Debt<div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2020 Term Loan</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 31, 2020, the Company entered into a term loan of up to $35.0&#160;million, or the 2020 Term Loan, consisting of term loans in an aggregate amount of $25.0&#160;million, or the Term A Loan, and term loans in an aggregate amount of $10.0&#160;million, or the Term B Loan, governed by a loan and security agreement, or the Loan Agreement, between the Company and Oxford Finance LLC, or Oxford, as Collateral Agent and a Lender, and SVB, as a Lender. The Term A Loan was funded in full on August 31, 2020, or the Funding Date.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Term B Loan will be available, subject to Collateral Agent&#8217;s discretion and customary terms and conditions, during the period commencing on the date the Company has delivered to the Collateral Agent and the Lenders evidence: (i) the Company or one of the Company&#8217;s collaboration partners has enrolled its first patient for a Phase 1 clinical trial evaluating the treatment of methylmalonic acidemia, or MMA, and (ii) the Company has enrolled the first patient in each of two Phase 3 pivotal trials evaluating SEL-212, or the Second Draw Period Milestone, and ending on the earliest of (i) the date which is 30 days following the date the Second Draw Period Milestone is achieved, (ii) September 30, 2021 (iii) and the occurrence of an event of default, other than an event of default that has been waived in writing by Collateral Agent and the Lenders in their sole discretion, with such period referred to as the Second Draw Period.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2020 Term Loan will mature on August 1, 2025. Each advance under the Term Loan accrues interest at a floating per annum rate equal to the greater of (a) 7.90%, and (b) the lesser of (x) the sum of (i) the prime rate reported in The Wall Street Journal on the last business day of the month that immediately precedes the month in which the interest will accrue, and (ii) 4.65% and (y) 10.00%. The Term Loan provides for interest-only payments on a monthly basis until April 1, 2022; provided however, if the Company has delivered to the Collateral Agent and the Lenders prior to September 30, 2021 evidence that Borrower has achieved the Second Draw Period Milestone, the Term Loan provides for interest-only payments on a monthly basis until October 1, 2022. Thereafter, amortization payments will be payable monthly in equal installments of principal and interest to fully amortize the outstanding principal over the remaining term of the loan, subject to recalculation upon a change in the prime rate. The Company may prepay the Term Loan in full but not in part provided that the Company (i) provides ten days&#8217; prior written notice to Collateral Agent, (ii) pays on the date of such prepayment (A) all outstanding principal plus </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">accrued and unpaid interest, and (B) a prepayment fee of between 3.0% and 1.0% of the aggregate original principal amount advanced by the lender depending on the timing of the prepayment. Amounts outstanding during an event of default are payable upon SVB&#8217;s demand and shall accrue interest at an additional rate of 5.0% per annum of the past due amount outstanding. At the end of the loan term (whether at maturity, by prepayment in full or otherwise), the Company shall make a final payment to the lender in the amount of 9.0% of the aggregate original principal amount advanced by the lender. The final payment fee totaling $2.3&#160;million is recorded as a loan discount.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Term Loan is secured by a lien on substantially all of the assets of the Company, other than intellectual property, provided that such lien on substantially all assets includes any rights to payments and proceeds from the sale, licensing or disposition of intellectual property. The Company has also granted the Collateral Agent a negative pledge with respect to its intellectual property.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Loan Agreement contains customary covenants and representations, including but not limited to financial reporting obligations and limitations on dividends, indebtedness, collateral, investments, distributions, transfers, mergers or acquisitions, taxes, corporate changes, deposit accounts, and subsidiaries. The Loan Agreement also contains other customary provisions, such as expense reimbursement, non-disclosure obligations as well as indemnification rights for the benefit of the Collateral Agent.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The events of default under the Loan Agreement include, but are not limited to, the Company&#8217;s failure to make any payments of principal or interest under the Loan Agreement or other transaction documents, the Company&#8217;s breach or default in the performance of any covenant under the Loan Agreement or other transaction documents, the occurrence of a material adverse change, the Company making a false or misleading representation or warranty in any material respect under the Loan Agreement, the Company&#8217;s insolvency or bankruptcy, any attachment or judgment on the Company&#8217;s assets of at least $0.5&#160;million, or the occurrence of any default under any agreement or obligation of the Company involving indebtedness in excess of $0.5&#160;million. If an event of default occurs, the Collateral Agent is entitled to take enforcement action, including acceleration of amounts due under the Loan Agreement.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company incurred $0.4&#160;million in debt issuance costs in connection with the closing of the 2020 Term Loan. Debt issuance costs are presented in the consolidated balance sheet as a direct deduction from the associated liability and amortized to interest expense over the term of the related debt.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assessed all terms and features of the 2020 Term Loan to identify any potential embedded features that would require bifurcation. As part of this analysis, the Company assessed the economic characteristics and risks of the 2020 Term Loan, including any put, call, and contingent features. The Company determined that the interest rate collar and prepayment call option did not require bifurcation; whereas the contingent put option and default (contingent) interest rate feature met bifurcation criteria resulting in immaterial amounts.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Warrants</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 31, 2020, in connection with the 2020 Term A Loan, the Company issued warrants to the Lenders to purchase an aggregate of 196,850 shares of its common stock at an exercise price equal to $2.54 per share. In accordance with ASC 815-40, these warrants are classified as permanent equity in the accompanying consolidated balance sheets and will expire ten years from the date of issuance. The initial grant date fair value of the warrants was $0.4&#160;million as determined by the Black-Scholes valuation model and recorded to shareholders' equity, with the SVB portion allocated to the reacquisition price of the 2017 Term Loan and the Oxford fair value portion as a loan discount to the Term A Loan.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, on August 31, 2020, pursuant to the terms of a Warrant Side Letter agreement among the Company and the Lenders, the Company agreed to issue to the Lenders, on the date the Company draws the Term B Loan and in accordance with each party&#8217;s respective pro rata share with respect to the Term B Loan, one or more warrants to purchase an aggregate number of shares of its common stock that is equal to $200,000 divided by the average closing price of the Company&#8217;s common stock on The Nasdaq Stock Market LLC for the ten consecutive trading days ending the day before such issuance, rounded down to the nearest whole number of shares, and having an exercise price equal to the Term B Warrant Price.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Payoff</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On the Funding Date, the Company entered into a payoff letter with SVB, pursuant to which the Company utilized $13.7&#160;million of the 2020 Term Loan to pay off all outstanding obligations under the previous term loan, consisting of the principal payment, final prepayment and accrued interest. During the three months ended September 30, 2020, the Company recognized a loss on extinguishment of debt in the amount of $0.5&#160;million determined as the difference between the reacquisition price and carrying value at August 31, 2020.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2021 and December 31, 2020, the outstanding principal balance under the 2020 Term Loan was $25.0 million.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future minimum principal and interest payments on the 2020 Term Loan as of March 31, 2021 are as follows (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:87.204%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.596%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021 (remainder)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,509&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,343&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,611&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,027&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,274&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total minimum debt payments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32,764&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: Amount representing interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5,514)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: Debt discount and deferred charges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,239)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: Current portion of loan payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(460)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loan payable, net of current portion</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24,551&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140279223759144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Equity</a></td>
<td class="text">Equity<div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Equity Financings</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">August 2020 Shelf Registration Statement</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August&#160;6, 2020, the Company filed an updated universal shelf registration statement on Form S-3 (Reg. No. 333-241692) with the SEC to sell an aggregate amount of up to $200.0 million of certain of its securities. The shelf registration statement was declared effective by the SEC on August&#160;14, 2020.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8220;At-the-Market&#8221; Offerings</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2017, the Company entered into a sales agreement, or the 2017 Sales Agreement, with Jefferies LLC, as sales agent, to sell shares of its common stock with an aggregate value of up to $50.0&#160;million in an &#8220;at the market offering.&#8221; On August 6, 2020, concurrent with the filing of the updated shelf registration statement, the Company entered into a sales agreement, or the 2020 Sales Agreement with Jefferies LLC, as sales agent, pursuant to which the Company may, from time to time, issue and sell common stock with an aggregate value of up to $50.0&#160;million in an &#8220;at the market offering.&#8221; The 2017 Sales Agreement terminated pursuant to its terms in August 2020.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales of common stock, if any, pursuant to the 2020 Sales Agreement, may be made in sales deemed to be an &#8220;at the market offering&#8221; as defined in Rule 415(a) of the Securities Act, including sales made directly through the Nasdaq Stock Market or on any other existing trading market for the Company&#8217;s common stock. The Company intends to use the proceeds from the offering for working capital and other general corporate purposes. The Company may suspend or terminate the 2020 Sales Agreement at any time.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2020, the Company sold 1,069,486 shares of its common stock pursuant to the 2020 and 2017 Sales Agreements at an average price of approximately $2.16 per share for aggregate net proceeds of $2.1 million, after deducting commissions and other transaction costs.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2021, the Company sold 4,706,844 shares of its common stock pursuant to the 2020 Sales Agreement at an average price of approximately $4.59 per share for aggregate net proceeds of $20.9 million, after deducting commissions and other transaction costs.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">June 2020 Sobi Stock Purchase</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 11, 2020, the Company entered into a stock purchase agreement with Sobi, pursuant to which the Company sold an aggregate of 5,416,390 shares of its common stock at a purchase price equal to $4.6156 per share, which represented 120% of the 10-day volume-weighted average price of the Company&#8217;s common stock prior to signing, for aggregate gross proceeds of $25.0&#160;million, or the Sobi Private Placement. The closing of the Sobi Private Placement occurred on July 31, 2020. The shares of common stock acquired in the Sobi Private Placement are subject to a one-year lock-up from closing, during which time Sobi is prohibited from selling or otherwise disposing of such shares.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with ASC 815, this forward sale treatment qualified as equity classification as the shares are not within the scope of ASC 480. The gross proceeds of $25.0&#160;million were determined to include a premium to the fair value of the Company&#8217;s shares as of July 28, 2020 of approximately $14.5&#160;million. As a result, such amount was included in the transaction price for revenue recognition of the Sobi License. See Note 12 for details.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also on June 11, 2020, the Company entered into a registration rights agreement (as amended by that certain letter agreement, dated as of November 4, 2020) with Sobi, pursuant to which the Company agreed to prepare and file a registration statement with respect to the resale of the shares of common stock acquired in the Sobi Private Placement. The Company will be required to file this resale registration statement within 30 days following receipt by the Company of a written request from </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sobi to file such resale registration statement, and to have the registration statement declared effective within 10 business days after the SEC informs the Company that no review of such resale registration statement will be made or that the SEC has no further comments on such resale registration statement.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">December 2019 Financing</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On December 18, 2019, the Company entered into a securities purchase agreement, or the 2019 Purchase Agreement, with a group of institutional investors and certain members of the board of directors. Pursuant to the 2019 Purchase Agreement, the Company sold an aggregate of 37,634,883 shares of its common stock at a purchase price of $1.46 per share, warrants to purchase an aggregate of 22,988,501 shares of common stock at a purchase price of $0.125 per share underlying each common warrant, and pre-funded warrants to purchase an aggregate of 8,342,128 shares of common stock at a purchase price of $1.46 per share, all with five year terms, or the 2019 PIPE. The closing of the 2019 PIPE occurred on December 23, 2019. The exercise price of the pre-funded warrants is $0.0001 per share and the exercise price for the common warrants is $1.46 per share. In the event of a certain sale of the Company, the terms of the common warrants require us to make a payment to such common warrant holders based on a Black-Scholes valuation (using variables as specified in the warrants). This provision does not apply to the pre-funded warrants. Therefore, the Company is required to account for the common warrants as liabilities and record them at fair value, while the pre-funded warrants met the criteria to be classified as permanent equity. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded the fair value of the common warrants of $40.7&#160;million upon issuance using the Black-Scholes valuation model. Issuance costs were allocated between the equity component with an offset to additional paid-in capital and the liability component recorded as expense on a relative fair value basis. Total net proceeds from the equity offering was $65.6 million, after deducting transaction costs and commissions of $4.4 million which was paid in the three months ended March 31, 2020.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The common warrants were revalued as of March 31, 2021 at $45.5 million. During the three months ended March 31, 2021 and 2020, the Company recorded losses on the increases in the fair value of the warrants of $(16.7) million and $(0.8) million, respectively, in the unaudited consolidated statements of operations.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Warrants</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2021 and 2020, there were no warrants issued, exercised, or canceled.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.361%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.602%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Warrants</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Equity<br/>&#160;classified</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Liability classified</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted average<br/>exercise price</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding at March 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">292,469&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,085,547&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,378,016&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.60&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Common Stock</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2021, the Company had 200,000,000 shares of common stock authorized for issuance, $0.0001 par value per share, with 112,977,004 shares issued and outstanding. The voting, dividend and liquidation rights of the common stockholders are subject to and qualified by the rights, powers and preferences of the preferred stock. The common stock has the following characteristics:</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Voting</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The common stockholders are entitled to one vote for each share of common stock held with respect to all matters voted on by the stockholders of the Company.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Dividends</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The common stockholders are entitled to receive dividends, if and when declared by the Board of Directors. Through March 31, 2021, no dividends have been declared or paid on common stock.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Liquidation</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon liquidation of the Company, the common stockholders are entitled to receive all assets of the Company available for distribution to such stockholders.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reserved Shares</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has authorized shares of common stock for future issuance as follows:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.929%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.522%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Period ended</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercise of common warrants</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,378,016&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,378,016&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shares available for future stock incentive awards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,719,817&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,916,374&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">RSUs reserved for issuance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">98,750&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unvested restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">544,313&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">87,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding common stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,187,394&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,775,249&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30,928,290&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25,157,139&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140279220548056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Incentive Plans<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock Incentive Plans</a></td>
<td class="text">Stock Incentive Plans<div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains the 2008 Stock Incentive Plan, or the 2008 Plan, for employees, consultants, advisors, and directors. The 2008 Plan provided for the granting of incentive and non-qualified stock option and restricted stock awards as determined by the Board. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the Company&#8217;s stockholders approved the 2016 Incentive Award Plan, or the 2016 Plan, which authorized 1,210,256 shares of common stock for future issuance under the 2016 Plan and ceased granting awards under the 2008 Plan. Upon the effective date of the 2016 Plan, awards issued under the 2008 Plan remain subject to the terms of the 2008 Plan. Awards granted under the 2008 Plan that expire, lapse or terminate become available under the 2016 Plan as shares available for future grants.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, pursuant to the terms of the 2016 Plan, the Board is authorized to grant awards with respect to common stock, and may delegate to a committee of one or more members of the Board or executive officers of the Company the authority to grant options and restricted stock units. On December 9, 2020, the Board established a Stock Option Committee authorized to grant awards to certain employees and consultants subject to conditions and limitations within the 2016 Plan. In January 2021 and 2020, the number of shares of common stock that may be issued under the 2016 Plan was increased by 4,322,850 and 3,453,022 shares, respectively. As of March 31, 2021, 3,248,520 shares remain available for future issuance under the 2016 Plan.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2018, the Company&#8217;s 2018 Employment Inducement Incentive Award Plan, or the 2018 Inducement Incentive Award Plan was adopted by the Board without stockholder approval pursuant to Rule 5635(c)(4) of the Nasdaq Stock Market LLC listing rules, which authorized 1,175,000 shares of its common stock for issuance. In March 2019, the Board approved the amendment and restatement of the 2018 Inducement Incentive Award Plan to reserve an additional 2,000,000 shares of the Company&#8217;s common stock for issuance thereunder. As of March 31, 2021, there are 1,358,333 shares available for future grant under the 2018 Inducement Incentive Award Plan.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock-based Compensation Expense</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense by classification included within the condensed consolidated statements of operations and comprehensive loss was as follows (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.777%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">754&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">623&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,026&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">786&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total stock-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,780&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,409&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock Options</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Employees</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated grant date fair values of employee stock option awards granted under the 2016 Plan and the 2018 Inducement Incentive Award Plan were calculated using the Black-Scholes option pricing model, based on the following weighted-average assumptions:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.777%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.44&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.73&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expected term</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.28</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.08</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">83.26&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">87.96&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-average fair value of common stock</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.30&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average grant date fair value of stock options granted to employees during the three months ended March 31, 2021 and 2020 was $1.99 and $1.69, respectively. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2021 total unrecognized compensation expense related to unvested employee stock options was $11.8 million, which is expected to be recognized over a weighted average period of 2.7 years.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Non-employee consultants</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2021, there was no unrecognized compensation expense related to non-employee consultants stock options.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the stock option activity under the 2008 Plan, 2016 Plan, and 2018 Inducement Incentive Award Plan:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.321%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.501%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-average</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">remaining</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number&#160;of</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-average</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">contractual&#160;term</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">intrinsic&#160;value</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">exercise price ($)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in&#160;years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in&#160;thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Employees</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding at December 31, 2020</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,302,176&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.98&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.43</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,456&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,628,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(153,278)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.47&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(62,577)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.19&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding at March 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,714,321&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.78&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.65</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15,665&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested at March 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,064,130&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.46&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.63</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,313&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested and expected to vest at March 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,920,548&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.88&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.59</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,231&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Non-employee consultants</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding at December 31, 2020</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">473,073&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.89&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.23</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">86&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding at March 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">473,073&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.89&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.98</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">366&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested at March 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">462,186&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.82&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.92</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">366&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested and expected to vest at March 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">473,073&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.89&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.98</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">366&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Restricted Stock Units</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, the Company granted 369,800 restricted stock awards to employees under the 2016 Plan which will vest over a four year term.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, during the first quarter of 2021, the Company awarded 197,500 restricted stock units to executives under the 2016 Plan, of which 98,750 were determined to be granted as of the award date consistent with ASC 718. The remaining 98,750 restricted stock units do not have a defined performance metric as of the award date, resulting in the restricted stock units being reserved for future issuance as of March 31, 2021. These restricted stock units will vest in two equal installments on the dates </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">an applicable performance condition is achieved, on or prior to December 31, 2021. If the performance conditions are not satisfied on or prior to December 31, 2021, the restricted stock units will be forfeited for no consideration.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The restricted stock units granted had a weighted average fair value of $2.99 per share based on the closing price of the Company&#8217;s common stock on the date of grant. The restricted stock units were valued at approximately $1.4 million on their grant date. Forfeitures are estimated at the time of grant and are adjusted, if necessary, in subsequent periods if actual forfeitures differ from those estimates. The Company has estimated a forfeiture rate of 10% for restricted stock awards to employees based on historical attrition trends.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unrecognized compensation expense for all restricted stock units was $1.5 million as of March 31, 2021, which is expected to be recognized over a weighted average period of 3.1 years.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s restricted stock units under the 2016 Plan and 2018 Inducement Incentive Award Plan:</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:69.721%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.122%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.124%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted average<br/>grant date<br/>fair value ($)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unvested at December 31, 2020</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">87,500&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.03&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">468,550&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.99&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(10,937)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.03&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Reserved for issuance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">98,750&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.99&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(800)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.99&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unvested at March 31, 2021</span></div></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">643,063&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.35&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Employee Stock Purchase Plan</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the Company approved the 2016 Employee Stock Purchase Plan, or the ESPP, which authorized 173,076 shares of common stock for future issuance under the ESPP to participating employees. In January 2021 and 2020, the number of shares of common stock authorized for issuance under the ESPP was increased by 1,080,711 shares and 863,254 shares, respectively. During the three months ended March 31, 2021, the Company issued 34,696 shares of common stock under the ESPP. As of March 31, 2021, 2,546,464 shares remain available for future issuance under the ESPP.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For each of the three months ended March 31, 2021 and 2020, the Company recognized less than $0.1 million of stock-based compensation expense under the ESPP.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140279218617144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Arrangements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">Revenue Arrangements</a></td>
<td class="text">Revenue Arrangements<div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Swedish Orphan Biovitrum</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">License and Development Agreement</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 11, 2020, the Company and Sobi entered into the Sobi License. Pursuant to the Sobi License, the Company has agreed to grant Sobi an exclusive, worldwide (except as to Greater China) license to develop, manufacture and commercialize the Company&#8217;s SEL-212 drug candidate, which is currently in development for the treatment of chronic refractory gout. The SEL-212 drug candidate is a pharmaceutical composition containing a combination of SEL-037, or the Compound, and ImmTOR. Pursuant to the Sobi License, in consideration of the license, Sobi agreed to pay the Company a one-time, up-front payment of $75.0&#160;million. Sobi has also agreed to make milestone payments totaling up to $630.0&#160;million to the Company upon the achievement of various development and regulatory milestones and, if commercialized, sales thresholds for annual net sales of SEL-212, and tiered royalty payments ranging from the low double digits on the lowest sales tier to the high teens on the highest sales tier.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Sobi License, the Company has agreed to supply (at cost) quantities of the Compound and ImmTOR as necessary for completion of the two Phase 3 clinical trials of SEL-212 (DISSOLVE I and DISSOLVE II) and a 6-month placebo extension. The Company is required to supply quantities of the Compound until all rights to the Compound and any materials needed to manufacture the Compound are transferred to Sobi. Sobi has agreed to reimburse the Company for all budgeted costs incurred to complete development of SEL-212, including but not limited to costs incurred while conducting and completing the Phase 3 DISSOLVE trials, except for any costs of additional development activities required that are related to ImmTOR and that are unrelated to SEL-212. Sobi will have control and responsibility over all regulatory filings, including any investigational drug applications (IND), biologics license applications (BLA), and marketing authorization applications (MAA) relating to the licensed product.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The transactions contemplated by the Sobi License were consummated on July 28, 2020 following the expiration or termination of the required waiting periods under the Hart-Scott-Rodino Antitrust Improvements Act of 1976. Sobi may terminate the Sobi License for any reason upon 180 days&#8217; written notice to the Company, whereby all rights granted under the Sobi License would revert back to the Company. In addition, if Sobi were to terminate the Sobi License, the Company has the option to obtain a license to all patents and know-how necessary to exploit SEL-212 in existence as of the termination date from Sobi in return for making an equitable royalty payment to Sobi.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, on June 11, 2020, the Company entered into the Sobi Purchase Agreement in connection with the Sobi License. The closing of the Sobi Private Placement occurred on July 31, 2020, following the closing of the transactions contemplated under the Sobi License. See Note 10 for details.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined that the Sobi License represents a service arrangement under the scope of ASC 606. In addition, given the Sobi License and Sobi Purchase Agreement were executed contemporaneously and negotiated as a package with a single commercial objective, the Company will account for the two agreements as a single contract. The term of the Sobi License commenced upon the effective date of July 28, 2020 and will continue on a product-by-product basis until the royalty terms for each country have expired. The royalty term for a given product begins upon the first commercial sale of the product in a country and ends at the later of ten years from the first commercial sale, expiration of the last valid patent claim covering the product and expiration of all regulatory exclusivity periods for the product in a country. Given the reversion of the rights under the Sobi License represents a penalty in substance for a termination by Sobi, the contract term would remain the stated term of the Sobi License.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined that the Sobi License contains three distinct performance obligations due to the nature of the promises in the contract, which includes conducting the Phase 3 DISSOLVE trials, Sobi&#8217;s option to set-up a second source supplier, and a combined obligation comprised of the delivery of the license to SEL-212, transfer of the know-how and the manufacturing and delivery of SEL-212 supply for development, or the Combined License Obligation. As the set-up of a second source supplier is optional for Sobi and the Company will be reimbursed at cost for its efforts in the subsequent set-up and technology transfer, the option for this future service was determined to be at a significant and incremental discount to its standalone selling price and treated as a material right in the arrangement, namely a distinct performance obligation.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In determining the transaction price, the Company concluded the upfront payment of $75.0&#160;million and the $5.0&#160;million development milestone associated with the dosing of the first patient in the Phase 3 DISSOLVE trials will be included in the transaction price. All other development milestones will be fully constrained and only be included in the transaction price when the respective milestone is deemed probable of achievement. Each of these variable consideration items was evaluated under the most likely amount method to determine whether such amounts were probable of occurrence, or whether such amounts should be constrained until they become probable. As part of the evaluation of the constraint, the Company considered numerous factors, including that receipt of such milestones is outside the control of the Company and probability of success criteria is estimated. The Company will re-evaluate the transaction price in each reporting period, as uncertain events are resolved. In accordance with ASC 606, the Company will only recognize revenue associated with sales-based milestones and royalties when the subsequent sales thresholds are reached and underlying sales occur, respectively. In connection with the Sobi Purchase Agreement, the Company determined that the gross proceeds of $25.0&#160;million from the Sobi Private Placement included a premium to the fair value of the Company&#8217;s shares as of July 28, 2020 equal to approximately $14.5&#160;million. The premium amount will be included in the transaction price for revenue recognition. The Company will estimate and include in the transaction price the total reimbursements to be received from Sobi for both the manufacturing and delivery of the Compound and ImmTOR as well as conducting the Phase 3 DISSOLVE trials. The Company determined that a significant financing component does not exist in its arrangement with Sobi.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company allocated the transaction price based on the relative standalone selling prices of the three distinct performance obligations. The Company estimated the standalone selling price of conducting the Phase 3 DISSOLVE trials by forecasting its anticipated costs and applying a margin reflective of the industry. The Company must determine the standalone selling price of the second source supplier option by determining the discount given to Sobi multiplied by the likelihood that Sobi will exercise the option in the future. Similar to the Phase 3 program estimate, the Company estimated the discount of the option by forecasting the set-up costs and applying a margin that is reflective of the industry. As the Company will be providing the set-up and technology transfer services and the future supply at cost, the discount of the option is equal to the margin amount. The Company considered discussions with Sobi as well as probability of regulatory success of SEL-212 in determining the likelihood of exercise. The Company estimated the standalone selling price of the Combined License Obligation by utilizing a discounted cash flow model.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined that the delivery of the supply to Sobi best represents the pattern of delivery of the Combined License Obligation as the supply is essential to the utility of the license and know-how. The Company will recognize the revenue allocated to the Combined License Obligation by utilizing the output method. The Company estimated the total supply of the Compound and ImmTOR to be required during the clinical trial period and will recognize revenue as this supply is shipped for use in the clinical trials. The Company will recognize the revenue allocated to the conducting of the Phase 3 DISSOLVE trials obligation by utilizing the input method. The Company estimated the total budgeted costs to be incurred over </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the Phase 3 DISSOLVE trials and will recognize revenue as these costs are incurred. The Company&#8217;s costs best represent the pattern of transfer as these will capture all performance of the trials completed to date and can be readily measured. The Company will recognize the revenue allocated to the second source supplier option when the future services and goods are transferred.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2021 and December 31, 2020, the Company recorded $72.0 million and $68.3&#160;million, respectively, as a short-term contract liability and $17.8 million and $24.2&#160;million, respectively, as a long-term contract liability, representing deferred revenue associated with this agreement.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, as of March 31, 2021 the Company has recorded $1.3 million of contract assets related to incremental costs that would not have been incurred if the Sobi License had not been obtained, of which $1.0 million is presented in prepaid expenses and other current assets and $0.3 million is presented in other assets in the accompanying unaudited consolidated balance sheets. Amortization of contract assets was less than $0.1 million for the three months ended March 31, 2021.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2021 and December 31, 2020, the Company recorded a total outstanding receivable of $8.3 million and $6.9 million, respectively, representing billings for the Phase 3 DISSOLVE program that are subject to reimbursement by Sobi. Revenue of $11.1 million related to the Sobi License was recognized during the three months ended March 31, 2021.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Sarepta Therapeutics, Inc.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research License and Option Agreement</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 13, 2020, the Company and Sarepta entered into a Research License and Option Agreement, or the Sarepta Agreement. Pursuant to the Sarepta Agreement, the Company agreed to grant Sarepta a license under the Company&#8217;s intellectual property rights covering the Company&#8217;s antigen-specific biodegradable nanoparticle encapsulating ImmTOR to research and evaluate ImmTOR in combination with Sarepta&#8217;s adeno-associated virus gene therapy technology, or gene editing technology, using viral or non-viral delivery, to treat Duchenne Muscular Dystrophy and certain Limb-Girdle Muscular Dystrophy subtypes, or the Indications. Sarepta will have an option term of 24 months during which it can opt-in to obtain an exclusive license to further develop and commercialize the Product to treat at least one Indication, with a potential to extend the option term for an additional fee. The Company will supply ImmTOR to Sarepta for clinical supply on a cost-plus basis.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sarepta paid a $2.0 million up-front payment to the Company upon signing of the Sarepta Agreement, and the Company is eligible to receive additional preclinical payments during the option term. If Sarepta opts-in to an exclusive license agreement, the Company could receive&#160;option exercise payments per Indication upon execution of the exclusive license, and the Company would be entitled to significant development and commercial milestone payments and tiered royalties ranging from the mid-to-high single digits based on net sales.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Sarepta Agreement, the Company determined the Sarepta Agreement represents a service arrangement under the scope of ASC 606, with a 24 month contract duration. Given the reversion of the rights under the Sarepta Agreement represents a penalty in substance for a termination by Sarepta, the contract term would remain the stated term of the Sarepta Agreement.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined that the Sarepta Agreement and supply obligation including the delivery of the research license, the licensed know-how, the manufactured supply and delivery of materials represent a single promise and performance obligation to be transferred to Sarepta over time due to the nature of the promises in the contract. The delivery of the manufactured supply is the predominant promise within the arrangement, as it is essential to the utility of the licensed intellectual property. As such, consideration in the initial transaction price will be allocated to the single performance obligation based on the contractual price.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In determining the transaction price, the Company concluded the payment associated with all the performance milestones will be fully constrained and only be included in the transaction price when the respective milestone is deemed probable of achievement. Each of these variable consideration items was evaluated under the most likely amount method to determine whether such amounts were probable of occurrence, or whether such amounts should be constrained until they become probable. As part of its evaluation of the constraint, the Company considered numerous factors, including that receipt of such study milestones is outside the control of the Company and probability of success criteria is estimated. As of March 31, 2021 and December 31, 2020, all milestones were constrained. The Company will re-evaluate the transaction price in each reporting period, as uncertain events are resolved. The Company will recognize the revenue associated with the upfront payment and combined single performance obligation utilizing the output method, over the 24 month term as the manufactured supply is delivered to Sarepta.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also determined the option to enter into a future commercial license agreement and extend the term of the option does not represent a material right since it was not priced at an incremental discount. Sarepta may terminate the Sarepta Agreement for any reason upon 30 days&#8217; written notice to the Company. The Sarepta Agreement contains other customary terms and conditions, including representations and warranties, covenants, termination, and indemnification obligations in favor of each party. During the year ended December 31, 2020, the Company and Sarepta entered into two amendments relating to an </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">additional feasibility study. During the three months ended March 31, 2021, the Company and Sarepta entered into a third amendment relating to feasibility study research plan. None of the amendments executed through March 31, 2021 had a material impact on deferred revenue or revenue recognition.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At each of March 31, 2021 and December 31, 2020, the Company recorded $2.0 million as a short-term contract liability representing deferred revenue associated with this agreement. No revenue related to the Sarepta Agreement was recognized during the three months ended March 31, 2021 and 2020.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Asklepios Biopharmaceutical, Inc.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">License Agreement for Pompe Disease</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 17, 2019, the Company and AskBio entered into a license agreement, or the AskBio License Agreement. Pursuant to the AskBio License Agreement, AskBio has exercised its option to exclusively license the Company&#8217;s intellectual property rights covering the Company&#8217;s ImmTOR platform to research, develop, and commercialize certain AAV gene therapy products utilizing ImmTOR, and targeting the GAA gene, or derivatives thereof, to treat Pompe Disease.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the AskBio License Agreement and ancillary documents, AskBio agreed to pay to the Company upfront fees of an aggregate of $7.0 million. Assuming successful development and commercialization, the Company could receive up to an additional $237.0 million in development, regulatory, and sales milestone payments. If commercialized, the Company would be eligible to receive tiered royalties on global net sales at percentages ranging from mid-to-high single digits. Under the terms of the agreement, the Company will be eligible to receive these royalties commencing on the first commercial sale of the licensed product until the expiration of the later of (i) ten years after the first commercial sale and (ii) expiration of the last to expire valid claim on patents covering the licensed product.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the AskBio License Agreement, the Company will supply AskBio with its ImmTOR platform, or the Supply Obligation, and AskBio will be responsible for all preclinical, clinical and commercial manufacture and supply of licensed products (other than ImmTOR) and carry out all other activities related to the research, development, and commercialization of licensed products at its sole expense, including all regulatory activities related thereto.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined that the AskBio License Agreement and Supply Obligation represent a single promise and performance obligation. This is because AskBio cannot derive benefit from the license without the simultaneous transfer of the patent protected ImmTOR supply. Therefore, the License Obligation and Supply Obligation represent the only promise in the arrangement and are combined as a single performance obligation.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In determining the transaction price, the Company concluded that the future development milestones, regulatory milestones, sales milestones, and sales royalties all represent variable consideration. Each of these variable consideration items was evaluated under the most likely amount method to determine whether such amounts were probable of occurrence, or whether such amounts should be constrained until they become probable. As part of its evaluation of the constraint, the Company considered numerous factors, including that receipt of such milestones is outside the control of the Company. Consideration related to sales-based milestones as well as royalties on net sales upon commercialization by AskBio, will be recognized when the related sales occur, as they were determined to relate predominantly to the intellectual property granted to AskBio and, therefore, have also been excluded from the transaction price in accordance with the royalty recognition constraint. As of March 31, 2021 and December&#160;31, 2020, all milestones were constrained. The Company will re-evaluate the transaction price in each reporting period, as uncertain events are resolved, or as other changes in circumstances occur.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total initial transaction price of the contract on the effective date was $7.0 million, comprised of a $2.0 million initial up-front payment upon agreement of terms, and a $5.0 million initial up-front execution fee.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At each of March 31, 2021 and December 31, 2020, the Company recorded $1.7 million as short-term and $5.3 million as a long-term, representing deferred revenue associated with this agreement. Revenue will be recognized over the period in which the particles are delivered. No revenue related to the AskBio License Agreement was recognized during the three months ended March 31, 2021 and 2020 as no deliveries were made during the periods.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Spark Therapeutics, Inc.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Spark License Agreement</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The disclosures relating to the Company&#8217;s license and option agreement, or the Spark License Agreement, with Spark pursuant to which the Company and Spark agreed to collaborate on the development of gene therapies for certain targets utilizing the ImmTOR platform reported in the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2020 which was filed with the SEC on March 12, 2021 have not materially changed since the Company filed such report.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Transaction Price Allocated to Future Performance Obligations</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Remaining performance obligations represent the transaction price of contracts for which work has not been performed (or has been partially performed). As of March 31, 2021, the aggregate amount of the transaction price allocated to remaining performance obligations was $108.1 million.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contract Balances from Contracts with Customers (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sobi, Sarepta, AskBio, and Spark</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">)</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents changes in the Company&#8217;s contract liabilities during the three months ended March 31, 2021 (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"><tr><td style="width:1.0%"/><td style="width:29.488%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.517%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.517%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.517%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.521%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">beginning of period</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Deductions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">end of period</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contract liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Deferred revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">110,796&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,730)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">108,066&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total contract liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">110,796&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,730)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">108,066&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130551-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130556-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130554-203045<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130550-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130554-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130554-203045<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130554-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130558-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130554-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140279218339704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related-Party Transactions<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related-Party Transactions</a></td>
<td class="text">Related-Party Transactions<div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Consulting Services</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company incurred expenses for consulting services provided by its founders totaling less than $0.1&#160;million during each of the three months ended March 31, 2021 and 2020. The Company entered into consulting agreements with its founders to serve on its Scientific Advisory Board, effective January 1, 2020 to December 31, 2021, under which they will be paid quarterly for their services.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI http://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140279219933352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_selb_CollaborationAndLicenseAgreementsTextBlock', window );">Collaboration Agreements</a></td>
<td class="text">Collaboration Agreements<div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Asklepios Biopharmaceutical, Inc.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Feasibility Study and License Agreement</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2019, the Company entered into a feasibility study and license agreement with AskBio, or the AskBio Collaboration Agreement. Pursuant to the AskBio Collaboration Agreement, the Company and AskBio agreed to license intellectual property rights to each other as part of a collaboration to research, develop, and commercialize certain AAV gene therapy products utilizing the Company&#8217;s ImmTOR platform to enable re-dosing of such AAV gene therapy products to treat serious rare and orphan genetic diseases for which there is a significant unmet medical need.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the AskBio Collaboration Agreement, the Company and AskBio agreed to conduct proof of concept studies to potentially validate the use of ImmTOR in conjunction with AskBio&#8217;s AAV gene therapy, or MMA-101, for the treatment of MMA, to mitigate the formation of neutralizing anti-AAV capsid antibodies, or the POC Studies. If the POC Studies are successful, or the parties otherwise elect to do so, the parties will proceed with a collaboration to pursue the development and commercialization of AAV gene therapy product candidates utilizing ImmTOR for the treatment of certain agreed serious rare and orphan genetic diseases. If the POC Studies fail to demonstrate a proof-of-concept, and the parties do not mutually agree in writing to proceed with the collaboration, the AskBio Collaboration Agreement will expire.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The SEL-399 program combines an empty AAV capsid (EMC-101), which is an AAV capsid containing no transgene, with ImmTOR and is being conducted in partnership with AskBio. Building on the preclinical data the Company has generated showing ImmTOR&#8217;s effect on mitigating or reducing the formation of neutralizing antibodies to AAV gene therapies, the Company has commenced a clinical trial of SEL-399 in healthy adult volunteers in Belgium. The goal of the SEL-399 clinical trial is to demonstrate the appropriate dose of ImmTOR in humans to mitigate the formation of antibodies to AAV capsids used in gene therapies.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company and AskBio will share responsibility for the research, development and commercialization of products developed under this collaboration. The parties will also share research, development, and commercialization costs equally for all collaboration products, but with a right of either party to opt out of certain products, and thereby no longer be required to share costs for such products. Each party will receive a percentage of net profits for each product sold under the collaboration equal to the percentage of shared costs borne by such party in the development of such product. Pursuant to the AskBio Collaboration Agreement, AskBio is responsible for manufacturing the AAV capsids and AAV vectors and the Company is responsible for manufacturing ImmTOR.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The AskBio Collaboration Agreement is considered to be within the scope of ASC 808, as both parties are active participants and exposed to the risks and rewards of the collaborative activity. The Company evaluated the terms of the AskBio </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Collaboration Agreement and have identified the following promises in the arrangement (1) conducting research and development activities to develop and commercialize products under the collaboration, or the R&amp;D Services, (2) granting a non-exclusive, non-transferable, royalty-free, fully paid up, worldwide license to certain intellectual property of the Company, or the IP Rights, for the purpose of performing the POC Studies, or the Research License, (3) granting an exclusive, nontransferable, worldwide license to the IP Rights for use in certain indications, or the Collaboration License, (4) providing manufactured supply of preclinical and clinical ImmTOR, or the Manufactured Supply, (5) participation on identified steering committees responsible for the oversight of the collaboration, or the JSC Participation, and (6) granting an exclusive option to obtain a license under the IP Rights to research, develop and commercialize Licensed Products. The Company determined that the R&amp;D Services, Research License, Collaboration License, Manufactured Supply, and JSC Participation were not capable of being distinct, and therefore must be combined into a single performance obligation. Therefore, promises (1) through (5) identified above were combined into a single performance obligation. Furthermore, the Company evaluated the Option Agreement and determined that it does not provide AskBio with a material right under ASC 606 as the option was not priced at a discount (see discussion of the option exercise in Note 12). The Company noted that AskBio did not meet the definition of a customer within the scope of ASC 606 for any distinct performance obligations as the Company concluded that such items were not an output of the Company&#8217;s ordinary activities. As such, the Company determined that the entire arrangement would be accounted for within the scope of ASC 808.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with ASC 808, collaboration expenses are recognized within R&amp;D expense and selling, general and administrative expense on the Company&#8217;s condensed consolidated statements of operations. For each of the three months ended March 31, 2021 and 2020, the Company recognized $1.2 million of collaboration expense under the AskBio Collaboration Agreement in which actual costs incurred by both parties approximate a 50% cost share.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under certain collaborative arrangements, the Company is entitled to reimbursement of certain R&amp;D expense. Activities under collaborative arrangements for which the Company is entitled to reimbursement are considered to be collaborative activities under the scope of ASC 808. For these units of account, the Company does not analogize to ASC 606 or recognize revenue. Rather, the Company analogizes to the guidance in ASC 730, which requires that reimbursements from counterparties be recognized as an offset to the related costs. In accordance with ASC 730, the Company records reimbursement payments received from collaborators as reductions to R&amp;D expense.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Massachusetts Institute of Technology</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2008, the Company entered into an exclusive patent license agreement, or the MIT License, with the Massachusetts Institute of Technology, or MIT, under which the Company received an exclusive royalty-bearing license to utilize patents held by MIT in exchange for upfront consideration and annual license maintenance fees. Such fees are expensed as incurred and have not been material to any period presented.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2020, the Company entered into a Fifth Amendment, or the MIT Amendment, to the MIT License, which is effective as of May 15, 2020. Pursuant to the MIT Amendment, certain of the Company&#8217;s diligence obligations were extended, including a diligence obligation to commence a Phase 3 trial for a licensed product by a specific date in the second quarter of 2021. Additionally, certain of the Company&#8217;s development and regulatory milestones and payments upon achievement of such milestones were adjusted.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2021, and in connection with the execution of the Spark License Agreement, the Company has made contractual payments pursuant to the MIT License totaling $2.2 million for the sublicense granted to Spark, and $0.4 million relative to the calculated premium paid by Spark for the equity investments made under the Spark Purchase Agreement. The Company made no additional payments during the three months ended March 31, 2021.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Shenyang Sunshine Pharmaceutical Co., Ltd</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2014, the Company entered into a license agreement, or the 3SBio License, with Shenyang Sunshine Pharmaceutical Co., Ltd., or 3SBio. The Company has paid to 3SBio an aggregate of $7.0 million in upfront and milestone-based payments under the 3SBio License as of March 31, 2021. The Company is required to make future payments to 3SBio contingent upon the occurrence of events related to the achievement of clinical and regulatory approval milestones of up to an aggregate of $15.0 million for products containing the Company&#8217;s ImmTOR platform.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_selb_CollaborationAndLicenseAgreementsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration And License Agreements</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">selb_CollaborationAndLicenseAgreementsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>selb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140279218672152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">Income Taxes<div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company provides for income taxes under ASC 740. Under ASC 740, the Company provides deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the Company&#8217;s financial statement carrying amounts and the tax bases of assets and liabilities using enacted tax rates expected to be in effect in the years in which the differences are expected to reverse.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March 31, 2021 and 2020, the Company did not record a current or deferred income tax expense or benefit.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has provided a full valuation allowance against its net deferred tax assets, as the Company believes that it is more likely than not that the deferred tax assets will not be realized.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Utilization of the net operating loss and research and development credit carryforwards may be subject to a substantial annual limitation under Section 382 and 383 of the Internal Revenue Code due to ownership change limitations that have occurred previously, or that could occur in the future. These ownership changes may limit the amount of net operating loss and research and development credit carryforwards that can be utilized annually to offset future taxable income and tax, respectively. As of December 31, 2020, the Company completed a Section 382 study. The Company has determined that all of the $234.5&#160;million of net operating losses are available in the future, with approximately $36.5&#160;million of that total limited under Section 382 and therefore available for future use through 2028.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company applies ASC 740,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Income Taxes </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to uncertain tax positions. As of March 31, 2021 and December 31, 2020, the Company had no unrecognized tax benefits or related interest and penalties accrued.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has not, as of yet, conducted a study of its research and development credit carryforwards. This study may result in an adjustment to the Company&#8217;s research and development credit carryforwards; however, until a study is completed, and any adjustment is known, no amounts are being presented as an uncertain tax position.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The statute of limitations for assessment by the United States Internal Revenue Service and Massachusetts tax authorities is open for tax years since inception. The Company files income tax returns in the United States and Massachusetts. There are currently no federal, state or foreign audits in progress.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140279224801000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Defined Contribution Plan<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock', window );">Defined Contribution Plan</a></td>
<td class="text">Defined Contribution PlanThe Company maintains a defined contribution plan, or the 401(k) Plan, under Section&#160;401(k) of the Internal Revenue Code. The 401(k) Plan covers all employees who meet defined minimum age and service requirements and allows participants to defer a portion of their annual compensation on a pretax basis. The 401(k) Plan provides for matching contributions on a portion of participant contributions pursuant to the 401(k) Plan&#8217;s matching formula. All matching contributions vest ratably over 4 years and participant contributions vest immediately. Contributions by the Company totaled less than $0.1 million during each of the three months ended March 31, 2021 and 2020.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for retirement benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section S99<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=21916913&amp;loc=d3e273930-122802<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (o)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (p)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -URI http://asc.fasb.org/topic&amp;trid=2235017<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 60<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6414203&amp;loc=d3e39689-114964<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(03)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (q)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (l)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140279219964008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">Commitments and Contingencies<div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2021, the Company was not a party to any litigation that could have a material adverse effect on the Company&#8217;s business, financial position, results of operations or cash flows.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 4, 2020, a putative stockholder of Selecta filed a stockholder derivative action, purportedly on behalf of Selecta and against certain current and former members of the Company&#8217;s Board of Directors, as well as one affiliated company owned by a current board member, in the Court of Chancery of the State of Delaware, namely Franchi v. Barabe, et al. The complaint alleges that the individual defendants breached their fiduciary duties and committed corporate waste when they authorized a private placement transaction, announced on December 19, 2019, at a price allegedly below fair value. The complaint further alleges that the four defendant directors who participated in the private placement were unjustly enriched in connection with the transaction. On September 25, 2020, the defendants filed a motion to dismiss the lawsuit. On November 6, 2020, the plaintiff filed an amended complaint, and the defendants filed a second motion to dismiss on January 8, 2021. On December 31, 2020, the Company received a litigation demand letter from two other putative stockholders relating to the same private placement transaction. On April 12, 2021, the Court of Chancery in the State of Delaware granted a motion to stay the litigation pending a review by a Special Committee appointed by the Company&#8217;s Board of Directors. At this time, the Company has not accrued a liability for this matter, as any liability has been determined to be either not estimable or not probable.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As permitted under Delaware law, the Company indemnifies its directors for certain events or occurrences while the director is, or was, serving at the Company&#8217;s request in such capacity. The term of the indemnification is for the director&#8217;s lifetime. The maximum potential amount of future payments the Company could be required to make is unlimited; however, the Company has directors&#8217; insurance coverage that limits its exposure and enables it to recover a portion of any future amounts paid. The Company also has indemnification arrangements under certain of its facility leases that require it to indemnify the landlord against certain costs, expenses, fines, suits, claims, demands, liabilities, and actions directly resulting from certain breaches, violations, or non-performance of any covenant or condition of the Company&#8217;s lease. The term of the indemnification is for the term of the related lease agreement. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is unlimited. To date, the Company had not experienced any material losses related to any of its indemnification obligations, and no material claims with respect thereto were outstanding.</span></div>The Company is a party in various other contractual disputes and potential claims arising in the ordinary course of business. The Company does not believe that the resolution of these matters will have a material adverse effect the Company&#8217;s business, financial position, results of operations or cash flows.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140279219972376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text">Subsequent Events<div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8220;At-the-Market&#8221; Offerings</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subsequent to March 31, 2021 through May 13, 2021, the Company sold 206,593 shares of its common stock pursuant to the 2020 Sales Agreement, at an average price of approximately $4.51 per share for aggregate net proceeds of $0.9 million, after deducting commissions and other transaction costs.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Milestone Event</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 13, 2021, the Company was notified by Sarepta of the achievement of the milestone event related to the completion of a non-clinical study for Duchenne muscular dystrophy and certain limb-girdle muscular dystrophies under the Company&#8217;s Research License and Option Agreement. Under the terms of the Agreement, Sarepta is obligated to pay a non-refundable, non-creditable milestone payment of $3.0&#160;million to the Company within 60 days of Sarepta&#8217;s receipt of the related invoice from the Company.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The AskBio Collaboration Agreement</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 29, 2021, the Company was notified by AskBio that it intended to opt-out of development of the MMA indication. Consequently, the Company will assume all rights to the MMA program and intends to continue to progress the MMA-101 and ImmTOR combination through clinical development.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140279234202824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recently Adopted</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the FASB issued ASU 2019-12,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Income Taxes (Topic 740) - Simplifying the Accounting for Income Taxes.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ASU 2019-12 simplifies the accounting for income taxes by removing certain exceptions to the general principles in Topic 740. The Company adopted the new standard effective January 1, 2021, and there was no impact on its consolidated financial statements.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2020, the FASB issued ASU 2020-10, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Codification Improvements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which updates various codification topics by clarifying or improving disclosure requirements to align with the SEC&#8217;s regulations. The Company adopted the new standard effective January 1, 2021, and there was no impact on its consolidated financial statements.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Not Yet Adopted</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, the FASB issued ASU 2020-06, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt &#8211; Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging &#8211; Contracts in Entity&#8217;s Own Equity (Subtopic 815 &#8211; 40)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. ASU 2020-06 simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts on an entity&#8217;s own equity. This ASU is effective for smaller reporting companies for fiscal years beginning after December 15, 2023, with early adoption permitted no earlier than January 1, 2021. The Company is assessing the impact this standard will have on its consolidated financial statements and disclosures.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the FASB issued ASU 2016-13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments-Credit Losses (Topic 326), Measurement of Credit Losses on Financial Instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Subsequently, in November 2018, the FASB issued ASU 2018-19,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Codification Improvements to Topic 326, Financial Instruments-Credit Losses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.&#160;ASU 2016-13 requires entities to measure all expected credit losses for most financial assets held at the reporting date based on an expected loss model which includes historical experience, current conditions, and reasonable and supportable forecasts. ASU 2016-13 also requires enhanced disclosures to help financial statement users better understand significant estimates and judgments used in estimating credit losses. This ASU is effective for smaller reporting companies for fiscal years beginning after December 15, 2022, with early adoption permitted. The Company is assessing the impact this standard will have on its consolidated financial statements and disclosures.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140279218644392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable Securities (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock', window );">Summary of Available-for-Sale Marketable Securities</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the marketable securities held as of March 31, 2021 (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.923%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.602%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized gains</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,032&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,031&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20,374&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20,374&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22,406&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22,405&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140279218656312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Computation of Basic and Diluted Net Loss Per Share</a></td>
<td class="text">The following table sets forth the computation of basic and diluted net loss per share (in thousands, except share and per-share data):<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.777%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss attributable to common stockholders</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(24,597)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(19,620)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-average common shares and pre-funded warrants outstanding&#8212;basic and diluted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">110,742,150&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">94,723,513&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss per share attributable to common stockholders &#8212;basic and diluted</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.22)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.21)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Potential Common Shares Issuable Upon Conversion of Warrants</a></td>
<td class="text">Potential dilutive common share equivalents consist of the following:<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.777%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock options to purchase common stock</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,187,394&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,745,936&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unvested restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">544,313&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">170,313&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Warrants to purchase common stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,378,016&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23,084,120&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23,109,723&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31,000,369&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140279233607848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Summary of Assets Measured at Fair Value on a Recurring Basis</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present the Company&#8217;s assets and liabilities that are measured at fair value on a recurring basis as of March 31, 2021 and December 31, 2020 (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.923%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.602%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level&#160;1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level&#160;2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level&#160;3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">58,158&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">58,158&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,031&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,031&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20,374&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20,374&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">80,563&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">58,158&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22,405&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Warrant liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">45,455&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">45,455&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">45,455&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">45,455&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.923%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.602%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level&#160;1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level&#160;2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level&#160;3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">80,576&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">80,576&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">80,576&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">80,576&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Warrant liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28,708&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28,708&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28,708&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28,708&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Schedule of Fair Value Measurement Inputs and Valuation Techniques</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the Black-Scholes pricing model assumptions used to record the fair value of the warrant liability is as follows:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:87.204%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.596%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.35&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expected life (in years)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.73</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">101.13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Schedule Of Changes In The Warrant Liabilities</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reflects a roll-forward of fair value for the Company&#8217;s Level 3 warrant liabilities (see Note 10), for the three months ended March 31, 2021 (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:87.204%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.596%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Warrant liabilities</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair value as of December 31, 2020</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28,708&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Change in fair value</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16,747&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair value as of March 31, 2021</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">45,455&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock', window );">Schedule of Cash and Cash Equivalents</a></td>
<td class="text">The Company&#8217;s consolidated statement of cash flows includes the following as of March 31, 2021 and 2020 (in thousands):<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.777%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">125,407&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">72,606&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Short-term restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">279&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Long-term restricted cash</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,379&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,379&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total cash, cash equivalents, and restricted cash shown in the consolidated statement of cash flows</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">126,786&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">74,264&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock', window );">Schedule of Restricted Cash and Cash Equivalents</a></td>
<td class="text">The Company&#8217;s consolidated statement of cash flows includes the following as of March 31, 2021 and 2020 (in thousands):<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.777%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">125,407&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">72,606&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Short-term restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">279&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Long-term restricted cash</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,379&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,379&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total cash, cash equivalents, and restricted cash shown in the consolidated statement of cash flows</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">126,786&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">74,264&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19279-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140279220426088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property and Equipment</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment consists of the following (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.777%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,429&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,427&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Computer equipment and software</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">694&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">532&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">327&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">327&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Office equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">163&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">163&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Construction in process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">163&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total property and equipment</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,681&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,650&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less accumulated depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4,380)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4,255)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,301&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,395&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140279220419064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Expenses</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses consist of the following (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.777%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payroll and employee related expenses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,840&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,049&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Collaboration and licensing</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,350&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,350&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued patent fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">471&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">534&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued external research and development costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,010&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,029&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued professional and consulting services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">802&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">798&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">170&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">170&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">204&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">216&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Accrued expenses</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,847&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,146&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140279219955528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_selb_LesseeComponentsOfOperatingLeaseTableTextBlock', window );">Schedule of Lessee, Components Of Operating Lease</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2021 and December 31, 2020, the components of the operating leases were as follows (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.484%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, </span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Right-of-use asset, net</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,676&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,948&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Current operating lease liabilities</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">942&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">908&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Non-current operating lease liabilities</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,403&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,647&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total operating lease liabilities</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,345&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,555&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Schedule of Lease, Cost</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March 31, 2021 and 2020 the components of lease costs were as follows (in thousands):  </span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.484%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">444&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">472&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Variable lease cost</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">288&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">199&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Short-term lease cost</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total lease cost</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">735&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">673&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following summarizes additional information related to operating leases:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.484%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-average remaining lease term</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.1 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.0 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-average discount rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Lessee, Operating Lease, Liability, Maturity</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The maturity of the Company&#8217;s operating lease liabilities as of March 31, 2021 were as follows (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:87.204%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.596%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021 (remainder)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,368&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,866&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,922&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,980&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,039&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,945&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total future minimum lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,120&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,775&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total operating lease liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,345&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLeaseIncomeTableTextBlock', window );">Schedule of Operating Lease, Lease Income</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The supplemental disclosure for the statement of cash flows related to operating leases were as follows (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.777%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.451%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">444&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">487&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_selb_LesseeComponentsOfOperatingLeaseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Components Of Operating Lease</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">selb_LesseeComponentsOfOperatingLeaseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>selb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLeaseIncomeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of components of income from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121576215&amp;loc=SL77919372-209981<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6A<br> -URI http://asc.fasb.org/extlink&amp;oid=121640914&amp;loc=SL77927221-108306<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLeaseIncomeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140279219972376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock', window );">Schedule of Future Minimum Payments on the Term Loans</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future minimum principal and interest payments on the 2020 Term Loan as of March 31, 2021 are as follows (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:87.204%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.596%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021 (remainder)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,509&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,343&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,611&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,027&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,274&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total minimum debt payments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32,764&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: Amount representing interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5,514)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: Debt discount and deferred charges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,239)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: Current portion of loan payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(460)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loan payable, net of current portion</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24,551&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturity and sinking fund requirement for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140279218655464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Schedule of Stockholders' Equity Note, Warrants or Rights</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.361%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.602%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Warrants</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Equity<br/>&#160;classified</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Liability classified</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted average<br/>exercise price</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding at March 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">292,469&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,085,547&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,378,016&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.60&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfStockByClassTextBlock', window );">Schedule of Authorized Shares of Common Stock for Future Issuance</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has authorized shares of common stock for future issuance as follows:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.929%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.522%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Period ended</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercise of common warrants</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,378,016&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,378,016&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shares available for future stock incentive awards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,719,817&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,916,374&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">RSUs reserved for issuance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">98,750&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unvested restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">544,313&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">87,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding common stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,187,394&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,775,249&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30,928,290&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25,157,139&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockByClassTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's stock, including par or stated value per share, number and dollar amount of share subscriptions, shares authorized, shares issued, shares outstanding, number and dollar amount of shares held in an employee trust, dividend per share, total dividends, share conversion features, par value plus additional paid in capital, the value of treasury stock and other information necessary to a fair presentation, and EPS information.  Stock by class includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. Includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity. If more than one issue is outstanding, state the title of each issue and the corresponding dollar amount; dollar amount of any shares subscribed but unissued and the deduction of subscriptions receivable there from; number of shares authorized, issued, and outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=65888546&amp;loc=d3e21300-112643<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21553-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=65877616&amp;loc=d3e177068-122764<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21538-112644<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21521-112644<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21488-112644<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21506-112644<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21484-112644<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockByClassTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6784392&amp;loc=d3e188667-122775<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140279216877256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Incentive Plans (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock', window );">Schedule of Stock-Based Compensation</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense by classification included within the condensed consolidated statements of operations and comprehensive loss was as follows (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.777%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">754&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">623&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,026&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">786&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total stock-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,780&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,409&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Weighted Average Assumptions Used</a></td>
<td class="text">The estimated grant date fair values of employee stock option awards granted under the 2016 Plan and the 2018 Inducement Incentive Award Plan were calculated using the Black-Scholes option pricing model, based on the following weighted-average assumptions:<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.777%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.44&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.73&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expected term</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.28</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.08</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">83.26&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">87.96&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-average fair value of common stock</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.30&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Options Activity</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the stock option activity under the 2008 Plan, 2016 Plan, and 2018 Inducement Incentive Award Plan:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.321%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.501%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-average</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">remaining</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number&#160;of</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-average</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">contractual&#160;term</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">intrinsic&#160;value</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">exercise price ($)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in&#160;years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in&#160;thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Employees</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding at December 31, 2020</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,302,176&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.98&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.43</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,456&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,628,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(153,278)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.47&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(62,577)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.19&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding at March 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,714,321&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.78&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.65</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15,665&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested at March 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,064,130&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.46&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.63</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,313&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested and expected to vest at March 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,920,548&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.88&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.59</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,231&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Non-employee consultants</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding at December 31, 2020</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">473,073&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.89&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.23</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">86&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding at March 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">473,073&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.89&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.98</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">366&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested at March 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">462,186&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.82&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.92</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">366&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested and expected to vest at March 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">473,073&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.89&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.98</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">366&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock', window );">Disclosure of Share-based Compensation Arrangements by Share-based Payment Award</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s restricted stock units under the 2016 Plan and 2018 Inducement Incentive Award Plan:</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:69.721%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.122%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.124%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted average<br/>grant date<br/>fair value ($)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unvested at December 31, 2020</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">87,500&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.03&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">468,550&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.99&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(10,937)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.03&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Reserved for issuance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">98,750&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.99&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(800)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.99&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unvested at March 31, 2021</span></div></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">643,063&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.35&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140279218602456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Arrangements (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock', window );">Schedule of Changes in Contract Liabilities</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents changes in the Company&#8217;s contract liabilities during the three months ended March 31, 2021 (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"><tr><td style="width:1.0%"/><td style="width:29.488%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.517%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.517%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.517%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.521%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">beginning of period</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Deductions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">end of period</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contract liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Deferred revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">110,796&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,730)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">108,066&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total contract liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">110,796&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,730)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">108,066&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130551-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140279236252344">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Nature of the Business and Basis of Presentation - Liquidity (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsLineItems', window );"><strong>Cash and Cash Equivalents [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_selb_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndDebtSecuritiesAvailableForSale', window );">Cash, cash equivalents, restricted cash and marketable securities</a></td>
<td class="nump">$ 149,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalents', window );">Restricted cash and cash equivalents</a></td>
<td class="nump">1,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="nump">429,226<span></span>
</td>
<td class="nump">$ 404,629<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_RU', window );">Russian subsidiary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsLineItems', window );"><strong>Cash and Cash Equivalents [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash maintained in Russian bank accounts</a></td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_selb_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndDebtSecuritiesAvailableForSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Debt Securities, Available-For-Sale</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">selb_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndDebtSecuritiesAvailableForSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>selb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118262064&amp;loc=SL116631418-115840<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 45<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=118262064&amp;loc=SL116631419-115840<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_RU">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_RU</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140279224707320">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Marketable Securities - Summary of Available-for-Sale Marketable Securities (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized cost</a></td>
<td class="nump">$ 22,406,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized losses</a></td>
<td class="num">(1,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value</a></td>
<td class="nump">22,405,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember', window );">Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized cost</a></td>
<td class="nump">2,032,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized losses</a></td>
<td class="num">(1,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value</a></td>
<td class="nump">2,031,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized cost</a></td>
<td class="nump">20,374,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value</a></td>
<td class="nump">$ 20,374,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140279235935304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable Securities - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale', window );">Marketable securities adjusted for other than temporary declines in fair value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities:</a></td>
<td class="nump">$ 22,405,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of other-than-temporary impairment (OTTI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), recognized in earnings and other comprehensive loss (OCI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8A<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=SL6284422-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140279223135992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share - Computation of Basic and Diluted Net Loss Per Share (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss attributable to common stockholders</a></td>
<td class="num">$ (24,597)<span></span>
</td>
<td class="num">$ (19,620)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted&#8209;average common shares outstanding&#8212;basic and diluted (in shares)</a></td>
<td class="nump">110,742,150<span></span>
</td>
<td class="nump">94,723,513<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per share attributable to common stockholders&#8212;basic and diluted (in dollars per share)</a></td>
<td class="num">$ (0.22)<span></span>
</td>
<td class="num">$ (0.21)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1377-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140279248473816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share - Schedule of Potential Common Shares Issuable Upon Conversion of Warrants (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Potential common shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total (in shares)</a></td>
<td class="nump">23,109,723<span></span>
</td>
<td class="nump">31,000,369<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Potential common shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total (in shares)</a></td>
<td class="nump">10,187,394<span></span>
</td>
<td class="nump">7,745,936<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Unvested restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Potential common shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total (in shares)</a></td>
<td class="nump">544,313<span></span>
</td>
<td class="nump">170,313<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrants to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Potential common shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total (in shares)</a></td>
<td class="nump">12,378,016<span></span>
</td>
<td class="nump">23,084,120<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140279224996840">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Summary of Assets Measured at Fair Value on a Recurring Basis (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities:</a></td>
<td class="nump">$ 22,405,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrant liabilities</a></td>
<td class="nump">45,455,000<span></span>
</td>
<td class="nump">28,708,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember', window );">Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities:</a></td>
<td class="nump">2,031,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities:</a></td>
<td class="nump">20,374,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">80,563,000<span></span>
</td>
<td class="nump">80,576,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrant liabilities</a></td>
<td class="nump">45,455,000<span></span>
</td>
<td class="nump">28,708,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">45,455,000<span></span>
</td>
<td class="nump">28,708,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | (Level&#160;1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">58,158,000<span></span>
</td>
<td class="nump">80,576,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrant liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | (Level&#160;2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">22,405,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrant liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | (Level&#160;3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrant liabilities</a></td>
<td class="nump">45,455,000<span></span>
</td>
<td class="nump">28,708,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">45,455,000<span></span>
</td>
<td class="nump">28,708,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities:</a></td>
<td class="nump">2,031,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Corporate bonds | (Level&#160;1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities:</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Corporate bonds | (Level&#160;2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities:</a></td>
<td class="nump">2,031,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Corporate bonds | (Level&#160;3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities:</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities:</a></td>
<td class="nump">20,374,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Commercial paper | (Level&#160;1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities:</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Commercial paper | (Level&#160;2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities:</a></td>
<td class="nump">20,374,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Commercial paper | (Level&#160;3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities:</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market funds</a></td>
<td class="nump">58,158,000<span></span>
</td>
<td class="nump">80,576,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Money market funds | (Level&#160;1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market funds</a></td>
<td class="nump">58,158,000<span></span>
</td>
<td class="nump">80,576,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Money market funds | (Level&#160;2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market funds</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Money market funds | (Level&#160;3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market funds</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140279224137576">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Assumptions used to record the fair value of the warrants (Details) - Valuation Technique, Option Pricing Model<br></strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationTechniqueAxis=us-gaap_ValuationTechniqueOptionPricingModelMember', window );">Risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and rights outstanding, measurement input</a></td>
<td class="nump">0.0035<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationTechniqueAxis=us-gaap_ValuationTechniqueOptionPricingModelMember', window );">Dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and rights outstanding, measurement input</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationTechniqueAxis=us-gaap_ValuationTechniqueOptionPricingModelMember', window );">Expected life (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants and rights outstanding, term</a></td>
<td class="text">3 years 8 months 23 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationTechniqueAxis=us-gaap_ValuationTechniqueOptionPricingModelMember', window );">Expected volatility</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and rights outstanding, measurement input</a></td>
<td class="nump">1.0113<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationTechniqueAxis=us-gaap_ValuationTechniqueOptionPricingModelMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationTechniqueAxis=us-gaap_ValuationTechniqueOptionPricingModelMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140279223125544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Change in the warrant liabilities (Details) - Warrant liabilities<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Fair value as of December 31, 2020</a></td>
<td class="nump">$ 28,708<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Change in fair value</a></td>
<td class="nump">16,747<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Fair value as of March 31, 2021</a></td>
<td class="nump">$ 45,455<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140279237760872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet', window );">Fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, transfers, net</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet', window );">Fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, transfers, net</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transfer of financial instrument classified as an asset into (out of) level 3 of the fair value hierarchy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transfers of financial instrument classified as a liability into (out of) level 3 of the fair value hierarchy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140279236252472">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Schedule of Cash and Cash Equivalents (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 125,407<span></span>
</td>
<td class="nump">$ 138,685<span></span>
</td>
<td class="nump">$ 72,606<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue', window );">Short-term restricted cash</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">279<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent', window );">Long-term restricted cash</a></td>
<td class="nump">1,379<span></span>
</td>
<td class="nump">1,379<span></span>
</td>
<td class="nump">1,379<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Total cash, cash equivalents, and restricted cash shown in the consolidated statement of cash flows</a></td>
<td class="nump">$ 126,786<span></span>
</td>
<td class="nump">$ 140,064<span></span>
</td>
<td class="nump">$ 74,264<span></span>
</td>
<td class="nump">$ 91,551<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6812-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140279224707048">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property and Equipment - Schedule of Property and Equipment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">$ 5,681<span></span>
</td>
<td class="nump">$ 5,650<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less accumulated depreciation</a></td>
<td class="num">(4,380)<span></span>
</td>
<td class="num">(4,255)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">1,301<span></span>
</td>
<td class="nump">1,395<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=selb_LaboratoryEquipmentMember', window );">Laboratory equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">4,429<span></span>
</td>
<td class="nump">4,427<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer equipment and software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">694<span></span>
</td>
<td class="nump">532<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">38<span></span>
</td>
<td class="nump">38<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">327<span></span>
</td>
<td class="nump">327<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Office equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">163<span></span>
</td>
<td class="nump">163<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction in process</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">$ 30<span></span>
</td>
<td class="nump">$ 163<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=selb_LaboratoryEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=selb_LaboratoryEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140279220406568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">$ 0.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140279224653432">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Expenses (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Payroll and employee related expenses</a></td>
<td class="nump">$ 1,840<span></span>
</td>
<td class="nump">$ 3,049<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_selb_AccruedCollaborationandLicensing', window );">Collaboration and licensing</a></td>
<td class="nump">1,350<span></span>
</td>
<td class="nump">1,350<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_selb_AccruedPatentFeesCurrent', window );">Accrued patent fees</a></td>
<td class="nump">471<span></span>
</td>
<td class="nump">534<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_selb_AccruedResearchAndDevelopmentCostsCurrent', window );">Accrued external research and development costs</a></td>
<td class="nump">2,010<span></span>
</td>
<td class="nump">2,029<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_selb_AccruedAuditFeesCurrent', window );">Accrued professional and consulting services</a></td>
<td class="nump">802<span></span>
</td>
<td class="nump">798<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_selb_AccruedInterestCurrent', window );">Accrued interest</a></td>
<td class="nump">170<span></span>
</td>
<td class="nump">170<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">204<span></span>
</td>
<td class="nump">216<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">$ 6,847<span></span>
</td>
<td class="nump">$ 8,146<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_selb_AccruedAuditFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Audit Fees, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">selb_AccruedAuditFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>selb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_selb_AccruedCollaborationandLicensing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Collaboration and Licensing</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">selb_AccruedCollaborationandLicensing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>selb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_selb_AccruedInterestCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Interest, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">selb_AccruedInterestCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>selb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_selb_AccruedPatentFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of patent fees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">selb_AccruedPatentFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>selb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_selb_AccruedResearchAndDevelopmentCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of research and development costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">selb_AccruedResearchAndDevelopmentCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>selb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140279221300632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Narrative (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jul. 31, 2019 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Lessee-paid construction costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 735<span></span>
</td>
<td class="nump">$ 673<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Operating lease, weighted average discount rate, percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.90%<span></span>
</td>
<td class="nump">8.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_selb_LeaseArrangementAxis=selb_A65GroveStreetWatertownMAMember', window );">65 Grove Street, Watertown,MA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AreaOfRealEstateProperty', window );">Area of additional office space leased | ft&#178;</a></td>
<td class="nump">25,078<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Lessee-paid construction costs</a></td>
<td class="nump">$ 800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Term of contract</a></td>
<td class="text">8 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember', window );">Letter of credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Long-term restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,400<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AreaOfRealEstateProperty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area of a real estate property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AreaOfRealEstateProperty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasedAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasedAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6812-107765<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_selb_LeaseArrangementAxis=selb_A65GroveStreetWatertownMAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">selb_LeaseArrangementAxis=selb_A65GroveStreetWatertownMAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140279218445544">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Components of Operating Leases (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use asset, net</a></td>
<td class="nump">$ 10,676<span></span>
</td>
<td class="nump">$ 10,948<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current operating lease liabilities</a></td>
<td class="nump">942<span></span>
</td>
<td class="nump">908<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Non-current operating lease liabilities</a></td>
<td class="nump">9,403<span></span>
</td>
<td class="nump">9,647<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liabilities</a></td>
<td class="nump">$ 10,345<span></span>
</td>
<td class="nump">$ 10,555<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140279218654616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Components of lease costs (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">$ 444<span></span>
</td>
<td class="nump">$ 472<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease cost</a></td>
<td class="nump">288<span></span>
</td>
<td class="nump">199<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermLeaseCost', window );">Short-term lease cost</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total lease cost</a></td>
<td class="nump">$ 735<span></span>
</td>
<td class="nump">$ 673<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term lease cost, excluding expense for lease with term of one month or less.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140279224929112">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Operating Lease, Liability, Maturity (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">2021 (remainder)</a></td>
<td class="nump">$ 1,368<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2022</a></td>
<td class="nump">1,866<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2023</a></td>
<td class="nump">1,922<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2024</a></td>
<td class="nump">1,980<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2025</a></td>
<td class="nump">2,039<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_selb_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour', window );">Thereafter</a></td>
<td class="nump">4,945<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total future minimum lease payments</a></td>
<td class="nump">14,120<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less imputed interest</a></td>
<td class="nump">3,775<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Lease liabilities</a></td>
<td class="nump">$ 10,345<span></span>
</td>
<td class="nump">$ 10,555<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_selb_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Liability, To Be Paid, After Year Four</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">selb_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>selb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140279219983768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Other Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Cash paid for amounts included in the measurement of lease liabilities:</a></td>
<td class="nump">$ 444<span></span>
</td>
<td class="nump">$ 487<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140279219904424">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Lease Term and Discount Rate (Details)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Operating lease, weighted average remaining lease term</a></td>
<td class="text">7 years 1 month 6 days<span></span>
</td>
<td class="text">8 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Operating lease, weighted average discount rate, percent</a></td>
<td class="nump">8.90%<span></span>
</td>
<td class="nump">8.90%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140279235866296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt - Term Loans (Narrative) (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Aug. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid', window );">Final payment fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of warrant or right, number of securities called by warrants or rights (in shares)</a></td>
<td class="nump">196,850<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share)</a></td>
<td class="nump">$ 2.54<span></span>
</td>
<td class="nump">$ 1.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_selb_ClassOfWarrantOrRightExpirationPeriod', window );">Class of warrant or right, expiration period</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Adjustments to additional paid in capital, warrant issued</a></td>
<td class="nump">$ 400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=selb_A2020TermLoansMember', window );">2020 Term Loans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity</a></td>
<td class="nump">35,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_selb_DebtInstrumentAdditionalAccruedInterestInTheEventOfDefault', window );">Debt instrument, additional accrued interest in the event of default</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.050<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed', window );">Debt instrument, redemption price, percentage of principal amount redeemed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_selb_DebtInstrumentDefaultBankruptcyOrInsolvencyValueOfTriggeringAcceleratedRedemption', window );">Debt instrument, default, bankruptcy, or insolvency value of triggering accelerated redemption</a></td>
<td class="nump">500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet', window );">Debt issuance costs, line of credit arrangements (less than)</a></td>
<td class="nump">400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Term loan facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=selb_TermALoansMember', window );">Term A Loans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity</a></td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=selb_TermBLoansMember', window );">Term B Loans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity</a></td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=selb_A2017TermLoansMember', window );">2017 Term Loans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLinesOfCredit', window );">Repayments of lines of credit</a></td>
<td class="nump">13,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_WarrantMember', window );">Warrants to purchase common stock | Term B Loans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Sale common stock</a></td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | 2020 Term Loans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_selb_DebtInstrumentPrepaymentFeePercentage', window );">Debt instrument, prepayment fee, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.030<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | 2020 Term Loans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_selb_DebtInstrumentPrepaymentFeePercentage', window );">Debt instrument, prepayment fee, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.010<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodOneMember', window );">Debt Instrument, Redemption, Period One | 2020 Term Loans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodTwoMember', window );">Debt Instrument, Redemption, Period Two | 2020 Term Loans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.65%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodThreeMember', window );">Debt Instrument, Redemption, Period Three | 2020 Term Loans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_selb_ClassOfWarrantOrRightExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Right, Expiration Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">selb_ClassOfWarrantOrRightExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>selb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_selb_DebtInstrumentAdditionalAccruedInterestInTheEventOfDefault">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Additional Accrued Interest In the Event Of Default</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">selb_DebtInstrumentAdditionalAccruedInterestInTheEventOfDefault</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>selb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_selb_DebtInstrumentDefaultBankruptcyOrInsolvencyValueOfTriggeringAcceleratedRedemption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Default, Bankruptcy, Or Insolvency Value Of Triggering Accelerated Redemption</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">selb_DebtInstrumentDefaultBankruptcyOrInsolvencyValueOfTriggeringAcceleratedRedemption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>selb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_selb_DebtInstrumentPrepaymentFeePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Prepayment Fee, Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">selb_DebtInstrumentPrepaymentFeePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>selb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109126253&amp;loc=d3e4724-112606<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of payment greater than the preceding installment payments to be paid at final maturity date of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of principal amount of debt redeemed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs related to line of credit arrangements. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section S45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68176171&amp;loc=SL68176184-208336<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for payment of an obligation from a lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=selb_A2020TermLoansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=selb_A2020TermLoansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=selb_TermALoansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=selb_TermALoansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=selb_TermBLoansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=selb_TermBLoansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=selb_A2017TermLoansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=selb_A2017TermLoansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140279221523048">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Debt - Schedule of Future Minimum Payments on the Term Loans (Details) - 2017 Term Loans<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtByMaturityAbstract', window );"><strong>Long-term Debt, Fiscal Year Maturity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear', window );">2021 (remainder)</a></td>
<td class="nump">$ 1,509<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths', window );">2022</a></td>
<td class="nump">7,343<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">2023</a></td>
<td class="nump">8,611<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree', window );">2024</a></td>
<td class="nump">8,027<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour', window );">2025</a></td>
<td class="nump">7,274<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total minimum debt payments</a></td>
<td class="nump">32,764<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_selb_DebtInstrumentInterestPortion', window );">Less: Amount representing interest</a></td>
<td class="num">(5,514)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Less: Debt discount and deferred charges</a></td>
<td class="num">(2,239)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Less: Current portion of loan payable</a></td>
<td class="num">(460)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Loan payable, net of current portion</a></td>
<td class="nump">$ 24,551<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_selb_DebtInstrumentInterestPortion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The interest portion of gross outstanding debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">selb_DebtInstrumentInterestPortion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>selb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unamortized debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtByMaturityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtByMaturityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=selb_A2017TermLoansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=selb_A2017TermLoansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140279222026616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Aug. 06, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 28, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 11, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 18, 2019 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 31, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($) </div>
<div>vote </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 31, 2020 </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Shares issued, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,991,000<span></span>
</td>
<td class="nump">$ 1,141,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Class of warrant or right, outstanding (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,378,016,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.54<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrant liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 45,455,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28,708,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">112,977,004<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">108,071,249<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">112,977,004<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">108,071,249<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_selb_VotesPerShareofCommonStock', window );">Number of votes per share that common stockholders are entitled to | vote</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsCommonStock', window );">Dividends declared or paid on common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Exercise of common warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Class of warrant or right, outstanding (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">292,469,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=selb_August2020ShelfRegistrationStatementMember', window );">August 2020 Shelf Registration Statement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Sale common stock</a></td>
<td class="nump">$ 200,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=selb_AtTheMarketOfferingMember', window );">At-The-Market Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Sale common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock, number of shares issued in transaction (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,706,844<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,069,486<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Share price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.59<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Shares issued, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=selb_A2020SaleAgreementAtTheMarketOfferingMember', window );">2020 Sale Agreement - At-the-Market Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Sale common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=selb_SOBIPurchaseAgreementMember', window );">SOBI Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Sale common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock, number of shares issued in transaction (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,416,390<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Share price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.6156<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_selb_SaleofStockPercentageOfTenDayVolumeWeightedAveragePriceOfCommonStock', window );">Sale of stock, percentage of ten-day volume weighted average price of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">120.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_selb_LockUpFromClosingTerm', window );">Lock-up from closing, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RedemptionPremium', window );">Redemption premium</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=selb_DecemberTwoThousandNineteenFinancingMember', window );">December 2019 Financing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Sale common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 65,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock, number of shares issued in transaction (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,634,883<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Share price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.46<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Class of warrant or right, outstanding (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,988,501<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_selb_WarrantIssued', window );">Warrant Issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrant liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 45,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount', window );">Warrant, increase (decrease) in equity, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (16,700,000)<span></span>
</td>
<td class="num">$ (800,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=selb_DecemberTwoThousandNineteenFinancingMember', window );">December 2019 Financing | Pre-Funded Warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_selb_ClassOfWarrantOrRightNumberOfWarrantsExercised', window );">Class of warrant or right, number of warrants exercised (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,342,128<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=selb_DecemberTwoThousandNineteenFinancingMember', window );">December 2019 Financing | Common Warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Share price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.46<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=selb_A2017PIPEMember', window );">2017 PIPE</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_selb_ClassOfWarrantOrRightNumberOfWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Number Of Warrants Exercised</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">selb_ClassOfWarrantOrRightNumberOfWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>selb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_selb_LockUpFromClosingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lock-up From Closing, Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">selb_LockUpFromClosingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>selb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_selb_SaleofStockPercentageOfTenDayVolumeWeightedAveragePriceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sale of Stock, Percentage Of Ten-Day Volume Weighted Average Price Of Common Stock</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">selb_SaleofStockPercentageOfTenDayVolumeWeightedAveragePriceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>selb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_selb_VotesPerShareofCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Votes Per Share of Common Stock</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">selb_VotesPerShareofCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>selb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_selb_WarrantIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrant Issued</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">selb_WarrantIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>selb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid common stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 405<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6957935&amp;loc=d3e64057-112817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RedemptionPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The excess of the (1) fair value of consideration transferred to the holders of a security in excess of (2) the carrying amount of the security reported on the registrant's balance sheet, which will be deducted from net earnings to derive net earnings available to common shareholders. This amount is generally an adjustment considered in the computation of earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RedemptionPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of (increase) decrease in equity for down round feature triggered for warrant classified as equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=SL109261905-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12B<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL109261756-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=selb_August2020ShelfRegistrationStatementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=selb_August2020ShelfRegistrationStatementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=selb_AtTheMarketOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=selb_AtTheMarketOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=selb_A2020SaleAgreementAtTheMarketOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=selb_A2020SaleAgreementAtTheMarketOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=selb_SOBIPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=selb_SOBIPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=selb_DecemberTwoThousandNineteenFinancingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=selb_DecemberTwoThousandNineteenFinancingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=selb_PreFundedWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=selb_PreFundedWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=selb_CommonWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=selb_CommonWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=selb_A2017PIPEMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=selb_A2017PIPEMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140279223927784">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Equity - Warranty Activity (Details) - $ / shares<br> shares in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Aug. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Class of warrant or right, outstanding (in shares)</a></td>
<td class="nump">12,378,016<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share)</a></td>
<td class="nump">$ 1.60<span></span>
</td>
<td class="nump">$ 2.54<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Exercise of common warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Class of warrant or right, outstanding (in shares)</a></td>
<td class="nump">292,469<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=us-gaap_WarrantMember', window );">Exercise of common warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Class of warrant or right, outstanding (in shares)</a></td>
<td class="nump">12,085,547<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140279223804632">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Equity - Schedule of Authorized Shares of Common Stock for Future Issuance (Details) - shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total (in shares)</a></td>
<td class="nump">30,928,290<span></span>
</td>
<td class="nump">25,157,139<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_StockCompensationPlanMember', window );">Shares available for future stock incentive awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total (in shares)</a></td>
<td class="nump">7,719,817<span></span>
</td>
<td class="nump">4,916,374<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=selb_RestrictedStockUnitsRSUsReservedForIssuanceMember', window );">RSUs reserved for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total (in shares)</a></td>
<td class="nump">98,750<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=selb_RestrictedStockUnitsUnvestedMember', window );">Unvested restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total (in shares)</a></td>
<td class="nump">544,313<span></span>
</td>
<td class="nump">87,500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Outstanding common stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total (in shares)</a></td>
<td class="nump">10,187,394<span></span>
</td>
<td class="nump">7,775,249<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Exercise of common warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total (in shares)</a></td>
<td class="nump">12,378,016<span></span>
</td>
<td class="nump">12,378,016<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_StockCompensationPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_StockCompensationPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=selb_RestrictedStockUnitsRSUsReservedForIssuanceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=selb_RestrictedStockUnitsRSUsReservedForIssuanceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=selb_RestrictedStockUnitsUnvestedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=selb_RestrictedStockUnitsUnvestedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140279223740680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Incentive Plans - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Mar. 25, 2019</div></th>
<th class="th"><div>Sep. 25, 2018</div></th>
<th class="th"><div>Jun. 21, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock authorized and reserved for future issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,928,290<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,157,139<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock&#8209;based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,780,000<span></span>
</td>
<td class="nump">$ 1,409,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_selb_ShareBasedGoodsAndNonEmployeeServicesTransactionCompensationNotYetRecognizedStockOptions', window );">Unrecognized compensation expense related to unvested non-employee stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_StockCompensationPlanMember', window );">Employee stock option grants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock authorized and reserved for future issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,719,817<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,916,374<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_selb_ShareBasedCompensationArrangementByShareBasedPaymentAwardForfeituresRate', window );">Estimated forfeitures rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value of stock options (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.99<span></span>
</td>
<td class="nump">$ 1.69<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized compensation expense related to unvested employee stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted average period for recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Unvested restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Grants in period (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.99<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Grants in period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">468,550<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_selb_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReservedForIssuance', window );">Reserved for issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">98,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_selb_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReservedForIssuanceWeightedAverageGrantDateFairValue', window );">Reserved for issuance (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.99<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=selb_StockIncentivePlan2016Member', window );">2016 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares authorized for grants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,210,256<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_selb_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantIncreaseDecrease', window );">Number of shares authorized, increase (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,322,850<span></span>
</td>
<td class="nump">3,453,022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock authorized and reserved for future issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,248,520<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=selb_StockIncentivePlan2016Member', window );">2016 Plan | Unvested restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue', window );">Vested in period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Grants in period (in shares)</a></td>
<td class="nump">369,800<span></span>
</td>
<td class="nump">98,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_selb_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAwardedInPeriod', window );">Awarded in period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">197,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_selb_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReservedForIssuance', window );">Reserved for issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">98,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=selb_EmploymentInducementIncentiveAwardPlanMember', window );">Employment Inducement Incentive Award Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares authorized for grants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,358,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock authorized and reserved for future issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="nump">1,175,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=selb_EmploymentInducementIncentiveAwardPlanMember', window );">Employment Inducement Incentive Award Plan | Unvested restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted average period for recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years 1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unrecognized compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=selb_EmployeeStockPurchasePlan2016Member', window );">ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_selb_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantIncreaseDecrease', window );">Number of shares authorized, increase (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,080,711<span></span>
</td>
<td class="nump">863,254<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock authorized and reserved for future issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,546,464<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">173,076<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock&#8209;based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_selb_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAwardedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Awarded in Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">selb_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAwardedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>selb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_selb_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReservedForIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Reserved For Issuance</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">selb_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReservedForIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>selb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_selb_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReservedForIssuanceWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Reserved For Issuance, Weighted Average Grant Date Fair Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">selb_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReservedForIssuanceWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>selb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_selb_ShareBasedCompensationArrangementByShareBasedPaymentAwardForfeituresRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the percentage of forfeitures rate of the stock options based on the historical trends.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">selb_ShareBasedCompensationArrangementByShareBasedPaymentAwardForfeituresRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>selb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_selb_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Number Of Shares Available For Grant, Increase (Decrease)</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">selb_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>selb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_selb_ShareBasedGoodsAndNonEmployeeServicesTransactionCompensationNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-Based Goods And Non Employee Services Transaction, Compensation Not Yet Recognized, Stock Options</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">selb_ShareBasedGoodsAndNonEmployeeServicesTransactionCompensationNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>selb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_StockCompensationPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_StockCompensationPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=selb_StockIncentivePlan2016Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=selb_StockIncentivePlan2016Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=selb_EmploymentInducementIncentiveAwardPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=selb_EmploymentInducementIncentiveAwardPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=selb_EmployeeStockPurchasePlan2016Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=selb_EmployeeStockPurchasePlan2016Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140279218395128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Incentive Plans - Schedule of Stock-Based Compensation Expense Related to Stock Options and Restricted Common Stock (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 1,780<span></span>
</td>
<td class="nump">$ 1,409<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=selb_ResearchAndDevelopmentMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">754<span></span>
</td>
<td class="nump">623<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 1,026<span></span>
</td>
<td class="nump">$ 786<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=selb_ResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=selb_ResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140279218446280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Incentive Plans - Schedule of Assumptions (Details) - Shares available for future stock incentive awards - $ / shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">0.44%<span></span>
</td>
<td class="nump">1.73%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">5 years 3 months 10 days<span></span>
</td>
<td class="text">6 years 29 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">83.26%<span></span>
</td>
<td class="nump">87.96%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_selb_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageFairValue', window );">Weighted-average fair value of common stock (in dollars per share)</a></td>
<td class="nump">$ 3.13<span></span>
</td>
<td class="nump">$ 2.30<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_selb_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighed-average fair value relating to the share-based payment award.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">selb_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>selb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_StockCompensationPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_StockCompensationPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140279224847752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Incentive Plans - Summary of Options Activity (Details) - 2008 Plan, 2016 Plan, and 2018 Inducement Incentive Award Plan - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=selb_A2008Plan2016PlanAnd2018InducementIncentiveAwardPlanMember', window );">Employees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Beginning balance (in shares)</a></td>
<td class="nump">7,302,176<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">2,628,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares)</a></td>
<td class="num">(153,278)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeited (in shares)</a></td>
<td class="num">(62,577)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Ending balance (in shares)</a></td>
<td class="nump">9,714,321<span></span>
</td>
<td class="nump">7,302,176<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Vested (in shares)</a></td>
<td class="nump">3,064,130<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Vested and expected to vest (in shares)</a></td>
<td class="nump">8,920,548<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted-average exercise price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Beginning balance (in dollars per share)</a></td>
<td class="nump">$ 3.98<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in dollars per share)</a></td>
<td class="nump">3.13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in dollars per share)</a></td>
<td class="nump">1.47<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Forfeited (in dollars per share)</a></td>
<td class="nump">5.19<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Ending balance (in dollars per share)</a></td>
<td class="nump">3.78<span></span>
</td>
<td class="nump">$ 3.98<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_selb_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsVestedWeightedAverageExercisePrice', window );">Vested (in dollars per share)</a></td>
<td class="nump">5.46<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Vested and expected to vest (in dollars per share)</a></td>
<td class="nump">$ 3.88<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_selb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract', window );"><strong>Weighted-average remaining contractual term</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Outstanding, term</a></td>
<td class="text">8 years 7 months 24 days<span></span>
</td>
<td class="text">8 years 5 months 4 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_selb_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedOutstandingWeightedAverageRemainingContractualTerm', window );">Vested, term</a></td>
<td class="text">7 years 7 months 17 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Vested and expected to vest, term</a></td>
<td class="text">8 years 7 months 2 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_selb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValueAbstract', window );"><strong>Aggregate intrinsic value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Outstanding</a></td>
<td class="nump">$ 15,665<span></span>
</td>
<td class="nump">$ 4,456<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_selb_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedOutstandingIntrinsicValue', window );">Vested</a></td>
<td class="nump">4,313<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Vested and expected to vest</a></td>
<td class="nump">$ 14,231<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=selb_A2008Plan2016PlanAnd2018InducementIncentiveAwardPlanMember', window );">Non-employee consultants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Beginning balance (in shares)</a></td>
<td class="nump">473,073<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeited (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Ending balance (in shares)</a></td>
<td class="nump">473,073<span></span>
</td>
<td class="nump">473,073<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Vested (in shares)</a></td>
<td class="nump">462,186<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Vested and expected to vest (in shares)</a></td>
<td class="nump">473,073<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted-average exercise price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Beginning balance (in dollars per share)</a></td>
<td class="nump">$ 5.89<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in dollars per share)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in dollars per share)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Forfeited (in dollars per share)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Ending balance (in dollars per share)</a></td>
<td class="nump">5.89<span></span>
</td>
<td class="nump">$ 5.89<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_selb_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsVestedWeightedAverageExercisePrice', window );">Vested (in dollars per share)</a></td>
<td class="nump">5.82<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Vested and expected to vest (in dollars per share)</a></td>
<td class="nump">$ 5.89<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_selb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract', window );"><strong>Weighted-average remaining contractual term</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Outstanding, term</a></td>
<td class="text">4 years 11 months 23 days<span></span>
</td>
<td class="text">5 years 2 months 23 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_selb_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedOutstandingWeightedAverageRemainingContractualTerm', window );">Vested, term</a></td>
<td class="text">4 years 11 months 1 day<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Vested and expected to vest, term</a></td>
<td class="text">4 years 11 months 23 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_selb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValueAbstract', window );"><strong>Aggregate intrinsic value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Outstanding</a></td>
<td class="nump">$ 366<span></span>
</td>
<td class="nump">$ 86<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_selb_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedOutstandingIntrinsicValue', window );">Vested</a></td>
<td class="nump">366<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Vested and expected to vest</a></td>
<td class="nump">$ 366<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_selb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>n/a</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">selb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>selb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_selb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>n/a</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">selb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>selb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_selb_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement By Share-based Payment Award, Options, Vested, Outstanding, Intrinsic Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">selb_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>selb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_selb_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedOutstandingWeightedAverageRemainingContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement By Share-based Payment Award, Options, Vested, Outstanding, Weighted Average Remaining Contractual Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">selb_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedOutstandingWeightedAverageRemainingContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>selb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_selb_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsVestedWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Exercise Price</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">selb_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsVestedWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>selb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options vested.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=selb_A2008Plan2016PlanAnd2018InducementIncentiveAwardPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=selb_A2008Plan2016PlanAnd2018InducementIncentiveAwardPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_StockCompensationPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_StockCompensationPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=selb_NonEmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=selb_NonEmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140279224900904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Incentive Plans - Restricted Stock Units (Details) - Unvested restricted stock units<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2021 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested at beginning of period (in shares) | shares</a></td>
<td class="nump">87,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Grants in period (in shares) | shares</a></td>
<td class="nump">468,550<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested in period (in shares) | shares</a></td>
<td class="num">(10,937)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_selb_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReservedForIssuance', window );">Reserved for issuance (in shares) | shares</a></td>
<td class="nump">98,750<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited in period (in shares) | shares</a></td>
<td class="num">(800)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested at end of period (in shares) | shares</a></td>
<td class="nump">643,063<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Unvested at beginning of period (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 6.03<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Grants in period (in dollars per share) | $ / shares</a></td>
<td class="nump">2.99<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested in period (in dollars per share) | $ / shares</a></td>
<td class="nump">6.03<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_selb_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReservedForIssuanceWeightedAverageGrantDateFairValue', window );">Reserved for issuance (in dollars per share) | $ / shares</a></td>
<td class="nump">2.99<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited in period (in dollars per share) | $ / shares</a></td>
<td class="nump">2.99<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Unvested at end of period (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 3.35<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_selb_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReservedForIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Reserved For Issuance</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">selb_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReservedForIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>selb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_selb_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReservedForIssuanceWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Reserved For Issuance, Weighted Average Grant Date Fair Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">selb_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReservedForIssuanceWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>selb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140279225011464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Incentive Plans - Employee Stock Purchase Plan (Narrative) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Jun. 21, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock authorized and reserved for future issuance (in shares)</a></td>
<td class="nump">30,928,290<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,157,139<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 1,780<span></span>
</td>
<td class="nump">$ 1,409<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=selb_EmployeeStockPurchasePlan2016Member', window );">ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock authorized and reserved for future issuance (in shares)</a></td>
<td class="nump">2,546,464<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">173,076<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_selb_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantIncreaseDecrease', window );">Number of shares authorized, increase (in shares)</a></td>
<td class="nump">1,080,711<span></span>
</td>
<td class="nump">863,254<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod', window );">Shares of common stock issued to employees under the ESPP (in shares)</a></td>
<td class="nump">34,696<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 100<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_selb_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Number Of Shares Available For Grant, Increase (Decrease)</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">selb_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>selb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=selb_EmployeeStockPurchasePlan2016Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=selb_EmployeeStockPurchasePlan2016Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140279221589720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Arrangements - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jul. 28, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 13, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 11, 2020 </div>
<div>USD ($) </div>
<div>obligation</div>
</th>
<th class="th">
<div>Dec. 17, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Short-term contract liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,764,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 72,050,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Long-term contract liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,301,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,746,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostAmortization', window );">Contract assets amortization (less than)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,342,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,224,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,730,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Remaining performance obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">108,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=selb_SOBIPurchaseAgreementMember', window );">SOBI Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Sale common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RedemptionPremium', window );">Redemption premium</a></td>
<td class="nump">$ 14,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Short-term contract liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">72,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">68,300,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Long-term contract liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,200,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNetCurrent', window );">Contract assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,900,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=selb_SOBIPurchaseAgreementMember', window );">SOBI Purchase Agreement | Prepaid Expenses and Other Current Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNetCurrent', window );">Contract assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=selb_SOBIPurchaseAgreementMember', window );">SOBI Purchase Agreement | Other Current Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNetCurrent', window );">Contract assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_selb_LicenseAndOptionAgreementUpfrontCashPayment', window );">Upfront cash payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_selb_LicenseAndOptionAgreementSalesMilestonePaymentsThatMayBeReceived', window );">Sales milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 630,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_selb_LicenseAndOptionAgreementWrittenDayNoticePeriodBeforeCancellation', window );">License and option agreement, written day notice period before cancellation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">180 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_selb_EligiblePeriodToReceiveRoyalties', window );">Period after first commercial sale when the Company is eligible to receive royalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_selb_RevenueNumberOfPerformanceObligations', window );">Number of obligations | obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_selb_LicenseAndOptionAgreementDevelopmentMilestone', window );">Development milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=selb_SareptaTherapeuticsInc.Member', window );">Sarepta Therapeutics, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_selb_LicenseAndOptionAgreementUpfrontCashPayment', window );">Upfront cash payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_selb_LicenseAndOptionAgreementWrittenDayNoticePeriodBeforeCancellation', window );">License and option agreement, written day notice period before cancellation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Short-term contract liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_selb_LicenseAndOptionAgreementOptionTerm', window );">Option term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">24 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=selb_LicenseAgreementForPompeDiseaseMember', window );">License Agreement For Pompe Disease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_selb_LicenseAndOptionAgreementUpfrontCashPayment', window );">Upfront cash payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_selb_LicenseAndOptionAgreementSalesMilestonePaymentsThatMayBeReceived', window );">Sales milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 237,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_selb_EligiblePeriodToReceiveRoyalties', window );">Period after first commercial sale when the Company is eligible to receive royalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Short-term contract liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,700,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Long-term contract liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,300,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_selb_LicenseAndOptionAgreementInitialUpFrontCashPayment', window );">Initial up-front cash payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_selb_LicenseAndOptionAgreementExecutionFeePayment', window );">Initial upfront execution fee payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_selb_EligiblePeriodToReceiveRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Eligible Period To Receive Royalties</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">selb_EligiblePeriodToReceiveRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>selb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_selb_LicenseAndOptionAgreementDevelopmentMilestone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License And Option Agreement, Development Milestone</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">selb_LicenseAndOptionAgreementDevelopmentMilestone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>selb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_selb_LicenseAndOptionAgreementExecutionFeePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License And Option Agreement, Execution Fee Payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">selb_LicenseAndOptionAgreementExecutionFeePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>selb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_selb_LicenseAndOptionAgreementInitialUpFrontCashPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License And Option Agreement, Initial Up-Front Cash Payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">selb_LicenseAndOptionAgreementInitialUpFrontCashPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>selb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_selb_LicenseAndOptionAgreementOptionTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License And Option Agreement, Option Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">selb_LicenseAndOptionAgreementOptionTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>selb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_selb_LicenseAndOptionAgreementSalesMilestonePaymentsThatMayBeReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License And Option Agreement, Sales Milestone Payments That May Be Received</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">selb_LicenseAndOptionAgreementSalesMilestonePaymentsThatMayBeReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>selb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_selb_LicenseAndOptionAgreementUpfrontCashPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License And Option Agreement, Upfront Cash Payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">selb_LicenseAndOptionAgreementUpfrontCashPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>selb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_selb_LicenseAndOptionAgreementWrittenDayNoticePeriodBeforeCancellation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License And Option Agreement, Written Day Notice Period Before Cancellation</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">selb_LicenseAndOptionAgreementWrittenDayNoticePeriodBeforeCancellation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>selb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_selb_RevenueNumberOfPerformanceObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue, Number Of Performance Obligations</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">selb_RevenueNumberOfPerformanceObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>selb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedContractCostAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for asset recognized from cost incurred to obtain or fulfill contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=68051541&amp;loc=SL49131252-203054<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedContractCostAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130533-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RedemptionPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The excess of the (1) fair value of consideration transferred to the holders of a security in excess of (2) the carrying amount of the security reported on the registrant's balance sheet, which will be deducted from net earnings to derive net earnings available to common shareholders. This amount is generally an adjustment considered in the computation of earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RedemptionPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction price allocated to performance obligation that has not been recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=selb_SOBIPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=selb_SOBIPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OtherCurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_OtherCurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=selb_SareptaTherapeuticsInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=selb_SareptaTherapeuticsInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=selb_LicenseAgreementForPompeDiseaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=selb_LicenseAgreementForPompeDiseaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140279223088856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Arrangements - Schedule of Changes in Contract Liabilities (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_selb_ChangeInContractWithCustomerLiabilityRollForward', window );"><strong>Contract liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_selb_ContractwithCustomerLiabilityDeferredRevenue', window );">Deferred revenue, beginning of period</a></td>
<td class="nump">$ 110,796<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Contract liabilities, beginning of period</a></td>
<td class="nump">110,796<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_selb_ContractwithCustomerLiabilityDeferredRevenueIncreaseFromCashReceipts', window );">Deferred revenue, additions</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_selb_ContractwithCustomerLiabilityIncreaseFromCashReceipts', window );">Contract liabilities, additions</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_selb_ContractwithCustomerLiabilityDeferredRevenueRevenueRecognized', window );">Deferred revenue, deductions</a></td>
<td class="num">(2,730)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Contract liabilities, deductions</a></td>
<td class="num">(2,730)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_selb_ContractwithCustomerLiabilityDeferredRevenue', window );">Deferred revenue, end of period</a></td>
<td class="nump">108,066<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Contract liabilities, end of period</a></td>
<td class="nump">$ 108,066<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_selb_ChangeInContractWithCustomerLiabilityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change In Contract With Customer, Liability [Roll Forward]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">selb_ChangeInContractWithCustomerLiabilityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>selb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_selb_ContractwithCustomerLiabilityDeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contract with Customer, Liability, Deferred Revenue</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">selb_ContractwithCustomerLiabilityDeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>selb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_selb_ContractwithCustomerLiabilityDeferredRevenueIncreaseFromCashReceipts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contract with Customer, Liability, Deferred Revenue, Increase From Cash Receipts</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">selb_ContractwithCustomerLiabilityDeferredRevenueIncreaseFromCashReceipts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>selb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_selb_ContractwithCustomerLiabilityDeferredRevenueRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contract with Customer, Liability, Deferred Revenue, Revenue Recognized</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">selb_ContractwithCustomerLiabilityDeferredRevenueRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>selb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_selb_ContractwithCustomerLiabilityIncreaseFromCashReceipts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contract with Customer, Liability, Increase From Cash Receipts</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">selb_ContractwithCustomerLiabilityIncreaseFromCashReceipts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>selb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140279219765800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related-Party Transactions - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=selb_FounderMember', window );">Founders</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty', window );">Consulting services expenses (less than)</a></td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=selb_FounderMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=selb_FounderMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140279218430360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements - AskBio (Narrative) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Operating expenses</a></td>
<td class="nump">$ 18,208<span></span>
</td>
<td class="nump">$ 18,822<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=selb_AskBioLicenseMember', window );">AskBio License</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Operating expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_selb_CollaborativeArrangementCostSharePercentage', window );">Cost share percentage</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_selb_CollaborativeArrangementCostSharePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Cost Share Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">selb_CollaborativeArrangementCostSharePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>selb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=selb_AskBioLicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=selb_AskBioLicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140279218633928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements - MIT (Narrative) (Details) - Spark License Agreement<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_selb_LicenseAndOptionAgreementContractualPaymentsMade', window );">Contractual payments defined in the Exclusive Patent License agreement</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=selb_ExclusivePatentLicenseAgreementWithMassachusettsInstituteOfTechnologyMember', window );">MIT</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_selb_LicenseAndOptionAgreementContractualPaymentsMade', window );">Contractual payments defined in the Exclusive Patent License agreement</a></td>
<td class="nump">2,200,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_selb_LicenseAndOptionAgreementCalculatedPremiumPaidForEquityInvestmentUnderPurchaseAgreement', window );">License and option agreement, payments made relative to calculated premium paid for initial equity investment made under the purchase agreement</a></td>
<td class="nump">$ 400,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_selb_LicenseAndOptionAgreementCalculatedPremiumPaidForEquityInvestmentUnderPurchaseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License And Option Agreement, Calculated Premium Paid For Equity Investment Under Purchase Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">selb_LicenseAndOptionAgreementCalculatedPremiumPaidForEquityInvestmentUnderPurchaseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>selb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_selb_LicenseAndOptionAgreementContractualPaymentsMade">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License And Option Agreement, Contractual Payments Made</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">selb_LicenseAndOptionAgreementContractualPaymentsMade</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>selb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=us-gaap_LicenseAgreementTermsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=us-gaap_LicenseAgreementTermsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=selb_ExclusivePatentLicenseAgreementWithMassachusettsInstituteOfTechnologyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=selb_ExclusivePatentLicenseAgreementWithMassachusettsInstituteOfTechnologyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140279219787656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements - Shenyang Sunshine Pharmaceutical Co., Ltd (Narrative) (Details) - 3SBio License<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_selb_AggregateAmountOfUpfrontAndMilestoneBasedPaymentsPaid', window );">Aggregate amount of upfront and milestone-based payments</a></td>
<td class="nump">$ 7.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_selb_AggregateAmountForFuturePaymentsUponAchievementOfClinicalAndRegulatoryApprovalMilestonesForProductsContainingImmTORPlatform', window );">Aggregate amount for future payments upon achievement of clinical and regulatory approval milestones for products containing ImmTOR platform</a></td>
<td class="nump">$ 15.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_selb_AggregateAmountForFuturePaymentsUponAchievementOfClinicalAndRegulatoryApprovalMilestonesForProductsContainingImmTORPlatform">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate Amount For Future Payments Upon Achievement Of Clinical And Regulatory Approval Milestones For Products Containing ImmTOR Platform</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">selb_AggregateAmountForFuturePaymentsUponAchievementOfClinicalAndRegulatoryApprovalMilestonesForProductsContainingImmTORPlatform</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>selb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_selb_AggregateAmountOfUpfrontAndMilestoneBasedPaymentsPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate Amount Of Upfront And Milestone Based Payments Paid</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">selb_AggregateAmountOfUpfrontAndMilestoneBasedPaymentsPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>selb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=selb_LicenseAgreementWithShenyangSunshinePharmaceuticalCompanyLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=selb_LicenseAgreementWithShenyangSunshinePharmaceuticalCompanyLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140279220426648">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration', window );">Operating loss carryforwards, carried forward indefinitely</a></td>
<td class="nump">$ 234,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration', window );">Net operating losses available for use through 2028</a></td>
<td class="nump">36,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are not subject to expiration dates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are subject to expiration dates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140279220081352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Defined Contribution Plan - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_selb_DefinedContributionPlanEmployersMatchingContributionVestingPeriod', window );">Vesting period</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanCostRecognized', window );">Employer contribution made</a></td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_selb_DefinedContributionPlanEmployersMatchingContributionVestingPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period which an employee's right to exercise a plan is no longer contingent on satisfaction of either a service condition, market condition or a performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">selb_DefinedContributionPlanEmployersMatchingContributionVestingPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>selb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanCostRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanCostRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140279237948216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 13, 2021</div></th>
<th class="th"><div>May 13, 2021</div></th>
<th class="th"><div>Aug. 31, 2017</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=selb_SareptaTherapeuticsInc.Member', window );">Sarepta Therapeutics, Inc. | Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_selb_LicenseAndOptionAgreementMilestonePayments', window );">Milestone payment</a></td>
<td class="nump">$ 3.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=selb_A2020SaleAgreementAtTheMarketOfferingMember', window );">2020 Sale Agreement - At-the-Market Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Sale common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | 2020 Sale Agreement - At-the-Market Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock, number of shares issued in transaction (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">206,593<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Share price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Sale common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_selb_LicenseAndOptionAgreementMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License And Option Agreement, Milestone Payments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">selb_LicenseAndOptionAgreementMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>selb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=selb_SareptaTherapeuticsInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=selb_SareptaTherapeuticsInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=selb_A2020SaleAgreementAtTheMarketOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=selb_A2020SaleAgreementAtTheMarketOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>87
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M*P#]I9E44MFN.E<;*O1Q'6XK%^K8 A1G"1JAMHVB,)A G72H$R_J;UR1\@2
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MEG_B4PYIB"O?Q766/TK(<8UA.AE!GN631_BF0Y[3R#<]P/?>W*(G[B;R([C
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MZ((!ZRMK:;<)#H:7<_D;4$L#!!0    ( &] K5*^/;]JV ,  ,X(   9
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M=UDT3QB\  R?*H37NFF%^@J5L-08K38.2Q"@2+IF:>I5<"3G*H,(39\<Y.0
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MAMED&L;)%5!)Q-,\3(CC)^W(<SI(XAG7"KL0QX1Y-8.7GL3H:,90=VS]).7
M=,KUXV8X'8;U=3^COHGWDYY"MI44F!HWI!J/)N, 3#\]^XW3K9]8:^UH_OEE
M13\XT+  W6\TI6Z_80/#3YC5OU!+ P04    " !O0*U2<N,+0UX)   T&P
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MK# 0[_4SR(:X?(,LWOJVBP>G%&_@!'2=--X7JT1'6]T@@L6CY2K8VRN-3B0
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MC@/079/I-E8UOK!WRE*;\,N*^C)J=X'.2Z5LOW$.ADZ_^@-02P,$%     @
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M!UJ\38K/"A[OHIAWOUSSTN;I6/P\U(;8X>VZIA@A1:QK8X0]8MW$_/=82=9
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M5(*+7DA$'VN,7DAV9$AWH.<F]Z_J($K+\$]IJW,CMFG??RCZ6NL$X!MA<\J
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MKH5>B:R7@&B4NGSVM9%YMLJPWK",>FOS$J\K!>-G2=V_DSM9I49(@PRK587
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M 9!&H>,%+K,)T5)FD=4@@*#=-GATF :43".T8F<)2#T/8Y8A)AGF2Y(A=/S
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M7^"O)Y>SZZN+,_SUXOGLXMDS\;/A3MD)KCQTBJFW)9XG;Z0$P6[IO9N6W\;
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MMQT=IHY)#WNPI>PU.(SK=Z% <EQT0$G,BDEJ)?Z3M2S-AHH93:61'GBHCSC
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MSYZ<A#$TO6E-P[\50;N,28]?%@HY8VD!OE\;3(WQ#1W0_7CHU7\ 4$L#!!0
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MN>@DU9S\>T:RFV))3N?"8;S_2PPS*.06@>PD3\PM"1QG'4Y7%5*[UQGTTM+
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M>ESD&_?=\?S=@A);8<(J2Q5$9Y.7ST<JY&^!O$B^E?OWTB?<YN6QQN<3!3Z
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M104Y7WO/ATUT<'P&%_\"4$L#!!0    ( &] K5(XPQ*WH@8  !80   9
M>&PO=V]R:W-H965T<R]S:&5E=#(S+GAM;+5866\;-Q#^*X0*]$F5;-EIW,0V
MX*-!6R!M$/=X*/K 7<YJ67/)#<F5HO[Z?D-RU_(1H^>#M==PCF]F/@Y]NG7^
M-K1$47SLC UGLS;&_M5R&>J6.AD6KB>++XWSG8QX].MEZ#U)E19U9KDZ./AR
MV4EM9^>GZ=T[?W[JAFBTI7=>A*'KI-]=DG';L]GA;'SQ7J_;R"^6YZ>]7-,-
MQ9_Z=QY/RTF+TAW9H)T5GIJSV<7AJ\MCED\"/VO:AKU[P9%4SMWRP[?J;';
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M_:H%PN1WHQLWP(B263)R*SW-A94=(=8W'I*M%IN%N)1>5O@"XI=F(7[$.G;
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MR5HPR^ENZ+ Y1@20-M@._)9JK1DBCR*]W.6]?A^5O#D#=W82)E(:.GE+;'O
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M-ZP3]D[MON*03^'X2B6,_\*NCRWR ,K.6-4,8%+0<-G_V?-0AS> T_@30#H
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MT&!V8D,O(2JK0.<;27T_+JR#Z6U=_@M02P,$%     @ ;T"M4H;E%(#L!0
M&@\  !D   !X;"]W;W)K<VAE971S+W-H965T,S0N>&ULG5??<]LV#/Y7<%ZZ
M2^X46;\EITGNG";K^M VEZ;MPVX/C$3;O$BB1U)VO+]^ "7+CA.[N;U(E$@
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MX>65*UJ \Q,IS?J##/37X<O_ %!+ P04    " !O0*U2%540&;\"   ;!@
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M+(6J^GXU,;)PK7,M#39B-\SPJ01E W!_(Z4Y3.P'FL=W^AM02P,$%     @
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M<VAE970T,2YX;6RMFFU/XT80Q[_**JTJ3FJ)O4\.%"(=H%,K'1*"WMWK)=F
MA1_2]0;NI'[X^@F/<[;'&SEO($YF)C-_CW_>V?CB+34OV;/6EGR/HR2[G#U;
MNSV?S[/5LXY5=IIN=9)_LDE-K&Q^:)[FV=9HM2Z=XFA./4_.8Q4FL^5%^=Z=
M65ZD.QN%B;XS)-O%L3(_KG24OEW._-G[&_?AT[,MWI@O+[;J23]H^V5[9_*C
M>1-E'<8ZR<(T(49O+F<?_?/KH'0H+;Z&^BUKO29%*8]I^E(<_+V^G'E%1CK2
M*UN$4/F_5WVMHZB(E.?Q;QUTUGQGX=A^_1[]4UE\7LRCRO1U&GT+U_;Y<K:8
MD;7>J%UD[].WOW1=D"CBK=(H*_^2M]K6FY'5+K-I7#OG&<1A4OU7WVLA6@X^
M'W"@M0-U=6"U RL+K3(KR[I15BTO3/I&3&&=1RM>E-J4WGDU85*<Q@=K\D_#
MW,\N/ZG0D*\JVFERJU6V,SH_1S8C?Y"'ZL22=$,^9IG.WZL-UD19TO(K3@:Y
MUZN=,6'R1*Y4%F;DY$9;%4;9ASS2EX<;<O+KAXNYS1,NOG:^JI.[JI*C \G=
M*G-*F/\[H1[U>]RO<?<;O6K<O7WW>2Y3HQ5MM*)E/#80KY+A'(G$FDBLC,2'
M"WO)]7F,-,D*X4(;ZI\#5P)5<609I[@D7Y>4<D]X7E[0:UN*KB%8[.7(FQPY
M6NWG4#V&45]F>^%$$TZ@)7]3QJC$D@C"]M5;!1&M,KC@HJ?>KB%=!-ZB;;B7
MIVSRE&B>UZG9ID9931[39)TAE0=-Q&!BVRR:2(LCM<VBJX['_$%QSIH$SD;$
MB6-M5J&*R%9MM4%J\CT@D#=1'[]%,_]("M6!?I(HX(,:^8 )GZ))-"S$2@)4
M^&RJ/'!)^QS-[)_4YJ=.E1%[1>$=41:>D*Q[^?5;!G)8/@"%+XX!'A^N:!^_
MI!W14T=Q8$^/)0X?'UCA!PYG:"S3P#G3KN5(IL B'X<1W/'_(R>?]:N.?OO%
ME]Z?_@?LI %I_+.);4^!,-2;U/:U>ULEL?#%HJMGCR7>]A301?UCM#UMK59P
M##FV?1U%]*X<ZJHQD_WL &L47P(Y-7H= \T-,]G/#3!)<4P.M3;%6IL"X"@.
M.(?6!K91G&VCK=V#JOX%9(_ED)! ,XHO?5Q[&J!#<>BX]G1W_=,I%S/9SPZ8
M1?'ED5M/GXWGAIGL#QS 0(8S<*BG&=;3#.C%<'HYS$8 +H:#:ZRGV3BQ4)/]
MM%HS&[X0<VQF!IAA.&8<FYEUEUH#=_L>2_QNSX!9#!_?G%J;.4]O/98CF0(1
M&4[$=J.[#W,,F,:FCG,,<,:.-="Q R<Z!M!B.+00O0Y9V7$@$9\Z[W' #C_6
MO,>[\][0!@F BCL.>J/2H2L'#@CB4V=!WMK>P>ES@'0]6,%ZCP-5.$X5=P'1
MVQ0'.' Y54   <='M0,$[$YA0](!.KC[^'7 M@P'+O"I YB 2U[@BP]WJ41W
MP,*W902P0N"LP!0[A'0"^""F;A@+N/3%L;:,A?-$)  6PGTB&M$.19UH;1=/
M'9($7/4"7Q(<H%W/N(2W'^!"X+@X0$(4=@(0(193)00:"'R5<("$SL.+!'Y(
M]^'E-DWT#Q*7^9#-#E_62:"#G#K 2+CN);XN&$NQ$DIV9Y2!7:<>2WS720)6
M)(X57-E#L"@!)A+_9<E!:L"$Q%<0CE)WQXTAJ;N6(U*W?EAR'TQ&I48I*@$Z
M<NJP(@$G<F18<9-Z?.L%-=E/#O@DW:>847%1O@9 I6#J(!, ?H*10<9)W#I(
M_Z^\E;BH297<O/6X0/&L1L[VIS#)2*0WN8]W&N1GQE2//U0'-MV63Q \IM:F
M<?GR6:NU-H5!_ODF3>W[0?%00O,0RO)_4$L#!!0    ( &] K5(4'":SV@(
M $8)   9    >&PO=V]R:W-H965T<R]S:&5E=#0R+GAM;,56;4_;,!#^*Z=\
M @F:-PH%M95X&1K2T"K8X,.T#R:Y-!9.'&RGI?]^9R>$;"K1IDGPI;$=WW//
M/=>[RW0MU:/.$0T\%Z+4,R\WICKQ?9WD6# ]DA66]":3JF"&MFKIZTHA2YU1
M(?PH" []@O'2FT_=V4+-I[(V@I>X4*#KHF!J<X9"KF=>Z+T<W/!E;NR!/Y]6
M;(FW:+Y7"T4[OT-)>8&EYK($A=G,.PU/SL+8&K@;=QS7NK<&&\J#E(]V<Y7.
MO, R0H&)L1",'BL\1R$L$O%X:D&]SJ<U[*]?T"]=\!3, ]-X+L4]3TT^\R8>
MI)BQ6I@;N?Z,;4!CBY=(H=TOK-N[@0=)K8TL6F-B4/"R>;+G5HB>031^PR!J
M#2+'NW'D6%XPP^93)=>@[&U"LPL7JK,F<KRT6;DUBMYRLC/S2\85W#%1(UPC
MT[5"DMQHV(=339FJK'0::HTI&$EI2*2B58Z06<.5,Y29.UDSI9BUW;E P[C0
MNX1BH9G3_QLF><F?:MR#KPX6%HHGO%S"M4Q13'U#X5A2?M)2/VNH1V]0OV9J
M!'&X!U$0A;^;^Z1")T7421$YO(,W\&ZX?MS/%"+PTJ!";4 Q@P/(<8<<.^3X
MGT2&J[*J22Y6IMMDTO#C"^' E<%"_QQ@<="Q.!B,[_XE/]:ALO]6#52GVM">
MTK '18\;M]RVY:3Q<>Q\V))?S8-1$,3CJ;_:PFW<<1L/<KO@*YXB\=IP%.E
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M!D4[:VTJCF2:36AK [SPH$J&<11=A!47*DBGWG=CTJEN4 H%-X;9IJJX>5Z
MU+M9, [VCENQ*=$YPG1:\PW< =[7-X:LL,]2B J4%5HQ ^M9,!]?+B<NW@<\
M"-C9@S5S2C*M'YWQK9@%D2L().3H,G#ZV\(2I'2)J(S?7<Z@IW3 P_4^^Y77
M3EHR;F&IY0]18#D+/@>L@#5O)-[JW5?H]/@"<RVM_V6[+C8*6-Y8U%4'I@HJ
MH=I__M2=PP& \AP'Q!T@_AMP\08@Z0")%]I6YF6M./)T:O2.&1=-V=S"GXU'
MDQJA7!?OT-"N(!RF5UP8]L!E ^P:N&T,4(O0LH_L.S>&NS-F)RM +J0])>_]
MW8J=?#B=ADCD+D68=T2+EBA^@RAAUUIA:=D754!Q!+\<QH_C@00AJ>ZEQWOI
MBW@PXS4W9RP9CU@<Q>-C!0W#5Y#W\&B@G*3O1.+S)>]W8B5L+K5KAF4_YYE%
M0[?]UP#'><]Q[CG.ASBVCF/$JM=VTYW#DC5*9Q;,EF<2F%!U0]? 0*Y5+J3@
M[M&-G-T8(]3&O1UA1XQ;"SAB5*&R:S#D48#';D=;V(4OS(V6;4J'MCT\[J&(
M/]1.>K63_ZR6=C+:QN=_43QY5_%01*LX/'C9%9B-'WB6Y;I1V#[RWMO/U+D?
M)>%K>#N0Z;IOA+),PIJ@T=DG8C?MD&L-U+6?$YE&FCI^6=)W 8P+H/VUUK@W
M'$'_I4E? %!+ P04    " !O0*U2<[02L-L"  !1"   &0   'AL+W=O<FMS
M:&5E=',O<VAE970T-2YX;6R-5MM.XS 0_14KX@$D(/>TH+02-$6[$DB( ONP
MV@<WF3863EQLIV7_?FTG9'L))2_$3LZ9.6?&'1-O&'\3.8!$'P4MQ<C*I5Q=
MV[9(<RBPN&0K*-67!>,%EFK+E[98<<"9(174]APGL@M,2FL<FW>/?!RS2E)2
MPB-'HBH*S/_> F6;D>5:GR^>R#*7^H4]CE=X"3.0+ZM'KG9V&R4C!92"L!)Q
M6(RL&_=Z&FF\ ;P2V(BM-=).YHR]Z<W/;&0Y6A!02*6.@-5C#1.@5 =2,MZ;
MF%:;4A.WUY_1[XQWY66.!4P8_44RF8^LH84R6."*RB>V^0&-GU#'2QD5YB_:
M-%C'0FDE)"L:LE)0D+)^XH^F#EL$-_B"X#4$KR_!;PA^7T+0$(*^A+ A&.MV
M[=T4+L$2CV/.-HAKM(JF%Z;ZAJWJ14I]3F:2JZ]$\>3X#A..7C&M #T %A4'
M=0BD0!=HIHYD5E% ;($F6.0(EUF]F+Y79(VIP9TF(#&AXDPQ7F8).CTY0R>(
ME.@Y9Y50%!';4NG4V>RTT71;:_*^T/2 ^27RW7/D.9[;09\<IR>0MG2G@Y[T
MS]Y%G_;.[E[MTFW5F[9!7ML@S\3SOV]00D1*F>Z10+]OYD)R]3/[<R2'W^;P
M38[@BQQM>U.]@/_M[>I='2HRH?046H]=+PR<06ROMWO4 ?.'T3#<A26'L($7
M.5&+VO$3M'Z"HWYF.>/R0@(OU"A392*IA-I<EZ$Z5K@EP=D3>8CP!E?=$L-6
M8GA4XCTKE[T5A@?Y77]+0%WP/J#D&]".E:BU$AVU\LPDID;[^<$!.C?':L\B
M$CG;E'I(R!Q0RDK!*,FP_BRD>N@)I*>.P2[43=9Y#J..<Q@-AM%>63I@@;I#
M@[W"',(&@;>/FAZBKMPP=/?J9V^-8WW9JHFR)*5 %!:*YUP.5/UY?8'5&\E6
M9D+/F53SWBQS=><#UP#U?<&8_-SHH=_^%S'^!U!+ P04    " !O0*U2(^UO
M$H(#  "K#@  &0   'AL+W=O<FMS:&5E=',O<VAE970T-BYX;6R]EUV/FS@4
MAO^*A7K12M,!FY"/*HFTS6RUE5IMU.G'Q6HO/'"86#68VF8R\^_WF#! $L)T
MI<S<)#:<<_SZ ;_8\ZW2/\T&P)+[3.9FX6VL+=[YOHDWD'%SJ0K(\4ZJ=,8M
M=O6M;PH-/*F2,NFS(!C[&1>YMYQ7U]9Z.5>EE2*'M2:FS#*N']Z#5-N%1[W'
M"U_$[<:Z"_YR7O!;N ;[K5AK[/E-E41DD!NA<J(A77A_T'<K%KJ$*N*[@*WI
MM(F;RHU2/UWG8[+P J<(),36E>#X=P<KD-)50AV_ZJ)>,Z9+[+8?JW^H)H^3
MN>$&5DK^$(G=++RI1Q)(>2GM%[7]"^H)1:Y>K*2I?LFVC@T\$I?&JJQ.1@69
MR'?__+X&T4F@HQ,)K$Y@OYL0U@D5.7^GK)K6%;=\.==J2[2+QFJN4;&ILG$V
M(G>/\=IJO"LPSR[7&M\(;1\(SQ/RYZ]2%/B,+'E+KO&%24H)1*7D1-#K*[!<
M2/,&P[]=7Y'7K]Z05T3DY.M&E09CS=RWJ-&-Y,>UGO<[/>R$GL]<7Y*07A 6
M,-J3OAI.OX*X20_VTWTDT^!A#1Y6U0N?P'-!UI+CE/<!_/,)P\E'"YGY=V"P
ML!DLK 8;G1CLJ[)<DJ(+&Q['ZB.YJS:NJKGE>K>,QE.$=M?EU1<4!4W0GM!1
M(W0T*/03&(,+,"ZS4G(+":X;])!8<+<R^Y3NRD4=$6]'X30XD-H7Q:*H7VO4
M:(T&M:Y[<5Z0''J91D<::!@<,NT+FIW0.6YTCH>9\ANEN57ZX=1#WRL[:<I.
MGO\%GC:#3<_Z D^/.(Y&;'8 NS=HT@][U@B=#0I=J:PH+>A67B76J-1NN88!
M%#1HC35X?O*TX^/TK.SK<EVNX]GH@'U/4!2R?O:T]53*GK /_.YNE$R(R%#P
M'3B-9HA"ZZ T? 'HK0_282/\W]"/+2Z<'C(?C-D7VIH@'7;!#Z7.A2TU5!I3
M<>_:@\A;WZ+C%T#>^AF=G!?YY!AGQSYJYL-!^U);-Z3#=OAWFHH8?LO.:>M<
M=/;\N%GK8BPX*^ZZW-ZW<1P>X'XB:%]JZX!LV %7*C=6E[OC >Y"472,&Y4A
M#)UMX OL UEK8^R\.T%VO,L+#W=7/3''T/W.2<(=XW [?BMR0R2DF!5<3O"9
MZ=W):->QJJ@.%S?*XE&E:F[P- G:!>#]5"G[V''GE>9\NOP/4$L#!!0    (
M &] K5()Z1[1/@(  "$%   9    >&PO=V]R:W-H965T<R]S:&5E=#0W+GAM
M;(U476_:,!3]*U=1'UJI(R%AW5:%2'QTVAZ84%&WAVD/)KD0JXZ=VJ;0?]]K
M)V2T K:7Q+Z^Y]PO'Z=;I1]-B6AA5PEIAD%I;7T;AB8OL6*FIVJ4=+)2NF*6
MMGH=FEHC*SRH$F$<13=AQ;@,LM3;YCI+U<8*+G&NP6RJBNF7,0JU'0;]8&^X
MY^O2.D.8I35;XP+M0SW7M L[EH)7* U7$C2NAL&H?SL9.'_O\)/CUARLP56R
M5.K1;;X7PR!R":' W#H&1K]GG* 0CHC2>&HY@RZD QZN]^Q??>U4RY(9G"CQ
MBQ>V' :? RAPQ3;"WJOM-VSK^>CX<B6,_\*V\;WY$D"^,595+9@RJ+AL_FS7
M]N$ 0#S' 7$+B-\#!B< 20M(?*%-9KZL*;,L2[7:@G;>Q.86OC<>3=5PZ::X
ML)I..>%L-M=T(;1] 28+N'O:\)I&9.$#_&!:,]=BN)RB95R8*[(^+*9P>7$%
M%\ ES+@0- J3AI8R<7QAWD8=-U'C$U$3F"EI2P-WLL#B+3ZD"KHRXGT9X_@L
MX8SI'B3]:XBCN'\DG\G_PZ,SZ21=5Q//E_RCJ]<P%XS:^;:YOT=+8S5=X#]G
M0@VZ4 ,?:G BU!1)O3EG7A2X(W4;/#:0AJ4?>1JG[><LZE&KG@^[=-0I[IR:
M!,.#VU:A7GL1&LC51MIF8IVUT_G(7^]W]C'IOY'K7YKF\:!YK+DT('!%E%'O
M$ZE'-X)L-E;5_DXOE26%^&5);QAJYT#G*Z7L?N,"=*]B]@I02P,$%     @
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M9ZZ%AV(9QMW62[$^-S:B"NE >6H+0\KTIO7IBQ^=9]@[.M"JZC\E55GJ'S4
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MI<'QYI8%_H! V0#<7TIIMH9-T/[2LK]02P,$%     @ ;T"M4A L@ZO& @
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M;K##$J]OD&8#/E\*H3\FYH+H_Q!,W@%02P,$%     @ ;T"M4EH4C(%0 @
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MTIL%OYIH7 +'-UK3P7&+V;_#LU]02P,$%     @ ;T"M4K'ADT+3!0  M!D
M !D   !X;"]W;W)K<VAE971S+W-H965T-34N>&ULM9E;;]LV%(#_"F%T0 )X
MMD3*EQ2)@21NL0!-%R3M^C#L@99HFXLD:B05QT!__ XE151@B;8+^"71A>?P
M7'@^'LJ7&R&?U9HQC5Z3.%57O;76V<?A4(5KEE U$!E+X<U2R(1JN)6KH<HD
MHU$AE,1#['GC84)YVIM=%L\>Y.Q2Y#KF*7N02.5)0N7VAL5B<]7S>V\/'OEJ
MK<V#X>PRHROVQ/3W[$'"W;#6$O&$I8J+%$FVO.I=^Q\_!<0(%"/^XFRC&M?(
MN+(0XMG<W$57/<]8Q&(6:J."PK\7=LOBV&@"._ZKE/;J.8U@\_I-^^?">7!F
M016[%?$/'NGU56_:0Q%;TCS6CV+S!ZL<&AE]H8A5\1=MJK%>#X6YTB*IA,&"
MA*?E?_I:!:(AX <= K@2P(<*D$J '"H05 +!H0*C2J!P?5CZ7@1N3C6=74JQ
M0=*,!FWFHHA^(0WQXJE9*$]:PEL.<GHV9PN-?D??F$S0%T%3A<Z^4BFI2=\Y
M.ILS37FLSF'(]Z<Y.OMPCCZ@(5)K*IE"/$7?4ZY5'Q["];>UR!5-(W4YU&":
MF6 85F;<E&;@#C.N\]4 $;^/L(>]%O%;M_@]E;6XWR(^=XL_L0S$O<[9/[G%
MYRSL,GX(Z:AS@NN<X$(?Z=#W!>Z16*);R2*NT6<:\ICK+?J[>'&G6:+^<4Q#
MZFE(,4W0,<UGGM(8970+=:_1DK&VN)<JQH4* YV7&28>./G2,G%03QPX)[Z-
MJ5+&P8U9:3"WD$B:@NZC-$\63)IWBH6YY)K#,@MI'+,(+;9O JJ6@.4*"Z]<
MCN=MRZZT9-2PW[\83T<='HQJ#T9.#SZ],AERQ5 F><@*&R(1QU0JE('YA3VM
MYI1JI\UP#D9!;4P9\]U!_F#<;O"X-GC\JR%GKQDW]0[4!MNYB-KL=FOW/;1E
MX+QC44YJ0R=.5=?1OP ]LR(5T@+1""H 3"L6*H\,94*:<4WC?NT*5RIGK59/
M=A9OT+5VI[5]4Z=]IL0;M'1X?%%KO#AEM?N>);WG-/V>OO(D3]!"2)#EZ<J$
M$F;3VU9>>SN50T9>5_C\QG[C.ZTH-AR>*BUSD^5^,\4T#"6D$EYK!@5MQB&]
M9HB]&$)!C*H.H'6#J/8YOV&P-_!&'?9:%OOX.'LA32S)RGHQU=\W91/"*^BK
MC(WP, UY9MQ)1 YV&P&6M*[0VSV37PP\[S=7\BWK?3?L=]RH0MF'-BM]EGFF
MPVW?4 '&B!CB'6[1"XWSPB4-J%@!&V#)0(J@R0->0)IL)%H7$-E90*/.Y6.W
M#M^]=Y1^0,73%, ;"F6ZC[@JH; LH8(+*U9"Y"QF0#Z]IFDKD/W=#:*3$;[=
M'GSW_E  (@9 H&55SJW)'^UNKN]*K&H^]@U[;Z3=$GPWM0LCK_=RS+?H]B<G
M)9EEL.^&\)$DF^ZDV!4_RVW_8G_\;O;&#UM 8^^4\<.6P=C-X./B5RE[UT-Y
MG?'#C2[7#3?L^9/#ME)L,8?)24-H.83=''ID5>-<=%7FK;($:HUB2R=*)IU1
MM*C!;M1\$::Q2Z&-TY#(G*MU4F^6BS9+YGB7)YU@QI8FV$V3'V^M.71M62[#
M-9S>@<]) K;!*39\1C_1H15CB8-/2AQLB8/=Q'FB\7MO6E,\W06UYZ@42QKL
M)LU;O?Y$A[>?Q&*'G!0[Q&*''-GZ99(UCI_-1JKU*-K>X9'VZ!++(>+FT#U/
MCX]NXY!]4B(12R1R2&?TZ]$-6J/K=T37\HFX^528==<PZ['N&OOHH3APHC\A
M$D=%WU*)C$\:?4LBXCZWWE#%%2H_UAH<OU#)Z0*@85KEUGB[]4T&%\[.GUAT
M$3>Z#DG MXTX+@$67>2DI]O 4BQPGVZ/3L >?<%@/'(E(+#8"P[ WKX$K"4[
MK@8"R[?@I)\3 XNZP'W&/#X%;GV^UW7\'38^>)O?,^ZI7 'Z4,R6H,D;3(!)
MLOR)H+S1(BN^@2^$UB(I+M=@)9-F +Q?"J'?;LQG]?J'FMG_4$L#!!0    (
M &] K5(1JN=^$@,  (D(   9    >&PO=V]R:W-H965T<R]S:&5E=#4V+GAM
M;(V6;4_;,!#'OXH5\0(D((F3-"UJ*_$@M$D@510V3=->N,VUL4CLS'8H?/N=
MW1#*FK:\:>S8=__?V;V[#%=2/>L<P)#7LA!ZY.7&5!>^K^<YE$R?RPH$KBRD
M*IG!J5KZNE+ ,F=4%CX-@IY?,BZ\\="]FZCQ4-:FX (FBNBZ+)EZNX)"KD9>
MZ+V_>.#+W-@7_GA8L25,P3Q5$X4SO_62\1*$YE(0!8N1=QE>7(74&K@=/SBL
M],:8V%!F4C[;R?=LY 66" J8&^N"X>,%KJ$HK"?D^-LX]5I-:[@Y?O=^ZX+'
M8&9,P[4L?O+,Y".O[Y$,%JPNS(-<?8,FH,3ZF\M"NU^R:O8&'IG7VLBR,4:"
MDHOUD[TV![%A0,,=!K0Q< ?AKX4<Y0TS;#Q4<D64W8W>[,"%ZJP1C@M[*U.C
M<)6CG1G?P,R0,S+%V\[J HA<D-O:U K(/1>\K$LR86]X"T83/$.3 WD$59([
MR80FQS=@&"_T"7J@09ANKAT1+LAC+FO-1*:'OD%8*^G/&["K-1C= 7;/U#F)
MPE-T3,.GZ0TY/CKY[,7'4-MX:1LO=6ZC'6[OI%B>&8MI(S\EMUS/64%^ 5/D
MGF'@W+R1WY<S;13^8?[L48Q:Q<@IQCL4+3\Y5F!3) -UTG44:P\]Y\'FT<LX
M3(+!T'_IT(U;W?B0+NW26ELE&UII%$?=6DFKE1S2BKJTDBVM?B\,N[5ZK5;O
MD%;<I=7;U@IHVJV5MEKI(:VD2RO=/D.:QMU:_5:KOU?K41K\(Y9-UF4V+ZLF
M];H0^EL($4U[.Q@&+<-@+\,=:'U!+DM9"X,U%^N\1GTNEIC,F#2@31?*8 OE
M+$G"'2AA\%&9@B_ N *5898Z)JPEMN:"4I"1><[4$KIK2[#-1&FT(Z7"C6H9
M?H'IND9]I*FD<JT%BV:!1<_>%YL5T D4;@/%O6 'ST<U"^E^G@W94R*PBR/+
M_#->)P[=JC@TQDO[C\??:"RV26-17G(L[@4LT"XX3S$>M>Y[ZXF1E>LU,VFP
M<[EACM\*H.P&7%](:=XGMGVU7Q_C?U!+ P04    " !O0*U2 3NXB(<'  !P
M)@  &0   'AL+W=O<FMS:&5E=',O<VAE970U-RYX;6RU6EMOV[@2_BN$L0NT
M0&*+%*G+(@G0QLXVQ5Z"9B\/BWU@)-H6JHN7HI)V<7[\(27&E"R)5C9U'N(;
M9^:;X?";T4@73P7_7&X9$^!+EN;EY6PKQ.Z'Q:*,MBRCY;S8L5S^LBYX1H7\
MR#>+<L<9C6NA+%T@Q_$6&4WRV=5%_=T=O[HH*I$F.;OCH*RRC/*O[UE:/%W.
MX.SYBT_)9BO4%XNKBQW=L'LF?M_=<?EIL=<2)QG+RZ3( 6?KR]D[^,-'XBN!
M>L4?"7LJ6^^!<N6A*#ZK#[?QY<Q1B%C*(J%44/GRR*Y9FBI-$L<_6NEL;U,)
MMM\_:[^IG9?./-"271?IGTDLMI>S8 9BMJ95*CX53Q^8=H@H?5&1EO5_\*37
M.C,05:4H,BTL$61)WKS2+SH0+0$$1P20%D!3!5PMX!X(N/Z( -8">*H T0)D
M*B1/"W@' GA,P-<"_E0+@18(IOH0:H'PT (>VSCG>>><.H.:+:_S94D%O;K@
MQ1/@:KW4I][425?+RS1)<G4^[@67OR923ERM_JD2\16<@U\HYU3E*GBS9((F
M:?GV8B&D!;5N$6EM[QMM:$3;NVHS!XYW!I"#G-_OE^#-=T-:KNU:/E;I'*#@
MF);E,2WY'$#8T?(=6(!R2SDKF_\#6E=VK4L62:TU-AA.UWHS(6YNC17ZXQ[_
M:-?R,^7/6A#46AX+P2;@^S!=LV5';B?$SGWQCGR<'#OD&'5=10MY+/9G ^W/
M!JHUNR.:[ZN',HD363;.P#U-&2C6X%X4T6?PUT]R*;@5+"O_MAAR]X;<VA >
M,U0C!DE95BP^ X\TK=C0]C=:O%J+*GR/5\@)0^@XSL7BL;V;_840XLZZ#DZ\
MQXFM.*]36I8J"D^*+'(!"@ZX*D!G0);>4M \3O(->)/D>A/>@O\-;D?C3F.,
MM%$BUP\<Z(TB)7NDQ(IT]87Q*"D9V/$D8C6BN$A3RDNP8[S!I,"-Y4L#L+$1
MM '.O6ZH/_;7H#G!P^B]/7K/BOY/'=XTH0])FHAD&)[7VV5,,"&]=+CM+T2!
M[P2C4?;W.'U[/A19)GN<4IV),QU'0"NQ+7CR+XLG)X+?2P39WC5_!YY,6=EQ
M)=B[$KS E1WES2G\KYG3&/-;.)VYQ @/W#FZK.-+N/<E?/FV-.1BW8:P?QXA
M"GW?<? ![H&5,IU\B' X#!TZIA]Q7@Z^S2XV#[3N*2X,+3WB0ZNG@E8??JFR
M!YDKDBA5^6TE#A!;*D#4<G%;I#&3N:5^9+E(1"HW21322R4ZZ"/L Q\!; H=
M1%; R^0QB5D>E_+2(I*Y+C%(:M_11+[F';R#B%"/7T9.(S05$=I+XI[ 91"U
M?5UT;)4=FDH&\6EK.S2E"-IKT3>NFMI:AP-#A+UPE .AJ3O07GAD+R4O.NI.
M"MQO6;H&G]@F*86Z,I [<"^H#(M,4UM<3/& _HFWP) [M+-[K?Y(&K_7.KSI
MQ04:1H9V2GXGSG_;LG/91W]F ORZ7C,N]]S6HQK"1,YIPX@,KR$[KTT)XXW6
MT0XCL481M?IQ.TT]NZ>+0[ZGV6Z-DP=)9FQ>TF8$,_5@:>/M@X5]QPOP8>D8
M6 @=+\2!-^*@83TTX4+@=3VKMM!N2/&<A(<N]%>A.1S#;U@5V2\0IE[(:#4'
M5S)##=_02FA+)D/+R$[+#<FIC'JWX:RF-7 .Y$$5+SNHAER1=^*#:J@5V1OS
M:0?5?^E!-7R+CO#MK^]OP5W%HRTM6_&U^6:H%(4GOBHWU.K:>]$I85QJ'9T,
M);8PNH9OW0E\>RJ^6[K]1I)@Z+GA&&[#T^X1GGXUC2VU!;]#8QXD(Q3EMD8M
M1RBV&U,)*9*923?UEX+EYS']*GOOM,H8>*JGZS+"])%QM:1QR;2DXTEA!P&1
MNL[[WI:DAG-=.^?^)"&<5SNPYD4&HK0H)5^=24]X-CA"LBN#X"NCW(;+\*MK
MY]=/+&;9KL[('6=94@WAN=9*.J,J3&RGQ_"M:V]FERQB]8%1HUIPD^0TC^Q<
M[AJ"=4_<N[J&2]W7]ZXKM]^[>L2SA='PK6MO74]*0BNW/TIP?<_%0>".S"H-
M>^,C[/UJ%EII"]T)(![A(&QX'=MY_=M>$:YPG\@1"H. C V2L&%R;&?RYTGD
M;;W)@\;[%__8\2V9APU58SM+*J/RS*KL+P\O^YLYMU;0:=FQS79KTFTGPHDC
M6-QO3YL)["@"PY_8SI\:P9D\61%GJH]Z$[/FW5MUVEA]Y^X,T*RH#ELK#:[/
MK>?0\P?:[ ]#2P.;&X:%\7]B89G0=YR=WU1Y+,E#^VKA2VRH&9^8FK&A9GQD
M:#Q^C@U-/H^M -,CK<ES\94VWT[OP,4(HF!D5PRI8SNI?Y/[(RMM9.K\FACJ
M)G;J'D\:/1X^GC#$L#&!ITT88NB4G+HQ7FD+$':"#A$9B;EA6S)QXOHZ>/W!
MPGC%)(:.B9V.U7UQ<'=[M[)M0^OF(#GQCAOZ(W;Z^U:WR+29%]SY(H8QR4MN
MX[WZWI>V=I05%JVG5M2S6#]3ODGR$J1L+06=N2^=Y<WC3<T'4>SJ!UD>"B&*
MK'Z[931F7"V0OZ^+0CQ_4,_&[!\RN_H_4$L#!!0    ( &] K5)J0,OOD@(
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M,TBS .<70NA-QY3^X:K/_@)02P,$%     @ ;T"M4C9TL-U, P  G@L  !D
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M*HT!/)\*H5\FID5K6_+A?U!+ P04    " !O0*U2AZ!F\F8&   F(   &0
M 'AL+W=O<FMS:&5E=',O<VAE970V,"YX;6S-6FMOVS84_2N$]T +M+%(ZMDE
M 1([;3*LA=$@[8=A'QB;MH5*HD=123/LQX^D%%&V*=I)5]0)$$LRS^4A[[WG
MDE2.[QG_4BXI%>!KGA7ER6 IQ.K-<%A.ES0GY1%;T4)^,V<\)T+>\L6P7'%*
M9AJ49T/D>>$P)VDQ.#W6SR;\])A5(DL+.N&@K/*<\(=SFK'[DP$</#[XF"Z6
M0CT8GAZOR()>4W&SFG!Y-VRMS-*<%F7*"L#I_&1P!M]<^KX"Z!:?4GI?=JZ!
M&LHM8U_4S=7L9. I1C2C4Z%,$/EQ1T<TRY0ER>/OQNB@[5,!N]>/UM_JP<O!
MW)*2CECV.9V)Y<D@'H 9G9,J$Q_9_25M!A0H>U.6E?HON&_:>@,PK4K!\@8L
M&>1I47^2K\U$= #2CAV &@#: * ^ &X >+,'OP?@-P!_7T#0 ()] 6$#"/<%
M1 T@VA<0-X!8>[=VA_;EF AR>LS9/>"JM;2F+G1 :+1T85JHV+T67'Z;2IPX
MO19L^@5<%5-:J" "DXP4)7@-/A#.B7[R8DP%2;/RI7QZ<ST&+WY^>3P4LFME
M8#AMNCFONT$]W4#PGA5B68*+8D9G%OS(C<<._% .N1TW>ASW.7(:_)T41P##
M5P!Y"-KXN.'O"7?"Q_O#/0O\P@T?TZD3_G:/WE&@X#"QP-^YX==TU<)C"_QR
MQ\Q7<N:1)@]#AR=Q&\%8V\-]=):$T]=*OV9@Q'(IZB71LG@F([A84"FT MP^
M@&Z["7G0C\_N"9^!/_^0)L&5H'GYEX.0WQ+R-2&_AY DD<ON2YU9I!)+QM-_
M9*>DF$FU+RF_DS>RZH!Y)2I.05J6%9$)"%ZD$J58EK8,&]6]!KI759+N3K&7
MH!@E,@3NNL&SW1 %,(@@3MJ&:P,+VH$%SH%IK?CUIQAYR6_U/$Z[\TV_JFMJ
MHU[;#3N,8!1[\F>=^=C2SO>2;KLUXF%+/'02ORDXG;)%H=U@XRS]DA$AOQ0,
M5,4=+=5UP8K7-%]E[('2QIMLI5"E;8CA%O4>TE%+.G*2OK!U#18RID7IB-*X
M-1\?1MHD+:'DAZ1-LI4-4023&$8;6;/=SD]@B"/?[D;HF0KKN1U9BC37T279
MSVFJV)= 5E=KJNPP!KTCS_O%,=VP4_FAT]1GO:Y3,WQ'N5RGUK$%9I(8F).4
M@SN2512P^7KPZ_F>L2PCO 0KRNNYMTY]0R#NYO-1DFPDO;55V*-5$)GAH>^0
M]/LG?-/]FEA!+6H]B0]-18/X:9Z1TYRR.OJ;02E:5E9NRP@\4.6W&.3U>@HB
MZ? 'EZ! 4_>@N_#=/$ZBC&_!TZFZK*>QDH2=?9@2!(/#D"UHB@MT5Y=W6I*!
MS(K&34](D' K]%$W0=89F<H!W:7#RL@AD8VY->T+XR#H"V138V#L)/*QJ]O[
M"G9CL\LFB:->,J:^0'>!Z2>SI[.2)S@+F?* W(JNEL%ZV^7:U1A11_ P\@,9
M(49N(?Y0Y;=R8E4=T4[O%G?EBGI)LR,J+IM.NE$!$?10$/8XP*@M<FNB@]\K
MF4-33N4L[0K:IH^U%,((Q<'F$M?2$/L!]A#J&8>17_1C]AW(LO% ?AR@GHQ$
M1LR1>T/1AC[X%SR_>""CU"@\D.0P4HW<4OVI'G0KU58'1+9M4?]" QE]1FY]
M?F*A.$?;THS#)-[<QXTL[1P2CHR$([>$:R=TIVMG[&ZOZF$BB?0PP4:UL5NU
MGU79&IM[3@LVHH_=*_DZ-E7^I,4"",IS:^]N(WZ]-'2=R!C)QV[)K_>N.F^N
MBEDUI<WEXREC37A'T<.=$Z #.0+"1HRQ6XS_EZ(WPMO2"W$08XQ[0L9(+W9+
M[W<J%F^;;M<.GSQO^ZCGG:4AA"HS^[+!J#QVK\?W#[YO*CO8:#R.#B0\C?!C
MM_!_PPYSAV7<[#!AO<,$X:[])3;JC]WJOW-';Z6;;!?/P%$\?5,"_!WG.M>3
MB>NXV,BW?R!K=M\(N/_L-?O^:V+?LF3W8B^"<&--;&D8AQ@%/4=OOBD,OGMI
M_]V.XK<7\9)M*'_71W9I:0@C[$4]FQ:_\X[!75^>?Q;?&%Y+"(M CW>WJZD/
M.R\?<\H7^D5T*>E4A:C?Q[5/VY?=9_H5[\;S$7PSKE]9&S/U&_3WA"_2H@09
MG4N3WE$DYY/7+Z7K&\%6^A7G+1."Y?IR2<F,<M5 ?C]G3#S>J [:?PTX_0]0
M2P,$%     @ ;T"M4AV:N"(' P  \P@  !D   !X;"]W;W)K<VAE971S+W-H
M965T-C$N>&ULS59=3]LP%/TK5L0#2$#2I%^@MA(M;$,:6D5A>YCVX":WC84_
M,MMM8;]^UTX:2M=6>T'BI?7'/2?GGNOXIK=2^LGD )8\"RY-/\BM+2[#T*0Y
M"&K.50$2=V9*"VIQJN>A*330S(,$#^,H:H>",AD,>GYMK <]M;"<21AK8A9"
M4/TR!*Y6_: 1K!?NV3RW;B$<] HZAPG8QV*L<1;6+!D3( U3DFB8]8.KQN6H
M$3F C_C.8&4VQL2E,E7JR4UNLWX0.47 (;6.@N+?$D; N6-"';\KTJ!^I@-N
MCM?LGWSRF,R4&A@I_H-E-N\'W8!D,*,+;N_5Z@M4";4<7ZJX\;]D5<5& 4D7
MQBI1@5&!8++\I\^5$1L Y-D-B"M O UH[@$D%2#QB9;*?%K7U-)!3ZL5T2X:
MV=S >^/1F V3KHP3JW&7(<X.)E:E3^16IB"=GV3,J33DC$SPO&0+#D3-B(\Y
M&Z)9&1DI@2?(4%^#FV<W!G(/G%K<M*J,)=\*MV\(E1EN&JM9:DNP0%@9<WP-
MEC)N3O!ICY-K<GQT0HX(D^0A5PN#2-,++6;H=(9IE<VPS";>DTU"[I2TN2$W
M,H/L+3Y$9VI[XK4]P_@@X1W5YR1IG)(XBAL[](S^'QX=D)/4U4H\7[*O6CG5
M<#;UE1C3%WR=++G2FLHYN/'INB*9=WY$"V8I9W\@.R570BTP^N=7I"2W%H3Y
M=4!0LQ;4](*:>P0]*'P ,?Z E++2S0,"I9Q=A2QYVY[7W37+0:/318^6F^[N
M"&I&%W70&\FM6G+KH&0\CT!UFGN+,ECB358X\PZXT:ZIVQ^C/)U:4.>=RE/R
MMC:<[[2:6]7Y-Z8=)[N+TZT%=P\*_@P2-$IV_M ,[SN&EP=U-],!-RYJ\HN/
M49Y&]'K[1N]4H(KXS;L1Q>VM$NV(ZG3;6S4*-]J' #WW7=6@$DRYO"KKU;IS
M7_E^M;4^=!W=MZ57FO)S "_".<.&P&&&E-%Y!T^-+CML.;&J\$UJJBRV/#_,
M\:L$M O _9E2=CUQ#ZB_<P9_ 5!+ P04    " !O0*U2N][JB2T#  #3"
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MV\0O&2P>M_IQJ4]4CO;Z\DE1N"<JG!'78R,;"!,CBH!P^%$]3T5TP?="ZOI
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M%7)=?0PN-&!VF:H_@+97VP_.5]5G5L<,K[]6?^)2ERT%2L1*F[K30*<OZP_
M]8G*M]4WU(=<J3RM#C>"1T*6 _3OJSQ7SR=E@/8S_.(?4$L#!!0    ( &]
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M9NZL395B8H5T>@W,G^%0;L:>W?!TRU1Z!>^^E]P\TP90"$L[H>&+R5"!R9B
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M4%2]5C51?&^:B0U7U)J884+]*0IM0-^WG*OGB=Z@Z7AG_P%02P,$%     @
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M=:HWWW%T&'BHV=.?/T=3RNM-Z0\2?^'UTM FSI<$CD/Y<YD.+J*-6XM;LY#
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M8BZ-&P"_+[2VVPOW)G/WNO[B7U!+ P04    " !O0*U2'NXGH:\"  !4"
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M\9!$ZQWX?&$,[38^0#=V\V=02P,$%     @ ;T"M4F 6G2>A @  00<  !D
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M;HB?:EB6/$S1>@<^7QI#NXT/T(WG_ U02P,$%     @ ;T"M4F T*#<& P
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MY2_+[YV3N_>"<WU;,3S]!5!+ P04    " !O0*U2'YV%;PD"  #8*@  $P
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M&5!+ 0(4 Q0    ( &] K5('04UB@0   +$    0              "  0
M  !D;V-0<F]P<R]A<' N>&UL4$L! A0#%     @ ;T"M4@4W^W/N    *P(
M !$              ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%
M  @ ;T"M4IE<G",0!@  G"<  !,              ( !S $  'AL+W1H96UE
M+W1H96UE,2YX;6Q02P$"% ,4    " !O0*U2BD^L"D8%   ,%@  &
M        @($-"   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%
M  @ ;T"M4NQ^O#8\!@  3AD  !@              ("!B0T  'AL+W=O<FMS
M:&5E=',O<VAE970R+GAM;%!+ 0(4 Q0    ( &] K5*''-W$V0(  (D)   8
M              " @?L3  !X;"]W;W)K<VAE971S+W-H965T,RYX;6Q02P$"
M% ,4    " !O0*U2>B' $,T$  #5$   &               @($*%P  >&PO
M=V]R:W-H965T<R]S:&5E=#0N>&UL4$L! A0#%     @ ;T"M4NAL7=]/!@
M2AX  !@              ("!#1P  'AL+W=O<FMS:&5E=',O<VAE970U+GAM
M;%!+ 0(4 Q0    ( &] K5*/[IA/0@<  -,=   8              " @9(B
M  !X;"]W;W)K<VAE971S+W-H965T-BYX;6Q02P$"% ,4    " !O0*U2/0++
M(VP-  "V)   &               @($**@  >&PO=V]R:W-H965T<R]S:&5E
M=#<N>&UL4$L! A0#%     @ ;T"M4M!  <S3!0  E \  !@
M ("!K#<  'AL+W=O<FMS:&5E=',O<VAE970X+GAM;%!+ 0(4 Q0    ( &]
MK5*>K'6H+@,  $4'   8              " @;4]  !X;"]W;W)K<VAE971S
M+W-H965T.2YX;6Q02P$"% ,4    " !O0*U2OCV_:M@#  #."   &0
M        @($900  >&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+ 0(4 Q0
M   ( &] K5)RXPM#7@D  #0;   9              " @2A%  !X;"]W;W)K
M<VAE971S+W-H965T,3$N>&UL4$L! A0#%     @ ;T"M4@\T0"#Q @  B@8
M !D              ("!O4X  'AL+W=O<FMS:&5E=',O<VAE970Q,BYX;6Q0
M2P$"% ,4    " !O0*U2_V#*6L$"  #U!0  &0              @('E40
M>&PO=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4 Q0    ( &] K5+690)2
M&08  !$/   9              " @=U4  !X;"]W;W)K<VAE971S+W-H965T
M,30N>&UL4$L! A0#%     @ ;T"M4K)F3 \J#@  N24  !D
M ("!+5L  'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q02P$"% ,4    " !O
M0*U2IP'#XGT,  !G(P  &0              @(&.:0  >&PO=V]R:W-H965T
M<R]S:&5E=#$V+GAM;%!+ 0(4 Q0    ( &] K5*$4:"X' L  .(@   9
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M970R,2YX;6Q02P$"% ,4    " !O0*U2\+!X_2,#   2!P  &0
M    @('4KP  >&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4 Q0    (
M &] K5(XPQ*WH@8  !80   9              " @2ZS  !X;"]W;W)K<VAE
M971S+W-H965T,C,N>&UL4$L! A0#%     @ ;T"M4MPK +@3!   ]0@  !D
M             ("!![H  'AL+W=O<FMS:&5E=',O<VAE970R-"YX;6Q02P$"
M% ,4    " !O0*U2]@#9^FH%   &#@  &0              @(%1O@  >&PO
M=V]R:W-H965T<R]S:&5E=#(U+GAM;%!+ 0(4 Q0    ( &] K5)C@3PAL0(
M ,\%   9              " @?+#  !X;"]W;W)K<VAE971S+W-H965T,C8N
M>&UL4$L! A0#%     @ ;T"M4D_/QKNB P  -0@  !D              ("!
MVL8  'AL+W=O<FMS:&5E=',O<VAE970R-RYX;6Q02P$"% ,4    " !O0*U2
M@;2TR1$%   D$   &0              @(&SR@  >&PO=V]R:W-H965T<R]S
M:&5E=#(X+GAM;%!+ 0(4 Q0    ( &] K5)[U()ZV (  "4&   9
M      " @?O/  !X;"]W;W)K<VAE971S+W-H965T,CDN>&UL4$L! A0#%
M  @ ;T"M4@:4KY_0 @  ^04  !D              ("!"M,  'AL+W=O<FMS
M:&5E=',O<VAE970S,"YX;6Q02P$"% ,4    " !O0*U2*,(]$U($  "]"P
M&0              @($1U@  >&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM;%!+
M 0(4 Q0    ( &] K5*MZXBPWP(   D&   9              " @9K:  !X
M;"]W;W)K<VAE971S+W-H965T,S(N>&UL4$L! A0#%     @ ;T"M4ACVD>5=
M P  9P<  !D              ("!L-T  'AL+W=O<FMS:&5E=',O<VAE970S
M,RYX;6Q02P$"% ,4    " !O0*U2AN44@.P%   :#P  &0
M@(%$X0  >&PO=V]R:W-H965T<R]S:&5E=#,T+GAM;%!+ 0(4 Q0    ( &]
MK5(551 9OP(  !L&   9              " @6?G  !X;"]W;W)K<VAE971S
M+W-H965T,S4N>&UL4$L! A0#%     @ ;T"M4F34JCZW @  '0<  !D
M         ("!7>H  'AL+W=O<FMS:&5E=',O<VAE970S-BYX;6Q02P$"% ,4
M    " !O0*U2U41\J?P"  !="P  &0              @(%+[0  >&PO=V]R
M:W-H965T<R]S:&5E=#,W+GAM;%!+ 0(4 Q0    ( &] K5+DD,[$:0(  +H%
M   9              " @7[P  !X;"]W;W)K<VAE971S+W-H965T,S@N>&UL
M4$L! A0#%     @ ;T"M4N2DZS_F @  B <  !D              ("!'O,
M 'AL+W=O<FMS:&5E=',O<VAE970S.2YX;6Q02P$"% ,4    " !O0*U2?GP>
M./X"  !X"0  &0              @($[]@  >&PO=V]R:W-H965T<R]S:&5E
M=#0P+GAM;%!+ 0(4 Q0    ( &] K5(2827]@ 4  ) B   9
M  " @7#Y  !X;"]W;W)K<VAE971S+W-H965T-#$N>&UL4$L! A0#%     @
M;T"M4A0<)K/: @  1@D  !D              ("!)_\  'AL+W=O<FMS:&5E
M=',O<VAE970T,BYX;6Q02P$"% ,4    " !O0*U2,]23.98"  #_!0  &0
M            @($X @$ >&PO=V]R:W-H965T<R]S:&5E=#0S+GAM;%!+ 0(4
M Q0    ( &] K5+(MFB^=P(  '4&   9              " @04% 0!X;"]W
M;W)K<VAE971S+W-H965T-#0N>&UL4$L! A0#%     @ ;T"M4G.T$K#; @
M40@  !D              ("!LP<! 'AL+W=O<FMS:&5E=',O<VAE970T-2YX
M;6Q02P$"% ,4    " !O0*U2(^UO$H(#  "K#@  &0              @('%
M"@$ >&PO=V]R:W-H965T<R]S:&5E=#0V+GAM;%!+ 0(4 Q0    ( &] K5()
MZ1[1/@(  "$%   9              " @7X. 0!X;"]W;W)K<VAE971S+W-H
M965T-#<N>&UL4$L! A0#%     @ ;T"M4B^CE+[] @  ^P@  !D
M     ("!\Q ! 'AL+W=O<FMS:&5E=',O<VAE970T."YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( &] K5):%(R!4 (  #0%   9              "
M@3(@ 0!X;"]W;W)K<VAE971S+W-H965T-3,N>&UL4$L! A0#%     @ ;T"M
M4G!B6D(K @  DP4  !D              ("!N2(! 'AL+W=O<FMS:&5E=',O
M<VAE970U-"YX;6Q02P$"% ,4    " !O0*U2L>&30M,%  "T&0  &0
M        @($;)0$ >&PO=V]R:W-H965T<R]S:&5E=#4U+GAM;%!+ 0(4 Q0
M   ( &] K5(1JN=^$@,  (D(   9              " @24K 0!X;"]W;W)K
M<VAE971S+W-H965T-38N>&UL4$L! A0#%     @ ;T"M4@$[N(B'!P  <"8
M !D              ("!;BX! 'AL+W=O<FMS:&5E=',O<VAE970U-RYX;6Q0
M2P$"% ,4    " !O0*U2:D#+[Y("  #V!P  &0              @($L-@$
M>&PO=V]R:W-H965T<R]S:&5E=#4X+GAM;%!+ 0(4 Q0    ( &] K5(V=+#=
M3 ,  )X+   9              " @?4X 0!X;"]W;W)K<VAE971S+W-H965T
M-3DN>&UL4$L! A0#%     @ ;T"M4H>@9O)F!@  )B   !D
M ("!>#P! 'AL+W=O<FMS:&5E=',O<VAE970V,"YX;6Q02P$"% ,4    " !O
M0*U2'9JX(@<#  #S"   &0              @($50P$ >&PO=V]R:W-H965T
M<R]S:&5E=#8Q+GAM;%!+ 0(4 Q0    ( &] K5*[WNJ)+0,  -,(   9
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M970V-BYX;6Q02P$"% ,4    " !O0*U2'NXGH:\"  !4"   &0
M    @($[7@$ >&PO=V]R:W-H965T<R]S:&5E=#8W+GAM;%!+ 0(4 Q0    (
M &] K5* &*685 (  ((%   9              " @2%A 0!X;"]W;W)K<VAE
M971S+W-H965T-C@N>&UL4$L! A0#%     @ ;T"M4F 6G2>A @  00<  !D
M             ("!K&,! 'AL+W=O<FMS:&5E=',O<VAE970V.2YX;6Q02P$"
M% ,4    " !O0*U2=:I@H\("  !=!P  &0              @(&$9@$ >&PO
M=V]R:W-H965T<R]S:&5E=#<P+GAM;%!+ 0(4 Q0    ( &] K5)L[\V7N0(
M .D%   9              " @7UI 0!X;"]W;W)K<VAE971S+W-H965T-S$N
M>&UL4$L! A0#%     @ ;T"M4K\#8BYA @  H@4  !D              ("!
M;6P! 'AL+W=O<FMS:&5E=',O<VAE970W,BYX;6Q02P$"% ,4    " !O0*U2
MX/*V%ED"  "J!0  &0              @($%;P$ >&PO=V]R:W-H965T<R]S
M:&5E=#<S+GAM;%!+ 0(4 Q0    ( &] K5)@-"@W!@,   ()   9
M      " @95Q 0!X;"]W;W)K<VAE971S+W-H965T-S0N>&UL4$L! A0#%
M  @ ;T"M4J-&W' R P  ]A,   T              ( !TG0! 'AL+W-T>6QE
M<RYX;6Q02P$"% ,4    " !O0*U2EXJ[',     3 @  "P
M@ $O> $ 7W)E;',O+G)E;'-02P$"% ,4    " !O0*U2,4'U"LD%  "5,
M#P              @ $8>0$ >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @
M;T"M4L?7<T]' @  U2L  !H              ( !#G\! 'AL+U]R96QS+W=O
M<FMB;V]K+GAM;"YR96QS4$L! A0#%     @ ;T"M4A^=A6\) @  V"H  !,
M             ( !C8$! %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&     %(
,4@!U%@  QX,!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.21.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>195</ContextCount>
  <ElementCount>392</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>72</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>7</UnitCount>
  <MyReports>
    <Report instance="selb-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.selectabio.com/role/Coverpage</Role>
      <ShortName>Cover page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="selb-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001002 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.selectabio.com/role/ConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="selb-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002003 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.selectabio.com/role/ConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="selb-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003004 - Statement - Consolidated Statements of Operations and Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.selectabio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss</Role>
      <ShortName>Consolidated Statements of Operations and Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="selb-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1004005 - Statement - Consolidated Statements of Changes in Stockholders??? (Deficit) Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.selectabio.com/role/ConsolidatedStatementsofChangesinStockholdersDeficitEquity</Role>
      <ShortName>Consolidated Statements of Changes in Stockholders??? (Deficit) Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="selb-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1005006 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.selectabio.com/role/ConsolidatedStatementsofCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="selb-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - Nature of the Business and Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.selectabio.com/role/NatureoftheBusinessandBasisofPresentation</Role>
      <ShortName>Nature of the Business and Basis of Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="selb-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2103102 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.selectabio.com/role/SummaryofSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="selb-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2105103 - Disclosure - Marketable Securities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.selectabio.com/role/MarketableSecurities</Role>
      <ShortName>Marketable Securities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="selb-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2109104 - Disclosure - Net Loss Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.selectabio.com/role/NetLossPerShare</Role>
      <ShortName>Net Loss Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="selb-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2113105 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.selectabio.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="selb-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2120106 - Disclosure - Property and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.selectabio.com/role/PropertyandEquipment</Role>
      <ShortName>Property and Equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="selb-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2124107 - Disclosure - Accrued Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.selectabio.com/role/AccruedExpenses</Role>
      <ShortName>Accrued Expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="selb-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2127108 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.selectabio.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="selb-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2135109 - Disclosure - Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.selectabio.com/role/Debt</Role>
      <ShortName>Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="selb-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2139110 - Disclosure - Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.selectabio.com/role/Equity</Role>
      <ShortName>Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="selb-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2144111 - Disclosure - Stock Incentive Plans</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.selectabio.com/role/StockIncentivePlans</Role>
      <ShortName>Stock Incentive Plans</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="selb-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2152112 - Disclosure - Revenue Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.selectabio.com/role/RevenueArrangements</Role>
      <ShortName>Revenue Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="selb-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2156113 - Disclosure - Related-Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.selectabio.com/role/RelatedPartyTransactions</Role>
      <ShortName>Related-Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="selb-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2158114 - Disclosure - Collaboration Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.selectabio.com/role/CollaborationAgreements</Role>
      <ShortName>Collaboration Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="selb-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2162115 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.selectabio.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="selb-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2164116 - Disclosure - Defined Contribution Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.selectabio.com/role/DefinedContributionPlan</Role>
      <ShortName>Defined Contribution Plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="selb-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2166117 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.selectabio.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="selb-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2167118 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.selectabio.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="selb-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2204201 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.selectabio.com/role/SummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.selectabio.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="selb-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2306301 - Disclosure - Marketable Securities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.selectabio.com/role/MarketableSecuritiesTables</Role>
      <ShortName>Marketable Securities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.selectabio.com/role/MarketableSecurities</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="selb-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2310302 - Disclosure - Net Loss Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.selectabio.com/role/NetLossPerShareTables</Role>
      <ShortName>Net Loss Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.selectabio.com/role/NetLossPerShare</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="selb-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2314303 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.selectabio.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.selectabio.com/role/FairValueMeasurements</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="selb-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2321304 - Disclosure - Property and Equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.selectabio.com/role/PropertyandEquipmentTables</Role>
      <ShortName>Property and Equipment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.selectabio.com/role/PropertyandEquipment</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="selb-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2325305 - Disclosure - Accrued Expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.selectabio.com/role/AccruedExpensesTables</Role>
      <ShortName>Accrued Expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.selectabio.com/role/AccruedExpenses</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="selb-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2328306 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.selectabio.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.selectabio.com/role/Leases</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="selb-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2336307 - Disclosure - Debt (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.selectabio.com/role/DebtTables</Role>
      <ShortName>Debt (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.selectabio.com/role/Debt</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="selb-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2340308 - Disclosure - Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.selectabio.com/role/EquityTables</Role>
      <ShortName>Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.selectabio.com/role/Equity</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="selb-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2345309 - Disclosure - Stock Incentive Plans (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.selectabio.com/role/StockIncentivePlansTables</Role>
      <ShortName>Stock Incentive Plans (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.selectabio.com/role/StockIncentivePlans</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="selb-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2353310 - Disclosure - Revenue Arrangements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.selectabio.com/role/RevenueArrangementsTables</Role>
      <ShortName>Revenue Arrangements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.selectabio.com/role/RevenueArrangements</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="selb-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2402401 - Disclosure - Nature of the Business and Basis of Presentation - Liquidity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.selectabio.com/role/NatureoftheBusinessandBasisofPresentationLiquidityDetails</Role>
      <ShortName>Nature of the Business and Basis of Presentation - Liquidity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.selectabio.com/role/NatureoftheBusinessandBasisofPresentation</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="selb-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2407402 - Disclosure - Marketable Securities - Summary of Available-for-Sale Marketable Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.selectabio.com/role/MarketableSecuritiesSummaryofAvailableforSaleMarketableSecuritiesDetails</Role>
      <ShortName>Marketable Securities - Summary of Available-for-Sale Marketable Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="selb-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2408403 - Disclosure - Marketable Securities - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.selectabio.com/role/MarketableSecuritiesNarrativeDetails</Role>
      <ShortName>Marketable Securities - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="selb-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2411404 - Disclosure - Net Loss Per Share - Computation of Basic and Diluted Net Loss Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.selectabio.com/role/NetLossPerShareComputationofBasicandDilutedNetLossPerShareDetails</Role>
      <ShortName>Net Loss Per Share - Computation of Basic and Diluted Net Loss Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="selb-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2412405 - Disclosure - Net Loss Per Share - Schedule of Potential Common Shares Issuable Upon Conversion of Warrants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.selectabio.com/role/NetLossPerShareScheduleofPotentialCommonSharesIssuableUponConversionofWarrantsDetails</Role>
      <ShortName>Net Loss Per Share - Schedule of Potential Common Shares Issuable Upon Conversion of Warrants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="selb-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2415406 - Disclosure - Fair Value Measurements - Summary of Assets Measured at Fair Value on a Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.selectabio.com/role/FairValueMeasurementsSummaryofAssetsMeasuredatFairValueonaRecurringBasisDetails</Role>
      <ShortName>Fair Value Measurements - Summary of Assets Measured at Fair Value on a Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="selb-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2416407 - Disclosure - Fair Value Measurements - Assumptions used to record the fair value of the warrants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.selectabio.com/role/FairValueMeasurementsAssumptionsusedtorecordthefairvalueofthewarrantsDetails</Role>
      <ShortName>Fair Value Measurements - Assumptions used to record the fair value of the warrants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="selb-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2417408 - Disclosure - Fair Value Measurements - Change in the warrant liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.selectabio.com/role/FairValueMeasurementsChangeinthewarrantliabilitiesDetails</Role>
      <ShortName>Fair Value Measurements - Change in the warrant liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="selb-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2418409 - Disclosure - Fair Value Measurements - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.selectabio.com/role/FairValueMeasurementsNarrativeDetails</Role>
      <ShortName>Fair Value Measurements - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="selb-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2419410 - Disclosure - Fair Value Measurements - Schedule of Cash and Cash Equivalents (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.selectabio.com/role/FairValueMeasurementsScheduleofCashandCashEquivalentsDetails</Role>
      <ShortName>Fair Value Measurements - Schedule of Cash and Cash Equivalents (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="selb-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2422411 - Disclosure - Property and Equipment - Schedule of Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.selectabio.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails</Role>
      <ShortName>Property and Equipment - Schedule of Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="selb-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>2423412 - Disclosure - Property and Equipment - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.selectabio.com/role/PropertyandEquipmentNarrativeDetails</Role>
      <ShortName>Property and Equipment - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="selb-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>2426413 - Disclosure - Accrued Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.selectabio.com/role/AccruedExpensesDetails</Role>
      <ShortName>Accrued Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.selectabio.com/role/AccruedExpensesTables</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="selb-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>2429414 - Disclosure - Leases - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.selectabio.com/role/LeasesNarrativeDetails</Role>
      <ShortName>Leases - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="selb-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>2430415 - Disclosure - Leases - Components of Operating Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.selectabio.com/role/LeasesComponentsofOperatingLeasesDetails</Role>
      <ShortName>Leases - Components of Operating Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="selb-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>2431416 - Disclosure - Leases - Components of lease costs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.selectabio.com/role/LeasesComponentsofleasecostsDetails</Role>
      <ShortName>Leases - Components of lease costs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="selb-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>2432417 - Disclosure - Leases - Operating Lease, Liability, Maturity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.selectabio.com/role/LeasesOperatingLeaseLiabilityMaturityDetails</Role>
      <ShortName>Leases - Operating Lease, Liability, Maturity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="selb-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>2433418 - Disclosure - Leases - Other Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.selectabio.com/role/LeasesOtherInformationDetails</Role>
      <ShortName>Leases - Other Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="selb-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>2434419 - Disclosure - Leases - Lease Term and Discount Rate (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.selectabio.com/role/LeasesLeaseTermandDiscountRateDetails</Role>
      <ShortName>Leases - Lease Term and Discount Rate (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="selb-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>2437420 - Disclosure - Debt - Term Loans (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.selectabio.com/role/DebtTermLoansNarrativeDetails</Role>
      <ShortName>Debt - Term Loans (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="selb-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>2438421 - Disclosure - Debt - Schedule of Future Minimum Payments on the Term Loans (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.selectabio.com/role/DebtScheduleofFutureMinimumPaymentsontheTermLoansDetails</Role>
      <ShortName>Debt - Schedule of Future Minimum Payments on the Term Loans (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="selb-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>2441422 - Disclosure - Equity - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.selectabio.com/role/EquityNarrativeDetails</Role>
      <ShortName>Equity - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="selb-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>2442423 - Disclosure - Equity - Warranty Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.selectabio.com/role/EquityWarrantyActivityDetails</Role>
      <ShortName>Equity - Warranty Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="selb-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>2443424 - Disclosure - Equity - Schedule of Authorized Shares of Common Stock for Future Issuance (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.selectabio.com/role/EquityScheduleofAuthorizedSharesofCommonStockforFutureIssuanceDetails</Role>
      <ShortName>Equity - Schedule of Authorized Shares of Common Stock for Future Issuance (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="selb-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>2446425 - Disclosure - Stock Incentive Plans - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.selectabio.com/role/StockIncentivePlansNarrativeDetails</Role>
      <ShortName>Stock Incentive Plans - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="selb-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>2447426 - Disclosure - Stock Incentive Plans - Schedule of Stock-Based Compensation Expense Related to Stock Options and Restricted Common Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.selectabio.com/role/StockIncentivePlansScheduleofStockBasedCompensationExpenseRelatedtoStockOptionsandRestrictedCommonStockDetails</Role>
      <ShortName>Stock Incentive Plans - Schedule of Stock-Based Compensation Expense Related to Stock Options and Restricted Common Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="selb-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>2448427 - Disclosure - Stock Incentive Plans - Schedule of Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.selectabio.com/role/StockIncentivePlansScheduleofAssumptionsDetails</Role>
      <ShortName>Stock Incentive Plans - Schedule of Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="selb-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>2449428 - Disclosure - Stock Incentive Plans - Summary of Options Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.selectabio.com/role/StockIncentivePlansSummaryofOptionsActivityDetails</Role>
      <ShortName>Stock Incentive Plans - Summary of Options Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="selb-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>2450429 - Disclosure - Stock Incentive Plans - Restricted Stock Units (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.selectabio.com/role/StockIncentivePlansRestrictedStockUnitsDetails</Role>
      <ShortName>Stock Incentive Plans - Restricted Stock Units (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="selb-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>2451430 - Disclosure - Stock Incentive Plans - Employee Stock Purchase Plan (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.selectabio.com/role/StockIncentivePlansEmployeeStockPurchasePlanNarrativeDetails</Role>
      <ShortName>Stock Incentive Plans - Employee Stock Purchase Plan (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="selb-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>2454431 - Disclosure - Revenue Arrangements - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.selectabio.com/role/RevenueArrangementsNarrativeDetails</Role>
      <ShortName>Revenue Arrangements - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="selb-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>2455432 - Disclosure - Revenue Arrangements - Schedule of Changes in Contract Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.selectabio.com/role/RevenueArrangementsScheduleofChangesinContractLiabilitiesDetails</Role>
      <ShortName>Revenue Arrangements - Schedule of Changes in Contract Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="selb-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>2457433 - Disclosure - Related-Party Transactions - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.selectabio.com/role/RelatedPartyTransactionsNarrativeDetails</Role>
      <ShortName>Related-Party Transactions - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="selb-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>2459434 - Disclosure - Collaboration Agreements - AskBio (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.selectabio.com/role/CollaborationAgreementsAskBioNarrativeDetails</Role>
      <ShortName>Collaboration Agreements - AskBio (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="selb-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>2460435 - Disclosure - Collaboration Agreements - MIT (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.selectabio.com/role/CollaborationAgreementsMITNarrativeDetails</Role>
      <ShortName>Collaboration Agreements - MIT (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.selectabio.com/role/CollaborationAgreements</ParentRole>
      <Position>70</Position>
    </Report>
    <Report instance="selb-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>2461436 - Disclosure - Collaboration Agreements - Shenyang Sunshine Pharmaceutical Co., Ltd (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.selectabio.com/role/CollaborationAgreementsShenyangSunshinePharmaceuticalCoLtdNarrativeDetails</Role>
      <ShortName>Collaboration Agreements - Shenyang Sunshine Pharmaceutical Co., Ltd (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report instance="selb-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>2463437 - Disclosure - Income Taxes - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.selectabio.com/role/IncomeTaxesNarrativeDetails</Role>
      <ShortName>Income Taxes - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>72</Position>
    </Report>
    <Report instance="selb-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>2465438 - Disclosure - Defined Contribution Plan - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.selectabio.com/role/DefinedContributionPlanNarrativeDetails</Role>
      <ShortName>Defined Contribution Plan - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>73</Position>
    </Report>
    <Report instance="selb-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>2468439 - Disclosure - Subsequent Events (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.selectabio.com/role/SubsequentEventsDetails</Role>
      <ShortName>Subsequent Events (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.selectabio.com/role/SubsequentEvents</ParentRole>
      <Position>74</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="selb-20210331.htm">selb-20210331.htm</File>
    <File>exhibit101_dircompprogram.htm</File>
    <File>exhibit311_03312021.htm</File>
    <File>exhibit312_03312021.htm</File>
    <File>exhibit321_03312021.htm</File>
    <File>exhibit322_03312021.htm</File>
    <File>selb-20210331.xsd</File>
    <File>selb-20210331_cal.xml</File>
    <File>selb-20210331_def.xml</File>
    <File>selb-20210331_lab.xml</File>
    <File>selb-20210331_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/country/2020-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>92
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "selb-20210331.htm": {
   "axisCustom": 1,
   "axisStandard": 23,
   "contextCount": 195,
   "dts": {
    "calculationLink": {
     "local": [
      "selb-20210331_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "selb-20210331_def.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml",
      "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "selb-20210331.htm"
     ]
    },
    "labelLink": {
     "local": [
      "selb-20210331_lab.xml"
     ],
     "remote": [
      "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-doc-2020-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "selb-20210331_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-ref-2020-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "selb-20210331.xsd"
     ],
     "remote": [
      "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd",
      "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd",
      "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-parts-codification-2020-01-31.xsd"
     ]
    }
   },
   "elementCount": 535,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2020-01-31": 5,
    "total": 5
   },
   "keyCustom": 50,
   "keyStandard": 342,
   "memberCustom": 28,
   "memberStandard": 39,
   "nsprefix": "selb",
   "nsuri": "http://www.selectabio.com/20210331",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "selb-20210331.htm",
      "contextRef": "i93f17f89c13f486486776019ba38a82f_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover page",
     "role": "http://www.selectabio.com/role/Coverpage",
     "shortName": "Cover page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "selb-20210331.htm",
      "contextRef": "i93f17f89c13f486486776019ba38a82f_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "selb-20210331.htm",
      "contextRef": "i93f17f89c13f486486776019ba38a82f_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2109104 - Disclosure - Net Loss Per Share",
     "role": "http://www.selectabio.com/role/NetLossPerShare",
     "shortName": "Net Loss Per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "selb-20210331.htm",
      "contextRef": "i93f17f89c13f486486776019ba38a82f_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "selb-20210331.htm",
      "contextRef": "i93f17f89c13f486486776019ba38a82f_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2113105 - Disclosure - Fair Value Measurements",
     "role": "http://www.selectabio.com/role/FairValueMeasurements",
     "shortName": "Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "selb-20210331.htm",
      "contextRef": "i93f17f89c13f486486776019ba38a82f_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "selb-20210331.htm",
      "contextRef": "i93f17f89c13f486486776019ba38a82f_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2120106 - Disclosure - Property and Equipment",
     "role": "http://www.selectabio.com/role/PropertyandEquipment",
     "shortName": "Property and Equipment",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "selb-20210331.htm",
      "contextRef": "i93f17f89c13f486486776019ba38a82f_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "selb-20210331.htm",
      "contextRef": "i93f17f89c13f486486776019ba38a82f_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2124107 - Disclosure - Accrued Expenses",
     "role": "http://www.selectabio.com/role/AccruedExpenses",
     "shortName": "Accrued Expenses",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "selb-20210331.htm",
      "contextRef": "i93f17f89c13f486486776019ba38a82f_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "selb-20210331.htm",
      "contextRef": "i93f17f89c13f486486776019ba38a82f_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2127108 - Disclosure - Leases",
     "role": "http://www.selectabio.com/role/Leases",
     "shortName": "Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "selb-20210331.htm",
      "contextRef": "i93f17f89c13f486486776019ba38a82f_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "selb-20210331.htm",
      "contextRef": "i93f17f89c13f486486776019ba38a82f_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2135109 - Disclosure - Debt",
     "role": "http://www.selectabio.com/role/Debt",
     "shortName": "Debt",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "selb-20210331.htm",
      "contextRef": "i93f17f89c13f486486776019ba38a82f_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "selb-20210331.htm",
      "contextRef": "i93f17f89c13f486486776019ba38a82f_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2139110 - Disclosure - Equity",
     "role": "http://www.selectabio.com/role/Equity",
     "shortName": "Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "selb-20210331.htm",
      "contextRef": "i93f17f89c13f486486776019ba38a82f_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "selb-20210331.htm",
      "contextRef": "i93f17f89c13f486486776019ba38a82f_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2144111 - Disclosure - Stock Incentive Plans",
     "role": "http://www.selectabio.com/role/StockIncentivePlans",
     "shortName": "Stock Incentive Plans",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "selb-20210331.htm",
      "contextRef": "i93f17f89c13f486486776019ba38a82f_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "selb-20210331.htm",
      "contextRef": "i93f17f89c13f486486776019ba38a82f_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2152112 - Disclosure - Revenue Arrangements",
     "role": "http://www.selectabio.com/role/RevenueArrangements",
     "shortName": "Revenue Arrangements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "selb-20210331.htm",
      "contextRef": "i93f17f89c13f486486776019ba38a82f_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "selb-20210331.htm",
      "contextRef": "i93f17f89c13f486486776019ba38a82f_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2156113 - Disclosure - Related-Party Transactions",
     "role": "http://www.selectabio.com/role/RelatedPartyTransactions",
     "shortName": "Related-Party Transactions",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "selb-20210331.htm",
      "contextRef": "i93f17f89c13f486486776019ba38a82f_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "selb-20210331.htm",
      "contextRef": "ied8d945ebce54ed8a4badfed477a64e8_I20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001002 - Statement - Consolidated Balance Sheets",
     "role": "http://www.selectabio.com/role/ConsolidatedBalanceSheets",
     "shortName": "Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "selb-20210331.htm",
      "contextRef": "ied8d945ebce54ed8a4badfed477a64e8_I20210331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "selb-20210331.htm",
      "contextRef": "i93f17f89c13f486486776019ba38a82f_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "selb:CollaborationAndLicenseAgreementsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2158114 - Disclosure - Collaboration Agreements",
     "role": "http://www.selectabio.com/role/CollaborationAgreements",
     "shortName": "Collaboration Agreements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "selb-20210331.htm",
      "contextRef": "i93f17f89c13f486486776019ba38a82f_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "selb:CollaborationAndLicenseAgreementsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "selb-20210331.htm",
      "contextRef": "i93f17f89c13f486486776019ba38a82f_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2162115 - Disclosure - Income Taxes",
     "role": "http://www.selectabio.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "selb-20210331.htm",
      "contextRef": "i93f17f89c13f486486776019ba38a82f_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "selb-20210331.htm",
      "contextRef": "i93f17f89c13f486486776019ba38a82f_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2164116 - Disclosure - Defined Contribution Plan",
     "role": "http://www.selectabio.com/role/DefinedContributionPlan",
     "shortName": "Defined Contribution Plan",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "selb-20210331.htm",
      "contextRef": "i93f17f89c13f486486776019ba38a82f_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "selb-20210331.htm",
      "contextRef": "i93f17f89c13f486486776019ba38a82f_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2166117 - Disclosure - Commitments and Contingencies",
     "role": "http://www.selectabio.com/role/CommitmentsandContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "selb-20210331.htm",
      "contextRef": "i93f17f89c13f486486776019ba38a82f_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "selb-20210331.htm",
      "contextRef": "i93f17f89c13f486486776019ba38a82f_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2167118 - Disclosure - Subsequent Events",
     "role": "http://www.selectabio.com/role/SubsequentEvents",
     "shortName": "Subsequent Events",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "selb-20210331.htm",
      "contextRef": "i93f17f89c13f486486776019ba38a82f_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "selb-20210331.htm",
      "contextRef": "i93f17f89c13f486486776019ba38a82f_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2204201 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "role": "http://www.selectabio.com/role/SummaryofSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "selb-20210331.htm",
      "contextRef": "i93f17f89c13f486486776019ba38a82f_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "selb-20210331.htm",
      "contextRef": "i93f17f89c13f486486776019ba38a82f_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2306301 - Disclosure - Marketable Securities (Tables)",
     "role": "http://www.selectabio.com/role/MarketableSecuritiesTables",
     "shortName": "Marketable Securities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "selb-20210331.htm",
      "contextRef": "i93f17f89c13f486486776019ba38a82f_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "selb-20210331.htm",
      "contextRef": "i93f17f89c13f486486776019ba38a82f_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2310302 - Disclosure - Net Loss Per Share (Tables)",
     "role": "http://www.selectabio.com/role/NetLossPerShareTables",
     "shortName": "Net Loss Per Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "selb-20210331.htm",
      "contextRef": "i93f17f89c13f486486776019ba38a82f_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "selb-20210331.htm",
      "contextRef": "i93f17f89c13f486486776019ba38a82f_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2314303 - Disclosure - Fair Value Measurements (Tables)",
     "role": "http://www.selectabio.com/role/FairValueMeasurementsTables",
     "shortName": "Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "selb-20210331.htm",
      "contextRef": "i93f17f89c13f486486776019ba38a82f_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "selb-20210331.htm",
      "contextRef": "i93f17f89c13f486486776019ba38a82f_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2321304 - Disclosure - Property and Equipment (Tables)",
     "role": "http://www.selectabio.com/role/PropertyandEquipmentTables",
     "shortName": "Property and Equipment (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "selb-20210331.htm",
      "contextRef": "i93f17f89c13f486486776019ba38a82f_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "selb-20210331.htm",
      "contextRef": "ied8d945ebce54ed8a4badfed477a64e8_I20210331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002003 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "role": "http://www.selectabio.com/role/ConsolidatedBalanceSheetsParenthetical",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "selb-20210331.htm",
      "contextRef": "ied8d945ebce54ed8a4badfed477a64e8_I20210331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "selb-20210331.htm",
      "contextRef": "i93f17f89c13f486486776019ba38a82f_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2325305 - Disclosure - Accrued Expenses (Tables)",
     "role": "http://www.selectabio.com/role/AccruedExpensesTables",
     "shortName": "Accrued Expenses (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "selb-20210331.htm",
      "contextRef": "i93f17f89c13f486486776019ba38a82f_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "selb-20210331.htm",
      "contextRef": "i93f17f89c13f486486776019ba38a82f_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "selb:LesseeComponentsOfOperatingLeaseTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2328306 - Disclosure - Leases (Tables)",
     "role": "http://www.selectabio.com/role/LeasesTables",
     "shortName": "Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "selb-20210331.htm",
      "contextRef": "i93f17f89c13f486486776019ba38a82f_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "selb:LesseeComponentsOfOperatingLeaseTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "selb-20210331.htm",
      "contextRef": "i93f17f89c13f486486776019ba38a82f_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2336307 - Disclosure - Debt (Tables)",
     "role": "http://www.selectabio.com/role/DebtTables",
     "shortName": "Debt (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "selb-20210331.htm",
      "contextRef": "i93f17f89c13f486486776019ba38a82f_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "selb-20210331.htm",
      "contextRef": "i93f17f89c13f486486776019ba38a82f_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2340308 - Disclosure - Equity (Tables)",
     "role": "http://www.selectabio.com/role/EquityTables",
     "shortName": "Equity (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "selb-20210331.htm",
      "contextRef": "i93f17f89c13f486486776019ba38a82f_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "selb-20210331.htm",
      "contextRef": "i93f17f89c13f486486776019ba38a82f_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2345309 - Disclosure - Stock Incentive Plans (Tables)",
     "role": "http://www.selectabio.com/role/StockIncentivePlansTables",
     "shortName": "Stock Incentive Plans (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "selb-20210331.htm",
      "contextRef": "i93f17f89c13f486486776019ba38a82f_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "selb-20210331.htm",
      "contextRef": "i93f17f89c13f486486776019ba38a82f_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2353310 - Disclosure - Revenue Arrangements (Tables)",
     "role": "http://www.selectabio.com/role/RevenueArrangementsTables",
     "shortName": "Revenue Arrangements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "selb-20210331.htm",
      "contextRef": "i93f17f89c13f486486776019ba38a82f_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "selb-20210331.htm",
      "contextRef": "ied8d945ebce54ed8a4badfed477a64e8_I20210331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "selb:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndDebtSecuritiesAvailableForSale",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402401 - Disclosure - Nature of the Business and Basis of Presentation - Liquidity (Details)",
     "role": "http://www.selectabio.com/role/NatureoftheBusinessandBasisofPresentationLiquidityDetails",
     "shortName": "Nature of the Business and Basis of Presentation - Liquidity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "selb-20210331.htm",
      "contextRef": "ied8d945ebce54ed8a4badfed477a64e8_I20210331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "selb:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndDebtSecuritiesAvailableForSale",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "selb-20210331.htm",
      "contextRef": "ied8d945ebce54ed8a4badfed477a64e8_I20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2407402 - Disclosure - Marketable Securities - Summary of Available-for-Sale Marketable Securities (Details)",
     "role": "http://www.selectabio.com/role/MarketableSecuritiesSummaryofAvailableforSaleMarketableSecuritiesDetails",
     "shortName": "Marketable Securities - Summary of Available-for-Sale Marketable Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "selb-20210331.htm",
      "contextRef": "ied8d945ebce54ed8a4badfed477a64e8_I20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "selb-20210331.htm",
      "contextRef": "i93f17f89c13f486486776019ba38a82f_D20210101-20210331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2408403 - Disclosure - Marketable Securities - Narrative (Details)",
     "role": "http://www.selectabio.com/role/MarketableSecuritiesNarrativeDetails",
     "shortName": "Marketable Securities - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "selb-20210331.htm",
      "contextRef": "i93f17f89c13f486486776019ba38a82f_D20210101-20210331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "selb-20210331.htm",
      "contextRef": "i93f17f89c13f486486776019ba38a82f_D20210101-20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2411404 - Disclosure - Net Loss Per Share - Computation of Basic and Diluted Net Loss Per Share (Details)",
     "role": "http://www.selectabio.com/role/NetLossPerShareComputationofBasicandDilutedNetLossPerShareDetails",
     "shortName": "Net Loss Per Share - Computation of Basic and Diluted Net Loss Per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "selb-20210331.htm",
      "contextRef": "i93f17f89c13f486486776019ba38a82f_D20210101-20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "selb-20210331.htm",
      "contextRef": "i93f17f89c13f486486776019ba38a82f_D20210101-20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003004 - Statement - Consolidated Statements of Operations and Comprehensive Loss",
     "role": "http://www.selectabio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
     "shortName": "Consolidated Statements of Operations and Comprehensive Loss",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "selb-20210331.htm",
      "contextRef": "i93f17f89c13f486486776019ba38a82f_D20210101-20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "selb-20210331.htm",
      "contextRef": "i93f17f89c13f486486776019ba38a82f_D20210101-20210331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2412405 - Disclosure - Net Loss Per Share - Schedule of Potential Common Shares Issuable Upon Conversion of Warrants (Details)",
     "role": "http://www.selectabio.com/role/NetLossPerShareScheduleofPotentialCommonSharesIssuableUponConversionofWarrantsDetails",
     "shortName": "Net Loss Per Share - Schedule of Potential Common Shares Issuable Upon Conversion of Warrants (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "selb-20210331.htm",
      "contextRef": "i93f17f89c13f486486776019ba38a82f_D20210101-20210331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "selb-20210331.htm",
      "contextRef": "ied8d945ebce54ed8a4badfed477a64e8_I20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2415406 - Disclosure - Fair Value Measurements - Summary of Assets Measured at Fair Value on a Recurring Basis (Details)",
     "role": "http://www.selectabio.com/role/FairValueMeasurementsSummaryofAssetsMeasuredatFairValueonaRecurringBasisDetails",
     "shortName": "Fair Value Measurements - Summary of Assets Measured at Fair Value on a Recurring Basis (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "selb-20210331.htm",
      "contextRef": "ief7e41d172914136a4d75381f191624f_I20210331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "selb-20210331.htm",
      "contextRef": "i09c393762b464d30a19a24b55c2f5d20_I20210331",
      "decimals": "4",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:WarrantsAndRightsOutstandingMeasurementInput",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2416407 - Disclosure - Fair Value Measurements - Assumptions used to record the fair value of the warrants (Details)",
     "role": "http://www.selectabio.com/role/FairValueMeasurementsAssumptionsusedtorecordthefairvalueofthewarrantsDetails",
     "shortName": "Fair Value Measurements - Assumptions used to record the fair value of the warrants (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "selb-20210331.htm",
      "contextRef": "i09c393762b464d30a19a24b55c2f5d20_I20210331",
      "decimals": "4",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:WarrantsAndRightsOutstandingMeasurementInput",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "selb-20210331.htm",
      "contextRef": "i118f57dc685b47c8b1b5f190c4eed731_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2417408 - Disclosure - Fair Value Measurements - Change in the warrant liabilities (Details)",
     "role": "http://www.selectabio.com/role/FairValueMeasurementsChangeinthewarrantliabilitiesDetails",
     "shortName": "Fair Value Measurements - Change in the warrant liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "selb-20210331.htm",
      "contextRef": "i118f57dc685b47c8b1b5f190c4eed731_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "selb-20210331.htm",
      "contextRef": "i93f17f89c13f486486776019ba38a82f_D20210101-20210331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2418409 - Disclosure - Fair Value Measurements - Narrative (Details)",
     "role": "http://www.selectabio.com/role/FairValueMeasurementsNarrativeDetails",
     "shortName": "Fair Value Measurements - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "selb-20210331.htm",
      "contextRef": "i93f17f89c13f486486776019ba38a82f_D20210101-20210331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "selb-20210331.htm",
      "contextRef": "ied8d945ebce54ed8a4badfed477a64e8_I20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2419410 - Disclosure - Fair Value Measurements - Schedule of Cash and Cash Equivalents (Details)",
     "role": "http://www.selectabio.com/role/FairValueMeasurementsScheduleofCashandCashEquivalentsDetails",
     "shortName": "Fair Value Measurements - Schedule of Cash and Cash Equivalents (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "selb-20210331.htm",
      "contextRef": "iff7e2530342c41bca8c84fce55f0cc6f_I20200331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "selb-20210331.htm",
      "contextRef": "ied8d945ebce54ed8a4badfed477a64e8_I20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2422411 - Disclosure - Property and Equipment - Schedule of Property and Equipment (Details)",
     "role": "http://www.selectabio.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails",
     "shortName": "Property and Equipment - Schedule of Property and Equipment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "selb-20210331.htm",
      "contextRef": "ied8d945ebce54ed8a4badfed477a64e8_I20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "selb-20210331.htm",
      "contextRef": "i93f17f89c13f486486776019ba38a82f_D20210101-20210331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2423412 - Disclosure - Property and Equipment - Narrative (Details)",
     "role": "http://www.selectabio.com/role/PropertyandEquipmentNarrativeDetails",
     "shortName": "Property and Equipment - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "selb-20210331.htm",
      "contextRef": "i93f17f89c13f486486776019ba38a82f_D20210101-20210331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "selb-20210331.htm",
      "contextRef": "ied8d945ebce54ed8a4badfed477a64e8_I20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2426413 - Disclosure - Accrued Expenses (Details)",
     "role": "http://www.selectabio.com/role/AccruedExpensesDetails",
     "shortName": "Accrued Expenses (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "selb-20210331.htm",
      "contextRef": "ied8d945ebce54ed8a4badfed477a64e8_I20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "selb-20210331.htm",
      "contextRef": "i93f17f89c13f486486776019ba38a82f_D20210101-20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCost",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2429414 - Disclosure - Leases - Narrative (Details)",
     "role": "http://www.selectabio.com/role/LeasesNarrativeDetails",
     "shortName": "Leases - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "selb-20210331.htm",
      "contextRef": "i8a6242358159403bbb0d1d272fafb3bc_I20190731",
      "decimals": "0",
      "lang": "en-US",
      "name": "us-gaap:AreaOfRealEstateProperty",
      "reportCount": 1,
      "unique": true,
      "unitRef": "sqft",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "selb-20210331.htm",
      "contextRef": "i8f5d5586be294d54be1415ab00417669_I20191231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004005 - Statement - Consolidated Statements of Changes in Stockholders\u2019 (Deficit) Equity",
     "role": "http://www.selectabio.com/role/ConsolidatedStatementsofChangesinStockholdersDeficitEquity",
     "shortName": "Consolidated Statements of Changes in Stockholders\u2019 (Deficit) Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "selb-20210331.htm",
      "contextRef": "i8f5d5586be294d54be1415ab00417669_I20191231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "selb-20210331.htm",
      "contextRef": "ied8d945ebce54ed8a4badfed477a64e8_I20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2430415 - Disclosure - Leases - Components of Operating Leases (Details)",
     "role": "http://www.selectabio.com/role/LeasesComponentsofOperatingLeasesDetails",
     "shortName": "Leases - Components of Operating Leases (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "selb-20210331.htm",
      "contextRef": "i93f17f89c13f486486776019ba38a82f_D20210101-20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2431416 - Disclosure - Leases - Components of lease costs (Details)",
     "role": "http://www.selectabio.com/role/LeasesComponentsofleasecostsDetails",
     "shortName": "Leases - Components of lease costs (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "selb-20210331.htm",
      "contextRef": "i93f17f89c13f486486776019ba38a82f_D20210101-20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "selb-20210331.htm",
      "contextRef": "ied8d945ebce54ed8a4badfed477a64e8_I20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2432417 - Disclosure - Leases - Operating Lease, Liability, Maturity (Details)",
     "role": "http://www.selectabio.com/role/LeasesOperatingLeaseLiabilityMaturityDetails",
     "shortName": "Leases - Operating Lease, Liability, Maturity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "selb-20210331.htm",
      "contextRef": "ied8d945ebce54ed8a4badfed477a64e8_I20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:OperatingLeaseLeaseIncomeTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "selb-20210331.htm",
      "contextRef": "i93f17f89c13f486486776019ba38a82f_D20210101-20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2433418 - Disclosure - Leases - Other Information (Details)",
     "role": "http://www.selectabio.com/role/LeasesOtherInformationDetails",
     "shortName": "Leases - Other Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:OperatingLeaseLeaseIncomeTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "selb-20210331.htm",
      "contextRef": "i93f17f89c13f486486776019ba38a82f_D20210101-20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "selb-20210331.htm",
      "contextRef": "ied8d945ebce54ed8a4badfed477a64e8_I20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2434419 - Disclosure - Leases - Lease Term and Discount Rate (Details)",
     "role": "http://www.selectabio.com/role/LeasesLeaseTermandDiscountRateDetails",
     "shortName": "Leases - Lease Term and Discount Rate (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "selb-20210331.htm",
      "contextRef": "ied8d945ebce54ed8a4badfed477a64e8_I20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "selb-20210331.htm",
      "contextRef": "ied8d945ebce54ed8a4badfed477a64e8_I20210331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2437420 - Disclosure - Debt - Term Loans (Narrative) (Details)",
     "role": "http://www.selectabio.com/role/DebtTermLoansNarrativeDetails",
     "shortName": "Debt - Term Loans (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "selb-20210331.htm",
      "contextRef": "ied8d945ebce54ed8a4badfed477a64e8_I20210331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "selb-20210331.htm",
      "contextRef": "i867f4cd50cdf4945bf8a2b4c13258dfd_I20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2438421 - Disclosure - Debt - Schedule of Future Minimum Payments on the Term Loans (Details)",
     "role": "http://www.selectabio.com/role/DebtScheduleofFutureMinimumPaymentsontheTermLoansDetails",
     "shortName": "Debt - Schedule of Future Minimum Payments on the Term Loans (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "selb-20210331.htm",
      "contextRef": "i867f4cd50cdf4945bf8a2b4c13258dfd_I20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "selb-20210331.htm",
      "contextRef": "i93f17f89c13f486486776019ba38a82f_D20210101-20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProceedsFromIssuanceOfCommonStock",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2441422 - Disclosure - Equity - Narrative (Details)",
     "role": "http://www.selectabio.com/role/EquityNarrativeDetails",
     "shortName": "Equity - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "selb-20210331.htm",
      "contextRef": "ied8d945ebce54ed8a4badfed477a64e8_I20210331",
      "decimals": "INF",
      "lang": "en-US",
      "name": "selb:VotesPerShareofCommonStock",
      "reportCount": 1,
      "unique": true,
      "unitRef": "vote",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "selb-20210331.htm",
      "contextRef": "ied8d945ebce54ed8a4badfed477a64e8_I20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2442423 - Disclosure - Equity - Warranty Activity (Details)",
     "role": "http://www.selectabio.com/role/EquityWarrantyActivityDetails",
     "shortName": "Equity - Warranty Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "selb-20210331.htm",
      "contextRef": "id99ce4003b574f658d3b62852041d661_I20210331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfStockByClassTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "selb-20210331.htm",
      "contextRef": "ied8d945ebce54ed8a4badfed477a64e8_I20210331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2443424 - Disclosure - Equity - Schedule of Authorized Shares of Common Stock for Future Issuance (Details)",
     "role": "http://www.selectabio.com/role/EquityScheduleofAuthorizedSharesofCommonStockforFutureIssuanceDetails",
     "shortName": "Equity - Schedule of Authorized Shares of Common Stock for Future Issuance (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfStockByClassTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "selb-20210331.htm",
      "contextRef": "icaed7df33b254fc68b5b0e15b600935f_I20210331",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "selb-20210331.htm",
      "contextRef": "i93f17f89c13f486486776019ba38a82f_D20210101-20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005006 - Statement - Consolidated Statements of Cash Flows",
     "role": "http://www.selectabio.com/role/ConsolidatedStatementsofCashFlows",
     "shortName": "Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "selb-20210331.htm",
      "contextRef": "i93f17f89c13f486486776019ba38a82f_D20210101-20210331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:OtherDepreciationAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfStockByClassTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "selb-20210331.htm",
      "contextRef": "ied8d945ebce54ed8a4badfed477a64e8_I20210331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2446425 - Disclosure - Stock Incentive Plans - Narrative (Details)",
     "role": "http://www.selectabio.com/role/StockIncentivePlansNarrativeDetails",
     "shortName": "Stock Incentive Plans - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "selb-20210331.htm",
      "contextRef": "ied8d945ebce54ed8a4badfed477a64e8_I20210331",
      "decimals": "INF",
      "lang": "en-US",
      "name": "selb:ShareBasedGoodsAndNonEmployeeServicesTransactionCompensationNotYetRecognizedStockOptions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "selb-20210331.htm",
      "contextRef": "i93f17f89c13f486486776019ba38a82f_D20210101-20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2447426 - Disclosure - Stock Incentive Plans - Schedule of Stock-Based Compensation Expense Related to Stock Options and Restricted Common Stock (Details)",
     "role": "http://www.selectabio.com/role/StockIncentivePlansScheduleofStockBasedCompensationExpenseRelatedtoStockOptionsandRestrictedCommonStockDetails",
     "shortName": "Stock Incentive Plans - Schedule of Stock-Based Compensation Expense Related to Stock Options and Restricted Common Stock (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "selb-20210331.htm",
      "contextRef": "i16033c04e5ea4cc5bbfdba5f3c1bd666_D20210101-20210331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "selb-20210331.htm",
      "contextRef": "i0a83cea2026d4acd853ecd648a6ff3cf_D20210101-20210331",
      "decimals": "4",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2448427 - Disclosure - Stock Incentive Plans - Schedule of Assumptions (Details)",
     "role": "http://www.selectabio.com/role/StockIncentivePlansScheduleofAssumptionsDetails",
     "shortName": "Stock Incentive Plans - Schedule of Assumptions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "selb-20210331.htm",
      "contextRef": "i0a83cea2026d4acd853ecd648a6ff3cf_D20210101-20210331",
      "decimals": "4",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "selb-20210331.htm",
      "contextRef": "i9b0d673a9945438a9e404b6c6b57eba2_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2449428 - Disclosure - Stock Incentive Plans - Summary of Options Activity (Details)",
     "role": "http://www.selectabio.com/role/StockIncentivePlansSummaryofOptionsActivityDetails",
     "shortName": "Stock Incentive Plans - Summary of Options Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "selb-20210331.htm",
      "contextRef": "ia87a6b98f0714c88b1aa992fc475f7a1_D20210101-20210331",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "selb-20210331.htm",
      "contextRef": "i23dc483d5e024cd3ab41d280f32cf960_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2450429 - Disclosure - Stock Incentive Plans - Restricted Stock Units (Details)",
     "role": "http://www.selectabio.com/role/StockIncentivePlansRestrictedStockUnitsDetails",
     "shortName": "Stock Incentive Plans - Restricted Stock Units (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "selb-20210331.htm",
      "contextRef": "i23dc483d5e024cd3ab41d280f32cf960_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfStockByClassTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "selb-20210331.htm",
      "contextRef": "ied8d945ebce54ed8a4badfed477a64e8_I20210331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2451430 - Disclosure - Stock Incentive Plans - Employee Stock Purchase Plan (Narrative) (Details)",
     "role": "http://www.selectabio.com/role/StockIncentivePlansEmployeeStockPurchasePlanNarrativeDetails",
     "shortName": "Stock Incentive Plans - Employee Stock Purchase Plan (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "selb-20210331.htm",
      "contextRef": "i3a0400d76b2a4414a1b0b75fa0e22620_D20210101-20210331",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "selb-20210331.htm",
      "contextRef": "ied8d945ebce54ed8a4badfed477a64e8_I20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerLiabilityCurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2454431 - Disclosure - Revenue Arrangements - Narrative (Details)",
     "role": "http://www.selectabio.com/role/RevenueArrangementsNarrativeDetails",
     "shortName": "Revenue Arrangements - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "selb-20210331.htm",
      "contextRef": "i93f17f89c13f486486776019ba38a82f_D20210101-20210331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:CapitalizedContractCostAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R67": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "selb-20210331.htm",
      "contextRef": "ib56f1adc867e406ca7face50c5da1c9c_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "selb:ContractwithCustomerLiabilityDeferredRevenue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2455432 - Disclosure - Revenue Arrangements - Schedule of Changes in Contract Liabilities (Details)",
     "role": "http://www.selectabio.com/role/RevenueArrangementsScheduleofChangesinContractLiabilitiesDetails",
     "shortName": "Revenue Arrangements - Schedule of Changes in Contract Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "selb-20210331.htm",
      "contextRef": "ib56f1adc867e406ca7face50c5da1c9c_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "selb:ContractwithCustomerLiabilityDeferredRevenue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R68": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "selb-20210331.htm",
      "contextRef": "i961e2381798844178d4558010699b490_D20210101-20210331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2457433 - Disclosure - Related-Party Transactions - Narrative (Details)",
     "role": "http://www.selectabio.com/role/RelatedPartyTransactionsNarrativeDetails",
     "shortName": "Related-Party Transactions - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "selb-20210331.htm",
      "contextRef": "i961e2381798844178d4558010699b490_D20210101-20210331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R69": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "selb-20210331.htm",
      "contextRef": "i93f17f89c13f486486776019ba38a82f_D20210101-20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingExpenses",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2459434 - Disclosure - Collaboration Agreements - AskBio (Narrative) (Details)",
     "role": "http://www.selectabio.com/role/CollaborationAgreementsAskBioNarrativeDetails",
     "shortName": "Collaboration Agreements - AskBio (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "selb-20210331.htm",
      "contextRef": "i2d6aabf5381c4d8eafad236940060193_D20200101-20200331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:OperatingExpenses",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "selb-20210331.htm",
      "contextRef": "i93f17f89c13f486486776019ba38a82f_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - Nature of the Business and Basis of Presentation",
     "role": "http://www.selectabio.com/role/NatureoftheBusinessandBasisofPresentation",
     "shortName": "Nature of the Business and Basis of Presentation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "selb-20210331.htm",
      "contextRef": "i93f17f89c13f486486776019ba38a82f_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R70": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "selb-20210331.htm",
      "contextRef": "iec431b313cb846b2aa7358a0b7afcf53_D20210101-20210331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "selb:LicenseAndOptionAgreementContractualPaymentsMade",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2460435 - Disclosure - Collaboration Agreements - MIT (Narrative) (Details)",
     "role": "http://www.selectabio.com/role/CollaborationAgreementsMITNarrativeDetails",
     "shortName": "Collaboration Agreements - MIT (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "selb-20210331.htm",
      "contextRef": "iec431b313cb846b2aa7358a0b7afcf53_D20210101-20210331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "selb:LicenseAndOptionAgreementContractualPaymentsMade",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R71": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "selb-20210331.htm",
      "contextRef": "ibb68c9bff506451eb919c2f81711b851_I20210331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "selb:AggregateAmountOfUpfrontAndMilestoneBasedPaymentsPaid",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2461436 - Disclosure - Collaboration Agreements - Shenyang Sunshine Pharmaceutical Co., Ltd (Narrative) (Details)",
     "role": "http://www.selectabio.com/role/CollaborationAgreementsShenyangSunshinePharmaceuticalCoLtdNarrativeDetails",
     "shortName": "Collaboration Agreements - Shenyang Sunshine Pharmaceutical Co., Ltd (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "selb-20210331.htm",
      "contextRef": "ibb68c9bff506451eb919c2f81711b851_I20210331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "selb:AggregateAmountOfUpfrontAndMilestoneBasedPaymentsPaid",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R72": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "selb-20210331.htm",
      "contextRef": "ied8d945ebce54ed8a4badfed477a64e8_I20210331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2463437 - Disclosure - Income Taxes - Narrative (Details)",
     "role": "http://www.selectabio.com/role/IncomeTaxesNarrativeDetails",
     "shortName": "Income Taxes - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "selb-20210331.htm",
      "contextRef": "ied8d945ebce54ed8a4badfed477a64e8_I20210331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R73": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "selb-20210331.htm",
      "contextRef": "i93f17f89c13f486486776019ba38a82f_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "selb:DefinedContributionPlanEmployersMatchingContributionVestingPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2465438 - Disclosure - Defined Contribution Plan - Narrative (Details)",
     "role": "http://www.selectabio.com/role/DefinedContributionPlanNarrativeDetails",
     "shortName": "Defined Contribution Plan - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "selb-20210331.htm",
      "contextRef": "i93f17f89c13f486486776019ba38a82f_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "selb:DefinedContributionPlanEmployersMatchingContributionVestingPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R74": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "selb-20210331.htm",
      "contextRef": "iebf9f6ef11cf4e6e8cfcb2c64010f2ad_D20210413-20210413",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "selb:LicenseAndOptionAgreementMilestonePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2468439 - Disclosure - Subsequent Events (Details)",
     "role": "http://www.selectabio.com/role/SubsequentEventsDetails",
     "shortName": "Subsequent Events (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "selb-20210331.htm",
      "contextRef": "iebf9f6ef11cf4e6e8cfcb2c64010f2ad_D20210413-20210413",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "selb:LicenseAndOptionAgreementMilestonePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "selb-20210331.htm",
      "contextRef": "i93f17f89c13f486486776019ba38a82f_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2103102 - Disclosure - Summary of Significant Accounting Policies",
     "role": "http://www.selectabio.com/role/SummaryofSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "selb-20210331.htm",
      "contextRef": "i93f17f89c13f486486776019ba38a82f_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "selb-20210331.htm",
      "contextRef": "i93f17f89c13f486486776019ba38a82f_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2105103 - Disclosure - Marketable Securities",
     "role": "http://www.selectabio.com/role/MarketableSecurities",
     "shortName": "Marketable Securities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "selb-20210331.htm",
      "contextRef": "i93f17f89c13f486486776019ba38a82f_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 72,
   "tag": {
    "country_RU": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "RUSSIAN FEDERATION",
        "terseLabel": "Russian subsidiary"
       }
      }
     },
     "localname": "RU",
     "nsuri": "http://xbrl.sec.gov/country/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/NatureoftheBusinessandBasisofPresentationLiquidityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/Coverpage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/Coverpage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/Coverpage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/Coverpage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/Coverpage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/Coverpage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r469"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/Coverpage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r470"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/Coverpage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/Coverpage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/Coverpage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/Coverpage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/Coverpage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/Coverpage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r471"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/Coverpage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/Coverpage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/Coverpage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r471"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/Coverpage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r473"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Entity Ex Transition Period",
        "terseLabel": "Entity Extended Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/Coverpage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/Coverpage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r471"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/Coverpage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/Coverpage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r472"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/Coverpage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r471"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/Coverpage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r471"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/Coverpage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r471"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Smaller Reporting Company"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/Coverpage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r471"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/Coverpage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/Coverpage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r467"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/Coverpage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r468"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/Coverpage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/Coverpage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "selb_A2008Plan2016PlanAnd2018InducementIncentiveAwardPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2008 Plan, 2016 Plan, and 2018 Inducement Incentive Award Plan",
        "label": "2008 Plan, 2016 Plan, and 2018 Inducement Incentive Award Plan [Member]",
        "terseLabel": "2008 Plan, 2016 Plan, and 2018 Inducement Incentive Award Plan"
       }
      }
     },
     "localname": "A2008Plan2016PlanAnd2018InducementIncentiveAwardPlanMember",
     "nsuri": "http://www.selectabio.com/20210331",
     "presentation": [
      "http://www.selectabio.com/role/StockIncentivePlansSummaryofOptionsActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "selb_A2017PIPEMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2017 PIPE [Member]",
        "label": "2017 PIPE [Member]",
        "terseLabel": "2017 PIPE"
       }
      }
     },
     "localname": "A2017PIPEMember",
     "nsuri": "http://www.selectabio.com/20210331",
     "presentation": [
      "http://www.selectabio.com/role/EquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "selb_A2017TermLoansMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2017 Term Loans [Member]",
        "label": "2017 Term Loans [Member]",
        "terseLabel": "2017 Term Loans"
       }
      }
     },
     "localname": "A2017TermLoansMember",
     "nsuri": "http://www.selectabio.com/20210331",
     "presentation": [
      "http://www.selectabio.com/role/DebtScheduleofFutureMinimumPaymentsontheTermLoansDetails",
      "http://www.selectabio.com/role/DebtTermLoansNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "selb_A2020SaleAgreementAtTheMarketOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2020 Sale Agreement - At-The-Market Offering",
        "label": "2020 Sale Agreement - At-The-Market Offering [Member]",
        "terseLabel": "2020 Sale Agreement - At-the-Market Offering"
       }
      }
     },
     "localname": "A2020SaleAgreementAtTheMarketOfferingMember",
     "nsuri": "http://www.selectabio.com/20210331",
     "presentation": [
      "http://www.selectabio.com/role/EquityNarrativeDetails",
      "http://www.selectabio.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "selb_A2020TermLoansMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2020 Term Loans",
        "label": "2020 Term Loans [Member]",
        "terseLabel": "2020 Term Loans"
       }
      }
     },
     "localname": "A2020TermLoansMember",
     "nsuri": "http://www.selectabio.com/20210331",
     "presentation": [
      "http://www.selectabio.com/role/DebtTermLoansNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "selb_A65GroveStreetWatertownMAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "65 Grove Street, Watertown,MA [Member]",
        "label": "65 Grove Street, Watertown,MA [Member]",
        "terseLabel": "65 Grove Street, Watertown,MA"
       }
      }
     },
     "localname": "A65GroveStreetWatertownMAMember",
     "nsuri": "http://www.selectabio.com/20210331",
     "presentation": [
      "http://www.selectabio.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "selb_AccruedAuditFeesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.selectabio.com/role/AccruedExpensesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Audit Fees, Current",
        "label": "Accrued Audit Fees, Current",
        "terseLabel": "Accrued professional and consulting services"
       }
      }
     },
     "localname": "AccruedAuditFeesCurrent",
     "nsuri": "http://www.selectabio.com/20210331",
     "presentation": [
      "http://www.selectabio.com/role/AccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "selb_AccruedCollaborationandLicensing": {
     "auth_ref": [],
     "calculation": {
      "http://www.selectabio.com/role/AccruedExpensesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Collaboration and Licensing",
        "label": "Accrued Collaboration and Licensing",
        "terseLabel": "Collaboration and licensing"
       }
      }
     },
     "localname": "AccruedCollaborationandLicensing",
     "nsuri": "http://www.selectabio.com/20210331",
     "presentation": [
      "http://www.selectabio.com/role/AccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "selb_AccruedInterestCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.selectabio.com/role/AccruedExpensesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Interest, Current",
        "label": "Accrued Interest, Current",
        "terseLabel": "Accrued interest"
       }
      }
     },
     "localname": "AccruedInterestCurrent",
     "nsuri": "http://www.selectabio.com/20210331",
     "presentation": [
      "http://www.selectabio.com/role/AccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "selb_AccruedPatentFeesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.selectabio.com/role/AccruedExpensesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of patent fees.",
        "label": "Accrued Patent Fees Current",
        "terseLabel": "Accrued patent fees"
       }
      }
     },
     "localname": "AccruedPatentFeesCurrent",
     "nsuri": "http://www.selectabio.com/20210331",
     "presentation": [
      "http://www.selectabio.com/role/AccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "selb_AccruedResearchAndDevelopmentCostsCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.selectabio.com/role/AccruedExpensesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of research and development costs.",
        "label": "Accrued Research And Development Costs Current",
        "terseLabel": "Accrued external research and development costs"
       }
      }
     },
     "localname": "AccruedResearchAndDevelopmentCostsCurrent",
     "nsuri": "http://www.selectabio.com/20210331",
     "presentation": [
      "http://www.selectabio.com/role/AccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "selb_AggregateAmountForFuturePaymentsUponAchievementOfClinicalAndRegulatoryApprovalMilestonesForProductsContainingImmTORPlatform": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate Amount For Future Payments Upon Achievement Of Clinical And Regulatory Approval Milestones For Products Containing ImmTOR Platform",
        "label": "Aggregate Amount For Future Payments Upon Achievement Of Clinical And Regulatory Approval Milestones For Products Containing ImmTOR Platform",
        "terseLabel": "Aggregate amount for future payments upon achievement of clinical and regulatory approval milestones for products containing ImmTOR platform"
       }
      }
     },
     "localname": "AggregateAmountForFuturePaymentsUponAchievementOfClinicalAndRegulatoryApprovalMilestonesForProductsContainingImmTORPlatform",
     "nsuri": "http://www.selectabio.com/20210331",
     "presentation": [
      "http://www.selectabio.com/role/CollaborationAgreementsShenyangSunshinePharmaceuticalCoLtdNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "selb_AggregateAmountOfUpfrontAndMilestoneBasedPaymentsPaid": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate Amount Of Upfront And Milestone Based Payments Paid",
        "label": "Aggregate Amount Of Upfront And Milestone Based Payments Paid",
        "terseLabel": "Aggregate amount of upfront and milestone-based payments"
       }
      }
     },
     "localname": "AggregateAmountOfUpfrontAndMilestoneBasedPaymentsPaid",
     "nsuri": "http://www.selectabio.com/20210331",
     "presentation": [
      "http://www.selectabio.com/role/CollaborationAgreementsShenyangSunshinePharmaceuticalCoLtdNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "selb_AskBioLicenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "AskBio License [Member]",
        "label": "AskBio License [Member]",
        "terseLabel": "AskBio License"
       }
      }
     },
     "localname": "AskBioLicenseMember",
     "nsuri": "http://www.selectabio.com/20210331",
     "presentation": [
      "http://www.selectabio.com/role/CollaborationAgreementsAskBioNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "selb_AtTheMarketOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "At-The-Market Offering [Member]",
        "label": "At-The-Market Offering [Member]",
        "terseLabel": "At-The-Market Offering"
       }
      }
     },
     "localname": "AtTheMarketOfferingMember",
     "nsuri": "http://www.selectabio.com/20210331",
     "presentation": [
      "http://www.selectabio.com/role/EquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "selb_August2020ShelfRegistrationStatementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "August 2020 Shelf Registration Statement",
        "label": "August 2020 Shelf Registration Statement [Member]",
        "terseLabel": "August 2020 Shelf Registration Statement"
       }
      }
     },
     "localname": "August2020ShelfRegistrationStatementMember",
     "nsuri": "http://www.selectabio.com/20210331",
     "presentation": [
      "http://www.selectabio.com/role/EquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "selb_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndDebtSecuritiesAvailableForSale": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Debt Securities, Available-For-Sale",
        "label": "Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Debt Securities, Available-For-Sale",
        "terseLabel": "Cash, cash equivalents, restricted cash and marketable securities"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndDebtSecuritiesAvailableForSale",
     "nsuri": "http://www.selectabio.com/20210331",
     "presentation": [
      "http://www.selectabio.com/role/NatureoftheBusinessandBasisofPresentationLiquidityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "selb_ChangeInContractWithCustomerLiabilityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change In Contract With Customer, Liability [Roll Forward]",
        "label": "Change In Contract With Customer, Liability [Roll Forward]",
        "terseLabel": "Contract liabilities:"
       }
      }
     },
     "localname": "ChangeInContractWithCustomerLiabilityRollForward",
     "nsuri": "http://www.selectabio.com/20210331",
     "presentation": [
      "http://www.selectabio.com/role/RevenueArrangementsScheduleofChangesinContractLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "selb_ClassOfWarrantOrRightExpirationPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class Of Warrant Or Right, Expiration Period",
        "label": "Class Of Warrant Or Right, Expiration Period",
        "terseLabel": "Class of warrant or right, expiration period"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExpirationPeriod",
     "nsuri": "http://www.selectabio.com/20210331",
     "presentation": [
      "http://www.selectabio.com/role/DebtTermLoansNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "selb_ClassOfWarrantOrRightNumberOfWarrantsExercised": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of Warrant or Right, Number Of Warrants Exercised",
        "label": "Class Of Warrant Or Right, Number Of Warrants Exercised",
        "terseLabel": "Class of warrant or right, number of warrants exercised (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfWarrantsExercised",
     "nsuri": "http://www.selectabio.com/20210331",
     "presentation": [
      "http://www.selectabio.com/role/EquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "selb_CollaborationAndLicenseAgreementsTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration And License Agreements",
        "label": "Collaboration And License Agreements [Text Block]",
        "terseLabel": "Collaboration Agreements"
       }
      }
     },
     "localname": "CollaborationAndLicenseAgreementsTextBlock",
     "nsuri": "http://www.selectabio.com/20210331",
     "presentation": [
      "http://www.selectabio.com/role/CollaborationAgreements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "selb_CollaborativeArrangementCostSharePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Cost Share Percentage",
        "label": "Collaborative Arrangement, Cost Share Percentage",
        "terseLabel": "Cost share percentage"
       }
      }
     },
     "localname": "CollaborativeArrangementCostSharePercentage",
     "nsuri": "http://www.selectabio.com/20210331",
     "presentation": [
      "http://www.selectabio.com/role/CollaborationAgreementsAskBioNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "selb_CommonWarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common Warrant [Member]",
        "label": "Common Warrant [Member]",
        "terseLabel": "Common Warrant"
       }
      }
     },
     "localname": "CommonWarrantMember",
     "nsuri": "http://www.selectabio.com/20210331",
     "presentation": [
      "http://www.selectabio.com/role/EquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "selb_ContractwithCustomerLiabilityDeferredRevenue": {
     "auth_ref": [],
     "calculation": {
      "http://www.selectabio.com/role/RevenueArrangementsScheduleofChangesinContractLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_ContractWithCustomerLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract with Customer, Liability, Deferred Revenue",
        "label": "Contract with Customer, Liability, Deferred Revenue",
        "periodEndLabel": "Deferred revenue, end of period",
        "periodStartLabel": "Deferred revenue, beginning of period"
       }
      }
     },
     "localname": "ContractwithCustomerLiabilityDeferredRevenue",
     "nsuri": "http://www.selectabio.com/20210331",
     "presentation": [
      "http://www.selectabio.com/role/RevenueArrangementsScheduleofChangesinContractLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "selb_ContractwithCustomerLiabilityDeferredRevenueIncreaseFromCashReceipts": {
     "auth_ref": [],
     "calculation": {
      "http://www.selectabio.com/role/RevenueArrangementsScheduleofChangesinContractLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "selb_ContractwithCustomerLiabilityIncreaseFromCashReceipts",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract with Customer, Liability, Deferred Revenue, Increase From Cash Receipts",
        "label": "Contract with Customer, Liability, Deferred Revenue, Increase From Cash Receipts",
        "terseLabel": "Deferred revenue, additions"
       }
      }
     },
     "localname": "ContractwithCustomerLiabilityDeferredRevenueIncreaseFromCashReceipts",
     "nsuri": "http://www.selectabio.com/20210331",
     "presentation": [
      "http://www.selectabio.com/role/RevenueArrangementsScheduleofChangesinContractLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "selb_ContractwithCustomerLiabilityDeferredRevenueRevenueRecognized": {
     "auth_ref": [],
     "calculation": {
      "http://www.selectabio.com/role/RevenueArrangementsScheduleofChangesinContractLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_ContractWithCustomerLiabilityRevenueRecognized",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract with Customer, Liability, Deferred Revenue, Revenue Recognized",
        "label": "Contract with Customer, Liability, Deferred Revenue, Revenue Recognized",
        "negatedLabel": "Deferred revenue, deductions"
       }
      }
     },
     "localname": "ContractwithCustomerLiabilityDeferredRevenueRevenueRecognized",
     "nsuri": "http://www.selectabio.com/20210331",
     "presentation": [
      "http://www.selectabio.com/role/RevenueArrangementsScheduleofChangesinContractLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "selb_ContractwithCustomerLiabilityIncreaseFromCashReceipts": {
     "auth_ref": [],
     "calculation": {
      "http://www.selectabio.com/role/RevenueArrangementsScheduleofChangesinContractLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract with Customer, Liability, Increase From Cash Receipts",
        "label": "Contract with Customer, Liability, Increase From Cash Receipts",
        "totalLabel": "Contract liabilities, additions"
       }
      }
     },
     "localname": "ContractwithCustomerLiabilityIncreaseFromCashReceipts",
     "nsuri": "http://www.selectabio.com/20210331",
     "presentation": [
      "http://www.selectabio.com/role/RevenueArrangementsScheduleofChangesinContractLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "selb_DebtInstrumentAdditionalAccruedInterestInTheEventOfDefault": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Additional Accrued Interest In the Event Of Default",
        "label": "Debt Instrument, Additional Accrued Interest In the Event Of Default",
        "terseLabel": "Debt instrument, additional accrued interest in the event of default"
       }
      }
     },
     "localname": "DebtInstrumentAdditionalAccruedInterestInTheEventOfDefault",
     "nsuri": "http://www.selectabio.com/20210331",
     "presentation": [
      "http://www.selectabio.com/role/DebtTermLoansNarrativeDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "selb_DebtInstrumentDefaultBankruptcyOrInsolvencyValueOfTriggeringAcceleratedRedemption": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Default, Bankruptcy, Or Insolvency Value Of Triggering Accelerated Redemption",
        "label": "Debt Instrument, Default, Bankruptcy, Or Insolvency Value Of Triggering Accelerated Redemption",
        "terseLabel": "Debt instrument, default, bankruptcy, or insolvency value of triggering accelerated redemption"
       }
      }
     },
     "localname": "DebtInstrumentDefaultBankruptcyOrInsolvencyValueOfTriggeringAcceleratedRedemption",
     "nsuri": "http://www.selectabio.com/20210331",
     "presentation": [
      "http://www.selectabio.com/role/DebtTermLoansNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "selb_DebtInstrumentInterestPortion": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The interest portion of gross outstanding debt.",
        "label": "Debt Instrument Interest Portion",
        "negatedTerseLabel": "Less: Amount representing interest"
       }
      }
     },
     "localname": "DebtInstrumentInterestPortion",
     "nsuri": "http://www.selectabio.com/20210331",
     "presentation": [
      "http://www.selectabio.com/role/DebtScheduleofFutureMinimumPaymentsontheTermLoansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "selb_DebtInstrumentPrepaymentFeePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Prepayment Fee, Percentage",
        "label": "Debt Instrument, Prepayment Fee, Percentage",
        "terseLabel": "Debt instrument, prepayment fee, percentage"
       }
      }
     },
     "localname": "DebtInstrumentPrepaymentFeePercentage",
     "nsuri": "http://www.selectabio.com/20210331",
     "presentation": [
      "http://www.selectabio.com/role/DebtTermLoansNarrativeDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "selb_DecemberTwoThousandNineteenFinancingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "December Two Thousand Nineteen Financing [Member]",
        "label": "December Two Thousand Nineteen Financing [Member]",
        "terseLabel": "December 2019 Financing"
       }
      }
     },
     "localname": "DecemberTwoThousandNineteenFinancingMember",
     "nsuri": "http://www.selectabio.com/20210331",
     "presentation": [
      "http://www.selectabio.com/role/EquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "selb_DefinedContributionPlanEmployersMatchingContributionVestingPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period which an employee's right to exercise a plan is no longer contingent on satisfaction of either a service condition, market condition or a performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Defined Contribution Plan Employers Matching Contribution Vesting Period",
        "terseLabel": "Vesting period"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployersMatchingContributionVestingPeriod",
     "nsuri": "http://www.selectabio.com/20210331",
     "presentation": [
      "http://www.selectabio.com/role/DefinedContributionPlanNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "selb_EligiblePeriodToReceiveRoyalties": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Eligible Period To Receive Royalties",
        "label": "Eligible Period To Receive Royalties",
        "terseLabel": "Period after first commercial sale when the Company is eligible to receive royalties"
       }
      }
     },
     "localname": "EligiblePeriodToReceiveRoyalties",
     "nsuri": "http://www.selectabio.com/20210331",
     "presentation": [
      "http://www.selectabio.com/role/RevenueArrangementsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "selb_EmployeeStockPurchasePlan2016Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represent information pertaining to the 2016 Employee Stock Purchase Plan.",
        "label": "Employee Stock Purchase Plan2016 [Member]",
        "terseLabel": "ESPP"
       }
      }
     },
     "localname": "EmployeeStockPurchasePlan2016Member",
     "nsuri": "http://www.selectabio.com/20210331",
     "presentation": [
      "http://www.selectabio.com/role/StockIncentivePlansEmployeeStockPurchasePlanNarrativeDetails",
      "http://www.selectabio.com/role/StockIncentivePlansNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "selb_EmploymentInducementIncentiveAwardPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employment Inducement Incentive Award Plan [Member]",
        "label": "Employment Inducement Incentive Award Plan [Member]",
        "terseLabel": "Employment Inducement Incentive Award Plan"
       }
      }
     },
     "localname": "EmploymentInducementIncentiveAwardPlanMember",
     "nsuri": "http://www.selectabio.com/20210331",
     "presentation": [
      "http://www.selectabio.com/role/StockIncentivePlansNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "selb_EquityOfferingCostsInAccruedLiabilities": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Offering Costs In Accrued Liabilities",
        "label": "Equity Offering Costs In Accrued Liabilities",
        "terseLabel": "Equity offering costs in accrued liabilities"
       }
      }
     },
     "localname": "EquityOfferingCostsInAccruedLiabilities",
     "nsuri": "http://www.selectabio.com/20210331",
     "presentation": [
      "http://www.selectabio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "selb_ExclusivePatentLicenseAgreementWithMassachusettsInstituteOfTechnologyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Exclusive patent license agreement with Massachusetts Institute of Technology. \"",
        "label": "Exclusive Patent License Agreement With Massachusetts Institute Of Technology [Member]",
        "terseLabel": "MIT"
       }
      }
     },
     "localname": "ExclusivePatentLicenseAgreementWithMassachusettsInstituteOfTechnologyMember",
     "nsuri": "http://www.selectabio.com/20210331",
     "presentation": [
      "http://www.selectabio.com/role/CollaborationAgreementsMITNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "selb_FounderMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to founder member.",
        "label": "Founder [Member]",
        "terseLabel": "Founders"
       }
      }
     },
     "localname": "FounderMember",
     "nsuri": "http://www.selectabio.com/20210331",
     "presentation": [
      "http://www.selectabio.com/role/RelatedPartyTransactionsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "selb_LaboratoryEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to laboratory equipment.",
        "label": "Laboratory Equipment [Member]",
        "terseLabel": "Laboratory equipment"
       }
      }
     },
     "localname": "LaboratoryEquipmentMember",
     "nsuri": "http://www.selectabio.com/20210331",
     "presentation": [
      "http://www.selectabio.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "selb_LeaseArrangementAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease Arrangement [Axis]",
        "label": "Lease Arrangement [Axis]",
        "terseLabel": "Lease Arrangement [Axis]"
       }
      }
     },
     "localname": "LeaseArrangementAxis",
     "nsuri": "http://www.selectabio.com/20210331",
     "presentation": [
      "http://www.selectabio.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "selb_LeaseArrangementDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "[Domain] for Lease Arrangement [Axis]",
        "label": "Lease Arrangement [Domain]",
        "terseLabel": "Lease Arrangement [Domain]"
       }
      }
     },
     "localname": "LeaseArrangementDomain",
     "nsuri": "http://www.selectabio.com/20210331",
     "presentation": [
      "http://www.selectabio.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "selb_LesseeComponentsOfOperatingLeaseTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Components Of Operating Lease",
        "label": "Lessee, Components Of Operating Lease [Table Text Block]",
        "terseLabel": "Schedule of Lessee, Components Of Operating Lease"
       }
      }
     },
     "localname": "LesseeComponentsOfOperatingLeaseTableTextBlock",
     "nsuri": "http://www.selectabio.com/20210331",
     "presentation": [
      "http://www.selectabio.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "selb_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour": {
     "auth_ref": [],
     "calculation": {
      "http://www.selectabio.com/role/LeasesOperatingLeaseLiabilityMaturityDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Liability, To Be Paid, After Year Four",
        "label": "Lessee, Operating Lease, Liability, To Be Paid, After Year Four",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityToBePaidAfterYearFour",
     "nsuri": "http://www.selectabio.com/20210331",
     "presentation": [
      "http://www.selectabio.com/role/LeasesOperatingLeaseLiabilityMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "selb_LicenseAgreementForPompeDiseaseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License Agreement For Pompe Disease [Member]",
        "label": "License Agreement For Pompe Disease [Member]",
        "terseLabel": "License Agreement For Pompe Disease"
       }
      }
     },
     "localname": "LicenseAgreementForPompeDiseaseMember",
     "nsuri": "http://www.selectabio.com/20210331",
     "presentation": [
      "http://www.selectabio.com/role/RevenueArrangementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "selb_LicenseAgreementWithShenyangSunshinePharmaceuticalCompanyLimitedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to License agreement with Shenyang Sunshine Pharmaceutical co., ltd.",
        "label": "License Agreement With Shenyang Sunshine Pharmaceutical Company Limited [Member]",
        "terseLabel": "3SBio License"
       }
      }
     },
     "localname": "LicenseAgreementWithShenyangSunshinePharmaceuticalCompanyLimitedMember",
     "nsuri": "http://www.selectabio.com/20210331",
     "presentation": [
      "http://www.selectabio.com/role/CollaborationAgreementsShenyangSunshinePharmaceuticalCoLtdNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "selb_LicenseAndOptionAgreementCalculatedPremiumPaidForEquityInvestmentUnderPurchaseAgreement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License And Option Agreement, Calculated Premium Paid For Equity Investment Under Purchase Agreement",
        "label": "License And Option Agreement, Calculated Premium Paid For Equity Investment Under Purchase Agreement",
        "terseLabel": "License and option agreement, payments made relative to calculated premium paid for initial equity investment made under the purchase agreement"
       }
      }
     },
     "localname": "LicenseAndOptionAgreementCalculatedPremiumPaidForEquityInvestmentUnderPurchaseAgreement",
     "nsuri": "http://www.selectabio.com/20210331",
     "presentation": [
      "http://www.selectabio.com/role/CollaborationAgreementsMITNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "selb_LicenseAndOptionAgreementContractualPaymentsMade": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License And Option Agreement, Contractual Payments Made",
        "label": "License And Option Agreement, Contractual Payments Made",
        "verboseLabel": "Contractual payments defined in the Exclusive Patent License agreement"
       }
      }
     },
     "localname": "LicenseAndOptionAgreementContractualPaymentsMade",
     "nsuri": "http://www.selectabio.com/20210331",
     "presentation": [
      "http://www.selectabio.com/role/CollaborationAgreementsMITNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "selb_LicenseAndOptionAgreementDevelopmentMilestone": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License And Option Agreement, Development Milestone",
        "label": "License And Option Agreement, Development Milestone",
        "terseLabel": "Development milestone"
       }
      }
     },
     "localname": "LicenseAndOptionAgreementDevelopmentMilestone",
     "nsuri": "http://www.selectabio.com/20210331",
     "presentation": [
      "http://www.selectabio.com/role/RevenueArrangementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "selb_LicenseAndOptionAgreementExecutionFeePayment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License And Option Agreement, Execution Fee Payment",
        "label": "License And Option Agreement, Execution Fee Payment",
        "terseLabel": "Initial upfront execution fee payment"
       }
      }
     },
     "localname": "LicenseAndOptionAgreementExecutionFeePayment",
     "nsuri": "http://www.selectabio.com/20210331",
     "presentation": [
      "http://www.selectabio.com/role/RevenueArrangementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "selb_LicenseAndOptionAgreementInitialUpFrontCashPayment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License And Option Agreement, Initial Up-Front Cash Payment",
        "label": "License And Option Agreement, Initial Up-Front Cash Payment",
        "terseLabel": "Initial up-front cash payment"
       }
      }
     },
     "localname": "LicenseAndOptionAgreementInitialUpFrontCashPayment",
     "nsuri": "http://www.selectabio.com/20210331",
     "presentation": [
      "http://www.selectabio.com/role/RevenueArrangementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "selb_LicenseAndOptionAgreementMilestonePayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License And Option Agreement, Milestone Payments",
        "label": "License And Option Agreement, Milestone Payments",
        "terseLabel": "Milestone payment"
       }
      }
     },
     "localname": "LicenseAndOptionAgreementMilestonePayments",
     "nsuri": "http://www.selectabio.com/20210331",
     "presentation": [
      "http://www.selectabio.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "selb_LicenseAndOptionAgreementOptionTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License And Option Agreement, Option Term",
        "label": "License And Option Agreement, Option Term",
        "terseLabel": "Option term"
       }
      }
     },
     "localname": "LicenseAndOptionAgreementOptionTerm",
     "nsuri": "http://www.selectabio.com/20210331",
     "presentation": [
      "http://www.selectabio.com/role/RevenueArrangementsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "selb_LicenseAndOptionAgreementSalesMilestonePaymentsThatMayBeReceived": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License And Option Agreement, Sales Milestone Payments That May Be Received",
        "label": "License And Option Agreement, Sales Milestone Payments That May Be Received",
        "terseLabel": "Sales milestone payments"
       }
      }
     },
     "localname": "LicenseAndOptionAgreementSalesMilestonePaymentsThatMayBeReceived",
     "nsuri": "http://www.selectabio.com/20210331",
     "presentation": [
      "http://www.selectabio.com/role/RevenueArrangementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "selb_LicenseAndOptionAgreementUpfrontCashPayment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License And Option Agreement, Upfront Cash Payment",
        "label": "License And Option Agreement, Upfront Cash Payment",
        "terseLabel": "Upfront cash payment"
       }
      }
     },
     "localname": "LicenseAndOptionAgreementUpfrontCashPayment",
     "nsuri": "http://www.selectabio.com/20210331",
     "presentation": [
      "http://www.selectabio.com/role/RevenueArrangementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "selb_LicenseAndOptionAgreementWrittenDayNoticePeriodBeforeCancellation": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License And Option Agreement, Written Day Notice Period Before Cancellation",
        "label": "License And Option Agreement, Written Day Notice Period Before Cancellation",
        "terseLabel": "License and option agreement, written day notice period before cancellation"
       }
      }
     },
     "localname": "LicenseAndOptionAgreementWrittenDayNoticePeriodBeforeCancellation",
     "nsuri": "http://www.selectabio.com/20210331",
     "presentation": [
      "http://www.selectabio.com/role/RevenueArrangementsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "selb_LockUpFromClosingTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lock-up From Closing, Term",
        "label": "Lock-up From Closing, Term",
        "terseLabel": "Lock-up from closing, term"
       }
      }
     },
     "localname": "LockUpFromClosingTerm",
     "nsuri": "http://www.selectabio.com/20210331",
     "presentation": [
      "http://www.selectabio.com/role/EquityNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "selb_NonEmployeeStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An arrangement whereby a non-employee is entitled to receive in the future, subject to vesting and other restrictions, a number of shares in the entity at a specified price, as defined in the agreement.",
        "label": "Non Employee Stock Option [Member]",
        "terseLabel": "Non-employee stock options",
        "verboseLabel": "Non-employee consultants"
       }
      }
     },
     "localname": "NonEmployeeStockOptionMember",
     "nsuri": "http://www.selectabio.com/20210331",
     "presentation": [
      "http://www.selectabio.com/role/StockIncentivePlansNarrativeDetails",
      "http://www.selectabio.com/role/StockIncentivePlansScheduleofAssumptionsDetails",
      "http://www.selectabio.com/role/StockIncentivePlansSummaryofOptionsActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "selb_PreFundedWarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pre-Funded Warrant [Member]",
        "label": "Pre-Funded Warrant [Member]",
        "terseLabel": "Pre-Funded Warrant"
       }
      }
     },
     "localname": "PreFundedWarrantMember",
     "nsuri": "http://www.selectabio.com/20210331",
     "presentation": [
      "http://www.selectabio.com/role/EquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "selb_ResearchAndDevelopmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to research and development expenses included in the income statement.",
        "label": "Research And Development [Member]",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentMember",
     "nsuri": "http://www.selectabio.com/20210331",
     "presentation": [
      "http://www.selectabio.com/role/StockIncentivePlansScheduleofStockBasedCompensationExpenseRelatedtoStockOptionsandRestrictedCommonStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "selb_RestrictedStockUnitsRSUsReservedForIssuanceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restricted Stock Units (RSUs) Reserved For Issuance",
        "label": "Restricted Stock Units (RSUs) Reserved For Issuance [Member]",
        "terseLabel": "RSUs reserved for issuance"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUsReservedForIssuanceMember",
     "nsuri": "http://www.selectabio.com/20210331",
     "presentation": [
      "http://www.selectabio.com/role/EquityScheduleofAuthorizedSharesofCommonStockforFutureIssuanceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "selb_RestrictedStockUnitsUnvestedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restricted Stock Units, Unvested",
        "label": "Restricted Stock Units, Unvested [Member]",
        "terseLabel": "Unvested restricted stock units"
       }
      }
     },
     "localname": "RestrictedStockUnitsUnvestedMember",
     "nsuri": "http://www.selectabio.com/20210331",
     "presentation": [
      "http://www.selectabio.com/role/EquityScheduleofAuthorizedSharesofCommonStockforFutureIssuanceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "selb_RevenueNumberOfPerformanceObligations": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue, Number Of Performance Obligations",
        "label": "Revenue, Number Of Performance Obligations",
        "terseLabel": "Number of obligations"
       }
      }
     },
     "localname": "RevenueNumberOfPerformanceObligations",
     "nsuri": "http://www.selectabio.com/20210331",
     "presentation": [
      "http://www.selectabio.com/role/RevenueArrangementsNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "selb_SOBIPurchaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "SOBI Purchase Agreement [Member]",
        "label": "SOBI Purchase Agreement [Member]",
        "terseLabel": "SOBI Purchase Agreement"
       }
      }
     },
     "localname": "SOBIPurchaseAgreementMember",
     "nsuri": "http://www.selectabio.com/20210331",
     "presentation": [
      "http://www.selectabio.com/role/EquityNarrativeDetails",
      "http://www.selectabio.com/role/RevenueArrangementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "selb_SaleofStockPercentageOfTenDayVolumeWeightedAveragePriceOfCommonStock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of Stock, Percentage Of Ten-Day Volume Weighted Average Price Of Common Stock",
        "label": "Sale of Stock, Percentage Of Ten-Day Volume Weighted Average Price Of Common Stock",
        "terseLabel": "Sale of stock, percentage of ten-day volume weighted average price of common stock"
       }
      }
     },
     "localname": "SaleofStockPercentageOfTenDayVolumeWeightedAveragePriceOfCommonStock",
     "nsuri": "http://www.selectabio.com/20210331",
     "presentation": [
      "http://www.selectabio.com/role/EquityNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "selb_SareptaTherapeuticsInc.Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sarepta Therapeutics, Inc. [Member]",
        "label": "Sarepta Therapeutics, Inc. [Member]",
        "terseLabel": "Sarepta Therapeutics, Inc."
       }
      }
     },
     "localname": "SareptaTherapeuticsInc.Member",
     "nsuri": "http://www.selectabio.com/20210331",
     "presentation": [
      "http://www.selectabio.com/role/RevenueArrangementsNarrativeDetails",
      "http://www.selectabio.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "selb_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAwardedInPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Awarded in Period",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Awarded in Period",
        "terseLabel": "Awarded in period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAwardedInPeriod",
     "nsuri": "http://www.selectabio.com/20210331",
     "presentation": [
      "http://www.selectabio.com/role/StockIncentivePlansNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "selb_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReservedForIssuance": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Reserved For Issuance",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Reserved For Issuance",
        "terseLabel": "Reserved for issuance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReservedForIssuance",
     "nsuri": "http://www.selectabio.com/20210331",
     "presentation": [
      "http://www.selectabio.com/role/StockIncentivePlansNarrativeDetails",
      "http://www.selectabio.com/role/StockIncentivePlansRestrictedStockUnitsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "selb_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReservedForIssuanceWeightedAverageGrantDateFairValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Reserved For Issuance, Weighted Average Grant Date Fair Value",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Reserved For Issuance, Weighted Average Grant Date Fair Value",
        "terseLabel": "Reserved for issuance (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReservedForIssuanceWeightedAverageGrantDateFairValue",
     "nsuri": "http://www.selectabio.com/20210331",
     "presentation": [
      "http://www.selectabio.com/role/StockIncentivePlansNarrativeDetails",
      "http://www.selectabio.com/role/StockIncentivePlansRestrictedStockUnitsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "selb_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageFairValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighed-average fair value relating to the share-based payment award.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Fair Value",
        "terseLabel": "Weighted-average fair value of common stock (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageFairValue",
     "nsuri": "http://www.selectabio.com/20210331",
     "presentation": [
      "http://www.selectabio.com/role/StockIncentivePlansScheduleofAssumptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "selb_ShareBasedCompensationArrangementByShareBasedPaymentAwardForfeituresRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the percentage of forfeitures rate of the stock options based on the historical trends.",
        "label": "Share-based Compensation Arrangement By Share-based Payment Award Forfeitures Rate",
        "terseLabel": "Estimated forfeitures rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardForfeituresRate",
     "nsuri": "http://www.selectabio.com/20210331",
     "presentation": [
      "http://www.selectabio.com/role/StockIncentivePlansNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "selb_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantIncreaseDecrease": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Number Of Shares Available For Grant, Increase (Decrease)",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Number Of Shares Available For Grant, Increase (Decrease)",
        "terseLabel": "Number of shares authorized, increase (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantIncreaseDecrease",
     "nsuri": "http://www.selectabio.com/20210331",
     "presentation": [
      "http://www.selectabio.com/role/StockIncentivePlansEmployeeStockPurchasePlanNarrativeDetails",
      "http://www.selectabio.com/role/StockIncentivePlansNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "selb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "n/a",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value [Abstract]",
        "terseLabel": "Aggregate intrinsic value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValueAbstract",
     "nsuri": "http://www.selectabio.com/20210331",
     "presentation": [
      "http://www.selectabio.com/role/StockIncentivePlansSummaryofOptionsActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "selb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "n/a",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term [Abstract]",
        "terseLabel": "Weighted-average remaining contractual term"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract",
     "nsuri": "http://www.selectabio.com/20210331",
     "presentation": [
      "http://www.selectabio.com/role/StockIncentivePlansSummaryofOptionsActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "selb_ShareBasedGoodsAndNonEmployeeServicesTransactionCompensationNotYetRecognizedStockOptions": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Goods And Non Employee Services Transaction, Compensation Not Yet Recognized, Stock Options",
        "label": "Share-Based Goods And Non Employee Services Transaction, Compensation Not Yet Recognized, Stock Options",
        "terseLabel": "Unrecognized compensation expense related to unvested non-employee stock options"
       }
      }
     },
     "localname": "ShareBasedGoodsAndNonEmployeeServicesTransactionCompensationNotYetRecognizedStockOptions",
     "nsuri": "http://www.selectabio.com/20210331",
     "presentation": [
      "http://www.selectabio.com/role/StockIncentivePlansNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "selb_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedOutstandingIntrinsicValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement By Share-based Payment Award, Options, Vested, Outstanding, Intrinsic Value",
        "label": "Share-based Compensation Arrangement By Share-based Payment Award, Options, Vested, Outstanding, Intrinsic Value",
        "terseLabel": "Vested"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedOutstandingIntrinsicValue",
     "nsuri": "http://www.selectabio.com/20210331",
     "presentation": [
      "http://www.selectabio.com/role/StockIncentivePlansSummaryofOptionsActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "selb_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedOutstandingWeightedAverageRemainingContractualTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement By Share-based Payment Award, Options, Vested, Outstanding, Weighted Average Remaining Contractual Term",
        "label": "Share-based Compensation Arrangement By Share-based Payment Award, Options, Vested, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Vested, term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedOutstandingWeightedAverageRemainingContractualTerm",
     "nsuri": "http://www.selectabio.com/20210331",
     "presentation": [
      "http://www.selectabio.com/role/StockIncentivePlansSummaryofOptionsActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "selb_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsVestedWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Exercise Price",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Exercise Price",
        "verboseLabel": "Vested (in dollars per share)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsVestedWeightedAverageExercisePrice",
     "nsuri": "http://www.selectabio.com/20210331",
     "presentation": [
      "http://www.selectabio.com/role/StockIncentivePlansSummaryofOptionsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "selb_StockIncentivePlan2016Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to the 2016 stock incentive plan, which provides for the granting of stock based awards to employees, directors, and consultants under terms and provisions established by the board of directors.",
        "label": "Stock Incentive Plan2016 [Member]",
        "terseLabel": "2016 Plan"
       }
      }
     },
     "localname": "StockIncentivePlan2016Member",
     "nsuri": "http://www.selectabio.com/20210331",
     "presentation": [
      "http://www.selectabio.com/role/StockIncentivePlansNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "selb_TermALoansMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term A Loans",
        "label": "Term A Loans [Member]",
        "terseLabel": "Term A Loans"
       }
      }
     },
     "localname": "TermALoansMember",
     "nsuri": "http://www.selectabio.com/20210331",
     "presentation": [
      "http://www.selectabio.com/role/DebtTermLoansNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "selb_TermBLoansMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term B Loans",
        "label": "Term B Loans [Member]",
        "terseLabel": "Term B Loans"
       }
      }
     },
     "localname": "TermBLoansMember",
     "nsuri": "http://www.selectabio.com/20210331",
     "presentation": [
      "http://www.selectabio.com/role/DebtTermLoansNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "selb_VotesPerShareofCommonStock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Votes Per Share of Common Stock",
        "label": "Votes Per Share of Common Stock",
        "terseLabel": "Number of votes per share that common stockholders are entitled to"
       }
      }
     },
     "localname": "VotesPerShareofCommonStock",
     "nsuri": "http://www.selectabio.com/20210331",
     "presentation": [
      "http://www.selectabio.com/role/EquityNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "selb_WarrantIssued": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrant Issued",
        "label": "Warrant Issued",
        "terseLabel": "Warrant Issued"
       }
      }
     },
     "localname": "WarrantIssued",
     "nsuri": "http://www.selectabio.com/20210331",
     "presentation": [
      "http://www.selectabio.com/role/EquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r246",
      "r248",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r400",
      "r440",
      "r442"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/DebtTermLoansNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r246",
      "r248",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r400",
      "r440",
      "r442"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/DebtTermLoansNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r226",
      "r246",
      "r248",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r400",
      "r440",
      "r442"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/DebtTermLoansNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r226",
      "r246",
      "r248",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r400",
      "r440",
      "r442"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/DebtTermLoansNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioForecastMember": {
     "auth_ref": [
      "r247"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forecast [Member]",
        "terseLabel": "Forecast"
       }
      }
     },
     "localname": "ScenarioForecastMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioUnspecifiedDomain": {
     "auth_ref": [
      "r247"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Domain]",
        "terseLabel": "Scenario [Domain]"
       }
      }
     },
     "localname": "ScenarioUnspecifiedDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r135",
      "r136",
      "r214",
      "r219",
      "r441",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/NatureoftheBusinessandBasisofPresentationLiquidityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r135",
      "r136",
      "r214",
      "r219",
      "r441",
      "r452",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/NatureoftheBusinessandBasisofPresentationLiquidityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_StatementScenarioAxis": {
     "auth_ref": [
      "r175",
      "r247",
      "r368"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]",
        "terseLabel": "Scenario [Axis]"
       }
      }
     },
     "localname": "StatementScenarioAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.",
        "label": "Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]",
        "terseLabel": "Accrued Expenses"
       }
      }
     },
     "localname": "AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/AccruedExpenses"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r30"
     ],
     "calculation": {
      "http://www.selectabio.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r3",
      "r18",
      "r138",
      "r139"
     ],
     "calculation": {
      "http://www.selectabio.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/ConsolidatedBalanceSheets",
      "http://www.selectabio.com/role/RevenueArrangementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": {
     "auth_ref": [
      "r77"
     ],
     "calculation": {
      "http://www.selectabio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Accretion (Amortization) of Discounts and Premiums, Investments",
        "negatedTerseLabel": "Amortization of premiums and discounts on marketable securities"
       }
      }
     },
     "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r34"
     ],
     "calculation": {
      "http://www.selectabio.com/role/AccruedExpensesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.selectabio.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "totalLabel": "Accrued expenses",
        "verboseLabel": "Accrued expenses"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/AccruedExpensesDetails",
      "http://www.selectabio.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r29",
      "r167"
     ],
     "calculation": {
      "http://www.selectabio.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedTerseLabel": "Less accumulated depreciation"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r21",
      "r45",
      "r46",
      "r47",
      "r433",
      "r447",
      "r448"
     ],
     "calculation": {
      "http://www.selectabio.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r44",
      "r47",
      "r48",
      "r93",
      "r94",
      "r95",
      "r308",
      "r443",
      "r444"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "verboseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/ConsolidatedStatementsofChangesinStockholdersDeficitEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r19",
      "r284"
     ],
     "calculation": {
      "http://www.selectabio.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r93",
      "r94",
      "r95",
      "r281",
      "r282",
      "r283"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/ConsolidatedStatementsofChangesinStockholdersDeficitEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalOther": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of other increase (decrease) in additional paid in capital (APIC).",
        "label": "Adjustments to Additional Paid in Capital, Other",
        "terseLabel": "Other financing fees"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalOther",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/ConsolidatedStatementsofChangesinStockholdersDeficitEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r250",
      "r252",
      "r287",
      "r288"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/ConsolidatedStatementsofChangesinStockholdersDeficitEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued": {
     "auth_ref": [
      "r179",
      "r190",
      "r198"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.",
        "label": "Adjustments to Additional Paid in Capital, Warrant Issued",
        "terseLabel": "Adjustments to additional paid in capital, warrant issued"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/DebtTermLoansNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r252",
      "r277",
      "r286"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-based Payment Arrangement, Expense",
        "netLabel": "Stock-based compensation expense",
        "terseLabel": "Stock\u2011based compensation expense",
        "verboseLabel": "Total stock-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/StockIncentivePlansEmployeeStockPurchasePlanNarrativeDetails",
      "http://www.selectabio.com/role/StockIncentivePlansNarrativeDetails",
      "http://www.selectabio.com/role/StockIncentivePlansScheduleofStockBasedCompensationExpenseRelatedtoStockOptionsandRestrictedCommonStockDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r112"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Total (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/NetLossPerShareScheduleofPotentialCommonSharesIssuableUponConversionofWarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r112"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/NetLossPerShareScheduleofPotentialCommonSharesIssuableUponConversionofWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "verboseLabel": "Potential common shares"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/NetLossPerShareScheduleofPotentialCommonSharesIssuableUponConversionofWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r112"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/NetLossPerShareScheduleofPotentialCommonSharesIssuableUponConversionofWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AreaOfRealEstateProperty": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area of a real estate property.",
        "label": "Area of Real Estate Property",
        "terseLabel": "Area of additional office space leased"
       }
      }
     },
     "localname": "AreaOfRealEstateProperty",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "areaItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/CollaborationAgreementsAskBioNarrativeDetails",
      "http://www.selectabio.com/role/CollaborationAgreementsMITNarrativeDetails",
      "http://www.selectabio.com/role/CollaborationAgreementsShenyangSunshinePharmaceuticalCoLtdNarrativeDetails",
      "http://www.selectabio.com/role/RevenueArrangementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r86",
      "r123",
      "r126",
      "r132",
      "r152",
      "r306",
      "r309",
      "r325",
      "r417",
      "r430"
     ],
     "calculation": {
      "http://www.selectabio.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets",
        "verboseLabel": "Assets:"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/ConsolidatedBalanceSheets",
      "http://www.selectabio.com/role/LeasesComponentsofOperatingLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r4",
      "r5",
      "r41",
      "r86",
      "r152",
      "r306",
      "r309",
      "r325"
     ],
     "calculation": {
      "http://www.selectabio.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r314"
     ],
     "calculation": {
      "http://www.selectabio.com/role/FairValueMeasurementsSummaryofAssetsMeasuredatFairValueonaRecurringBasisDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/FairValueMeasurementsSummaryofAssetsMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Fair Value Disclosure [Abstract]",
        "terseLabel": "Assets:"
       }
      }
     },
     "localname": "AssetsFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/FairValueMeasurementsSummaryofAssetsMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r147"
     ],
     "calculation": {
      "http://www.selectabio.com/role/MarketableSecuritiesSummaryofAvailableforSaleMarketableSecuritiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Unrealized gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/MarketableSecuritiesSummaryofAvailableforSaleMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r148"
     ],
     "calculation": {
      "http://www.selectabio.com/role/MarketableSecuritiesSummaryofAvailableforSaleMarketableSecuritiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedTerseLabel": "Unrealized losses"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/MarketableSecuritiesSummaryofAvailableforSaleMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r145",
      "r159"
     ],
     "calculation": {
      "http://www.selectabio.com/role/MarketableSecuritiesSummaryofAvailableforSaleMarketableSecuritiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Amortized Cost",
        "totalLabel": "Amortized cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/MarketableSecuritiesSummaryofAvailableforSaleMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r141",
      "r146",
      "r159",
      "r420"
     ],
     "calculation": {
      "http://www.selectabio.com/role/FairValueMeasurementsSummaryofAssetsMeasuredatFairValueonaRecurringBasisDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      },
      "http://www.selectabio.com/role/MarketableSecuritiesSummaryofAvailableforSaleMarketableSecuritiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale",
        "terseLabel": "Fair value",
        "verboseLabel": "Marketable securities:"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/FairValueMeasurementsSummaryofAssetsMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.selectabio.com/role/MarketableSecuritiesNarrativeDetails",
      "http://www.selectabio.com/role/MarketableSecuritiesSummaryofAvailableforSaleMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": {
     "auth_ref": [
      "r143",
      "r159"
     ],
     "calculation": {
      "http://www.selectabio.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.",
        "label": "Debt Securities, Available-for-sale, Current",
        "terseLabel": "Marketable securities"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r253",
      "r279"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/EquityScheduleofAuthorizedSharesofCommonStockforFutureIssuanceDetails",
      "http://www.selectabio.com/role/StockIncentivePlansNarrativeDetails",
      "http://www.selectabio.com/role/StockIncentivePlansRestrictedStockUnitsDetails",
      "http://www.selectabio.com/role/StockIncentivePlansScheduleofAssumptionsDetails",
      "http://www.selectabio.com/role/StockIncentivePlansSummaryofOptionsActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "auth_ref": [
      "r80",
      "r81",
      "r82"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "terseLabel": "Purchase of property and equipment not yet paid"
       }
      }
     },
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CapitalizedContractCostAmortization": {
     "auth_ref": [
      "r164"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense for asset recognized from cost incurred to obtain or fulfill contract with customer.",
        "label": "Capitalized Contract Cost, Amortization",
        "terseLabel": "Contract assets amortization (less than)"
       }
      }
     },
     "localname": "CapitalizedContractCostAmortization",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/RevenueArrangementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Cash": {
     "auth_ref": [
      "r27",
      "r449",
      "r450"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash",
        "terseLabel": "Cash maintained in Russian bank accounts"
       }
      }
     },
     "localname": "Cash",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/NatureoftheBusinessandBasisofPresentationLiquidityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r2",
      "r27",
      "r78"
     ],
     "calculation": {
      "http://www.selectabio.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.selectabio.com/role/FairValueMeasurementsScheduleofCashandCashEquivalentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/ConsolidatedBalanceSheets",
      "http://www.selectabio.com/role/FairValueMeasurementsScheduleofCashandCashEquivalentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of cash and cash equivalent balance.",
        "label": "Cash and Cash Equivalents [Axis]",
        "terseLabel": "Cash and Cash Equivalents [Axis]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/FairValueMeasurementsSummaryofAssetsMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://www.selectabio.com/role/FairValueMeasurementsSummaryofAssetsMeasuredatFairValueonaRecurringBasisDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Money market funds"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/FairValueMeasurementsSummaryofAssetsMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Cash and Cash Equivalents [Line Items]",
        "terseLabel": "Cash and Cash Equivalents [Line Items]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/NatureoftheBusinessandBasisofPresentationLiquidityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r72",
      "r78",
      "r83"
     ],
     "calculation": {
      "http://www.selectabio.com/role/FairValueMeasurementsScheduleofCashandCashEquivalentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents, and restricted cash at end of period",
        "periodStartLabel": "Cash, cash equivalents, and restricted cash at beginning of period",
        "totalLabel": "Total cash, cash equivalents, and restricted cash shown in the consolidated statement of cash flows"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.selectabio.com/role/FairValueMeasurementsScheduleofCashandCashEquivalentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r72",
      "r330"
     ],
     "calculation": {
      "http://www.selectabio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net change in cash, cash equivalents, and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Class of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/EquityScheduleofAuthorizedSharesofCommonStockforFutureIssuanceDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r191"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "terseLabel": "Exercise price (in dollars per share)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/DebtTermLoansNarrativeDetails",
      "http://www.selectabio.com/role/EquityNarrativeDetails",
      "http://www.selectabio.com/role/EquityWarrantyActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ClassOfWarrantOrRightLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Warrant or Right [Line Items]",
        "terseLabel": "Class of Warrant or Right [Line Items]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/EquityWarrantyActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "auth_ref": [
      "r191"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.",
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "terseLabel": "Class of warrant or right, number of securities called by warrants or rights (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/DebtTermLoansNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Outstanding",
        "terseLabel": "Class of warrant or right, outstanding (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/EquityNarrativeDetails",
      "http://www.selectabio.com/role/EquityWarrantyActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ClassOfWarrantOrRightTable": {
     "auth_ref": [
      "r199",
      "r251"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure for warrants or rights issued, which includes the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.",
        "label": "Class of Warrant or Right [Table]",
        "terseLabel": "Class of Warrant or Right [Table]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/EquityWarrantyActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CollaborativeArrangementMember": {
     "auth_ref": [
      "r305"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual arrangement that involves two or more parties that both: (i) actively participate in a joint operating activity and (ii) are exposed to significant risks and rewards that depend on the commercial success of the joint operating activity.",
        "label": "Collaborative Arrangement [Member]",
        "terseLabel": "Collaborative Arrangement"
       }
      }
     },
     "localname": "CollaborativeArrangementMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/RevenueArrangementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/CollaborationAgreementsAskBioNarrativeDetails",
      "http://www.selectabio.com/role/CollaborationAgreementsMITNarrativeDetails",
      "http://www.selectabio.com/role/CollaborationAgreementsShenyangSunshinePharmaceuticalCoLtdNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommercialPaperMember": {
     "auth_ref": [
      "r177"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.",
        "label": "Commercial Paper [Member]",
        "terseLabel": "Commercial paper"
       }
      }
     },
     "localname": "CommercialPaperMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/FairValueMeasurementsSummaryofAssetsMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.selectabio.com/role/MarketableSecuritiesSummaryofAvailableforSaleMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r37",
      "r174",
      "r421",
      "r437"
     ],
     "calculation": {
      "http://www.selectabio.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies (Note\u00a017)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r171",
      "r172",
      "r173",
      "r176"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/CommitmentsandContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r39"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Total (in shares)",
        "verboseLabel": "Common stock authorized and reserved for future issuance (in shares)"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/EquityScheduleofAuthorizedSharesofCommonStockforFutureIssuanceDetails",
      "http://www.selectabio.com/role/StockIncentivePlansEmployeeStockPurchasePlanNarrativeDetails",
      "http://www.selectabio.com/role/StockIncentivePlansNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r93",
      "r94"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common\u00a0stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/ConsolidatedStatementsofChangesinStockholdersDeficitEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.selectabio.com/role/EquityNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "verboseLabel": "Common stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.selectabio.com/role/EquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.selectabio.com/role/EquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r17",
      "r190"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)",
        "terseLabel": "Common stock, shares outstanding"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.selectabio.com/role/ConsolidatedStatementsofChangesinStockholdersDeficitEquity",
      "http://www.selectabio.com/role/EquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r17"
     ],
     "calculation": {
      "http://www.selectabio.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.0001 par value; 200,000,000 shares authorized; 112,977,004 and 108,071,249 shares issued and outstanding as of March 31, 2021 and December 31, 2020, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Benefits [Abstract]",
        "terseLabel": "Retirement Benefits [Abstract]"
       }
      }
     },
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r50",
      "r52",
      "r53",
      "r56",
      "r423",
      "r439"
     ],
     "calculation": {
      "http://www.selectabio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Total comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComputerEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.",
        "label": "Computer Equipment [Member]",
        "terseLabel": "Computer equipment and software"
       }
      }
     },
     "localname": "ComputerEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConstructionInProgressMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.",
        "label": "Construction in Progress [Member]",
        "terseLabel": "Construction in process"
       }
      }
     },
     "localname": "ConstructionInProgressMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": {
     "auth_ref": [
      "r204"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.",
        "label": "Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]",
        "terseLabel": "Schedule of Changes in Contract Liabilities"
       }
      }
     },
     "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/RevenueArrangementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContractWithCustomerAssetNetCurrent": {
     "auth_ref": [
      "r201",
      "r203",
      "r215"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current.",
        "label": "Contract with Customer, Asset, after Allowance for Credit Loss, Current",
        "terseLabel": "Contract assets"
       }
      }
     },
     "localname": "ContractWithCustomerAssetNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/RevenueArrangementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiability": {
     "auth_ref": [
      "r201",
      "r202",
      "r215"
     ],
     "calculation": {
      "http://www.selectabio.com/role/RevenueArrangementsScheduleofChangesinContractLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Contract with Customer, Liability",
        "periodEndLabel": "Contract liabilities, end of period",
        "periodStartLabel": "Contract liabilities, beginning of period"
       }
      }
     },
     "localname": "ContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/RevenueArrangementsScheduleofChangesinContractLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "auth_ref": [
      "r201",
      "r202",
      "r215"
     ],
     "calculation": {
      "http://www.selectabio.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Contract with Customer, Liability, Current",
        "terseLabel": "Deferred revenue",
        "verboseLabel": "Short-term contract liability"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/ConsolidatedBalanceSheets",
      "http://www.selectabio.com/role/RevenueArrangementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityNoncurrent": {
     "auth_ref": [
      "r201",
      "r202",
      "r215"
     ],
     "calculation": {
      "http://www.selectabio.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.",
        "label": "Contract with Customer, Liability, Noncurrent",
        "terseLabel": "Deferred revenue",
        "verboseLabel": "Long-term contract liability"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/ConsolidatedBalanceSheets",
      "http://www.selectabio.com/role/RevenueArrangementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": {
     "auth_ref": [
      "r216"
     ],
     "calculation": {
      "http://www.selectabio.com/role/RevenueArrangementsScheduleofChangesinContractLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.",
        "label": "Contract with Customer, Liability, Revenue Recognized",
        "negatedTotalLabel": "Contract liabilities, deductions",
        "terseLabel": "Revenue recognized"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityRevenueRecognized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/RevenueArrangementsNarrativeDetails",
      "http://www.selectabio.com/role/RevenueArrangementsScheduleofChangesinContractLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CorporateBondSecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes information about long-term debt securities that are issued by either a domestic or foreign corporate business entity with a date certain promise of repayment and a return to the holder for the time value of money (for example, variable or fixed interest, original issue discount).",
        "label": "Corporate Bond Securities [Member]",
        "terseLabel": "Corporate bonds"
       }
      }
     },
     "localname": "CorporateBondSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/FairValueMeasurementsSummaryofAssetsMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.selectabio.com/role/MarketableSecuritiesSummaryofAvailableforSaleMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfRevenueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cost of Revenue [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "CostOfRevenueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Axis]",
        "terseLabel": "Credit Facility [Axis]"
       }
      }
     },
     "localname": "CreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/DebtScheduleofFutureMinimumPaymentsontheTermLoansDetails",
      "http://www.selectabio.com/role/DebtTermLoansNarrativeDetails",
      "http://www.selectabio.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Domain]",
        "terseLabel": "Credit Facility [Domain]"
       }
      }
     },
     "localname": "CreditFacilityDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/DebtScheduleofFutureMinimumPaymentsontheTermLoansDetails",
      "http://www.selectabio.com/role/DebtTermLoansNarrativeDetails",
      "http://www.selectabio.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]",
        "terseLabel": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r184"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "Debt"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/Debt"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.",
        "label": "Debt Instrument, Basis Spread on Variable Rate",
        "terseLabel": "Basis spread on variable rate"
       }
      }
     },
     "localname": "DebtInstrumentBasisSpreadOnVariableRate1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/DebtTermLoansNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of payment greater than the preceding installment payments to be paid at final maturity date of debt.",
        "label": "Debt Instrument, Periodic Payment Terms, Balloon Payment to be Paid",
        "terseLabel": "Final payment fee"
       }
      }
     },
     "localname": "DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/DebtTermLoansNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodAxis": {
     "auth_ref": [
      "r427"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information about timing of debt redemption features under terms of the debt agreement.",
        "label": "Debt Instrument, Redemption, Period [Axis]",
        "terseLabel": "Debt Instrument, Redemption, Period [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/DebtTermLoansNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodDomain": {
     "auth_ref": [
      "r427"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period as defined under terms of the debt agreement for debt redemption features.",
        "label": "Debt Instrument, Redemption, Period [Domain]",
        "terseLabel": "Debt Instrument, Redemption, Period [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/DebtTermLoansNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodOneMember": {
     "auth_ref": [
      "r427"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period one representing most current period of debt redemption features under terms of the debt agreement.",
        "label": "Debt Instrument, Redemption, Period One [Member]",
        "terseLabel": "Debt Instrument, Redemption, Period One"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodOneMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/DebtTermLoansNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodThreeMember": {
     "auth_ref": [
      "r427"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period three representing third most current period of debt redemption features under terms of the debt agreement.",
        "label": "Debt Instrument, Redemption, Period Three [Member]",
        "terseLabel": "Debt Instrument, Redemption, Period Three"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodThreeMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/DebtTermLoansNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodTwoMember": {
     "auth_ref": [
      "r427"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period two representing second most current period of debt redemption features under terms of the debt agreement.",
        "label": "Debt Instrument, Redemption, Period Two [Member]",
        "terseLabel": "Debt Instrument, Redemption, Period Two"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodTwoMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/DebtTermLoansNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of principal amount of debt redeemed.",
        "label": "Debt Instrument, Redemption Price, Percentage of Principal Amount Redeemed",
        "terseLabel": "Debt instrument, redemption price, percentage of principal amount redeemed"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/DebtTermLoansNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet": {
     "auth_ref": [
      "r180",
      "r339"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unamortized debt discount (premium) and debt issuance costs.",
        "label": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net",
        "negatedTerseLabel": "Less: Debt discount and deferred charges"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/DebtScheduleofFutureMinimumPaymentsontheTermLoansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet": {
     "auth_ref": [
      "r340"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt issuance costs related to line of credit arrangements. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.",
        "label": "Debt Issuance Costs, Line of Credit Arrangements, Net",
        "terseLabel": "Debt issuance costs, line of credit arrangements (less than)"
       }
      }
     },
     "localname": "DebtIssuanceCostsLineOfCreditArrangementsNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/DebtTermLoansNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTable": {
     "auth_ref": [
      "r151"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale [Table]",
        "terseLabel": "Debt Securities, Available-for-sale [Table]"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/MarketableSecuritiesSummaryofAvailableforSaleMarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": {
     "auth_ref": [
      "r151"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale [Table Text Block]",
        "terseLabel": "Summary of Available-for-Sale Marketable Securities"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/MarketableSecuritiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are not subject to expiration dates.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards, Not Subject to Expiration",
        "terseLabel": "Operating loss carryforwards, carried forward indefinitely"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are subject to expiration dates.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration",
        "terseLabel": "Net operating losses available for use through 2028"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanCostRecognized": {
     "auth_ref": [
      "r245"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost for defined contribution plan.",
        "label": "Defined Contribution Plan, Cost",
        "terseLabel": "Employer contribution made"
       }
      }
     },
     "localname": "DefinedContributionPlanCostRecognized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/DefinedContributionPlanNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r76",
      "r165"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "verboseLabel": "Depreciation expense"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/PropertyandEquipmentNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Disaggregation of Revenue [Line Items]",
        "terseLabel": "Disaggregation of Revenue [Line Items]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/RevenueArrangementsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "auth_ref": [
      "r214",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table]",
        "terseLabel": "Disaggregation of Revenue [Table]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/RevenueArrangementsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r289"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement [Text Block]",
        "terseLabel": "Stock Incentive Plans"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/StockIncentivePlans"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement [Abstract]",
        "terseLabel": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock": {
     "auth_ref": [
      "r253",
      "r279"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of share-based payment arrangement.",
        "label": "Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block]",
        "terseLabel": "Disclosure of Share-based Compensation Arrangements by Share-based Payment Award"
       }
      }
     },
     "localname": "DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/StockIncentivePlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DividendsCommonStock": {
     "auth_ref": [
      "r198",
      "r426"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of paid and unpaid common stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK).",
        "label": "Dividends, Common Stock",
        "terseLabel": "Dividends declared or paid on common stock"
       }
      }
     },
     "localname": "DividendsCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/EquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDiluted": {
     "auth_ref": [
      "r110"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic and Diluted",
        "terseLabel": "Net loss per share attributable to common stockholders\u2014basic and diluted (in dollars per share)",
        "verboseLabel": "Basic and diluted (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.selectabio.com/role/NetLossPerShareComputationofBasicandDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDilutedAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Basic and Diluted [Abstract]",
        "terseLabel": "Net loss per share:"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDilutedAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r112",
      "r113",
      "r114",
      "r115"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Net Loss Per Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/NetLossPerShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents": {
     "auth_ref": [
      "r330"
     ],
     "calculation": {
      "http://www.selectabio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from the effect of exchange rate changes on cash and cash equivalent balances held in foreign currencies.",
        "label": "Effect of Exchange Rate on Cash and Cash Equivalents",
        "terseLabel": "Effect of exchange rate changes on cash"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashAndCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r34"
     ],
     "calculation": {
      "http://www.selectabio.com/role/AccruedExpensesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Payroll and employee related expenses"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/AccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/StockIncentivePlansScheduleofStockBasedCompensationExpenseRelatedtoStockOptionsandRestrictedCommonStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r278"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "verboseLabel": "Weighted average period for recognition"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/StockIncentivePlansNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": {
     "auth_ref": [
      "r278"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized compensation expense"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/StockIncentivePlansNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "auth_ref": [
      "r278"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized compensation expense related to unvested employee stock options"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/StockIncentivePlansNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r275"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-based Payment Arrangement, Option [Member]",
        "terseLabel": "Stock options to purchase common stock",
        "verboseLabel": "Outstanding common stock options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/EquityScheduleofAuthorizedSharesofCommonStockforFutureIssuanceDetails",
      "http://www.selectabio.com/role/NetLossPerShareScheduleofPotentialCommonSharesIssuableUponConversionofWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]",
        "terseLabel": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r93",
      "r94",
      "r95",
      "r97",
      "r102",
      "r104",
      "r117",
      "r153",
      "r190",
      "r198",
      "r281",
      "r282",
      "r283",
      "r298",
      "r299",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r443",
      "r444",
      "r445"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/ConsolidatedStatementsofChangesinStockholdersDeficitEquity",
      "http://www.selectabio.com/role/EquityNarrativeDetails",
      "http://www.selectabio.com/role/EquityScheduleofAuthorizedSharesofCommonStockforFutureIssuanceDetails",
      "http://www.selectabio.com/role/EquityWarrantyActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAdjustmentOfWarrants": {
     "auth_ref": [
      "r76",
      "r185"
     ],
     "calculation": {
      "http://www.selectabio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.selectabio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 5.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability.",
        "label": "Fair Value Adjustment of Warrants",
        "negatedTerseLabel": "Change in fair value of warrant liabilities",
        "terseLabel": "Warrant liabilities revaluation"
       }
      }
     },
     "localname": "FairValueAdjustmentOfWarrants",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.selectabio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/FairValueMeasurementsSummaryofAssetsMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r314",
      "r315",
      "r316",
      "r323"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/FairValueMeasurementsSummaryofAssetsMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]",
        "terseLabel": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/FairValueMeasurementsAssumptionsusedtorecordthefairvalueofthewarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": {
     "auth_ref": [
      "r317"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table]",
        "terseLabel": "Fair Value Measurement Inputs and Valuation Techniques [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/FairValueMeasurementsAssumptionsusedtorecordthefairvalueofthewarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": {
     "auth_ref": [
      "r317"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]",
        "terseLabel": "Schedule of Fair Value Measurement Inputs and Valuation Techniques"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r227",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r242",
      "r315",
      "r373",
      "r374",
      "r375"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/FairValueMeasurementsSummaryofAssetsMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByLiabilityClassAxis": {
     "auth_ref": [
      "r322",
      "r323"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by class of liability.",
        "label": "Liability Class [Axis]",
        "terseLabel": "Liability Class [Axis]"
       }
      }
     },
     "localname": "FairValueByLiabilityClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/EquityWarrantyActivityDetails",
      "http://www.selectabio.com/role/FairValueMeasurementsChangeinthewarrantliabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r314",
      "r315",
      "r318",
      "r319",
      "r324"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/FairValueMeasurementsSummaryofAssetsMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]",
        "terseLabel": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r322"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/FairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r227",
      "r229",
      "r234",
      "r242",
      "r315",
      "r373"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "(Level\u00a01)"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/FairValueMeasurementsSummaryofAssetsMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r227",
      "r229",
      "r234",
      "r242",
      "r315",
      "r374"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "(Level\u00a02)"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/FairValueMeasurementsSummaryofAssetsMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r227",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r242",
      "r315",
      "r375"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "(Level\u00a03)"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/FairValueMeasurementsSummaryofAssetsMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": {
     "auth_ref": [
      "r320"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents classes of liabilities measured and disclosed at fair value.",
        "label": "Fair Value by Liability Class [Domain]",
        "terseLabel": "Fair Value by Liability Class [Domain]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/EquityWarrantyActivityDetails",
      "http://www.selectabio.com/role/FairValueMeasurementsChangeinthewarrantliabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]",
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/FairValueMeasurementsChangeinthewarrantliabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]",
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/FairValueMeasurementsChangeinthewarrantliabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable": {
     "auth_ref": [
      "r320",
      "r323"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of information required and determined to be provided for purposes of reconciling beginning and ending balances of fair value measurements of liabilities using significant unobservable inputs (level 3). Separately presenting changes during the period, attributable to: (1) total gains or losses for the period (realized and unrealized) and location reported in the statement of income (or activities); (2) purchases, sales, issuances, and settlements (net); (3) transfers in and/or out of Level 3.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]",
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/FairValueMeasurementsChangeinthewarrantliabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "auth_ref": [
      "r320",
      "r323"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "terseLabel": "Schedule Of Changes In The Warrant Liabilities"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/FairValueMeasurementsSummaryofAssetsMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transfer of financial instrument classified as an asset into (out of) level 3 of the fair value hierarchy.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers, Net",
        "terseLabel": "Fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, transfers, net"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": {
     "auth_ref": [
      "r321"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings",
        "terseLabel": "Change in fair value"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/FairValueMeasurementsChangeinthewarrantliabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transfers of financial instrument classified as a liability into (out of) level 3 of the fair value hierarchy.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Transfers, Net",
        "terseLabel": "Fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, transfers, net"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": {
     "auth_ref": [
      "r320"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value",
        "periodEndLabel": "Fair value as of March 31, 2021",
        "periodStartLabel": "Fair value as of December 31, 2020"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/FairValueMeasurementsChangeinthewarrantliabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r227",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r242",
      "r373",
      "r374",
      "r375"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/FairValueMeasurementsSummaryofAssetsMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r322",
      "r324"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/FairValueMeasurementsSummaryofAssetsMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinanceLeaseRightOfUseAssetAmortization": {
     "auth_ref": [
      "r343",
      "r346",
      "r355"
     ],
     "calculation": {
      "http://www.selectabio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to right-of-use asset from finance lease.",
        "label": "Finance Lease, Right-of-Use Asset, Amortization",
        "terseLabel": "Non-cash lease expense"
       }
      }
     },
     "localname": "FinanceLeaseRightOfUseAssetAmortization",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r149",
      "r150",
      "r154",
      "r155",
      "r156",
      "r157",
      "r158",
      "r160",
      "r161",
      "r162",
      "r163",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/FairValueMeasurementsSummaryofAssetsMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.selectabio.com/role/MarketableSecuritiesSummaryofAvailableforSaleMarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": {
     "auth_ref": [
      "r326",
      "r327",
      "r328",
      "r329"
     ],
     "calculation": {
      "http://www.selectabio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 3.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.",
        "label": "Foreign Currency Transaction Gain (Loss), before Tax",
        "terseLabel": "Foreign currency transaction gain, net"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionGainLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture and Fixtures [Member]",
        "terseLabel": "Furniture and fixtures"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": {
     "auth_ref": [
      "r76"
     ],
     "calculation": {
      "http://www.selectabio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.",
        "label": "Gain (Loss) on Disposition of Property Plant Equipment",
        "negatedLabel": "Loss on disposal of property and equipment"
       }
      }
     },
     "localname": "GainLossOnSaleOfPropertyPlantEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "auth_ref": [
      "r76",
      "r182",
      "r183"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.",
        "label": "Gain (Loss) on Extinguishment of Debt",
        "negatedTerseLabel": "Loss on extinguishment of debt"
       }
      }
     },
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/DebtTermLoansNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r60"
     ],
     "calculation": {
      "http://www.selectabio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r57"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/StockIncentivePlansScheduleofStockBasedCompensationExpenseRelatedtoStockOptionsandRestrictedCommonStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]",
        "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r169"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/RevenueArrangementsNarrativeDetails",
      "http://www.selectabio.com/role/StockIncentivePlansScheduleofStockBasedCompensationExpenseRelatedtoStockOptionsandRestrictedCommonStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/RevenueArrangementsNarrativeDetails",
      "http://www.selectabio.com/role/StockIncentivePlansScheduleofStockBasedCompensationExpenseRelatedtoStockOptionsandRestrictedCommonStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]",
        "terseLabel": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r294",
      "r296",
      "r297",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r75"
     ],
     "calculation": {
      "http://www.selectabio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r75"
     ],
     "calculation": {
      "http://www.selectabio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedTerseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities": {
     "auth_ref": [
      "r75"
     ],
     "calculation": {
      "http://www.selectabio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in accrued expenses, and obligations classified as other.",
        "label": "Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities",
        "terseLabel": "Accrued expenses and other liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "auth_ref": [
      "r75"
     ],
     "calculation": {
      "http://www.selectabio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r75"
     ],
     "calculation": {
      "http://www.selectabio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses, deposits and other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/ConsolidatedStatementsofChangesinStockholdersDeficitEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r54",
      "r122",
      "r338",
      "r339",
      "r424"
     ],
     "calculation": {
      "http://www.selectabio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 4.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r71",
      "r73",
      "r79"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Cash paid for interest"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeNet": {
     "auth_ref": [
      "r61",
      "r62"
     ],
     "calculation": {
      "http://www.selectabio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accretion (amortization) of discount (premium), and investment expense, of interest income and dividend income on nonoperating securities.",
        "label": "Investment Income, Net",
        "terseLabel": "Investment income"
       }
      }
     },
     "localname": "InvestmentIncomeNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments, Debt and Equity Securities [Abstract]",
        "terseLabel": "Investments, Debt and Equity Securities [Abstract]"
       }
      }
     },
     "localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r151",
      "r414",
      "r425",
      "r451"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for  investments in certain debt and equity securities.",
        "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]",
        "terseLabel": "Marketable Securities"
       }
      }
     },
     "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/MarketableSecurities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseCost": {
     "auth_ref": [
      "r353",
      "r355"
     ],
     "calculation": {
      "http://www.selectabio.com/role/LeasesComponentsofleasecostsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease cost recognized by lessee for lease contract.",
        "label": "Lease, Cost",
        "terseLabel": "Lessee-paid construction costs",
        "totalLabel": "Total lease cost"
       }
      }
     },
     "localname": "LeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/LeasesComponentsofleasecostsDetails",
      "http://www.selectabio.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r353"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Schedule of Lease, Cost"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r166"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]",
        "terseLabel": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r354"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Schedule of Lessee, Operating Lease, Liability, Maturity"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r354"
     ],
     "calculation": {
      "http://www.selectabio.com/role/LeasesOperatingLeaseLiabilityMaturityDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.selectabio.com/role/LeasesOperatingLeaseLiabilityMaturityDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total future minimum lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/LeasesOperatingLeaseLiabilityMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r354"
     ],
     "calculation": {
      "http://www.selectabio.com/role/LeasesOperatingLeaseLiabilityMaturityDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/LeasesOperatingLeaseLiabilityMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r354"
     ],
     "calculation": {
      "http://www.selectabio.com/role/LeasesOperatingLeaseLiabilityMaturityDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/LeasesOperatingLeaseLiabilityMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r354"
     ],
     "calculation": {
      "http://www.selectabio.com/role/LeasesOperatingLeaseLiabilityMaturityDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/LeasesOperatingLeaseLiabilityMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r354"
     ],
     "calculation": {
      "http://www.selectabio.com/role/LeasesOperatingLeaseLiabilityMaturityDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/LeasesOperatingLeaseLiabilityMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "auth_ref": [
      "r354"
     ],
     "calculation": {
      "http://www.selectabio.com/role/LeasesOperatingLeaseLiabilityMaturityDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year",
        "terseLabel": "2021 (remainder)"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/LeasesOperatingLeaseLiabilityMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r354"
     ],
     "calculation": {
      "http://www.selectabio.com/role/LeasesOperatingLeaseLiabilityMaturityDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "terseLabel": "Less imputed interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/LeasesOperatingLeaseLiabilityMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "auth_ref": [
      "r345"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Term of Contract",
        "terseLabel": "Term of contract"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r356"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LetterOfCreditMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A document typically issued by a financial institution which acts as a guarantee of payment to a beneficiary, or as the source of payment for a specific transaction (for example, wiring funds to a foreign exporter if and when specified merchandise is accepted pursuant to the terms of the letter of credit).",
        "label": "Letter of Credit [Member]",
        "terseLabel": "Letter of credit"
       }
      }
     },
     "localname": "LetterOfCreditMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r33",
      "r86",
      "r127",
      "r152",
      "r307",
      "r309",
      "r310",
      "r325"
     ],
     "calculation": {
      "http://www.selectabio.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities [Abstract]",
        "terseLabel": "Liabilities:"
       }
      }
     },
     "localname": "LiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/LeasesComponentsofOperatingLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r24",
      "r86",
      "r152",
      "r325",
      "r419",
      "r435"
     ],
     "calculation": {
      "http://www.selectabio.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders\u2019 (deficit) equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and stockholders\u2019 (deficit) equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r35",
      "r86",
      "r152",
      "r307",
      "r309",
      "r310",
      "r325"
     ],
     "calculation": {
      "http://www.selectabio.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosure": {
     "auth_ref": [
      "r314"
     ],
     "calculation": {
      "http://www.selectabio.com/role/FairValueMeasurementsSummaryofAssetsMeasuredatFairValueonaRecurringBasisDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial and nonfinancial obligations.",
        "label": "Financial and Nonfinancial Liabilities, Fair Value Disclosure",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/FairValueMeasurementsSummaryofAssetsMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Fair Value Disclosure [Abstract]",
        "terseLabel": "Liabilities:"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/FairValueMeasurementsSummaryofAssetsMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LicenseAgreementTermsMember": {
     "auth_ref": [
      "r291",
      "r292"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Terms of the license agreements under research and development arrangements accounted for as a contract to perform research and development for others.",
        "label": "License Agreement Terms [Member]",
        "terseLabel": "Spark License Agreement"
       }
      }
     },
     "localname": "LicenseAgreementTermsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/CollaborationAgreementsMITNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LineOfCredit": {
     "auth_ref": [
      "r14",
      "r418",
      "r428"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.",
        "label": "Long-term Line of Credit",
        "terseLabel": "Term loan facility"
       }
      }
     },
     "localname": "LineOfCredit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/DebtTermLoansNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Line of Credit Facility [Line Items]",
        "terseLabel": "Line of Credit Facility [Line Items]"
       }
      }
     },
     "localname": "LineOfCreditFacilityLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/DebtScheduleofFutureMinimumPaymentsontheTermLoansDetails",
      "http://www.selectabio.com/role/DebtTermLoansNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "auth_ref": [
      "r31"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity",
        "terseLabel": "Maximum borrowing capacity"
       }
      }
     },
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/DebtTermLoansNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityTable": {
     "auth_ref": [
      "r31",
      "r88"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to short-term or long-term contractual arrangements with lenders, including letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line.",
        "label": "Line of Credit Facility [Table]",
        "terseLabel": "Line of Credit Facility [Table]"
       }
      }
     },
     "localname": "LineOfCreditFacilityTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/DebtScheduleofFutureMinimumPaymentsontheTermLoansDetails",
      "http://www.selectabio.com/role/DebtTermLoansNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LoansPayableCurrent": {
     "auth_ref": [
      "r34"
     ],
     "calculation": {
      "http://www.selectabio.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of portion of long-term loans payable due within one year or the operating cycle if longer.",
        "label": "Loans Payable, Current",
        "terseLabel": "Loan payable"
       }
      }
     },
     "localname": "LoansPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r14",
      "r181",
      "r418",
      "r431"
     ],
     "calculation": {
      "http://www.selectabio.com/role/DebtScheduleofFutureMinimumPaymentsontheTermLoansDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt",
        "totalLabel": "Total minimum debt payments"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/DebtScheduleofFutureMinimumPaymentsontheTermLoansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtByMaturityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-term Debt, Fiscal Year Maturity [Abstract]",
        "terseLabel": "Long-term Debt, Fiscal Year Maturity [Abstract]"
       }
      }
     },
     "localname": "LongTermDebtByMaturityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/DebtScheduleofFutureMinimumPaymentsontheTermLoansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongTermDebtCurrent": {
     "auth_ref": [
      "r32"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt, Current Maturities",
        "negatedLabel": "Less: Current portion of loan payable"
       }
      }
     },
     "localname": "LongTermDebtCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/DebtScheduleofFutureMinimumPaymentsontheTermLoansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": {
     "auth_ref": [
      "r91",
      "r178"
     ],
     "calculation": {
      "http://www.selectabio.com/role/DebtScheduleofFutureMinimumPaymentsontheTermLoansDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year One",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/DebtScheduleofFutureMinimumPaymentsontheTermLoansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": {
     "auth_ref": [
      "r91",
      "r178"
     ],
     "calculation": {
      "http://www.selectabio.com/role/DebtScheduleofFutureMinimumPaymentsontheTermLoansDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Four",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/DebtScheduleofFutureMinimumPaymentsontheTermLoansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": {
     "auth_ref": [
      "r91",
      "r178"
     ],
     "calculation": {
      "http://www.selectabio.com/role/DebtScheduleofFutureMinimumPaymentsontheTermLoansDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Three",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/DebtScheduleofFutureMinimumPaymentsontheTermLoansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": {
     "auth_ref": [
      "r91",
      "r178"
     ],
     "calculation": {
      "http://www.selectabio.com/role/DebtScheduleofFutureMinimumPaymentsontheTermLoansDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Two",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/DebtScheduleofFutureMinimumPaymentsontheTermLoansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear": {
     "auth_ref": [
      "r91"
     ],
     "calculation": {
      "http://www.selectabio.com/role/DebtScheduleofFutureMinimumPaymentsontheTermLoansDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in remainder of current fiscal year.",
        "label": "Long-Term Debt, Maturity, Remainder of Fiscal Year",
        "terseLabel": "2021 (remainder)"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/DebtScheduleofFutureMinimumPaymentsontheTermLoansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "auth_ref": [
      "r36"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt, Excluding Current Maturities",
        "terseLabel": "Loan payable, net of current portion"
       }
      }
     },
     "localname": "LongTermDebtNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/DebtScheduleofFutureMinimumPaymentsontheTermLoansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermLoansPayable": {
     "auth_ref": [
      "r36"
     ],
     "calculation": {
      "http://www.selectabio.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of loans payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.",
        "label": "Loans Payable, Noncurrent",
        "terseLabel": "Loan payable, net of current portion"
       }
      }
     },
     "localname": "LongTermLoansPayable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MarketableSecuritiesUnrealizedGainLoss": {
     "auth_ref": [
      "r58"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized gain (loss) on investment in marketable security.",
        "label": "Marketable Securities, Unrealized Gain (Loss)",
        "terseLabel": "Unrealized (losses) on marketable securities"
       }
      }
     },
     "localname": "MarketableSecuritiesUnrealizedGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MeasurementInputExpectedDividendRateMember": {
     "auth_ref": [
      "r317"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using expected dividend rate to be paid to holder of share per year.",
        "label": "Measurement Input, Expected Dividend Rate [Member]",
        "terseLabel": "Dividend yield"
       }
      }
     },
     "localname": "MeasurementInputExpectedDividendRateMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/FairValueMeasurementsAssumptionsusedtorecordthefairvalueofthewarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputExpectedTermMember": {
     "auth_ref": [
      "r317"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date.",
        "label": "Measurement Input, Expected Term [Member]",
        "terseLabel": "Expected life (in years)"
       }
      }
     },
     "localname": "MeasurementInputExpectedTermMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/FairValueMeasurementsAssumptionsusedtorecordthefairvalueofthewarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputPriceVolatilityMember": {
     "auth_ref": [
      "r317"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns.",
        "label": "Measurement Input, Price Volatility [Member]",
        "terseLabel": "Expected volatility"
       }
      }
     },
     "localname": "MeasurementInputPriceVolatilityMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/FairValueMeasurementsAssumptionsusedtorecordthefairvalueofthewarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputRiskFreeInterestRateMember": {
     "auth_ref": [
      "r317"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss.",
        "label": "Measurement Input, Risk Free Interest Rate [Member]",
        "terseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "MeasurementInputRiskFreeInterestRateMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/FairValueMeasurementsAssumptionsusedtorecordthefairvalueofthewarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "auth_ref": [
      "r317"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Axis]",
        "terseLabel": "Measurement Input Type [Axis]"
       }
      }
     },
     "localname": "MeasurementInputTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/FairValueMeasurementsAssumptionsusedtorecordthefairvalueofthewarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Domain]",
        "terseLabel": "Measurement Input Type [Domain]"
       }
      }
     },
     "localname": "MeasurementInputTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/FairValueMeasurementsAssumptionsusedtorecordthefairvalueofthewarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r227"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money market funds"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/FairValueMeasurementsSummaryofAssetsMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r72"
     ],
     "calculation": {
      "http://www.selectabio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by (used in) financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]",
        "terseLabel": "Cash flows from financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r72"
     ],
     "calculation": {
      "http://www.selectabio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash (used in) investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]",
        "terseLabel": "Cash flows from investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r72",
      "r74",
      "r77"
     ],
     "calculation": {
      "http://www.selectabio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash (used in) operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]",
        "terseLabel": "Cash flows from operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r0",
      "r49",
      "r51",
      "r55",
      "r77",
      "r86",
      "r96",
      "r98",
      "r99",
      "r100",
      "r101",
      "r103",
      "r104",
      "r108",
      "r123",
      "r125",
      "r128",
      "r131",
      "r133",
      "r152",
      "r325",
      "r422",
      "r438"
     ],
     "calculation": {
      "http://www.selectabio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.selectabio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.selectabio.com/role/ConsolidatedStatementsofChangesinStockholdersDeficitEquity",
      "http://www.selectabio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "auth_ref": [
      "r98",
      "r99",
      "r100",
      "r101",
      "r105",
      "r106",
      "r109",
      "r111",
      "r123",
      "r125",
      "r128",
      "r131",
      "r133"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.",
        "label": "Net Income (Loss) Available to Common Stockholders, Basic",
        "netLabel": "Net loss attributable to common stockholders"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/NetLossPerShareComputationofBasicandDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss) Available to Common Stockholders, Basic [Abstract]",
        "terseLabel": "Numerator:"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasicAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/NetLossPerShareComputationofBasicandDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recent Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Noncash Investing and Financing Items [Abstract]",
        "terseLabel": "Noncash investing and financing activities"
       }
      }
     },
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OfficeEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine.",
        "label": "Office Equipment [Member]",
        "terseLabel": "Office equipment"
       }
      }
     },
     "localname": "OfficeEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.selectabio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "terseLabel": "Operating expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/CollaborationAgreementsAskBioNarrativeDetails",
      "http://www.selectabio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r123",
      "r125",
      "r128",
      "r131",
      "r133"
     ],
     "calculation": {
      "http://www.selectabio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r347",
      "r355"
     ],
     "calculation": {
      "http://www.selectabio.com/role/LeasesComponentsofleasecostsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "terseLabel": "Operating lease cost"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/LeasesComponentsofleasecostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLeaseIncomeTableTextBlock": {
     "auth_ref": [
      "r116",
      "r357"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of components of income from operating lease.",
        "label": "Operating Lease, Lease Income [Table Text Block]",
        "terseLabel": "Schedule of Operating Lease, Lease Income"
       }
      }
     },
     "localname": "OperatingLeaseLeaseIncomeTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r342"
     ],
     "calculation": {
      "http://www.selectabio.com/role/LeasesComponentsofOperatingLeasesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.selectabio.com/role/LeasesOperatingLeaseLiabilityMaturityDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Lease liabilities",
        "totalLabel": "Total operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/LeasesComponentsofOperatingLeasesDetails",
      "http://www.selectabio.com/role/LeasesOperatingLeaseLiabilityMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r342"
     ],
     "calculation": {
      "http://www.selectabio.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://www.selectabio.com/role/LeasesComponentsofOperatingLeasesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Current operating lease liabilities",
        "verboseLabel": "Lease liability"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/ConsolidatedBalanceSheets",
      "http://www.selectabio.com/role/LeasesComponentsofOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r342"
     ],
     "calculation": {
      "http://www.selectabio.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      },
      "http://www.selectabio.com/role/LeasesComponentsofOperatingLeasesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Non-current operating lease liabilities",
        "verboseLabel": "Lease liability"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/ConsolidatedBalanceSheets",
      "http://www.selectabio.com/role/LeasesComponentsofOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r344",
      "r350"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "terseLabel": "Cash paid for amounts included in the measurement of lease liabilities:"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/LeasesOtherInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r341"
     ],
     "calculation": {
      "http://www.selectabio.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Right-of-use asset, net"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/ConsolidatedBalanceSheets",
      "http://www.selectabio.com/role/LeasesComponentsofOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r352",
      "r355"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Operating lease, weighted average discount rate, percent"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/LeasesLeaseTermandDiscountRateDetails",
      "http://www.selectabio.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r351",
      "r355"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Operating lease, weighted average remaining lease term"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/LeasesLeaseTermandDiscountRateDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingLeasedAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Operating Leased Assets [Line Items]",
        "terseLabel": "Operating Leased Assets [Line Items]"
       }
      }
     },
     "localname": "OperatingLeasedAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r1",
      "r311"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "terseLabel": "Nature of the Business and Basis of Presentation"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/NatureoftheBusinessandBasisofPresentation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r7",
      "r8",
      "r9",
      "r34"
     ],
     "calculation": {
      "http://www.selectabio.com/role/AccruedExpensesDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/AccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssets": {
     "auth_ref": [
      "r13",
      "r416",
      "r429"
     ],
     "calculation": {
      "http://www.selectabio.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of assets classified as other.",
        "label": "Other Assets",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": {
     "auth_ref": [
      "r42"
     ],
     "calculation": {
      "http://www.selectabio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax",
        "terseLabel": "Currency translation adjustment",
        "verboseLabel": "Foreign currency translation adjustment"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/ConsolidatedStatementsofChangesinStockholdersDeficitEquity",
      "http://www.selectabio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossTaxAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Tax [Abstract]",
        "terseLabel": "Other comprehensive loss:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossTaxAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "auth_ref": [
      "r43",
      "r45"
     ],
     "calculation": {
      "http://www.selectabio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 3.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax",
        "terseLabel": "Unrealized (losses) on marketable securities"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/ConsolidatedStatementsofChangesinStockholdersDeficitEquity",
      "http://www.selectabio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCurrentAssetsMember": {
     "auth_ref": [
      "r312",
      "r313"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other current assets.",
        "label": "Other Current Assets [Member]",
        "terseLabel": "Other Current Assets"
       }
      }
     },
     "localname": "OtherCurrentAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/RevenueArrangementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherDepreciationAndAmortization": {
     "auth_ref": [
      "r59",
      "r76",
      "r165"
     ],
     "calculation": {
      "http://www.selectabio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense charged against earnings to allocate the cost of tangible and intangible assets over their remaining economic lives, classified as other.",
        "label": "Other Depreciation and Amortization",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "OtherDepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Liabilities, Noncurrent [Abstract]",
        "terseLabel": "Non-current liabilities:"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r63"
     ],
     "calculation": {
      "http://www.selectabio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 6.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Other income (expense), net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale": {
     "auth_ref": [
      "r144"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of other-than-temporary impairment (OTTI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), recognized in earnings and other comprehensive loss (OCI).",
        "label": "Other-than-temporary Impairment Loss, Debt Securities, Available-for-sale",
        "terseLabel": "Marketable securities adjusted for other than temporary declines in fair value"
       }
      }
     },
     "localname": "OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/MarketableSecuritiesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaidInKindInterest": {
     "auth_ref": [
      "r76"
     ],
     "calculation": {
      "http://www.selectabio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest paid other than in cash for example by issuing additional debt securities. As a noncash item, it is added to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Paid-in-Kind Interest",
        "terseLabel": "Non-cash interest expense"
       }
      }
     },
     "localname": "PaidInKindInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables and Accruals [Abstract]",
        "terseLabel": "Payables and Accruals [Abstract]"
       }
      }
     },
     "localname": "PayablesAndAccrualsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PaymentsOfFinancingCosts": {
     "auth_ref": [
      "r70"
     ],
     "calculation": {
      "http://www.selectabio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for loan and debt issuance costs.",
        "label": "Payments of Financing Costs",
        "negatedTerseLabel": "Issuance costs paid for December 2019 financing"
       }
      }
     },
     "localname": "PaymentsOfFinancingCosts",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "auth_ref": [
      "r70"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.",
        "label": "Payments of Stock Issuance Costs",
        "terseLabel": "Issuance costs"
       }
      }
     },
     "localname": "PaymentsOfStockIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/EquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": {
     "auth_ref": [
      "r64",
      "r65",
      "r142"
     ],
     "calculation": {
      "http://www.selectabio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Payments to Acquire Debt Securities, Available-for-sale",
        "negatedTerseLabel": "Purchases of marketable securities"
       }
      }
     },
     "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r66"
     ],
     "calculation": {
      "http://www.selectabio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": {
     "auth_ref": [
      "r226",
      "r228",
      "r234",
      "r235",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r249"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for retirement benefits.",
        "label": "Retirement Benefits [Text Block]",
        "terseLabel": "Defined Contribution Plan"
       }
      }
     },
     "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/DefinedContributionPlan"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r253",
      "r279"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/StockIncentivePlansEmployeeStockPurchasePlanNarrativeDetails",
      "http://www.selectabio.com/role/StockIncentivePlansNarrativeDetails",
      "http://www.selectabio.com/role/StockIncentivePlansSummaryofOptionsActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/StockIncentivePlansEmployeeStockPurchasePlanNarrativeDetails",
      "http://www.selectabio.com/role/StockIncentivePlansNarrativeDetails",
      "http://www.selectabio.com/role/StockIncentivePlansSummaryofOptionsActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "verboseLabel": "Preferred stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares issued"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r16"
     ],
     "calculation": {
      "http://www.selectabio.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock, $0.0001 par value; 10,000,000 shares authorized; no shares issued and outstanding at March 31, 2021 and December 31, 2020"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r4",
      "r25",
      "r26"
     ],
     "calculation": {
      "http://www.selectabio.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing prepaid expenses and other current assets.",
        "label": "Prepaid Expenses and Other Current Assets [Member]",
        "terseLabel": "Prepaid Expenses and Other Current Assets"
       }
      }
     },
     "localname": "PrepaidExpensesAndOtherCurrentAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/RevenueArrangementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r67"
     ],
     "calculation": {
      "http://www.selectabio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Net proceeds from issuance of common stock",
        "verboseLabel": "Shares issued, value"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.selectabio.com/role/EquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities": {
     "auth_ref": [
      "r68",
      "r70",
      "r90"
     ],
     "calculation": {
      "http://www.selectabio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities classified as other.",
        "label": "Proceeds from (Payments for) Other Financing Activities",
        "terseLabel": "Other financing fees"
       }
      }
     },
     "localname": "ProceedsFromPaymentsForOtherFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r67",
      "r280"
     ],
     "calculation": {
      "http://www.selectabio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds from exercise of stock options"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockPlans": {
     "auth_ref": [
      "r67"
     ],
     "calculation": {
      "http://www.selectabio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from the stock plan during the period.",
        "label": "Proceeds from Stock Plans",
        "terseLabel": "Proceeds from issuance of common stock under Employee Stock Purchase Plan"
       }
      }
     },
     "localname": "ProceedsFromStockPlans",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]",
        "terseLabel": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r29",
      "r168"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Long-Lived Tangible Asset [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r170",
      "r454",
      "r455",
      "r456"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "terseLabel": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/PropertyandEquipment"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r28",
      "r166"
     ],
     "calculation": {
      "http://www.selectabio.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Total property and equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r11",
      "r12",
      "r168",
      "r436"
     ],
     "calculation": {
      "http://www.selectabio.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.selectabio.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/ConsolidatedBalanceSheets",
      "http://www.selectabio.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r11",
      "r168"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Schedule of Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/PropertyandEquipmentTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r11",
      "r166"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Long-Lived Tangible Asset [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RedemptionPremium": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The excess of the (1) fair value of consideration transferred to the holders of a security in excess of (2) the carrying amount of the security reported on the registrant's balance sheet, which will be deducted from net earnings to derive net earnings available to common shareholders. This amount is generally an adjustment considered in the computation of earnings per share.",
        "label": "Redemption Premium",
        "terseLabel": "Redemption premium"
       }
      }
     },
     "localname": "RedemptionPremium",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/EquityNarrativeDetails",
      "http://www.selectabio.com/role/RevenueArrangementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r236",
      "r360",
      "r361"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Domain]",
        "terseLabel": "Related Party [Domain]"
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/RelatedPartyTransactionsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty": {
     "auth_ref": [
      "r360"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.",
        "label": "Related Party Transaction, Expenses from Transactions with Related Party",
        "terseLabel": "Consulting services expenses (less than)"
       }
      }
     },
     "localname": "RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/RelatedPartyTransactionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Related Party Transaction [Line Items]",
        "terseLabel": "Related Party Transaction [Line Items]"
       }
      }
     },
     "localname": "RelatedPartyTransactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/RelatedPartyTransactionsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]",
        "terseLabel": "Related Party Transactions [Abstract]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r236",
      "r360",
      "r363",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]",
        "terseLabel": "Related Party [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/RelatedPartyTransactionsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r358",
      "r359",
      "r361",
      "r364",
      "r365"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "terseLabel": "Related-Party Transactions"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/RelatedPartyTransactions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RepaymentsOfLinesOfCredit": {
     "auth_ref": [
      "r69",
      "r89"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for payment of an obligation from a lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.",
        "label": "Repayments of Lines of Credit",
        "terseLabel": "Repayments of lines of credit"
       }
      }
     },
     "localname": "RepaymentsOfLinesOfCredit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/DebtTermLoansNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfLongTermDebt": {
     "auth_ref": [
      "r69"
     ],
     "calculation": {
      "http://www.selectabio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.",
        "label": "Repayments of Long-term Debt",
        "negatedTerseLabel": "Repayments of principal on outstanding debt"
       }
      }
     },
     "localname": "RepaymentsOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis": {
     "auth_ref": [
      "r291",
      "r292"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by form of arrangement related to research and development.",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/CollaborationAgreementsMITNarrativeDetails",
      "http://www.selectabio.com/role/RevenueArrangementsNarrativeDetails",
      "http://www.selectabio.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain": {
     "auth_ref": [
      "r291",
      "r292"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others.",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/CollaborationAgreementsMITNarrativeDetails",
      "http://www.selectabio.com/role/RevenueArrangementsNarrativeDetails",
      "http://www.selectabio.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r290",
      "r466"
     ],
     "calculation": {
      "http://www.selectabio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalents": {
     "auth_ref": [
      "r10",
      "r78",
      "r83",
      "r415",
      "r432"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Restricted Cash and Cash Equivalents",
        "terseLabel": "Restricted cash and cash equivalents"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/NatureoftheBusinessandBasisofPresentationLiquidityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r2",
      "r10",
      "r78",
      "r83"
     ],
     "calculation": {
      "http://www.selectabio.com/role/FairValueMeasurementsScheduleofCashandCashEquivalentsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Restricted Cash and Cash Equivalents, Current",
        "terseLabel": "Short-term restricted cash"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/FairValueMeasurementsScheduleofCashandCashEquivalentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents [Domain]",
        "terseLabel": "Cash and Cash Equivalents [Domain]"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/FairValueMeasurementsSummaryofAssetsMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsNoncurrent": {
     "auth_ref": [
      "r6",
      "r13",
      "r78",
      "r83",
      "r453"
     ],
     "calculation": {
      "http://www.selectabio.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.selectabio.com/role/FairValueMeasurementsScheduleofCashandCashEquivalentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Restricted Cash and Cash Equivalents, Noncurrent",
        "terseLabel": "Long-term restricted cash"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/ConsolidatedBalanceSheets",
      "http://www.selectabio.com/role/FairValueMeasurementsScheduleofCashandCashEquivalentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashNoncurrent": {
     "auth_ref": [
      "r6",
      "r13",
      "r83",
      "r453"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash, Noncurrent",
        "terseLabel": "Long-term restricted cash"
       }
      }
     },
     "localname": "RestrictedCashNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Unvested restricted stock units"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/NetLossPerShareScheduleofPotentialCommonSharesIssuableUponConversionofWarrantsDetails",
      "http://www.selectabio.com/role/StockIncentivePlansNarrativeDetails",
      "http://www.selectabio.com/role/StockIncentivePlansRestrictedStockUnitsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r20",
      "r198",
      "r284",
      "r434",
      "r446",
      "r448"
     ],
     "calculation": {
      "http://www.selectabio.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "negatedLabel": "Accumulated deficit",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/ConsolidatedBalanceSheets",
      "http://www.selectabio.com/role/NatureoftheBusinessandBasisofPresentationLiquidityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r93",
      "r94",
      "r95",
      "r97",
      "r102",
      "r104",
      "r153",
      "r281",
      "r282",
      "r283",
      "r298",
      "r299",
      "r443",
      "r445"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/ConsolidatedStatementsofChangesinStockholdersDeficitEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer [Abstract]",
        "terseLabel": "Revenue from Contract with Customer [Abstract]"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r120",
      "r121",
      "r124",
      "r129",
      "r130",
      "r134",
      "r135",
      "r137",
      "r213",
      "r214",
      "r401"
     ],
     "calculation": {
      "http://www.selectabio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Grant and collaboration revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "auth_ref": [
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r211",
      "r212",
      "r217",
      "r225"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.",
        "label": "Revenue from Contract with Customer [Text Block]",
        "terseLabel": "Revenue Arrangements"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/RevenueArrangements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligation": {
     "auth_ref": [
      "r210"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue.",
        "label": "Revenue, Remaining Performance Obligation, Amount",
        "terseLabel": "Remaining performance obligation"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/RevenueArrangementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash received on stock transaction after deduction of issuance costs.",
        "label": "Sale of Stock, Consideration Received on Transaction",
        "verboseLabel": "Sale common stock"
       }
      }
     },
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/DebtTermLoansNarrativeDetails",
      "http://www.selectabio.com/role/EquityNarrativeDetails",
      "http://www.selectabio.com/role/RevenueArrangementsNarrativeDetails",
      "http://www.selectabio.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/DebtTermLoansNarrativeDetails",
      "http://www.selectabio.com/role/EquityNarrativeDetails",
      "http://www.selectabio.com/role/RevenueArrangementsNarrativeDetails",
      "http://www.selectabio.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "terseLabel": "Sale of stock, number of shares issued in transaction (in shares)"
       }
      }
     },
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/EquityNarrativeDetails",
      "http://www.selectabio.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.",
        "label": "Sale of Stock, Price Per Share",
        "verboseLabel": "Share price (in dollars per share)"
       }
      }
     },
     "localname": "SaleOfStockPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/EquityNarrativeDetails",
      "http://www.selectabio.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Accrued Expenses"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/AccruedExpensesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r112"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/NetLossPerShareScheduleofPotentialCommonSharesIssuableUponConversionofWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r112"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of Potential Common Shares Issuable Upon Conversion of Warrants"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/NetLossPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Securities, Available-for-sale [Line Items]",
        "terseLabel": "Debt Securities, Available-for-sale [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/MarketableSecuritiesSummaryofAvailableforSaleMarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCashAndCashEquivalentsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of cash and cash equivalent balances. This table excludes restricted cash balances.",
        "label": "Schedule of Cash and Cash Equivalents [Table]",
        "terseLabel": "Schedule of Cash and Cash Equivalents [Table]"
       }
      }
     },
     "localname": "ScheduleOfCashAndCashEquivalentsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/NatureoftheBusinessandBasisofPresentationLiquidityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of cash and cash equivalents.",
        "label": "Schedule of Cash and Cash Equivalents [Table Text Block]",
        "terseLabel": "Schedule of Cash and Cash Equivalents"
       }
      }
     },
     "localname": "ScheduleOfCashAndCashEquivalentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r305"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/CollaborationAgreementsAskBioNarrativeDetails",
      "http://www.selectabio.com/role/CollaborationAgreementsMITNarrativeDetails",
      "http://www.selectabio.com/role/CollaborationAgreementsShenyangSunshinePharmaceuticalCoLtdNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock": {
     "auth_ref": [
      "r276"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.",
        "label": "Share-based Payment Arrangement, Cost by Plan [Table Text Block]",
        "terseLabel": "Schedule of Stock-Based Compensation"
       }
      }
     },
     "localname": "ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/StockIncentivePlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r111"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Computation of Basic and Diluted Net Loss Per Share"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/NetLossPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r252",
      "r276",
      "r286"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/StockIncentivePlansScheduleofStockBasedCompensationExpenseRelatedtoStockOptionsandRestrictedCommonStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "auth_ref": [
      "r314",
      "r315"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Summary of Assets Measured at Fair Value on a Recurring Basis"
       }
      }
     },
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": {
     "auth_ref": [
      "r178"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt.",
        "label": "Schedule of Maturities of Long-term Debt [Table Text Block]",
        "terseLabel": "Schedule of Future Minimum Payments on the Term Loans"
       }
      }
     },
     "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/DebtTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfOperatingLeasedAssetsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of long-lived, depreciable assets that are subject to a operating lease agreements and are used in the normal conduct of business to produce goods and services. Examples may include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Schedule of Operating Leased Assets [Table]",
        "terseLabel": "Schedule of Operating Leased Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfOperatingLeasedAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r29",
      "r168"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "auth_ref": [
      "r87",
      "r362",
      "r363"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Schedule of Related Party Transactions, by Related Party [Table]",
        "terseLabel": "Schedule of Related Party Transactions, by Related Party [Table]"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/RelatedPartyTransactionsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock": {
     "auth_ref": [
      "r10",
      "r83",
      "r415",
      "r432"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage.",
        "label": "Restrictions on Cash and Cash Equivalents [Table Text Block]",
        "terseLabel": "Schedule of Restricted Cash and Cash Equivalents"
       }
      }
     },
     "localname": "ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r253",
      "r279"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/StockIncentivePlansEmployeeStockPurchasePlanNarrativeDetails",
      "http://www.selectabio.com/role/StockIncentivePlansNarrativeDetails",
      "http://www.selectabio.com/role/StockIncentivePlansRestrictedStockUnitsDetails",
      "http://www.selectabio.com/role/StockIncentivePlansScheduleofAssumptionsDetails",
      "http://www.selectabio.com/role/StockIncentivePlansSummaryofOptionsActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r256",
      "r265",
      "r268"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Summary of Options Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/StockIncentivePlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r270"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of Weighted Average Assumptions Used"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/StockIncentivePlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r38",
      "r84",
      "r118",
      "r119",
      "r186",
      "r188",
      "r189",
      "r191",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]",
        "terseLabel": "Schedule of Stock by Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/EquityScheduleofAuthorizedSharesofCommonStockforFutureIssuanceDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfStockByClassTextBlock": {
     "auth_ref": [
      "r15",
      "r16",
      "r17",
      "r187",
      "r188",
      "r189",
      "r191",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's stock, including par or stated value per share, number and dollar amount of share subscriptions, shares authorized, shares issued, shares outstanding, number and dollar amount of shares held in an employee trust, dividend per share, total dividends, share conversion features, par value plus additional paid in capital, the value of treasury stock and other information necessary to a fair presentation, and EPS information.  Stock by class includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. Includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity. If more than one issue is outstanding, state the title of each issue and the corresponding dollar amount; dollar amount of any shares subscribed but unissued and the deduction of subscriptions receivable there from; number of shares authorized, issued, and outstanding.",
        "label": "Schedule of Stock by Class [Table Text Block]",
        "terseLabel": "Schedule of Authorized Shares of Common Stock for Future Issuance"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/EquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": {
     "auth_ref": [
      "r199",
      "r251"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.",
        "label": "Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]",
        "terseLabel": "Schedule of Stockholders' Equity Note, Warrants or Rights"
       }
      }
     },
     "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/EquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r75"
     ],
     "calculation": {
      "http://www.selectabio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r254"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period",
        "terseLabel": "Award vesting term"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/StockIncentivePlansNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r260"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedTerseLabel": "Forfeited in period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/StockIncentivePlansRestrictedStockUnitsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r264"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "terseLabel": "Forfeited in period (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/StockIncentivePlansRestrictedStockUnitsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r262"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Grants in period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/StockIncentivePlansNarrativeDetails",
      "http://www.selectabio.com/role/StockIncentivePlansRestrictedStockUnitsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r262"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Grants in period (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/StockIncentivePlansNarrativeDetails",
      "http://www.selectabio.com/role/StockIncentivePlansRestrictedStockUnitsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r261"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Unvested at end of period (in shares)",
        "periodStartLabel": "Unvested at beginning of period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/StockIncentivePlansRestrictedStockUnitsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/StockIncentivePlansRestrictedStockUnitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r261"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Unvested at end of period (in dollars per share)",
        "periodStartLabel": "Unvested at beginning of period (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/StockIncentivePlansRestrictedStockUnitsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/StockIncentivePlansRestrictedStockUnitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r263"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedTerseLabel": "Vested in period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/StockIncentivePlansRestrictedStockUnitsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue": {
     "auth_ref": [
      "r267"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value",
        "terseLabel": "Vested in period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/StockIncentivePlansNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r263"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Vested in period (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/StockIncentivePlansRestrictedStockUnitsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r273"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "verboseLabel": "Dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/StockIncentivePlansScheduleofAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r272"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "verboseLabel": "Expected volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/StockIncentivePlansScheduleofAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r274"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "verboseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/StockIncentivePlansScheduleofAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/StockIncentivePlansEmployeeStockPurchasePlanNarrativeDetails",
      "http://www.selectabio.com/role/StockIncentivePlansNarrativeDetails",
      "http://www.selectabio.com/role/StockIncentivePlansRestrictedStockUnitsDetails",
      "http://www.selectabio.com/role/StockIncentivePlansScheduleofAssumptionsDetails",
      "http://www.selectabio.com/role/StockIncentivePlansSummaryofOptionsActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r279"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Number of shares authorized for grants (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/StockIncentivePlansNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r260"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period",
        "negatedTerseLabel": "Forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/StockIncentivePlansSummaryofOptionsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/StockIncentivePlansNarrativeDetails",
      "http://www.selectabio.com/role/StockIncentivePlansSummaryofOptionsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r266"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted average grant date fair value of stock options (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/StockIncentivePlansNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r279"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/StockIncentivePlansSummaryofOptionsActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r258",
      "r279"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/StockIncentivePlansSummaryofOptionsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Number of Options"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/StockIncentivePlansSummaryofOptionsActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r257"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Ending balance (in dollars per share)",
        "periodStartLabel": "Beginning balance (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/StockIncentivePlansSummaryofOptionsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted-average exercise price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/StockIncentivePlansSummaryofOptionsActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "auth_ref": [
      "r268"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value",
        "verboseLabel": "Vested and expected to vest"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/StockIncentivePlansSummaryofOptionsActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "auth_ref": [
      "r269"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "verboseLabel": "Vested and expected to vest (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/StockIncentivePlansSummaryofOptionsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r269"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "verboseLabel": "Vested and expected to vest (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/StockIncentivePlansSummaryofOptionsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod": {
     "auth_ref": [
      "r279"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period",
        "terseLabel": "Shares of common stock issued to employees under the ESPP (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/StockIncentivePlansEmployeeStockPurchasePlanNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r251",
      "r255"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/EquityScheduleofAuthorizedSharesofCommonStockforFutureIssuanceDetails",
      "http://www.selectabio.com/role/StockIncentivePlansNarrativeDetails",
      "http://www.selectabio.com/role/StockIncentivePlansRestrictedStockUnitsDetails",
      "http://www.selectabio.com/role/StockIncentivePlansScheduleofAssumptionsDetails",
      "http://www.selectabio.com/role/StockIncentivePlansSummaryofOptionsActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Exercised (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/StockIncentivePlansSummaryofOptionsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Forfeited (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/StockIncentivePlansSummaryofOptionsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/StockIncentivePlansSummaryofOptionsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r271",
      "r285"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term",
        "verboseLabel": "Expected term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/StockIncentivePlansScheduleofAssumptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r269"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Outstanding, term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/StockIncentivePlansSummaryofOptionsActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r269"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Vested and expected to vest, term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/StockIncentivePlansSummaryofOptionsActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options vested.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares",
        "terseLabel": "Vested (in shares)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/StockIncentivePlansSummaryofOptionsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShortTermLeaseCost": {
     "auth_ref": [
      "r348",
      "r355"
     ],
     "calculation": {
      "http://www.selectabio.com/role/LeasesComponentsofleasecostsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less.",
        "label": "Short-term Lease, Cost",
        "terseLabel": "Short-term lease cost"
       }
      }
     },
     "localname": "ShortTermLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/LeasesComponentsofleasecostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r92"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/SummaryofSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r40",
      "r93",
      "r94",
      "r95",
      "r97",
      "r102",
      "r104",
      "r117",
      "r153",
      "r190",
      "r198",
      "r281",
      "r282",
      "r283",
      "r298",
      "r299",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r443",
      "r444",
      "r445"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/ConsolidatedStatementsofChangesinStockholdersDeficitEquity",
      "http://www.selectabio.com/role/EquityNarrativeDetails",
      "http://www.selectabio.com/role/EquityScheduleofAuthorizedSharesofCommonStockforFutureIssuanceDetails",
      "http://www.selectabio.com/role/EquityWarrantyActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/ConsolidatedStatementsofChangesinStockholdersDeficitEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]",
        "terseLabel": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r93",
      "r94",
      "r95",
      "r117",
      "r401"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/ConsolidatedStatementsofChangesinStockholdersDeficitEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockCompensationPlanMember": {
     "auth_ref": [
      "r112"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement in which award of equity shares are granted. Arrangement includes, but is not limited to, grantor incurring liability for product and service based on price of its shares.",
        "label": "Share-based Payment Arrangement [Member]",
        "netLabel": "Employees",
        "terseLabel": "Shares available for future stock incentive awards",
        "verboseLabel": "Employee stock option grants"
       }
      }
     },
     "localname": "StockCompensationPlanMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/EquityScheduleofAuthorizedSharesofCommonStockforFutureIssuanceDetails",
      "http://www.selectabio.com/role/StockIncentivePlansNarrativeDetails",
      "http://www.selectabio.com/role/StockIncentivePlansScheduleofAssumptionsDetails",
      "http://www.selectabio.com/role/StockIncentivePlansSummaryofOptionsActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "auth_ref": [
      "r16",
      "r17",
      "r190",
      "r198"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.",
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "verboseLabel": "Issuance of common stock under Employee Stock Purchase Plan (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/ConsolidatedStatementsofChangesinStockholdersDeficitEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesOther": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued attributable to transactions classified as other.",
        "label": "Stock Issued During Period, Shares, Other",
        "terseLabel": "Issuance of common stock through at-the-market offering, net (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesOther",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/ConsolidatedStatementsofChangesinStockholdersDeficitEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": {
     "auth_ref": [
      "r190",
      "r198"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Gross",
        "terseLabel": "Issuance of vested restricted stock units (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/ConsolidatedStatementsofChangesinStockholdersDeficitEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r16",
      "r17",
      "r190",
      "r198",
      "r259"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Exercised (in shares)",
        "terseLabel": "Issuance of common stock upon exercise of options (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/ConsolidatedStatementsofChangesinStockholdersDeficitEquity",
      "http://www.selectabio.com/role/StockIncentivePlansSummaryofOptionsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": {
     "auth_ref": [
      "r16",
      "r17",
      "r190",
      "r198"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.",
        "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan",
        "terseLabel": "Issuance of common stock under Employee Stock Purchase Plan"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/ConsolidatedStatementsofChangesinStockholdersDeficitEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueOther": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of shares of stock issued attributable to transactions classified as other.",
        "label": "Stock Issued During Period, Value, Other",
        "terseLabel": "Issuance of common stock through at-the-market offering, net"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueOther",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/ConsolidatedStatementsofChangesinStockholdersDeficitEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross": {
     "auth_ref": [
      "r16",
      "r17",
      "r190",
      "r198"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate value of stock related to Restricted Stock Awards issued during the period.",
        "label": "Stock Issued During Period, Value, Restricted Stock Award, Gross",
        "terseLabel": "Issuance of vested restricted stock units"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/ConsolidatedStatementsofChangesinStockholdersDeficitEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r40",
      "r190",
      "r198"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Issuance of common stock upon exercise of options"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/ConsolidatedStatementsofChangesinStockholdersDeficitEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r17",
      "r22",
      "r23",
      "r86",
      "r140",
      "r152",
      "r325"
     ],
     "calculation": {
      "http://www.selectabio.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total stockholders\u2019 (deficit) equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/ConsolidatedBalanceSheets",
      "http://www.selectabio.com/role/ConsolidatedStatementsofChangesinStockholdersDeficitEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders\u2019 (deficit) equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r85",
      "r198",
      "r200"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/Equity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsequentEventLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.",
        "label": "Subsequent Event [Line Items]",
        "terseLabel": "Subsequent Event [Line Items]"
       }
      }
     },
     "localname": "SubsequentEventLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r337",
      "r367"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTable": {
     "auth_ref": [
      "r337",
      "r367"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.",
        "label": "Subsequent Event [Table]",
        "terseLabel": "Subsequent Event [Table]"
       }
      }
     },
     "localname": "SubsequentEventTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r337",
      "r367"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r337",
      "r367"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]",
        "terseLabel": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r366",
      "r369"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent Events"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/SubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Different names of stock transactions and the different attributes of each transaction.",
        "label": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]",
        "terseLabel": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]"
       }
      }
     },
     "localname": "SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/EquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/DebtTermLoansNarrativeDetails",
      "http://www.selectabio.com/role/EquityNarrativeDetails",
      "http://www.selectabio.com/role/RevenueArrangementsNarrativeDetails",
      "http://www.selectabio.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsidiarySaleOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Subsidiary, Sale of Stock [Line Items]",
        "terseLabel": "Subsidiary, Sale of Stock [Line Items]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/EquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplement cash flow information"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r149",
      "r150",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/FairValueMeasurementsSummaryofAssetsMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.selectabio.com/role/MarketableSecuritiesSummaryofAvailableforSaleMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r305"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/CollaborationAgreementsAskBioNarrativeDetails",
      "http://www.selectabio.com/role/CollaborationAgreementsMITNarrativeDetails",
      "http://www.selectabio.com/role/CollaborationAgreementsShenyangSunshinePharmaceuticalCoLtdNarrativeDetails",
      "http://www.selectabio.com/role/RevenueArrangementsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "auth_ref": [
      "r293",
      "r295"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrecognized tax benefits.",
        "label": "Unrecognized Tax Benefits",
        "terseLabel": "Unrecognized tax benefits"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefits",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ValuationTechniqueAxis": {
     "auth_ref": [
      "r317"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by valuation approach and technique.",
        "label": "Valuation Approach and Technique [Axis]",
        "terseLabel": "Valuation Approach and Technique [Axis]"
       }
      }
     },
     "localname": "ValuationTechniqueAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/FairValueMeasurementsAssumptionsusedtorecordthefairvalueofthewarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ValuationTechniqueDomain": {
     "auth_ref": [
      "r317"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Valuation approach and technique.",
        "label": "Valuation Approach and Technique [Domain]",
        "terseLabel": "Valuation Approach and Technique [Domain]"
       }
      }
     },
     "localname": "ValuationTechniqueDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/FairValueMeasurementsAssumptionsusedtorecordthefairvalueofthewarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ValuationTechniqueOptionPricingModelMember": {
     "auth_ref": [
      "r317"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Valuation technique calculating price of option.",
        "label": "Valuation Technique, Option Pricing Model [Member]",
        "terseLabel": "Valuation Technique, Option Pricing Model"
       }
      }
     },
     "localname": "ValuationTechniqueOptionPricingModelMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/FairValueMeasurementsAssumptionsusedtorecordthefairvalueofthewarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_VariableLeaseCost": {
     "auth_ref": [
      "r349",
      "r355"
     ],
     "calculation": {
      "http://www.selectabio.com/role/LeasesComponentsofleasecostsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.",
        "label": "Variable Lease, Cost",
        "terseLabel": "Variable lease cost"
       }
      }
     },
     "localname": "VariableLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/LeasesComponentsofleasecostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_VariableRateAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of variable rate.",
        "label": "Variable Rate [Axis]",
        "terseLabel": "Variable Rate [Axis]"
       }
      }
     },
     "localname": "VariableRateAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/DebtTermLoansNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableRateDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.",
        "label": "Variable Rate [Domain]",
        "terseLabel": "Variable Rate [Domain]"
       }
      }
     },
     "localname": "VariableRateDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/DebtTermLoansNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount": {
     "auth_ref": [
      "r107",
      "r111",
      "r192"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of (increase) decrease in equity for down round feature triggered for warrant classified as equity.",
        "label": "Warrant, Down Round Feature, (Increase) Decrease in Equity, Amount",
        "terseLabel": "Warrant, increase (decrease) in equity, amount"
       }
      }
     },
     "localname": "WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/EquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Warrant [Member]",
        "netLabel": "Warrant liabilities",
        "terseLabel": "Warrants to purchase common stock",
        "verboseLabel": "Exercise of common warrants"
       }
      }
     },
     "localname": "WarrantMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/DebtTermLoansNarrativeDetails",
      "http://www.selectabio.com/role/EquityNarrativeDetails",
      "http://www.selectabio.com/role/EquityScheduleofAuthorizedSharesofCommonStockforFutureIssuanceDetails",
      "http://www.selectabio.com/role/EquityWarrantyActivityDetails",
      "http://www.selectabio.com/role/FairValueMeasurementsChangeinthewarrantliabilitiesDetails",
      "http://www.selectabio.com/role/NetLossPerShareScheduleofPotentialCommonSharesIssuableUponConversionofWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantsAndRightsOutstanding": {
     "auth_ref": [],
     "calculation": {
      "http://www.selectabio.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      },
      "http://www.selectabio.com/role/FairValueMeasurementsSummaryofAssetsMeasuredatFairValueonaRecurringBasisDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.",
        "label": "Warrants and Rights Outstanding",
        "terseLabel": "Warrant liabilities",
        "verboseLabel": "Warrant liabilities"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/ConsolidatedBalanceSheets",
      "http://www.selectabio.com/role/EquityNarrativeDetails",
      "http://www.selectabio.com/role/FairValueMeasurementsSummaryofAssetsMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WarrantsAndRightsOutstandingMeasurementInput": {
     "auth_ref": [
      "r319"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.",
        "label": "Warrants and Rights Outstanding, Measurement Input",
        "terseLabel": "Warrants and rights outstanding, measurement input"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstandingMeasurementInput",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/FairValueMeasurementsAssumptionsusedtorecordthefairvalueofthewarrantsDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "us-gaap_WarrantsAndRightsOutstandingTerm": {
     "auth_ref": [
      "r319"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Warrants and Rights Outstanding, Term",
        "terseLabel": "Warrants and rights outstanding, term"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstandingTerm",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/FairValueMeasurementsAssumptionsusedtorecordthefairvalueofthewarrantsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).",
        "label": "Weighted Average Number of Shares Outstanding, Basic and Diluted",
        "terseLabel": "Weighted\u2011average common shares outstanding\u2014basic and diluted (in shares)",
        "verboseLabel": "Basic and diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.selectabio.com/role/NetLossPerShareComputationofBasicandDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]",
        "terseLabel": "Weighted average common shares outstanding:",
        "verboseLabel": "Denominator:"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.selectabio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.selectabio.com/role/NetLossPerShareComputationofBasicandDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    }
   },
   "unitCount": 7
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1448-109256"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1377-109256"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL109261756-109256"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "270",
   "URI": "http://asc.fasb.org/extlink&oid=121640914&loc=SL77927221-108306"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70191-108054"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70229-108054"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4428-111522"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4531-111522"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=d3e26610-111562"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=d3e26853-111562"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=d3e26626-111562"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=SL6284422-111562"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27232-111563"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=SL120269820-111563"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "http://asc.fasb.org/topic&trid=2196928"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919244-210447"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919249-210447"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919253-210447"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919258-210447"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919230-210447"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121558606&loc=SL82898722-210454"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922888-210455"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922895-210455"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922900-210455"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=68051541&loc=SL49131252-203054"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "http://asc.fasb.org/topic&trid=2155823"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=d3e1835-112601"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=109126253&loc=d3e4724-112606"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6031897-161870"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6031897-161870"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=117329964&loc=d3e12317-112629"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=117329964&loc=d3e12355-112629"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "http://asc.fasb.org/topic&trid=2208564"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=109262497&loc=d3e20148-110875"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=65877616&loc=d3e177068-122764"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=65877616&loc=d3e177068-122764"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21553-112644"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=SL109261905-112644"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21484-112644"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21488-112644"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "50",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130531-203044"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130532-203044"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130533-203044"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130551-203045"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130556-203045"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130556-203045"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130558-203045"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130543-203045"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130549-203045"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130549-203045"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130550-203045"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "http://asc.fasb.org/topic&trid=49130388"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(l)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(o)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(p)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(q)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(r)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(r)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=21916913&loc=d3e273930-122802"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "60",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=6414203&loc=d3e39689-114964"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "70",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "715",
   "URI": "http://asc.fasb.org/topic&trid=2235017"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121326096&loc=d3e4534-113899"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11149-113907"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11178-113907"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=SL37586934-109318"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32705-109319"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32857-109319"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330215-122817"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "http://asc.fasb.org/topic&trid=2197479"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5618551-113959"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "182",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121582272&loc=SL5629052-113961"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19279-110258"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL6742756-110258"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=120253306&loc=d3e28228-110885"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=121605123&loc=d3e30226-110892"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=109240200&loc=d3e30690-110894"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450222&loc=d3e30840-110895"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28555-108399"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=68176171&loc=SL68176184-208336"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918638-209977"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918643-209977"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918673-209980"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918701-209980"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121568110&loc=SL77918982-209971"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/subtopic&trid=77888251"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121576215&loc=SL77919372-209981"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "http://asc.fasb.org/topic&trid=2122745"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "http://asc.fasb.org/topic&trid=2122774"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.28,29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=119991564&loc=SL119991595-234733"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "940",
   "URI": "http://asc.fasb.org/subtopic&trid=2176304"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/subtopic&trid=2209399"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "405",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6957935&loc=d3e64057-112817"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Subparagraph": "e",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(10))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121643868&loc=SL117782755-158439"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117819544-158441"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=118262064&loc=SL116631418-115840"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e637-108580"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=118262064&loc=SL116631419-115840"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "946",
   "URI": "http://asc.fasb.org/subtopic&trid=2324412"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=120413173&loc=SL116631458-115580"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=SL120174063-112916"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e681-108580"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r467": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r468": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r469": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669686-108580"
  },
  "r470": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r471": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r472": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r473": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL34724394-108580"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6801-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e557-108580"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(7)(c))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.3)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6812-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(a),(b))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3151-108585"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6911-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3367-108585"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3044-108585"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4297-108586"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6935-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4304-108586"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4313-108586"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4332-108586"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=SL98516268-108586"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(k))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(e),(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e7018-107765"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04.(a))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21914-107793"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21930-107793"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21711-107793"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>93
<FILENAME>0001453687-21-000069-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001453687-21-000069-xbrl.zip
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MJMB3(O1$#,H6>K42$["KQA$/9Z4@83SB0<! Z(2<".;Q>,1XZ#/Q9R+-C'D
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MB^]3EJ=1N5O;(SKT_O-+_^;W_&#HZQGM7&WI+Q0F[;V38;!S!GS*M9]5WX$
M$^,L9^&UU>7(!>0M7IP,_G#M?Y.;D0"=G<AX,2,Q-X0XU]+</XQ9J]'<P\E)
MM!=@DXX1"'89@ 5Q0T4VH,A8H=24.I3D_-DHL&8TK.)T"5D8?]G^EGAHS:*#
MJ)=BX"C'X)3W&4:3N#!^JX6=5*D@)X+$IX#0&'!3<+^P$_1TD8;"#*PCR2;;
M5IL>@XR(B51)C"-K$0K,TF@.Q)\ 1$8 K'@Y><J0C>Z962',#)6 $9=#-DRL
M(T@G27&018:N.0+K$X:T:GZ !>\#:+A>2#GZ<(I7:>8ESDM]$5BAO^Q)EXA7
M8S\YG\8G2OJ47^)8MDH&QGI,X 1 $"9V?CL7R2Q"F7PLD^65CZ:+HC6@!BFE
MGPX:YF#-,C&='0PDA.FV#+<\ZX,:9<D%-A26#/V*^QX#J@ ZL!9'H+(_HEY;
MG8YAX0#<M0M:['2/BW:6S80'R0( 8->!>(DFQ>R$$$X7T6R5X\/7&A,JCZ]]
M^6,I_5"BVEOS7MZA%#=D*2VT8"]HS-\.#H+V*FG]J<K.#0YM!+\L=ZM)K;4H
M^'24:&\$V00[L(U24NZU'C(G^F[\Q<<=TKC7@6N!I8!X#JTU+H7>/9TRGD?O
M9$?FUD.+H8!$A;#E)9V?+Y%4.;>Y:9PRXTK'2@N;^:E0L!PJK]=FO9BYIFN(
M52# 1,=4 NE:6X%#@[4MWS&P)B!;(LR7Y(J?R4[0V6P=?+S@,: E/X-8AF84
MX_/.' VEADL#/*V*,^18F( KZ/GG^?9,P)^UAG!YXG^9M.P#:@3=FPL^MR4@
M-I6@-1[ ),.$1LLWE2Z8'(^%+V&Q(%M!(4-YQ\Z5A8+F3U&DZEILP-N/,>";
M8?F[._FX[N0:\_=,QBZ-LRMLI*88"+O =7A7N8L$?B[D:X?#K'X^6M8WE=ON
M#EOV'BWU5/]?#]G]0Y63%Q:JE,N?+*(5@RD=9N4V;P]G0&A,P6R(BX97XR&N
ME ,1UY"T\FA4F5=A\UX 3P;>-6^;33#7](?<J;2%![H[L%Z5)S+97_O02-DC
MJQ?3-KIQ![!<Y=Y*2-I(6BUG/F_<=98_,+\X$XG5F/0TY+()?,AQ2%PKG@LP
M5J_2\VEXF]1N$Z(/55^*CGC=9R.\UQV[RP6 Y&^P)Y0Q^;ED)'=T*Y\L\H&:
M@#<9)//*+[ =(2$_!]]MW8RJ/5,9B_GIQ8K=UFU926/'C&0,M1I_+=PK*R:"
MXMOB'A:Y%D+L]=J*T]+8BLV5HYNTJNH8]R%M:JQ)M.-7.T53^O,9O<]">ZCF
MEUIZSSQ"@W%D)+2KFXL4LDA+6UJG",6%MK<+D5I[3()B#C A8!71LOP$40N^
M#^&3,.Q7'D!JNDT694@]I]6Z.KTTA#MHX./:FAY^<&#)^>G95SP:5OJ3$[^*
M&)L2)2A9Y[VRE<@)0$>N,#TS;06=>DPV9M=F5L6ZSO;.WKNE#IP59RKX!!CB
MPZ4@2$^=9T=/TFHSB6,ES>2LBR\$"Y(RVV]#^.S0#'7( !STVJ'$KE#&4:]L
MD&LG%ZND*PHAC#+,'Y$O?L",M$IN1U;U"8>)Y2UM[XB\DDQLIK-*9W<TW?.$
MR.4"MR_ ]!?[.HC, ;IYA.8+&X7A^XPHO%K,V*P$AK#3"KFF(XD=B9@E8<I[
M#9^S]')R0V]:(*M8B,2\CF#R^<)#:3$7R'RM1 ^%I&&&:%Z:*-YGT0;'(!GI
M)&RTZB3!84EO=5D@:7O6]\ NW\*@95:#U8P,@C2@9N6PR74_E><E6@O70>:8
M8(>W9 RZF,RK8).GJBS%\BHQB_J <;0"WOU]).G9?!+&Q,\?7HWY9SE.QJ0X
M\Y J.SQQG\!J_CZ1A:+BJV2VFXUW5%"*;2;X9/'1BYRQ*\^07;/6:"$A\N-U
M'_MG_9OKUS)D]\ 2J1L[JM",4.Z]/A&?D0.T\IZ;4:)RR-+,#GA?&KV)4U^7
M*AP?J\26R]8%#YE-E]Z=MS3MP^/,2YBLIJ%;1MP>:N*__7M!BQGV;^;^+7D3
MK6Y?V$NO#G[_/U!+ P04    " !O0*U2$WCB<@H(   S*   %P   &5X:&EB
M:70S,3%?,#,S,3(P,C$N:'1M[5IK<]LV%OV^OP)59E-[1B_J83NRXYG$=J>>
M:1/7]4YF/^U !"AB31$L $K6_OH]%Z >MJ1&CI.F<9M,&)$$+N[CX-Q[29Y\
M=_[^[.;?5Q<L=>.,7?WK[4^79ZS6:+4^=,]:K?.;<_;CS<\_L5ZS';$;PW.K
MG-(YSUJMBW<U5DN=*P:MUG0Z;4Z[36U&K9OK%HGJM3*MK6P*)VJG)W0%1\G%
MZ3].OFLTV+F.R[','8N-Y$X*5EJ5C]@'(>TM:S2J46>ZF!DU2AWKM#L1^Z#-
MK9KP<-\IE\G3N9R35C@_:?E%3H9:S$Y/A)HP)5[7U$&OUS]J]T2O?YCT>C+A
M8MCO\/BHTSOJ1NUH^)\(2K8P/,RQ;I;)U[6QRANII/4'W8/"'4^5<.D@:K?_
M6?/C3D\2G3LL9C Y_ PRUB5Q,X*PH79.CP=1!\*<O',-GJE1/O FA@LJ%[!F
M<- M7"V(GXN(=:;-X$7;_SFF.XV$CU4V&WQ_H\;2LG=RRJ[UF.??URWBU+#2
MJ"0,M.I_<A!%6-6?3H--AY"3J5S.;8PZ9-C%7:J&RK%NU(SN6[6S/3%,D.8K
MZ7]V<7US^</EV9N;R_?O?OU$"_Y;6J>2V1<WH;?1A,LZ.^/&.IFSMZ;,\SJ[
M2IOG319+0UHQEW+W\D7_Z/ACUCE= *Y8L^!"8'\U,IE46%Y%6R,Z^@/@MMG6
MJ/GR1730/EX_7K*43R0S<J+D% SA4F79+R4WP%8V8]>RT,8QG;,?M!FSJ-WX
MA>F$_2HS&3O.WBIM8R7S6-HZN\QC+--_]1P<UMGJL+?<PDUPR'C&;G,]S:08
MR7KPFPG>$AJ*Y!JTBW6XRAG/9ZS,G2DE[  1>TZ&&SD;X\PHGK&$Q[ADF!Z#
M%9P.X]8&Y!*>MMS,:,B8WTJLNR+3XIJ ,E@R\X2.-6A K P(',,H4-!$2,.F
MJ8I39DLZ+.=/I9&5$#)@K&P&IJ>D,54NA8&V0.!I=9);0#4M8.8$TP0;SE;=
M\%R@T'T\%"1+5 YG4]R6SJT#!QB.VV;EOLH3["Q.^1Z_XZP4D(D KGBRCN K
MVHT%_$_0(4AEV1(;55CL@Z4!/^$+B3J-*#,, " THN:7LUZ?F-N4)9F>VCE:
MC!PIZU"%.,;I8M ;6M97@F[GRJQI^USBWML:]YM[3GKYXJ@3'1[;*K)5^J M
MHY-$X=2[[Y)Q(WV@X'@US"0YE$F@8Y@IF])P&C8&71!ET+E0-LZT+3&/B,3H
M+$2L,#J6 I<MVT. A$3$0Q0N[N*4YR/)WF"/7I<91D1=WHCZ>W+?3XWZ(IR%
M4T451!Z00O(9;>05 (6 DBX[+Y3<6RC!0F3G0UAA!*6=)Z37P\Y#J'0ZS?Y7
M \L>W]^&EG-I4>S ;YYK/Q[4.J6!F)=V]RG$QT.) %4K!8;7I8$ ;->)LIX$
M,$KF7@[5-DOZ6*4@(S/N(UY1_#)J]8J>Z*8"E4 7JS,E?&-ARZ%50G&CR  5
M$I$GQ9PDE9:2@]\@UF<23QGH7* 06@H_J4#-H>(RX\1T,,LKL4PRF!%2UFJF
MQ:^AI($@(\R7X@GD\V=#U'!'1.V\B=> M?OVWQE?P.1$"8(-MVA@B>>X!>2H
M\B L<2/F<072%!^J3+D999Y-RQ+*/01\= - [PU=J5P\G=Y5!A6E*8 NZS-E
M'&LCO *^AAG)' DP \AP1Q:$7AJ"^BP "2A7!1CM&4$IW@JEBPG/2K^#R<\R
M25!&J D\9#>4 XM,MP,CA=/-%8)'#B:"36RH0X:Z=-LUV(4S^6*TI"(K^7A]
MRH;S\LUO!AD\ 7U\X&F!YQ%\L9U'@E_7XT/]2I7@_9V-('@$>U"VT7%<&HK"
M"K5OD#K6UN$Z/=R +!M#T&^A&V5[6Z8D@!/V]8/1E>(H;Z5OM:@+R\N%7OM!
MJY3;11XD1O#PD\)3I?='16,S-%2W,JOZK@?CZT]VT0)R[!D4SOW/7#C[!Q1B
MCM7Z<M\2C:SB9;F%*>*/R(MKM<Y"-8YZQVEC%ZG(7X#(,?IT)^7OD.10(]G1
M?:&@GQ>R!U2!DRQQ'OZGJFN^%>1OI8+Z'O9E'OO^;/\O41^_02=+=85"S*DY
MH#;#/U-251I9U*E3R6\I+X2\[C.#KTC\<Y-Y5_NHT%<E96C--FQU+C#1RL5.
MWPJ3JH[!%,0:Y48])">+S&3+,2(%7WEC*H;=V/\_L\2SO8!]@_R2&&RE.@(@
M_>Y'"/T#IRK6]4#/*I_H;"*)HW,^JIZ;F8HPY+C(]$SB[C35@27X/20A\I\E
M@35W?+X-7Q^O1"BXWODBN!H_!#2D:2 $&2^L',Q_'(/>BHS/!BKWCO23CB?$
MB,AIU>-RR*Q>CKQZU3SJ=^G]B#/X)^;BJU<G3?_JI.7$^KW>8?-5[VCK[78S
MVGKO]\0>--N'O<\NM==I'ASNIFS+.R(X TZU!<]?U[JU^81JGPPZQ1V+-KZ$
MV.#L/W[?^'=>88LL(%=9_K=1WX11GXY#HO"'I@5>V6Q=)Z:_7]"ZG_F,1=VZ
M?RG\M,!M,NUK1VW]^#0;P]O8/Y.5/>0X?]SXFO,+HO9KA_;Y@74'BZK*PE>&
M!=2D)[-LKM\WA-N_L?J7MN@KP-%+'"B'I>(=K+PRZ#FIO?+MW%FJ9,(N[F1<
MTE-+]CX\N0BO3,^KQO]3\-LFS]1V<N,CAGZ3'M^["L_DT9*M.7I_W;<MWSQM
M:-;F0H^H<=;A$[M!>-\UD6N?G2V)U?=V[>44/@2[EF[[E&T?:6W]AJTZAL_I
M_(=]I_\'4$L#!!0    ( &] K5)?WOKF^@<  !@H   7    97AH:6)I=#,Q
M,E\P,S,Q,C R,2YH=&WM6FMSVS86_=Y?@2K3U)[1BY+\DAW/.+8S]4R;I*YW
M,OMI!R1 "35%L  H6?OK]UR >MB2$GGC-*G;9,*(Y,7%?1R<>T'RY/N+=^<W
M_WY_R89NE+'W_WK]\]4YJS5:K0_=\U;KXN:"_73SR\^LUVQ'[,;PW"JG=,ZS
M5NOR;8W5ALX5_59K,IDT)]VF-H/6S76+5/5:F=96-H43M=,3NH*CY.+TNY/O
M&PUVH9-R)'/'$B.YDX*55N4#]D%(>\L:C4KJ7!=3HP9#QSKM3L0^:'.KQCS<
M=\IE\G2FYZ05SD]:?I*36(OIZ8E08Z;$JYKJ=@[C.#XZ.NJ)N+>_?\1C*0_W
M#L5^VCOL1MW]_T0PL@7Q,,:Z:29?U48J;PPES=_O[A?N>**$&_:C=ON'FI<[
M/4EU[C"9P>#P,^A8U<3- ,IB[9P>]:,.E#EYYQH\4X.\[UT,%U0NX$U_OUNX
M6E _4Y'H3)O^B[;_<TQW&BD?J6S:__%&C:1E;^6$7>L1SW^L6^2I8:51:1"T
MZK^R'T68U9].@D\'T).I7,Y\C#KDV.7=4,7*L6[4[-SW:FM_$K@@S5>R__SR
M^N;JS=7YV<W5N[>__9\>_%Y:I]+I%W>AM]:%JSI[;;A(M1'LHLDN^'!DZRR1
MAFQB;LC=RQ=[A\>?\LWI F#%C 47 JNKD<FT0O(RUAK1X9\ MO6>1LV7+Z+]
M]O'J\8H-^5@R(\=*3L /;J@L^[7D!LC*INQ:%MHXIG/V1IL1B]J-7YE.V6\R
MDXGC[+72-E$R3R0"=Y4GF&;OZ#D$K+,Q8*^Y19@0D-&4W>9ZDDDQD/40-Q.B
M)30,R35(%_-PE3.>3UF9.U-*^ $:]HR,,'(VPIE1/&,I3W#),#T")S@=Y%8$
M<HE(6VZF)#+BMQ+S+NFTN"9@#*;,/)UC#A)(E %]0XP2!4N$-&PR5,F0V9(.
MB_$3:62EA!P8*9N!YZED3)0;PD%;(/$T.^DM8)H6<'.,88+%T^4P/!<H=!\/
M!<E2E2/8E+=%<.O  <1QVRS=5SGX!UE&M<?O)"L%="*!2Y&L(_F*5F.!^!-T
M"%)9ML!&E1;[8&K 3_@VHDX2908! $(C:WXZZ^U)N!VR--,3.T.+D0-E'7H0
MQSA=#';#ROI2TNW,F!5KGTO>>QOS?G,O2"]?'':B@V-;9;8J'[1D=)HJG/KP
M73%NI$\4 J_B3%) F00ZXDS9(8F3V AT091!YT+9)-.VQ#@B$J.SD+'"Z$0*
M7+9L!PD2$AD/6;B\2X8\'TAVAC5Z76:0B+J\$>WMR%T_--H3X2R<*NH?\H 4
MTL]H(2\!*"24;-EZHO3>1"DF(C\?P@H25'8^H[P>=!Y"I=-I[GTUL.SPW4UH
MN9 6K0[BYKGVTTFM4QE(>&FW'T)\'$LDJ)HI,+PN#11@N8Z5]20 *9E[/=3;
M+.ACF8*,S+C/>$7QBZS5*WJBFPI4 ENLSI3PVPI;QE8)Q8TB!U0H1)X4<])4
M6BH.?H%87TD\96#? H.PH?"#"O0<*BDS3DP'M[P1BR*#$:%D+5=:_(HE"8*,
M,%Z*SR"?;PU1\9:(VGH1KP!K^^6_-;Z R;$2!!MNL7TEGN,6D*/.@[#$C9CE
M%4A3/%:9<E.J/.NF)91["/CL!H#>$UWJ7#R=WE4.%:4I@"[K*V62H,'W!O@>
M9B!S%, ,(,,=61!Z203]60 24*X*,-HS@E*R$4J78YZ5?@53G&6:HHU08T3(
MKFD'YI5N"T8*I^L[!(\<# 2;V-"'Q+ITFRW8AC/Y7%I2DY5^NC]E\:Q]\XM!
MADC 'I]XFN!Y)%]LYI$0U]7\T'ZE*O#^SEH0/((]J-KH)"D-96&)VM=H'6GK
M<)T>;4"73:#HC[ ;93L;AJ2 $];U ^G*<+2WTF^U:!>6EW.[=H-50V[G=9 8
MP<-/"D^5/AX5C4VQH;J56;7O>B!?_^P0S2''GD'CO/?$C;-_0"%F6*TOUBW1
MR#)>%DN8,OZ(NKC2Z\Q-X^AWG#9V7HK\!:@<89_NI/P(2<8:Q8[N"P7[O)(=
MH J<9(GS\#]U7;.E(/\H%<SWL"_SQ._/=O\6_?$9=K+45RCDG#8'M,WPSY14
M54;F?>I$\ENJ"Z&N^\K@.Q+_W&2VJWU4ZJN6,FS-UBQU+C#0ROE*WPB3JH_!
M$.0:[48]%">+RF3+$3*%6'EG*H9=N_]_9H5G<P-[AOJ2&BRE.A(@_>I'"OT#
MIRK7]4#/*A_K;"R)HW,^J)Z;F8HPY*C(]%3B[F2H TOP>TA"YI^D@#6W?+J-
M6!\O92B$WODFN)*/ 0UI&DA!Q@LK^[,?QZ"W(N/3OLI](/V@XS$Q(FI:]; <
M.JM7(T='S8/V ;T=<0;_Q$Q]]>*DZ5^<M)Q8O=?K-0^.>AMOMYO1QGL?4[O?
M;!\^O=;>7O.PT]E*;<L'(@0#0;4%SU_5NK79@&J=]#O%'8ONOX*@I;,FTG_^
MHO&ON\+ZF..M<OL?C[YQCYX6?H%.UGO72>CO%_3N%SYE4;?NWP0_OZRM'C_/
MQ_ *]EORLH?2YH^K[S:_(&2_=EZ?'U*W\*CJ)GPW6,!,>AK+9O;]A4#[)$!M
MDY>UK1#P"-%O(WI>8U\Y3)5L$<_SH9(I>S-O9-^%[?0_R_]OX]%ZC'ZLK_@*
M,-UY'YZU Z$+K-(>^6SQ.+Z"[NXJ=EM^C[1F3[;\)5FAPW=T_?!::RQ7OBU;
M<*G?PK470W@,0BW=YB&;OL3:^*%:=0S?S/FO]T[_!U!+ P04    " !O0*U2
MAWOQO/\$  #J&   %P   &5X:&EB:70S,C%?,#,S,3(P,C$N:'1M[5EM;]LV
M$/Z^7W%SL#8!].YWV0W@V"X:H(W36$773P,M4C976=0H.H[WZW>DY-6MX\+;
M^I)VM0'9TI''>YX['H]4_^?19!B]N1[#0BU3N'YU\?QR"#7;=5_7AZX[BD;P
M+'KQ'!J.YT,D259PQ45&4M<=7]6@ME J#UUWO5X[Z[HCY-R-;ERMJN&F0A3,
MH8K6SOOZ"5X9H><_]7^V;1B)>+5DF8)8,J(8A57!LSF\IJQX"[9=M1J*?"/Y
M?*$@\ (?7@OYEM^24JZX2MGY5D_?+>_[KAFD/Q-T<]ZG_!8X?5+CC;A+NUY,
MVEZ7-69^,&OYG2X-&&EVFQWFL=]\--+%YF6?0FU2]J2VY)F]8'K\L-[*56_-
MJ5J$ON?]4C/MSON)R!0.)K%S^;?4L:^)R#DJFPFEQ#+T U2FV)VR2<KG66@@
ME@]X1A%-V*KGJE:JWZJ(12ID>.*93T]+[(0L>;H)'T=\R0JX8FNX$4N2/;8*
M])-=,,F3LF'!_V2A[^.HYG9=8FJCGI1G;(O1#S2P\=V"S[B">N#X[Z/:P;-C
M?(SV,OF5C!V.;Z++IY?#070YN<+HO9F^&EQ%$$T>O.5^!UXY4V?HP'0\--;[
M]:9G/7B[!U,8C";7T7BT2_>C$[_E]1Z\\5NJNUX+)D\A>C:&Z>#F8G UGMJ3
M7Y^/W\!@&&E)X'G!\6@.3=U[,L/1.>'W5:%XLOGL1#7N)>K2@B&1A6(97,A5
MEEEPO7!&#OY(5G"-$TA&8;C@+('Q'8M7BM\RF"0)CYD$D<"4I2Q6!"ZX*&+.
MLI@5%EQFL0.G:L'@T4DG"+S>4"QSDFW,G=\[LV#!))MM )5H]!;D*UFL" ZG
M!+R;,CK<VCTS88 40*C(]1JRV[ALHAV-QN@1IT3.2,8*>W*7L@T,8J4EVM$6
MRHFR="_=<,8*(UINX&TFUBFC<_;HI-DY'-Z5)Y7(<7% ?G-"*:YF=LJ2:N78
M#1#;[WR!Y'Z_7WVGG*G[UPB1OUP1B>&<;N"&Y4(B"QD\%7()OF>_W/)8N0P2
M(<U]CI8("@S!47A!9+R NF^5"_:NJTN56T]#LDIQG!B5I1SQK;E:&'62_;'B
MDNDUO2CC*-8%!V;'4W(&.*;?/*5G?SL5(T]B18(:QG?Q@F1SMO6LWZTWRNA8
M&MO0A=V>CMKOP(W!1]W(,_3-DAC:8M1%L#_%IX:QRK,)X=K/.4YGS;2EQ21-
M ;NA221%/Q0Y4E]8IE?",Y+%^CDJI*8$- D 6ZW2TE$" \&,67P0*<Z1&;")
MT'=<T#3L*C)+V;;]3$C*I(TLIR0O6+C]TZ.\R%.R"7EFN#*=>K<ZA\0DK1(J
MZJP*N&[7Z33KNH93F)X5W:JORCO'E'>NHONR1MOI-CH'Q9[C'Y1]3&W+\=J-
M3ZZU$3BM]G'&NH:(D@PDM4"W/:G5:]L.U40(@_P._/>7*3TW[F'ZR\\+4Y1_
M4(94L'\@>N"(/FWXE>GD?G1!K+^?$=T+LL&EJES^OC^O[5__&\:J?'Y *!OM
M7F&N]]:_GS%JO[9KO[]@/0)155"8BB]',T7**6SM^X;B]D>L_J\1?85P-!I#
MKG"H^ B41QT;6$8XPMU?K(3\-_'K:69J1]'X#YI^DXR?7DN..[8<MVQ[1)_M
M<^N:/=/.'NV8$ZS=L_%<E&\&0LE2H@?;.RU_EW3-=L][UX7,,/.NU.$NA\X/
M#QZ]5]?R+8!Y'W'^%U!+ P04    " !O0*U2*E7HM $%  "N&   %P   &5X
M:&EB:70S,C)?,#,S,3(P,C$N:'1M[5EM<]HX$/Y^OV)+YMID!K\""1B:&0)D
MFIDVI,&=7C_="$L&76W+E44(]^MO)9N&%M)+VVN3]IK,>#!:/=KGV?5J+7J/
MAN-!^.9B!'.5)G#QZN3YV0!JEN.\;@P<9Q@.X5GXXCDT;=>#4)*LX(J+C"2.
M,SJO06VN5!XXSG*YM)<-6\B9$UXZ&JKI)$(4S*:*UHY[^AN\,D*/?^L]LBP8
MBFB1LDQ!)!E1C,*BX-D,7E-6O 7+JJP&(E])/ILK\%W?@]="ON57I!Q77"7L
M>(W3<\K[GF,6Z4T%71WW*+\"3I_6>*?==MNQ%R%,I]GQ#Z=-K\/<ED\]YGNL
MS?[TT$D'S<LYA5HE[&DMY9DU9WK]H'&8J^Z24S4//-?]O6;LCGNQR!0N)G%R
M^;'$V$8B<H9@4Z&42 //1S#%KI5%$C[+ D.Q_()G%-D$AXU<U4KX-40D$B&#
M/=?\=?6(%9.4)ZO@2<A35L Y6\*E2$GVI%Y@G*R"21Z7A@7_FP6>AZN:VV7)
MZ0AQ$IZQ-4?/U\1&UW,^Y0H:ONU_R&J#SX;S$?K+Y#TY.QA=AF>G9X-^>#8^
MQ^R]G+SJGX<0CA^\YUX;7MD3>V##9#0PWGN-EEM_\'[W)] ?CB_"T7!3[L=[
MWJ';??#.KZ7NN(<P/H7PV0@F_<N3_OEH8HW_>#YZ _U!J$=\U_W\Y-]1"';/
M^FM1*!ZOOKD(S9TBG-7A1!(:"TEA:,.0S-.B#H,Y9S&<\HQD$2<)C..81TR"
MB&'"$A8I B=<%!%G6<30_BR+;-A7<P:/]]J^[W8'(LU)MC)W7O>@#G,FV70%
M"*+)UB%?R&)!D*\2<)/].G..NB;W@11 J,CU=K!I7)KHF*$S>L4)D5.2L<(:
M7R=L!?U(Z1$=LSJ.$U77L[3AE!5F*%W!VTPL$T9G[/%>JWU[IE:%6HD<ZSS*
MF1-*<6.R$A97F\!FF;:\]G>HT[O#Z-GE0[=]#9'YRP61F)G)"BY9+B2JD,&I
MD"EXKO5RK6,5,L!4,/<Y>B(H,"1'X061T1P:7KW<>S=#74*N(PWQ(L%U(@1+
M./);<C4W<)*]6W#)]/9<E'D4Z=X!"]T^.0!<TVOMTX/W06710F)S@0BCZVA.
MLAE;1];K-)IE=J3&-PQAIPLDHS]!&/U/AI%G&)N4&-DBQ"(XG^*W1K$JLC'A
M.LZY9(56NJZ'29( 3D.7\%'&@1RE+^IF5OS^$4= :KHY+:6V6B1EH 0F@EFS
M^"A3['\3O&IP6DA](P0MHZXBTX2M[:=8?9BT4.6$Y 4+UA^ZE!=Y0E8!SXQ6
M9E+W2M>0B"15_43,JA?K=.PC]TBW8PI+KZ)K^*I3LTVGYBBZ/=9R[<-6Y]9A
MU_9N'?L4;,,^:K3_<]2F;S?<QIU@'2-$*0:*6F#8GM8:M?6$ZD$(_/P:O ^[
MT&I7VB'V]W\T3(O]45-1,?]%ZH<@]>5YJ&OTQ]3*NK*;G1_I_V_([@59X9Y5
M[H-?%[A=U.X[:MO7K^-8ML0/B67SJ%N8ZW;?^PU3]K[C^O-EZAT856V%Z?MR
M=%,DG,+:OQ\H:7\EZO^7T3WDHD$,N,*EHCNPO.6LX$MRU-7L:W>2ZC-,[ZSJ
MI_J*>Q!V_T)RE#1'36_4U2]G_2@2BTSI(_)*[(-MM1WSLK3Q<G:78ZG-\^U<
ME*?[@60)OO]=L:T3[YLZ:][SW)LI9(K%=J%NG_(9IV8?7,N3?/.;PO$_4$L#
M!!0    ( &] K5+UP1*O%OL! & @%0 1    <V5L8BTR,#(Q,#,S,2YH=&WL
M?6E7&TFSYO?[*S3<F;G=YU X]\7=+W-H@_W2UP(;A'WABT^NJ$ +K87MUT]D
M20*!P08CD$JH%UM2565E9BSY1&1DQ)__[[S9J)R&3C=OM_ZUA%?04N7_K?[Y
MO[+L?_[:^5A9;[M^,[1ZE7>=8'K!5\[R7KWRU8?N<25VVLW*UW;G.#\U658\
M\ZY]<M')#^N]"D$$W[K8>1L5U9CYD#D?4<:""YE!AF1>>LL$"DICLGSXUBAF
MO1$D(PC^8)C:3!D6,D85-5X';T)8]F\EYDH$Z4F@B$6A%164&1MT0!)+C=-K
MZST8'8RPU7V;G_>R;G#_6JKW>B=OW[PY.SM;@>\KA^W3-WFKD;="&O&;7L>T
MNK'=:9H>S,@;@C#/D,HH7AJVT^WTKMJ(IFM7VIW#-_ CW$I0AO#8K?#*&Z\[
MMYU&<?O/W@=#%Z-&SN'6XQO-G-&B$:RU?E-<'=W:[W7N?A]!2+^!J]<=N^\^
M3,<Z=]5N-SLTYN3[80\OW#'TU&1^;V?22[H]TW)A=+]K]UN]SL75$\7=(_(,
M+][QFFYHV%L4;037,S9OK[AV,SV!$1WK5C>_:RJA2_C-_U0_[KIZ:)KL5N?N
MG_S$7N,C]OG- 0S;%F\&%T>W^I#?/5"X<!<;==N,8/FCV1S<,7K@.XZY>7>Z
M;$UW,+RW#=,Z_-=2:&5[NTL@,,'XU3^;H6<JZ?DL_-//3_^U]*[=ZH$:R&H7
M)_"8&WS[UU(OG/?>%)/P9O4__N,__NSEO498343)1C/_YYO!CW^^&31MV_YB
M]4^?GU:ZO8M&^->2S[LG#7/QMM5N!>A ?OXVW1@Z@X^Y]Z%5?(3K6Z"+.KD;
MO/^\MQ/BOY9R32.646F':61*P']2"H2U-5091>*W]:(K\&]VS0TMTTRO#OG;
M-5!O/JFX]PUSN%3)/33IZ9<+N]X^_4AV3O=IM>^/-DX//NBC[2-WOE4[) <U
M?UQM[EU6UW>:6T?'K'JY?[GUX7U^4&LTJNMPS^7Q^4>ZU=B_;--J;8]M-??H
MP?K?C>KE&CHXVN?;ZU52O=RI[S?W^$%M#>YQO/I%H8_DX&+_JQ-;S?VSZM>M
MYO;ZE^.#VOMC:+M^L'[(]\EG<K!^D&\UJY?5YOOC[=K:J8?WV@][ EJ\V*]5
MS[=KC?K!UZVCK?7JV59SDU:;&PC>U4AOW&]NDBK9'S[S!=[%6P>U-O3^[WKU
M<H-O?WW?V"=5N'^-[!\Y:.\SC&LOC2[?/]J_/&BHBX^UC5YU%YU_K*U]<\%C
MA%3(N.0L8QZ3#,B@,R-=--9R:9E<6HVFT0U_OKE!PN>DZ&C->I]WG6GL!]-Y
M#[]T%[3]&6TOQVF+-5<ZLI@QY&"M)EH";0U\]8(&@P6%!7=I-<W_U$C["=IO
M^P5Q'T1<-$Y<KSRW"+-,"P0D98)GRAH-Q*4^,FJD9'YI]?-+DG:C!>O$Q3L@
M;L<T-EL^G/]WN%B0]6=D)>-D%20Z:43,N+,4@#..F4619#@:+K RWD2^M(H
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ME(1DW@4%D,T!;,4,:6(-]LX8F%JI.*=R"L99F5>GJ5B--PCJJ/8A.&TLH#.
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MLBZ0*(3AI$0Q/&O0@L\;_1ZLH=<"LG'N&GT?_/M.NYF6V7ZOR&>R'4?8:'1
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MG:>4H^@8,9;-FSB]))$F&+ &5BT*1#"')&-6*&\HT9X2 !>&2SIGDO2N71R
M=LE_O]F"1P]!Z95E?6*$4.D4I32FH[-&(2TI,HXJ 2 PE""X<-9I]22YNHH&
MZ?X3>]_%@O1[G;?IPNCA!T>"*",((Y0KS#5#U%J+//9$$D"0EMHBK0@&W#)[
M5!\XEQ)T7TL.VL,"MH_YG=8$_Y#0_&ZO$T+OJP&3N=<^:U77GI/&6&=(3NAT
M00P $A%6%($\(J$4CYXI$,BT?Q*+2AZ),L5NR8)$/R'1^(;)@$@/VC"Y3<\G
M;)AH%6 Q)((:Z9G3$21-4FH0QH)S7@; \JX3?-Y[;URQ57+;ANX!];;CX)[9
M5:,WC>=T^D%J39"UC'! D10#79SV$?OH2^"2FA&23+"Z*-..<P-H/EH6A+'.
M&4P<1YI&;34?UKA5Y2+)0-NEGJ?8FX]MTWKV,M%J0FG'C)=.8F6\$,PCKKTT
M@!2#Y@HL8Z1+3(]$BK4RT<)&Q0"> 4:/8$UAI)0,3'M+'9'6#WU]Y:7%7V6B
M!7)::<$Q\FDC V$;=22!.1<#-0"=2Q3+LAYL[SISUT[PH3F(0"MFX^::\N-[
MMUL_"T6=?2TZ Y$U-K&53EQCF4CYF"-AP4B0<\ G6):(M29#Q2EP<NVL/8^L
MQ9'R6"DD/24,::)%P)HB@:FFC'A:(M::(*WK8'TN]-;3]19#45/OK2&*&1Q,
M9)YZ+9RW01&B2L!<W4[O[4YR5 P)!U^KYCQO]G\6+[_@CY_S!XU!"B.(TQRS
MZ( _, \J.L7@/\3+I'Q>:%V[BQWSU@/8L9S\01$%IN".(,D<128$'34!F*V%
M(8&_.OXH)16)9P+Q(!75F"$B# 9Q%PJ#G6J,HW%XP!>,U*RTUNJ+4O&6S?J3
M@L%J,E142 N<9(WZ9'MX185SC#.:DGE3]H*NAFD9^(0:@@3U&+' M(B*IZK9
MP,G.IP-I;@I\7 K.D=YX2Y%3C@L&,% 31BQ!WE%"L1%R'N3_P=ZJ![]JMV^[
MN<]-YV+7-,)VW.VUW?&4RI._/,]$$RGRFFL)DF5E5-+XE"/".F*CE&P>> ;6
M#"SG>LTP$H>4<-UAPY@0H"5-L%QS014V** A%>4PM0?2%"VH^!,J/G";.MVJ
M,XHF0,7@B=9$@EV6EGO)0(]':N!'B:*C93AQ/0L;<!-,!XV1 ?D)3"87'66*
M1N(MEU2G"!W#RQDV\/(;HI.*&5!"1N8\1X #F6;<1F6(90Y3PI6/)0@.GIIR
M>YZ";BI:@K5V I25).D$LL+4>V.)TLA?X4TDLM&'627,#T#@@#[]PWZWET:Q
M6P^-N!,.\VZO4R2/V.V!NG^>P.#O@042#P86U[<^Q1BU"B&'A;<L,ANI-L$)
M:W1P7+&HB[P!6*98N6SP879E[Z<D[M7J89!,=CO&\#R)W6[$PLF"3 ^*A9,3
M@XJ>(8UCL$)BR;Q5V@>.HY;,4NT)=O-$T4)>X=+:82<, B!?!XU=(%Y906R@
MBFE'E%*">$*DMD$$3*>0Z6]NI/;%<A#>C#]R8+(1KHT&"R\@K;6(3*4C'DII
M/#P7M2#D5&"ID#*"@::,QY%YXA0%(YP&9+CU,J R!8W,!)&FOY'"C43":NH=
M(B!M7HN@G$'$"2F(]B4HRSX3A'P6HT,$2841!I8SSZ*,UN'@C4;<AB@-&:UM
M @]=7?"AK$3:W?YK\U._X^KI%,<(PCS_ZB8R_%#'U_BM3XJ-HLQBYK%BG%E$
ME&%.&F;2X0#CV+#NUH*4CUO?;E#G*6X73V!U4UYRX1G8#39JQ;'4E",10BA3
M\,B,D&GZ*QP*G$1-O+#.,N^15D;&@%R4)%7 (Z,- Z*RT8<%31^Y?4#4 [7H
M^*U/V<J+!*P\&EVPB'&NK 7+  G!@Z5$\S XM8@)5MGH0UEINAY<\6SMK%VK
MM_M=T_);>2OT0F@-*V(_NV&OD_V 'T+BV[<^16Q9(+ N6H&$9L9'0[SSW$M"
MG,>4A,&1X05E?WW=O$VL)Q7L" 1S32(G&G -T\BX&"4-T7@ JVA!K$>%:8S<
M["FU0.\BI6)KM\)52;"B/ZG8?;OU EE#)\@E:6>7I:1L4EFF!-<*A53BQ0;
M6TSRA=9^-G;YU FI;%SP+Q+?,YT5PUH,X,ZY:"0H(6,T<01('X5 +C@E%TJH
M?%SU+'J(H2@Q4E&GI$Y48:VHHQ$C&\%$ 'UT:\^@S%;>]-'CXS81)A;E[XB&
M5<5)YP.#]449XJA'+#(!BP^? [?FM-'C!/V<Q$OK%4-!6K#'M35,Z* !/\I
MN?-NCKPN,R"/4W'"6%B)5>0&6429T]I0I"@G 3O"/>(ER('RD_6PG'G\"364
M(>%5C)A):0Q*N1^T4"@=UPTER)SW@, (+#]M?MJ878I<Y5P[;??"=SG7BE&D
M*Z.G'YQTS</0@\'1*>>9A061@YI%VFE8#R6/)4@%-4,R-\'JN$( T 3#5Q#!
MA,<F$(^,M2SYMC N0;[_M3/3\=_G.BQ$+]$([B_"!5.&Q-D5NYMA1 I92Y51
M"8(XSZT)RF"GO<"&J*!F7U9FAB@3K.1D@I<^4FH)9]$) .X6!<RM2,<Z>"R=
MI!2Z?"=T>YT\5<@K:+,'ZKN[L[O7A=]#YS3X]^W.9K?;!RQ8EHJ+.D2IHD1&
M.LJP(#8R6&&(3 <'&'.N=,(S4W2:X*$"QUT(KB@%Q)3$FOJHM!#"N:BQ+P':
M>RB=]EJG\&OP)1$@PC4/RE*8,PWR(JQ%RL#B0VG0J0[Z_ C0BQ!F<A+C'9,.
M"ZZ)\:#3G%**,!^8CM$J5H8*UO? @HWF2:-]$4)!F4$IT)+(BC%8"NT<B1XQ
MKPW0P9N(410*2T9*4#5F1D@RP:A@KAV8,Q8;D2)L@O;$@Y%#I30T4#G8_15(
MD)DE20+%6Z8YKKT*,FS"X@Z-GX9T0QK$L^YPB!3'1B:"G+E& C%J*=<L$FRY
M#Y(@Y3V-1J RU4"=(FEFP6TJ $8;9!523("N\U0[>$/06GF!<(EVJF:%CE/9
MCM(82^44(=091I$PB$2&B#12,,M("9#W3&C("<((I:6UF*F4;  ,(@LX&_1E
M.O7)#;9V$%ZFD":\1!090(C4SF;+]]VPP/J00 7L>&[O#U8I103AD_ J( L$
M)]0PI=/L:>R"=T(B3H+B;%0SA"XH]#@*Z21#$Z%0RIW/B!-1.,8"BAJG2%P,
M7Q"0K*1:;?H4FJ"6 ]1-J4,L\&"8<]S:Z*WAD3IL :*+$N% H$&[&:YVA#ZV
M7>'.ONEO"*;CZFNP3H?3T&@_4PVSZ<-"2:@U-BCK%,"( -B0FLB$Y0#RM<"V
M1+!P1LDZ%93(F/(<!4R(" QL:D.5!*T:O%=6QQ#G15I'-WT(K= Q#2#LFF_F
MK6&:D=.P<9YVJY[!JSY]R64<UD83K/"P2EI8+ITT8,EIKCRA@;-YD=S9(/%4
MI!@915TPT*;PS#BO. W."Z:,B+#PEDF*I[NG/'UI1>D@O!6$$^*8CEY'P1%(
MK);$(*11B:1UAD@Y'0^,15Y(:K0>YA<.##$K'( F&:PAI=TV^!4*/L4^6DO9
MS4;.GO0WZ/9D]T_-6II@O$F,7/M .0@\$YPI#D2T*6<4F$P"WQ;W!;.4A%FF
MG]/(*&F$U2HBB9E3RF(#FHA$QR2/TN#7B0GFC+.FE+^'2,^"T)%XAJ0PEHL0
M%'<X($-*&-/SNAGJ>>+S!%+4&L0(E0Q;I56('"OE3 ISC>7#/@7!MMJMQX=,
MS!6'3# F/6J#O/288\\P9<K+2+"QF$A'0KB]S[Q@E5*PRO1Q#XXD(B4U8HZR
MJ(2VU&O#+'-6&\)">7'/@J^FB7JP8=$2X9&D,>6),9@C*U':U?*"N1*D1U^P
MT_-B'H\P5L1KFG(_:P*@1V#IM:;1>N2HN:UY\.RRRJ1";YZ*R.\Y$#%3^@5/
M*.X.@Z7.*;>86S#1F48NV C<0[5F.I 2K5L+[GGQU4F &1ZH\DX*S3"CEA%#
M!?.<&J,(*E,^@P4Q/7-*  DU)H;AE+.*(DX#=HA9;T@)#B$^5Y!3:9CH><ZA
MR(B$9\H1H9@GTJ2- B0L,39B*<KDTGWU##)]+4.H=TQ1SP,B8+]08QGV1*%(
MB8M:H-*YZ*8IY)/SBP6ME C$:<4%2\<NA!8V&&6Y V*$,/O*?X;(,LEJ7$JQ
M**DECC DC(XA'0KDFF*FE:&E/'!VP_0?97$NV;DS:A!#R,NT##* O@9;9"6/
M!@5"!$'SL"B^&(6FORK)X&*JI<01TF#&6".]XS@Z8F&%BL&5*/YIQL@YE1@H
M*X-.N3J<=XYI@XU'*DCK1 @N)2*:_=5L^E1\GL-H*36>CK"0A611A'0VC3EK
MM14A*J5+5.@E08WMN)82<AT.ZM#=P!WOVHV&L>U!$/#87<\O;B]2ZN4JE5O;
M-O+#(FSA[H1NU]='+3T\K5NTH'YM)-P0ABDRH)IE5(8;YRT@H-FO(#,S//(\
M-62T(089"GC',NNT1=Q9#8)L)<:*E\!FF)$R(\]C.F#,;%16&9<B@+'EA".%
MO9.!(DQ+$ LS>]29G+V-B&1>>B*)LHS[8$-TU&"E4GDZ14N0;^=!IV(^=<*)
MR?WP$$QWK>6W>_70>=?O=)(V['9#[V>%L4O,+A.L6F\5!_.$1(,Y"YI8%YFA
MPB$C&*6(S0F[+)CCEV)$0-&#N:,=V &,$Z8H_"DHP&P""S,55Z":CD UG54N
MN?L([!@T>@<#[QC7J[4_A4YL=YKOVYV":[I_7=P*,MDUH'QZI@87S4GH]W+7
M!29<>1$ 3A\.P.GU*WY]'S;X -84TH12%B+6*9=.))HJ%9")8O;7^E(2_GDB
M5"V%Y@AERA+&'=(T<$X5L89)J8*>?55?=EI.<-E.Q'3(:0^T-)P94Y1##1'6
M<T5<F;9.2TG4Z3N6L;0.<4O 3$Y9ZHAQ%@?0U21@:WS4)7(LEY\#IN*+-H@Y
M%)7C.@!T1U(AR:0SS&'#,//7M>#DJ!:<? T<\#%WR22\PMIPYZ=T!FH]AW<\
M=[Z$88DM^0!.N'WK4W0!L@);H;55B$FD5=0Q>DR9!&..A!+L2I2: 9YGA2=<
MX8!\B%PQ!7+.C5 \:DH")5K:UX6\ITG3R2%P[2EW0+YHP'PV*:*>4(V50@)%
M)/1K16U3U=A3.G-,(F)(,T:02CM0"G$68077D2#!2I65=GXX83I9500.A"HL
MM5*,8:E\JL8.E$_+.=-EBO?9"0V8!/\)INVB!N3O M'A!B#S^)4Q<K]OI]*G
MG7D4<!2E1=0##@N.B8!T()(9$4WPPBC,2R7@,TG6J4@K >H9&SD(K&->!1.-
M)U1HAF -QYJ6B*SWA! ,3C5VC__*VT-M/)=T!#,)]*UT3!I&G=%."L0PX@(T
M,!=ERNX_*W2<BIIU7@O#3<1"$E@]J8Y&HI13&3-/M%-S0L>-<]?H=]-)0YBG
M5N\V3/J:]^I5TP7%7.]W0Z_7W00;)>_U>]!@+;AZJ]UH'UY,:L=S0H!OU-SM
MP=1"I_FSW=E2\BH  8HMQ=19Q5)XMY&4*X.L--'!DE(B7EVPP"^&#UNAG+8Q
M<K#R. Y68^U(!/2/L54<S[ZC[D=:ZBZUM%L/K0NX=[??ZM;S5OA4-YVF<85G
MWC12<BK3NOB8-_,2E9K3D7,@F&<B,A>X(<)KXVUT07(M98GDN%S4G+[\"FUU
MQ&  (&N8,4YK9!($T1@AP\E(A;,1Z?GL!L0\H.HW0>G2%0.L]6KU4#6=X]#;
M!K.VD[<.)QE$%?[IPTLV3I/^_SZ5W<T;GI^WV,-YBT\FU,9(!MB5,,UC9!@[
MXWBJG&Q\\)03(H9KPX*ERL)2-Q>?<2YY4KQFU%&$" P261!!N>@L<<EGC"(P
MRT@##4+RB@^SQB[=3N^Z+/TN+#(&1C]DDW1I^ L@QN!,]V>$>6G,.MTX$_;
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MEU#>8;MS<5>"A615=MX-;RBE.31,:/>A"OWY#&U5SPYJ5;ZU7J7[7\%,.MI
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ME,?,JB"?10W]K#[4['MLXP]\H\N5_&Z';A[OVGTJ]IP B;;:Q991OSOPJ\)
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MIEEWX7K_^@RZ<S\OO[K(63J9R%GTS*&S+Q@03F8H./W'?7E,ZLJEU5HAN:G
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M;#W8WO6WH?V]T*./TJ-N'.%1K#PR+&8!%L&,64DSI4"9,N:C%]XSFK(L$P(
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MA?\^"]:)N;@K!=8BY_)<@OU);<R,V.?3@'L69^%^">&S<5^%H 9;JGW&)5*
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M!B*7'B129!H6:H#OSF664IO9J+23@ ><I""FZ,GI,%[.)3 '!6#+Y\-8#S&
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MW9^SKYOSL[*6>AT.TIWL487N%P>ZLF<%0:TB+;BZQ:ZW_MSX:OPJO'(\UD[
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MCY@V/@CG%:PS]F!XYWUA(159(1_?ANK\0Q+#K/-WUOD)%:0<>A,%!B@U#$0
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M90YPS"WS4LDMLV-_00)UZ/M%>[H(>;[=W.R\!E%@^5[S;:DEF38,H3&20.D
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MQ@.I/0.>&.JIPE1KG:[G"LA;LE&>P%4]YD:PJ:<E]WB4N4H":F(<PEWALF:
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MNE7L<&=,+8X3LQCV=:?CCB<\8T+9#WW_*!SK+YED+T:RT50AGL\G2A(:E/3
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M8_Y=A+4L5;VJ'I;ZS:.AQ/9&0G39N;(0AMEOG2L:6R@C3@&F4P58A1!04&&
M+7(J2E5X8K>V60MAN217\D/Z5E961V_'^.YIAI<1>;:64FJJ;^7'2)G9WLV0
M\AN_"C((,\PQ$(8F-[3WP+ @@8BD'6FM/<%B:_O.'N@&Z_!#>U56%A<R>F<I
M92FMMU<E[[%+L4:^\:A(QJ#7V@%FH$I78@/03'-@(;$01ZDJIYNUR6Y8[,HG
MWTLE+*(YWJ]*FWX=A[&4_=OY4=;/W]MP/\I?5[*KF^U\UI5[675[.5!E,?0Z
M_=:7P@(6'A,+@A0&4&-<"E0) %(<O+"26Q@M! 1;BMPY+B\'JN3CLRRE1DLI
M!R%LJN2SE+*4FD9*[\5<GB:D7WW5=;IWMH@1_7,JF@WI&U+1:4/ZP]Z)<HY%
M+FH AU:E*,  C'086"$#PY@&E\J&CG2Z061TD\,3^F=Q9*=GA>Z#_ID'Y[KZ
MZ%.5W>"3VK2*CI^?-'*S?'\-M["/4KF ;$TO!&$?KV7'D]00PRB07DE 87(%
MXOB#1M&Y*%_)9;2FF9(M)99US2W')N1SDS61TL/&)MP5-VLV. N;F?G=##:G
MPQ0.7Y]@;K50P@%%# 64!PN,D)'X(>\5BN\*1;:V40M1U%#0S*$*&<PSF&<I
MK9R4'L_WDK?<A[549J(6#DZXL,I;I@%QZ8:Z,1(8(GBZ@:F(9DPJXYJWYVY
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MY>-_VAL2#30B*%V$IMWXH"1N3!/*EHG78L3KZY_'IU,7[.R)E8%HK1Q 5A-
M+39 "09!X-0P+;221&]M(]7B^"[<J\'(L)9:O';XO992>BR3.&/M V'M-T8N
MYRP@PD@J8\<!#<P!J04'VI" F"926],LL-V T^-GNEWGC-/]XD!7]JP@J%4D
M%;K+N;'I5LY78#BNIR3.ONL.3-L7:3CC=_O=BZ=),+UNNW3#=U8/PQ;+)">@
MU(X28ZR+_Y @)6)"(F>1T\8'<;)_]P1RS^O,?W6\_BAIW*#?Z^M.FMB<.FXQ
M#(,C_!KRQ6-[(H7BVD;@,D&XR!>=!5(X UC0T&B)-.1\:UN*%HPPA@1>4@+,
M9>C3':C,HZE[T\#RWX\AN 4$UB0 O,[A;H=^<ZKGG'7;<>YZ>_\;E/W+S,T6
MQK6I1#/';T\8M99!J0!').*:X1)H!@E@# ;FN>3$H*WM.P?V-0/.EG%8F2$Q
M0^(2()$[SZR#.D0\I%QYS2*_"$9I+: 6S,R'Q,6R=&6TO!M:OIY"RX,3(0UG
MEF, H;;)D)5 2<8 U\);+#V!2FYM$X9:2"ZK1/L:8.9]G$9D',XXO!3_(H6"
M*<H$BRJK0S!0J<B N U4<*3=?"!>W*V8$7D)B#QUCG.\=T*(II %"CA._)6F
M>RE.2D"LD!S3((EF"9%9BXCK11X7#J)9 S#.P)F!<QG R16BGF#FD&:44*D0
MU)13Y$206%J:@;-AP#D3:LQ.(FAZYIT"@43SGZ;?%(426.@E#2X0SB*7I2TF
M,VYFW,RXN2S<#$%XS @D%%N*C-721GVSGK$ K>4AXV;3<'/V,)M9;:E# 9#$
M,R-N"B"1,< '+Z7G$CN#M[9E2_ 5Q\V?G($O+YXPMUSUEGFIY)9YJ>26>:GD
MEGFIY)9-;IF72FZ9ETINF9=*;IF72F[9Y)9YJ>26>:GDEGFIY)9YJ>2636Z9
METINF9=*;IF72FZ9ETINV>26>:GDEGFIY)9YJ>26>:GDEDUN62^5W_K:M'W\
MUY6?MO^(/\:?.-?5:=D9!XCSB_[OHU=24#B?O4AB?:?OJZWA#8GM/TSUV_95
M//J<Y_[L*>/F]J[W+-3XGD7]P*>IZEMI?WSS J>;%\=GOM V%:;6G<NR<UIT
MNOWX=;J*+W>*,G;UM-+MXD)7_:(;BOZ9[_EBT-$#5_;KBM:=.FI>IS]"V=$=
M6\;FO7Y\H:Y)-YZ@^QGL#X?V9*YP1LU(DLQ%MU<7NWM:^92E_Y/__7/I^F?C
MC!13GQJM$3CYB#9Q\(/^_(_<N]@1O-%4B-FIF/Z9>EM?9!&(2>Z%PYY &KB2
MA!.JC5<>"B04.D$*;HT_=5:-AW"A3STPE=<?@0YQA$]U^[.^[&W]-JL.41>F
M9_W;"9L[+2'<V[0,E=)YVZWJ\@Q/!QWGJ]0J]DDWIB_%697N/?WK!@(B49\3
MSB5-?9[N3-4*J+>_)_VY&$AF,9#<&0,7?^Z] 87XKG:\\6UO^[IX5G9[MO0=
MZWNM8:Z1_8Y]$G'0%6\&IE>Z4E>E[WV3AN3;43=D4,^GD?G-%1[72T/WSHH7
M[>[G7M,'\<O.>7>0>EUVXM;3'<1'N=ZO-]ETYRVOF@=,$+V^_Q4'T]87/?]T
M_,OO8QY1=NH^U1_Z]K)7_)81C"GU1#*2D&S$2$>/'X'<DQKDQJQEYCT!GRC"
MYKX-GZ"Y[_WHL0@_88C?ZK$_?H\1?#^=%3=][$I0SJ79,2N4#O?[R9FNQJ1N
M,J:AEC[.J*X!$!S2X\K[XB"V.^L5>W%/=I-DOW/'NA21WR 'U-SKJ]^YP=KL
M:<80HQM,YXT&?/.)&Q&3ZX]:JXF=GX^ZR<"X-'VZ?>D ]?-GK,]"^>7MV*:_
M=L=^)5;!/:Z7)J>F_[XP:X(?$L$O0M4]+[H7/IF5G=,BY5'X5/:C%7,3N%U"
MGL*F/*-YZ_#A$*Y1*W:QJH&+#''-DO]\;X1KD\1'D8!$D,HB$JCD\7]"<(B4
M2<5,) YU51HTKDJ#UKHJS?'.*)'/Q<?W_QQ<OO_GKX^''_XN#_]Y"P^^QN?]
M\PZ]^_J?\\/S]^>'7U^4A[OQMW*<R.>B?/?A%!_&]P^./Z+#XP/X[L/[C^_^
MV2?O/OP=^Q7?.WX'#U^^NWS__)M$/N?_*8]VXTC/W\4^O$6Q;^7A>>S?!Y>^
M^W-\#QU^>!W[_I^/__UZ,,H:N=<_V#GASG&KA09$TP"H\P1($P20T'+-E$*(
MA\@]:8LIT8QZ-$OBAAF.UA..<I&LU8.CRRLX$H+1*)8 E(8.4&]<JHQ%00@&
M:VPD\LHVJSS6JC#/#;6JO@\HD_+MO:+?+2H?(<26;5]T1N0UO9I^M\G\&O2\
M2\<6W[.]GF;C:V5:+LGX&I(!_ 2S9B_R77\1%W99'T+7)Y_ZO!L[][5^8;-J
MNC^L.3/+#8[Z9[Z:EL5.Q^U,22+3A87HPML9ZX5KJ2V60"+H 171<%'!,."#
M]I0XZKW'R7-^W73)97'716&70/BSPMZOPD[X/91>81[Y/7?0 *J1!Y(KF,*E
MB(%44"=E5%B"&J^PS:,W#\[P5X4(32MO"IJ*FGU>#LY[-2F*\V.'@4GQS7-=
M??2CN")O!]6/CU=N4 1XK9%WF9[?60C>L;;R-?1.B>XH[(YE%1'YU4B(^YU/
M?F3*96!>")C?33,I@P.DA!E@)2> !H]2\2 .7 @:*PVU$&YK&RVKDEN#BEED
M=5X>D9IVF'[U5=?IWEG6[<?1[2G290TV"A&0RME$TN45,# XX"1A2 5"'-,I
MZD]BA']OO((WCTYE#]2\4(!N!]0>U+;7/5_X+Q>^T_/9]?10KJ<7]2TN_V>:
M_;]2GX["VY[?Z?5\/QNTM\96.\V;'(V&K"(FFK$T>:"L 4KBR* D5(0&RC6T
MT: 5N/$&;?9 -<8#E?7VGO1VPHFBS(3!E #'30"46@XDTP[(X G!,)H]Q&QM
M$\X;K[?-8SG-/6K^]EI<V7'1N'B*4$VE'@=H4LA(\CVE^>GV='OHH4IGS?W+
MVD/E_S<H+Y(1],W=SVR_+IT^W<1^?:G+3I+94>=-!-^C\&HDJU=MW>GOC665
ML7DA;#Z=.=6C.@CH&6#61WLU[J?17D4>1#O5<^@P<QBMCKV:'5*/R*OF^)>S
M#M^/#D_X%85(<X\%<*D^*(44 Z.I UZGW =(8BW9UO:=C_FRMRE[F\;(4E?X
MC:NL5R>S.4^^IN&17_8[/2AQ^G$9YC-=^6=)1L^G1)21=B&D_3C-EHB"5F$N
M0-P8.:!8(& P$X '3(.6/'B53NY:0EZ/F&Z:+9M]4 TYO,LZ_  Z/&%+"FFO
M)*1 P&"B#A,)#,<$<(Q5%*BR N.DPQ2JQNMP\WA0#HSZV?E<2@Y8^5[_3E1I
M$TS2I1_1O=*EV^_\?V4G_AS*(./H0CBZ][G&T)H/[9SHP%@@$@/+!0:4(0:,
M8@3$W5%3*I301FUM$WGG@/#L-FJLCB[]."[KZ!)T].!*1ST*CC)M@2&( NIM
MU%%,./"$R2@P27@Z,D>8-%Y'FT=@LG-H#G[\HZM*=_I%N]2F;-=QW47E/^GV
M(%^':XIOZ(4NJ[^C1/SD>NY1& DN!X N"+E?IFD1CN:ET<@ 9)2/]B670#JO
M@)>":<9%-#%YA%S>$C1?E5M?95Y^H%+6V*5J[(0D"6XQ=EX#Y14"5&,$I)<,
M:$PMIA&!A1=;VY+F^*1')$G-Z_#ZM<PB>/26&^85?7ZF.Z>^]TW&EQ1\.[PQ
M.F5"Y.POJ]-RJ0:O:O82WK&C.\V5M[[\E"XT;Y:%^\ )+&]LXNYW;)6B^G?]
M\-_]SEA4?UU)*O/FQ7@SFK9TG4!81R,'((H5H"X(H&V4G->,<LV8"MJGDU2$
M9)/SQV4;MPE!HUFM'U>MI\QA3072E !B;32'&7= 0ND!#!!Y2#V%EFYMLU9<
MA=D@;A*)^I$IT' 2]:KR%[ITXYB(7BO"1%TO<&@&=%.:J)%=L%GQ$JM#KD8B
MW/7!5Y5W>T-)[G1<G>.KOE"9W90+XC*>.5B0WN.4.=P0;P$-3 ,510@X=<X8
M*+4R-=UBZ/H%Z)O3K1QLT5P%7_J90M;B!]+B";MBG"+'"052&P$H%5&+38@\
MRS+D4EE2Q=36-K]^6Z=!*MP\KI1=4S]T35WHR\WS2SUFJ.E\(_754!090Q?#
M4#+-A"P) :$@ *-> :I0NH:# K"482?B%FE-"K%@S<]LFGU/C8FOR"J[?)6=
MT!X9$">008"D4LEX(9'VL !"2I$G"6($P:UM27*,13[@7^N6F^35&UN1*?K7
M=P8;=M6I\87]KN]XSV.?4F__*?MGSP>].'6^^G,4@G&9][_%]C\V35F5QU83
M8P!4$@-*B$IEMQ!@6@;KA#>*I.H9+8'O<E::G7?KS%=ODC$KZ_1]Z_2$TW+F
MH_)""R(>"T"M)=$,I1A81XB%7B!B_>KDSFH>5<J\=H5:;IA?M1KXR6GUU!GU
M5,#J9GE;5Y#MCL3XYT1DXW.NHW$L\M1[>:M<:*O<G[D49PCG@F &M(0$4,@Q
MT-@K(*'"WG%&I5)UXJ3O.(!RJ. ZZ/S])9C,BOW@BCWAP$J(X!6D@ @<[5HA
MHHJ'2(2IA]Y+%RU;&K:V);Z>2ZE!:MT\-O7@_L0FTZVAI?3P/P_'1:E_&56E
M_O6[9:GOXM4TW<KY"O2[%T_3DNYUVZ4KTH2N^6[P* PPRO-Y%.>KJONIC-O.
ML\NW4:S[G:L]8>=*I'E+6&Q+N)PYG?<>&80@B+3. :H- EH9#*P.6)D0/*,T
MY9QI(7(][<S"OLZ;:= *>4$W%1(>Y3))AH1[A(0)2[0BRM02 8B7D1M2DTX_
MF 6*(X<0IH309/ZA%E=+./YX#$AH'C%\<-==,RBD^/X]\T3C0KO[N5>$JGL>
MN5RJ=GE#'K<,^[]YSVC>.LS^_A5JN0%VYZM!9<]T\N]W0U/*E<=-K?E4[B$O
MHKW2EW71XN/NCOW?H*S\SB==MI.<7G2K5''FS96T=KW)V407I'$S%_X-U5@&
M!X$21 +JD .&& 84]18'Y()B<FL;XQ;%UZ\&/U 4RU!!5BN$Y=&4NGGQ*UF=
M[UN=)U994%8JQ0EP++AHE6D-)-<!6&R$%)8KHD0SXE=^JM3-XT>9S*Y0R[6R
M@&] 9G]2\S0?7M]_*8IOMKF9JH@['9<+(]YRAYNY*!B8PQ1C"(*5)A)6SX%A
M$ *ON=)$,.-0B(25-?EP.L><-"=?0E;;>U3;"3&%7CFKK *($A_5UB"@F(WL
MU FBH5/8HU2U@C1:;YO'<C(E7:&6602/WG(#7-P-"JU:Z$@NQU&L1&C5_EBF
M.8[BEL3H8*;D'E%01$$*@"1,E=Z5!%I%HX8+S0CAG#FNA@YX>A=NE$.KU@L2
M[B_V/NO]/>K]Q"#2BCMN?12/MC+='M= <8*!E9(9%8@(]?69.QE$.7@JNXYO
M%CP5RH[NV!P\U:AUF"W+%6JY 9;E7_YBY"P='CB5$3$N=+N(3*4[Z/?ZNI-&
M$EF&N=VYTR;D#%ER'-6\F(N)J(["G]W.Z;&OSG-PQ>*4[>M,PA]LE:1. (@%
M!Y09#J34 7AL(>9>2&]1,X(K'MTL6ST=?F#CZ\9NF*S)2]/DJ8S=#"$OC <<
M!1N-+T2 UAJF0J'<0&499C"E[D+?J8?2H-1=S6-!F;*N4,LL@D=OF47PZ"VS
M"!Z]91;!H[=<*Y_G]QE^.J"^J+JQWVY\9;37&^B.]<F=8;OGY]W4I:[]" K=
M!_TS#X8WQ.+;(7YCYW2SHFF;>CML),(748+[(P$>A>>U^-XDZ67+:#'+:":I
M,=:&(H$#$(H[0%.Z#TT8 G&E1=DJ9%1(]\%@2ZE<BF-]%?HA/1Q9H9>OT-.E
M7R6+JFR L=("BBT&2DD*L/&0*ZJ5Q:*NZ$R;K\_-HTV9XZY0RPTXHAOC9QQ?
MKRX25[H$Q,6NM_[<^*K D95-3OOS,=WC'M.]NG+MOQB+Y'D27-[Q%MKQ7L\D
M)J:><":E X9[EW8\ A16$B@DI$.&4BUI/J9;41UNZC%=UN2E:?*$NQHFN57$
M @;374\8N:NT3 +'%&(1FHTW=FN;MHC,M76;PIE6SR]89Q&?BH ,?M,*/320
M&$WY!,;0^J);U:*Z M@<B7Y;E)U-[AO9$7+6 >XCMM* &#!:>B"@#0%%_)6&
M+(TO99_?6O.E.7=*LCK?MSI/IX!"4$.H :*T+F$F@&92 R<QE%P9SBC<VD94
MY)OVV=.WIBTWP-/W:N8DVW_QE2U[]4EV?81=="^23C]".M/-(;+S][CZV.IH
M*(&]D6A<WM46V]7@-$EUR:<'#006ADA2$2- $N&!H9X9A"AT"&UM8TJS0V]M
M57;YN9^RRBY=9:?JB!EN'+$!*.Q2T1A$@914 J&T1D$Z+1S?VKY>+Z9I"ML\
M>I/==W.)T+R0OH@KSE?%WOE%NWOI?5&K>S'.H%F\:NM.]OD]&E5*TY^M_@7!
M=B:/NZ5(: $]0"F3!%6* $4U!TIA81F5R'BVM2UP]M^MK9K>/SW*:GH[-9UP
M(AZP(0Y;P#PA@ :#@;)> ,AHJK$*B=,X5<VZLQF3/72;[1YZ]"R %Z/\486Y
MG,H(N%">F;ND_UK-#& -O7(Q)R58/KFY\^: ISF<QM0+%YF;#4X BK@#$K%H
M/Q,-F7<AZI?>VL:H1>#UPYO;6<TWUI\5\H&M&2:L:L'5C [+0(<)=:3.:>N)
M (8+!"C1T<*S1@(>B$:&.D9MV-IF+2*6D+/BD7"A>50QN]JFH&@O!&_3==C"
M?[%GNG/JBTKW?3'\O9<2@27N=Q='V@:#]S*S/,\B]%!N1V%O)+6_HM"..@FT
M=SHN_9-J7'R*R-S) <N+8O1,<1K(4: 8<6!Q\"FI*P$:*06DQ!YI8R)$PZWM
M)43>-(:W+=$YM\&J?W^1=UGU[U7U)_2,0*U58!10P9)G#X=$U 10,, 4=2>)
M(%O;\KIC;U5TOWF,*SO\OLEN,N)DY9"&M8:..#]1\%9='+#RO7Y5VKYWMV=K
MV=1^E)H<";"_ >V_KJ0Y O79%Z9:OHISTHV&N:V\[OE=/_PW_MT>)#E-[Q##
M72/O!XOM!W3F0!8SH0@F@.A( "GW$$@'(:"*.&B1L0J9E-^_A85<67L]^_&:
MSP<SN*P+N$S=\<#:80D9L!9&LFE())L$"L 9$D);K()+U11%"\N[&)O9&9B=
M@7/Q[/G-*6:A^X7QIV6GDTY^4^V &BURP-T<^#>,!Z2=C9S24\BM%D%;SZ!E
M3B.K[,E^0GV$[W"D>R>PS]B]&';/9-CS@09%D >:(0FHI 9(;A2P7F(HG-*:
MDG0_#[8@;WX84 [7NZV2:^,<YYIPH2B--J-1G%,DI G$!L5U4G*DLI*OD))/
M'=8&8S%B.&HU98"RH('!G@-FL&)6:B]]5'*%6HSEM'N-(F*KY_E;D(CY^/)<
M"G:_-GG39N[?]S?\==FEO)-.4>9-Y)\T_J&IT2YX1Z.=R:F7-16]6W1AWJ4>
M;I=Z.UM[F G)0F  $6[B+D4<4";N5S(HKP1BCAL7J2CF+2'YAD4<9B3,2#B#
MA"$(CQF!A&)+D;%:6DE#A$46H+4\#(WRC(0KA(13F08#8I!Q 8@A(B*A8L H
M(8$.(A 5B#8Z\G5!6_CN-GGVJF:OZMS"S&\&%Q=MGQ)D#0E[JM%<E)TAA,3%
M=I>BS%,KCL0UY;H#T_;7EMQCEVQ>6B^;MWZSV?IM"?*K!.5EW&F3L7J7M _K
MR;36DDPM/:7 _FC]O(H+ZM#GT^4%R=!,0E N!40V\B 4ISV=4&B@")% <LD\
M#)@Y@[>VJ5K#7$L9;M82;I:>&B'#S5WA9JI"4804Y:4#S&,=;2]A@#(" A6H
M@DPR1T4JQDSNG+LD9XK:;-OJL-NI;:JR\RFJ;IV$H.,62TGP0#;0 S^C>:LQ
M9]M=H999!(_>,HO@T5MN@,OF*EUBBA^HNA>Q9Y?U'IKB#BYJIV6GVR\N4Z'E
M2(RS+V<CC*NE^W*>ZXNRK]M[7RY\QY7]032T]CMV4%7>/1OT#[O]=[XVO++5
MM9C5-7-5G5K&,.8(>"HAH!Y*H*C#0 K'F+40N73BA:[G$FF:T95]/!F&[L7'
MDV'HWF!HZN ][AJ(&P$BZ,@(0SC"$-,>L$ \AYQ +?A*P%#S".F&^G[FI"Z*
M##62U6X(\>.=TV)8'[GL%-K::N!=T2ZU*=O?]?[<^9I"TR;CYAO&]T:X+AO&
MTGAKS[?-T^$".QJMK[KVZWYG9[BX_IRLK;Q9++99S-RI=TI#RV  (E4UHU@@
M8+1*.5805]Q3X[7<VJ;7[],W[4;%PD[;#$%K"4%+XZP9@NX5@J8.*QG6V!@'
M&$I%;8SCP!"* 9-0LR@BBS&,$-3\.@O-8Z'9U3H%(F\[E8^]^!J9Z2_M;J_G
M>[^F])KGNOKH^SI%1/9\M$47XZO9P=&XS:(9"4(/KI;5FZM5-5F!+W79^3.N
MP;QQ++9QS%S[IY@J800##$H9-PY(@:(T "^U"%A8Y67RM]X]6TOVM&8@:CQK
MG;X2]=577:=[9QF4'@B4ILH1D2"L$ZE@F*. !B&200V!\E@A 0T*PJ=:,A(C
M_'MVP>8 CG5NF47PZ"VS"!Z]91;!H[?,(GCTEK4(?JO)9_S7E9^V_X@_QI\X
MU]5IV1E?49WF+M:GBR$C!K_]AZE^V[[B1[=\RM+L #6V ^H'/DVQ#:7]L66
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M]G]J- MI-IP'T%.^L*1T0DM*+T%]PD2_HK5%S# "5MN*V7.0O0&E<7CK52I
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MKRFL'_L$ZRD\MU5IR%N%9ESW\\,X37&B0E:NI&OPU">L4R1<6$IXT+ (U@K
M5:&(ED:9A:;@$P/K-;CZR3;:_^[T>MME(9*PW=ZRW1PA^FJ*;#T1V-:GP9;X
M: @.%EG#P1K5%L"6F@!V:= 1!R=UR 4-Y9KB#VZL]X(/PU9&A9ZU7A^D/U=U
M%A]_?5Z+W C&^ A/84XHGJ30@3E)M:"8DR E64)=VTH/?W[1L#<M&KQD"F2
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M1.>CX/"'Y<Z&% .HP5;RJ*O\C]5"K*,9M8(+;5.4*+&L5@21D,.<(.FY5@P
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M&'/,Q"BLID*S5X]?8'6Y@_FDWK!EAJ,^_/?%%U_M[(&5+)S@CD;D5<K/8UZ
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MVUZYL<>\X?7W9)#OPC@;"#;H2[:Z4J+0VP/L8&HU,8@KC1%/68&*>_B5R:C
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MA/5%P,72([]:%3_N'A*MO=9!E(5WQ'-D/$M9 ((A99E%@3E-"B6U#J"*>;/
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M'G,*&8LM\DIKQR-E :M7KSG>N*IG[#@]9W2:CKZJ2K1&B0=I[:^"C).>#QT
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M"UU\&JRZ[6V79$V.5PO@-]17/LZ5+X;O?4V)^O>.^B$T6G#=T:#Q-M'U3[V
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M]1'>2OI[?]9GT-R&6&")@I8:<:\Y4L)29!U3H+Z+:#GX#&R#/%16VQIQ4]5
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M#S:['M9E 6D&>V#[#<K1SF/-+?35RS,.W??6Q?L#JJ0)5EOD E&(4UD@K;1
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M+X(KAD#T_P5F#>OL#-P"CNUOTLH<^UZ79%6./?%J?A-VO1=6ON777U_SPWV
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M\93F'_SE@5AGQGI=+:.VB/LJ;+"A/7E9VE_J'WXU17G9D]>_%'V_+?Y+LS&
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M:R#\\24^]ATIB20/)J1W0#-EMUY414OE\;D<=>7U;_:MU1;XG7G&U*7YX5\
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MLP=(];_C8CBULAO6,X8/>J$'%.YDV;XHS8)Q9&S!%B;>AVVK6?,$4DU_"?\
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M&N/,]1+QC09FFXA<% 88#_&=0:KBE54SD2:-KFE5LOD\;47(.I4XL>#IAQ1
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MY)@ 8@W&X#,222-DGJ5QE,8/B\I>ZL5[C.#LCL_^KQE149MV+Z2Q[0$#*WM
M^;X?5:T<^.VGYU&K/"QUCDHV8:6W6K^Q!$5O@ VLIY/A%X4Q-Y':6-4IA$_/
M!VTOV:RJHF+X]+(5Y#$1X%.)LOZY2=@M;$E/*LR&MK4!ONWN'+AV?#3>-5\*
MN')SA'#H<J90SFQ0=O"53.I3S:Y^K]]'I]-;_QA.XG?\%J/D_V\:8=Q4GZ!:
M*'(65_3:I7_>O7Z%PP4VPGB3G_O9^NHA=8HNEM;R[AA351AI[UD8TCL,PSIV
MMZ4,;BAE(+:E#-9@+M^SE,&&E298+'./6\[)-]XYN=<N@/A[B -YTXJ5F43C
ME!LOKM[ZDJB5,WM!-% Y$W"TT)5;NW&#A*AX\@!DS7E5K,G'!U0O@&W]"9["
MC\*?4<7TG+AYX.?%'O^=*A"Y3@.I(EHJ7_+\S*8*60YO7>BJWF9K,@.JOE4:
M?4(FDP*33JT1:2H38;/E9I8[M[=N%)AJ[BTJG!#A,[:_=%GW:U><9B9F)LLT
M 9W&$&$T)SG/&,F9C%U.=20CT&$9S6[HF/10C!TD\$=000MW_8-86:T,=WX+
M'3G+$(KSJKF>'A[5:G+9^:E>\YJH! -5[$RJ.-=A4 UT_<:SO7%K?YXFCQL2
M#.[5H_2._6_W^J8Q;GC1?0RO_0VXW*=G>/5]Z?(8.&V:R9Q0FG,B1)J3#)E
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MGE865%AIU%XIH(VI94ZO<N%"IN;EIS7V]K[6"M%:Y7VTS3RF"6@R&?%S%;:
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MO3I;1V( !@9\^T=J"!" C3>#H(":>4E8IG]3L%UX<%*G#S]X#\.D@"9@(ZN
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MCTJ#G;89J?.-YW;C3##<LU\'O"%@K%7*LI:V"[3F6P3PN32KQ!K<KP\XO4N
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M>GQ=M],O_E[B12O'V;GA0(3K6SN8;%#GBCUP@/BFNJ=&&GQKDU@V!C)8!]1
M3T2L]83HKD"@#,O"E4]F8#[:I6$D(=\\9ZQU9G<$D8$]I+A:UV)JW(1R%[?
M?X_5O3 3:8G=06",&&53\:+4>/&H1H!]D.DE$DGD_$U3\:C)5PL.>S[-T068
M^&BIZ]A-HKC)*=HTB$O$B@/B_E(3KP)H&4?^3^Y2;R_)^V+_(.;^C$.7,HT]
M#!>A2?<EGN/]8IO1))E>?XUL\I0T4ND<J;NOPH7JER_4E:,Q'%8!#8;U<5;_
M5JSYDK_"K=\JJ^,>]'.,AG\LHN%;S]"_%.13U,7H% ]5W@.+9BI) :2P6DZV
MKX$?J871RDE)(.=^ROJ9/,95E-_D1J%:9;)94+L:Q:CK.>B(T,J E;_0<U[
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M0;?)+-F N329)<:H*-5#,=/,$V]*!5Z8"VT@IV#].ZUA;[<U..A:8&8<TK'
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M?N[U.CT=!6Y)K(1SG:.XMJ(AB#@OQ[G)%# $;>5BE-YJ80DOP1!S>@=5GW
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MKA2X6A+!)J4YLCL9ML2;+';4<8[(#YJAQTI_F1F&AL>T..&*00I7%_/S"(B
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MOG9MN N?PDI&"9E)SG%H.O%<D7R(A31YY %SQ+PVUV3R"=^^,J'/H?;8W V
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M[\?0OI<.HD;[?OQTA(W)/.BOSCQX-8K]!?QGFLW"?_Q_4$L#!!0    ( &]
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M]?0NMH+OZ3R)"_!CF-<;PIS[-R7R6H3%.Z<V8;6_DW>^CO><OI4 TSY:/3^
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M-2)KE0RW*"C7@9_=A!>8]21E'8 G8*K-]40/(AN2RUB',;?./*EJG+U=QO+
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MW8?TNQMKII%6@_V:KFJ,_)LTVTQ7[>>$-9U>/O?+-U_Z63DD\;B<"KN4:W5
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M,S%?9&5F+GAM;.Q]6Y-;-Y+F^_P*K^=UT<;]TC$]&[I8O8JP+84D=^\^,1)
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MO251NC?#L<_EQZ/)[8'2WW'X<02?/]7B=]/#I&Q2E($KIGR@*5+7)$?EIQO
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M2P:E:<[EGABB2]V;R8(%XSF-U80J6)4A-VH%>6H,?,3=.D4";F.\!L3[=3C
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M"A@*.DO.(!*OC90WBJ2[0',6Y#F.;3K,.9L*\ L!^/US)?Z+B^&X/SM2ZB6
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M'-2R\M/$G47QKL\9-A"PY;YI<PF/LP?;(:M6\?6D*/%-<E^!Q9B5904S9QK
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M__O=_<OKG<N;VBD>><F&B9#)QRQ<LZ!L8(9'I<C9S,8M\&O%U;:M7_V$:70
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M3QM<UDX /TWAS0;H0F%3!>)!$L^G20P@TSVNSP$%TM;AM8M264SV=;>$.FU
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MK'7W\T,+F%J[]&J7_)*3>U$^D/8&):TV"QH%_D/+"182$,XSO921N?J7S)@
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MZ)LQXL"8.F; %9RMN#6:3=I-([$#Y]P"H$&+"AH,.V[]0',<]DH%6MPZM:J
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M=F"443?"CFOY?%NJX\KSO^_+;UDY\\(D30.,H?!] K'P.53_%! AZ84R89%
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M%PO,J2&G5+[FV*)A>IO=\L!%-GN;5UGU].6>S.>OEF66B[*<18D,))4Q#*-
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MX#2H#AQE2ZR&/D$P&7KT$P4+/ Z=,-C<;I]I<*D>S/7#W\W)[4Q&<1Q@[L.
M1 QBZ3-( AS"P$\#@E,6>L(H&7?OR5.CG;5P0$MGGDNP"U<W?YP%@F.&,-3?
M*G'@H*YGI SL/F^T9(&#:FRG"1R^X-R6B">2B9X9VRPB'DJ(@#*2&&(2A#"5
MW(,T(@DCH1\2NT2!GG),[;-N^E:25?/@_6;P>E/L@\YM7"?6]>UB:#=?9I;&
M"+/@F%>V?5"C)$:G#M29>+II-V@GR@OU%.R%U_'&@?T>UR/EX(U@M45T\W5Q
M<[=8ENI-^Y3EHA(B?Y?E)&>;!A8$TY"EJ?*]_!1!G"01)!Q[D*1>RD.2D, S
MSS4P'W=JE+F2'/@>2L%:6*N>]<:8=].@0R2=.UPMB$IJL!(;K.3>H-HGD< "
M7HL, C<PCY0Z,!S<=HD#]J!U9@Q8/&Z\5 %['7=R!'K<WG.?;1UXUX;AONKH
M-%BVK09?/6\UN+'0:.#YQ(\9Y"RF.@*%PX1Q!N,D)H2I-0$38;4?-ZQ\DULV
M-K&GJ_#V$^U&R\Y^HY8;? -/ON%&X,M-J>OU:^#9=&K5.YJ&0?<B!Q9QW#U+
M-_CN[6TZ&J;?<O*[T#6]!+]\% 6Y%;L)'E?+JJS42J;6KDM:UG449YSS.!*>
M!SG!(<1Q$$#*)84BHF'*.$&26QTZVPHPM05A)3\@C0+K"*,F#F:QT> O=EQO
M/3,Q3>+(9S&,21SI]FP)3*BO_O!I&! /1UC$=N%'+N=FG&BD-R)?W"O[2S&K
M:_C-UE*7D#I>+-=O>BO[?IK?EOP7FXVNE2H#+H5]41QRK;.68=3%K"]"SU>K
MWL\9+@GH]ZRZ^RU?4)ULK:VKNM%Q>2TT$MD\JY=,_<]EH1M?ZBVV\D-&:-WN
MIW[6C!*2$E\Y-21B=0FQ!%+)*?322'#,/11YT>RA/EO\4I&B,F-')[+:?._/
M)7;WZ=<9,'4H)R!UP=CU3D2 +H#^0,[/+CI_FJ,D09C''F21]" .0@03[E'U
MST 0)E%"<-I.\]N<?U>3O))WQ"G^6%=G;^<736%^S5;8%Y\QQ\OP)AOM8J?7
MXU>E(]A6$C1:@ETU=5!,JV=]*E5>@+6JS6/=9K(--A6N,][.%_3%,^,&P]HD
M@VZXP7J<?UW>WA;BEE3B\GZQS*LK^=N#@DCYRCG_F,U%62WR'1^Z_$PR/O,0
MX322L7)>$Z86#"^$) DX1!2QE$8TH;%168'^(DS-FUTK 4BMA5X(EHT>]>GU
M_4J3=O?KH=7%XERGWU09G* YGP#7L4EK[!L%P)4$K0I Z0#62H!7VSN/)=!Z
M.)\ BS,VYQ,QTG&;FPFQ.WH["\O.4[A^3Q[O0.XLS7?.YLY[4H_5Z$.3_[DH
MGG1=R8>M7&3"XSC&?@2)C(CNZT44D2($?<ECG 2I6GG,5YRCPTQM5=D("L1*
M4@O".@ZGP:HP"$B.F7\+G[60?4(FC@-EP=Z# #9:+<4'72=4<VZ6Z^Y.S7F=
M\IDKDNG(*]VT87[@[?MY('H^"58G!1^_>SR:/:G!#I6>OKIG//"I@[!CYV"[
M&Y*7CR2;:^?CW:+X53>M480;!0$F,:08(X@C+"&E(84QCJ(XIB0AB55/$U>"
M3HVR/SVOG4B6U=VBR/Z[K<A[V_2"ZE\[T=6$FVT236$:'2\J)M$,G<$,!^HX
MKO6MWX%:XP&CEAW/R:!AS:YD'3?NV3'B>X'1KL?KF6^O^T%>,E8L!5]M266B
M?+TL"B7 S,<1PIQRZ!-=?)+S&*9()- /$T&2D& 1& 5,FPTWM86@EM8R<[X;
M3S.&'@XEQSQ;"PI:2<&6J!>@%7; S'@C4 9-B.\><=P\>"/M]]+?S>[J1QT?
MLER7_B@$SQ11Q![R_4CWIPI]B-6+ Y,X2B$)E<_/"*9)(FV(8OOA4Z.%&U'<
M@_F"Y$ 25N_AVW'$#G!FC- 7#M?.^R*_A96&0PM8E^RI11SNJS^D^)#?^,[S
M1_VB#VGV_/L]>,WY1T3*=GBWK):%6&WZ_?:@3!%VEXG'VA110ZHG98S,+W-^
M+6Z7\]KMO7QX*!:/9+[>."S5@SX7"[YD5:F;33?[#N_O[V^NKC^K>_2NQ,S#
M7H02&4.?>E(7O2 P\1"#89I$A ><15'O@Z8Q%9D:"^T=5VFW1-9HK(^FP%+A
M <@&D+H,7 M)?:A5K$$!I$5E<]!5UL]\:($!;(T,:* !#RTV_4]@1GT5[0_2
MIOJ"C7T<ISNR-$!L3GHT%& +"WU$M$*C/B/:X %6@&S.C<KZF2M,P.N]=^OS
M]_5N]3\CG.H[]E(GC5-\U\XZN'R)";8Y_AQ5OA<[1'V)6>@ZBGT1>?IY>I]$
M]9J4=VJ4QXP+_NKIMU+W/ED75[MD5?98>Y:S5 :^\ODBZ#$_@%BDNCY)',"$
MAXA3X4O$@UFUJ,C<S \T']K*/EL+X/ 4052 *='!C\NR[O_S$UBLRPJ2M=AV
MKJ/%3)@YEF[P=6R>:&BUU& EMM[+__&W%<R;ZHV7IV&V]DCM$1O27[48?51O
MUAZ5Y[YNCR><L>6]M1OV26G8;(BM\YF2@+(X)#YD^@\<^R$D:4(@02F3 4LE
MYU:%Q$\/.37O4DD(6Q'!?".X92*9 =06.^*# 3C*KOC.;OA&7B<Y8>;P#+X_
MWCWJ^'OD1B@<W"<WN[/'[MOG0KQ;YHK3?B?ZN&\5E^3%4@8\]&"<R$A7GR P
ME11!$H8^37TA0QH9;XP='F-JK**DA(V8H)73PKL_ J/!IL[YX#AFC'U<^H3
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M$A'X, DX(HBF",=6^^[&(T^->4W:G=;B#]E%=GLFS!C6";YC&*8FT([>2_8
M7N-UD]T>?$+]9 ]@8M=1]M #^M'8:_*0563^]MN#R'FF0]O+]TT<%7^UK#XM
MJK^+JJZG1T,I8\X9%$G((8ZD[H,=<<C#*(FE\&CL6?51,!UX:B3V63WH3C>6
M7TB=9:=+-SW567GK6DT@7U3@253@P;C.H?5LF#&9"XP=$UDK,MB6&:R$!G19
M@4\MNL,4+>P+U9 <9CSVJ!1FB\AS!K.^WS)*LZAF7RI2U:<<OXK%;4$>[NK,
MF_KHDR<LE(3 Q ^4S14G$E(<406^'Z6,TB2,C=BJ<Y2I4=.V?%9GG-U8=G/-
M8 @Y)A8;<,RC#DV4[Z *=?\63:A_/:>([@'&B4XTT7$=GVAT<<^:>TM:UH>9
MU=O'VL-;MX5#A"4$^R%$A.BH[$# !%.BM[^0A['B@L"NR_:QD:;VQ6\$!8VD
MED7MCB)J9E\,@I/C[WX/(O"'FQ[6I[ 8M)S;T<'&K<=V2N>]@FHG;QBY'&=3
MH.U]62YUWEKC7,UB2B.!%? B]HFBDS"!-(W5/S%6/Y$B8J'5;OJ@TDV.@MJ^
M<7+=2*Y2\PFR6FA=SE8YKO/%DU#7Z)CU E1W KS]\OGS"]3B/#C;AE3W4G/H
MFA[/K[K9O@&-BD!-:J/D! IM=F$_B>J:!P7\/DIJ=F$[6!W-SD'.#)R]Y/^U
M+*NF:D.;2%/.E,^(.8^4_>C[ F+BI9#$00(CGGI>3 /E3@:SO*X(P6]Z1,X>
M&M2(#=*&#?:&=K@3<Z=G1W_/<M-J2]'\US9W:RO#N&<D[<$9\!.UU J&($48
M*\^=>+HK: A%**4RYW$22*L8PO.A'[,YZSZVH! :^OJ+&1)GLV5O,/1<'Q^O
MFXR!C:3Z;5W)ZB!4N0L2)T'*!P=\F?#D+MV/!B9WWC1,B.!NI,[E_:*H= GX
MUXNRJCMXS4(4(A$2 0,O9A#CD,,4Q_H8PX]\B5."_=2FUHVM %:,,T+%F[6$
MRGPO#3.[>X-OQCDN(1WC&/94?. &\M==D)\=)FB*F\LXP9,RO&B@H"E"IR(%
MC9_3C^3>MAYT$_$B#EO3GQ;YHRAUYV-M.)<WFCNV?Z^%:0Y==(O#VUP+^$6[
MZE?UN7(YXT($3!FXD##L0XP\71>:1!!Y'D9)2)F45INHHT@]-0/NM[Q8RZDW
M1#;^M-#G8*50YER3W5 MP++5?;U%TNZ=+!K=[,AXG)?$C,$G-_4C;J*L-T<V
MWFU=2JB=ZG;/Y*H-S=%*KD^T-WI>M'4UAUL<1IV2(5>4<00?=1D:=2Z>KUWC
M#N[$JF=L>;^L6?378E&6FG/)7(OP*\GR5T)96N*&?)MA9<U+X6%(A4<@UE7A
M$I\G4"]E 9(I]V.K@G"#2#7%!:L1$]PJ.<_,#^HW48.X!</#/PE?8:,6J/4"
M6Q.F-;L M-8-*.5&<R7LL![1OS 4;$I.AQV6EIZ(Y<-['KZNXCVNI"X&^FZ^
M^%JN2T7Z/ J#-(XAXYA#+)(8)E21<!11+^1(4IG:A69T##8U;EW+6C=9T;5O
M:W%-JDG: VUXC#D0?*X-ZO[(V9\N&D RZ&%AUWCCGOT9:+YWE&=R3X]ZF]?B
M4>1+L6J<]UD4=7M<I<<5G6>WI'$_@X"R)"4,\B3!$'NI;E:5<"@DQ2)**8N$
M>5\:HR&GQBF;%I>+C9 6]2;-<.XF$S?H.::45MYUD] K";9D!E<.T;0HYCDX
MJJ,UMCX;7;M2GU9 =5;^-'O2>(5 K33;J0MJ=V?/!H*+_%;WTM.&YD=2M8;F
MM5AUKU+#%EG.L@>=<?EW08IWZAV;^8(C2I"$A <!Q"P*(,5Q (7PJ!^'OJ"^
M5?)0+RFF1N7J50PMFQ#V M_,,G0.J6-^K]L:UET>M087H-7AZ0)H88&6=L .
MA^> -6@KQ%Z"C-LS\1RL]IHKGO6P?I3WN<WR^ZS>M^HRYV]7B7ZOGG22>9TC
M0YE'* ^9FJ) &::$8Y@R71R>>Z$B/N;'U"K'VV#,J=%9_0%^R!X%!S?JYYFN
M.W19EJ+J56[1!'0S8AL8RC%HK ^*UAQF@<N0C&4R[*C\9('#<S:RN;7GT;^4
M@BE?^^TW5H=C7BOO^RK7GK<:3O]'#_E(YIK[9D%$E945!C"1$8$XD!$D&!$8
M>*GT6, 3+S#RCOL,/C4V:F37?K)HI0>%[E?8_+T$B[QN]&5YQFXS&X9'Y8XP
M=DQ3&WA7@@,MN8:UWJ[3"?'U7[;$'_ PNP=H@YY)VXP_[M%R#V3V3HC[/*,?
MO;W/V>)>K/<4/^B9UYD!>G5/0]^G(?4A3[D^OD4!3$D8PPBEU,,!XQZURL+J
M&&MJY-6("C:[X"MA>YE272";D=1 T#GFI-ZH6?./ 1Y#TDW7<*.RBX'>S\G$
MY)9^W+%5Y/I]_K"L=*$)5@G^)M.]"'.N::NM^R0Y"8(PC""BNA!^D,90_8!"
MG* D3FE,?2ELJ,1\Z*DQRTI"\)2)N65Q&@O S6C%#8R.66:['GXM]058R0W6
MZ-:VT/"5MNP!&Y*&+$8?E97L47E.4CV>T+O)5ITD7<?*-<F-5\NJK)2YG.6W
M,X)TU9J0*),'I7H7*8*IGV#H<X*\@,4!C:5EQZV.X:;&36_;)E--&GDM\SJY
M>$MLZVY<78AW$]7P.+IVR\Z$L$_;+@-DSN_AU37(V V]#!0^T-W+Y*Y!G:BV
MJG L<8I\FD"D"T+C5&*81EQCC'P215)P9G7TUCG:U"BEPR7H5>^Y&^JSG*G)
M560^ [NA'"IW99:[!YR"4]5="-GLIAYQ6.I)__CMX9V2\O5\46;-:=LLQ3SV
M$C^"4L:!(A$:PT32$ ;"]VD<,1ZGYG%7!X>8&G-H(>'R >CY JR1\P*HD>\M
MPH,.@]E-$\- Y/R4JD%'2PA>K]"Y&0(=BV"ILU$:*3BJ!UIVP5"=0'0&/QV^
M<[Q@IT[)=X*;NJ_L&<PDRE*(JP=1J#<@O_V@W$"QZBC_U";RE6^60@<2W'Q=
MS+R(A +IYAHD4K94+#SU-X]#'/@Q]1,O%9'5EK3E^%/C2/4Z!98!3): FUE4
M#F%TS:.UY#H=M)4=U,)?@+7X%SI1F(JZVG$;RJ14&#"2J1]V@\8P68HP;O12
M/WSVXI9Z/J:'!??V&YLOR^Q1?%;&H3(-,Z;SSB]O"U&;BK]GU=U'4I:$W2U+
M456EKC*?5<M*7,D;P>[RQ7QQ^[1J71%%S)-A"B7!5#N/*22)YT./IS&B >78
M)\9VWX""38T)/[Z_L3!\AIPA V/RA7!WO=6UT@HT:H%6+[!6#&C-P(YJ8*V;
MCE#?:'=ZK][M+%H8O2\TFZ/E$3RHQVDR!%E>1Z_7.PXZRDHYMGJ!5,OA9NH?
MFJF?MU-/UE/_M6OJ%]M3_S/X82 KW,',=-KN0XXWGL7O *4=/\'%\WMZ%UFN
M'OJZ$#RKWA%6+_4W.E=WAOT(Q7&(82+#$&)/[\FF"8-)2GC(<1S'Q.B<Y^1(
M4ULGM:!U2F<M*EC)"OZHI;7<C#V.KZ';, 1JKAV$GH#9^P&GP!C4XC\ZV+BV
M_2F=]ZSXDS?TW8=0[H"NJ5(_;%.%W_-EZ D>0L$T3PA?0A)B!@5-D!<)S"E#
M=OL-!\>9&DM\87>"+^?UB]_ZPYV5\JPP-=U2.!LIYUL':V!:-@!.^AJ<0&+8
MC8##0XWL\'?JN^_8=U_>PX'O72U;Q^563UN-+J^J.U'<W)&\+<MTK4SKXE'P
M=XM"U]36F:&S($Y]CWH>E#+18;:Z.V48)#!("46I[[,D-*J2-+[H4Z.ME8A
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MA*[9(5.LP">!LJ5C'ZH)X)@&C 62K\KRW)CG4SJ8@]W2/3<C9%ZNE-A.OKP
M7'TYS1KN=&+,%@AW[[KC]6*-[5<E.5B)OG,:N_H2KD]_"=;K1C_<AEQ&+"48
M=57IA\[S1:;G4_JN.??W65/>^3+G>N@LOQ4Y4Y_LFZQD\T6I;+EU[7(L&*)>
MPJ#D@:*^  7*%@X9U.V] \H$QW;=GZQ&G]J*LR5\?::T(S[8R-^[J+S=W)@2
MGR/$G?/><&#W8+T>H U+>C8"C,QY/;#9I[P^#^G'>)]$U73ITPWYUMTC;Q:-
M'UO;]7>+N7I>^8J4&9N%48B\-)00DUB7S" 44D9BZ",44N))AGU=@+$R8SS+
MT>TLO,HQXRGA@>Z:"DA5%1E=-AU3J\5.P;96?#NJLYT4,[)S ?8X=*>1;D1O
MFY9N^IQJO+?W7%H-+D"MPW"DUQ.\(6G/5H11B:\G/L^IK^]C^A3_KAMW7$DI
MBOKPO:S*]_DE8\52\.UR-SA))/.QFA%)B')P:0+5PSPH8QPQ&@MEY)F7'S$<
M=&K&7=NT9M'*K1A."0ZR')!&=/O"0E93T,UOKH!U3&HMIBN1Z[3I4M$<:*4&
M)K6*^F-J4SM\>&S':O8V!,:6%<+MP.JN$F[XK!$KA=MIMULMW/+>?@;M.JWM
M??ZPK,H/XE',45O,AY X"5(O@-3W4^6P>QBF/N,PC$DD" FB*$QM'/:.L:;&
MX#_6POWKGU#D_17]9&>.=D%J9GH.!)1C1M[D\5Z 1M +4(L*T.FZ4M86I0$F
M0UJ/7<.-:BD:Z/W<*C2YI6^;M;-#/>TC.V<T266D[$K(22@@3D*LZTX&$"D6
M2@4/0O'_J'O7)K=Q+&WPKS!B-N:MCA!Z2 (D@>Y/Z4OU.M9E>[-<73%;'Q2X
MVII62MFBY"K/KU^ %XFZ40 %,%G1T>5TFB3.>4 ^N)WS'&E?4^:EO)@:P]5^
MN.1&O.Q+8#&I_3-T;6!.OKLPW%G&0X#DA@F]5:XEZ";^=HVT3OA3O&4#BMN]
M8._>+H;W$L:-7#SO!?$_+[;WDL8,36&AJU*;8_8 7^\V&VW5'"6)4G%6@%SD
M"*!48H Q% "J0E!*A"#(*0#Q0AM3F]D8$Z/GVD371)1S .U6;'?"$GA64%D7
M->;-HL9 GZDC5[WWFQERWLS(B1]7_3S/Z[A^Z9T[-0]E*:NCSLXNT$^2FE-.
M\=%4<-'-:6[1%WQ8KS;M7\T!0-FD<E"60X(SH!)& >)9;++2.2!($4PXA[&;
M$H@WRZ;&)-T=CKWU501!U_YAR1S^NM-Q3VG,3AIQ!^J._AF^%^4+RR [5W<;
M]S+[7+XPO;HKYJV!83S^J">'FX5)=7Y-RZ\F8D7_83;[O]&EB6'1C?)F[B$@
MH2E4B:GB$ -4D 30 D$@:(*ER&228:?)FWW34V/B*A'6;%5%F[T/$=?6NY&N
M _9VK!H&T<"T>3 Z,N;6(7'FAX[AE5 U]SU1=(?+)S,ZM#XJ];FC<LIM YXP
MM, PWQ@-IS>R_K,ZD32:3>U<=PX+EA1$<B X*@#*>0YPPG+ 2*(*7. T9LR%
MLVZV.#6J:LT;M@2]#; =,7F%+3 ?M;9&/[36_L4$R^R!_'0#R &UBRW!\5O-
M^%:C(]<WML3@O.*Q[8TCJ[C7 1.'@GCEQ^U7N?G\E:Z:;;F]3OWC>KG\<;TQ
M-\V+@F8II!2P'.G%<(P2_5.J20N)G$,D>)$7SA)MHYD_-?+SH+C5!"%U@(@J
M)**MAN)P;K!'0_^X,T?;51)LG5C\FT$H:B!R%5D8]_6S8_/IOE13.,^<ROLT
MGA[]7=TZ"6GZ81[\.53J[^H=;X+U]UDQ(#[H]5=CTKM5?PIBA_M2G$N!A0 I
M5AP@AB%@C&. :)Y")J$DL7VHN&OK4QLY+^4]_\TAA,(9?8N FI"8!AXX:M--
M[/(>V%^O)#T/FBX,P]PAW"0D]B.%B03H [>@CJ$8]@9C.#]TO""*H?X>!3\,
M?LBPY=Z#$%7Q+[K\1!="-TN?%UNZ;.*E4Y9!KO("%+DI6I!("(A,%,!$Q2J#
M2K',:0>\M[6I#0D'8Z-G;2U8K")>V^NVI.F'V&X%X@VXP+S?P>Q3@UEC:H"8
M="M0?$ZW^QL<=79LY?OI9-;NIF%$4DUOZ[.]>2Q5G).4@S0I($ YQ("EF022
MQA@IE$M<.$4X=)X]-9*HU[*TLLV-%KJ V9' 0!@"?_(U @_]"#A_VQ=\]?DE
M=Q\_ZG=[P:_3K_32)<.^R>98W<PUJUR4O<BWW#PUPP\1>8Z0QBC/8 X0S J
M,YF +,TSDI"8I<I)%>9VDU/[@O?E!)8+):,?](CU7=)-Z9AU9@&UW4?N%\#
MWW['V#H'K5-&LM+-]C_HV^/CDR\L6AV51NQ1.&47ASL'KBA6VX58+'?;Q3?Y
MLPG?J?92/NBWZ,W:Q%W/BP*F$F6IG@X4"" L<L @ET!QI$PZ&8J)DVK_K0:G
M1CA=>Z.#P;/(F!S]5AOM>&QR$W3+989'*$.O-.Y#T7VQ80F-U_7&K3;'77)8
M(G"VZK"];QC?O%F4],N7C9'(U$L;HSY=J>R]7ZSDNZU\*N=*+T8*5 @@96:.
MF"$$&*$,Y#$F,C&U0KA3'OVM!J?&-\?VU@KMM<KD;\;FJ#+:D6]N@F['-SZA
M#,PW=Z+HS#>VT/CDFYMMCLHWM@B<\HWU?0-5-XUL=",B?7C?.2MPA@D&&<\U
MR4C& $U( A 3B"DF($N<)C476YD:L]1:YWOU\^%T<AE3.PZY&ZG01V$#0')7
MN>P#P:N:Y<6&QE6M[//U3)VR]^*A9R;_LRMKQ<O/:Z/FN^*+I3P2@_N\-B'
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M3E+"]>N0,>AZ:#_9U^%%SO__+&^"Y< XO;X-/=3>KSN\5Q;NKVS9(A!5$$Q
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MF^CHW<RBQEI_XX,=*CY'@1LMCLKU=MZ?,KKE7<-XVRKFYL-Z51=,J<HQE)4
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MJYQKXV2WD*[5]</FC*_7FV<CMR%?K5?BD/361,Q1A8N<4@)@2B5 .5. ,5F
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M"M*$)!AFF*O8ZG.W;&]JW_[;MCAIQV8CBV"J$NKY96-Y9$QWK^O:AWL_-01
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M"=1\E@*>"PH0,^J.<9X!!5&**.9I@IQHSJ;1J9%;M8XZ&&VR&ENS*ZT,;?A
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MX%C_-8MY+J'^B/%\N][2I=T'?+4EIV]YWUZXU_>S:2.BE;F.(J%7P;3[HKU
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M(19FT467G_3+_V[UFCXO]"KC5[JI"M^6Y4Z*N: QQIE>&>5*%'I:030Y(,X
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M#OOF&Q4W(RO,_[W3S/+PC2Z6YL$_KC=FG_)GLXZKCI*K(A\)-^40" &)2A1
M<9( DB42Y#A#:<$9Q3@94%S%T8P!00MCU%QIT_&K?.XGNOF7W%:[/N7>>#<&
M<>T<.W()@?4XO--:7FF>U[97@0_1P>)9M/<&J/4&E+0G5L29E@9"YY.Q7$T8
ME<P&XG/*<T,?,R!YHTYJ;[33FXT+5F@VH[%>A&']'P0+"2C+$\"@@"GG$K+8
MZG3C6@-3F^XT.@J-C0YA\9? Z^<@'Y $)IEC-&[OY=C!XA#O?R<\(T7LN\+D
M%FK?@T%OL/RE^\8+=^^Q^BA@O>^Z@4NWBXJN'6G>5]\/ES3T^O [W0@3Q;K]
M?HB>+ROIQL]?Z>IC%0I?_L/86+Y;U1)$)\6GJW]\HZ=7^U."N5 9U'V2@T((
M!%#&$<!&WI4512+B),\+Z*3!.!G/IL;:M?GF)/"Y<L!/%,Q4T+9=*$_%W@D-
M8%V1[BXJ7:5N4VGUHIBWP686U>AT$K+*J%;>W6J H@:A671X!5M]NA:GJ &J
MOB0R4$6'4W*/^P13ZW^OFQ.3<6[<'9')N'UM&V9R!@Z<-/"O4NQ,*-J^)OE[
M:6RNU6_J#4LL42SU/ N0/-&+H1BE@!)&0$YI7A3ZN0HZ*5?8-#JUH;:UV6SK
M[*V.:K-;&:AA6\0V/6 Y$GK&-?0@Y0%2]]'" 2.O1&[3[K@<ZX#$&?VYW'NW
M&&G%I&53V;$@DD-.&5"2$("$R/7\16(0IRJ50E+-1TZ'45?:F1K_'$N3'HF)
M#M8 /<+5^@C\7K3&V;MI(MQK(X-*@E["(9 RZ%%3+R40>LG?'IW0BY=[3:K?
MOJ:;S7=-0?6J$>8R2PL)0:RX)H@4YWJVH@I B(0$BBPGG'O(KS]N=7)TT::-
M<_.#/-CM)<?^!'%+ZO"-8V@BN99Y/XOH-FJM]KV:=4)IA(3\DX:GD)M_&0O+
M-/TK-_L).'Y<E/_Z<2/ENY7^QF6Y?=0KM6;SOTA(0K),PYY2"I L., \$299
M3Z T1EF1HWNBCJ\W/35J,I8"I4V-%HVMD=%>N2_\N =Y.W8*@V=@BKH0B&SL
MCHSA46MY9$P?(1[Y-F(A@Y)[6G_1R.3;J-P*3[9XPL R?4=+MWUZQKS F&4Y
M%$"1/ >(( RPX!#D*B<QS?2,*J7SK:EG:D=55]IQXJ5]:^$^IKI"ZWJ_$;$T
MUD;+QESGP)UKZ.94<)8E":!(*( *E0$J1:)7LCAGD.("9VZU#SV@.P+KOP^#
MIAVY>\ H,).?[']ULO\\UC+L1\%K"<,K38U;N;#?W[."A3<N'QY0O1 +NOG^
M<5/O_?\DMU_7XMWJF^9R*3MYX*^^GU_<7E9O U.2BUQA"*J9)*)%JEF$2SV3
M3*$0D)(B=:J X=.XJ1'.P5RC^]J<9M;N1:WAL^A($*$Z$;UT6WO]\"!P;Z^
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ME=H&XG/*=$,?,_@,5S]0/^=05N:S_&/[2COVKWF<I@E2*0<02[/;A24@ @F
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M_NU^L[Y[WJPWO.QVZ0Y(9KP@)$=:PD03 S$B=G_"$8)I:M*,4_MW%M14XM*
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MDK3DNB:T%/CZ!"F'VN4QJBQ;=;%[BJZQ\V(CX.M0K70 LENG$(_O^%E$6X>
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M\OY(G,P6FQ[BER,,)J5VA1)8@'ER9NG;#-%H#MX'])8IDEZ32T-/4C6N11M
MZP_;(P^D@@[P]#><DV,S(UY>Y+/I?%KELZ9U=\6.LS8Z%BQDLJZ@##H(H=19
MG(A&<9\+-CGU?(:N<:W6\)@:4@T=H.KZPODE_:M)T74@,PK(MA:0&\_ !U,
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M'6#ED:[\E\QDGH-1+@*+]5JM102O0@04-GFAF)%M)@D_2=6X)UK#8V@X%72
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MT__:_#A1.FBFF '% J.=+$CP0G@(2B<7'&,E-4'\<X2-:YS'A\ZV3.)0>NP
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M]G4*1G1U/I>DT"%F(2"QG'TI)H@V_4>:%U[<-LX3YS1C5DK@V>AZB36!L\:
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M'.3#6/^*&\Z2EER1:VT%2<=P#ZXD#L(I%0N7*9LF*>:GR=H)3?9;05,#570
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MV?BEU<V52M(8 5EZ<LE2(!8%5<#YC,(JI7UJ,H/G:=(F7AD_#@;N(FM<@70
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MKBLQBZCFMRX!/!T)Z(EQ+*108KLY8$.)G'C6?%M]VD)0'8#PE_.P6KTMV\+
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MA7L=*(S'?8:2DB_&)>"7[>8F0DPE@^8!D[?.2-MDHNZC5/77?7#XRS.>&'K
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M]4O)[OC9=[OAVKTXWWPZ_?1VI=A/CN"&])??J]PW8O]Q&;4OS%NMH.8X:Z8
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MEB@\A5LZDN7/E6?<T>71MA;F:QW &;+\(\J"3%EE;>]UM ??R5-(Y'5Q)R?
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M \C3.;\LYIL[_$OX.EN'\\T!;V857EW4>.)U!XTT+D4I/9!9R^B A4-TQ4'
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M-VH@>H2H8?@ZK5C^Z,+H %B/6@-;KM$Y%Y_F]3J=H:MS@+4$ITJL=;QDBYI
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M]&I_U:+\\KG^YFHVO[) KZS.&:[&'16ZVW>VFR-ZP-F//&0TL.BB,171FYT
MY'F2C5: 863"D"<J[V[Y.XDAHQO=?\G[U_/''9\;"\R]L3YA4."P6%!:67)^
MDH7H-:*(4;$PK(MWUV^>>LC8^%BY]0@W%<34QMW5H?Y]WZ%^W1*T9?&9)H;)
MJ")86P=_A-K-C$E"T;Q(;874:B#"=OC6:=!U!,DOCB&&O?'U=5-C^6$=ENOV
M ;<SSKG)V2LR5KT#I8R#*+D'+7R6C$>I69/.N4>IFJ9/X'C(&U\TDZ-MY\MT
MM0MN\WR0@[Z);7]=K\XBM]E8Z<"9@/1<<$T>.C$ H^?*H)4WUHZ.INL>HF::
M!H&.=> H8NOZ[7WPA*EVN$IBK71LTS,6(&(Q(%PV7FO)C1"' _,@)(Z>8>@)
MB:,(9G_H+=;A_+@J\N?DB@X:N2.'OVAC0*7$(-;._6PSRLULI3B^;MPOVS5Z
MEJ(G*(XJJ -VYGVJV_NF2,MFF;,KTI,13+Q505KP7&YB4"%ZP[2(319M-$C+
MCI[WZ,R./$QXAX+SX_'5YIGT@@R1'$"4.HD@(K$R20:&GH.44%L^E;<\>B:D
M8Z6XDQ@.]%]^FQ]!"Y[QI&W4W-:1OYKL#!-K3RR#E)PDHY>(<DVVRAWN*X^>
M">E,Q^TDFE&QUB E<E[UYCMRR+_?' &\7ZKC@<\:+84QA-;14A/W?]EUG-ED
M)5AD K)DJNX42! 3YAHO<39YY^E/V^0D'B?L\'SM_9__ZVR5SA>KB^6-)8$Y
M%;I&SM7YY+48, 4(W@JBFEF4VM$?-<K+#*9QZJ3%B"CZ.77;1E(])W#O/_$X
M.QT'?G9C;7:D[8Y/X-([]-9S!\()\B@5*Q!=H7_(HERPV3K>J!ZCK7:[RGG7
M*HK[O^GE]UM_LADVIK/G-N4$)=1;RIR%((V F!TW.CN%ILEV\KVH[5SC[8*L
MG]J@FTNOBX*I(4>[7-26R9'.=:2B576- J=#1<- ",MU3IB\/^HM_9G$B<>!
MM\?+P#?Y0.%U!LOM;$]F++G8)H.IN[54\0Z<)U=+!Y.2-T8)W=P$[F&8<RNA
M/X*M/20P=1KLU>*"+)?E=H1K5,$9Y>L88#)#E6?D3,?@@6<FG:+W ?VP N);
M']L/#O81T&(4;G6F*VY<B-^O*U9="L0+<GM<JFT[B1CD,PJPV@6='$J+3=8S
M/478M",CNWFN]A-4O\"[&DY><[DWV5FC>S?_REDRR1C-#>A4:A&,B^ P>I!"
MRQ!M,,XU230=2'<_:N]P$ U#:!.)]AOXN+%.[49WR%YQCH<^:J2PQB!*1XIB
M_&.QR/^>G9^_F.?71.Y\,S3R<E#\CQC8M>-9<D"GE01;9"T9(F49ZJ#1PD(1
MNC#.2I/:PYVH/#!M>9/W\WQW>^WJ1SS0AB@,\@)%1[)#=8T'"OIELE)$,D0#
M3\/,K^'?.:V2:H>5.RG+)B(X.<WT8O6OE[/%&''9W;Z@K18;<JI)=%MR7G.T
M"7QU#90/!NA=$T!,%,X86U)L$J \BF[[V3Q^:+OH=JUI>N"/;QH*6]M9)ND-
MW3SF UDF4G#P$3ED9HIB= >5:#(O:?RCG))VW06M#X> )P%!!S[._:NB9112
M%:SSRR3Q- @%T8L .GKZA11!ER;5(ONO;S]"U'<:B Q:^KZ+O#H W>Z[HXDM
M)3,R;IBK1=(((5@.+JHBC*XOO&X!QV>P]'TG9!R\]'VXF*:.'U\:7UN#>DL_
M=[EXC1J82Z;:Z1:\8QJB23RCX\3)8;MF[OGP4UO6OH,D%R.RM0/E-(*:_Q&L
MBF2)E!@X*1<>B)'<@^,A@\[9:LDP2VRRT7W,0_02QN[B_9T,'1W<C+=?-X/B
MYY^NXJ5G7@J=$BJP40JZVK8.AN09O%'6>%\PRB8>ST^43*M>IP/%W1V7!TEH
MZC?Y(3;6>:0?/I,DWN$R5;E^PK,<K<\A.F";=O;L-!W)< C%9^Y-"=$/>ZMW
M^-)I%>'D(&LJHY.+2?[Q^F/#@.1]G]XV&OGD>:9)LU@7 RDI$('7[4I%@:N/
M=B"]EF-DDK7Q_$X]%"E0:N^T NV9)+<OD\87Y  Z'IWG2,^ ;1+ ^6N'(G=!
MZQ%"D;N H /S\OX AN!1$?V\-N$13[G7]'X85Q>-<B]-E,XU2;3^-4*1.T%D
M4"AR%WEU +I=(R.B>#3)%HB&(RBL\S*)3: #S_3_UHO8!([/(!2Y$S(.#$7N
M(J:IW9[?_I/.+U9T4]\%LK#6=Y/\M0CIC["B WZ^H'=GO7H]7ZUGZXLUL?@C
MIL_SQ?GBT_>K<VO'DG9DUR-=944V/O@@. B!C!O%O,5A[>,C$G5:H<^=D+/H
M0(P=*-'W)%(BX#/Q]\8VRUO>X64#],?%=B+LJ\7R[?HS$?#R>U46&_U 3JB.
MFM'C$UVL@V=Y#54XL+)X(YPDPAN5\8Y _;,+DAYB&1P?#Z=]">J1MR7^D7LO
MM4X@8Z*GD1=2/U)4]1-)+V5??IJ6.?DE^$']U)7#1T?=>+C?$P(=X/[N0U<7
M8OQX3).63'$HUO"J1#SX.D.#>1\%*RZ5NU':<=#\"$TGB]%]$;)H(ZX.D#=J
M1#S(Q+SP 3 :#RHS S$R#587$Q+/GGO5 JI'S]0V6R/6F1$R&3JF]B<?W/]Q
MI5LNPOEV_<?JCY#QC/$BF.,"ZGJ9FJ<)$.H6+%%$Y)(5+>^&V'9=O_+ -S^C
MK.U. !FTK64,:4VZ:O:)XX7S=''96G6Y+_Q=F&5Z['[[[XO-O-1ON%K7G_NS
M-JZ^NZ W,]QXM<Z,DEQGYT%G7A?N*@U!U 6H7@G!(YHH#EP9=!B!SRA7W #:
MQY/]R>65/WS&^7<2R(>+^>HSR>#=Y[#\$A)>K&<IG/^R^'V=&^:=]_GVMGGI
M@_DQ2=X:M=<^!0DL5L.%20;.1G(EO>#&,:9(8_^=M[ZG-"^)[*(24)*H)2,E
M0@C: "(/R6E60FF2[_]KYZUW0>LQ6FAV $$';NC]V:XB B9''G36GGSI1-YZ
MC,*!]='8)+5(KDD3W5\C;[T31 ;EK7>15P>@VS6MA<X+7?<\FEA#.Y)%<"PQ
M$ XE2R$9R9L,UWP&>>N=D'%@WGH7,?429[B9X7S*6OOR-<R__S[[,B/;_ZH]
MQ!95I)2@@ZY#K((E?S89>HN"]Z78&.^F_9[PY ZCY[2RU3OAY3[?[(C"ZT!K
MCEM#S;*V69$B<+52P$@#GE=1%.%DSEJ:-I5I?_?V-#(,)D/'U)K\Q78A,+[X
MLKB8K]^6/[^6NGR<SOW'[!Q7Z\4<7X95G8)T&8BL\9HS8VN;@$&(NO;U)1,@
MLBC!6&XT4\YH:P8I[KV^_AG%CG>"RN*H<NL,F:\6RU<7:W)=KP[TYU>2-\D*
MOVWX2XJ$/J:^5L2"]_BI!AD7R^\OOGY=+KZ%\VNFK.B#WBT7^2*M5S7.?KFM
M^O67+Q_?OG]'?Z<F7L^LC,)+'2!D86LE&"<^B02I6":LT<(HN0^^CWF(9Q2&
M'NN6=(NA?D/5KTE47_!C^ _N%6N^^=='"A8_2-%(T=[KS[\G6A:%])9\/D@$
M25!.Z3I200)A,\>8C22+N(7=]PA-A]K%]WSTC]%BWI-M'R-AV&;",$,#SEL/
M+CON4W EYR8E:8\1->WK/Q8Z[AJ@HXGA)%3)&&FLQSYN?%5SE$338^!2VNG(
ME *)29'I5B<W9ZW(NR'#+6MMR>D_,=5SM7F-/OPR/W'=P_[[8K7ZA3C^O5RN
MX%J]6:P_7,3_A[4Z[K?_?)U=I@K/D'@1<HZ0-O-%C/$U<>&JB8#11<ET:#*$
MX&#*^U5BN^#LKA([KD [""KM<.#[3IN$,"+7+8-DQ]8:MP"N. '<9E:X"E&V
MZ2@[C.QI'8L.L'NH*#L [I_SY?5B53KQ2YQCF=5UZ$HF;X*&5'/"BCM7Y^-H
M\(Y.IV)"F9M4;3] S[15K:V@-@;S^S7SZ"*1XYXW-8RS>%$_D'SB^3XFWD,?
M-9)Y-XC2D4R[FD+!^2ILQSF_Q_5LN8DYW(,MF5C,3-8=#-7<1WH)O<^$@[IO
M5$=R,523;4P[T'BH_GE'WW/Y+9L.AW<+^MCKK[NZ$/>Y0IH%YSR+4)*-H**1
M$# (0!N$=2H$'4(+WNQ+\-2QZC:HNZO1CB+.DU-Y8WBY0S^ZK4H\BO>["U@)
M,H9)*P&C3O142@[.E41/)9<$6GI\2SY1%;D)7#\@A]\(,HOO!.<_PIJN_OS3
MS1_X)ZZJN?INL^[Y+%@E9$@!.*M; :1BX#@9*-&0(R40C='I*?"-0\KIJ,!=
M4'4KSW!<<77@/SQPX#H*[OVU;7N&+ 3%/()#I>E=J4O+&$;PR17K4*-M4WDV
MB+JI\V-M8=E.4/T^P\33+[--]\@JS#='ION%\S3;+W?UV,>-UO@PD.+QGMBK
M[WMQY_ONRV<$10RIVZZ,+82[:"!ZF8#<T>B\9IJ))E,Y=J+R\+JP 5]V8_\Y
MYN*3$1!4M9*S4!#(9P>?A53*:HVJ4>77+F1._N0V0MG/95O-A->OFOMP$5?X
MWQ?T8;]]PSV7M_WT&2,IM,=I&TF+W?V2'T$Y5Z(,6H#THHX9(Q3Y4I">L>R4
MC]K&W$1A/430P5U6=S[WQLXO+HJ5RD,V=;:S)TO129001681DXS*-TG,/TC1
MQ&TF8R#BI_:F4;A_.GKD@"C%0Q_52*NTC$(\"*581-3<6LC)&5!8UY#20P7H
MD@@^%L=CFQ5?QU$NES74Z&Q1QF3(F<ZG"I(;:GP&:Z(T/EBC39--[/<1TZE*
MV04'3ZB4W7G>@>M_]PQ7T[.X#T;'J@J%5Y4OY$WF2(XDTCFTL1)SDZ['!^CI
M"CU["/H)Y.S#]3[!LQUL9:WG5FD.*!RY =HD"('[NN">R>Q9R:7)$*8'*>H+
M0'O)^VD,[<'\_E"T;4AC13O4F8,M/%=ODAR[$$OM_W%,FA31'D,!]=!+.)*D
M'\?/'FSO!#NS/ O+[Q]";3_[L":+?G.U5$F*%:+<)%7+=]%!5,& )FN?YV)=
MB&T6)SQ$T<0=>BV>L,,YWP.$?I#_)GRI0YQ_=*ULKYDH.KO*(E\W[:C" VGH
M0!<N<AY59D6Y)F4*3Y,VO6(: 0-WD36N0";O?*O"K6>Z;M%^L?[X&?\(RW_A
M^FTA@F;S3]==V-EDYLD?MR6!RIFTK_8(3&+B)5B+:=@PM!V^=&((C2SLQ1$X
MWX'2&F=$<C36B8"D=TSPH#QJB"&XNB)4%A\P\#:C;8XWJ+W=C-2QW]/C2_2T
M87S#"G;.:R.\ Q9+ *6X@<B%!TN&+*-;C>IN?^_D,.[%,9T =4U&K>\"@:D-
M@@\DF:_K0"_1,GS=S&19O9ZG_[U]B$+P7HM4@.,FQQ$5>),\))M51F683VJ0
M"?#HUYPLZO:5^:*) *:$TG)]]H%$MN'7AX3SL)PM-K<Q1&LL&2_@G*@[FA+=
M1LP1D(PHRU%YYH<4-= 7W%"%]*N[:O!!"@:!2W7_,H_#X:DALJ7[S_GJ*Z99
MF6'>7A\EK)!D] (*6]N0F:^S(AD8'J1PW$==AB2'AL'D(2JFT4,C278Q-IL[
MP0HI6TQA=142%))IAHYDZE*DUYVDZZW3I!!3*:HXY=R0ZNR=@'*;A E1,HY<
M[T'* 4SNP'"_HV1_OQ[NHC/Z31[#9Q'JUIT,=6<J'<MG'I+,A34I$GZ(H$'0
MT=V_1:/RO0?\W C[7-0+0+^H2\=7KU>K"\ROYS?"0&?%,%<XG4V1A4O_L!)<
MK?OCW(08A*83ML'4#D1.'X@]'!:/Q&%'E5%?^'NWG*6Z['YSMK,8R96U].*K
MY!0H'0($+>B:!O)MA28=[9MT:SY$4%=9H]%QM3_O)UV(<L])R&-=S3)>S@]X
MCPEGWS"_O75%#,HBC S +*M-YC*"=W19BG,ZJN"4P29=;CM1V554=72\C2RE
MCK?R7$^WNQJ.=^:-YS(9!M9* RIS!\Y+"]):H8+ X-6=BL==%^W\])U=!0(.
M U-+;K<O*M[^0?U'#"O\/__K_P-02P$"% ,4    " !O0*U2M69\TE@-  "5
M6   '0              @ $     97AH:6)I=#$P,5]D:7)C;VUP<')O9W)A
M;2YH=&U02P$"% ,4    " !O0*U2$WCB<@H(   S*   %P
M@ &3#0  97AH:6)I=#,Q,5\P,S,Q,C R,2YH=&U02P$"% ,4    " !O0*U2
M7][ZYOH'   8*   %P              @ '2%0  97AH:6)I=#,Q,E\P,S,Q
M,C R,2YH=&U02P$"% ,4    " !O0*U2AWOQO/\$  #J&   %P
M    @ $!'@  97AH:6)I=#,R,5\P,S,Q,C R,2YH=&U02P$"% ,4    " !O
M0*U2*E7HM $%  "N&   %P              @ $U(P  97AH:6)I=#,R,E\P
M,S,Q,C R,2YH=&U02P$"% ,4    " !O0*U2]<$2KQ;[ 0!@(!4 $0
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64$L%!@     +  L Z0(  !=B!     $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
